Admission O
Date O
: O
  O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2135 O
- O
1 O
- O
31 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2085 O
- O
2 O
- O
3 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
NEUROLOGY O


 O
Allergies O
: O

 O
Hurricaine O


 O
Attending:[**Last O
Name O
( O
NamePattern1 O
) O
1838 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Called O
by O
Emergency O
Department O
as O
a O
Code O
Stroke O
for O
Left-sided O

 O
weakness O
and O
aphasia O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
IV-tPA B-ROU

 I-DRUG
MERCI O
clot O
retrieval O


 O
History O
of O
Present O
Illness O
: O

 O
NIH O
Stroke O
Scale O
score O
was O
0 O
: O
17 O

 O
1a O
. O
Level O
of O
Consciousness O
: O
0 O

 O
1b O
. O
LOC O
Question O
: O
1 O

 O
1c O
. O
LOC O
Commands O
: O
0 O

 O
2 O
. O
Best O
gaze O
: O
2 O

 O
3 O
. O
Visual O
fields O
: O
2 O

 O
4 O
. O
Facial O
palsy O
: O
2 O

 O
5a O
. O
Motor O
arm O
, O
left O
: O
4 O

 O
5b O
. O
Motor O
arm O
, O
right O
: O
0 O

 O
6a O
. O
Motor O
leg O
, O
left O
: O
4 O

 O
6b O
. O
Motor O
leg O
, O
right O
: O
0 O

 O
7 O
. O
Limb O
Ataxia O
: O
0 O

 O
8 O
. O
Sensory O
: O
1 O

 O
9 O
. O
Language O
: O
0 O

 O
10 O
. O
Dysarthria O
: O
0 O

 O
11 O
. O
Extinction O
and O
Neglect O
: O
1 O



 O
HPI O
: O


 O
Ms. O
[ O
* O
* O
Known O
lastname O
104742 O
* O
* O
] O
is O
a O
49 O
y/o O
woman O
with O
a O
PMH O
significant O
for O

 O
myelodysplastic O
syndrome O
, O
HTN O
and O
hypothyroidism O
, O
who O
presents O

 O
with O
left O
sided O
weakness O
. O
She O
reportedly O
went O
to O
bed O
in O
her O

 O
normal O
state O
of O
health O
at O
2300 O
. O
Her O
partner O
heard O
her O
thrashing O

 O
in O
bed O
at O
0130 O
and O
at O
that O
time O
, O
he O
noted O
her O
speech O
to O
be O

 O
slurred O
and O
her O
left O
side O
to O
be O
weak O
, O
though O
apparently O
still O

 O
able O
to O
move O
. O
As O
it O
seems O
that O
the O
thrashing O
likely O
was O
around O

 O
the O
time O
of O
onset O
of O
the O
stroke O
, O
we O
considered O
0130 O
to O
be O
the O

 O
last O
known O
well O
time O
. O
She O
was O
initially O
taken O
to O
OSH O
, O
where O
she O

 O
had O
a O
CT O
head O
that O
was O
negative O
for O
hemorrhage O
; O
it O
was O
there O

 O
determined O
that O
she O
was O
" O
out O
of O
the O
tPA B-DRUG
window O
" O
and O
she O
was O

 O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
further O
care O
. O


 O
Full O
ROS O
unable O
to O
be O
obtained O
as O
patient O
very O
agitated O
and O

 O
seemingly O
confused O
when O
providing O
her O
own O
history O
. O
However O
, O
she O

 O
does O
not O
appear O
to O
have O
any O
recent O
febrile O
illnesses O
and O
there O

 O
is O

 O
no O
current O
chest O
pain O
, O
shortness O
of O
breath O
, O
palpitations O
or O

 O
abdominal O
pain O
. O



 O
Past O
Medical O
History O
: O

 O
-HTN O

 O
-gout O

 O
-hypothyroidism O

 O
-myelodysplastic O
syndrome O

 O
-alcohol O
abuse O

 O
-lumbar O
surgery O
( O
exact O
nature O
of O
surgery O
unknown O
) O



 O

Social O
History O
: O

 O
She O
was O
previously O
employed O
as O
a O
hairdresser O
, O

 O
though O
says O
she O
has O
nt O
worked O
in O
4 O
years O
. O
Not O
reported O
by O

 O
patient O
, O

 O
but O
there O
is O
apparently O
a O
history O
of O
alochol O
abuse O
. O



 O
Family O
History O
: O

 O
unknown O



 O
Physical O
Exam O
: O

 O
on O
admission O
: O


 O
Vitals O
: O
T O
: O
97 O
P O
: O
67 O
  O
BP O
: O
138/49 O
SaO2 O
: O
99 O
% O
NC O


 O
General O
: O
Awake O
, O
agitated O

 O
HEENT O
: O
no O
oral O
lesions O

 O
Neck O
: O
Supple O

 O
Pulmonary O
: O
Lungs O
CTA O
bilaterally O

 O
Cardiac O
: O
RRR O
, O
S1S2 O

 O
Abdomen O
: O
soft O
, O
+ O
BS O

 O
Extremities O
: O
warm O
, O
well O
perfused O


 O
Neurologic O
: O


 O
-Mental O
Status O
: O
Alert O
, O
oriented O
to O
person O
, O
" O
hospital O
" O
, O
and O
year O

 O
but O
not O
month O
. O
  O
Naming O
generally O
intact O
, O
with O
some O
errors O
on O
low O

 O
frequency O
objects O
. O
Left O
sided O
neglect O
. O


 O
-Cranial O
Nerves O
: O
PEERL O
6 O
- O
->4 O
mm O
b/l O
. O
Gaze O
deviation O
to O
right O
. O

 O
Left O
sided O
hemianopia O
. O
Would O
not O
cross O
midline O
to O
commands O
but O

 O
is O

 O
able O
to O
track O
acorss O
midline O
. O
Left O
facial O
droop O
. O
Sensory O
loss O

 O
left O
face O
. O


 O
Motor O
: O
L O
hemiparesis- O
no O
antigravity O
ability O
at O
all O
on O
left O
. O

 O
Right O
sided O
strength O
full O
. O


 O
Sensory O
: O
Light O
touch O
intact O
at O
times O
when O
testing O
sensation O
, O
but O

 O
sometimes O
she O
would O
not O
realize O
when O
someone O
was O
holding O
her O

 O
left O

 O
arm O
, O
indicating O
a O
possible O
sensory O
componenent O
. O
Dimimihed O

 O
pinprick O
on O
left O
. O


 O
Reflexex O
: O
Patellar O
reflexes O
2 O
+ O
b/l O
. O
Biceps O
reflex O
2 O
+ O
on O
right O
, O

 O
remaining O
reflexes O
1 O
+ O
. O
Toe O
upgoing O
on O
left O
and O
mute O
on O
right O
. O


 O
Coordination O
: O
finger-nose O
intact O
on O
right O



 O

Pertinent O
Results O
: O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
06:20PM O
   O
TYPE-ART O
PO2 O
- O
104 O
PCO2 O
- O
33 O
* O
PH-7.45 O
TOTAL O

 O
CO2 O
- O
24 O
BASE O
XS-0 O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
05:02PM O
   O
TYPE-ART O
TEMP-37.1 O
RATES-/25 O
TIDAL O
VOL-500 O

 O
PEEP-5 O
O2 O
- O
40 O
PO2 O
- O
148 O
* O
PCO2 O
- O
30 O
* O
PH-7.47 O
* O
TOTAL O
CO2 O
- O
22 O
BASE O
XS-0 O

 O
INTUBATED-INTUBATED O
VENT-SPONTANEOU O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
05:02PM O
   O
GLUCOSE-82 O
K+-3.7 O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
05:02PM O
   O
freeCa-1.08 O
* O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
10:44AM O
   O
TYPE-ART O
TEMP-35.0 O
RATES-15/ O
TIDAL O
VOL-500 O

 O
PEEP-5 O
PO2 O
- O
139 O
* O
PCO2 O
- O
35 O
PH-7.42 O
TOTAL O
CO2 O
- O
23 O
BASE O
XS-0 O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
10:44AM O
   O
GLUCOSE-124 O
* O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
10:44AM O
   O
freeCa-1.07 O
* O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
08:39AM O
   O
TYPE-ART O
PO2 O
- O
187 O
* O
PCO2 O
- O
34 O
* O
PH-7.44 O
TOTAL O

 O
CO2 O
- O
24 O
BASE O
XS-0 O
INTUBATED-INTUBATED O
VENT-CONTROLLED O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
08:39AM O
   O
HGB-9.5 O
* O
calcHCT-29 O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
07:38AM O
   O
TYPE-ART O
PO2 O
- O
169 O
* O
PCO2 O
- O
36 O
PH-7.44 O
TOTAL O

 O
CO2 O
- O
25 O
BASE O
XS-1 O
INTUBATED-INTUBATED O
VENT-CONTROLLED O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
07:38AM O
   O
GLUCOSE-146 O
* O
LACTATE-1.5 O
NA+-135 O
K+-3.0 O
* O

 O
CL--101 O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
07:38AM O
   O
HGB-10.2 O
* O
calcHCT-31 O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
07:38AM O
   O
freeCa-1.10 O
* O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
04:35AM O
   O
GLUCOSE-119 O
* O
UREA O
N-24 O
* O
CREAT-1.4 O
* O
SODIUM-138 O

 O
POTASSIUM-3.7 O
CHLORIDE-99 O
TOTAL O
CO2 O
- O
26 O
ANION O
GAP-17 O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
04:35AM O
   O
ASA-NEG O
ETHANOL-NEG O
ACETMNPHN-NEG O

 O
bnzodzpn-NEG O
barbitrt-NEG O
tricyclic-NEG O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
04:35AM O
URINE O
  O
HOURS-RANDOM O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
04:35AM O
   O
WBC-11.3 O
* O
RBC-4.08 O
* O
HGB-11.7 O
* O
HCT-36.2 O
MCV-89 O

 O
MCH-28.6 O
MCHC-32.3 O
RDW-17.7 O
* O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
04:35AM O
   O
PLT O
COUNT-523 O
* O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
04:35AM O
   O
PT-12.2 O
PTT-21.3 O
* O
INR(PT)-1.0 O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
04:35AM O
URINE O
  O
COLOR-Yellow O
APPEAR-Clear O
SP O
[ O
* O
* O
Last O
Name O
( O
un O
) O
155**]-1.017 O

 O
[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
04:35AM O
URINE O
  O
BLOOD-TR O
NITRITE-NEG O
PROTEIN-25 O

 O
GLUCOSE-NEG O
KETONE-NEG O
BILIRUBIN-NEG O
UROBILNGN-NEG O
PH-6.5 O

 O
LEUK-NEG O

 O

[ O
* O
* O
2135 O
- O
1 O
- O
21 O
* O
* O
] O
04:35AM O
URINE O
  O
RBC-0 O
WBC-0 O
BACTERIA-NONE O
YEAST-NONE O

 O
EPI-0 O
- O
2 O


 O
CTA O
head/neck O
[ O
* O
* O
1 O
- O
21 O
* O
* O
] O
: O

 O
Occlusion O
of O
the O
right O
middle O
cerebral O
artery O
near O
its O
origin O
. O

 O
Likely O
retrograde O
collateral O
flow O
present O
, O
reconstituting O
more O

 O
distal O
branches O
of O
this O
vascular O
distribution O
. O
Evolving O
infarct O

 O
within O
the O
right O
basal O
ganglia O
region O
. O


 O
CT O
head O
[**1 O
- O
21**]:Hyperdense O
regions O
within O
the O
head O
of O
the O
right O

 O
caudate O
nucleus O
and O
right O
lentiform O
nucleus O
. O
The O
findings O
are O
of O

 O
concern O
for O
either O
hemorrhagic O
transformation O
of O
the O
infarct O
, O

 O
versus O
extravascular O
accumulation O
of O
contrast O
material O
. O
A O

 O
followup O
MR O
study O
may O
be O
of O
help O
in O
differentiating O
between O

 O
these O
two O
entities O
. O


 O
rpt O
CT O
head O
[ O
* O
* O
1 O
- O
22 O
* O
* O
] O
: O

 O
1 O
. O
Evolving O
right O
basal O
ganglia O
hemorrhage O
with O
underlying O

 O
infarct O
with O

 O
intraventricular O
extension O
of O
hemorrhage O
and O
3 O
mm O
leftward O

 O
shift O
. O

 O
2 O
. O
Persistent O
moderate O
left O
subgaleal O
hematoma O
, O
felt O
to O
be O
due O

 O
to O

 O
anticoagulants O
on O
earlier O
studies- O
correlate O
clinically O
. O

 O
3 O
. O
Paranasal O
sinus O
disease O
. O


 O
rpt O
CT O
head O
[ O
* O
* O
1 O
- O
23 O
* O
* O
] O
: O


 O
1 O
. O
No O
new O
foci O
of O
acute O
intracranial O
hemorrhage O
. O

 O
2 O
. O
Expected O
interval O
evolution O
of O
the O
known O
right O
basal O
ganglia O

 O
hemorrhagic O
conversion O
, O
with O
interval O
decreased O
attenuation O
of O

 O
the O
hyperdense O
hemorrhagic O
foci O
but O
increase O
of O
peri-hemorrhagic O

 O
edema O
. O

 O
3 O
. O
Essentially O
unchanged O
mild O
leftward O
shift O
of O
normally O
midline O

 O
structures O
, O
with O
persistent O
effacement O
of O
the O
right O
frontal O

 O
[ O
* O
* O
Doctor O
Last O
Name O
534 O
* O
* O
] O
. O

 O
4 O
. O
Unchanged O
trace O
intraventricular O
hemorrhagic O
extension O
at O
the O

 O
right O

 O
occipital O
[ O
* O
* O
Doctor O
Last O
Name O
534 O
* O
* O
] O
without O
developing O
hydrocephalus O
. O

 O
5 O
. O
Interval O
decreased O
soft O
tissue O
swelling O
and O
hematoma O
in O
the O

 O
left O
temporal O
and O
frontal O
region O
. O

 O
6 O
. O
Paranasal O
sinus O
disease O
as O
described O
above O
. O


 O
[ O
* O
* O
1 O
- O
26 O
* O
* O
] O
: O
attempted O
MRI O

 O
Incomplete O
examination O
due O
to O
lack O
of O
patient O
cooperation O
. O
Right O

 O
basal O

 O
ganglia O
hemorrhage/hematoma O
is O
again O
noted O
. O



 O
Brief O
Hospital O
Course O
: O

 O
Initial O
Assessment O
: O



 O
Ms. O
[ O
* O
* O
Known O
lastname O
104742 O
* O
* O
] O
is O
a O
49 O
y/o O
woman O
with O
a O
PMH O
significant O
for O

 O
myelodysplastic O
syndrome O
, O
HTN O
and O
hypothyroidism O
, O
who O
presents O

 O
with O
sudden O
onset O
left O
sided O
weakness O
. O
On O
her O
exam O
, O
her O
NIHSS O
is O

 O
17 O
and O
she O
has O
a O
dense O
left O
sided O
hemiparesis O
as O
well O
as O
right O

 O
gaze O
deviation O
, O
left O
hemianopia O
and O
neglect O
. O
Her O
imaging O
shows O

 O
an O

 O
occlusion O
of O
R O
MCA O
near O
its O
origin O
. O
Her O
history O
, O
exam O
and O

 O
imaging O

 O
are O
consistent O
with O
acute B-REA
embolic I-REA
stroke I-REA
in O
R O
MCA O
. O
The O
time O
of O

 O
onset O
was O
taken O
to O
be O
0130 O
; O
the O
time O
of O
her O
thrashing O
, O
and O
so O

 O
when O
she O
was O
seen O
here O
, O
she O
remained O
within O
the O
window O
for O
IV B-ROU

 I-ROU
tPA B-DRUG
. I-DRUG
The O
decision O
was O
made O
to O
proceed O
with O
the O
IV B-ROU
tPA B-DRUG
. I-DRUG
The O
plan O

 O
at O
this O
time O
is O
to O
proceed O
with O
tPA B-DRUG
infusion B-FOR
and O
if O
clinical O

 O
exam O

 O
remains O
unchanged O
in O
30 O
minutes O
, O
then O
plan O
is O
to O
proceed O
with O

 O
angio O
for O
IA O
tPA B-DRUG
vs. O
Merci O
. O


 O
Neuro O
: O

 O
Ms. O
[ O
* O
* O
Known O
lastname O
104742 O
* O
* O
] O
was O
admitted O
to O
the O
neurology O
ICU O
, O
attending O
Dr. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
. O

 O
There O
was O
no O
improvement O
with O
tPA B-DRUG
, I-DRUG
and O
she O
developed O
hematomas B-ADE

 I-ADE
of I-ADE
the I-ADE
right I-ADE
knee I-ADE
, I-ADE
left I-ADE
scalp I-ADE
, I-ADE
and I-ADE
left I-ADE
clavicular I-ADE
area I-ADE
, I-ADE
so O
IV B-ROU

 I-ROU
TPA B-DRUG
was O
stopped O
. O
The O
team O
proceeded O
with O
angio O
and O
MERCI O
device O

 O
was O
used O
. O
This O
resulted O
in O
opening O
of O
inferior O
division O
of O
the O

 O
right O
MCA O
, O
but O
opening O
of O
the O
superior O
division O
was O

 O
unsuccessful O
. O
  O
She O
was O
monitored O
in O
the O
ICU O
and O
then O
was O

 O
transferred O
to O
the O
step O
down O
unit O
, O
then O
to O
the O
floor O
for O
further O

 O
management O
. O
She O
was O
started O
on O
Aspirin B-DRUG
81 B-STR
mg I-STR
and O
Lovenox B-DRUG
40 B-STR
mg I-STR

 I-STR
daily B-FRE
( O
given O
possible O
MDS/malignancy B-REA
. I-REA
) O
  O
Her O
CT O
scans O
showed O

 O
hemorrhagic O
conversion O
in O
the O
Right O
striatum O
and O
white O
matter O
. O

 O
An O
MRI O
was O
attempted O
, O
but O
she O
was O
unable O
to O
tolerate O
this O
. O

 O
There O
was O
no O
need O
to O
attempt O
repeating O
this O
MRI O
, O
per O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O

 O
stroke O
attending O
. O
Imaging O
otherwise O
as O
above O
. O



 O
CVR O
: O

 O
Blood B-REA
pressure I-REA
was O
controlled O
metoprolol B-DRUG
25 B-STR
mg I-STR
TID B-FRE
and O
as B-FRE
needed I-FRE

 I-FRE
hydralazine B-DRUG
. I-DRUG
  O
Her O
metoprolol B-DRUG
was O
increased O
to O
50 B-STR
mg I-STR
TID B-FRE
prior O
to O

 O
discharge O
. O
  O
She O
had O
an O
transthoracic O
echocardiogram O
which O
showed O

 O
no O
ASD O
or O
LV O
thrombus O
. O
There O
was O
normal O
global O
and O
regional O

 O
biventricular O
systolic O
function O
. O
  O
There O
was O
mild O
pulmonary O

 O
hypertension O
. O
  O
A O
bubble O
study O
was O
not O
done O
. O
  O
A O
transesophageal O

 O
echocardiogram O
was O
attempted O
, O
however O
Ms. O
[ O
* O
* O
Known O
lastname O
104742 O
* O
* O
] O
developed O

 O
methemoglobinemia B-REA
( O
level O
29 O
) O
after O
receiving O
benzocaine B-DRUG
spray B-FOR
. I-FOR

 O
She O
received O
Methylene B-DRUG
blue I-DRUG
140 B-STR
mg I-STR
IV B-ROU
by O
anesthesia O
and O
had O
rapid O

 O
clinical O
improvement O
. O
Her O
methemoglobinemia O
level O
was O
zero O

 O
before O
returning O
to O
the O
neurology O
floor O
. O
  O
A O
transthoracic O
echo O

 O
with O
bubble O
was O
later O
done O
which O
showed O
No O
atrial O
septal O
defect O

 O
or O
patent O
foramen O
ovale O
is O
seen O
by O
2D O
, O
color O
Doppler O
or O
saline O

 O
contrast O
with O
maneuvers O
. O
  O
She O
had O
lower O
extremity O
doppler O

 O
studies O
which O
were O
negative O
for O
DVT O
. O
  O
Hypercoagulable O
work O
up O
is O

 O
pending O
at O
the O
time O
of O
discharge O
: O
antithrombin O
3 O
, O
prothrombin O

 O
gene O
mutation O
, O
factor O
v O
leiden O
. O


 O
Heme O
: O
Due O
to O
her O
myelodysplastic O
syndrome O
and O
bleeding B-ADE
with O
tPA B-DRUG
, I-DRUG

 O
heme-onc O
was O
consulted O
, O
and O
they O
did O
not O
believe O
there O
were O
any O

 O
restrictions O
on O
her O
stroke O
management O
due O
to O
her O
MDS O
. O

 O
Additionally O
, O
the O
team O
spoke O
with O
her O
outpatient O
hematologist O

 O
who O
confirmed O
no O
need O
for O
epo B-DRUG
or O
aranesp B-DRUG
while O
in O
the O
hospital O
. O

 O
Her O
HCT O
was O
stable O
during O
her O
hospitalization O
. O


 O
FEN/GI O
: O
She O
was O
initially O
NPO O
. O
  O
She O
was O
followed O
closely O
by O

 O
speech O
and O
language O
team O
and O
was O
started O
on O
NGT O
feeds O
. O
  O
When O

 O
able O
, O
a O
regular O
diet O
was O
initiated O
and O
advanced O
. O
  O
At O
the O
time O
of O

 O
discharge O
she O
was O
tolerating O
a O
regular O
diet O
with O
nectar-thick O

 O
liquids O
. O
  O
Her O
electrolytes O
were O
monitored O
carefully O
, O
and O

 O
repleted O
as O
necessary O
. O

 O
She O
received O
Famotidine B-DRUG
for O
GI B-REA
prophylaxis I-REA
. I-REA


 O
Psych/ETOH O
: O
  O
Initially O
Ms. O
[ O
* O
* O
Known O
lastname O
104742 O
* O
* O
] O
had O
significant O
alcohol B-REA

 I-REA
withdrawal I-REA
. I-REA
  O
She O
was O
on O
a O
CIWA O
scale O
and O
received O
multiple O
doses O

 O
of O
Ativan B-DRUG
in O
addition O
to O
Valium B-DRUG
q12 B-FRE
. I-FRE
  O
She O
also O
received O
thiamine B-DRUG

 I-DRUG
and O
folate B-DRUG
. I-DRUG
  O
CIWA O
was O
discontinued O
and O
she O
had O
no O
further O

 O
symptoms O
prior O
to O
discharge O
. O
She O
received O
Trazadone B-DRUG
for O
sleep B-REA
. I-REA


 O
MSK O
: O
  O
Ms. O
[ O
* O
* O
Known O
lastname O
104742 O
* O
* O
] O
had O
intermittent O
pain O
, O
especially O
in O
left O

 O
shoulder O
. O
  O
She O
had O
an O
XR O
which O
showed O
no O
evidence O
of O
cortical O

 O
disruptions O
suggestive O
of O
fracture O
or O
AC O
separation O
. O
  O
Pain B-REA
was O

 O
treated O
with O
tylenol B-DRUG
and O
oxycodone B-DRUG
. I-DRUG



 O
Medications O
on O
Admission O
: O

 O
-amlodipine B-DRUG
5 B-STR
mg I-STR
daily B-FRE

 I-FRE
-omeprazole B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
-atenolol B-DRUG
50 B-STR
mg I-STR
daily B-FRE

 I-FRE
-levothyroxine B-DRUG
50mcg B-STR
daily B-FRE

 I-FRE
-vit B-DRUG
B-12 I-DRUG
1000mcg B-STR
daily B-FRE

 I-FRE
-vit B-DRUG
B1 I-DRUG
100 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
-folic B-DRUG
acid I-DRUG
1 B-STR
mg I-STR
daily B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
enoxaparin B-DRUG
40 B-STR
mg/0.4 I-STR
mL I-STR
Syringe B-FOR
Sig O
: O
Forty B-DOS
( I-DOS
40 I-DOS
) I-DOS
MG I-DOS

 I-DOS
Subcutaneous B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
senna B-DRUG
8.8 B-STR
mg/5 I-STR
mL I-STR
Syrup B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
3 O
. O
docusate B-DRUG
sodium I-DRUG
50 B-STR
mg/5 I-STR
mL I-STR
Liquid B-FOR
Sig O
: O
Ten B-DOS
( I-DOS
10 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
bisacodyl B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O

 O
constipation B-REA
. I-REA

 O
5 O
. O
aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE

 I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
7 O
. O
trazodone B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE

 I-FRE
as I-FRE
needed I-FRE
for O
insomnia B-REA
. I-REA

 O
8 O
. O
thiamine B-DRUG
HCl I-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
folic B-DRUG
acid I-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
10 O
. O
multivitamin B-DRUG
     O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
famotidine B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
metoprolol B-DRUG
tartrate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE

 I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
85 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
86 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
diagnosis O
: O

 O
-Stroke O
( O
Right O
PCA+MCA-territory O
infarction O
) O


 O
Secondary O
diagnoses O
: O

 O
- O
EtOHism O
/ O
withdrawal O

 O
- O
chronic O
LBP O

 O
- O
chronic O
mild O
anemia O
, O
possible O
MDS O

 O
- O
methemoglobinemia B-ADE
secondary O
to O
benzocaine B-DRUG
spray B-FOR
. I-FOR



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Confused O
- O
sometimes O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Out O
of O
Bed O
with O
assistance O
to O
chair O
or O

 O
wheelchair O
. O



 O

Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
after O
you O
had O
a O
large O
stroke B-REA
. I-REA
  O
You O

 O
initially O
received O
TPA B-DRUG
in O
attempt O
to O
break B-REA
up I-REA
the I-REA
clot I-REA
in I-REA
your I-REA

 I-REA
brain I-REA
, I-REA
however O
this O
did O
not O
improve O
your O
symptoms O
and O
you O

 O
developed O
bruising B-ADE
. I-ADE
  O
You O
then O
had O
a O
MERCI O
retrieval O
which O
was O

 O
able O
to O
open O
up O
part O
of O
your O
blood O
vessels O
. O
  O
You O
were O
started O
on O

 O
medication O
, O
Lovenox B-DRUG
, I-DRUG
and O
Aspirin B-DRUG
, I-DRUG
to O
prevent B-REA
further I-REA
clots I-REA
and I-REA

 I-REA
strokes I-REA
. I-REA
You O
were O
also O
started O
on O
a O
blood B-DRUG
pressure I-DRUG
medication I-DRUG
. I-DRUG

 O
You O
had O
multiple O
tests O
including O
head O
CT O
scans O
, O
attempted O
brain O

 O
MRI O
, O
echocardiograms O
, O
and O
ultrasounds O
of O
your O
legs O
to O
determine O

 O
the O
cause O
of O
your O
stroke O
. O
  O
Additionally O
, O
multiple O
laboratory O

 O
tests O
were O
sent O
which O
are O
still O
pending O
. O


 O
While O
you O
were O
in O
the O
hospital O
you O
were O
treated O
for O
alcohol O

 O
withdrawal O
. O
  O
You O
also O
developed O
a O
reaction O
to O
benzocaine B-DRUG
spray B-FOR
, I-FOR

 O
called O
methemoglobinemia B-ADE
, I-ADE
in O
which O
you O
developed O
breathing O

 O
problems O
requiring O
treatment O
in O
the O
ICU O
. O


 O
Followup O
Instructions O
: O

 O
Provider O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
640 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
3445 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
2574 O
* O
* O
] O

 O
Date/Time:[**2135 O
- O
3 O
- O
14 O
* O
* O
] O
1:30 O


 O
The O
following O
tests O
are O
pending O
at O
the O
time O
of O
discharge O
: O

 O
antithrombin O
3 O
, O
factor O
v O
leiden O
, O
prothrombin O
gene O
mutation O
. O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2164 O
- O
10 O
- O
15 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2164 O
- O
11 O
- O
4 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2103 O
- O
10 O
- O
13 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Sulfa B-DRUG
( I-DRUG
Sulfonamide I-DRUG
Antibiotics I-DRUG
) I-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
2745 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
transfer O
for O
management O
of O
pancreatitis O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Central O
line O

 O
Arterial O
line O


 O
History O
of O
Present O
Illness O
: O

 O
HPI O
: O
This O
is O
a O
61 O
year-old O
female O
with O
a O
history O
of O
EtOH O
abuse O
, O

 O
cholelithiasis O
s/p O
cholecystectomy O
, O
who O
presents O
from O
an O
OSH O

 O
with O
likely O
acute O
pancreatitis O
. O

 O
. O

 O
Pt O
was O
initially O
admitted O
to O
the O
OSH O
[ O
* O
* O
Date O
range O
( O
1 O
) O
29693 O
* O
* O
] O
for O
two O

 O
episodes O
of O
epigastric O
pain O
and O
abnormal O
LFTs O
( O
AST O
466 O
ALT O
268 O
) O
. O

 O
US O
and O
MRCP O
were O
reportedly O
normal O
. O
She O
was O
discharged O
with O

 O
diagnosis O
of O
alcoholic O
hepatitis O
. O
That O
evening O
, O
pt O
called O
her O
GI O

 O
doctor O
complaining O
of O
severe O
abdominal O
pain O
, O
n/v O
, O
tremulousness O
. O

 O
She O
presented O
to O
the O
ED O
and O
was O
re-admitted O
. O
She O
was O
noted O
to O
be O

 O
jaundiced O
, O
groggy O
, O
with O
a O
protuberant O
abdomen O
. O
WBC O
was O
13.8 O
, O
K O

 O
2.8 O
, O
Bili O
7.7 O
, O
AST O
324 O
, O
ALT O
370 O
, O
alk O
phos O
251 O
, O
lipast O
4877 O
. O
Tox O

 O
screen O
and O
EtOH O
levels O
were O
negative O
. O
Her O
abdomen O
became O

 O
distended O
, O
tense O
, O
very O
tender O
, O
with O
no O
bowel O
sounds O
. O
She O
was O

 O
transferred O
to O
the O
ICU O
for O
closer O
monitoring O
. O
She O
was O
treated O

 O
with O
IVF B-DRUG
and O
aggressive B-REA
pain I-REA
control I-REA
with O
dilaudid B-DRUG
1 B-STR
mg I-STR
IV B-ROU
q3 B-FRE
. I-FRE

 O
Additionally O
she O
was O
sedated B-ADE
on O
precedex B-DRUG
and O
an O
ativan B-DRUG
drip B-ROU
at O

 O
4mg/h B-STR
. I-STR
Pt O
was O
intubated O
for O
airway O
protection O
on O
the O
morning O
of O

 O
[ O
* O
* O
10 O
- O
14 O
* O
* O
] O
. O
CT O
of O
the O
abdomen O
revealed O
enlarged O
indistinct O
pancreas O
, O

 O
extensive O
peripancreatic O
fluid O
consistent O
with O
severe O

 O
pancreatitis O
and O
pancreatic O
necrosis O
, O
no O
loculated O
or O
drainable O

 O
fluid O
collections O
or O
evidence O
of O
perforation O
. O
Also O
noted O
were O

 O
small O
bilateral O
pleural O
effusions O
and O
moderate O
amount O
of O
free O

 O
fluid O
in O
the O
deep O
pelvis O
. O

 O
. O



 O
Past O
Medical O
History O
: O

 O
EtOH O
abuse O

 O
HTN O

 O
h/o O
cholelithiasis O
s/p O
cholecystectomy O

 O
OA O
of O
hips O
s/p O
bilateral O
THR O

 O
Depression O

 O
h/o O
heart O
murmur O



 O
Social O
History O
: O

 O
Divorced O
, O
no O
children O
, O
lives O
alone O
. O
Works O
as O
a O
ballet O
teacher O
. O

 O
Former O
smoker O
, O
quit O
20 O
years O
ago O
. O
Drinks O
1 O
bottle O
of O
wine O
per O

 O
day O
. O


 O
Family O
History O
: O

 O
Family O
Medical O
History O
: O
  O
Mother O
died O
of O
lung O
CA O
at O
age O
76 O
. O

 O
Father O
died O
of O
MI O
at O
43 O
. O
Brother O
with O
hypertension O
. O
Multiple O

 O
family O
members O
with O
alcoholism O
. O



 O
Physical O
Exam O
: O

 O
Vitals O
: O
T O
: O
97.9 O
, O
BP O
: O
103/52 O
HR O
: O
77 O
RR O
: O
19 O
O2Sat O
: O
100 O
% O

 O
Vent O
settings O
: O
PS O
10/5 O
, O
RR O
19 O
, O
FiO2 O
40 O
% O
, O
Vt O
400s O

 O
GEN O
: O
intubated O
, O
sedated O

 O
HEENT O
: O
icteric O
sclera O
, O
pupils O
pinpoint O
and O
sluggishly O

 O
responsive O
, O
NGT O
( O
with O
bilious O
drainage O
) O
and O
dobhoff O

 O
NECK O
: O
No O
JVD O
, O
no O
bruits O
, O
no O
cervical O
lymphadenopathy O
, O
trachea O

 O
midline O
, O
L O
infraclavicular O
line O

 O
COR O
: O
RRR O
, O
2 O
- O
3/6 O
SEM O
at O
LLSB O

 O
PULM O
: O
Lungs O
CTAB O
anteriorly O

 O
ABD O
: O
tense O
, O
distended O
, O
very O
decreased O
bowel O
sounds O

 O
EXT O
: O
cool O
hands O
and O
feet O
, O
no O
C/C/E O

 O
NEURO O
: O
sedated O
, O
non-responsive O
to O
painful O
stimuli O

 O
SKIN O
: O
jaundiced O


 O
Pertinent O
Results O
: O

 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
Radiology/Neurology O

 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
MRCP O
[ O
* O
* O
10 O
- O
16 O
* O
* O
] O

 O
1 O
. O
Necrotozing O
, O
hemorrhagic O
pancreatitis O
involving O
majority O
of O

 O
the O
body O
and O

 O
tail O
and O
portions O
of O
the O
head O
and O
neck O
. O
Small O
portion O
of O

 O
enhancing O
pancreatic O

 O
tissue O
remains O
in O
the O
distal O
tail O
and O
portions O
of O
the O
head O
. O

 O
There O
is O
no O

 O
pancreatic O
ductal O
dilatation O
, O
however O
, O
a O
portion O
in O
the O
region O

 O
of O
the O
genu O
is O

 O
attenuated O
but O
not O
disrupted O
at O
this O
time O
. O

 O
2 O
. O
Large O
bilateral O
pleural O
effusions O
and O
small-to-moderate O

 O
ascites O
. O

 O
3 O
. O
The O
portal O
vein O
, O
SMV O
, O
and O
SMA O
are O
patent O
. O
Note O
is O
made O


 O
CT O
Head O
[ O
* O
* O
10 O
- O
16 O
* O
* O
] O

 O
There O
is O
no O
evidence O
of O
acute O
intracranial O
hemorrhages O
, O
edema O
, O

 O
masses O
, O
mass O

 O
effect O
, O
or O
large O
area O
of O
infarction O
. O
The O
lateral O
ventricles O
are O

 O
slightly O

 O
prominent O
for O
age O
and O
represent O
mild O
volume O
loss O
. O
The O
sulci O
are O

 O
normal O
in O

 O
caliber O
and O
configuration O
. O
There O
is O
no O
evidence O
of O
bony O

 O
fracture O
. O


 O
EEG O
[ O
* O
* O
10 O
- O
17 O
* O
* O
] O

 O
Markedly O
abnormal O
portable O
EEG O
due O
to O
the O
moderately O
severe O

 O
suppression O
of O
the O
background O
throughout O
. O
The O
background O
was O

 O
slow O
, O
and O

 O
it O
was O
intermittent O
, O
alternating O
with O
much O
lower O
voltage O

 O
patterns O
. O

 O
There O
was O
a O
brief O
episode O
of O
some O
" O
lightening O
, O
" O
but O
the O

 O
background O

 O
remained O
encephalopathic O
throughout O
. O
Medication O
effect O
is O

 O
probably O
the O

 O
most O
common O
cause O
of O
such O
recordings O
. O
There O
were O
no O
areas O
of O

 O
prominent O

 O
focal O
slowing O
, O
but O
encephalopathies O
may O
obscure O
focal O
findings O
. O

 O
There O

 O
were O
no O
epileptiform O
features O
. O



 O
MR O
[ O
* O
* O
Name13 O
( O
STitle O
) O
430 O
* O
* O
] O
[ O
* O
* O
10 O
- O
18 O
* O
* O
] O

 O
No O
intracranial O
abnormalities O
detected O
. O
Specifically O
, O
no O

 O
evidence O
of O
hemorrhage O
or O
infarction O
. O
Incidentally O
noted O
adipose O

 O
accumulation O

 O
over O
the O
right O
malar O
eminence O
and O
right O
maxillary O
sinus O

 O
air-fluid O
level O
. O


 O
CT O
A/p O
[ O
* O
* O
10 O
- O
19 O
* O
* O
] O

 O
IMPRESSION O
: O

 O
1 O
. O
Severe O
pancreatitis O
with O
extensive O
pancreatic O
necrosis O

 O
sparing O
portions O
of O

 O
the O
head O
and O
tail O
. O

 O
2 O
. O
Bilateral O
pleural O
effusions O
, O
slightly O
increased O
. O

 O
3 O
. O
Marked O
narrowing O
of O
the O
splenic O
vein O
and O
possible O
non- O

 O
occlusive O
thrombus O

 O
within O
its O
mid O
portion O
. O

 O
4 O
. O
Peripancreatic O
phlegmon O
and O
free O
fluid O
in O
pelvis O
. O



 O
TTE O
[ O
* O
* O
10 O
- O
19 O
* O
* O
] O

 O
The O
left O
atrium O
is O
normal O
in O
size O
. O
The O
right O
atrial O
pressure O
is O

 O
indeterminate O
. O
Left O
ventricular O
wall O
thicknesses O
and O
cavity O
size O

 O
are O
normal O
. O
Due O
to O
suboptimal O
technical O
quality O
, O
a O
focal O
wall O

 O
motion O
abnormality O
can O
not O
be O
fully O
excluded O
. O
Left O
ventricular O

 O
systolic O
function O
is O
hyperdynamic O
( O
EF>75 O
% O
) O
. O
The O
estimated O

 O
cardiac O
index O
is O
high O
( O
> O
4.0L/min/m2 O
) O
. O
There O
is O
a O
mild O
resting O

 O
left O
ventricular O
outflow O
tract O
obstruction O
. O
Right O
ventricular O

 O
chamber O
size O
and O
free O
wall O
motion O
are O
normal O
. O
The O
aortic O
valve O

 O
leaflets O
( O
3 O
) O
appear O
structurally O
normal O
with O
good O
leaflet O

 O
excursion O
. O
No O
masses O
or O
vegetations O
are O
seen O
on O
the O
aortic O

 O
valve O
, O
but O
can O
not O
be O
fully O
excluded O
due O
to O
suboptimal O
image O

 O
quality O
. O
There O
is O
no O
valvular O
aortic O
stenosis O
. O
The O
increased O

 O
transaortic O
velocity O
is O
likely O
related O
to O
increased O
stroke O

 O
volume O
due O
to O
high O
cardiac O
output O
. O
No O
aortic O
regurgitation O
is O

 O
seen O
. O
The O
mitral O
valve O
leaflets O
are O
structurally O
normal O
. O
There O

 O
is O
no O
mitral O
valve O
prolapse O
. O
No O
masses O
or O
vegetations O
are O
seen O

 O
on O
the O
mitral O
valve O
, O
but O
can O
not O
be O
fully O
excluded O
due O
to O

 O
suboptimal O
image O
quality O
. O
No O
masses O
or O
vegetations O
are O
seen O
on O

 O
the O
tricuspid O
valve O
, O
but O
can O
not O
be O
fully O
excluded O
due O
to O

 O
suboptimal O
image O
quality O
. O
There O
is O
moderate O
pulmonary O
artery O

 O
systolic O
hypertension O
. O
There O
is O
an O
anterior O
space O
which O
most O

 O
likely O
represents O
a O
fat O
pad O
. O

 O
IMPRESSION O
: O
Suboptimal O
image O
quality O
. O
No O
valvular O
vegetations O

 O
identified O
, O
but O
can O
not O
definitively O
exclude O
given O
poor O
acoustic O

 O
windows O
. O
Hyperdynamic O
left O
ventricular O
function O
with O
resting O

 O
tachycardia O
. O
Normal O
left O
ventricular O
systolic O
function O
. O

 O
Technically O
suboptimal O
to O
exclude O
focal O
wall O
motion O
abnormality O
. O

 O
Moderate O
pulmonary O
hypertension O



 O
CT O
Chest O
[ O
* O
* O
10 O
- O
23 O
* O
* O
] O

 O
1 O
. O
Multifocal O
patchy O
areas O
of O
consolidation O
may O
reflect O
an O

 O
infectious O

 O
process O
. O

 O
2 O
. O
Moderate O
pulmonary O
edema O
including O
moderate O
pleural O

 O
effusions O
, O
slightly O

 O
smaller O
compared O
to O
the O
recent O
abdominal O
CT O
. O

 O
3 O
. O
2.3-cm O
spiculated O
right O
right O
lobe O
nodule O
is O
worrisome O
for O

 O
malignancy O
. O
for O

 O
which O
short O
interval O
followup O
, O
after O
patient O
's O
acute O
symptoms O

 O
resolved O
, O
is O

 O
recommended O
. O

 O
4 O
. O
Anasarca O
. O

 O
5 O
. O
Hemorrhagic O
pancreatitis O
, O
incompletely O
assessed O
. O


 O
CT O
Chest O
[ O
* O
* O
10 O
- O
26 O
* O
* O
] O

 O
IMPRESSION O
: O

 O
1 O
. O
No O
pulmonary O
embolism O
. O

 O
2 O
. O
Interval O
worsening O
of O
multifocal O
areas O
of O
consolidation O
, O

 O
probably O

 O
reflecting O
an O
ongoing O
infectious O
process O
. O

 O
3 O
. O
Moderate O
pulmonary O
edema O
with O
slightly O
increased O
moderate O

 O
pleural O

 O
effusions O
bilaterally O
. O

 O
4 O
. O
8-mm O
right O
lower O
lobe O
opacity O
, O
smaller O
compared O
to O
the O

 O
previously O
seen O
2.3 O

 O
cm O
spiculated O
right O
lower O
lobe O
nodule O
and O
probably O
represents O

 O
atelectasis O

 O
versus O
consolidation O
. O
A O
chest O
CT O
following O
resolution O
of O

 O
patient O
's O
acute O

 O
symptoms O
is O
again O
advised O
. O

 O
5 O
. O
Anasarca O
. O


 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
Labs O

 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O


 O
[ O
* O
* O
2164 O
- O
10 O
- O
15 O
* O
* O
] O
05:29PM O
   O
LACTATE-1.3 O

 O
[ O
* O
* O
2164 O
- O
10 O
- O
15 O
* O
* O
] O
05:24PM O
   O
ALT(SGPT)-174 O
* O
AST(SGOT)-80 O
* O
LD(LDH)-764 O
* O
ALK O

 O
PHOS-107 O
AMYLASE-614 O
* O
TOT O
BILI-2.8 O
* O

 O
[ O
* O
* O
2164 O
- O
10 O
- O
15 O
* O
* O
] O
05:24PM O
   O
LIPASE-676 O
* O

 O
[ O
* O
* O
2164 O
- O
10 O
- O
15 O
* O
* O
] O
05:24PM O
   O
ALBUMIN-2.3 O
* O
CALCIUM-7.8 O
* O
PHOSPHATE-2.4 O
* O

 O
MAGNESIUM-2.2 O

 O
[ O
* O
* O
2164 O
- O
10 O
- O
15 O
* O
* O
] O
05:24PM O
   O
NEUTS-59 O
BANDS-20 O
* O
LYMPHS-11 O
* O
MONOS-7 O
EOS-0 O

 O
BASOS-0 O
ATYPS-0 O
METAS-2 O
* O
MYELOS-1 O
* O
NUC O
RBCS-1 O
* O

 O
[ O
* O
* O
2164 O
- O
10 O
- O
15 O
* O
* O
] O
05:24PM O
   O
PT-13.3 O
PTT-29.7 O
INR(PT)-1.1 O



 O
Brief O
Hospital O
Course O
: O

 O
# O
Acute O
severe O
hemorrhagic O
pancreatitis O
: O
Lipase O
was O
elevated O
to O

 O
4788 O
at O
the O
OSH O
. O
OSH O
CT O
showed O
pancreatitis O
and O
concern O
for O

 O
pancreatic O
necrosis O
. O
EtOH O
pancreatitis O
is O
the O
most O
likely O

 O
etiology O
. O
She O
underwent O
MRCP O
at O
our O
hospital O
which O
demonstrated O

 O
hemorrhagic O
, O
necrotic O
pancreatitis O
. O
Patient O
was O
managed O

 O
conservatively O
with O
aggressive O
fluid O
replacement O
. O
A O
surgery O

 O
consult O
was O
obtained O
and O
did O
not O
advise O
any O
operative O
or O
IR O

 O
procedures O
for O
the O
peripancreatic O
inflammation O
. O
She O
subsequently O

 O
developed O
acute O
lung O
injury O
, O
bilat O
pleural O
effusions O
, O

 O
anasarca O
, O
and O
ascites O
as O
a O
result O
of O
the O
severe O
pancreatitis O
. O
Her O

 O
course O
was O
complicated O
by O
vent O
associated O
pneumonia O
as O
well O
. O
She O

 O
also O
showed O
altered O
mental O
status O
during O
her O
ICU O
stay O
related O
to O

 O
toxic O
and O
metabolic O
encephalopathy O
. O
Patient O
required O
insulin B-DRUG

 I-DRUG
replacement O
therapy O
while O
she O
was O
in O
the O
unit O
and O
on O
the O
floor O
. O

 O
She O
was O
then O
transferred O
from O
the O
ICU O
to O
the O
floor O
. O
There O
, O
she O

 O
had O
PT/OT O
, O
blood B-DRUG
transfusion B-ROU
for O
anemia B-REA
from O
hemorrhagic O

 O
pancreatitis O
, O
and O
diuresis O
. O
Before O
transfer O
to O
rehab O
she O
was O

 O
noted O
to O
have O
significant O
and O
had O
CXR O
. O
This O
showed O
possible O

 O
loculated O
left O
upper O
lobe O
effusion O
. O
She O
underwent O
repeat O
CT O
of O

 O
the O
chest O
on O
[ O
* O
* O
2164 O
- O
11 O
- O
2 O
* O
* O
] O
which O
showed O
moderate O
bilateral O
pleural O

 O
effusions O
and O
anterior O
loculated O
left O
pleural O
effusion O
. O
  O
Case O

 O
was O
discussed O
with O
interventional O
pulmonary O
service O
and O
given O

 O
the O
patient O
's O
improving O
clinical O
status O
and O
lack O
of O
active O

 O
evidence O
of O
infection O
, O
they O
recommended O
not O
performing O
a O

 O
paracentesis O
to O
evaluate O
the O
loculated O
effusion O
. O
  O
The O
patient O

 O
was O
educated O
to O
return O
if O
she O
develops O
fevers O
, O
rigors O
, O
sweats O
, O

 O
worsening O
difficulty O
breathing O
. O

 O
. O

 O
# O
Altered O
mental O
status O
: O
Her O
mental O
status O
was O
altered O
and O

 O
related O
to O
toxic O
and O
metabolic O
encephalopathy O
. O
Head O
imaging O
was O

 O
negative O
( O
CT O
and O
MRI)including O
EEG O
. O
She O
is O
back O
to O
normal O
mental O

 O
functioning O
after O
her O
prolonged O
and O
complicated O
course O
. O

 O
. O


 O
# O
VAP O
: O
Sputum O
grew O
MSSA O
( O
imipenem O
sensitive O
) O
. O
She O
was O
initially O

 O
on O
Vancomycin B-DRUG
and O
imipenem B-DRUG
. I-DRUG
Vancomycin B-DRUG
d/ced O
( O
[ O
* O
* O
Date O
range O
( O
1 O
) O
82010 O
* O
* O
] O
) O
. O
She O

 O
was O
transition O
ed O
from O
Imipenem B-DRUG
( O
[ O
* O
* O
10 O
- O
16 O
* O
* O
] O
? O
? O
? O
? O
? O
? O
[ O
* O
* O
10 O
- O
22 O
* O
* O
] O
) O
to O
Nafcillin B-DRUG
on O

 O
[ O
* O
* O
10 O
- O
22 O
* O
* O
] O
, O
but O
Imipenem B-DRUG
was O
restarted O
again O
given O
decompensating O

 O
respiratory O
status O
. O
CT O
chest O
on O
[ O
* O
* O
10 O
- O
26 O
* O
* O
] O
was O
concerning O
for O

 O
worsening B-REA
multifocal I-REA
pneumonia I-REA
, I-REA
so O
her O
antibiotics B-DRUG
were O
changed O

 O
from O
Imipenem B-DRUG
to O
Vanco/Zosyn B-DRUG
. I-DRUG
Microbiology O
data O
has O
been O

 O
negative O
since O
[ O
* O
* O
10 O
- O
17 O
* O
* O
] O
. O
14 B-DUR
day I-DUR
course O
of O
antibiotics B-DRUG
were O
completed O

 O
on O
[ O
* O
* O
10 O
- O
30 O
* O
* O
] O
. O
Cough O
improved O
with O
expectorant O
and O
mucous O
clearing O

 O
device O
. O
Before O
transfer O
to O
rehab O
she O
was O
noted O
to O
have O

 O
significant O
and O
had O
CXR O
. O
This O
showed O
possible O
loculated O
left O

 O
upper O
lobe O
effusion O
. O
She O
underwent O
repeat O
CT O
of O
the O
chest O
on O

 O
[ O
* O
* O
2164 O
- O
11 O
- O
2 O
* O
* O
] O
which O
showed O
left O
anterior O
loculated O
effusion O
. O

 O
. O

 O
# O
Pulmonary B-REA
edema/Acute I-REA
lung I-REA
injury I-REA
: I-REA
  O
Extubated O
[ O
* O
* O
10 O
- O
21 O
* O
* O
] O
but O

 O
emergently O
re-intubated O
[ O
* O
* O
10 O
- O
23 O
* O
* O
] O
during O
event O
with O
SVT O
and O

 O
hypotension O
. O
Patient O
was O
extubated O
again O
[ O
* O
* O
10 O
- O
25 O
* O
* O
] O
. O
CT O
chest O
showed O

 O
interstitial O
changes O
and O
pleural O
effusions O
. O
Bronchoscopy O
on O
[ O
* O
* O
10 O
- O
17 O
* O
* O
] O

 O
was O
WNL O
, O
and O
samples O
significant O
only O
for O
2 O
+ O
polys O
and O
staph O

 O
aureus O
. O
She O
continued O
to O
receive O
to O
Lasix B-DRUG
with O
effective B-REA

 I-REA
diuresis I-REA
. I-REA

 O
. O

 O
# O
SVT B-REA
: I-REA
Patient O
has O
prior O
h/o O
of O
Afib O
. O
Reportedly O
never O

 O
anticoagulated O
. O
Episodes O
of O
SVT O
appear O
to O
be O
precipitated O
by O

 O
diuresis O
. O
She O
was O
emergently O
re O
intubated O
on O
[ O
* O
* O
10 O
- O
23 O
* O
* O
] O
during O
episode O

 O
of O
SVT B-REA
with O
hypotension O
that O
did O
not O
respond O
to O
electrical O

 O
cardioversion O
. O
Patient O
was O
loaded O
on O
amiodarone B-DRUG
and O
remained O
in O

 O
NSR O
thereafter O
. O
CTA O
was O
negative O
for O
PE O
. O
She O
was O
then O
placed O
on O

 O
maintenance O
dose O
of O
200 B-DOS
mg I-DOS
/day I-DOS
. I-DOS
Patient O
was O
also O
continued O
on O

 O
home O
dose O
of O
metoprolol B-DRUG
. I-DRUG

 O
. O

 O
# O
Horase O
voice O
: O
patient O
had O
traumatic O
intubation O
and O
continues O

 O
to O
have O
a O
hoarse O
voice O
. O
ENT O
reports O
vocal O
cords O
functional O
and O

 O
will O
continue O
to O
take O
time O
to O
recover O
. O

 O
Plan O
for O
pt O
to O
f/u O
with O
ENT O
in O
2 O
wks O
after O
discharge O
. O

 O
. O


 O
# O
RLL O
nodule O
? O
? O
? O
? O
? O
? O
RLL O
nodule O
appreciated O
on O
Chest O
CT O
. O
This O
will O

 O
require O
outpatient O
follow O
up O
in O
10 O
- O
30 O
days O
after O
discharge O
. O

 O
PCP O
was O
notified O
on O
[ O
* O
* O
2164 O
- O
11 O
- O
2 O
* O
* O
] O
. O

 O
. O

 O
# O
Nasal O
skin O
necrosis O
possibly O
related O
to O
her O
ICU O
stay O
. O
She O
was O

 O
seen O
by O
plastic O
surgery O
on O
[ O
* O
* O
2164 O
- O
11 O
- O
2 O
* O
* O
] O
. O
The O
necrosis O
is O
not O

 O
infected O
. O
They O
recommended O
local O
care O
and O
out O
patient O
follow O
up O

 O
at O
their O
resident O
clinic O
. O

 O
. O

 O
. O

 O
. O






 O
Medications O
on O
Admission O
: O

 O
Toprol B-DRUG
xl I-DRUG
50 B-STR
qd B-FRE

 I-FRE
Celexa B-DRUG
80 B-STR
qd B-FRE

 I-FRE
Lisinopril B-DRUG
40 B-STR
mg I-STR
pO B-ROU
qd B-FRE

 I-FRE
HCTZ B-DRUG
25 B-STR

 I-STR
Oxycodone B-DRUG
5 B-STR
q6 B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Polyvinyl B-DRUG
Alcohol-Povidone I-DRUG
1.4 B-STR
- I-STR
0.6 I-STR
% I-STR
Dropperette B-FOR
Sig O
: O
[ O
* O
* O
11 O
- O
16 O
* O
* O
] O

 O
Drops B-FOR
Ophthalmic B-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
3 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE

 I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
fever B-REA
. I-REA

 O
4 O
. O
Loperamide B-DRUG
2 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
5 O
. O
Trazodone B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
as I-FRE

 I-FRE
needed I-FRE
. I-FRE

 O
6 O
. O
Guaifenesin B-DRUG
100 B-STR
mg/5 I-STR
mL I-STR
Syrup B-FOR
Sig O
: O
5 B-DOS
- I-DOS
10 I-DOS
MLs I-DOS
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
7 O
. O
White B-DRUG
Petrolatum-Mineral I-DRUG
Oil I-DRUG
42.5 B-STR
- I-STR
56.8 I-STR
% I-STR
Ointment B-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-ROU
Ophthalmic I-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Lorazepam B-DRUG
0.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q8H B-FRE
( I-FRE
every I-FRE
8 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
anxiety B-REA
. I-REA

 O
9 O
. O
Lorazepam B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE

 I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
10 O
. O
Lisinopril B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Metoprolol B-DRUG
Succinate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sustained I-FOR
Release I-FOR
24 I-FOR
hr I-FOR

 I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
Sustained I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( I-STR
0.083 I-STR
% I-STR
) I-STR
Solution B-FOR
for I-FOR

 I-FOR
Nebulization I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Inhalation B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
14 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
0.02 B-STR
% I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Inhalation B-ROU

 I-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
15 O
. O
Amiodarone B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
16 O
. O
Amlodipine B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
17 O
. O
Lasix B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
for B-DUR
5 I-DUR

 I-DUR
days I-DUR
. I-DUR



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Location O
( O
un O
) O
582 O
* O
* O
] O
Of O
[ O
* O
* O
Location O
( O
un O
) O
620 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
severe O
necrotizing O
haemorrhagic O
pancreatitis O

 O
acute O
respiratoy O
failure O

 O
acute O
lung O
injury O

 O
VAP O



 O
Discharge O
Condition O
: O

 O
stable O
. O



 O
Discharge O
Instructions O
: O

 O
You O
had O
severe O
necrotizing O
haemorrhagic O
pancreatitis O
resulted O
in O

 O
respiratoy O
failure O
, O
intubation O
, O
acute O
lung O
injury O
, O
lung O

 O
infection O
and O
anemia O
. O
we O
found O
a O
small O
lung O
lesion O
that O
needs O
to O

 O
be O
followed O
up O
with O
repeat O
CT O
of O
the O
chest O
once O
you O
recover O
. O


 O
Followup O
Instructions O
: O

 O
PCP O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
, O
[ O
* O
* O
Name11 O
( O
NameIs O
) O
* O
* O
] O
[ O
* O
* O
Name O
Initial O
( O
NameIs O
) O
* O
* O
] O
. O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2115 O
* O
* O
] O
. O
Please O
call O
the O
office O
at O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
82011 O
* O
* O
] O
to O
schedule O
appointment O
in O
a O
1 O
or O
2 O
. O



 O

Admission O
Date O
: O
  O
[ O
* O
* O
2122 O
- O
1 O
- O
14 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2122 O
- O
2 O
- O
6 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2057 O
- O
2 O
- O
17 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Penicillins B-DRUG
/ O
Fentanyl B-DRUG
/ O
Oxycodone B-DRUG
/ O
Meperidine B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
11040 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
ARDS O
seconrday O
to O
septic O
shock O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Tracheostomy O
and O
G-tube O
placement O
. O



 O
History O
of O
Present O
Illness O
: O

 O
Ms. O
[ O
* O
* O
Known O
lastname O
69940 O
* O
* O
] O
is O
a O
64 O
year O
old O
woman O
with O
HTN O
, O
RA O
, O
Type O
2 O
DM O

 O
admitted O
to O
OSH O
on O
[ O
* O
* O
1 O
- O
10 O
* O
* O
] O
with O
confusion O
, O
chills O
, O
fevers O
to O
103 O

 O
and O
a O
week O
of O
green O
sputum O
found O
to O
have O
PNA O
on O
CXR O
, O

 O
hypotension O
, O
and O
hypoxic O
respiratory O
failure O
. O
She O
was O
intubated O

 O
in O
ED O
, O
started O
on O
dopamine B-DRUG
, I-DRUG
and O
transfered O
to O
the O
ICU O
. O
She O
ruled O

 O
in O
for O
NSTEMI O
. O
She O
was O
switched O
to O
Norepinephrine B-DRUG
( O
per O
cards O
) O

 O
and O
hydrocort B-DRUG
. I-DRUG
She O
also O
received O
Xigris B-DRUG
. I-DRUG
Within O
24 O
hours O
her O
HCT O

 O
dropped O
from O
35 O
% O
to O
28 O
% O
and O
Xigris B-DRUG
was O
stopped O
. O
Pt O
was O
initially O

 O
on O
Ceftriaxone B-DRUG
and O
Azithro B-DRUG
which O
was O
changed O
to O
Levoquin B-DRUG
Vanco B-DRUG

 I-DRUG
and O
Clinda B-DRUG
which O
was O
stopped O
on O
[ O
* O
* O
1 O
- O
14 O
* O
* O
] O
. O
Due O
to O
possible O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
exposure O
, O
Doxycycline B-DRUG
was O
also O
started O
. O
She O
went O
into O
A O
flutter O

 O
with O
RVR O
and O
was O
cardioverted O
once O
unsuccessfully O
at O
the O
OSH O
. O

 O
She O
was O
started O
on O
Diltiezem B-DRUG
drip B-ROU
for O
rate B-REA
control I-REA
. I-REA
For O
? O
PCP O

 O
PNA B-REA
, I-REA
she O
was O
started O
on O
high O
dose O
Bactrim B-DRUG
as O
well O
. O
Throughout O

 O
her O
OSH O
course O
she O
developed O
an O
increasing O
O2 O
requirment O
, O
and O

 O
there O
was O
concern O
for O
ARDS O
with O
increasing O
difficulty O
in O

 O
ventilation O
. O
Her O
last O
ABG O
on O
transfer O
was O
7.30/45/51 O
sating O
88 O
% O

 O
on O
100%FiO2 O
; O
IMVO O
14 O
; O
PEEP O
8 O
; O
Tv O
700 O
. O
She O
was O
transfered O
here O

 O
for O
further O
management O
. O

 O
. O

 O
PCP O
: O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O



 O
Past O
Medical O
History O
: O

 O
RA- O
Stopped O
Methotrexate B-DRUG
5 O
months O
ago O
for O
a O
" O
reverse O
effect O
" O

 O
according O
to O
notes O
. O
Maintained O
on O
20 B-STR
mg I-STR
Prednisone B-DRUG
daily B-FRE

 I-FRE
HTN O

 O
NIDDM O

 O
GERD O



 O
Social O
History O
: O

 O
Lives O
with O
husband O
, O
quit O
smoking O
23 O
years O
ago O
, O
occasional O
wine O
, O

 O
no O
drug O
use O
. O


 O
Family O
History O
: O

 O
Non-contributory O



 O
Physical O
Exam O
: O

 O
PE O
: O
Admitted O
intubated O
, O
on O
rotating O
bed O

 O
T:36.9 O
HR:104 O
BP:133/51 O
( O
off O
pressors O
) O
RR:19 O
90 O
% O
O2 O
Sats O

 O
Wt:98.6 O
kg O

 O
AC O
Tv:400 O
FiO2:100 O
% O
Peep:15 O
PP:24 O

 O
Gen O
: O
intubated O
, O
sedated O

 O
HEENT O
: O
ET O
tube O
in O
place O

 O
NECK O
: O
unable O
to O
asses O
JVP O
2/2 O
habitus O

 O
CV O
: O
Regular O
Rate O
and O
rhythym O
, O
occasional O
PVCs O
. O

 O
LUNGS O
: O
course O
BS O
anteriorly/laterally O

 O
ABD O
: O
Soft O
, O
NT O
, O
ND O
. O
NL O
BS O
. O

 O
EXT O
: O
No O
edema O
. O
2 O
+ O
DP O
pulses O
BL O

 O
SKIN O
: O
No O
lesions O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2122 O
- O
1 O
- O
14 O
* O
* O
] O
11:03PM O
   O
PT-12.9 O
PTT-27.2 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2122 O
- O
1 O
- O
14 O
* O
* O
] O
11:03PM O
   O
PLT O
COUNT-268 O

 O
[ O
* O
* O
2122 O
- O
1 O
- O
14 O
* O
* O
] O
11:03PM O
   O
WBC-15.9 O
* O
RBC-3.81 O
* O
HGB-11.4 O
* O
HCT-31.7 O
* O

 O
MCV-83 O
MCH-30.1 O
MCHC-36.1 O
* O
RDW-16.8 O
* O

 O
[ O
* O
* O
2122 O
- O
1 O
- O
14 O
* O
* O
] O
11:03PM O
   O
CALCIUM-5.9 O
* O
PHOSPHATE-1.9 O
* O
MAGNESIUM-2.1 O

 O
[ O
* O
* O
2122 O
- O
1 O
- O
14 O
* O
* O
] O
11:03PM O
   O
estGFR-Using O
this O

 O
[ O
* O
* O
2122 O
- O
1 O
- O
14 O
* O
* O
] O
11:03PM O
   O
GLUCOSE-275 O
* O
UREA O
N-30 O
* O
CREAT-0.9 O
SODIUM-138 O

 O
POTASSIUM-3.8 O
CHLORIDE-108 O
TOTAL O
CO2 O
- O
22 O
ANION O
GAP-12 O

 O
[ O
* O
* O
2122 O
- O
1 O
- O
14 O
* O
* O
] O
11:09PM O
   O
freeCa-0.72 O
* O

 O
[ O
* O
* O
2122 O
- O
1 O
- O
14 O
* O
* O
] O
11:09PM O
   O
LACTATE-2.3 O
* O

 O
[ O
* O
* O
2122 O
- O
1 O
- O
14 O
* O
* O
] O
11:09PM O
   O
TYPE-ART O
PO2 O
- O
69 O
* O
PCO2 O
- O
45 O
PH-7.38 O
TOTAL O
CO2 O
- O
28 O

 O
BASE O
XS-0 O

 O
. O

 O
OSH O
MICRO O
DATA O
: O

 O
Mycoplasma O
IgG O
- O
posative O

 O
Blood O
Cx O
[ O
* O
* O
1 O
- O
10 O
* O
* O
] O
- O
Gm O
posative O
cocci O
, O
speciation/sensis O
pending O

 O
Legionella O
- O
negative O

 O
Strep O
Pneumo O
antigen O
- O
negative O

 O
RSV O
- O
negative O

 O
Influenza O
A/B O
- O
negative O

 O
. O

 O
STUDIES O
: O
CXR O
- O
has O
large O
left O
pulmonary O
infiltrate O

 O
. O

 O
[ O
* O
* O
1 O
- O
21 O
* O
* O
] O
CT O
abd/pelvis O
: O

 O
1 O
. O
Uncomplicated O
pancreatitis O
with O
no O
evidence O
of O
abscess O
or O

 O
fluid O
collection O
. O

 O
2 O
. O
Pleural O
effusions O
, O
left O
greater O
than O
right O
, O
with O

 O
consolidation O
in O
the O
right O
lower O
lobe O
consistent O
with O
pneumonia O
. O

 O
3 O
. O
Old O
fractures O
of O
the O
pelvis O
. O



 O

Brief O
Hospital O
Course O
: O

 O
# O
Hypoxic O
Respiratory O
Failure O
- O
Secondary O
to O
mycoplasma B-REA
PNA I-REA
for O

 O
which O
she O
completed O
14 B-DUR
day I-DUR
course O
of O
levofloxacin B-DRUG
, I-DRUG
evolved O
to O

 O
ARDS O
from O
sepsis O
. O
Subsequently O
complicated O
by O
likely O
ventilator B-REA

 I-REA
associated I-REA
pneumonia I-REA
, I-REA
culture O
and O
bronchial O
lavage O
negative O
, O

 O
empirically O
treated O
with O
a O
course O
of O
Vancomycin B-DRUG
and O
Cefepime B-DRUG
. I-DRUG

 O
Also O
, O
complicated O
by O
severe O
polyneuropathy O
from O
likely O
critical O

 O
care O
neuropathy O
. O
NIF O
was O
measured O
and O
was O
in O
the O
30s O
range O
. O
Pt O

 O
was O
weaned O
to O
PS O
5/0 O
on O
the O
13th O
day O
of O
hospitalization O
and O

 O
extubation O
was O
attempted O
. O
However O
the O
patient O
became O

 O
increasingly O
tachypneic O
and O
agitated O
about O
12 O
hours O
after O

 O
extubation O
and O
was O
reintubated O
. O
Failure O
was O
thought O
to O
be O
due O
to O

 O
respiratory O
muscle O
fatigue O
, O
poor O
underlying O
lung O
function O
in O
the O

 O
context O
of O
pneumonia O
, O
possible O
component O
of O
volume O
overload O
. O
A O

 O
tracheostomy O
was O
placed O
the O
next O
day O
as O
well O
as O
a O
PEG O
tube O
. O
She O

 O
was O
successful O
with O
trach O
mask O
trials O
several O
days O
after O
trach O

 O
placement O
on O
high O
flow O
O2 O
. O
  O
She O
was O
successful O
for O
> O
12hours O

 O
daily O
, O
but O
on O
several O
occasions O
became O
tachypneic O
in O
the O

 O
evening O
, O
thought O
to O
be O
influenced O
largely O
by O
anxiety O
rather O
than O

 O
fatigue O
, O
requiring O
placement O
back O
on O
PS O
overnight O
. O
  O
She O
was O
, O

 O
however O
, O
trialed O
for O
24 O
hours O
on O
trach O
mask O
and O
was O
fatigued O
the O

 O
following O
day O
requiring O
full O
24 O
hours O
back O
on O
PS O
. O
  O
This O
was O

 O
likely O
[ O
* O
* O
3 O
- O
6 O
* O
* O
] O
to O
true O
respiratory O
muscle O
fatigue O
. O

 O
. O

 O
# O
PNA B-REA
: I-REA
From O
mycoplasma O
, O
treated O
with O
14 B-DUR
day I-DUR
course O
of O

 O
levofloxacin B-DRUG
. I-DRUG
Subsequently O
complicated O
by O
likely O
ventilator B-REA

 I-REA
associated I-REA
pneumonia I-REA
, I-REA
culture O
and O
bronchial O
lavage O
negative O
, O

 O
empirically O
treated O
with O
a O
course O
of O
Vancomycin B-DRUG
and O
Cefepime B-DRUG
. I-DRUG

 O
. O

 O
# O
Septic B-REA
shock I-REA
: I-REA
Lactate O
on O
admission O
2.3 O
, O
hypotension O
, O
elevated O

 O
WBC O
with O
2 O
bands O
, O
tachypnea O
and O
tachycardia O
. O
Initially O
with O

 O
pressor O
requirement O
. O
Initial O
broad B-DRUG
spectrum I-DRUG
Abx I-DRUG
were O

 O
discontinued O
once O
source O
of O
sepsis O
was O
found O
to O
be O
due O
to O

 O
mycoplasma O
and O
a O
course O
of O
14 B-DUR
days I-DUR
of O
Levofloxacin B-DRUG
was O

 O
completed O
. O
The O
patient O
also O
was O
treated O
with O
stress O
dose O

 O
steroids B-DRUG
initially O
, O
which O
were O
subsequently O
weaned O
to O
baseline O

 O
Prednisone B-DRUG
dose O
for O
chronic B-REA
RA I-REA
of O
20 B-STR
mg I-STR
. I-STR

 O
. O

 O
# O
Clostridium B-REA
difficile I-REA
infection I-REA
: I-REA
diagnosed O
on O
[ O
* O
* O
1 O
- O
22 O
* O
* O
] O
. O
Pt O
. O
will O

 O
complete O
a O
7 B-DUR
day I-DUR
( O
post O
other O
antibiotics O
) O
course O
of O
flagyl B-DRUG

 I-DRUG
( O
flagyl O
course O
to O
be O
completed O
on O
[ O
* O
* O
2122 O
- O
2 O
- O
6 O
* O
* O
] O
after O
receiving O
her O
tid O

 O
dosing O
that O
day O
) O
. O
Diarrhea O
is O
much O
improved O
. O

 O
. O


 O
# O
Pancreatitis B-ADE
: I-ADE
  O
Thought O
[ O
* O
* O
3 O
- O
6 O
* O
* O
] O
to O
propofol B-DRUG
originally O
with O

 O
elevated O
amylase O
and O
lipase O
. O
  O
Once O
her O
propofol B-DRUG
was O
d/c'd O
, O
her O

 O
amylase O
normalized O
. O
  O
Her O
lipase O
decreased O
, O
but O
remained O
elevated O

 O
in O
the O
150s O
. O
  O
Other O
LFTs O
were O
normal O
. O
  O
Her O
tube O
feeds O
were O
held O

 O
transiently O
when O
her O
lipase O
failed O
to O
completely O
resolve O
and O
she O

 O
had O
mild O
epigastric O
discomfort O
. O
  O
Given O
that O
her O
epigastric O

 O
discomfort O
was O
post O
G O
tube O
placement O
, O
it O
resolved O
and O
tube O
feeds O

 O
were O
reinitiated O
. O
  O
She O
did O
have O
high O
residuals O
so O
was O
not O

 O
originally O
at O
goal O
. O
  O
Reglan B-DRUG
was O
started O
and O
tube O
feeds O
were O

 O
advanced O
. O
  O
She O
is O
now O
tolerating O
tube O
feeds O
at O
goal O
without O

 O
reglan B-DRUG
. I-DRUG

 O
. O

 O
# O
Critical O
illness O
neuropathy O
: O
severe O
distal O
weakness O
, O
slight O

 O
improvement O
towards O
the O
end O
of O
her O
hospital O
stay O
. O
EMG O
and O
nerve O

 O
conduction O
studies O
showed O
mild O
, O
proximal O
myopathy O
with O
a O

 O
superimposed O
geneneralized O
polyneuropathy O
, O
predominantly O
axonal O
. O

 O
The O
picture O
is O
consistent O
with O
critical O
illness O
polyneuropathy O

 O
and O
myopathy O
. O
  O
Her O
strength O
has O
been O
consistently O
increasing O
, O

 O
but O
deficit O
remains O
. O
  O
She O
will O
need O
continued O
physical O
therapy O

 O
for O
this O
. O

 O
. O

 O
# O
Rash B-ADE
, I-ADE
eosinophilia B-ADE
: I-ADE
  O
During O
her O
course O
of O
cefepime B-DRUG
and O

 O
vancomycin B-DRUG
she O
developed O
a O
rash O
and O
eosinophilia O
. O
  O
Once O
her O
7 O

 O
day O
course O
of O
cefepime B-DRUG
and O
vanco B-DRUG
was O
complete O
, O
her O
rash O
resolved O

 O
although O
she O
remained O
mildly O
subjectively O
itchy B-REA
requiring O

 O
fexofenadine B-DRUG
. I-DRUG
  O
Her O
eosinophils O
remained O
elevated O
, O
but O
this O
also O

 O
started O
to O
resolve O
. O
  O
There O
was O
no O
other O
clear O
drug O
source O
and O

 O
suspiscion O
for O
infective O
cause O
was O
very O
low O
. O

 O
. O

 O
# O
Low O
grade O
fever O
: O
Intermittent O
low O
grade O
fever O
to O
Tmax O
of O

 O
100.2 O
. O
  O
She O
has O
BAL O
, O
Urine O
and O
blood O
cultures O
pending O
from O

 O
[ O
* O
* O
2122 O
- O
2 O
- O
5 O
* O
* O
] O
, O
but O
suspiscion O
for O
infection O
is O
low O
given O
normal O
WBC O

 O
count O
and O
no O
left O
shift O
on O
diff O
. O
  O
These O
cultures O
should O
be O

 O
followed O
up O
. O

 O
. O


 O
# O
Rheumatoid B-REA
arthritis I-REA
: I-REA
  O
Patient O
was O
transiently O
on O
stress O
dose O

 O
steroids B-DRUG
in O
the O
setting O
of O
sepsis O
. O
  O
Steroids B-DRUG
were O
reduced O
to O
her O

 O
home O
dose O
of O
20 B-STR
mg I-STR
PO B-ROU
prednisone B-DRUG
with O
the O
resolution O
of O
sepsis O
. O

 O
The O
need O
for O
PCP B-REA
prophylaxis I-REA
was O
discussed O
given O
chronically O
on O

 O
20 B-STR
mg I-STR
prednisone B-DRUG
daily B-FRE
. I-FRE
  O
The O
need O
for O
this O
dose O
in O
the O
setting O
of O

 O
her O
RA B-REA
and O
PCP B-REA
prophylaxis I-REA
was O
discussed O
with O
her O
rheumatologist O

 O
and O
her O
dose O
of O
prednisone B-DRUG
was O
decreased O
to O
15 B-STR
mg I-STR
po B-ROU
prednisone B-DRUG

 I-DRUG
as O
she O
is O
not O
currently O
complaining O
of O
joint O
symptoms O
. O
  O
She O
was O

 O
not O
started O
on O
bactrim B-DRUG
while O
inpatient O
and O
if O
her O
chronic O

 O
prednisone B-DRUG
dose O
requirement O
increases O
, O
this O
should O
be O

 O
readdressed O
. O
  O
Additionally O
, O
given O
her O
age O
, O
sex O
and O
chronic O

 O
prednisone B-DRUG
, I-DRUG
she O
was O
started O
on O
vitamin B-DRUG
D I-DRUG
and O
calcium B-DRUG
. I-DRUG

 O
. O

 O
# O
Anemia O
with O
hct O
drop O
: O
HCT O
has O
been O
stable O
24 O
- O
26 O
from O
original O

 O
drop O
from O
29 O
- O
31 O
. O
  O
Anemia O
w/u O
included O
abd O
CT O
not O
revealing O
for O

 O
bleed O
. O
  O
LDH O
is O
elevated O
, O
haptoglobin O
elevated O
as O
well O
, O
but O
this O

 O
is O
in O
the O
setting O
of O
inflammation O
and O
, O
thus O
may O
not O
reflect O

 O
accurately O
hemolysis O
. O
  O
Stools O
were O
guaiac O
negative O
. O
  O
Iron O

 O
revealed O
normal O
iron O
, O
elevated O
ferritin O
, O
and O
low O
TIBC O
c/w O
ACD O
. O

 O
. O

 O
# O
Depression B-REA
: I-REA
  O
Patient O
has O
a O
history O
of O
depression B-REA
and O
was O
on O

 O
elavil B-DRUG
previously O
. O
  O
She O
is O
not O
sure O
why O
this O
was O
discontinued O

 O
originally O
. O
  O
While O
hospitalized O
, O
she O
was O
experiencing O
low O
mood O

 O
and O
general O
anxiety O
. O
  O
Thus O
, O
celexa B-DRUG
was O
started O
at O
20 B-STR
mg I-STR
daily B-FRE
on O

 O
[ O
* O
* O
2122 O
- O
1 O
- O
31 O
* O
* O
] O
. O
  O
This O
can O
be O
titrated O
as O
appropriate O
upon O
discharge O
. O

 O
. O

 O
# O
Hypertension B-REA
: I-REA
after O
hypotension O
in O
the O
context O
of O
sepsis O
has O

 O
resolved O
, O
the O
patient O
hypertension B-REA
which O
was O
controlled O
with O

 O
Labetalol B-DRUG
and O
Captopril B-DRUG
. I-DRUG
  O
She O
did O
require O
occasional O
fluid B-DRUG
bolus B-DOS

 I-DOS
in O
setting O
of O
negative B-REA
fluid I-REA
status I-REA
and O
low B-REA
UOP I-REA
and O
transient B-REA

 I-REA
hypotension I-REA
, I-REA
to O
which O
her O
BP O
responded O
well O
. O

 O
. O

 O
# O
A-Flutter B-REA
: I-REA
transient O
episodes O
in O
the O
context O
of O
high O

 O
adrenergic O
state O
after O
acute O
sepsis O
resolved O
. O
Hemodynamically O

 O
stable O
and O
was O
in O
NSR O
for O
> O
1week O
prior O
to O
discharge O
, O
continued O

 O
on O
BB B-DRUG
. I-DRUG

 O
. O

 O
# O
Steroid B-REA
induced I-REA
hypergylcemia B-ADE
: I-ADE
transiently O
on O
glargine B-DRUG
, I-DRUG
then O

 O
changed O
to O
Regular B-DRUG
SS O
only O
as O
steroids B-DRUG
were O
weaned O
. O
  O
Her O
blood O

 O
sugars O
have O
been O
well O
controlled O
. O
  O
She O
has O
not O
been O
requiring O
SS O

 O
coverage O
, O
but O
this O
should O
be O
initiated O
if O
glucose O
control O

 O
worsens O
. O


 O
# O
FEN O
: O
PEG O
tube O
in O
place O
. O
Tube O
feeds O
restarted O
after O
PEG O
tube O

 O
placement O
on O
[ O
* O
* O
2122 O
- O
1 O
- O
29 O
* O
* O
] O
. O

 O
. O


 O
# O
PPx B-REA
: I-REA
Heparin B-DRUG
SQ B-ROU
, I-ROU
PPI B-DRUG

 I-DRUG
. O

 O
# O
CODE O
: O
Full O
Code O



 O
Medications O
on O
Admission O
: O

 O
MEDS O
on O
Transfer O
: O

 O
Doxycycline B-DRUG
100 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Lopressor B-DRUG
2.5 B-STR
mg I-STR
IV B-ROU
q4 B-FRE
' I-FRE
and O
5 B-STR
mg I-STR
IV B-ROU
q6 B-FRE
' I-FRE

 O
ASA B-DRUG
81 B-STR
mg I-STR
daily B-FRE

 I-FRE
Zithromax B-DRUG
500 B-STR
mg I-STR
IV B-ROU
Daily B-FRE
( O
started O
[**1 O
- O
14**]- O
one O
dose O
given O
) O

 O
Bactrim B-DRUG
400 B-STR
mg I-STR
IV B-ROU
q8 B-FRE
' I-FRE
( O
started O
[**1 O
- O
14**]- O
one O
dose O
given O
) O

 O
Solumedrol B-DRUG
60 B-STR
mg I-STR
IV B-ROU
q6 B-FRE
' I-FRE
( O
was O
125 B-STR
mg I-STR
IV B-ROU
q6hour B-FRE
until O
[ O
* O
* O
1 O
- O
13 O
* O
* O
] O
) O

 O
Fludrocortisone B-DRUG
0.1 B-STR
mg I-STR
NGT B-ROU
Daily B-FRE

 I-FRE
Reglan B-DRUG
5 B-STR
mg I-STR
IV B-ROU
q8 B-FRE
' I-FRE

 O
Vancomycin B-DRUG
1gm B-STR
IV B-ROU
q12 B-FRE
' I-FRE
( O
started O
[**1 O
- O
14**]- O
got O
one O
dose O
) O

 O
Digoxin B-DRUG
0.125 B-STR
mg I-STR
Daily B-FRE
NG B-ROU
since O
[ O
* O
* O
1 O
- O
12 O
* O
* O
] O

 O
Lovenox B-DRUG
40 B-STR
mg I-STR
SC B-ROU
Daily B-FRE

 I-FRE
Nexium B-DRUG
40 B-STR
mg I-STR
Daily B-FRE

 I-FRE
Lantus B-DRUG
20u B-STR
SC B-ROU
daily B-FRE

 I-FRE
Lopid B-DRUG
300 B-STR
mg I-STR
via O
NG B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
RISS B-DRUG

 I-DRUG
Ativan B-DRUG
PRN B-FRE

 I-FRE
Tylenol B-DRUG
ORN B-FRE

 I-FRE
Morphine B-DRUG
PRN B-FRE

 I-FRE
Levaquin B-DRUG
500 B-STR
mg I-STR
IV B-ROU
Daily B-FRE
( O
started O
[ O
* O
* O
1 O
- O
10 O
* O
* O
] O
) O



 O

Discharge O
Medications O
: O

 O
1 O
. O
Lansoprazole B-DRUG
30 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
, I-FOR
DR I-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
, I-FOR
DR I-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
DAILY B-FRE
( O
Daily O
) O
. O

 O
2 O
. O
Nystatin B-DRUG
100,000 B-STR
unit/mL I-STR
Suspension B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
QID B-FRE

 I-FRE
( O
4 O
times O
a O
day O
) O
as O
needed O
. O

 O
3 O
. O
Albuterol-Ipratropium B-DRUG
103 B-STR
- I-STR
18 I-STR
mcg/Actuation I-STR
Aerosol B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
Six B-DOS

 I-DOS
( I-DOS
6 I-DOS
) I-DOS
Puff B-FOR
Inhalation B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
when B-REA
on I-REA

 I-REA
vent I-REA
. I-REA

 O
4 O
. O
Albuterol B-DRUG
90 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
Six B-DOS
( I-DOS
6 I-DOS
) I-DOS
Puff B-FOR

 I-FOR
Inhalation B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
when B-REA
on I-REA
vent I-REA
. I-REA

 O
5 O
. O
Insulin B-DRUG
Regular I-DRUG
Human I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
See O
sliding B-DOS

 I-DOS
scale I-DOS
for O
appropriate O
dosing O
  O
Injection B-ROU
ASDIR B-FRE
( O
AS O
DIRECTED O
) O
. O

 O
6 O
. O
Heparin B-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
5,000 B-STR
unit/mL I-STR
Solution B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Injection B-ROU
TID B-FRE
( O
3 O
times O
a O
day O
) O
. O

 O
7 O
. O
Trazodone B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( O
at O
bedtime O
) O
as O

 O
needed O
. O

 O
8 O
. O
Captopril B-DRUG
12.5 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( O
3 O
times O

 O
a O
day O
) O
. O

 O
9 O
. O
Labetalol B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( O
3 O
times O
a O

 O
day O
) O
. O

 O
10 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q4 B-FRE
- I-FRE
6H I-FRE
( O
every O

 O
4 O
to O
6 O
hours O
) O
as O
needed O
. O

 O
11 O
. O
Acyclovir B-DRUG
5 O
% O
Ointment B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU
6X/D B-FRE
( O
6 O

 O
times O
a O
day O
) O
. O

 O
12 O
. O
Citalopram B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
13 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
0.083 B-STR
% O
Solution B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
[ O
* O
* O
2 O
- O
3 O
* O
* O
] O
  O
Inhalation B-ROU
Q4H B-FRE

 I-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
shortness B-REA
of I-REA
breath I-REA
, I-REA
wheeze B-REA
. I-REA

 O

14 O
. O
Cholecalciferol B-DRUG
( O
Vitamin O
D3 O
) O
400 B-STR
unit I-STR
Tablet B-FOR
[ O
* O
* O
Month/Day O
( O
2 O
) O
* O
* O
] O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
15 O
. O
Calcium B-DRUG
Carbonate I-DRUG
1,250 B-STR
mg/5 I-STR
mL(500 I-STR
mg O
) O
Suspension B-FOR
[ O
* O
* O
Month/Day O
( O
2 O
) O
* O
* O
] O
: O
Ten B-DOS

 I-DOS
( I-DOS
10 I-DOS
) I-DOS
ML O
PO B-ROU
TID B-FRE
( O
3 O
times O
a O
day O
) O
. O

 O
16 O
. O
Metronidazole B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Month/Day O
( O
2 O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( O
3 O

 O
times O
a O
day O
) O
for O
2 O
doses O
: O
to O
complete O
3 O
doses O
on O
[ O
* O
* O
2122 O
- O
2 O
- O
6 O
* O
* O
] O
and O
then O

 O
to O
be O
discontinued O
. O

 O
17 O
. O
Prednisone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Date O
Range O
* O
* O
] O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
18 O
. O
Heparin B-DRUG
Lock I-DRUG
Flush I-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
100 B-STR
unit/mL I-STR
Syringe B-FOR
[ O
* O
* O
Date O
Range O
* O
* O
] O
: O
[ O
* O
* O
2 O
- O
3 O
* O
* O
] O

 O
MLs O
Intravenous B-ROU
DAILY B-FRE
( O
Daily O
) O
as O
needed O
. O

 O
19 O
. O
Ativan B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Month/Day O
( O
2 O
) O
* O
* O
] O
: O
0.5 B-DOS
- I-DOS
1 I-DOS
Tablet B-FOR
PO B-ROU
every O
4 B-FRE
- I-FRE
6 I-FRE
hours I-FRE
as I-FRE

 I-FRE
needed I-FRE
for O
anxiety B-REA
. I-REA



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital O
* O
* O
] O
Medical O
Center O
- O
[ O
* O
* O
Hospital1 O
3597 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
1 O
. O
Hypoxic O
respiratory O
failure O
requiring O
intubation O
now O
s/p O

 O
tracheostomy O
and O
PEG O

 O
2 O
. O
Community O
acquired O
pneumonia O

 O
3 O
. O
Ventilator O
associated O
pneumonia O

 O
4 O
. O
ARDS O

 O
5 O
. O
Pancreatitis O

 O
6 O
. O
Depression O

 O
7 O
. O
Rheumatoid O
arthritis O

 O
8 O
. O
Polyneuropathy O
and O
myopathy O
of O
critical O
illness O

 O
9 O
. O
Anemia O

 O
10 O
. O
Clostridium O
difficile O
colitis O



 O
Discharge O
Condition O
: O

 O
Stable O
, O
had O
been O
tolerating O
trach O
mask O
, O
currently O
on O
pressure O

 O
support O
and O
tolerating O
well O
. O



 O
Discharge O
Instructions O
: O

 O
Return O
to O
the O
emergency O
room O
if O
you O
develop O
fever O
, O
chills O
, O
if O

 O
diarrhea O
persists O
or O
worsens O
post O
antibiotic O
course O
, O
worsening O

 O
abdominal O
pain O
, O
nausea O
, O
inability O
to O
advance O
tube O
feeds O
. O

 O
. O

 O
Please O
take O
your O
medications O
as O
prescribed O
. O
  O
Please O
note O
we O
have O

 O
started O
you O
on O
the O
antidepressant O
celexa B-DRUG
. I-DRUG
  O
Additionally O
, O
we O
have O

 O
decreased O
your O
prednisone B-DRUG
for O
rheumatoid B-REA
arthritis I-REA
to O
15 B-STR
mg I-STR

 I-STR
daily B-FRE
. I-FRE
  O
If O
your O
dose O
increases O
chronically O
from O
this O
, O
you O
should O

 O
discuss O
with O
your O
doctor O
the O
need O
for O
PCP O
[ O
* O
* O
Name O
Initial O
( O
PRE O
) O
1102 O
* O
* O
] O
. O


 O
Followup O
Instructions O
: O

 O
Please O
follow O
up O
with O
your O
primary O
care O
doctor O
[ O
* O
* O
First O
Name O
( O
Titles O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Titles O
) O
69941**]t O
when O
appropriate O
from O
rehab O
. O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2120 O
- O
6 O
- O
17 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2120 O
- O
6 O
- O
25 O
* O
* O
] O



 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
No O
Known O
Allergies O
/ O
Adverse O
Drug O
Reactions O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1515 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
worsening O
shortness O
of O
breath O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
percutaneouos O
aortic O
valve O
replacement O
( O
CoreValve O
) O

 O
pacemaker O
placement O



 O
History O
of O
Present O
Illness O
: O

 O
This O
[ O
* O
* O
Age O
over O
90 O
* O
* O
] O
year O
old O
patient O
with O
a O
history O
of O
prior O
CABG O
has O
been O

 O
experiencing O
fatigue O
and O
severe O
shortness O
of O
breath O
with O
minimal O

 O
activity O
, O
which O
is O
new O
over O
the O
last O
few O
months O
. O
He O
denies O
any O

 O
symptoms O
occurring O
at O
rest O
. O
He O
denies O
any O
chest O
pain O
. O
He O
denies O

 O
claudication O
, O
orthopnea O
, O
pnd O
, O
lightheadedness O
  O
or O
lower O

 O
extremity O
edema O
. O
He O
was O
seen O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
59323 O
* O
* O
] O
who O
referred O
him O

 O
for O
an O
echocardiogram O
. O
This O
revealed O
worsening O
of O
his O
aortic O

 O
stenosis O
. O
He O
was O
seen O
and O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
6349 O
* O
* O
] O
and O
was O
deemed O
appropriate O

 O
for O
TAVI/CoreValve O
placement O
. O

 O
NYHA O
Class O
: O
II O


 O
Past O
Medical O
History O
: O

 O
PMH O
: O

 O
CAD O
, O
s/p O
inferior O
, O
posterior O
MI O
, O

 O
s/p O
CABG O
x O
4 O
in O
[**8-/2113**](SVG/OM O
, O
Diag O
, O
PLB O
, O
and O
LIMA O
to O
LAD O
) O

 O
Pancreatitis O
post O
CABG O

 O
S/P O
Cholescystectomy O
in O
[ O
* O
* O
10/2113 O
* O
* O
] O

 O
S/P O
cataract O
extraction O
OD O

 O
S/P O
right O
carpal O
tunnel O
release O

 O
S/P O
right O
knee O
arthroscopy O

 O
S/P O
Upper O
GI O
scope O
with O
gastric O
biopsy O
, O
esophageal O
biopsy O
, O
and O

 O
balloon O
dilatation O
in O
[ O
* O
* O
4-/2116 O
* O
* O
] O

 O
H/O O
diverticulosis O

 O
H/O O
GIB O
S/P O
right O
hemicolectomy O
  O
( O
17 O
units O
of O
blood O
) O

 O
H/O O
right O
carotid O
bruit O

 O
H/O O
NSVT O

 O
Hypertension O

 O
Hyperlipidemia O

 O
Chronic O
renal O
failure O

 O
Mitral O
regurgitation O

 O
Depression O

 O
Insomnia O

 O
Hearing O
impaired O

 O
Polymyalgia O
rheumatica- O
on O
Prednisone O

 O
Arthritis O

 O
BPH O
s/p O
TURP O


 O
Past O
Surgical O
History O
: O

 O
S/P O
Cholescystectomy O
in O
[ O
* O
* O
10/2113 O
* O
* O
] O

 O
S/P O
cataract O
extraction O
OD O

 O
S/P O
right O
carpal O
tunnel O
release O

 O
S/P O
right O
knee O
arthroscopy O

 O
s/p O
TURP O

 O
s/p O
R O
hemicolectomy O

 O
s/p O
CABGx4 O
( O
SVG/OM O
, O
Diag O
, O
PLB O
, O
and O
LIMA O
to O
LAD O
) O
[ O
* O
* O
8 O
- O
25 O
* O
* O
] O



 O
Social O
History O
: O

 O
SOCIAL O
HISTORY O
: O
Pt O
lives O
alone O
independently O
in O
a O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
house O
in O

 O
NH O
. O
He O
plans O
to O
stay O
with O
his O
daughter O
, O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
after O
discharge O
. O

 O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
37190 O
* O
* O
] O
(dtr)[**Telephone/Fax O
( O
1 O
) O
82471 O
* O
* O
] O

 O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
( O
dtr-in-law O
) O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
82472 O
* O
* O
] O

 O
Lives O
with O
: O
lives O
alone O

 O
Occupation O
: O
retired O
GE O
tester O
( O
jet O
engines O
) O

 O
Tobacco O
: O
1/2ppd O
x O
15yrs O
- O
quit O
60yrs O
ago O

 O
ETOH O
: O
none O



 O
Family O
History O
: O

 O
Longevity O
( O
sisters O
x O
2 O
deceased O
age O
[ O
* O
* O
Age O
over O
90 O
* O
* O
] O
) O



 O
Physical O
Exam O
: O

 O
ADMISSION O
EXAM O

 O
Pulse O
: O
65 O

 O
B/P O
: O
146/65 O

 O
Resp O
: O
18 O

 O
O2 O
Sat O
: O

 O
Temp O
: O
97.1 O

 O
General O
: O
Alert O
hard O
of O
hearing O
pleasant O
elderly O
gentleman O
in O
NAD O

 O
at O
rest O
, O
spleaking O
comfortably O
. O

 O
Skin O
: O
Color O
pale O
pink O
, O
turgor O
fair O
. O
No O
ulcerations O
, O
no O
lesions O
. O

 O
HEENT O
: O
Normocephalic O
, O
anicteric O
. O
Oropharynx O
moist O
. O
Conjunctiva O

 O
pale O
pink O
. O
Lower O
partials O
. O

 O
Neck O
: O
Neck O
supple O
, O
trachea O
midline O
. O
Bilat O
carotid O
bruit O
vs. O

 O
referred O
murmer O
. O
JVD O
. O

 O
Chest O
: O
Well O
healed O
sternal O
incision O
. O
No O
obvious O
deformity O
. O

 O
Heart O
: O
RRR O
. O
V/VI O
murmer O
throughout O

 O
Abdomen O
: O
soft O
, O
nontender O
, O
nondistended O
, O
(+)bowel O
sounds O
all O
quad O

 O
Extremities O
: O
No O
hair O
growth O
below O
knees O
. O
Trace O
pedal O
edema O

 O
bilat O
. O

 O
Neuro O
: O
Alert O
and O
oriented O
, O
mildly O
anxious O
. O
Gross O
FROM O
. O
OOB O
, O
gait O

 O
steady O
. O

 O
Pulses O
: O
[**12 O
- O
24**]+ O
palpable O
peripheral O
pulses O
throughout O



 O
DISCHARGE O
EXAM O

 O
VITALS O
: O
Temp O
current O
: O
98.7 O
HR O
: O
75 O
- O
95 O
RR O
: O
18 O
  O
BP O
: O
126 O
- O
147/60s O
  O
O2 O

 O
Sat O
: O
100 O
% O
RA O

 O
General O
: O
resting O
comfortably O
in O
bed O
, O
NAD O

 O
HEENT O
: O
Oropharynx O
moist O
. O

 O
Neck O
: O
Neck O
supple O
. O

 O
Chest O
: O
Well O
healed O
sternal O
incision O
. O
No O
obvious O
deformity O
. O
Skin O

 O
[ O
* O
* O
Month/Day O
( O
2 O
) O
1994 O
* O
* O
] O
from O
tape O
removal O
center O
chest O
, O
dressing O
not O
removed O
for O

 O
exam O
. O
Lungs O
CTA O
bilaterally O
with O
good O
air O
entry O
. O

 O
Heart O
: O
RRR O
, O
paradoxical O
split O
S2 O
. O

 O
Abdomen O
: O
soft O
, O
nontender O
, O
nondistended O
, O
(+)bowel O
sounds O
all O

 O
quad O
. O

 O
Well O
healed O
surgical O
scar O
. O

 O
Extremities O
: O
No O
hair O
growth O
below O
knees O
. O
No O
pedal O
edema O
. O
Small O

 O
( O
nickel-sized O
) O
right O
groin O
hematoma O
, O
mildly O
TTP O
. O
Palpable O
DP O

 O
pulses O
. O

 O
Neuro O
: O
Alert O
and O
oriented O
, O
mildly O
anxious O
. O
Gross O
FROM O
. O
OOB O
, O
gait O

 O
steady O
. O

 O
Skin O
: O
Color O
pink O
, O
skin O
warm O
and O
dry O
. O
Heels O
and O
sacrum O
intact O
. O



 O
Pertinent O
Results O
: O

 O
Admission O
labs O

 O
[ O
* O
* O
2120 O
- O
6 O
- O
17 O
* O
* O
] O
WBC-7.8 O
RBC-3.19 O
* O
Hgb-11.2 O
* O
Hct-31.4 O
* O
MCV-99 O
* O
MCH-35.1 O
* O

 O
MCHC-35.7 O
* O
RDW-16.3 O
* O
Plt O
Ct-189 O

 O
PT-13.7 O
* O
PTT-22.6 O
INR(PT)-1.2 O
* O

 O
Glucose-121 O
* O
UreaN-34 O
* O
Creat-1.5 O
* O
Na-143 O
K-4.7 O
Cl-109 O
* O
HCO3 O
- O
26 O

 O
AnGap-13 O

 O
Albumin-4.0 O

 O
Calcium-9.0 O
Phos-2.9 O
Mg-2.0 O

 O
% O
HbA1c-5.7 O
eAG-117 O

 O
ALT-18 O
AST-37 O
CK(CPK)-29 O
* O
AlkPhos-40 O
TotBili-0.9 O

 O
CK-MB-3 O
proBNP-2320 O
* O


 O
Discharge O
labs O
: O

 O
[ O
* O
* O
2120 O
- O
6 O
- O
25 O
* O
* O
] O
WBC-9.4 O
RBC-2.78 O
* O
Hgb-9.2 O
* O
Hct-27.6 O
* O
MCV-99 O
* O
MCH-33.1 O
* O

 O
MCHC-33.3 O
RDW-15.8 O
* O
Plt O
Ct-240 O

 O
PT-13.5 O
* O
PTT-25.0 O
INR(PT)-1.2 O
* O

 O
Glucose-92 O
UreaN-29 O
* O
Creat-1.4 O
* O
Na-142 O
K-4.1 O
Cl-108 O
HCO3 O
- O
24 O

 O
AnGap-14 O

 O
Calcium-8.4 O
Phos-2.5 O
* O
Mg-1.9 O

 O
proBNP-2338 O
* O


 O
Imaging O

 O
ECG O
: O
( O
[ O
* O
* O
6 O
- O
17 O
* O
* O
] O
) O

 O
Sinus O
rhythm O
. O
Right O
bundle-branch O
block O
. O
Left O
anterior O

 O
fascicular O
block O
. O

 O
Inferolateral O
lead O
ST-T O
wave O
changes O
are O
primary O
and O

 O
non-specific O
. O
Since O
the O
previous O
tracing O
of O
[ O
* O
* O
2120 O
- O
5 O
- O
17 O
* O
* O
] O

 O
inferolateral O
lead O
ST-T O
wave O
changes O
appear O
less O
prominent O
. O

 O
. O


 O
ECHO O
( O
[ O
* O
* O
6 O
- O
18 O
* O
* O
] O
) O

 O
PRE O
VALVE O
DEPLOYMENT O
The O
left O
atrium O
is O
dilated O
. O
No O
spontaneous O

 O
echo O
contrast O
or O
thrombus O
is O
seen O
in O
the O
body O
of O
the O
left O
atrium O

 O
or O
left O
atrial O
appendage O
. O
A O
patent O
foramen O
ovale O
is O
present O
. O
A O

 O
left-to-right O
shunt O
across O
the O
interatrial O
septum O
is O
seen O
at O

 O
rest O
. O
There O
is O
mild O
symmetric O
left O
ventricular O
hypertrophy O
. O
The O

 O
left O
ventricular O
cavity O
size O
is O
normal O
. O
There O
is O
moderate O

 O
regional O
left O
ventricular O
systolic O
dysfunction O
with O
severe O

 O
inferior O
, O
inferolateral O
, O
and O
inferoseptal O
hypokinesis O
. O
The O

 O
remaining O
myocardial O
segments O
are O
mildly O
, O
globally O
depressed O
. O

 O
The O
right O
ventricle O
displays O
mild O
global O
free O
wall O
hypokinesis O
. O

 O
The O
descending O
thoracic O
aorta O
is O
mildly O
dilated O
. O
There O
are O

 O
simple O
atheroma O
in O
the O
descending O
thoracic O
aorta O
. O
There O
are O

 O
three O
aortic O
valve O
leaflets O
. O
The O
aortic O
valve O
leaflets O
are O

 O
severely O
thickened/deformed O
. O
There O
is O
critical O
aortic O
valve O

 O
stenosis O
( O
valve O
area O
< O
0.8cm2 O
) O
. O
Mild O
to O
moderate O
( O
[**12 O
- O
24**]+ O
) O
aortic O

 O
regurgitation O
is O
seen O
. O
The O
mitral O
valve O
leaflets O
are O
moderately O

 O
thickened O
. O
There O
is O
more O
significant O
calcification O
of O
the O
base O

 O
of O
the O
posterior O
mitral O
leaflet O
and O
posterior O
mitral O
annulus O
. O

 O
Mild O
to O
moderate O
( O
[**12 O
- O
24**]+ O
) O
mitral O
regurgitation O
is O
seen O
. O
There O
is O
a O

 O
trivial/physiologic O
pericardial O
effusion O
. O

 O
. O

 O
POST O
VALVE O
DEPLOYMENT O
At O
initail O
deployment O
, O
the O
patient O

 O
developed O
near O
cardiac O
arrest O
with O
right O
ventricular O
akinesis O
. O

 O
The O
aortic O
valve O
was O
quickly O
replaced O
and O
epinephrine O
was O
given O

 O
with O
resolution O
of O
right O
ventricular O
failure O
. O
The O
right O

 O
ventriclular O
function O
then O
returned O
to O
the O
pre-deployment O
state O
. O

 O
The O
mitral O
regurgitation O
was O
worsened O
and O
severe O
immediately O

 O
after O
this O
event O
but O
after O
valve O
replacement O
returned O
to O

 O
baseline O
( O
mild O
to O
moderate O
) O
. O
The O
aortic O
valve O
and O
supporting O

 O
structure O
is O
in O
situ O
. O
The O
leaflets O
can O
be O
seen O
moving O
. O
The O

 O
maximum O
gradient O
across O
the O
valve O
was O
7 O
mmHg O
with O
a O
mean O
of O
4 O

 O
mmHg O
. O
There O
is O
mild O
aortic O
regurgitation O
with O
two O
paravalvular O

 O
jets O
seen O
. O

 O
. O

 O
ECG O
( O
[ O
* O
* O
6 O
- O
18 O
* O
* O
] O
) O

 O
Sinus O
rhythm O
with O
atrial O
sensed O
and O
ventricular O
paced O
rhythm O
. O

 O
Since O
the O

 O
previous O
tracing O
of O
the O
same O
date O
ventricular O
paced O
rhythm O
is O

 O
now O
present O
. O

 O
TRACING O
# O
2 O

 O
. O

 O
CXR O
( O
[ O
* O
* O
6 O
- O
18 O
* O
* O
] O
) O

 O
A O
CoreValve O
is O
in O
place O
. O
The O
left-sided O
pacemaker O
with O
the O
leads O

 O
terminating O
at O
right O
atrium O
and O
right O
ventricle O
is O
noted O
. O
Lungs O

 O
are O
essentially O
clear O
. O
Heart O
size O
and O
mediastinal O
silhouette O
are O

 O
stable O
. O
There O
is O
no O
pleural O
effusion O
or O
pneumothorax O
noted O
. O

 O
. O


 O
ECHO O
( O
[ O
* O
* O
6 O
- O
20 O
* O
* O
] O
) O

 O
The O
left O
atrium O
is O
mildly O
dilated O
. O
There O
is O
mild O
symmetric O
left O

 O
ventricular O
hypertrophy O
. O
Overall O
left O
ventricular O
systolic O

 O
function O
is O
moderately O
depressed O
( O
LVEF= O
35 O
% O
) O
secondary O
to O

 O
jypokinesis O
of O
the O
inferior O
septum O
, O
inferior O
free O
wall O
, O
and O

 O
posterior O
wall O
. O
The O
right O
ventricular O
free O
wall O
is O

 O
hypertrophied O
. O
Right O
ventricular O
chamber O
size O
is O
normal O
. O
with O

 O
borderline O
normal O
free O
wall O
function O
. O
An O
aortic O
CoreValve O

 O
prosthesis O
is O
present O
. O
A O
paravalvular O
aortic O
valve O
leak O

 O
( O
trace-to-mild O
) O
is O
probably O
present O
. O
The O
mitral O
valve O
leaflets O

 O
are O
mildly O
thickened O
. O
There O
is O
no O
mitral O
valve O
prolapse O
. O
Mild O
to O

 O
moderate O
( O
[**12 O
- O
24**]+ O
) O
mitral O
regurgitation O
is O
seen O
. O
[ O
Due O
to O
acoustic O

 O
shadowing O
, O
the O
severity O
of O
mitral O
regurgitation O
may O
be O

 O
significantly O
UNDERestimated O
. O
] O
There O
is O
borderline O
pulmonary O

 O
artery O
systolic O
hypertension O
. O
There O
is O
no O
pericardial O
effusion O
. O


 O
. O

 O
CXR O
( O
[ O
* O
* O
6 O
- O
20 O
* O
* O
] O
) O

 O
IMPRESSION O
: O
Very O
satisfactory O
postoperative O
situation O
. O
Permanent O

 O
pacer O
with O
two O
intracavitary O
electrodes O
in O
unremarkable O

 O
position O
. O
No O
pneumothorax O
identified O
. O

 O
. O

 O
ECHO O
( O
[ O
* O
* O
6 O
- O
25 O
* O
* O
] O
) O

 O
The O
left O
atrium O
is O
moderately O
dilated O
. O
There O
is O
moderate O

 O
symmetric O
left O
ventricular O
hypertrophy O
. O
The O
left O
ventricular O

 O
cavity O
size O
is O
normal O
. O
There O
is O
mild O
regional O
left O
ventricular O

 O
systolic O
dysfunction O
with O
basal O
inferoseptal O
, O
inferior O
, O
and O

 O
inferolateral O
akinesis O
. O
Right O
ventricular O
chamber O
size O
and O
free O

 O
wall O
motion O
are O
normal O
. O
An O
aortic O
CoreValve O
prosthesis O
is O

 O
present O
and O
appears O
well-seated O
. O
The O
transaortic O
gradient O
is O

 O
normal O
for O
this O
prosthesis O
. O
Mild O
( O
1 O
+ O
) O
aortic O
regurgitation O
is O

 O
seen O
( O
probably O
paravalvular O
) O
. O
The O
mitral O
valve O
leaflets O
are O

 O
mildly O
thickened O
. O
Moderate O
( O
2 O
+ O
) O
mitral O
regurgitation O
is O
seen O
. O

 O
Moderate O
[ O
2 O
+ O
] O
tricuspid O
regurgitation O
is O
seen O
. O
There O
is O
no O

 O
pericardial O
effusion O
. O

 O
. O

 O
Compared O
with O
the O
prior O
study O
( O
images O
reviewed O
) O
of O
[ O
* O
* O
2120 O
- O
6 O
- O
20 O
* O
* O
] O
, O

 O
left O
ventricular O
systolic O
function O
appears O
similar O
. O
Left O

 O
ventricular O
ejection O
fraction O
may O
have O
been O
slightly O

 O
underestimated O
in O
the O
prior O
report O
. O
Estimated O
pulmonary O
artery O

 O
systolic O
pressure O
is O
now O
higher O
. O
Mitral O
regurgitation O
is O
now O

 O
more O
prominent O
. O
Tricuspid O
regurgitation O
is O
now O
more O
prominent O
. O

 O
. O

 O
ECG O
( O
[ O
* O
* O
6 O
- O
25 O
* O
* O
] O
) O

 O
Ventricular O
paced O
rhythm O
at O
a O
rate O
of O
80 O
beats O
per O
minute O
. O
No O

 O
diagnostic O

 O
change O
compared O
to O
previous O
tracing O
. O



 O

Brief O
Hospital O
Course O
: O

 O
Pt O
is O
a O
[ O
* O
* O
Age O
over O
90 O
* O
* O
] O
yo O
M O
with O
a O
PMH O
significant O
for O
critical O
AS O
, O
CABG O
x4 O

 O
and O
MR O
[ O
* O
* O
First O
Name O
( O
Titles O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Titles O
) O
82473 O
* O
* O
] O
for O
percutaneous O
aortic O
valve O

 O
replacement O
with O
CoreValve O
device O
. O


 O
# O
1 O
Severe O
symptomatic O
aortic O
stenosis O
s/p O
CoreValve O
[ O
* O
* O
6 O
- O
18 O
* O
* O
] O
: O

 O
At O
initail O
deployment O
, O
the O
patient O
developed O
near O
cardiac B-REA
arrest I-REA

 I-REA
with O
right O
ventricular O
akinesis O
. O
The O
aortic O
valve O
was O
quickly O

 O
replaced O
and O
epinephrine B-DRUG
was O
given O
with O
resolution O
of O
right O

 O
ventricular O
failure O
. O
The O
right O
ventriclular O
function O
then O

 O
returned O
to O
the O
pre-deployment O
state O
. O
The O
mitral O
regurgitation O

 O
was O
worsened O
and O
severe O
immediately O
after O
this O
event O
but O
after O

 O
valve O
replacement O
returned O
to O
baseline O
( O
mild O
to O
moderate O
) O
. O

 O
Perioperative O
permanent O
pacemaker O
placed O
following O
occlusion O
of O

 O
RCA O
, O
has O
right O
BBB O
and O
paced O
beats O
. O
ECHO O
shows O
good O
valve O

 O
placement O
and O
mild O
perivalvular O
leak O
. O
One B-DOS
unit I-DOS
PRBC B-DRUG
given O
post O

 O
procedure O
for O
low B-REA
hct I-REA
. I-REA
Pt O
will O
need O
aspirin B-DRUG
and O
Plavix B-DRUG
for B-DUR
a I-DUR

 I-DUR
total I-DUR
of I-DUR
3 I-DUR
months I-DUR
and O
will O
follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
and O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
1022 O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
32655 O
* O
* O
] O
NP O
for O
routine O
post O
procedure O
care O
. O

 O
. O

 O
# O
2 O
Complete O
Heart O
Block O
during O
CoreValve O
placement O
: O
common O

 O
occurance O
in O
patients O
with O
right O
bundle O
branch O
block O
. O
A O

 O
[ O
* O
* O
Company O
1543 O
* O
* O
] O
DDD O
pacemaker O
model O
Sensia O
SEDR01 O
, O

 O
serial O
number O
[ O
* O
* O
Serial O
Number O
82474 O
* O
* O
] O
. O
One O
week O
wound O
check O
and O

 O
interrogation O
occurred O
while O
pt O
was O
still O
hospitalized O
and O
pt O

 O
will O
need O
to O
f/u O
every O
6 O
months O
for O
a O
pacemaker O
check O
. O


 O
# O
3 O
CAD B-REA
: I-REA
s/p O
CABG O
x O
4 O
( O
[ O
* O
* O
2112 O
* O
* O
] O
) O
. O
Bypass O
graft O
angiography O

 O
demonstrates O
  O
the O
vein O
graft O
to O
the O
obtuse O
marginal O
and O
the O
LIMA O

 O
to O
LAD O
to O
be O
  O
patent O
, O
however O
during O
CoreValve O
procedure O
the O
RCA O

 O
graft O
was O
TO O
. O
Pt O
had O
no O
significant O
chest O
pain O
during O

 O
hospitalization O
and O
was O
discharged O
on O
home O
aspirin B-DRUG
, I-DRUG
plavix B-DRUG
, I-DRUG

 O
metoprolol B-DRUG
and O
Lipitor B-DRUG
. I-DRUG

 O
. O

 O
# O
4 O
Chronic B-REA
Systolic I-REA
Dysfunction I-REA
: I-REA
EF O
35 O
% O
. O
Appeared O
euvolemic O
at O

 O
discharge O
. O

 O
Had O
not O
been O
on O
ACEi B-DRUG
[ O
* O
* O
1 O
- O
24 O
* O
* O
] O
AS O
and O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
. O
Would O
consider O
starting O
low B-DOS

 I-DOS
dose I-DOS
ACEi B-DRUG
as O
outpatient O
. O
Started O
Lasix B-DRUG
20 B-STR
mg I-STR
PO B-ROU
for O
inc B-REA
TR I-REA

 I-REA
gradient I-REA
. I-REA

 O
. O


 O
# O
Diarrhea B-ADE
. I-ADE
Possibly O
due O
to O
antibiotics B-DRUG
and O
bowel O
regimen O
. O
No O

 O
fever O
or O
leukocytosis O
. O
Resolved O
at O
discharge O
. O

 O
. O

 O
# O
Skin O
[ O
* O
* O
Last O
Name O
( O
un O
) O
1994 O
* O
* O
] O
. O
Likely O
secondary O
to O
prednisone B-DRUG
. I-DRUG
Mild O
serosanguinous B-ADE

 I-ADE
oozing I-ADE
at O
site O
. O
Wound O
nurse O
[ O
* O
* O
First O
Name O
( O
Titles O
) O
6349 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Titles O
) O
1994 O
* O
* O
] O
and O
wrote O

 O
recommendations O
to O
VNA O
for O
dressing O
. O

 O
. O

 O
# O
. O
Polymyalgia B-REA
Rheumatica I-REA
: I-REA
On O
chronic O
steroids B-DRUG
at O
home O
, O

 O
continued O
in O
hospital O
. O

 O
. O

 O
# O
. O
CKD O
: O
baseline O
creatinine O
1.5 O
. O
Increased O
to O
1.6 O
, O
possibly O

 O
secondary O
to O
intravascular O
depletion O
from O
diuresis/diarrhea O
. O
Pt O

 O
will O
have O
his O
labs O
rechecked O
as O
an O
outpatient O
. O




 O
Medications O
on O
Admission O
: O

 O
atenolol B-DRUG
25 B-STR
mg I-STR
daily B-FRE

 I-FRE
aspirin B-DRUG
81 B-STR
mg I-STR
daily B-FRE

 I-FRE
lipitor B-DRUG
10 B-STR
mg I-STR
QOD B-FRE
( I-FRE
every I-FRE
other I-FRE
am I-FRE
) I-FRE

 I-FRE
prednisone B-DRUG
10 B-STR
mg I-STR
daily B-FRE

 I-FRE
tamulosiin B-DRUG
SR I-DRUG
0.4 B-STR
mg I-STR
qevening B-FRE

 I-FRE
multivitamin B-DRUG
1 B-DOS
tab B-FOR
daily B-FRE

 I-FRE
fish B-DRUG
oil I-DRUG
capsule B-FOR
1000 B-STR
mg I-STR
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
systane B-DRUG
lubricant I-DRUG
eye I-DRUG
drops B-FOR
1gtt B-ROU
TID B-FRE


 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Outpatient O
Lab O
Work O

 O
Please O
check O
Chem-7 O
and O
CBC O
on O
Thursday O
[ O
* O
* O
6 O
- O
27 O
* O
* O
] O
with O
results O
to O
[ O
* O
* O
First O
Name5 O
( O
NamePattern1 O
) O
1022 O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
32655 O
* O
* O
] O
at O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
32656 O
* O
* O
] O
fax O
and O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
79809 O
* O
* O
] O
phone O

 O
2 O
. O
metoprolol B-DRUG
succinate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Extended I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
Sig O
: O

 O
1.5 B-DOS
Tablet B-FOR
Extended I-FOR
Release I-FOR
24 I-FOR
hrs I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*45 O
Tablet B-FOR
Extended I-FOR
Release I-FOR
24 I-FOR
hr(s I-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O

 O
3 O
. O
aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR

 I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
atorvastatin B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QODHS B-FRE
( I-FRE
every I-FRE

 I-FRE
other I-FRE
day I-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
prednisone B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
6 O
. O
tamsulosin B-DRUG
0.4 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Ext I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Ext I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
multivitamin B-DRUG
     O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
8 O
. O
omega-3 B-DRUG
fatty I-DRUG
acids I-DRUG
     O
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
clopidogrel B-DRUG
75 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s B-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O



 O
Facility O
: O

 O
[ O
* O
* O
Company O
1519 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Aortic O
Stenosis O

 O
Acute O
Systolic O
Dysfunction O
, O
no O
ACE/[**Last O
Name O
( O
un O
) O
* O
* O
] O
[ O
* O
* O
1 O
- O
24 O
* O
* O
] O
acute O
kidney O
injury O

 O
Hypertension O

 O
Anemia O

 O
Complete O
heart O
block O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
requires O
assistance O
or O
aid O
( O
walker O

 O
or O
cane O
) O
. O



 O
Discharge O
Instructions O
: O

 O
You O
had O
a O
percutaneous O
replacement O
of O
your O
aortic O
valve O
with O
a O

 O
CoreValve O
bioprosthetic B-REA
valve I-REA
. I-REA
You O
will O
need O
to O
take O
asprin B-DRUG
and O

 O
Plavix B-DRUG
for B-DUR
3 I-DUR
months I-DUR
to B-REA
prevent I-REA
blood I-REA
clots I-REA
around I-REA
the I-REA
valve I-REA
. I-REA
Do O

 O
not O
stop O
taking O
aspirin B-DRUG
and O
Plavix B-DRUG
unless O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
tells O
you O
it O

 O
is O
OK O
to O
do O
so O
. O
You O
also O
needed O
a O
pacemaker O
after O
the O
procedure O

 O
for O
a O
slow O
heart O
rhythm O
, O
you O
will O
need O
to O
see O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
11250 O
* O
* O
] O
and O

 O
an O
electrophysiology O
doctor O
[ O
* O
* O
First O
Name O
( O
Titles O
) O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
3844 O
* O
* O
] O
to O
have O
the O

 O
pacemaker O
checked O
every O
6 O
months O
. O
No O
lifting O
more O
than O
5 O
pounds O

 O
with O
your O
left O
arm O
or O
lift O
your O
left O
arm O
over O
your O
head O
for O
6 O

 O
weeks O
. O
There O
are O
no O
activity O
restrictions O
for O
your O
right O
arm O
. O

 O
You O
can O
shower O
when O
you O
get O
home O
. O
You O
needed O
a O
blood B-DRUG
transfusion I-DRUG

 I-DRUG
for O
anemia B-REA
, I-REA
your O
blood O
count O
is O
better O
now O
. O
You O
heart O
is O

 O
slightly O
weaker O
now O
than O
before O
. O
You O
need O
to O
watch O
your O
salt O

 O
intake O
and O
take O
all O
of O
your O
medicines O
daily O
. O
Information O

 O
regarding O
your O
medicines O
and O
diet O
was O
discussed O
with O
you O
before O

 O
discharge O
. O

 O
Weigh O
yourself O
every O
morning O
, O
call O
Dr.[**Last O
Name O
( O
STitle O
) O
11250 O
* O
* O
] O
if O
weight O
goes O

 O
up O
more O
than O
3 O
lbs O
in O
1 O
day O
or O
5 O
pounds O
in O
3 O
days O
. O

 O
. O

 O
We O
made O
the O
following O
changes O
to O
your O
medicines O
: O

 O
1 O
. O
Stop O
taking O
Atenolol B-DRUG
, I-DRUG
take O
metoprolol B-DRUG
instead O
to O
lower B-REA
your I-REA

 I-REA
heart I-REA
rate I-REA
and O
help B-REA
your I-REA
heart I-REA
pump I-REA
better I-REA

 I-REA
2 O
. O
Start O
taking O
plavix B-DRUG
every B-FRE
day I-FRE
to B-REA
prevent I-REA
blood I-REA
clots I-REA
on O
the O

 O
new O
valve O
. O



 O

Followup O
Instructions O
: O

 O
Department O
: O
CARDIAC O
SERVICES O

 O
When O
: O
THURSDAY O
[ O
* O
* O
2120 O
- O
7 O
- O
18 O
* O
* O
] O
at O
3:00 O
PM O

 O
With O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
62 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O

 O
You O
will O
have O
an O
Echocardiogram O
at O
the O
same O
time O
as O
this O
appt O
. O

 O
. O

 O
PCP O


 O
Name O
: O
AUNG O
, O
THET O
H O

 O
Address O
: O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
Numeric O
Identifier O
77486 O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
77350 O
* O
* O
] O

 O
Appointment O
: O
Thursday O
[ O
* O
* O
2120 O
- O
6 O
- O
27 O
* O
* O
] O
11:30am O




 O
Completed O
by:[**2120 O
- O
6 O
- O
29 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2125 O
- O
9 O
- O
13 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2125 O
- O
9 O
- O
18 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2055 O
- O
6 O
- O
5 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Ampicillin B-DRUG
/ O
Aspirin B-DRUG


 I-DRUG
Attending:[**Doctor O
First O
Name O
2080 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Diarrhea O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O



 O
History O
of O
Present O
Illness O
: O

 O
70 O
y/o O
lady O
with O
h/o O
recurrent O
C.diff O
colitis O
since O
[ O
* O
* O
Month O
( O
only O
) O
958 O
* O
* O
] O
of O

 O
[ O
* O
* O
2124 O
* O
* O
] O
presenting O
worsening O
diarrhea O
. O
Patient O
has O
noticed O

 O
increased O
amount O
of O
bowel O
movements O
> O
10 O
per O
day O
in O
the O
last O
two O

 O
days O
. O
She O
has O
noticed O
some O
bright O
blood O
and O
dark O
colored O
stool O

 O
occasionally O
. O
She O
has O
a O
hard O
time O
explaining O
the O
quality O
and O

 O
quantitiy O
of O
stool O
. O
Her O
appetite O
was O
very O
poor O
and O
did O
not O
eat O

 O
in O
the O
last O
two O
days O
. O
Denies O
nausea/vomitting O
. O
She O
had O
mild O

 O
abdominal O
pain O
prior O
to O
bowel O
movement O
yesterday O
. O
She O
felt O
very O

 O
tired O
and O
decided O
to O
come O
to O
the O
ED O
. O

 O
. O

 O
In O
the O
ED O
, O
initial O
vs O
were O
: O
T97.4 O
P95 O
BP128/65 O
R20 O
O292 O
% O
sat O
in O

 O
RA O
. O
She O
spiked O
a O
temp B-REA
to I-REA
102.4 I-REA
approx O
5 O
hours O
after O

 O
presentation O
. O
Patient O
recieved O
1 B-DOS
gram I-DOS
of O
tylenol B-DRUG
and O
became O

 O
afebrile O
. O
She O
initially O
recieved O
1 B-DOS
L I-DOS
NS B-DRUG
. I-DRUG
Her O
SBP B-REA
dropped I-REA
to I-REA
80s I-REA

 I-REA
( O
per O
verbal O
signout O
) O
and O
she O
was O
started O
on O
peripheral O
levophed B-DRUG

 I-DRUG
and O
additional O
2 B-DOS
L I-DOS
NS B-DRUG
were O
given O
. O
Patient O
refused O
central O
line O
. O

 O
She O
had O
2 O
PIV O
( O
18 O
G O
) O
placed O
in O
ED O
per O
verbal O
signout O
. O
CXR O
was O

 O
concerning O
LLL B-REA
PNA I-REA
. I-REA
Patient O
was O
also O
given O
1 B-STR
gram I-STR
of O
IV B-ROU

 I-ROU
vancomycin B-DRUG
, I-DRUG
500 B-STR
mg I-STR
IV B-ROU
flagyl B-DRUG
, I-DRUG
750 B-STR
mg I-STR
IV B-ROU
levofloxacin B-DRUG
and O
2 B-STR
grams I-STR

 I-STR
of O
IV B-ROU
calcium B-DRUG
. I-DRUG

 O
. O

 O
On O
the O
floor O
, O
patient O
was O
comfortable O
. O

 O
. O

 O
Review O
of O
sytems O
: O

 O
Denies O
fevers O
at O
home O
, O
chills O
, O
night O
sweats O
, O
headache O
, O

 O
rhinorrhea O
or O
congestion O
. O
Denied O
cough O
, O
shortness O
of O
breath O
. O

 O
Denied O
chest O
pain O
or O
tightness O
, O
palpitations O
. O
Denied O
arthralgias O

 O
or O
myalgias O
, O
new O
weakness O
or O
numbness O
. O
Has O
chronic O
right O

 O
shoulder O
weakness O
. O



 O

Past O
Medical O
History O
: O

 O
- O
Recurrent O
C O
Diff O
colitis O
beginning O
[ O
* O
* O
1-/2125 O
* O
* O
] O
, O
last O
episode O
and O

 O
hospitalization O
[ O
* O
* O
2125 O
- O
8 O
- O
1 O
* O
* O
] O
to O
[ O
* O
* O
2125 O
- O
8 O
- O
10 O
* O
* O
] O
, O
confirmed O
colitis B-REA
on O
CT O
and O

 O
flex-sig O
without O
pseudomembranes O
and O
patient O
refused O
biopsy O
, O
was O

 O
treated O
with O
a O
pulse B-DOS
and O
taper B-DOS
dose O
of O
vancomycin B-DRUG
( O
completed O
on O

 O
[ O
* O
* O
2125 O
- O
9 O
- O
2 O
* O
* O
] O
) O
, O
Florastor B-DRUG
[ O
* O
* O
Hospital1 O
* O
* O
] O
, O
and O
was O
started O
on O
rifaximin B-DRUG
400 B-STR
mg I-STR

 I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
on O
[ O
* O
* O
2125 O
- O
9 O
- O
3 O
* O
* O
] O
. O

 O
- O
RUE B-REA
DVT I-REA
following O
PICC O
Placement O
in O
[ O
* O
* O
2125 O
- O
7 O
- O
20 O
* O
* O
] O
, O
on O
coumadin B-DRUG

 I-DRUG
- O
Anxiety O

 O
- O
HTN O

 O
- O
CAD O
s/p O
NSTEMI O
in O
the O
setting O
of O
demand O
ischemia O
in O
[ O
* O
* O
Month O
( O
only O
) O
958 O
* O
* O
] O
of O

 O
[ O
* O
* O
2124 O
* O
* O
] O

 O
- O
s/p O
ORIF O
of O
R O
wrist O
in O
[ O
* O
* O
1-/2125 O
* O
* O
] O

 O
- O
Anemia O



 O
Social O
History O
: O

 O
Usually O
lives O
alone O
and O
is O
able O
to O
do O
activities O
of O
daily O
living O

 O
including O
driving O
herself O
but O
since O
her O
MI O
in O
[ O
* O
* O
Month O
( O
only O
) O
958 O
* O
* O
] O
she O
has O
been O

 O
afraid O
to O
leave O
the O
house O
and O
her O
son O
has O
been O
living O
with O
her O

 O
to O
help O
with O
activities O
around O
the O
house O
. O
She O
has O
a O
neice O
who O

 O
works O
in O
the O
[ O
* O
* O
Name O
( O
NI O
) O
13042 O
* O
* O
] O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
. O
Quit O
tobacco O
in O
[ O
* O
* O
2 O
- O
5 O
* O
* O
] O
but O
smoked O
for O

 O
50 O
years O
[ O
* O
* O
12 O
- O
1 O
* O
* O
] O
ppd O
before O
that O
. O
No O
alcohol O
or O
other O
drug O
use O
. O



 O
Family O
History O
: O

 O
One O
brother O
with O
kidney O
tumor O
, O
CHF O
, O
OA O
, O
obesity O
. O
Dad O
had O
DM O
. O


 O
Physical O
Exam O
: O

 O
Vitals O
: O
T:97.3 O
BP:101/44 O
P:84 O
R O
: O
18 O
O2 O
: O
96 O
% O
on O
2LNC O

 O
General O
: O
Alert O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
MMM O
, O
oropharynx O
clear O

 O
Neck O
: O
supple O
, O
JVP O
7 O
cm O

 O
Lungs O
: O
distant O
BS O
diffusely O
, O
no O
wheezes O
, O
rales O
, O
ronchi O

 O
Heart O
: O
Regular O
rate O
and O
rhythm O
, O
normal O
S1 O
+ O
S2 O
, O
I/VI O

 O
holosystolic O
murmur O
at O
left O
lower O
sternal O
border O

 O
Abdomen O
: O
soft O
, O
non-tender O
, O
non-distended O
, O
bowel O
sounds O
present O
, O

 O
no O
rebound O
tenderness O
or O
guarding O
, O
no O
organomegaly O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
no O
clubbing O
, O
cyanosis O
or O
edema O

 O
Guaic O
negative O
in O
ED O



 O

Pertinent O
Results O
: O

 O
Admission O
Labs O
: O

 O
[ O
* O
* O
2125 O
- O
9 O
- O
13 O
* O
* O
] O
03:09PM O
   O
GLUCOSE-109 O
* O
UREA O
N-18 O
CREAT-0.8 O
SODIUM-134 O

 O
POTASSIUM-4.5 O
CHLORIDE-106 O
TOTAL O
CO2 O
- O
19 O
* O
ANION O
GAP-14 O

 O
[ O
* O
* O
2125 O
- O
9 O
- O
13 O
* O
* O
] O
03:09PM O
   O
ALT(SGPT)-29 O
AST(SGOT)-30 O
LD(LDH)-183 O
ALK O

 O
PHOS-170 O
* O
TOT O
BILI-0.4 O

 O
[ O
* O
* O
2125 O
- O
9 O
- O
13 O
* O
* O
] O
03:09PM O
   O
GGT-153 O
* O

 O
[ O
* O
* O
2125 O
- O
9 O
- O
13 O
* O
* O
] O
08:41AM O
   O
GLUCOSE-109 O
* O
UREA O
N-20 O
CREAT-0.9 O
SODIUM-135 O

 O
POTASSIUM-5.0 O
CHLORIDE-106 O
TOTAL O
CO2 O
- O
22 O
ANION O
GAP-12 O

 O
[ O
* O
* O
2125 O
- O
9 O
- O
13 O
* O
* O
] O
08:41AM O
   O
ALBUMIN-3.1 O
* O
CALCIUM-7.6 O
* O
PHOSPHATE-3.5 O

 O
MAGNESIUM-1.6 O

 O
[ O
* O
* O
2125 O
- O
9 O
- O
13 O
* O
* O
] O
08:41AM O
   O
WBC-4.5 O
# O
RBC-3.04 O
* O
HGB-9.2 O
* O
HCT-28.2 O
* O
MCV-93 O

 O
MCH-30.1 O
MCHC-32.4 O
RDW-14.8 O

 O
[ O
* O
* O
2125 O
- O
9 O
- O
13 O
* O
* O
] O
04:35AM O
   O
LACTATE-1.4 O
K+-5.0 O

 O
[ O
* O
* O
2125 O
- O
9 O
- O
12 O
* O
* O
] O
11:08PM O
   O
CALCIUM-9.6 O
PHOSPHATE-3.4 O
MAGNESIUM-1.8 O

 O
[ O
* O
* O
2125 O
- O
9 O
- O
12 O
* O
* O
] O
11:08PM O
   O
NEUTS-84 O
* O
BANDS-9 O
* O
LYMPHS-3 O
* O
MONOS-3 O
EOS-0 O

 O
BASOS-0 O
ATYPS-0 O
METAS-1 O
* O
MYELOS-0 O

 O
. O

 O
CT O
Abd/Pelvis O
: O

 O
IMPRESSIONS O
: O

 O
1 O
. O
Wall O
thickening O
and O
stranding O
along O
the O
colon O
from O
the O

 O
splenic O
flexure O

 O
through O
the O
sigmoid O
colon O
, O
similar O
to O
that O
seen O
on O
[ O
* O
* O
2125 O
- O
8 O
- O
1 O
* O
* O
] O
. O

 O
Findings O
again O

 O
represent O
nonspecific O
colitis O
, O
possibly O
ischemic O
, O
infectious O
or O

 O
inflammatory O

 O
in O
etiology O
. O
No O
free O
air O
, O
definite O
abscess O
, O
pneumatosis O
, O
or O

 O
portal O
gas O
seen O
. O

 O
2 O
. O
Left O
kidney O
with O
hyperdense O
cyst O
and O
other O
subcentimeter O

 O
hypodensities O
. O

 O
3 O
. O
Atherosclerotic O
disease O
. O

 O
. O

 O
Stool O
cx O
: O

 O
/15/09 O
1:55 O
am O
STOOL O
     O
CONSISTENCY O
: O
SOFT O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2125 O
- O
9 O
- O
17 O
* O
* O
] O
* O
* O


    O
FECAL O
CULTURE O
( O
Final O
[ O
* O
* O
2125 O
- O
9 O
- O
14 O
* O
* O
] O
) O
: O
    O
NO O
SALMONELLA O
OR O
SHIGELLA O

 O
FOUND O
. O


    O
CAMPYLOBACTER O
CULTURE O
( O
Final O
[ O
* O
* O
2125 O
- O
9 O
- O
15 O
* O
* O
] O
) O
: O
    O
NO O
CAMPYLOBACTER O

 O
FOUND O
. O


    O
CLOSTRIDIUM O
DIFFICILE O
TOXIN O
A O
& O
B O
TEST O
( O
Final O
[ O
* O
* O
2125 O
- O
9 O
- O
13 O
* O
* O
] O
) O
: O

       O
REPORTED O
BY O
PHONE O
TO O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
KITCHEN O
ON O
[ O
* O
* O
2125 O
- O
9 O
- O
13 O
* O
* O
] O
AT O
1:10PM O
. O

       O
CLOSTRIDIUM O
DIFFICILE O
. O

          O
FECES O
POSITIVE O
FOR O
C. O
DIFFICILE O
TOXIN O
BY O
EIA O
. O

            O
( O
Reference O
Range-Negative O
) O
. O

          O
A O
positive O
result O
in O
a O
recently O
treated O
patient O
is O
of O

 O
uncertain O

          O
significance O
unless O
the O
patient O
is O
currently O

 O
symptomatic O

          O
( O
relapse O
) O
. O



 O

Brief O
Hospital O
Course O
: O

 O
C. B-REA
difficile I-REA
colitis/Sepsis B-REA
: I-REA
Given O
history O
of O
recurrent O
C. O

 O
difficile O
colitis O
, O
diarrhea O
, O
and O
sepsis O
, O
etiology O
was O
presumed O

 O
to O
be O
CDAD O
, O
confirmed O
on O
stool O
cx O
. O
  O
She O
was O
started O
on O
PO B-ROU
vanco B-DRUG
, I-DRUG

 O
IV B-ROU
flagyl B-DRUG
empirically O
. O
  O
CT O
scan O
demonstrated O
colitis O
. O
  O
Patient O

 O
was O
admitted O
to O
the O
ICU O
for O
aggressive O
IVF B-DRUG
, I-DRUG
though O
patient O

 O
refused O
central O
line O
. O
  O
She O
was O
briefly O
on O
peripheral O
levophed B-DRUG
. I-DRUG

 O
ID O
and O
GI O
were O
consulted O
. O
  O
After O
adequate O
resuscitation O
, O
she O

 O
stabilized O
clinically O
and O
was O
transferred O
to O
the O
medical O
floor O
. O

 O
Her O
diarrhea O
improved O
, O
though O
her O
flagyl B-DRUG
was O
stopped O
after O
she O

 O
developed O
parasthesias B-ADE
. I-ADE
  O
Reviewing O
the O
record O
, O
it O
appeared O
that O

 O
she O
stopped O
her O
previous O
taper O
early O
. O
  O
Therefore O
, O
a O
more O

 O
aggressive O
taper O
was O
pursued O
, O
deferring O
possible O
fecal O

 O
transplantation O
to O
the O
outpatient O
setting O
, O
as O
well O
as O
rifamixin B-DRUG
. I-DRUG

 O
. O

 O
ARF B-REA
: I-REA
Likely O
pre-renal O
. O
  O
Resolved O
with O
IVF B-DRUG
resusitation O

 O
. O

 O
h/o B-REA
DVT I-REA
: I-REA
Coumadin B-DRUG
was O
reversed O
initially O
. O
  O
However O
, O
once O
she O

 O
stabilized O
it O
was O
restarted O
with O
lovenox B-DRUG
bridge O
. O
  O
She O
will O
need O

 O
close O
follow O
up O
to O
ensure O
her O
coumadin B-DRUG
returns O
to O
therapeutic O

 O
range O
2 O
- O
3 O
and O
was O
dicharged O
on O
warfarin B-DRUG
4 B-STR
mg I-STR
daily B-FRE
and O
lovenox B-DRUG

 I-DRUG
40 B-STR
mg I-STR
SC B-ROU
q12 B-FRE
to O
bridge O

 O
. O

 O
Plexopathy B-REA
: I-REA
Continued O
coumadin B-DRUG

 I-DRUG
. O

 O
HTN B-REA
, I-REA
benign I-REA
: I-REA
will O
restart O
home O
antihypertensives B-DRUG
on O
discharge O

 O
. O

 O
Chronic O
diastolic O
CHF O
: O
was O
euvolemic O
on O
exam O
. O
  O
Continued O
home O

 O
medications O


 O
Medications O
on O
Admission O
: O

 O
Citalopram B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
Gabapentin B-DRUG
100 B-STR
mg I-STR
TID B-FRE

 I-FRE
Alprazolam B-DRUG
1 B-STR
mg I-STR
TID B-FRE
prn I-FRE

 I-FRE
Lisinopril B-DRUG
10 B-STR
mg I-STR
daily B-FRE

 I-FRE
Metoprolol B-DRUG
Tartrate I-DRUG
12.5 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
Oxycodone B-DRUG
5 B-STR
mg I-STR
q6h B-FRE
prn I-FRE
pain B-REA

 I-REA
Trazodone B-DRUG
50 B-STR
mg I-STR
qhs B-FRE
prn I-FRE

 I-FRE
Vitamin B-DRUG
D-3 I-DRUG
800 B-STR
units I-STR
daily B-FRE

 I-FRE
Calcium B-DRUG
Carbonate I-DRUG
500 B-STR
mg I-STR
( I-STR
1,250 I-STR
mg I-STR
) I-STR
2tabs B-FOR
daily B-FRE

 I-FRE
Multivitamin B-DRUG
daily B-FRE

 I-FRE
Lidocaine B-DRUG
HCl I-DRUG
5 B-STR
% I-STR
Ointment B-FOR
topical B-ROU
TID B-FRE
prn I-FRE
rectal B-REA
pain I-REA

 I-REA
Warfarin B-DRUG
6 B-STR
mg I-STR
for B-FRE
the I-FRE
first I-FRE
day I-FRE
follwed O
by O
4 B-STR
mg I-STR
in B-FRE
the I-FRE
next I-FRE
two I-FRE

 I-FRE
days I-FRE



 I-FRE

Discharge O
Medications O
: O

 O
1 O
. O
Vancomycin B-DRUG
125 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
as O

 O
directed O
: O
125 B-STR
mg I-STR
4 B-FRE
times I-FRE
per I-FRE
day I-FRE
through O
[ O
* O
* O
2125 O
- O
9 O
- O
26 O
* O
* O
] O
, O
14 B-DUR
days I-DUR
, I-DUR
then O

 O
125 B-STR
mg I-STR
2 B-FRE
times I-FRE
per I-FRE
day I-FRE
through O
[ O
* O
* O
2125 O
- O
10 O
- O
3 O
* O
* O
] O
, O
7 B-DUR
days I-DUR
, I-DUR
then O

 O
125 B-STR
mg I-STR
1 B-FRE
time I-FRE
per I-FRE
day I-FRE
through O
[ O
* O
* O
2125 O
- O
10 O
- O
10 O
* O
* O
] O
, O
7 B-DUR
days I-DUR
, I-DUR
then O

 O
125 B-STR
mg I-STR
every B-FRE
other I-FRE
day I-FRE
through O
[ O
* O
* O
2125 O
- O
10 O
- O
18 O
* O
* O
] O
, O
8 B-DUR
days I-DUR
, I-DUR
then O

 O
125 B-STR
mg I-STR
every B-FRE
3rd I-FRE
day I-FRE
through O
[ O
* O
* O
2125 O
- O
11 O
- O
2 O
* O
* O
] O
, O
15 B-DUR
days I-DUR
. I-DUR

 O
Disp:*90 O
Capsule(s O
) O
* O
Refills:*0 O
* O

 O
2 O
. O
Citalopram B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
3 O
. O
Gabapentin B-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FRE
, I-FRE
Delayed I-FRE
Release I-FRE
( I-FRE
E.C. I-FRE
) I-FRE
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Cholecalciferol B-DRUG
( I-DRUG
Vitamin I-DRUG
D3 I-DRUG
) I-DRUG
400 B-STR
unit I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
Calcium B-DRUG
Carbonate I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Multivitamin B-DRUG
     O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
8 O
. O
Acetaminophen B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
9 O
. O
Alprazolam B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Trazodone B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
as I-FRE

 I-FRE
needed I-FRE
for O
insomnia B-REA
. I-REA

 O
11 O
. O
Warfarin B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Once B-FRE
Daily I-FRE
at I-FRE
4 I-FRE

 I-FRE
PM I-FRE
: I-FRE
please O
have O
INR O
checked O
2 O
days O
after O
discharge O
and O
adjust O

 O
according O
to O
your O
PCP O
. O
  O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
18303 O
* O
* O
] O
INR O
[ O
* O
* O
1 O
- O
2 O
* O
* O
] O
. O

 O
12 O
. O
Outpatient O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
Work O

 O
PT/INR O
on O
[ O
* O
* O
2125 O
- O
9 O
- O
20 O
* O
* O
] O
, O
[ O
* O
* O
2125 O
- O
9 O
- O
22 O
* O
* O
] O
. O

 O
to O
fax O
to O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
20561 O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
26190 O
* O
* O
] O

 O
Fax O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
81080 O
* O
* O
] O


 O
13 O
. O
Enoxaparin B-DRUG
40 B-STR
mg/0.4 I-STR
mL I-STR
Syringe B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
injection B-FOR

 I-FOR
Subcutaneous B-ROU
Q12 B-FRE
HR I-FRE
( O
): O
subcutaneously B-ROU
until O
INR O
2 O
. O

 O
Disp:*10 O
injection O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
* O
* O
] O
VNA O


 O
Discharge O
Diagnosis O
: O

 O
# O
C-diff O
colitis O
, O
protracted O

 O
# O
Sepsis O
due O
to O
c-diff O
colitis O

 O
# O
acute O
exacerbation O
of O
diastolic O
heart O
failure O

 O
# O
Acute O
renal O
failure O

 O
# O
Right O
brachial O
plexopathy O

 O
# O
Peripheral B-ADE
neuropathy I-ADE
, I-ADE
new O
; O
likely O
d/t O
Flagyl B-DRUG

 I-DRUG
# O
Anticoagulation B-REA
on O
coumadin B-DRUG



 I-DRUG
Discharge O
Condition O
: O

 O
stable O
, O
diarrhea O
, O
improved O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
with O
recurrent O
diarrhea O
due O
to O
your O
c-diff B-REA

 I-REA
infection I-REA
. I-REA
  O
Please O
take O
your O
medications O
as O
prescribed O
. O
  O
It O
will O

 O
be O
very O
important O
to O
complete O
the O
full O
course O
of O
vancomycin B-DRUG
, I-DRUG

 O
even O
if O
you O
start O
feeling O
better O
. O
  O
You O
will O
be O
tapered O
off O
this O

 O
medication O
. O
  O
Please O
seek O
medical O
attention O
if O
you O
develop O

 O
worsened O
diarrhea O
, O
abdominal O
pain O
, O
blood O
in O
your O
stools O
, O
fevers O
, O

 O
chills O
, O
or O
any O
other O
concerns O
. O
  O
Also O
, O
your O
coumadin B-DRUG
is O
not O
in O

 O
the O
desired O
range O
. O
  O
You O
will O
need O
to O
take O
Lovenox B-DRUG
injections B-FOR

 I-FOR
until O
your O
coumadin B-DRUG
level O
is O
therapeutic O
. O

 O
. O


 O
New O
medication O
: O

 O
Vancomycin B-DRUG
, I-DRUG
oral B-ROU
: I-ROU

 O
125 B-STR
mg I-STR
4 B-FRE
times I-FRE
per I-FRE
day I-FRE
through O
[ O
* O
* O
2125 O
- O
9 O
- O
26 O
* O
* O
] O
, O
14 B-DUR
days I-DUR
, I-DUR
then O

 O
125 B-STR
mg I-STR
2 B-FRE
times I-FRE
per I-FRE
day I-FRE
through O
[ O
* O
* O
2125 O
- O
10 O
- O
3 O
* O
* O
] O
, O
7 B-DUR
days I-DUR
, I-DUR
then O

 O
125 B-STR
mg I-STR
1 B-FRE
time I-FRE
per I-FRE
day I-FRE
through O
[ O
* O
* O
2125 O
- O
10 O
- O
10 O
* O
* O
] O
, O
7 B-DUR
days I-DUR
, I-DUR
then O

 O
125 B-STR
mg I-STR
every B-FRE
other I-FRE
day I-FRE
through O
[ O
* O
* O
2125 O
- O
10 O
- O
18 O
* O
* O
] O
, O
8 B-DUR
days I-DUR
, I-DUR
then O

 O
125 B-STR
mg I-STR
every B-FRE
3rd I-FRE
day I-FRE
through O
[ O
* O
* O
2125 O
- O
11 O
- O
2 O
* O
* O
] O
, O
15 B-DUR
days I-DUR

 I-DUR
. O

 O
Lovenox B-DRUG
40 B-STR
mg I-STR
subcutaneously B-ROU
twice B-FRE
daily I-FRE
until O
INR O
is O
2 O
. O

 O
. O

 O
Appointments O
have O
been O
made O
for O
you O
. O
  O
Please O
return O
to O
the O

 O
hospital O
if O
you O
experience O
fevers/chills O
, O
worsening O
abdominal O

 O
pain O
, O
lightheadedness O
, O
or O
any O
other O
symptoms O
. O


 O
Followup O
Instructions O
: O

 O
Appointment O
# O
1 O

 O
MD O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
20561 O
* O
* O
] O

 O
Specialty O
: O
Internal O
Medicine O
/ O
PCP O

 O
Date O
and O
time O
: O
Monday O
, O
[ O
* O
* O
10 O
- O
1 O
* O
* O
] O
, O
1:20pm O

 O
Location O
: O
One O
Pearl O
St O
, O
[ O
* O
* O
Hospital1 O
1474 O
* O
* O
] O
MA O

 O
Phone O
number O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
26190 O
* O
* O
] O

 O
Special O
instructions O
if O
applicable O
: O

 O
. O

 O
Appointment O
# O
2 O

 O
MD O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
2643 O
* O
* O
] O

 O
Specialty O
: O
Gastroenterology O

 O
Date O
and O
time O
: O
Monday O
, O
[ O
* O
* O
10 O
- O
15 O
* O
* O
] O
, O
11 O
am O

 O
Location O
: O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
, O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
Buidling O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
Location O
( O
un O
) O
86 O
* O
* O
] O

 O
Phone O
number O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
463 O
* O
* O
] O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2104 O
- O
12 O
- O
31 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2038 O
- O
10 O
- O
7 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
NEUROLOGY O


 O
Allergies O
: O

 O
Penicillins B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
2569 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
R-sided O
weakness O
and O
R O
facial O
droop O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O


 O
History O
of O
Present O
Illness O
: O

 O
66 O
year-old O
right-handed O
man O
with O
PMH O

 O
significant O
for O
HTN O
, O
a.fib B-REA
( O
on O
Coumadin B-DRUG
) I-DRUG
, O
s/p O

 O
defibrillator/pacemaker O
( O
he O
says O
for O
bradycardia O
) O
CAD O
s/p O
2 O

 O
stents O
, O
prior O
stroke(initially O
with O
left O
sided O
weakness O
but O
he O

 O
reports O
no O
residual O
weakness O
) O
presented O
to O
[ O
* O
* O
Hospital6 O
50929 O
* O
* O
] O
this O
morning O
with O
right O
sided O
weakness O
. O
He O
says O
he O
woke O

 O
up O
at O
4AM O
to O
go O
to O
the O
bathroom O
, O
but O
upon O
awakening O
, O
noticed O

 O
that O

 O
his O
right O
hand O
and O
arm O
was O
weak O
. O
He O
tried O
getting O
out O
of O
bed O
, O

 O
but O

 O
fell O
to O
the O
ground O
because O
of O
right O
sided O
weakness O
. O
He O
says O
he O

 O
stayed O
on O
the O
ground O
for O
a O
few O
minutes O
, O
but O
was O
able O
to O
get O

 O
himself O
up O
. O
He O
noticed O
that O
the O
right O
side O
of O
his O
face O
was O

 O
drooping O
and O
that O
his O
speech O
was O
slurred O
. O
He O
was O
initially O

 O
brought O
to O
OSH O
, O
where O
a O
NCHCT O
showed O
a O
left O
basal O
ganglia O

 O
hemorrhage O
. O
He O
was O
given O
10 B-STR
mg I-STR
of O
Vitamin B-DRUG
K I-DRUG
for O
an O
INR B-REA
of I-REA
2.6 I-REA

 I-REA
( O
no O

 O
FFP B-DRUG
was O
given O
) O
and O
Labetalol B-DRUG
20 B-STR
mg I-STR
IV B-ROU
for O
a O
SBP B-REA
in I-REA
the I-REA
170s I-REA
. I-REA
He O

 O
was O
then O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
further O
management O
. O

   O
He O
says O
that O
he O
believes O
his O
right O
arm O
is O
most O
affected O

 O
( O
weakest O
, O
no O
sensory O
changes O
reported O
) O
, O
followed O
by O
his O
face O
and O

 O
then O
his O
leg O
. O
He O
says O
there O
has O
not O
been O
any O
progression O
of O
his O

 O
symptoms O
since O
onset O
this O
morning O
upon O
awakening O
. O
No O
other O

 O
symptoms O
aside O
from O
right O
sided O
weakness O
and O
slurred O
speech O
, O

 O
inlcuding O
no O
sensory O
changes O
, O
visual O
changes O
, O
headache O
, O
vertigo O
, O

 O
nausea/vomiting O
. O
In O
the O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
, O
he O
received O
Profilinine B-DRUG
, I-DRUG
was O

 O
ordered O
for O
2 B-DOS
units I-DOS
FFP B-DRUG
( O
did O
not O
receive O
while O
in O
ED O
, O
but O
was O

 O
due O

 O
to O
receive O
in O
ICU O
) O
and O
started O
on O
a O
Nicardipine B-DRUG
gtt B-ROU
. I-ROU



 O

Neuro O
ROS O
: O
Positive O
for O
right O
sided O
weakness O
and O
dysarthria O
as O

 O
per O
HPI O
. O
He O
does O
note O
neck O
pain O
beginning O
yetserday O
evening O
, O
but O

 O
no O
headache O
, O
loss O
of O
vision O
, O
blurred O
vision O
, O
diplopia O
, O

 O
dysphagia O
, O

 O
lightheadedness O
, O
vertigo O
, O
tinnitus O
or O
hearing O
difficulty O
. O
No O

 O
difficulties O
producing O
or O
comprehending O
speech O
. O
No O
focal O

 O
numbness O
, O
parasthesiae O
. O
He O
does O
report O
episode O
of O
urinary O

 O
incontinence O
with O
standing O
this O
morning O
, O
but O
no O
prior O
episode O
of O

 O
urinary O
incontinence O
. O


 O
General O
ROS O
: O
No O
fever O
or O
chills O
. O
No O
cough O
, O
shortness O
of O
breath O
, O

 O
chest O
pain O
or O
tightness O
, O
palpitations O
, O
nausea O
, O
vomiting O
, O

 O
diarrhea O
, O
constipation O
or O
abdominal O
pain O
. O
No O
dysuria O
. O
No O
rash O
. O


 O
Past O
Medical O
History O
: O

 O
-HTN O

 O
-a B-REA
. I-REA
fib I-REA
( O
on O
Coumadin B-DRUG
) I-DRUG

 O
-pacemaker/defibrillator O
( O
he O
reports O
for O
slow O
heart O
rate O
) O

 O
-CAD O
s/p O
2 O
stents O

 O
-2 O
prior O
strokes O
( O
one O
resulted O
in O
left O
sided O
weakness O
at O

 O
presentation O
but O
no O
residual O
deficits O
) O

 O
-left O
wrist O
surgery O

 O
-depression O



 O
Social O
History O
: O

 O
He O
lives O
with O
his O
son O
. O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
is O
retired O
; O
he O
previously O
worked O
for O
a O

 O
construction O
company O
. O
He O
has O
a O
distant O
smoking O
history O
, O
quit O

 O
over O
40 O
years O
ago O
. O
No O
alcohol O
or O
illicit O
drug O
use O
. O



 O
Family O
History O
: O

 O
Mother O
deceased O
at O
age O
77 O
with O
history O
of O
diabetes O
and O

 O
CAD O
. O
Father O
deceased O
at O
age O
56 O
from O
a O
stroke O
. O
Sister O
with O

 O
[ O
* O
* O
Name2 O
( O
NI O
) O
* O
* O
] O
. O



 O
Physical O
Exam O
: O

 O
Admission O
Physical O
Exam O
: O


 O
Vitals O
: O
T O
: O
98.6 O
P O
: O
50 O
R O
: O
16 O
  O
BP O
: O
178/95 O
( O
up O
to O
200s O
systolic O
) O

 O
SaO2 B-DRUG
: I-DRUG
98 O
% O
on O
2L B-DOS
NC B-ROU


 I-ROU
General O
: O
Awake O
, O
cooperative O
, O
NAD O
. O

 O
HEENT O
: O
NC/AT O
, O
no O
scleral O
icterus O
noted O
, O
dry O
mucus O
membranes O

 O
Neck O
: O
Supple O

 O
Chest O
: O
lcta O
b/l O
. O
there O
is O
well-healed O
scar O
on O
anterior O
left O

 O
chest O

 O
with O
underlying O
device O
( O
pacemaker/defib O
) O
. O

 O
Cardiac O
: O
bradycardic O
, O
S1S2 O

 O
Abdomen O
: O
soft O
, O
nondistended O
, O
+ O
BS O

 O
Extremities O
: O
warm O
, O
well O
perfused O

 O
Skin O
: O
no O
rashes O
or O
lesions O
noted O
. O


 O
Neurologic O
: O



 O
Mental O
Status O
: O
Awake O
, O
alert O
, O
oriented O
to O
person O
, O
" O
hospital O
, O
" O

 O
month O
and O
year O
, O
but O
not O
to O
date O
. O
  O
Able O
to O
relate O
history O
without O

 O
difficulty O
. O
Able O
to O
name O
POTUS O
. O
Inattentive O
, O
unable O
to O
name O
[ O
* O
* O
Doctor O
Last O
Name O
1841 O
* O
* O
] O

 O
forwards O
or O
backwards O
; O
able O
to O
name O
DOW O
backwards O
. O
Able O
to O

 O
follow O

 O
both O
midline O
and O
appendicular O
commands O
. O
No O
right-left O
confusion O
. O

 O
Able O
to O
register O
3 O
objects O
and O
recall O
[ O
* O
* O
12 O
- O
19 O
* O
* O
] O
at O
5 O
minutes O
( O
[ O
* O
* O
1 O
- O
17 O
* O
* O
] O
with O

 O
prompting O
) O
. O
No O
evidence O
of O
apraxia O
or O
neglect O


 O
Language O
: O
speech O
is O
dysarthric O
, O
but O
is O
otherwise O
fluent O
with O

 O
intact O
naming O
, O
repetition O
and O
comprehension O
. O
Normal O
prosody O
. O


 O
Cranial O
Nerves O
: O

 O
I O
: O
Olfaction O
not O
tested O
. O

 O
II O
: O
PERRL O
3 O
to O
2 O
mm O
. O
  O
VFF O
to O
confrontation O
. O
Funduscopic O
exam O

 O
revealed O
no O
papilledema O
, O
exudates O
, O
or O
hemorrhages O
. O

 O
III O
, O
IV O
, O
VI O
: O
EOMI O
without O
nystagmus O
. O

 O
V O
: O
Facial O
sensation O
intact O
to O
light O
touch O
. O

 O
VII O
: O
right O
lower O
facial O
droop O

 O
VIII O
: O
Hearing O
intact O
to O
finger-rub O
bilaterally O
. O

 O
IX O
, O
X O
: O
Palate O
elevates O
symmetrically O
. O

 O
[ O
* O
* O
Doctor O
First O
Name O
81 O
* O
* O
] O
: O
5/5 O
strength O
in O
trapezii O
and O
SCM O
bilaterally O
. O

 O
XII O
: O
Tongue O
protrudes O
in O
midline O
. O


 O
Motor O
: O
Normal O
bulk O
. O
Slightly O
increased O
tone O
in O
RLE O
. O
Right O

 O
pronator O
drift O
. O
No O
adventitious O
movements O
, O
such O
as O
tremor O
, O

 O
noted O
. O

 O
No O
asterixis O
noted O
. O

   O
Delt O
Bic O
Tri O
WrE O
FFl O
FE O
IP O
Quad O
Ham O
TA O
Gastroc O

 O
L O
  O
5 O
    O
5 O
   O
5 O
   O
5 O
   O
5 O
  O
5 O
  O
5 O
   O
5 O
    O
5 O
  O
5 O
     O
5 O

 O
R O
  O
4 O
+ O
   O
5 O
   O
5- O
  O
5- O
  O
5 O
  O
5- O
5- O
  O
5 O
    O
5 O
  O
5 O
     O
5 O


 O
Sensory O
: O
No O
deficits O
to O
light O
touch O
, O
pinprick O
, O
proprioception O

 O
throughout O
. O
Vibratory O
sense O
3 O
seconds O
at O
right O
great O
toe O
and O
5 O

 O
seconds O
at O
left O
great O
toe O
. O
No O
extinction O
to O
DSS O
. O


 O
DTRs O
: O

   O
[ O
* O
* O
Name2 O
( O
NI O
) O
* O
* O
] O
Tri O
[ O
* O
* O
Last O
Name O
( O
un O
) O
1035 O
* O
* O
] O
Pat O
Ach O

 O
L O
  O
3 O
  O
2 O
    O
3 O
    O
3 O
   O
0 O

 O
R O
  O
1 O
  O
1 O
    O
1 O
    O
2 O
   O
0 O

 O
Plantar O
response O
was O
extensor O
bilaterally O
. O


 O
Coordination O
: O
no O
dysmetria O
or O
intention O
tremor O
on O
F-N O
or O
F-N-F O

 O
on O

 O
left O
. O
There O
is O
dysmetria O
on O
F-N-F O
on O
right O
( O
did O
not O
appear O
out O

 O
of O

 O
proportion O
to O
weakness O
. O
RAMs O
are O
slow O
and O
slightly O
clumsy O
b/l O
, O

 O
but O
more O
impaired O
on O
right O
. O


 O
Gait O
: O
deferred O

 O
. O

 O
. O


 O
DISCHARGE O
PHYSICAL O
EXAM O
: O

 O
A+Ox3 O
Spanish O
speaking O
but O
speaks O
good O
English O
and O
follows O

 O
commands O
well O
. O
Speech O
is O
dysarhtric O
but O
fluent O
and O
no O
evidence O

 O
of O
mental O
status O
abnormalities O
with O
no O
neglect O
. O
Right O
facial O

 O
droop O
and O
otherwise O
CN O
exam O
unremarkable O
. O
Right O
pronator O
drift O

 O
with O
mild O
right O
hemiparesis O
( O
delt O
[ O
* O
* O
2 O
- O
19 O
* O
* O
] O
, O
tri/WE/FE/IP O
4+/5 O
) O
. O

 O
Plantars O
extensor O
bilaterally O
. O


 O
Pertinent O
Results O
: O

 O
Laboratory O
investigations O
: O

 O
ADMISSION O
LABS O
: O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
02:00PM O
BLOOD O
WBC-5.6 O
RBC-4.68 O
Hgb-14.8 O
Hct-41.4 O
MCV-88 O

 O
MCH-31.7 O
MCHC-35.8 O
* O
RDW-13.6 O
Plt O
Ct-188 O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
02:00PM O
BLOOD O
Neuts-79.6 O
* O
Lymphs-11.2 O
* O
Monos-5.9 O

 O
Eos-2.6 O
Baso-0.6 O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
02:00PM O
BLOOD O
PT-24.2 O
* O
PTT-35.4 O
INR(PT)-2.3 O
* O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
02:00PM O
BLOOD O
Glucose-105 O
* O
UreaN-23 O
* O
Creat-1.3 O
* O
Na-141 O

 O
K-3.2 O
* O
Cl-105 O
HCO3 O
- O
27 O
AnGap-12 O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
02:49AM O
BLOOD O
ALT-49 O
* O
AST-30 O
AlkPhos-99 O
TotBili-1.9 O
* O

 O
. O

 O
Other O
pertinent O
labs O
: O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
02:00PM O
BLOOD O
cTropnT-<0.01 O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
12:09AM O
BLOOD O
cTropnT-<0.01 O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
02:49AM O
BLOOD O
ALT-49 O
* O
AST-30 O
AlkPhos-99 O
TotBili-1.9 O
* O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
02:49AM O
BLOOD O
Albumin-4.0 O
Calcium-9.2 O
Phos-3.4 O
Mg-2.0 O

 O
Cholest-240 O
* O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
02:49AM O
BLOOD O
Triglyc-111 O
HDL-41 O
CHOL/HD-5.9 O

 O
LDLcalc-177 O
* O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
02:49AM O
BLOOD O
% O
HbA1c-5.4 O
eAG-108 O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
02:00PM O
BLOOD O
PT-24.2 O
* O
PTT-35.4 O
INR(PT)-2.3 O
* O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
06:03PM O
BLOOD O
PT-14.9 O
* O
PTT-29.1 O
INR(PT)-1.4 O
* O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
02:49AM O
BLOOD O
PT-12.8 O
* O
PTT-29.6 O
INR(PT)-1.2 O
* O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
31 O
* O
* O
] O
04:45AM O
BLOOD O
PT-11.2 O
PTT-26.7 O
INR(PT)-1.0 O

 O
. O

 O
Discharge O
labs O
: O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
31 O
* O
* O
] O
04:45AM O
BLOOD O
WBC-5.5 O
RBC-4.51 O
* O
Hgb-13.3 O
* O
Hct-40.1 O

 O
MCV-89 O
MCH-29.5 O
MCHC-33.2 O
RDW-13.7 O
Plt O
Ct-185 O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
31 O
* O
* O
] O
04:45AM O
BLOOD O
PT-11.2 O
PTT-26.7 O
INR(PT)-1.0 O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
31 O
* O
* O
] O
04:45AM O
BLOOD O
Glucose-116 O
* O
UreaN-32 O
* O
Creat-1.6 O
* O
Na-142 O

 O
K-3.6 O
Cl-107 O
HCO3 O
- O
28 O
AnGap-11 O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
31 O
* O
* O
] O
04:45AM O
BLOOD O
Calcium-9.0 O
Phos-3.2 O
Mg-2.1 O

 O
. O

 O
. O


 O
Urine O
: O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
03:26AM O
URINE O
Color-Yellow O
Appear-Clear O
Sp O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
-1.012 O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
03:26AM O
URINE O
Blood-NEG O
Nitrite-NEG O
Protein-NEG O

 O
Glucose-NEG O
Ketone-NEG O
Bilirub-NEG O
Urobiln-NEG O
pH-6.5 O
Leuks-NEG O

 O
. O

 O
. O

 O
Mictobiology O
: O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
5:45 O
pm O
MRSA O
SCREEN O
      O
Source O
: O
Nasal O
swab O
. O


    O
MRSA O
SCREEN O
( O
Pending O
) O
: O

 O
. O

 O
. O

 O
Radiology O
: O

 O
CT O
HEAD O
W/O O
CONTRAST O
Study O
Date O
of O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
4:58 O
PM O

 O
Preliminary O
report O

 O
FINDINGS O
: O
A O
17 O
x O
14 O
mm O
intraparenchymal O
bleed O
in O
the O
left O

 O
lentiform O
nucleus O
is O
unchanged O
from O
the O
prior O
CT O
approximately O

 O
six O
hours O
prior O
. O
There O
is O
mild O
mass O
effect O
due O
to O
surrounding O

 O
edema O
with O
compression O
of O
the O
adjacent O
sulci O
, O
but O
no O
shift O
of O

 O
the O
normal O
midline O
structures O
or O
evidence O
of O
herniation O
. O
No O
new O

 O
foci O
of O
hemorrhage O
are O
present O
. O

 O
A O
hypodense O
region O
just O
anterior O
to O
the O
hemorrhage O
is O
likely O
an O

 O
old O
lacunar O
infarct O
. O
The O
ventricles O
and O
sulci O
are O
normal O
in O
size O

 O
and O
configuration O
. O
The O
basal O
cisterns O
are O
patent O
. O
The O
visualized O

 O
paranasal O
sinuses O
, O
mastoid O
air O
cells O
, O
and O
middle O
ear O
cavities O

 O
are O
clear O
. O


 O
IMPRESSION O
: O
No O
change O
in O
the O
left O
lentiform O
nucleus O

 O
intraparenchymal O
hemorrhage O
. O
This O
is O
likely O
secondary O
to O

 O
hypertension O
. O
Further O
workup O
to O
exclude O
vascular O
or O
neoplastic O

 O
etiologies O
can O
be O
pursued O
based O
on O
clinical O
correlation O
. O

 O
. O

 O
CTA O
HEAD O
W&W/O O
C O
& O
RECONS O
Study O
Date O
of O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
3:18 O
AM O

 O
FINDINGS O
: O
As O
seen O
on O
the O
previous O
CT O
, O
there O
is O
a O
1.7 O
cm O
x O
1.4 O
cm O

 O
x O
2.4 O
cm O

 O
sized O
acute O
intracranial O
hematoma O
in O
the O
left O
basal O
ganglia O
with O

 O
surrounding O

 O
edema O
. O
There O
is O
no O
appreciable O
mass O
effect O
on O
the O
lateral O

 O
ventricle O
. O
There O

 O
is O
no O
midline O
shift O
. O
An O
old O
infarct O
is O
seen O
in O
the O
left O
anterior O

 O
basal O

 O
ganglia O
extending O
into O
the O
corona O
radiata O
with O
ex O
vacuo O

 O
dilatation O
of O
the O
left O

 O
lateral O
ventricle O
. O
Also O
seen O
are O
multiple O
chronic O
lacunar O

 O
infarcts O
in O
the O

 O
right O
caudate O
and O
lentiform O
nuclei O
. O
Visualized O
orbits O
, O
paranasal O

 O
sinuses O
, O
and O

 O
mastoid O
air O
cells O
are O
unremarkable O
. O
No O
fracture O
is O
seen O
. O


 O
CTA O
HEAD O
: O
Bilateral O
intracranial O
internal O
carotid O
arteries O
, O

 O
vertebral O

 O
arteries O
, O
basilar O
artery O
and O
their O
major O
branches O
are O
patent O

 O
with O
no O
evidence O

 O
of O
stenosis O
, O
occlusion O
, O
or O
dissection O
. O
A O
small O
less O
than O
2-mm O

 O
sized O
aneurysm O

 O
is O
seen O
arising O
from O
the O
left O
ICA O
bifurcation O
. O
The O
anterior O

 O
communicating O

 O
artery O
appears O
bulbous O
without O
any O
definite O
saccular O
aneurysm O
. O



 O
IMPRESSION O
: O

 O
1 O
. O
Unchanged O
left O
basal O
ganglia O
hemorrhage O
. O


 O
2 O
. O
Chronic O
infarct O
in O
the O
left O
anterior O
basal O
ganglia O
with O
ex O

 O
vacuo O

 O
dilatation O
of O
the O
left O
lateral O
ventricle O
as O
described O
above O
. O


 O
3 O
. O
Less O
than O
2-mm O
sized O
outpouching O
from O
the O
left O
ICA O

 O
bifurcation O
may O

 O
represent O
a O
tiny O
aneurysm O
. O
The O
anterior O
communicating O
artery O

 O
appears O
bulbous O
without O
any O
definite O
saccular O
aneurysm O
. O

 O
. O

 O
Cardiology O
: O

 O
ECG O
Study O
Date O
of O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
  O
2:45:18 O
PM O



 O
Sinus O
bradycardia O
. O
A-V O
conduction O
delay O
. O
Prolonged O
Q-T O
interval O
. O

 O
Marked O

 O
anterior O
and O
anterolateral O
T O
wave O
inversion O
consistent O
with O

 O
metabolic O

 O
abnormality O
or O
myocardial O
ischemia O
. O
No O
previous O
tracing O

 O
available O
for O

 O
comparison O
. O



 O
Read O
by O
: O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
E. O


   O
Intervals O
Axes O

 O
Rate O
PR O
QRS O
QT/QTc O
P O
QRS O
T O

 O
50 O
238 O
96 O
540/522 O
31 O
-1 O
-87 O


 O
Brief O
Hospital O
Course O
: O

 O
66 O
RHM O
with O
PMH O
significant O
for O
HTN O
, O
AF B-REA
( O
on O
warfarin B-DRUG
) I-DRUG
, O
s/p O

 O
defibrillator/pacemaker O
( O
for O
? O
bradycardia O
) O
CAD O
s/p O
2 O
stents O
, O

 O
prior O
stroke O
( O
initially O
with O
left O
sided O
weakness O
but O
no O
residual O

 O
deficit O
) O
presented O
to O
[ O
* O
* O
Hospital6 O
3105 O
* O
* O
] O
with O
right O
sided O

 O
weakness O
( O
arm O
> O
face O
> O
leg O
) O
and O
dysarthria O
. O
CT O
revealed O
a O
left O
basal O

 O
ganglia O
IPH O
and O
he O
was O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
on O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
. O
Given O

 O
the O
presence O
of O
the O
IPH O
, O
his O
warfarin B-DRUG
was O
reversed O
and O
stopped O
. O

 O
Patient O
was O
initially O
admitted O
to O
the O
ICU O
given O
significant O

 O
hypertension B-REA
requirinng O
an O
IV B-ROU
nicardipine B-DRUG
infusion B-ROU
. I-ROU
He O
was O

 O
transferred O
to O
the O
floor O
on O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
. O
CTA O
was O
stable O
and O
no O

 O
significant O
aneurysm O
was O
identified O
. O
Although O
the O
most O
likely O

 O
cause O
for O
his O
IPH O
is O
hypertension O
, O
it O
was O
not O
possible O
to O
do O
an O

 O
MRI O
to O
look O
for O
an O
underlying O
lesion O
given O
pacemaker O
. O
Aspirin B-DRUG

 I-DRUG
should O
be O
started O
in O
1 O
week O
and O
he O
will O
not O
be O
continued O
on O

 O
warfarin B-DRUG
. I-DRUG
He O
was O
transferred O
to O
rehab O
on O
[ O
* O
* O
2104 O
- O
12 O
- O
31 O
* O
* O
] O
and O
has O

 O
neurology O
follow-up O
. O
He O
should O
have O
a O
repeat O
CT O
head O
with O
and O

 O
without O
contrast O
prior O
to O
his O
follow-up O
to O
assess O
for O
the O

 O
presence O
of O
an O
underlying O
mass O
lesion O
. O

 O
. O

 O
. O


 O
# O
Neuro O
: O
Patient O
had O
a O
previous O
stroke O
as O
above O
with O
no O
residual O

 O
deficits O
and O
presented O
with O
right O
face O
, O
arm O
and O
leg O
weakness O
in O

 O
the O
setting O
of O
some O
mild O
neck O
pain O
but O
no O
clear O
headache O
on O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
29 O
* O
* O
] O
. O
At O
OSH O
he O
was O
found O
to O
have O
a O
left O
basal O
ganglia O

 O
hemorrhage O
. O
He O
was O
given O
10 B-STR
mg I-STR
of O
Vitamin B-DRUG
K I-DRUG
for O
an O
INR B-REA
of I-REA
2.6 I-REA

 I-REA
( O
no O
FFP B-DRUG
was O
given O
) O
and O
Labetalol B-DRUG
20 B-STR
mg I-STR
IV B-ROU
for O
a O
SBP B-REA
in I-REA
the I-REA
170s I-REA
. I-REA

 O
He O
was O
then O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
further O
management O
. O
At O

 O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
, O
he O
received O
Profilinine B-DRUG
( I-DRUG
activated I-DRUG
factor I-DRUG
IX I-DRUG
) I-DRUG
and O

 O
received O
2 B-DOS
units I-DOS
FFP B-DRUG
later O
for O
INR B-REA
2.3 I-REA
. I-REA
Examination O
revealed O

 O
right O
hemiparesis O
and O
right O
facial O
droop O
with O
dysarthria O
but O
no O

 O
aphasia O
, O
neglect O
or O
visual O
field O
defect O
. O
He O
was O
started O
on O
a O

 O
Nicardipine B-DRUG
infusion B-FOR
for O
SBP B-REA
up I-REA
to I-REA
200s I-REA
and O
was O
admitted O
to O
the O

 O
neuro O
ICU O
. O


 O
His O
head O
CTs O
remained O
stable O
showing O
no O
extension O
of O
the O
bleed O
. O

 O
CTA O
showed O
an O
old O
infarct O
in O
the O
left O
anterior O
basal O
ganglia O

 O
extending O
into O
the O
corona O
radiata O
with O
ex O
vacuo O
dilatation O
of O

 O
the O
left O
lateral O
ventricle O
in O
addition O
to O
multiple O
chronic O

 O
lacunar O
infarcts O
in O
the O
right O
caudate O
and O
lentiform O
nuclei O
and O

 O
angiography O
demonstrated O
a O
less O
than O
2-mm O
sized O
aneurysm O
arising O

 O
from O
the O
left O
ICA O
bifurcation O
. O


 O
Stroke O
risk O
factors O
were O
assessed O
with O
HbA1c O
5.4 O
% O
and O
FLP O

 O
revealed O
Cholesterol B-REA
240 I-REA
TGCs B-REA
111 I-REA
HDL B-REA
41 I-REA
LDL B-REA
177 I-REA
. I-REA
CEs O
were O

 O
negative O
. O
He O
was O
initially O
monitored O
with O
glucose O
fingersticks O

 O
and O
this O
was O
stopped O
after O
several O
normal O
readings O
. O
He O
was O

 O
therefore O
started O
on O
atorvastatin B-DRUG
40 B-STR
mg I-STR
daily B-FRE
and O
his O
fasting O

 O
lipids O
should O
be O
repeated O
in O
3 O
months O
. O


 O
He O
continued O
to O
receive O
daily B-FRE
vitamin B-DRUG
K I-DRUG
until O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
and O
INR O

 O
on O
[ O
* O
* O
2104 O
- O
12 O
- O
31 O
* O
* O
] O
was O
1.0 O
. O
He O
passed O
bedside O
swallow O
evaluation O
and O

 O
was O
placed O
on O
a O
regular O
diet O
. O
He O
slowly O
improved O
and O
was O

 O
transferred O
to O
the O
neurology O
floor O
on O
[ O
* O
* O
2104 O
- O
12 O
- O
30 O
* O
* O
] O
. O
We O
held O
all O

 O
antiplatelets B-DRUG
and O
aspirin B-DRUG
325 B-STR
mg I-STR
should O
be O
started O
in O
1 O
week O
. O
We O

 O
stopped O
warfarin B-DRUG
due O
to O
his O
hemorrhage B-ADE
. I-ADE
We O
were O
unable O
to O
obtain O

 O
an O
MRI O
given O
the O
patient O
's O
pacemaker O
and O
he O
will O
therefore O
need O

 O
a O
repeat O
CT O
scan O
with O
contrast O
to O
evaluate O
any O
possible O

 O
malignancy O
underlying O
the O
hemorrhage O
before O
his O
neurology O

 O
appointment O
. O



 O
The O
most O
likely O
cause O
of O
his O
hemorrhage O
is O
a O
hypertensive O
bleed O

 O
although O
his O
hypertension O
was O
controlled O
previously O
. O
As O
above O
we O

 O
will O
evaluate O
with O
interval O
scan O
to O
look O
for O
an O
underlying O

 O
lesion O
which O
may O
have O
bled O
. O


 O
His O
weakness O
was O
slowly O
improving O
at O
the O
time O
of O
discharge O
. O
He O

 O
was O
stable O
and O
BP O
was O
controlled O
on O
his O
home O
medications O
. O
He O
was O

 O
assessed O
by O
PT O
and O
deemed O
to O
benefit O
from O
rehab O
. O
He O
was O

 O
therefore O
transferred O
to O
rehab O
on O
[ O
* O
* O
2104 O
- O
12 O
- O
31 O
* O
* O
] O
. O

 O
. O

 O
# O
CVS O
: O
BP O
was O
initially O
uncontrolled O
and O
was O
markely O

 O
hypertensive O
requiring O
IV O
meds O
and O
ICU O
admission O
. O
This O
was O

 O
latterly O
controlled O
and O
BP O
on O
discharge O
was O
SBP O
120s-130s O
. O
He O

 O
was O
briefly O
hypotensive B-ADE
in O
the O
setting O
IV B-ROU
nicardipine B-DRUG
and O
home O

 O
anti-hypertensives B-DRUG
and O
this O
resolved O
before O
transfer O
to O
the O

 O
flor O
. O
We O
continued O
patient O
's O
home O
lisinopril B-DRUG
and O
carvedilol B-DRUG
. I-DRUG
  O
We O

 O
monitored O
his O
INR O
daily O
and O
was O
1.0 O
on O
discharge O
. O
Warfarin B-DRUG
was O

 O
stopped O
and O
he O
should O
be O
restarted O
on O
aspirin B-DRUG
325 B-STR
mg I-STR
daily B-FRE
in O
1 O

 O
week O
. O
Patient O
was O
started O
on O
atorvastatin B-DRUG
40 B-STR
mg I-STR
daily B-FRE
as O
above O

 O
and O
should O
have O
repeat O
FLP O
in O
3 O
months O
. O

 O
. O

 O
# O
Renal O
: O
Patient O
was O
admitted O
with O
Cr O
1.3 O
. O
He O
was O
not O
known O
to O

 O
have O
CRF O
. O
His O
Cr O
rose O
to O
1.6 O
post-CT O
contrast O
on O
[ O
* O
* O
2104 O
- O
12 O
- O
31 O
* O
* O
] O
. O
This O

 O
should O
be O
repeated O
in O
2 O
days O
time O
and O
then O
at O
least O
weekly O
. O

 O
. O

 O
# O
Code O
: O
Full O
Code O

 O
. O

 O
. O

 O
TRANSITIONAL O
CARE O
  O
ISSUES O
: O

 O
Patient O
will O
need O
a O
repeat O
CT O
head O
scan O
with O
contrast O
as O
an O

 O
outpatient O
in O
[ O
* O
* O
4 O
- O
24 O
* O
* O
] O
weeks O
from O
discharge O
. O
This O
has O
been O
requested O
. O

 O
Restart O
aspirin B-DRUG
at O
325 B-STR
mg I-STR
daily B-FRE
in O
1 O
week O
. O

 O
Please O
monitor O
Chem O
7 O
as O
Cr O
rose O
from O
1.3 O
to O
1.6 O
following O
CT O

 O
contrast O
. O

 O
Repeat O
fasting O
lipids O
in O
3 O
months O
. O


 O
Medications O
on O
Admission O
: O

 O
-Nitroglycerin B-DRUG
0.4 B-STR
mg I-STR
SL B-ROU
prn B-FRE
chest B-REA
pain I-REA

 I-REA
-Lisinopril B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
-Sertraline B-DRUG
100 B-STR
mg I-STR
daily B-FRE

 I-FRE
-Pantropazole B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
-Coumadin B-DRUG
5 B-STR
mg I-STR
daily B-FRE

 I-FRE
-ASA B-DRUG
81 B-STR
mg I-STR
daily B-FRE

 I-FRE
-Carvedilol B-DRUG
25 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O



 O

Discharge O
Medications O
: O

 O
1 O
. O
acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
2 O
. O
nitroglycerin B-DRUG
0.4 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Sublingual I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Sublingual B-ROU
once B-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
chest B-REA
pain I-REA
. I-REA

 O
3 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
4 O
. O
sertraline B-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
5 O
. O
carvedilol B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
6 O
. O
lisinopril B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
7 O
. O
pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
8 O
. O
atorvastatin B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE
bedtime I-FRE
. I-FRE




 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
diagnosis O
: O

 O
Left O
basal O
ganglia O
intraparenchymal O
hemorrhage O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
requires O
assistance O
or O
aid O
( O
[ O
* O
* O
Hospital6 O
* O
* O
] O

 O
or O
cane O
) O
. O

 O
Neurologic O
: O
A+Ox3 O
Spanish O
speaking O
but O
speaks O
good O
English O
and O

 O
follows O
commands O
well O
. O
Speech O
is O
dysarhtric O
but O
fluent O
and O
no O

 O
evidence O
of O
mental O
status O
abnormalities O
with O
no O
neglect O
. O
Right O

 O
facial O
droop O
and O
otherwise O
CN O
exam O
unremarkable O
. O
Right O
pronator O

 O
drift O
with O
mild O
right O
hemiparesis O
( O
delt O
[ O
* O
* O
2 O
- O
19 O
* O
* O
] O
, O
tri/WE/FE/IP O
4+/5 O
) O
. O

 O
Plantars O
extensor O
bilaterally O
. O



 O

Discharge O
Instructions O
: O

 O
It O
was O
a O
pleasure O
taking O
care O
of O
you O
during O
your O
stay O
at O
the O

 O
[ O
* O
* O
Known O
firstname O
3867 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
First O
Name O
( O
Titles O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Titles O
) O
* O
* O
] O
. O
You O
presented O
with O

 O
right-sided O
weakness O
and O
facial O
droop O
. O
You O
had O
a O
CT O
scan O
and O

 O
were O
found O
to O
have O
a O
bleed B-ADE
in I-ADE
your I-ADE
brain I-ADE
in O
the O
area O
of O
the O
left O

 O
basal O
ganglia O
. O
As O
you O
were O
on O
warfarin B-DRUG
( I-DRUG
Coumadin I-DRUG
) I-DRUG
which O
is O
a O

 O
blood B-REA
thinner I-REA
and O
worsens B-ADE
bleeding I-ADE
, I-ADE
this O
was O
reversed O
with O

 O
medications O
and O
Coumadin B-DRUG
was O
stopped O
. O
Your O
blood O
pressure O
was O

 O
initially O
high O
and O
you O
had O
to O
be O
treated O
with O
IV O
medications O
to O

 O
lower O
your O
blood O
pressure O
in O
the O
ICU O
. O
Your O
blood O
pressure O

 O
normalised O
and O
you O
were O
transferred O
to O
the O
neurology O
floor O
. O
You O

 O
did O
well O
and O
your O
strength O
on O
the O
right O
side O
was O
slowly O

 O
improving O
. O
Your O
warfarin B-DRUG
was O
stopped O
and O
should O
not O
be O
continued O

 O
due O
to O
further O
risk O
of O
bleeding O
. O
You O
should O
stop O
aspirin B-DRUG

 I-DRUG
currently O
and O
restrat O
at O
325 B-STR
mg I-STR
daily B-FRE
in O
1 O
week O
. O
We O
also O
started O

 O
atorvastatin B-DRUG
for O
high B-REA
cholesterol I-REA
as O
your O
cholesterol O
was O
found O

 O
to O
be O
high O
. O
This O
should O
be O
repeated O
in O
3 O
months O
time O
. O
Your O

 O
kidney O
function O
tests O
were O
also O
slightly O
abnormal O
following O
the O

 O
CT O
contrast O
and O
this O
will O
be O
followed O
at O
rehab O
. O
You O
were O

 O
continued O
on O
your O
other O
home O
medications O
. O
The O
most O
likely O
cause O

 O
of O
this O
brain O
hemorrhage O
was O
high O
blood O
pressure O
although O
given O

 O
your O
pacemaker O
we O
were O
unable O
to O
do O
an O
MRI O
. O
As O
a O
result O
you O
will O

 O
need O
to O
have O
a O
repeat O
CT O
scan O
in O
6 O
weeks O
  O
as O
at O
this O
point O
the O

 O
blood O
should O
have O
reabsorbed O
and O
we O
will O
be O
able O
to O
look O
to O
see O

 O
if O
there O
is O
any O
lesion O
underlying O
your O
hemorrhage O
. O
You O
were O

 O
deemed O
appropriate O
for O
rehab O
and O
transferred O
to O
rehab O
on O

 O
[ O
* O
* O
2104 O
- O
12 O
- O
31 O
* O
* O
] O
. O

 O
. O

 O
Medication O
changes O
: O

 O
We O
STOPPED O
aspirin B-DRUG
and O
this O
should O
be O
restarted O
at O
325 B-STR
mg I-STR
daily B-FRE

 I-FRE
in O
1 O
week O

 O
We O
STOPPED O
warfarin B-DRUG
( I-DRUG
Coumadin I-DRUG
) I-DRUG

 I-DRUG
We O
STARTED O
atorvastatin B-DRUG
40 B-STR
mg I-STR
daily B-FRE
for O
high B-REA
cholesterol I-REA

 I-REA
Please O
continue O
your O
other O
medications O
as O
previously O
prescribed O


 O
Followup O
Instructions O
: O

 O
Please O
see O
your O
PCP O
Dr O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
4886 O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
92176 O
* O
* O
] O
following O

 O
discharge O
from O
rehab O
. O

 O
. O

 O
We O
have O
arranged O
the O
following O
neurology O
follow-up O
: O



 O
Department O
: O
NEUROLOGY O

 O
When O
: O
FRIDAY O
[ O
* O
* O
2105 O
- O
2 O
- O
27 O
* O
* O
] O
at O
10:00 O
AM O

 O
With O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
162 O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2574 O
* O
* O
] O

 O
Building O
: O
[ O
* O
* O
Hospital6 O
29 O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
858 O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O


 O
You O
are O
due O
to O
have O
a O
CT O
scan O
before O
this O
appointment O
. O



                              O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
162 O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(2 O
) O
2575 O
* O
* O
] O


 O

Admission O
Date O
: O
  O
[ O
* O
* O
2122 O
- O
7 O
- O
21 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2122 O
- O
7 O
- O
31 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2063 O
- O
10 O
- O
26 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Penicillins B-DRUG
/ O
Dilaudid B-DRUG
/ O
Chlorhexidine B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
7333 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Ventricular O
Tachycardia O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Electrophysiology O
Study O
for O
attempted O
Ventricular O
Tachycardia O

 O
Ablation O

 O
Cardiac O
Catheterization O



 O
History O
of O
Present O
Illness O
: O

 O
58 O
year O
old O
male O
with O
a O
PMH O
of O
a-fib O
, O
OSA O
, O
PVD O
secondary O
to O
a O

 O
gunshot O
wound O
to O
his O
right O
lower O
leg O
, O
and O
non-ischemic O

 O
cardiomyopathy O
with O
a O
reported O
EF O
of O
15 O
- O
20 O
% O
in O
the O
past O
and O
a O

 O
recent O
EF O
of O
40 O
% O
. O
He O
had O
an O
AICD O
placed O
in O
[ O
* O
* O
5 O
- O
30 O
* O
* O
] O
, O
and O
he O
has O
had O

 O
4 O
episodes O
of O
syncope O
in O
the O
past O
2 O
months O
. O
He O
has O
been O
shocked O

 O
8x O
in O
total O
, O
with O
one O
episode O
shocking O
him O
four O
times O

 O
consecutively O
. O
  O
His O
history O
of O
cardiomyopathy O
( O
best O
attributed O

 O
to O
a O
possible O
viral O
illness O
, O
per O
patient O
report O
) O
, O
dates O
back O
8 O

 O
years O
. O
  O
He O
has O
also O
had O
long O
standing O
a-fib O
, O
and O
it O
is O
unclear O

 O
whether O
he O
had O
the O
cardiomyopathy O
or O
a-fib O
first O
as O
he O
has O
never O

 O
been O
symptomatic O
until O
[ O
* O
* O
Month O
( O
only O
) O
205 O
* O
* O
] O
. O

 O
. O

 O
He O
has O
had O
3 O
hospitalizations O
for O
syncope O
since O
[ O
* O
* O
2122 O
- O
5 O
- O
21 O
* O
* O
] O
. O
The O

 O
first O
of O
which O
was O
[ O
* O
* O
5 O
- O
24 O
* O
* O
] O
weekend O
, O
when O
his O
wife O
reports O

 O
witnessing O
him O
lose O
consciousness O
for O
a O
few O
seconds O
and O
falling O

 O
out O
of O
a O
chair O
. O
  O
He O
was O
evaluated O
at O
[ O
* O
* O
Hospital O
107 O
* O
* O
] O
Hospital O
, O
was O

 O
found O
to O
have O
VT B-REA
, I-REA
and O
had O
an O
AICD O
placed O
on O
[ O
* O
* O
2122 O
- O
5 O
- O
26 O
* O
* O
] O
. O

 O
. O


 O
0n O
[ O
* O
* O
7 O
- O
9 O
* O
* O
] O
he O
woke O
up O
from O
sleep O
, O
his O
AICD O
fired O
and O
15 O
minutes O

 O
later O
it O
fired O
again O
. O
He O
was O
asymptomatic O
at O
the O
time O
, O
he O
was O

 O
then O
taken O
to O
[ O
* O
* O
Hospital3 O
8544 O
* O
* O
] O
and O
transferred O
to O
[ O
* O
* O
Hospital O
107 O
* O
* O
] O

 O
hospital O
. O
  O
He O
was O
given O
a O
loading B-DOS
dose I-DOS
of O
amiodarone B-DRUG
, I-DRUG
and O

 O
converted O
to O
lower O
dose O
because O
of O
dizziness O
. O
  O
He O
was O
discharged O

 O
home O
and O
on O
[ O
* O
* O
7 O
- O
17 O
* O
* O
] O
, O
he O
was O
feeding O
his O
horses O
and O
felt O
dizzy O
and O

 O
lightheaded O
, O
fell O
to O
the O
ground O
had O
a O
jerking O
motion O
, O
his O
family O

 O
again O
witnessed O
the O
event O
. O
  O
He O
did O
n't O
feel O
like O
he O
was O
shocked O
, O

 O
and O
had O
no O
palpitations O
at O
the O
time O
. O
He O
lost O
consciousness O
and O

 O
his O
wife O
was O
able O
to O
get O
him O
into O
the O
car O
and O
take O
him O
to O
the O

 O
hospital O
. O
  O
He O
was O
initially O
treated O
for O
what O
was O
thought O
to O
be O

 O
ischemic O
chest O
pain O
. O
At O
[ O
* O
* O
Hospital3 O
* O
* O
] O
they O
gave O
him O
dilaudid B-DRUG

 I-DRUG
for O
chest B-REA
discomfort I-REA
which O
caused O
him O
to O
flush B-ADE
and O
have O

 O
diaphoresis B-ADE
. I-ADE
  O
He O
was O
transferred O
to O
[ O
* O
* O
Location O
( O
un O
) O
796 O
* O
* O
] O
and O
they O
gave O
him O

 O
nitroglycerin B-DRUG
, I-DRUG
which O
caused O
his O
blood B-ADE
pressure I-ADE
to I-ADE
drop I-ADE
. I-ADE
This O

 O
entire O
course O
he O
was O
kept O
on O
  O
amiodarone B-DRUG
of O
400 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O
He O
had O

 O
several O
6 O
- O
7 O
beat O
runs O
of O
NSVT B-REA
while O
there O
and O
on O
Monday O
[ O
* O
* O
7 O
- O
20 O
* O
* O
] O
he O

 O
was O
intially O
increased O
to O
400 B-STR
mg I-STR
TID B-FRE
of O
amio B-DRUG
, I-DRUG
then O
due O
to O

 O
persistent O
episodes O
of O
NSVT B-REA
he O
was O
put O
on O
IV B-ROU
amio B-DRUG
at O
1mg/min B-STR
and O

 O
transitioned O
today O
to O
0.5mg/min B-STR
. I-STR

 O
. O

 O
His O
outpatient O
cardiologist O
was O
concerned O
for O
AICD O
lead O

 O
migration O
and O
on O
[ O
* O
* O
7 O
- O
21 O
* O
* O
] O
he O
was O
taken O
to O
the O
cath O
lab O
for O
lead O

 O
replacement O
. O
Subsequently O
he O
developed O
20 O
beats O
of O
VT B-REA
, I-REA
at O
which O

 O
time O
the O
aforementioned O
amio B-DRUG
drip B-ROU
was O
started O
at O
1mg/minute B-STR
. I-STR

 O
Since O
that O
time O
his O
EKG O
and O
tele O
has O
shown O
paced O
beats O
and O

 O
ectopy O
. O

 O
. O

 O
Of O
note O
at O
the O
OSH O
his O
creatinine O
was O
1.1 O
, O
CE O
negative O
x O
3 O
, O

 O
electrolytes O
WNL O
, O
Vanc B-DRUG
ppx B-REA
for O
lead O
placement O
, O
Coreg B-DRUG
was O

 O
decreased O
to O
25 B-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
, O
Coumadin B-DRUG
was O
held O
, O
mag B-DRUG
oxide I-DRUG
added O
to O
keep O

 O
a-fib B-REA
better I-REA
controlled I-REA
. I-REA
He O
was O
continued O
on O
digoxin B-DRUG
and O

 O
lisinopril B-DRUG
. I-DRUG
BPs O
ranged O
86 O
- O
126/46 O
- O
60 O
. O

 O
. O


 O
On O
review O
of O
systems O
, O
he O
denies O
any O
prior O
history O
of O
stroke O
, O

 O
TIA O
, O
deep O
venous O
thrombosis O
, O
pulmonary O
embolism O
, O
bleeding O
at O
the O

 O
time O
of O
surgery O
, O
myalgias O
, O
joint O
pains O
, O
cough O
, O
hemoptysis O
, O
black O

 O
stools O
or O
red O
stools O
. O
S/he O
denies O
recent O
fevers O
, O
chills O
or O

 O
rigors O
. O
S/he O
denies O
exertional O
buttock O
or O
calf O
pain O
. O
All O
of O
the O

 O
other O
review O
of O
systems O
were O
negative O
. O

 O
. O

 O
Cardiac O
review O
of O
systems O
is O
notable O
for O
syncope O
, O
orthopnea O

 O
( O
chronic O
) O
, O
and O
lower O
extremity O
edema O
right O
greater O
than O
left O
, O
as O

 O
well O
as O
absence O
of O
chest O
pain O
, O
dyspnea O
on O
exertion O
, O
paroxysmal O

 O
nocturnal O
dyspnea O
, O
palpitations O
. O

 O
. O

 O
On O
the O
floor O
, O
initial O
vitals O
were O
T O
: O
96.5 O
, O
BP O
: O
98/72 O
, O
HR O
: O
93 O
, O

 O
RR O
: O
23 O
, O
SaO2 O
95 O
% O
on O
RA O
, O
resting O
comfortably O
in O
bed O
, O
asymptomatic O

 O
with O
his O
wife O
and O
son O
at O
the O
bedside O
. O

 O
. O


 O
Past O
Medical O
History O
: O

 O
1 O
. O
CARDIAC O
RISK O
FACTORS O
: O
None O

 O
2 O
. O
CARDIAC O
HISTORY O
: O

 O
Ventricular O
tachycardia O

 O
Chronic O
a-fib O

 O
nonischemic O
cardiomyopathy O
with O
(?)EF O
of O
20 O
- O
25 O
% O

 O
-CABG O
: O

 O
-PERCUTANEOUS O
CORONARY O
INTERVENTIONS O
: O

 O
-PACING/ICD O
: O
AICD O
placed O
in O
[ O
* O
* O
2122 O
- O
5 O
- O
26 O
* O
* O
] O

 O
3 O
. O
OTHER O
PAST O
MEDICAL O
HISTORY O
: O

 O
. O
  O
OSA O
on O
nasal O
CPAP O

 O
. O
  O
PVD O
secondary O
to O
gunshot O
wound O
at O
17 O

 O
. O
  O
Colecystectomy O



 O
Social O
History O
: O

 O
Former O
boxer O
, O
asymptomatic O
with O
activity O
. O
Currently O
a O
farmer O
. O

 O
-Tobacco O
history O
: O
denies O

 O
-ETOH O
: O
rare O
alcohol O
use O

 O
-Illicit O
drugs O
: O
denies O



 O
Family O
History O
: O

 O
2 O
sisters O
died O
from O
acute O
myocardial O
infarction O
. O
  O
One O
sister O
was O

 O
33 O
at O
the O
time O
of O
her O
death O
, O
and O
his O
other O
sister O
was O
50 O
when O

 O
she O
died O
of O
myocardial O
infarction O
. O
He O
states O
they O
do O
n't O
know O

 O
what O
caused O
the O
heart O
attacks O
. O



 O
Physical O
Exam O
: O

 O
VS O
: O
T O
: O
96.5 O
, O
BP O
: O
98/72 O
, O
HR O
: O
93 O
, O
RR O
: O
23 O
, O
SaO2 O
95 O
% O
on O
RA O

 O
GENERAL O
: O
Well O
appearing O
man O
in O
NAD O
. O
Oriented O
x3 O
. O
Mood O
, O
affect O

 O
appropriate O
. O
Appears O
his O
stated O
age O
. O

 O
HEENT O
: O
NCAT O
. O
Sclera O
anicteric O
. O
PERRL O
, O
EOMI O
. O
No O
pallor O
or O

 O
cyanosis O
of O
the O
oral O
mucosa O
. O

 O
NECK O
: O
Supple O
with O
JVP O
of O
~7 O
cm O
. O

 O
CARDIAC O
: O
Irregular O
rate O
with O
frequent O
extra O
beats O
, O
normal O
S1 O
, O

 O
S2 O
. O
No O
m/r/g O
. O

 O
LUNGS O
: O
No O
chest O
wall O
deformities O
, O
scoliosis O
or O
kyphosis O
. O
Resp O

 O
were O
unlabored O
, O
no O
accessory O
muscle O
use O
. O
Sparse O
end O
inspiratory O

 O
wheezes O
, O
but O
in O
all O
lung O
fields O
. O
  O
Mild O
scattered O
expiratory O

 O
rhonchi O
. O

 O
ABDOMEN O
: O
Soft O
, O
NTND O
. O
No O
HSM O
or O
tenderness O
. O
Abd O
aorta O
not O

 O
enlarged O
by O
palpation O
. O
No O
abdominial O
bruits O
. O
Scar O
on O
the O

 O
umbilicus O
from O
prior O
cholecystectomy O
. O

 O
EXTREMITIES O
: O
No O
c/c/e O
. O
Well O
healed O
scar O
, O
and O
considerable O

 O
indentation O
close O
to O
the O
medial O
tibial O
plateau O
with O
scar O
vs O
skin O

 O
graft O
well O
healed O
x O
many O
years O
on O
the O
right O
lower O
extremity O

 O
SKIN O
: O
No O
stasis O
dermatitis O
, O
ulcers O
, O
or O
scars O
. O

 O
PULSES O
: O

 O
Right O
: O
Carotid O
2 O
+ O
  O
DP O
2 O
+ O
PT O
2 O
+ O

 O
Left O
: O
Carotid O
2 O
+ O
  O
DP O
2 O
+ O
PT O
2 O
+ O

 O
. O

 O
Exam O
on O
Discharge O
: O


 O
VS O
: O
Tmax O
: O
98.9 O
T O
current O
: O
98.1 O
BP O
: O
100 O
- O
125/50 O
- O
71 O
HR O
: O
69 O
- O
85 O
RR O
: O

 O
18 O
SaO2 O
98 O
% O
on O
RA O

 O
24 O
hours O
: O
I=1040 O
O= O
1440 O

 O
8 O
hours O
: O
I=180 O
O=750 O

 O
GENERAL O
: O
Well O
appearing O
man O
in O
NAD O
. O

 O
HEENT O
: O
NCAT O
. O
Sclera O
anicteric O
. O

 O
NECK O
: O
Supple O
, O
no O
JVD O
. O

 O
CARDIAC O
: O
irregular O
rate O
, O
normal O
S1 O
, O
S2 O
. O
No O
m/r/g O
. O

 O
LUNGS O
: O
Resp O
were O
unlabored O
, O
no O
accessory O
muscle O
use O
. O
Wheezes O

 O
posteriorly O
. O
No O
cough O
. O

 O
ABDOMEN O
: O
Soft O
, O
NTND O
. O
No O
HSM O
or O
tenderness O
. O

 O
EXTREMITIES O
: O
No O
c/c/e O
. O
Right O
groin O
sites O
with O
minimal O
ecchymosis O

 O
and O
no O
hematoma O
. O

 O
SKIN O
: O
Rash O
improving O
, O
few O
patchy O
areas O
around O
pacer O
site O
, O
none O

 O
on O
neck O
now O
. O
Has O
peeling O
skin O
on O
left O
hand O
only O
, O
pt O
states O
this O

 O
is O
chronic O
. O

 O
PULSES O
: O

 O
Right O
: O
DP O
2 O
+ O
PT O
2 O
+ O

 O
Left O
: O
DP O
2 O
+ O
PT O
2 O
+ O



 O

Pertinent O
Results O
: O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
21 O
* O
* O
] O
08:42PM O
BLOOD O
WBC-8.3 O
RBC-3.95 O
* O
Hgb-12.1 O
* O
Hct-34.4 O
* O

 O
MCV-87 O
MCH-30.7 O
MCHC-35.3 O
* O
RDW-13.7 O
Plt O
Ct-218 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
22 O
* O
* O
] O
04:36AM O
BLOOD O
WBC-8.4 O
RBC-4.13 O
* O
Hgb-12.7 O
* O
Hct-36.2 O
* O

 O
MCV-88 O
MCH-30.7 O
MCHC-35.1 O
* O
RDW-13.8 O
Plt O
Ct-219 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
23 O
* O
* O
] O
06:13AM O
BLOOD O
WBC-8.9 O
RBC-4.19 O
* O
Hgb-12.6 O
* O
Hct-37.2 O
* O

 O
MCV-89 O
MCH-30.2 O
MCHC-34.0 O
RDW-13.8 O
Plt O
Ct-226 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
24 O
* O
* O
] O
02:28AM O
BLOOD O
WBC-10.0 O
RBC-4.20 O
* O
Hgb-12.8 O
* O
Hct-36.4 O
* O

 O
MCV-87 O
MCH-30.4 O
MCHC-35.1 O
* O
RDW-13.6 O
Plt O
Ct-234 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
21 O
* O
* O
] O
08:42PM O
BLOOD O
Neuts-78.7 O
* O
Lymphs-14.1 O
* O
Monos-4.7 O

 O
Eos-2.2 O
Baso-0.3 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
21 O
* O
* O
] O
08:42PM O
BLOOD O
PT-17.2 O
* O
PTT-25.1 O
INR(PT)-1.5 O
* O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
21 O
* O
* O
] O
08:42PM O
BLOOD O
Plt O
Ct-218 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
22 O
* O
* O
] O
04:36AM O
BLOOD O
PT-17.6 O
* O
PTT-40.7 O
* O
INR(PT)-1.6 O
* O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
22 O
* O
* O
] O
04:36AM O
BLOOD O
Plt O
Ct-219 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
23 O
* O
* O
] O
06:13AM O
BLOOD O
PT-15.8 O
* O
PTT-53.5 O
* O
INR(PT)-1.4 O
* O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
24 O
* O
* O
] O
02:28AM O
BLOOD O
PT-14.7 O
* O
PTT-23.9 O
INR(PT)-1.3 O
* O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
24 O
* O
* O
] O
02:28AM O
BLOOD O
Plt O
Ct-234 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
24 O
* O
* O
] O
08:36AM O
BLOOD O
PTT-58.3 O
* O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
21 O
* O
* O
] O
08:42PM O
BLOOD O
Glucose-114 O
* O
UreaN-18 O
Creat-1.3 O
* O
Na-137 O

 O
K-4.2 O
Cl-103 O
HCO3 O
- O
26 O
AnGap-12 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
22 O
* O
* O
] O
04:36AM O
BLOOD O
Glucose-115 O
* O
UreaN-18 O
Creat-1.3 O
* O
Na-139 O

 O
K-4.2 O
Cl-103 O
HCO3 O
- O
27 O
AnGap-13 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
23 O
* O
* O
] O
06:13AM O
BLOOD O
Glucose-109 O
* O
UreaN-22 O
* O
Creat-1.5 O
* O
Na-136 O

 O
K-4.3 O
Cl-101 O
HCO3 O
- O
27 O
AnGap-12 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
24 O
* O
* O
] O
02:28AM O
BLOOD O
Glucose-100 O
UreaN-26 O
* O
Creat-1.5 O
* O
Na-137 O

 O
K-4.1 O
Cl-100 O
HCO3 O
- O
27 O
AnGap-14 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
24 O
* O
* O
] O
08:36AM O
BLOOD O
Na-136 O
K-4.4 O
Cl-100 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
22 O
* O
* O
] O
04:36AM O
BLOOD O
ALT-51 O
* O
AST-29 O
AlkPhos-98 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
23 O
* O
* O
] O
06:13AM O
BLOOD O
Calcium-8.6 O
Phos-4.3 O
Mg-2.7 O
* O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
24 O
* O
* O
] O
02:28AM O
BLOOD O
Calcium-8.7 O
Phos-4.0 O
Mg-2.9 O
* O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
24 O
* O
* O
] O
08:36AM O
BLOOD O
Mg-2.5 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
21 O
* O
* O
] O
08:42PM O
BLOOD O
Calcium-9.0 O
Phos-3.3 O
Mg-2.4 O

 O

[ O
* O
* O
2122 O
- O
7 O
- O
22 O
* O
* O
] O
04:36AM O
BLOOD O
Triglyc-115 O
HDL-40 O
CHOL/HD-2.8 O
LDLcalc-48 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
22 O
* O
* O
] O
04:36AM O
BLOOD O
TSH-4.3 O
* O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
22 O
* O
* O
] O
04:36AM O
BLOOD O
Digoxin-0.9 O

 O
. O

 O
ECHO O
: O

 O
The O
left O
atrium O
is O
moderately O
dilated O
. O
The O
right O
atrium O
is O

 O
markedly O
dilated O
. O
The O
estimated O
right O
atrial O
pressure O
is O

 O
10 O
- O
20mmHg O
. O
There O
is O
mild O
symmetric O
left O
ventricular O
hypertrophy O
. O

 O
The O
left O
ventricular O
cavity O
is O
moderately O
dilated O
. O
Due O
to O

 O
suboptimal O
technical O
quality O
, O
a O
focal O
wall O
motion O
abnormality O

 O
can O
not O
be O
fully O
excluded O
. O
Overall O
left O
ventricular O
systolic O

 O
function O
appears O
severely O
depressed O
( O
LVEF= O
20 O
- O
25 O
% O
) O
but O
is O

 O
difficult O
to O
assess O
due O
to O
poor O
image O
quality O
and O
frequent O

 O
ventricular O
ectopy O
. O
Relative O
preservation O
of O
basal O
inferolateral O

 O
wall O
function O
. O
There O
is O
considerable O
beat-to-beat O
variability O
of O

 O
the O
left O
ventricular O
ejection O
fraction O
due O
to O
an O
irregular O

 O
rhythm/premature O
beats O
. O
The O
right O
ventricular O
cavity O
is O

 O
moderately O
dilated O
with O
depressed O
free O
wall O
contractility O
. O
The O

 O
aortic O
valve O
leaflets O
( O
3 O
) O
appear O
structurally O
normal O
with O
good O

 O
leaflet O
excursion O
and O
no O
aortic O
stenosis O
. O
Trace O
aortic O

 O
regurgitation O
is O
seen O
. O
The O
mitral O
valve O
leaflets O
are O

 O
structurally O
normal O
. O
There O
is O
no O
mitral O
valve O
prolapse O
. O
Trivial O

 O
mitral O
regurgitation O
is O
seen O
. O
The O
pulmonary O
artery O
systolic O

 O
pressure O
could O
not O
be O
determined O
. O
There O
is O
an O
anterior O
space O

 O
which O
most O
likely O
represents O
a O
prominent O
fat O
pad O
. O

 O
. O

 O
IMPRESSION O
: O
Suboptimal O
image O
quality O
. O
Dilated O
left O
ventricle O

 O
with O
severe O
systolic O
dysfunction O
. O
Right O
ventricular O
dilation O
and O

 O
dysfunction O
. O

 O
. O

 O
Cardiac O
Cath O
Study O
Date O
of O
[ O
* O
* O
2122 O
- O
7 O
- O
28 O
* O
* O
] O

 O
COMMENTS O
: O

 O
1 O
. O
  O
Coronary O
angiography O
in O
this O
right O
dominant O
system O

 O
demonstrated O
no O

 O
angiongraphically O
apparent O
disease O
. O
The O
LMCA O
, O
LAD O
, O
LCx O
and O
RCA O

 O
had O
no O

 O
evidence O
of O
angiographically O
apparent O
disease O
. O

 O
2 O
. O
  O
Resting O
hemodyanamics O
revealed O
slightly O
elevated O
right O
sided O

 O
filling O

 O
pressures O
with O
RVEDP O
of O
15mmHg O
. O
  O
Cardiac O
output O
was O
preserved O
at O

 O
7 O

 O
l/min O
. O


 O
FINAL O
DIAGNOSIS O
: O

 O
1 O
. O
Coronary O
arteries O
are O
normal O
. O

 O
2 O
. O
Normal O
ventricular O
function O
. O

 O
. O


 O
TTE O
( O
Complete O
) O
Done O
[ O
* O
* O
2122 O
- O
7 O
- O
29 O
* O
* O
] O

 O
Conclusions O

 O
The O
left O
atrium O
is O
moderately O
dilated O
. O
The O
right O
atrium O
is O

 O
moderately O
dilated O
. O
No O
atrial O
septal O
defect O
is O
seen O
by O
2D O
or O

 O
color O
Doppler O
. O
There O
is O
moderate O
global O
left O
ventricular O

 O
hypokinesis O
( O
LVEF O
= O
30 O
- O
35 O
% O
) O
. O
The O
estimated O
cardiac O
index O
is O

 O
normal O
( O
> O
= O
2.5L/min/m2 O
) O
. O
Tissue O
Doppler O
imaging O
suggests O
an O

 O
increased O
left O
ventricular O
filling O
pressure O
( O
PCWP>18mmHg O
) O
. O
The O

 O
right O
ventricular O
cavity O
is O
mildly O
dilated O
with O
borderline O

 O
normal O
free O
wall O
function O
. O
The O
ascending O
aorta O
is O
mildly O

 O
dilated O
. O
The O
aortic O
valve O
leaflets O
( O
3 O
) O
appear O
structurally O

 O
normal O
with O
good O
leaflet O
excursion O
and O
no O
aortic O
regurgitation O
. O

 O
There O
is O
no O
aortic O
valve O
stenosis O
. O
The O
mitral O
valve O
leaflets O
are O

 O
mildly O
thickened O
. O
There O
is O
no O
mitral O
valve O
prolapse O
. O
Trivial O

 O
mitral O
regurgitation O
is O
seen O
. O
There O
is O
borderline O
pulmonary O

 O
artery O
systolic O
hypertension O
. O
There O
is O
a O
trivial/physiologic O

 O
pericardial O
effusion O
. O

 O
Compared O
with O
the O
prior O
study O
( O
images O
reviewed O
) O
of O
[ O
* O
* O
2122 O
- O
7 O
- O
22 O
* O
* O
] O
, O

 O
biventricular O
systolic O
cavity O
sizes O
are O
smaller O
and O
systolic O

 O
function O
is O
slightly O
improved O
. O

 O
. O



 O
Brief O
Hospital O
Course O
: O

 O
58 O
year O
old O
with O
a O
PMH O
significant O
for O
non-ischemic O

 O
cardiomyopathy O
, O
chronic O
a-fib O
, O
and O
ventricullar O
tachycardia O
s/p O

 O
AICD O
placement O
on O
[ O
* O
* O
2122 O
- O
5 O
- O
26 O
* O
* O
] O
, O
that O
was O
transferred O
from O
[ O
* O
* O
Hospital O
107 O
* O
* O
] O

 O
Hospital O
in O
RI O
for O
treatment O
of O
ventricular O
tachycardia O
with O

 O
ablation O
. O

 O
. O


 O
# O
Ventricular O
tachycardia/dialated O
cardiomyopathy O
: O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
has O

 O
ventricular O
tachycardia O
in O
the O
setting O
of O
non-ischemic O

 O
cardiomyopathy O
. O
  O
These O
episodes O
of O
ventricular O
tachycardia O

 O
started O
in O
[ O
* O
* O
2122 O
- O
5 O
- O
21 O
* O
* O
] O
, O
he O
is O
s/p O
AICD O
placement O
and O
has O
had O

 O
several O
instances O
recently O
of O
firing O
of O
his O
AICD O
. O
  O
Etiology O
of O

 O
his O
v-tach O
is O
likely O
cardiomyopathy O
resulting O
in O
ectopy O
. O
  O
An O

 O
initial O
echo O
was O
done O
the O
morning O
after O
admission O
and O
showed O

 O
dilated O
left O
ventricle O
with O
severe O
systolic O
dysfunction O
, O
also O

 O
right O
ventricular O
dilation O
and O
dysfunction O
. O
Hemodynamically O

 O
stable O
and O
asymptomatic O
. O
  O
He O
was O
conitnued O
on O
an O
amiodarone B-DRUG
drip B-ROU

 I-ROU
of O
0.5mg/min B-STR
until O
he O
was O
taken O
for O
EP O
procedure O
on O
[ O
* O
* O
2122 O
- O
7 O
- O
23 O
* O
* O
] O
. O

 O
During O
the O
study O
, O
they O
were O
beginning O
to O
warm O
a O
site O
for O

 O
ablation O
, O
and O
he O
went O
into O
fast O
VT O
, O
so O
the O
study O
was O
aborted O
. O

 O
He O
converted O
back O
to O
his O
normal O
rhythm O
. O
  O
His O
amiodarone B-DRUG
was O

 O
converted O
to O
200 B-STR
mg I-STR
PO B-ROU
TID B-FRE
and O
he O
still O
had O
VT B-REA
with O
walking O

 O
minimal O
distances O
, O
therefore O
loading O
dose O
was O
increased O
to O
400 B-STR
mg I-STR

 I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
, O
with O
plan O
to O
transition O
to O
200 B-STR
mg I-STR
PO B-ROU
BID B-FRE
in O
one O
week O

 O
( O
starting O
[ O
* O
* O
2122 O
- O
8 O
- O
1 O
* O
* O
] O
) O
. O
  O
Now O
currently O
undergoing O
workup O
for O
heart O

 O
transplant O
. O
  O
CT O
chest O
completed O
which O
showed O
multifocal O
small O

 O
ground-glass O
nodules O
predominantly O
involving O
the O
upper O
lobes O
, O

 O
requiring O
a O
follow O
up O
repeat O
CT O
in O
[ O
* O
* O
2 O
- O
24 O
* O
* O
] O
weeks O
as O
an O
outpatient O
. O

 O
CT O
abd/pelvis O
showed O
hypoattenuating O
left O
upper O
pole O
renal O

 O
lesion O
, O
most O
likely O
benign O
, O
but O
a O
renal O
US O
could O
be O
considered O

 O
as O
an O
outpatient O
. O
  O
Hepatitis O
A O
, O
B O
, O
C O
, O
CMV O
and O
HIV O
serologies O
were O

 O
negative O
. O



 O
While O
on O
the O
floor O
[ O
* O
* O
2122 O
- O
7 O
- O
27 O
* O
* O
] O
and O
[ O
* O
* O
2122 O
- O
7 O
- O
28 O
* O
* O
] O
he O
had O
increased O
runs O
of O

 O
VTach O
resulting O
in O
AICD O
firing O
. O
  O
The O
device O
fired O
once O
on O
[ O
* O
* O
2122 O
- O
7 O
- O
27 O
* O
* O
] O

 O
at O
9:30 O
in O
the O
morning O
when O
he O
was O
walking O
with O
the O
EP O
team O
to O

 O
reproduce O
symptoms O
. O
  O
On O
the O
7th O
, O
he O
was O
washing O
his O
hair O
sitting O

 O
at O
the O
sink O
and O
he O
became O
symptomatic O
with O
lightheadedness O
and O

 O
flushing O
. O
  O
He O
had O
2 O
runs O
of O
VTach O
that O
both O
resulted O
in O
ICD O

 O
firings O
at O
8:09 O
and O
8:10 O
in O
the O
morning O
. O
  O
He O
was O
taken O
to O
cath O

 O
immediately O
following O
, O
and O
then O
he O
was O
taken O
to O
the O
EP O
lab O
for O

 O
readjustment O
of O
his O
leads O
. O
  O
The O
lead O
wires O
were O
adjusted O
to O

 O
remove O
slack O
from O
the O
wires O
. O
  O
He O
tolerated O
the O
procedure O
well O

 O
and O
has O
been O
without O
any O
runs O
of O
VTach O
since O
. O


 O
He O
received O
a O
TTE O
on O
[ O
* O
* O
2122 O
- O
7 O
- O
29 O
* O
* O
] O
when O
compared O
with O
the O
prior O
study O

 O
( O
images O
reviewed O
) O
of O
[ O
* O
* O
2122 O
- O
7 O
- O
22 O
* O
* O
] O
, O
biventricular O
systolic O
cavity O

 O
sizes O
are O
smaller O
and O
systolic O
function O
is O
slightly O
improved O
to O

 O
30 O
- O
35 O
% O
. O
A O
right/left O
heart O
cardiac O
catheterization O
that O
showed O
: O

 O
right O
dominant O
system O
that O
demonstrated O
no O
angiongraphically O

 O
apparent O
disease O
. O
The O
LMCA O
, O
LAD O
, O
LCx O
and O
RCA O
had O
no O
evidence O
of O

 O
angiographically O
apparent O
disease O
. O
Resting O
hemodyanamics O

 O
revealed O
slightly O
elevated O
right O
sided O
filling O
pressures O
with O

 O
RVEDP O
of O
15mmHg O
. O
  O
Cardiac O
output O
was O
preserved O
at O
7 O
l/min O
. O
His O

 O
volume B-REA
status I-REA
was O
medically O
managed O
and O
he O
was O
transitioned O
back O

 O
to O
his O
home O
PO B-ROU
Lasix B-DRUG
of O
20 B-STR
mg I-STR
daily B-FRE
. I-FRE

 O
. O

 O
# O
Contact O
dermatitis/cellulitis O
: O
He O
developed O
a O
likely O
contact O

 O
dermatitis O
after O
lead O
replacement O
at O
OSH O
. O
  O
The O
contact B-ADE

 I-ADE
dermatitis I-ADE
may O
have O
been O
from O
the O
chlorhexadine B-DRUG
prep O
during O
the O

 O
procedure O
as O
the O
patient O
reported O
that O
this O
happened O
in O
the O
past O

 O
during O
a O
prior O
cath O
. O
  O
The O
contact O
dermatitis O
likely O
became O

 O
super-infected O
and O
he O
developed O
erispelas B-REA
which O
was O
treated O

 O
successfully O
with O
doxycyline B-DRUG
for B-DUR
7 I-DUR
days I-DUR
last O
dose O
[ O
* O
* O
2122 O
- O
7 O
- O
28 O
* O
* O
] O
. O

 O
. O

 O
# O
Atrial B-REA
fibrillation I-REA
: I-REA
His O
atrial O
fibrillation O
was O
rate O

 O
controlled O
and O
medically O
managed O
. O
  O
His O
coumadin B-DRUG
was O
held O

 O
secondary O
to O
need O
for O
cardiac B-REA
catheterization I-REA
and O
he O
was O
placed O

 O
on O
a O
heparin B-DRUG
drip B-ROU
throughout O
his O
admission O
. O

 O
. O

 O
# O
Sleep O
apnea O
: O
His O
sleep O
apnea O
was O
medically O
managed O
with O
his O

 O
CPAP O
mask O
at O
night O
without O
complications O
. O

 O
. O

 O
The O
patient O
was O
full O
code O
for O
this O
admission O
. O
Pt O
was O
discharged O

 O
home O
with O
further O
outpt O
follow-up O
planned O
. O



 O

Medications O
on O
Admission O
: O

 O
On O
Transfer O
from O
OSH O
: O

 O
. O
  O
Coumadin B-DRUG
last O
dose O
8/28 O
for O
a-fib B-REA

 I-REA
. O
  O
Digoxin B-DRUG
0.25 B-STR
mg I-STR
PO B-ROU
Q24 B-FRE

 I-FRE
. O
  O
Lisinopril B-DRUG
40 B-STR
mg I-STR
PO B-ROU
Q24 B-FRE

 I-FRE
. O
  O
Coreg B-DRUG
25 B-STR
mg I-STR
PO B-ROU
Q12 B-FRE

 I-FRE
. O
  O
Mag B-DRUG
Oxide I-DRUG
400 B-STR
mg I-STR
PO B-ROU
Q24 B-FRE

 I-FRE
. O
  O
Lovastatin B-DRUG
20 B-STR
mg I-STR
PO B-ROU
Q24 B-FRE

 I-FRE
. O
  O
Aldactone B-DRUG
12.5 B-STR
mg I-STR
PO B-ROU
Q24 B-FRE

 I-FRE
. O
  O
Amiodarone B-DRUG
0.5mg/min B-STR
IV B-ROU


 I-ROU
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Ventricular O
Tachycardia O

 O
Non-ischemic O
Cardiomyopathy O

 O
Acute O
Renal O
Failure O



 O
Discharge O
Condition O
: O

 O
Alert O
and O
Oriented O
x3 O

 O
Independent O
Ambulation O



 O
Discharge O
Instructions O
: O

 O
Dear O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
, O

 O
You O
were O
initially O
admitted O
to O
the O
hospital O
for O
loss O
of O

 O
consciousness O
, O
and O
were O
found O
to O
have O
an O
abnormal O
heart O
rhythm O

 O
called O
ventricular O
tachycardia O
. O
  O
You O
were O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O

 O
for O
further O
management O
of O
your O
ventricular O
tachycardia O
and O

 O
evaluation O
for O
potential O
ablation O
. O
  O
Unfortunately O
, O
the O
site O
of O

 O
the O
abnormal O
heart O
rhythm O
could O
not O
be O
localized O
for O
ablation O
on O

 O
this O
attempt O
. O
Your O
pacemaker/defibrillator O
settings O
were O

 O
adjusted O
to O
optimize O
your O
own O
normal O
heart O
rhythm O
and O

 O
conduction O
. O
  O
You O
felt O
significantly O
improved O
following O
the O

 O
adjustment O
, O
and O
it O
was O
decided O
that O
your O
irregular O
heart O
rhythm O

 O
would O
be O
controlled O
with O
medications O
. O
We O
required O
you O
to O
stay O
in O

 O
the O
hospital O
for O
a O
few O
days O
  O
to O
best O
optimize O
your O
medications O

 O
for O
rhythm O
control O
. O


 O
During O
this O
hospitalization O
, O
we O
also O
began O
the O
evaluation O
for O
a O

 O
heart O
transplant O
in O
case O
this O
is O
something O
that O
might O
benefit O

 O
you O
in O
the O
future O
. O


 O
Other O
issues O
on O
this O
hospitalization O
included O
a O
rash O
involving O

 O
your O
chest O
, O
shoulders O
and O
neck O
. O
  O
It O
was O
believed O
to O
be O
related O

 O
to O
contact B-ADE
allergy I-ADE
to O
" O
chlorhexidine B-DRUG
" I-DRUG
, O
a O
cleaning O
[ O
* O
* O
Doctor O
Last O
Name O
360 O
* O
* O
] O
we O

 O
commonly O
use O
before O
procedures O
. O
  O
We O
also O
believe O
this O
skin B-REA
rash I-REA

 I-REA
became I-REA
secondarily I-REA
infected I-REA
, I-REA
for O
which O
we O
treated O
you O
with O

 O
antibiotics B-DRUG
. I-DRUG



 O
The O
following O
changes O
were O
made O
to O
your O
home O
medications O
: O

 O
- O
Amiodarone B-DRUG
was O
continued O
at O
400 B-STR
mg I-STR
TWICE B-FRE
daily I-FRE
for B-DUR
3 I-DUR
more I-DUR
days I-DUR
, I-DUR

 O
then O
decrease O
to O
400 B-STR
mg I-STR
once B-FRE
daily I-FRE
on O
[ O
* O
* O
2122 O
- O
9 O
- O
2 O
* O
* O
] O
. O
Please O
continue O

 O
that O
dose O
until O
you O
see O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
. O

 O
- O
Start O
Metoprolol B-DRUG
Succinate I-DRUG
to O
control O
your O
ventricular B-REA

 I-REA
tachycardia I-REA

 I-REA
- O
STOP O
taking O
Carvedilol B-DRUG
, I-DRUG
Magnesium B-DRUG
and O
Digoxin B-DRUG

 I-DRUG
- O
DECREASE O
the O
dose O
of O
Warfarin B-DRUG
to O
4 B-STR
mg I-STR
daily B-FRE
. I-FRE
Please O
check O
your O

 O
INR O
on O
Monday O
[ O
* O
* O
8 O
- O
3 O
* O
* O
] O
with O
results O
to O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
. O

 O
- O
Start O
taking O
clindamycin B-DRUG
, I-DRUG
an O
antibiotic B-DRUG
, I-DRUG
to O
prevent B-REA
infection I-REA

 I-REA
at I-REA
the I-REA
ICD I-REA
site I-REA

 I-REA
- O
Start O
taking O
Tylenol B-DRUG
as B-FRE
needed I-FRE
for O
pain B-REA
at O
the O
ICD O
site O

 O
- O
Start O
taking O
Lorazepam B-DRUG
if O
you O
need O
for O
anxiety B-REA
or O
sleep B-REA
. I-REA


 O
Please O
weigh O
yourself O
every O
morning O
, O
[ O
* O
* O
Name8 O
( O
MD O
) O
138 O
* O
* O
] O
MD O
if O
weight O
goes O
up O

 O
more O
than O
3 O
lbs O
in O
1 O
day O
or O
6 O
pounds O
in O
3 O
days O
. O


 O
Check O
your O
INR O
at O
Dr.[**Name O
( O
NI O
) O
87185 O
* O
* O
] O
office O
on O
Monday O
[ O
* O
* O
8 O
- O
3 O
* O
* O
] O
. O
You O
should O

 O
have O
the O
INR O
followed O
closely O
now O
that O
you O
are O
on O
amiodarone B-DRUG
. I-DRUG


 O
Please O
be O
sure O
to O
have O
your O
blood O
drawn O
at O
your O
doctor O
's O
office O

 O
in O
[ O
* O
* O
11 O
- O
22 O
* O
* O
] O
months O
to O
check O
your O
thyroid O
and O
liver O
function O
tests O

 O
because O
amiodarone B-DRUG
can O
sometimes O
affect O
these O
with O
time O
. O
You O

 O
will O
also O
need O
to O
have O
pulmonary O
function O
tests O
done O
to O
make O

 O
sure O
the O
amiodarone B-DRUG
is O
not O
affecting O
your O
lungs O
. O


 O
Your O
initial O
CT O
scan O
of O
your O
chest O
here O
showed O
that O
you O
have O

 O
some O
non-specific O
nodules O
that O
may O
be O
due O
to O
an O
infection O
, O

 O
inflammatory O
disease O
, O
or O
even O
cancer O
. O
  O
Please O
talk O
to O
your O

 O
primary O
care O
doctor O
and O
cardiologist O
regarding O
ordering O
a O
follow O

 O
up O
CT O
of O
your O
chest O
in O
[ O
* O
* O
2 O
- O
24 O
* O
* O
] O
weeks O
to O
evaluate O
whether O
there O
is O

 O
any O
change O
. O


 O
Followup O
Instructions O
: O

 O
Please O
be O
sure O
to O
keep O
all O
of O
your O
followup O
appointments O
, O
as O

 O
listed O
below O
: O



 O
Department O
: O
CARDIAC O
SERVICES O

 O
When O
: O
MONDAY O
[ O
* O
* O
2123 O
- O
1 O
- O
25 O
* O
* O
] O
at O
1:30 O
PM O

 O
With O
: O
DR O
. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
62 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O

 O
. O

 O
Department O
: O
Primary O
Care O

 O
Name O
: O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
335 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O

 O
When O
: O
Monday O
[ O
* O
* O
2122 O
- O
8 O
- O
17 O
* O
* O
] O
at O
2 O
PM O

 O
Location O
: O
PRIMARY O
CARE O
CENTER O
OF O
[ O
* O
* O
Location O
* O
* O
] O

 O
Address O
: O
[ O
* O
* O
Street O
Address(2 O
) O
87186 O
* O
* O
] O
, O
[ O
* O
* O
Location O
* O
* O
] O
, O
[ O
* O
* O
Numeric O
Identifier O
87187 O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
87188 O
* O
* O
] O


 O
Department O
: O
Interventional O
Cardiology O

 O
Name O
: O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
Hordes O

 O
When O
: O
Friday O
[ O
* O
* O
2122 O
- O
8 O
- O
7 O
* O
* O
] O
at O
3 O
PM O
. O
Please O
call O
the O
office O

 O
on O
[ O
* O
* O
2122 O
- O
8 O
- O
7 O
* O
* O
] O
after O
1 O
PM O
to O
verify O
this O
appointment O
. O

 O
Location O
: O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
CARDIOLOGY O

 O
Address O
: O
[ O
* O
* O
Street O
Address(2 O
) O
51165 O
* O
* O
] O
[ O
* O
* O
Apartment O
Address(1 O
) O
51166 O
* O
* O
] O
, O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
Numeric O
Identifier O
51167 O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
51168 O
* O
* O
] O


 O
Department O
: O
CARDIAC O
SERVICES O

 O
When O
: O
MONDAY O
[ O
* O
* O
2122 O
- O
8 O
- O
24 O
* O
* O
] O
at O
12:30 O
PM O

 O
With O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
539 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
13861 O
* O
* O
] O
, O
NP O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
62 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
    O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O



 O
Department O
: O
CARDIAC O
SERVICES O

 O
When O
: O
MONDAY O
[ O
* O
* O
2122 O
- O
8 O
- O
24 O
* O
* O
] O
at O
1 O
PM O

 O
With O
: O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
62 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
   O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O




 O
Completed O
by:[**2122 O
- O
7 O
- O
31 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2200 O
- O
7 O
- O
15 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2151 O
- O
4 O
- O
20 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Haldol B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
30 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
acute O
mental O
status O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
none O


 O
History O
of O
Present O
Illness O
: O

 O
49yo O
M O
currently O
at O
HRI O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
( O
rehab O
center O
) O
in O
a O
dual O

 O
diagnosis O
unit O
for O
depression/ETOH O
detox O
admitted O
with O
AMS O
over O

 O
the O
last O
2 O
days O
. O
The O
patient O
completed O
treatment O
for O
EtOH B-REA

 I-REA
withdrawal I-REA
with O
Librium B-DRUG
on O
[ O
* O
* O
7 O
- O
11 O
* O
* O
] O
. O
He O
was O
noted O
to O
have O
increasing O

 O
confusion O
, O
visual O
hallucinations O
( O
angels O
) O
, O
and O
was O
not O
oriented O

 O
to O
place O
. O
He O
was O
transferred O
here O
for O
evaluation O
of O
AMS O
. O
No O
h/o O

 O
fevers O
, O
chills O
, O
head O
trauma O
, O

 O
. O

 O
VS O
on O
presentation O
to O
ED O
: O
97.3 O
83 O
108/85 O
15 O
100 O
. O
He O
was O
confused O

 O
on O
exam O
in O
ED O
. O
UA O
and O
Utox O
were O
positive O
for O
benzos B-DRUG
. I-DRUG
Ammonia O

 O
level O
32 O
. O
EKG O
showed O
NSR O
, O
no O
ischemic O
changes O
. O
CXR O
was O
negative O
. O

 O
CT O
head O
was O
negative O
. O
Pt O
has O
baseline O
myoclonic O
jerking O
from O

 O
Familial O
Myoclonus O
. O
He O
received O
Valium B-DRUG
5 B-STR
mg I-STR
, I-STR
Ativan B-DRUG
2 B-STR
mg I-STR
, I-STR
and O
a O

 O
nicotine B-DRUG
patch B-FOR
in O
the O
ED O
. O
Prior O
to O
transfer O
to O
the O
floor O
, O
vitals O

 O
were O
: O
83 O
, O
103/70 O
, O
15 O
, O
100 O
% O

 O
. O

 O
On O
the O
floor O
, O
vitals O
were O
: O
96 O
110/80 O
86 O
14 O
99RA O
. O
The O
patient O
was O

 O
agitated O
and O
kept O
asking O
where O
his O
cigarettes O
were O
. O
He O
was O

 O
paranoid O
and O
accused O
staff O
members O
of O
throwing O
his O
cigarettes O

 O
away O
. O
He O
was O
not O
oriented O
to O
place O
. O
He O
left O
the O
floor O
and O
a O
Code O

 O
Purple O
was O
called O
. O
He O
calmed O
down O
after O
administration O
of O
2 B-STR
mg I-STR
IV B-ROU

 I-ROU
Ativan B-DRUG
. I-DRUG
The O
patient O
was O
placed O
in O
restraints O
and O
is O
currently O

 O
lying O
in O
bed O
. O



 O
Past O
Medical O
History O
: O

 O
Familial O
myoclonus O

 O
ETOH O
abuse O

 O
Depression O



 O
Social O
History O
: O

 O
Homeless O
. O
Currently O
at O
dual O
diagnosis O
center O
for O
ETOH O
withdrawal O

 O
and O
depression O
. O
Recently O
divorced O
. O
Worked O
as O
a O
truck O
driver O
. O


 O
Family O
History O
: O

 O
h/o O
familial O
myoclonus O



 O
Physical O
Exam O
: O

 O
VITALS O
: O
96 O
110/80 O
86 O
14 O
99%RA O

 O
GEN O
: O
agitated O
man O
, O
pacing O
around O
the O
room O

 O
HEENT O
: O
PERRL O
, O
EOMI O
, O
vertical O
nystagmus O

 O
NECK O
: O
supple O

 O
LUNGS O
: O
CTA O
b/l O
, O
no O
wheezing O

 O
HEART O
: O
RRR O
, O
normal O
S1S2 O
, O
no O
m/r/g O

 O
ABD O
: O
soft O
, O
nt O
, O
nd O
, O
+ O
bs O
, O
no O
masses O

 O
EXTREM O
: O
no O
edema O

 O
NEURO O
: O
AAOx2 O
, O
not O
oriented O
to O
place O
, O
5/5 O
strength O
throughout O
, O

 O
myoclonic O
jerking O

 O
PSYCH O
: O
confused O
, O
not O
oriented O
to O
place O
, O
paranoid O
, O
no O
SI O



 O

Pertinent O
Results O
: O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
15 O
* O
* O
] O
05:20AM O
BLOOD O
WBC-4.8 O
RBC-4.09 O
* O
Hgb-13.6 O
* O
Hct-40.8 O

 O
MCV-100 O
* O
MCH-33.4 O
* O
MCHC-33.4 O
RDW-13.5 O
Plt O
Ct-171 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
14 O
* O
* O
] O
04:08AM O
BLOOD O
WBC-4.2 O
RBC-4.53 O
* O
Hgb-14.8 O
Hct-44.9 O

 O
MCV-99 O
* O
MCH-32.7 O
* O
MCHC-32.9 O
RDW-13.4 O
Plt O
Ct-136 O
* O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
13 O
* O
* O
] O
04:40AM O
BLOOD O
WBC-5.7 O
RBC-4.48 O
* O
Hgb-14.3 O
Hct-45.4 O

 O
MCV-101 O
* O
MCH-32.0 O
MCHC-31.6 O
RDW-13.4 O
Plt O
Ct-101 O
* O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
12:30PM O
BLOOD O
WBC-4.2 O
RBC-4.44 O
* O
Hgb-14.5 O
Hct-44.2 O

 O
MCV-100 O
* O
MCH-32.7 O
* O
MCHC-32.8 O
RDW-13.5 O
Plt O
Ct-102 O
* O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
13 O
* O
* O
] O
04:40AM O
BLOOD O
Neuts-62.8 O
Lymphs-24.5 O
Monos-9.7 O
Eos-2.2 O

 O
Baso-0.8 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
12:30PM O
BLOOD O
Neuts-50.7 O
Lymphs-35.5 O
Monos-9.2 O
Eos-4.0 O

 O
Baso-0.7 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
14 O
* O
* O
] O
04:08AM O
BLOOD O
PT-12.2 O
PTT-28.5 O
INR(PT)-1.0 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
13 O
* O
* O
] O
04:40AM O
BLOOD O
PT-11.3 O
PTT-24.8 O
INR(PT)-0.9 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
15 O
* O
* O
] O
05:20AM O
BLOOD O
Glucose-100 O
UreaN-18 O
Creat-0.9 O
Na-141 O

 O
K-3.7 O
Cl-111 O
* O
HCO3 O
- O
23 O
AnGap-11 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
14 O
* O
* O
] O
04:08AM O
BLOOD O
Glucose-88 O
UreaN-15 O
Creat-0.8 O
Na-141 O

 O
K-3.8 O
Cl-111 O
* O
HCO3 O
- O
20 O
* O
AnGap-14 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
13 O
* O
* O
] O
04:40AM O
BLOOD O
Glucose-85 O
UreaN-23 O
* O
Creat-0.9 O
Na-141 O

 O
K-3.7 O
Cl-109 O
* O
HCO3 O
- O
20 O
* O
AnGap-16 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
12:30PM O
BLOOD O
Glucose-99 O
UreaN-24 O
* O
Creat-1.0 O
Na-140 O

 O
K-4.3 O
Cl-106 O
HCO3 O
- O
24 O
AnGap-14 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
14 O
* O
* O
] O
04:08AM O
BLOOD O
ALT-74 O
* O
AST-62 O
* O
LD(LDH)-198 O
AlkPhos-70 O

 O
TotBili-0.7 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
13 O
* O
* O
] O
04:40AM O
BLOOD O
ALT-79 O
* O
AST-76 O
* O
LD(LDH)-336 O
* O
AlkPhos-73 O

 O
TotBili-0.7 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
12:30PM O
BLOOD O
ALT-79 O
* O
AST-62 O
* O
AlkPhos-84 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
14 O
* O
* O
] O
04:08AM O
BLOOD O
Albumin-3.7 O
Calcium-8.2 O
* O
Phos-2.6 O
* O
Mg-2.3 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
13 O
* O
* O
] O
04:40AM O
BLOOD O
Albumin-4.2 O
Calcium-8.4 O
Phos-2.7 O
Mg-2.2 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
12:30PM O
BLOOD O
Albumin-4.7 O
Calcium-9.5 O
Phos-3.5 O
Mg-2.4 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
12:30PM O
BLOOD O
VitB12 O
- O
563 O
Folate-GREATER O
TH O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
12:30PM O
BLOOD O
Ammonia-32 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
12:30PM O
BLOOD O
TSH-1.1 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
13 O
* O
* O
] O
04:40AM O
BLOOD O
HBsAg-NEGATIVE O
HBsAb-NEGATIVE O

 O
HBcAb-NEGATIVE O
HAV O
Ab-NEGATIVE O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
12:30PM O
BLOOD O
ASA-NEG O
Ethanol-NEG O
Acetmnp-NEG O

 O
Bnzodzp-POS O
Barbitr-NEG O
Tricycl-NEG O

 O

[ O
* O
* O
2200 O
- O
7 O
- O
13 O
* O
* O
] O
04:40AM O
BLOOD O
HCV O
Ab-NEGATIVE O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
04:45PM O
URINE O
Color-Yellow O
Appear-Clear O
Sp O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
-1.022 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
04:45PM O
URINE O
Blood-NEG O
Nitrite-NEG O
Protein-NEG O

 O
Glucose-NEG O
Ketone-NEG O
Bilirub-NEG O
Urobiln-NEG O
pH-5.0 O
Leuks-NEG O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
04:45PM O
URINE O
RBC-0 O
- O
2 O
WBC-0 O
- O
2 O
Bacteri-RARE O
Yeast-NONE O

 O
Epi-0 O
- O
2 O

 O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
04:45PM O
URINE O
bnzodzp-POS O
barbitr-NEG O
opiates-NEG O

 O
cocaine-NEG O
amphetm-NEG O
mthdone-NEG O

 O
. O

 O
. O

 O
CXR O
: O

 O
HISTORY O
: O
49-year-old O
male O
with O
altered O
mental O
status O
. O


 O
No O
prior O
studies O
available O
for O
comparison O
. O


 O
CHEST O
, O
PA O
AND O
LATERAL O
: O
The O
cardiomediastinal O
and O
hilar O
contours O

 O
are O

 O
unremarkable O
. O
The O
lungs O
are O
clear O
without O
consolidation O
or O

 O
edema O
. O
There O
is O

 O
no O
pleural O
effusion O
or O
pneumothorax O
. O


 O
IMPRESSION O
: O
No O
acute O
cardiopulmonary O
abnormality O
. O


 O
The O
study O
and O
the O
report O
were O
reviewed O
by O
the O
staff O
radiologist O
. O



 O
DR O
. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O

 O
DR O
. O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Initial O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O

 O
Approved O
: O
SAT O
[ O
* O
* O
2200 O
- O
7 O
- O
12 O
* O
* O
] O
3:06 O
PM O

 O
. O

 O
Head O
CT O
: O

 O
preliminary O
read O
shows O
no O
acute O
process O


 O
Brief O
Hospital O
Course O
: O

 O
49 O
M O
with O
h/o O
familial O
myoclonus O
, O
depression O
, O
EtOH O
abuse O

 O
transferred O
from O
HRI O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
for O
due O
to O
changes O
in O
mental O

 O
status O
. O

 O
. O


 O
# O
. O
acute O
mental O
status O
changes O
: O
Initially O
the O
pt O
was O
quite O

 O
agitated O
and O
confused O
, O
and O
was O
transferred O
to O
the O
ICU O
due O
to O

 O
demanding O
nursing O
care O
. O
He O
was O
placed O
in O
restraints O
and O
given O
1x B-DOS

 O
5 B-STR
mg I-STR
zyprexa B-DRUG
and O
2 B-STR
mg I-STR
ativan B-DRUG
IV B-ROU
for O
agitation B-REA
. I-REA
Broad O
differential O

 O
initially O
included O
infectious O
, O
ischemic O
, O
metabolic O
, O
toxic O
, O

 O
withdrawal O
symptoms O
, O
and O
psych O
. O
Likely O
not O
infectious O
- O
no O

 O
elevated O
WBC O
, O
no O
fever O
, O
UA O
negative O
, O
CXR O
negative O
. O
Likely O
not O

 O
ischemic O
- O
EKG O
normal O
, O
CT O
head O
negative O
. O
Ca O
, O
glucose O
, O
ammonia O

 O
normal O
. O
Pt O
was O
also O
not O
hypoxic O
. O
Hepatic O
encephalopathy O
was O

 O
unlikely O
as O
patient O
does O
not O
have O
ascites O
, O
no O
appreciable O

 O
asterixis O
. O
His O
TSH O
, O
B12 O
, O
folate O
were O
all O
normal O
. O
Most O
likely O

 O
causes O
are O
EtOH O
withdrawal O
( O
EtOH O
on O
tox O
screen O
negative O
) O
with O

 O
concurrent O
Benzo B-DRUG
intoxication B-ADE
( O
pos O
on O
tox O
screen O
and O
received O

 O
450 B-STR
mg I-STR
librium B-DRUG
over B-DUR
4 I-DUR
days I-DUR
at O
HRI O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
) O
, O
or O
depression O
with O

 O
psychosis O
. O
Psych O
was O
consulted O
and O
felt O
that O
benzo B-DRUG
intoxication B-ADE

 I-ADE
was O
likely O
. O
There O
were O
no O
hemodynamic O
signs O
of O
withdrawal O
, O
pt O

 O
was O
placed O
on O
CIWA O
scale O
but O
did O
not O
require O
any O
benzos B-DRUG
. I-DRUG
He O

 O
improved O
with O
rest O
, O
IV B-ROU
fluids B-DRUG
, I-DRUG
and O
treatment O
with O
vitamins B-DRUG
( O
MVI B-DRUG
, I-DRUG

 O
folate B-DRUG
, I-DRUG
thiamine B-DRUG
, I-DRUG
B B-DRUG
vits I-DRUG
) I-DRUG
. O
Upon O
discharge O
the O
pt O
was O
feeling O

 O
much O
better O
and O
was O
AOx3 O
, O
cooperative O
, O
ambulatory O
, O
tolerating O
a O

 O
normal O
diet O
with O
stable O
vitals O
( O
never O
had O
any O
evidence O
of O
ETOH O

 O
withdrawal O
during O
his O
admission O
) O
. O
We O
recommend O
to O
not O
treat O
the O

 O
patient O
with O
benzos B-DRUG
as O
he O
is O
not O
withdrawing O
and O
to O
continue O

 O
monitoring O
and O
supportive O
care O
with O
nutrition O
, O
PT O
( O
ambulation O
) O
, O

 O
and O
social O
work O
for O
long O
term O
support O
. O
Notably O
, O
he O
also O
has O

 O
allergies O
to O
haldol B-DRUG
( O
unknown O
reaction O
) O
so O
this O
drug O
should O
be O

 O
avoided O
. O

 O
. O

 O
# O
Psych O
/ O
familial O
myoclonus O
- O
psych O
service O
was O
consulted O
and O

 O
we O
held O
the O
pt O
's O
  O
vistaril B-DRUG
, I-DRUG
lexapro B-DRUG
, I-DRUG
inderal B-DRUG
and O
topamax B-DRUG
. I-DRUG

 O
Psychiatry O
recommended O
to O
hold O
his O
psych O
meds O
until O
further O

 O
outpatient O
evaluation O
. O

 O
. O

 O
# O
Thrombocytopenia O
- O
Pt O
has O
low O
platelet O
count O
of O
102 O
, O
which O
is O

 O
likely O
secondary O
to O
chronic O
EtOH O
use O
. O
We O
continued O
to O
monitor O

 O
and O
upon O
discharge O
the O
pt O
's O
Plt O
count O
was O
improved O
to O
171 O
. O

 O
. O



 O

Medications O
on O
Admission O
: O

 O
Ativan B-DRUG
1 B-STR
mg I-STR
PO B-ROU
BID B-FRE
prn O
agitation B-REA

 I-REA
Folic B-DRUG
acid I-DRUG
1 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Inderal B-DRUG
20 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
Lexapro B-DRUG
20 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Librium B-DRUG
taper B-DOS
( O
finished O
[ O
* O
* O
7 O
- O
11 O
* O
* O
] O
) O

 O
Magnesium B-DRUG
oxide I-DRUG
400 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
Multivitamin B-DRUG
1 B-DOS
tab B-FOR
PO B-ROU
daily B-FRE

 I-FRE
Potassium B-DRUG
chloride I-DRUG
20mEq B-STR
PO B-ROU
BID B-FRE

 I-FRE
Thiamine B-DRUG
100 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Topamax B-DRUG
150 B-STR
mg I-STR
PO B-ROU
qhs B-FRE

 I-FRE
Vistaril B-DRUG
50 B-STR
mg I-STR
Po B-ROU
TID B-FRE

 I-FRE
Vitamin B-DRUG
B I-DRUG
Complex I-DRUG
1 B-DOS
tab B-FOR
PO B-ROU
daily B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Folic B-DRUG
Acid I-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s B-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O

 O
2 O
. O
B-Complex B-DRUG
with I-DRUG
Vitamin I-DRUG
C I-DRUG
     O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Cap B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
Disp:*30 O
tablets B-FOR
* I-FOR
Refills:*2 O
* O

 O
3 O
. O
Multivitamin B-DRUG
     O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s B-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O

 O
4 O
. O
Thiamine B-DRUG
HCl I-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
Disp:*30 O
Tablet(s B-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
alcohol O
intoxication O
compounded O
by O
librium B-DRUG
intoxication B-ADE

 I-ADE
. O

 O
Secondary O
: O

 O
Familial O
myoclonus O

 O
ETOH O
abuse O

 O
Depression O



 O
Discharge O
Condition O
: O

 O
afebrile O
, O
stable O
vitals O
, O
tolerating O
POs O
, O
ambulatory O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
due O
to O
changes B-ADE
in I-ADE
your I-ADE
mental I-ADE
status I-ADE
which O
was O

 O
thought O
to O
be O
either O
due O
to O
depression O
with O
psychosis O
or O
alcohol O

 O
intoxication O
compounded O
by O
intoxication B-ADE
with O
librium B-DRUG
given O
at O

 O
your O
rehab O
center O
. O
You O
were O
initially O
quite O
agitated O
and O
we O
had O

 O
to O
transfer O
you O
to O
the O
ICU O
for O
monitoring O
. O
You O
were O
worked O
up O

 O
for O
other O
potential O
causes O
of O
your O
mental O
status O
changes O
but O

 O
they O
were O
negative O
. O
You O
did O
not O
have O
any O
signs O
of O
alcohol O

 O
withdrawal O
. O
In O
the O
ICU O
you O
were O
given O
some O
medicine O
to O
lower O

 O
your O
agitation O
and O
calm O
you O
. O
Once O
you O
were O
more O
stable O
and O
less O

 O
agitated O
you O
were O
transferred O
to O
the O
medical O
floor O
where O
you O
had O

 O
improved O
mental O
status O
. O
You O
were O
cooperative O
and O
were O
able O
to O

 O
ambulate O
, O
use O
the O
bathroom O
normally O
, O
and O
tolerate O
a O
normal O
diet O
. O

 O
You O
were O
given O
vitamins B-DRUG
and O
IV B-ROU
fluids B-DRUG
during O
the O
time O
that O
you O

 O
improved O
. O

 O
. O


 O
You O
will O
be O
discharged O
with O
new O
medicines O
: O
thiamine B-DRUG
100 B-STR
mg I-STR
daily B-FRE
, I-FRE

 O
multivitamin B-DRUG
daily B-FRE
, I-FRE
vitamin B-DRUG
B I-DRUG
complex I-DRUG
1 B-DOS
tab B-FOR
daily B-FRE
, I-FRE
folic B-DRUG
acid I-DRUG

 I-DRUG
1 B-STR
mg I-STR
daily B-FRE
. I-FRE
You O
will O
not O
be O
discharged O
with O
any O
of O
your O

 O
psychiatric O
medicines O
, O
so O
please O
do O
not O
take O
your O
Topamax B-DRUG
150 B-STR
mg I-STR

 I-STR
PO B-ROU
qhs B-FRE
, I-FRE
Vistaril B-DRUG
50 B-STR
mg I-STR
Po B-ROU
TID B-FRE
, I-FRE
Inderal B-DRUG
20 B-STR
mg I-STR
PO B-ROU
BID B-FRE
, I-FRE
Lexapro B-DRUG
20 B-STR
mg I-STR

 I-STR
PO B-ROU
daily B-FRE
. I-FRE
Your O
outpatient O
psychiatrist O
will O
re-evaluate O
your O

 O
medications O
and O
prescribe O
them O
for O
you O
at O
that O
time O
. O


 O
. O

 O
Please O
take O
all O
medications O
as O
prescribed O
. O

 O
Please O
attend O
all O
appointments O
as O
instructed O
. O

 O
Please O
do O
not O
hesitate O
to O
return O
to O
the O
hospital O
if O
you O
have O

 O
chest O
pain O
, O
changes O
in O
mental O
status O
, O
difficulty O
breathing O
, O
or O

 O
any O
other O
concerning O
symptoms O
. O

 O
. O


 O
Followup O
Instructions O
: O

 O
Please O
follow O
up O
with O
your O
PCP O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
25821 O
* O
* O
] O
at O

 O
your O
earliest O
convenience O
. O
Please O
follow O
up O
with O
Neuro O

 O
appointment O
at O
[ O
* O
* O
Hospital1 O
2025 O
* O
* O
] O
which O
is O
already O
planned O
. O
Please O
follow O
up O

 O
with O
psychiatry O
. O
Please O
attend O
Alcoholics O
Anonymous O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2141 O
- O
4 O
- O
6 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2141 O
- O
4 O
- O
11 O
* O
* O
] O



 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
2145 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
shortness O
of O
breath O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
none O


 O
History O
of O
Present O
Illness O
: O

 O
86 O
yo O
Iranian O
( O
farsi O
speaking O
) O
male O
with O
h/o O
COPD B-REA
( O
on O
home O
o2 B-DRUG

 I-DRUG
( O
uses O
2 B-FRE
- I-FRE
3h I-FRE
qdaily I-FRE
of O
home O
o2 O
overall O
) O
, O
HTN O
, O
restless O
leg O

 O
syndrome O
, O
h/o O
anemia O
( O
prior O
studies O
showing O
thalesemia O
) O
and O
BPH O

 O
presenting O
today O
with O
2 O
days O
symptoms O
of O
SOB O
and O
AMS O
. O
  O
Per O

 O
daughter O
and O
pt O
- O
pt O
was O
in O
his O
USOH O
till O
2 O
days O
prior O
- O
started O

 O
having O
increasing O
SOB O
along O
with O
new O
cough O
with O
increasing O

 O
sputum O
production O
, O
no O
f/c O
, O
no O
cp O
, O
no O
HA O
, O
ab O
pain O
, O
n/v O
, O
but O
+ O

 O
constipation O
- O
along O
with O
sob O
sx O
- O
pt O
with O
decreasing O
po O
intake O

 O
- O
noted O
decreased O
urinary O
production O
yesterday O
with O
darker O
urine O

 O
- O
today O
in O
ED O
with O
increased O
intake O
has O
finally O
increased O

 O
production O
. O
  O
Pt O
denies O
any O
recent O
changes O
in O
urination O
prior O
- O

 O
BPH O
controlled O
without O
sx O
of O
dribbing O
, O
urgency O
, O
change O
of O

 O
frequency O
till O
just O
yesterday O
. O
  O
In O
terms O
of O
mentation O
- O
pt O
also O

 O
has O
been O
having O
mild O
increased O
confusion O
- O
usually O
AA0x3 O
- O
only O

 O
x2 O
now O
with O
process O
as O
above O
. O

 O
< O
br O
> O


 O
In O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
pt O
initially O
91 O
% O
on O
RA O
- O
noted O
pt O
usually O
uses O
o2 B-DRUG
3h/day B-FRE
- O

 O
but O
using O
more O
frequency O
past O
couple O
days O
without O
response O
. O

 O
Also O
noted O
pt O
having O
increased O
fatigue O
and O
generalized O
weakness O

 O
past O
couple O
days O
without O
ambulation O
- O
at O
baseline O
can O
ambulate O

 O
( O
+ O
/- O
can/walker O
at O
times O
) O
. O
   O
Pt O
noted O
afebrile O
in O
ED O
- O
given O

 O
nebs B-DRUG
, I-DRUG
IV B-ROU
solumedrol B-DRUG
and O
dose O
of O
levoquin B-DRUG
IV B-ROU
and O
admitted O
for O

 O
copd B-REA
exacerbation I-REA
. I-REA

 O
< O
br O
> O


 O
Review O
of O
systems O
: O

 O
. O


 O
Constitutional O
: O
  O
No O
weight O
loss/gain O
, O
+ O
fatigue O
, O
malaise O
, O
fevers O
, O

 O
chills O
, O
rigors O
, O
night O
sweats O
, O
anorexia O
. O

 O
HEENT O
: O
+ O
chronic O
loss O
of O
vision O
, O
no O
photophobia O
. O
  O
No O
dry O
motuh O
, O

 O
oral O
ulcers O
, O
bleeding O
nose O
or O
[ O
* O
* O
Male O
First O
Name O
( O
un O
) O
* O
* O
] O
, O
tinnitus O
, O
or O
sinus O
pain O
. O

 O
Cardiac O
: O
  O
No O
chest O
pain O
, O
palpitations O
, O
LE O
edema O
, O
orthopnea O
, O
PND O
, O

 O
but O
+ O
DOE O
. O

 O
Respiratory O
: O
  O
+ O
SOB O
, O
NO O
pleuritic O
pain O
, O
no O
hemoptysis O
, O
+ O
cough O
. O

 O
GI O
: O
  O
No O
nausea O
, O
vomiting O
, O
abdominal O
pain O
, O
abdominal O
swelling O
, O

 O
diarrhea O
, O
but O
notable O
for O
+ O
constiatpion O
, O
no O
hematemesis O
, O

 O
hematochezia O
, O
or O
melena O
. O

 O
Heme O
: O
No O
bleeding O
, O
bruising O
. O

 O
Lymph O
: O
  O
No O
lymphadenopathy O
. O

 O
GU O
: O
  O
+ O
per O
HPI O
. O

 O
Skin O
: O
No O
rashes O
, O
pruritius O
. O

 O
Endocrine O
: O
  O
No O
change O
in O
skin O
or O
hair O
, O
no O
heat O
or O
cold O

 O
intolerance O
. O

 O
MS O
: O
  O
No O
myalgias O
, O
arthralgias O
, O
back O
or O
nec O
pain O
. O

 O
Neuro O
: O
  O
No O
numbness O
, O
weakness O
or O
parasthesias O
. O
  O
No O
dizziness O
, O

 O
lightheadedness O
, O
vertigo O
. O
  O
No O
confusion O
or O
headache O
. O
  O
but O

 O
positive O
pains O
in O
LE O
from O
restless O
leg O
- O
controlled O
with O
home O

 O
meds O

 O
Psychiatric O
: O
No O
active O
depression O
or O
anxiety O
. O


 O
Past O
Medical O
History O
: O

 O
COPD B-REA
- O
uses O
prn B-FRE
home O
o2 B-DRUG

 I-DRUG
Restless O
Leg O
Syndrome O

 O
HTN O

 O
CKD O
Stage O
III O
based O
on O
review O
of O
labs O
this O
admission O
( O
baseline O

 O
1.8 O
- O
2.0 O
) O

 O
Depression O

 O
Knee O
Replacement O

 O
Macular O
Degeneration O

 O
BPH O

 O
Thalasemia O


 O
Social O
History O
: O

 O
Lives O
at O
home O
with O
wife O
, O
daughter O
lives O
on O
floor O
below O
. O

 O
Heavy O
Tobacco O
history O
, O
70 O
years O
smoking O
, O
quit O
few O
years O
ago O
. O

 O
no O
etoh O
, O
no O
drugs O



 O
Family O
History O
: O

 O
NC O
- O
no O
CAD O
, O
but O
+ O
h/o O
COPD O
in O
family O
. O


 O
Physical O
Exam O
: O

 O
Exam O

  O
VS O
  O
T O
current O
  O
99.2 O
  O
BP O
  O
120/59 O
   O
HR O
  O
105 O
  O
RR O
20 O
O2sat B-DRUG
: O
  O
96 O
% O
4L O

 O
o2nc O



 O
Gen O
: O
  O
In O
NAD O
. O

 O
HEENT O
: O
  O
PERRL O
, O
EOMI O
. O
  O
No O
scleral O
icterus O
. O
  O
No O
conjunctival O

 O
injection O
. O
   O
Mucous O
membranes O
moist O
. O
  O
No O
oral O
ulcers O
. O

 O
Neck O
: O
  O
Supple O
, O
no O
LAD O
, O
no O
JVP O
elevation O
. O

 O
Lungs O
: O
+ O
prolonged O
exp O
phase O
with O
end O
exp O
wheezing O
- O
mild-mod O

 O
tight O
airflow O

 O
CV O
: O
  O
RRR O
, O
+ O
[ O
* O
* O
2 O
- O
24 O
* O
* O
] O
HSM O
at O
apex O
, O
no O
r/g O

 O
Abdomen O
: O
  O
soft O
, O
NT O
, O
ND O
, O
NABS O

 O
Extremities O
: O
  O
warm O
and O
well O
perfused O
, O
no O
cyanosis O
, O
clubbing O
, O

 O
+ O
trace O
pedal O
edema O

 O
Neurological O
: O
  O
alert O
and O
oriented O
X O
2 O
- O
baseline O
aa0x3 O
of O
note O

 O
per O
daughter O
in O
room O
, O
CN O
[ O
* O
* O
Name O
( O
NI O
) O
12428 O
* O
* O
] O
intact O
. O
Notable O
that O
pt O
well O

 O
alert O
- O
no O
evidence O
of O
somnulance O

 O
Psychiatric O
: O
  O
Appropriate O
. O

 O
GU O
: O
  O
deferred O
. O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2141 O
- O
4 O
- O
6 O
* O
* O
] O
09:50AM O
URINE O
  O
BLOOD-NEG O
NITRITE-NEG O
PROTEIN-NEG O

 O
GLUCOSE-NEG O
KETONE-NEG O
BILIRUBIN-NEG O
UROBILNGN-NEG O
PH-5.0 O

 O
LEUK-NEG O

 O
< O
br O
> O

 O
[ O
* O
* O
2141 O
- O
4 O
- O
6 O
* O
* O
] O
10:00AM O
   O
LACTATE-1.1 O

 O
[ O
* O
* O
2141 O
- O
4 O
- O
6 O
* O
* O
] O
09:50AM O
BLOOD O
WBC-11.6 O
* O
RBC-4.79 O
Hgb-9.1 O
* O
Hct-32.0 O
* O

 O
MCV-67 O
* O
MCH-19.1 O
* O
MCHC-28.6 O
* O
RDW-16.5 O
* O
Plt O
Ct-209 O

 O
[ O
* O
* O
2141 O
- O
4 O
- O
6 O
* O
* O
] O
09:50AM O
BLOOD O
Neuts-79.6 O
* O
Lymphs-13.3 O
* O
Monos-5.1 O

 O
Eos-1.8 O
Baso-0.2 O

 O
[ O
* O
* O
2141 O
- O
4 O
- O
9 O
* O
* O
] O
05:00AM O
BLOOD O
WBC-8.4 O
RBC-4.45 O
* O
Hgb-8.9 O
* O
Hct-28.8 O
* O

 O
MCV-65 O
* O
MCH-20.0 O
* O
MCHC-30.9 O
* O
RDW-17.5 O
* O
Plt O
Ct-176 O

 O
[ O
* O
* O
2141 O
- O
4 O
- O
7 O
* O
* O
] O
02:00PM O
BLOOD O
Type-ART O
pO2 O
- O
69 O
* O
pCO2 O
- O
105 O
* O
pH-7.16 O
* O

 O
calTCO2 O
- O
40 O
* O
Base O
XS-4 O
Intubat-NOT O
INTUBA O

 O
[ O
* O
* O
2141 O
- O
4 O
- O
8 O
* O
* O
] O
12:15PM O
BLOOD O
Type-ART O
pO2 O
- O
69 O
* O
pCO2 O
- O
70 O
* O
pH-7.31 O
* O

 O
calTCO2 O
- O
37 O
* O
Base O
XS-5 O


 O
Admisson O
CXR O
: O

 O
PA O
AND O
LATERAL O
CHEST O
RADIOGRAPH O
: O
Lungs O
are O
clear O
. O
There O
is O
no O

 O
consolidation O
, O
effusion O
or O
pneumothorax O
. O
Trace O
pleural O

 O
thickening O
is O
seen O
in O
the O
major O
fissure O
on O
lateral O
film O
, O
likely O

 O
right O
sided O
. O
A O
small O
calcified O
nodule O
in O
the O
right O
mid O
lung O

 O
likely O
reflects O
a O
granuloma O
. O
Hilar O
and O
cardiomediastinal O

 O
contours O
are O
unchanged O
. O
The O
aorta O
is O
tortuous O
. O
There O
is O
no O

 O
evidence O
for O
volume O
overload O
. O
There O
is O
degenerative O
change O
in O

 O
the O
thoracic O
spine O
, O
with O
unchanged O
wedge O
deformity O
of O
a O
mid O

 O
thoracic O
vertebral O
body O
. O
There O
are O
no O
suspicious O
lytic O
or O

 O
sclerotic O
osseous O
lesions O
. O

 O
. O


 O
IMPRESSION O
: O

 O
1 O
. O
No O
acute O
cardiopulmonary O
process O
. O

 O
2 O
. O
Unchanged O
degenerative O
change O
with O
wedge O
deformity O
of O
a O
mid O

 O
thoracic O

 O
vertebral O
body O
. O

 O
< O
br O
> O

 O
. O

 O
EKG O
: O
reviewed O
- O
sinus O
tach O
- O
no O
acute O
ST/TW O
changes O
, O
old O
LAD O
, O

 O
poor O
r-wave O
progression O
, O
possible O
LAE O

 O
< O
br O
> O


 O
Brief O
Hospital O
Course O
: O

 O
86 O
yo O
Iranian O
( O
farsi O
speaking O
) O
male O
with O
h/o O
COPD B-REA
( O
on O
home O
o2 B-DRUG

 I-DRUG
( O
uses O
2 B-FRE
- I-FRE
3h I-FRE
qdaily I-FRE
of O
home O
o2 B-DRUG
overall O
) O
, O
HTN O
, O
restless O
leg O

 O
syndrome O
, O
BPH O
transferred O
for O
hypercarbic O
respiratory O
failure O
. O


 O
# O
Acute O
on O
Chronic O
Hypercarbic O
repiratory O
failure O
: O

 O
# O
Acute O
COPD O
exacerbation O

 O
He O
presented O
to O
the O
ED O
with O
shortness O
of O
breath O
and O
change O
in O

 O
mental O
status O
. O
  O
He O
was O
admitted O
to O
the O
floor O
for O
ARF O
and O
COPD O

 O
exacerbation O
. O
  O
He O
then O
develooped O
AMS B-ADE
and O
and O
decreased B-ADE

 I-ADE
respiratory I-ADE
rate I-ADE
with O
a O
gas O
of O
7.16/105/69 O
. O
  O
This O
was O
thought O
to O

  O
be O
secondary O
to O
methadone B-DRUG
overdose B-ADE
due O
to O
taking O
30 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
rather O
than O
15 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
when O
he O
received O
10 B-STR
mg I-STR
tabs B-FOR
rather O
than O
5 B-STR
mg I-STR

 I-STR
tabs O
from O
his O
pharmacy O
. O
  O
He O
required O
BiPAP O
the O
first O
day O
in O
the O

 O
ICU O
given O
that O
his O
PCO2 O
was O
105 O
on O
the O
floor O
. O
  O
He O
was O
started O
on O

 O
a O
narcan B-DRUG
gtt B-ROU
with O
improvement O
of O
his O
respiratory B-REA
status I-REA
. I-REA
  O
His O

 O
narcan B-DRUG
gtt B-ROU
was O
discontinued O
on O
[ O
* O
* O
4 O
- O
8 O
* O
* O
] O
in O
the O
AM O
as O
he O
was O
alert O

 O
and O
speaking O
farsi O
. O
  O
He O
was O
given O
fentanyl B-DRUG
boluses B-DOS
and O
ativan B-DRUG

 I-DRUG
while O
in O
the O
ICU O
to O
help O
with O
withdrawal B-REA
and O
to O
tx O
his O
restless B-REA

 I-REA
leg I-REA
syndrome I-REA
. I-REA
  O
He O
was O
started O
on O
Solumedrol B-DRUG
125 B-STR
mg I-STR
IV B-ROU
q6hrs B-FRE
which O

 O
was O
continued O
x2 B-DUR
days I-DUR
, I-DUR
then O
transitioned O
to O
prednisone B-DRUG
. I-DRUG
He O
was O

 O
also O
started O
on O
azithromycin B-DRUG
. I-DRUG
  O
[ O
* O
* O
4 O
- O
9 O
* O
* O
] O
his O
home O
dose O
of O
methadone B-DRUG

 I-DRUG
was O
restarted O
15 B-STR
mg I-STR
PO B-ROU
BID B-FRE
. I-FRE
  O
Pt O
is O
on O
2L B-DOS
oxygen B-DRUG
at O
home O
but O
taken O

 O
off O
oxygen B-DRUG
this O
AM O
with O
goal B-REA
O2 I-REA
sat I-REA
88 I-REA
- I-REA
92 I-REA
% I-REA
as O
likely O
is O
chronic O

 O
CO2 O
retainer O
. O
Patient??????s O
mental O
status O
is O
at O
baseline O
now O

 O
oriented O
to O
self O
and O
yr O
by O
his O
calendar O
, O
confirmed O
with O
family O

 O
that O
his O
mental O
status O
is O
good O
. O


 O
He O
was O
given O
Rx O
for O
albuterol B-DRUG
MDI B-FOR
and O
is O
to O
continue O
his O
home O

 O
inhalers O
as O
well O
. O


 O
# O
Acute B-REA
on I-REA
Chronic I-REA
Renal I-REA
Failure I-REA
? O
? O
? O
? O
? O
? O
appeared O
pre O
renal O
in O

 O
etiology O
, O
now O
resolved O
. O

 O
He O
is O
to O
continue O
his O
home O
Tamsulosin B-DRUG
and O
Finasteride B-DRUG
, I-DRUG
lasix B-DRUG
. I-DRUG



 O
# O
Restless B-ADE
Leg I-ADE
syndrome I-ADE
? O
? O
? O
? O
? O
? O
See O
above O
patient O
may O
have O

 O
accidentally O
overdosed B-ADE
on O
his O
methadone B-DRUG
. I-DRUG
  O
His O
mental B-REA
status I-REA

 I-REA
responded O
to O
a O
narcan B-DRUG
gtt B-ROU
. I-ROU
  O
He O
was O
given O
prn B-FRE
fentanyl B-DRUG
until O
[ O
* O
* O
4 O
- O
9 O
* O
* O
] O

 O
at O
which O
point O
he O
was O
restarted O
on O
his O
home O
methadone B-DRUG
15 B-STR
mg I-STR
PO B-ROU

 I-ROU
BID B-FRE
. I-FRE
  O
Emphasized O
appropriate O
dosing O
to O
pt O
, O
family O
, O
and O
have O
set O

 O
up O
VNA O
services O
to O
ensure O
he O
understands O
his O
medication O
. O


 O
# O
Anemia O
, O
microcytic O
- O
has O
h/o O
thalessemia O
. O
HCT O
stable O
during O

 O
admission O
. O


 O
# O
Code O
status O
: O
he O
did O
not O
require O
intubation O
and O
family O
reports O

 O
he O
does O
not O
have O
any O
history O
of O
COPD O
hospitalizations O
. O
  O
Code O

 O
status O
is O
full O
, O
but O
his O
providers O
did O
discuss O
with O
family O
the O

 O
possibility O
of O
a O
comfort-focused O
, O
noninvasive O
approach O
when O
he O

 O
was O
very O
ill O
in O
the O
unit O
. O
  O
Recommend O
that O
further O
goals O
of O
care O

 O
discussion O
continue O
with O
his O
PCP O
. O


 O
Medications O
on O
Admission O
: O

 O
Below O
medications O
confirmed O
with O
family O
with O
pill O
boxes O
: O

 O
. O

 O
lasix B-DRUG
40 B-STR
mg I-STR
qdaily B-FRE

 I-FRE
atrovent B-DRUG
tid B-FRE

 I-FRE
methadone B-DRUG
15 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
flomax B-DRUG
0.4 B-STR
mg I-STR
qdaily B-FRE

 I-FRE
finasteride B-DRUG
5 B-STR
mg I-STR
qdaily B-FRE

 I-FRE
ocuvite B-DRUG
150 B-DOS
- I-DOS
30 I-DOS
- I-DOS
6 I-DOS
- I-DOS
150 I-DOS
cap B-FOR
qdaily B-FRE

 I-FRE
vit B-DRUG
b12 I-DRUG
1000mcg B-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
cranberry-vit B-DRUG
c I-DRUG
-vit I-DRUG
E I-DRUG
140 B-STR
-100 I-STR
- I-STR
3- I-STR
cap B-FOR
tid B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Finasteride B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
2 O
. O
Methadone B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
one B-DOS
and I-DOS
a I-DOS
half I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE

 I-FRE
day I-FRE
: I-FRE
Please O
look O
carefully O
at O
your O
bottle O
at O
home O
. O
  O
Your O
family O

 O
reports O
that O
the O
pharmacy O
recently O
gave O
you O
10 B-STR
mg I-STR
tablets B-FOR
. I-FOR
  O
You O

 O
should O
take O
15 B-STR
mg I-STR
per O
dose O
, O
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
3 O
. O
Tamsulosin B-DRUG
0.4 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Sust I-FOR
. I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Sust I-FOR
. I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Albuterol B-DRUG
90 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
puff B-ROU

 I-ROU
Inhalation I-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
shortness B-REA
of I-REA
breath I-REA

 I-REA
or O
wheezing B-REA
. I-REA

 O
Disp:*1 O
1 O
* O
Refills:*0 O
* O

 O
5 O
. O
Atrovent B-DRUG
HFA O
17 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
puffs B-FOR

 I-FOR
Inhalation B-ROU
three B-FRE
times I-FRE
a I-FRE
day I-FRE
: I-FRE
please O
continue O
to O
take O
this O

 O
medication O
as O
you O
were O
at O
home O
. O
  O
I O
have O
not O
made O
any O
deliberate O

 O
changes O
. O

 O
6 O
. O
Cyanocobalamin B-DRUG
500 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
: I-FRE
Continue O
taking O
this O
medication O
( O
vitamin B-DRUG
B12 I-DRUG
) I-DRUG
as O

 O
you O
were O
at O
home O
. O

 O
7 O
. O
Lasix B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
8 O
. O
Ocuvite B-DRUG
150 B-STR
- I-STR
30 I-STR
- I-STR
6 I-STR
- I-STR
150 I-STR
mg-unit-mg-mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
PO B-ROU
daily B-FRE
( O
): O
Continue O
as O
you O
have O
been O
taking O
at O
home O
. O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital O
119 O
* O
* O
] O
Homecare O


 O
Discharge O
Diagnosis O
: O

 O
Hypercarbic O
respiratory O
failure O

 O
Acute O
COPD O
exacerbation O

 O
Restless O
legs O
syndrome O

 O
Chronic O
kidney O
disease O

 O
Anxiety O



 O
Discharge O
Condition O
: O

 O
stable O



 O
Discharge O
Instructions O
: O

 O
Please O
seek O
medical O
attention O
if O
you O
develop O
new O
shortness O
of O

 O
breath O
, O
fever O
, O
coughing O


 O
Review O
your O
medication O
list O
carefully O
and O
compare O
to O
your O

 O
bottles O
at O
home O
. O
  O
Your O
methadone B-DRUG
should O
be O
15 B-STR
mg I-STR
twice B-FRE
daily I-FRE
. I-FRE


 O
If O
you O
do O
not O
already O
have O
an O
albuterol B-DRUG
inhaler B-FOR
, I-FOR
you O
should O
fill O

 O
out O
the O
prescription O
we O
have O
given O
you O
. O
  O
If O
you O
already O
have O
one O

 O
at O
home O
, O
you O
can O
continue O
taking O
it O
as O
prescribed O
by O
your O

 O
primary O
care O
physician O
. O
  O
[ O
* O
* O
Name O
Initial O
( O
NameIs O
) O
* O
* O
] O
have O
not O
changed O
any O
of O
your O
other O

 O
medications O
. O


 O
Followup O
Instructions O
: O

 O
Please O
contact O
your O
primary O
care O
physician O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
2903 O
* O
* O
] O
for O
a O

 O
follow-up O
appointment O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
18651 O
* O
* O
] O
in O
the O
next O
1 O
- O
2 O
weeks O



                              O

[ O
* O
* O
Name6 O
( O
MD O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(2 O
) O
2158 O
* O
* O
] O


 O
Completed O
by:[**2141 O
- O
4 O
- O
11 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2113 O
- O
3 O
- O
22 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2113 O
- O
3 O
- O
28 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2036 O
- O
1 O
- O
16 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
No O
Known O
Allergies O
/ O
Adverse O
Drug O
Reactions O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1390 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
right O
hemopneumothorax O
, O
bilateral O
pulmonary O
contusions O
, O
right O

 O
rib O
fractures O
, O
multiple O
facial O
fractures O
, O
degloving O
injury O
to O

 O
ear O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
right O
chest O
tube O
placement O


 O
History O
of O
Present O
Illness O
: O

 O
74 O
M O
was O
struck O
by O
his O
car O
after O
attempting O
to O
do O
some O
mechanical O

 O
work O
on O
it O
. O
Car O
rolled O
over O
him O
and O
dragged O
him O
several O
feet O
. O

 O
He O
was O
brought O
to O
the O
ED O
by O
ambulance O
. O
He O
had O
concerns O
of O
RUQ O

 O
pain O
, O
chest O
pain O
and O
a O
laceration O
to O
the O
head O
. O
  O
He O
denied O
loss O

 O
of O
consciousness O
. O
A O
chest O
tube O
was O
placed O
in O
the O
ED O
for O

 O
hemopneumothorax O
. O
  O
Following O
the O
chest O
tube O
placement O
, O
the O

 O
patient O
had O
an O
episode O
of O
hematemesis O
and O
hypotension O
, O
but O
this O

 O
resolved O
spontaneously O
. O
At O
baseline O
the O
patient O
is O
functional O
at O

 O
home O
and O
take O
no O
anticoagulant B-DRUG
medications I-DRUG
. I-DRUG
He O
suffered O
multiple O

 O
facial O
fractures O
, O
an O
ear O
laceration O
, O
bilateral O
pulmonary O

 O
contusions O
, O
multiple O
right O
sided O
rib O
fractures O
and O
a O
dens O

 O
fracture O
. O


 O
Past O
Medical O
History O
: O

 O
Hypertension O


 O
Social O
History O
: O

 O
Patient O
lives O
in O
[ O
* O
* O
Location O
1411 O
* O
* O
] O
with O
his O
wife O
. O
  O
Denies O
tobacco O
or O
IVDA O
, O

 O
drinks O
2 O
glasses O
wine O
nightly O
. O



 O
Family O
History O
: O

 O
Non-contributory O
. O


 O
Physical O
Exam O
: O

 O
VS O
: O
97.6 O
90 O
138/77 O
18 O
98%RA O

 O
GA O
: O
alert O
and O
oriented O
x O
3 O
, O
no O
acute O
distress O

 O
CVS O
: O
normal O
S1 O
, O
S2 O
, O
no O
murmurs O

 O
Resp O
: O
mild O
bibasilar O
crackles O

 O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
: O
soft O
, O
nontender O
, O
nondistended O

 O
Ext O
: O
warm O
, O
no O
edema O
, O
well O
perfused O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
22 O
* O
* O
] O
01:25PM O
   O
GLUCOSE-107 O
* O
LACTATE-2.6 O
* O
NA+-143 O
K+-4.6 O

 O
CL--95 O
* O
TCO2 O
- O
31 O
* O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
22 O
* O
* O
] O
01:28PM O
   O
PT-13.1 O
PTT-24.1 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
22 O
* O
* O
] O
01:28PM O
   O
PLT O
COUNT-201 O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
22 O
* O
* O
] O
01:28PM O
   O
WBC-9.1 O
RBC-4.44 O
* O
HGB-15.4 O
HCT-43.1 O
MCV-97 O

 O
MCH-34.7 O
* O
MCHC-35.8 O
* O
RDW-13.1 O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
22 O
* O
* O
] O
01:28PM O
   O
ASA-NEG O
ETHANOL-NEG O
ACETMNPHN-NEG O

 O
bnzodzpn-NEG O
barbitrt-NEG O
tricyclic-NEG O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
22 O
* O
* O
] O
01:28PM O
   O
LIPASE-74 O
* O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
22 O
* O
* O
] O
01:28PM O
   O
UREA O
N-17 O
CREAT-1.1 O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
26 O
* O
* O
] O
05:00AM O
BLOOD O
WBC-6.4 O
RBC-2.59 O
* O
Hgb-9.0 O
* O
Hct-24.6 O
* O

 O
MCV-95 O
MCH-34.8 O
* O
MCHC-36.7 O
* O
RDW-14.8 O
Plt O
Ct-135 O
* O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
26 O
* O
* O
] O
05:00AM O
BLOOD O
Plt O
Ct-135 O
* O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
25 O
* O
* O
] O
05:10AM O
BLOOD O
Glucose-84 O
UreaN-11 O
Creat-0.8 O
Na-137 O

 O
K-4.0 O
Cl-102 O
HCO3 O
- O
29 O
AnGap-10 O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
25 O
* O
* O
] O
05:10AM O
BLOOD O
Calcium-8.1 O
* O
Phos-2.6 O
* O
Mg-2.1 O


 O
[ O
* O
* O
2113 O
- O
3 O
- O
22 O
* O
* O
] O
CT O
SINUS/MANDIBLE/MAXIL O
: O

 O
1 O
. O
Numerous O
facial O
fractures O
as O
enumerated O
before O
corresponding O

 O
most O
closely O
to O
a O
Le O
Fort O
type O
III O
on O
the O
left O
and O

 O
anterior O
, O
lateral O
and O
superior O
walls O
of O
the O
maxillary O
sinus O
on O

 O
the O
right O
including O
the O
inferior O
orbital O
rim O
. O

 O
2 O
. O
Hemorrhage O
contained O
within O
the O
maxillary O
sinuses O
. O

 O
3 O
. O
Chronic O
non-displaced O
fracture O
of O
the O
tip O
of O
the O
dens O
. O


 O
[ O
* O
* O
2113 O
- O
3 O
- O
27 O
* O
* O
] O
CHEST O
( O
PORTABLE O
AP O
) O
: O

 O
Small O
right O
apical O
pneumothorax O
at O
the O
level O
of O
the O
second O

 O
posterior O

 O
interspace O
, O
slightly O
smaller O
than O
on O
[ O
* O
* O
3 O
- O
26 O
* O
* O
] O
. O
Small O
right O

 O
pleural O
effusion O
has O
probably O
developed O
. O
Lungs O
low O
in O
volume O
but O

 O
clear O
. O
Moderate O
cardiomegaly O
unchanged O
. O
Healed O
right O
lower O
and O

 O
lateral O
rib O
fractures O
. O



 O
Brief O
Hospital O
Course O
: O

 O
Summary O
of O
Injuries O
sustained O
: O
anterior O
right O
2 O
- O
7th O
rib O

 O
fractures O
, O
right O
hemopneumothorax O
, O
bilateral O
pulmonary O

 O
contusions O
, O
L O
zygomatic O
arch O
fracture O
, O
left O
lateral O
pterygoid O

 O
plate O
fractures O
, O
left O
lateral O
orbital O
wall O
fractures O
, O
left O

 O
minimally O
displaced O
orbital O
fractures O
, O
nondisplaced O
lamina O

 O
papyrica O
fracture O
, O
right O
orbital O
floor O
fracture O
, O
bilateral O

 O
lateral O
wall O
maxillary O
sinus O
fracture O
, O
right O
ear O
skin O
avulsion O
. O


 O
Review O
of O
Systems O
: O



 O
Neurologic O
: O
Patient O
was O
neurologically O
intact O
. O
He O
recieved O

 O
dilaudid B-DRUG
IV B-ROU
prn B-FRE
during O
his O
ICU O
stay O
, O
he O
was O
then O
transitioned O
to O

 O
PO B-ROU
pain B-DRUG
medication I-DRUG
. I-DRUG
At O
discharge O
he O
was O
not O
requiring O
pain B-DRUG

 I-DRUG
medication I-DRUG
. I-DRUG
  O
Opthalmology O
assessed O
patient O
to O
assess O
visual O

 O
status O
following O
displaced O
orbital O
fractures O
. O
  O
Plastic O
surgery O

 O
assessed O
facial O
fractures O
and O
as O
patient O
is O
refusing O
surgery O
, O

 O
they O
will O
follow O
up O
with O
him O
as O
an O
outpatient O
. O
For O
his O
facial O

 O
fractures O
he O
was O
placed O
under O
sinus O
precautions O
and O
is O

 O
restricted O
to O
a O
soft O
diet O
. O
Neurosurgery O
assessed O
patient O
for O
his O

 O
dens O
fracture O
and O
it O
was O
determined O
that O
his O
fracture O
resulted O

 O
from O
an O
injury O
20 O
years O
ago O
when O
he O
dove O
into O
a O
pool O
. O
On O

 O
hospital O
day O
6 O
he O
was O
triggered O
for O
altered B-REA
mental I-REA
status I-REA
after O

 O
receiving O
valium B-DRUG
. I-DRUG
  O
Standing O
zyprexa B-DRUG
was O
administered O
with O
return O

 O
to O
baseline O
mental O
status O
without O
further O
incidient O
. O
  O
He O

 O
requires O
no O
further O
neurosurgical O
follow-up O
for O
his O
dens O

 O
fracture O
. O


 O
Cardiovascular O
: O
Following O
transfer O
to O
the O
ICU O
patient O
remained O

 O
hemodynamically O
stable O
. O
  O
He O
suffered O
an O
intial O
period O
of O

 O
hypotension O
in O
the O
emergency O
room O
but O
after O
resuscitation O
he O
was O

 O
hemodynamically O
stable O
. O


 O
Pulmonary O
: O
A O
chest O
tube O
was O
placed O
for O
hemopneumothorax O
in O
the O

 O
ED O
. O
The O
chest O
tube O
was O
discontinued O
on O
HD6 O
. O
There O
was O
a O
small O

 O
increase O
in O
pneumothorax O
upon O
discontinuation O
, O
however O
follow O
up O

 O
CXR O
revealed O
this O
change O
to O
be O
stable O
. O
His O
respiratory O
status O

 O
was O
stable O
. O
  O
While O
in O
the O
ICU O
, O
he O
was O
monitored O
for O
respiratory O

 O
decompensation O
due O
to O
splinting O
from O
his O
rib O
fractures O
, O
however O

 O
his O
respiratory O
status O
remained O
stable O
and O
he O
did O
not O
require O
an O

 O
epidural O
for O
pain O
control O
. O


 O
GI O
: O
Patient O
suffered O
no O
intraabdominal O
injury O
. O
He O
tolerated O
a O

 O
soft O
diet O
without O
issue O
. O
He O
was O
restricted O
to O
a O
soft O
diet O
due O
to O

 O
his O
facial O
fractures O
. O


 O
GU/Renal O
: O
Patient O
has O
a O
foley O
catheter O
placed O
while O
in O
the O
ICU O

 O
but O
it O
was O
discontinued O
when O
he O
was O
transferred O
to O
the O
floor O
. O

 O
His O
electrolytes O
were O
repleted O
as O
necessary O
. O
His O
creatinine O

 O
remained O
stable O
. O


 O
Endocrine O
: O
He O
was O
placed O
on O
insulin B-DRUG
sliding B-DOS
scale I-DOS
while O
in O
the O

 O
ICU O
. O
At O
discharge O
sliding O
scale O
had O
be O
discontinued O
and O
patient O

 O
was O
no O
longer O
requiring O
insulin B-DRUG
. I-DRUG
A O
right O
thyroid O
nodule O
was O

 O
noted O
on O
CT O
and O
needs O
to O
be O
followed O
up O
with O
ultrasound O
as O
an O

 O
outpatient O
, O


 O
Heme O
: O
Patient O
underwent O
serial O
hematocrit O
checks O
which O
trended O

 O
down O
slowly O
. O
He O
received O
one B-DOS
blood B-DRUG
transfusion B-FOR
while O
in O

 O
hospital O
, O
after O
which O
he O
required O
no O
further O
transfusions O
as O
his O

 O
hematocrit O
was O
stable O
. O
  O
He O
was O
placed O
on O
SQH B-DRUG
for O
DVT B-REA

 I-REA
prophylaxis I-REA
. I-REA


 O
Skin O
: O
Patient O
right O
ear O
laceration O
was O
repaired O
primarily O
by O

 O
plastic O
surgery O
. O
He O
was O
placed O
on O
levofloxacin B-DRUG
, I-DRUG
which O
following O

 O
treatment O
course O
, O
was O
discontinued O
. O



 O

Medications O
on O
Admission O
: O

 O
lopressor B-DRUG
( O
unknown O
dosage O
) O
, O
timolol B-DRUG


 I-DRUG
Discharge O
Medications O
: O

 O
Metoprolol B-DRUG
Tartrate I-DRUG
12.5 B-STR
mg I-STR
PO/NG B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
, O
Timolol B-DRUG
Maleate I-DRUG
0.5 B-STR
% I-STR
1 B-DOS

 I-DOS
DROP B-FOR
BOTH B-ROU
EYES I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
, O
Levofloxacin B-DRUG
500 B-STR
mg I-STR
PO B-ROU
Q24H B-FRE
x O
4 B-DUR
days I-DUR


 I-DUR
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Location O
( O
un O
) O
932 O
* O
* O
] O
vna O


 O
Discharge O
Diagnosis O
: O

 O
Anterior O
right O
rib O
fractures O
[ O
* O
* O
2 O
- O
6 O
* O
* O
] O

 O
Right O
pneumothorax O

 O
Bilateral O
pulmonary O
contusions O

 O
Left O
zygomatic O
arch O
fracture O

 O
Left O
lateral O
pterygoid O
plate O
fracture O

 O
Left O
lateral O
orbital O
wall O
fracture O

 O
Left O
minimally O
displaced O
orbital O
floor O
fracture O

 O
Bilateral O
lateral O
wall O
maxillary O
sinus O
fractures O

 O
Right O
ear O
skin O
avulsion O



 O
Discharge O
Condition O
: O

 O
Good O


 O
Discharge O
Instructions O
: O

 O
Please O
call O
your O
doctor O
or O
nurse O
practitioner O
if O
you O
experience O

 O
the O
following O
: O

 O
* O
You O
experience O
new O
chest O
pain O
, O
pressure O
, O
squeezing O
or O

 O
tightness O
. O

 O
* O
New O
or O
worsening O
cough O
, O
shortness O
of O
breath O
, O
or O
wheeze O
. O

 O
* O
If O
you O
are O
vomiting O
and O
can O
not O
keep O
down O
fluids O
or O
your O

 O
medications O
. O

 O
* O
You O
are O
getting O
dehydrated O
due O
to O
continued O
vomiting O
, O
diarrhea O
, O

 O
or O
other O
reasons O
. O
Signs O
of O
dehydration O
include O
dry O
mouth O
, O
rapid O

 O
heartbeat O
, O
or O
feeling O
dizzy O
or O
faint O
when O
standing O
. O

 O
* O
You O
see O
blood O
or O
dark/black O
material O
when O
you O
vomit O
or O
have O
a O

 O
bowel O
movement O
. O

 O
* O
You O
experience O
burning O
when O
you O
urinate O
, O
have O
blood O
in O
your O

 O
urine O
, O
or O
experience O
a O
discharge O
. O

 O
* O
Your O
pain O
is O
not O
improving O
within O
8 O
- O
12 O
hours O
or O
is O
not O
gone O

 O
within O
24 O
hours O
. O
Call O
or O
return O
immediately O
if O
your O
pain O
is O

 O
getting O
worse O
or O
changes O
location O
or O
moving O
to O
your O
chest O
or O

 O
back O
. O

 O
* O
You O
have O
shaking O
chills O
, O
or O
fever O
greater O
than O
101.5 O
degrees O

 O
Fahrenheit O
or O
38 O
degrees O
Celsius O
. O

 O
* O
Any O
change O
in O
your O
symptoms O
, O
or O
any O
new O
symptoms O
that O
concern O

 O
you O
. O

 O
. O

 O
General O
Discharge O
Instructions O
: O

 O
Please O
resume O
all O
regular O
home O
medications O
, O
unless O
specifically O

 O
advised O
not O
to O
take O
a O
particular O
medication O
. O
  O
Also O
, O
please O
take O

 O
any O
new O
medications O
as O
prescribed O
. O

 O
Please O
get O
plenty O
of O
rest O
, O
continue O
to O
ambulate O
several O
times O

 O
per O
day O
, O
and O
drink O
adequate O
amounts O
of O
fluids O
. O
  O
Avoid O
lifting O

 O
weights O
greater O
than O
[ O
* O
* O
5 O
- O
9 O
* O
* O
] O
lbs O
until O
you O
follow-up O
with O
your O

 O
surgeon O
, O
who O
will O
instruct O
you O
further O
regarding O
activity O

 O
restrictions O
. O

 O
Avoid O
driving O
or O
operating O
heavy O
machinery O
while O
taking O
pain B-DRUG

 I-DRUG
medications I-DRUG
. I-DRUG

 O
Please O
follow-up O
with O
your O
surgeon O
and O
Primary O
Care O
Provider O

 O
( O
PCP O
) O
as O
advised O
. O

 O
Incision O
Care O
: O

 O
* O

Please O
call O
your O
doctor O
or O
nurse O
practitioner O
if O
you O
have O

 O
increased O
pain O
, O
swelling O
, O
redness O
, O
or O
drainage O
from O
the O
incision O

 O
site O
. O

 O
* O
Avoid O
swimming O
and O
baths O
until O
your O
follow-up O
appointment O
. O

 O
* O
You O
may O
shower O
, O
and O
wash O
surgical O
incisions O
with O
a O
mild O
soap O

 O
and O
warm O
water O
. O
  O
Gently O
pat O
the O
area O
dry O
. O

 O
* O
If O
you O
have O
staples O
, O
they O
will O
be O
removed O
at O
your O
follow-up O

 O
appointment O
. O

 O
* O
If O
you O
have O
steri-strips O
, O
they O
will O
fall O
off O
on O
their O
own O
. O

 O
Please O
remove O
any O
remaining O
strips O
7 O
- O
10 O
days O
after O
surgery O
. O


 O
Followup O
Instructions O
: O

 O
Please O
call O
ACS O
at O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
600 O
* O
* O
] O
to O
make O
a O
follow-up O
appointment O

 O
within O
2 O
- O
3 O
weeks O


 O
Please O
contact O
the O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
90000 O
* O
* O
] O
at O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
5343 O
* O
* O
] O
with O
Plastic O

 O
Surgery O
to O
make O
a O
follow-up O
appointment O
for O
1 O
week O
from O

 O
discharge O
. O


 O
Please O
contact O
your O
primary O
care O
provider O
and O
make O
[ O
* O
* O
Name O
Initial O
( O
PRE O
) O
* O
* O
] O
follow-up O

 O
appointment O
within O
2 O
weeks O
. O
  O
You O
will O
need O
to O
have O
an O
ultrasound O

 O
of O
your O
thyroid O
as O
well O
as O
work-up O
of O
an O
inguinal O
hernia O
. O




 O
Completed O
by:[**2113 O
- O
3 O
- O
29 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2146 O
- O
4 O
- O
3 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2146 O
- O
4 O
- O
7 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2120 O
- O
3 O
- O
29 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1042 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Abdominal O
Pain O
, O
Nausea O
, O
Vomitting O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O


 O
History O
of O
Present O
Illness O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
64236 O
* O
* O
] O
is O
a O
26 O
y/o O
man O
with O
IDDM O
for O
8 O
years O
who O
presents O

 O
with O
several O
days O
of O
nausea/vomiting O
and O
abdominal O
pain O
. O
Two O

 O
weeks O
ago O
, O
he O
was O
diagnosed O
with O
sinusitis/sinus B-REA
infection I-REA
and O

 O
given O
antibiotics B-DRUG
. I-DRUG
He O
first O
noticed O
epigastric O
abdominal O
pain O

 O
about O
one O
week O
ago O
, O
constant O
, O
without O
relation O
to O
food O
. O
It O
was O
a O

 O
strong O
, O
sharp O
pain O
that O
did O
not O
radiate O
. O
Notably O
, O
he O
had O
been O

 O
taking O
ibuprofen B-DRUG
800 B-STR
mg I-STR
q3h B-FRE
for O
headache B-REA
associated I-REA
with I-REA

 I-REA
sinusitis I-REA
at O
that O
time O
. O
In O
past O
2 O
- O
3 O
days O
noticed O
increased O

 O
nausea O
with O
vomiting O
. O
Denies O
hematemesis O
. O
Notes O
that O
he O
last O

 O
kept O
something O
liquid O
down O
yesterday O
morning O
, O
but O
vomitted O
up O

 O
everything O
( O
both O
liqiuds O
and O
solids O
) O
through O
the O
day O
and O
night O
. O

 O
Thus O
, O
he O
came O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
that O
night O
. O
Took O
insulin B-DRUG
during O
that O

 O
time O
intermittently O
but O
this O
is O
typical O
for O
him O
. O

 O
. O

 O
His O
insulin B-DRUG
control O
and O
FSG O
checking O
has O
chronically O
been O
very O

 O
poor O
. O
He O
admits O
to O
taking O
insulin B-DRUG
about O
5 B-FRE
times I-FRE
per I-FRE
week I-FRE
. I-FRE

 O
Further O
, O
when O
he O
does O
take O
it O
, O
he O
taked O
a O
standing O
dose O
of O
10U B-DOS

 I-DOS
Reg B-DRUG
and O
30U B-DOS
of O
70/30 B-DRUG
. I-DRUG
He O
takes O
his O
FSG O
about O
1 O
per O
month O
due O
to O

 O
discomfort O
with O
the O
prick O
. O
He O
has O
chronic O
polyuria O
and O

 O
polydypsia O
. O
He O
reports O
getting O
regular O
vision O
checks O
with O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O

 O
center O
and O
no O
knowledge O
of O
neuropathy O
, O
kidney O
disease O
, O
or O
eye O

 O
problems O
. O

 O
. O

 O
On O
ROS O
, O
he O
denies O
HA O
, O
changes O
in O
vision O
, O
hearing O
, O
or O
swallowing O
. O

 O
No O
fever O
, O
sweats O
, O
chills O
, O
weight O
loss O
. O
He O
eats O
very O
well O
. O
No O
CP O
, O

 O
palps O
, O
PND O
, O
orthopnea O
. O
No O
SOB O
, O
pain O
with O
breathing O
, O
cough O
, O

 O
wheeze O
. O
No O
recent O
bowel O
of O
bladder O
dysfunction O
. O
No O
troubles O
with O

 O
limb O
weakness O
, O
sensory O
changes O
, O
poor O
coordination O
. O
He O
does O
feel O

 O
episodes O
of O
hypoglycemia B-ADE
if O
he O
does O
not O
eat O
following O
insulin B-DRUG
: I-DRUG

 O
sweating B-ADE
, I-ADE
palpitations B-ADE
, I-ADE
and O
anxiety B-ADE
. I-ADE


 O
Past O
Medical O
History O
: O

 O
IDDM O
: O
Poorly O
controlled O

 O
DKA O
X O
3 O

 O
Periperal O
neuropathy O



 O
Social O
History O
: O

 O
Patient O
denies O
any O
tobacco O
use O
. O
Uses O
ETOH O
socially O
. O
No O
drug O
use O
. O

 O
Patient O
is O
a O
mental O
health O
worker O
in O
[ O
* O
* O
Last O
Name O
( O
un O
) O
64237 O
* O
* O
] O
center O
, O
he O

 O
currently O
lives O
with O
fiance O
. O
Pt O
is O
engaged O
and O
expecting O

 O
daughter O
in O
next O
week O
. O
Lives O
in O
[ O
* O
* O
Location O
18600 O
* O
* O
] O
. O



 O
Family O
History O
: O

 O
Family O
history O
positive O
for O
DM O
, O
CVA O
, O
cardiac O
disease O

 O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
mother O
died O
at O
age O
45 O
from O
heart O
disease O
related O
to O

 O
diabetes O

 O
No O
family O
history O
of O
sickle O
cell O
disease O



 O
Physical O
Exam O
: O

 O
T O
: O
98.8 O
BP O
: O
139/78 O
HR O
: O
112 O
RR O
: O
17 O
O2 O
100 O
% O
RA O

 O
Gen O
: O
Pleasant O
, O
well O
appearing O
young O
male O
in O
no O
acute O
distress O
, O

 O
lying O
comfortably O
in O
bed O

 O
HEENT O
: O
No O
conjunctival O
pallor O
. O
No O
scleral O
icterus O
. O
MM O
slightly O

 O
dry O
. O
OP O
clear O
. O
Eye O
funduscopic O
exam O
WNL O
( O
no O
exudates O
, O
edema O
, O

 O
wiring O
) O

 O
NECK O
: O
Supple O
, O
No O
LAD O
, O
JVD O
not O
elevated O
while O
sitting O
upright O
. O
No O

 O
goiter O

 O
CV O
: O
Tachycardic O
, O
regular O
, O
no O
appreciable O
murmur O
. O
Physiologically O

 O
splitting O
S2 O
. O

 O
LUNGS O
: O
clear O
to O
auscultation O
bilaterally O
, O
no O
wheezing O
or O
rhonchi O


 O
ABD O
: O
soft O
, O
nontender O
to O
palpation O
, O
no O
hepatosplenomegaly O

 O
EXT O
: O
warm O
, O
well O
perfused O
throughout O
, O
no O
peripheral O
edema O

 O
SKIN O
: O
No O
rashes O
or O
ecchymoses O
. O

 O
NEURO O
: O
A&Ox3 O
. O
Appropriate O
. O
CN O
2 O
- O
12 O
grossly O
intact O
. O
5/5 O
strength O

 O
throughout O
. O
[**1 O
- O
19**]+ O
reflexes O
, O
equal O
BL O
. O
Normal O
coordination O
. O
Distal O

 O
foot O
sensation O
to O
light O
touch O
decreased O
. O



 O
Pertinent O
Results O
: O

 O
MICU O
Results O
: O

 O
[ O
* O
* O
2146 O
- O
4 O
- O
3 O
* O
* O
] O
08:17PM O
BLOOD O
WBC-14.6 O
* O
# O
RBC-5.97 O
Hgb-15.6 O
Hct-48.8 O

 O
MCV-82 O
MCH-26.2 O
* O
MCHC-32.0 O
RDW-12.6 O
Plt O
Ct-327 O

 O
[ O
* O
* O
2146 O
- O
4 O
- O
3 O
* O
* O
] O
08:17PM O
BLOOD O
Glucose-404 O
* O
UreaN-16 O
Creat-1.3 O
* O
Na-143 O

 O
K-4.5 O
Cl-99 O
HCO3 O
- O
12 O
* O
AnGap-37 O
* O

 O
[ O
* O
* O
2146 O
- O
4 O
- O
4 O
* O
* O
] O
02:46AM O
BLOOD O
Calcium-9.8 O
Phos-2.9 O
Mg-1.9 O

 O
[ O
* O
* O
2146 O
- O
4 O
- O
3 O
* O
* O
] O
09:52PM O
BLOOD O
ALT-13 O
AST-11 O
AlkPhos-75 O
TotBili-0.3 O

 O
[ O
* O
* O
2146 O
- O
4 O
- O
4 O
* O
* O
] O
12:22PM O
BLOOD O
% O
HbA1c-14.8 O
* O



 O
Floor O
Transfer O
: O

 O
[ O
* O
* O
2146 O
- O
4 O
- O
5 O
* O
* O
] O
04:30AM O
BLOOD O
WBC-10.1 O
RBC-4.97 O
Hgb-13.2 O
* O
Hct-39.9 O
* O

 O
MCV-80 O
* O
MCH-26.6 O
* O
MCHC-33.1 O
RDW-13.0 O
Plt O
Ct-267 O

 O
[ O
* O
* O
2146 O
- O
4 O
- O
5 O
* O
* O
] O
04:30AM O
BLOOD O
Glucose-187 O
* O
UreaN-10 O
Creat-0.7 O
Na-142 O

 O
K-3.0 O
* O
Cl-110 O
* O
HCO3 O
- O
19 O
* O
AnGap-16 O

 O
[ O
* O
* O
2146 O
- O
4 O
- O
6 O
* O
* O
] O
06:30AM O
BLOOD O
Glucose-232 O
* O
UreaN-8 O
Creat-0.7 O
Na-145 O

 O
K-3.9 O
Cl-111 O
* O
HCO3 O
- O
24 O
AnGap-14 O

 O
[ O
* O
* O
2146 O
- O
4 O
- O
5 O
* O
* O
] O
04:30AM O
BLOOD O
Calcium-9.1 O
Phos-2.2 O
* O
Mg-1.8 O


 O
CXR O
: O

 O
FINDINGS O
: O
The O
lungs O
are O
well O
expanded O
and O
clear O
. O
The O
mediastinum O

 O
is O
unremarkable O
. O
The O
cardiac O
silhouette O
is O
within O
normal O
limits O

 O
for O
size O
. O
No O
effusion O
or O
pneumothorax O
is O
evident O
. O
The O
visualized O

 O
osseous O
structures O
are O
unremarkable O
. O


 O
IMPRESSION O
: O
No O
acute O
pulmonary O
process O
. O



 O
Brief O
Hospital O
Course O
: O

 O
On O
arrival O
to O
MICU O
, O
patient O
complaining O
of O
ongoing O
nausea O
and O

 O
epigastric O
pain O
. O
Vomitting O
X O
2 O
was O
witnessed O
by O
house O
staff O
, O
the O

 O
second O
episode O
occurring O
with O
a O
small O
amount O
of O
hematemesis O
. O
No O

 O
subsequent O
hematemesis O
or O
significant O
Hct O
change O
. O
In O
the O
MICU O
, O

 O
he O
was O
placed O
on O
insulin B-DRUG
drip B-ROU
, I-ROU
IVF B-DRUG
, I-DRUG
and O
electrolytes B-DRUG
( I-DRUG
most I-DRUG

 I-DRUG
notably I-DRUG
K I-DRUG
) I-DRUG
were O
repleted O
as O
needed O
. O
His O
Anion O
Gap O
narrowed O
from O

 O
30 O
to O
13 O
by O
transfer O
to O
floor O
. O
His O
FSGs O
were O
initially O
high O
400s O

 O
and O
fluctuated O
between O
200 O
- O
500 O
in O
the O
MICU O
. O
Following O

 O
stabilization O
, O
the O
patient O
was O
transferred O
to O
the O
medical O
floor O
. O

 O
His O
FSG O
was O
420 O
upon O
transfer O
. O
He O
was O
receiving O
standing O
NPH B-DRUG
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
and O
Regular B-DRUG
ISS I-DRUG
with B-FRE
meals I-FRE
. I-FRE
On O
floor O
day O
1 O
, O
his O
FSGs O
were O
in O
the O

 O
200s O
. O
His O
anion O
gap O
closed O
. O
Potassium B-DRUG
and O
Phos B-DRUG
were O
repleted O
. O

 O
The O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
center O
was O
also O
consulted O
. O

 O
. O



 O

Discharge O
Medications O
: O

 O
1 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet O
, O
Delayed O
Release O
(E.C.)(s O
) O
* O
Refills:*2 O
* O

 O
2 O
. O
Insulin B-DRUG
Lispro I-DRUG
100 B-STR
unit/mL I-STR
Insulin B-FOR
Pen I-FOR
Sig O
: O
As O
per O
sliding B-DOS

 I-DOS
scale I-DOS
Units O
Subcutaneous B-ROU
four B-FRE
times I-FRE
a I-FRE
day I-FRE
: I-FRE
Use O
number O
of O
units O

 O
indicated O
on O
sliding B-DOS
scale I-DOS
for O
your O
measured O
blood O
glucose O
level O

 O
before B-FRE
breakfast I-FRE
, I-FRE
lunch I-FRE
, I-FRE
dinner I-FRE
, I-FRE
and I-FRE
at I-FRE
bedtime I-FRE
. I-FRE

 O
Disp:*2 O
Pens O
* O
Refills:*5 O
* O

 O
3 O
. O
Insulin B-DRUG
Glargine I-DRUG
300 B-STR
unit/3 I-STR
mL I-STR
Insulin B-FOR
Pen I-FOR
Sig O
: O
Forty B-DOS
( I-DOS
40 I-DOS
) I-DOS

 I-DOS
Units I-DOS
Subcutaneous B-ROU
at B-FRE
bedtime I-FRE
. I-FRE

 O
Disp:*2 O
Pens O
* O
Refills:*2 O
* O

 O
4 O
. O
Lancets B-DRUG
     O
Misc O
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
lancet B-FOR
Miscellaneous O
qachs B-FRE
. I-FRE

 O
Disp:*120 O
lancets O
* O
Refills:*2 O
* O

 O
5 O
. O
Test O
strips O

 O
One O
test O
strip O

 O
qachs O

 O
dispense O
120 O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O
Diabetic O
ketoacidosis O
, O
IDDM O
with O
features O
of O
insulin B-DRUG

 I-DRUG
resistance O
. O



 O
Discharge O
Condition O
: O

 O
Good O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
hospital O
for O
diabetic O
keto-acidosis O
. O

 O
Diabetic O
ketoacidosis O
( O
DKA O
) O
is O
a O
severe O
and O
life O
threatening O

 O
condition O
that O
results O
from O
uncontrolled O
blood O
sugar O
. O
This O

 O
episode O
of O
DKA O
happened O
becuase O
you O
were O
not O
regularly O
taking O

 O
insulin B-DRUG
and O
becuase O
your O
blood O
sugar O
was O
very O
high O
. O
Your O
recent O

 O
sinus O
infection O
could O
have O
also O
worsened O
your O
condition O
. O
As O
a O

 O
result O
of O
this O
condition O
, O
you O
required O
admission O
to O
the O

 O
intensive O
care O
unit O
. O
During O
your O
hospitalization O
, O
your O
blood O

 O
sugar O
, O
electrolytes O
, O
and O
metabolism O
, O
in O
general O
, O
were O
restored O

 O
to O
a O
more O
normal O
condition O
. O


 O
It O
is O
extremely O
important O
that O
you O
keep O
your O
blood O
sugars O
at O

 O
more O
normal O
levels O
or O
this O
life-threatening O
condition O
will O

 O
happen O
again O
. O
Also O
, O
you O
will O
develop O
eye O
problems O
, O
kidney O

 O
disease O
, O
worse O
leg O
numbness O
, O
and O
heart O
disease O
if O
your O
sugars O

 O
are O
not O
controlled O
better O
. O


 O
In O
order O
to B-REA
control I-REA
your I-REA
sugars I-REA
, I-REA
you O
need O
to O
follow O
the O
Insulin B-DRUG

 I-DRUG
regimen O
that O
was O
prescribed O
by O
the O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
center O
. O
You O
will O
have O

 O
to O
take O
2 O
types O
of O
insulin B-DRUG
. I-DRUG
You O
will O
take O
a O
dose O
of O
long O
acting O

 O
insulin B-DRUG
( I-DRUG
Lantus I-DRUG
) I-DRUG
every B-FRE
night I-FRE
and O
this O
dose O
will O
be O
constant O
. O
You O

 O
will O
take O
a O
dose O
of O
Humalog B-DRUG
insulin I-DRUG
before B-FRE
every I-FRE
meal I-FRE
based O
on O

 O
the O
sliding B-DOS
scale I-DOS
chart O
- O
thus O
you O
have O
to O
check O
your O
sugar O
at O

 O
this O
time O
. O


 O
If O
you O
find O
that O
you O
are O
unable O
to O
follow O
the O
above O
insulin B-DRUG

 I-DRUG
plan O
, O
you O
have O
to O
call O
your O
doctor O
at O
the O
[ O
* O
* O
Hospital O
* O
* O
] O
clinic O
. O



 O
Due O
to O
your O
high O
use O
of O
Motrin B-DRUG
before O
admission O
, O
you O
irritated B-ADE

 I-ADE
the I-ADE
lining I-ADE
of I-ADE
your I-ADE
stomach I-ADE
. I-ADE
Thus O
, O
we O
treated O
this O
problem O
with O
a O

 O
medicine O
to O
decrease B-REA
the I-REA
acid I-REA
in I-REA
your I-REA
stomach I-REA
called O

 O
pantoprazole B-DRUG
. I-DRUG
You O
should O
continue O
taking O
this O
medicine O
until O
you O

 O
see O
your O
PCP O
and O
[ O
* O
* O
Name9 O
( O
PRE O
) O
10748 O
* O
* O
] O
your O
stomach O
problem O
. O


 O
If O
you O
begin O
to O
again O
experience O
increasing O
nausea O
, O
vomitting O
, O

 O
abdominal O
pain O
, O
or O
any O
other O
concerning O
symptom O
, O
you O
should O

 O
contact O
your O
PCP O
or O
go O
to O
the O
ER O
. O


 O
Followup O
Instructions O
: O

 O
You O
need O
to O
follow O
up O
with O
Dr. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
3636 O
* O
* O
] O
for O
diabetes O
care O
. O

 O
Your O
first O
appointment O
is O
[ O
* O
* O
4 O
- O
29 O
* O
* O
] O
at O
4PM O
. O
This O
appointment O
is O

 O
very O
important O
! O
! O
! O


 O
You O
can O
call O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
17484 O
* O
* O
] O
and O
ask O
for O
Dr.[**Name O
( O
NI O
) O
64238 O
* O
* O
] O
office O
if O
this O

 O
time O
does O
not O
work O
. O


 O
You O
need O
to O
schedule O
an O
appointment O
with O
you O
primary O
care O
doctor O

 O
within O
the O
next O
few O
weeks O
to O
followup O
your O
stomach O
pain O
after O

 O
taking O
Motrin B-DRUG
. I-DRUG




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2158 O
- O
11 O
- O
20 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2158 O
- O
12 O
- O
20 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2108 O
- O
8 O
- O
19 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Percocet B-DRUG
/ O
Sulfonamides B-DRUG
/ O
Iodine B-DRUG
; I-DRUG
Iodine B-DRUG
Containing O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
4748 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
RLE O
pain O
and O
swelling O



 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Right O
lower O
extremity O
open O
venous O
thrombectomy O
, O
fasciotomy O

 O
Right O
lower O
extremity O
lateral O
and O
medial O
debridement O
w/ O
medial O

 O
VAC O
closure O

 O
Right O
lower O
extremity O
lateral O
debridement O
at O
bedside O



 O
History O
of O
Present O
Illness O
: O

 O
50 O
year O
old O
female O
presents O
to O
the O
ED O
with O
severe O
RLE O
and O
R. O

 O
back O
pain O
. O
She O
was O
in O
her O
usual O
state O
of O
health O
until O
about O
2 O
- O
3 O

 O
weeks O
ago O
when O
she O
was O
admitted O
to O
[ O
* O
* O
Hospital O
* O
* O
] O
Hospital O
with O

 O
shortness O
of O
breath O
and O
diagnosed O
with O
a O
RLE O
DVT O
and O
PE O
. O
She O
was O

 O
started O
on O
heparin B-DRUG
ggt B-ROU
, I-ROU
however O
she O
developed O
a O
rectus O
sheath O

 O
hematoma O
, O
so O
this O
was O
stopped O
and O
an O
IVC O
filter O
was O
placed O
. O
She O

 O
was O
discharged O
home O
around O
[ O
* O
* O
11 O
- O
7 O
* O
* O
] O
and O
had O
been O
well O
until O

 O
3 O
days O
ago O
when O
she O
developed O
acute O
onset O
of O
R. O
lower O
back O
pain O

 O
and O
right O
groin O
pain O
. O
This O
progressed O
over O
the O
past O
3 O
days O
until O

 O
she O
came O
to O
the O
ED O
. O



 O
Past O
Medical O
History O
: O

 O
- O
HTN O

 O
- O
hyperlipidemia O

 O
- O
asthma O

 O
- O
L. O
back O
melanoma O

 O
PSH O
: O
IVC O
filter O
around O
[ O
* O
* O
2158 O
- O
11 O
- O
7 O
* O
* O
] O
, O
L. O
back O
melanoma O
excision O
with O

 O
axillary O
lymph O
node O
dissection O
, O
laparotomy O
x O
2 O
for O
ovarian O
cysts O

 O
as O
a O
teenager O
, O
C-section O
, O
appendectomy O
, O
lap O
cholecystectomy O



 O
Social O
History O
: O

 O
Lives O
with O
husband O
and O
kids O


 O
Family O
History O
: O

 O
N/C O


 O
Physical O
Exam O
: O

 O
VS O
: O
TM O
100.3 O
TL97.1 O
80 O
137/72 O
16 O
96 O
% O
RA O

 O
Gen O
; O
AAOx3 O
, O
NAD O

 O
HENT O
: O
supple O
no O
bruits O

 O
card O
: O
RRR O
, O
nl O
S1S2 O

 O
Lungs O
: O
CTA O
b/l O
, O
no O
distress O

 O
Abd O
: O
obese O
, O
NT O
, O
ND O

 O
Extremities O
: O
both O
well O
perfused O
and O
warm O
. O

 O
Right O
: O
has O
bilateral O
faciotomies O
( O
lateral O
and O
medial O
) O
, O
the O

 O
medial O
is O
beefy O
and O
granulating O
, O
the O
lateral O
s/p O
debridement O
at O

 O
the O
bedside O
[ O
* O
* O
12 O
- O
20 O
* O
* O
] O
, O
is O
mildly O
cellulitic O
around O
, O
no O
exudate O
, O

 O
medial O
thigh O
staples O
are O
intact O
, O
incision O
is O
healed O
and O
well O

 O
anastomosed O
. O
The O
right O
groin O
has O
an O
area O
of O
wound O
dehescense O

 O
with O
clean O
and O
beefy O
base O
. O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2158 O
- O
12 O
- O
20 O
* O
* O
] O
06:02AM O
BLOOD O
WBC-7.1 O
RBC-3.33 O
* O
Hgb-9.8 O
* O
Hct-29.4 O
* O

 O
MCV-88 O
MCH-29.4 O
MCHC-33.3 O
RDW-17.8 O
* O
Plt O
Ct-341 O

 O
[ O
* O
* O
2158 O
- O
12 O
- O
19 O
* O
* O
] O
05:27AM O
BLOOD O
WBC-6.9 O
RBC-3.38 O
* O
Hgb-10.0 O
* O
Hct-29.9 O
* O

 O
MCV-88 O
MCH-29.6 O
MCHC-33.5 O
RDW-17.7 O
* O
Plt O
Ct-351 O

 O
[ O
* O
* O
2158 O
- O
12 O
- O
20 O
* O
* O
] O
06:02AM O
BLOOD O
PT-16.0 O
* O
INR(PT)-1.4 O
* O

 O
[ O
* O
* O
2158 O
- O
12 O
- O
19 O
* O
* O
] O
05:27AM O
BLOOD O
PT-16.5 O
* O
INR(PT)-1.5 O
* O

 O
[ O
* O
* O
2158 O
- O
12 O
- O
20 O
* O
* O
] O
06:02AM O
BLOOD O
Glucose-109 O
* O
UreaN-14 O
Creat-0.7 O
Na-141 O

 O
K-4.0 O
Cl-102 O
HCO3 O
- O
29 O
AnGap-14 O

 O
[ O
* O
* O
2158 O
- O
12 O
- O
15 O
* O
* O
] O
05:48AM O
BLOOD O
Glucose-98 O
UreaN-17 O
Creat-0.6 O
Na-138 O

 O
K-4.2 O
Cl-101 O
HCO3 O
- O
29 O
AnGap-12 O


 O
Cardiology O
reports O
: O

 O
ECG O
Study O
Date O
of O
[ O
* O
* O
2158 O
- O
11 O
- O
20 O
* O
* O
] O
  O
2:10:10 O
PM O

 O
Sinus O
rhythm O
. O
Low O
precordial O
lead O
QRS O
voltage O
is O
non-specific O

 O
and O
tracing O
is O
probably O
within O
normal O
limits O
. O
No O
previous O

 O
tracing O
available O
for O
comparison O
. O


 O
ECG O
Study O
Date O
of O
[ O
* O
* O
2158 O
- O
11 O
- O
22 O
* O
* O
] O
  O
2:21:10 O
AM O

 O
Sinus O
rhythm O
with O
borderline O
sinus O
tachycardia O
. O
QRS O

 O
configuration O
in O

 O
leads O
III O
and O
aVF O
raises O
the O
consideration O
of O
prior O
inferior O

 O
myocardial O

 O
infarction O
although O
is O
non-diagnostic O
. O
Otherwise O
, O
tracing O
may O
be O

 O
within O
normal O
limits O
but O
unstable O
baseline O
and O
baseline O

 O
artifacts O
in O
lead O
V3 O
makes O
assessment O
difficult O
. O
Clinical O

 O
correlation O
is O
suggested O
. O
Since O
the O
previous O
tracing O
of O
[ O
* O
* O
2158 O
- O
11 O
- O
20 O
* O
* O
] O

 O
axis O
is O
more O
leftward O
with O
a O
change O
in O
QRS O
configuration O
in O
lead O

 O
aVF O
and O
late O
precordial O
QRS O
transition O
is O
present O
. O
Otherwise O
, O

 O
there O
may O
be O
no O
significant O
change O
. O


 O
Portable O
TTE O
( O
Complete O
) O
Done O
[ O
* O
* O
2158 O
- O
11 O
- O
22 O
* O
* O
] O
at O
9:31:26 O
AM O

 O
FINAL O
: O
The O
left O
atrium O
is O
dilated O
. O
Left O
ventricular O
wall O

 O
thicknesses O
are O
normal O
. O
The O
left O
ventricular O
cavity O
size O
is O

 O
normal O
. O
Overall O
left O
ventricular O
systolic O
function O
is O
normal O

 O
( O
LVEF>55 O
% O
) O
. O
Tissue O
Doppler O
imaging O
suggests O
a O
normal O
left O

 O
ventricular O
filling O
pressure O
( O
PCWP<12mmHg O
) O
. O
There O
is O
a O
mild O

 O
resting O
left O
ventricular O
outflow O
tract O
obstruction O
. O
Right O

 O
ventricular O
chamber O
size O
and O
free O
wall O
motion O
are O
normal O
. O
The O

 O
aortic O
valve O
leaflets O
( O
3 O
) O
are O
mildly O
thickened O
. O
There O
is O
no O

 O
aortic O
valve O
stenosis O
( O
velocities O
increased O
due O
to O
mild O
left O

 O
ventricular O
outflow O
gradient O
) O
. O
No O
aortic O
regurgitation O
is O
seen O
. O

 O
The O
mitral O
valve O
leaflets O
are O
mildly O
thickened O
. O
There O
is O

 O
moderate O
pulmonary O
artery O
systolic O
hypertension O
. O
There O
is O
an O

 O
anterior O
space O
which O
most O
likely O
represents O
a O
fat O
pad O
. O



 O
ECG O
Study O
Date O
of O
[ O
* O
* O
2158 O
- O
12 O
- O
11 O
* O
* O
] O
  O
3:01:38 O
PM O

 O
Sinus O
tachycardia O
. O
Consider O
left O
atrial O
abnormality O
. O
Consider O

 O
prior O
inferior O
myocardial O
infarction O
, O
although O
it O
is O

 O
non-diagnostic O
. O
Delayed O
R O
wave O
progression O
with O
late O
precordial O

 O
QRS O
transition O
. O
Findings O
are O
non-specific O
. O
Since O
the O
previous O

 O
tracing O
of O
[ O
* O
* O
2158 O
- O
11 O
- O
22 O
* O
* O
] O
no O
significant O
change O
. O


 O
Radiology O
reports O
: O

 O
[ O
* O
* O
2158 O
- O
11 O
- O
20 O
* O
* O
] O
2:23 O
PM O

 O
CHEST O
( O
PORTABLE O
AP O
) O
IMPRESSION O
: O
Left O
basilar O
atelectasis O
, O

 O
otherwise O
normal O
. O
Limited O
study O
. O


 O
[ O
* O
* O
2158 O
- O
11 O
- O
20 O
* O
* O
] O
2:36 O
PM O

 O
CT O
ABDOMEN O
W/O O
CONTRAST O
; O
CT O
PELVIS O
W/O O
CONTRAST O
; O
CT O
CHEST O
W/O O

 O
CONTRAST O

 O
IMPRESSION O
: O

 O
1 O
. O
Right O
rectus O
abdominus O
muscle O
hematoma O
. O

 O
2 O
. O
No O
retroperitoneal O
hematoma O
. O

 O
3 O
. O
18 O
x O
23 O
mm O
hyperdense O
retroperitoneal O
lesion O
within O
the O

 O
aortocaval O
region O
, O
likely O
a O
lymph O
node O
, O
new O
from O
prior O
. O
A O
pelvic O

 O
MR O
can O
be O
obtained O
for O
further O
characterization O
. O


 O
[ O
* O
* O
2158 O
- O
11 O
- O
20 O
* O
* O
] O
7:48 O
PM O
BILAT O
LOWER O
EXT O
VEINS O

 O
IMPRESSION O
: O
Extensive O
venous O
thrombosis O
extending O
through O
all O

 O
the O
deep O
veins O
of O
the O
right O
lower O
extremity O
and O
no O
evidence O
of O

 O
left O
lower O
extremity O
deep O
venous O
thrombosis O
. O


 O
[ O
* O
* O
2158 O
- O
11 O
- O
20 O
* O
* O
] O
7:49 O
PM O
RENAL O
U.S. O

 O
IMPRESSION O
: O
Normal O
study O


 O
[ O
* O
* O
2158 O
- O
11 O
- O
21 O
* O
* O
] O
11:14 O
AM O
CT O
PELVIS O
W/O O
CONTRAST O

 O
IMPRESSION O
: O

 O
1 O
. O
Ovoid O
area O
of O
high O
density O
within O
the O
aortocaval O
space O
at O
the O

 O
level O
of O
the O
IVC O
filter O
with O
adjacent O
fatty O
stranding O
which O
is O

 O
unchanged O
in O
size O
compared O
to O
the O
prior O
study O
. O
This O
finding O
is O

 O
concerning O
for O
a O
small O
, O
atable O
appearing O
retroperitoneal O

 O
hematoma O
. O

 O
2 O
. O
Stable O
right O
rectus O
abdominis O
muscle O
hematoma O
. O


 O
[ O
* O
* O
2158 O
- O
11 O
- O
23 O
* O
* O
] O
7:42 O
AM O

 O
BILAT O
LOWER O
EXT O
VEINS O
PORT O

 O
IMPRESSION O
: O
Limited O
exam O
, O
however O
a O
small O
amount O
of O
flow O
is O
now O

 O
visualized O
in O
the O
right O
common O
and O
superficial O
femoral O
veins O
, O

 O
which O
remain O
partially O

 O
occluded O
. O
Reconstituted O
flow O
within O
the O
right O
popliteal O
vein O
is O

 O
observed O
. O


 O
[ O
* O
* O
2158 O
- O
11 O
- O
27 O
* O
* O
] O
8:26 O
AM O
PORTABLE O
ABDOMEN O

 O
IMPRESSION O
: O
Small O
bowel O
dilatation O
most O
consistent O
with O
ileus O
. O


 O
[ O
* O
* O
2158 O
- O
11 O
- O
29 O
* O
* O
] O
3:06 O
PM O
LIVER O
OR O
GALLBLADDER O
US O
( O
SINGLE O
ORGAN O
) O

 O
IMPRESSION O
: O
Normal-appearing O
liver O
without O
focal O
lesion O
or O

 O
biliary O
ductal O

 O
dilatation O
. O



 O
[ O
* O
* O
2158 O
- O
12 O
- O
10 O
* O
* O
] O
7:10 O
PM O
UNILAT O
LOWER O
EXT O
VEINS O
LEFT O

 O
IMPRESSION O
: O
Limited O
exam O
; O
however O
, O
no O
evidence O
of O
DVT O
. O
Calf O

 O
veins O
could O
not O
be O
visualized O
. O


 O
[ O
* O
* O
2158 O
- O
12 O
- O
11 O
* O
* O
] O
9:46 O
AM O
CT O
ABDOMEN O
W/O O
CONTRAST O
; O
CT O
PELVIS O
W/O O
CONTRAST O

 O
IMPRESSION O
: O

 O
1 O
. O
Minimal O
contraction O
in O
the O
right O
rectus O
sheath O
hematoma O
. O

 O
2 O
. O
New O
asymmetric O
expansion O
of O
the O
left O
iliopsoas O
muscles O
, O
with O

 O
adjacent O
left O
retroperitoneal O
stranding O
and O
small O
focal O
fluid O

 O
collection O
posterior O
to O
the O
inferior O
pole O
of O
the O
left O
kidney O
. O

 O
Findings O
are O
compatible O
with O
new O
left O
retroperitoneal O
hematoma O
. O

 O
3 O
. O
Post-surgical O
changes O
in O
the O
right O
groin O
, O
without O
associated O

 O
right O
groin O
or O
thigh O
hematoma O
. O
Inflammatory O
stranding O
is O
noted O

 O
throughout O
the O
soft O
tissues O
of O
the O
right O
thigh O
. O

 O
4 O
. O
Aortocaval O
density O
is O
again O
demonstrated O
. O
As O
previously O

 O
described O
, O
it O
is O
decreased O
in O
size O
and O
attenuation O
, O
most O
likely O

 O
representing O
a O
small O
resolving O
hematoma O
. O


 O
Study O
Date O
of O
[ O
* O
* O
2158 O
- O
12 O
- O
13 O
* O
* O
] O
11:22 O
AM O

 O
CT O
ABDOMEN O
W/O O
CONTRAST O
; O
CT O
PELVIS O
W/O O
CONTRAST O

 O
IMPRESSION O
: O

 O
1 O
. O
Interval O
enlargement O
of O
left O
retroperitoneal O
hematoma O
, O
as O

 O
described O
above O
. O

 O
2 O
. O
New O
small O
left O
pleural O
effusion O
with O
associated O
atelectasis O
. O

 O
Otherwise O
unchanged O
CT O
examination O
of O
the O
abdomen O
and O
pelvis O

 O
compared O
to O

 O
[ O
* O
* O
2158 O
- O
12 O
- O
11 O
* O
* O
] O
. O



 O
Brief O
Hospital O
Course O
: O

 O
[ O
* O
* O
2158 O
- O
11 O
- O
20 O
* O
* O
] O
Patient O
admitted O
via O
ED O
for O
increasing O
right O
lower O

 O
extremity O
pain O
and O
swelling O
. O
S/p O
IVC O
filter O
placement O
from O
an O

 O
OSH O
complicated O
by O
right O
rectus O
muscle O
hematoma O
, O
s/p O
several O

 O
units O
blood O
transfusion O
. O
In O
ED O
found O
to O
have O
creatinine O
in O
8.4 O
, O

 O
hydrated O
overnight O
, O
creatinine O
came O
down O
to O
6.8 O
. O
Renal O
consulted O

 O
and O
following O
. O
RLE O
US O
showed O
clot O
in O
deep O
veins O
of O
RLE O
from O
calf O

 O
to O
common O
femoral O
, O
can O
not O
visualize O
iliacs O
. O
CT O
of O
pelvis O
and O

 O
abd O
. O
was O
done-Right O
rectus O
abdominus O
muscle O
hematoma O
. O
Renal O

 O
US-showed O
Both O
kidneys O
show O
patent O
main O
renal O
arteries O
and O
veins O

 O
with O
appropriate O
arterial O
and O
venous O
waveforms O
. O
RLE O
was O
ace O

 O
wrapped O
and O
elevated O
. O
Started O
heparin B-DRUG
drip B-ROU
conservatively O
. O
Kept O

 O
NPO O
. O
RLE O
noted O
to O
have O
significantly O
diminished O
sensation O
from O

 O
toes O
-knee O
with O
no O
foot O
motor O
fucntion O
and O
drop O
foot O
. O



 O
[ O
* O
* O
2158 O
- O
11 O
- O
21 O
* O
* O
] O
Patient O
was O
scheduled O
for O
angiojet O
thrombectomy O
. O
Kept O

 O
NPO O
, O
pre-oped O
and O
consented O
. O
Patient O
had O
abd/pelvic O
CT-that O

 O
showed O
stable O
rectus O
muscle O
hematoma O
. O
Became O
unstable O
, O
BP O
down O

 O
to O
the O
70 O
's O
, O
given O
fluid B-DRUG
, I-DRUG
blood B-DRUG
products I-DRUG
, I-DRUG
transferred O
to O
the O

 O
CVICU O
. O
Arterial O
line O
and O
central O
access O
lines O
were O
placed O
for O

 O
blood O
pressure O
monitoring O
. O
Continued O
to O
be O
oliguric O
, O
and O

 O
creatinine O
remain O
elevated O
. O
CPKs O
were O
sent O
that O
came O
back O

 O
elevated O
. O
Reanl O
consult O
placed O
, O
recommended O
Bicarb B-DRUG
infusion B-FOR

 I-FOR
which O
was O
started O
. O
In O
the O
CVICU O
patient O
recieved O
more O
blood B-DRUG

 I-DRUG
tranfusions B-FOR
, I-FOR
started O
on O
Neo B-DRUG
drip B-ROU
for O
BP B-REA
support I-REA
. I-REA
Angio O

 O
thrombectomy O
cancelled O
. O
Renal O
service O
following O
. O
Heparin B-DRUG
drip B-ROU

 I-ROU
continued O
. O
Patient O
had O
problems O
w/ O
hyperkalemia-treated B-REA
w/ O

 O
Insulin/Bicarb/D50/CaGluconate B-DRUG
IV B-ROU
. I-ROU


 O
[ O
* O
* O
2158 O
- O
11 O
- O
22 O
* O
* O
] O
Remained O
in O
CVICU O
, O
continued O
to O
require O
fluid O

 O
resucitation O
w/ O
Bicard B-DRUG
drip B-ROU
and O
Neo B-DRUG
drip B-ROU
to O
maintain B-REA
BP I-REA
. I-REA

 O
Compartment O
pressures O
were O
done O
by O
ortho O
service-found O
to O
be O

 O
elevated O
, O
w/ O
CPK O
elevated O
as O
well O
. O
Pre-oped O
and O
consented O
for O

 O
open O
venous O
thrombectomy O
and O
faciotomy O
. O
Taken O
to O
OR O
and O

 O
underwent O
RLE O
open O
venous O
thrombectomy O
and O
fasciotomy O
. O
Patient O

 O
tolerated O
procedure O
, O
was O
transferred O
back O
to O
the O
CVICU O
for O

 O
recovery O
. O
Portable O
TTE O
was O
done-w/ O
LVEF O
> O
55 O
% O
. O


 O
[ O
* O
* O
2158 O
- O
11 O
- O
23 O
* O
* O
] O
ICUD2/POD1 O
: O
Remained O
Oliguric B-REA
, I-REA
BP B-REA
remain I-REA
labile I-REA

 I-REA
requiring O
pressors B-DRUG
and O
fluid B-DRUG
boluses B-FOR
. I-FOR
Continued O
to O
require O
blood B-DRUG

 I-DRUG
transfusions B-FOR
for O
low B-REA
HCT I-REA
. I-REA
Remained O
intubated O
and O
sedated O
. O
Renal O

 O
following O
, O
started O
on O
Lasix B-DRUG
drip B-ROU
. I-ROU
Started O
on O
heparin B-DRUG
drip B-ROU
. I-ROU

 O
Patient O
had O
copious O
liquid O
stools-rectal O
tube O
was O
placed O
, O
stools O

 O
came O
back O
negative O
for O
c-diff O
. O
Noted O
to O
have O
increased O
swelling O

 O
of O
LE O
's O
bilateral O
US O
were O
done-ruled O
out O
for O
DVT O
. O


 O
12/11 O
- O
13/09 O
ICU3 O
- O
5 O
POD2 O
- O
4 O
: O
remained O
in O
the O
ICU O
, O
intubated O
and O

 O
sedatedsedated O
. O
On O
Lasix B-DRUG
drip B-ROU
to O
keep O
UOP B-REA
> I-REA
100cc/h I-REA
, I-REA
heparin B-DRUG
and O

 O
Bicarb B-DRUG
drips B-ROU
. I-ROU
R O
lateral O
faciotomy O
w/ O
muscle O
noted O
to O
be O
necrotic O

 O
at O
superficial O
level O
. O
Creatinine O
continued O
to O
rise O
and O
started O

 O
to O
improve O
[ O
* O
* O
11 O
- O
26 O
* O
* O
] O
. O
Renal O
following O
. O
Failed O
extubation O
[ O
* O
* O
11 O
- O
25 O
* O
* O
] O
. O

 O
Started O
on O
Cefazolin B-DRUG
[ O
* O
* O
11 O
- O
24 O
* O
* O
] O
, O
added O
Cipro B-DRUG
[ O
* O
* O
11 O
- O
25 O
* O
* O
] O
. O
Transfused O
PRBCs B-DRUG

 I-DRUG
for O
low B-REA
HCT I-REA
. I-REA



 O
[ O
* O
* O
11 O
- O
27 O
* O
* O
] O
ICU6/POD5 O
: O
Remained O
in O
ICU O
. O
On O
lasix B-DRUG
drip B-ROU
and O
Diamox B-DRUG
. I-DRUG

 O
Started O
tube O
feeds O
. O
Remained O
intubated O
on O
CPAP/PS O
ventillation O
. O

 O
Remains O
lightly O
sedated B-REA
on O
Fentanyl B-DRUG
and O
Versed B-DRUG
drips B-ROU
, I-ROU
and O

 O
continued O
on O
Heparin B-DRUG
drip B-ROU
. I-ROU
Continued O
antibiotics B-DRUG
. I-DRUG
Renal O

 O
continued O
to O
follow O
. O
CK O
's O
and O
creatinine O
improving O
. O
Bicarb B-DRUG
drip B-ROU

 I-ROU
discontinued O
. O
Patient O
's O
abdomen O
became O
distended O
and O
w/ O

 O
vomiting O
, O
abd O
. O
x-ray O
showed O
ileus-tube O
feeds O
stopped O
. O


 O
[ O
* O
* O
2158 O
- O
11 O
- O
28 O
* O
* O
] O
ICU7/POD6 O
: O
Patient O
remained O
in O
ICU O
, O
now O
weaned O
and O

 O
extubated O
. O
ARF/Rhabdo B-REA
improving O
with O
hydration O
. O
Lasix B-DRUG
drip B-ROU
off O
. O

 O
Renal O
signed O
off O
. O
PCA O
fentany O
for O
pain O
, O
tolerated O
well O
. O
Patient O

 O
found O
to O
be O
confused O
but O
not O
agitated O
. O


 O
[ O
* O
* O
2158 O
- O
11 O
- O
29 O
* O
* O
] O
ICU8/POD7 O
: O
Remained O
in O
ICU O
. O
Maintained O
off O
ventillator O
. O

 O
Continued O
Heparin B-DRUG
drip B-ROU
, I-ROU
started O
Coumadin B-DRUG
. I-DRUG
Now O
auto O
diuresing O
. O

 O
CK O
's O
and O
creatine O
continued O
to O
trend O
down O
. O
Physical O
therapy O

 O
consulted O
, O
patient O
taken O
out O
of O
bed O
to O
chair O
w/ O
a O
lift O
, O

 O
tolerated O
. O
Continue O
to O
have O
diarrhea O
w/ O
rectal O
tube O
. O
patient O

 O
reamied O
confused O
. O
Started O
PO O
liquids O
. O
Abdomen O
remain O
distended- O

 O
Gallbladder O
US-showed O
normal O
biliary O
ductal O
dilatation O
. O


 O
[ O
* O
* O
2158 O
- O
11 O
- O
30 O
* O
* O
] O
ICU9/POD8 O
: O
Continued O
heparin B-DRUG
drip B-ROU
, I-ROU
dosed O
with O
Coumadin B-DRUG
. I-DRUG

 O
Transferred O
to O
VICU O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
5 O
. O
Continued O
to O
be O
confused O
. O
Continued O

 O
to O
have O
diarrhea O
, O
priorly O
negative O
for O
C-diff O
. O
Tolerating O
PO O
's O

 O
but O
w/ O
poor O
intake O
. O


 O
[ O
* O
* O
2075 O
- O
11 O
- O
30 O
* O
* O
] O
POD9 O
- O
16 O
: O
Remained O
in O
VICU O
, O
continued O
to O
be O
dosed O
w/ O

 O
Coumadin B-DRUG
, I-DRUG
Heparin B-DRUG
drip B-ROU
came O
off O
, O
INR O
came O
up O
to O
5.9 O
Coumadin B-DRUG

 I-DRUG
held O
for O
a O
couple O
days O
. O
Patient O
now O
AAOx3 O
. O
Wound O
vac O
taken O
down O

 O
and O
replaced O
every O
third O
day O
. O
The O
R O
lateral O
wound O
was O
debrided O

 O
and O
w/ O
wet-dry O
dressing O
. O
Thigh O
incision O
dehised O
, O
dressing O
w/ O

 O
DSD O
. O
Pain B-REA
management O
changed O
to O
PO B-ROU
Dilaudid B-DRUG
. I-DRUG
Physical O
therapy O

 O
working O
w/ O
patient O
to O
get O
OOB O
. O
Creatinine O
normalized O
, O
CKs O
down O

 O
to O
the O
4k O
, O
stopped O
cycling O
. O
HCt O
had O
been O
stable O
in O
the O
high O
20 O
's O

 O
all O
week O
. O



 O
[ O
* O
* O
Date O
range O
( O
1 O
) O
105490**]/10 O
POD17 O
- O
24 O
: O
Remained O
in O
the O
VICU O
. O
Left O
LLE O
noted O
to O

 O
be O
more O
swollen O
, O
unilateral O
US O
done O
negative O
for O
DVT O
. O
This O
week O

 O
patient O
's O
HCT O
went O
down O
to O
22 O
from O
27 O
. O
Abd./pelcis O
CT O
showed O

 O
-stable O
R O
rectus O
sheath O
hematoma O
and O
w/ O
Minimal O
contraction O
in O

 O
the O
right O
rectus O
sheath O
hematoma O
. O
New O
asymmetric O
expansion O
of O

 O
the O
left O
iliopsoas O
muscles O
, O
with O
adjacent O
left O
retroperitoneal O

 O
stranding O
and O
small O
focal O
fluid O
collection O
posterior O
to O
the O

 O
inferior O
pole O
of O
the O
left O
kidney O
. O
Findings O
are O
compatible O
with O

 O
new O
left O
retroperitoneal O
hematoma O
. O
Patient O
recived O
numerous O

 O
blood O
transfusions O
. O
Heme O
oncology O
consulted-recommended O
to O
d/c O

 O
Aspirin B-DRUG
and O
lower O
INR O
goal O
to O
1.5 O
- O
2.2 O
. O
Aspirin B-DRUG
was O
d/c'd O
. O

 O
Coumadin B-DRUG
was O
held O
and O
res-started O
to O
target O
goal O
INR O
per O
Heme O

 O
recommendations O
. O
Kept O
on O
bedrest O
. O


 O
[ O
* O
* O
Date O
range O
( O
1 O
) O
105491 O
* O
* O
] O
POD O
25 O
- O
27 O
: O
Remained O
in O
the O
VICU O
. O
HCT O
had O
been O
stable O

 O
at O
29 O
- O
30 O
, O
transfused O
another O
unit O
of O
blood O
to O
keep O
HCT O
above O
29 O
. O

 O
Patient O
is O
stable O
hymodynamically O
. O
Re-started O
out O
of O
bed O

 O
activity O
. O
Wound O
vac O
therpay O
continued O
on O
R O
medial O
wound O
and O
R O

 O
groin O
wound O
. O
The O
R O
lateral O
wound O
was O
again O
debrided O
at O
the O

 O
bedside O
w/ O
routine O
wet-dry O
dressing O
found O
to O
be O
cellulitic B-REA
all O

 O
around O
started O
Nafcillin B-DRUG
IV B-ROU
. I-ROU
Physical O
therapy O
recommended O
rehab O
. O

 O
Rehab O
screening O
initiated O
. O


 O
[ O
* O
* O
2158 O
- O
12 O
- O
20 O
* O
* O
] O
POD28 O
: O
Patient O
's O
HCT O
had O
been O
stable O
for O
almost O
1 O
week O

 O
now O
, O
w/ O
almost O
stable O
Coumadin B-DRUG
dose O
between O
5 O
- O
7.5 O
daily O
, O
keeping O

 O
an O
INR O
between O
1.5 O
- O
2.2 O
. O
Patient O
was O
discharged O
to O
Rehab O
in O

 O
stable O
condition O
. O
The O
right O
LE O
remain O
to O
have O
no O
motor O
function O
, O

 O
sensation O
is O
almost O
normal O
w/ O
new O
cellulitis B-REA
around O
the O
lateral O

 O
faciotomy O
, O
now O
being O
treated O
w/antibiotics B-DRUG
. I-DRUG
Patient O
's O
PO O
intake O

 O
remain O
poor O
but O
improving O
. O
Her O
creatinine O
is O
now O
normal O
. O
Patient O

 O
will O
FU O
w/ O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
1391 O
* O
* O
] O
in O
2 O
weeks O
to O
re-evaluate O
wounds O
and O

 O
assess O
for O
possible O
skin O
grafting O
. O
Instructions O
provided O
to O

 O
patient O
. O



 O
Medications O
on O
Admission O
: O

 O
Triamterene-HCTZ B-DRUG
37.5/25 B-STR
mg I-STR
qd B-FRE

 I-FRE
Lisinopril B-DRUG
20 B-STR
mg I-STR
qd B-FRE

 I-FRE
Spiriva B-DRUG
18 B-STR

 I-STR
Coreg B-DRUG
25 B-STR
mg I-STR
qd B-FRE

 I-FRE
Omeprazole B-DRUG
20 B-STR
mg I-STR
qd B-FRE

 I-FRE
Effexor B-DRUG
XL I-DRUG
150 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Carbamazepine B-DRUG
100 B-STR
mg I-STR
po B-ROU
BID B-FRE

 I-FRE
Neurontin B-DRUG
600 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Simvastatin B-DRUG
20 B-STR
mg I-STR
qd B-FRE

 I-FRE
Singulair B-DRUG
10 B-STR
mg I-STR
qd B-FRE

 I-FRE
ProAir B-DRUG
HFA I-DRUG
90 B-STR
mcg I-STR
inhaler B-FOR



 I-FOR
Discharge O
Medications O
: O

 O
1 O
. O
Dicloxacillin B-DRUG
500 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
four B-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
for B-DUR
2 I-DUR
weeks I-DUR
. I-DUR

 O
2 O
. O
Outpatient O
Lab O
Work O

 O
INR O
three O
times O
a O
week O
( O
goal O
INR O
1.5 O
- O
2.2 O
) O
patient O
has O
history O
of O

 O
bleeding O

 O
3 O
. O
Carbamazepine B-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Chewable I-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O
day O
) O
. O

 O
4 O
. O
Venlafaxine B-DRUG
75 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O

 O
a O
day O
) O
. O

 O
5 O
. O
Montelukast B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
6 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( O
0.083 O
% O
) O
Solution B-FOR
for I-FOR

 I-FOR
Nebulization I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Inhalation B-ROU
Q2H B-FRE
( I-FRE
every I-FRE
2 I-FRE
hours I-FRE
) I-FRE
as I-FRE

 I-FRE
needed I-FRE
for O
wheezing B-REA
. I-REA

 O
7 O
. O
Amlodipine B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O



 O
8 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( O
every O
24 O
hours O
) O
. O

 O
9 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
10 O
. O
Zolpidem B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( O
at O
bedtime O
) O

 O
as O
needed O
for O
insomnia B-REA
. I-REA

 O
11 O
. O
Acetaminophen B-DRUG
650 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
fever B-REA
or O
pain B-REA
. I-REA

 O
12 O
. O
Simethicone B-DRUG
80 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Chewable I-FOR
PO B-ROU
QID B-FRE
( O
4 O
times O
a O
day O
) O
as O
needed O
for O
gas B-REA
. I-REA

 O
13 O
. O
Oxycodone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE

 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
14 O
. O
Bisacodyl B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
as O
needed O
for O

 O
constipation B-REA
. I-REA

 O
15 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1.5 B-DOS
Tablets B-FOR
PO B-ROU
TID B-FRE
( O
3 O

 O
times O
a O
day O
) O
. O

 O
16 O
. O
Miconazole B-DRUG
Nitrate I-DRUG
2 O
% O
Powder B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
17 O
. O
Camphor-Menthol B-DRUG
0.5 B-STR
- I-STR
0.5 I-STR
% O
Lotion B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU

 I-ROU
QID B-FRE
( O
4 O
times O
a O
day O
) O
as O
needed O
for O
itching B-REA
. I-REA

 O
18 O
. O
Warfarin B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Once B-FRE
Daily I-FRE

 I-FRE
at I-FRE
4 I-FRE
PM I-FRE
: I-FRE
titrate O
to O
INR O
goal O
of O
1.5 O
- O
2.2 O
. O

 O
19 O
. O
Miconazole B-DRUG
Nitrate I-DRUG
2 O
% O
Cream B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Vaginal B-ROU
HS B-FRE

 I-FRE
( O
at O
bedtime O
) O
for O
5 B-FRE
days I-FRE
: I-FRE
d/c O
[ O
* O
* O
2158 O
- O
12 O
- O
25 O
* O
* O
] O
. O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
459 O
* O
* O
] O
for O
the O
Aged O
- O
MACU O



 O
Discharge O
Diagnosis O
: O

 O
- O
Right O
lower O
extremity O
venous O
thrombosis O
now O
s/p O
Common O
Iliac O

 O
thrombus O
s/p O
thrombecomy/embolectomy O

 O
- O
Rectus O
muscle O
hematoma O

 O
- O
Anemia-secondary O
to O
bleeding O

 O
- O
Acute B-REA
renal I-REA
failure- I-REA
on O
arrival O
creatinine O
peaked O
at O
8.9 O
, O

 O
recovered O
w/ O
fluid O
resusciation O
, O
alcalinization O
w/ O
Bicarb B-DRUG
drip B-ROU
, I-ROU

 O
creatinine O
now O
normal O

 O
Rhabdomyolysis- O
RLE O
ischemia O
2nd O
to O
compartment O
syndrome O
, O

 O
required O
faciotomy-now O
resolved O

 O
- O
R O
Foot O
drop- O
prior O
to O
hospitalization O
, O
persistent O
, O
will O
need O

 O
agressive O
physical O
therapy O
and O
splinting O

 O
History O
of O
: O

 O
HTN O

 O
hyperlipidemia O

 O
asthma O

 O
L O
back O
melanoma O

 O
PSH O
: O
IVC O
filter O
( O
[ O
* O
* O
10 O
- O
23 O
* O
* O
] O
) O
, O
L O
back O
melanoma O
excision O
with O
ax O
LN O

 O
dxn O
, O
laparotomy O
x O
2 O
for O
ovarian O
cysts O
, O
C-section O
, O
app O
, O
lap O
chole O




 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O

 O
Activity O
Status O
: O
Out O
of O
Bed O
with O
assistance O
to O
chair O
or O

 O
wheelchair O


 O
Labs O
: O
INR O
three O
times O
a O
week O
( O
if O
daily O
can O
not O
be O
done O
) O
INR O
upon O

 O
discharge O
is O
1.4 O
( O
goal O
INR O
is O
between O
1.5 O
- O
2.2 O
) O



 O
Discharge O
Instructions O
: O

 O
- O
You O
were O
admitted O
for O
right O
lower O
extremity O
pain O
, O
found O
to O

 O
have O

 O
right O
rectus O
sheath O
hematoma O
and O
venous O
thrombosis O
extending O

 O
through O
all O
the O
deep O
veins O
of O
the O
right O
lower O
extremity O
, O


 O
-You O
became O
critically O
ill O
from O
the O
released O
chemicals O
from O
your O

 O
right O
lower O
extremity O
muscles O
, O
you O
required O
ICU O
care O
before O
and O

 O
after O
your O
surgery O
, O


 O
-You O
had O
to O
be O
taken O
to O
the O
OR O
for O
removal O
of O
thrombus O
and O

 O
faciotomy O
to O
relieve O
pressure O
in O
your O
right O
calf O
, O


 O
-As O
part O
of O
your O
therapy O
we O
started O
you O
on O
Coumadin B-DRUG
that O
you O

 O
will O
need O
to O
be O
on O
for O
an O
extended O
period O
of O
time O
. O
You O
will O
need O

 O
INR O
levels O
checked O
frequently O
until O
your O
dose O
and O
INR O
levels O
are O

 O
stable O
. O


 O
-You O
were O
discharged O
on O
antibiotics O
that O
you O
will O
take O
for O
2 O

 O
weeks O
, O


 O
-You O
will O
have O
a O
wound O
vac O
placed O
in O
your O
wounds O
at O
the O
rehab O

 O
facility(right O
medial O
and O
groin O
wounds O
) O
to O
be O
changed O
every O

 O
third O
day O
until O
you O
get O
seen O
in O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
1391 O
* O
* O
] O
for O
FU O
. O


 O
-You O
also O
developed O
right O
" O
drop O
foot O
" O
, O
you O
will O
need O
a O
spilt O
to O

 O
for O
this O
, O
this O
was O
custom O
nade O
for O
you O
and O
will O
be O
delivered O
to O

 O
your O
rehab O
. O


 O
-You O
will O
FU O
w/ O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
1391 O
* O
* O
] O
in O
2 O
weeks O
to O
re-evaluate O
your O

 O
wounds O
for O
the O
need O
for O
skin O
grafting O
. O


 O
Followup O
Instructions O
: O

 O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
1391 O
* O
* O
] O
in O
2 O
weeks O
. O
Call O
to O
make O
an O
appointment O

 O
Phone:[**Telephone/Fax O
( O
1 O
) O
1393 O
* O
* O
] O




 O

Completed O
by:[**2158 O
- O
12 O
- O
20 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2195 O
- O
9 O
- O
14 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2195 O
- O
9 O
- O
14 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2121 O
- O
1 O
- O
23 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
NEUROSURGERY O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1854 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
consulted O
for O
SDH O
found O
on O
CT O
at O
OSH O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
none O


 O
History O
of O
Present O
Illness O
: O

 O
74 O
year O
old O
male O
on O
coumadin B-DRUG
for O
ICD B-REA
was O
not O
feeling O
well O

 O
around O
8 O
pm O
last O
night O
and O
he O
went O
to O
sleep O
at O
that O
time O
. O
This O

 O
morning O
at O
5:30 O
am O
his O
wife O
noticed O
that O
he O
had O
not O
moved O

 O
positions O
since O
he O
went O
to O
bed O
and O
one O
of O
his O
legs O
was O
hanging O

 O
over O
the O
side O
of O
the O
bed O
. O
She O
was O
unable O
to O
arouse O
him O
and O
he O

 O
went O
to O
an O
OSH O
. O
He O
was O
intubated O
and O
had O
a O
head O
CT O
which O

 O
revealed O

 O
a O
large O
right O
SDH B-REA
with O
midline O
shift O
. O
The O
patient O
was O
given O

 O
cerebryx B-DRUG
and O
50 B-STR
mg I-STR
of O
mannitol B-DRUG
and O
sent O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
. O
When O

 O
neurosurgery O
was O
called O
the O
patient O
the O
ER O
had O
ordered O
another O

 O
50 B-STR

 I-STR
mg I-STR
of O
mannitol B-DRUG
to O
be O
given O
as O
well O
as O
vitamin B-DRUG
K I-DRUG
and O
Profiline B-DRUG


 I-DRUG
Past O
Medical O
History O
: O

 O
Has O
ICD B-REA
- O
on O
coumadin B-DRUG

 I-DRUG
adenocarcinoma O
of O
the O
prostate O
- O
s/p O
brachytherapy O


 O
Social O
History O
: O

 O
lives O
with O
wife O
, O
has O
a O
daughter O
, O
son O
, O
and O

 O
daughter-in-law O
who O
are O
here O
in O
the O
ER O
with O
him O



 O
Family O
History O
: O

 O
non-contributory O


 O
Physical O
Exam O
: O

 O
PHYSICAL O
EXAM O
upon O
admission O
: O

 O
T:99.8 O
  O
BP:109/56 O
     O
HR:74 O
    O
RR:16 O
       O
O2Sats:100 O
% O
vented O

 O
Gen O
: O
intubated O
and O
sedated O

 O
HEENT O
: O
Pupils:5 O
mm O
, O
unreactive O
bilaterally O
    O
EOMs-unable O

 O
Neck O
: O
Supple O
. O

 O
Lungs O
: O
CTA O
bilaterally O
. O

 O
Cardiac O
: O
RRR O
. O
S1/S2 O
. O

 O
Abd O
: O
Soft O
, O
NT O
, O
BS+ O

 O
Extrem O
: O
Warm O
and O
well-perfused O
. O

 O
Neuro O
: O

 O
Mental O
status O
: O
Unresponsive O
. O


 O
Cranial O
Nerves O
: O

 O
I O
: O
Not O
tested O

 O
II O
: O
Pupils O
5 O
mm O
, O
unreactive O
bilaterally O
. O

 O
III-XII O
: O
unable O
to O
test O


 O
Motor O
: O
Upper O
extremities O
extending O
to O
pain O
. O
Lower O
extremities O

 O
withdrawing O
to O
pain O
. O


 O
Toes O
upgoing O
bilaterally O



 O
Pertinent O
Results O
: O

 O
CT O
Head O
from O
OSH O
[ O
* O
* O
2195 O
- O
9 O
- O
14 O
* O
* O
] O
: O

 O
The O
patient O
had O
a O
very O
large O
right O
SDH O
with O
midline O
shift O
and O

 O
herniation O
. O
Formal O
read O
is O
unavailable O
at O
this O
time O
. O



 O
Brief O
Hospital O
Course O
: O

 O
The O
patient O
was O
admitted O
to O
the O
ICU O
after O
the O
decision O
was O
made O

 O
to O
keep O
him O
comfortable O
since O
he O
had O
a O
devasting O
hemorrhage O
with O

 O
herniation O
. O
He O
was O
extubated O
several O
hours O
later O
after O
the O

 O
family O
had O
a O
chance O
to O
see O
him O
and O
spend O
some O
time O
with O
him O
. O
The O

 O
patient O
expired O
about O
1 O
[ O
* O
* O
1 O
- O
23 O
* O
* O
] O
after O
extubation O
. O


 O
Medications O
on O
Admission O
: O

 O
Vytorin B-DRUG
10 B-STR
- I-STR
80 I-STR
mg I-STR
PO B-ROU
QHS B-FRE

 I-FRE
HCTZ B-DRUG
25 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Lopressor B-DRUG
200 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
KCL B-DRUG
20 B-STR
mEq I-STR
PO B-ROU
daily B-FRE

 I-FRE
Diovan B-DRUG
320 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Coumadin B-DRUG
dose O
changes O

 O
Tylenol B-DRUG
80 B-STR
- I-STR
160 I-STR
mg I-STR
PO B-ROU
PRN B-FRE
pain B-REA


 I-REA
Discharge O
Medications O
: O

 O
none O


 O
Discharge O
Disposition O
: O

 O
Expired O


 O
Discharge O
Diagnosis O
: O

 O
Right O
SDH O
with O
mass O
effect O
and O
herniation O



 O
Discharge O
Condition O
: O

 O
expired O



 O
Discharge O
Instructions O
: O

 O
n/a O



 O
Followup O
Instructions O
: O

 O
n/a O




 O
Completed O
by:[**2195 O
- O
9 O
- O
14 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2148 O
- O
7 O
- O
7 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2080 O
- O
10 O
- O
31 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
IV O
Dye B-DRUG
, I-DRUG
Iodine B-DRUG
Containing O
/ O
Keflex B-DRUG
/ O
Codeine B-DRUG
/ O
Isoniazid B-DRUG
/ O

 O
Indocin B-DRUG
/ O
Percocet B-DRUG
/ O
Vicodin B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
2763 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
GI O
bleed O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
EGD O


 O
History O
of O
Present O
Illness O
: O

 O
67 O
yo O
F O
with O
a O
PMH O
of O
SLE O
, O
DMI O
, O
HTN O
, O
ESRD O
on O
HD O
T O
, O
Th O
, O
Sat O
, O

 O
paroxysmal O
afib O
s/p O
PV O
isolation O
x2 O
, O
tachy-brady O
syndrome O
s/p O

 O
pacer O
and O
PVD O
with O
SFA O
stent O
placement O
, O
NSTEMI O
with O
DES O
to O
LAD O

 O
and O
BMS O
to O
OM1 O
on O
[ O
* O
* O
6 O
- O
21 O
* O
* O
] O
presenting O
with O
lightheadedness O
and O
bright O

 O
red O
blood O
per O
rectum O
. O
  O
She O
stated O
that O
last O
night O
, O
she O
noted O

 O
large O
red O
" O
clots O
" O
in O
her O
stool O
, O
along O
with O
BRB O
with O
wiping O
. O
  O
Of O

 O
note O
, O
she O
has O
hemorhoids O
. O
  O
She O
had O
more O
bowel O
movemets O
with O

 O
clots O
this O
AM O
and O
felt O
lightheaded O
. O
  O
Of O
note O
, O
she O
is O
on O
aspirin B-DRUG
, I-DRUG

 O
plavix B-DRUG
, I-DRUG
and O
coumadin B-DRUG
, I-DRUG
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
took O
none O
of O
her O
meds O
this O
AM O
. O

 O
. O

 O
On O
arrival O
to O
the O
ED O
, O
initial O
vitals O
were O
97.9 O
70 O
85/47 O
22 O
96 O
% O

 O
RA O
. O
  O
By O
the O
time O
she O
got O
to O
her O
room O
, O
her O
SBPs O
had O
come O
up O
tot O

 O
he O
90s/100s O
without O
any O
fluids O
. O
  O
Labs O
were O
notable O
for O
a O
Hct O
of O

 O
23.7 O
down O
from O
32.7 O
one O
week O
ago O
on O
discharge O
. O
  O
K+ O
was O
7.2 O
, O
she O

 O
was O
given O
insulin B-DRUG
, I-DRUG
D50 B-DRUG
, I-DRUG
calcium B-DRUG
gluconate I-DRUG
. I-DRUG
  O
ECG O
was O
V O
paced O

 O
without O
any O
T O
wave O
changes O
. O
10 B-STR
mg I-STR
IV B-ROU
Vitamin B-DRUG
K I-DRUG
given O
, O
1 B-DOS
unit I-DOS
FFP B-DRUG

 I-DRUG
and O
PRBCs B-DRUG
ordered O
( O
and O
given O
in O
ED O
) O
. O
CTA O
done O
in O
the O
ED O
. O
  O
GI O
and O

 O
renal O
aware O
. O
  O
On O
transfer O
, O
vitals O
were O
70s O
paced O
106/59 O
no O

 O
fluids O
RR O
15 O
98 O
% O
RA O
. O
  O
A O
left O
groin O
cordis O
was O
placed O
. O

 O
. O

 O
On O
arrival O
to O
the O
MICU O
, O
patient O
had O
large O
melanotic O
bowel O

 O
movement O
, O
otherwise O
HD O
stable O
. O

 O
. O

 O
Of O
note O
, O
patient O
states O
that O
she O
had O
an O
EGD O
at O
[ O
* O
* O
Hospital1 O
112 O
* O
* O
] O
showing O

 O
gastritis O
and O
healed O
ulcers O
, O
as O
well O
as O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
which O
showed O

 O
polyps O
that O
were O
removed O
. O



 O
Past O
Medical O
History O
: O

 O
Diabetes O

 O
Hypertension O

 O
CAD O
s/p O
DES O
to O
midLAD O
and O
BMS O
to O
OM1 O
[ O
* O
* O
2148 O
- O
6 O
- O
20 O
* O
* O
] O

 O
Tachy-brady O
syndrome O
s/p O
[ O
* O
* O
Company O
1543 O
* O
* O
] O
pacemaker O
implanted O
[ O
* O
* O
2143 O
* O
* O
] O
for O

 O
offset O
pauses O

 O
Symptomatic O
paroxysmal O
atrial O
fibrillation O
s/p O
afib O
ablation O
x2 O

 O
last O
one O
[ O
* O
* O
9-/2147 O
* O
* O
] O
by O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
at O
[ O
* O
* O
Hospital1 O
112 O
* O
* O
] O
. O
Does O
not O
tolerate O
1C O

 O
agents O
due O
to O
lightheadedness O
. O

 O
PVD B-REA
, I-REA
recent O
left O
SFA O
stent B-REA
placement I-REA
on O
plavix B-DRUG

 I-DRUG
Mohs O
procedure O
for O
SQC O
carcinoma O
of O
leg O

 O
SLE O

 O
Type O
1 O
diabetes O
mellitus O

 O
ESRD O
( O
end O
stage O
renal O
disease O
) O
on O
dialysis O
x~2yr O
( O
T O
, O
TH O
, O
Sat O
) O

 O
Calcification/fibroadenoma O
of O
left O
breast O

 O
h/o O
squamous O
cell O
carcinoma O
, O
leg O
and O
face O

 O
DJD O
of O
knee O
and O
hip O

 O
Anemia O
in O
chronic O
kidney O
disease O

 O
Hyperphosphatemia O

 O
Hyperparathyroidism O
due O
to O
renal O
insufficiency O

 O
Cataract O

 O
Moderate O
Nonproliferative O
Diabetic O
Retinopathy O

 O
Colonic O
Adenoma O

 O
Neuritis/Radiculitis O
due O
to O
Herniated O
Lumbar O
Disc O

 O
OBESITY O
- O
MORBID O

 O
SPINAL O
STENOSIS O
- O
LUMBAR O

 O
GLOMERULONEPHRITIS O
- O
MEMBRANOUS O

 O
THROMBOCYTOPENIA O
- O
IMMUNE O

 O
ESOPHAGEAL O
REFLUX O

 O
ANTICARDIOLIPIN O
ANTIBODY O
SYNDROME O

 O
GLAUCOMA O
SUSPECT O
W O
OPEN O
ANGLE O

 O
VARICOSE O
VEINS O

 O
ESOTROPIA O

 O
HISTORY O
BASAL O
CELL O
CARCINOMA O

 O
POSITIVE O
PPD O

 O
PERICARDITIS O

 O
S/p O
cholecystectomy O
, O
hysterectomy O


 O
Social O
History O
: O

 O
Used O
to O
work O
as O
a O
nurse O
. O
[ O
* O
* O
First O
Name O
( O
Titles O
) O
1817 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Titles O
) O
1818 O
* O
* O
] O
, O
quit O
40yrs O
ago O
. O
Denies O

 O
ETOH O
and O
other O
drugs O
. O



 O
Family O
History O
: O

 O
brother O
who O
died O
of O
esophageal O
CA O
Father O
- O
DM O
, O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
Cancer O

 O
( O
70s O
) O
, O
Mother O
-DM O
, O
CAD/PVD O
, O
Sister O
- O
Lupus O
, O
Sister O
- O
Breast O

 O
[ O
* O
* O
Name2 O
( O
NI O
) O
3730 O
* O
* O
] O
( O
age O
43 O
) O
, O
Sister O
- O
Bladder O
[ O
* O
* O
Name O
( O
NI O
) O
3730 O
* O
* O
] O
. O
Paternal O
GF O
- O
CRC O



 O
Physical O
Exam O
: O

 O
ADMISSION O
EXAM O
: O

 O
General O
: O
Alert O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
MMM O
, O
oropharynx O
clear O
, O
EOMI O
, O
PERRL O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
CV O
: O
Regular O
rate O
and O
rhythm O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O

 O
gallops O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O
rales O
, O

 O
ronchi O

 O
Abdomen O
: O
soft O
, O
non-tender O
, O
non-distended O
, O
bowel O
sounds O
present O
, O

 O
no O
organomegaly O

 O
GU O
: O
no O
foley O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
no O
clubbing O
, O
cyanosis O
or O

 O
edema O

 O
Neuro O
: O
CNII-XII O
intact O
, O
5/5 O
strength O
upper/lower O
extremities O
, O

 O
grossly O
normal O
sensation O
, O
2 O
+ O
reflexes O
bilaterally O
, O
gait O

 O
deferred O
, O
finger-to-nose O
intact O

 O
. O

 O
DISCHARGE O
EXAM O
: O

 O
General O
: O
Alert O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
MMM O
, O
oropharynx O
clear O
, O
EOMI O
, O
PERRL O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
CV O
: O
Regular O
rate O
and O
rhythm O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O

 O
gallops O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O
rales O
, O

 O
ronchi O

 O
Abdomen O
: O
soft O
, O
non-tender O
, O
non-distended O
, O
bowel O
sounds O
present O
, O

 O
no O
organomegaly O

 O
GU O
: O
no O
foley O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
no O
clubbing O
, O
cyanosis O
or O

 O
edema O

 O
Neuro O
: O
CNII-XII O
intact O
, O
5/5 O
strength O
upper/lower O
extremities O
, O

 O
grossly O
normal O
sensation O
, O
2 O
+ O
reflexes O
bilaterally O
, O
gait O

 O
deferred O
, O
finger-to-nose O
intact O
, O
She O
was O
able O
to O
get O
out O
of O
bed O

 O
with O
a O
two O
person O
assist O
and O
was O
able O
to O
shuffle O
herself O
to O
a O

 O
wheelchair O
. O


 O
Pertinent O
Results O
: O

 O
ADMISSION O
LABS O
: O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
07:35AM O
BLOOD O
WBC-12.5 O
* O
# O
RBC-2.43 O
* O
# O
Hgb-7.5 O
* O
# O

 O
Hct-23.7 O
* O
# O
MCV-98 O
MCH-31.0 O
MCHC-31.6 O
RDW-18.8 O
* O
Plt O
Ct-182 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
07:35AM O
BLOOD O
Neuts-90.6 O
* O
Lymphs-5.2 O
* O
Monos-2.3 O
Eos-1.5 O

 O
Baso-0.4 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
07:35AM O
BLOOD O
PT-55.3 O
* O
PTT-75.5 O
* O
INR(PT)-5.5 O
* O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
07:35AM O
BLOOD O
Glucose-194 O
* O
UreaN-57 O
* O
Creat-7.5 O
* O
# O
Na-138 O

 O
K-7.2 O
* O
Cl-100 O
HCO3 O
- O
23 O
AnGap-22 O
* O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
07:35AM O
BLOOD O
Calcium-7.8 O
* O
Phos-6.8 O
* O
Mg-2.0 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
07:45AM O
BLOOD O
Lactate-1.6 O

 O
. O

 O
PERTINENT O
LABS O
: O

 O
. O

 O
DISCHARGE O
LABS O
: O

 O
. O

 O
MICRO O
: O
none O

 O
. O


 O
IMAGING O
: O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
CT O
abdomen/pelvis O
w/o O
con O
: O

 O
1 O
. O
Left O
femoral O
venous O
catheter O
has O
an O
unusually O
short O

 O
intra-vascular O
course O
. O

 O
2 O
. O
4.6-cm O
rounded O
structure O
in O
the O
gallbladder O
fossa O
contains O
a O

 O
dependent O
calcification O
and O
demonstrates O
no O
inflammatory O
change O
. O

 O
This O
potentially O
represents O
a O
post-operative O
collection O
without O

 O
surrounding O
inflammation O
or O
a O
retained O
portion O
of O
the O

 O
gallbladder O
. O
Correlation O
with O
detailed O
surgical O
history O
is O

 O
suggested O
. O

 O
3 O
. O
Sigmoid O
diverticulosis O
without O
evidence O
of O
diverticulitis O

 O
4 O
. O
Focus O
of O
air O
within O
bladder O
. O
Please O
correlate O
with O
history O

 O
for O
recent O
instrumentation O
. O

 O
5 O
. O
Severe O
vascular O
calcifications O
. O

 O
. O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
GI O
Bleeding O
Study O
: O
Blood O
flow O
images O
show O
normal O
tracer O

 O
flow O
through O
the O
large O
vessels O
of O
the O
abdominal O
and O
pelvic O

 O
vasculature O
. O
Dynamic O
images O
of O
the O
abdomen O
show O
tracer O

 O
extravasation O
in O
the O
right O
upper O
quadrant O
likely O
in O
the O
hepatic O

 O
flexure O
of O
the O
[ O
* O
* O
Month/Day/Year O
499 O
* O
* O
] O
at O
the O
onset O
of O
the O
study O
. O
Over O
72 O
minutes O
, O

 O
there O
is O
relatively O
little O
transit O
of O
isotope O
reaching O
only O
the O

 O
region O
of O
the O
mid-transverse O
[ O
* O
* O
Month/Day/Year O
499 O
* O
* O
] O
; O
slow O
transit O
is O
typical O
of O

 O
bleeding O
in O
the O
large O
bowel O
. O

 O
IMPRESSION O
: O
GI O
bleed O
likely O
in O
the O
region O
of O
the O
hepatic O
flexure O

 O
of O
the O
[ O
* O
* O
Month/Day/Year O
499 O
* O
* O
] O
. O

 O
. O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
CXR O
: O
Exam O
is O
limited O
as O
the O
bilateral O
bases O
are O

 O
excluded O
from O
the O
field O
of O
view O
. O
Where O
seen O
the O
lungs O
appear O

 O
clear O
. O
Cardiac O
silhouette O
is O
slightly O
enlarged O
likely O

 O
accentuated O
by O
positioning O
however O
is O
unchanged O
. O
Dense O

 O
atherosclerotic O
calcifications O
noted O
at O
the O
arch O
. O
Osseous O
and O

 O
soft O
tissue O
structures O
are O
unchanged O
. O

 O
. O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
Mesenteric O
angiogram O
by O
IR O
: O

 O
1 O
. O
Extensive O
atherosclerotic O
disease O
, O
with O
calcification O
of O

 O
multiple O
vessels O
seen O
on O
fluoroscopic O
images O
without O
contrast O
. O

 O
2 O
. O
Right O
common O
femoral O
artery O
access O
was O
obtained O
. O

 O
Atherosclerotic O
disease O
but O
patent O
right O
common O
femoral O
artery O

 O
with O
contrast O
flowing O
through O
and O
around O
the O
sheath O
. O

 O
3 O
. O
SMA O
angiography O
demonstrated O
no O
evidence O
of O
active O

 O
extravasation O
, O
specifically O
within O
the O
right O
[ O
* O
* O
Month/Day/Year O
499 O
* O
* O
] O
or O
hepatic O

 O
flexure O
. O
Additional O
selective O
angiography O
of O
the O
middle O
colic O

 O
and O
right O
colic O
arteries O
demonstrated O
no O
active O
extravasation O

 O
within O
the O
[ O
* O
* O
Month/Day/Year O
499 O
* O
* O
] O
or O
visualized O
portions O
of O
small O
bowel O
branches O
. O



 O
4 O
. O
Celiac O
artery O
angiography O
demonstrated O
no O
active O

 O
extravasation O
within O
the O
right O
upper O
quadrant O
. O
Specifically O
, O
no O

 O
active O
extravasation O
is O
seen O
within O
the O
GDA O
. O

 O
5 O
. O
Angiography O
of O
the O
hepatic O
artery O
demonstrated O
a O
5 O
- O
6 O
mm O

 O
pseudoaneurysm O
arising O
off O
the O
right O
hepatic O
artery O
. O
This O
is O

 O
likely O
an O
incidental O
finding O
. O
No O
active O
extravasation O
was O
seen O

 O
from O
this O
into O
any O
biliary O
ducts O
or O
outside O
of O
the O
vessel O
lumen O
. O

 O
IMPRESSION O
: O
No O
evidence O
of O
active O
extravasation O
on O
this O

 O
mesenteric O
angiogram O
. O

 O
. O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
3 O
* O
* O
] O
CTA O
abdomen/pelvis O
: O

 O
1 O
. O
Suboptimal O
bolus O
limits O
evaluation O
for O
active O
GI O
bleeding O
, O

 O
although O
existing O
high-density O
intraluminal O
contents O
suggests O

 O
extravasation O
from O
prior O
angiogram O
. O

 O
2 O
. O
Mild O
bladder O
wall O
thickening O
and O
surrounding O
fat O
stranding O
is O

 O
suggestive O
of O
cystitis O
, O
correlate O
with O
urinalysis O
. O
Further O
, O
air O

 O
seen O
within O
the O
bladder O
wall O
may O
relate O
to O
prior O
Foley O
placement O

 O
but O
emphysematous O
cystitis O
is O
not O
excluded O
. O

 O
3 O
. O
Extensive O
atherosclerosis O
, O
without O
aneurysm O
. O

 O
4 O
. O
Sigmoid O
diverticulosis O
without O
diverticulitis O
and O

 O
cholelithiasis O
in O
a O
gallbladder O
remnant O
without O
cholecystitis O
. O

 O
5 O
. O
Left O
adnexal O
cystic O
lesion O
is O
not O
fully O
characterized O
on O
this O

 O
study O
. O
  O
If O
warranted O
, O
a O
non-urgent O
pelvic O
ultrasound O
may O
be O

 O
performed O
. O


 O
Brief O
Hospital O
Course O
: O

 O
67 O
year O
old O
female O
with O
SLE O
, O
DMI O
, O
HTN O
, O
ESRD O
on O
HD O
, O
paroxysmal O

 O
afib O
s/p O
PV O
isolation O
x2 O
, O
tachy-brady O
syndrome O
s/p O
pacer O
, O
PVD O

 O
with O
SFA O
stent O
placement O
, O
and O
NSTEMI O
s/p O
DES O
to O
LAD O
and O
BMS O
to O

 O
OM1 O
on O
[ O
* O
* O
2148 O
- O
6 O
- O
21 O
* O
* O
] O
on O
aspirin B-DRUG
, I-DRUG
plavix B-DRUG
, I-DRUG
and O
coumadin B-DRUG
who O
presented O

 O
with O
melena O
and O
BRBPR O
. O

 O
. O

 O
# O
GIB O
: O
Patient O
presented O
with O
melena O
and O
BRBPR O
, O
suspicious O
for O

 O
either O
an O
upper O
or O
lower O
GI O
source O
. O
The O
EGD O
showed O
mild O

 O
gastritis O
but O
no O
active O
bleeding O
. O
The O
flex O
sig O
was O
also O
negative O

 O
for O
active O
bleeding O
. O
The O
tagged O
RBC O
scan O
was O
positive O
in O
the O

 O
hepatic O
flexure O
, O
however O
when O
she O
was O
taken O
to O
IR O
for O
a O

 O
mesenteric O
angiogram O
, O
there O
was O
no O
active O
bleeding O
. O
She O

 O
continued O
to O
have O
melena O
so O
underwent O
an O
abdominal O
CTA O
( O
after O

 O
prep O
for O
her O
iodine B-DRUG
allergy O
) O
, O
which O
was O
also O
negative O
for O
active O

 O
bleeding O
. O
She O
was O
scheduled O
for O
a O
colonoscopy O
which O
was O
then O

 O
cancelled O
due O
to O
her O
Afib O
with O
RVR O
( O
see O
below O
) O
. O
Overall O
she O

 O
received O
8 B-DOS
units I-DOS
of O
PRBCs B-DRUG
, I-DRUG
3 B-DOS
units I-DOS
of O
FFP B-DRUG
, I-DRUG
and O
1 B-DOS
unit I-DOS
of O

 O
platelets B-DRUG
while O
in O
the O
ICU O
. O
  O
It O
was O
determined O
by O
the O
team O
that O

 O
the O
colonoscopy O
can O
be O
deferred O
to O
the O
outpatient O
setting O
given O

 O
her O
relative O
stability O
. O

 O
. O


 O
# O
Atrial B-REA
fibrillation I-REA
: I-REA
S/p O
two O
ablations O
in O
the O
past O
, O
now O
with O

 O
pacemaker O
. O
We O
continued O
her O
amiodarone B-DRUG
but O
initially O
held O
her O

 O
home O
metoprolol B-DRUG
and O
diltizem B-DRUG
in O
the O
setting O
of O
the O
GIB O
. O
She O
went O

 O
into O
AFib B-REA
with O
RVR O
on O
MICU O
day O
# O
3 O
so O
she O
was O
given O
IV B-ROU
diltiazem B-DRUG

 I-DRUG
and O
metoprolol B-DRUG
and O
her O
home O
metoprolol B-DRUG
and O
diltiazem B-DRUG
were O

 O
restarted O
. O
However O
, O
she O
continued O
to O
have O
RVR O
and O
required O
a O

 O
diltiazem B-DRUG
gtt B-ROU
. I-ROU
  O
She O
was O
eventually O
transitioned O
to O
her O
home O

 O
doses O
. O

 O
. O

 O
# O
ESRD O
: O
On O
Tues/Thurs/Sat O
dialysis O
schedule O
, O
which O
was O
continued O

 O
in O
the O
MICU O
. O

 O
. O

 O
# O
CAD O
: O
Patient O
with O
NSTEMI O
one O
week O
ago O
s/p O
DES O
to O
LAD O
and O
BMS O

 O
to O
OM1 O
. O
We O
continued O
aspirin/plavix B-DRUG
despite O
the O
GIB O
given O
risk O

 O
for O
in-stent B-REA
thrombosis I-REA
one O
week O
out O
. O
This O
was O
discussed O
with O

 O
her O
[ O
* O
* O
Date O
Range O
* O
* O
] O
outpatient O
cardiologist O
. O

 O
. O

 O
# O
PVD O
s/p O
SFA O
stenting O
recently O
: O
Recent O
peripheral O
angiogram O
by O

 O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
3407 O
* O
* O
] O
with O
angioplasty/stenting B-REA
of O
the O
left O
SFA O
and O

 O
angioplasty O
of O
the O
left O
tibial O
artery O
; O
had O
been O
on O
plavix B-DRUG
prior O

 O
to O
NSTEMI O
. O
She O
has O
2 O
gangrenous O
toes O
, O
which O
appear O
similar O
to O

 O
prior O
. O
Continued O
aspirin/Plavix B-DRUG
. I-DRUG

 O
. O

 O
# O
Chronic B-REA
pain I-REA
: I-REA
Continued O
home O
gabapentin B-DRUG
and O
dilaudid B-DRUG
. I-DRUG

 O
. O

 O
# O
Depression B-REA
: I-REA
Continued O
sertraline B-DRUG
. I-DRUG


 O
# O
Goals O
of O
Care O
: O
Patient O
expressing O
interest O
in O
rethinking O
her O

 O
goals O
of O
care O
. O
  O
She O
is O
considering O
a O
do O
not O
hospitalize O
, O
but O

 O
would O
like O
to O
talk O
things O
over O
with O
her O
family O
before O
making O

 O
these O
decisions O
. O
  O
She O
will O
speak O
to O
her O
primary O
care O
doctor O
, O
Dr. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
1057 O
* O
* O
] O
, O
about O
these O
issues O
. O
She O
had O
declined O
rehab O
while O
in O
the O

 O
MICU O
and O
was O
very O
insistent O
on O
going O
home O
. O
Because O
she O
had O
good O

 O
family O
support O
and O
very O
good O
insight O
into O
her O
condition O
, O
she O
was O

 O
discharged O
home O
with O
close O
follow O
up O
by O
the O
MICU O
team O
. O
She O
felt O

 O
weak O
at O
home O
and O
was O
not O
able O
to O
navigate O
her O
home O
as O
well O
as O

 O
she O
would O
have O
liked O
. O
The O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
2287 O
* O
* O
] O
case O
managers O
arranged O
for O
her O

 O
to O
go O
to O
[ O
* O
* O
Hospital O
1785 O
* O
* O
] O
Rehab O
from O
home O
the O
day O
after O
admission O
. O
The O

 O
MICU O
team O
was O
in O
communication O
with O
the O
case O
manager O
and O
primary O

 O
care O
doctor O
during O
the O
post-discharge O
period O
in O
order O
to O

 O
faciliatate O
a O
proper O
disposition O
. O
There O
is O
a O
separate O
note O
in O

 O
OMR O
detailing O
this O
. O


 O
Medications O
on O
Admission O
: O

 O
1 O
. O
diltiazem B-DRUG
HCl I-DRUG
120 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Extended I-FOR
Release I-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS



 I-DOS
Capsule B-FOR
, I-FOR
Extended I-FOR
Release I-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O
day O
) O
: O
Take O
360 B-STR
mg I-STR
in B-FRE

 I-FRE
morning I-FRE
and I-FRE
night I-FRE
and O
240 B-STR
mg I-STR
in B-FRE
afternoon I-FRE
. I-FRE

 O
2 O
. O
diltiazem B-DRUG
HCl I-DRUG
240 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Extended I-FOR
Release I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Extended I-FOR
Release I-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
: O
Take O
360 B-STR
mg I-STR
in B-FRE

 I-FRE
morning I-FRE
and I-FRE
night I-FRE
and O
240 B-STR
mg I-STR
in B-FRE
afternoon I-FRE
. I-FRE

 O
3 O
. O
metoprolol B-DRUG
succinate I-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Extended I-FOR
Release I-FOR
24 I-FOR
hr I-FOR

 I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
Extended I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O

 O
day O
) O
. O

 O
4 O
. O
warfarin B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
4.5 B-DOS
Tablets B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
: I-FRE
Take O

 O
4.5 B-STR
mg I-STR
daily B-FRE
. I-FRE

 O
5 O
. O
amiodarone B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
TUES B-FRE
, I-FRE
THURS I-FRE
, I-FRE
SAT I-FRE
( O
) O
. O

 O
6 O
. O
fluorouracil B-DRUG
0.5 B-STR
% O
Cream B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
application B-FOR
Topical B-ROU

 I-ROU
once B-FRE
a I-FRE
day I-FRE
for B-DUR
2 I-DUR
weeks I-DUR
: I-DUR
apply O
to O
face O
with O
bactroban B-DRUG
. I-DRUG

 O
7 O
. O
Bactroban B-DRUG
2 O
% O
Cream B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
application B-FOR
Topical B-ROU
once B-FRE
a I-FRE

 I-FRE
day I-FRE
for B-DUR
2 I-DUR
weeks I-DUR
: I-DUR
Apply O
to O
face O
with O
Fluorouracil B-DRUG
. I-DRUG

 O
8 O
. O
gabapentin B-DRUG
300 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
TID B-FRE
( O
3 O

 O
times O
a O
day O
) O
. O

 O
9 O
. O
sertraline B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
10 O
. O
Ferrlecit B-DRUG
62.5 B-STR
mg/5 I-STR
mL I-STR
Solution B-FOR
Intravenous B-ROU

 I-ROU
11 O
. O
lorazepam B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O

 O
day O
) O
as O
needed O
. O

 O
12 O
. O
tramadol B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O

 O
day O
) O
as O
needed O
for O
pain B-REA
. I-REA

 O
13 O
. O
omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS


 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
14 O
. O
Voltaren B-DRUG
1 O
% O
Gel B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
application B-FOR
Topical B-ROU
four O
times O


 O
a O
day O
: O
Apply O
to O
affected O
area O
up O
to O
4times B-FRE
daily I-FRE
. I-FRE

 O
15 O
. O
Epogen B-DRUG
  O
Injection B-FOR

 I-FOR
16 O
. O
insulin B-DRUG
aspart I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
injection B-FOR

 I-FOR
Subcutaneous B-ROU
four B-FRE
times I-FRE
a I-FRE
day I-FRE
: I-FRE
Take O
as O
directed O
according O
to O

 O
home O
sliding B-DOS
scale I-DOS
. I-DOS

 O
17 O
. O
hydromorphone B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q3H B-FRE
( I-FRE
every I-FRE

 I-FRE
3 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
Pain B-REA
. I-REA

 O
18 O
. O
sevelamer B-DRUG
carbonate I-DRUG
800 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1.5 B-DOS
Tablets B-FOR
PO B-ROU
TID B-FRE

 I-FRE
W/MEALS I-FRE
( O
3 O
TIMES O
A O
DAY O
WITH O
MEALS O
) O
. O

 O
19 O
. O
B B-DRUG
complex-vitamin I-DRUG
C-folic I-DRUG
acid I-DRUG
1 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Cap B-FOR



 I-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
20 O
. O
acetaminophen B-DRUG
650 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE

 I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
Pain B-REA
. I-REA

 O
21 O
. O
aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
22 O
. O
nitroglycerin B-DRUG
0.3 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Sublingual I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet O
, O


 O
Sublingual O
Sublingual B-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
Chest B-REA
pain I-REA
: I-REA

 O
Place O
1 B-DOS
tablet B-FOR
under B-ROU
the I-ROU
tongue I-ROU
for O
chest B-REA
pressure I-REA
. I-REA
Take O
1 B-DOS
every O


 O
5 O
minutes O
, O
up O
to O
three B-DUR
times I-DUR
in I-DUR
a I-DUR
row I-DUR
. I-DUR

 O
Disp:*30 O
Tablet O
, O
Sublingual(s O
) O
* O
Refills:*0 O
* O

 O
23 O
. O
atorvastatin B-DRUG
80 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( O
at O

 O
bedtime O
) O
. O

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
24 O
. O
clopidogrel B-DRUG
75 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
25 O
. O
doxercalciferol B-DRUG
  O
Intravenous B-ROU


 I-ROU
Discharge O
Medications O
: O

 O
1 O
. O
Amiodarone B-DRUG
200 B-STR
mg I-STR
PO B-ROU
QTUTHSA B-FRE
( O
TU O
, O
TH O
, O
SA O
) O

 O
2 O
. O
Aspirin B-DRUG
81 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
3 O
. O
Atorvastatin B-DRUG
80 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
4 O
. O
Clopidogrel B-DRUG
75 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
5 O
. O
Gabapentin B-DRUG
300 B-STR
mg I-STR
PO B-ROU
TID B-FRE

 I-FRE
6 O
. O
HYDROmorphone B-DRUG
( O
Dilaudid B-DRUG
) I-DRUG
2 B-STR
mg I-STR
PO B-ROU
Q3H B-FRE
: I-FRE
PRN I-FRE
pain B-REA

 I-REA
7 O
. O
Insulin B-DRUG
SC B-ROU

       I-ROU
Sliding B-DOS
Scale I-DOS


 I-DOS
Fingerstick O
QACHS B-FRE

 I-FRE
Insulin B-DRUG
SC B-ROU
Sliding B-DOS
Scale I-DOS
using O
HUM B-DRUG
Insulin I-DRUG

 I-DRUG
8 O
. O
Lorazepam B-DRUG
1 B-STR
mg I-STR
PO B-ROU
BID B-FRE
: I-FRE
PRN O
anxiety B-REA

 I-REA
Hold O
for O
sedation O
or O
RR<12 O
. O

 O
9 O
. O
Mupirocin B-DRUG
Cream B-FOR
2 B-STR
% I-STR
1 B-DOS
Appl B-FOR
TP B-ROU
QD B-FRE

 I-FRE
10 O
. O
Nephrocaps B-DRUG
1 B-DOS
CAP B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
11 O
. O
sevelamer B-DRUG
CARBONATE I-DRUG
1200 B-STR
mg I-STR
PO B-ROU
TID B-FRE
W/MEALS I-FRE

 I-FRE
12 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
PO B-ROU
Q12H B-FRE

 I-FRE
RX O
* O
pantoprazole B-DRUG
40 B-STR
mg I-STR
1 B-DOS
Tablet(s B-FOR
) O
by B-ROU
mouth I-ROU
twice B-FRE
a I-FRE
day I-FRE
Disp O

 O
# O
* O
60 O
Capsule O
Refills:*0 O

 O
13 O
. O
Diltiazem B-DRUG
Extended-Release B-FOR
360 B-STR
mg I-STR
PO B-ROU
QAM B-FRE

 I-FRE
14 O
. O
Diltiazem B-DRUG
Extended-Release B-FOR
240 B-STR
mg I-STR
PO B-ROU
QPM B-FRE

 I-FRE
15 O
. O
Diltiazem B-DRUG
Extended-Release B-FOR
360 B-STR
mg I-STR
PO B-ROU
QHS B-FRE

 I-FRE
hold O
for O
sbp<100 O
, O
hr<55 O

 O
16 O
. O
Sertraline B-DRUG
150 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
17 O
. O
TraMADOL B-DRUG
( O
Ultram B-DRUG
) I-DRUG
50 B-STR
mg I-STR
PO B-ROU
BID B-FRE
: I-FRE
PRN O
pain B-REA

 I-REA
18 O
. O
Metoprolol B-DRUG
Succinate I-DRUG
XL I-DRUG
200 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
19 O
. O
Nitroglycerin B-DRUG
SL B-FOR
0.3 B-STR
mg I-STR
SL B-ROU
PRN B-FRE
chest B-REA
pain I-REA

 I-REA
take O
one B-DOS
tab B-FOR
under B-ROU
your I-ROU
tongue I-ROU
if O
you O
have O
chest B-REA
pain I-REA
. I-REA
[ O
* O
* O
Month O
( O
only O
) O
116 O
* O
* O
] O

 O
repeat O
up O
to O
three B-DUR
times I-DUR
, I-DUR
five O
minutes O
apart O
. O
Please O
call O
9 O
- O
1 O
- O
1 O

 O
if O
your O
chest O
pain O
persists O
. O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital O
2255 O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
2256 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Lower O
GI O
Bleed O



 O

Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
Dear O
Ms. O
[ O
* O
* O
Known O
lastname O
21056 O
* O
* O
] O
: O


 O
It O
was O
a O
pleasure O
to O
take O
care O
of O
you O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
. O
  O
You O
were O
seen O

 O
in O
the O
hospital O
because O
of O
a O
gastrointestinal O
bleed O
, O
likely O

 O
secondary O
to O
a O
high O
INR O
. O
  O
Your O
coumadin B-DRUG
was O
held O
and O
you O
were O

 O
transfused O
with O
multiple O
units O
of O
blood O
. O
  O
Your O
blood O
counts O
then O

 O
remained O
stable O
. O
  O
You O
will O
likely O
need O
to O
follow O
up O
with O
an O

 O
outpatient O
gastroenterologist O
for O
a O
colonosocpy O
at O
some O
point O
in O

 O
the O
next O
several O
months O
. O


 O
We O
made O
the O
following O
changes O
to O
your O
medications O
: O

 O
STOP O
Coumadin B-DRUG
- O
You O
should O
have O
a O
conversation O
with O
your O
primary O

 O
care O
doctor O
about O
when O
you O
should O
restart O
this O
medication O
given O

 O
your O
bleed O

 O
DECREASE O
aspirin B-DRUG
to O
81 B-STR
mg I-STR
daily B-FRE

 I-FRE
START O
pantoprazole B-DRUG
40 B-STR
mg I-STR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
STOP O
Omeprazole B-DRUG



 I-DRUG
Followup O
Instructions O
: O

 O
You O
need O
to O
make O
an O
appointment O
to O
see O
your O
primary O
care O
doctor O

 O
within O
the O
next O
week O
. O



                              O
[ O
* O
* O
Name6 O
( O
MD O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(2 O
) O
2764 O
* O
* O
] O


 O
Completed O
by:[**2148 O
- O
7 O
- O
9 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2134 O
- O
4 O
- O
19 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2134 O
- O
5 O
- O
11 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2061 O
- O
11 O
- O
2 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
12131 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Hypotension O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Endoscopy O

 O
Sigmoidoscopy O

 O
Portacath O
removal O

 O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
catheter O
placement O

 O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O



 O
History O
of O
Present O
Illness O
: O

 O
72 O
M O
with O
pmh O
significant O
for O
metastatic O
rectal O
cancer O
was O
at O

 O
radiology O
clinic O
receiving O
scheduled O
imaging O
when O
blood B-REA
pressure I-REA

 I-REA
at I-REA
triage I-REA
recorded I-REA
60/40 I-REA
. I-REA
Recheck O
was O
70/40 O
. O
His O
port O
was O

 O
accessed O
and O
he O
was O
bolused B-DOS
with O
300cc B-DOS
of O
IVF B-DRUG
and O
transferred O
to O

 O
the O
ED O
. O
He O
denied O
syncope O
or O
lightheadedness O
but O
reported O
mild O

 O
SOB O
and O
fatigue O
. O
He O
reports O
having O
several O
days O
of O
diahrrea O
, O

 O
which O
began O
last O
wednesday O
[ O
* O
* O
4 O
- O
14 O
* O
* O
] O
. O
His O
last O
dose O
of O
irinotecan B-DRUG
and O

 O
panitumab B-DRUG
chemotherapy B-DRUG
was O
Monday O
[ O
* O
* O
2134 O
- O
3 O
- O
29 O
* O
* O
] O
( O
patient O
reports O
was O

 O
[ O
* O
* O
4 O
- O
12 O
* O
* O
] O
but O
not O
recorded O
in O
OMR O
) O
, O
and O
he O
reports O
always O
getting O

 O
diahrrea B-ADE
with O
his O
chemotherapy B-DRUG
. I-DRUG
He O
reports O
haveing O
watery B-REA
bowel I-REA

 I-REA
movements I-REA
roughly O
every O
45 O
minutes O
since O
wednesday O
. O
HIs O
bowel O

 O
movements O
are O
not O
bloody O
or O
melanaic O
. O
He O
has O
been O
taking O

 O
immodium B-DRUG
and O
diphenoxylate-atropine B-DRUG
without O
improvement O
. O
Sunday O

 O
night O
, O
he O
reports O
acute O
worsening O
of O
his O
diahrrea O
, O
which O

 O
continued O
through O
Monday O
. O
EMS O
gave O
him O
another O
500cc B-STR
of O
NS B-DRUG
prior O

 O
to O
arrival O
to O
the O
ED O
. O

 O
. O

 O
On O
arrival O
to O
the O
ED O
his O
vitals O
were O
98.0 O
100/50 O
83 O
18 O
100%RA O
. O

 O
Cr O
was O
1.3 O
from O
1.1 O
. O
Hct O
was O
27.3 O
. O
Mg O
was O
0.8 O
mg O
. O
He O
was O
guaiac O

 O
negative O
. O
CT O
torso O
was O
without O
PE O
or O
dissection O
, O
but O
did O
have O

 O
multiple O
stable O
pulmonary O
nodules O
, O
and O
a O
small O
right O
pleural O

 O
effusion O
. O
He O
also O
had O
stable O
metastatic O
disease O
. O
EKG O
was O
sinus O

 O
in O
the O
70 O
's O
. O
He O
was O
given O
3L B-DOS
of O
NS B-DRUG
and O
4 B-STR
grams I-STR
of O
Mg B-DRUG
. I-DRUG

 O
. O

 O
Review O
of O
Systems O
: O

 O
( O
+ O
) O
Per O
HPI O

 O
. O

 O
He O
is O
denying O
fevers O
, O
abdominal O
pain O
, O
chest O
pain O
, O
hematochezia O
, O

 O
melena O
. O



 O

Past O
Medical O
History O
: O

 O
Past O
Oncologic O
History O
: O

 O
Adenocarcinoma O
of O
the O
rectum O

 O
- O
[ O
* O
* O
6-/2131 O
* O
* O
] O
: O
  O
The O
patient O
presented O
with O
a O
change O
in O
bowel O
habits O

 O
and O
was O
noted O
to O
have O
an O
abnormal O
rectal O
exam O
by O
his O
primary O

 O
care O

 O
physician O
, O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
39262 O
* O
* O
] O
[ O
* O
* O
Name O
Initial O
( O
NameIs O
) O
* O
* O
] O
gastrointestinal O
evaluation O
. O

 O
- O
[ O
* O
* O
2131 O
- O
7 O
- O
23 O
* O
* O
] O
colonoscopy O
: O
  O
Exophytic O
cancer O
of O
the O
rectum O
[ O
* O
* O
9 O
- O
9 O
* O
* O
] O

 O
cm O

 O
above O
the O
anal O
margin O
. O
  O
Polyp O
noted O
at O
the O
anorectal O
junction O
. O

 O
Biopsy O
: O
  O
Invasive O
, O
moderately O
differentiated O
adenocarcinoma O

 O
arising O
in O
association O
with O
adenoma O
. O
Polyp O
: O
  O
Adenoma O
with O

 O
high-grade O
dysplasia O
. O

 O
- O
[ O
* O
* O
2131 O
- O
7 O
- O
25 O
* O
* O
] O
rectal O
ultrasound O
: O
  O
T3 O
posterior O
midline O
tumor O
with O

 O
luminal O
narrowing O
of O
the O
rectum O
. O

 O
- O
[ O
* O
* O
2131 O
- O
8 O
- O
2 O
* O
* O
] O
CT O
scan O
of O
the O
torso O
: O
  O
Irregular O
, O
polypoid O
lesion O

 O
seen O
within O
the O
rectum O
, O
with O
multiple O
subcentimeter O
presacral O

 O
and O

 O
pericolic O
lymph O
nodes O
identified O
. O
  O
Two O
pulmonary O
nodules O
seen O
in O

 O
the O
left O
lower O
lobe O
, O
the O
largest O
measuring O
2.9 O
x O
2.2 O
cm O
. O

 O
Multiple O

 O
low-attenuation O
lesions O
seen O
within O
the O
liver O
, O
the O

 O
largest O
of O
which O
may O
represent O
cyst O
, O
smaller O
lesions O
are O
not O

 O
fully O
characterized O
. O
  O
Low-attenuation O
lesions O
seen O
within O
the O

 O
left O
kidney O
, O
possibly O
a O
cyst O
, O
although O
too O
small O
to O

 O
characterize O
. O

 O
Per O
report O
, O
a O
CT O
PET O
performed O
elsewhere O
demonstrated O
uptake O
in O

 O
the O
left O
base O
of O
the O
lung O
. O

 O
- O
[ O
* O
* O
2131 O
- O
8 O
- O
14 O
* O
* O
] O
to O
[ O
* O
* O
2131 O
- O
9 O
- O
25 O
* O
* O
] O
: O
  O
Neoadjuvant O
chemoradiation O
with O

 O
continuous O
5-FU O
at O
225 O
mg/m2/day O
and O
radiation O
therapy O
five O
days O

 O
weekly O
. O

 O
- O
[ O
* O
* O
2131 O
- O
12 O
- O
10 O
* O
* O
] O
: O
  O
Proctosigmoidectomy O
with O
stapled O
coloanal O

 O
anastomosis O
and O
diverting O
loop O
ileostomy O
. O
  O
Pathology O
revealed O

 O
adenocarcinoma O
of O
the O
rectum O
, O
low-grade O
, O
with O
invasion O
into O
the O

 O
perirectal O
adipose O
tissue O
and O
metastasis O
to O
7 O
of O
13 O
regional O

 O
lymph O
nodes O
( O
T3N2 O
) O
. O
  O
The O
resection O
margins O
were O
uninvolved O
. O

 O
- O
[ O
* O
* O
2132 O
- O
1 O
- O
28 O
* O
* O
] O
PET O
Scan O
: O
Interval O
progression O
of O
disease O
with O
an O

 O
increase O
in O
the O
size O
of O
the O
previously O
identified O

 O
lung O
metastasis O
. O
There O
is O
a O
new O
FDG-avid O
focus O
in O
segment O
4A O
of O

 O
the O
liver O
which O
most O
likely O
represents O
metastasis O
. O

 O

- O
[ O
* O
* O
2132 O
- O
2 O
- O
13 O
* O
* O
] O
: O
Ileostomy O
takedown O
with O
simultaneous O
flexible O

 O
bronchoscopy O
and O
VATS O
with O
left O
lower O
lobe O
resection O
. O
  O
Pathology O

 O
from O
the O
ileostomy O
stoma O
demonstrated O
no O
evidence O
of O
malignancy O
. O


 O
The O
left O
lower O
lobe O
wedge O
resection O
demonstrated O
an O

 O
adenocarcinoma O
, O
4.1 O
cm O
, O
consistent O
with O
metastasis O
of O
rectal O

 O
origin O
. O
  O
The O
pleural O
and O
apparent O
stapled O
margins O
were O
free O
of O

 O
malignancy O
. O

 O
- O
[ O
* O
* O
2132 O
- O
2 O
- O
14 O
* O
* O
] O
: O
Evaluation O
by O
the O
hepatobiliary O
surgery O
consult O

 O
team O
due O
to O
the O
finding O
on O
his O
recent O
PET O
scan O
of O
a O
likely O
liver O

 O
metastasis O
. O
It O
was O
felt O
that O
the O
lesion O
was O
amenable O
to O
surgical O

 O
resection O
, O
and O
it O
was O
planned O
that O
the O
patient O
would O
undergo O
two O

 O
cycles O
of O
chemotherapy O
prior O
to O
proceeding O
with O
hepatic O

 O
resection O
. O

 O
- O
[ O
* O
* O
2132 O
- O
4 O
- O
9 O
* O
* O
] O
: O
FOLFOX B-DRUG
chemotherapy I-DRUG
initiated O
. O
The O
patient O
completed O

 O
two B-DOS
cycles O
of O
therapy O
on O
[ O
* O
* O
2132 O
- O
6 O
- O
3 O
* O
* O
] O
. O

 O
- O
[ O
* O
* O
2132 O
- O
7 O
- O
11 O
* O
* O
] O
: O
Hepatic O
resection O
of O
a O
1.7 O
cm O
segment O
4a O
metastatic O

 O
lesion O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
. O

 O
- O
[ O
* O
* O
2132 O
- O
10 O
- O
22 O
* O
* O
] O
: O
Cycle O
1 O
Day O
1 O
5FU/LV B-DRUG
for O
further O
adjuvant O

 O
chemotherapy B-DRUG
. I-DRUG
Oxaliplatin B-DRUG
eliminated O
due O
to O
neuropathy B-ADE
. I-ADE
The O

 O
patient O
completed O
therapy O
in O
[ O
* O
* O
1 O
- O
5 O
* O
* O
] O
. O

 O
- O
[ O
* O
* O
2132 O
- O
11 O
- O
26 O
* O
* O
] O
: O
Hospital O
admission O
for O
SVC B-REA
syndrome I-REA
secondary O
to O
a O

 O
catheter-associated O
thrombus O
causing O
occlusion O
of O
the O
SVC O
and O

 O
bilateral O
brachiocephalic O
veins O
. O
The O
patient O
underwent O
TPA O

 O
infusion O
followed O
by O
venous O
angioplasty O
with O
balloon O
dilation O

 O
with O
resolution O
of O
symptoms O
. O
He O
was O
discharged O
on O
enoxaparin B-DRUG
. I-DRUG

 O
- O
[ O
* O
* O
2133 O
- O
8 O
- O
3 O
* O
* O
] O
: O
Initiation O
of O
ininotecan B-DRUG
for O
recurrent B-REA
disease I-REA
. I-REA

 O
- O
[ O
* O
* O
2134 O
- O
2 O
- O
8 O
* O
* O
] O
: O
Due O
to O
laboratory O
and O
radiographic O
evidence O
of O

 O
disease O

 O
progression O
, O
cetuximab B-DRUG
was O
added O
to O
ininotecan B-DRUG
; I-DRUG
due O
to O
an O

 O
allergic B-REA
reaction I-REA
, I-REA
cetuximab B-DRUG
was O
changed O
to O
panitumumab B-DRUG
on O

 O
[ O
* O
* O
2134 O
- O
2 O
- O
16 O
* O
* O
] O
. O


 O
. O

 O
Other O
Past O
Medical O
History O
: O

 O
1 O
. O
  O
Hypertension O
. O

 O
2 O
. O
  O
Hyperlipidemia O
. O

 O
3 O
. O
  O
ASCVD O
, O
status O
post O
MI O
in O
[ O
* O
* O
2111 O
* O
* O
] O
. O

 O
4 O
. O
  O
Status O
post O
appendectomy O
. O

 O
5 O
. O
  O
Diabetes O



 O
Social O
History O
: O

 O
The O
patient O
lives O
alone O
and O
is O
divorced O
. O
  O
He O
has O

 O
three O
sons O
in O
their O
40s O
. O
  O
He O
is O
a O
construction O
inspector O
. O
  O
He O

 O
denies O
alcohol O
use O
and O
drug O
use O
. O
  O
He O
smoked O
one O
pack O
of O

 O
cigarettes O
daily O
for O
30 O
years O
before O
quitting O
. O


 O
Family O
History O
: O

 O
The O
patient O
's O
paternal O
uncle O
had O
an O
abdominal O

 O
cancer O
, O
details O
unknown O
. O
  O
His O
father O
died O
of O
an O
MI O
. O
  O
His O
mother O

 O
died O
of O
[ O
* O
* O
Name O
( O
NI O
) O
2481 O
* O
* O
] O
disease O
. O
  O
He O
has O
two O
brothers O
who O
are O
well O
. O


 O
Physical O
Exam O
: O

 O
Admission O
: O

 O
GEN O
: O
awake O
, O
alert O
, O
NAD O

 O
VS O
: O
97.6 O
110/46 O
88 O
19 O
100 O
% O
2L O

 O
HEENT O
: O
EOMI O
, O
MMM O

 O
CV O
: O
irregularly O
irregular O
, O
no O
m/g/r O

 O
PULM O
: O
crackles O
at O
RLL O

 O
ABD O
: O
well O
healed O
scars O
on O
abdomen O
, O
soft O
, O
NT O
, O
ND O

 O
LIMBS O
: O
no O
edema O

 O
SKIN O
: O
erythema O
and O
excoriation O
over O
left O
antecubital O
fossa O
. O


 O
Discharge O
: O

 O
GEN O
: O
NAD O
, O
aaox3 O

 O
HEENT O
: O
MMM O
, O
oropharynx O
clear O
. O

 O
CV O
: O
RRR O
, O
No O
m/r/g O

 O
PULM O
: O
CTAB O
, O
decreased O
breath O
sounds O
at O
bases O
. O
Tunneled O
[ O
* O
* O
Name O
( O
NI O
) O
2286 O
* O
* O
] O

 O
catheter O
noted O
on O
right O
chest O
, O
c/d/i O

 O
ABD O
: O
Soft O
, O
distended O
, O
NT O
, O
+ O
BS O
. O

 O
EXTR O
: O
2 O
+ O
bilateral O
lower O
extremity O
edema O
, O
2 O
+ O
bilateral O
upper O

 O
extremity O
edema O
, O
left O
> O
right O
2 O
+ O
DP O
pulses O
bilaterally O
. O

 O
SKIN O
: O
blanching O
macules O
noted O
scattered O
across O
forearms O
and O

 O
upper O
back O
. O


 O
Pertinent O
Results O
: O

 O
Admission O
labs O
: O

 O
[ O
* O
* O
2134 O
- O
4 O
- O
19 O
* O
* O
] O
11:35AM O
BLOOD O
WBC-2.8 O
* O
RBC-3.30 O
* O
Hgb-9.3 O
* O
Hct-27.3 O
* O

 O
MCV-83 O
MCH-28.3 O
MCHC-34.2 O
RDW-20.0 O
* O
Plt O
Ct-283 O

 O
[ O
* O
* O
2134 O
- O
4 O
- O
19 O
* O
* O
] O
11:35AM O
BLOOD O
PT-14.0 O
* O
PTT-35.5 O
* O
INR(PT)-1.2 O
* O

 O
[ O
* O
* O
2134 O
- O
4 O
- O
19 O
* O
* O
] O
11:35AM O
BLOOD O
Glucose-199 O
* O
UreaN-23 O
* O
Creat-1.3 O
* O
Na-139 O

 O
K-4.0 O
Cl-106 O
HCO3 O
- O
22 O
AnGap-15 O

 O
[ O
* O
* O
2134 O
- O
4 O
- O
19 O
* O
* O
] O
11:35AM O
BLOOD O
Calcium-8.3 O
* O
Phos-2.4 O
* O
Mg-0.8 O
* O

 O
. O

 O
Discharge O
labs O
: O


 O
Micro O
: O

 O
[ O
* O
* O
4 O
- O
20 O
* O
* O
] O
: O

 O
CLOSTRIDIUM O
DIFFICILE O
TOXIN O
A O
& O
B O
TEST O
( O
Final O
[ O
* O
* O
2134 O
- O
4 O
- O
21 O
* O
* O
] O
) O
: O

       O
Feces O
negative O
for O
C.difficile O
toxin O
A O
& O
B O
by O
EIA O
. O

            O
( O
Reference O
Range-Negative O
) O
. O


    O
FECAL O
CULTURE O
( O
Final O
[ O
* O
* O
2134 O
- O
4 O
- O
22 O
* O
* O
] O
) O
: O
    O
NO O
SALMONELLA O
OR O
SHIGELLA O

 O
FOUND O
. O


    O
CAMPYLOBACTER O
CULTURE O
( O
Final O
[ O
* O
* O
2134 O
- O
4 O
- O
22 O
* O
* O
] O
) O
: O
    O
NO O
CAMPYLOBACTER O

 O
FOUND O
. O

 O
. O


 O
[ O
* O
* O
2134 O
- O
5 O
- O
4 O
* O
* O
] O
12:58 O
am O
STOOL O
     O
CONSISTENCY O
: O
SOFT O
      O
Source O
: O

 O
Stool O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2134 O
- O
5 O
- O
4 O
* O
* O
] O
* O
* O


    O
CLOSTRIDIUM O
DIFFICILE O
TOXIN O
A O
& O
B O
TEST O
( O
Final O
[ O
* O
* O
2134 O
- O
5 O
- O
4 O
* O
* O
] O
) O
: O

       O
Feces O
negative O
for O
C.difficile O
toxin O
A O
& O
B O
by O
EIA O
. O

            O
( O
Reference O
Range-Negative O
) O
. O


 O
[ O
* O
* O
2134 O
- O
4 O
- O
27 O
* O
* O
] O
11:47 O
am O
CATHETER O
TIP-IV O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2134 O
- O
4 O
- O
29 O
* O
* O
] O
* O
* O


    O
GRAM O
STAIN O
( O
Final O
[ O
* O
* O
2134 O
- O
4 O
- O
27 O
* O
* O
] O
) O
: O

       O
TEST O
CANCELLED O
, O
PATIENT O
CREDITED O
. O

       O
INAPPROPRIATE O
SPECIMEN O
FOR O
GRAM O
STAIN O
. O


    O
WOUND O
CULTURE O
( O
Final O
[ O
* O
* O
2134 O
- O
4 O
- O
29 O
* O
* O
] O
) O
: O

       O
STAPH O
AUREUS O
COAG O
+ O
. O
    O
> O
15 O
colonies O
. O

          O
Staphylococcus O
species O
may O
develop O
resistance O
during O

 O
prolonged O

          O
therapy O
with O
quinolones O
. O
   O
Therefore O
, O
isolates O
that O
are O

 O
initially O

          O
susceptible O
may O
become O
resistant O
within O
three O
to O
four O

 O
days O
after O

          O
initiation O
of O
therapy O
. O
  O
Testing O
of O
repeat O
isolates O
may O

 O
be O

          O
warranted O
. O


                               O
SENSITIVITIES O
: O
MIC O
expressed O
in O

 O
MCG/ML O


 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

                              O
STAPH O
AUREUS O
COAG O
+ O

                              O
| O

 O
CLINDAMYCIN-----------<=0.25 B-DRUG
S O

 O
ERYTHROMYCIN----------<=0.25 B-DRUG
S O

 O
GENTAMICIN------------ B-DRUG
< O
= O
0.5 O
S O

 O
LEVOFLOXACIN----------<=0.12 B-DRUG
S O

 O
OXACILLIN------------- B-DRUG
   O
0.5 O
S O

 O
TRIMETHOPRIM/SULFA---- B-DRUG
< O
= O
0.5 O
S O


 O
[ O
* O
* O
2134 O
- O
4 O
- O
24 O
* O
* O
] O
2:47 O
pm O
BLOOD O
CULTURE O
      O
Source O
: O
Line-PICC O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2134 O
- O
4 O
- O
29 O
* O
* O
] O
* O
* O


    O
Blood O
Culture O
, O
Routine O
( O
Final O
[ O
* O
* O
2134 O
- O
4 O
- O
29 O
* O
* O
] O
) O
: O

       O
STAPH O
AUREUS O
COAG O
+ O
. O

          O
SENSITIVITIES O
PERFORMED O
ON O
CULTURE O
# O
294 O
- O
1510A O

 O
[ O
* O
* O
2134 O
- O
4 O
- O
23 O
* O
* O
] O
. O

          O
Consultations O
with O
ID O
are O
recommended O
for O
all O
blood O

 O
cultures O

          O
positive O
for O
Staphylococcus O
aureus O
and O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
564 O
* O
* O
] O
species O
. O


       O
STAPH O
AUREUS O
COAG O
+ O
. O
    O
SECOND O
MORPHOLOGY O
. O

          O
Consultations O
with O
ID O
are O
recommended O
for O
all O
blood O

 O
cultures O

          O
positive O
for O
Staphylococcus O
aureus O
and O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
564 O
* O
* O
] O
species O
. O



          O
Staphylococcus O
species O
may O
develop O
resistance O
during O

 O
prolonged O

          O
therapy O
with O
quinolones O
. O
   O
Therefore O
, O
isolates O
that O
are O

 O
initially O

          O
susceptible O
may O
become O
resistant O
within O
three O
to O
four O

 O
days O
after O

          O
initiation O
of O
therapy O
. O
  O
Testing O
of O
repeat O
isolates O
may O

 O
be O

          O
warranted O
. O


                               O
SENSITIVITIES O
: O
MIC O
expressed O
in O

 O
MCG/ML O


 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

                              O
STAPH O
AUREUS O
COAG O
+ O

                              O
| O

 O
CLINDAMYCIN-----------<=0.25 B-DRUG
S O

 O
ERYTHROMYCIN----------<=0.25 B-DRUG
S O

 O
GENTAMICIN------------ B-DRUG
< O
= O
0.5 O
S O

 O
LEVOFLOXACIN---------- B-DRUG
  O
0.25 O
S O

 O
OXACILLIN------------- B-DRUG
     O
1 O
S O

 O
TRIMETHOPRIM/SULFA---- B-DRUG
< O
= O
0.5 O
S O


    O
Anaerobic O
Bottle O
Gram O
Stain O
( O
Final O
[ O
* O
* O
2134 O
- O
4 O
- O
26 O
* O
* O
] O
) O
: O

       O
GRAM O
POSITIVE O
COCCI O
IN O
PAIRS O
AND O
CLUSTERS O
. O


    O
Aerobic O
Bottle O
Gram O
Stain O
( O
Final O
[ O
* O
* O
2134 O
- O
4 O
- O
26 O
* O
* O
] O
) O
: O

       O
GRAM O
POSITIVE O
COCCI O
IN O
CLUSTERS O
. O


 O
[ O
* O
* O
4 O
- O
19 O
* O
* O
] O
ECG O
: O

 O
Sinus O
rhythm O
with O
ventricular O
premature O
beat O
. O
Right O

 O
bundle-branch O
block O
. O
Since O

 O
the O
previous O
tracing O
of O
[ O
* O
* O
2132 O
- O
11 O
- O
27 O
* O
* O
] O
inferior O
lead O
Q O
waves O
are O
less O

 O
prominent O
. O

 O
. O

 O
[ O
* O
* O
4 O
- O
19 O
* O
* O
] O
CT O
torso O
: O

 O
1 O
. O
No O
evidence O
of O
pulmonary O
embolism O
or O
dissection O
. O
Multiple O

 O
small O
pulmonary O

 O
nodules O
are O
overall O
stable O
in O
size O
. O
Stable O
small O
right-sided O

 O
pleural O

 O
effusion O
. O


 O
2 O
. O
Stable O
extent O
of O
metastatic O
disease O
in O
the O
abdomen O
. O


 O
3 O
. O
Two O
small O
ventral O
wall O
hernias O
containing O
loops O
of O
small O

 O
bowel O
, O
but O
no O

 O
evidence O
of O
obstruction O
with O
oral O
contrast O
seen O
to O
the O
colon O
. O


 O
4 O
. O
Cholelithiasis O
. O

 O
. O

 O
[ O
* O
* O
2134 O
- O
4 O
- O
26 O
* O
* O
] O
RUE O
ultrasound O
. O


 O
INDICATION O
: O
72-year-old O
man O
with O
swollen O
left O
arm O
and O
left-sided O

 O
Port-A-Cath O
. O


 O
COMPARISON O
: O
None O
. O


 O
TECHNIQUE O
: O
Grayscale O
and O
Doppler O
evaluation O
of O
left O
upper O

 O
extremity O
. O


 O
FINDINGS O
: O
Grayscale O
and O
Doppler O
evaluation O
of O
the O
left O
internal O

 O
jugular O
, O

 O
subclavian O
, O
axillary O
, O
basilic O
, O
and O
brachial O
veins O
demonstrate O

 O
normal O
flow O
, O

 O
compressibility O
, O
and O
response O
to O
augmentation O
wherever O

 O
applicable O
. O
No O

 O
intraluminal O
thrombus O
was O
identified O
. O


 O
IMPRESSION O
: O
No O
evidence O
of O
DVT O
in O
the O
left O
upper O
extremity O
. O


 O
[ O
* O
* O
2134 O
- O
4 O
- O
27 O
* O
* O
] O
renal O
ultrasound O
: O


 O
INDICATION O
: O
72 O
year O
old O
man O
with O
acute O
kidney O
failure O
and O

 O
sepsis O
. O


 O
COMPARISON O
: O
CTA O
chest O
performed O
[ O
* O
* O
2134 O
- O
4 O
- O
19 O
* O
* O
] O
. O



 O
RENAL O
ULTRASOUND O
: O
The O
left O
kidney O
measures O
10.9 O
cm O
. O
The O
right O

 O
kidney O

 O
measures O
10.7 O
cm O
. O
There O
is O
no O
hydronephrosis O
, O
stone O
or O
mass O
in O

 O
either O
kidney O
. O

 O
The O
bladder O
is O
unremarkable O
. O


 O
IMPRESSION O
: O
Unremarkable O
renal O
ultrasound O
without O
evidence O
of O

 O
hydronephrosis O
. O



 O
Brief O
Hospital O
Course O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
1683 O
* O
* O
] O
is O
a O
72 O
yo O
M O
with O
h/o O
metastatic O
rectal O
CA O
and O
SVC B-REA

 I-REA
syndrome I-REA
, I-REA
now O
resolved O
on O
lovenox B-DRUG
tx O
, O
who O
was O
admitted O
to O
OMED O

 O
on O
[ O
* O
* O
4 O
- O
19 O
* O
* O
] O
with O
intractable B-ADE
diarrhea I-ADE
thought O
[ O
* O
* O
3 O
- O
2 O
* O
* O
] O
chemo B-DRUG
and O

 O
transferred O
to O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
on O
[ O
* O
* O
4 O
- O
24 O
* O
* O
] O
with O
BRBPR O
and O
hematemesis O
. O
GI O

 O
was O
consulted O
and O
an O
EGD O
was O
performed O
on O
[ O
* O
* O
4 O
- O
24 O
* O
* O
] O
which O
showed O

 O
diffuse B-REA
erythema/ulceration I-REA
, I-REA
in I-REA
esophagus I-REA
, I-REA
stomach I-REA
, I-REA
duodenum I-REA
. I-REA

 O
This O
was O
thought O
due O
to O
irinotecan B-DRUG
induced O
GI B-ADE
toxicity I-ADE
. I-ADE
  O
They O

 O
recommended O
PPI B-DRUG
and O
carafate B-DRUG
slurry B-FOR
. I-FOR
  O
They O
were O
concerned O
that O

 O
patient O
's O
whole O
GI O
tract O
was O
diffusely O
inflamed O
as O
was O
seen O
on O

 O
EGD O
and O
that O
the O
anastamotic O
site O
from O
his O
colectomy O
might O
be O
a O

 O
bleeding O
source O
; O
a O
flex O
sigmoidoscopy O
was O
done O
on O
as O
well O
and O

 O
showed O
as O
well O
diffuse O
ulceration O
and O
inflammation B-REA
. I-REA
HCTs O
and O
q6H O

 O
hemodynamics O
remained O
stable O
throughout O
his O
hospital O
course O
. O

 O
The O
patient O
was O
started O
on O
steroid B-DRUG
enemas B-FOR
and O
mesalamine B-DRUG

 I-DRUG
suppositories B-FOR
to O
decrease O
inflammation B-REA
. I-REA
  O
The O
steroid B-DRUG
enemas B-FOR
were O

 O
discontinued O
, O
but O
the O
mesalamine B-DRUG
suppositories B-FOR
were O
continued O

 O
through O
to O
discharge O
. O
  O
In O
total O
, O
he O
received O
3 B-DOS
units I-DOS
PRBCs B-DRUG
and O
2 O

 O
units O
of O
FFP B-DRUG
. I-DRUG
Stool O
cultures O
revealed O
no O
evidence O
of O
infection O
. O

 O
. O

 O
On O
[ O
* O
* O
4 O
- O
24 O
* O
* O
] O
, O
the O
patient O
was O
found O
to O
have O
that O
2/2 O
bottles O
of O
his O

 O
blood O
cultures O
drawn O
from O
his O
portacath O
were O
growing O
GPCs O
, O

 O
speciation O
showed O
MSSA O
. O
He O
was O
treated O
for O
this O
with O
IV B-ROU

 I-ROU
vancomycin B-DRUG
, I-DRUG
leaving O
the O
portacath O
and O
PICC O
in O
place O
. O
Daily O

 O
surveillance O
blood O
cultures O
were O
performed O
and O
he O
was O
noted O
to O

 O
clear O
his O
bacteremia B-REA
on O
[ O
* O
* O
4 O
- O
26 O
* O
* O
] O
. O
  O
Infectious O
diseases O
was O
consulted O

 O
and O
the O
patient O
was O
switched O
to O
nafcillin B-DRUG
with O
confirmation O
of O

 O
MSSA B-REA
. I-REA
  O
The O
port-a-cath O
was O
removed O
which O
was O
the O
source O
of O

 O
infection O
. O



 O
The O
patient O
however O
despite O
aggressive O
crystalloid B-DRUG
and O
colloid B-DRUG

 I-DRUG
( O
albumin B-DRUG
, I-DRUG
a O
further O
2 B-DOS
units I-DOS
of O
blood B-DRUG
) I-DRUG
resuscitation B-REA
then O

 O
developed O
sepsis O
related O
acute O
tubular O
necrosis O
. O
  O
The O
patient O

 O
became O
anuric O
and O
nephrology O
was O
consulted O
. O
  O
Hemodialysis O
was O

 O
initiated O
which O
the O
patient O
tolerated O
well O
, O
and O
a O
permanent O

 O
tunneled O
catheter O
line O
was O
placed O
on O
[ O
* O
* O
2134 O
- O
5 O
- O
7 O
* O
* O
] O
. O
  O
The O
patient O
was O

 O
started O
on O
phosphate B-DRUG
binders I-DRUG
, I-DRUG
nephrocaps B-DRUG
and O
erythropoeitin B-DRUG

 I-DRUG
dosed O
at O
hemodialysis O
. O
  O
The O
carafate B-DRUG
was O
discontinued O
due O
to O

 O
risk O
of O
aluminum B-ADE
toxicity I-ADE
. I-ADE
  O
The O
nafcillin B-DRUG
was O
also O
changed O
to O

 O
Cefazolin B-DRUG
dosed O
2 B-STR
mg I-STR
at O
each O
[ O
* O
* O
Date O
Range O
2286 O
* O
* O
] O
session O
for O
ease B-REA
of I-REA

 I-REA
administration I-REA
and O
avoiding B-REA
extra I-REA
volume I-REA
loading I-REA
. I-REA
  O
Should O
the O

 O
patient O
miss O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
2286 O
* O
* O
] O
session O
, O
extra O
doses O
of O
cefazolin B-DRUG
should O

 O
be O
administered O
as O
needed O
. O
  O
The O
patient O
was O
planned O
for B-DUR
a I-DUR
28 I-DUR
day I-DUR

 I-DUR
course I-DUR
of O
cefazolin B-DRUG
to O
be O
finished O
on O
[ O
* O
* O
2134 O
- O
5 O
- O
22 O
* O
* O
] O
. O

 O
. O

 O
Other O
parts O
of O
his O
hospitalization O
are O
outlined O
by O
problem O

 O
below O
: O

 O
. O

 O
# O
Hypotension/Tachycardia O
: O
In O
setting O
of O
extensive O
diahrrea O
. O
Ct O

 O
torso O
is O
without O
PE O
or O
dissection O
. O
His O
BP O
initally O
recovered O

 O
with O
500cc B-DOS
NS B-DRUG
bolus B-DOS
. I-DOS
  O
Once O
he O
had O
an O
episode O
of O
BRBPR O
, O
he O
became O

 O
tacycardic B-REA
to I-REA
the I-REA
140s I-REA
, I-REA
with O
BP B-REA
90s/60s I-REA
. I-REA
  O
He O
was O
bolused B-DOS
NS B-DRUG
and O

 O
given O
PRBC B-DRUG
with O
improved O
HR O
to O
the O
110s O
, O
and O
BP O
to O
120s/80s O
. O

 O
. O

 O
# O
SVC O
syndrome O
: O
occurred O
in O
[ O
* O
* O
2132 O
* O
* O
] O
. O
s/p O
TPA O
infusion O
followed O
by O

 O
venous O
angioplasty O
with O
balloon O
dilation O
with O
resolution O
of O

 O
symptoms O
. O
  O
He O
was O
initially O
treated O
with O
lovenox B-DRUG
( O
dose O

 O
recalculated O
this O
admission O
, O
should O
be O
lower O
than O
his O
admission O

 O
dose O
) O
, O
but O
this O
was O
held O
secondary O
to O
GI O
bleed O
. O
  O
This O
was O
not O

 O
restarted O
at O
discharge O
given O
the O
patient O
's O
renal O
failure O
. O

 O
. O

 O
# O
Diarrhea B-REA
- O
the O
patient O
continued O
to O
have O
diarrhea O
that O
was O

 O
controlled O
with O
titration O
of O
his O
anti-diarrheal B-DRUG
medications I-DRUG
. I-DRUG

 O
Infectious O
sources O
were O
ruled O
out O
and O
the O
cause O
was O
likely O

 O
irinotecan-induced B-DRUG
GI B-ADE
toxicity I-ADE
and O
radiation B-ADE
proctitis I-ADE
. I-ADE



 O
# O
Generalized O
anasarca O
- O
The O
patient O
was O
noted O
to O
have O
an O

 O
extremely O
low O
albumin O
on O
admission O
, O
likely O
related O
to O
poor O

 O
nutrition O
due O
to O
his O
GI O
pathology O
. O
  O
Albumins O
ranged O
between O
2.7 O

 O
and O
1.9 O
. O
  O
During O
volume O
resuscitation O
the O
patient O
became O
grossly O

 O
edematous O
, O
and O
albumin O
was O
administered O
to O
little O
effect O
. O
  O
His O

 O
left O
upper O
extremity O
was O
noted O
to O
be O
more O
edematous O
than O
the O

 O
rest O
of O
his O
body O
, O
and O
a O
LUE O
ultrasound O
was O
acquired O
. O
  O
This O

 O
demonstrated O
no O
evidence O
of O
clot O
. O
  O
The O
patient O
slowly O
became O

 O
less O
edematous O
when O
[ O
* O
* O
Year O
( O
4 O
digits O
) O
2286 O
* O
* O
] O
was O
initiated O
and O
ultrafiltration O

 O
was O
started O
. O


 O
Mr. O
[ O
* O
* O
Known O
lastname O
1683 O
* O
* O
] O
' O
code O
status O
was O
confirmed O
as O
FULL O
CODE O
  O
this O
hospital O

 O
admission O
. O



 O
Medications O
on O
Admission O
: O

 O
DIPHENOXYLATE-ATROPINE B-DRUG
- O
2.5 B-STR
mg-0.025 I-STR
mg I-STR
Tablet B-FOR
- O
[ O
* O
* O
1 O
- O
30 O
* O
* O
] O
Tablet(s B-FOR
) I-FOR


 I-FOR
by B-ROU
mouth I-ROU
q6hr B-FRE
as I-FRE
needed I-FRE
for O
diarrhea B-REA

 I-REA
ENOXAPARIN B-DRUG
[ O
LOVENOX B-DRUG
] I-DRUG
- O
150 B-STR
mg/mL I-STR
Syringe B-FOR
- O
Inject B-FOR
150 B-STR
mg I-STR
once O
a O


 O
day O

 O
LISINOPRIL B-DRUG
- O
( O
Prescribed O
by O
Other O
Provider O
) O
- O
10 B-STR
mg I-STR
Tablet B-FOR
- O
1 B-DOS

 I-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
daily B-FRE

 I-FRE
METOPROLOL B-DRUG
SUCCINATE I-DRUG
[ O
TOPROL B-DRUG
XL I-DRUG
] I-DRUG
- O
( O
Prescribed O
by O
Other O

 O
Provider O
) O
- O
100 B-STR
mg I-STR
Tablet B-FOR
Sustained I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
- O
1 B-DOS
Tablet(s B-FOR
) I-FOR


 I-FOR
by B-ROU
mouth I-ROU
daily B-FRE

 I-FRE
METRONIDAZOLE B-DRUG
[ O
METROGEL B-DRUG
] I-DRUG
- O
1 O
% O
Gel B-FOR
- O
apply O
to O
rash B-REA
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
PROCHLORPERAZINE B-DRUG
MALEATE I-DRUG
- O
10 B-STR
mg I-STR
Tablet B-FOR
- O
1 B-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU

 I-ROU
q6hr B-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA

 I-REA
SIMVASTATIN B-DRUG
- O
( O
Prescribed O
by O
Other O
Provider O
) O
- O
20 B-STR
mg I-STR
Tablet B-FOR
- O
1 B-DOS


 I-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
daily B-FRE

 I-FRE
LOPERAMIDE B-DRUG
[ O
IMODIUM B-DRUG
A-D I-DRUG
] I-DRUG
- O
2 B-STR
mg I-STR
Tablet B-FOR
- O
2 B-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU

 I-ROU
q4he B-FRE
as I-FRE
needed I-FRE
for O
diarrhea B-REA

 I-REA
PYRIDOXINE B-DRUG
- O
( O
OTC O
) O
- O
50 B-STR
mg I-STR
Tablet B-FOR
- O
2 B-DOS
Tablet(s B-FOR
) O
by B-ROU
mouth I-ROU
once O
a O


 O
day O



 O
Discharge O
Medications O
: O

 O
1 O
. O
Diphenoxylate-Atropine B-DRUG
2.5 B-STR
- I-STR
0.025 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR

 I-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
diarrhea B-REA
. I-REA

 O
2 O
. O
Compazine B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE

 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
. I-REA

 O
3 O
. O
Simvastatin B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
4 O
. O
Loperamide B-DRUG
2 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
every B-FRE
four I-FRE

 I-FRE
( I-FRE
4 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
diarrhea B-REA
. I-REA

 O
5 O
. O
Pyridoxine B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
6 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE

 I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
0.02 B-STR
% I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
neb B-FOR

 I-FOR
Inhalation B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
shortness B-REA
of I-REA
breath I-REA

 I-REA
or O
wheezing B-REA
. I-REA

 O
8 O
. O
Simethicone B-DRUG
80 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Chewable I-FOR
PO B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
bloating B-REA
, I-REA
gas B-REA
. I-REA

 O
9 O
. O
Heparin B-DRUG
Flush B-FOR
( O
10 B-STR
units/ml I-STR
) I-STR
2 B-DOS
mL I-DOS
IV B-ROU
PRN B-FRE
line B-FOR
flush I-FOR

 I-FOR
PICC B-ROU
, I-ROU
heparin B-DRUG
dependent O
: O
Flush B-FOR
with O
10mL B-DOS
Normal B-DRUG
Saline I-DRUG
followed O

 O
by O
Heparin B-DRUG
as O
above O
daily B-FRE
and O
PRN B-FRE
per O
lumen O
. O

 O
10 O
. O
Ondansetron B-DRUG
4 B-STR
mg I-STR
IV B-ROU
Q8H B-FRE
: I-FRE
PRN I-FRE
nausea B-REA

 I-REA
11 O
. O
Prochlorperazine B-DRUG
10 B-STR
mg I-STR
IV B-ROU
Q6H B-FRE
: I-FRE
PRN I-FRE
nausea B-REA

 I-REA
12 O
. O
CefazoLIN B-DRUG
2 B-STR
g I-STR
IV B-ROU
HD O
PROTOCOL O

 O
HD O
protocol O
, O
to O
be O
given O
during O
hemodialysis O

 O
13 O
. O
Diphenoxylate-Atropine B-DRUG
2.5 B-STR
- I-STR
0.025 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
diarrhea B-REA
. I-REA

 O
14 O
. O
Calcium B-DRUG
Acetate I-DRUG
667 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
TID B-FRE

 I-FRE
W/MEALS I-FRE
( I-FRE
3 I-FRE
TIMES I-FRE
A I-FRE
DAY I-FRE
WITH I-FRE
MEALS I-FRE
) I-FRE
. I-FRE

 O
15 O
. O
B B-DRUG
Complex-Vitamin I-DRUG
C-Folic I-DRUG
Acid I-DRUG
1 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Cap B-FOR

 I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
16 O
. O
Heparin B-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
1,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
4000-[**Numeric B-DOS
Identifier O
2249 O
* O
* O
] O

 O
Unit B-FOR
Injection B-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
line B-REA
flush I-REA
: I-REA
DWELL O

 O
PRN B-FRE
line B-REA
flush I-REA

 I-REA
[ O
* O
* O
Numeric O
Identifier O
* O
* O
] O
Catheter O
( O
Tunneled O
2-Lumen O
) O
: O
[ O
* O
* O
Numeric O
Identifier O
* O
* O
] O
NURSE O
ONLY O
: O

 O
Withdraw O
4 O
mL O
prior O
to O
flushing B-FOR
with O
10 B-DOS
mL I-DOS
NS B-DRUG
followed O
by O

 O
Heparin B-DRUG
as O
above O
according O
to O
volume O
per O
lumen O
. O

 O
. O


 O
17 O
. O
Insulin B-DRUG
Lispro I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
Sliding B-DOS
scale I-DOS
units O

 O
Subcutaneous B-ROU
ASDIR B-FRE
( I-FRE
AS I-FRE
DIRECTED I-FRE
) I-FRE
: I-FRE
2 O
units O
for O
101 O
- O
150 O

 O
4 O
units O
for O
151 O
- O
200 O

 O
6 O
units O
for O
201 O
- O
250 O

 O
8 O
units O
for O
251 O
- O
300 O

 O
10 O
units O
for O
301 O
- O
350 O

 O
12 O
units O
for O
351 O
- O
400 O
. O

 O
18 O
. O
Mesalamine B-DRUG
1,000 B-STR
mg I-STR
Suppository B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Suppository B-FOR

 I-FOR
Rectal B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
19 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FRE
, I-FRE
Delayed I-FRE
Release I-FRE
( I-FRE
E.C. I-FRE
) I-FRE
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
20 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( I-STR
0.083 I-STR
% I-STR
) I-STR
Solution B-FOR
for I-FOR

 I-FOR
Nebulization I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
nebulizer B-FOR
Inhalation B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
dyspnea B-REA
. I-REA

 O
21 O
. O
Epogen B-DRUG
10,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
Hemodialysis O
  O
Protocol O

 O
Injection B-FOR
with O
each O
[ O
* O
* O
Numeric O
Identifier O
2286 O
* O
* O
] O
session O
. O

 O
22 O
. O
Heparin B-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
5,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
mL B-FOR

 I-FOR
Injection B-FOR
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
979 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
246 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Rectal O
cancer O

 O
Diarrhea O

 O
Sepsis O

 O
Acute O
Renal O
Failure O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
hospital O
with O
diarrhea O
. O
We O
believe O
the O

 O
diarrhea B-ADE
was O
a O
side O
effect O
of O
the O
chemotherapy B-DRUG
you O
had O
received O
; O

 O
it O
was O
treated O
with O
3 O
anti-diarrheal B-DRUG
medications I-DRUG
. I-DRUG
You O
also O
have O

 O
a O
low O
blood O
pressure O
on O
admission O
, O
this O
was O
likely O
due O
to O

 O
dehydration O
in O
the O
setting O
of O
diarrhea O
, O
and O
it O
improved O
with O

 O
rehydration B-REA
with O
IV B-ROU
fluids B-DRUG
. I-DRUG
Your O
diarrhea O
then O
became O
bloody O
, O

 O
and O
you O
also O
had O
an O
episode O
of O
vomit O
with O
blood O
in O
it O
. O
As O
a O

 O
result O
, O
you O
were O
transferred O
to O
the O
ICU O
. O
  O
You O
had O
an O
upper O

 O
endoscopy O
and O
a O
sigmoidoscopy O
, O
which O
showed O
ulceration B-ADE
in I-ADE
your I-ADE

 I-ADE
esophagus I-ADE
, I-ADE
stomach I-ADE
and I-ADE
colon I-ADE
. I-ADE
  O
This O
was O
thought O
to O
be O
due O
to O
the O

 O
chemotherapy B-DRUG
and O
radiation O
that O
you O
have O
been O
receiving O
for O
your O

 O
colon B-REA
cancer I-REA
. I-REA

 O
. O

 O
While O
admitted O
, O
you O
also O
had O
a O
severe O
bacterial O
infection O
that O

 O
got O
into O
your O
blood O
. O
  O
This O
severely O
damaged O
your O
kidneys O
, O

 O
requiring O
you O
to O
be O
started O
on O
hemodialysis O
. O
  O
You O
had O
a O

 O
permanent O
[ O
* O
* O
Location O
( O
un O
) O
2286 O
* O
* O
] O
catheter O
placed O
and O
you O
will O
need O
to O
continue O

 O
getting O
[ O
* O
* O
Location O
( O
un O
) O
2286 O
* O
* O
] O
3 O
times O
a O
week O
. O



 O
You O
were O
started O
on O
several O
new O
medications O
when O
you O
were O

 O
admitted O
. O


 O
Nephrocaps B-DRUG
1 B-DOS
capsule B-FOR
daily B-FRE

 I-FRE
Phos-lo B-DRUG
667 B-STR
mg I-STR
three B-FOR
times I-FOR
a I-FOR
day I-FOR

 I-FOR
mesalamine B-DRUG
1000 B-STR
mg I-STR
suppositories B-FOR
once B-FRE
a I-FRE
day I-FRE

 I-FRE
Cefazolin B-DRUG
2 B-STR
g I-STR
given O
with O
hemodialysis O

 O
pantoprazole B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
Erythropoetin B-DRUG
given O
with O
hemodialysis O


 O
Your O
metoprolol B-DRUG
was O
changed O
from O
100 B-STR
mg I-STR
once B-FRE
a I-FRE
day I-FRE
to O
25 B-STR
mg I-STR
three B-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE


 I-FRE
Your O
lisinopril B-DRUG
and O
enoxaparin B-DRUG
have O
been O
discontinued O
. O



 O
Followup O
Instructions O
: O

 O
You O
need O
to O
follow O
up O
with O
your O
outpatient O
oncologists O
, O
Drs O
. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
and O
[ O
* O
* O
Name5 O
( O
PTitle O
) O
* O
* O
] O
[ O
* O
* O
Name5 O
( O
PTitle O
) O
* O
* O
] O
discuss O
any O
further O
treatment O
for O
you O

 O
rectal O
cancer O
. O


 O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
636 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
and O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
in O
Colorectal O
Cancer O
Clinic O
on O

 O
[ O
* O
* O
5 O
- O
31 O
* O
* O
] O
at O
10 O
AM O
. O
You O
can O
reach O
the O
office O
by O
calling O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
22249 O
* O
* O
] O
. O


 O
Provider O
: O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
2747 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
5780 O
* O
* O
] O
, O
RN O
Phone:[**Telephone/Fax O
( O
1 O
) O
22 O
* O
* O
] O

 O
Date/Time:[**2134 O
- O
5 O
- O
24 O
* O
* O
] O
10:00 O




 O
Completed O
by:[**2134 O
- O
5 O
- O
12 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2163 O
- O
4 O
- O
16 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2163 O
- O
4 O
- O
25 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2131 O
- O
9 O
- O
11 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
NEUROSURGERY O


 O
Allergies O
: O

 O
Azithromycin B-DRUG
/ O
Rocephin B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
78 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Headache O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
CEREBRAL O
ANGIOGRAM O



 O
History O
of O
Present O
Illness O
: O

 O
31 O
year O
old O
hispanic O
male O
who O
was O
in O
usual O
state O
of O
health O
until O

 O
day O
of O
admission O
. O
  O
He O
was O
doing O
stretching O
exercises O
at O
the O

 O
local O
gym O
when O
he O
had O
a O
sudden O
onset O
of O
headache O
. O
  O
He O
went O
to O
an O

 O
OSH O
where O
CT O
scan O
demonstrated O
subarachnoid O
hemorrhage O
. O
He O
was O

 O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
further O
eval O
. O


 O
Past O
Medical O
History O
: O

 O
DM O
type O
I O


 O
Social O
History O
: O

 O
employed O

 O
engaged O
- O
planning O
a O
wedding O
for O
this O
[ O
* O
* O
Month O
( O
only O
) O
216 O
* O
* O
] O

 O
rare O
tob O
, O
no O
ETOH O
, O
no O
drugs O
or O
steroids O
however O
admits O
to O
taking O

 O
a O
" O
white O
pill O
" O
a O
week O
prior O
to O
admission O
for O
weight O
gain O
. O
  O
He O

 O
does O
not O
know O
the O
makeup O
of O
the O
pill O
and O
states O
he O
only O
took O
it O

 O
once O
. O


 O
Family O
History O
: O

 O
non O
contibutory O


 O
Physical O
Exam O
: O

 O
98 O
96 O
161/69 O
16 O
100 O
% O
RA O

 O
AAOx3 O
NAD O

 O
RRR O

 O
CTAB O

 O
soft O
NT/ND O

 O
no O
edema O
extrem O
warm O

 O
CN O
II-XII O

 O
Motor O
5 O
+ O
upper O
and O
lower O
extrem O

 O
coordination O
intact O

 O
sensation O
equal O
and O
intact O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
Known O
lastname O
81043**],[**Known O
firstname O
* O
* O
] O
[ O
* O
* O
Medical O
Record O
Number O
81044 O
* O
* O
] O
M O
  O
[ O
* O
* O
2070 O
- O
9 O
- O
25 O
* O
* O
] O


 O
Radiology O
Report O
CTA O
HEAD O
W&W/O O
C O
& O
RECONS O
Study O
Date O
of O

 O
[ O
* O
* O
2163 O
- O
4 O
- O
16 O
* O
* O
] O
2:11 O
PM O



 O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
EU O
   O
[ O
* O
* O
2163 O
- O
4 O
- O
16 O
* O
* O
] O
2:11 O
PM O

 O
CTA O
HEAD O
W&W/O O
C O
& O
RECONS O
   O
Clip O
# O
[ O
* O
* O
Clip O
Number O
( O
Radiology O
) O
81045 O
* O
* O
] O

 O
Reason O
: O
? O
aneurysmal O
bleed O

 O
Contrast O
: O
OPTIRAY O
Amt O
: O
80 O




 O
[ O
* O
* O
Hospital O
93 O
* O
* O
] O
MEDICAL O
CONDITION O
: O

    O
31 O
year O
old O
man O
with O
hx O
of O
sudden O
onset O
worst O
HA O
of O
life O
, O

 O
mod/lg O
SAH O
on O
OSH O

    O
non-con O
CT O
head O
. O

 O
REASON O
FOR O
THIS O
EXAMINATION O
: O

    O
? O
aneurysmal O
bleed O

 O
CONTRAINDICATIONS O
FOR O
IV B-ROU
CONTRAST B-DRUG
: I-DRUG

    O
None O
. O




 O

Wet O
Read O
: O
AKSb O
SAT O
[ O
* O
* O
2163 O
- O
4 O
- O
16 O
* O
* O
] O
5:25 O
PM O

 O
Focal O
SAH O
in O
the O
perimesencephalic O
and O
prepontine O
cisterns O
. O
No O

 O
definite O

 O
aneurysm O
or O
AVM O
identified O
. O
Possible O
etiologies O
include O

 O
perimesencephalic O

 O
( O
venous O
) O
bleed O
, O
or O
AVM/aneurysm O
obscured O
by O
hemorrhage O
. O
d/w O

 O
Neurosurg O
. O



 O
Final O
Report O

 O
INDICATION O
: O
31-year-old O
with O
history O
of O
sudden O
onset O
worst O

 O
headache O
of O
life O

 O
with O
moderate O
subarachnoid O
hemorrhage O
on O
outside O
hospital O
CT O
. O

 O
Evaluate O
for O

 O
aneurysm O
. O


 O
No O
prior O
examinations O
available O
for O
comparison O
. O


 O
TECHNIQUE O
: O
Non-contrast O
CT O
of O
the O
head O
was O
performed O
, O
followed O

 O
by O
enhanced O

 O
CTA O
of O
the O
circle O
of O
[ O
* O
* O
Location O
( O
un O
) O
431 O
* O
* O
] O
including O
multiplanar O
and O

 O
volume-rendered O
images O
. O


 O
NON-CONTRAST O
HEAD O
CT O
: O
There O
is O
high O
attenuation O
focal O
hemorrhage O

 O
within O
the O
perimesencephalic O
and O
prepontine O
cisterns O
. O
No O

 O
extension O
of O
hemorrhage O
within O
the O
ventricles O
and O
no O
evidence O
of O

 O
hydrocephalus O
. O
No O
additional O
foci O
of O
subarachnoid O
hemorrhage O
. O

 O
High O
attenuation O
area O
along O
the O
left O
tentorium O

 O
likely O
represents O
a O
sagittal O
sinus O
( O
2:11 O
) O
. O
The O
visualized O

 O
paranasal O
sinuses O
and O
mastoid O
air O
cells O
are O
normally O
pneumatized O

 O
and O
aerated O
. O


 O
CTA O
: O
The O
visualized O
course O
of O
intracranial O
carotid O
and O
vertebral O

 O
arteries O
and O
their O
major O
branches O
are O
normal O
. O
There O
is O
no O

 O
evidence O
of O
stenosis O
, O
occlusion O
, O
or O
aneurysm O
formation O
. O


 O
IMPRESSION O
: O
Focal O
subarachnoid O
hemorrhage O
within O
the O

 O
perimesencephalic O
and O

 O
prepontine O
cisterns O
, O
without O
a O
definite O
aneurysm O
seen O
on O
the O

 O
CTA O
. O
Differential O
considerations O
included O
a O
perimesencephalic O

 O
( O
venous O
) O
hemorrhage O
or O
an O
occult O
aneurysm O
or O
AVM O
. O


 O
Findings O
were O
discussed O
with O
the O
neurosurgical O
team O
at O
the O
time O

 O
of O
the O
exam O
. O



 O
The O
study O
and O
the O
report O
were O
reviewed O
by O
the O
staff O
radiologist O
. O





 O
[ O
* O
* O
Known O
lastname O
81043**],[**Known O
firstname O
* O
* O
] O
[ O
* O
* O
Medical O
Record O
Number O
81044 O
* O
* O
] O
M O
  O
[ O
* O
* O
2070 O
- O
9 O
- O
25 O
* O
* O
] O


 O
Radiology O
Report O
MRA O
NECK O
W&W/O O
CONTRAST O
Study O
Date O
of O
[ O
* O
* O
2163 O
- O
4 O
- O
17 O
* O
* O
] O

 O
12:39 O
PM O



 O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
742 O
* O
* O
] O
NSURG O
SICU-A O
[ O
* O
* O
2163 O
- O
4 O
- O
17 O
* O
* O
] O
12:39 O
PM O

 O
MR O
HEAD O
W O
& O
W/O O
CONTRAST O
; O
MRA O
BRAIN O
W/O O
CONTRAST O
; O
MRA O
NECK O
W&W/O O

 O
CONTRAST O
   O
Clip O
# O
[ O
* O
* O
Clip O
Number O
( O
Radiology O
) O
81046 O
* O
* O
] O

 O
Reason O
: O
eval O
for O
bleed O

 O
Contrast B-DRUG
: I-DRUG
MAGNEVIST B-DRUG
Amt O
: O
20 B-DOS




 I-DOS

[ O
* O
* O
Hospital O
93 O
* O
* O
] O
MEDICAL O
CONDITION O
: O

    O
31 O
M O
bodybuilder O
, O
stritching O
yesterday O
he O
had O
sudden O
onset O

 O
HA O
. O
CT O
at O
OSH O
shows O
     O
SAH O
. O
No O
other O
complaints O
or O
deficits O
. O

 O
Loaded O
dilantin B-DRUG
and O
given O
nimodpine B-DRUG
at O
     O
OSH O
. O
Transferred O
to O

 O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
further O
management O
. O
Angio O
neg O
for O
aneurysm O

 O
REASON O
FOR O
THIS O
EXAMINATION O
: O

    O
eval O
for O
bleed O

 O
CONTRAINDICATIONS O
FOR O
IV B-ROU
CONTRAST B-DRUG
: I-DRUG

    O
None O
. O




 O
Provisional O
Findings O
Impression O
: O
DFDkq O
SUN O
[ O
* O
* O
2163 O
- O
4 O
- O
17 O
* O
* O
] O
6:12 O
PM O

 O
Subarachnoid O
hemorrhage O
in O
the O
perimesencephalic O
and O
prepontine O

 O
cisterns O
, O
as O
well O
as O
in O
the O
sulci O
of O
both O
convexities O
. O
Normal O

 O
MRA O
of O
the O
neck O
. O
MRA O
of O
the O
head O
is O
slightly O
limited O
by O
motion O
, O

 O
but O
no O
aneurysms O
are O
identified O
. O



 O
Final O
Report O

 O
INDICATION O
: O
Subarachnoid O
hemorrhage O
. O


 O
COMPARISON O
: O
Head O
CTA O
performed O
on O
[ O
* O
* O
2163 O
- O
4 O
- O
16 O
* O
* O
] O
and O

 O
conventional O
cerebral O

 O
angiogram O
performed O
on O
[ O
* O
* O
2163 O
- O
4 O
- O
16 O
* O
* O
] O
. O


 O
TECHNIQUE O
: O
Sagittal O
T1-weighted O
and O
axial O
T1-weighted O
, O

 O
T2-weighted O
, O
FLAIR O
, O

 O
gradient O
echo O
, O
and O
diffusion-weighted O
images O
of O
the O
head O
. O

 O
Three-dimensional O
time-of-flight O
MRA O
of O
the O
head O
. O
Dynamic O

 O
coronal O
VIBE O
imaging O
of O
the O
neck O
obtained O
during O
intravenous B-ROU

 I-ROU
gadolinium B-DRUG
administration O
. O
Following O
intravenous B-ROU
gadolinium B-DRUG

 I-DRUG
administration O
, O
multiplanar O
T1-weighted O
images O
of O
the O
head O
were O

 O
obtained O
. O


 O
HEAD O
MRI O
: O
T1 O
isointense O
and O
T2 O
hypointense O
blood O
products O
are O

 O
seen O
in O
the O

 O
perimesencephalic O
and O
prepontine O
cisterns O
, O
corresponding O
to O
the O

 O
subarachnoid O
hemorrhage O
seen O
on O
the O
non-contrast O
portion O
of O
the O

 O
preceding O
head O
CTA O
. O
In O
addition O
, O
there O
is O
high O
signal O
in O
the O

 O
sulci O
on O
FLAIR O
images O
involving O
the O
right O
frontal O
, O
bilateral O

 O
parietal O
, O
and O
bilateral O
occipital O
lobes O
. O
This O
is O
consistent O
with O

 O
additional O
subarachnoid O
hemorrhage O
which O
is O
occult O
by O
CT O
. O
There O

 O
is O
no O
evidence O
of O
edema O
, O
infarction O
, O
mass O
or O
other O
pathologic O

 O
enhancement O
in O
the O
brain O
. O
There O
is O
no O
evidence O
of O
a O
meningeal O

 O
mass O
. O
The O
ventricles O
are O
normal O
in O
size O
and O
configuration O
. O


 O
NECK O
MRA O
: O
The O
cervical O
common O
carotid O
, O
internal O
carotid O
, O
and O

 O
vertebral O

 O
arteries O
appear O
normal O
. O
The O
distal O
cervical O
internal O
carotid O

 O
arteries O
measure O
at O
least O
4 O
mm O
in O
diameter O
. O


 O
HEAD O
MRA O
: O
The O
study O
is O
slightly O
limited O
by O
artifacts O
. O
Flow O
is O

 O
seen O
in O
the O

 O
intracranial O
internal O
carotid O
and O
vertebral O
arteries O
, O
and O
their O

 O
major O

 O
branches O
, O
without O
evidence O
of O
stenoses O
or O
aneurysms O
. O


 O
IMPRESSION O
: O


 O
1 O
. O
Subarachnoid O
hemorrhage O
in O
the O
basal O
cisterns O
as O
well O
as O
in O

 O
the O
cerebral O
sulci O
. O


 O
2 O
. O
Normal O
neck O
MRA O
. O


 O
3 O
. O
Unremarkable O
head O
MRA O
. O




 O

[ O
* O
* O
Known O
lastname O
81043**],[**Known O
firstname O
* O
* O
] O
[ O
* O
* O
Medical O
Record O
Number O
81044 O
* O
* O
] O
M O
  O
[ O
* O
* O
2070 O
- O
9 O
- O
25 O
* O
* O
] O


 O
Radiology O
Report O
CHEST O
( O
PORTABLE O
AP O
) O
Study O
Date O
of O
[ O
* O
* O
2163 O
- O
4 O
- O
18 O
* O
* O
] O
4:27 O

 O
AM O



 O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
742 O
* O
* O
] O
NSURG O
SICU-A O
[ O
* O
* O
2163 O
- O
4 O
- O
18 O
* O
* O
] O
4:27 O
AM O

 O
CHEST O
( O
PORTABLE O
AP O
) O
   O
Clip O
# O
[ O
* O
* O
Clip O
Number O
( O
Radiology O
) O
81047 O
* O
* O
] O

 O
Reason O
: O
eval O
for O
infiltrate O




 O
[ O
* O
* O
Hospital O
93 O
* O
* O
] O
MEDICAL O
CONDITION O
: O

    O
31 O
year O
old O
man O
with O
SAH O
, O
w/ O
dark O
sputum O
and O
intermittent O

 O
low-normal O
O2 O

    O
saturation O
. O
To O
eval O
for O
infiltrate O
. O

 O
REASON O
FOR O
THIS O
EXAMINATION O
: O

    O
eval O
for O
infiltrate O




 O
Preliminary O
Addendum O

 O
Preliminary O
reports O
are O
not O
available O
for O
viewing O
. O


 O
DR O
. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
2618 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
2619 O
* O
* O
] O


 O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
742 O
* O
* O
] O
NSURG O
SICU-A O
[ O
* O
* O
2163 O
- O
4 O
- O
18 O
* O
* O
] O
4:27 O
AM O

 O
CHEST O
( O
PORTABLE O
AP O
) O
   O
Clip O
# O
[ O
* O
* O
Clip O
Number O
( O
Radiology O
) O
81047 O
* O
* O
] O

 O
Reason O
: O
eval O
for O
infiltrate O




 O
[ O
* O
* O
Hospital O
93 O
* O
* O
] O
MEDICAL O
CONDITION O
: O

    O
31 O
year O
old O
man O
with O
SAH O
, O
w/ O
dark O
sputum O
and O
intermittent O

 O
low-normal O
O2 O

    O
saturation O
. O
To O
eval O
for O
infiltrate O
. O

 O
REASON O
FOR O
THIS O
EXAMINATION O
: O

    O
eval O
for O
infiltrate O




 O
Final O
Report O

 O
REASON O
FOR O
EXAMINATION O
: O
Decrease O
in O
saturations O
in O
a O
patient O

 O
with O

 O
subarachnoid O
hemorrhage O
. O


 O
Portable O
AP O
chest O
radiograph O
was O
reviewed O
with O
no O
comparison O
to O

 O
the O
prior O

 O
studies O
. O
There O
is O
a O
large O
opacity O
in O
the O
left O
lower O
lung O
most O

 O
likely O

 O
involving O
the O
left O
lower O
lobe O
and O
lingula O
. O
There O
is O
additional O

 O
opacity O
in O
the O
right O
lower O
lobe O
. O
The O
findings O
are O
concerning O
for O

 O
bilateral O
aspiration O
or O
multifocal O
pneumonia O
. O
Slight O
left O

 O
ventricle O
engorgement O
is O
present O
also O
may O
be O
projectional O
due O
to O

 O
the O
position O
of O
this O
film O
. O
No O
appreciable O
pleural O
effusion O
is O

 O
demonstrated O
. O





 O
Brief O
Hospital O
Course O
: O

 O
Pt O
was O
admitted O
through O
the O
emergency O
room O
after O
transfer O
from O

 O
OSH O
for O
perimesencephalic O
hemorrhage O
after O
working O
out O
at O
gym O
. O


 O
Pt O
was O
placed O
on O
dilantin B-DRUG
and O
nimodipine B-DRUG
and O
and O
a-line O
was O

 O
placed O
. O
Systolic O
BP O
was O
controlled O
to O
less O
than O
140 O
. O
A O
cerebral O

 O
angiogram O
was O
done O
on O
[ O
* O
* O
2163 O
- O
4 O
- O
17 O
* O
* O
] O
which O
was O
negative O
for O
aneurysm O
. O



 O
A O
CXR O
was O
done O
on O
[ O
* O
* O
2163 O
- O
4 O
- O
18 O
* O
* O
] O
for O
low O
O2 O
sats O
and O
dark O
sputum O
. O
  O
The O

 O
findings O
were O
suggestive O
of O
pneumonia O
vs. O
aspiration O
however O
the O

 O
pt O
is O
afebrile O
without O
elevated O
WBC O
, O
so O
no O
antibiotics B-DRUG
were O

 O
started O
at O
this O
time O
. O
  O
A O
blood O
gas O
was O
obtained O
that O
showed O

 O
poosr O
oxygenation O
. O
  O
This O
was O
discussed O
with O
the O
ICU O
attending O

 O
and O
CTA O
of O
the O
chest O
was O
then O
oobtained O
without O
evidence O
of O
PE O
. O

 O
Pt O
was O
supported O
on O
increasing O
amounts O
of O
O2 O
throughout O
the O

 O
night O
and O
on O
the O
am O
  O
of O
[ O
* O
* O
2163 O
- O
4 O
- O
19 O
* O
* O
] O
it O
was O
decided O
that O
he O
would O

 O
need O
ventilatory O
support O
. O
  O
Prior O
to O
intubation O
he O
was O
mentating O

 O
well O
and O
his O
neuro O
exm O
remianed O
stable O
. O
  O
Consent O
for O
HIV O
testing O

 O
was O
obtained O
and O
found O
to O
be O
negative O
. O
  O
Bronchoscopy O
for O
sputum O

 O
culture O
and O
or O
mucous O
plugging O
was O
performed O
. O
Lasix B-DRUG
gtt B-ROU
was O

 O
started O
for O
ARDS B-REA
treatment I-REA
. I-REA
He O
required O
mechanical O
ventilation O

 O
and O
was O
weaned O
to O
room O
air O
on O
[ O
* O
* O
4 O
- O
20 O
* O
* O
] O
a O
CXR O
showed O
improved O

 O
bibasilar O
opacities O
prior O
to O
transfer O
to O
floor O
. O


 O
He O
was O
monitored O
on O
the O
surgical O
floor O
for O
3 O
days O
and O
had O
a O

 O
repeat O
CTA O
which O
showed O
a O

 O
Normal O
CT O
of O
the O
head O
with O
no O
evidence O
of O
aneurysm O
formation O
. O

 O
Mild O
vasospasm O

 O
is O
noted O
at O
the O
distal O
basilar O
artery O
. O
He O
was O
cleared O
for O

 O
discharge O
he O
had O
no O
focal O
neurological O
deficits O
on O
discharge O
and O

 O
his O
headache O
was O
minimal O
. O
The O
patient O
felt O
comfortable O
managing O

 O
his O
diabetes O
as O
to O
his O
prior O
regiman O
. O
He O
was O
sent O
with O
a O

 O
prescription O
of O
Levaquin B-DRUG
to O
finish O
his O
treatment O
of O
his O

 O
pneumonia B-REA
. I-REA



 O
Medications O
on O
Admission O
: O

 O
lantus B-DRUG
, I-DRUG
novuloge B-DRUG
, I-DRUG

 O
body O
building O
proteins O
and O
supplements O



 O
Discharge O
Medications O
: O

 O
1 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Capsule(s O
) O
* O
Refills:*2 O
* O

 O
2 O
. O
Butalbital-Acetaminophen-Caff B-DRUG
50 B-STR
- I-STR
325 I-STR
- I-STR
40 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
[ O
* O
* O
1 O
- O
28 O
* O
* O
] O

 O
Tablets B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
headache B-REA
: I-REA
DO O
NOT O

 O
DRIVE O
WHILE O
TAKING O
THIS O
MEDICATION O
. O

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
3 O
. O
Phenytoin B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
Four B-DOS
( I-DOS
4 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Chewable I-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
: I-FRE
YOU O
WERE O
PRESCRIBED O
THIS O

 O
MEDICATION O
TO O
PREVENT B-REA
SEIZURE I-REA
. I-REA
  O
DO O
NOT O
STOP O
TAKING O
IT O
UNLESS O

 O
DIRECTED O
BY O
A O
PHYSICIAN O
. O
. O

 O
Disp:*360 O
Tablet O
, O
Chewable(s O
) O
* O
Refills:*2 O
* O

 O
4 O
. O
Outpatient O
Lab O
Work O

 O
DILANTIN B-DRUG
LEVEL O
FRIDAY O
[ O
* O
* O
2163 O
- O
3 O
- O
30 O
* O
* O
] O

 O
PLEASE O
FAX O
RESULTS O
TO O
PTS O
PRIMARY O
CARE O
OFFICE O
. O

 O
5 O
. O
Nimodipine B-DRUG
30 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE

 I-FRE
hours I-FRE
) I-FRE
for B-DUR
12 I-DUR
days I-DUR
: I-DUR
do O
not O
stop O
taking O
htis O
medication O
on O
your O

 O
own O
.... O
you O
must O
complete O
the O
full O
course O
prescribed O
for O
you O
. O

 O
Disp:*144 O
Capsule(s O
) O
* O
Refills:*0 O
* O

 O
6 O
. O
Levofloxacin B-DRUG
250 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q24H B-FRE

 I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
for B-DUR
3 I-DUR
days I-DUR
. I-DUR

 O
Disp:*9 O
Tablet(s O
) O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Perimesencaphalic O
hemorrhage O

 O
Respiratory O
failure/hypoxia O
  O
requiring O
mechanical O
ventilation O

 O
Pneumonia O
= O
Community O
aquired O

 O
Hyperglycemia O
= O
DM O
I O

 O
MEDICATION O
REACTION O
/ O
NEW O
ALLERGY O
TO O
AZITHROMYCIN B-DRUG
AND O
ROCEPHIN B-DRUG



 I-DRUG
Discharge O
Condition O
: O

 O
NEUROLOGICALLY O
STABLE O



 O
Discharge O
Instructions O
: O

 O
Angiogram O


 O
YOU O
HAVE O
BEEN O
PRESCRIBED O
DILANTIN B-DRUG
FOR O
SEIZURE B-REA
CONTROL I-REA
. I-REA
  O
DO O
NOT O

 O
STOP O
TAKING O
THIS O
ON O
YOUR O
OWN O
. O
  O
YOUR O
PRIMARY O
CARE O
PHYSICIAN O
WILL O

 O
FOLLOW O
YOUR O
LEVELS O
. O
YOUR O
FIRST O
LEVEL O
TO O
BE O
DRAWN O
IS O
IN O
5 O
DAYS O

 O
? O
? O
? O
? O
? O
? O
	 O
Continue O
all O
other O
medications O
you O
were O
taking O
before O
, O
unless O

 O
otherwise O
directed O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
make O
take O
Tylenol B-DRUG
or O
prescribed O
pain B-DRUG
medications I-DRUG
for O
any O

 O
post B-REA
procedure I-REA
pain I-REA
or O
discomfort O



 O
What O
activities O
you O
can O
and O
can O
not O
do O
: O

 O
? O
? O
? O
? O
? O
? O
	 O
When O
you O
go O
home O
, O
you O
may O
walk O
and O
go O
up O
and O
down O
stairs O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
may O
shower O
( O
let O
the O
soapy O
water O
run O
over O
groin O
incision O
, O

 O
rinse O
and O
pat O
dry O
) O

 O
? O
? O
? O
? O
? O
? O
	 O
Your O
groin O
site O
should O
be O
well O
healed O
at O
this O
point O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
No O
heavy O
lifting O
, O
pushing O
or O
pulling O
( O
greater O
than O
5 O
lbs O
) O
for O

 O
1 O
week O
( O
to O
allow O
groin O
puncture O
to O
heal O
) O

 O
? O
? O
? O
? O
? O
? O
	 O
After O
1 O
week O
, O
you O
may O
resume O
sexual O
activity O

 O
? O
? O
? O
? O
? O
? O
	 O
After O
1 O
week O
, O
gradually O
increase O
your O
activities O
and O
distance O

 O
walked O
as O
you O
can O
tolerate O

 O
? O
? O
? O
? O
? O
? O
	 O
No O
driving O
until O
you O
are O
no O
longer O
taking O
pain O
medications O

 O
- O
You O
should O
not O
return O
to O
work O
for O
one O
week O

 O
What O
to O
report O
to O
office O
: O

 O
? O
? O
? O
? O
? O
? O
	 O
Changes O
in O
vision O
( O
loss O
of O
vision O
, O
blurring O
, O
double O
vision O
, O

 O
half O
vision O
) O

 O
? O
? O
? O
? O
? O
? O
	 O
Slurring O
of O
speech O
or O
difficulty O
finding O
correct O
words O
to O
use O

 O
? O
? O
? O
? O
? O
? O
	 O
Severe O
headache O
or O
worsening O
headache O
not O
controlled O
by O
pain O

 O
medication O

 O
? O
? O
? O
? O
? O
? O
	 O
A O
sudden O
change O
in O
the O
ability O
to O
move O
or O
use O
your O
arm O
or O
leg O

 O
or O
the O
ability O
to O
feel O
your O
arm O
or O
leg O

 O
? O
? O
? O
? O
? O
? O
	 O
Trouble O
swallowing O
, O
breathing O
, O
or O
talking O

 O
? O
? O
? O
? O
? O
? O
	 O
Numbness O
, O
coldness O
or O
pain O
in O
lower O
extremities O

 O
? O
? O
? O
? O
? O
? O
	 O
Temperature O
greater O
than O
101.5F O
for O
24 O
hours O

 O
? O
? O
? O
? O
? O
? O
	 O
New O
or O
increased O
drainage O
from O
incision O
or O
white O
, O
yellow O
or O

 O
green O
drainage O
from O
incisions O

 O
? O
? O
? O
? O
? O
? O
	 O
Bleeding O
from O
groin O
puncture O
site O


 O
* O
SUDDEN O
, O
SEVERE O
BLEEDING O
OR O
SWELLING O

 O
( O
Groin O
puncture O
site O
) O

 O
Lie O
down O
, O
keep O
leg O
straight O
and O
have O
someone O
apply O
firm O
pressure O

 O
to O
area O
for O
10 O
minutes O
. O
If O
bleeding O
stops O
, O
call O
our O
office O
. O
If O

 O
bleeding O
does O
not O
stop O
, O
call O
911 O
for O
transfer O
to O
closest O

 O
Emergency O
Room O



 O
Followup O
Instructions O
: O

 O
YOU O
SHOULD O
FOLLOW O
UP O
AT O
DR O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
' O
OFFICE O
/ O
NEUROSURGERY O
IN O
ONE O

 O
MONTH O
  O
- O
Please O
call O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
* O
* O
] O
to O
schedule O
an O
appointment O


 O
YOU O
SHOULD O
BE O
SEEN O
BY O
YOUR O
PRIMARY O
CARE O
PHYSICIAN O
WITHIN O
TWO O

 O
WEEKS O
OF O
DISCHARGE O
TO O
NOTIFGY O
HIM/HER O
OF O
YOUR O
HOSPITALIZATION O

 O
AND O
DIAGNOSIS O
' O



 O
YOU O
WERE O
SEEN O
BY O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
DIABETES O
SPECIALISTS O
WHILE O
HERE O
AT O

 O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
. O
  O
THEY O
RECOMMEND O
YOU O
RETURN O
TO O
YOUR O
PRIOR O
GLUCOSE O
CONTROL O

 O
REGIME O
UPON O
DISCHARGE O
. O




 O
Completed O
by:[**2163 O
- O
5 O
- O
9 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2192 O
- O
9 O
- O
24 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2192 O
- O
10 O
- O
5 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2148 O
- O
6 O
- O
18 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
[ O
* O
* O
Doctor O
First O
Name O
147 O
* O
* O
] O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
695 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
ESLD O
secondary O
to O
Hep O
C O
cirrhosis O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
s/p O
Liver O
transplant O
cadaveric O
[ O
* O
* O
2192 O
- O
9 O
- O
24 O
* O
* O
] O



 O
History O
of O
Present O
Illness O
: O

 O
44 O
yo O
male O
with O
ESLD O
secondary O
to O
HCV O
cirrhosis O


 O
Past O
Medical O
History O
: O

 O
Hep O
C O

 O
EtOH O
abuse O

 O
HTN O

 O
Portal O
HTN O


 O
Social O
History O
: O

 O
EtOH O
abuse O


 O
Physical O
Exam O
: O

 O
NAD O

 O
AAO O
times O
3 O

 O
PERRLA O
, O
EOMI O

 O
RRR O
S1+S2 O

 O
CTA O
Bilat O

 O
Soft O
, O
NT O
Mild O
Distention O


 O
Pertinent O
Results O
: O

 O
Pathology O
Examination O

 O
DIAGNOSIS O
: O

 O
Liver O
, O
native O
hepatectomy O
: O

 O
1 O
. O
  O
Established O
cirrhosis O
, O
trichrome O
stains O
evaluated O
. O

 O
2 O
. O
  O
Mild O
to O
moderate O
septal O
mononuclear O
inflammation O
with O

 O
minimal O
lobular O
inflammation O
( O
grade O
[ O
* O
* O
1 O
- O
13 O
* O
* O
] O
inflammation O
) O
. O

 O
3 O
. O
  O
Mild O
predominantly O
macrovesicular O
steatosis O
. O

 O
4 O
. O
  O
Mild O
increase O
of O
iron O
in O
Kupffer-cells O
and O
hepatocytes O
seen O

 O
on O
special O
stain O
. O

 O
5 O
. O
  O
Small O
cell O
dysplasia O
nodule O
with O
focal O
area O
suggestive O
of O

 O
early O
evolving O
hepatocellular O
carcinoma O
. O
  O
The O
dysplastic O
nodule O

 O
measures O
1 O
cm O
in O
maximum O
dimension O
. O

 O
6 O
. O
  O
Negative O
vascular O
and O
biliary O
margins O
. O

 O
7 O
. O
  O
Chronic O
cholecystitis O
. O


 O
[ O
* O
* O
2192 O
- O
9 O
- O
24 O
* O
* O
] O
11:29AM O
BLOOD O
WBC-2.9 O
* O
# O
RBC-3.21 O
* O
Hgb-11.3 O
* O
Hct-31.4 O
* O

 O
MCV-98 O
MCH-35.2 O
* O
MCHC-36.0 O
* O
RDW-14.8 O
Plt O
Ct-35 O
* O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
24 O
* O
* O
] O
11:29AM O
BLOOD O
PT-14.4 O
* O
PTT-34.1 O
INR(PT)-1.3 O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
24 O
* O
* O
] O
11:29AM O
BLOOD O
Glucose-247 O
* O
UreaN-16 O
Creat-0.9 O
Na-134 O

 O
K-4.0 O
Cl-100 O
HCO3 O
- O
25 O
AnGap-13 O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
24 O
* O
* O
] O
11:29AM O
BLOOD O
ALT-30 O
AST-61 O
* O
AlkPhos-218 O
* O
TotBili-4.3 O
* O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
24 O
* O
* O
] O
09:16PM O
BLOOD O
ALT-2308 O
* O
AST-4755 O
* O
AlkPhos-84 O
Amylase-62 O

 O
TotBili-3.6 O
* O
DirBili-2.8 O
* O
IndBili-0.8 O



 O
[ O
* O
* O
2192 O
- O
10 O
- O
5 O
* O
* O
] O
10:00AM O
BLOOD O
WBC-7.0 O
RBC-3.66 O
* O
Hgb-11.4 O
* O
Hct-32.6 O
* O

 O
MCV-89 O
MCH-31.1 O
MCHC-34.9 O
RDW-16.5 O
* O
Plt O
Ct-68 O
* O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
25 O
* O
* O
] O
03:57AM O
BLOOD O
Glucose-256 O
* O
UreaN-34 O
* O
Creat-1.8 O
* O
Na-139 O

 O
K-4.4 O
Cl-103 O
HCO3 O
- O
19 O
* O
AnGap-21 O
* O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
25 O
* O
* O
] O
10:33AM O
BLOOD O
Glucose-141 O
* O
UreaN-38 O
* O
Creat-2.2 O
* O
Na-140 O

 O
K-4.5 O
Cl-104 O
HCO3 O
- O
20 O
* O
AnGap-21 O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
25 O
* O
* O
] O
01:45PM O
BLOOD O
Glucose-137 O
* O
UreaN-42 O
* O
Creat-2.5 O
* O
Na-140 O

 O
K-4.8 O
Cl-105 O
HCO3 O
- O
20 O
* O
AnGap-20 O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
26 O
* O
* O
] O
05:25AM O
BLOOD O
Glucose-123 O
* O
UreaN-65 O
* O
Creat-3.7 O
* O
Na-140 O

 O
K-4.9 O
Cl-102 O
HCO3 O
- O
18 O
* O
AnGap-25 O
* O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
29 O
* O
* O
] O
11:19AM O
BLOOD O
Glucose-197 O
* O
UreaN-147 O
* O
Creat-6.8 O
* O
Na-141 O

 O
K-3.7 O
Cl-100 O
HCO3 O
- O
18 O
* O
AnGap-27 O
* O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
29 O
* O
* O
] O
05:34PM O
BLOOD O
Glucose-117 O
* O
UreaN-148 O
* O
Creat-7.1 O
* O
Na-141 O

 O
K-3.6 O
Cl-100 O
HCO3 O
- O
16 O
* O
AnGap-29 O
* O

 O
[ O
* O
* O
2192 O
- O
10 O
- O
5 O
* O
* O
] O
10:00AM O
BLOOD O
Glucose-199 O
* O
UreaN-110 O
* O
Creat-4.2 O
* O
Na-136 O

 O
K-3.6 O
Cl-99 O
HCO3 O
- O
21 O
* O
AnGap-20 O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
25 O
* O
* O
] O
03:57AM O
BLOOD O
ALT-2859 O
* O
AST-[**Numeric O
Identifier O
47481 O
* O
* O
] O
* O
LD(LDH)-7535 O
* O

 O
AlkPhos-104 O
TotBili-4.6 O
* O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
26 O
* O
* O
] O
01:45AM O
BLOOD O
ALT-2615 O
* O
AST-6009 O
* O
AlkPhos-124 O
* O

 O
TotBili-3.3 O
* O

 O
[ O
* O
* O
2192 O
- O
9 O
- O
29 O
* O
* O
] O
11:19AM O
BLOOD O
ALT-1179 O
* O
AST-450 O
* O
AlkPhos-174 O
* O

 O
TotBili-3.2 O
* O

 O
[ O
* O
* O
2192 O
- O
10 O
- O
5 O
* O
* O
] O
10:00AM O
BLOOD O
ALT-191 O
* O
AST-49 O
* O
AlkPhos-199 O
* O

 O
TotBili-3.6 O
* O


 O
DUPLEX O
DOPP O
ABD/PEL O
  O
[ O
* O
* O
2192 O
- O
9 O
- O
25 O
* O
* O
] O
9:08 O
AM O

 O
IMPRESSION O
: O

 O
1 O
) O
Patent O
intrahepatic O
vasculature O
. O
Please O
note O
that O
no O
flow O
was O

 O
noted O
in O
the O
retrohepatic O
vena O
cava O
but O
this O
was O
considered O
most O

 O
likely O
technical O
since O
this O
was O
a O
portable O
study O
. O

 O
2 O
) O
5.8 O
X O
5.4 O
cm O
rounded O
hypoechoic O
structure O
abutting O
the O
vena O

 O
cava O
has O
son[**Name O
( O
NI O
) O
493 O
* O
* O
] O
features O
suggestive O
of O
a O
small O
hematoma O
. O



 O

Brief O
Hospital O
Course O
: O

 O
Pt O
admitted O
on O
[ O
* O
* O
2192 O
- O
9 O
- O
24 O
* O
* O
] O
for O
OLT O
secondary O
to O
h/o O
HCV O
cirrhosis O
. O

 O
Pt O
taken O
to O
the O
OR O
for O
OLT O
and O
pt O
tol O
the O
procedure O
. O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
, O
pt O

 O
transeferred O
to O
the O
SICU O
intubated O
and O
sedated O
. O
Pt O
did O
well O
in O

 O
the O
immediate O
post-op O
period O
and O
was O
extubated O
on O
[ O
* O
* O
2192 O
- O
9 O
- O
25 O
* O
* O
] O
. O
Pt O

 O
started O
on O
MMF B-DRUG
1000 B-STR
mg I-STR
and O
a O
tapering B-DOS
dose I-DOS
of O
SM B-DRUG
. I-DRUG
However O
, O
pt O
's O

 O
BUN/Cr O
began O
to O
increase O
on O
POD O
2 O
, O
with O
developement O
of O
ARF O
and O

 O
oliguria O
. O
Pt O
clinically O
continued O
to O
improve O
. O
RUQ O
US O
and O
CT O
Scan O

 O
with O
evidence O
of O
peri-hepatic O
hematoma O
and O
poss O
compression O
of O

 O
IVC O
. O
Pt O
hydrated O
and O
hematoma O
watched O
. O
Oliguria O
began O
to O
resolve O

 O
by O
POD O
3 O
and O
pt O
transferred O
to O
the O
floor O
on O
POD O
5 O
. O
Pt O
continued O

 O
MMF B-DRUG
, I-DRUG
SM B-DRUG
tapered O
to O
20 B-STR
mg I-STR
prednisone B-DRUG
and O
CSA B-DRUG
100 B-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
added O
and O

 O
titrated O
to O
125 B-STR
. I-STR
Pt O
continued O
to O
improve O
, O
with O
resolving O
ARF O
. O
Pt O

 O
started O
with O
PT O
and O
advancing O
diet O
. O
Pt O
tolerated O
full O
diet O
and O

 O
did O
well O
in O
PT O
. O
Pt O
with O
new O
onset O
diabetes B-ADE
secondary O
to O
high O

 O
dose O
steroids B-DRUG
. I-DRUG
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
consulted O
and O
BS O
controlled O
. O
Pt O
mobilized O

 O
fluid O
and O
decreased O
weight O
from O
109 O
kg O
to O
100 O
kg O
by O
POD O
9 O
. O
Pt O

 O
continued O
to O
do O
well O
and O
Pt O
d/c'd O
home O
with O
VNA O
for O
diabetic O

 O
teaching O
on O
POD O
11 O
, O
[ O
* O
* O
2192 O
- O
10 O
- O
5 O
* O
* O
] O


 O
Discharge O
Medications O
: O

 O
1 O
. O
Trimethoprim-Sulfamethoxazole B-DRUG
80 B-STR
- I-STR
400 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
QD B-FRE
( I-FRE
once I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Mycophenolate B-DRUG
Mofetil I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Pantoprazole B-DRUG
Sodium I-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE



 O
5 O
. O
Prednisone B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QD B-FRE
( I-FRE
once I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
Oxycodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
325 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU

 I-ROU
Q4 B-FRE
- I-FRE
6H I-FRE
( I-FRE
every I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
7 O
. O
Fluconazole B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE

 I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Neoral B-DRUG
25 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
every B-FRE
twelve I-FRE

 I-FRE
( I-FRE
12 I-FRE
) I-FRE
hours I-FRE
. I-FRE

 O
9 O
. O
Lasix B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
10 O
. O
Valcyte B-DRUG
450 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
every B-FRE
other I-FRE

 I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
Care O
Network O
VNA O


 O
Discharge O
Diagnosis O
: O

 O
End O
stage O
liver O
disease O
secondary O
to O
Hep O
C O
cirrhosis O



 O
Discharge O
Condition O
: O

 O
stable O


 O
Discharge O
Instructions O
: O

 O
Please O
return O
for O
all O
follow-up O
appointments O

 O
Take O
all O
medications O
as O
directed O

 O
Return O
to O
the O
ER O
for O
any O
increased O
pain O
, O
nausea O
and O
vomitting O
, O

 O
shortness O
of O
breath O
, O
chest O
pain O
, O
significant O
weight O
gain O
or O

 O
weight O
loss O
, O
or O
fevers O


 O
Followup O
Instructions O
: O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
[ O
* O
* O
Hospital O
* O
* O
] O
CLINIC O
TRANSPLANT O
CENTER O
( O
NHB O
) O
Where O
: O

 O
LM O
[ O
* O
* O
Hospital O
5628 O
* O
* O
] O
CLINIC O
Phone:[**Telephone/Fax O
( O
1 O
) O
673 O
* O
* O
] O

 O
Date/Time:[**2192 O
- O
10 O
- O
8 O
* O
* O
] O
10:40 O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
[ O
* O
* O
Hospital O
* O
* O
] O
CLINIC O
TRANSPLANT O
CENTER O
( O
NHB O
) O
Where O
: O

 O
LM O
[ O
* O
* O
Hospital O
5628 O
* O
* O
] O
CLINIC O
Phone:[**Telephone/Fax O
( O
1 O
) O
673 O
* O
* O
] O

 O
Date/Time:[**2192 O
- O
10 O
- O
15 O
* O
* O
] O
10:40 O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
[ O
* O
* O
Hospital O
* O
* O
] O
CLINIC O
TRANSPLANT O
CENTER O
( O
NHB O
) O
Where O
: O

 O
LM O
[ O
* O
* O
Hospital O
5628 O
* O
* O
] O
CLINIC O
Phone:[**Telephone/Fax O
( O
1 O
) O
673 O
* O
* O
] O

 O
Date/Time:[**2192 O
- O
10 O
- O
22 O
* O
* O
] O
10:40 O



                              O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
707 O
* O
* O
] O
MD O
, O
[ O
* O
* O
MD O
Number(3 O
) O
709 O
* O
* O
] O


 O
Completed O
by:[**2192 O
- O
10 O
- O
8 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2155 O
- O
1 O
- O
4 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2074 O
- O
11 O
- O
21 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Sulfa B-DRUG
( I-DRUG
Sulfonamides I-DRUG
) I-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
1973 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Delta O
MS O
, O
respiratory O
distress O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
R O
chest O
tube O
place O

 O
Intubation O
and O
mechanical O
ventilation O

 O
R O
IJ O
central O
line O
placed O

 O
L O
SC O
central O
line O
placed O

 O
PICC O
line O
placed O



 O
History O
of O
Present O
Illness O
: O

 O
80yo O
M O
with O
h/o O
hyperlipidemia O
, O
RA O
, O
new O
diagnosis O
of O

 O
glioblastoma B-REA
multiforme I-REA
( O
grade O
4 O
) O
p/w O
altered O
mental O
status O
and O

 O
respiratory O
distress O
. O
  O
He O
was O
diagnosed O
in O
[ O
* O
* O
Month O
( O
only O
) O
1096 O
* O
* O
] O
with O
GBM O
( O
by O

 O
biopsy O
) O
in O
the O
setting O
of O
increasing O
confusion O
, O
memory O
loss O
. O
  O
He O

 O
was O
started O
in O
[ O
* O
* O
Month O
( O
only O
) O
1096 O
* O
* O
] O
on O
high B-REA
dose I-REA
radiation I-REA
therapy I-REA
at O
which O

 O
time O
he O
was O
also O
started O
on O
high B-DOS
dose I-DOS
decadron B-DRUG
w/ O
q3day B-FRE
taper B-DOS

 I-DOS
( O
most O
recently O
on O
3 B-STR
mg I-STR
) I-STR
; O
last O
radiation O
session O
was O
late O

 O
[ O
* O
* O
Month O
( O
only O
) O
1096 O
* O
* O
] O
. O
  O
He O
also O
recently O
had O
a O
port O
placed O
through O
which O
he O

 O
was O
receiving O
avastin B-DRUG
( O
last O
2 O
weeks O
ago O
) O
. O
  O
His O
family O
reports O

 O
mildly O
productive O
cough O
( O
cold O
sx O
) O
beginning O
approximately O
1 O
week O

 O
ago O
; O
he O
had O
a O
CXR O
3 O
- O
4 O
days O
ago O
which O
reportedly O
was O
negative O
for O

 O
pneumonia B-REA
and O
took O
atovaquone B-DRUG
. I-DRUG

 O
. O

 O
After O
the O
onset O
of O
these O
pulmonary O
symptoms O
, O
he O
later O
developed O

 O
left B-REA
knee I-REA
" I-REA
bursitis I-REA
" I-REA
last O
week O
for O
which O
he O
received O
injection B-FOR

 I-FOR
most O
recently O
yesterday O
by O
PCP O
( O
presumably O
steroid B-DRUG
injection B-FOR
) I-FOR
. O

 O
He O
had O
largely O
been O
bed O
bound O
over O
the O
last O
few O
days O
[ O
* O
* O
1 O
- O
4 O
* O
* O
] O
to O
left O

 O
knee O
pain O
. O
  O
Beginning O
this O
morning O
, O
he O
was O
very O
exhausted O
. O
  O
He O

 O
took O
a O
nap O
this O
morning O
and O
when O
he O
awoke O
, O
he O
was O
confused O
, O

 O
somnolent O
, O
lethargic O
. O
  O
His O
wife O
called O
EMS O
and O
he O
was O

 O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
. O
  O
En O
route O
to O
the O
ED O
, O
he O
was O
noted O
to O
be O

 O
in O
a.fib B-REA
with I-REA
RVR I-REA
for O
which O
he O
received O
diltiazem B-DRUG
. I-DRUG

 O
. O


 O
In O
the O
ED O
initial O
vitals O
were O
T O
96.7 O
HR O
112 O
BP O
105/67 O
RR O
28 O
  O
O2 O

 O
sat O
85 O
% O
RA O
. O
  O
CXR O
showed O
multifocal B-REA
PNA I-REA
at O
RUL O
, O
RLL O
, O
LLL O
. O
  O
He O
was O

 O
placed O
on O
NRB O
and O
shortly O
thereafter O
O2 O
sats O
again O
dropped O
to O

 O
the O
80s O
, O
thus O
he O
was O
intubated O
4:30 O
pm O
. O
  O
Blood O
cultures O
were O

 O
drawn O
and O
he O
received O
levofloxacin B-DRUG
750 B-STR
g I-STR
IV B-ROU
x1 B-DOS
, I-DOS
vancomycin B-DRUG
1 B-STR
g I-STR
IV B-ROU

 I-ROU
x1 B-DOS
, I-DOS
ceftriaxone B-DRUG
1 B-STR
g I-STR
IV B-ROU
x1 B-DOS
, I-DOS
and O
azithromycin B-DRUG
500 B-STR
mg I-STR
x1 B-DOS
. I-DOS
  O
He O
also O

 O
received O
10 B-STR
mg I-STR
IV B-ROU
decadron B-DRUG
. I-DRUG
  O
He O
was O
initially O
normotensive O
, O
but O

 O
dropped B-REA
pressure I-REA
at O
6:30 O
pm O
into O
70s O
requiring O
initiation O
of O

 O
phenylephrine B-DRUG
gtt B-ROU
. I-ROU
  O
Over O
his O
entire O
ED O
course O
, O
received O
total O
5L B-DOS

 I-DOS
NS B-DRUG
. I-DRUG

 O
. O

 O
Head O
CT O
demonstrated O
" O
no O
new O
findings O
" O
and O
was O
reportedly O

 O
reviewed O
by O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
neurosurgery O
however O
there O
is O
no O
note O
in O

 O
chart/OMR O
. O
  O
Additionally O
he O
was O
seen O
by O
his O
neurologist O
who O

 O
follows O
him O
at O
[ O
* O
* O
Hospital1 O
2025 O
* O
* O
] O
, O
however O
there O
is O
no O
documentation O
of O
this O
. O


 O
Past O
Medical O
History O
: O

 O
# O
Grade O
4 O
glioblastoma B-REA
multiforme I-REA
left O
temporal O
lobe O
; O
s/p O
high B-REA

 I-REA
dose I-REA
radiotherapy I-REA
, I-REA
previously O
on O
high O
dose O
steroids B-DRUG
, I-DRUG
recently O

 O
tapered B-DOS
. I-DOS
  O
Recently O
placed O
Portacath O
with O
steristrips O
still O

 O
present O
. O

 O
# O
Rheumatoid B-REA
arthritis I-REA
; I-REA
on O
remicade B-DRUG
until O
recently O

 O
# O
L O
knee O
bursitis O

 O
# O
Hyperlipidemia O


 O
Social O
History O
: O

 O
Lives O
at O
home O
with O
wife O
. O
  O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
and O
daughter-in-law O
( O
who O
is O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
MD O
) O

 O
live O
locally O
. O
  O
Smoking O
, O
Etoh O
history O
unknown O
. O


 O
Family O
History O
: O

 O
nc O



 O
Physical O
Exam O
: O

 O
S O
: O
Temp O
: O
97.2 O
BP O
: O
99/69 O
HR O
: O
138 O
a. O
fib O
RR O
: O
22 O
O2sat O
92 O
% O
AC O

 O
500/19 O
PEEP O
14 O
FiO2 O
1.0 O

 O
GEN O
: O
Intubated O
, O
unresponsive O
on O
minimal O
sedation O

 O
HEENT O
: O
Pupils O
pinpoint O
, O
symmetric O
, O
unresponsive O
to O
light O
, O

 O
scleral O
mildy O
icteric O
, O
dry O
MM O
, O
Multiple O
pinpoint O
white O
plaques O

 O
on O
roof O
of O
mouth O

 O
NECK O
: O
no O
supraclavicular O
or O
cervical O
lymphadenopathy O
, O
no O
jvd O
, O
no O

 O
carotid O
bruits O
, O
no O
thyromegaly O
or O
thyroid O
nodules O

 O
CHEST O
: O
  O
Portacath O
site O
right O
anterior O
chest O
with O
steri O
strips O
in O

 O
place O
, O
mildly O
erythematous O
, O
no O
significant O
increase O

 O
warmth/induration/fluctuance O

 O
RESP O
: O
Clear O
anteriorly O
, O
decrease O
BS O
right O
laterally O
, O
no O

 O
wheezing/rales O

 O
CV O
: O
irreg O
irreg O
, O
no O
mrg O
appreciated O

 O
ABD O
: O
nd O
, O
+ O
b/s O
, O
soft O
, O
nt O
, O
no O
masses O
or O
hepatosplenomegaly O

 O
EXT O
: O
1 O
+ O
pedal O
edema O
b/l O
, O
right O
foot O
cooler O
than O
left O
1 O
+ O
DP O
on O

 O
right O
, O
2 O
+ O
DP O
on O
left O
, O
palpable O
PT O
pulses O
b/l O
, O
left O
knee O
with O

 O
small O
effusion O
, O
increased O
warmth O
without O
significant O
increased O

 O
erythema O

 O
SKIN O
: O
appears O
mildly O
jaundiced O

 O
NEURO O
: O
Downgoing O
toes O
b/l O
. O
  O
DTRs O
[ O
* O
* O
Name O
( O
NI O
) O
20772 O
* O
* O
] O
throughout O

 O
including O
biceps O
, O
patellar O
, O
achilles O
. O



 O
Pertinent O
Results O
: O

 O
ADMISSION O
LABS O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
04:45PM O
BLOOD O
WBC-6.0 O
RBC-3.78 O
* O
Hgb-11.7 O
* O
Hct-34.3 O
* O

 O
MCV-91 O
MCH-31.0 O
MCHC-34.1 O
RDW-13.6 O
Plt O
Ct-74 O
* O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
04:45PM O
BLOOD O
Neuts-80 O
* O
Bands-6 O
* O
Lymphs-9 O
* O
Monos-3 O

 O
Eos-0 O
Baso-0 O
Atyps-0 O
Metas-2 O
* O
Myelos-0 O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
04:45PM O
BLOOD O
Hypochr-NORMAL O
Anisocy-NORMAL O

 O
Poiklo-NORMAL O
Macrocy-NORMAL O
Microcy-NORMAL O
Polychr-NORMAL O

 O
[ O
* O
* O
2155 O
- O
1 O
- O
2 O
* O
* O
] O
02:38AM O
BLOOD O
Plt O
Ct-179 O

 O
[ O
* O
* O
2155 O
- O
1 O
- O
2 O
* O
* O
] O
02:38AM O
BLOOD O
PT-14.6 O
* O
PTT-35.5 O
* O
INR(PT)-1.3 O
* O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
04:45PM O
BLOOD O
PT-13.3 O
PTT-31.5 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
04:45PM O
BLOOD O
Plt O
Smr-VERY O
LOW O
Plt O
Ct-74 O
* O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
04:45PM O
BLOOD O
Glucose-98 O
UreaN-44 O
* O
Creat-1.1 O
Na-138 O

 O
K-5.3 O
* O
Cl-105 O
HCO3 O
- O
23 O
AnGap-15 O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
04:45PM O
BLOOD O
CK(CPK)-52 O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
04:45PM O
BLOOD O
CK-MB-NotDone O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
04:45PM O
BLOOD O
Calcium-8.0 O
* O
Phos-3.7 O
Mg-2.7 O
* O
UricAcd-3.4 O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
10:47PM O
BLOOD O
calTIBC-146 O
* O
VitB12 O
- O
1418 O
* O
Folate-3.5 O

 O
Ferritn-1409 O
* O
TRF-112 O
* O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
10:47PM O
BLOOD O
TSH-0.69 O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
15 O
* O
* O
] O
06:26AM O
BLOOD O
Cortsol-26.9 O
* O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
06:50PM O
BLOOD O
Type-ART O
pO2 O
- O
60 O
* O
pCO2 O
- O
50 O
* O
pH-7.30 O
* O

 O
calTCO2 O
- O
26 O
Base O
XS--1 O
Intubat-INTUBATED O
Vent-CONTROLLED O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
14 O
* O
* O
] O
07:15PM O
BLOOD O
Lactate-2.2 O
* O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
15 O
* O
* O
] O
12:25AM O
BLOOD O
O2 O
Sat-98 O

 O
[ O
* O
* O
2154 O
- O
12 O
- O
15 O
* O
* O
] O
12:25AM O
BLOOD O
freeCa-1.10 O
* O


 O
Brief O
Hospital O
Course O
: O

 O
Note O
: O
the O
majority O
of O
this O
hospital O
course O
refers O
to O
the O

 O
patient O
's O
ICU O
course O
. O
  O
He O
was O
on O
the O
medical O
floor O
for O
16 O
hours O

 O
prior O
to O
discharge O
and O
was O
stable O
during O
this O
time O
. O

 O
. O


 O
# O
Septic O
Shock O
: O
  O
Met O
criteria O
for O
septic O
shock O
. O
  O
On O
presentation O

 O
had O
clear O
pulmonary O
source O
of O
infection O
. O
  O
Initial O
sputums O
grew O

 O
out O
pneumococci O
. O
  O
Patient O
relatively O
immunocompromised B-ADE
due O
both O

 O
to O
cancer O
diagnosis O
and O
chronic O
steroid B-DRUG
use O
secondary O
to O
brain B-REA

 I-REA
tumor I-REA
. I-REA

   O
On O
admission O
patient O
had O
central O
line O
placed O
, O
CVPs O
maintained O

 O
[ O
* O
* O
7 O
- O
15 O
* O
* O
] O
. O
  O
Patient O
needed O
pressors B-DRUG
to O
maintain B-REA
BP I-REA
initially O
. O
  O
On O

 O
levophed B-DRUG
, I-DRUG
but O
developed O
some O
tachyarrhythmnias B-REA
( I-REA
Afib I-REA
with I-REA
RVR I-REA
) I-REA

 I-REA
so O
was O
switched O
to O
neo B-DRUG
. I-DRUG
  O
Initially O
covered O
with O
Zosyn B-DRUG
, I-DRUG
levoflox B-DRUG

 I-DRUG
and O
vanco B-DRUG
. I-DRUG
  O
Patient O
was O
continued O
on O
atovaquone B-DRUG
for O
PCP B-REA

 I-REA
[ O
* O
* O
Name O
Initial O
( O
PRE O
) O
6187 O
* O
* O
] O
. O
  O
Patient O
was O
also O
intubated O
on O
presentation O
, O
and O

 O
maintained O
on O
AC O
. O
  O
Patient O
had O
EKGs O
without O
signs O
of O
ischemia O
, O

 O
and O
  O
multiple O
sets O
of O
normal O
cardiac O
enzymes O
. O
  O
Pressors O
were O

 O
largely O
weaned O
by O
HD O
# O
3 O
. O
  O
He O
did O
rarely O
require O
brief O
periods O
of O

 O
neosynepherine B-DRUG
, I-DRUG
due O
to O
too-rapid B-REA
diuresis I-REA
. I-REA

    O
The O
patient O
had O
a O
normal O
cortisol O
stim O
test O
. O

    O
Historically O
, O
it O
was O
noted O
that O
the O
patient O
had O
a O
red O
left O

 O
knee O
a O
few O
days O
prior O
to O
admission O
. O
  O
This O
knee O
was O
tapped O
by O

 O
ortho O
and O
found O
to O
be O
floridly O
septic O
. O
  O
He O
was O
taken O
to O
the O
OR O

 O
and O
washed O
out O
by O
Ortho O
( O
please O
see O
seperate O
op O
note O
for O
full O

 O
accounting O
of O
this O
procedure O
) O
. O
  O
This O
infection O
was O
found O
to O
be O

 O
MSSA O
, O
which O
also O
grew O
out O
of O
his O
blood O
and O
eventually O
out O
of O
his O

 O
R O
chest O
chemo-port O
, O
which O
was O
removed O
by O
surgery O
. O
  O
He O
was O

 O
maintained O
on O
a O
6week B-DUR
course I-DUR
of O
Nafcillin B-DRUG
for O
this O
staph B-REA

 I-REA
infection I-REA
. I-REA
  O
A O
TEE O
demonstrated O
no O
signs O
of O
endocarditis O
. O

 O
Infectious O
disease O
was O
consulted O
and O
assisted O
with O
his O

 O
antibiotic B-DRUG
regimen O
. O

    O
The O
patient O
completed O
a O
full O
14d B-DUR
course I-DUR
of O
Levoflox B-DRUG
for O

 O
pneumonia B-REA
. I-REA
  O
The O
patient O
also O
had O
a O
full O
course O
of O
Clinda B-DRUG
for O
a O

 O
question O
of O
toxic B-REA
shock I-REA
syndrome I-REA
or O
aspiration B-REA
pneumonia I-REA
. I-REA
  O
His O

 O
Vanco B-DRUG
was O
d/c'd O
after O
5d B-DUR
due O
to O
only O
MSSA O
growing O
out O
. O
  O
On O
[ O
* O
* O
12 O
- O
20 O
* O
* O
] O

 O
his O
pre-existing O
R O
chest O
chemo O
port O
was O
noted O
to O
be O
purulent O
and O

 O
was O
removed O
by O
surgery O
. O
  O
This O
grew O
out O
MSSA O
. O
  O
Once O
more O
, O
the O

 O
nafcillin B-DRUG
was O
continued O
for B-DUR
6week I-DUR
total O
course O
. O

   O
A O
[ O
* O
* O
12 O
- O
21 O
* O
* O
] O
culture O
grew O
out O
yeast B-REA
and O
he O
was O
started O
on O
a O
course O

 O
of O
fluconisol B-DRUG
as O
per O
ID O
. O
  O
He O
recieved O
a O
full O
Ophtho O
eval O
which O

 O
demonstrated O
no O
ocular O
involvment O
. O

   O

Planned O
course O
of O
treatment O
is O
for O
nafcillin B-DRUG
for B-DUR
total I-DUR
of I-DUR
6 I-DUR

 I-DUR
weeks I-DUR
to O
end O
[ O
* O
* O
1 O
- O
30 O
* O
* O
] O
, O
fluconazole B-DRUG
for B-DUR
2 I-DUR
weeks I-DUR
total O
to O
end O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
, O
and O

 O
ceftriaxone B-DRUG
to O
end O
[ O
* O
* O
1 O
- O
10 O
* O
* O
] O
. O

 O
. O

 O
# O
Afib B-REA
c I-REA
RvR I-REA
: I-REA
  O
New-onset O
afib O
in O
the O
face O
of O
sepsis B-REA
, I-REA

 O
hypotension B-REA
, I-REA
infection B-REA
. I-REA
  O
Patient O
initially O
controlled O
with O

 O
boluses B-DOS
of O
Diltiazem B-DRUG
or O
Lopressor B-DRUG
. I-DRUG
  O
Often O
returned O
into O
Afib B-REA

 I-REA
during O
times O
of O
increased O
activity O
or O
stress O
. O
  O
Used O

 O
neosynepharine B-DRUG
which O
seemed O
less O
arrhythmagenic O
. O
  O
Amiodarone B-DRUG
was O

 O
tried O
initially O
for O
control B-REA
, I-REA
but O
the O
patient O
became O
to O

 O
bradycardic B-ADE
on O
this O
[ O
* O
* O
Doctor O
Last O
Name O
360 O
* O
* O
] O
. O
  O
As O
patient O
was O
weaned O
from O
pressors B-DRUG

 I-DRUG
he O
was O
begun O
on O
a O
regimen O
of O
metoprolol B-DRUG
which O
seemed O
to O
control B-REA

 I-REA
his I-REA
rate I-REA
well O
. O
  O
He O
did O
ocassionally O
return O
to O
RVR B-REA
, I-REA
which O
was O

 O
treated O
with O
boluses B-DOS
of O
dilt B-DRUG
or O
lopressor B-DRUG
with O
good O
effect O
. O
He O

 O
was O
then O
restarted O
on O
amiodarone B-DRUG
[ O
* O
* O
1 O
- O
1 O
* O
* O
] O
and O
responded O
to O
it O
well O
. O

 O
Due O
to O
his O
brain O
tumor O
he O
was O
note O
anticoagulated O
during O
his O

 O
time O
in O
the O
ICU O
. O
The O
risks O
and O
benefits O
were O
discussed O
. O
It O
was O

 O
felt O
that O
the O
risks O
of O
ICH O
outweighed O
the O
benefits O
of O
stroke O

 O
prevention O
at O
this O
time O
. O
Plans O
were O
made O
to O
readdress O
this O
issue O

 O
once O
the O
patient O
's O
mental O
status O
improved O
. O

 O
. O

 O
# O
Septic B-REA
Arthritis I-REA
: I-REA
  O
As O
above O
, O
had O
septic O
arthritis O
of O
L O
knee O

 O
treated O
via O
washout O
by O
ortho O
on O
[ O
* O
* O
12 O
- O
17 O
* O
* O
] O
. O
  O
Nafcillin B-DRUG
x6weeks B-DUR
per O
ID O

 O
started O
on O
[ O
* O
* O
12 O
- O
19 O
* O
* O
] O
. O
Nafcillin B-DRUG
is O
scheduled O
to O
finish O
on O
[ O
* O
* O
1 O
- O
30 O
* O
* O
] O
. O

 O
Patient O
did O
have O
a O
swollen O
L O
wrist O
later O
in O
his O
course O
, O
but O
this O

 O
was O
tapped O
by O
Ortho O
and O
never O
grew O
out O
any O
bacteria O
. O

 O
Plastics-hand O
was O
consulted O
and O
felt O
clinically O
that O
this O
was O

 O
not O
a O
septic O
joint O
, O
instead O
just O
a O
manifestation O
of O
his O
chronic O

 O
RA O
. O

  O
Ortho O
also O
felt O
it O
was O
not O
prudent O
to O
washout O
his O
R O
knee O
, O
which O

 O
was O
clinically O
asymptomatic O
during O
his O
ICU O
course O
. O
His O
L O
knee O

 O
healed O
well O
and O
the O
staples O
and O
drain O
were O
removed O
without O

 O
incidence O
. O
  O
He O
has O
been O
signed O
off O
from O
direct O
ortho O
care O
, O
and O

 O
is O
weight-bearing O
as O
tolerated O
at O
time O
of O
ICU O
discharge O
. O

 O
. O


 O
# O
Respiratory O
status O
: O
  O
Patient O
was O
maintained O
on O
ARDS-style O

 O
ventilation O
while O
on O
the O
ventilator O
. O
  O
He O
has O
a O
bronchoscopy O
on O

 O
[ O
* O
* O
12 O
- O
18 O
* O
* O
] O
which O
showed O
diffuse O
thick O
bloody O
sputum O
greatest O
in O
the O
R O

 O
LL O
. O
  O
By O
[ O
* O
* O
12 O
- O
19 O
* O
* O
] O
the O
patient O
was O
changed O
to O
pressure O
support O

 O
ventilation O
. O
  O
The O
patient O
was O
activily O
diuresed O
at O
this O
time O
, O

 O
with O
good O
effect O
and O
improving O
respiratory O
status O
. O
  O
The O
patient O

 O
tested O
negative O
for O
legionella O
and O
influenza O
. O
  O
The O
patient O
was O

 O
quickly O
weaned O
to O
CPAP+PS O
of O
[ O
* O
* O
4 O
- O
7 O
* O
* O
] O
, O
but O
was O
difficult O
to O
wean O

 O
fully O
from O
the O
vent O
due O
mainly O
to O
his O
mental O
status O
. O
   O
He O
was O

 O
extubated O
on O
[ O
* O
* O
12 O
- O
24 O
* O
* O
] O
with O
great O
success O
. O

   O
On O
[ O
* O
* O
12 O
- O
25 O
* O
* O
] O
the O
patient O
was O
noted O
to O
have O
an O
increasing O
o2 O

 O
requirement O
and O
a O
CXR O
demonstrated O
a O
moderate-sized O
R O

 O
pneumothorax O
. O
  O
Thoracic O
surgery O
was O
consulted O
and O
placed O
a O
chest O

 O
tube O
. O
  O
This O
tube O
was O
intermittantly O
to O
wall-suction O
, O
water-seal O

 O
or O
clamped O
. O
  O
On O
[ O
* O
* O
1 O
- O
2 O
* O
* O
] O
it O
was O
d/c'd O
, O
with O
the O
pneumothoax O
smaller O

 O
in O
size O
. O

 O
. O

 O
# O
GBM O
: O
  O
Head O
CTs O
compared O
to O
his O
baseline O
[ O
* O
* O
Hospital1 O
2025 O
* O
* O
] O
scans O
showed O
no O

 O
interval O
change O
. O
  O
He O
was O
maintained O
on O
his O
baseline O
3 B-STR
mg I-STR
of O

 O
Dexamethasone B-DRUG
while O
inpatient O
here O
. O
It O
appears O
that O
neurooncs O

 O
original O
plans O
were O
to O
taper B-DOS
the O
dexamethasone B-DRUG
. I-DRUG
We O
were O
unable O

 O
to O
contact O
primary O
neuro-oncoligist O
to O
discuss O
steroid B-DRUG
taper B-DOS
but O

 O
this O
should O
be O
discussed O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
when O
he O
becomes O

 O
available O
. O

 O
. O

 O
# O
Anemia/thrombocytopenia O
: O
  O
Had O
anemia O
of O
chronic O
disease O
, O

 O
admitted O
with O
thrombocytopenia B-ADE
attributed O
to O
Avastin B-DRUG
and O

 O
timador B-DRUG
. I-DRUG
  O
His O
thrombocytopenia O
was O
asymptomatic O
during O
his O

 O
hospital O
course O
, O
and O
steadily O
improved O
. O
  O
His O
anemia O
was O
mild O
, O

 O
and O
did O
require O
occasional O
transfusion O
. O

 O
. O

 O
# O
Hyperglycemia B-REA
: I-REA
  O
Intitally O
hyperglycemic O
in O
face O
of O
sepsis O
, O

 O
controlled O
with O
SS O
insulin B-DRUG
and O
resolved O
on O
its O
own O
. O

 O
. O

 O
# O
R O
Chest B-REA
wound I-REA
: I-REA
  O
Con't O
to O
drain O
purulent O
material O
s/p O
removal O
of O

 O
port O
. O
  O
Surgery O
recommended O
QID B-FRE
dilute([**12 B-STR
- O
6 O
* O
* O
] O
) O
Dakin B-DRUG
's I-DRUG
solution I-DRUG
and O

 O
close O
f/u O
. O
  O
Any O
fluctuant O
areas O
must O
be O
debrided O
. O

 O
. O


 O
# O
Mental O
Status O
: O
  O
The O
patient O
presented O
with O
altered O
mental O

 O
status O
felt O
to O
be O
due O
to O
sepsis O
. O
  O
He O
did O
take O
some O
days O
to O

 O
awaken O
from O
his O
intubated O
and O
sedated O
state O
. O
  O
He O
continued O
to O
be O

 O
Aox1 O
- O
2 O
in O
the O
MICU O
, O
with O
symptoms O
consistent O
with O
delerium O
. O
A O

 O
repeat O
head O
CT O
showed O
no O
change O
; O
his O
delerium O
was O
felt O
to O
be O

 O
mainly O
post-septic O
and O
ICU O
related O
and O
appeared O
to O
be O
slowly O

 O
intervally O
improving O
each O
day O
. O

 O
. O

 O
# O
Prophylaxis B-REA
: I-REA
Patient O
was O
initially O
on O
pneumoboots O
and O
then O

 O
Heparin B-DRUG
SC B-ROU
, I-ROU
a O
bowel O
regmimen O
and O
a O
Gi O
prophlyaxsis O
throughout O

 O
his O
hospital O
course O
. O

 O
. O

 O
# O
Electrolytes O
: O
  O
The O
patient O
required O
extensive O
repletion O
of O
his O

 O
potassium O
during O
his O
ICU O
course O
, O
often O
requiring O
q6hr O
lyte O

 O
checks O
and O
100 O
- O
200meq O
of O
K+ O
per O
day O
. O
  O
This O
was O
felt O
to O
be O
mostly O

 O
due O
to O
a O
diarrhea O
and O
thus O
GI O
loss O
, O
and O
was O
resolving O
at O
the O
end O

 O
of O
his O
hospital O
course O
as O
diarrhea O
resolved O
. O

 O
. O

 O
# O
Nutrition O
: O
  O
The O
patient O
was O
maintained O
on O
TF O
while O
intubated O
, O

 O
and O
also O
s/p O
intubation O
as O
he O
failed O
his O
initial O
speech O
and O

 O
swallow O
exams O
. O
On O
[ O
* O
* O
1 O
- O
3 O
* O
* O
] O
he O
passed O
his O
speech O
and O
swallow O
bedside O

 O
test O
. O

 O
. O

 O
# O
LFTs O
: O
  O
Patient O
had O
elevated O
LFTs O
on O
presentation O
which O
were O

 O
attributed O
to O
sepsis O
. O
  O
This O
abnormality O
resolved O
as O
the O

 O
patient O
's O
clinical O
picture O
improved O
. O
  O
He O
should O
continue O
on O

 O
weekly O
LFT O
checks O
due O
to O
his O
continuing O
nafcillin B-DRUG
. I-DRUG

 O
. O

 O
# O
PT/OT O
: O
  O
after O
extubation O
the O
patient O
was O
followed O
actively O
by O

 O
PT O
and O
OT O
. O



 O
Medications O
on O
Admission O
: O

 O
# O
Naproxen B-DRUG
prn B-FRE

 I-FRE
# O
Mepron B-DRUG
( O
prophylaxis B-REA
) I-REA

 O
# O
Hydrocodone B-DRUG

 I-DRUG
# O
Dexamethasone B-DRUG
3 B-STR
mg I-STR

 I-STR
# O
Avastin B-DRUG
( O
last O
received O
2wks O
ago O
, O
due O
on O
Monday O
[ O
* O
* O
2154 O
- O
12 O
- O
16 O
* O
* O
] O
) O

 O
# O
Lipid O
lowering O
[ O
* O
* O
Doctor O
Last O
Name O
360 O
* O
* O
] O
( O
wife O
unsure O
of O
name O
) O

 O
# O
Timador B-DRUG
( O
was O
previously O
on O
this O
, O
but O
was O
stopped O
[ O
* O
* O
1 O
- O
4 O
* O
* O
] O
to O

 O
thrombocytopenia B-ADE
) I-ADE



 O
Discharge O
Medications O
: O

 O
1 O
. O
Heparin B-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
5,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
5000 B-DOS
( I-DOS
5000 I-DOS
) I-DOS

 I-DOS
units I-DOS
Injection B-FOR
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
3 O
. O
Docusate B-DRUG
Sodium I-DRUG
50 B-STR
mg/5 I-STR
mL I-STR
Liquid B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ml I-DOS
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Atovaquone B-DRUG
750 B-STR
mg/5 I-STR
mL I-STR
Suspension B-FOR
Sig O
: O
Seven O
[ O
* O
* O
Age O
over O
90 O
1230**]y O

 O
( B-DOS
750 I-DOS
) I-DOS
mg I-DOS
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Nystatin B-DRUG
100,000 B-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
QID B-FRE

 I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
6 O
. O
Dexamethasone B-DRUG
1.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
8 O
. O
Guaifenesin B-DRUG
100 B-STR
mg/5 I-STR
mL I-STR
Syrup B-FOR
Sig O
: O
Fifteen B-DOS
( I-DOS
15 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
Q6H B-FRE

 I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
cough B-REA
. I-REA

 O
9 O
. O
Fluconazole B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE

 I-FRE
24 I-FRE
hours I-FRE
) I-FRE
for B-DUR
2 I-DUR
weeks I-DUR
: I-DUR
last O
day O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
. O

 O
10 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
: I-FRE
hold O
for O
HR<50 O
and O
SBP<100 O
. O

 O
11 O
. O
Amiodarone B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
: I-FRE
[ O
* O
* O
Hospital1 O
* O
* O
] O
until O
[ O
* O
* O
1 O
- O
7 O
* O
* O
] O
then O
400 B-STR
mg I-STR
daily B-FRE
. I-FRE

 O
12 O
. O
Famotidine B-DRUG
10 B-STR
mg/mL I-STR
Solution B-FOR
Sig O
: O
Twenty B-DOS
( I-DOS
20 I-DOS
) I-DOS
mg I-DOS
Intravenous B-ROU

 I-ROU
Q12H B-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Ceftriaxone-Dextrose B-DRUG
( I-DRUG
Iso-osm I-DRUG
) I-DRUG
1 B-STR
gram/50 I-STR
mL I-STR
Piggyback B-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
gram I-DOS
Intravenous B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
14 O
. O
Nafcillin B-DRUG
in I-DRUG
D2.4W I-DRUG
2 B-STR
gram/100 I-STR
mL I-STR
Piggyback B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
grams I-DOS
Intravenous B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
for B-DUR
6 I-DUR
weeks I-DUR
: I-DUR
last O
day O

 O
[ O
* O
* O
1 O
- O
30 O
* O
* O
] O
. O

 O
15 O
. O
Heparin B-DRUG
Lock I-DRUG
Flush I-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
100 B-STR
unit/mL I-STR
Syringe B-FOR
Sig O
: O
Two B-DOS

 I-DOS
( I-DOS
2 I-DOS
) I-DOS
ML I-DOS
Intravenous B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
16 O
. O
Insulin B-DRUG
NPH I-DRUG
Human I-DRUG
Recomb I-DRUG
100 B-STR
unit/mL I-STR
Cartridge B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS

 I-DOS
units I-DOS
Subcutaneous B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
17 O
. O
Insulin B-DRUG
Regular I-DRUG
Human I-DRUG
300 B-STR
unit/3 I-STR
mL I-STR
Insulin B-DRUG
Pen B-FOR
Sig O
: O
sliding B-DOS

 I-DOS
scale I-DOS
  O
Subcutaneous B-ROU
four B-FRE
times I-FRE
a I-FRE
day I-FRE
: I-FRE
sliding B-DOS
scale I-DOS
. I-DOS



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O



 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
7 O
* O
* O
] O
& O
Rehab O
Center O
- O
[ O
* O
* O
Hospital1 O
8 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
Septic O
Shock O

 O
Community O
Aquired O
Pneumonia O

 O
Respiratory O
Failure O

 O
Acute O
Renal O
Failure O

 O
Septic O
Arthritis O
( O
L O
Knee O
) O

 O
Bacteremia O

 O
Infected O
R O
Chest O
Catheter O

 O
Afib O
with O
RVR O

 O
Delerium O

 O
Anemia O

 O
Thrombocytopenia O

 O
Hyperglycemia O

 O
Pneumothorax O
( O
R O
) O

 O
Hypokalemia O

 O
Transaminitis O


 O
Secondary O
: O

 O
# O
Grade O
4 O
glioblastoma O
multiforme O
left O
temporal O
lobe O
; O
s/p O
high O

 O
dose O
radiotherapy O
, O
previously O
on O
high O
dose O
steroids B-DRUG
, I-DRUG
recently O

 O
tapered B-DOS
. I-DOS
  O
Recently O
placed O
Portacath O
with O
steristrips O
still O

 O
present O
. O

 O
# O
Rheumatoid B-REA
arthritis I-REA
; I-REA
on O
remicade B-DRUG
until O
recently O

 O
# O
L O
knee O
bursitis O

 O
# O
Hyperlipidemia O



 O
Discharge O
Condition O
: O

 O
fair O
- O
multifactorial O
delirium O
with O
waxing O
and O
[ O
* O
* O
Doctor O
Last O
Name O
688 O
* O
* O
] O
mental O

 O
status O
A+Ox1 O
- O
2 O



 O
Discharge O
Instructions O
: O

   O
You O
were O
admitted O
for O
pneumonia B-REA
and O
multiple B-REA
infections I-REA

 I-REA
including O
of O
your O
knee O
and O
blood O
stream O
. O
  O
you O
were O
treated O
with O

 O
several O
antibiotics B-DRUG
and O
had O
a O
stay O
in O
the O
intensive O
care O
unit O

 O
which O
required O
intubation O
. O
  O
Currently O
you O
are O
being O
treated O
for O

 O
these O
infections O
and O
are O
on O
tube O
feedings O
and O
slowly O
eating O

 O
again O
. O

   O
Regarding O
your O
brain O
tumor O
, O
we O
felt O
that O
this O
issue O
, O
while O

 O
serious O
, O
was O
stable O
during O
your O
stay O
here O
. O
  O
It O
is O
very O
important O

 O
that O
you O
followup O
with O
your O
neuro-oncologist O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
at O

 O
[ O
* O
* O
Hospital1 O
2025 O
* O
* O
] O
. O
  O
You O
need O
to O
discuss O
with O
him O
whether O
you O
should O
be O
on O

 O
blood B-DRUG
thinners I-DRUG
. I-DRUG

 O
. O



 O
Followup O
Instructions O
: O

 O
f/u O
with O
Dr. O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Initial O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
1005 O
* O
* O
] O
of O
orthopedic O
surgery O
at O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
15940 O
* O
* O
] O
to O
schedule O
a O
followup O
appointment O
in O
1 O
month O
. O

 O
f/u O
with O
your O
outpatient O
rheumatologist O
in O
[ O
* O
* O
1 O
- O
6 O
* O
* O
] O
weeks O
. O

 O
f/u O
with O
your O
outpatient O
neurooncologist O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
on O
Monday O

 O
by O
phone O
- O
he O
should O
be O
involved O
in O
deciding O
steroid O
taper O
and O

 O
deciding O
about O
anticoagulation O
. O

 O
Some O
of O
your O
labs O
will O
be O
faxed O
to O
Dr. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
of O
infectious O

 O
disease O
at O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1353 O
* O
* O
] O
( O
phone O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
17490 O
* O
* O
] O
) O
, O
she O
will O

 O
contact O
you O
regarding O
followup O
. O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2112 O
- O
5 O
- O
10 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2030 O
- O
4 O
- O
22 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1481 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
sepsis O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
trach O

 O
fluid O
collection O
aspiration O

 O
fistula O
intubation O

 O
multiple O
wound O
debridements O


 O
History O
of O
Present O
Illness O
: O

 O
This O
is O
an O
81 O
year O
old O
male O
who O
was O
transferred O
from O
an O
OSH O
on O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
, O
POD O
15 O
from O
a O
left O
colectomy O
for O
a O
lower B-REA
GI I-REA
bleed I-REA
. I-REA
( O
8 O

 O
units O
of O
RBC B-DRUG
transfused O
) O
. O
  O
On O
POD O
8 O
, O
the O
patient O
had O
an O

 O
anastamotic O
leak O
and O
underwent O
a O
Hartmann O
's O
procedure O
with O

 O
creation O
of O
an O
ascending O
colostomy O
. O
  O
His O
post O
operative O
course O

 O
was O
subsequently O
complicated O
by O
acute O
renal O
failure O
, O
small O

 O
peripheral O
pulmonary O
emboli O
, O
HIT O
positivity O
on O
argatroban B-DRUG
, I-DRUG
and O

 O
atrial B-REA
fibrillation I-REA
aon O
an O
amiodarone B-DRUG
drip B-ROU
. I-ROU


 O
Past O
Medical O
History O
: O

 O
HTN O
, O
hyperlipidemia O
, O
EF O
60 O
% O
, O
DM2 O
diet O
controlled O
, O
history O
of O

 O
throat O
cancer O
s/p O
resection O
+ O
xrt O
' O
[ O
* O
* O
89 O
* O
* O
] O
, O
s/p O
empyema O
w/ O
CT O

 O
drainage O
, O
legally O
blind O
right O
eye O
secondary O
to O
injury O


 O
Social O
History O
: O

 O
widowed O
, O
lives O
alone O
independently O


 O
Family O
History O
: O

 O
noncontributory O


 O
Physical O
Exam O
: O

 O
ON O
ADMISSION O

 O
VS- O
T O
98.6 O
, O
P O
61 O
, O
BP O
120/40 O
, O
RR O
18 O
, O
O2 O
97 O
% O
on O
ventillator O

 O
Gen- O
NAD O
, O
intubated O
, O
sedated O

 O
Heart- O
irregularly O
irregular O

 O
Lungs- O
coarse O
rhonchi O
throughout O

 O
Abdomen- O
soft O
, O
diffusley O
tender O
to O
palpationmidline O
incision O

 O
with O
necrotic O
edges O
, O
ostomy O
pink O
with O
green O
stool O

 O
Extremities- O
2 O
+ O
edema O
b/l O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
11:55PM O
   O
TYPE-ART O
PO2 O
- O
95 O
PCO2 O
- O
50 O
* O
PH-7.30 O
* O
TOTAL O

 O
CO2 O
- O
26 O
BASE O
XS--1 O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
11:17PM O
URINE O
  O
HOURS-RANDOM O
CREAT-97 O
SODIUM-39 O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
11:17PM O
URINE O
  O
COLOR-Amber O
APPEAR-Hazy O
SP O
[ O
* O
* O
Last O
Name O
( O
un O
) O
155**]-1.018 O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
11:17PM O
URINE O
  O
BLOOD-LG O
NITRITE-NEG O
PROTEIN-30 O

 O
GLUCOSE-NEG O
KETONE-TR O
BILIRUBIN-SM O
UROBILNGN-NEG O
PH-5.0 O
LEUK-SM O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
11:17PM O
URINE O
  O
RBC-[**6 O
- O
7 O
* O
* O
] O
* O
WBC-[**3 O
- O
2 O
* O
* O
] O
BACTERIA-MOD O

 O
YEAST-NONE O
EPI-0 O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
11:17PM O
URINE O
  O
GRANULAR-<1 O
HYALINE-0 O
- O
2 O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
11:12PM O
   O
TYPE-ART O
PO2 O
- O
86 O
PCO2 O
- O
54 O
* O
PH-7.26 O
* O
TOTAL O

 O
CO2 O
- O
25 O
BASE O
XS--3 O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
10:04PM O
   O
TYPE-ART O
PO2 O
- O
105 O
PCO2 O
- O
56 O
* O
PH-7.25 O
* O
TOTAL O

 O
CO2 O
- O
26 O
BASE O
XS--3 O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
10:04PM O
   O
LACTATE-2.0 O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
10:04PM O
   O
freeCa-1.05 O
* O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
09:54PM O
   O
GLUCOSE-135 O
* O
UREA O
N-63 O
* O
CREAT-2.6 O
* O
SODIUM-139 O

 O
POTASSIUM-4.6 O
CHLORIDE-105 O
TOTAL O
CO2 O
- O
21 O
* O
ANION O
GAP-18 O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
09:54PM O
   O
CALCIUM-7.5 O
* O
PHOSPHATE-2.8 O
MAGNESIUM-2.1 O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
09:54PM O
   O
WBC-22.1 O
* O
RBC-3.15 O
* O
HGB-9.4 O
* O
HCT-28.9 O
* O
MCV-92 O

 O
MCH-29.7 O
MCHC-32.4 O
RDW-16.0 O
* O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
09:54PM O
   O
NEUTS-83 O
* O
BANDS-3 O
LYMPHS-5 O
* O
MONOS-2 O
EOS-3 O

 O
BASOS-1 O
ATYPS-0 O
METAS-2 O
* O
MYELOS-1 O
* O
NUC O
RBCS-1 O
* O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
09:54PM O
   O
HYPOCHROM-1 O
+ O
ANISOCYT-1 O
+ O
POIKILOCY-NORMAL O

 O
MACROCYT-NORMAL O
MICROCYT-NORMAL O
POLYCHROM-OCCASIONAL O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
09:54PM O
   O
PLT O
SMR-LOW O
PLT O
COUNT-104 O
* O

 O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
09:54PM O
   O
PT-38.5 O
* O
PTT-100.0 O
* O
INR(PT)-4.2 O
* O


 O
Brief O
Hospital O
Course O
: O

 O
Briefly O
, O
Mr. O
[ O
* O
* O
Known O
lastname O
77982 O
* O
* O
] O
was O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
from O
[ O
* O
* O
Hospital1 O
* O
* O
] O
on O
[ O
* O
* O
2112 O
- O
3 O
- O
30 O
* O
* O
] O
after O
subtotal O
colectomy O
for O
LGIB B-REA
requiring O
a O

 O
massive O
transfusion O
of O
8u B-DOS
pRBC B-DRUG
. I-DRUG


 O
His O
[ O
* O
* O
Hospital O
18 O
* O
* O
] O
hospital O
course O
is O
broken O
down O
by O
systems O
: O



 O
Neuro O

 O
He O
was O
intermittently O
sedated B-REA
with O
fentanyl B-DRUG
and O
propofol B-DRUG
. I-DRUG
  O
His O

 O
sedation O
was O
weaned O
to O
prn B-FRE
dilaudid B-DRUG
and O
oxycodone B-DRUG
liquid B-FOR
. I-FOR
  O
Pain O

 O
gradually O
became O
a O
nonissue O
. O
  O
He O
should O
not O
require O
pain O

 O
medication O
even O
for O
VAC O
changes O
. O
  O
He O
was O
seen O
by O
neurology O
for O

 O
dystonia O
, O
who O
recommended O
an O
MRI O
of O
the O
brain O
whcih O
showed O
an O

 O
acute O
left O
parietal O
subcortical O
infarct O
. O
  O
The O
neurologist O
felt O

 O
that O
coumadinizing O
him O
with O
a O
goal O
INR O
2.5- O
3.5 O
would O
be O
best O
to O

 O
prevent O
another O
stroke O
. O
  O
The O
etiology O
of O
his O
stoke O
is O
presumed O

 O
cardiac O
given O
his O
atrial O
fibrillation O
. O
  O
His O
cognition O
gradually O

 O
improved O
throughout O
his O
hospital O
course O
, O
as O
did O
his O
dystonia B-REA
, I-REA

 O
for O
which O
he O
is O
on O
cogentin B-DRUG
per O
neurology O
. O
  O
At O
present O
, O
he O
is O

 O
alert O
and O
can O
communicate O
effectovely O
. O


 O
Cards O

 O
On O
admission O
, O
Mr. O
[ O
* O
* O
Known O
lastname O
77982 O
* O
* O
] O
had O
afib B-REA
with O
RVR O
for O
which O
he O
was O
on O

 O
an O
amiodarone B-DRUG
gtt B-ROU
. I-ROU
  O
He O
was O
evaluated O
by O
cardiology O
and O
weaned O

 O
off O
amiodarone B-DRUG
. I-DRUG
  O
After O
amiodarone B-DRUG
was O
weaned O
, O
his O
rhythm O
was O

 O
intermittently O
in O
and O
out O
of O
afib B-REA
. I-REA
  O
He O
eventually O
stabilized O
on O

 O
PO B-ROU
lopressor B-DRUG
and O
PO B-ROU
amiodarone B-DRUG
. I-DRUG
  O
In O
addition O
, O
he O
was O

 O
intermittently O
on O
and O
off O
pressors B-DRUG
, I-DRUG
including O
levophed B-DRUG
and O

 O
pitressin B-DRUG
. I-DRUG
  O
Eventually O
he O
stabilized O
and O
has O
been O
off O
of O
all O

 O
pressors B-DRUG
for O
over O
2 O
weeks O
prior O
to O
discharge O
. O


 O
Pulm O

 O
The O
patient O
had O
a O
tracheostomy O
. O
  O
He O
was O
gradually O
weaned O
on O
the O

 O
ventillator O
. O
  O
Eventually O
he O
was O
weaned O
to O
trach O
collar O
, O
which O
he O

 O
has O
been O
tolerating O
for O
over O
2 O
weeks O
. O
  O
On O
[ O
* O
* O
5 O
- O
4 O
* O
* O
] O
, O
he O
did O
tolerate O
a O

 O
Passy-muir O
valve O
trial O
. O
  O
He O
requires O
supervision O
with O
the O
PM O

 O
valve O
, O
because O
he O
desaturates O
. O
  O
He O
does O
require O
suctioning O

 O
intermittently O
. O



 O
FEN/GI O

 O
Tube O
feeds O
via O
Dobhoff O
, O
TPN O
, O
ostomy O
, O
serial O
abdominal O

 O
debridements O
[ O
* O
* O
4 O
- O
4 O
* O
* O
] O
, O
[ O
* O
* O
4 O
- O
8 O
* O
* O
] O
, O
and O
abdominal O
VAC O
[ O
* O
* O
4 O
- O
12 O
* O
* O
] O
, O
16 O
, O
17 O
, O
20 O
, O
24 O
, O

 O
26 O
and O
Q O
3 O
days O
thereafter O
. O
  O
Last O
VAC O
change O
was O
[ O
* O
* O
2112 O
- O
5 O
- O
8 O
* O
* O
] O
. O
  O
His O

 O
abdominal O
wound O
has O
been O
healing O
very O
well O
with O
a O
VAC O
dressing O
. O

 O
It O
is O
granulating O
nicely O
. O
  O
There O
had O
been O
a O
fistulous O
connection O

 O
between O
the O
ostomy O
and O
the O
wound O
. O
  O
This O
has O
since O
closed O
off O

 O
after O
a O
few O
vicryl O
sutures O
were O
placed O
at O
the O
bedside O
. O
  O
He O
was O

 O
seen O
and O
evaluated O
by O
plastic O
surgery O
who O
recommended O
outpatient O

 O
skin O
grafting O
. O
  O
He O
has O
been O
tolerating O
tube O
feeds O
at O
goal O
for O

 O
over O
2 O
weeks O
prior O
to O
discharge O
and O
his O
ostomy O
is O
productive O
. O

 O
He O
gets O
his O
tube O
feeds O
via O
a O
Dobhoff O
. O
  O
We O
did O
not O
feel O
that O
a O

 O
PEG O
was O
a O
good O
idea O
in O
him O
beacause O
of O
his O
anatomy O
. O
  O
He O
was O

 O
hypernatremic O
to O
153 O
at O
a O
maximum O
, O
but O
he O
did O
respond O
to O
free O

 O
water B-DRUG
boluses B-DOS
and O
his O
sodium O
has O
since O
stabilized O
. O
  O
We O
have O

 O
since O
decreased O
his O
free O
water B-DRUG
boluses B-DOS
. I-DOS


 O
GU O

 O
He O
developed O
ARF B-REA
and O
started O
hemodialysis O
at O
the O
referring O

 O
institution O
x3 O
days O
. O
  O
Daily O
CVVH O
was O
started O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
via O
R O
fem O

 O
HD O
catheter O
, O
and O
he O
was O
weaned O
off O
CVVH O
, O
intermittently O
on O

 O
lasix B-DRUG
, I-DRUG
and O
he O
now O
makes O
appropriate O
urine O
output O
without O
any O

 O
assistance O
. O
  O
His O
azotemia O
gradually O
cleared O
. O
  O
Withing O
the O
past O

 O
week O
, O
we O
have O
started O
gradual O
diuresis O
to O
make O
him O
about O
a O
liter O

 O
negative O
daily O
. O
  O
His O
weights O
have O
been O
retruning O
to O
baseline O
of O

 O
98 O
kg O
. O


 O
H O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
77982 O
* O
* O
] O
was O
found O
to O
have O
small O
peripheral O
PEs B-REA
and O
HIT B-REA
at O

 O
the O
referring O
institution O
, O
and O
was O
continued O
on O
an O
argatroban B-DRUG

 I-DRUG
gtt B-ROU
. I-ROU
  O
Eventually O
he O
was O
transitioned O
off O
the O
argatroban B-DRUG
to O

 O
coumadin B-DRUG
. I-DRUG
  O
He O
was O
found O
to O
be O
HIT O
negative O
by O
seratonin O
release O

 O
assay O
. O
  O
He O
is O
currently O
on O
coumadin B-DRUG
, I-DRUG
goal O
INR O
2.5- O
3.5 O
. O



 O
ID O

 O
The O
patient O
had O
a O
long O
and O
complicated O
infectious O
disease O

 O
course O
. O

 O
Meropenem B-DRUG
( O
[ O
* O
* O
4 O
- O
16 O
* O
* O
] O
) O
and O
vancomycin B-DRUG
( O
[ O
* O
* O
4 O
- O
17 O
* O
* O
] O
) O
for O
MRSA B-REA
PNA I-REA
, I-REA
fluconazole B-DRUG

 I-DRUG
for O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
* O
* O
] O
torulopsis B-REA
in O
the O
urine O
and O
sputum O
[ O
* O
* O
4 O
- O
19 O
* O
* O
] O
, O
flagyl B-DRUG

 I-DRUG
empircally O
for O
C. B-REA
diff I-REA
( O
although O
he O
never O
tested O
positive O
) O
[ O
* O
* O
4 O
- O
20 O
* O
* O
] O

 O
Cultures O
include O

 O
Klebsiella O
in O
blood O
at O
OSH O

 O
[ O
* O
* O
3 O
- O
31 O
* O
* O
] O
Wound O
cx O
: O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
* O
* O
] O
, O
klebs O

 O
[ O
* O
* O
4 O
- O
3 O
* O
* O
] O
Sputum O
: O
budding O
yeast O
, O
GNR O
, O
MRSA O

 O
[ O
* O
* O
4 O
- O
10 O
* O
* O
] O
Sputum O
: O
sparse O
klebs O
[ O
* O
* O
Last O
Name O
( O
un O
) O
36 O
* O
* O
] O
to O
cipro/bactrim B-DRUG

 I-DRUG
[ O
* O
* O
4 O
- O
14 O
* O
* O
] O
Sputum O
: O
MRSA O
, O
Klebs O

 O
[ O
* O
* O
4 O
- O
17 O
* O
* O
] O
sputum O
: O
MRSA O
, O
2+budding O
yeast O
, O
sparse O
GNR O

 O
[ O
* O
* O
4 O
- O
20 O
* O
* O
] O
sputum O
: O
MRSA O
and O
1+budding O
yeast O


 O
Eventually O
, O
all O
antiobiotics B-DRUG
were O
stopped O
on O
[ O
* O
* O
2112 O
- O
5 O
- O
4 O
* O
* O
] O
. O


 O
Endo O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
77982 O
* O
* O
] O
was O
kept O
on O
a O
strict O
insulin B-DRUG
sliding B-DOS
scale I-DOS
to O
keep B-REA

 I-REA
his I-REA
sugars I-REA
within I-REA
a I-REA
tight I-REA
range I-REA
. I-REA


 O
Medications O
on O
Admission O
: O

 O
lisinipril B-DRUG
20 B-STR
' I-STR
, O
acebutolol B-DRUG
400 B-STR
' I-STR
, O
allopurinol B-DRUG
300 B-STR
' I-STR
, O
lipitor B-DRUG
10 B-STR
' I-STR
, O

 O
ASA B-DRUG
325 B-STR
' I-STR
, O
MVI B-DRUG



 I-DRUG
Discharge O
Medications O
: O

 O
1 O
. O
Maalox B-DRUG
200 B-STR
- I-STR
200 I-STR
- I-STR
20 I-STR
mg/5 I-STR
mL I-STR
Suspension B-FOR
[ O
* O
* O
Known O
lastname O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
TID B-FRE

 I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
2 O
. O
Artificial B-DRUG
Tear I-DRUG
with I-DRUG
Lanolin I-DRUG
0.1 B-STR
- I-STR
0.1 I-STR
% O
Ointment B-FOR
[ O
* O
* O
Known O
lastname O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Appl B-FOR
Ophthalmic B-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Polyvinyl B-DRUG
Alcohol I-DRUG
1.4 B-STR
% O
Drops B-FOR
[ O
* O
* O
Known O
lastname O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Drop B-FOR
Ophthalmic B-ROU

 I-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Docusate B-DRUG
Sodium I-DRUG
50 B-STR
mg/5 I-STR
mL I-STR
Liquid B-FOR
[ O
* O
* O
Known O
lastname O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Oxycodone B-DRUG
5 B-STR
mg/5 I-STR
mL I-STR
Solution B-FOR
[ O
* O
* O
Known O
lastname O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
PO B-ROU
every B-FRE
eight I-FRE
( I-FRE
8) I-FRE

 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
6 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Known O
lastname O
* O
* O
] O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE

 I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
, I-REA
fever B-REA
. I-REA

 O
7 O
. O
Lansoprazole B-DRUG
30 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
, I-FOR
DR I-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
, I-FOR
DR I-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Zinc B-DRUG
Sulfate I-DRUG
220 B-STR
mg I-STR
Capsule B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Allopurinol B-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
1.5 B-DOS
Tablets B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
10 O
. O
Benztropine B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Amiodarone B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE

 I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Warfarin B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
ONCE B-FRE
( I-FRE
Once I-FRE
) I-FRE
for B-DUR

 I-DUR
1 I-DUR
doses I-DUR
: I-DUR
check O
daily O
INR O
. O

 O
14 O
. O
Furosemide B-DRUG
10 B-STR
mg/mL I-STR
Solution B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Injection B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 O

 O
times O
a O
day O
) O
. O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O



 O
Facility O
: O

 O
[ O
* O
* O
Hospital1 O
685**]- O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
LGIB O
s/p O
colectomy O

 O
anastomotic O
leak O
s/p O
exlap O
, O
Hartmann O
's O

 O
renal O
failure O

 O
pulmonary O
emboli O

 O
sepsis O

 O
rapid O
atrial O
fibrillation O

 O
large O
abdominal O
wound O

 O
dystonia O

 O
CVA O



 O
Discharge O
Condition O
: O

 O
good O



 O
Discharge O
Instructions O
: O

 O
Please O
call O
or O
come O
to O
the O
ED O
with O
any O
fevers O
> O
101 O
, O
nausea O
, O

 O
vomiting O
, O
abdominal O
pain O
, O
purulence O
from O
wounds O
, O
oliguria O
, O

 O
hypotension O
, O
rapid O
atrail O
fibrillation O
, O
or O
any O
other O
worrisome O

 O
issues O
. O
  O
Please O
continue O
all O
medications O
as O
directed O
. O
  O
Activity O

 O
as O
tolerated O
. O


 O
Followup O
Instructions O
: O

 O
Please O
call O
the O
office O
of O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
to O
schedule O
a O
follow-up O

 O
appointment O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1483 O
* O
* O
] O




 O
Completed O
by:[**2112 O
- O
5 O
- O
9 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2183 O
- O
2 O
- O
3 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2127 O
- O
12 O
- O
9 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Codeine B-DRUG
/ O
Darvon B-DRUG
/ O
Nafcillin B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
689 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
s/p O
recent O
fall O
with O
" O
inability O
to O
walk O
. O
" O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
# O
L2-S1 O
laminectomy O
, O
foraminotomy O
, O
facetectomy O
, O
irrigation O
, O
for O

 O
severe O
spinal O
stenosis O
and O
epidural O
abscess O
on O
[ O
* O
* O
2184 O
- O
1 O
- O
2 O
* O
* O
] O
. O

 O
# O
C2-C7 O
laminectomy O
, O
irrigation O
for O
epidural O
abscess O
. O
  O
C3-C7 O

 O
posterior O
instrumentation O
and O
fusion O
for O
cervical O
instability O
on O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
8 O
* O
* O
] O
. O

 O
# O
Aspiration O
of O
retropharyngeal O
abscess O
. O

 O
# O
Chest O
tube O
placement O
for O
pulmonary O
empyema O
. O

 O
# O
Bilateral O
knee O
arthrocentesis O
, O
partial O
synovectomy O
, O
surgical O

 O
debridement O
and O
washout O
for O
septic O
joints O
on O
[ O
* O
* O
2183 O
- O
1 O
- O
10 O
* O
* O
] O
. O

 O
# O
Debridement O
of O
postoperative O
lumbar O
wound O
, O
decompression O
of O

 O
L4-L5 O
and O
repair O
of O
dural O
leak O
on O
[ O
* O
* O
2183 O
- O
1 O
- O
25 O
* O
* O
] O
. O



 O
History O
of O
Present O
Illness O
: O

 O
pt O
is O
a O
a O
55 O
F O
with O
h/o B-REA
RA I-REA
( O
on O
methotrexate B-DRUG
, I-DRUG
enbrel B-DRUG
, I-DRUG
prednisone B-DRUG
) I-DRUG

 O
and O
spinal O
stenosis O
who O
presented O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
on O
[ O
* O
* O
2184 O
- O
1 O
- O
1 O
* O
* O
] O
s/p O

 O
recent O
fall O
with O
" O
inability O
to O
walk O
. O
" O
Pt O
apparently O
had O

 O
developed O
increasing O
weakness O
of O
her O
lower O
extremities O
with O
some O

 O
urinary O
incontinence O
. O
Upon O
arrival O
to O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
pt O
was O
treated O
with O

 O
narcotics B-DRUG
for O
pain B-REA
of I-REA
the I-REA
left I-REA
lower I-REA
extremity I-REA
and I-REA
back I-REA
, I-REA
and O

 O
developed O
mental B-ADE
status I-ADE
changes I-ADE
. I-ADE
Her O
O2 B-ADE
sats I-ADE
acutely I-ADE
dropped I-ADE
, I-ADE

 O
( O
etiology O
unclear O
, O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O
narcotics B-DRUG
versus O
infiltrate O
) O
, O
with O

 O
tachycardia B-ADE
to O
140s O
, O
hypoxia B-ADE
to O
88 O
% O
, O
and O
CTA B-ADE
showing I-ADE
RLL/RML I-ADE

 I-ADE
opacity O
but O
no O
PE O
. O
Pt O
was O
intubated O
for O
airway O
protection O
and O

 O
transferred O
to O
MICU O
. O

 O
. O


 O
MRI O
spine O
on O
[ O
* O
* O
1 O
- O
1 O
* O
* O
] O
revealed O
severe O
L3-L5 O
spinal O
stenosis O
for O

 O
which O
pt O
underwent O
lumbar O
decompression O
of O
L2-S1 O
on O
[ O
* O
* O
1 O
- O
2 O
* O
* O
] O
with O

 O
gross O
pus O
evident O
in O
epidural O
space O
. O
X-ray O
of O
the O
foot O
revealed O

 O
left O
ankle O
fracture O
, O
for O
which O
she O
was O
placed O
in O
a O
walking O
cast O
. O

 O
She O
also O
had O
cervical O
and O
retropharyngeal O
abscesses O
, O
for O
which O

 O
she O
underwent O
cervical O
decompression O
and O
drainage O
of O
cervical O

 O
abscesses O
, O
from O
C2-C7 O
, O
with O
instrumentation O
and O
fusion O
from O

 O
C3-C7 O
, O
on O
[ O
* O
* O
2183 O
- O
1 O
- O
8 O
* O
* O
] O
. O
Retropharyngeal O
abcesses O
were O
drained O
, O
and O

 O
she O
had O
bilateral O
knee O
arthrocentesis O
and O
washout O
for O
septic B-REA

 I-REA
joints I-REA
. I-REA
Pt O
was O
treated O
with O
vancomycin B-DRUG
after O
nafcillin B-DRUG
resulted O

 O
in O
rash B-ADE
( O
pt O
seen O
by O
derm O
, O
termed O
" O
drug O
hypersensitivity O
" O
) O
. O
In O

 O
addition O
, O
on O
[ O
* O
* O
1 O
- O
3 O
* O
* O
] O
pt O
noted O
to O
have O
SVT B-REA
, I-REA
with I-REA
rate I-REA
up I-REA
to I-REA
the I-REA

 I-REA
160s I-REA
, I-REA
and O
SBP B-REA
decrease I-REA
. I-REA
She O
was O
cardioverted O
x2 O
and O
started O
on O

 O
amiodarone B-DRUG
, I-DRUG
which O
has O
since O
been O
discontinued O
. O
Pt O
seen O
by O

 O
cardiology O
, O
without O
apparent O
further O
recommendation O
. O

 O
. O

 O
Pt O
most O
recently O
taken O
to O
OR O
on O
[ O
* O
* O
2183 O
- O
1 O
- O
25 O
* O
* O
] O
for O
debridement O
of O

 O
postoperative O
lumbar O
wound O
, O
and O
decompression O
of O
L4 O
- O
5 O
and O
repair O

 O
of O
dural O
leak O
after O
pt O
was O
persistently O
febrile O
and O
MRI O
of O

 O
lumbar O
spine O
showed O
fluid O
collection O
( O
+ O
GPC O
per O
aspiration O
) O
. O
Pt O

 O
last O
febrile O
on O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
. O

 O
. O

 O
Pt O
exubated O
on O
[ O
* O
* O
1 O
- O
21 O
* O
* O
] O
per O
notes O
, O
and O
now O
breathing O
comfortably O
on O

 O
RA O
. O
Lower O
extremity O
weakness O
appears O
largely O
resolved O
, O
though O
pt O

 O
signficantly O
deconditioned O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O
hospitalization O
. O
Per O
ortho/spine O
, O

 O
pt O
full O
weight O
bearing O
, O
though O
must O
wear O
hard O
cervical O
collar O
at O

 O
all O
times O
, O
and O
TLSO O
brace O
whenever O
out O
of O
bed O
. O


 O
Past O
Medical O
History O
: O

 O
HTN O

 O
Rheumatoid O
arthritis O

 O
depression O

 O
migraine O

 O
hiatal O
hernia O

 O
anxiety O

 O
spinal O
stenosis O

 O
lumbar O
radiculopathy O

 O
myofascial O
pain O


 O
Social O
History O
: O

 O
Single O
, O
She O
is O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
RN O
but O
has O
been O
working O
as O
a O
nurse O
's O
aid O
. O

 O
Drinks O
EtOH O
rarely O
, O
denies O
smoking O
or O
other O
drug O
use O
. O


 O
Family O
History O
: O

 O
Mother O
with O
CAD O
, O
duodenal O
ulcers O
. O
  O
Father O
with O
CAD O
died O
of O

 O
esophageal O
CA O
with O
mets O
to O
the O
brain O
. O
  O
Breast O
cancer O
in O
paternal O

 O
aunt O
. O



 O
Physical O
Exam O
: O

 O
On O
presentation O
to O
the O
ED O
: O

 O
VS O
: O
  O
98.3 O
   O
132 O
  O
142/72 O
16 O
   O
95%RA O

 O
GEN O
: O
Uncomfortable O
with O
movement O

 O
HEENT O
: O
PERRLA O
, O
EOMI O
, O
sclera O
anicteric O
, O
OP O
clear O
, O
dry O
mucous O

 O
membranes O
, O
no O
LAD O

 O
CV O
: O
tachy O
, O
nl O
s1 O
, O
s2 O
, O
no O
m/r/g O
. O

 O
PULM O
: O
CTA O
anteriorly O

 O
ABD O
: O
soft O
, O
mild O
diffuse O
tenderness O

 O
EXT O
: O
warm O
, O
2 O
+ O
dp/radial O
pulses O
BL O
. O
  O
finger O
ulnar O
deviation O
, O

 O
swollen O
PIP O
and O
MCP O
joints O
. O
  O
echymosis O
of O
left O
ankle O

 O
NEURO O
: O
alert O
& O
oriented O
x O
3 O
, O
CN O
II-XII O
grossly O
intact O
. O

 O
PSYCH O
: O
tangential O



 O

Pertinent O
Results O
: O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
03:55PM O
   O
GLUCOSE-133 O
* O
UREA O
N-48 O
* O
CREAT-0.8 O
SODIUM-141 O

 O
POTASSIUM-4.2 O
CHLORIDE-108 O
TOTAL O
CO2 O
- O
23 O
ANION O
GAP-14 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
04:03PM O
   O
LACTATE-2.1 O
* O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
05:22PM O
   O
TYPE-ART O
O2 O
- O
100 O
PO2 O
- O
250 O
* O
PCO2 O
- O
43 O
PH-7.34 O
* O

 O
TOTAL O
CO2 O
- O
24 O
BASE O
XS--2 O
AADO2 O
- O
429 O
REQ O
O2 O
- O
73 O
INTUBATED-INTUBATED O

 O
VENT-CONTROLLED O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
03:55PM O
   O
GLUCOSE-133 O
* O
UREA O
N-48 O
* O
CREAT-0.8 O
SODIUM-141 O

 O
POTASSIUM-4.2 O
CHLORIDE-108 O
TOTAL O
CO2 O
- O
23 O
ANION O
GAP-14 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
05:42PM O
   O
PT-12.3 O
PTT-28.2 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
03:55PM O
   O
ALT(SGPT)-28 O
AST(SGOT)-48 O
* O
LD(LDH)-228 O
ALK O

 O
PHOS-184 O
* O
AMYLASE-24 O
TOT O
BILI-0.5 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
03:55PM O
   O
CK-MB-5 O
cTropnT-<0.01 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
03:55PM O
   O
ALBUMIN-2.4 O
* O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
03:55PM O
   O
WBC-4.6 O
RBC-3.93 O
* O
HGB-10.6 O
* O
HCT-30.8 O
* O
MCV-78 O
* O

 O
MCH-27.0 O
MCHC-34.5 O
RDW-18.0 O
* O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
03:55PM O
   O
NEUTS-72 O
* O
BANDS-13 O
* O
LYMPHS-9 O
* O
MONOS-5 O
EOS-0 O

 O
BASOS-0 O
ATYPS-1 O
* O
METAS-0 O
MYELOS-0 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
8 O
* O
* O
] O
02:44AM O
BLOOD O
Neuts-90.8 O
* O
Bands-0 O
Lymphs-7.3 O
* O

 O
Monos-1.4 O
* O
Eos-0.4 O
Baso-0 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
17 O
* O
* O
] O
05:26PM O
PLEURAL O
WBC-450 O
* O
RBC-1570 O
* O
Polys-11 O
* O
Lymphs-62 O
* O

 O
Monos-2 O
* O
Meso-12 O
* O
Macro-2 O
* O
Other-11 O
* O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
17 O
* O
* O
] O
05:26PM O
PLEURAL O
TotProt-1.6 O
Glucose-130 O
LD(LDH)-147 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
9 O
* O
* O
] O
08:44AM O
JOINT O
FLUID O
WBC-6500 O
* O
RBC-3700 O
* O
Polys-97 O
* O

 O
Lymphs-1 O
Monos-2 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
7 O
* O
* O
] O
11:55AM O
JOINT O
FLUID O
WBC-[**Numeric O
Identifier O
15362 O
* O
* O
] O
* O
RBC-[**Numeric O
Identifier O
15363 O
* O
* O
] O
* O
Polys-85 O
* O

 O
Lymphs-3 O
Monos-12 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
9 O
* O
* O
] O
08:44AM O
JOINT O
FLUID O
Crystal-NONE O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
7 O
* O
* O
] O
11:55AM O
JOINT O
FLUID O
Crystal-NONE O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
24 O
* O
* O
] O
11:45AM O
OTHER O
BODY O
FLUID O
TotProt-1.5 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
24 O
* O
* O
] O
11:45AM O
OTHER O
BODY O
FLUID O
TotProt-0.4 O
Glucose-54 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
31 O
* O
* O
] O
05:52AM O
BLOOD O
WBC-9.5 O
RBC-3.28 O
* O
Hgb-9.3 O
* O
Hct-29.3 O
* O

 O
MCV-89 O
MCH-28.3 O
MCHC-31.7 O
RDW-16.2 O
* O
Plt O
Ct-521 O
* O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
31 O
* O
* O
] O
05:52AM O
BLOOD O
Neuts-70.0 O
Lymphs-19.0 O
Monos-7.1 O
Eos-3.0 O

 O
Baso-0.9 O

 O

[ O
* O
* O
2183 O
- O
1 O
- O
31 O
* O
* O
] O
05:52AM O
BLOOD O
Glucose-79 O
UreaN-9 O
Creat-0.4 O
Na-134 O
K-3.5 O

 O
Cl-98 O
HCO3 O
- O
29 O
AnGap-11 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
30 O
* O
* O
] O
06:30AM O
BLOOD O
ALT-16 O
AST-33 O
LD(LDH)-406 O
* O
CK(CPK)-26 O

 O
AlkPhos-112 O
TotBili-0.7 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
30 O
* O
* O
] O
11:31PM O
BLOOD O
CK(CPK)-9 O
* O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
31 O
* O
* O
] O
05:52AM O
BLOOD O
Calcium-9.2 O
Phos-3.7 O
Mg-2.1 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
30 O
* O
* O
] O
05:08PM O
BLOOD O
TSH-1.2 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
30 O
* O
* O
] O
05:08PM O
BLOOD O
Free O
T4 O
- O
1.4 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
2 O
* O
* O
] O
03:21PM O
BLOOD O
Cortsol-7.5 O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
29 O
* O
* O
] O
05:40AM O
BLOOD O
CRP-66.6 O
* O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
2 O
* O
* O
] O
10:15AM O
BLOOD O
PEP-HYPOGAMMAG O
IgG-312 O
* O
IgA-119 O
IgM-35 O
* O

 O
IFE-POSSIBLE O
T O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
30 O
* O
* O
] O
06:30AM O
BLOOD O
Vanco-30.7 O
* O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
31 O
* O
* O
] O
05:52AM O
BLOOD O
WBC-9.5 O
RBC-3.28 O
* O
Hgb-9.3 O
* O
Hct-29.3 O
* O

 O
MCV-89 O
MCH-28.3 O
MCHC-31.7 O
RDW-16.2 O
* O
Plt O
Ct-521 O
* O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
27 O
* O
* O
] O
MRSA O
blood O
cultures O
negative O

 O
[ O
* O
* O
2183 O
- O
1 O
- O
27 O
* O
* O
] O
VRE O
rectal O
swab O
negative O

 O
. O

 O
IMAGING O
: O

 O
CT B-REA
ABDOMEN I-REA
W/CONTRAST B-DRUG
  O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
6:01 O
PM O

 O
1 O
. O
No O
major O
organ O
injury O
in O
the O
abdomen O
. O

 O
2 O
. O
Bilateral O
acute O
and O
chronic O
rib O
fractures O
as O
described O
above O
, O

 O
as O
seen O
on O
the O
prior O
chest O
CT O
. O

 O
3 O
. O
Bilateral O
pleural O
effusion O
with O
bibasilar O
atelectasis O
as O
seen O

 O
on O
the O
prior O
CT O
. O

 O
4 O
. O
Small O
left O
retroperitoneal O
fluid O
. O

 O
. O

 O
CTA O
CHEST O
W&W/O O
C O
& O
RECONS O
  O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
11:40 O
AM O

 O
1 O
. O
Airspace O
opacities O
in O
the O
lower O
lobe O
and O
right O
middle O
lobe O

 O
with O
volume O
loss O
suggesting O
atelectasis O
, O
but O
pneumonia O
can O
not O
be O

 O
completely O
excluded O
on O
the O
radiology O
basis O
. O

 O
2 O
. O
Bilateral O
pleural O
effusions O
. O

 O
3 O
. O
No O
pulmonary O
embolus O
identified O
. O

 O
4 O
. O
Multiple O
old O
fractures O
of O
the O
ribs O
bilaterally O
at O
different O

 O
stages O
. O
Some O
are O
clearly O
healed O
, O
some O
are O
healing O
and O
some O

 O
appear O
somewhat O
acute O
. O
Clinical O
correlation O
is O
recommended O
. O

 O
. O

 O
MR O
L O
SPINE O
W/O O
CONTRAST B-DRUG
  O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
5:56 O
PM O

 O
At O
L2/3 O
, O
moderate O
canal O
stenosis O
due O
to O
degenerative O
changes O
and O

 O
epidural O
lipomatosis O
. O
At O
L3/4 O
and O
L4/5 O
, O
severe O
canal O
stenosis O

 O
and O
severe O
right O
foraminal O
stenosis O
due O
to O
combination O
of O

 O
degenerative O
changes O
, O
disk O
herniations O
, O
and O
epidural O

 O
lipomatosis O
. O

 O
. O


 O
CHEST O
( O
PA O
& O
LAT O
) O
  O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
8:45 O
AM O

 O
Bibasilar O
atelectasis O
with O
possible O
infiltrate O
at O
the O
right O

 O
base O
. O

 O
No O
other O
obvious O
acute O
findings O
. O

 O
. O

 O
ANKLE O
( O
AP O
, O
MORTISE O
& O
LAT O
) O
LEFT O
  O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
7:04 O
AM O

 O
1 O
. O
Base O
of O
fifth O
metatarsal O
fracture O
. O

 O
2 O
. O
Possible O
nondisplaced O
distal O
fibular O
fracture O
. O

 O
. O

 O
ECG O
Study O
Date O
of O
[ O
* O
* O
2183 O
- O
1 O
- O
1 O
* O
* O
] O
  O
4:23:48 O
PM O

 O
Sinus O
tachycardia O

 O
Right O
bundle O
branch O
block O

 O
Low O
voltage O

 O
Inferior O
ST O
segment O
elevation O
suggestive O
of O
inferior O
myocardial O

 O
infarction O

 O
Since O
previous O
tracing O
of O
[ O
* O
* O
2182 O
- O
12 O
- O
2 O
* O
* O
] O
, O
inferior O
changes O
are O
new O
- O

 O
clinical O

 O
correlation O
is O
suggested O

 O
. O

 O
ECHO O
Study O
Date O
of O
[ O
* O
* O
2183 O
- O
1 O
- O
3 O
* O
* O
] O

 O
The O
left O
atrium O
is O
normal O
in O
size O
. O
Left O
ventricular O
wall O

 O
thicknesses O
and O

 O
cavity O
size O
are O
normal O
. O
The O
left O
ventricular O
cavity O
size O
is O

 O
normal O
. O
Overall O
left O
ventricular O
systolic O
function O
is O
normal O

 O
( O
LVEF>55 O
% O
) O
. O
Right O
ventricular O
chamber O
size O
and O
free O
wall O
motion O

 O
are O
normal O
. O
The O
aortic O
valve O
leaflets O
(3)appear O
structurally O

 O
normal O
with O
good O
leaflet O
excursion O
. O
There O
is O
no O
aortic O
valve O

 O
stenosis O
. O
No O
aortic O
regurgitation O
is O
seen O
. O
The O
mitral O
valve O

 O
appears O
structurally O
normal O
with O
trivial O
mitral O
regurgitation O
. O

 O
There O
is O
moderate O
pulmonary O
artery O
systolic O
hypertension O
. O
There O

 O
is O
a O
very O
small O
pericardial O
effusion O
. O
There O
are O
no O

 O
echocardiographic O
signs O
of O
tamponade O
. O

 O
. O

 O
MR B-REA
[ O
* O
* O
Name13 O
( O
STitle O
) O
* O
* O
] O
W O
& O
W/O O
CONTRAST B-DRUG
  O
[ O
* O
* O
2183 O
- O
1 O
- O
11 O
* O
* O
] O
9:43 O
PM O

 O
1 O
. O
Overall O
improved O
prevertebral O
area O
of O
abscess O
seen O
on O
[ O
* O
* O
2183 O
- O
1 O
- O
6 O
* O
* O
] O
. O

 O
Secondary O
to O
inadequate O
post-contrast B-DRUG
T1-weighted O
images O
, O
the O

 O
tissue O
remaining O
in O
this O
area O
could O
represent O
either O
persistent O

 O
abscess O
versus O
postoperative O
changes O
. O
If O
clinically O
indicated O
, O
a O

 O
repeat O
, O
contrast-enhanced O
scan O
could O
be O
performed O
. O

 O
2 O
. O
Unchanged O
intraspinal O
epidural O
signal O
that O
overall O
appears O

 O
less O
extensive O
compared O
to O
previous O
exam O
. O

 O
3 O
. O
New O
hyperintense O
signal O
at O
the O
T2 O
to O
T3 O
interspace O
could O

 O
represent O
progression O
of O
discitis O
. O

 O
4 O
. O
Likely O
bilateral O
pleural O
effusions O
. O
Infectious O
etiology O

 O
can O
not O
be O
ruled O
out O
based O
on O
these O
images O
secondary O
to O
poor O

 O
post-contrast B-DRUG
study O
. O

 O
. O

 O
CHEST O
PORT O
. O
LINE O
PLACEMENT O
  O
[ O
* O
* O
2183 O
- O
1 O
- O
31 O
* O
* O
] O
9:55 O
AM O

 O
Interval O
placement O
of O
right-sided O
PICC O
line O
with O
tip O
in O
the O

 O
right O
atrium O
. O



 O
Brief O
Hospital O
Course O
: O

 O
Upon O
arrival O
to O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
pt O
was O
treated O
with O
narcotics B-DRUG
for O
pain B-REA
of I-REA
the I-REA

 I-REA
left I-REA
lower I-REA
extremity I-REA
and O
back O
, O
and O
developed O
mental O
status O

 O
changes O
. O
  O
Her O
O2 O
sats O
acutely O
dropped O
, O
( O
etiology O
unclear O
, O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O

 O
narcotics B-DRUG
versus O
infiltrate O
) O
, O
with O
tachycardia O
to O
140s O
, O
hypoxia O

 O
to O
88 O
% O
, O
and O
CTA O
showing O
RLL/RML O
opacity O
but O
no O
PE O
. O
  O
Pt O
was O

 O
intubated O
for O
airway O
protection O
and O
transferred O
to O
MICU O
. O

 O
. O

 O
MRI O
spine O
on O
[ O
* O
* O
1 O
- O
1 O
* O
* O
] O
revealed O
severe O
L3-L5 O
spinal O
stenosis O
. O
  O
X-ray O

 O
of O
the O
foot O
revealed O
left O
ankle O
fracture O
, O
for O
which O
she O
was O

 O
placed O
in O
a O
walking O
cast O
. O
  O
She O
also O
had O
cervical O
and O

 O
retropharyngeal O
abscesses O
, O
and O
was O
transferred O
to O
the O
SICU O
. O

 O
. O

 O
SICU O
Course O

 O
Pt O
was O
admitted O
to O
SICU O
post-operatively O
after O
L3/L4 O
& O
L5/s1 O

 O
decompression/laminectomy O
for O
epidural O
abscess O
on O
[ O
* O
* O
1 O
- O
2 O
* O
* O
] O
. O

 O
Neuro O
: O
PT O
was O
admitted O
with O
altered O
MS O
, O
and O
was O
maintained O
on O

 O
propofol B-DRUG
while O
intubated O
for O
sedation B-REA
. I-REA

 O
. O

 O
CV O
: O
PT O
had O
episode B-REA
of I-REA
SVT I-REA
on O
[ O
* O
* O
1 O
- O
3 O
* O
* O
] O
, O
was O
shocked O
twice O
and O

 O
returned O
to O
[ O
* O
* O
Location O
15364 O
* O
* O
] O
was O
consulted O
and O
recommended O

 O
amiodarone B-DRUG
, I-DRUG
which O
was O
d/c'd O
prior O
to O
transfer O
to O
floor O
. O
  O
Pt O
had O

 O
a O
TEE O
on O
[ O
* O
* O
1 O
- O
14 O
* O
* O
] O
that O
was O
negative O
for O
thrombus O
( O
concern O
for O
septic O

 O
emboli O
) O
. O
  O
Pt O
also O
had O
an O
IVC O
filter O
placed O
on O
[ O
* O
* O
1 O
- O
14 O
* O
* O
] O
for O
PE O

 O
prophylaxis O
. O
  O
Pt O
was O
maintained O
on O
lopressor B-DRUG
with O
tight B-REA
BP I-REA

 I-REA
control I-REA
while O
in O
the O
SICU O
, O
and O
she O
had O
no O
further O
cardiac O

 O
issues O
. O

 O
. O


 O
Resp O
: O
Pt O
was O
extubated O
initially O
on O
[ O
* O
* O
2183 O
- O
1 O
- O
5 O
* O
* O
] O
, O
but O
was O

 O
re-intubated O
on O
[ O
* O
* O
2183 O
- O
1 O
- O
6 O
* O
* O
] O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O
respiratory O
distress O
. O
  O
On O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
, O
pt O
had O

 O
R O
VATS/decortication/washout O
for O
R O
empyema O
, O
and O
on O
[ O
* O
* O
1 O
- O
17 O
* O
* O
] O
pt O
had O
a O

 O
pleural O
tap O
; O
the O
pleural O
fluid O
from O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
grew O
MSSA O
, O
and O
the O

 O
pleural O
fluid O
from O
[ O
* O
* O
1 O
- O
17 O
* O
* O
] O
was O
no O
growth O
. O
  O
Additionally O
, O
the O
pt O
had O

 O
2 O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
drains O
post-operatively O
that O
were O
pulled O
on O
[ O
* O
* O
1 O
- O
16 O
* O
* O
] O
and O

 O
[ O
* O
* O
1 O
- O
22 O
* O
* O
] O
. O

 O
. O

 O
Musculoskeletal O
: O
Pt O
had O
L3/L4 O
and O
L5/S1 O

 O
laminectomy/decompression O
on O
[ O
* O
* O
1 O
- O
2 O
* O
* O
] O
, O
on O
[ O
* O
* O
1 O
- O
7 O
* O
* O
] O
pt O
had O
C5 O
- O
6 O
ACDF O

 O
w/ICBG O
& O
Post O
Cervical O
decompression O
for O
cervical O
prevertebral O

 O
abscess O
, O
on O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
pt O
had O
knee O
tap O
with O
MSSA O
and O
subsequent O
bilat O

 O
knee O
washouts O
( O
left O
knee O
was O
not O
infected O
- O
the O
drains O
were O

 O
d/c'd O
on O
[ O
* O
* O
1 O
- O
11 O
* O
* O
] O
. O
  O
On O
[ O
* O
* O
1 O
- O
24 O
* O
* O
] O
, O
pt O
went O
to O
IR O
for O
drainage O
of O
L3,4,5 O

 O
collection O
( O
approx O
10cc O
out O
) O
. O
  O
On O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
, O
pt O
returned O
to O
OR O
w/ O

 O
ortho O
spine O
for O
debridement O
of O
postoperative O
lumbar O
wound O
, O
and O

 O
decompression O
of O
L4 O
- O
5 O
and O
repair O
of O
dural O
leak O
after O
pt O
was O

 O
persistently O
febrile O
and O
MRI O
of O
lumbar O
spine O
showed O
fluid O

 O
collection O
( O
+ O
GPC O
per O
aspiration O
) O
. O
  O
Pt O
last O
febrile O
on O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
. O

 O
. O

 O
ID O
: O
Pt O
was O
initially O
started O
on O
nafcillin/gentamicin B-DRUG
; I-DRUG
initial O
Cx O

 O
were O
positive B-REA
for I-REA
MSSA I-REA
and O
pt O
was O
maintained O
on O
nafcillin B-DRUG
until O

 O
[ O
* O
* O
1 O
- O
13 O
* O
* O
] O
, O
when O
she O
developed B-ADE
a I-ADE
drug I-ADE
rash I-ADE
and O
was O
changed O
to O

 O
vancomycin B-DRUG
. I-DRUG
  O
Additionally O
, O
on O
[ O
* O
* O
1 O
- O
18 O
* O
* O
] O
pt O
developed B-ADE
papular I-ADE
rash I-ADE

 I-ADE
over I-ADE
posterior I-ADE
thighs I-ADE
and I-ADE
peri-rectal I-ADE
area I-ADE
and O
was O
started O
on O

 O
acyclovir B-DRUG
. I-DRUG
  O
Pt O
was O
intermittently O
febrile O
without O
obvious O
source O

 O
throug O
much O
of O
ICU O
stay O
, O
but O
was O
afebrile O
for O
several O
days O
prior O

 O
to O
transfer O
to O
floor O
. O
  O
Her O
pertinent O
Cx O
data O
is O
below O
: O

 O
. O


 O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
: O
abscess O
Cx O
: O
coag O
+ O
staph O

 O
[ O
* O
* O
1 O
- O
21 O
* O
* O
] O
: O
UCx/BCx O
- O
NG O

 O
[ O
* O
* O
1 O
- O
18 O
* O
* O
] O
: O
+ O
HSV2 O
; O
skin O
tiss O
: O
rare O
CSNx2 O
, O
enterr O
, O
coryn O
, O
diptheriod O

 O
1/12,11 O
: O
BCx/Ucx/Scx/pleural/cath O
- O
all O
NG O

 O
1/7,8 O
: O
Ucx/Scx/BCx/cdiffx2 O
- O
all O
NG O

 O
[ O
* O
* O
1 O
- O
10 O
* O
* O
] O
: O
L O
knee/cath O
- O
NG O
; O
R O
knee/pleur O
- O
MSSA O
; O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
: O
tissue/pleur O
  O
- O

 O
MSSA O

 O
[ O
* O
* O
1 O
- O
8 O
* O
* O
] O
Bld O
Cx O
neg O
; O
[ O
* O
* O
1 O
- O
7 O
* O
* O
] O
tissue/joint/wound O
: O
MSSA O
; O
[ O
* O
* O
1 O
- O
2 O
* O
* O
] O
C5-C6 O
Cx O
: O

 O
MSSA O

 O
12/27,28,31 O
: O
BLd O
Cx O
MSSA O

 O
GI O
: O
While O
patient O
was O
intubated O
, O
she O
was O
started O
on O
tubefeeds O

 O
for O
nutrition O
; O
following O
extubation O
, O
pt O
was O
advanced O
to O
a O

 O
regular O
diet O
without O
problem O
. O
  O
Pt O
was O
maintained O
on O
GI B-REA
ulcer I-REA

 I-REA
prophylaxis I-REA
with O
H2-blocker B-DRUG
while O
in O
the O
ICU O
. O

 O
. O

 O
Medicine O
Floor O
Course O

 O
. O

 O
# O
Neuro O
: O
mental O
status O
improved O
spontaneously O
. O
  O
Neuro O
exam O

 O
stable O
. O
  O
CN2 O
- O
12 O
intact O
, O
MAE O
. O
4/4 O
strength O
B/L O
uppers O
, O
left O
> O

 O
right O
. O
  O
LE O
grossly O
intact O
bilaterally O
. O
  O
wiggles O
left O
toes O
. O
  O
hip O

 O
flexion O
, O
knee O
flexion O
and O
extension O
[ O
* O
* O
1 O
- O
10 O
* O
* O
] O
b/l O
. O
  O
[ O
* O
* O
5 O
- O
10 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
un O
) O
15365 O
* O
* O
] O
and O

 O
plantar O
flexion O
of O
right O
LE O
. O
  O
left O
LE O
wiggles O
toes O
, O
mobility O

 O
limited O
by O
cast O
. O
  O
Per O
ortho/spine O
, O
pt O
full O
weight O
bearing O
, O

 O
though O
must O
wear O
hard O
cervical O
collar O
at O
all O
times O
, O
and O
TLSO O

 O
brace O
for O
6 O
weeks O
whenever O
sitting O
up O
unsupported O
or O
out O
of O
bed O
. O


 O
-Vancomycin B-DRUG
was O
continued O
per O
ID O
recs O
for O
multiple B-REA
abcesses I-REA
, I-REA
at O

 O
least O
8 B-DUR
week I-DUR
duration O
s/p O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
debridement O
. O
Hardware O
cleared O
for O

 O
repeat O
MRI O
if O
needed O
. O

 O
. O


 O
# O
ID O
: O
last O
fever O
on O
[ O
* O
* O
1 O
- O
22 O
* O
* O
] O
was O
102.3 O
, O
pt O
was O
followed O
by O
ID O
for O

 O
multiple O
spinal O
abcesses O
, O
on O
vancomycin B-DRUG
for O
MSSA B-REA
given O
pt O
had O

 O
rash B-ADE
in O
reaction O
to O
nafcillin B-DRUG
( O
seen O
by O
derm O
, O
" O
drug B-ADE

 I-ADE
hypersensitivity I-ADE
reaction I-ADE
" I-ADE
on O
[ O
* O
* O
2183 O
- O
1 O
- O
13 O
* O
* O
] O
) O
. O
  O
Pt O
was O
placed O
on O

 O
acyclovir B-DRUG
for O
perianal B-REA
ulcers I-REA
which O
grew O
HSV O
2 O
on O
[ O
* O
* O
2183 O
- O
1 O
- O
18 O
* O
* O
] O
, O
but O

 O
this O
was O
d/c'ed O
[ O
* O
* O
2183 O
- O
1 O
- O
28 O
* O
* O
] O
. O
Leukocytosis O
trending O
down O
with O
normal O

 O
diff O
. O
  O
Prednisone B-DRUG
for O
RA B-REA
as O
above O
, O
but O
further O
immunosupression O

 O
was O
avoided O
. O
Vancomycin B-DRUG
was O
continued O
for O
now O
, O
plan O
for B-DUR
8 I-DUR
week I-DUR

 I-DUR
course O
s/p O
last O
debridement B-REA
on O
[ O
* O
* O
2183 O
- O
1 O
- O
25 O
* O
* O
] O
. O
  O
Vancomycin B-DRUG
end O
date O
is O

 O
[ O
* O
* O
2183 O
- O
3 O
- O
24 O
* O
* O
] O
. O
A O
psoas O
abcesses O
was O
too O
small O
to O
drain O
per O
IR O
. O

 O
Bilateral O
knee O
swelling O
s/p O
arthrocentesis O
and O
washout O
decreased O

 O
over O
time O
, O
without O
redness O
tenderness O
. O

 O
Needs O
weekly O
CBC O
w/diff O
, O
BUN/creat O
ratio O
, O
vanco B-DRUG
trough O
. O

 O
. O

 O
# O
PULMONARY O
: O
pt O
initially O
presented O
without O
respiratory O

 O
symptoms O
, O
however O
was O
intubated O
in O
ED O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O
increasing O
mental B-ADE

 I-ADE
status I-ADE
changes I-ADE
( O
? O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O
narcotic B-DRUG
medications I-DRUG
) I-DRUG
for O
airway O

 O
protection O
. O
  O
subsequent O
CT O
showed O
? O
right O
side O
pneumonia O
. O
  O
Pt O

 O
extubated O
on O
[ O
* O
* O
1 O
- O
5 O
* O
* O
] O
s/p O
OR O
for O
spinal O
procedure O
, O
then O
reintubated O

 O
on O
[ O
* O
* O
1 O
- O
6 O
* O
* O
] O
( O
presumably O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O
developing O
empyema O
felt O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O
septic O
emboli O

 O
for O
which O
pt O
went O
to O
OR O
on O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
for O
VATS O
and O
chest O
tube O

 O
placement O
, O
though O
not O
clear O
) O
, O
and O
extuabted O
on O
[ O
* O
* O
1 O
- O
21 O
* O
* O
] O
. O
  O
[ O
* O
* O
Name O
( O
NI O
) O
15366 O
* O
* O
] O
, O

 O
pt O
without O
SOB O
, O
on O
RA O
. O
  O
chest O
tube O
removed O
[ O
* O
* O
1 O
- O
27 O
* O
* O
] O
, O
and O
CXR O
s/p O

 O
removal O
showing O
small O
right O
side O
effusion O
, O
no O
PTX O
, O
no O
pneumonia O
. O

  O
O2 B-DRUG
was O
weaned O
, O
and O
ipratropium B-DRUG
nebs B-FOR
continued O
. O

 O
. O


 O
# O
CARDIAC O
: O
Pt O
was O
placed O
on O
telemetry O
. O
  O
Episode B-REA
of I-REA
SVT I-REA
on O
[ O
* O
* O
1 O
- O
30 O
* O
* O
] O

 O
to O
120s O
, O
no O
chest O
pain O
or O
SOB O
. O
  O
EKG O
showed O
sinus B-REA
tachy I-REA
, I-REA
old O
RBBB O

 O
and O
new O
ST O
depressions O
in O
V3 O
, O
V4 O
and O
inferior O
leads O
. O
  O
ST O

 O
depressions O
quickly O
resolved O
. O
  O
Troponin O
and O
CK-MB O
were O
negative O

 O
x O
3 O
. O
  O
Metoprolol B-DRUG
increased O
in O
house O
to O
75 B-STR
mg I-STR
PO B-ROU
TID B-FRE
. I-FRE
ASA B-DRUG
was O

 O
started O
. O

 O
. O

 O
# O
RENAL O
: O
pt O
with O
foley O
in O
place O
, O
presumably O
placed O
given O
initial O

 O
urinary O
incontinence O
, O
however O
, O
pt O
may O
be O
able O
to O
urinate O
on O
her O

 O
own O
now O
. O
  O
for O
now O
will O
continue O
foley O
given O
pt O
difficulty O
on O

 O
bedpan O
. O
  O
creatinine O
trending O
downward O
from O
1.1 O
. O
on O
admission O
to O

 O
0.5 O
presently O
, O
likely O
represents O
loss O
of O
muscle O
mass O
. O

 O
. O

 O
# O
GI O
: O
pt O
with O
h/o O
hiatal B-REA
hernia I-REA
, I-REA
on O
omeprazole B-DRUG
at O
home O
. O
Did O
not O

 O
have O
complaints O
of O
abdominal O
pain O
presently O
, O
LFTs O
and O
alk O

 O
phosphate O
mildly O
elevated O
on O
admission O
, O
now O
within O
normal O

 O
limits O
. O
  O
Pt O
tolerating O
regular O
diet O
without O
difficulty O
. O
  O
Per O

 O
intervential O
radiology O
, O
psoas B-REA
abcess I-REA
too O
small O
to O
drain O
. O

 O
Lansoprazole B-DRUG
continued O
given O
steroid B-DRUG
regimen O
. O

 O
. O

 O
# O
GU O
: O
no O
urinary O
complaints O
presently O
, O
foley O
in O
place O
presumably O

 O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O
incontinence O
earlier O
during O
admission O
. O

 O
. O

 O
# O
ENDO O
: O
  O
pt O
on O
prednisone B-DRUG
chronically B-DUR
for O
RA B-REA
, I-REA
and O
initially O

 O
received O
pulse O
dose O
of O
steroids B-DRUG
( I-DRUG
hydrocort/fludrocort I-DRUG
) I-DRUG
given O

 O
concern O
for O
adrenal B-ADE
insufficiency I-ADE
. I-ADE
  O
insulin B-DRUG
sc B-ROU
sliding B-DOS
scale I-DOS
was O

 O
dc/d O
on O
[ O
* O
* O
2 O
- O
1 O
* O
* O
] O
due O
to O
blood O
sugars O
less O
than O
150 O
for O
24 O
hours O
. O

 O
pt O
seen O
by O
endocrine O
service O
who O
recommend O
minimum O
dose O
of O

 O
prednisone B-DRUG
10 B-STR
mg I-STR
po B-ROU
qdaily B-FRE
give O
almost O
certain O
component O
of O

 O
adrenal B-REA
insufficiency I-REA
. I-REA
  O
home O
regimen O
of O
prednisone B-DRUG
15 B-STR
mg I-STR
qdaily B-FRE

 I-FRE
( O
home O
regimen O
for O
RA B-REA
) I-REA
was O
continued O

 O
. O

 O
# O
PAIN B-REA
: I-REA
pt O
with O
h/o B-REA
LBP I-REA
[ I-REA
* I-REA
* I-REA
2 I-REA
- I-REA
7 I-REA
* I-REA
* I-REA
] I-REA
spinal I-REA
stenosis I-REA
, I-REA
and O
myofascial B-REA
pain I-REA

 I-REA
syndrome I-REA
. I-REA
  O
pt O
being O
seen O
by O
pain O
service O
during O
this O
admission O
. O

  O
pt O
on O
ultram B-DRUG
, I-DRUG
oxycodone B-DRUG
, I-DRUG
and O
indomethacin B-DRUG
at O
home O
. O
  O
Was O
placed O

 O
on O
hydromorphone B-DRUG
transiently O
, O
but O
this O
decreased B-ADE
her I-ADE
alertness I-ADE
. I-ADE

 O
now O
on O
percocet B-DRUG
[ O
* O
* O
1 O
- O
7 O
* O
* O
] O
tab B-FOR
PRN B-FRE
, I-FRE
fentanyl B-DRUG
patch B-FOR
, I-FOR
standing O

 O
acetaminophen B-DRUG
and O
ibuprofen B-DRUG
with B-FRE
meals I-FRE

 I-FRE
. O


 O
# O
RHEUM B-REA
: I-REA
Pt O
with O
h/o O
RA B-REA
, I-REA
on O
enbrel B-DRUG
, I-DRUG
methotrexate B-DRUG
, I-DRUG
indomethacin B-DRUG
, I-DRUG

 O
sulfadiazine B-DRUG
( O
? O
) O
at O
home O
, O
however O
( O
except O
prednisone B-DRUG
) I-DRUG
all O
are O

 O
being O
held O
presently O
in O
light O
of O
multiple O
infections O
. O
  O
Knee O
exam O

 O
without O
obvious O
effusion O
presently O
, O
healing O
well O
s/p O

 O
athrothrocentesis O
. O
  O
will O
follow O
for O
now O
and O
encourage O
PT O
. O

 O
Continued O
on O
nsaids B-DRUG
for O
RA B-REA
. I-REA
DMARDS B-DRUG
were O
not O
restarted O
due O
to O

 O
abscesses O
. O
Should O
followup O
with O
her O
outpatient O
rheumatologist O
. O

 O
. O

 O
# O
PSYCH O
: O
Pt O
with O
h/o O
anxiety B-REA
and O
depression B-REA
, I-REA
presently O
somewhat O

 O
anxious O
, O
especially O
during O
movement O
, O
transition O
to O
sitting O
. O

 O
Ativan B-DRUG
was O
continuedprn B-FRE
. I-FRE

 O
. O

 O
# O
FEN O
: O
Advanced O
to O
regular O
diet O
with O
ensure O
for O
increased O
caloric O

 O
intake O
. O
  O
Mg O
and O
K O
were O
replete O
lytes O
as O
needed O
. O

 O
. O

 O
# O
PPx B-REA
: I-REA
Pt O
was O
given O
lovenox B-DRUG
and O
IVC O
filter O
for O
DVT B-REA
prophylaxis I-REA
. I-REA

 O
PPI B-DRUG
given O
steroid B-DRUG
regimen O
. O
Bowel O
regimen O

 O
. O

 O
# O
DC O
to O
Rehab O
. O


 O
Medications O
on O
Admission O
: O

 O
HCTZ B-DRUG

 I-DRUG
lisinopril B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
Toprol-XL B-DRUG
50 B-STR
mg I-STR
daily B-FRE

 I-FRE
Caltrate B-DRUG

 I-DRUG
Zovirax B-DRUG
p.r.n B-FRE
. I-FRE

 I-FRE
methotrexate B-DRUG
2.5 B-STR
mg I-STR
eight B-DOS
every B-FRE
week I-FRE

 I-FRE
omeprazole B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
Indocin B-DRUG
SR I-DRUG
75 B-STR
mg I-STR
b.i.d B-FRE
. I-FRE

 I-FRE
prednisone B-DRUG
15 B-STR
mg I-STR
qd B-FRE

 I-FRE
Cafergot B-DRUG

 I-DRUG
sulfadiazine B-DRUG
500 B-STR
mg I-STR
b.i.d B-FRE
. I-FRE

 I-FRE
Lidex B-DRUG
ointment B-FOR
which O
she O
is O
not O
using O
actively O
now O

 O
Ultram B-DRUG
50 B-STR
mg I-STR
q.6h B-FRE
. I-FRE
p.r.n I-FRE
. I-FRE

 I-FRE
Fosamax B-DRUG
one B-FRE
every I-FRE
week I-FRE

 I-FRE
oxycodone B-DRUG
one B-DOS
to I-DOS
two I-DOS
q.6h B-FRE
. I-FRE
p.r.n I-FRE
. I-FRE

 I-FRE
Cymbalta B-DRUG
60 B-STR
mg I-STR
daily B-FRE

 I-FRE
iron B-DRUG
one B-DOS
b.i.d B-FRE
. I-FRE

 I-FRE
Ambien B-DRUG
CR I-DRUG
12.5 B-STR
mg I-STR
q.h.s B-FRE

 I-FRE
Enbrel B-DRUG



 I-DRUG
Discharge O
Medications O
: O

 O
1 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Month/Day O
( O
2 O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 I-FRE
2 O
. O
Artificial B-DRUG
Tear I-DRUG
with I-DRUG
Lanolin I-DRUG
0.1 B-STR
- I-STR
0.1 I-STR
% I-STR
Ointment B-FOR
[ O
* O
* O
Month/Day O
( O
2 O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Appl B-ROU
Ophthalmic I-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
[ O
* O
* O
Month/Day O
( O
2 O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Miconazole B-DRUG
Nitrate I-DRUG
2 B-STR
% I-STR
Powder B-FOR
[ O
* O
* O
Month/Day O
( O
2 O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-ROU
Topical I-ROU
QID B-FRE

 I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 I-FRE
5 O
. O
Lansoprazole B-DRUG
30 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
, I-FOR
DR I-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
, I-FOR
DR I-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
Metoclopramide B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QIDACHS B-FRE
( I-FRE
4 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
( I-FRE
before I-FRE
meals I-FRE
and I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Camphor-Menthol B-DRUG
0.5 B-STR
- I-STR
0.5 I-STR
% I-STR
Lotion B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU

 I-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
8 O
. O
Mupirocin B-DRUG
Calcium I-DRUG
2 B-STR
% I-STR
Cream B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( B-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Duloxetine B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Three B-DOS

 I-DOS
( I-DOS
3 I-DOS
) I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
as I-FRE
needed I-FRE

 I-FRE
for O
chronic B-REA
pain I-REA
. I-REA

 O
10 O
. O
Fentanyl B-DRUG
100 B-STR
mcg/hr I-STR
Patch B-FOR
72HR I-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Transdermal B-ROU

 I-ROU
Q72H B-FRE
( I-FRE
every I-FRE
72 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Enoxaparin B-DRUG
30 B-STR
mg/0.3 I-STR
mL I-STR
Syringe B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Subcutaneous B-ROU

 I-ROU
Q12H B-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Calcium B-DRUG
Carbonate I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR
PO B-ROU
TID B-FRE
W/MEALS I-FRE
( I-FRE
3 I-FRE
TIMES I-FRE
A I-FRE
DAY I-FRE
WITH I-FRE
MEALS I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Cholecalciferol B-DRUG
( I-DRUG
Vitamin I-DRUG
D3 I-DRUG
) I-DRUG
400 B-STR
unit I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O

14 O
. O
Simethicone B-DRUG
80 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Chewable I-FOR
PO B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
gassy B-REA
pain I-REA
. I-REA

 O
15 O
. O
Tramadol B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
16 O
. O
Acetaminophen B-DRUG
650 B-STR
mg I-STR
Suppository B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Suppository B-FOR

 I-FOR
Rectal B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
T>101.4 B-REA
. I-REA

 O
17 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
18 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
19 O
. O
Oxycodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
325 I-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR

 I-FOR
PO B-ROU
Q4 B-FRE
- I-FRE
6H I-FRE
( I-FRE
every I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
20 O
. O
Ibuprofen B-DRUG
600 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
W/MEALS I-FRE

 I-FRE
( I-FRE
3 I-FRE
TIMES I-FRE
A I-FRE
DAY I-FRE
WITH I-FRE
MEALS I-FRE
) I-FRE
. I-FRE

 O
21 O
. O
Diphenhydramine B-DRUG
HCl I-DRUG
25 B-STR
mg I-STR
Capsule B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
HS B-FRE

 I-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
22 O
. O
Lorazepam B-DRUG
0.5 B-STR
- I-STR
2 I-STR
mg I-STR
IV B-ROU
Q4H B-FRE
: I-FRE
PRN I-FRE

 I-FRE
23 O
. O
Prednisone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
24 O
. O
Vancomycin B-DRUG
in I-DRUG
Dextrose I-DRUG
1 B-STR
g/200 I-STR
mL I-STR
Piggyback B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Intravenous B-ROU
Q18HR B-FRE
( O
) O
for B-DUR
7 I-DUR
weeks I-DUR
. I-DUR

 O
25 O
. O
Heparin B-DRUG
Flush B-FOR
PICC I-FOR
( O
100 B-STR
units/ml I-STR
) I-STR
2 B-DOS
ml I-DOS
IV B-ROU
DAILY B-FRE
: I-FRE
PRN I-FRE

 I-FRE
10 B-DOS
ml I-DOS
NS B-DRUG
followed O
by O
2 B-DOS
ml I-DOS
of O
100 B-STR
Units/ml I-STR
heparin B-DRUG
( O
200 B-DOS
units I-DOS

 I-DOS
heparin B-DRUG
) I-DRUG
each B-ROU
lumen I-ROU
Daily B-FRE
and I-FRE
PRN I-FRE
. I-FRE
  O
Inspect O
site O
every O
shift O
. O

 O
26 O
. O
Sodium B-DRUG
Chloride I-DRUG
0.9 B-STR
% I-STR
  O
Flush B-FOR
3 B-DOS
ml I-DOS
IV B-ROU
DAILY B-FRE
: I-FRE
PRN I-FRE

 I-FRE
Peripheral B-ROU
IV I-ROU
- O
Inspect O
site O
every O
shift O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
85 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
86 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
- O
Rheumatoid O
arthritis O

 O
- O
Lumbar O
spinal O
stenosis O

 O
- O
Cervical O
and O
lumbar O
epidural O
abscesses O

 O
- O
Bacteremia O

 O
- O
Fractured O
left O
ankle O

 O
- O
Pulmonary O
empyema O

 O
- O
Septic O
knee O
joints O



 O
Discharge O
Condition O
: O

 O
Stable O



 O
Discharge O
Instructions O
: O

 O
Please O
continue O
your O
hospital O
medications O
at O
rehab O
. O



 O
Please O
obtain O
the O
following O
blood O
tests O
every O
week O
: O
CBC O
with O

 O
differential O
, O
BUN/creatinine O
, O
vanco B-DRUG
trough O
. O
  O
Fax O
the O
results O
to O

 O
the O
infectious O
disease O
clinic O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
* O
* O
] O
. O


 O
Followup O
Instructions O
: O

 O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
CARDIOLOGY O
: O

 O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
1989 O
* O
* O
] O
Date/Time:[**2183 O
- O
2 O
- O
12 O
* O
* O
] O
2:40pm O


 O
PLEASE O
FOLLOWUP O
WITH O
RHEUMATOLOGY O
OUTPT O
PHYSICIAN O
. O


 O
You O
have O
a O
follow-up O
appointment O
with O
your O
infectious O
disease O

 O
provider O
: O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Doctor O
Last O
Name O
9406 O
* O
* O
] O
Phone:[**Telephone/Fax O
( O
1 O
) O
457 O
* O
* O
] O
Date/Time:[**2183 O
- O
3 O
- O
4 O
* O
* O
] O

 O
10:30 O


 O
You O
have O
a O
follow-up O
appointment O
with O
your O
orthopedic O
spine O

 O
surgeon O
, O
DR O
. O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Initial O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
Phone:[**Telephone/Fax O
( O
1 O
) O
1228 O
* O
* O
] O

 O
Date/Time:[**2183 O
- O
3 O
- O
13 O
* O
* O
] O
10:45 O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2112 O
- O
10 O
- O
6 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2112 O
- O
10 O
- O
14 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2055 O
- O
4 O
- O
7 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Ativan B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
2777 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Abdominal O
Pain O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2112 O
- O
10 O
- O
10 O
* O
* O
] O
Thoracic O
Endovascular O
Aortic O
Aneurysm O
Repair O



 O
History O
of O
Present O
Illness O
: O

 O
HPI O
: O
57F O
heavy O
smoker O
with O
recent O
admission O
[ O
* O
* O
2112 O
- O
10 O
- O
1 O
* O
* O
] O
- O
[ O
* O
* O
2112 O
- O
10 O
- O
3 O
* O
* O
] O

 O
with O

 O
chest O
and O
abdominal B-REA
pain I-REA
and O
odynophagia B-REA
who O
was O
found O
to O
have O

 O
circumferential O
mural O
thrombus O
in O
the O
supra-renal O
aorta O
on O
cross O

 O
sectional O
imaging O
. O
At O
that O
time O
the O
aortic O
pathology O
was O
though O

 O
to O
be O
chronic O
. O
Ultimately O
, O
her O
pain O
resolved O
with O
the O
initiation O

 O
of O
a O
PPI B-DRUG
and O
GI B-DRUG
cocktail I-DRUG
, I-DRUG
and O
was O
discharged O
home O
after O
a O
3 O
day O

 O
hospital O
stay O
. O
On O
[ O
* O
* O
10 O
- O
6 O
* O
* O
] O
she O
again O
presented O
to O
an O
OSH O
with O

 O
abdominal O
pain O
where O
a O
CT O
abdomen O
was O
done O
which O
showed O
an O

 O
aortic O

 O
dissection O
. O
She O
was O
emergently O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
where O
a O
CTA O

 O
of O
the O
torso O
confirmed O
an O
aortic O
dissection O
of O
the O
descending O

 O
thoracic O
aorta O
( O
at O
the O
level O
of O
the O
left O
pulmonary O
vein O
) O
to O
just O

 O
below O
the O
takeoff O
of O
the O
celiac O
. O
At O
the O
time O
of O
presentation O
to O

 O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
she O
was O
not O
complaining O
of O
any O
abdominal O
pain O
and O
her O

 O
vascular O
exam O
was O
unchanged O
( O
palpable O
bilateral O
upper O
and O
lower O

 O
extremity O
pulses O
) O
. O

 O
. O



 O
Past O
Medical O
History O
: O

 O
Sinusitis O


 O
Past O
Surgical O
History O
: O

 O
Lap O
CCY O
, O
Tubal O
Ligation O


 O
Social O
History O
: O

 O
Married O
to O
retired O
police O
officer O
, O
5 O
children O
. O
Current O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
PPD O

 O
smoker O
with O
> O
30 O
yr O
smoking O
history O
. O
No O
alcohol O
or O
IVDA O
. O



 O
Family O
History O
: O

 O
89yo O
father O
with O
CHF O



 O
Physical O
Exam O
: O

 O
Physical O
Exam O
: O

 O
Alert O
and O
oriented O
x O
3 O

 O
VS O
: O
BP O
110 O
' O
70 O
's O
         O
HR O
  O
70 O
- O
80 O
's O
       O
RR O
stable O
/ O
AF O

 O
Carotids O
: O
2 O
+ O
, O
no O
bruits O
or O
JVD O

 O
COR O
; O
S1 O
S2 O

 O
Resp O
: O
Lungs O
clear O

 O
Abd O
: O
Soft O
, O
non O
tender O
/ O
obese O
/ O
( O
+ O
BM O
) O

 O
Ext O
: O
Pulses O
: O
  O
palpable O
DP O
/PT O
bilaterally O
/Feet O
warm O
, O
  O
well O

 O
perfused O
. O
  O
No O
open O
areas O

 O
Incisions O
: O
CDI O

 O
Wounds O
: O
Left O
Right O
groin O
puncture O
site O
: O
Dressing O
clean O
dry O
and O

 O
intact O
. O
Soft O
, O
no O
hematoma O
or O
ecchymosis O

 O
Lumbar O
drian O
site O
intact O
/ O
no O
drainage O
/ O
no O
fluctuance O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2112 O
- O
10 O
- O
6 O
* O
* O
] O
PORTABLE O
CHEST O

 O
FINDINGS O
: O
  O
The O
heart O
size O
is O
within O
normal O
limits O
. O
  O
The O

 O
mediastinal O
contours O
are O
prominent O
. O
  O
The O
lungs O
are O
clear O
of O

 O
consolidation O
, O
although O
there O
is O
minimal O
bibasilar O
atelectasis O
. O

 O
There O
is O
prominence O
of O
the O
central O
pulmonary O
vasculature O
as O

 O
well O
. O
  O
There O
is O
no O
large O
pleural O
effusion O
or O
pneumothorax O
. O


 O
IMPRESSION O
: O
  O
Mediastinal O
prominence O
may O
represent O
an O
unfolded O

 O
aorta O
, O
although O
correlation O
with O
subsequent O
torso O
CTA O
performed O

 O
on O
the O
same O
date O
is O
recommended O
; O
minimal O
pulmonary O
vascular O

 O
congestion O
and O
bibasilar O
atelectasis O
. O


 O
[ O
* O
* O
2112 O
- O
10 O
- O
6 O
* O
* O
] O
ct O
chest O

 O
CT O
OF O
THE O
CHEST O
WITH O
CONTRAST O
: O
  O
The O
thyroid O
gland O
is O
normal O
and O

 O
symmetric O
in O
appearance O
. O
  O
The O
trachea O
and O
central O
airways O
are O

 O
patent O
to O
the O
segmental O
level O
. O


 O
Extensive O
emphysema O
is O
seen O
throughout O
the O
upper O
lungs O
. O

 O
Bibasilar O
atelectasis O
is O
noted O
. O


 O
The O
esophagus O
is O
normal O
. O
  O
There O
is O
no O
axillary O
, O
mediastinal O
, O
or O

 O
hilar O

 O
lymphadenopathy O
. O


 O
A O
small O
amount O
of O
pericardial O
fluid O
in O
the O
superior O
recess O
is O
of O

 O
relative O
low O
attenuation O
but O
slightly O
above O
that O
of O
simple O
fluid O

 O
( O
20 O
- O
25 O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
) O
. O
Coronary O
calcification O
is O
noted O
. O


 O
CT O
OF O
THE O
ABDOMEN O
WITH O
CONTRAST O
: O
  O
The O
liver O
is O
normal O
in O

 O
attenuation O
without O
focal O
lesion O
or O
intra- O
or O
extra-hepatic O

 O
biliary O
ductal O
dilatation O
. O
  O
The O
gallbladder O
is O
surgically O

 O
absent O
. O
  O
The O
CBD O
is O
mildly O
prominent O
, O
compatible O
with O

 O
post-cholecystectomy O
state O
, O
measuring O
11 O
mm O
, O
probably O
due O
to O

 O
prior O
cholecystectomy O
. O
  O
The O
pancreas O
, O
spleen O
, O
and O
right O
adrenal O

 O
gland O
are O
normal O
. O


 O
A O
9 O
mm O
hypodensity O
in O
the O
left O
adrenal O
gland O
( O
2:99 O
) O
is O

 O
indeterminate O
on O
this O
study O
but O
unchanged O
. O
  O
A O
6 O
mm O
hypodense O

 O
focus O
in O
the O
interpolar O
region O
of O
the O
right O
kidney O
is O
too O
small O

 O
to O
characterize O
. O
  O
There O
is O
no O
hydronephrosis O
. O



 O
The O
stomach O
, O
small O
and O
large O
bowel O
appear O
unremarkable O
with O
the O

 O
exception O
of O
sigmoid O
diverticula O
without O
active O
inflammatory O

 O
changes O
. O
  O
A O
fat-containing O
ventral O
hernia O
is O
noted O
. O
  O
There O
is O
no O

 O
mesenteric O
or O
retroperitoneal O
adenopathy O
. O
  O
There O
is O
no O
free O
air O

 O
or O
free O
fluid O
in O
the O
abdomen O
. O


 O
CT O
OF O
THE O
PELVIS O
WITH O
CONTRAST B-DRUG
: I-DRUG
  O
The O
bladder O
is O
densely O
filled O

 O
with O
contrast B-DRUG
. I-DRUG
  O
From O
the O
prior O
study O
, O
the O
uterus O
and O
ovaries O
are O

 O
unremarkable O
. O
  O
The O
rectum O
is O
normal O
. O
  O
There O
is O
no O
pelvic O
or O

 O
inguinal O
adenopathy O
. O
  O
There O
is O
no O
free O
pelvic O
fluid O
. O


 O
OSSEOUS O
STRUCTURES O
: O
  O
There O
is O
no O
lytic O
or O
sclerotic O
bony O
lesion O

 O
concerning O
for O
osseous O
malignancy O
. O
  O
Minimal O
multilevel O

 O
degenerative O
changes O
are O
seen O
in O
the O
spine O
. O


 O
CTA O
: O
  O
Extensive O
high O
density O
thickening O
of O
the O
aortic O
wall O

 O
involving O
the O

 O
descending O
aorta O
, O
beginning O
at O
the O
level O
of O
the O
left O
subclavian O

 O
artery O
and O

 O
extending O
to O
the O
level O
just O
below O
the O
renal O
arteries O
is O
similar O

 O
or O
slightly O
progressed O
from O
the O
previous O
examination O
of O
[ O
* O
* O
9 O
- O
30 O
* O
* O
] O
and O

 O
compatible O
with O
intramural O
hematoma O
. O
  O
A O
new O
frank O
type O
B O

 O
dissection O
flap O
across O
the O
lumen O
begins O
at O
the O
level O
of O
the O
left O

 O
pulmonary O
vein O
( O
2:47 O
) O
and O
extends O
just O
to O
the O
level O
just O
beyond O

 O
the O
celiac O
artery O
. O
  O
The O
celiac O
artery O
appears O
to O
fill O
off O
the O

 O
false O
lumen O
, O
with O
the O
remainder O
of O
the O
intra-abdominal O
arteries O

 O
filling O
off O
the O
true O
lumen O
. O
  O
Minimal O
intramural O
hematoma O

 O
involves O
the O
proximal O
superior O
mesenteric O
artery O
. O
  O
Multiple O

 O
areas O
of O
intramural O
contrast B-DRUG
extravasation O
and/or O
ulceration O
are O

 O
new O
along O
the O
upper O
descending O
aorta O
within O
the O
intramural O

 O
hematoma O
, O
but O
above O
formation O
of O
the O
flap O
( O
2:25 O
, O
2:39 O
, O
2:38 O
and O

 O
2:101 O
) O
. O
  O
There O
are O
ulcerating O
Atherosclerotic O
plaques O
and O
patchy O

 O
calcification O
along O
the O
lower O

 O
descending O
thoracic O
aorta O
. O


 O
Just O
beyond O
the O
origin O
of O
the O
left O
common O
carotid O
and O
left O

 O
subclavian O
there O
is O
focal O
irregularity O
( O
2:6 O
and O
2:5 O
) O
, O
which O
are O

 O
likely O
related O
to O
plaque O
at O
a O
site O
of O
vessel O
tortuosity O
. O


 O
Axial O
measurements O
of O
the O
aortic O
lumen O
measure O
up O
to O
35 O
x O
31 O
mm O

 O
in O
axial O

 O
dimensions O
along O
the O
proximal O
descending O
aorta O
. O
Along O
the O
upper O

 O
ascending O

 O
aorta O
measurements O
up O
to O
37 O
x O
34 O
mm O
correspond O
to O
slight O

 O
ectasia O
. O


 O
An O
aortic O
aneurysm O
is O
seen O
( O
2:139 O
) O
at O
the O
level O
of O
the O
inferior O

 O
mesenteric O

 O
artery O
takeoff O
, O
measuring O
2.7 O
cm O
, O
distinct O
from O
the O
dissection O

 O
and O
consistent O
with O
an O
incidental O
finding O
. O


 O
BONES O
: O
There O
are O
no O
suspicious O
lytic O
or O
blastic O
lesions O
. O


 O
IMPRESSION O
: O



 O
1 O
. O
  O
Type O
B O
aortic O
dissection O
extending O
from O
the O
level O
of O
the O

 O
left O
pulmonary O
vein O
to O
just O
beyond O
the O
celiac O
artery O
with O
the O

 O
celiac O
artery O
filling O
off O
the O
false O
lumen O
. O
  O
Minimal O
fluid O
in O
the O

 O
superior O
pericardial O
recess O
is O
mildly O
hyperdense O
, O
so O
a O

 O
hemorrhagic O
component O
is O
possible O
although O
apparent O
measured O

 O
increase O
in O
attenuation O
may O
be O
technical O
in O
etiology O
. O


 O
2 O
. O
  O
Distal O
infrarenal O
aortic O
aneurysm O
just O
above O
the O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
899 O
* O
* O
] O
takeoff O

 O
measuring O
2.7 O
cm O
; O
attention O
in O
follow-up O
imaging O
is O
recommended O

 O
for O
surveillance O
. O


 O
3 O
. O
  O
Indeterminate O
9 O
mm O
hypodense O
left O
adrenal O
lesion O
, O
but O
most O

 O
likely O
benign O
, O
although O
not O
fully O
characterized O
. O
  O
Attention O
in O

 O
follow-up O
imaging O
surveillance O
is O
recommended O
; O
alternatively O
if O

 O
further O
characterization O
is O
desired O
at O
this O
time O
or O
before O

 O
follow-up O
imaging O
of O
the O
dissection O
, O
dedicated O
CT O
or O
MR O
protocol O

 O
could O
be O
considered O
. O


 O
4 O
. O
  O
Diverticulosis O
without O
evidence O
of O
active O
inflammation O
. O


 O
5 O
. O
  O
Coronary O
artery O
calcifications O
. O


 O
Preliminary O
findings O
were O
discussed O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
by O
Dr. O

 O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
in O
person O
at O
2231 O
at O
the O
time O
of O
discovery O
on O
[ O
* O
* O
2112 O
- O
10 O
- O
6 O
* O
* O
] O
. O


 O
[ O
* O
* O
2112 O
- O
10 O
- O
7 O
* O
* O
] O
CT O
HEAD O

 O
FINDINGS O
: O
  O
There O
is O
no O
evidence O
of O
hemorrhage O
, O
edema O
, O
mass O
, O
mass O

 O
effect O
, O
or O
infarction O
. O
  O
The O
ventricles O
and O
sulci O
are O
normal O
in O

 O
size O
and O
configuration O
. O
  O
The O
basal O
cisterns O
appear O
patent O
and O

 O
there O
is O
preservation O
of O
[ O
* O
* O
Doctor O
Last O
Name O
352**]-white O
matter O
differentiation O
. O


 O
No O
fracture O
is O
identified O
. O
  O
The O
visualized O
paranasal O
sinuses O
, O

 O
mastoid O
air O

 O
cells O
and O
middle O
ear O
cavities O
are O
clear O
. O
  O
The O
globes O
are O

 O
unremarkable O
. O


 O
CONCLUSION O
: O
  O
No O
evidence O
of O
hemorrhage O
, O
mass O
, O
mass O
effect O
, O
or O

 O
acute O

 O
infarction O
. O


 O
[ O
* O
* O
2112 O
- O
10 O
- O
10 O
* O
* O
] O
: O
  O
CT O
CHEST/ O
ABD/ O
PELVIS O
: O

 O
FINDINGS O
: O


 O
CT O
CHEST O
: O
  O
The O
visualized O
portion O
of O
the O
thyroid O
is O
unremarkable O

 O
in O

 O
appearance O
. O
There O
are O
multiple O
subcentimeter O
nodules O
in O

 O
bilateral O
breasts O
. O
  O
The O
trachea O
is O
midline O
. O
  O
The O
airways O
are O

 O
patent O
to O
the O
subsegmental O
level O
. O


 O
There O
is O
severe O
centrilobular O
emphysema O
throughout O
the O
lungs O

 O
with O
apical O

 O
predilection O
. O
  O
There O
is O
bibasilar O
atelectasis O
. O
  O
There O
are O
no O

 O
effusions O
, O

 O
nodules O
or O
pneumothorax O
. O


 O
There O
is O
no O
supraclavicular O
, O
axillary O
, O
mediastinal O
or O
hilar O

 O
lymphadenopathy O
. O



 O
Pericardial O
fluid O
is O
again O
noted O
, O
but O
is O
slightly O
decreased O
in O

 O
amount O
from O
previous O
examination O
. O
  O
Coronary O
artery O
calcification O

 O
is O
noted O
. O
  O
The O
heart O
and O
great O
vessels O
are O
otherwise O

 O
unremarkable O
in O
appearance O
. O


 O
CT O
ABDOMEN O
: O
  O
The O
liver O
is O
homogeneous O
in O
appearance O
with O
no O

 O
focal O
lesions O

 O
without O
intrahepatic O
biliary O
duct O
dilatation O
. O
  O
The O
gallbladder O

 O
is O
surgically O
absent O
and O
the O
CBD O
is O
prominent O
measuring O
1.2 O
cm O

 O
in O
diameter O
compatible O
with O
post-cholecystectomy O
. O
  O
The O
pancreas O

 O
and O
spleen O
are O
unremarkable O
in O
appearance O
. O
The O
right O
adrenal O

 O
gland O
is O
unremarkable O
in O
appearance O
. O
  O
There O
is O
a O
stable O
9-mm O

 O
hypodensity O
in O
the O
left O
adrenal O
gland O
, O
likely O
representing O

 O
adenoma O
. O
  O
There O
is O
a O
stable O
6-mm O
hypodensity O
in O
the O
interpolar O

 O
region O
of O
the O
right O
kidney O
that O
is O
too O
small O
to O
fully O

 O
characterize O
by O
CT O
examination O
, O
but O
likely O
representing O
a O
simple O

 O
cyst O
. O
  O
Otherwise O
, O
bilateral O
kidneys O
present O
symmetric O
uptake O
and O

 O
excretion O
of O
contrast O
without O
hydronephrosis O
, O
stones O
, O
worrisome O

 O
lesions O
or O
perinephric O
abnormalities O
. O


 O
The O
stomach O
, O
duodenum O
and O
small O
bowel O
are O
unremarkable O
in O

 O
appearance O
with O
no O
focal O
wall O
thickening O
or O
obstruction O
noted O
. O

 O
There O
are O
scattered O
diverticula O
throughout O
the O
large O
intestine O
, O

 O
predominantly O
located O
in O
the O
sigmoid O
colon O
. O
  O
There O
is O
no O

 O
mesenteric O
or O
retroperitoneal O
lymphadenopathy O
. O
  O
There O
is O
no O
free O

 O
air O
or O
ascites O
within O
the O
abdomen O
. O
  O
There O
is O
a O
fat-containing O

 O
ventral O
hernia O
as O
well O
as O
a O
small O
umbilical O
hernia O
. O


 O
CT O
PELVIS O
: O
  O
The O
uterus O
and O
bilateral O
ovaries O
are O
unremarkable O
in O

 O
appearance O
. O
  O
There O
is O
a O
small O
amount O
of O
air O
within O
the O
bladder O
, O

 O
compatible O
with O
recent O
instrumentation O
. O
  O
There O
is O
no O
pelvic O
or O

 O
inguinal O
lymphadenopathy O
. O
  O
There O
is O
no O
free O
pelvic O
fluid O
. O


 O
OSSEOUS O
STRUCTURES O
: O
  O
Degenerative O
changes O
are O
noted O
throughout O

 O
the O
spine O
. O
  O
There O
are O
no O
focal O
lesions O
in O
the O
visualized O
osseous O

 O
structures O
concerning O
for O
malignancy O
. O



 O
CTA O
: O
  O
Again O
noted O
is O
extensive O
high-density O
thickening O
of O
the O

 O
aortic O
wall O

 O
beginning O
proximally O
at O
the O
level O
of O
the O
left O
subclavian O
artery O

 O
and O
extending O
to O
just O
inferior O
of O
the O
renal O
arteries O
as O
well O
as O

 O
dissection O
flap O
, O
beginning O
at O
the O
level O
of O
the O
left O
pulmonary O

 O
vein O
and O
extending O
just O
beyond O
the O
celiac O
artery O
. O
  O
The O
extent O
of O

 O
dissection O
is O
stable O
; O
however O
, O
there O
is O
increased O
amount O
of O

 O
hematoma O
within O
the O
false O
lumen O
at O
the O
level O
of O
the O
celiac O

 O
artery O
which O
is O
narrowing O
the O
false O
lumen O
and O
presenting O
mass O

 O
effect O
on O
the O
true O
lumen O
. O
  O
Despite O
the O
increased O
mass O
effect O
, O

 O
the O
celiac O
artery O
has O
preserved O
flow O
and O
is O
filling O
off O
of O
the O

 O
false O
lumen O
. O
  O
The O
SMA O
and O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
899 O
* O
* O
] O
are O
patent O
, O
receiving O
flow O
from O

 O
the O
true O
lumen O
. O
  O
There O
are O
multiple O
areas O
of O
descending O
aorta O

 O
ulceration O
as O
well O
as O
atherosclerotic O
plaques O
, O
which O
are O
stable O

 O
from O
previous O
examination O
. O
  O
Maximum O
dimensions O
of O
the O
aortic O

 O
lumen O
within O
the O
ascending O
aorta O
measures O
4.0 O
x O
3.7 O
cm O
and O
in O

 O
the O
descending O
aorta O
3.5 O
x O
3.5 O
cm O
, O
representing O
slight O
ectasia O
. O

 O
Again O
noted O
is O
a O
focal O
aortic O
aneurysm O
at O

 O
the O
level O
of O
the O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
899 O
* O
* O
] O
measuring O
2.7 O
cm O
. O


 O
IMPRESSION O
: O

 O
1 O
. O
  O
Type O
B O
aortic O
dissection O
extending O
from O
the O
level O
of O
the O

 O
left O
pulmonary O
vein O
to O
just O
beyond O
the O
celiac O
artery O
with O
the O

 O
celiac O
artery O
filling O
from O
the O
false O
lumen O
. O
  O
Extent O
of O

 O
dissection O
is O
unchanged O
; O
however O
, O
there O
is O
increased O
amount O
of O

 O
clot O
in O
the O
false O
lumen O
, O
narrowing O
the O
false O
lumen O
, O
presenting O

 O
greater O
mass O
effect O
on O
the O
true O
lumen O
. O
  O
However O
, O
flow O
is O

 O
preserved O
. O

 O
2 O
. O
  O
Distal O
infrarenal O
aortic O
aneurysm O
at O
the O
level O
of O
the O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
899 O
* O
* O
] O
. O

 O
3 O
. O
  O
9 O
mm O
hypodense O
lesion O
in O
the O
left O
adrenal O
gland O
, O
most O
likely O

 O
representing O
an O
adenoma O
. O
  O
Attention O
on O
followup O
imaging O
is O

 O
recommended O
. O

 O
4 O
. O
  O
Diverticulosis O
. O

 O
5 O
. O
  O
Coronary O
artery O
calcifications O
as O
well O
as O
multiple O

 O
ulcerative O

 O
atherosclerotic O
plaques O
within O
the O
aorta O
. O

 O
6 O
. O
  O
Fat-containing O
umbilical O
as O
well O
as O
ventral O
hernia O
. O

 O
7 O
. O
  O
Small O
right O
interpolar O
renal O
hypodensity O
too O
small O
to O
fully O

 O
characterize O
by O
CT O
, O
but O
likely O
representing O
a O
simple O
cyst O
. O

 O
8 O
. O
  O
Extensive O
emphysema O
. O

 O
9 O
. O
  O
Small O
focus O
of O
air O
within O
the O
bladder O
that O
could O
represent O

 O
recent O

 O
instrumentation O
or O
infection O
. O
  O
Clinical O
correlation O
is O

 O
recommended O
. O



  O
[ O
* O
* O
2112 O
- O
10 O
- O
11 O
* O
* O
] O
CT O
Chest O
abd O
pelvis O

 O
Final O
Report O
INDICATION O
: O
  O
57-year-old O
woman O
with O
known O
type O
B O

 O
dissection O
status O
post O
repair O
presents O
with O
epigastric O
pain O
, O

 O
evaluate O
for O
flow O
within O
the O
SMA O
and O
celiac O
. O


 O
COMPARISON O
: O
  O
CTA O
torso O
[ O
* O
* O
2112 O
- O
10 O
- O
10 O
* O
* O
] O
. O


 O
TECHNIQUE O
: O
  O
Helical O
axial O
MDCT O
images O
were O
obtained O
from O
the O

 O
chest O
, O
abdomen O
and O
pelvis O
after O
the O
administration O
of O
IV B-ROU

 I-ROU
contrast B-DRUG
in O
the O
arterial O
phase O
. O
  O
Multiplanar O
reformatted O
images O

 O
were O
obtained O
in O
the O
sagittal O
and O
coronal O
planes O
. O


 O
DOSE O
REPORT O
: O
  O
Total O
DLP O
[**2074**].98 O
mGy-cm O
. O


 O
FINDINGS O
: O


 O
CT O
OF O
THE O
CHEST O
: O
  O
The O
visualized O
portion O
of O
the O
thyroid O
is O

 O
unremarkable O
. O
The O
trachea O
is O
midline O
. O
  O
The O
airways O
are O
patent O
to O

 O
the O
subsegmental O
levels O
. O
  O
Severe O
emphysematic O
changes O
are O
noted O

 O
in O
bilateral O
lungs O
. O
  O
Bilateral O
pleural O
effusions O
are O
new O
since O

 O
most O
recent O
prior O
examination O
. O
  O
There O
is O
adjacent O
opacification O

 O
which O
most O
likely O
represents O
compressive O
atelectasis O
; O
however O
, O

 O
infectious O
process O
can O
not O
be O
completely O
excluded O
. O


 O
There O
is O
atherosclerotic O
calcification O
involving O
the O
coronary O

 O
vessels O
. O
  O
There O
is O
no O
evidence O
of O
pericardial O
effusion O
. O

 O
Mediastinal O
, O
axillary O
and O
hilar O
lymph O
nodes O
do O
not O
meet O
CT O
size O

 O
criteria O
for O
pathology O
. O


 O
The O
heart O
and O
great O
vessels O
are O
otherwise O
unremarkable O
in O

 O
appearance O
. O


 O
CT O
OF O
THE O
ABDOMEN O
: O
  O
The O
liver O
is O
homogenous O
in O
appearance O

 O
without O
evidence O
of O
focal O
liver O
lesions O
. O
  O
There O
is O
no O
evidence O

 O
of O
intrahepatic O
biliary O
dilation O
. O
  O
The O
patient O
is O
status O
post O

 O
cholecystectomy O
. O
  O
The O
spleen O
, O
pancreas O
and O
right O
adrenal O
gland O

 O
are O
unremarkable O
. O
9 O
mm O
left O
adrenal O
nodule O
is O
unchanged O
from O
the O

 O
prior O
examination O
. O
  O
Bilateral O
kidneys O
show O
no O
evidence O
of O

 O
hydronephrosis O
. O


 O
Retroperitoneal O
and O
mesenteric O
lymph O
nodes O
do O
not O
meet O
CT O
size O

 O
criteria O
for O
pathology O
. O
  O
There O
is O
no O
free O
air O
or O
free O
fluid O

 O
within O
the O
abdomen O
. O


 O
CT O
OF O
THE O
PELVIS O
: O
  O
The O
bladder O
contains O
a O
Foley O
. O
  O
Air O
within O
the O

 O
bladder O

 O
likely O
represents O
instrumentation O
. O
  O
The O
uterus O
appears O

 O
unremarkable O
. O
  O
There O
is O
evidence O
of O
sigmoid O
and O
descending O
colon O

 O
diverticulosis O
without O
evidence O
of O
diverticulitis O
. O


 O
Bilateral O
pelvic O
side O
wall O
lymph O
nodes O
do O
not O
meet O
CT O
size O

 O
criteria O
for O

 O
pathology O
. O
  O
Small O
fat-containing O
ventral O
hernia O
is O
noted O
. O



 O
CTA O
: O
  O
Patient O
is O
status O
post O
repair O
of O
type O
B O
dissection O
with O

 O
EVAR O
stent O
graft O
extending O
from O
the O
level O
of O
the O
left O
subclavian O

 O
artery O
and O
to O
just O
inferior O
to O
the O
origin O
of O
the O
renal O
arteries O
. O

  O
The O
dissection O
appears O
to O
extend O
into O
the O
celiac O

 O
trunk(301:104 O
) O
; O
it O
is O
difficult O
to O
say O
if O
this O
was O
present O
on O

 O
the O
prior O
study O
. O
Both O
sides O
of O
the O
dissection O
flap O
, O
however O

 O
appear O
perfused O
homogenously O
with O
patent O
celiac O
trunk O
. O
  O
The O
SMA O

 O
and O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
899 O
* O
* O
] O
are O
patent O
. O
  O
Again O
noted O
are O
areas O
of O
aortic O
ulcerations O

 O
as O
well O
as O
atherosclerotic O
plaques O
stable O
from O
the O
prior O

 O
examination O
. O
  O
Maximum O
dimension O
of O
the O
aortic O
lumen O
within O
the O

 O
ascending O
aorta O
measures O
2.8 O
x O
3.6 O
cm O
and O
the O
3.1 O
x O
3.1 O
cm O

 O
within O
the O
descending O
aorta O
. O
  O
Again O

 O
noted O
is O
a O
focal O
aortic O
aneurysmal O
morphology O
at O
the O
level O
of O

 O
the O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
899 O
* O
* O
] O

 O
measuring O
2.7 O
cm O
( O
3:140 O
and O
602b:47 O
) O
. O


 O
3D O
reformations O
generated O
in O
the O
imaging O
lab O
of O
the O
aorta O
and O

 O
endovascular O
stent O
include O
3D O
MIP O
and O
VR O
rotations O
, O
curved O

 O
reformatted O
images O
, O
and O
3D O
measurements O
( O
below O
) O
. O
These O
were O

 O
reviewed O
in O
the O
interpretation O
of O
this O
examination O
. O


 O
Measurements O
: O

 O
Aortic O
valve O
: O
3.8 O
cm O

 O
Aortic O
cusps O
: O
4.4 O
cm O

 O
Ascending O
aorta/[**MD O
Number(3 O
) O
26547 O
* O
* O
] O
: O
4.0 O
cm O

 O
Ascending O
aorta/Proximal O
arch O
: O
3.6 O
cm O

 O
Proximal O
descending O
thoracic O
aorta/Distal O
arch O
( O
stent O
lumen O
+ O

 O
aorta O
wall O
) O
: O
2.8 O
cm O
Maximum O
, O
descending O
thoracic O
aorta O
( O
stent O

 O
lumen O
+ O
aorta O
wall O
) O
: O
5.0 O
cm O
Abdominal O
aorta O
, O
celiac O
trunk O
( O
stent O

 O
lumen O
+ O
aorta O
wall O
) O
: O
2.8 O
cm O
Abdominal O
aorta O
, O
SMA O
( O
stent O
lumen O
+ O

 O
aorta O
wall O
) O
: O
2.8 O
cm O


 O
IMPRESSION O
: O


 O
1 O
. O
  O
Status O
post O
repair O
of O
type O
B O
aortic O
dissection O
with O
EVAR O

 O
stent O
graft O

 O
extending O
from O
the O
level O
of O
the O
left O
subclavian O
artery O
to O
just O

 O
below O
the O

 O
origin O
of O
the O
renal O
arteries O
. O

 O
2 O
. O
  O
Distal O
infrarenal O
aortic O
aneurysm O
at O
the O
level O
of O
the O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
899 O
* O
* O
] O
, O

 O
unchanged O
. O

 O
3 O
. O
  O
Dissection O
appears O
to O
extend O
into O
the O
celiac O
trunk O
. O
Both O

 O
sides O
of O
the O

 O
dissection O
flap O
demonstrate O
homogenous O
perfusion O
with O
patency O
of O

 O
celiac O
trunk O
SMA O
and O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
899 O
* O
* O
] O
. O

 O
4 O
. O
Unchanged O
9 O
mm O
right O
adrenal O
nodule O
. O

 O
5 O
. O
Bilateral O
pleural O
effusions O
with O
adjacent O
compressive O

 O
atelectasis O
new O
from O
the O
prior O
exam O
. O

 O
6 O
. O
Ventral O
fat O
containing O
hernia O
. O


 O
[ O
* O
* O
2112 O
- O
10 O
- O
13 O
* O
* O
] O
CXR O

 O
Final O
Report O

 O
CHEST O
RADIOGRAPH O



 O
INDICATION O
: O
  O
Fever O
, O
evaluation O
for O
pneumothorax O
and O
line O

 O
position O
. O


 O
FINDINGS O
: O
  O
As O
compared O
to O
the O
previous O
radiograph O
from O
[ O
* O
* O
10 O
- O
12 O
* O
* O
] O
, O
[ O
* O
* O
2112 O
* O
* O
] O
, O
the O
venous O
introduction O
sheath O
on O
the O
right O
has O
been O

 O
changed O
to O
a O
right O
internal O
jugular O
vein O
catheter O
. O
  O
The O
signs O

 O
indicative O
of O
bilateral O
parenchymal O
opacities O
at O
the O
lung O
bases O
, O

 O
most O
likely O
fluid O
overload O
, O
have O
decreased O
in O
severity O
. O
  O
The O

 O
size O
of O
the O
cardiac O
silhouette O
, O
including O
the O
aortic O
stent O

 O
graft O
, O
is O
unchanged O
. O






 O
Brief O
Hospital O
Course O
: O

 O
On O
[ O
* O
* O
10 O
- O
6 O
* O
* O
] O
the O
pt O
presented O
to O
an O
OSH O
with O
abdominal O
pain O
where O
a O

 O
CT O
abdomen O
was O
done O
which O
showed O
an O
aortic O
dissection O
. O
She O
was O

 O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
and O
had O
a O
confirmatory O
CTA O
. O
  O
She O
was O

 O
admitted O
to O
the O
ICU O
for O
blood O
pressure O
control O
and O
serial O

 O
abdominal O
exams O
. O


 O
At O
the O
time O
of O
presentation O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
she O
was O
not O
complaining O
of O

 O
any O
abdominal O
pain O
and O
her O
vascular O
exam O
was O
unchanged O
( O
palpable O

 O
bilateral O
upper O
and O
lower O
extremity O
pulses O
) O
. O
  O
She O
was O
agitated B-REA

 I-REA
while O
in O
the O
ICU O
and O
received O
Ativan B-DRUG
to O
which O
she O
became O

 O
delerious B-ADE
. I-ADE
  O
She O
was O
seen O
by O
psychiatry O
for O
acute B-ADE
delerium I-ADE
and O

 O
they O
asked O
to O
hold O
ativan B-DRUG
and O
to O
use O
Hadol B-DRUG
for O
any O
agitation B-REA
. I-REA


 O
She O
remained O
stable O
and O
the O
plan O
was O
to O
manage O
her O
medially O
. O

 O
She O
was O
transferred O
to O
the O
VICU O
. O
  O
On O
the O
morning O
of O
[ O
* O
* O
2112 O
- O
10 O
- O
10 O
* O
* O
] O
she O

 O
was O
complaining O
of O
upper O
abdominal O
pain O
and O
retro O
sternal O
pain O
. O

 O
Her O
VS O
were O
stable O
at O
that O
pt O
as O
was O
her O
EKG O
. O
  O
On O
exam O
she O

 O
looked O
slightly O
pale O
without O
diaphoresis O
. O
  O
Her O
distal O
pulses O

 O
were O
all O
palpable O
at O
that O
time O
. O
She O
was O
sent O
for O
stat O
CTA O
and O

 O
then O
sent O
to O
prep O
and O
hold O
where O
she O
was O
consented O
for O
TEVAR O
. O

 O
It O
was O
noted O
on O
the O
CT O
that O
she O
had O
extension O
of O
her O
dissection O

 O
with O
possible O
compressive O
thrombus O
. O


 O
She O
underwent O
the O
procedure O
without O
complication O
. O
She O
was O

 O
recovered O
in O
the O
VICU O
and O
did O
well O
. O
  O
Her O
diet O
and O
activity O
were O

 O
advanced O
. O
She O
was O
voiding O
freely O
and O
tolerating O
an O
oral O
diet O
. O

 O
She O
ambulated O
without O
assistance O
. O
  O
Her O
follow O
up O
appts O
were O

 O
scheduled O
. O
  O
She O
was O
councelled O
to O
follow O
up O
with O
her O
PCP O
within O

 O
two O
weeks O
. O



 O

Medications O
on O
Admission O
: O

 O
Preadmission O
medications O
listed O
are O
correct O
and O
complete O
. O

 O
Information O
was O
obtained O
from O
  O
last O
discharge O
. O

 O
1 O
. O
Omeprazole B-DRUG
40 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
2 O
. O
Donnatol B-DRUG
10 B-DOS
mL I-DOS
PO B-ROU
BID B-FRE
: I-FRE
PRN I-FRE
abdominal B-REA
pain I-REA

 I-REA
3 O
. O
Atorvastatin B-DRUG
20 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
4 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
5 O
. O
DiCYCLOmine B-DRUG
10 B-STR
mg I-STR
PO B-ROU
QID B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Aspirin B-DRUG
EC I-DRUG
325 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
2 O
. O
Atorvastatin B-DRUG
20 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
3 O
. O
DiCYCLOmine B-DRUG
10 B-STR
mg I-STR
PO B-ROU
QID B-FRE

 I-FRE
4 O
. O
Omeprazole B-DRUG
40 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
5 O
. O
Acetaminophen-Caff-Butalbital B-DRUG
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
TAB B-FOR
PO B-ROU
Q6H B-FRE
: I-FRE
PRN I-FRE
headache B-REA

 I-REA
RX O
* O
butalbital-acetaminophen-caff B-DRUG
50 B-STR
mg-325 I-STR
mg-40 I-STR
mg I-STR
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O

 O
tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
q B-FRE
4 I-FRE
hours I-FRE
Disp O
# O
* O
30 O
Tablet O
Refills:*0 O

 O
6 O
. O
Ciprofloxacin B-DRUG
HCl I-DRUG
500 B-STR
mg I-STR
PO B-ROU
Q12H B-FRE
Duration O
: O
7 B-DUR
Days I-DUR

 I-DUR
RX O
* O
ciprofloxacin B-DRUG
[ I-DRUG
Cipro I-DRUG
] I-DRUG
500 B-STR
mg I-STR
1 B-DOS
tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
twice B-FRE
a I-FRE

 I-FRE
day I-FRE
Disp O
# O
* O
14 O
Tablet O
Refills:*0 O

 O
7 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
12.5 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
hold O
for O
SBP O
< O
100 O
, O
HR O
< O
60 O

 O
RX O
* O
metoprolol B-DRUG
tartrate I-DRUG
25 B-STR
mg I-STR
0.5 B-DOS
( I-DOS
One I-DOS
half I-DOS
) I-DOS
tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU

 I-ROU
twice B-FRE
a I-FRE
day I-FRE
Disp O
# O
* O
30 O
Tablet O
Refills:*0 O

 O
8 O
. O
Donnatol B-DRUG
10 B-DOS
mL I-DOS
PO B-ROU
BID B-FRE
: I-FRE
PRN I-FRE
abdominal B-REA
pain I-REA



 I-REA
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Aortic O
Dissection O
/ O
Type O
B O

 O
Intramural O
Aortic O
Thrombus O

 O
complicated O
urinary O
tract O
infection O

 O
delerium O
/ O
acute O
/ O
medication O
reaction O

 O
headache O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
hospital O
with O
a O
Type O
B O
Aortic O

 O
Dissection O

 O
You O
underwent O
a O
Envovascular O
repair O
of O
this O
aneurysm O
without O

 O
complication O
. O
You O
were O
found O
to O
have O
a O
urinary O
tract O
infection O

 O
and O
were O
started O
on O
antibiotics O
for O
this O
. O
  O
You O
also O
had O
a O

 O
reaction O
to O
ATIVAN B-DRUG
that O
caused O
you O
to O
be O
very B-ADE
confused I-ADE
- O
This O
is O

 O
now O
listed O
in O
our O
system O
as O
an O
allergy O
to O
avoid O
this O
reaction O

 O
again O
. O


 O
Division O
of O
Vascular O
and O
Endovascular O
Surgery O

 O
Endovascular O
Abdominal O
Aortic O
Aneurysm O
( O
AAA O
) O
Discharge O

 O
Instructions O


 O
MEDICATIONS O
: O

 O
? O
? O
? O
? O
? O
? O
	 O
Take O
Aspirin B-DRUG
325 B-STR
mg I-STR
( O
enteric O
coated O
) O
once B-FRE
daily I-FRE

 I-FRE
? O
? O
? O
? O
? O
? O
	 O
Do O
not O
stop O
Aspirin B-DRUG
unless O
your O
Vascular O
Surgeon O
instructs O
you O

 O
to O
do O
so O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Continue O
all O
other O
medications O
you O
were O
taking O
before O
surgery O
, O

 O
unless O
otherwise O
directed O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
make O
take O
Tylenol B-DRUG
or O
prescribed O
pain B-DRUG
medications I-DRUG
for O
any O

 O
post B-REA
procedure I-REA
pain I-REA
or O
discomfort O



 O
WHAT O
TO O
EXPECT O
AT O
HOME O
: O

 O
It O
is O
normal O
to O
have O
slight O
swelling O
of O
the O
legs O
: O

 O
? O
? O
? O
? O
? O
? O
	 O
Elevate O
your O
leg O
above O
the O
level O
of O
your O
heart O
( O
use O
[ O
* O
* O
2 O
- O
26 O
* O
* O
] O

 O
pillows O
or O
a O
recliner O
) O
every O
2 O
- O
3 O
hours O
throughout O
the O
day O
and O
at O

 O
night O

 O
? O
? O
? O
? O
? O
? O
	 O
Avoid O
prolonged O
periods O
of O
standing O
or O
sitting O
without O
your O

 O
legs O
elevated O

 O
It O
is O
normal O
to O
feel O
tired O
and O
have O
a O
decreased O
appetite O
, O
your O

 O
appetite O
will O
return O
with O
time O

 O
? O
? O
? O
? O
? O
? O
	 O
Drink O
plenty O
of O
fluids O
and O
eat O
small O
frequent O
meals O

 O
? O
? O
? O
? O
? O
? O
	 O
It O
is O
important O
to O
eat O
nutritious O
food O
options O
( O
high O
fiber O
, O

 O
lean O
meats O
, O
vegetables/fruits O
, O
low O
fat O
, O
low O
cholesterol O
) O
to O

 O
maintain O
your O
strength O
and O
assist O
in O
wound O
healing O

 O
? O
? O
? O
? O
? O
? O
	 O
To B-REA
avoid I-REA
constipation I-REA
: I-REA
eat O
a O
high O
fiber O
diet O
and O
use O
stool B-DRUG

 I-DRUG
softener I-DRUG
while O
taking O
pain B-DRUG
medication I-DRUG


 I-DRUG
ACTIVITIES O
: O

 O
? O
? O
? O
? O
? O
? O
	 O
When O
you O
go O
home O
, O
you O
may O
walk O
and O
go O
up O
and O
down O
stairs O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
may O
shower O
( O
let O
the O
soapy O
water O
run O
over O
groin O
incision O
, O

 O
rinse O
and O
pat O
dry O
) O

 O
? O
? O
? O
? O
? O
? O
	 O
Your O
incision O
may O
be O
left O
uncovered O
, O
unless O
you O
have O
small O

 O
amounts O
of O
drainage O
from O
the O
wound O
, O
then O
place O
a O
dry O
dressing O
or O

 O
band O
aid O
over O
the O
area O
that O
is O
draining O
, O
as O
needed O

 O
? O
? O
? O
? O
? O
? O
	 O
No O
heavy O
lifting O
, O
pushing O
or O
pulling O
( O
greater O
than O
5 O
lbs O
) O
for O

 O
1 O
week O
( O
to O
allow O
groin O
puncture O
to O
heal O
) O

 O
? O
? O
? O
? O
? O
? O
	 O
After O
1 O
week O
, O
you O
may O
resume O
sexual O
activity O

 O
? O
? O
? O
? O
? O
? O
	 O
After O
1 O
week O
, O
gradually O
increase O
your O
activities O
and O
distance O

 O
walked O
as O
you O
can O
tolerate O

 O
? O
? O
? O
? O
? O
? O
	 O
No O
driving O
until O
you O
are O
no O
longer O
taking O
pain O
medications O


 O
CALL O
THE O
OFFICE O
FOR O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
90383 O
* O
* O
] O

 O
? O
? O
? O
? O
? O
? O
	 O
Numbness O
, O
coldness O
or O
pain O
in O
lower O
extremities O

 O
? O
? O
? O
? O
? O
? O
	 O
Temperature O
greater O
than O
101.5F O
for O
24 O
hours O

 O
? O
? O
? O
? O
? O
? O
	 O
New O
or O
increased O
drainage O
from O
incision O
or O
white O
, O
yellow O
or O

 O
green O
drainage O
from O
incisions O

 O
? O
? O
? O
? O
? O
? O
	 O
Bleeding O
from O
groin O
puncture O
site O



 O
FOR O
SUDDEN O
, O
SEVERE O
BLEEDING O
OR O
SWELLING O
( O
Groin O
puncture O
site O
or O

 O
incision O
) O

 O
? O
? O
? O
? O
? O
? O
	 O
Lie O
down O
, O
keep O
leg O
straight O
and O
have O
someone O
apply O
firm O

 O
pressure O
to O
area O
for O
10 O
minutes O
. O
If O
bleeding O
stops O
, O
call O

 O
vascular O
office O
. O
If O
bleeding O
does O
not O
stop O
, O
call O
911 O
for O

 O
transfer O
to O
closest O
Emergency O
Room O
. O



 O
Followup O
Instructions O
: O

 O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
would O
like O
to O
see O
you O
in O
the O
office O
in O
one O

 O
months O
time O
- O
an O
appointment O
has O
been O
made O
for O
you O
- O
if O
you O
need O

 O
to O
change O
the O
date/time O
, O
please O
call O
the O
office O
at O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
* O
* O
] O

 O
thank O
you O


 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
SCAN O
Phone:[**Telephone/Fax O
( O
1 O
) O
590 O
* O
* O
] O
Date/Time:[**2112 O
- O
11 O
- O
14 O
* O
* O
] O
1:15 O

 O
Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
3469 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
2625 O
* O
* O
] O

 O
Date/Time:[**2112 O
- O
11 O
- O
14 O
* O
* O
] O
2:45 O


 O
As O
always O
, O
please O
call O
your O
primary O
care O
physician O
for O
an O

 O
appointment O
to O
be O
seen O
in O
the O
next O
two O
weeks O
to O
inform O
and O

 O
update O
them O
of O
your O
care O
. O
I O
attempted O
to O
make O
an O
appointment O
for O

 O
you O
but O
the O
office O
was O
closed O
. O
  O
This O
is O
very O
improtant O
that O
you O

 O
follow O
up O
. O

 O
Name O
: O
ATTAR,[**Female O
First O
Name O
( O
un O
) O
* O
* O
] O

 O
Address O
: O
[ O
* O
* O
Last O
Name O
( O
un O
) O
28705 O
* O
* O
] O
, O
[ O
* O
* O
Location O
( O
un O
) O
28706**],[**Numeric O
Identifier O
28707 O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
24306 O
* O
* O
] O

 O
Fax O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
75010 O
* O
* O
] O




 O
Completed O
by:[**2112 O
- O
10 O
- O
14 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2134 O
- O
5 O
- O
28 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2134 O
- O
6 O
- O
12 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2070 O
- O
2 O
- O
22 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Tetracycline B-DRUG
/ O
Dicloxacillin B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
1377 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
UTI O
and O
urolithiasis O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Lithotripsy O

 O
PICC O
line O
placement/removal O



 O
History O
of O
Present O
Illness O
: O

 O
64 O
year O
old O
male O
with O
a O
history O
of O
nephrolithiasis O
, O
recurrent O

 O
UTIs O
, O
DVT/PE O
, O
HIV O
, O
HBV O
cirrhosis O
& O
HCC O
s/p O
orthotopic O
liver O

 O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
in O
[ O
* O
* O
6 O
- O
4 O
* O
* O
] O
, O
who O
presented O
on O
[ O
* O
* O
5 O
- O
28 O
* O
* O
] O
for O
a O
direct O
admission O

 O
to O
be O
bridged O
from O
coumadin B-DRUG
to O
heparin B-DRUG
for O
a O
lithotripsy O

 O
procedure O
. O
  O
As O
the O
patient O
was O
being O
admitted O
, O
an O
outpatient O

 O
urine O
culture O
was O
reported O
as O
growing O
Vancomycin B-REA
Resistant I-REA

 I-REA
Enterococcus I-REA
, I-REA
and O
daptomycin B-DRUG
therapy O
was O
begun O
. O
  O
Patient O
was O

 O
stable O
and O
without O
complaint O
. O


 O
Past O
Medical O
History O
: O

 O
* O
s/p O
Liver O
[ O
* O
* O
Month/Day O
( O
2 O
) O
* O
* O
] O
on O
[ O
* O
* O
2133 O
- O
5 O
- O
30 O
* O
* O
] O
for O
Hep O
B O
cirrhosis O
c/b O
HCC O
s/p O


 O
RFA O

 O
* O
HIV O
diagnosed O
in O
[ O
* O
* O
2111 O
* O
* O
] O
with O
undetectable O
viral O
load O
( O
CD4 O
159 O

 O
[ O
* O
* O
2133 O
- O
11 O
- O
10 O
* O
* O
] O
, O
HIV O
VL O
274 O
[ O
* O
* O
2133 O
- O
11 O
- O
10 O
* O
* O
] O
) O

 O
* O
Hepatitis O
B O
diagnosed O
in O
[ O
* O
* O
2093 O
* O
* O
] O
with O
undetectable O
viral O
load O

 O
( O
[ O
* O
* O
2133 O
- O
5 O
- O
13 O
* O
* O
] O
HBVL O
< O
40 O
) O

 O
* O
h/o O
PE B-REA
in O
[ O
* O
* O
5 O
- O
5 O
* O
* O
] O
s/p O
5.5 O
months O
of O
coumadin B-DRUG

 I-DRUG
* O
Herpes O
simplex O

 O
* O
HPV O

 O
* O
Peripheral B-ADE
neuropathy I-ADE
( O
feet O
) O
secondary O
to O
Stavudine B-DRUG

 I-DRUG
* O
Nephrolithiasis O

 O
* O
Left O
sided O
kidney O
stones O
surgical O
removal O
in O
the O
early O
[ O
* O
* O
2103 O
* O
* O
] O
's O


 O
and O
had O
lithotrypsy O
3 O
times O
in O
the O
[ O
* O
* O
2103 O
* O
* O
] O
's O
. O

 O
* O
Pancytopenia O

 O
* O
Depression O

 O
* O
Benign O
prostatic O
hypertrophy O

 O
* O
Basal O
cell O
carcinoma O
with O
Moh??????s O
surgery O

 O
* O
Gonorrhea O

 O
* O
Hypogonadism O



 O
Social O
History O
: O

 O
Patient O
is O
retired O
restaurant/bar O
manager O
( O
on O
disability O
since O

 O
[ O
* O
* O
2126 O
* O
* O
] O
due O
to O
neuropathy O
) O
. O
Homosexual O
male O
. O
He O
is O
the O
primary O

 O
caregiver O
for O
his O
mother O
who O
has O
dementia O
. O
Patient O
is O
not O

 O
married O
. O
  O
Never O
smoked O
and O
no O
current O
alcohol O
. O
No O
illicit O
drug O

 O
use O
. O



 O

Family O
History O
: O

 O
Mother O
with O
[ O
* O
* O
Name2 O
( O
NI O
) O
499 O
* O
* O
] O
cancer O
. O
Father O
had O
brain O
tumor O
. O


 O
Physical O
Exam O
: O

 O
On O
Admission O
: O

 O
General O
Appearance O
: O
No O
acute O
distress O

 O
Eyes O
/ O
Conjunctiva O
: O
PERRL O
, O
Pupils O
dilated O

 O
Head O
, O
Ears O
, O
Nose O
, O
Throat O
: O
Normocephalic O
, O
Poor O
dentition O

 O
Cardiovascular O
: O
( O
S1 O
: O
Normal O
) O
, O
( O
S2 O
: O
Normal O
) O
, O
( O
Murmur O
: O
Systolic O
) O

 O
Peripheral O
Vascular O
: O
( O
Right O
radial O
pulse O
: O
Present O
) O
, O
( O
Left O
radial O

 O
pulse O
: O
Present O
) O
, O
( O
Right O
DP O
pulse O
: O
Present O
) O
, O
( O
Left O
DP O
pulse O
: O

 O
Present O
) O

 O
Respiratory O
/ O
Chest O
: O
( O
Breath O
Sounds O
: O
Clear O
: O
, O
Crackles O
: O
at O

 O
bilateral O
bases O
) O

 O
Abdominal O
: O
Soft O
, O
Non-tender O
, O
Bowel O
sounds O
present O

 O
Extremities O
: O
Right O
lower O
extremity O
edema O
: O
3 O
+ O
, O
Left O
lower O

 O
extremity O
edema O
: O
3 O
+ O

 O
Musculoskeletal O
: O
Unable O
to O
stand O

 O
Skin O
: O
  O
Not O
assessed O

 O
Neurologic O
: O
Attentive O
, O
Responds O
to O
: O
Not O
assessed O
, O
Movement O
: O
Not O

 O
assessed O
, O
Tone O
: O
Not O
assessed O
, O
hemiplegia O
and O
aphasia O


 O
On O
Discharge O
: O

 O
Vitals O
: O
97.9 O
120/69 O
63 O
18 O
98%RA O

 O
GENERAL O
- O
Sitting O
up O
in O
bed O
, O
cachectic O

 O
HEENT O
- O
sclerae O
anicteric O
, O
MMM O

 O
NECK O
- O
no O
JVD O

 O
LUNGS O
- O
CTA O
bilat O
, O
no O
rales/rhonchi/wheezes O
, O

 O
HEART O
- O
RRR O
, O
no O
MRG O

 O
ABDOMEN O
- O
BS+ O
, O
moderately O
distended O
, O
increased O
from O
prior O
exam O
, O

 O
nontender O

 O
GU O
- O
Foley O
in O
place O
, O
no O
CVA O
tenderness O

 O
EXTREMITIES O
- O
WWP O
, O
2 O
+ O
DP O
b/l O

 O
SKIN O
- O
no O
rashes/lesions O
, O
no O
bruising O

 O
NEURO O
- O
AOx3 O
, O
awake O
, O
no O
asterixis O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2134 O
- O
5 O
- O
28 O
* O
* O
] O
11:34PM O
URINE O
  O
COLOR-Straw O
APPEAR-Clear O
SP O
[ O
* O
* O
Last O
Name O
( O
un O
) O
155**]-1.015 O

 O
[ O
* O
* O
2134 O
- O
5 O
- O
28 O
* O
* O
] O
11:34PM O
URINE O
  O
BLOOD-SM O
NITRITE-NEG O
PROTEIN-75 O

 O
GLUCOSE-100 O
KETONE-NEG O
BILIRUBIN-NEG O
UROBILNGN-NEG O
PH-5.0 O

 O
LEUK-MOD O

 O
[ O
* O
* O
2134 O
- O
5 O
- O
28 O
* O
* O
] O
11:34PM O
URINE O
  O
RBC-0 O
WBC-21 O
- O
50 O
* O
BACTERIA-OCC O
YEAST-NONE O

 O
EPI-0 O

 O
[ O
* O
* O
2134 O
- O
5 O
- O
27 O
* O
* O
] O
11:30AM O
   O
FREE O
TEST-2.3 O
* O

 O
[ O
* O
* O
2134 O
- O
5 O
- O
27 O
* O
* O
] O
11:30AM O
   O
PT-14.2 O
* O
INR(PT)-1.2 O
* O

 O
. O

 O
LIVER O
and O
Gallbladder O
U/S O
[ O
* O
* O
2134 O
- O
6 O
- O
2 O
* O
* O
] O
IMPRESSION O
: O
1 O
. O
Small O
amount O

 O
of O
ascitic O
fluid O
in O
the O
lower O
quadrants O
. O
2 O
. O
Splenomegaly O
. O
3 O
. O

 O
Distended O
bladder O
with O
echogenic O
foci O
most O
likely O
representing O

 O
patient O
's O
known O
bladder O
stones O
. O

 O
. O


 O
Portal O
Abdominal O
Xray O
- O
[ O
* O
* O
2134 O
- O
6 O
- O
2 O
* O
* O
] O
IMPRESSION O
: O
1 O
. O
Fragmentation O
of O

 O
left O
renal O
stones O
and O
clearance O
of O
bladder O
stones O
. O
  O
2 O
. O
Left O

 O
ureteral O
stent O
placement O
. O



 O
Brief O
Hospital O
Course O
: O

 O
64yo O
M O
with O
HIV O
, O
HBV O
, O
HCV O
, O
HCC O
, O
cirrhosis O
status O
post O
orthotopic O

 O
liver O
[ O
* O
* O
Year O
( O
4 O
digits O
) O
* O
* O
] O
( O
[ O
* O
* O
6 O
- O
4 O
* O
* O
] O
) O
, O
a O
history O
of O
DVT/PE O
and O

 O
nephrolithiasis O
, O
who O
was O
admitted O
on O
[ O
* O
* O
5 O
- O
28 O
* O
* O
] O
for O
antibiotic B-DRUG

 I-DRUG
treatment O
of O
a O
VRE B-REA
UTI I-REA
and O
bridge O
from O
coumadin B-DRUG
to O
heparin B-DRUG
for O

 O
lithotripsy B-REA
procedure I-REA
[ O
* O
* O
6 O
- O
1 O
* O
* O
] O
. O
  O
His O
post-operative O
course O
was O

 O
complicated O
by O
fevers O
, O
confusion O
, O
unstable O
vitals O
consistent O

 O
with O
urosepsis/shock O
, O
requiring O
transfer O
to O
the O
  O
MICU O
and O
broad O

 O
antibiotic B-DRUG
therapy O
, O
now O
transferred O
back O
to O
the O
[ O
* O
* O
Doctor O
Last O
Name O
3271**]-[**Doctor O
Last O
Name O
679 O
* O
* O
] O

 O
service O
, O
stable O
, O
and O
ready O
for O
discharge O
. O

 O
. O


 O
# O
UTI/Urosepsis/Urolithiasis O
: O
On O
admission O
, O
an O
oupatient O
culture O

 O
was O
reported O
as O
growing O
Vancomycin B-DRUG
Resistant O
Enterococcus O
. O

 O
Treatment O
of O
a O
VRE B-REA
UTI I-REA
infection I-REA
with O
daptomycin B-DRUG
was O
initated O
on O

 O
[ O
* O
* O
5 O
- O
28 O
* O
* O
] O
, O
with O
a O
documented O
negative O
urine O
culture O
on O
[ O
* O
* O
5 O
- O
31 O
* O
* O
] O
. O
    O
On O
[ O
* O
* O
6 O
- O
1 O
* O
* O
] O

 O
patient O
underwent O
lithotripsy O
and O
placement O
of O
a O
stent O
. O
  O
During O

 O
the O
middle O
of O
the O
night O
, O
he O
was O
noted O
to O
have O
altered O
mental O

 O
status O
. O
  O
He O
had O
taken O
off O
his O
heparin B-DRUG
gtt B-ROU
and O
was O
walking O
around O

 O
saying O
that O
he O
was O
ready O
to O
go O
home O
. O
  O
They O
continued O
to O
hold O
his O

 O
heparin B-DRUG
gtt B-ROU
at O
that O
time O
. O
  O
He O
was O
placed O
back O
in O
bed O
, O
and O
noted O

 O
to O
be O
febrile O
with O
a O
Tm O
of O
102.7 O
at O
0030 O
this O
morning O
. O
  O
His O
BP O

 O
was O
80/d O
at O
the O
time O
, O
HR O
in O
the O
50s O
. O
  O
He O
received O
1L O
bolus O

 O
without O
effect O
in O
his O
BP O
. O
  O
At O
530 O
this O
morning O
, O
his O
BP O
was O
104/d O

 O
and O
HR O
88 O
. O
  O
After O
the O
1L B-DOS
of O
IVFs B-DRUG
, I-DRUG
his O
O2 O
sat O
was O
noted O
to O
be O
87 O
% O

 O
on O
RA O
. O
  O
He O
was O
placed O
on O
2L B-DOS
NC B-DRUG
and O
improved O
. O
  O
He O
received O
a O

 O
second O
L O
bolus O
and O
at O
8 O
am O
this O
morning O
, O
was O
rigoring O
again O
with O

 O
T O
102.6 O
, O
BP O
110/50 O
, O
P O
100 O
, O
R O
36 O
and O
97 O
% O
on O
2L O
. O
  O
The O
MICU O
was O

 O
called O
for O
transfer O
. O
A O
urine O
culture O
drawn O
at O
this O
time O
grew O
out O

 O
polymicrobial B-REA
( O
klebsiella O
, O
enterobacter O
, O
nonpsuedomonas O

 O
nonfermenter O
) O
and O
the O
patient O
was O
appropriately O
started O
on O

 O
meropenem B-DRUG
on O
[ O
* O
* O
6 O
- O
4 O
* O
* O
] O
. O
   O
Urology O
confirmed O
placement O
and O
draining O
of O

 O
stent O
on O
[ O
* O
* O
6 O
- O
4 O
* O
* O
] O
. O
  O
A O
larger O
foley O
was O
placed O
to O
aid O
in O
the O
drainage O

 O
of O
the O
stones O
. O
  O
On O
[ O
* O
* O
6 O
- O
7 O
* O
* O
] O
the O
patient O
had O
a O
PICC O
line O
placed O
for O

 O
outpatient O
antibiotic B-DRUG
administration O
. O
  O
On O
[ O
* O
* O
6 O
- O
7 O
* O
* O
] O
, O
per O
ID O

 O
recommendations O
relating O
to O
culture O
sensitivies O
, O
the O
meropenem B-DRUG

 I-DRUG
was O
switched O
to O
Cipro B-DRUG
. I-DRUG
  O
The O
patient O
completed O
his O
course O
of O

 O
daptomycin B-DRUG
on O
[ O
* O
* O
6 O
- O
12 O
* O
* O
] O
. O
  O
The O
patient O
will O
continue O
PO B-ROU
Cipro B-DRUG
until O

 O
[ O
* O
* O
6 O
- O
15 O
* O
* O
] O
. O
  O
He O
will O
follow O
up O
with O
the O
[ O
* O
* O
Hospital O
159 O
* O
* O
] O
clinic O
as O
an O

 O
outpatient O
. O
  O
He O
will O
follow O
up O
with O
ID O
as O
an O
outpatient O
. O

 O
. O


 O
Hospital O
Acquired O
Pneumonia O
: O

 O
The O
patient O
was O
transferred O
to O
the O
MICU O
with O
hypoxia O
thought O
to O

 O
be O
secondary O
to O
an O
aspiration O
. O
Other O
etiologies O
considered O
were O

 O
hypoxia B-ADE
secondary O
to O
volume O
overload O
from O
IV B-ROU
fluid B-DRUG
boluses B-DOS
( O
last O

 O
echo O
in O
[ O
* O
* O
2132 O
* O
* O
] O
was O
normal O
) O
and O
pneumonia O
. O
Antibiotic B-DRUG
coverage O
for O

 O
hospital B-REA
acquired I-REA
pneumonia I-REA
with O
meropenem B-DRUG
was O
started O
on O
[ O
* O
* O
6 O
- O
2 O
* O
* O
] O

 O
and O
vancomycin B-DRUG
was O
added O
on O
[ O
* O
* O
6 O
- O
3 O
* O
* O
] O
to O
provide O
better O
coverage O
for O

 O
MRSA B-REA
. I-REA
  O
CXR O
on O
[ O
* O
* O
6 O
- O
3 O
* O
* O
] O
showed O
a O
stable O
left O
lower O
lobe O
consolidation O

 O
with O
new O
opacity O
and O
air O
bronchograms O
in O
the O
right O
middle O
lobe O

 O
that O
could O
possible O
be O
atelectasis O
. O
  O
Respiratory O
aspirate O

 O
cultures O
  O
were O
without O
growth O
. O
  O
On O
transfer O
to O
the O
floors O
, O
the O

 O
patient O
was O
continued O
on O
meropenem B-DRUG
for O
possible O
hospital B-REA

 I-REA
acquired I-REA
pneumonia I-REA
. I-REA
  O
Vancomycin B-DRUG
was O
stopped O
as O
per O
ID O
's O

 O
recommendations O
. O
  O
Antibiotics B-DRUG
were O
continued O
as O
discussed O
above O
. O

 O
. O

 O
History O
of O
DVT/PE O
: O

 O
The O
patient O
had O
a O
PE B-REA
in O
[ O
* O
* O
2132 O
* O
* O
] O
and O
was O
placed O
on O
heparin B-DRUG
. I-DRUG
On O

 O
arrival O
to O
the O
hospital O
, O
a O
heparin B-DRUG
bridge O
was O
initiated O
to O

 O
prepare O
for O
the O
lithotripsy B-REA
procedure I-REA
. I-REA
  O
On O
[ O
* O
* O
6 O
- O
1 O
* O
* O
] O
the O
heparin B-DRUG
was O

 O
held O
, O
the O
patient O
underwent O
the O
lithotripsy O
, O
and O
the O
heparin B-DRUG
gtt B-ROU

 I-ROU
was O
restarted O
after O
the O
procedure O
. O
  O
The O
heparin B-DRUG
was O
held O
during O

 O
the O
events O
leading O
up O
the O
[ O
* O
* O
Hospital O
228 O
* O
* O
] O
transfer O
to O
the O
MICU O
, O

 O
resulting O
in O
subtherapeutic O
PTTs O
. O
  O
He O
was O
restarted O
on O
heparin B-DRUG

 I-DRUG
in O
the O
MICU O
and O
bridged O
to O
coumadin B-DRUG
. I-DRUG
  O
On O
transfer O
to O
the O
floors O
, O

 O
his O
INR O
was O
supratherapeutic O
, O
requiring O
adjustment O
of O
the O

 O
coumadin B-DRUG
to O
5 B-STR
mg I-STR
. I-STR
  O
When O
the O
patient O
was O
transitioned O
to O
cipro B-DRUG
, I-DRUG

 O
his O
coumadin B-DRUG
was O
empirically O
lowered O
to O
3 B-STR
mg I-STR
. I-STR
  O
His O
INR O
trended O

 O
downwards O
and O
his O
coumadin B-DRUG
was O
increased O
to O
5 B-STR
mg I-STR
. I-STR
  O
He O
will O
have O

 O
his O
INR O
checked O
with O
this O
labs O
on O
Monday O
[ O
* O
* O
6 O
- O
14 O
* O
* O
] O
and O
reviewed O
at O

 O
his O
clinic O
appointment O
on O
[ O
* O
* O
6 O
- O
16 O
* O
* O
] O
. O

 O
. O


 O
S/P O
OLT O
: O

 O
The O
patient O
has O
a O
hx O
of O
hepatitis O
B O
, O
HCC O
, O
and O
is O
s/p O
OLT O
one O

 O
year O
prior O
to O
presentation O
. O
  O
On O
admission O
he O
had O
stable O
LFTs O
and O

 O
no O
signs O
of O
encephalopathy O
on O
tacrolimus B-DRUG
, I-DRUG
cellcept B-DRUG
, I-DRUG
and O
bactrim B-DRUG

 I-DRUG
prophyllaxis O
. O
  O
Following O
his O
lithotripsy O
, O
the O
patient O
developed O

 O
with O
abdominal O
distension O
concerning O
for O
ascites O
, O
confirmed O
by O

 O
ultrasound O
, O
along O
with O
positive O
asterixis O
. O
  O
In O
combination O
with O

 O
his O
altered O
mental O
status O
, O
this O
was O
concerning O
for O
hepatic O

 O
encephalopathy O
. O
  O
On O
[ O
* O
* O
6 O
- O
2 O
* O
* O
] O
the O
patient O
was O
started O
on O
lactulose B-DRUG
for O

 O
treatment O
of O
hepatic B-REA
encephalopathy I-REA
, I-REA
then O
transitioned O
to O

 O
rifaxamin B-DRUG
on O
[ O
* O
* O
6 O
- O
4 O
* O
* O
] O
. O
  O
The O
patient O
was O
continued O
on O
his O
tacrolimus B-DRUG

 I-DRUG
and O
cellcept B-DRUG
. I-DRUG
  O
He O
will O
follow O
up O
in O
[ O
* O
* O
Month/Day O
( O
4 O
) O
* O
* O
] O
clinic O
, O
where O
he O

 O
will O
be O
assessed O
for O
future O
liver O
biopsy O
. O
  O
He O
will O
require O
an O

 O
INPATIENT O
stay O
for O
this O
biopsy O
so O
that O
he O
can O
bridged O
from O

 O
coumadin B-DRUG
to O
heparin B-DRUG
prior O
to O
the O
procedure O
. O

 O
. O

 O
Pancytopenia O
: O

 O
Patient O
has O
a O
longstanding O
history O
of O
pancytopenia O
. O
  O
WBC O
was O
1.9 O

 O
on O
admission O
and O
ranged O
from O
1.5 O
- O
3.1 O
over O
his O
hospital O
course O
. O

 O
HCT O
was O
in O
the O
low O
20s O
and O
required O
1 B-DOS
transfusion B-FOR
of O
pRBCs B-DRUG
. I-DRUG
This O

 O
is O
of O
uncertain O
origin O
, O
likely O
multifactorial O
[ O
* O
* O
12 O
- O
29 O
* O
* O
] O
infection O
, O

 O
medication O
( O
HIV O
, O
antibiotics B-DRUG
, I-DRUG
etc O
) O
. O
In O
setting O
of O
increasing O

 O
splenomegaly O
, O
we O
have O
considered O
a O
hem/onc O
process O
. O
  O
As O
per O
Dr. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
2148 O
* O
* O
] O
, O
this O
is O
already O
being O
worked O
up O
in O
the O
outpatient O

 O
setting O
. O

 O
. O

 O
HIV O
: O

 O
Stable O
, O
CD4 O
65 O
, O
VL O
120 O
, O
immunosuppressed O
on O
anti-rejection O

 O
medications O
. O
  O
No O
modifications O
were O
made O
to O
his O
HAART O
regimen O

 O
( O
RiTONAvir B-DRUG
, I-DRUG
Raltegravir B-DRUG
) I-DRUG
and O
bactrim B-DRUG
ppx O
. O
Lyrica B-DRUG
( O
for O
HIV B-REA

 I-REA
neuropathy I-REA
) I-REA
was O
held O
while O
in O
MICU O
, O
but O
restarted O
on O
the O
floors O
. O

 O
. O

 O
DM B-REA
: I-REA

 O
Stable O
, O
continue O
insulin B-DRUG
sliding B-DOS
scale I-DOS
. I-DOS

 O
. O

 O
Depression B-REA
: I-REA

 O
Continued O
mirtazapine B-DRUG
and O
lexapro B-DRUG
. I-DRUG

 O
. O

 O
BPH B-REA
: I-REA

 O
Continue O
terazosin B-DRUG
. I-DRUG



 O
Medications O
on O
Admission O
: O

 O
DARUNAVIR B-DRUG
[ O
PREZISTA B-DRUG
] I-DRUG
600 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
EMTRICITABINE-TENOFOVIR B-DRUG
[ O
TRUVADA B-DRUG
] I-DRUG
200 B-STR
mg-300 I-STR
mg I-STR
QOD B-FRE

 I-FRE
ESCITALOPRAM B-DRUG
[ O
LEXAPRO B-DRUG
] I-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
FENOFIBRATE B-DRUG
NANOCRYSTALLIZED I-DRUG
[ O
TRICOR B-DRUG
] I-DRUG
48 B-STR
mg I-STR
Tablet B-FOR
daily B-FRE

 I-FRE
HEPATITIS B-DRUG
B I-DRUG
IMMUNE I-DRUG
GLOBULIN I-DRUG
[ O
NABI-HB O
] O
10,000 B-STR
units I-STR
q B-FRE
month I-FRE

 I-FRE
INSULIN B-DRUG
GLARGINE I-DRUG
[ O
LANTUS B-DRUG
] I-DRUG
20 B-DOS
u I-DOS
qAM B-FRE

 I-FRE
INSULIN B-DRUG
LISPRO I-DRUG
[ O
HUMALOG B-DRUG
] I-DRUG
sliding B-DOS
scale I-DOS

 I-DOS
LEVOFLOXACIN B-DRUG
[ O
LEVAQUIN B-DRUG
] I-DRUG
250 B-STR
mg I-STR
x7 B-DUR
day I-DUR
? O

 O
MIRTAZAPINE B-DRUG
- O
15 B-STR
mg I-STR
Tablet B-FOR
- O
1 B-DOS
Tablet(s B-FOR
) O
by B-ROU
mouth I-ROU
at B-FRE
bedtime I-FRE

 I-FRE
MYCOPHENOLATE B-DRUG
MOFETIL I-DRUG
250 B-STR
mg I-STR
Capsule B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
PREGABALIN B-DRUG
[ I-DRUG
LYRICA I-DRUG
] I-DRUG
150 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
RALTEGRAVIR B-DRUG
[ O
ISENTRESS B-DRUG
] I-DRUG
400 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
RITONAVIR B-DRUG
[ O
NORVIR B-DRUG
] I-DRUG
100 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
SULFAMETHOXAZOLE-TRIMETHOPRIM B-DRUG
800 B-STR
mg-160 I-STR
mg I-STR
qMWF B-FRE

 I-FRE
TACROLIMUS B-DRUG
0.5 B-STR
mg I-STR
qMonday B-FRE

 I-FRE
TERAZOSIN B-DRUG
2 B-STR
mg I-STR
qHS B-FRE

 I-FRE
WARFARIN B-DRUG
6 B-STR
mg I-STR
daily B-FRE

 I-FRE
CALCIUM B-DRUG
CARBONATE-VIT I-DRUG
D3-MIN I-DRUG
600 B-STR
mg-400 I-STR
unit I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
FERROUS B-DRUG
SULFATE I-DRUG
325 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O



 O
Discharge O
Medications O
: O

 O
1 O
. O
Darunavir B-DRUG
600 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O

 O
day O
) O
. O

 O
2 O
. O
Ritonavir B-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O

 O
a O
day O
) O
. O

 O
3 O
. O
Tacrolimus B-DRUG
0.5 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
1X/WEEK B-FRE

 I-FRE
( O
MO O
) O
. O

 O
4 O
. O
Sulfamethoxazole-Trimethoprim B-DRUG
800 B-STR
- I-STR
160 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
3X/WEEK B-FRE
( O
MO O
, O
WE O
, O
FR O
) O
. O

 O
5 O
. O
Mirtazapine B-DRUG
15 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( O
at O

 O
bedtime O
) O
. O

 O
6 O
. O
Raltegravir B-DRUG
400 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O

 O
a O
day O
) O
. O

 O
7 O
. O
Mycophenolate B-DRUG
Mofetil I-DRUG
250 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU

 I-ROU
BID B-FRE
( O
2 O
times O
a O
day O
) O
. O

 O
8 O
. O
Ciprofloxacin B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q24H B-FRE

 I-FRE
( O
every O
24 O
hours O
) O
for B-DUR
3 I-DUR
days I-DUR
. I-DUR

 O
Disp:*3 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
9 O
. O
Tricor B-DRUG
48 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
10 O
. O
Lantus B-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
20 B-DOS
U B-FOR
  O
Subcutaneous B-ROU
qAM B-FRE
. I-FRE

 O
11 O
. O
Insulin B-DRUG
Lispro I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
Sliding B-DOS
Scale I-DOS

 I-DOS
Subcutaneous B-ROU
qmeal B-FRE
. I-FRE

 O
12 O
. O
Outpatient O
Lab O
Work O

 O
PLEASE O
DRAW O
LABS O
: O
COMPLETE O
BLOOD O
COUNT O
AND O
CHEMISTRY O
PANEL O

 O
( O
ELECTROLYTES O
, O
BUN/CREATININE O
) O
AND O
FAX O
RESULTS O
TO O
: O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
[ O
* O
* O
Name O
Prefix O
( O
Prefixes O
) O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
Prefixes O
) O
* O
* O
] O
, O
MD- O
INFECTIOUS O
DISEASES O
FAX O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1419 O
* O
* O
] O

 O
13 O
. O
Warfarin B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
14 O
. O
Truvada B-DRUG
200 B-STR
- I-STR
300 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QOD B-FRE
. I-FRE

 O
15 O
. O
Nabi-HB B-DRUG
> B-STR
1,560 I-STR
unit/5 I-STR
mL I-STR
Solution B-FOR
Sig O
: O
   O
[ O
* O
* O
Numeric O
Identifier O
961 O
* O
* O
] O
Intramuscular B-ROU

 I-ROU
once B-FRE
a I-FRE
month I-FRE
. I-FRE

 O
16 O
. O
Calcium B-DRUG
Carbonate-Vitamin I-DRUG
D3 I-DRUG
600 B-STR
mg(1,500 I-STR
mg I-STR
) I-STR
-400 I-STR
unit I-STR

 I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
17 O
. O
Lyrica B-DRUG
150 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
18 O
. O
Lexapro B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
19 O
. O
Terazosin B-DRUG
2 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
at B-FRE
bedtime I-FRE
. I-FRE

 O

20 O
. O
Ferrous B-DRUG
Sulfate I-DRUG
325 B-STR
mg I-STR
( O
65 O
mg O
Iron O
) O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
PRIMARY O
: O
urosepsis O
, O
VRE O
urinary O
tract O
infection O
, O
bladder O
stones O

 O
SECONDARY O
: O
HIV O
, O
HBV O
, O
HCV O
s/p O
OLT O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
It O
was O
a O
pleasure O
to O
participate O
in O
your O
care O
Mr. O
[ O
* O
* O
Known O
lastname O
26080 O
* O
* O
] O
. O
  O
You O

 O
were O
admitted O
to O
the O
hospital O
for O
anticoagulation B-REA
with O
heparin B-DRUG

 I-DRUG
prior O
to O
your O
lithotripsy B-REA
procedure I-REA
. I-REA
  O
Following O
your O
procedure O
, O

 O
you O
had O
an O
infection O
that O
caused O
you O
to O
have O
low O
blood O
pressure O
. O

  O
You O
have O
now O
completed O
intravenous B-ROU
antibiotic B-DRUG
therapy O
for O
that O

 O
infection B-REA
and O
have O
three B-DUR
days I-DUR
remaining O
of O
an O
oral B-ROU
antibiotic B-DRUG

 I-DRUG
( O
see O
below O
) O
. O


 O
Please O
see O
below O
for O
your O
follow-up O
appointments O
. O


 O
Your O
medications O
have O
CHANGED O
as O
follows O
: O


 O
1 O
. O
We O
ADDED O
Ciprofloxacin B-DRUG
500 B-STR
mg I-STR
daily B-FRE
to O
treat O
the O
serious O

 O
infection B-REA
you O
had O
during O
your O
hospital O
stay O
. O
  O
The O
course O
of O
this O

 O
medications O
will O
be O
complete O
on O
[ O
* O
* O
6 O
- O
15 O
* O
* O
] O
. O


 O
2 O
. O
  O
We O
DECREASED O
your O
Coumadin B-DRUG
dose O
to O
5 B-STR
mg I-STR
daily B-FRE
. I-FRE


 O
Please O
continue O
to O
take O
your O
other O
medications O
as O
you O
have O
been O
, O

 O
and O
keep O
your O
follow O
up O
appointments O
. O


 O
BECAUSE O
OF O
YOUR O
CONDITION O
CALLED O
HEPATIC O
ENCEPHALOPATHY O
WHICH O

 O
CAN O
OCCUR O
AT O
ANY O
TIME O
, O
YOU O
ABSOLUTELY O
[ O
* O
* O
Street O
Address(1 O
) O
56354 O
* O
* O
] O
! O
! O
! O
DRIVING O

 O
CAN O
CAUSE O
SERIOUS O
INJURY O
OR O
DEATH O
TO O
YOU O
AND O
OTHERS O
. O


 O
Followup O
Instructions O
: O

 O
1 O
. O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
2088 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
673 O
* O
* O
] O

 O
Date/Time:[**2134 O
- O
6 O
- O
14 O
* O
* O
] O
3:00 O
PM O


 O
2 O
. O
Please O
follow-up O
in O
Infectious O
Disease O
clinic O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
724 O
* O
* O
] O
. O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
28019 O
* O
* O
] O
Call O
to O
schedule O
an O
appointment O
. O
You O
will O
need O
labs O

 O
drawn O
next O
week O
and O
faxed O
to O
the O
ID O
doctors O
( O
see O
below O
) O
. O


 O
3 O
. O
Please O
follow-up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
27027 O
* O
* O
] O
in O
the O
[ O
* O
* O
Hospital O
159 O
* O
* O
] O
clinic O

 O
within O
1 O
month O
. O
The O
number O
is O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
164 O
* O
* O
] O



 O
4 O
. O
Please O
follow-up O
in O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
* O
* O
] O
hepatology O
( O
liver O
) O
clinic O
with O

 O
Dr. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
on O
Weds O
[ O
* O
* O
6 O
- O
16 O
* O
* O
] O
at O
2 O
PM O
as O
you O
may O
need O
to O

 O
discuss O
inpatient O
liver O
biopsy O
. O



                              O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(1 O
) O
1379 O
* O
* O
] O


 O

Admission O
Date O
: O
  O
[ O
* O
* O
2129 O
- O
4 O
- O
20 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2129 O
- O
4 O
- O
23 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2072 O
- O
5 O
- O
1 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
No O
Known O
Allergies O
/ O
Adverse O
Drug O
Reactions O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1115 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
hypotension O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
none O


 O
History O
of O
Present O
Illness O
: O

 O
56 O
yo O
W O
with O
ESRD O
on O
HD O
( O
MWF O
) O
, O
HTN O
( O
last O
sBPs O
in O
150s O
) O
, O
HCV O

 O
cirrhosis O
, O
Hypothyroidism O
, O
Anxiety O
, O
chronic B-REA
back I-REA
pain I-REA
on O

 O
methadone B-DRUG
, I-DRUG
presenting O
with O
systolic O
BPs O
in O
the O
60s O
prior O
to O
and O

 O
during O
[ O
* O
* O
Hospital O
58910 O
* O
* O
] O
transferred O
to O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
for O
evaluation O
and O
management O
of O

 O
hypotension O
. O

 O
. O

 O
She O
reports O
1 O
month O
of O
increasing O
fatigue O
, O
weakness O
, O
and O

 O
occasional O
falls O
( O
knee O
buckling O
) O
. O
Occasional O
cough O
with O
brown O

 O
sputum O
and O
chronic O
loose O
stools O
, O
but O
no O
fevers O
, O
chills O
, O
sweats O
, O

 O
dyspnea O
, O
nausea O
, O
vomiting O
, O
black O
or O
bloody O
stools O
. O
Regarding O
her O

 O
complaints O
, O
she O
reports O
that O
her O
BP O
medications O
have O
been O

 O
adjusted O
, O
but O
this O
has O
not O
helped O
. O
She O
has O
also O
experienced O

 O
intermittent O
L-sided O
sharp B-REA
chest I-REA
pains I-REA
that O
worsen O
with O
arm O

 O
movement O
, O
and O
was O
prescribed O
nitroglycerin B-DRUG
that O
she O
ended O
up O

 O
taking O
daily B-FRE
instead O
of O
on O
a O
PRN B-FRE
basis O
. O

 O
. O

 O
In O
the O
ED O
, O
initial O
vs O
were O
: O
T O
97.4 O
P O
69 O
BP O
64/53 O
R O
14 O
97 O
% O
O2 O
sat O

 O
on O
RA O
. O
Per O
report O
, O
she O
was O
mentating O
appropriately O
. O
A O
triple O

 O
lumen O
femoral O
CVC O
was O
placed O
. O
She O
was O
bolused O
500 O
cc O
, O
given O

 O
Vancomycin B-DRUG
and O
Zosyn B-DRUG
, I-DRUG
and O
started O
on O
Levophed B-DRUG
at O
0.06 B-STR
. I-STR
CXR O
was O

 O
unremarkable O
. O
CT O
C/A/P O
were O
obtained O
and O
prelim O
only O
significant O

 O
for O
a O
right O
adenexal O
cyst O
( O
present O
since O
[ O
* O
* O
Month O
( O
only O
) O
404 O
* O
* O
] O
) O
. O

 O
. O

 O
On O
the O
floor O
, O
the O
patient O
was O
appropriate O
and O
comfortable O
. O
She O

 O
was O
placed O
on O
a O
Nicom O
. O
CI O
and O
SVI O
improved O
with O
leg O
raise O
so O
Pt O

 O
was O
given O
250 O
cc O
, O
then O
on O
repeat O
given O
additional O
250 O
cc O
. O

 O
Levophed B-DRUG
was O
weaned O
off O
. O

 O
. O

 O
Review O
of O
sytems O
: O
per O
HPI O
, O
otherwise O
negative O



 O
Past O
Medical O
History O
: O

 O
-HTN O

 O
-ESRD O
on O
hemodialysis O

 O
-HCV O
cirrhosis O

 O
-spinal O
stenosis O
with O
back O
pain O

 O
-seizure O
disorder O

 O
-depression O

 O
-hypothyroidism O

 O
-substance O
abuse O

 O
-Lumbar O
laminectomy O

 O
-status O
post O
failed O
renal O
transplant O

 O
-cholecystectomy O

 O
-thyroidectomy O



 O

Social O
History O
: O

 O
Retired O
special O
education O
teacher O
. O
Widowed O
, O
lives O
at O
home O
with O

 O
sister O
, O
who O
is O
primary O
caregiver O
. O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
one O
son O
, O
who O
is O
healthy O
. O

 O
# O
Tobacco O
: O
3 O
packs O
per O
week O
since O
teenager O

 O
# O
Alcohol O
: O
Denies O

 O
# O
Drugs O
: O
Past O
IVDU O
, O
but O
not O
in O
several O
years O



 O
Family O
History O
: O

 O
Father O
: O
ESRD O
and O
hypertension O

 O
Mother O
: O
lung O
cancer O



 O
Physical O
Exam O
: O

 O
VS O
: O
97.6 O
, O
63 O
, O
133/86 O
, O
98 O
% O
on O
RA O

 O
General O
: O
alert O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
muddy O
sclera O
, O
dry O
MM O
, O
oropharynx O
clear O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O
rales O
, O

 O
rhonchi O

 O
CV O
: O
Regular O
rate O
and O
rhythm O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O

 O
gallops O

 O
Abdomen O
: O
  O
soft O
, O
obese O
, O
+ O
BS O
, O
TTP O
in O
RUQ O
with O
mild O
voluntary O

 O
guarding O

 O
GU O
: O
no O
foley O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
symmetric O
pulses O
, O
no O
clubbing O
, O

 O
cyanosis O
or O
edema O
, O
R O
hallux O
with O
nail O
bed O
removed O
, O
crusted O

 O
blood O
, O
no O
erythema O
or O
fluctuance O
, O
no O
purulence O

 O
Neuro O
: O
face O
symmetric O
, O
moves O
all O
extremities O
, O
sensation O
intact O
, O

 O
gait O
not O
observed O



 O
Brief O
Hospital O
Course O
: O

 O
56 O
yo O
W O
with O
Hx O
of O
ESRD O
on O
HD O
, O
HCV O
cirrhosis O
, O
HTN O
, O

 O
Hypothyroidism O
, O
and O
chronic B-REA
pain I-REA
on O
methadone B-DRUG
presenting O
from O
HD O

 O
with O
hypotension O
to O
systolic O
BPs O
, O
initially O
admitted O
to O
ICU O
, O

 O
quickly O
transferred O
to O
medical O
floor O
. O

 O
. O

 O
# O
Hypotension O
: O
Appears O
to O
have O
been O
developing O
subacutely O
, O
over O

 O
the O
last O
month O
. O
Hypotension B-ADE
is O
likely O
secondary O
to O
a O
too O

 O
aggressive O
antihypertensive B-DRUG
regimen I-DRUG
, I-DRUG
current O
medication O
misuse O
, O

 O
or O
possibly O
over-diuresis O
at O
HD O
( O
with O
need O
for O
reassessment O
of O

 O
dry O
weight O
) O
. O
Supporting O
a O
possible O
over O
beta-blockade B-DRUG
is O
a O
HR O

 O
that O
has O
consistently O
remained O
in O
the O
60s O
despite O
BPs O
in O
the O

 O
60s O
. O
Additionally O
she O
was O
started O
on O
nitroglycerin B-DRUG
and O
had O
been O

 O
taking O
it O
daily B-FRE
rather O
than O
on O
a O
PRN B-FRE
basis O
. O
She O
is O
responsible O

 O
for O
her O
medications O
, O
yet O
unable O
to O
correctly O
remember O
dosing O

 O
regimen O
. O
Other O
etiologies O
to O
consider O
given O
the O
chronicity O

 O
include O
endocrine O
causes O
such O
untreated O
hypothyroidism O
( O
pill O

 O
bottle O
not O
in O
bag O
) O
or O
adrenal O
insufficiency O
. O
  O
Received O
a O
total O

 O
of O
1.5 O
L O
of O
volume O
resuscitation O
. O
Levophed B-DRUG
weaned O
off O
. O
Outpt O

 O
Nephrologist O
reports O
dry O
weight O
as O
74 O
kg O
. O
She O
was O
started O

 O
initially O
on O
road O
spectrum O
antibiotics B-DRUG
which O
were O
quickly O

 O
discontinued O
when O
all O
cultures O
were O
negative O
. O

 O
. O


 O
TSH O
, O
free O
T4 O
, O
and O
AM O
Cortisol O
obtained O
and O
pt O
restarted O
home O

 O
levothyroxine B-DRUG
dose O
for O
significant B-REA
hypothyroidism I-REA
. I-REA
CT O
abd/pelvis O

 O
was O
unremarkable O
except O
for O
stable O
adnexal O
cyst O
. O
Blood O
pressures O

 O
remained O
stable O
while O
patient O
was O
off O
her O
anti-hypertensives B-DRUG
. I-DRUG

 O
After O
chart O
review O
she O
had O
been O
started O
on O
these O
during O
an O

 O
admission O
for O
chest O
pain O
at O
which O
time O
a O
cath O
revealed O
clean O

 O
coronary O
arteries O
. O
Therefore O
it O
is O
felt O
she O
does O
not O
need O
these O

 O
medications O
and O
they O
were O
stopped O
. O
She O
will O
continue O
on O

 O
simvastatin B-DRUG
for O
her O
cholesterol B-REA
management I-REA
and O
ASA B-DRUG
to O
reduce B-REA
her I-REA

 I-REA
risk I-REA
of I-REA
stroke I-REA
. I-REA
She O
will O
follow O
up O
with O
her O
PCP O
or O
in O

 O
[ O
* O
* O
Name9 O
( O
PRE O
) O
1944 O
* O
* O
] O
clinic O
for O
a O
BP O
check O
off O
of O
her O
medications O
and O

 O
will O
have O
VNA O
checking O
her O
BPs O
at O
home O
as O
well O
. O
Her O
PCP O
can O

 O
titrate O
medications O
as O
necessary O

 O
. O

 O
# O
Elevated O
bicarbonate O
: O
Likely O
[ O
* O
* O
2 O
- O
16 O
* O
* O
] O
recent O
HD O
session O
, O
as O
well O
as O

 O
contraction O
from O
intravascular O
depletion O
. O
Supporting O
this O
is O
a O

 O
Hct O
above O
baseline O
likely O
reflecting O
hemoconcentration O
. O
Pt O
is O
on O

 O
advair B-DRUG
without O
documented O
hx O
of O
COPD B-REA
. I-REA
CXR O
not O
reflective O
of O
this O

 O
and O
bicarb O
not O
chronically O
elevated O
. O

 O
. O

 O
# O
Hyperkalemia B-REA
: I-REA
Likely O
[ O
* O
* O
2 O
- O
16 O
* O
* O
] O
ESRD O
. O
No O
evidence O
of O
peaked O
T O
waves O

 O
on O
EKG O
. O
She O
was O
given O
insulin B-DRUG
, I-DRUG
kayexelate B-DRUG
overnight O
and O
repeated O

 O
insulin B-DRUG
per O
renal O
recs O
prior O
to O
dialysis O
this O
AM O
. O
K O
was O
noted O
to O

 O
be O
wnl O
on O
follow O
up O
AM O
labs O
. O

 O
. O

 O
# O
Prolonged O
PT/PTT O
: O
INR O
mildly O
elevated O
likely O
[ O
* O
* O
2 O
- O
16 O
* O
* O
] O
underlying O

 O
poor O
synthetic O
liver O
function O
from O
cirrhosis O
. O
Also O
may O
have O
a O

 O
nutritional O
component O
as O
well O
. O
Prolonged B-ADE
PTT I-ADE
likely O
[ O
* O
* O
2 O
- O
16 O
* O
* O
] O
heparin B-DRUG

 I-DRUG
received O
at O
HD O
. O
No O
evidence O
to O
support O
bleeding O
. O

 O
PTT O
resolved O
off O
heparin B-DRUG
. I-DRUG

 O
. O

 O
# O
Thrombocytopenia O
: O
Chronic O
issue O
, O
likely O
[ O
* O
* O
2 O
- O
16 O
* O
* O
] O
cirrhosis O
. O

 O
Platelets O
were O
stable O
and O
did O
not O
require O
transfusion O
. O

 O
. O

 O
# O
Anemia B-REA
: I-REA
[ O
* O
* O
2 O
- O
16 O
* O
* O
] O
ESRD O
. O
BL O
Hct O
around O
31 O
. O
On O
EPO B-DRUG
as O
outpt O
. O
Hct O
was O

 O
trended O
and O
stable O
; O
pt O
did O
not O
require O
transfusion O
of O
blood O

 O
components O
during O
her O
ICU O
stay O
. O

 O
. O


 O
# O
CAD B-REA
: I-REA
No O
evidence O
to O
suggest O
acute O
ischemia O
. O
EKG O
consistent O

 O
with O
prior O
. O
Trop O
at O
0.05 O
, O
likely O
[ O
* O
* O
2 O
- O
16 O
* O
* O
] O
demand O
in O
setting O
of O
CKI O
. O

 O
CK O
and O
CKMB O
added O
on O
and O
non-concerning O
for O
ACS O
. O
Pt O

 O
asymptomatic O
. O
She O
was O
continued O
on O
asa B-DRUG
81 B-STR
mg I-STR
, I-STR
simvastatin B-DRUG
20 B-STR
mg I-STR
. I-STR

 O
BBlocker B-DRUG
and O
ACEi B-DRUG
held O
for O
observation O
of O
hemodynamic O
stability O

 O
given O
admission O
complaint O
. O

 O
. O

 O
# O
Hypothyroidism B-REA
: I-REA
  O
TSH O
grossly O
elevated O
with O
very O
low O
T4 O
. O

 O
Levothyroxine B-DRUG
was O
not O
in O
her O
pill O
bag O
, O
in O
discussion O
with O
her O

 O
pharmacy O
this O
prescription O
had O
not O
been O
filled O
in O
many O
months O
. O

 O
Pt O
was O
started O
on O
Levothyroxine B-DRUG
188mcg B-STR
daily B-FRE
, I-FRE
will O
need O
repeat O

 O
TFT O
's O
in O
[ O
* O
* O
4 O
- O
20 O
* O
* O
] O
weeks O
. O
  O
[ O
* O
* O
Month O
( O
only O
) O
116 O
* O
* O
] O
be O
contributing O
to O
hypotension O
, O
fatigue O

 O
and O
depression O
. O
  O
Arranged O
for O
her O
pills O
to O
be O
delivered O
in O
a O

 O
bubble O
pack O
to O
help O
with O
med O
compliance O
in O
the O
future O
. O

 O
. O

 O
# O
Seizure B-REA
Disorder I-REA
: I-REA
Continued O
on O
Keppra B-DRUG
250 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O

 O
. O

 O
# O
Depression/Anxiety B-REA
: I-REA
SHe O
has O
severe O
depression O
, O
uncontrolled O
. O

 O
No O
SI/HI O
. O
  O
Restarted O
home O
clonazepam B-DRUG
( O
held O
on O
admission O
given O

 O
hypotention O
) O
, O
social O
work O
consulted O
, O
fluoxitine B-DRUG
increased O
from O

 O
40 B-STR
to O
60 B-STR
mg I-STR
daily B-FRE
. I-FRE
  O
She O
is O
interested O
in O
outpt O
therapy O
, O
to O

 O
arranged O
by O
her O
PCP O
at O
follow O
up O
. O

 O
. O

 O
# O
Chronic B-REA
Pain I-REA
: I-REA
On O
Gabapentin B-DRUG
and O
methadone B-DRUG
dose O
was O
confirmed O

 O
with O
[ O
* O
* O
Doctor O
Last O
Name O
7594 O
* O
* O
] O
Op O
Co O
to O
be O
44 B-STR
mg I-STR
daily B-FRE
. I-FRE

 O
. O

 O
# O
Given O
prior O
hx O
of O
renal O
nodule O
seen O
on O
CT O
scan O
, O
pt O
was O
ordered O

 O
for O
MRI O
to O
be O
completed O
during O
her O
stay O
given O
concern O
for O
poor O

 O
outpt O
followup O
. O
  O
MRI O
renal O
wo O
contrast O
was O
performed O
; O
read O
was O

 O
pending O
at O
time O
of O
d/c O
and O
needs O
to O
be O
followed O
up O
by O
outpatient O

 O
providers O
( O
either O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
805 O
* O
* O
] O
or O
PCP O
) O

 O
. O

 O
# O
Right O
adnexal O
Cyst O
: O
Patient O
was O
told O
to O
follow O
up O
with O
pelvic O

 O
ultrasound O
for O
right O
adnexal O
cyst O
seen O
on O
CT O
scan O
. O
PCP O
[ O
* O
* O
Name O
Initial O
( O
PRE O
) O
* O
* O
] O
/or O

 O
[ O
* O
* O
Hospital O
1944 O
* O
* O
] O
clinic O
will O
help O
her O
coordinate O
this O
study O
. O

 O
. O

 O
Contact O
: O
sister O
[ O
* O
* O
Name2 O
( O
NI O
) O
* O
* O
] O
at O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
98152 O
* O
* O
] O



 O
# O
Transitions O
of O
care O
: O

 O
- O
Right O
adnexal O
cyst O
needs O
transvaginal O
ultrasound O
for O
further O

 O
evaluation O
. O
To O
be O
coordinated O
with O
PCP O
's O
help O

 O
- O
Blood O
cultures O
pending O
at O
time O
of O
discharge O
and O
need O
to O
be O

 O
followed O
up O
at O
[ O
* O
* O
Hospital O
1944 O
* O
* O
] O
clinic O

 O
- O
Patient O
had O
MRI O
of O
abdomen O
to O
evaluate O
a O
renal O
cyst O
. O
Final O

 O
read O
pending O
at O
discharge O
and O
needs O
to O
be O
followed O
up O
through O

 O
outpatient O
providers O
either O
at O
[ O
* O
* O
Hospital O
1944 O
* O
* O
] O
clinic O
or O
with O
Dr. O

 O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
805 O
* O
* O
] O

 O
- O
Patient O
seemed O
depressed B-REA
and O
her O
fluoxetine B-DRUG
was O
increased O
from O

 O
40 B-STR
mg I-STR
to O
60 B-STR
mg I-STR
daily B-FRE
. I-FRE
  O
Denied O
SI O
. O
At O
her O
[ O
* O
* O
Hospital O
1944 O
* O
* O
] O
clinic O

 O
please O
assess O
her O
mood O
and O
help O
arrange O
outpt O
therapy O
. O

 O
- O
Patient O
's O
BP B-DRUG
meds I-DRUG
were O
held O
given O
hypotension B-ADE
. I-ADE
Post-D/c O
clinic O

 O
will O
check O
her O
BP O
to O
ensure O
stable O
off O
meds O
still O
. O

 O
- O
Patient O
had O
a O
low O
blood O
count O
( O
and O
chronically O
low O
plts O
) O
which O

 O
should O
be O
repeated O
at O
her O
post-discharge O
follow O
up O
appt O


 O
Medications O
on O
Admission O
: O

 O
-Metoprolol B-DRUG
succinate I-DRUG
25 B-STR
daily B-FRE

 I-FRE
-Nitrostat B-DRUG
PRN B-FRE

 I-FRE
-Simvastatin B-DRUG
20 B-STR
daily B-FRE

 I-FRE
-ASA B-DRUG
81 B-STR
daily B-FRE

 I-FRE
-Fluoxetine B-DRUG
40 B-STR
daily B-FRE

 I-FRE
-Gabapentin B-DRUG
300 B-STR
daily B-FRE

 I-FRE
-Lisinopril B-DRUG
2.5 B-STR
daily B-FRE

 I-FRE
-Keppra B-DRUG
250 B-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
-Folic B-DRUG
acid I-DRUG
1 B-STR
mg I-STR
daily B-FRE

 I-FRE
-Sensipar B-DRUG
30 B-STR
mg I-STR
PRN B-FRE

 I-FRE
-Trazadone B-DRUG
50 B-STR
qhs B-FRE

 I-FRE
-Omeprazole B-DRUG
20 B-STR
daily B-FRE



 I-FRE

Discharge O
Medications O
: O

 O
1 O
. O
levetiracetam B-DRUG
250 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s B-FOR
) O
* O
Refills:*2 O
* O

 O
2 O
. O
fluticasone-salmeterol B-DRUG
250 B-STR
- I-STR
50 I-STR
mcg/dose I-STR
Disk B-FOR
with I-FOR
Device I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Disk B-FOR
with I-FOR
Device I-FOR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
Disp:*60 O
Disk O
with O
Device(s O
) O
* O
Refills:*2 O
* O

 O
3 O
. O
levothyroxine B-DRUG
100 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
4 O
. O
levothyroxine B-DRUG
88 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE

 I-FRE
day I-FRE
: I-FRE
With O
the O
100mcg O
tab O
. O

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
5 O
. O
gabapentin B-DRUG
300 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
QHD B-FRE
( I-FRE
each I-FRE

 I-FRE
hemodialysis I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Capsule(s O
) O
* O
Refills:*2 O
* O

 O
6 O
. O
clonazepam B-DRUG
0.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
methadone B-DRUG
10 B-STR
mg/mL I-STR
Concentrate B-FOR
Sig O
: O
Forty B-DOS
Four I-DOS
( I-DOS
44 I-DOS
) I-DOS
mg I-DOS
PO B-ROU

 I-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
fluoxetine B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*90 O
Capsule(s O
) O
* O
Refills:*2 O
* O

 O
9 O
. O
calcium B-DRUG
acetate I-DRUG
667 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
TID B-FRE

 I-FRE
W/MEALS I-FRE
( I-FRE
3 I-FRE
TIMES I-FRE
A I-FRE
DAY I-FRE
WITH I-FRE
MEALS I-FRE
) I-FRE
. I-FRE

 O
Disp:*90 O
Capsule(s O
) O
* O
Refills:*2 O
* O

 O
10 O
. O
aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet O
, O
Delayed O
Release O
(E.C.)(s O
) O
* O
Refills:*2 O
* O

 O
11 O
. O
simvastatin B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
12 O
. O
Sensipar B-DRUG
30 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
13 O
. O
omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Capsule O
, O
Delayed O
Release(E.C.)(s O
) O
* O
Refills:*2 O
* O

 O
14 O
. O
folic B-DRUG
acid I-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
15 O
. O
trazodone B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE
bedtime I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
Cargroup O
Home O
Care O


 O
Discharge O
Diagnosis O
: O

 O
Hypotension O
secondary O
to O
medications O
and O
dialysis O

 O
Hypothyroidism O

 O
Right O
adnexal O
cyst O

 O
Renal O
Cyst O



 O

Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
hospital O
with O
low B-ADE
blood I-ADE
pressure I-ADE
. I-ADE
This O

 O
was O
probably O
a O
combination O
of O
having O
dialysis O
and O
taking O
blood B-DRUG

 I-DRUG
pressure I-DRUG
medications I-DRUG
. I-DRUG
We O
have O
stopped O
your O
blood B-DRUG
pressure I-DRUG

 I-DRUG
medications I-DRUG
as O
you O
do O
n't O
need O
them O
. O
We O
looked O
for O
infections O

 O
( O
which O
can O
cause O
your O
blood O
pressure O
to O
be O
low O
) O
but O
could O
not O

 O
find O
any O
. O
Please O
take O
your O
medications O
exactly O
as O
prescribed O
. O

  O
You O
also O
had O
a O
CT O
scan O
which O
showed O
a O
cyst O
on O
your O
right O
ovary O
. O

 O
You O
need O
an O
ultrasound O
of O
your O
ovary O
to O
evaluate O
this O
. O
You O

 O
should O
coordinate O
this O
study O
with O
your O
primary O
care O
provider O
. O

  O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
2172 O
* O
* O
] O
CT O
scan O
also O
showed O
a O
cyst O
on O
your O
kidney O
. O
You O
had O
an O
MRI O

 O
to O
evaluate O
this O
. O
The O
read O
on O
the O
MRI O
is O
pending O
at O
this O
point O

 O
and O
you O
should O
follow O
up O
with O
your O
primary O
doctor O
to O
find O
out O
if O

 O
there O
is O
anything O
else O
that O
needs O
to O
be O
done O
about O
this O
. O

 O
. O

 O
Medication O
Changes O
: O

 O
START O
: O
Calcium B-DRUG
acetate I-DRUG
667 B-STR
TID B-FRE
with I-FRE
meals I-FRE
( O
to O
keep O
your O
calium B-REA

 I-REA
higher I-REA
and O
your O
phosphorous B-REA
lower I-REA
) I-REA

 O
START O
: O
Levothyroxine B-DRUG
200mcg B-STR
daily B-FRE

 I-FRE
STOP O
: O
Lisinopril B-DRUG

 I-DRUG
STOP O
: O
Metoprolol B-DRUG

 I-DRUG
STOP O
: O
Nitroglycerin B-DRUG

 I-DRUG
CHANGE O
: O
Fluoxetine B-DRUG
to O
60 B-STR
mg I-STR
daily B-FRE


 I-FRE
Followup O
Instructions O
: O

 O
You O
will O
be O
receiving O
a O
call O
with O
an O
appointment O
for O
next O
week O

 O
to O
come O
to O
the O
clinic O
and O
have O
your O
blood O
pressure O
checked O
and O

 O
go O
over O
your O
imaging O
tests O
. O
You O
will O
receive O
a O
call O
with O
this O

 O
appointment O
and O
if O
you O
do O
not O
you O
should O
call O
the O
clinic O
at O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
250 O
* O
* O
] O
to O
make O
an O
appointment O
. O


 O
Department O
: O
RADIOLOGY O

 O
When O
: O
MONDAY O
[ O
* O
* O
2129 O
- O
4 O
- O
25 O
* O
* O
] O
at O
9:30 O
AM O

 O
With O
: O
  O
RADIOLOGY O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
327 O
* O
* O
] O

 O
Building O
: O
CC O
CLINICAL O
CENTER O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
WEST O
     O
Best O
Parking O
: O
[ O
* O
* O
Street O
Address(1 O
) O
592 O
* O
* O
] O
Garage O


 O
Department O
: O
HEMODIALYSIS O

 O
When O
: O
MONDAY O
[ O
* O
* O
2129 O
- O
4 O
- O
25 O
* O
* O
] O
at O
7:30 O
AM O




 O
Completed O
by:[**2129 O
- O
4 O
- O
23 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2113 O
- O
3 O
- O
10 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2113 O
- O
4 O
- O
10 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2077 O
- O
9 O
- O
28 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Sulfa(Sulfonamide B-DRUG
Antibiotics I-DRUG
) I-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
473 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Cholelithiasis O
, O
duodenal O
perforation O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
10 O
* O
* O
] O
: O
ERCP O

 O
. O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
16 O
* O
* O
] O
: O
Successful O
CT-guided O
percutaneous O
drainage O
catheter O

 O
placement O
into O
the O
right O
perinephric O
space O

 O
. O

 O
[ O
* O
* O
2113 O
- O
3 O
- O
21 O
* O
* O
] O
: O

 O
1 O
. O
Wide O
incision O
and O
drainage O
of O
retroperitoneal O

 O
abscess/infection/hematoma O
. O

 O
2 O
. O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
patch O
of O
potential O
duodenal O
perforation O
region O
with O

 O
drainage O
. O

 O
3 O
. O
Antecolic O
isoperistaltic O
side-to-side O
gastrojejunostomy O
. O



 O

History O
of O
Present O
Illness O
: O

 O
35F O
with O
a O
h/o O
active O
IV O
drug O
abuse O
who O
presented O
to O
an O
OSH O
ED O

 O
c/o O
jaundice O
and O
abdominal O
pain O
on O
[ O
* O
* O
2113 O
- O
3 O
- O
6 O
* O
* O
] O
, O
found O
to O
have O
and O

 O
ultimately O
transferred O
to O
the O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
[ O
* O
* O
2113 O
- O
3 O
- O
10 O
* O
* O
] O
for O
ERCP O
. O
  O
Ms. O

 O
[ O
* O
* O
Last O
Name O
( O
un O
) O
110632 O
* O
* O
] O
reports O
noticing O
RUQ O
pain O
intermittently O
for O
the O

 O
past O
three O
months O
, O
but O
it O
had O
not O
become O
bad O
enough O
for O
her O
to O

 O
seek O
medical O
attention O
. O
  O
When O
she O
also O
developed O
jaundice O

 O
associated O

 O
with O
generalized O
malaise O
and O
myalgias O
, O
she O
presented O
to O
the O

 O
[ O
* O
* O
Hospital3 O
* O
* O
] O
ED O
, O
where O
she O
was O
found O
to O
have O
elevated O
LFTS O
( O
TB O

 O
9.6 O
, O
DB O
6.6 O
, O
alb O
3.6 O
, O
AST O
638 O
, O
ALT O
640 O
, O
AP O
615 O
, O
and O
WBC O
13.6 O
) O
, O

 O
and O
cholelithiasis O
without O
ductal O
dilation O
on O
ultrasound O
. O

 O
Hepatitis O
C O
titer O
was O
positive O
. O
  O
She O
was O
admitted O
for O
further O

 O
work-up O
. O

 O
When O
MRCP O
on O
[ O
* O
* O
1-/2030 O
* O
* O
] O
revealed O
cholelithiasis O
, O
possible O

 O
cholecystitis O
, O
and O
cystic O
duct O
stones O
without O
CBD O
or O
IHD O

 O
dilation O
, O
she O
was O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
on O
[ O
* O
* O
2113 O
- O
3 O
- O
10 O
* O
* O
] O
for O
ERCP O
. O

 O
ERCP O
revealed O
a O
laceration O
of O
the O
major O
papilla O
suggestive O
of O

 O
recent O
stone O
passage O
, O
and O
stones O
were O
noted O
in O
the O
lower O
CBD O

 O
with O
an O
impacted O
stone O
at O
the O
ampulla O
. O
  O
Sphincterotomy O
and O
stone O

 O
extraction O
were O
performed O
, O
but O
subsequent O
cholangiography O

 O
revealed O
constrast O
extravasation O
suggesting O
perforation O
. O
  O
Two O

 O
biliary O
stents O
and O
an O
NGT O
were O
placed O
, O
and O
arrangement O
for O

 O
direct O
admission O
to O
the O
West O
2A O
Surgery O
service O
was O
made O
. O



 O
Past O
Medical O
History O
: O

 O
PMH O
: O
  O
Cholelithiasis O
, O
hepatitis O
C O
, O
IV O
drug O
abuse O
, O
anxiety O
, O

 O
depression O
, O
chronic O
low O
back O
pain O
, O
migraines O


 O
PSH O
: O
  O
Tubal O
ligation O



 O
Social O
History O
: O

 O
Unemployed O
and O
currently O
homeless O
, O
though O
she O
stays O
frequently O

 O
with O
her O
ex-husband O
. O
  O
Two O
children O
: O
ages O
3 O
and O
5 O
. O
  O
+ O
tobacco O
use O
, O

 O
1PPD O
currently O
. O
   O
Denies O
ETOH O
. O
  O
Using O
heroin O
, O
marijuana O

 O
regularly O
, O
most O
recently O
Saturday O
prior O
to O
her O

 O
admission O
to O
the O
OSH O
on O
Monday O
. O



 O
Family O
History O
: O

 O
Mother O
and O
sister O
with O
symptomatic O
cholelithiasis O
requiring O
CCY O
. O

  O
Father O
died O
in O
[ O
* O
* O
2107 O
* O
* O
] O
from O
MI O
, O
mother O
, O
alive O
, O
with O
alcoholic O

 O
cirrhoisis O
. O



 O

Physical O
Exam O
: O

 O
On O
Admission O
: O

 O
Vitals O
: O
  O
98.9 O
79 O
127/55 O
22 O
99 O
% O
RA O

 O
GEN O
: O
A&O O
, O
markedly O
jaundiced O
, O
uncomfortable O

 O
HEENT O
: O
+ O
scleral O
icterus O
, O
mucus O
membranes O
dry O
, O
NGT O
in O
place O
, O

 O
very O

 O
poor O
dentition O
. O

 O
CV O
: O
RRR O
, O
No O
M/G/R O

 O
PULM O
: O
Clear O
to O
auscultation O
b/l O
, O
No O
W/R/R O

 O
ABD O
: O
+ O
diffuse O
TTP O
, O
no O
guard O
or O
rebound O
, O
soft O
, O
nondistended O
, O
no O

 O
palpable O
masses O

 O
SKIN O
: O
Marked O
jaundice O
, O
multiple O
tattoos O

 O
Ext O
: O
No O
LE O
edema O
, O
LE O
warm O
and O
well O
perfused O


 O
On O
Discharge O
: O

 O
VS O
; O
98.6 O
, O
92 O
, O
126/76 O
, O
14 O
, O
98 O
% O
RA O

 O
GEN O
: O
NAD O
, O
AAO O
x O
3 O

 O
CV O
: O
RRR O

 O
RESP O
: O
Diminished O
breath O
sounds O
on O
right O
base O
, O
left O
cta O

 O
ABD O
: O
Midline O
abdominal O
incision O
open O
to O
air O
with O
steri O
strips O

 O
and O
c/d/i O
. O
RLQ O
JP O
drain O
to O
bulb O
suction O
with O
stopcock O
for O

 O
flushing/aspirating O
. O

 O
EXTR O
: O
Warm O
, O
no O
c/c/e O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2113 O
- O
4 O
- O
10 O
* O
* O
] O
06:35AM O
BLOOD O
WBC-12.3 O
* O
RBC-4.10 O
* O
Hgb-11.6 O
* O
Hct-38.3 O

 O
MCV-93 O
MCH-28.2 O
MCHC-30.2 O
* O
RDW-13.6 O
Plt O
Ct-433 O

 O
[ O
* O
* O
2113 O
- O
4 O
- O
8 O
* O
* O
] O
08:10AM O
BLOOD O
Neuts-78.7 O
* O
Lymphs-14.7 O
* O
Monos-3.9 O

 O
Eos-2.1 O
Baso-0.6 O

 O
[ O
* O
* O
2113 O
- O
4 O
- O
10 O
* O
* O
] O
06:35AM O
BLOOD O
Glucose-90 O
UreaN-10 O
Creat-1.5 O
* O
Na-137 O

 O
K-4.0 O
Cl-94 O
* O
HCO3 O
- O
28 O
AnGap-19 O

 O
[ O
* O
* O
2113 O
- O
4 O
- O
7 O
* O
* O
] O
06:10AM O
BLOOD O
Calcium-8.2 O
* O
Phos-4.4 O
Mg-1.8 O


 O
[ O
* O
* O
2113 O
- O
4 O
- O
6 O
* O
* O
] O
8:31 O
am O
PERITONEAL O
FLUID O


    O
GRAM O
STAIN O
( O
Final O
[ O
* O
* O
2113 O
- O
4 O
- O
6 O
* O
* O
] O
) O
: O

       O
1 O
+ O
    O
( O
< O
1 O
per O
1000X O
FIELD O
) O
: O
   O
POLYMORPHONUCLEAR O

 O
LEUKOCYTES O
. O

       O
NO O
MICROORGANISMS O
SEEN O
. O



    O
FLUID O
CULTURE O
( O
Preliminary O
) O
: O

       O
Reported O
to O
and O
read O
back O
by O
DR O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
STitle O
) O
* O
* O
] O
# O
[ O
* O
* O
Numeric O
Identifier O
11536 O
* O
* O
] O

 O
[ O
* O
* O
2113 O
- O
4 O
- O
7 O
* O
* O
] O
10:46AM O
. O

       O
YEAST O
. O
    O
SPARSE O
GROWTH O
. O

          O
Fluconazole B-DRUG
Susceptibility O
testing O
requested O
by O
DR O
. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
STitle O
) O
* O
* O
] O

          O
# O
[ O
* O
* O
Numeric O
Identifier O
11536 O
* O
* O
] O
[ O
* O
* O
2113 O
- O
4 O
- O
7 O
* O
* O
] O
. O
  O
SENSITIVE O
TO O
Fluconazole B-DRUG
. I-DRUG

          O
sensitivity O
testing O
performed O
by O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
3077 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
3060 O
* O
* O
] O
. O

          O
This O
test O
has O
not O
been O
FDA O
approved O
but O
has O
been O

 O
verified O

          O
following O
Clinical O
and O
Laboratory O
Standards O
Institute O

 O
guidelines O

          O
by O
[ O
* O
* O
Hospital1 O
69 O
* O
* O
] O
Clinical O

 O
Microbiology O

          O
Laboratory O
.. O


    O
ANAEROBIC O
CULTURE O
( O
Preliminary O
) O
: O
    O
NO O
ANAEROBES O
ISOLATED O
. O


    O
FUNGAL O
CULTURE O
( O
Preliminary O
) O
: O

       O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
* O
* O
] O
ALBICANS O
, O
PRESUMPTIVE O
IDENTIFICATION O
. O

          O
ID O
PERFORMED O
ON O
CORRESPONDING O
ROUTINE O
CULTURE O
. O


 O
[ O
* O
* O
2113 O
- O
3 O
- O
15 O
* O
* O
] O
8:19 O
am O
BLOOD O
CULTURE O
      O
Source O
: O
Line-left O
picc O
1 O
OF O

 O
2 O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2113 O
- O
3 O
- O
21 O
* O
* O
] O
* O
* O


    O
Blood O
Culture O
, O
Routine O
( O
Final O
[ O
* O
* O
2113 O
- O
3 O
- O
21 O
* O
* O
] O
) O
: O

       O
STAPHYLOCOCCUS O
EPIDERMIDIS O
. O
    O
FINAL O
SENSITIVITIES O
. O

          O
This O
isolate O
is O
presumed O
to O
be O
resistant O
to O
clindamycin B-DRUG

 I-DRUG
based O
on O

          O
the O
detection O
of O
inducible O
resistance O
. O


                               O
SENSITIVITIES O
: O
MIC O
expressed O
in O

 O
MCG/ML O


 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

                              O
STAPHYLOCOCCUS O
EPIDERMIDIS O

                              O
| O

 O
CLINDAMYCIN----------- B-DRUG
       O
R O

 O
ERYTHROMYCIN---------- B-DRUG
   O
= O
> O
8 O
R O

 O
GENTAMICIN------------ B-DRUG
< O
= O
0.5 O
S O

 O
LEVOFLOXACIN---------- B-DRUG
     O
4 O
R O

 O
OXACILLIN-------------<=0.25 B-DRUG
S O

 O
TETRACYCLINE---------- B-DRUG
     O
2 O
S O

 O
VANCOMYCIN------------ B-DRUG
     O
2 O
S O


    O
Anaerobic O
Bottle O
Gram O
Stain O
( O
Final O
[ O
* O
* O
2113 O
- O
3 O
- O
16 O
* O
* O
] O
) O
: O

       O
GRAM O
POSITIVE O
COCCI O
IN O
CLUSTERS O
. O

       O
Reported O
to O
and O
read O
back O
by O
DR O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
2PM O
[ O
* O
* O
2113 O
- O
3 O
- O
16 O
* O
* O
] O
. O



 O
[ O
* O
* O
2113 O
- O
3 O
- O
12 O
* O
* O
] O
CT O
ABD O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Large O
amount O
of O
intraperitoneal O
and O
retroperitoneal O
free O
air O
. O

 O
A O
large O

 O
amount O
of O
fluid O
in O
the O
right O
anterior O
and O
posterior O
pararenal O

 O
spaces O
tracking O
down O
to O
the O
lower O
quadrant O
of O
the O
abdomen O
. O
No O

 O
obvious O
leak O
of O
contrast O
to O
identify O
the O
site O
of O
perforation O
. O
If O

 O
needed O
a O
delayed O
non-contrast O
CT O
abdomen O
can O
be O
obtained O
to O

 O
assess O
for O
a O
delayed O
leak O
. O

 O
2 O
. O
Small O
amount O
of O
pneumomediastinum O
. O

 O
3 O
. O
A O
small O
simple O
right O
pleural O
effusion O
with O
right O
basilar O

 O
atelectasis O
. O


 O
[ O
* O
* O
2113 O
- O
3 O
- O
16 O
* O
* O
] O
CT O
ABD O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Decreased O
but O
persistent O
large O
intraperitoneal O
and O

 O
retroperitoneal O
free O

 O
air O
. O
A O
large O
amount O
of O
fluid O
in O
the O
right O
retroperitoneum O
is O

 O
seen O
with O

 O
anterior O
displacement O
of O
the O
right O
kidney O
. O
No O
rim-enhancing O

 O
fluid O
collection O
is O
seen O
. O

 O
2 O
. O
Decreased O
pneumomediastinum O
. O

 O
3 O
. O
Bilateral O
pleural O
effusions O
with O
adjacent O
atelectasis O
as O

 O
described O
above O
. O


 O
[ O
* O
* O
2113 O
- O
3 O
- O
20 O
* O
* O
] O
CT O
ABD O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Improvement O
in O
right O
lower O
lobe O
consolidation O
and O
decrease O
in O

 O
right O

 O
pleural O
effusion O
. O

 O
2 O
. O
Slight O
decrease O
in O
fluid O
component O
of O
right O
perinephric O

 O
collection O
at O
site O
of O
Drain O
. O
Extensive O
multiloculated O

 O
phlegmonous O
change O
with O
no O
significant O
large O
fluid O
component O
to O

 O
target O
for O
drainage O
. O

 O
3 O
. O
No O
new O
collections O
are O
identified O
. O

 O
4 O
. O
Persistent O
extensive O
free O
intra-abdominal O
air O
with O
multiple O

 O
pockets O
of O
air O
surrounding O
the O
second O
part O
of O
duodenum O
, O
likely O

 O
at O
site O
of O
duodenal O

 O
perforation O
. O


 O
[ O
* O
* O
2113 O
- O
3 O
- O
29 O
* O
* O
] O
CT O
ABD O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Decrease O
in O
size O
of O
loculated O
gas-fluid O
collections O
with O
four O

 O
drains O
in O

 O
place O
. O
There O
are O
small O
pockets O
of O
loculated O
collections O
that O
may O

 O
not O
be O

 O
adequately O
drained O
. O
Significant O
resolution O
of O
intra-abdominal O

 O
free O
air O
. O

 O
2 O
. O
Right O
hydronephrosis O
likely O
from O
obstruction O
of O
ureter O
due O
to O

 O
surrounding O
inflammation O
. O

 O
3 O
. O
Slight O
improvement O
in O
right O
lower O
lobe O
consolidation O
; O

 O
however O
, O
slight O

 O
increase O
in O
right O
pleural O
effusion O
. O


 O
[ O
* O
* O
2113 O
- O
3 O
- O
31 O
* O
* O
] O
RENAL O
US O
: O

 O
FINDINGS O
: O

 O
1 O
. O
There O
is O
stable O
mild O
hydronephrosis O
in O
the O
right O
kidney O
. O

 O
Adjacent O
to O
the O
lower O
pole O
, O
is O
a O
partially O
imaged O
complex O
fluid O

 O
collection O
containing O
a O
drain O
. O
The O
right O
kidney O
measures O

 O
approximately O
14 O
cm O
. O

 O
2 O
. O
The O
left O
kidney O
measures O
approximately O
14.2 O
cm O
. O
There O
is O
no O

 O
hydronephrosis O
, O
renal O
lesion O
or O
nephrolithiasis O
. O

 O
3 O
. O
The O
bladder O
is O
minimally O
distended O
limiting O
evaluation O
and O

 O
grossly O

 O
unremarkable O
. O



 O
[ O
* O
* O
2113 O
- O
4 O
- O
6 O
* O
* O
] O
CT O
ABD O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Limited O
study O
due O
to O
lack O
of O
intravenous O
and O
oral O
contrast O

 O
demonstrates O
an O
interval O
decrease O
in O
the O
phlegmonous O
collection O

 O
in O
the O
right O
perinephric O
space O
now O
measuring O
8.0 O
x O
3.0 O
cm O
with O
a O

 O
drain O
in O
place O
. O
Multiple O
adjacent O
collections O
with O
air O
and O
fluid O

 O
are O
again O
noted O
and O
appear O
relatively O
stable O
to O
minimally O

 O
decreased O
in O
size O
. O
Three O
of O
the O
previously O
visualized O
drains O

 O
have O
since O
been O
removed O
. O

 O
2 O
. O
Continued O
mild O
right O
hydronephrosis O
. O

 O
3 O
. O
Resolution O
of O
right O
pleural O
effusion O
. O
Right O
lower O
lobe O

 O
opactiy O
has O

 O
decreased O
in O
size O
. O

 O
4 O
. O
Two O
common O
bile O
duct O
stents O
are O
in O
place O
with O
pneumobilia O
. O

 O
5 O
. O
2-mm O
non-obstructive O
left O
renal O
stone O
. O



 O

Brief O
Hospital O
Course O
: O

 O
The O
patient O
was O
admitted O
to O
the O
General O
Surgical O
Service O
with O

 O
duodenal O
perforation O
status O
post O
ERCP O
. O
The O
patient O
was O
made O
NPO O

 O
with O
NGT O
, O
started O
on O
IV B-ROU
fluids B-DRUG
and O
IV B-ROU
Zosyn B-DRUG
, I-DRUG
and O
Dilaudid B-DRUG
PCA B-FOR

 I-FOR
for O
pain B-REA
control I-REA
. I-REA
CT O
scan O
on O
HD O
# O
2 O
demonstrated O
large O
amount O
of O

 O
fluid O
in O
the O
right O
anterior O
and O
posterior O
pararenal O
spaces O

 O
tracking O
down O
to O
the O
lower O
quadrant O
of O
the O
abdomen O
and O
large O

 O
amount O
of O
free O
air O
. O
Nutritional O
consult O
was O
called O
for O
TPN O

 O
recommendations O
and O
PICC O
line O
was O
placed O
. O
The O
patient O
continued O

 O
to O
spike O
low O
grade O
fever O
and O
her O
blood O
cultures O
were O
positive O

 O
for O
STAPHYLOCOCCUS B-REA
EPIDERMIDIS I-REA
, I-REA
Vancomycin B-DRUG
Iv B-ROU
was O
added O
on O
HD O
# O

 O
6 O
. O
Repeat O
abdominal O
CT O
demonstrated O
  O
decreased O
but O
persistent O

 O
large O
intraperitoneal O
and O
retroperitoneal O
free O
  O
air O
with O
a O
large O

 O
amount O
of O
fluid O
in O
the O
right O
retroperitoneum O
is O
seen O
with O

 O
anterior O
displacement O
of O
the O
right O
kidney O
. O
The O
patient O
continued O

 O
to O
spike O
fever O
and O
IR O
drainage O
of O
the O
right O
retroperitoneal O

 O
fluid O
collection O
was O
ordered O
. O
The O
patient O
underwent O
CT-guided O

 O
percutaneous O
drainage O
catheter O
placement O
into O
the O
right O

 O
perinephric O
space O
on O
HD O
# O
6 O
and O
fluid O
was O
sent O
for O
cultures O
. O
The O

 O
patient O
's O
diet O
was O
advanced O
as O
tolerated O
on O
POD O
# O
8 O
, O
and O
was O

 O
well O
tolerated O
. O
The O
cultures O
were O
positive O
for O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
564 O
* O
* O
] O
Albicans O

 O
and O
IV B-ROU
Fluconazole B-DRUG
was O
added O
. O
Despite O
antibiotics B-DRUG
treatment O

 O
patient O
continued O
to O
spike O
fever O
and O
her O
abdominal B-REA
pain I-REA
was O

 O
continued O
to O
be O
significantly O
high O
requiring O
large O
amount O
of O
IV B-ROU

 I-ROU
Dilaudid B-DRUG
, I-DRUG
Ativan B-DRUG
and O
Ketorolac B-DRUG
to O
manage O
it O
, O
patient O
's O
WBC O
also O

 O
continued O
to O
increased O
(16->38).Repeat O
abdominal O
CT O
scan O
on O
HD O
# O

 O
10 O
revealed O
slight O
decrease O
in O
fluid O
component O
of O
right O

 O
perinephric O
collection O
, O
extensive O
multi O
loculated O
phlegmonous O

 O
change O
with O
no O
significant O
large O
fluid O
component O
to O
target O
for O

 O
drainage O
and O
persistent O
extensive O
free O
intra-abdominal O
air O
with O

 O
multiple O
pockets O
of O
air O
  O
surrounding O
the O
second O
part O
of O

 O
duodenum O
. O
The O
decision O
was O
made O
to O
take O
the O
patient O
in O
OR O
for O

 O
washout O
. O

 O

On O
[ O
* O
* O
2112 O
- O
3 O
- O
20 O
* O
* O
] O
, O
the O
patient O
underwent O
wide O
incision O
and O
drainage O
of O

 O
retroperitoneal O

 O
abscess/infection/hematoma O
, O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
patch O
of O
potential O
duodenal O

 O
perforation O
region O

 O
with O
drainage O
and O
antecolic O
isoperistaltic O
side-to-side O

 O
gastrojejunostomy O
and O
JP O
drains O
placement O
x O
4 O
, O
which O
went O
well O

 O
without O
complication O
( O
reader O
referred O
to O
the O
Operative O
Note O
for O

 O
details O
) O
. O
Intraoperatively O
patient O
received O
2 O
units O
of O
pRBC O
, O
she O

 O
was O
extubated O
post O
op O
and O
was O
transferred O
in O
ICU O
for O

 O
observation O
. O
On O
POD O
# O
2 O
, O
patient O
received O
2 B-DOS
units I-DOS
of O
pRBC B-DRUG
for O

 O
HCT B-REA
23.4 I-REA
, I-REA
her O
post O
transfusion O
Hct O
was O
28.3 O
. O
The O
patient O
was O

 O
transferred O
to O
the O
floor O
on O
POD O
# O
3 O
, O
NPO O
on O
TPN O
and O
IV B-ROU
fluids B-DRUG
, I-DRUG

 O
and O
Dilaudid B-DRUG
PCA B-FOR
for O
pain B-REA
control I-REA
. I-REA
The O
patient O
was O
continued O
to O

 O
have O
low B-REA
grade I-REA
fever I-REA
and O
she O
was O
continued O
on O
IV B-ROU
Vancomycin B-DRUG
, I-DRUG

 O
Zosyn B-DRUG
and O
Fluconazole B-DRUG
. I-DRUG
The O
patient O
was O
hydrodynamically O
stable O
. O



 O
Neuro O
: O
The O
patient O
is O
an O
active O
Heroin O
user O
. O
Her O
pain B-REA
was O

 O
controlled O
with O
Dilaudid B-DRUG
PCA B-FOR
and O
she O
had O
high O
requirements O
for O

 O
pain B-DRUG
medication I-DRUG
. I-DRUG
When O
tolerating O
oral O
intake O
, O
the O
patient O
was O

 O
transitioned O
to O
oral B-ROU
Dilaudid B-DRUG
and O
Chronic O
Pain O
Service O
was O

 O
consulted O
. O
The O
patient O
's O
pain B-DRUG
medications I-DRUG
was O
weaned O
to O
[ O
* O
* O
1 O
- O
14 O
* O
* O
] O
gm O

 O
of O
Dilaudid B-DRUG
PO B-ROU
Q4H B-FRE
and O
patient O
instructed O
to O
continue O
wean O
off O

 O
her O
pain O
medications O
in O
home O
. O

 O
CV O
: O
The O
patient O
remained O
stable O
from O
a O
cardiovascular O

 O
standpoint O
; O
vital O
signs O
were O
routinely O
monitored O
. O

 O
Pulmonary O
: O
The O
patient O
remained O
stable O
from O
a O
pulmonary O

 O
standpoint O
; O
vital O
signs O
were O
routinely O
monitored O
. O
Good O
pulmonary O

 O
toilet O
, O
early O
ambulation O
and O
incentive O
spirometry O
were O

 O
encouraged O
throughout O
hospitalization O
. O

 O
GI O
: O
The O
patient O
was O
started O
on O
TPN O
on O
admission O
. O
Her O
diet O
was O

 O
advanced O
to O
clears O
on O
HD O
# O
6 O
and O
to O
regular O
on O
HD O
# O
8 O
. O
The O

 O
patient O
was O
made O
NPO O
prior O
surgery O
and O
TPN O
was O
continued O
. O
Diet O

 O
was O
advanced O
to O
clears O
on O
POD O
# O
5 O
and O
to O
regular O
on O
POD O
# O
9 O
, O
TPN O

 O
was O
weaned O
off O
and O
d/c/d O
on O
POD O
# O
8 O
. O
The O
patient O
was O
able O
to O

 O
tolerate O
regular O
diet O
prior O
discharge O
. O
Electrolytes O
were O

 O
routinely O
followed O
, O
and O
repleted O
when O
necessary O
. O

 O
Renal/GU O
: O
The O
patient O
's O
Cre/BUN O
were O
monitored O
routinely O
, O
on O
HD O

 O
# O
21 O
( O
POD O
# O
10 O
) O
her O
Cre O
increased O
to O
1.9 O
. O
During O
hospitalization O

 O
patient O
underwent O
several O
abdominal O
CT O
scans O
with O
contrast O
, O
she O

 O
received O
IV B-ROU
Vancomycin B-DRUG
x O
14 B-FRE
days I-FRE
, I-FRE
and O
she O
received O
IV B-ROU
Toradol B-DRUG

 I-DRUG
for O
pain B-REA
control I-REA
. I-REA
The O
combination O
of O
these O
factors O
and O

 O
inflammatory O
respond O
from O
fluid O
collection O
, O
which O
lead O
to O
mild O

 O
right O
kidney O
hydronephrosis O
contributed O
to O
patient O
's O
acute O
renal O

 O
injury O
. O
Urology O
and O
Renal O
were O
called O
for O
consult O
and O
their O

 O
recommendations O
were O
followed O
. O
The O
kidney O
function O
started O
to O

 O
improve O
on O
POD O
# O
16 O
, O
and O
returned O
to O
1.5 O
prior O
discharge O
. O
The O

 O
patient O
continued O
to O
urinate O
without O
any O
difficulties O
and O
her O

 O
electrolyte O
balance O
was O
generally O
within O
normal O
limits O
. O
The O

 O
patient O
will O
required O
to O
have O
a O
follow O
up O
Renal O
US O
to O

 O
re-evaluate O
her O
hydronephrosis O
in O
6 O
months O
as O
outpatient O
. O

 O

ID O
: O
The O
patient O
had O
a O
positive O
blood O
cultures O
on O
admission O
with O

 O
STAPHYLOCOCCUS B-REA
EPIDERMIDIS I-REA
, I-REA
she O
was O
treated O
with O
IV B-ROU
Vancomycin B-DRUG

 I-DRUG
for B-DUR
14 I-DUR
days I-DUR
. I-DUR
Surveillance O
blood O
cultures O
were O
negative O
. O
Intra O

 O
abdominal O
fluid O
was O
positive O
for O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
564 O
* O
* O
] O
and O
patient O
was O
started O

 O
on O
IV B-ROU
Fluconazole B-DRUG
for B-DUR
14 I-DUR
days I-DUR
also O
. O
After O
discontinue O
of O
IV B-ROU

 I-ROU
antibiotics B-DRUG
, I-DRUG
the O
patient O
continued O
to O
spike O
low O
grade O
fever O
and O

 O
her O
increased O
on O
POD O
# O
15 O
. O
Blood O
and O
urine O
cultures O
were O

 O
negative O
, O
intra O
abdominal O
cultures O
were O
positive O
with O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
564 O
* O
* O
] O
. O

 O
The O
patient O
was O
restarted O
on O
PO B-ROU
Fluconazole B-DRUG
and O
Augmentin B-DRUG
. I-DRUG
WBC O

 O
and O
fevers O
subsided O
after O
abx O
was O
started O
. O
She O
will O
continue O
on O

 O
PO B-ROU
Abx B-DRUG
for B-DUR
10 I-DUR
days I-DUR
after O
discharge O
. O
She O
was O
discharged O
with O
one O

 O
JP O
left O
within O
biggest O
fluid O
collection O
, O
she O
will O
follow O
up O
with O

 O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
468 O
* O
* O
] O
in O
2 O
weeks O
with O
Ct O
scan O
to O
evaluate O
her O
fluid O

 O
collection O
and O
possible O
d/c O
JP O
drain O
. O

 O
Hematology O
: O
The O
patient O
's O
complete O
blood O
count O
was O
examined O

 O
routinely O
; O
she O
received O
total O
6 B-DOS
units I-DOS
of O
pRBC B-DRUG
during O

 O
hospitalization O
. O
Her O
Hct O
was O
stable O
prior O
discharge O
and O
no O

 O
further O
transfusions O
were O
required O
. O

 O
Prophylaxis B-REA
: I-REA
The O
patient O
received O
subcutaneous B-ROU
heparin B-DRUG
and O

 O
venodyne O
boots O
were O
used O
during O
this O
stay O
; O
was O
encouraged O
to O
get O

 O
up O
and O
ambulate O
as O
early O
as O
possible O
. O

 O
At O
the O
time O
of O
discharge O
, O
the O
patient O
was O
doing O
well O
, O
afebrile O

 O
with O
stable O
vital O
signs O
. O
  O
The O
patient O
was O
tolerating O
a O
regular O

 O
diet O
, O
ambulating O
, O
voiding O
without O
assistance O
, O
and O
pain O
was O
well O

 O
controlled O
. O
  O
The O
patient O
received O
discharge O
teaching O
and O

 O
follow-up O
instructions O
with O
understanding O
verbalized O
and O

 O
agreement O
with O
the O
discharge O
plan O
. O



 O
Medications O
on O
Admission O
: O

 O
Xanax B-DRUG
1 B-STR
' I-STR
' O
' O
, O
Fioricet B-DRUG
PRN B-FRE
, I-FRE
oxycodone B-DRUG
10 B-STR
mg I-STR
qid B-FRE



 I-FRE

Discharge O
Medications O
: O

 O
1 O
. O
lidocaine B-DRUG
5 B-STR
% I-STR
( I-STR
700 I-STR
mg/patch I-STR
) I-STR
Adhesive B-FOR
Patch I-FOR
, I-FOR
Medicated I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Adhesive B-FOR
Patch I-FOR
, I-FOR
Medicated I-FOR
Topical B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
for B-DUR
2 I-DUR

 I-DUR
weeks I-DUR
. I-DUR

 O
Disp:*14 O
Adhesive O
Patch O
, O
Medicated(s O
) O
* O
Refills:*0 O
* O

 O
2 O
. O
acyclovir B-DRUG
5 O
% O
Ointment B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU
ASDIR O
( O
AS O

 O
DIRECTED O
) O
. O

 O
Disp:*1 O
tube O
* O
Refills:*0 O
* O

 O
3 O
. O
alprazolam B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
anxiety B-REA
. I-REA

 O
4 O
. O
acetaminophen B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
gabapentin B-DRUG
300 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Capsule(s O
) O
* O
Refills:*0 O
* O

 O
6 O
. O
hydromorphone B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
Disp:*120 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
7 O
. O
amoxicillin-pot B-DRUG
clavulanate I-DRUG
500 B-STR
- I-STR
125 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
Q12H B-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
for B-DUR
10 I-DUR
days I-DUR
. I-DUR

 O
Disp:*20 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
8 O
. O
fluconazole B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE

 I-FRE
for B-DUR
10 I-DUR
days I-DUR
. I-DUR

 O
Disp:*20 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
9 O
. O
ZOFRAN B-DRUG
ODT I-DRUG
4 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Rapid I-FOR
Dissolve I-FOR
PO B-ROU
every B-FRE
eight I-FRE
( I-FRE
8) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
. I-REA

 O
Disp:*20 O
Tablet O
, O
Rapid O
Dissolve(s O
) O
* O
Refills:*0 O
* O

 O
10 O
. O
Xanax B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
three B-FRE
times I-FRE
a I-FRE
day I-FRE

 I-FRE
as I-FRE
needed I-FRE
for O
anxiety B-REA
. I-REA

 O
Disp:*10 O
Tablet(s O
) O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital1 O
1474 O
* O
* O
] O
VNA O


 O
Discharge O
Diagnosis O
: O

 O
1 O
. O
Choledocholithiasis O

 O
2 O
. O
Doudenal O
perforation O
s/p O
ERCP O

 O
3 O
. O
Infected O
right O
perinephric O
fluid O
collection O

 O
4 O
. O
Right O
hydronephrosis O

 O
5 O
. O
Acute O
kidney O
injury O

 O
6 O
. O
Chronic O
pain O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
surgery O
service O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
treatment O

 O
of O
duodenal O
perforation O
s/p O
ERCP O
. O
Your O
condition O
continuing O
to O

 O
improve O
and O
are O
now O
safe O
to O
return O
home O
to O
complete O
your O

 O
recovery O
with O
the O
following O
instructions O
: O


 O
* O

You O
will O
need O
to O
repeat O
Renal O
Ultrasound O
six O
months O
after O

 O
discharge O
. O
Please O
follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
( O
PCP O
) O
to O
schedule O
this O

 O
test O
. O


 O
* O
Please O
resume O
all O
regular O
home O
medications O
, O
unless O

 O
specifically O
advised O
not O
to O
take O
a O
particular O
medication O
. O
  O
Also O
, O

 O
please O
take O
any O
new O
medications O
as O
prescribed O
. O

 O
* O
Please O
get O
plenty O
of O
rest O
, O
continue O
to O
ambulate O
several O
times O

 O
per O
day O
, O
and O
drink O
adequate O
amounts O
of O
fluids O
. O
  O
Avoid O
lifting O

 O
weights O
greater O
than O
[ O
* O
* O
4 O
- O
20 O
* O
* O
] O
lbs O
until O
you O
follow-up O
with O
your O

 O
surgeon O
, O
who O
will O
instruct O
you O
further O
regarding O
activity O

 O
restrictions O
. O

 O
* O
Avoid O
driving O
or O
operating O
heavy O
machinery O
while O
taking O
pain O

 O
medications O
. O

 O
* O
Please O
follow-up O
with O
your O
surgeon O
and O
Primary O
Care O
Provider O

 O
( O
PCP O
) O
as O
advised O
. O


 O
Incision O
Care O
: O

 O
* O
Please O
call O
your O
doctor O
or O
nurse O
practitioner O
if O
you O
have O

 O
increased O
pain O
, O
swelling O
, O
redness O
, O
or O
drainage O
from O
the O
incision O

 O
site O
. O

 O
* O
Avoid O
swimming O
and O
baths O
until O
your O
follow-up O
appointment O
. O

 O
* O
You O
may O
shower O
, O
and O
wash O
surgical O
incisions O
with O
a O
mild O
soap O

 O
and O
warm O
water O
. O
  O
Gently O
pat O
the O
area O
dry O
. O

 O
* O
If O
you O
have O
steri-strips O
, O
they O
will O
fall O
off O
on O
their O
own O
. O

 O
Please O
remove O
any O
remaining O
strips O
7 O
- O
10 O
days O
after O
surgery O
. O


 O
JP O
Drain O
Care O
: O

 O
* O
Flush O
and O
aspirate O
drain O
with O
10 O
cc O
of O
NS O
daily O
. O

 O
* O
Please O
look O
at O
the O
site O
every O
day O
for O
signs O
of O
infection O

 O
( O
increased O
redness O
or O
pain O
, O
swelling O
, O
odor O
, O
yellow O
or O
bloody O

 O
discharge O
, O
warm O
to O
touch O
, O
fever O
) O
. O

 O
* O
Maintain O
suction O
of O
the O
bulb O
. O

 O
* O
Note O
color O
, O
consistency O
, O
and O
amount O
of O
fluid O
in O
the O
drain O
. O

 O
Call O
the O
doctor O
, O
nurse O
practitioner O
, O
or O
VNA O
nurse O
if O
the O
amount O

 O
increases O
significantly O
or O
changes O
in O
character O
. O

 O
* O
Be O
sure O
to O
empty O
the O
drain O
frequently O
. O
  O
Record O
the O
output O
, O
if O

 O
instructed O
to O
do O
so O
. O

 O
* O
You O
may O
shower O
; O
wash O
the O
area O
gently O
with O
warm O
, O
soapy O
water O
. O

 O
* O
Keep O
the O
insertion O
site O
clean O
and O
dry O
otherwise O
. O

 O
* O
Avoid O
swimming O
, O
baths O
, O
hot O
tubs O
; O
do O
not O
submerge O
yourself O
in O

 O
water O
. O

 O
* O
Make O
sure O
to O
keep O
the O
drain O
attached O
securely O
to O
your O
body O
to O

 O
prevent O
pulling O
or O
dislocation O
. O



 O

Followup O
Instructions O
: O

 O
Please O
follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
in O
1 O
week O
after O
discharge O
to O

 O
check O
you O
kidney O
function O
test O
. O

 O
Follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
( O
PCP O
) O
in O
6 O
month O
with O
Renal O
Ultrasound O

 O
to O
follow O
up O
on O
your O
right O
kidney O
hydronephrosis O
and O
left O
kidney O

 O
2-mm O
non-obstructive O
left O
renal O
stone O
. O

 O
. O

 O
Department O
: O
RADIOLOGY O

 O
When O
: O
MONDAY O
[ O
* O
* O
2113 O
- O
4 O
- O
24 O
* O
* O
] O
at O
9:15 O
AM O

 O
With O
: O
CAT O
SCAN O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
590 O
* O
* O
] O

 O
Building O
: O
Gz O
[ O
* O
* O
Hospital O
Ward O
Name O
2104 O
* O
* O
] O
Building O
( O
[ O
* O
* O
Hospital O
Ward O
Name O
1826**]/[**Hospital O
Ward O
Name O
1827 O
* O
* O
] O
Complex O
) O
[ O
* O
* O
Location O
( O
un O
) O
3202 O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
Main O
Garage O

 O
. O

 O
Department O
: O
SURGICAL O
SPECIALTIES O

 O
When O
: O
MONDAY O
[ O
* O
* O
2113 O
- O
4 O
- O
24 O
* O
* O
] O
at O
10:45 O
AM O

 O
With O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
251 O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2835 O
* O
* O
] O

 O
Building O
: O
[ O
* O
* O
Hospital6 O
29 O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O




 O
Completed O
by:[**2113 O
- O
4 O
- O
10 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2141 O
- O
10 O
- O
24 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2141 O
- O
10 O
- O
26 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2070 O
- O
7 O
- O
11 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Trileptal B-DRUG
/ O
Hydrochlorothiazide B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
2297 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
hyponatremia O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O



 O
History O
of O
Present O
Illness O
: O

 O
72 O
y/o O
with O
h/o O
HTN O
, O
L O
MCA O
CVa O
in O
[ O
* O
* O
6 O
- O
12 O
* O
* O
] O
with O
resudual O
language O

 O
impairment O
and O
seizures O
presents O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
with O
a O
Na O
of O
114 O
. O

 O
Because O
of O
her O
seizures B-REA
, I-REA
she O
was O
recently O
started O
on O
Trileptal B-DRUG

 I-DRUG
[ O
* O
* O
2141 O
- O
10 O
- O
13 O
* O
* O
] O
, O
and O
seen O
by O
Neuro O
[ O
* O
* O
2141 O
- O
10 O
- O
20 O
* O
* O
] O
. O
On O
[ O
* O
* O
2141 O
- O
10 O
- O
23 O
* O
* O
] O
, O
her O
Na O
was O
noted O

 O
to O
fall O
from O
139 O
on O
[ O
* O
* O
2141 O
- O
10 O
- O
13 O
* O
* O
] O
to O
126 O
on O
[ O
* O
* O
2141 O
- O
10 O
- O
21 O
* O
* O
] O
. O
Her O
trileptal B-DRUG
was O

 O
tapered O
and O
she O
received O
her O
last O
dose O
on O
[ O
* O
* O
2141 O
- O
10 O
- O
23 O
* O
* O
] O
and O
she O
was O

 O
started O
keppra B-DRUG
. I-DRUG
For O
hypertension B-REA
, I-REA
she O
was O
started O
HCTz B-DRUG
5 O
days O

 O
ago O
by O
her O
PCP O
. O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
, O
she O
presents O
with O
being O
very O
fatigued O
. O
No O

 O
fevers O
, O
chills O
, O
no O
nausea O
or O
vomiting O
no O
chest O
pain O
or O
shortness O

 O
of O
breath O
. O
Denied O
any O
headaches O
, O
blurred O
vision O
. O
She O
has O
been O

 O
drinking O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O
glasses O
of O
water O
per O
day O
and O
has O
not O
eaten O
very O

 O
much O
per O
the O
patient O
. O
per O
her O
son O
in O
law O
, O
she O
been O
urinating O

 O
very O
much O
. O



 O

Past O
Medical O
History O
: O

 O
Ischemic O
stroke O
L O
MCA O
superior O
division O
[**6 O
- O
12**]- O
mild O
Broca O
's O

 O
aphasia O
but O
no O
weakness O
on O
discharge O
, O
in O
follow O
up O
with O
Dr. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
in O
[ O
* O
* O
Month O
( O
only O
) O
* O
* O
] O
he O
describes O
that O
she O
had O
" O
hesitant O
, O
broken O
, O

 O
frustrated O
speech O
. O
On O
the O
other O
hand O
, O
she O
can O
string O
together O
at O

 O
least O
six O
words O
, O
and O
she O
is O
coherent O
. O
She O
can O
follow O
multiple O

 O
different O
two-step O
commands O
. O
She O
can O
salute O
. O
She O
can O
repeat O

 O
various O
different O
phrases O
except O
she O
did O
have O
difficulties O

 O
saying O
[ O
* O
* O
State O
350 O
* O
* O
] O
Institute O
of O
Technology O
. O
" O
Work O
up O
showed O

 O
evidence O
of O
rheumatic O
disease O
on O
mitral O
valve O
, O
no O
carotid O

 O
stenosis O
, O
no O
arrhythmias O
on O
telemetry O

 O
-CAD O
s/p O
MI O
5 O
yrs O
ago O
s/p O
stent O

 O
-High O
cholesterol O

 O
-Hypertension O

 O
-s/p O
basal O
cell O
ca O
resection O
[ O
* O
* O
5 O
- O
13 O
* O
* O
] O

 O
-GERD O



 O
Social O
History O
: O

 O
Social O
History O
: O

 O
Lives O
with O
husband O
, O
very O
physically O
active O
, O
takes O
care O
of O
4 O

 O
horses O
; O
no O
tob O
, O
etoh O
, O
drugs O
. O
  O
Has O
one O
son O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
, O
one O
daughter O
. O



 O
Family O
History O
: O

 O
Family O
History O
: O

 O
No O
known O
early O
strokes O
in O
family O
. O



 O
Physical O
Exam O
: O

 O
On O
admission O
: O

 O
T- O
96.3 O
BP- O
149/66 O
HR- O
56 O
RR- O
13 O
O2Sat- O
97 O
% O
on O
RA O

 O
Gen O
: O
Lying O
in O
bed O
, O
NAD O
. O
SLowed O
speech O
, O
but O
appropriately O

 O
answering O
questions O
. O

 O
HEENT O
: O
NC/AT O
, O
dry O
mucosa O

 O
Neck O
: O
No O
tenderness O
to O
palpation O
, O
normal O
ROM O
, O
supple O

 O
CV O
: O
RRR O
, O
Nl O
S1 O
and O
S2 O
, O
no O
murmurs/gallops/rubs O

 O
Lung O
: O
Clear O
to O
auscultation O
bilaterally O
. O
No O
RRW O

 O
aBd O
: O
+ O
BS O
soft O
, O
nontender O
, O
nondistended O

 O
ext O
: O
no O
edema O

 O
skin O
: O
dry O



 O
Pertinent O
Results O
: O

 O
Labs O
on O
Admission O
: O



 O
[ O
* O
* O
2141 O
- O
10 O
- O
24 O
* O
* O
] O
05:30PM O
BLOOD O
WBC-5.1 O
RBC-4.48 O
Hgb-14.2 O
Hct-38.6 O
MCV-86 O

 O
MCH-31.6 O
MCHC-36.7 O
* O
RDW-12.2 O
Plt O
Ct-258 O

 O
[ O
* O
* O
2141 O
- O
10 O
- O
24 O
* O
* O
] O
05:30PM O
BLOOD O
Neuts-73.9 O
* O
Lymphs-17.2 O
* O
Monos-7.6 O

 O
Eos-0.8 O
Baso-0.5 O

 O
[ O
* O
* O
2141 O
- O
10 O
- O
24 O
* O
* O
] O
05:30PM O
BLOOD O
Plt O
Ct-258 O

 O
[ O
* O
* O
2141 O
- O
10 O
- O
25 O
* O
* O
] O
03:40AM O
BLOOD O
PT-11.3 O
PTT-26.7 O
INR(PT)-1.0 O

 O
[ O
* O
* O
2141 O
- O
10 O
- O
24 O
* O
* O
] O
03:59PM O
BLOOD O
ESR-14 O

 O
[ O
* O
* O
2141 O
- O
10 O
- O
24 O
* O
* O
] O
05:30PM O
BLOOD O
Glucose-116 O
* O
UreaN-15 O
Creat-1.0 O
Na-114 O
* O

 O
K-4.5 O
Cl-78 O
* O
HCO3 O
- O
26 O
AnGap-15 O

 O
[ O
* O
* O
2141 O
- O
10 O
- O
24 O
* O
* O
] O
05:30PM O
BLOOD O
CK(CPK)-93 O

 O
[ O
* O
* O
2141 O
- O
10 O
- O
24 O
* O
* O
] O
05:30PM O
BLOOD O
CK-MB-NotDone O
cTropnT-<0.01 O

 O
[ O
* O
* O
2141 O
- O
10 O
- O
24 O
* O
* O
] O
05:30PM O
BLOOD O
Calcium-9.8 O
Phos-3.5 O
Mg-2.0 O

 O
[ O
* O
* O
2141 O
- O
10 O
- O
24 O
* O
* O
] O
09:40PM O
BLOOD O
Osmolal-245 O
* O

 O
[ O
* O
* O
2141 O
- O
10 O
- O
24 O
* O
* O
] O
05:30PM O
BLOOD O
TSH-1.3 O


 O
Brief O
Hospital O
Course O
: O

 O
72 O
y/o O
with O
h/o O
HTN O
, O
L O
MCA O
CVa O
in O
[ O
* O
* O
6 O
- O
12 O
* O
* O
] O
with O
resudual O
language O

 O
impairment O
and O
seizures O
presents O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
with O
slowed O
speech O

 O
and O
fatigue O
. O
Because O
of O
her O
seizures B-REA
, I-REA
she O
was O
recently O
started O

 O
on O
Trileptal B-DRUG
[ O
* O
* O
2141 O
- O
10 O
- O
13 O
* O
* O
] O
. O
On O
[ O
* O
* O
2141 O
- O
10 O
- O
21 O
* O
* O
] O
, O
her O
Na O
was O
noted O
to O
fall O
from O

 O
139 O
on O
[ O
* O
* O
2141 O
- O
10 O
- O
13 O
* O
* O
] O
to O
126 O
on O
[ O
* O
* O
2141 O
- O
10 O
- O
21 O
* O
* O
] O
. O
Her O
trileptal B-DRUG
was O
tapered O
and O

 O
she O
received O
her O
last O
dose O
on O
[ O
* O
* O
2141 O
- O
10 O
- O
23 O
* O
* O
] O
and O
she O
was O
started O

 O
keppra B-DRUG
. I-DRUG
For O
hypertension B-REA
, I-REA
she O
was O
started O
HCTz B-DRUG
5 O
days O
ago O
. O

 O
Today B-DRUG
, I-DRUG
she O
presents O
with O
being O
very O
fatigued O
with O
slowed O
speech O
. O

 O
She O
denied O
fevers O
, O
chills O
, O
nausea O
, O
vomiting O
, O
chest O
pain O
or O

 O
shortness O
of O
breath O
. O
Denied O
any O
headaches O
, O
blurred O
vision O
. O
She O

 O
has O
been O
drinking O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O
glasses O
of O
water O
per O
day O
and O
has O
not O
eaten O

 O
very O
much O
- O
per O
the O
patient O
. O
Per O
her O
son O
in O
law O
, O
she O
been O

 O
experiencing O
increased O
urination O
over O
the O
past O
week O
. O

 O
. O

 O
In O
the O
ED O
: O

 O
- O
80cc/hr B-STR
of O
NS B-DRUG
for O
a O
total O
of O
500 B-DOS
cc I-DOS
- O
and O
her O
Na O
increased O
to O

 O
116 O
. O

 O
. O


 O
Her O
Urine O
Sodium O
was O
48 O
, O
her O
serum O
Osm O
was O
248 O
and O
her O
Urine O
Osm O

 O
was O
in O
the O
432 O
consistent O
with O
SIADH O
. O
We O
also O
felt O
that O
she O
was O

 O
slightly O
hypovolemic O
. O
Hence O
she O
was O
treated O
with O
hypertonic B-DRUG

 I-DRUG
saline I-DRUG
with O
a O
goal O
of O
increasing B-REA
her I-REA
Na I-REA
~ O
8MeQ/24 O
hours O
. O
She O

 O
also O
received O
NS B-DRUG
for O
volume B-REA
repletion I-REA
. I-REA
Her O
trileptal B-DRUG
was O
tapered O

 O
off O
by O
the O
  O
Neurology O
sevice O
and O
transitioned O
over O
to O
keppra B-DRUG
for O

 O
antiseizure B-REA
prophylaxis I-REA
. I-REA
Also O
, O
her O
HCTZ B-DRUG
was O
discontinued O
and O
her O

 O
BP O
remained O
in O
the O
120s-130s O
in O
the O
ICU O
. O
Her O
Na O
gradually O

 O
improved O
to O
134 O
by O
the O
morning O
of O
[ O
* O
* O
2141 O
- O
10 O
- O
26 O
* O
* O
] O
. O
  O
The O
pt O
. O
remained O

 O
stable O
while O
in O
the O
ICU O
, O
showing O
no O
evidence O
of O
seizure O

 O
activity O
, O
and O
her O
mental O
status O
gradually O
improving O
. O
  O
Per O

 O
request O
of O
the O
Neurology O
service O
she O
underwent O
an O
[ O
* O
* O
Date O
Range O
* O
* O
] O
that O
on O

 O
prelim O
read O
showed O
slowing O
in O
the O
region O
of O
your O
old O
stroke O
- O

 O
however O
, O
the O
final O
read O
is O
pending O
at O
the O
time O
of O
your O

 O
discharge O
. O
  O
On O
HD O
3 O
the O
pt O
. O
Na O
had O
reached O
a O
normal O
level O
, O
she O

 O
was O
tolerating O
PO O
intake O
, O
was O
urinating O
without O
difficulty O
, O
was O

 O
ambulating O
without O
difficulty O
, O
and O
was O
ready O
for O
discharge O
. O

 O
Moreover O
, O
the O
pt O
. O
mental O
status O
was O
at O
baseline O
at O
the O
time O
of O

 O
discharge O
- O
A&O O
x3 O
and O
speaking O
in O
full O
sentences O
. O


 O
Medications O
on O
Admission O
: O

 O
keppra B-DRUG

 I-DRUG
HCTZ B-DRUG
25 B-STR
mg I-STR
daily B-FRE

 I-FRE
Atenolol B-DRUG
50 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Zetia B-DRUG
10 B-STR
mg I-STR
qd B-FRE

 I-FRE
Nexium B-DRUG
40 B-STR
mg I-STR
qd B-FRE

 I-FRE
Aspirin B-DRUG
325 B-STR
mg I-STR
qd B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( O
E.C. O
) O
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Levetiracetam B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
3 O
. O
Zetia B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
4 O
. O
Nexium B-DRUG
40 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) O
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Hyponatremia B-ADE
due O
to O
trileptal/HCTZ B-DRUG



 I-DRUG
Discharge O
Condition O
: O

 O
AAO O
x O
3 O
. O
Speaking O
fluently O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
hospital O
because O
your O
Sodium B-ADE
level I-ADE
was I-ADE

 I-ADE
low I-ADE
. I-ADE
This O
was O
most O
likely O
related O
to O
taking O
Trileptal B-DRUG
and O

 O
Hydrochlorthiazide B-DRUG
, I-DRUG
both O
of O
which O
can O
lower O
your O
Sodium O
levels O
. O

 O
Please O
STOP O
taking O
these O
medications O
. O

 O
. O


 O
Please O
also O
limit O
your O
fluid O
intake O
to O
64 O
ounces O
per O
day O
= O
2 O

 O
quarts O
. O
This O
will O
also O
help O
your O
sodium O
level O
to O
improve O
. O

 O
. O

 O
Please O
go O
to O
Dr.[**Name O
( O
NI O
) O
49335 O
* O
* O
] O
office O
on O
Friday O
to O
have O
your O
sodium O

 O
level O
checked O
. O
In O
addition O
, O
you O
will O
follow O
up O
with O
him O
on O

 O
Monday O
for O
an O
office O
visit O
. O


 O
Followup O
Instructions O
: O

 O
* O
* O
It O
is O
very O
important O
that O
you O
make O
the O
following O
appointments O
. O

  O
Please O
call O
to O
confirm O
appointments O
* O
* O

 O
. O

 O
You O
have O
an O
appointment O
at O
Dr.[**Last O
Name O
( O
STitle O
) O
* O
* O
] O
office O
on O
Friday O
for O
a O

 O
blood O
draw O
for O
your O
Sodium O
level O
. O

 O
. O

 O
You O
have O
an O
appointment O
on O
Monday O
the O
24th O
at O
Dr.[**Name O
( O
NI O
) O
49335 O
* O
* O
] O

 O
office O
at O
145pm O
for O
a O
follow O
up O
visit O
. O
Please O
bring O
a O
copy O
of O

 O
your O
discharge O
summary O
which O
we O
will O
provide O
for O
you O
for O
this O
. O

 O
. O

 O
Please O
call O
Dr.[**Name O
( O
NI O
) O
17720 O
* O
* O
] O
office O
at O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2574 O
* O
* O
] O
for O
to O
arrange O

 O
for O
a O
follow O
up O
appointment O
. O

 O
. O

 O
You O
have O
an O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
* O
* O
] O
test O
which O
is O
scheduled O
as O
below O
. O
This O
is O
to O

 O
follow O
up O
your O
stroke O
. O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
LAB O
Phone:[**Telephone/Fax O
( O
1 O
) O
19105 O
* O
* O
] O
Date/Time:[**2141 O
- O
10 O
- O
31 O
* O
* O
] O
3:00 O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2173 O
- O
12 O
- O
4 O
* O
* O
] O
       O
Discharge O
Date O
: O
  O
[ O
* O
* O
2173 O
- O
12 O
- O
15 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
   O
[ O
* O
* O
2124 O
- O
12 O
- O
5 O
* O
* O
] O
       O
Sex O
: O
  O
M O


 O
Service O
: O
  O
Transplant O
Surgery O


 O
HISTORY O
OF O
PRESENT O
ILLNESS O
: O
  O
The O
patient O
is O
a O
49-year-old O

 O
male O
who O
is O
well O
known O
to O
the O
Transplant O
Surgery O
Service O
who O

 O
was O
diagnosed O
in O
[ O
* O
* O
2170 O
* O
* O
] O
when O
he O
presented O
with O
acute O
upper O

 O
gastrointestinal O
bleed O
secondary O
to O
esophageal O
varices O
which O

 O
were O
banded O
. O


 O
The O
patient O
was O
diagnosed O
with O
hepatitis O
C O
and O
found O
on O
liver O

 O
biopsy O
to O
have O
cirrhosis O
and O
underwent O
URO B-REA
treatment I-REA
with O

 O
PEG-interferon B-DRUG
and O
ribavirin B-DRUG
. I-DRUG
  O
The O
patient O
's O
evaluation O
also O

 O
demonstrated O
a O
less O
than O
5 O
cm O
lesion O
in O
the O
liver O
for O
which O

 O
he O
had O
radiofrequency O
ablation O
therapy O
, O
and O
then O
the O
patient O

 O
was O
listed O
for O
transplant O
. O


 O
On O
presentation O
, O
the O
patient O
denied O
chest O
pain O
or O
shortness O

 O
of O
breath O
. O
  O
Denied O
a O
history O
of O
diabetes O
, O
coronary O
artery O

 O
disease O
, O
pulmonary O
or O
renal O
issues O
. O
  O
The O
patient O
had O
a O
good O

 O
appetite O
and O
approximately O
a O
25-pound O
weight O
gain O
. O
  O
The O

 O
patient O
complained O
of O
pruritus O
, O
dark O
urine O
, O
and O
loose O
stools O
. O


 O
PAST O
MEDICAL O
HISTORY O
: O

  O
1 O
. O
  O
Hepatitis O
C O
; O
chronic O
infection O
. O

  O
2 O
. O
  O
Cirrhosis O
. O

  O
3 O
. O
  O
End-stage O
liver O
disease O
. O

  O
4 O
. O
  O
Hepatocellular O
carcinoma O
; O
status O
post O
radiofrequency O

 O
ablation O
of O
a O
right O
lobe O
lesion O
, O
less O
than O
5 O
cm O
. O

  O
5 O
. O
  O
Upper O
gastrointestinal O
bleed O
secondary O
to O
varices O
; O

 O
status O
post O
multiple O
bandings O
. O

  O
6 O
. O
  O
CMV/EBB O
positive O
. O

  O
7 O
. O
  O
Hepatitis O
B O
core O
antibody O
positive O
. O

  O
8 O
. O
  O
Hemorrhoids O
. O

  O
9 O
. O
  O
[ O
* O
* O
2173 O
- O
7 O
- O
2 O
* O
* O
] O
echocardiogram O
with O
an O
ejection O
fraction O

 O
of O
greater O
than O
55 O
% O
. O

 O
10 O
. O
  O
Chest O
computed O
tomography O
with O
a O
right O
lower O
lobe O
5-mm O

 O
nodule O
consistent O
with O
granuloma O
. O

 O
11 O
. O
  O
Colonoscopy O
in O
[ O
* O
* O
2170 O
* O
* O
] O
where O
the O
patient O
had O
rule O
out O

 O
polyps O
. O


 O
PAST O
SURGICAL O
HISTORY O
: O
  O
Multiple O

 O
esophagogastroduodenoscopies O
. O


 O
ALLERGIES O
: O
  O
Possible O
allergy O
to O
CODEINE B-DRUG
( O
that O
causes O
fever B-ADE
) I-ADE
. O


 O
MEDICATIONS O
AT O
HOME O
: O
  O
Nadolol B-DRUG
20 B-STR
mg I-STR
by B-ROU
mouth I-ROU
in B-FRE
the I-FRE
evening I-FRE
. I-FRE


 O
SOCIAL O
HISTORY O
: O
  O
History O
of O
alcohol O
use O
. O
  O
Tobacco O
use O
until O

 O
the O
[ O
* O
* O
2149 O
* O
* O
] O
. O
  O
Intravenous O
drug O
use O
approximately O
30 O
years O
ago O
. O



 O
PHYSICAL O
EXAMINATION O
ON O
PRESENTATION O
: O
  O
Temperature O
on O

 O
admission O
was O
98.4 O
, O
heart O
rate O
was O
66 O
, O
blood O
pressure O
was O

 O
128/84 O
, O
respiratory O
rate O
was O
20 O
, O
and O
oxygen O
saturation O
was O

 O
98 O
% O
on O
room O
air O
. O
  O
The O
patient O
's O
weight O
was O
88.8 O
kilograms O
. O

 O
The O
patient O
was O
awake O
, O
alert O
, O
and O
oriented O
. O
  O
In O
no O
apparent O

 O
distress O
. O
  O
The O
patient O
's O
lungs O
revealed O
clear O
to O
auscultation O

 O
bilaterally O
. O
  O
Heart O
revealed O
a O
regular O
rate O
and O
rhythm O
. O

 O
Examination O
of O
the O
abdomen O
revealed O
a O
soft O
and O
reducible O

 O
umbilical O
hernia O
with O
positive O
bowel O
sounds O
. O
  O
The O
abdomen O
was O

 O
nontender O
and O
nondistended O
, O
no O
tap O
tenderness O
, O
no O
rebound O
. O

 O
No O
guarding O
. O
  O
Examination O
of O
the O
extremities O
revealed O
no O

 O
edema O
. O
  O
The O
patient O
had O
2 O
+ O
femoral O
pulses O
and O
dorsalis O
pedis O

 O
pulses O
bilaterally O
and O
equal O
. O
  O
Rectal O
examination O
revealed O
no O

 O
prolapse O
, O
no O
hemorrhoids O
. O
  O
External O
examination O
was O
done O
. O


 O
PERTINENT O
LABORATORY O
VALUES O
ON O
PRESENTATION O
: O
  O
White O
blood O

 O
cell O
count O
was O
6.6 O
, O
hematocrit O
was O
37.9 O
, O
and O
platelets O
were O

 O
143 O
. O
  O
Sodium O
was O
140 O
, O
potassium O
was O
3.4 O
, O
chloride O
was O
106 O
, O

 O
bicarbonate O
was O
29 O
, O
blood O
urea O
nitrogen O
was O
13 O
, O
creatinine O

 O
was O
0.7 O
, O
and O
blood O
glucose O
was O
120 O
. O
  O
INR O
was O
1.3 O
. O


 O
PERTINENT O
RADIOLOGY/IMAGING O
: O
  O
Electrocardiogram O
showed O
a O

 O
normal O
sinus O
rhythm O
at O
60 O
. O


 O
A O
chest O
x-ray O
showed O
no O
cardiomegaly O
. O
  O
No O
acute O

 O
cardiopulmonary O
process O
. O


 O
BRIEF O
SUMMARY O
OF O
HOSPITAL O
COURSE O
: O
  O
The O
patient O
was O
admitted O

 O
to O
the O
Transplant O
Surgery O
Service O
. O
  O
The O
patient O
was O
kept O

 O
nothing O
by O
mouth O
and O
was O
consented O
for O
a O
liver O
transplant O
. O


 O
The O
patient O
had O
the O
operation O
on O
the O
day O
after O
admission O
. O

 O
The O
patient O
was O
admitted O
to O
the O
Intensive O
Care O
Unit O
. O


 O
On O
postoperative O
day O
one O
, O
the O
patient O
remained O
afebrile O
with O

 O
stable O
vital O
signs O
. O
  O
The O
patient O
received O
morphine B-DRUG
as B-FRE
needed I-FRE

 I-FRE
for O
pain B-REA
. I-REA
  O
The O
patient O
was O
continued O
on O
Unasyn B-DRUG
, I-DRUG
Bactrim B-DRUG
, I-DRUG

 O
fluconazole B-DRUG
, I-DRUG
and O
ganciclovir B-DRUG
and O
was O
put O
on O
CellCept B-DRUG
and O

 O
Solu-Medrol B-DRUG
for O
immunosuppression B-REA
. I-REA


 O
On O
postoperative O
day O
two O
, O
the O
patient O
had O
no O
acute O

 O
complaints O
. O
  O
The O
patient O
was O
stable O
. O
  O
The O
patient O
continued O

 O
to O
be O
nothing O
by O
mouth O
with O
a O
nasogastric O
tube O
in O
place O
. O
  O
The O

 O
patient O
had O
a O
Foley O
and O
was O
doing O
well O
. O
  O
The O
patient O
's O
right O

 O
internal O
jugular O
cordis O
was O
changed O
over O
wire O
to O
triple O
lumen O

 O
catheter O
without O
any O
difficulties O
, O
and O
the O
patient O
was O

 O
extubated O
. O



 O
The O
patient O
's O
issues O
on O
postoperative O
day O
three O
were O

 O
bradycardia O
and O
the O
patient O
was O
hypertensive O
, O
most O
likely O
due O

 O
to O
the O
increase O
in O
the O
patient O
's O
volume O
from O
the O
surgery O
. O

 O
The O
patient O
was O
still O
intubated O
and O
kept O
nothing O
by O
mouth O

 O
with O
intravenous B-ROU
fluids B-DRUG
. I-DRUG
  O
The O
patient O
was O
given O
Lasix B-DRUG
for O

 O
diuresis B-REA
. I-REA
  O
The O
patient O
's O
perioperative O
antibiotics B-DRUG
were O

 O
discontinued O
, O
and O
he O
was O
Heplocked B-DRUG
. I-DRUG
  O
The O
patient O
was O

 O
transferred O
to O
the O
floor O
. O


 O
On O
postoperative O
day O
four O
, O
the O
patient O
was O
complaining O
of O

 O
some O
pain O
at O
the O
incision O
site O
on O
the O
back O
. O
  O
The O
patient O

 O
remained O
afebrile O
and O
continued O
to O
be O
somewhat O
hypertensive O
. O

 O
The O
patient O
was O
advanced O
to O
a O
regular O
diet O
as O
tolerated O
. O
  O
The O

 O
patient O
was O
also O
on O
............ O
of O
1 O
gram O
[ O
* O
* O
Hospital1 O
* O
* O
] O
and O

 O
prednisone B-DRUG
, I-DRUG
and O
Neoral B-DRUG
for O
immunosuppression B-REA
. I-REA


 O
On O
postoperative O
day O
five O
, O
the O
patient O
had O
no O
complaints O
. O
  O
He O

 O
remained O
afebrile O
. O
  O
He O
continued O
to O
be O
somewhat O
hypertensive O
. O

 O
The O
patient O
was O
continued O
on O
a O
prednisone B-DRUG
taper B-DOS
. I-DOS
  O
The O

 O
patient O
's O
Foley O
was O
removed O
and O
Heplocked B-DRUG
. I-DRUG
  O
He O
was O
encouraged O

 O
to O
be O
out O
of O
bed O
and O
ambulate O
. O


 O
On O
postoperative O
day O
six O
, O
the O
patient O
remained O
afebrile O
and O

 O
somewhat O
hypertensive O
. O
  O
With O
elevated O
blood O
sugars O
we O

 O
obtained O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
consultation O
to O
monitor O
the O
patient O
's O

 O
sugars O
, O
and O
the O
patient O
was O
continued O
on O
a O
prednisone B-DRUG
taper B-DOS
, I-DOS

 O
and O
CellCept B-DRUG
, I-DRUG
and O
Neoral B-DRUG
. I-DRUG


 O
On O
postoperative O
day O
seven O
, O
the O
patient O
had O
no O
complaints O
. O

 O
The O
patient O
was O
doing O
well O
. O
  O
The O
patient O
continued O
to O
be O
out O

 O
of O
bed O
with O
ambulation O
. O
  O
He O
was O
taking O
good O
oral O
intake O
. O


 O
On O
postoperative O
day O
eight O
, O
the O
patient O
was O
doing O
well O
. O
  O
He O

 O
remained O
afebrile O
with O
stable O
vital O
signs O
. O
  O
The O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
228 O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
1661**]-[**Location O
( O
un O
) O
1662 O
* O
* O
] O
drains O
were O
both O
removed O
without O
any O

 O
difficulties O
. O
  O
However O
, O
the O
patient O
's O
liver O
function O
tests O

 O
were O
elevated O
from O
the O
previous O
day O
. O
  O
Obtained O
a O
liver O
biopsy O

 O
which O
showed O
mild O
to O
severe O
rejection O
, O
focal O
acute O

 O
cholangitis O
and O
focal O
lobular O
neutrophilic O
aggregates O
and O

 O
mild O
............ O
perfusion O
injury O
. O
  O
The O
patient O
was O
promptly O

 O
put O
on O
Solu-Medrol B-DRUG
500 B-STR
mg I-STR
intravenously B-ROU
times O
three B-DOS
to B-REA
treat I-REA

 I-REA
the I-REA
acute I-REA
cellular I-REA
rejection I-REA
. I-REA



 O
On O
postoperative O
day O
number O
nine O
, O
the O
patient O
had O
no O

 O
complaints O
. O
  O
He O
remained O
afebrile O
with O
stable O
vital O
signs O
. O
He O

 O
was O
doing O
well O
on O
the O
high-dose B-DOS
steroids B-DRUG
. I-DRUG
  O
The O
patient O
's O

 O
blood O
sugars O
were O
well O
controlled O
, O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
input O
. O


 O
On O
postoperative O
day O
ten O
, O
the O
patient O
completed O
his O
last O
dose O

 O
of O
Solu-Medrol B-DRUG
and O
was O
put O
on O
a O
by B-ROU
mouth I-ROU
form O
of O
steroid B-DRUG

 I-DRUG
taper B-DOS
. I-DOS
  O
The O
patient O
's O
liver O
function O
tests O
had O
improved O
on O

 O
the O
Solu-Medrol B-DRUG
and O
continued O
to O
do O
well O
from O
that O
aspect O
. O


 O
FINAL O
DISCHARGE O
DIAGNOSES O
: O

  O
1 O
. O
  O
Hepatitis O
C O
; O
chronic O
infection O
. O

  O
2 O
. O
  O
Status O
post O
acute O
cellular O
rejection O
. O

  O
3 O
. O
  O
Cirrhosis O
. O

  O
4 O
. O
  O
End-stage O
liver O
disease O
. O

  O
5 O
. O
  O
Hepatocellular O
carcinoma O
. O

  O
6 O
. O
  O
Status O
post O
right O
radiofrequency O
ablation O
. O

  O
7 O
. O
  O
Upper O
gastrointestinal O
bleed O
due O
to O
esophageal O
varices O
; O

 O
status O
post O
multiple O
bandings O
. O

  O
8 O
. O
  O
CMV O
and O
EBB O
positive O
. O

  O
9 O
. O
  O
Hepatitis O
B O
core O
antibody O
positive O
. O

 O
10 O
. O
  O
Hemorrhoids O
. O

 O
11 O
. O
  O
Status O
post O
orthotopic O
liver O
transplantation O
. O


 O
MEDICATIONS O
ON O
DISCHARGE O
: O

 O
1 O
. O
  O
Fluconazole B-DRUG
400 B-STR
mg I-STR
by B-ROU
mouth I-ROU
every B-FRE
day I-FRE
. I-FRE

 O
2 O
. O
  O
Bactrim B-DRUG
single B-STR
strength I-STR
one B-DOS
tablet B-FOR
by B-ROU
mouth I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE

 O
3 O
. O
  O
Protonix B-DRUG
40 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE

 O
4 O
. O
  O
Percocet B-DRUG
one B-DOS
to I-DOS
two I-DOS
tablets B-FOR
by B-ROU
mouth I-ROU
q.4 B-FRE
- I-FRE
6h I-FRE
. I-FRE
as I-FRE
needed I-FRE

 I-FRE
( O
for O
pain O
) O
. O

 O
5 O
. O
  O
CellCept B-DRUG
[ O
* O
* O
Pager O
number O
* O
* O
] O
mg O
by B-ROU
mouth I-ROU
twice B-FRE
per I-FRE
day I-FRE
. I-FRE

 O
6 O
. O
  O
............ O
900 O
mg O
by O
mouth O
once O
per O
day O
. O

 O
7 O
. O
  O
Neoral B-DRUG
200 B-STR
mg I-STR
by B-ROU
mouth I-ROU
twice B-FRE
per I-FRE
day I-FRE
. I-FRE

 O
8 O
. O
  O
Prednisone B-DRUG
taper B-DOS
. I-DOS

 O
9 O
. O
  O
Insulin B-DRUG
sliding-scale B-DOS
. I-DOS


 O
DISCHARGE O
INSTRUCTIONS/FOLLOWUP O
: O
  O
The O
patient O
to O
follow O
up O

 O
with O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
; O
please O
call O
transplant O
coordinator O

 O
for O
a O
follow-up O
appointment O
. O







                             O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
, O
M.D. O
  O
[ O
* O
* O
MD O
Number(1 O
) O
1331 O
* O
* O
] O


 O
Dictated O
By:[**Last O
Name O
( O
NamePattern1 O
) O
3118 O
* O
* O
] O

 O
MEDQUIST36 O


 O
D O
: O
  O
[ O
* O
* O
2173 O
- O
12 O
- O
30 O
* O
* O
] O
  O
20:35 O

 O
T O
: O
  O
[ O
* O
* O
2173 O
- O
12 O
- O
30 O
* O
* O
] O
  O
21:39 O

 O
JOB O
# O
: O
  O
[ O
* O
* O
Job O
Number O
51683 O
* O
* O
] O

 O

Admission O
Date O
: O
  O
[ O
* O
* O
2104 O
- O
5 O
- O
19 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2104 O
- O
5 O
- O
26 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2049 O
- O
8 O
- O
22 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
NEUROSURGERY O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1835 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Syncope O
, O
seizure O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2104 O
- O
5 O
- O
22 O
* O
* O
] O
Right O
Frontal O
crani O
for O
mass O
x O
2 O
resection O



 O
History O
of O
Present O
Illness O
: O

 O
This O
is O
a O
54 O
year O
female O
with O
past O
medical O
history O
of O

 O
hypertension O
and O
osteoporosis O
, O
who O
presents O
as O
a O
transfer O
from O

 O
OSH O
s/p O
syncope O
and O
seizure O
, O
and O
with O
abnormal O
head O
CT O
. O
  O
In O

 O
summary O
, O
the O
patient O
was O
reportedly O
attending O
a O
funeral O
today O

 O
when O
she O
had O
a O
syncopal O
episode O
and O
fell O
. O
  O
She O
was O
sent O
to O

 O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
189 O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
Hospital O
for O
further O
evaluation O
. O
  O
Shortly O
following O

 O
admission O
, O
she O
was O
found O
slumped O
over O
and O
unresponsive O
in O
a O

 O
chair O
, O
and O
subsequently O
seized B-REA
. I-REA
Resolved O
with O
Ativan B-DRUG
. I-DRUG
  O
Continued O

 O
to O
seize B-REA
1 I-REA
- I-REA
2 I-REA
times I-REA
later O
in O
the O
evening O
. O
Received O
a O
total O
of O

 O
14 B-STR
mg I-STR
of O
Ativan B-DRUG
. I-DRUG
Intubated O
for O
increasing O
mental O
status O
changes O

 O
and O
lethargy O
. O
  O
Transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
continued O
care O
. O



 O
Past O
Medical O
History O
: O

 O
1 O
. O
Hypertension O

 O
2 O
. O
Osteoporosis O


 O
Social O
History O
: O

 O
She O
works O
as O
a O
registered O
nurse O
at O
the O
Home O
Away O
from O
Home O
. O
She O

 O
is O
a O
former O
smoker O
. O
She O
quit O
over O
15 O
years O
ago O
but O
has O
about O
30 O

 O
pack O
year O
hx O
. O
Her O
HCP O
is O

 O
her O
husband O
and O
she O
is O
DNR O
per O
her O
husband O
. O



 O
Family O
History O
: O

 O
She O
has O
no O
hx O
of O
cancers O
and O
FH O
only O
notable O
for O
maternal O
aunt O

 O
who O
was O
diagnosed O

 O
with O
breast O
cancer O
in O
her O
60 O
's O
. O


 O
Physical O
Exam O
: O

 O
On O
Admission O
: O

 O
PHYSICAL O
EXAM O
: O

 O
O O
: O
T O
: O
101.8 O
BP O
: O
119/76 O
         O
HR:76 O
    O
R:20 O
       O
O2Sats O
: O
100%t O

 O
Gen O
: O
WD/WN O
, O
comfortable O
, O
NAD O
. O
Off O
sedation B-DRUG
, I-DRUG
agitated O
. O

 O
HEENT O
: O
NC/AT O
Pupils O
: O
PERRLA O
         O
EOMs O
N/A O

 O
Extrem O
: O
Warm O
and O
well-perfused O
. O

 O
Neuro O
: O

 O
Mental O
status O
: O
Intubated O
. O
No O
EO O



 O
Cranial O
Nerves O
: O

 O
I O
: O
Not O
tested O

 O
II O
: O
Pupils O
equally O
round O
and O
reactive O
to O
light O
, O
4 O
to O
2 O
mm O

 O
bilaterally O
. O
Visual O
fields O
are O
full O
to O
confrontation O
. O

 O
III O
, O
IV O
, O
VI O
: O
N/A O

 O
V O
, O
VII O
: O
N/A O

 O
VIII O
: O
N/A O

 O
IX O
, O
X O
: O
Gag O
reflex O
Present O

 O
[ O
* O
* O
Doctor O
First O
Name O
81 O
* O
* O
] O
: O
N/A O

 O
XII O
: O
N/A O


 O
Motor O
: O
Normal O
bulk O
and O
tone O
bilaterally O
. O
No O
abnormal O
movements O
. O

 O
Moves O
all O
extremities O
x O
4 O
purposefully O
, O
equally O
, O
when O
off O

 O
sedation B-DRUG
. I-DRUG


 O
Toes O
downgoing O
bilaterally O
. O


 O
On O
Discharge O
: O

 O
Awake O
, O
alert O
and O
oriented O
to O
person O
, O
place O
and O
date O
. O
Face O
is O

 O
symmetric O
, O
tongue O
with O
a O
slight O
left O
deviation O
. O
Full O
strength O

 O
and O
sensation O
throughout O
. O
Wound O
is O
clean O
, O
dry O
and O
intact O
without O

 O
signs O
of O
infection O
. O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2104 O
- O
5 O
- O
19 O
* O
* O
] O
CT O
Head O
: O

 O
IMPRESSION O
: O
There O
are O
two O
rim-enhancing O
lesions O
peripherally O

 O
located O
within O
the O
right O
frontal O
lobe O
, O
as O
described O
above O
, O
with O

 O
associated O
vasogenic O
edema O
and O
mass O
effect O
. O
The O
inferior O
lesion O

 O
demonstrates O
a O
punctate O
focus O
of O
hemorrhage O
. O
While O
the O
superior O

 O
lesion O
does O
abut O
the O
dura O
, O
it O
lacks O
characteristic O
dural O
tail O
, O

 O
making O
meningioma O
a O
less O
likely O
consideration O
. O
  O
Moreover O
, O
the O

 O
more O
inferior O
lesion O
does O
appear O
intra-axial O
on O
coronal O
and O

 O
sagittal O
reformatted O
images O
. O
Differential O
diagnosis O

 O
includes O
metastatic O
disease O
versus O
abscess O
. O


 O
[ O
* O
* O
2104 O
- O
5 O
- O
19 O
* O
* O
] O
MRI O
Brain O
w/ O
& O
w/o O
: O

 O
1 O
. O
Two O
enhancing O
right O
frontal O
lesions O
most O
consistent O
with O

 O
metastases O
with O
surrounding O
vasogenic O
edema O
and O
right O
frontal O

 O
sucal O
effacment O
. O

 O
2 O
. O
2 O
mm O
leftward O
shift O
of O
midline O
structures O
. O


 O
CT O
Torso O
: O

 O
1 O
. O
No O
definite O
evidence O
of O
malignancy O
. O
Consolidation O
within O
the O

 O
superior O

 O
segment O
of O
the O
left O
lower O
lobe O
may O
represent O
infection O
, O
but O

 O
there O
is O
a O

 O
slightly O
more O
rounded O
appearance O
inferiorly O
, O
and O
consider O
repeat O

 O
chest O
CT O

 O
following O
treatment O
. O
Prominent O
left-sided O
intrapulmonary O
lymph O

 O
nodes O
may O
be O
reactive O
. O

 O
2 O
. O
Gallbladder O
sludge O
. O

 O
3 O
. O
Gas O
tracking O
in O
the O
posterior O
subcutaneous O
tissues O
and O

 O
extending O
into O
the O
left O
paraspinal O
musculature O
and O
left O
psoas O

 O
muscle O
. O
Findings O
are O
likely O

 O
related O
to O
pressure O
erosion O
. O
There O
is O
no O
focal O
fluid O
collection O
. O


 O
4 O
. O
Trace O
pelvic O
free O
fluid O
. O
Slightly O
limited O
evaluation O
of O
the O

 O
pelvis O
due O
to O
motion O
artifact O
, O
but O
no O
gross O
abnormalities O
are O

 O
identified O
. O


 O
CT O
head O
[ O
* O
* O
2104 O
- O
5 O
- O
22 O
* O
* O
] O
: O

 O
Expected O
postoperative O
appearance O
status-post O
right O
craniotomy O
. O

 O
Unchanged O
2 O
mm O
leftward O
shift O
of O
midline O
structures O



 O
MRI O
brain O
[ O
* O
* O
5 O
- O
23 O
* O
* O
] O
: O

 O
1 O
. O
Two O
curvilinear O
foci O
of O
residual O
enhancement O
of O
the O
right O

 O
frontal O
lobe O
. O
  O
Continued O
attention O
on O
followup O
studies O
is O

 O
recommended O
. O

 O
2 O
. O
Interval O
resection O
of O
the O
two O
right O
frontal O
lesions O
. O

 O
Persistent O
, O

 O
unchanged O
right O
frontal O
edema O
and O
2 O
mm O
leftward O
shift O
of O
midline O

 O
structures O
. O

 O
3 O
. O
No O
evidence O
of O
acute O
infarct O
. O



 O
Brief O
Hospital O
Course O
: O

 O
This O
is O
a O
54 O
year O
old O
F O
in O
her O
usual O
state O
of O
health O
until O
an O

 O
episode O
of O
syncope O
and O
seizure O
. O
OSH O
CT O
revealed O
a O
brain O
mass O

 O
with O
vasogenic O
edema O
. O
Patient O
was O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
where O
a O

 O
Head O
CT O
was O
repeated- O
again O
showing O
a O
  O
two O
rim-enhancing O
lesions O

 O
peripherally O
located O
within O
the O
right O
frontal O
lobe O
with O

 O
associated O
vasogenic O
edema O
and O
mass O
effect O
. O
  O
Pt O
was O
admitted O
to O

 O
the O
ICU O
under O
Dr.[**Name O
( O
NI O
) O
9034 O
* O
* O
] O
care O
. O
A O
Brain O
MRI O
was O
done O
on O

 O
[ O
* O
* O
2104 O
- O
5 O
- O
19 O
* O
* O
] O
which O
showed O
two O
enhancing O
right O
frontal O
lesions O
most O

 O
consistent O
with O
metastases O
with O
surrounding O
vasogenic O
edema O
and O

 O
right O
frontal O
sulcal O
effacement O


 O
A O
CT O
Torso O
was O
done O
on O
[ O
* O
* O
5 O
- O
19 O
* O
* O
] O
, O
which O
was O
negative O
for O
any O
primary O

 O
lesion O
or O
mets O
, O
but O
did O
show O
ground O
glass O
opacity O
in O
RUL O
. O


 O
She O
was O
consented O
and O
pre-oped O
, O
and O
went O
to O
the O
OR O
for O
resection O

 O
of O
this O
mass O
on O
[ O
* O
* O
5 O
- O
22 O
* O
* O
] O
. O
The O
procedure O
went O
well O
without O

 O
complications O
. O
The O
preliminary O
pathology O
report O
was O
metastatic O

 O
carcinoma O
. O
She O
remained O
in O
the O
PACU O
overnight O
for O
Q1 O
hour O
neuro O

 O
checks O
post-op O
. O
CT O
head O
was O
negative O
for O
hemorrhage O
. O


 O
She O
was O
stable O
on O
[ O
* O
* O
5 O
- O
23 O
* O
* O
] O
and O
she O
was O
transferred O
to O
the O
Step O
down O

 O
unit O
. O
Her O
Foley O
and O
A-line O
was O
discontinued O
. O
She O
had O
an O
MRI O
. O


 O
PT O
and O
OT O
were O
ordered O
. O
She O
was O
cleared O
for O
home O
on O
[ O
* O
* O
5 O
- O
26 O
* O
* O
] O
with O
PT O

 O
outpatient O
needs O
. O


 O
Medications O
on O
Admission O
: O

 O
1 O
. O
Ecotrin B-DRUG
81 B-STR
m I-STR
Daily B-FRE

 I-FRE
2 O
. O
Pepcid B-DRUG
20 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
3 O
. O
Lopressor B-DRUG
25 B-STR
mg I-STR
Daily B-FRE



 I-FRE

Discharge O
Medications O
: O

 O
1 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
2 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Capsule(s O
) O
* O
Refills:*0 O
* O

 O
3 O
. O
Famotidine B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
4 O
. O
Alendronate B-DRUG
70 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QSUN B-FRE
( I-FRE
every I-FRE

 I-FRE
Sunday I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Cholecalciferol B-DRUG
( I-DRUG
Vitamin I-DRUG
D3 I-DRUG
) I-DRUG
400 B-STR
unit I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
: I-REA
max O
APAP O
4g/24hrs O
. O

 O
7 O
. O
Levetiracetam B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*120 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
8 O
. O
Oxycodone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE

 I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
9 O
. O
Dexamethasone B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q12H B-FRE
( I-FRE
every I-FRE

 I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
10 O
. O
Outpatient O
Physical O
Therapy O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
486 O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
487 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Right O
sideded O
frontal O
brain O
masses O



 O
Discharge O
Condition O
: O

 O
Neurologically O
stable O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O



 O
Discharge O
Instructions O
: O

 O
General O
Instructions/Information O



 O
? O
? O
? O
? O
? O
? O
	 O
Have O
a O
friend/family O
member O
check O
your O
incision O
daily O
for O

 O
signs O
of O
infection O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Take O
your O
pain B-DRUG
medicine I-DRUG
as O
prescribed O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Exercise O
should O
be O
limited O
to O
walking O
; O
no O
lifting O
, O
straining O
, O

 O
or O
excessive O
bending O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
may O
wash O
your O
hair O
only O
after O
sutures O
have O
been O
removed O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
may O
shower O
before O
this O
time O
using O
a O
shower O
cap O
to O
cover O

 O
your O
head O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Increase O
your O
intake O
of O
fluids O
and O
fiber O
, O
as O
narcotic B-DRUG
pain I-DRUG

 I-DRUG
medicine I-DRUG
can O
cause O
constipation B-ADE
. I-ADE
We O
generally O
recommend O
taking O

 O
an O
over O
the O
counter O
stool B-DRUG
softener I-DRUG
, I-DRUG
such O
as O
Docusate B-DRUG
( I-DRUG
Colace I-DRUG
) I-DRUG

 I-DRUG
while O
taking O
narcotic B-DRUG
pain I-DRUG
medication I-DRUG
. I-DRUG

 O
? O
? O
? O
? O
? O
? O
	 O
Unless O
directed O
by O
your O
doctor O
, O
do O
not O
take O
any O

 O
anti-inflammatory B-DRUG
medicines I-DRUG
such O
as O
Motrin B-DRUG
, I-DRUG
Aspirin B-DRUG
, I-DRUG
Advil B-DRUG
, I-DRUG
and O

 O
Ibuprofen B-DRUG
etc O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
have O
been O
prescribed O
Keppra B-DRUG
for O
anti-seizure B-REA
medicine O
, O

 O
take O
it O
as O
prescribed O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
are O
being O
sent O
home O
on O
steroid B-DRUG
medication(taper B-DOS
to O
2 B-STR
mg I-STR

 I-STR
twice B-FRE
daily I-FRE
) I-FRE
, O
make O
sure O
you O
are O
taking O
a O
medication O
to O
protect B-REA

 I-REA
your I-REA
stomach I-REA
( O
Prilosec B-DRUG
, I-DRUG
Protonix B-DRUG
, I-DRUG
or O
Pepcid B-DRUG
) I-DRUG
, O
as O
these O

 O
medications O
can O
cause O
stomach B-REA
irritation I-REA
. I-REA
  O
Make O
sure O
to O
take O

 O
your O
steroid B-DRUG
medication I-DRUG
with O
meals O
, O
or O
a O
glass O
of O
milk O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Clearance O
to O
drive O
and O
return O
to O
work O
will O
be O
addressed O
at O

 O
your O
post-operative O
office O
visit O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Make O
sure O
to O
continue O
to O
use O
your O
incentive O
spirometer O
while O

 O
at O
home O
. O

 O
CALL O
YOUR O
SURGEON O
IMMEDIATELY O
IF O
YOU O
EXPERIENCE O
ANY O
OF O
THE O

 O
FOLLOWING O


 O
? O
? O
? O
? O
? O
? O
	 O
New O
onset O
of O
tremors O
or O
seizures O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Any O
confusion O
or O
change O
in O
mental O
status O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Any O
numbness O
, O
tingling O
, O
weakness O
in O
your O
extremities O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Pain B-REA
or O
headache B-REA
that O
is O
continually O
increasing O
, O
or O
not O

 O
relieved O
by O
pain B-DRUG
medication I-DRUG
. I-DRUG

 O
? O
? O
? O
? O
? O
? O
	 O
Any O
signs O
of O
infection O
at O
the O
wound O
site O
: O
increasing O
redness O
, O

 O
increased O
swelling O
, O
increased O
tenderness O
, O
or O
drainage O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Fever O
greater O
than O
or O
equal O
to O
101 O
? O
? O
? O
? O
? O
? O
F. O



 O

Followup O
Instructions O
: O

 O
? O
? O
? O
? O
? O
? O
Please O
return O
to O
the O
office O
in O
[ O
* O
* O
10 O
- O
30 O
* O
* O
] O
days O
( O
from O
your O
date O
of O

 O
surgery O
) O
for O
removal O
of O
your O
sutures O
and O
a O
wound O
check O
. O
This O

 O
appointment O
can O
be O
made O
with O
the O
Nurse O
Practitioner O
. O
  O
Please O

 O
make O
this O
appointment O
by O
calling O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1669 O
* O
* O
] O
. O
If O
you O
live O
quite O

 O
a O
distance O
from O
our O
office O
, O
please O
make O
arrangements O
for O
the O

 O
same O
, O
with O
your O
PCP O
. O

 O
? O
? O
? O
? O
? O
? O
You O
have O
an O
appointment O
in O
the O
Brain O
[ O
* O
* O
Hospital O
341 O
* O
* O
] O
Clinic O
on O
[ O
* O
* O
6 O
- O
9 O
* O
* O
] O

 O
at O
11:30 O
. O
  O
The O
Brain O
[ O
* O
* O
Hospital O
341 O
* O
* O
] O
Clinic O
is O
located O
on O
the O
[ O
* O
* O
Hospital O
Ward O
Name O
516 O
* O
* O
] O

 O
of O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
, O
in O
the O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Building O
, O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
. O
Their O
phone O
number O

 O
is O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1844 O
* O
* O
] O
. O
Please O
call O
if O
you O
need O
to O
change O
your O

 O
appointment O
, O
or O
require O
additional O
directions O
. O

 O
? O
? O
? O
? O
? O
? O
Please O
follow O
up O
with O
medical O
oncology O
. O
You O
should O
be O
receiving O

 O
a O
call O
from O
them O
once O
pathology O
has O
been O
finalizined O
. O
  O
If O
you O
do O

 O
not O
hear O
from O
them O
by O
Friday O
[ O
* O
* O
5 O
- O
30 O
* O
* O
] O
please O
call O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
at O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
86318 O
* O
* O
] O
to O
schedule O
an O
appointment O
or O
if O
you O
have O
any O

 O
questions O




 O
Completed O
by:[**2104 O
- O
5 O
- O
26 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2115 O
- O
2 O
- O
22 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2115 O
- O
3 O
- O
19 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2078 O
- O
8 O
- O
9 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Vicodin B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
4891 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Post-cardiac O
arrest O
, O
asthma O
exacerbation O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Intubation O

 O
Removal O
of O
chest O
tubes O
placed O
at O
an O
outside O
hospital O

 O
R O
CVL O
placement O



 O
History O
of O
Present O
Illness O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
3234 O
* O
* O
] O
is O
a O
36 O
year O
old O
gentleman O
with O
a O
PMH O
signifciant O

 O
with O
dilated O
cardiomyopathy O
s/p O
AICD O
, O
asthma O
, O
and O
HTN O
admitted O

 O
to O
an O
OSH O
with O
dyspnea O
now O
admitted O
to O
the O
MICU O
after O
PEA O
arrest O

 O
x2 O
. O
The O
patient O
initially O
presented O
to O
LGH O
ED O
with O
hypoxemic O

 O
respiratory O
distress O
. O
While O
at O
the O
OSH O
, O
he O
received O
CTX B-DRUG
, I-DRUG

 O
azithromycin B-DRUG
, I-DRUG
SC B-ROU
epinephrine B-DRUG
, I-DRUG
and O
solumedrol B-DRUG
. I-DRUG
While O
at O
the O
OSH O
, O

 O
he O
became O
confused O
and O
subsequently O
had O
an O
episode O
of O
PEA O
arrest O

 O
and O
was O
intubated O
. O
He O
received O
epinephrine B-DRUG
, I-DRUG
atropine B-DRUG
, I-DRUG
magnesium B-DRUG
, I-DRUG

 O
and O
bicarb B-DRUG
. I-DRUG
In O
addition O
, O
he O
had O
bilateral O
needle O
thoracostomies O

 O
with O
report O
of O
air O
return O
on O
the O
left O
, O
and O
he O
subsequently O
had O

 O
bilateral O
chest O
tubes O
placed O
. O
  O
After O
approximately O
15 O
- O
20 O
minutes O

 O
of O
rescucitation O
, O
he O
had O
ROSC O
. O
He O
received O
vecuronium B-DRUG
and O
was O

 O
started O
on O
an O
epi B-DRUG
gtt B-ROU
for O
asthma B-REA
and O
a O
cooling O
protocol O
, O
and O
was O

 O
then O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
further O
evaluation O
. O
Of O
note O
, O
the O

 O
patient O
was O
admitted O
to O
LGH O
in O
[ O
* O
* O
1 O
- O
4 O
* O
* O
] O
for O
dyspnea O
, O
and O
was O

 O
subsequently O
diagnosed O
with O
a O
CAP B-REA
and O
asthma B-REA
treated O
with O
CTX B-DRUG

 I-DRUG
and O
azithromycin B-DRUG
. I-DRUG
Per O
his O
family O
, O
he O
has O
also O
had O
multiple O

 O
admissions O
this O
winter O
for O
asthma O
exacerbations O
. O

 O
. O

 O
In O
the O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
, O
35.3 O
102 O
133/58 O
100%AC O
500x20 O
, O
5 O
, O
1.0 O
with O
an O

 O
ABG O
7.16/66/162 O
. O
He O
had O
a O
CTH O
which O
was O
unremarkable O
. O
He O
then O

 O
had O
a O
CTA O
chest O
, O
afterwhich O
he O
went O
into O
PEA O
arrest O
. O

 O
Rescucitation O
last O
approximately O
10 O
- O
15 O
minutes O
with O
multiple O

 O
rounds O
of O
epi B-DRUG
and O
bicarb B-DRUG
, I-DRUG
with O
ROSC O
. O
He O
was O
then O
admitted O
to O
the O

 O
MICU O
for O
further O
management O
. O

 O
. O

 O
Currently O
, O
the O
patient O
is O
intubated O
, O
sedated O
, O
and O
parlyzed O
. O


 O
Past O
Medical O
History O
: O

 O
Asthma O

 O
Dilated O
cardiomyopathy O

 O
Multiple O
admissions O
for O
dyspnea O
this O
winter O
( O
[ O
* O
* O
1 O
- O
26 O
* O
* O
] O
) O
. O

 O
Anxiety/depression O

 O
CKD O

 O
HLD O

 O
Obesity O

 O
HTN O


 O
Social O
History O
: O

 O
Unknown O



 O
Family O
History O
: O

 O
Unknown O


 O
Physical O
Exam O
: O

 O
ADMISSION O
: O

 O
VS O
: O
35.9 O
124 O
129/67 O
99 O
% O
AC O
480x24 O
, O
5 O
, O
1.0 O

 O
Gen O
: O
ETT O
in O
place O
, O
intubated O
, O
sedated O
. O

 O
HEENT O
: O
ETT O
in O
place O
. O

 O
CV O
: O
Tachy O
S1+S2 O

 O
Pulm O
: O
Poor O
air O
movement O
bilaterally O
. O
Diffuse O
wheezes O

 O
bilaterally O
. O

 O
Abd O
: O
S/D O
hypoactive O
BS O

 O
Ext O
: O
1 O
+ O
edema O
bilaterally O

 O
Neuro O
: O
Unresponsive O
. O

 O
. O

 O
Discharge O
: O
98.5 O
102/65 O
76 O
20 O
95 O
- O
98 O
% O
RA O

 O
In O
cage O
bed O
to O
prevent O
patient O
from O
falling O
out O
of O
bed O
. O

 O
Occasionally O
calling O
out O
. O
Lungs O
clear O
without O
wheezes O
. O



 O
Pertinent O
Results O
: O

 O
Labs O
on O
Admission O
: O

 O
[ O
* O
* O
2115 O
- O
2 O
- O
22 O
* O
* O
] O
08:50AM O
BLOOD O
WBC-19.5 O
* O
RBC-4.76 O
Hgb-14.9 O
Hct-44.3 O

 O
MCV-93 O
MCH-31.4 O
MCHC-33.7 O
RDW-12.9 O
Plt O
Ct-201 O

 O
[ O
* O
* O
2115 O
- O
2 O
- O
22 O
* O
* O
] O
08:50AM O
BLOOD O
PT-14.1 O
* O
PTT-25.9 O
INR(PT)-1.2 O
* O

 O
[ O
* O
* O
2115 O
- O
2 O
- O
22 O
* O
* O
] O
08:50AM O
BLOOD O
Glucose-306 O
* O
UreaN-21 O
* O
Creat-1.2 O
Na-144 O

 O
K-4.1 O
Cl-111 O
* O
HCO3 O
- O
28 O
AnGap-9 O

 O
[ O
* O
* O
2115 O
- O
2 O
- O
22 O
* O
* O
] O
08:50AM O
BLOOD O
Albumin-3.4 O
* O
Calcium-6.2 O
* O
Phos-5.5 O
* O

 O
Mg-2.2 O

 O
[ O
* O
* O
2115 O
- O
2 O
- O
22 O
* O
* O
] O
09:32AM O
BLOOD O
calTIBC-320 O
Ferritn-1129 O
* O
TRF-246 O

 O
[ O
* O
* O
2115 O
- O
2 O
- O
22 O
* O
* O
] O
07:17AM O
BLOOD O
Type-ART O
pO2 O
- O
162 O
* O
pCO2 O
- O
66 O
* O
pH-7.16 O
* O

 O
calTCO2 O
- O
25 O
Base O
XS--6 O
Intubat-INTUBATED O

 O
. O

 O
Labs O
on O
Discharge O

 O
[ O
* O
* O
2115 O
- O
3 O
- O
18 O
* O
* O
] O
11:34AM O
BLOOD O
Type-ART O
pO2 O
- O
95 O
pCO2 O
- O
33 O
* O
pH-7.54 O
* O

 O
calTCO2 O
- O
29 O
Base O
XS-5 O
Intubat-NOT O
INTUBA O

 O
[ O
* O
* O
2115 O
- O
3 O
- O
5 O
* O
* O
] O
05:35AM O
BLOOD O
ALT-49 O
* O
AST-23 O
AlkPhos-53 O
TotBili-0.9 O

 O
[ O
* O
* O
2115 O
- O
3 O
- O
19 O
* O
* O
] O
04:45AM O
BLOOD O
Glucose-73 O
UreaN-25 O
* O
Creat-1.4 O
* O
Na-133 O

 O
K-4.1 O
Cl-95 O
* O
HCO3 O
- O
21 O
* O
AnGap-21 O
* O

 O
[ O
* O
* O
2115 O
- O
3 O
- O
19 O
* O
* O
] O
04:45AM O
BLOOD O
WBC-12.4 O
* O
RBC-4.47 O
* O
Hgb-14.3 O
Hct-41.3 O

 O
MCV-93 O
MCH-32.0 O
MCHC-34.6 O
RDW-13.3 O
Plt O
Ct-352 O

 O
[ O
* O
* O
2115 O
- O
3 O
- O
19 O
* O
* O
] O
04:45AM O
BLOOD O
Neuts-56 O
Bands-0 O
Lymphs-38 O
Monos-3 O
Eos-3 O

 O
Baso-0 O
Atyps-0 O
Metas-0 O
Myelos-0 O

 O
. O

 O
CXR O
( O
in O
MICU O
) O
: O
Mr O
read O
- O
cardiomegaly O
, O
RIJ O
in O
SVC O
, O
ETT O
4.5 O
cm O

 O
above O
carina O
. O
Blunting O
of O
costophrenic O
angles O
bilaterally O
with O

 O
low O
lung O
volumes O
. O
Loss O
of O
retrocardiac O
diagphragm O
and O
bilateral O

 O
opacities O
( O
L O
> O
R O
) O

 O
. O


 O
CXR O
: O

 O
1 O
. O
NG O
tube O
at O
7.2 O
cm O
above O
the O
carina O
. O
[ O
* O
* O
Month O
( O
only O
) O
116 O
* O
* O
] O
consider O
advancing O

 O
for O
optimal O
placement O
. O

 O
2 O
. O
Severe O
cardiomegaly O
with O
globular O
shape O
. O
In O
the O
absence O
of O

 O
prior O

 O
comparison O
, O
the O
differential O
is O
broad O
, O
including O
moderate O

 O
pericardial O

 O
effusion O
, O
mediastinal O
hemorrhage O
, O
or O
acute O
cardiac O
failure O
. O

 O
Recommend O

 O
clinical O
correlation O
. O

 O
. O

 O
CTH O
: O
My O
read O
, O
no O
acute O
bleed O

 O
. O

 O
CTA O
Chest O
: O

 O
1 O
. O
No O
evidence O
of O
pulmonary O
embolism O
, O
although O
evaluation O
of O

 O
subsegmental O
branches O
is O
limited O
. O

 O
2 O
. O
Moderate O
cardiomegaly O
without O
pericardial O
effusion O
. O

 O
3 O
. O
Bilateral O
dependent O
atelectasis O
. O

 O
4 O
. O
Multiple O
nondisplaced O
rib O
fractures O
on O
the O
right O
, O
some O
of O

 O
which O
are O
subacute O
. O
Also O
possible O
subtle O
nondisplaced O
fractures O

 O
of O
the O
left O
ribs O
. O

 O
5 O
. O
Nondisplaced O
acute O
sternal O
fracture O
in O
addition O
to O
a O
subacute O

 O
nondisplaced O
sternal O
fracture O
. O

 O
. O

 O
TTE O
: O
The O
left O
atrium O
is O
moderately O
dilated O
. O
The O
estimated O
right O

 O
atrial O
pressure O
is O
10 O
- O
20mmHg O
. O
Left O
ventricular O
wall O
thicknesses O

 O
are O
normal O
. O
The O
left O
ventricular O
cavity O
is O
severely O
dilated O
. O
LV O

 O
systolic O
function O
appears O
depressed O
( O
ejection O
fraction O
? O
30 O

 O
percent O
) O
with O
regional O
variation O
. O
There O
is O
considerable O

 O
beat-to-beat O
variability O
of O
the O
left O
ventricular O
ejection O

 O
fraction O
due O
to O
an O
irregular O
rhythm/premature O
beats O
. O
The O
right O

 O
ventricular O
free O
wall O
thickness O
is O
normal O
. O
The O
right O
ventricular O

 O
cavity O
is O
dilated O
with O
depressed O
free O
wall O
contractility O
. O
The O

 O
aortic O
root O
is O
mildly O
dilated O
at O
the O
sinus O
level O
. O
The O
ascending O

 O
aorta O
is O
mildly O
dilated O
. O
The O
aortic O
valve O
leaflets O
( O
3 O
) O
appear O

 O
structurally O
normal O
with O
good O
leaflet O
excursion O
and O
no O
aortic O

 O
stenosis O
or O
aortic O
regurgitation O
. O
The O
mitral O
valve O
leaflets O
are O

 O
structurally O
normal O
. O
There O
is O
no O
mitral O
valve O
prolapse O
. O
Mild O

 O
( O
1 O
+ O
) O
mitral O
regurgitation O
is O
seen O
. O
The O
pulmonary O
artery O
systolic O

 O
pressure O
could O
not O
be O
determined O
. O
There O
is O
no O
pericardial O

 O
effusion O
. O

 O
. O

 O
ECG O
( O
post-arrest O
) O
: O
  O
Sinus O
with O
1:1 O
conduction O
. O
LAA O
. O
LAD O
, O
RBBB O
, O

 O
LAFB O
. O
STD O
in O
V4-V6 O
. O

 O
. O

 O
ECG O
( O
pre-arrest O
) O
: O
Sinus O
with O
1:1 O
conduction O
. O
LAD O
, O
bifascicular O

 O
block O
. O
No O
lateral O
STD O
. O

 O
. O

 O
ECG O
( O
OSH O
, O
unclear O
pre/post O
arrest O
) O
: O
Sinus O
with O
1:1 O
conduction O
. O

 O
Bifascicular O
( O
RBBB O
, O
LAFB O
) O
block O
. O
STD O
in O
V5 O
- O
6 O
. O

 O
. O


 O
EEG O
[ O
* O
* O
2 O
- O
27 O
* O
* O
] O

 O
IMPRESSION O
: O
This O
is O
an O
abnormal O
video O
EEG O
telemetry O
due O
to O
the O

 O
slow O
and O

 O
disorganized O
background O
of O
6.5 O
Hz O
with O
bursts O
of O
generalized O

 O
slowing O

 O
that O
showed O
no O
clear O
reactivity O
. O
These O
findings O
indicate O
a O

 O
severe O

 O
encephalopathy O
. O
This O
may O
be O
consistent O
with O
the O
patient O
's O

 O
history O
of O

 O
anoxia O
; O
however O
, O
toxic/metabolic O
disturbances O
, O
infection O
, O
and O

 O
medication O

 O
effects O
are O
also O
among O
the O
most O
frequent O
causes O
of O

 O
encephalopathy O
. O
No O

 O
clear O
epileptiform O
discharges O
or O
seizures O
were O
seen O
. O


 O
LUMBAR O
SPINE O
[ O
* O
* O
2115 O
- O
3 O
- O
11 O
* O
* O
] O


 O
CLINICAL O
INFORMATION O
: O
Evidence O
of O
fracture O
, O
seizure O
, O
fall O
, O
low O

 O
back O
pain O
. O


 O
FINDINGS O
: O


 O
Three O
views O
of O
the O
lumbar O
spine O
demonstrate O
mild O
narrowing O
of O

 O
the O
left O

 O
femoroacetabular O
joint O
. O
There O
is O
mild O
scoliosis O
of O
the O

 O
thoracolumbar O
spine O
. O
  O
The O
ventricular O
lead O
of O
a O
pacemaker O
is O

 O
identified O
. O
No O
fracture O
of O
L2 O
through O
L5 O
is O
identified O
. O
However O
, O

 O
there O
is O
a O
compression O
fracture O
of O
L1 O
, O
with O
compression O
of O
the O

 O
superior O
endplate O
, O
and O
a O
sclerotic O
fracture O
line O
. O
Given O
the O

 O
mechanism O
of O
fall O
, O
if O
there O
is O
acute O
pain O
referable O
to O
L1 O
, O
then O

 O
this O
would O
be O
considered O
an O
acute O
finding O
. O
There O
is O
no O
apparent O

 O
retropulsion O
of O
the O
posterior O
margin O
of O
L1 O
into O
the O
spinal O

 O
canal O
. O
No O
other O
fractures O
are O
identified O
at O
this O
time O
. O
Facet O

 O
joints O
are O
aligned O
. O
There O
is O
early O
calcification O
of O
the O
aorta O
. O

 O
IMPRESSION O
: O
Compression O
fracture O
of O
L1 O
with O
anterior O
wedge O

 O
deformity O
, O
likely O
an O
acute O
finding O
. O
No O
other O
fractures O

 O
identified O
. O

 O
EKG O
: O
Normal O
sinus O
rhythm O
. O
Complete O
right O
bundle-branch O
block O

 O
with O
left O
anterior O
fascicular O
block O
. O
Diffuse O
ST-T O
wave O
changes O

 O
laterally O
. O

 O
CT O
Head O
: O

 O
COMPARISON O
: O
[ O
* O
* O
2115 O
- O
2 O
- O
22 O
* O
* O
] O
. O

 O
TECHNIQUE O
: O
Non-contrast O
axial O
images O
were O
obtained O
through O
the O

 O
brain O
. O

 O
FINDINGS O
: O
There O
is O
no O
intracranial O
hemorrhage O
, O
edema O
, O
or O
loss O
of O

 O
[ O
* O
* O
Doctor O
Last O
Name O
352**]/white O
matter O
differentiation O
. O
Ventricles O
and O
sulci O
are O

 O
normal O
in O
size O
and O
configuration O
. O
The O
basilar O
cisterns O
are O
not O

 O
compressed O
. O
Paranasal O
sinuses O
demonstrate O
fluid O
in O
the O
sphenoid O

 O
air O
cells O
and O
right O
posterior O
ethmoid O
air O
cell O
, O
likely O
related O

 O
to O
prolonged O
hospitalization O
. O
  O
Mastoid O
air O
cells O
are O
well O

 O
aerated O
. O

 O
IMPRESSION O
: O
No O
evidence O
of O
acute O
intracranial O
abnormalities O
. O



 O

Brief O
Hospital O
Course O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
3234 O
* O
* O
] O
is O
a O
36 O
year O
old O
gentleman O
with O
a O
PMH O
signifciant O

 O
with O
dilated O
cardiomyopathy O
s/p O
AICD O
, O
PE O
not O
on O
anticoagulation O
, O

 O
asthma O
, O
and O
HTN O
admitted O
to O
an O
OSH O
with O
dyspnea O
now O
the O

 O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
MICU O
after O
PEA O
arrest O
x2 O
. O



 O
# O
PEA O
arrest O
and O
subsequent O
anoxic O
brain O
injury O
. O
: O
Suspect O
that O

 O
original O
OSH O
PEA O
arrest O
due O
to O
hypoxemia O
or O
acidosis O
, O
with O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O

 O
ED O
PEA O
arrest O
due O
to O
acidosis O
with O
admission O
pH O
7.16 O
on O
arrival O
. O

  O
TTE O
with O
evidence O
of O
RV O
failure O
to O
suggest O
PE O
. O
LVEF O
30 O
% O
with O

 O
known O
dilated O
cardiomyopathy O
. O
He O
was O
cooled O
per O
protocol O
. O

 O
Initially O
, O
his O
EEG O
was O
concerning O
without O
evident O
brain O

 O
activity O
. O
On O
hospital O
day O
3 O
, O
there O
was O
only O
comatose O
activity O

 O
and O
his O
prognosis O
was O
guarded O
. O
However O
, O
the O
patient O
was O
able O
to O

 O
be O
weaned O
off O
the O
vent O
and O
over O
the O
course O
of O
the O
next O
three O

 O
days O
his O
mental O
status O
improved O
. O
  O
He O
was O
alert O
, O
oriented O
to O

 O
place O
and O
day O
of O
the O
week O
and O
moving O
all O
4 O
extremities O
. O
  O
He O

 O
became O
more O
interactive O
on O
transfer O
to O
the O
floor O
, O
was O
initially O

 O
speaking O
in O
spanish O
and O
English O
and O
not O
always O
making O
sense O
but O

 O
then O
started O
responding O
more O
appropiately O
and O
following O

 O
commands O
. O
  O
On O
hospital O
day O
11 O
he O
had O
a O
witnessed O
grand B-REA
mal I-REA

 I-REA
seizure I-REA
and O
was O
given O
ativan B-DRUG
and O
started O
on O
Keppra B-DRUG
with O

 O
neurology O
consult O
. O
  O
His O
mental O
status O
was O
worse O
for O
24 O
hours O

 O
after O
the O
seizure O
but O
then O
he O
slowly O
returned O
to O
his O
recent O

 O
baseline O
. O
  O
He O
was O
somewhat O
aggitated B-REA
so O
his O
Keppra B-DRUG
was O
switched O

 O
to O
Topiramate B-DRUG
. I-DRUG
He O
had O
a O
subsequent O
seizure O
on O
[ O
* O
* O
3 O
- O
18 O
* O
* O
] O
with O
LUE O

 O
tonic O
clonic O
activity O
and O
impaired O
consciousness O
but O
this O

 O
resolved O
spontaneously O
after O
1 O
- O
2 O
minutes O
. O
He O
was O
contineud O
on O

 O
topamax B-DRUG
per O
neuro O
recommendations O
. O
OT O
and O
PT O
were O
consulted O
and O

 O
worked O
with O
the O
patient O
as O
he O
will O
likely O
require O
a O
long O

 O
rehabilitation O
course O
. O
  O
At O
the O
time O
of O
discharge O
the O
patient O
was O

 O
alert O
, O
oriented O
( O
though O
not O
always O
to O
date O
) O
, O
following O
commands O

 O
but O
impulsive O
with O
poor O
motor O
planning O
leading O
to O
several O
falls O
. O

  O
Neurology O
notes O
indicate O
the O
patient O
has O
the O
potential O

 O
toimprove O
from O
a O
neurologic O
standpoint O
. O
He O
also O
may O
have O

 O
recurrent B-REA
seizures I-REA
which O
should O
be O
treated O
with O
ativan B-DRUG
IV B-ROU
or O
IM B-ROU

 I-ROU
and O
do O
not O
neccessarily O
indicate O
patient O
needs O
to O
return O
to O

 O
hospital O
unless O
they O
continue O
for O
greater O
than O
5 O
minutes O
or O
he O

 O
has O
multiple O
recurrent O
seizures O
or O
complications O
such O
as O

 O
aspiration O
. O

 O
-patient O
will O
be O
on O
Topiramate B-DRUG
25 B-STR
mg I-STR
PO B-ROU
BID B-FRE
until O
[ O
* O
* O
3 O
- O
22 O
* O
* O
] O
PM B-DUR
then O

 O
increase O
to O
50 B-STR
mg I-STR
po B-ROU
BID B-FRE
for B-DUR
seven I-DUR
days I-DUR
then O
increase O
to O
75 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
ongoing B-FRE
. I-FRE

 O
-patient O
will O
follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
STitle O
) O
* O
* O
] O
in O
his O
s/p O

 O
arrest O
neurology O
clinic O

 O

-patient O
will O
require O
intensive O
PT O
and O
OT O
in O
an O
anoxic O
brain O

 O
injury O
unit O
. O

 O
. O

 O
# O
Respiratory O
failure O
: O
Believed O
to O
be O
due O
to O
status O
asthmaticus O
, O

 O
although O
inciting O
event O
unclear O
. O
[ O
* O
* O
Name2 O
( O
NI O
) O
227 O
* O
* O
] O
multiple O
cardiac O
arrests O
, O

 O
also O
a O
concern O
for O
development O
of O
ARDS O
. O
  O
The O
patient O
was O

 O
initially O
treated O
broadly O
with O
vancomycin B-DRUG
, I-DRUG
cefepime B-DRUG
, I-DRUG
flagyl B-DRUG
, I-DRUG

 O
cipro B-DRUG
, I-DRUG
and O
oseltamavir B-DRUG
. I-DRUG
He O
was O
treated O
with O
IV B-ROU
soludemedrol B-DRUG
and O

 O
albuterol B-DRUG
MDI B-FOR
. I-FOR
He O
was O
ventialted O
according O
to O
ARDS-Net O
protocol O
. O

 O
On O
admission O
, O
he O
had O
two O
chest O
tubes O
placed O
for O
pneumothoraces O
. O

 O
They O
were O
removed O
on O
hospital O
day O
1 O
. O
In O
his O
first O
several O
days O
, O

 O
his O
respiratory O
status O
was O
comprimised O
by O
lobar O
collapse O
, O
first O

 O
of O
the O
RUL O
and O
then O
of O
the O
RML O
. O
His O
extubation O
was O
initially O

 O
limited O
both O
by O
agitation B-REA
requiring O
sedation B-DRUG
and O
by O
requirements O

 O
for O
high O
PEEP O
to O
maintain O
oxygenation O
. O
His O
oxygenation O
was O

 O
improved O
with O
diuresis O
and O
agitation B-REA
was O
better O
controlled O
with O

 O
seroquel B-DRUG
. I-DRUG
He O
was O
extubated O
on O
[ O
* O
* O
3 O
- O
1 O
* O
* O
] O
and O
respiratory O
status O
was O

 O
stable O
. O
  O
His O
Asthma B-REA
was O
treated O
with O
standing B-DUR
and O
PRN B-DUR
albuterol B-DRUG

 I-DRUG
and O
ipratriopium B-DRUG
and O
a O
slow O
prednisone B-DRUG
taper B-DOS
which O
he O
l O

 O
completed O
on O
[ O
* O
* O
2115 O
- O
3 O
- O
18 O
* O
* O
] O
and O
he O
was O
restarted O
on O
Advair B-DRUG

 I-DRUG
-patient O
may O
require O
additional O
nebs O
on O
top O
of O
his O
standing B-DUR

 I-DUR
advair B-DRUG
though O
his O
respiratory O
status O
has O
been O
very O
stable O
, O

 O
without O
wheezing B-REA
for O
the O
last O
week O
. O

 O
- O
would O
like O
benefit O
from O
outpatient O
PFTs O
and O
is O
scheduled O
to O

 O
see O
a O
pulmonologist O
in O
follow O
up O
. O

 O
. O

 O
# O
Ventilator B-REA
associated I-REA
pneumonia I-REA
: I-REA
  O
Patient O
developed O
a O
fever O
on O

 O
[ O
* O
* O
2 O
- O
27 O
* O
* O
] O
with O
new O
infiltrates O
on O
chest O
xray O
while O
intubated O
. O
He O
was O

 O
initially O
covered O
with O
vanc/cefepime B-DRUG
and O
cipro B-DRUG
. I-DRUG
Cipro B-DRUG
was O

 O
eventually O
discontinued O
. O
He O
did O
not O
grow O
any O
organisms O
other O

 O
than O
yeast O
in O
his O
sputum O
. O
He O
completed O
an O
8 B-DUR
day I-DUR
course O
of O

 O
Vanco/Cefepime B-DRUG
. I-DRUG

 O
. O

 O
# O
Myoclonus O
: O
when O
mental O
status O
improved O
, O
was O
noted O
to O
have O

 O
myoclonic O
jerks O
. O
per O
neurology O
, O
likely O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
1683 O
* O
* O
] O
Syndrome O

 O
which O
is O
anoxic O
injury O
to O
the O
purkinje O
cells O
. O
  O
These O
jerks O

 O
continued O
for O
about O
one O
week O
and O
then O
became O
rare O
. O

 O
. O


 O
# O
dilated O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
89982 O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
30 O
% O
. O
s/p O
ICD O
. O
  O
Patient O
was O

 O
diuresed B-REA
with O
IV B-ROU
lasix B-DRUG
in O
the O
ED O
and O
then O
transitioned O
to O
PO B-ROU

 I-ROU
lasix B-DRUG
, I-DRUG
home B-DOS
dose I-DOS
, I-DOS
on O
the O
floor O
. O
  O
His O
respiratory O
status O
remained O

 O
stable O
. O
Also O
continued O
on O
home B-DOS
dose I-DOS
of O
carvedilol B-DRUG
and O
Lisinopril B-DRUG

 I-DRUG
but O
ACE B-DRUG
downtitrated O
from O
40 B-STR
to O
20 B-STR
when O
had O
elevated B-REA
Cr I-REA
1.9 I-REA
on O

 O
[ O
* O
* O
3 O
- O
18 O
* O
* O
] O
and O
slightly O
low B-REA
BPs I-REA
high O
90s/60s O
. O
BP O
improved O
to O
100s/60s O
. O


 O
. O

 O
# O
Hypertension B-REA
: I-REA
Patient O
's O
home O
regimen O
was O
continued O
on O
the O

 O
floor O
, O
but O
his O
SBP O
dipped O
into O
the O
high O
80s O
and O
low O
90s O
so O

 O
lisinopril B-DRUG
was O
decreased O
to O
20 B-STR
mg I-STR
po B-ROU
daily B-FRE
and O
his O
SBP O
remained O

 O
100 O
- O
130 O
. O

 O
. O

 O
# O
L1 O
compression O
fracture O
: O
After O
the O
patient O
fell O
, O
he O
was O

 O
complaining O
of O
low O
back O
pain O
so O
a O
L-spine O
Xray O
was O
performed O
and O

 O
showed O
L1 O
compressin O
fracture O
with O
No O
cord O
impingement O
on O

 O
imaging O
. O
  O
The O
patient O
had O
no O
localizing O
deficits O
on O
serial O
neuro O

 O
exam O
. O
  O
He O
was O
treated O
with O
pain B-REA
medication O
including O
low B-DOS
dose I-DOS

 I-DOS
ultram B-DRUG
, I-DRUG
standing B-DUR
tylenol B-DRUG
and O
a O
lidocaine B-DRUG
patch B-FOR
. I-FOR
  O
Calcitonin B-DRUG
was O

 O
tried O
for O
pain B-REA
with O
compression O
fracture O
but O
this O
did O
not O
seem O

 O
to O
help O
with O
symptoms O
so O
was O
discontinued O
. O

 O
. O

 O
# O
Leukocytosis O
: O
WBC O
> O
20 O
  O
persistently O
in O
the O
MICU O
even O
after O

 O
being O
treated O
for O
infection O
. O
  O
Since O
no O
new O
infection O
was O
found O

 O
this O
was O
presumed O
[ O
* O
* O
12 O
- O
26 O
* O
* O
] O
steroids B-DRUG
and O
the O
leukocytosis B-ADE
improved O

 O
with O
prednisone B-DRUG
taper O
. O
  O
WBC O
12 O
on O
day O
of O
discharge O

 O
. O

 O
# O
Hyperglycemia B-ADE
: I-ADE
Patient O
is O
not O
known O
to O
be O
a O
diabetic O
and O
was O

 O
felt O
[ O
* O
* O
12 O
- O
26 O
* O
* O
] O
steroids B-DRUG
, I-DRUG
  O
his O
sugars O
were O
controlled O
on O
sliding B-DOS
scale I-DOS

 I-DOS
insulin B-DRUG
in O
the O
hospital O
but O
he O
no O
longer O
had O
insulin B-DRUG

 I-DRUG
requirements O
as O
his O
prednisone B-DRUG
was O
tapered O
. O

 O
. O

 O
# O
. O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
: O
Cr O
1.9 O
on O
[ O
* O
* O
3 O
- O
18 O
* O
* O
] O
from O
1.2 O
which O
improved O
to O
1.4 O
on O
[ O
* O
* O
3 O
- O
19 O
* O
* O
] O

 O
with O
decreasing O
ACE B-DRUG
and O
500cc O
bolus O
. O
He O
should O
have O
repeat O

 O
creatinine O
and O
labs O
on O
[ O
* O
* O
3 O
- O
22 O
* O
* O
] O
to O
ensure O
stability O
. O


 O
# O
Guardianship O
: O
Guardianship O
paperwork O
was O
started O
in O
the O

 O
hospital O
. O


 O
Medications O
on O
Admission O
: O

 O
Carvedilol B-DRUG
25 B-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Lasix B-DRUG
80 B-STR
mg I-STR
po B-ROU
bid B-FRE

 I-FRE
Xanax B-DRUG
0.25 B-STR
mg I-STR
1 B-DOS
- I-DOS
2 I-DOS
tabs B-FOR
prn B-DUR

 I-DUR
albuterol B-DRUG
MDI B-FOR

 I-FOR
Ibuprofen B-DRUG
prn B-DUR

 I-DUR
Benadryl B-DRUG
prn B-DUR

 I-DUR
Advair B-DRUG
diskus B-FOR

 I-FOR
Lsinopril B-DRUG
40 B-STR
daily B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
bisacodyl B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed B-DUR
Release I-DUR
( O
E.C. O
) O
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed B-DUR
Release I-DUR
( O
E.C. O
) O
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
as B-FRE
needed I-FRE
for O

 O
Constipation B-REA
. I-REA

 O
2 O
. O
senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
Constipation B-REA
. I-REA

 O
3 O
. O
acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE

 I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain/fever B-REA
. I-REA

 O
4 O
. O
carvedilol B-DRUG
12.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 I-FRE
5 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID O
( O
2 O

 O
times O
a O
day O
) O
. O

 O
6 O
. O
furosemide B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
lisinopril B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
8 O
. O
olanzapine B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
Sig O
: O
[ O
* O
* O
11 O
- O
25 O
* O
* O
] O
Tablet B-FOR
, I-FOR
Rapid I-FOR

 I-FOR
Dissolves I-FOR
PO B-ROU
QHS B-FRE
( I-FRE
once I-FRE
a I-FRE
day I-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
sleep B-REA
. I-REA



 O
9 O
. O
calcium B-DRUG
carbonate I-DRUG
200 B-STR
mg I-STR
( I-STR
500 I-STR
mg I-STR
) I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
cholecalciferol B-DRUG
( O
vitamin O
D3 O
) O
400 B-STR
unit I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
11 O
. O
acetaminophen B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( O
3 O

 O
times O
a O
day O
) O
as B-FRE
needed I-FRE
for O
pain/fever B-REA
. I-REA

 O
12 O
. O
lidocaine B-DRUG
5 B-STR
% I-STR
( I-STR
700 I-STR
mg/patch I-STR
) I-STR
Adhesive B-FOR
Patch I-FOR
, I-FOR
Medicated I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Adhesive B-FOR
Patch I-FOR
, I-FOR
Medicated I-FOR
Topical B-ROU
DAILY B-FRE
( O
Daily O
) O
: O
12 B-FRE

 I-FRE
hours I-FRE
on I-FRE
and I-FRE
12 I-FRE
hours I-FRE
off I-FRE
every O
24 B-FRE
hour I-FRE
period I-FRE
. I-FRE

 O
13 O
. O
ipratropium B-DRUG
bromide I-DRUG
0.02 B-STR
% O
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
neb B-FOR

 I-FOR
Inhalation B-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
. I-FRE

 O
14 O
. O
albuterol B-DRUG
sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( I-STR
0.083 I-STR
% I-STR
) I-STR
Solution B-FOR
for O

 O
Nebulization B-ROU
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
neb B-FOR
Inhalation B-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
. I-FRE

 O
15 O
. O
albuterol B-DRUG
sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( I-STR
0.083 I-STR
% I-STR
) I-STR
Solution B-FOR
for O

 O
Nebulization B-ROU
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
neb B-FOR
Inhalation B-ROU
Q2H B-FRE
( I-FRE
every I-FRE
2 I-FRE
hours I-FRE
) I-FRE
as I-FRE

 I-FRE
needed I-FRE
for O
SOB B-REA
. I-REA

 O
16 O
. O
topiramate B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
for B-DUR
3 I-DUR
days I-DUR
: I-DUR
1 O
[ O
* O
* O
Hospital1 O
* O
* O
] O
until O
[ O
* O
* O
3 O
- O
22 O
* O
* O
] O
PM O
then O
increase O
to O
2 B-DOS

 I-DOS
tablets B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
for B-DUR
7 I-DUR
days I-DUR
then O
3 B-DOS
tablets B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
ongoing B-FRE
. I-FRE

 O
17 O
. O
tramadol B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
back B-REA
pain I-REA
. I-REA

 O
18 O
. O
fluticasone-salmeterol B-DRUG
250 B-STR
- I-STR
50 I-STR
mcg/dose I-STR
Disk B-FOR
with I-FOR
Device I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
inh B-FOR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( B-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
19 O
. O
lorazepam B-DRUG
2 B-STR
mg/mL I-STR
Syringe B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
mg I-DOS
Injection B-ROU
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
as I-FRE
needed I-FRE
for O
seizure B-REA
that O
last O
longer B-REA
than I-REA
5 I-REA
minutes I-REA
. I-REA



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
979 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
246 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Anoxic O
Brain O
Injury O
s/p O
PEA O
arrest O
x2 O

 O
Status O
Asthmaticus O

 O
Ventilator O
Associated O
Pneumonia O

 O
Chronic O
Systolic O
Heart O
Failure O

 O
L1 O
compression O
fracture O

 O
Seizures O
after O
hypoxic O
brain O
injury O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Confused O
- O
sometimes O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
requires O
assistance O
or O
aid O
( O
walker O

 O
or O
cane O
) O
because O
he O
has O
poor O
motor O
planning O



 O

Discharge O
Instructions O
: O

 O
You O
came O
to O
the O
hospital O
after O
having O
a O
cardiac O
arrest O
and O
an O

 O
asthma O
exacerbation O
. O
  O
You O
had O
another O
cardiac O
arrest O
in O
our O

 O
hospital O
and O
were O
admitted O
to O
the O
MICU O
. O
  O
You O
required O
intubation O

 O
but O
were O
able O
to O
wean O
off O
the O
machine O
and O
breathe O
on O
your O
own O
. O

 O
We O
treated O
you O
for O
pneumonia O
and O
asthma O
. O
  O
Your O
mental O
status O

 O
slowly O
improved O
, O
though O
you O
did O
have O
2 O
seizures B-REA
, I-REA
last O
on O
[ O
* O
* O
3 O
- O
18 O
* O
* O
] O
. O

 O
You O
were O
started O
ons B-DRUG
eizure I-DRUG
medications I-DRUG
for O
this O
. O

 O
. O

 O
Please O
take O
your O
medications O
as O
prescribed O
and O
follow O
up O
with O

 O
your O
doctors O
[ O
* O
* O
Name5 O
( O
PTitle O
) O
7928 O
* O
* O
] O
. O


 O
Followup O
Instructions O
: O

 O
Department O
: O
PULMONARY O
FUNCTION O
LAB O

 O
When O
: O
WEDNESDAY O
[ O
* O
* O
2115 O
- O
4 O
- O
3 O
* O
* O
] O
at O
1:10 O
PM O

 O
With O
: O
PULMONARY O
FUNCTION O
LAB O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
609 O
* O
* O
] O

 O
Building O
: O
[ O
* O
* O
Hospital6 O
29 O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O


 O
Department O
: O
MEDICAL O
SPECIALTIES O

 O
When O
: O
WEDNESDAY O
[ O
* O
* O
2115 O
- O
4 O
- O
3 O
* O
* O
] O
at O
1:30 O
PM O

 O
With O
: O
DR O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
/DR O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
612 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O


 O
Department O
: O
COGNITIVE O
NEUROLOGY O
UNIT O

 O
When O
: O
THURSDAY O
[ O
* O
* O
2115 O
- O
4 O
- O
11 O
* O
* O
] O
at O
1 O
PM O

 O
With O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
6403 O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1690 O
* O
* O
] O

 O
Building O
: O
Ks O
[ O
* O
* O
Hospital O
Ward O
Name O
860 O
* O
* O
] O
Building O
( O
[ O
* O
* O
Hospital O
Ward O
Name O
1826**]/[**Hospital O
Ward O
Name O
1827 O
* O
* O
] O
Complex O
) O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
Main O
Garage O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2172 O
- O
4 O
- O
19 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2172 O
- O
4 O
- O
24 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2105 O
- O
9 O
- O
27 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
NEUROLOGY O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
5341 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Nausea O
/ O
Vomiting O
/ O
Fatigue O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2172 O
- O
4 O
- O
21 O
* O
* O
] O
: O
S/p O
Left O
temporal-parietal O
crani O
for O
tumor O
resection O



 O
History O
of O
Present O
Illness O
: O

 O
Mr O
[ O
* O
* O
Known O
lastname O
97968 O
* O
* O
] O
is O
a O
66 O
year-old O
male O
with O
a O
history O
of O
lung O

 O
cancer O
, O
a O
left O
internal O
capsule O
stroke O
and O
left O
temporal O
grade O

 O
III O
infiltrating O
astrocytoma O
presented O
to O
the O
emergency O
room O

 O
this O
afternoon O
with O
multiple O
complaints O
. O
He O
is O
lethargic O
and O

 O
aphasic O
- O
history O
obtained O
primarily O
from O
his O
daughter O
who O

 O
accompanied O
him O
to O
the O
emergency O
room O
. O
Briefly O
he O
was O
diagnosed O

 O
with O
two O
seperate O
primaries O
last O
year O
( O
lung O
adenocarcinoma O

 O
treated O
with O
a O
lobectomy O
and O
an O
astrocytoma O
) O
. O
He O
was O
on O
high B-DOS

 I-DOS
dose I-DOS
steroid B-DRUG
therapy O
to O
reduce B-REA
the I-REA
cerebral I-REA
edema I-REA
and O
developed O

 O
a O
myopathy B-ADE
which O
prompted O
the O
gradual B-DOS
tapering I-DOS
of O
his O
steroids B-DRUG
. I-DRUG

 O
He O
was O
recently O
enrolled O
in O
the O
Xerecept B-DRUG
clinical O
trial O
and O
his O

 O
decadron B-DRUG
dose O
was O
reduced O
from O
12 B-STR
mg I-STR
qd B-FRE
down O
to O
6 B-STR
mg I-STR
qd B-FRE
. I-FRE
His O

 O
daughter O
notes O
that O
since O
the O
reduction O
of O
the O
steroids B-DRUG
he O
has O

 O
had O
become O
increasingly O
lethargic O
and O
fatigued O
. O
In O
addition O
, O
she O

 O
notes O
that O
over O
the O
past O
24 O
hours O
he O
has O
had O
several O
episodes O
of O

 O
urinary O
incontinence O
and O
emesis O
. O
She O
also O
notes O
he O
has O
had O

 O
increasing O
difficulty O
walking O
and O
performing O
his O
basic O
tasks O
. O

 O
His O
daughter O
reports O
that O
he O
has O
been O
drinking O
but O
has O
had O
a O

 O
decreased O
appetite O
over O
the O
past O
48 O
hours O
. O


 O
Review O
of O
Systems O
: O
Pt O
not O
able O
to O
provide O
. O
He O
was O
recently O

 O
diagnosed O
with O
a O
right B-REA
lower I-REA
extremity I-REA
DVT I-REA
for O
which O
he O
was O

 O
started O
on O
lovenox B-DRUG
therapy O
. O
Accoring O
to O
his O
daughter O
no O
chest O

 O
pain O
, O
shortness O
of O
breath O
or O
syncopal O
episodes O
today O
. O
She O
feels O

 O
the O
swelling O
in O
the O
lower O
leg O
is O
mildly O
improved O
todya O
on O
exam O
. O


 O
ER O
course O
- O
CT O
of O
head O
demonstrated O
increasing O
midline O
shift O

 O
leftward O
from O
the O
MRI O
done O
in O
[ O
* O
* O
2172 O
- O
2 O
- O
20 O
* O
* O
] O
; O
worsening O
edema O
; O
mass O

 O
effect O
on O
left O
ventricle O
; O
displacement O
of O
ipsilateral O
lateral O

 O
ventricle O
although O
degree O
of O
herniation O
has O
increased O
; O

 O
progressive O
left O
peduncle O
herniation O
. O
Pt O
discussed O
with O
Dr O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
724 O
* O
* O
] O

 O
and O
given O
dose O
of O
Dexadron B-DRUG
( O
10 B-STR
mg I-STR
IV B-ROU
) I-ROU
. O



 O

Past O
Medical O
History O
: O

 O
1 O
. O
Astrocytoma B-REA
, I-REA
grade I-REA
III I-REA
: I-REA
  O
Now O
, O
status-post O
: O

    O
- O
Open O
Brain O
Biopsy O
on O
[ O
* O
* O
2171 O
- O
7 O
- O
11 O
* O
* O
] O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O

    O
- O
Cyberknife O
SRS O
[ O
* O
* O
2171 O
- O
10 O
- O
2 O
* O
* O
] O
to O
left O
temporal O
area O
to O
1800 O
cGy O

    O
- O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
+ O
Navelbine B-DRUG
started O
[ O
* O
* O
2171 O
- O
10 O
- O
3 O
* O
* O
] O
for O
3 B-DOS
cycles I-DOS

    I-DOS
- O
Involved-field O
radiation O
( O
3.5 O
wks O
) O
+ O
Temodar B-DRUG
12 O
- O
1/04/07 O

 O
2 O
. O
Lung O
cancer O
: O
  O
Poorly O
differentiated O
adenocarcinoma O

    O
- O
VAT O
lobectomy O
[ O
* O
* O
2171 O
- O
8 O
- O
23 O
* O
* O
] O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O

 O
3 O
. O
Left O
eye O
surgery O
related O
to O
a O
wire O
injury O
. O

 O
4 O
. O
CVA O
( O
[ O
* O
* O
2171 O
- O
6 O
- O
20 O
* O
* O
] O
) O
: O
internal O
capsule O
stroke O
with O
residual O

 O
neurological O
deficits O
including O
aphasia O

 O
5 O
. O
DVT O



 O
Social O
History O
: O

 O
He O
lives O
with O
his O
wife O
. O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
turned O
his O
business O
in O
acoustic O

 O
ceilings O
over O
to O
his O
son O
. O
His O
daughter O
works O
in O
administration O

 O
at O
the O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
emergency O
department O
. O



 O
Family O
History O
: O

 O
Father O
- O
cerebral O
hemorrhage O

 O
Sister O
- O
stroke O

 O
Brother O
- O
heart O
disease O

 O
Mother O
- O
HTN O
. O




 O
Physical O
Exam O
: O

 O
vitals O
: O
BP O
114/68 O
, O
P-106 O
, O
R-20 O
and O
T-97 O

 O
gen O
- O
old O
male O
appears O
stated O
age O
; O
lethrgic O
on O
exam O
and O
answers O

 O
questions O
with O
" O
yes O
/ O
no O
" O
appropriately O
; O
oriented O
to O
person O
and O

 O
place O
; O
speech O
is O
mildly O
slurred O
with O
word O
finding O
difficulty O

 O
heent O
- O
clear O
OP O
; O
no O
conjunctival O
palor O

 O
cv O
- O
regular O
rate O
with O
a O
normal O
S1,S2 O
. O
No O
m/g O
or O
rub O
apparent O
on O

 O
exam O
. O

 O
lungs O
- O
clear O
to O
auscultation O
bilaterally O
without O
wheeze O
, O
rale O

 O
or O
rhonchi O
. O

 O
abdomen O
- O
soft O
, O
non-tender O
, O
non-distended O
. O
Normal O
bowel O
sounds O

 O
extremities O
- O
edema O
bilaterlly O
( O
R O
> O
L O
) O
in O
the O
lower O
extremities O

 O
skin O
- O
pink O
with O
normal O
turgor O

 O
neuro O
- O
right O
pupil O
is O
4mm-->2 O
mm O
and O
reactive O
; O
left O
pupil O
is O

 O
fixed O
and O
dilated O
( O
old O
) O
; O
mild O
right O
facial O
droop O
; O
palate O
and O

 O
tongue O
are O
midline O
; O
sensation O
is O
intact O
throughout O
; O
3+/5 O

 O
strength O
in O
RUE/RLE O
; O
[ O
* O
* O
5 O
- O
23 O
* O
* O
] O
otherwise O



 O
Pertinent O
Results O
: O

 O
ADMIT O
LABS O
( O
[ O
* O
* O
2172 O
- O
4 O
- O
19 O
* O
* O
] O
) O


 O
CBC O
: O

 O
WBC-7.0 O
# O
RBC-3.13 O
* O
HGB-10.8 O
* O
HCT-30.8 O
* O
MCV-98 O
MCH-34.4 O
* O

 O
MCHC-35.0 O
RDW-15.0 O

 O
NEUTS-65.0 O
LYMPHS-30.4 O
MONOS-3.7 O
EOS-0.3 O
BASOS-0.7 O
  O
MACROCYT-1 O
+ O



 O
CHEMISTRIES O
: O

 O
GLUCOSE-101 O
NA+-139 O
K+-4.2 O
CL--109 O
TCO2 O
- O
21 O
CREAT-1.3 O
* O


 O
CT O
HEAD O
( O
[ O
* O
* O
2172 O
- O
4 O
- O
20 O
* O
* O
] O
) O
: O

 O
1 O
. O
Worsening O
vasogenic O
edema O
and O
midline O
shift O
( O
subfalcine O

 O
heriation O
) O
secondary O
to O
large O
known O
GBM O
. O
There O
is O
similar O

 O
effacement O
of O
the O
ipsilateral O
lateral O
ventrical O
, O
although O
the O

 O
degree O
of O
subfalcine O
herniation O
has O
increased O
. O

 O
2 O
. O
There O
is O
increased O
sulcal O
effacement O
of O
the O
suprasellar O

 O
cistern O
and O
ambient O
cisterns O
on O
the O
left O
, O
indicating O
progressive O

 O
left O
uncal O
herniation O
with O
early O
transtentorial O
migration O
. O

 O
3 O
. O
Hypodensity O
within O
the O
left O
cerebral O
peduncle O
, O
likely O

 O
corresponds O
to O
signal O
abnormality O
noted O
on O
MRI O
from O
[ O
* O
* O
2172 O
- O
3 O
- O
16 O
* O
* O
] O
. O


 O
MRI O
BRAIN O
( O
[ O
* O
* O
2172 O
- O
4 O
- O
20 O
* O
* O
] O
) O
: O

 O
New O
left O
to O
right O
subfalcine O
and O
left O
uncal O
herniation O

 O
associated O
with O
a O
dramatic O
increase O
in O
peritumoral O
edema O

 O
surrounding O
a O
left O
temporal O
lobe O
lesion O
. O
The O
lesion O
itself O
is O

 O
only O
slightly O
increased O
in O
size O
. O
Slow O
diffusion O
in O
small O
focal O

 O
areas O
in O
this O
lesion O
suggests O
infarction O
. O
However O
, O
focal O
areas O

 O
of O
necrosis O
may O
produce O
this O
effect O
. O
Enhancement O
and O
FLAIR O

 O
signal O
hyperintensity O
along O
the O
sulci O
in O
the O
left O
cerebral O

 O
hemisphere O
are O
concerning O
for O
leptomeningeal O
carcinomatosis O
. O

 O
This O
finding O
makes O
associated O
radiation O
necrosis O
less O
likely O
. O
If O

 O
clinically O
indicated O
, O
MR O
perfusion O
and O
Spectroscopy O
imaging O

 O
could O
be O
performed O
. O


 O
CTX O
( O
[ O
* O
* O
2172 O
- O
4 O
- O
20 O
* O
* O
] O
) O
: O

 O
Increase O
in O
the O
right O
pleural O
effusion O
and/or O
adjacent O

 O
atelectasis O
. O
Otherwise O
, O
unchanged O
appearance O
of O
the O
post-surgery O

 O
chest O
. O



 O
Brief O
Hospital O
Course O
: O

 O
1 O
. O
Astrocytoma O
: O

 O
The O
CT O
of O
his O
demonstrated O
increasing O
midline O
shift O
along O
with O

 O
increasing O
edema O
likely O
accounting O
for O
the O
majority O
of O
his O

 O
symptoms O
. O
  O
Steroid B-DRUG
dose O
had O
been O
tapered B-DOS
recently O
given O
the O

 O
patient O
's O
steroid B-DRUG
myopathy B-ADE
. I-ADE
  O
Given O
this O
, O
he O
was O
given O
10 B-STR
mg I-STR
IV B-ROU

 I-ROU
decadrom B-DRUG
in O
the O
emergency O
room O
with O
continuation O
of O
IV B-ROU
steroids B-DRUG

 I-DRUG
thereafter O
. O



 O
He O
was O
seen O
by O
neurosurgery O
and O
taken O
to O
the O
OR O
on O
[ O
* O
* O
2172 O
- O
4 O
- O
21 O
* O
* O
] O
for O

 O
left O
temporal O
craniotomy O
for O
tumor O
debulking O
. O
  O
There O
were O
no O

 O
intraoperative O
or O
postoperative O
complications O
. O
  O
The O
patient O
was O

 O
taken O
to O
the O
trauma O
ICU O
overnight O
for O
close O
monitoring O
of O
his O

 O
neuro O
status O
and O
blood O
pressure O
. O
  O
PRN B-FRE
hydralazine B-DRUG
was O
used O
to O

 O
keep B-REA
SBP<140 I-REA
. I-REA
  O
A O
repeat O
CT O
showed O
" O
interval O
decompression O
and O

 O
improvement O
in O
the O
amount O
of O
mass O
effect O
, O
midline O
shift O
, O

 O
subfalcine O
herniation O
, O
and O
effacement O
of O
the O
left O
suprasellar O

 O
and O
ambient O
cisterns O
" O
and O
the O
patient O
remained O
without O
headache O

 O
or O
nausea/vomiting O
. O
  O
His O
speach O
aphasic O
and O
his O
right-sided O

 O
weakness O
was O
stable O
to O
mildly O
improved O
. O
  O
He O
was O
seen O
by O
physical O

 O
and O
occupational O
therapy O
and O
they O
felt O
he O
would O
benefit O
from O

 O
rehab O
. O


 O
At O
the O
time O
of O
discharge O
, O
the O
plan O
was O
for O
: O

 O
- O
Continued O
dexamethasone B-DRUG
, I-DRUG
with O
taper B-DOS

 I-DOS
- O
Follow-up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
4253 O
* O
* O
] O
on O
[ O
* O
* O
5 O
- O
5 O
* O
* O
] O
for O
chemotherapy B-DRUG

 I-DRUG
- O
Monitoring O
of O
mental O
status O

 O
- O
Metoprolol B-DRUG
was O
started O
for O
blood B-REA
pressure I-REA
control I-REA


 I-REA
2 O
. O
Steroid B-DRUG
Myopathy B-ADE
: I-ADE

 O
Patient O
had O
a O
history O
of O
steroid B-DRUG
induced O
myopathy B-ADE
and O
had O

 O
presented O
with O
an O
ongoing O
steroid B-DRUG
taper B-DOS
. I-DOS
  O
Given O
the O
amount O
of O

 O
edema B-ADE
seen O
and O
the O
symptoms O
secondary O
to O
this O
, O
steroids B-DRUG
were O

 O
increased O
at O
the O
time O
of O
admission O
and O
were O
continued O
; O
upon O

 O
discharge O
, O
plan O
was O
for O
a O
steroid B-DRUG
taper B-DOS
. I-DOS
  O
As O
above O
, O
both O
PT O
and O

 O
OT O
were O
consulted O
. O


 O
3 O
. O
DVT B-REA
: I-REA

 O
Patient O
had O
recent O
history O
of O
DVT O
, O
diagnosed O
[ O
* O
* O
2172 O
- O
4 O
- O
14 O
* O
* O
] O
. O
  O
Presented O

 O
on O
daily B-FRE
lovenox B-DRUG
, I-DRUG
which O
was O
held O
before O
surgery O
. O

 O
Post-operatively O
, O
the O
lovenox B-DRUG
was O
held O
for O
two O
days O
and O
resumed O

 O
on O
discharge O
. O


 O
4 O
. O
Lung O
cancer O
: O

 O
Was O
status-post O
lobectomry O
. O
  O
This O
issue O
was O
stable O
during O

 O
admission O
. O



 O
Medications O
on O
Admission O
: O

 O
Zoloft B-DRUG
100 B-STR
mg I-STR
HS B-FRE

 I-FRE
Keppra B-DRUG
1000 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Aggrenox B-DRUG
200/25 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Zocor B-DRUG
20 B-STR
mg I-STR
HS B-FRE

 I-FRE
Senna-C B-DRUG
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Colace B-DRUG
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Protonix B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
Lovenox B-DRUG
100 B-STR
mg I-STR
qd B-FRE

 I-FRE
Decadron B-DRUG
4 B-STR
mg I-STR
TID B-FRE
( O
? O
) O

 O
Decadron B-DRUG
4 B-STR
mg I-STR
qam B-FRE
and O
2 B-STR
mg I-STR
qpm B-FRE
( O
? O
) O

 O
Ativan B-DRUG
PRN B-FRE



 I-FRE

Discharge O
Medications O
: O

 O
1 O
. O
Sertraline B-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Levetiracetam B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Simvastatin B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Trimethoprim-Sulfamethoxazole B-DRUG
160 B-STR
- I-STR
800 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Insulin B-DRUG
Lispro I-DRUG
( I-DRUG
Human I-DRUG
) I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Subcutaneous B-ROU
ASDIR O
( O
AS O
DIRECTED O
) O
: O
Please O
see O
attached O
sliding B-DOS

 I-DOS
scale I-DOS
. I-DOS


 O
To O
be O
used O
while O
on O
steroids B-DRUG
. I-DRUG

 O
9 O
. O
Dexamethasone B-DRUG
4 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
: I-FRE
Taper O
as O
follows O
: O

 O
8 B-STR
mg I-STR
TID B-FRE
( O
[ O
* O
* O
Date O
range O
( O
1 O
) O
42062 O
* O
* O
] O
) O

 O
6 B-STR
mg I-STR
TID B-FRE
( O
[ O
* O
* O
Date O
range O
( O
1 O
) O
42063 O
* O
* O
] O
) O

 O
4 B-STR
mg I-STR
TID B-FRE
thereafter O
. O

 O
10 O
. O
Oxycodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
325 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR

 I-FOR
PO B-ROU
Q4 B-FRE
- I-FRE
6H I-FRE
( I-FRE
every I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
11 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Lovenox B-DRUG
80 B-STR
mg/0.8 I-STR
mL I-STR
Syringe B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Subcutaneous B-ROU

 I-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
979 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
246 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
1 O
. O
Anaplastic O
astrocytoma O


 O
Secondary O
: O

 O
1 O
. O
Poorly O
differentiated O
adenocarcinoma O
of O
the O
lung O

 O
2 O
. O
History O
of O
cerebral O
vascular O
accident O

 O
3 O
. O
Deep O
venous O
thrombosis O



 O
Discharge O
Condition O
: O

 O
Hemodynamically O
stable O
; O
persistent O
aphasia O
and O
right-sided O

 O
weakness O
. O


 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
with O
mental O
status O
change O
weakness O
and O

 O
underwent O
a O
surgery O
to O
remove O
a O
mass O
in O
the O
left O
temporal O
lobe O

 O
of O
your O
brain O
. O
  O
It O
will O
be O
extremely O
important O
for O
you O
to O

 O
continue O
with O
rehab O
and O
to O
keep O
all O
your O
future O
appointments O

 O
with O
your O
oncologist O
and O
other O
care O
givers O
. O



 O
Followup O
Instructions O
: O

 O
You O
have O
the O
following O
appiontments O
scheduled O
: O


 O
1 O
. O
[ O
* O
* O
Doctor O
First O
Name O
5005 O
* O
* O
] O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
44 O
* O
* O
] O
Date/Time:[**2172 O
- O
5 O
- O
5 O
* O
* O
] O

 O
9:00 O

 O
2 O
. O
CAT O
SCAN O
Phone:[**Telephone/Fax O
( O
1 O
) O
327 O
* O
* O
] O
Date/Time:[**2172 O
- O
7 O
- O
2 O
* O
* O
] O
10:15 O

 O
3 O
. O
[ O
* O
* O
Name6 O
( O
MD O
) O
1532 O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
1533 O
* O
* O
] O
, O
MD O
Phone:[**0 O
- O
0- O
* O
* O
] O

 O
Date/Time:[**2172 O
- O
7 O
- O
2 O
* O
* O
] O
11:00 O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2185 O
- O
5 O
- O
11 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2185 O
- O
5 O
- O
25 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2120 O
- O
1 O
- O
12 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Heparin B-DRUG
Agents O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
613 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Right O
lower O
extremity O
pain O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O



 O
History O
of O
Present O
Illness O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
1794 O
* O
* O
] O
is O
a O
65 O
year-old O
male O
with O
history O
of O
recent O

 O
hospitalization O
for O
bilateral O
pulmonary O
emboli O
, O
DVTs O
, O
and O

 O
spontaneous O
intra-hepatic O
hematoma O
requiring O
massive O
transfusion O

 O
protocal O
activation O
sent O
today O
from O
PCP O
's O
office O
after O
four O
days O

 O
of O
right O
lower O
extremity O
pain O
. O
  O
Patient O
found O
to O
have O
ultrasound O

 O
evidence O
of O
a O
full O
length O
right O
lower O
extremtiy O
DVT O
. O

 O
. O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
1794 O
* O
* O
] O
was O
admitted O
from O
[ O
* O
* O
2185 O
- O
4 O
- O
23 O
* O
* O
] O
- O
[ O
* O
* O
2185 O
- O
5 O
- O
1 O
* O
* O
] O
for O
left O
sided O

 O
chest O
pain O
and O
was O
found O
to O
have O
bilateral B-REA
PEs I-REA
. I-REA
  O
Patient O
was O

 O
initially O
anticoagulated B-REA
with O
heparin B-DRUG
, I-DRUG
which O
was O
transitioned O
to O

 O
lovenox B-DRUG
and O
warfarin B-DRUG
. I-DRUG
  O
Patient O
developed O
abdominal O
pain O
and O
was O

 O
found O
on O
CT O
scan O
to O
have O
an O
intrahepatic B-REA
hematoma I-REA
with I-REA

 I-REA
extravasation I-REA
. I-REA
  O
He O
was O
taken O
to O
IR O
, O
but O
no O
active O
extravasation O

 O
was O
discovered O
and O
nothing O
was O
embolized O
. O
  O
He O
received O
4 B-DOS
units I-DOS

 I-DOS
PRBC B-DRUG
with O
massive O
transfusion O
protocol O
and O
1 B-DOS
unit I-DOS
platelets B-DRUG
. I-DRUG
  O
He O

 O
received O
additional O
2 B-DOS
units I-DOS
of O
PRBC B-DRUG
on O
day O
1 O
of O
MICU O
stay O

 O
because O
of O
hypotension B-REA
, I-REA
which O
was O
attributed O
to O
hemorrhage O
. O

 O
Transplant O
surgery O
was O
consulted O
and O
recommended O
conservative O

 O
management O
of O
intrahepatic O
hematoma O
. O
  O
MICU O
course O
was O

 O
complicated O
by O
hypoxic O
respiratory O
failure O
requiring O
intubation O
. O

  O
As O
anticoagulation B-DRUG
was O
contra-indicated O
given O
bleed O
, O
IR O
placed O

 O
IVC O
filter O
on O
[ O
* O
* O
2185 O
- O
4 O
- O
25 O
* O
* O
] O
. O
  O
Patient O
was O
discharged O
on O
no O

 O
anticoagulation B-DRUG
. I-DRUG

 O
. O

 O
Today O
patient O
presented O
to O
his O
primary O
care O
doctor O
's O
office O

 O
complaining O
of O
4 O
days O
of O
right O
lower O
extremity O
pain O
with O

 O
numbness O
in O
his O
leg O
and O
loss O
of O
sensation O
in O
his O
right O
foot O
. O

 O
The O
pain O
is O
exacerbated O
by O
direct O
pressure O
on O
his O
foot O
. O
He O
notes O

 O
pain O
extending O
from O
his O
mid O
calf O
until O
the O
top O
of O
his O
thigh O
. O

 O
. O


 O
Patient O
was O
sent O
to O
the O
emergency O
department O
. O
Initial O
vitals O

 O
were O
T O
97.9 O
, O
HR O
116 O
, O
BP O
124/85 O
, O
R O
20 O
, O
O2 B-DRUG
Sat O
98 O
% O
on O
4L B-DOS
. I-DOS
  O
He O

 O
triggered O
on O
arrival O
for O
a O
pulseless O
right O
foot O
. O
Initially O
the O

 O
emergency O
department O
was O
concerned O
for O
arterial O
compromise O
. O
An O

 O
ultrasound O
of O
the O
RLE O
showed O
evidence O
of O
a O
full B-REA
RLE I-REA
DVT I-REA
. I-REA

 O
Vascular O
surgery O
was O
consulted O
and O
felt O
that O
the O
limb O
was O

 O
non-threatened O
as O
patient O
had O
palpable O
right O
femoral O
, O
popliteal O
, O

 O
and O
DP O
pulses O
and O
recommended O
anticoagulation B-DRUG
when O
safe O
, O

 O
elevation O
of O
RLE O
, O
and O
ACE O
wrap O
. O

 O
. O

 O
In O
ED O
patient O
also O
complained O
intermittent O
, O
vague O
abdominal O

 O
pain O
. O
He O
had O
a O
CT O
Abdomen/Pelvis O
showing O
a O
stable O
liver O

 O
hematoma O
. O
  O
The O
CT O
also O
showed O
the O
IVC O
filter O
with O
clot O
extending O

 O
2.2 O
cm O
above O
the O
filter O
in O
the O
IVC O
. O
  O
Patient O
was O
evaluated O
by O

 O
transplant O
surgery O
who O
felt O
there O
was O
no O
role O
for O
surgical O

 O
intervenstion O
adn O
the O
risk/benefit O
of O
anticoagulation B-DRUG
in O
the O

 O
setting O
of O
liver O
hematoma O
should O
be O
made O
by O
primary O
team O
. O

 O
Patient O
received O
no O
medications O
or O
blood B-DRUG
. I-DRUG
He O
received O
1.5 B-DOS
L I-DOS
of O

 O
IVF B-DRUG
. I-DRUG
  O
On O
transfer O
vitals O
were O
T O
100.1 O
, O
HR O
124 O
, O
BP O
138/98 O
, O
RR O
27 O
, O

 O
O2 O
sat O
98RA O
. O

 O
. O

 O
On O
the O
floor O
, O
patient O
reports O
that O
he O
has O
leg O
pain O
from O
his O

 O
right O
mid-posterior O
calf O
extending O
up O
though O
thigh O
to O
his O
right O

 O
groin O
. O
  O
He O
has O
some O
mild O
numbness O
and O
tingling O
on O
the O
back O
of O

 O
his O
right O
calf O
. O
  O
He O
denies O
abdominal O
pain O
unless O
someone O
presses O

 O
down O
on O
his O
abdomen O
. O
  O
He O
denies O
chest O
pain O
, O
dyspnea O
, O

 O
lightheadedness O
, O
syncope O
. O
  O
His O
abdominal O
pain O
is O
improved O
from O

 O
his O
last O
admission O
. O
  O
Patient O
has O
noted O
recent O
weight O
loss O
and O

 O
decreased O
appetite O
recently O
. O
Endorses O
fatigue O
and O
weakness O
. O

 O
. O

 O
Review O
of O
systems O
: O

 O
( O
+ O
) O
Per O
HPI O

 O
( O
- O
) O
Denies O
fever O
, O
chills O
, O
night O
sweats O
. O
Denies O
headache O
, O
sinus O

 O
tenderness O
, O
rhinorrhea O
or O
congestion O
. O
Denies O
cough O
, O
shortness O
of O

 O
breath O
, O
or O
wheezing O
. O
Denies O
chest O
pain O
, O
chest O
pressure O
, O

 O
palpitations O
. O
Denies O
nausea O
, O
vomiting O
, O
diarrhea O
, O
constipation O
, O

 O
abdominal O
pain O
, O
or O
changes O
in O
bowel O
habits O
. O
Denies O
BRBPR O
, O

 O
melena O
. O
  O
Denies O
dysuria O
, O
frequency O
, O
or O
urgency O
. O
Denies O

 O
arthralgias O
or O
myalgias O
. O
Denies O
rashes O
or O
skin O
changes O
. O


 O
Past O
Medical O
History O
: O

 O
b/l O
Pulmonary O
Emboli O

 O
Intra-hepatic O
hematoma O

 O
[ O
* O
* O
Doctor O
Last O
Name O
933 O
* O
* O
] O
Disease O

 O
Dyslipidemia O

 O
Hypertension O



 O
Social O
History O
: O

 O
Married O
, O
lives O
with O
wife O
. O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
involved O
in O
care O

 O
Occupation O
: O
Retired O
; O
previously O
worked O
with O
animals O
and O

 O
livestock O
; O
denies O
h/o O
pesticide O
exposure O
or O
factory O
work O

 O
Tobacco O
: O
Denies O

 O
EtoH O
: O
Denies O

 O
Drugs O
: O
Denies O


 O
Family O
History O
: O

 O
No O
history O
of O
clotting O
disorders O

 O
No O
history O
malignancy O


 O
Physical O
Exam O
: O

 O
On O
Admission O
: O

 O
Vitals O
: O
T O
: O
99.6 O
BP O
: O
152/76 O
P O
: O
112 O
R O
: O
20 O
O2 O
: O
96 O
% O
on O
RA O

 O
General O
: O
Alert O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
MMM O
, O
oropharynx O
clear O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O
rales O
, O

 O
ronchi O

 O
CV O
: O
Tachycardiac O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O
gallops O
, O
no O

 O
heaves O
or O
lifts O

 O
Abdomen O
: O
soft O
, O
mild O
right O
upper O
quadrant O
and O
right O
lower O

 O
quadradant O
tenderness O
to O
palpation O
, O
non-distended O
, O
bowel O
sounds O

 O
present O
, O
no O
rebound O
tenderness O
, O
? O
guarding O
, O
no O
organomegaly O

 O
GU O
: O
no O
foley O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
right O
calf O
larger O
than O
left O
calf O
, O
[**1 O
- O
2**]+ O

 O
DP O
pulses O
on O
right O
and O
left O
, O
1 O
+ O
PT O
pulses O
, O
no O
palpable O
cords O
, O

 O
lower O
extremity O
sensation O
intact O
to O
pinprick O
and O
light O
touch O


 O
On O
Discharge O
: O

  O
Tc+Tm O
99.6 O
, O
BP O
108/86 O
( O
108 O
- O
120/70 O
- O
86 O
) O
, O
HR O
107 O
( O
96 O
- O
112 O
) O
, O
98%RA O

 O
( O
98 O
- O
100%RA O
) O

 O
General O
: O
Alert O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
MMM O
, O
oropharynx O
clear O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O
few O

 O
basilar O
rales O
, O
ronchi O

 O
CV O
: O
Tachycardiac O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O
gallops O
, O
no O

 O
heaves O
or O
lifts O

 O
Abdomen O
: O
no O
TTP O
in O
RUQ O
or O
throughout O
abdomen O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
right O
calf O
in O
ace O
bandage O
, O
[**1 O
- O
2**]+ O
DP O

 O
pulses O
on O
right O
and O
left O
, O
1 O
+ O
PT O
pulses O
, O
no O
palpable O
cords O
, O
lower O

 O
extremity O
sensation O
intact O
to O
light O
touch O


 O
Pertinent O
Results O
: O

 O
Admission O
labs O
: O

 O
[ O
* O
* O
2185 O
- O
5 O
- O
11 O
* O
* O
] O
07:30PM O
BLOOD O
WBC-10.8 O
RBC-3.79 O
* O
Hgb-11.6 O
* O
Hct-32.4 O
* O

 O
MCV-85 O
MCH-30.6 O
MCHC-35.9 O
* O
RDW-14.4 O
Plt O
Ct-247 O

 O
[ O
* O
* O
2185 O
- O
5 O
- O
11 O
* O
* O
] O
07:30PM O
BLOOD O
Neuts-88.4 O
* O
Lymphs-7.2 O
* O
Monos-3.9 O
Eos-0.2 O

 O
Baso-0.3 O

 O
[ O
* O
* O
2185 O
- O
5 O
- O
11 O
* O
* O
] O
07:30PM O
BLOOD O
PT-13.9 O
* O
PTT-24.7 O
INR(PT)-1.2 O
* O

 O
[ O
* O
* O
2185 O
- O
5 O
- O
11 O
* O
* O
] O
07:30PM O
BLOOD O
Glucose-122 O
* O
UreaN-20 O
Creat-1.0 O
Na-133 O

 O
K-4.5 O
Cl-99 O
HCO3 O
- O
22 O
AnGap-17 O



 O
RLE O
Ultrasound O
: O

 O
IMPRESSION O
: O
Vein O
thrombosis O
seen O
throughout O
the O
entire O
extent O
of O

 O
the O
right O

 O
lower O
extremity O
. O
Dampened O
waveforms O
in O
contralateral O
left O
common O

 O
femoral O
vein O
are O
suggestive O
of O
more O
proximal O
thrombosis O
. O


 O
CTA O
Aorta O
, O
Bifem O
, O
Iliac O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Patent O
three-vessel O
runoff O
. O

 O
2 O
. O
Findings O
in O
the O
abdomen O
and O
pelvis O
, O
including O
subcapsular O

 O
liver O
hematoma O
and O
IVC O
thrombus O
extending O
into O
the O
right O
common O

 O
iliac O
, O
external O
iliac O
, O
and O
likely O
common O
femoral O
veins O
as O
well O

 O
as O
possibly O
into O
the O
left O
common O
iliac O
vein O
, O
better O
assessed O
on O

 O
CT O
abdomen/pelvis O
performed O
just O
prior O
to O
this O
, O
on O
[ O
* O
* O
2185 O
- O
5 O
- O
11 O
* O
* O
] O
at O

 O
21:50 O
, O
see O
that O
report O
. O

 O
3 O
. O
Apparent O
diffuse O
wall O
thickening O
of O
the O
urinary O
bladder O
may O

 O
relate O
to O
its O
underdistension O
, O
however O
, O
recommend O
correlation O

 O
with O
urinalysis O
to O
exclude O
underlying O
infection O
. O

 O
4 O
. O
Enlarged O
prostate O
gland O
; O
recommend O
correlation O
with O
serum O
PSA O

 O
if O
this O
has O
not O
already O
been O
performed O
. O


 O
CT O
Abdomen/Pelvis O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
17 O
x O
19 O
x O
6 O
cm O
subcapsular O
liver O
hematoma O
, O
which O
appears O

 O
stable O
compared O
to O
the O
[ O
* O
* O
Month O
( O
only O
) O
547 O
* O
* O
] O
examination O
. O
Active O
extravasation O

 O
does O
not O
appear O
present O
, O
but O
is O
limited O
on O
this O
single-phase O

 O
study O
. O

 O
2 O
. O
IVC O
filter O
with O
a O
clot O
extending O
cephalad O
2.2 O
cm O
above O
the O

 O
top O
of O
the O

 O
filter O
. O
However O
, O
thrombus O
does O
not O
extend O
into O
the O
renal O
veins O
. O

 O
Occlusive O

 O
thrombus O
into O
the O
right O
common O
iliac O
internal O
and O
external O

 O
iliacs O
and O
common O
femoral O
vein O
. O
There O
may O
be O
partially O
occlusive O

 O
thrombus O
in O
the O
left O
common O
iliac O
. O


 O
Labs O
on O
Discharge O
: O


 O
[ O
* O
* O
2185 O
- O
5 O
- O
25 O
* O
* O
] O
08:32AM O
BLOOD O
WBC-8.6 O
RBC-4.02 O
* O
Hgb-11.1 O
* O
Hct-34.0 O
* O

 O
MCV-85 O
MCH-27.7 O
MCHC-32.7 O
RDW-15.5 O
Plt O
Ct-460 O
* O

 O
[ O
* O
* O
2185 O
- O
5 O
- O
19 O
* O
* O
] O
06:35AM O
BLOOD O
Glucose-87 O
UreaN-19 O
Creat-1.1 O
Na-135 O

 O
K-4.9 O
Cl-101 O
HCO3 O
- O
24 O
AnGap-15 O

 O
[ O
* O
* O
2185 O
- O
5 O
- O
20 O
* O
* O
] O
06:30AM O
BLOOD O
LD(LDH)-798 O
* O

 O
[ O
* O
* O
2185 O
- O
5 O
- O
19 O
* O
* O
] O
06:35AM O
BLOOD O
Calcium-8.4 O
Phos-2.7 O
Mg-2.4 O


 O
Brief O
Hospital O
Course O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
1794 O
* O
* O
] O
is O
a O
65 O
year-old O
man O
with O
h/o O
recent O
hospitalization O

 O
and O
MICU O
stay O
for O
bilateral O
pulmonary O
embolism O
complicated O
by O

 O
spontaneous O
intra-hepatic O
hemorrhage O
presenting O
on O
this O

 O
admission O
with O
RLE O
pain O
and O
numbness O
found O
to O
have O
full O
length O

 O
RLE O
DVT O
. O

 O
. O


 O
# O
Right B-REA
Lower I-REA
Extremity I-REA
DVT I-REA
: I-REA
  O
Patient O
with O
history O
of O
recent O
b/l O

 O
PE O
, O
complicated O
by O
intra-hepatic O
hematoma O
on O
anticoagulation B-DRUG
. I-DRUG

 O
Patient O
discharged O
home O
on O
recent O
prior O
admission O
with O
IVC O

 O
filter O
, O
not O
on O
anticoagulation O
. O
  O
On O
this O
admission O
, O
patient O

 O
found O
to O
have O
a O
large O
RLE O
DVT O
. O
  O
Patient O
with O
palpable O
peripheral O

 O
pulses O
bilaterally O
. O
  O
Evaluated O
by O
vascular O
surgery O
in O
ED O
, O
who O

 O
felt O
that O
his O
RLE O
was O
non-threatened O
and O
no O
surgical O

 O
intervention O
was O
required O
. O
  O
Given O
the O
risk O
of O
extension O
of O
DVT B-REA

 I-REA
to O
the O
point O
where O
vascular O
compromise O
could O
be O
reached O
, O
as O
well O

 O
as O
the O
risk O
of O
further O
extending O
PEs O
, O
we O
cautiously O

 O
anticoagulated B-DRUG
the O
patient O
with O
careful O
monitoring O
for O
fear O
that O

 O
the O
pt O
would O
patient O
have O
another O
hepatic O
bleed O
. O
Patient O
was O

 O
admitted O
to O
ICU O
and O
anticoagulation B-REA
was O
started O
with O
heparin B-DRUG
gtt B-ROU

 I-ROU
with O
goal O
of O
60 O
- O
80 O
. O
  O
Patient O
reached O
the O
therapeutic O
level O
and O

 O
his O
HCT O
remained O
stable O
. O
  O
Serial O
vascular O
exams O
were O
stable O
. O

 O
The O
RLE O
was O
elevated O
and O
wrapped O
in O
ACE O
. O
  O
He O
was O
then O
sent O
to O

 O
the O
regular O
medicine O
floor O
. O
  O
However O
, O
unfortunately O
he O
then O
had O

 O
his O
platelets O
drop O
, O
and O
was O
found O
to O
have O
heparin B-DRUG
induced O

 O
thrombocytopenia B-ADE
( O
see O
below O
) O
, O
and O
was O
transitioned O
to O
argatroban B-DRUG

 I-DRUG
for O
his O
DVT B-REA
. I-REA
  O
He O
was O
then O
transitioned O
to O
coumadin B-DRUG
prior O
to O
D/C. O

  O
His O
INR O
was O
4.0 O
on O
day O
of O
discharge O
, O
and O
he O
was O
instructed O
to O

 O
follow O
up O
with O
his O
PCP O
for O
further O
monitoring O
of O
his O
INR O
with O
a O

 O
goal O
of O
between O
[ O
* O
* O
2 O
- O
3 O
* O
* O
] O
. O

 O
. O

 O
# O
Heparin B-DRUG
Induced O
Thrombocytopenia B-ADE
: I-ADE
Patient O
's O
platelets O
dropped O

 O
from O
247 O
on O
[ O
* O
* O
5 O
- O
11 O
* O
* O
] O
to O
118 O
on O
[ O
* O
* O
2185 O
- O
5 O
- O
14 O
* O
* O
] O
, O
which O
normally O
would O
not O
fit O

 O
with O
the O
traditional O
window O
for O
HIT B-ADE
, I-ADE
but O
pt O
had O
received O
heparin B-DRUG

 I-DRUG
on O
his O
prior O
admission O
also O
. O
  O
Hematology O
was O
consulted O
, O
and O

 O
recommended O
switching O
to O
argatroban B-DRUG
, I-DRUG
which O
we O
did O
. O
  O
Patient O
's O

 O
PF4 O
test O
was O
sent O
, O
and O
returned O
with O
an O
optical O
density O
of O
2.7 O
, O

 O
so O
the O
lab O
cancelled O
our O
serotonin O
release O
assay O
as O
the O
PF4 O
was O

 O
considered O
positive O
enough O
. O
  O
Patient O
was O
instructed O
to O
get O
a O

 O
heparin B-DRUG
allergy O
bracelet O
with O
help O
from O
his O
PCP O
. O

 O
. O


 O
# O
  O
Recent O
subcapsular O
hepatic O
bleed O
: O
Patient O
with O
recent O
ICU O

 O
stay O
requiring O
massive O
transfusion O
protocol O
following O

 O
spontaneous O
subcapsular B-ADE
hepatic I-ADE
bleed I-ADE
while O
on O
anticoagulation B-DRUG
. I-DRUG

 O
Patient O
discharged O
home O
from O
prior O
admission O
on O
no O

 O
anti-coagulation O
. O
  O
For O
this O
admission O
, O
imaging O
showed O
that O
his O

 O
liver O
hematoma O
had O
a O
stable O
appearance O
. O
  O
Surgery O
was O
consulted O

 O
in O
the O
ED O
and O
recommended O
no O
surgical O
intervention O
at O
this O
time O
. O

  O
Surgery O
recommended O
supportive O
care O
should O
the O
bleed O
recur O
, O
but O

 O
patient O
remained O
with O
stable O
VSs O
and O
no O
RUQ O
abdominal O
pain O
. O

 O
. O

 O
# O
Bilateral O
pulmonary O
embolism O
: O
Patient O
initially O
presented O
with O

 O
left O
sided O
chest O
and O
flank O
pain O
when O
admitted O
in O
[ O
* O
* O
2185 O
- O
4 O
- O
1 O
* O
* O
] O
. O

 O
The O
etiology O
of O
emboli O
is O
unclear O
- O
patient O
was O
discharged O
with O

 O
plan O
for O
outpatient O
hypercoagulable O
work-up O
. O
  O
Patient O
discharged O

 O
with O
IVC O
filter O
, O
not O
on O
anti-coagulation B-DRUG
. I-DRUG
  O
Concern O
for O
extension O

 O
of O
pulmonary O
embolism O
on O
this O
admission O
as O
clot O
extended O

 O
proximally O
above O
IVC O
filter O
. O
  O
Patient O
remained O
mildly O

 O
tachycardiac O
throughout O
the O
admission O
, O
but O
not O
hypoxic O
, O
dyspnic O
, O

 O
and O
did O
not O
have O
chest O
pain O
. O
  O
Patient O
's O
PE B-REA
's I-REA
were O
treated O
with O

 O
argatroban B-DRUG
when O
his O
DVT B-REA
was O
treated O
with O
argatroban B-DRUG
. I-DRUG
  O
HIT O
may O

 O
have O
contributed O
to O
extension O
of O
clots O
above O
IVC O
filter O
. O

 O
Patient O
will O
need O
outpatient O
anticoagulation B-DRUG
w/u O
, O
but O
this O
is O

 O
complicated O
by O
the O
fact O
that O
he O
is O
now O
on O
coumadin B-DRUG
for B-DUR
at I-DUR
least I-DUR

 I-DUR
6 I-DUR
months I-DUR
. I-DUR

 O
. O

 O
# O
h/o O
[ O
* O
* O
Doctor O
Last O
Name O
933 O
* O
* O
] O
disease O
: O
Previously O
followed O
by O
Endocrine O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
. O

 O
Per O
patient O
not O
receiving O
any O
treatment O
. O
Denies O
symptoms O
or O

 O
hyper/hypothyroid O
at O
this O
time O
. O
  O
TSH O
was O
wnl O
therefore O
no O

 O
intervention O
undertaken O
. O

 O
. O

 O
# O
Hypertension B-REA
: I-REA
Patient O
with O
history O
of O
hypertension O
, O
and O
was O

 O
hypertensive O
on O
admission O
. O
Patient O
had O
not O
been O
taking O

 O
lisinopril B-DRUG
since O
discharge O
. O
  O
Lisinopril B-DRUG
was O
held O
in O
the O
ICU O

 O
while O
anticoagulating B-DRUG
given O
bleeding O
risk O
, O
and O
patient O
remained O

 O
normotensive O
there O
as O
well O
as O
when O
transferred O
to O
the O
floor O
. O

 O
Therefore O
, O
we O
did O
not O
restart O
pt O
's O
lisinopril B-DRUG
at O
dispo O
and O

 O
instructed O
him O
to O
f/u O
with O
his O
PCP O
. O

 O
. O

 O
# O
Dyslipidemia B-REA
: I-REA
Simvastatin B-DRUG
10 B-STR
mg I-STR
qhs B-FRE
held O
after O
last O
admission O

 O
as O
patient O
had O
transaminitis O
likely O
[ O
* O
* O
2 O
- O
2 O
* O
* O
] O
subcapsular O
liver O
bleed O
. O

  O
LFTs O
were O
wnl O
. O
  O
Therefore O
we O
restarted O
simvastatin B-DRUG
on O
this O

 O
admission O
. O

 O
. O

 O
# O
Code O
: O
Full O
( O
discussed O
with O
patient O
) O


 O
PENDING O
LABS O
: O

 O
None O



 O
TRANSITIONAL O
CARE O
ISSUES O
: O

 O
Patient O
will O
need O
his O
INR O
monitored O
frequently O
until O
he O
is O

 O
stably O
threapeutic O
between O
2 O
and O
3 O
. O
  O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
, O
his O
new O
PCP O
was O

 O
[ O
* O
* O
Name O
( O
NI O
) O
653 O
* O
* O
] O
and O
his O
office O
agreed O
to O
follow O
pt O
's O
INR O
. O


 O
Medications O
on O
Admission O
: O

 O
None O
per O
pt O


 O
Discharge O
Medications O
: O

 O
1 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
Constipation B-REA
. I-REA

 O
3 O
. O
warfarin B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Four B-DOS
( I-DOS
4 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
: I-FRE
On O

 O
[ O
* O
* O
5 O
- O
25 O
* O
* O
] O
ONLY O
take O
7.5 B-STR
mg I-STR
( O
3 B-DOS
tabs B-FOR
) I-FOR
, O
then O
start O
this O
medication O
dose O

 O
( O
10 O
mg O
per O
day O
) O
on O
[ O
* O
* O
5 O
- O
26 O
* O
* O
] O
. O

 O
Disp:*120 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
4 O
. O
simvastatin B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
Uphams O
Corner O
Home O
Care O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O
right B-REA
lower I-REA
extremity I-REA
DVT I-REA
, I-REA
heparin-induced B-DRUG

 O
thrombocytopenia B-ADE

 I-ADE
Secondary O
: O
Pulmonay O
embolism O
, O
Hypertension O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
Dear O
Mr. O
[ O
* O
* O
Known O
lastname O
1794 O
* O
* O
] O
, O

 O
You O
were O
seen O
in O
the O
hospital O
for O
a O
blood B-REA
clot I-REA
in I-REA
your I-REA
leg I-REA
. I-REA

 O
While O
you O
were O
here O
, O
it O
was O
determined O
that O
you O
have O
an O
allergy O

 O
to O
heparin B-DRUG
. I-DRUG
  O
You O
should O
never O
be O
given O
heparin B-DRUG
in O
the O
future O
. O

 O
Please O
arrange O
with O
your O
PCP O
to O
have O
an O
allergy O
bracelet O
made O
so O

 O
that O
you O
are O
n't O
given O
heparin B-DRUG
. I-DRUG
  O
You O
were O
put O
on O
an O
oral B-ROU
blood B-REA

 I-REA
thinner I-REA
called O
coumadin B-DRUG
, I-DRUG
that O
you O
will O
have O
to O
continue O
to O
take O

 O
once O
a O
day O
until O
your O
doctors O
[ O
* O
* O
Name5 O
( O
PTitle O
) O
* O
* O
] O
[ O
* O
* O
Name5 O
( O
PTitle O
) O
* O
* O
] O
to O
stop O
taking O
it O
. O



 O
We O
made O
the O
following O
changes O
to O
your O
medications O
: O

 O
1 O
) O
We O
STARTED O
you O
on O
COUMADIN B-DRUG
( I-DRUG
WARFARIN I-DRUG
) I-DRUG
. I-DRUG
  O
You O
will O
take O
7.5 B-STR
mg I-STR

 I-STR
on O
[ O
* O
* O
5 O
- O
25 O
* O
* O
] O
, O
then O
take O
10 B-STR
mg I-STR
once B-FRE
per I-FRE
day I-FRE
starting O
on O
[ O
* O
* O
5 O
- O
26 O
* O
* O
] O
until O
Dr. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
tells O
you O
to O
change O
to O
a O
different O
dose O
. O
  O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
will O

 O
follow O
your O
coumadin B-DRUG
levels O
and O
adjust O
your O
dose O
of O
coumadin B-DRUG
as O

 O
needed O
. O
  O
If O
you O
have O
any O
questions O
, O
you O
should O
call O
him O
. O

 O
2 O
) O
We O
STOPPED O
your O
LISINOPRIL B-DRUG
because O
your O
blood O
pressure O
is O

 O
already O
well O
controlled O
on O
no O
anti-hypertensive B-DRUG
medications I-DRUG
. I-DRUG

 O
Your O
PCP O
may O
tell O
you O
to O
restart O
this O
medication O
at O
some O
point O
. O


 O
If O
you O
experience O
any O
of O
the O
below O
listed O
Danger O
Signs O
, O
or O
any O

 O
other O
new O
symptom O
, O
please O
call O
your O
doctor O
or O
go O
to O
the O
nearest O

 O
Emergency O
Room O
. O


 O
It O
was O
a O
pleasure O
taking O
care O
of O
you O
. O


 O
Followup O
Instructions O
: O

 O
Department O
: O
[ O
* O
* O
Hospital1 O
7975 O
* O
* O
] O
INTERNAL O
MEDICINE O

 O
When O
: O
FRIDAY O
[ O
* O
* O
2185 O
- O
5 O
- O
27 O
* O
* O
] O
at O
11:15 O
AM O

 O
With O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
7978 O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
7976 O
* O
* O
] O

 O
Building O
: O
[ O
* O
* O
Hospital1 O
7977 O
* O
* O
] O
( O
[ O
* O
* O
Location O
( O
un O
) O
686 O
* O
* O
] O
, O
MA O
) O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
OFF O
CAMPUS O
     O
Best O
Parking O
: O
Free O
Parking O
on O
Site O


 O
Department O
: O
HEMATOLOGY/ONCOLOGY O

 O
When O
: O
FRIDAY O
[ O
* O
* O
2185 O
- O
7 O
- O
8 O
* O
* O
] O
at O
10:00 O
AM O

 O
With O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
1730 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
5056 O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
22 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
24 O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O



                              O
[ O
* O
* O
First O
Name5 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(2 O
) O
617 O
* O
* O
] O


 O

Admission O
Date O
: O
  O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2174 O
- O
6 O
- O
7 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2099 O
- O
9 O
- O
12 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
689 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Tachypnea O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
none O



 O
History O
of O
Present O
Illness O
: O

 O
74 O
year O
old O
male O
with O
h/o O
DM O
, O
frequent O
aspiration O
, O
CVA O
( O
left O

 O
weakness O
, O
at O
baseline O
unable O
to O
converse O
) O
, O
presents O
to O
ED O
for O

 O
tachypnea O
. O


 O
Pt O
found O
at O
facility O
to O
be O
be O
congested O
, O
with O
difficulty O

 O
breathing O
. O
chief O
complaint O
of O
lung O
congestion O
, O
difficulty O

 O
breathing O
. O
Questionable O
seizure O
activity O
prior O
to O
being O
found O
. O

 O
Confirmed O
DNR/DNI O
with O
family O
but O
confirmed O
otherwise O
aggressive O

 O
care O
. O

 O
. O

 O
In O
the O
ED O
, O
initial O
vs O
were O
: O
98.4 O
105 O
159/72 O
30s-40s O
100 O
on O
3 O
- O
4L O
, O

 O
with O
eventual O
spike O
to O
101 O
rectally O
. O
Although O
CXR O
neg O
, O
exam O

 O
revealed O
diffuse O
crackles O
, O
pt O
was O
treated O
for O
possible O

 O
aspiration B-REA
pneumonia I-REA
with O
vanc B-DRUG
and O
zosyn B-DRUG
( O
levo B-DRUG
planned O
but O
not O

 O
yet O
administered O
) O
. O
Labs O
sig O
for O
WBC O
15.5 O
, O
hyperglycemia O
and O
UA O

 O
with O
SG O
1.[**Telephone/Fax O
( O
1 O
) O
59607 O
* O
* O
] O
glucose O
, O
lactate O
3.5 O
. O
Head O
CT O
ucnhanged O

 O
except O
newly O
dislocated O
lens O
in O
right O
eye O
. O
Stage O
2 O
sacral O
decub O

 O
appeared O
uninfected O
. O
EKG O
without O
ischemic O
changes O
. O

 O
. O

 O
VS O
on O
transfer O
: O
101.2 O
, O
124/56 O
, O
100 O
, O
32 O
, O
98 O
4L O


 O
Past O
Medical O
History O
: O

 O
strokes O
from O
ruptured O
intracerebral O
aneurysms O
in O
[ O
* O
* O
2160 O
* O
* O
] O
and O
[ O
* O
* O
2162 O
* O
* O
] O

 O
or O
[ O
* O
* O
2163 O
* O
* O
] O
with O
residual O
left O
sided O
deficits O
( O
has O
not O
been O
able O
to O

 O
walk O
since O
the O
stroke O
in O
' O
[ O
* O
* O
63 O
* O
* O
] O
) O
and O
aphasia O
, O
PEG O
for O
dysphagia O

 O
h/o O
seizure O
do O

 O
dementia O

 O
HTN O

 O
h/o O
HepC O
hepatitis O
, O
apparently O
not O
active O

 O
h/o O
neurosyphilis O
, O
treated O
in O
[ O
* O
* O
2163 O
* O
* O
] O

 O
hypothyroidism O



 O
Social O
History O
: O

 O
Nursing O
home O
resident O
( O
[ O
* O
* O
Hospital3 O
2558 O
* O
* O
] O
) O
since O
[ O
* O
* O
2163 O
* O
* O
] O
. O
Sent O
here O

 O
with O
no O
personal O
belongings O
. O



 O
Family O
History O
: O

 O
Noncontributory O



 O
Physical O
Exam O
: O

 O
Vitals O
: O
T O
: O
afeb O
BP O
: O
120/69 O
P O
: O
102 O
R O
: O
26 O
18 O
O2 O
: O

 O
General O
: O
NAD O

 O
HEENT O
: O
Sclera O
anicteric O
, O
PERRLA O
, O
MMM O

 O
Neck O
: O
supple O
, O
no O
LAD O

 O
Lungs O
: O
Diffuse O
ronchi O
, O
no O
resp O
distress O

 O
CV O
: O
Tachy O
, O
no O
murmurs O

 O
Abdomen O
: O
  O
soft O
, O
non-tender O
, O
non-distended O
, O
bowel O
sounds O
present O
, O

 O
no O
rebound O
tenderness O
or O
guarding O
, O
no O
organomegaly O
, O
G O
tube O
in O

 O
palce O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
no O
clubbing O
, O
cyanosis O
or O

 O
edema O

 O
Neuro O
: O
Opens O
eyes O
slightly O
to O
command O
, O
withdraws O
to O
pain O
on O

 O
right O
, O
no O
movement O
on O
left O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
12:00PM O
   O
WBC-15.5 O
* O
RBC-4.19 O
* O
HGB-12.4 O
* O
HCT-38.3 O
* O

 O
MCV-91 O
MCH-29.6 O
MCHC-32.4 O
RDW-15.0 O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
12:00PM O
   O
NEUTS-76 O
* O
BANDS-1 O
LYMPHS-12 O
* O
MONOS-10 O
EOS-0 O

 O
BASOS-0 O
ATYPS-1 O
* O
METAS-0 O
MYELOS-0 O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
12:00PM O
   O
HYPOCHROM-1 O
+ O
ANISOCYT-1 O
+ O
POIKILOCY-NORMAL O

 O
MACROCYT-NORMAL O
MICROCYT-NORMAL O
POLYCHROM-NORMAL O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
12:00PM O
   O
PLT O
SMR-NORMAL O
PLT O
COUNT-146 O
* O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
12:00PM O
   O
PTT-32.8 O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
12:00PM O
   O
cTropnT-<0.01 O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
12:00PM O
   O
GLUCOSE-327 O
* O
UREA O
N-23 O
* O
CREAT-0.9 O
SODIUM-139 O

 O
POTASSIUM-4.8 O
CHLORIDE-107 O
TOTAL O
CO2 O
- O
21 O
* O
ANION O
GAP-16 O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
12:40PM O
URINE O
  O
COLOR-Amber O
APPEAR-Clear O
SP O
[ O
* O
* O
Last O
Name O
( O
un O
) O
155**]-1.029 O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
12:40PM O
URINE O
  O
BLOOD-NEG O
NITRITE-NEG O
PROTEIN-25 O

 O
GLUCOSE-1000 O
KETONE-TR O
BILIRUBIN-NEG O
UROBILNGN-4 O
* O
PH-6.0 O

 O
LEUK-NEG O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
12:40PM O
URINE O
  O
RBC-0 O
WBC-0 O
- O
2 O
BACTERIA-FEW O
YEAST-NONE O

 O
EPI-0 O
- O
2 O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
12:40PM O
URINE O
  O
HYALINE-[**6 O
- O
30 O
* O
* O
] O
* O



 O
EEG O
: O
FINDINGS O
: O

 O
ROUTINE O
SAMPLING O
: O
The O
background O
activity O
was O
slow O
reaching O
a O

 O
maximum O

 O
of O
about O
6 O
Hz O
biposteriorly O
in O
the O
most O
awake O
parts O
of O
this O

 O
recording O
. O

 O
In O
addition O
, O
there O
was O
focal O
slowing O
in O
the O
delta O
and O
theta O

 O
range O
seen O

 O
in O
the O
right O
central O
area O
. O
There O
were O
sharp O
waves O
seen O

 O
independently O
in O

 O
the O
right O
frontal O
, O
right O
central O
parietal O
, O
as O
well O
as O
left O

 O
fronto-temporal O
areas O
. O

 O
SPIKE O
DETECTION O
PROGRAMS O
: O
Showed O
some O
of O
the O
above-mentioned O

 O
right O
and O

 O
left O
sharp O
waves O
. O

 O
SEIZURE O
DETECTION O
PROGRAMS O
: O
Captured O
periods O
of O
muscle O
artifact O

 O
as O
well O

 O
as O
blinking O
artifact O
but O
not O
ongoing O
seizure O
activity O
. O

 O
PUSHBUTTON O
ACTIVATIONS O
: O
There O
were O
no O
entries O
in O
these O
files O
. O

 O
SLEEP O
: O
The O
patient O
progressed O
from O
wakefulness O
to O
sleep O
. O
The O

 O
above-mentioned O
sharp O
waves O
were O
seen O
more O
frequently O
in O
sleep O
. O

 O
CARDIAC O
MONITOR O
: O
Showed O
a O
generally O
regular O
rhythm O
. O

 O
IMPRESSION O
: O
This O
telemetry O
captured O
no O
ongoing O
seizure O
activity O
. O


 O
Interictally O
, O
it O
captured O
epileptic O
discharges O
independently O
in O

 O
the O

 O
right O
frontal O
, O
right O
central O
parietal O
, O
and O
left O
fronto-temporal O

 O
areas O
. O

 O
The O
background O
activity O
was O
slow O
suggestive O
of O
diffuse O

 O
encephalopathy O

 O
with O
additional O
focal O
slowing O
seen O
in O
the O
right O
central O
area O

 O
suggestive O

 O
of O
subcortical O
dysfunction O
in O
that O
region O
. O


 O
CT O
Head O
: O
IMPRESSION O
: O

 O
1 O
. O
No O
acute O
intracranial O
process O
. O

 O
2 O
. O
Chronic O
left O
pontine O
lacunar O
infarct O
, O
new O
compared O
to O
[ O
* O
* O
Month O
( O
only O
) O
* O
* O
] O

 O
[ O
* O
* O
2172 O
* O
* O
] O
. O

 O
3 O
. O
Posterior O
dislocation O
of O
the O
right O
ocular O
lens O
, O
new O
since O
[ O
* O
* O
Month O
( O
only O
) O
* O
* O
] O

 O
[ O
* O
* O
2172 O
* O
* O
] O
. O


 O
CTA O
Chest O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
No O
central O
, O
segmental O
or O
large O
subsegmental O
pulmonary O

 O
embolism O
. O

 O
2 O
. O
Bibasilar O
consolidations O
, O
could O
reflect O
atelectasis O
or O

 O
pneumonia O
. O

 O
3 O
. O
Left O
thyroid O
lobe O
nodule O
. O

 O
4 O
. O
Coronary O
artery O
disease O
. O

 O
5 O
. O
Indeterminant O
right O
hepatic O
lobe O
lesion O
most O
likely O
cyst O
or O

 O
hemangioma O


 O
Micro O
: O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
5 O
* O
* O
] O
URINE O
URINE O
CULTURE O
negative O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
5 O
* O
* O
] O
URINE O
Legionella O
Urinary O
Antigen O
negative O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
5 O
* O
* O
] O
STOOL O
CLOSTRIDIUM O
DIFFICILE O
TOXIN O
A O
& O
B O

 O
TEST O
negative O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
4 O
* O
* O
] O
MRSA O
SCREEN O
MRSA O
SCREEN-positive O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
BLOOD O
CULTURE O
Blood O
Culture O
, O
pending O

 O
[ O
* O
* O
2174 O
- O
6 O
- O
3 O
* O
* O
] O
BLOOD O
CULTURE O
Blood O
Culture O
, O
pending O



 O

Brief O
Hospital O
Course O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
4587 O
* O
* O
] O
is O
a O
74 O
yo O
M O
with O
h/o O
strokes O
resultant O
in O
minimal O

 O
responsiveness O
, O
aphagia O
, O
frequent O
aspiration O
, O
who O
presented O
from O

 O
[ O
* O
* O
Hospital3 O
* O
* O
] O
with O
tachypnea O
and O
question O
of O
seizure-like O

 O
activity O
. O


 O
# O
? O
Aspiration O
Pneumonia O
: O

 O
Patient O
presented O
with O
tachypnea O
, O
fever O
, O
tachycardia O
, O
elevated O

 O
WBC O
and O
was O
admitted O
to O
the O
MICU O
. O
He O
was O
started O
empirically O
on O

 O
Vancomycin B-DRUG
and O
Zosyn B-DRUG
for O
aspiration B-REA
pneumonia I-REA
. I-REA
  O
Chest O
CT-A O
ruled O

 O
out O
PE O
, O
as O
he O
was O
not O
on O
any O
DVT O
prophylaxis O
at O
the O
nursing O

 O
facility O
. O
  O
Chest O
CT O
also O
showed O
bibasilar O
atelectasis O
vs O

 O
consolidation O
. O
Patient O
was O
transitioned O
to O
azithromycin B-DRUG
and O

 O
transferred O
to O
floor O
when O
hemodynamically O
stable O
. O
  O
On O
the O
floor O
, O

 O
he O
was O
restarted O
on O
Vancomycin B-DRUG
and O
Zosyn B-DRUG
for O
concern O
of O

 O
aspiration B-REA
pneumonia I-REA
, I-REA
re-evaluating O
bibasilar O
consolidations O
on O

 O
Chest O
CT O
, O
likely O
secondary O
to O
chronic O
aspiration O
from O
tube O

 O
feeds O
. O
  O
Pt O
was O
discharged O
bac O
kto O
the O
facility O
to O
continue O
IV B-ROU

 I-ROU
antibiotics B-DRUG
for O
a O
total O
of O
7 B-DUR
days I-DUR
. I-DUR
  O
Pt O
was O
without O
fevers O
or O

 O
leukocytosis O
at O
the O
time O
of O
discharge O
. O


 O
# O
History O
of O
Seizures B-REA
: I-REA

 O
Patient O
was O
reported O
to O
have O
had O
seizure-like O
activity O
prior O
to O

 O
presentation O
. O
Corrected O
Dilantin B-DRUG
level O
was O
within O
therapeutic O

 O
range O
. O
Pt O
was O
continued O
on O
seizure O
ppx O
, O
and O
had O
no O
clinically O

 O
evident O
seizure O
activity O
. O
A O
48 O
hr O
EEG O
was O
performed O
which O
showed O

 O
no O
seizure O
activity O
, O
only O
epileptic O
interictal O
discharges O
, O

 O
consistent O
with O
past O
stroke O
. O


 O
# O
Diabetes B-REA
Mellitus I-REA
: I-REA

 O
Patient O
was O
continued O
on O
home O
insulin B-DRUG
regimen O
. O


 O
# O
Hypertension B-REA
: I-REA

 O
Patient O
was O
continued O
on O
BB B-DRUG
, I-DRUG
Hydralazine B-DRUG
and O
Lisinopril B-DRUG
. I-DRUG


 O
# O
Anemia O
: O
Is O
normocytic O
, O
likely O
secondary O
to O
chronic O
disease O
. O

 O
Hct O
was O
stable O
, O
a O
fecal O
occult O
blood O
was O
ordered O
. O

 O
. O

 O
# O
Patient O
was O
DNR/DNI O
during O
this O
hospitalization O
. O
  O
Pt O
has O
a O

 O
left O
PICC O
for O
IV O
access O
. O
Pt O
was O
maintained O
on O
SC B-ROU
Heparin B-DRUG
for O
DVT B-REA

 I-REA
ppx I-REA
. I-REA
Pt O
was O
on O
tube O
feeds O
for O
nutrition O
. O


 O
Medications O
on O
Admission O
: O

 O
Lisinopril B-DRUG
60 B-STR
mg I-STR
via O
G B-ROU
tube I-ROU
daily B-FRE

 I-FRE
KCL B-DRUG
elixir B-FOR
20Meq B-STR
twice B-FRE
daily I-FRE

 I-FRE
Novolin B-DRUG
4 B-DOS
SS I-DOS

 I-DOS
Lantus B-DRUG
26U B-DOS
daily B-FRE

 I-FRE
Dilantin B-DRUG
25 B-STR
mg I-STR
at O
10 B-FRE
am I-FRE
, I-FRE
50 B-STR
mg I-STR
50 B-STR
mg I-STR
at O
bedtime B-FRE

 I-FRE
Enulose B-DRUG
30ml B-STR
via O
G B-ROU
tube I-ROU
BIC B-FRE

 I-FRE
Docusate B-DRUG
liquid B-FOR
150 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Metoprolol B-DRUG
10 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Hydralazine B-DRUG
40 B-STR
mg I-STR
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O

 O
MOM B-DRUG
30 B-STR
mg I-STR
NGT B-ROU
TIW B-FRE

 I-FRE
Albuterol B-DRUG
nasal B-ROU
neb B-ROU
q6h B-FRE
prn I-FRE
SOB B-REA



 I-REA
Discharge O
Medications O
: O

 O
1 O
. O
Lisinopril B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
2 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( O
2 O
times O
a O
day O
) O
. O

 O
3 O
. O
Hydralazine B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( O
every O
6 O

 O
hours O
) O
. O

 O
4 O
. O
Phenytoin B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR
PO B-ROU

 I-ROU
DAILY B-FRE
( O
Daily O
) O
as O
needed O
for O
10 O
am O
. O

 O
5 O
. O
Phenytoin B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Chewable I-FOR
PO B-ROU
QHS B-FRE
( O
once O
a O
day O
( O
at O
bedtime O
) O
) O
. O

 O
6 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( O
0.083 O
% O
) O
Solution B-FOR
for I-FOR

 I-FOR
Nebulization I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Inhalation B-FOR
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE

 I-FRE
needed I-FRE
for O
SOB B-REA
. I-REA

 O
7 O
. O
Docusate B-DRUG
Sodium I-DRUG
50 B-STR
mg/5 I-STR
mL I-STR
Liquid B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
8 O
. O
Lactulose B-DRUG
10 B-STR
gram/15 I-STR
mL I-STR
Syrup B-FOR
Sig O
: O
Thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS
ML B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
9 O
. O
Vancomycin B-DRUG
in I-DRUG
D5W I-DRUG
1 B-STR
gram/200 I-STR
mL I-STR
Piggyback B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Intravenous B-ROU
Q B-FRE
12H I-FRE
( O
Every O
12 O
Hours O
) O
for B-DUR
5 I-DUR
days I-DUR
. I-DUR

 O
10 O
. O
Piperacillin-Tazobactam-Dextrs B-DRUG
4.5 B-STR
gram/100 I-STR
mL I-STR
Piggyback B-FOR

 I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Intravenous B-ROU
Q8H B-FRE
( O
every O
8 O
hours O
) O
for B-DUR
5 I-DUR
days I-DUR
. I-DUR

 O
11 O
. O
Potassium B-DRUG
Chloride I-DRUG
20 B-STR
mEq I-STR
Packet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
PO B-ROU
twice B-FRE
a I-FRE

 I-FRE
day I-FRE
. I-FRE

 O
12 O
. O
Novolin B-DRUG
R I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
Four B-DOS
( I-DOS
4 I-DOS
) I-DOS
units O
Injection B-ROU

 I-ROU
four B-FRE
times I-FRE
a I-FRE
day I-FRE
: I-FRE
sliding B-DOS
scale I-DOS
. I-DOS

 O
13 O
. O
Lantus B-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
Twenty B-DOS
Six I-DOS
( I-DOS
26 I-DOS
) I-DOS
units O

 O
Subcutaneous B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
14 O
. O
Milk B-DRUG
of I-DRUG
Magnesia I-DRUG
400 B-STR
mg/5 I-STR
mL I-STR
Suspension B-FOR
Sig O
: O
Thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS
mg O

 O
PO B-ROU
three B-FRE
times I-FRE
a I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
2558 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Aspiration O
Pneumonia O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Confused O
- O
always O
. O

 O
Level O
of O
Consciousness O
: O
Lethargic O
but O
arousable O
. O

 O
Activity O
Status O
: O
Bedbound O
. O



 O

Discharge O
Instructions O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
4587 O
* O
* O
] O
was O
admitted O
to O
the O
hospital O
because O
he O
was O
having O

 O
difficulty O
breathing O
. O
  O
He O
was O
initially O
in O
the O
ICU O
, O
where O
he O
was O

 O
started O
on O
IV B-ROU
antibiotics B-DRUG
for O
aspiration B-REA
pneumonia I-REA
. I-REA
  O
Pt O
was O
then O

 O
transferred O
to O
the O
medicine O
floor O
. O
  O
An O
EEG O
was O
performed O
which O

 O
showed O
no O
seizure O
activity O
. O
  O
Pt O
was O
then O
discharged O
back O
to O
the O

 O
facility O
. O


 O
He O
needs O
immediate O
medical O
attention O
if O
he O
experiences O

 O
difficulty O
breathing O
, O
has O
fevers O
or O
any O
other O
concerning O

 O
symptoms O
. O


 O
Please O
make O
th O
following O
changes O
to O
his O
medications O
: O

 O
START O
Piperacillin-Tazobactam B-DRUG
4.5 B-STR
g I-STR
IV B-ROU
every B-FRE
8 I-FRE
hours I-FRE
for O
5 B-FRE
more I-FRE

 I-FRE
days I-FRE

 I-FRE
START O
Vancomycin B-DRUG
1000 B-STR
mg I-STR
IV B-ROU
every B-FRE
12 I-FRE
hours I-FRE
for O
5 B-FRE
more I-FRE
days I-FRE


 I-FRE
You O
will O
need O
to O
have O
your O
thyroid O
nodule O
followed O
up O
. O


 O
Followup O
Instructions O
: O

 O
You O
will O
be O
followed O
by O
doctors O
at O
the O
facility O
. O
  O
They O
will O

 O
provide O
you O
with O
a O
follow-up O
appointment O
with O
your O
primary O
care O

 O
doctor O
in O
the O
future O
. O




 O
Completed O
by:[**2174 O
- O
6 O
- O
7 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2171 O
- O
6 O
- O
5 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2095 O
- O
1 O
- O
20 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Bactrim B-DRUG
/ O
Vancomycin B-DRUG
/ O
Ambien B-DRUG
/ O
Augmentin B-DRUG
/ O
Cephalexin B-DRUG
/ O
IV O
Dye B-DRUG
, I-DRUG

 O
Iodine B-DRUG
Containing O
/ O
Sulfa B-DRUG
( O
Sulfonamide B-DRUG
Antibiotics I-DRUG
) I-DRUG


 O
Attending:[**First O
Name3 O
( O
LF O
) O
22990 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Respiratory O
Failure O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Intubation O

 O
Arterial O
Line O

 O
Centrous O
Venous O
Catheter O
- O
Femoral O
Line O



 O
History O
of O
Present O
Illness O
: O

 O
( O
History O
mostly O
obtained O
from O
ED O
and O
patient O
nodding O
or O
shaking O

 O
head O
as O
CPAP O
mask O
makes O
talking O
difficult O
) O
. O
This O
is O
a O
76 O
year O

 O
old O
man O
with O
multiple O
medical O
problems O
including O
chronic O

 O
systolic O
CHF O
, O
interstitial O
lung O
disease O
, O
COPD O
( O
baseline O
2L O
NC O
at O

 O
night O
) O
, O
CKD O
, O
and O
PVD O
presenting O
with O
sudden O
onset O
of O
SOB O
7 O
am O

 O
this O
morning O
and O
bloody O
, O
frothy O
sputum O
. O
Patient O
reports O
feeling O

 O
well O
yesterday O
and O
rather O
acute O
development O
of O
this O
this O
AM O
. O
He O

 O
denies O
any O
fevers O
or O
chills O
prior O
to O
arriving O
in O
the O
ED O
. O
He O

 O
denies O
any O
other O
localizing O
symptoms O
of O
infection O
likey O
dysuria O
, O

 O
diarrhea O
, O
or O
abdominal O
pain O
. O
He O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
653 O
* O
* O
] O
EMS O
for O
his O
dyspnea O

 O
and O
was O
put O
on O
100 O
% O
NRB O
oxygen O
and O
brought O
to O
the O
ED O
. O


 O
In O
the O
ED O
, O
initial O
vs O
were O
: O
T O
100.4 O
( O
102 O
rectal O
) O
, O
P O
80 O
, O
BP O

 O
165/71 O
, O
RR O
34 O
, O
O2 O
96 O
% O
on O
NRB O
. O
He O
was O
started O
on O
CPAP O
with O

 O
improvement O
in O
his O
O2 O
sats O
and O
in O
his O
work O
of O
breathing O
. O
Given O

 O
his O
relatively O
high O
blood O
pressures O
and O
concern O
of O
some O
element O

 O
of O
flash O
pulmonary O
edema O
, O
he O
was O
started O
on O
a O
NTG B-DRUG
drip B-ROU
, I-ROU
but O
then O

 O
developed O
hypotension O
with O
SBP O
's O
in O
the O
70 O
's O
to O
80 O
's O
, O
which O

 O
failed O
to O
improve O
with O
discontinuation O
of O
the O
NTG B-DRUG
. I-DRUG
Therefore O
, O
he O

 O
was O
started O
on O
peripheral O
dopamine B-DRUG
before O
having O
a O
femoral O
line O

 O
placed O
at O
which O
point O
he O
was O
transitioned O
to O
norepinephrine B-DRUG
for O

 O
presumed O
pneumosepsis O
and O
hypotension O
( O
lactate O
was O
3.8 O
) O
. O
CXR O

 O
showed O
bilateral O
multifocal O
infiltrates O
so O
he O
received O

 O
ceftriaxone/vancomycin/azithromycin B-DRUG
empirically O
. O
Vitals O
prior O
to O

 O
transfer O
were O
P O
68 O
, O
BP O
90/34 O
( O
up O
from O
70 O
's O
off O
pressors O
) O
, O
RR O
22 O
, O

 O
100 O
% O
on O
5 O
of O
CPAP O
. O


 O
In O
the O
MICU O
, O
the O
patient O
reported O
feeling O
better O
and O
was O
able O
to O

 O
nod O
or O
shake O
his O
head O
to O
answer O
questions O
. O
Still O
using O
accessory O

 O
muscles O
to O
breathe O
. O
He O
was O
asking O
for O
CPAP O
to O
be O
removed O
. O



 O
ROS:(limited O
due O
to O
needing O
to O
communicate O
w/ O
guestures O
) O

 O
( O
+ O
) O
Per O
HPI O

 O
( O
- O
) O
Denied O
fever O
, O
chills O
, O
night O
sweats O
. O
Denied O
headache O
. O
Denied O

 O
chest O
pain O
, O
chest O
pressure O
, O
palpitations O
, O
or O
weakness O
. O
Denies O

 O
nausea O
, O
vomiting O
, O
diarrhea O
, O
constipation O
, O
abdominal O
pain O
, O
or O

 O
changes O
in O
bowel O
habits O
. O
Denied O
dysuria O
, O
increased O
frequency O
, O

 O
and O
increased O
urgency O
. O
Denies O
arthralgias O
or O
myalgias O
. O
Denies O

 O
rashes O
or O
skin O
changes O
. O
Denied O
increased O
lower O
extremity O
edema O
. O




 O
Past O
Medical O
History O
: O

 O
- O
Chronic O
AF O
s/p O
AV O
node O
ablation O
, O
[ O
* O
* O
9-/2169 O
* O
* O
] O

 O
- O
History O
of O
ventricular O
tachycardia O
s/p O
biventricular O
ICD O
/ O
PPM O


 O
( O
[ O
* O
* O
Company O
1543 O
* O
* O
] O
pacemaker O
) O

 O
- O
Dilated O
cardiomyopathy O
with O
LVEF O
35 O
% O
, O
2 O
+ O
MR O

 O
- O
CAD O

 O
-Interstitial O
lung O
disease O
thought O
secondary O
to O
inhalational O

 O
injury O
while O
working O
as O
a O
firefighter O

 O
- O
COPD O
, O
on O
2 B-DOS
liters I-DOS
of O
oxygen B-DRUG
at B-FRE
night I-FRE
. I-FRE

 O
- O
History O
of O
pulmonary B-REA
embolism I-REA
on O
Coumadin B-DRUG

 I-DRUG
- O
Adrenal B-REA
insufficiency I-REA
, I-REA
on O
chronic B-DRUG
steroid I-DRUG
replacement I-DRUG
therapy O
. O


 O
- O
Chronic O
kidney O
disease O
, O
Stage O
IV O

 O
- O
history O
of O
SIADH O

 O
- O
Dyslipidemia O

 O
- O
Hypertension O
. O

 O
- O
Severe O
[ O
* O
* O
Company O
1106 O
* O
* O
] O
disease O
with O
multiple O
lower O
extremity O

 O
interventions O

 O
- O
Chronic O
anemia O

 O
- O
Rectal O
cancer O
status O
post O
transanal O
excision O
in O
[ O
* O
* O
2166 O
* O
* O
] O
. O

 O
- O
Umbilical O
hernia O
s/p O
mesh O
repair O

 O
- O
Allergic O
rhinitis O
status O
post O
nasal O
surgery O

 O
- O
rosacia O
, O
actinic O
keratosis O



 O
Social O
History O
: O

 O
- O
Tobacco O
: O
40 O
pack O
year O
smoking O
history O
but O
quit O
> O
30 O
years O
ago O

 O
- O
Alcohol O
: O
2 O
- O
3 O
beers O
a O
couple O
( O
2 O
- O
3 O
times O
) O
per O
week O

 O
- O
Illicits O
: O
None O

 O
He O
is O
a O
retired O
fireighter O
and O
has O
a O
history O
of O
a O
rather O
severe O

 O
inhalational O
injury O
at O
work O
. O
He O
lives O
with O
his O
sister O
currently O

 O
though O
has O
previously O
been O
in O
SNFs O
. O



 O
Family O
History O
: O

 O
His O
brother O
deceased O
in O
70 O
's O
. O
No O
family O
history O
of O
early O
cardiac O

 O
disease O
. O



 O
Physical O
Exam O
: O

 O
General O
: O
Alert O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
MMM O
, O
oropharynx O
clear O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O
rales O
, O

 O
ronchi O

 O
CV O
: O
Regular O
rate O
and O
rhythm O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O

 O
gallops O

 O
Abdomen O
: O
soft O
, O
non-tender O
, O
non-distended O
, O
bowel O
sounds O
present O
, O

 O
no O
rebound O
tenderness O
or O
guarding O
, O
no O
organomegaly O

 O
GU O
: O
no O
foley O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
no O
clubbing O
, O
cyanosis O
or O

 O
edema O



 O

Pertinent O
Results O
: O

 O
Labs O
on O
Admission O
: O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
08:48AM O
   O
WBC-21.9 O
* O
# O
RBC-4.11 O
* O
HGB-9.9 O
* O
HCT-34.7 O
* O
# O

 O
MCV-85 O
MCH-24.1 O
* O
MCHC-28.5 O
* O
RDW-18.0 O
* O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
08:48AM O
   O
NEUTS-88.5 O
* O
LYMPHS-7.2 O
* O
MONOS-2.0 O
EOS-1.9 O

 O
BASOS-0.4 O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
08:48AM O
   O
PLT O
COUNT-324 O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
08:48AM O
   O
PT-20.2 O
* O
PTT-33.7 O
INR(PT)-1.9 O
* O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
09:02AM O
   O
LACTATE-3.8 O
* O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
09:20AM O
URINE O
  O
BLOOD-NEG O
NITRITE-NEG O
PROTEIN-75 O

 O
GLUCOSE-NEG O
KETONE-NEG O
BILIRUBIN-NEG O
UROBILNGN-NEG O
PH-5.0 O

 O
LEUK-NEG O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
09:20AM O
URINE O
  O
RBC-0 O
WBC-0 O
BACTERIA-OCC O
YEAST-NONE O

 O
EPI-0 O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
04:31PM O
   O
TYPE-ART O
PO2 O
- O
71 O
* O
PCO2 O
- O
53 O
* O
PH-7.26 O
* O
TOTAL O

 O
CO2 O
- O
25 O
BASE O
XS--3 O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
04:31PM O
   O
LACTATE-0.9 O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
04:40PM O
   O
CK-MB-NotDone O
cTropnT-0.03 O
* O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
04:40PM O
   O
CK(CPK)-33 O
* O

 O
[ O
* O
* O
2171 O
- O
5 O
- O
19 O
* O
* O
] O
04:47PM O
   O
TYPE-[**Last O
Name O
( O
un O
) O
* O
* O
] O
PO2 O
- O
36 O
* O
PCO2 O
- O
56 O
* O
PH-7.22 O
* O
TOTAL O

 O
CO2 O
- O
24 O
BASE O
XS--6 O

 O
. O

 O
Labs O
on O
Discharge O
: O

 O
[ O
* O
* O
2171 O
- O
6 O
- O
5 O
* O
* O
] O
WBC-8.1 O
RBC-2.75 O
* O
Hgb-7.0 O
* O
Hct-22.7 O
* O
MCV-83 O
  O
Plt O
Ct-314 O

 O
[ O
* O
* O
2171 O
- O
6 O
- O
5 O
* O
* O
] O
PT-31.8 O
* O
INR(PT)-3.2 O
* O

 O
[ O
* O
* O
2171 O
- O
6 O
- O
5 O
* O
* O
] O
Glucose-82 O
UreaN-41 O
* O
Creat-1.4 O
* O
Na-133 O
K-4.8 O
Cl-92 O
* O

 O
HCO3 O
- O
33 O
* O

 O
. O

 O
Digoxin B-DRUG
Level O
( O
[ O
* O
* O
6 O
- O
5 O
* O
* O
] O
) O
: O
0.4 O

 O
. O

 O
Imaging O
: O

 O
CXR O
: O
[ O
* O
* O
5 O
- O
19 O
* O
* O
] O

 O
A O
left-sided O
pacer O
demonstrates O
leads O
in O
the O
right O
atrium O
, O
right O

 O
ventricle O
and O
coronary O
sinus O
. O
The O
heart O
size O
is O
enlarged O
. O

 O
Mediastinal O
contours O
are O
somewhat O
obscured O
by O
bilateral O
fluffy O

 O
appearing O
opacities O
. O
  O
Calcified O
atherosclerotic O
disease O
is O
noted O

 O
in O
the O
aortic O
knob O
. O
Small O
bilateral O
pleural O
effusions O
are O
seen O
. O

 O
No O
pneumothorax O
. O
IMPRESSION O
: O
Cardiomegaly O
and O
pulmonary O
edema O
, O

 O
increased O
compared O
with O
prior O
study O
. O



 O
CXR O
: O
[ O
* O
* O
5 O
- O
19 O
* O
* O
] O

 O
As O
compared O
to O
the O
previous O
radiograph O
, O
the O
patient O
has O
been O

 O
intubated O
. O
The O
tip O
of O
the O
tube O
projects O
4.8 O
cm O
above O
the O
carina O
. O

 O
Nasogastric O
tube O
in O
situ O
, O
the O
tip O
of O
the O
tube O
projects O
over O
the O

 O
middle O
parts O
of O
the O
stomach O
. O
Unchanged O
course O
and O
position O
of O

 O
the O
pacemaker O
leads O
. O
The O
pre-existing O
parenchymal O
opacities O
show O

 O
minimal O
regression O
at O
the O
level O
of O
the O
bases O
of O
the O
lungs O
; O
in O

 O
the O
more O
apical O
lung O
regions O
, O
however O
, O
the O
severity O
of O

 O
the O
opacities O
is O
unchanged O
. O
Increasing O
retrocardiac O
atelectasis O
. O

 O
The O
presence O
of O
bilateral O
small O
pleural O
effusions O
can O
not O
be O

 O
excluded O
. O
No O
evidence O
of O
pneumothorax O
. O


 O
CXR O
: O
[ O
* O
* O
5 O
- O
22 O
* O
* O
] O

 O
Since O
prior O
examination O
, O
mild O
improvement O
in O
still O
severe O

 O
airspace O
opacity O
involving O
the O
right O
upper O
lobe O
, O
though O
with O

 O
worsening O
of O
severe O
opacity O
in O
the O
left O
retrocardiac O
region O
that O

 O
is O
likely O
component O
of O
effusion O
and/or O
atelectasis O
. O
Othwise O

 O
stable O
diffuse O
multifocal O
opacification O
. O
Stable O
moderate O

 O
bilateral O
pleural O
effusions O
. O
Stable O
cardiomegaly O
and O
tortuosity O

 O
of O
the O
thoracic O
aorta O
. O
Persistent O
mild O
pulmonary O
[ O
* O
* O
Month/Year O
( O
2 O
) O
1106 O
* O
* O
] O

 O
engorgement O
. O

 O
IMPRESSION O
: O
Grossly O
stable O
combination O
of O
multifocal O
pneumonia O

 O
and O
pulmonary O
edema O
. O
Increased O
severe O
left O
basal O
atelectasis O
. O


 O
CXR O
: O
[ O
* O
* O
5 O
- O
31 O
* O
* O
] O

 O
Moderate O
cardiomegaly O
is O
stable O
. O
Left O
transvenous O
pacemaker O

 O
leads O
terminate O

 O
in O
the O
standard O
position O
in O
the O
right O
atrium O
, O
right O
ventricle O

 O
and O
through O
the O
coronary O
sinus O
. O
There O
is O
no O
evident O

 O
pneumothorax O
. O
Small O
bilateral O
pleural O
effusions O
are O
unchanged O
. O

 O
Bilateral O
diffuse O
opacities O
that O
were O
a O
combination O
of O
pulmonary O

 O
edema O
and O
pneumonia O
have O
markedly O
improved O
. O
Still O
there O
are O
some O

 O
opacities O
in O
the O
perihilar O
regions O
, O
right O
apex O
, O
and O
right O
lower O

 O
lobe O




 O
Brief O
Hospital O
Course O
: O

 O
76 O
year O
old O
male O
with O
multiple O
medical O
problems O
including O
CHF O
, O

 O
COPD O
, O
and O
ILD O
with O
very O
poor O
respiratory O
reserve O
presenting O
with O

 O
hypoxemic O
respiratory O
failure O
with O
fever O
and O
hypotension O
. O



 O
1 O
) O
Pulmonary O
( O
Hypoxic O
Respiratory O
Failure O
) O
: O
Patient O
was O

 O
initially O
admitted O
to O
MICU O
where O
intubation O
was O
required O
from O

 O
[ O
* O
* O
2085 O
- O
5 O
- O
18 O
* O
* O
] O
. O
Multiple O
etiologies O
were O
considered O
to O
explain O
his O

 O
hypoxic O
respiratory O
failure O
. O
At O
baseline O
patient O
has O

 O
interstitial O
lung O
disease O
and O
COPD O
. O
Given O
fever O
, O
leukocytosis O
, O

 O
sputum O
, O
elevated O
lactate O
multifocal B-REA
pneumonia I-REA
was O
also O

 O
considered O
and O
ultimately O
treated O
with O
Vancomycin B-DRUG
and O
Cefepime B-DRUG
. I-DRUG

 O
Unfortunately O
, O
all O
sputum O
cultures O
were O
contaminated O
. O
During O

 O
patient O
's O
MICU O
stay O
he O
was O
diuresed O
with O
IV B-ROU
lasix B-DRUG
gien O
concern O

 O
for O
a O
possible O
element O
of O
volume O
overload O
as O
well O
though O
BNP O
, O

 O
while O
elevated O
, O
was O
less O
than O
previous O
values O
on O
admission O
for O

 O
CHF O
exacerbation O
. O
PE O
was O
considered O
however O
thought O
to O
be O

 O
unlikely O
given O
evidence O
for O
multiple O
other O
processes O
to O
explain O

 O
respiratory O
failure O
. O
Further O
, O
patient O
was O
anticoagulated O
making O

 O
PE O
less O
likely O
. O
With O
history O
of O
COPD O
steroid O
taper O
was O
started O

 O
as O
well O
as O
standing O
nebs O
. O
Patient O
was O
eventually O
weaned O
to O
2L B-DOS
NC O

 O
and O
transferred O
to O
the O
floor O
. O
On O
the O
floor O
patient O
finished O
the O

 O
course O
of O
antibiotics B-DRUG
for O
HAP B-REA
, I-REA
continued O
diuresis O
, O
and O
standing O

 O
nebs O
. O
He O
continued O
to O
improve O
from O
a O
respiratory O
standpoint O

 O
until O
[ O
* O
* O
5 O
- O
31 O
* O
* O
] O
whent O
he O
patient O
was O
found O
to O
be O
somnolent O
with O

 O
decreased O
respiratory O
drive O
and O
ABG O
7.30/71/146/36 O
. O
Patient O
was O

 O
then O
transferred O
to O
the O
MICU O
where O
mental O
status O
cleared O
and O

 O
hypercarbic O
respiratory O
failure O
resolved O
. O
This O
somnolence O
and O

 O
diminished O
respiratory O
drive O
was O
thought O
to O
be O
secondary O
to O

 O
small O
increase O
in O
the O
patient O
's O
gabapentin B-DRUG
dose O
which O
he O
was O

 O
taking O
for O
post B-REA
herpetic I-REA
neuralgias I-REA
. I-REA
After O
patient O
returned O
to O

 O
the O
floor O
he O
was O
continued O
on O
a O
small O
dose O
of O
PO B-ROU
lasix B-DRUG
per O

 O
outpatient O
regimen O
, O
prednisone B-DRUG
taper B-DOS
, I-DOS
and O
standing O
nebs B-DRUG
. I-DRUG
Because O

 O
the O
patient O
was O
deconditioned O
and O
continued O
to O
have O
desats O
the O

 O
mid O
80s O
on O
2L O
while O
ambulating O
he O
was O
discharged O
to O
rehab O
. O

 O
. O

 O
2)AMS O
: O
On O
[ O
* O
* O
5 O
- O
31 O
* O
* O
] O
, O
he O
was O
noted O
to O
be O
increasingly O
altered O
and O

 O
confused O
, O
pulling O
at O
his O
oxygen O
, O
picking O
at O
his O
clothing O
and O

 O
mumbling O
nonsense O
. O
His O
ABG O
at O
the O
time O
was O
7.30/71/146/36 O
. O
His O

 O
O2 O
was O
removed O
to O
see O
if O
his O
respiratory O
drive O
was O
depressed O
, O

 O
but O
he O
desatted O
down O
to O
70 O
% O
and O
needed O
to O
have O
the O
oxygen O

 O
replaced O
. O
Transferred O
to O
the O
MICU O
as O
noted O
above O
. O
This O
AMS O
was O

 O
in O
the O
setting O
of O
neurontin B-DRUG
dosing O
for O
zoster B-REA
related I-REA
ear I-REA
pain I-REA
. I-REA

 O
He O
was O
monitored O
and O
improved O
in O
the O
ICU O
with O
very O
little O

 O
intervention O
other O
than O
holding O
his O
neurontin B-DRUG
. I-DRUG



 O
3 O
) O
Presumed O
Bacterial O
Pneumonia O
: O
The O
patient O
had O
increased O

 O
sputum O
in O
the O
context O
of O
fever O
, O
leukocytosis O
, O
and O
bilateral O

 O
pulmonary O
infiltrates O
suggesting O
pneumonia O
. O
All O
sputum O
cultures O

 O
were O
contaminated O
and O
urine O
legionella O
was O
negative O
. O
Given O

 O
history O
of O
MRSA O
and O
multifocal O
infiltrate O
patient O
was O
treated O

 O
with O
Vanc B-DRUG
, I-DRUG
Cefepime B-DRUG
for O
presumed O
hospital B-REA
acquired I-REA
pneumonia I-REA
. I-REA


 O
4 O
) O
Hypotension O
: O
The O
patient O
became O
hypotensive B-ADE
in O
the O
context O
of O

 O
receiving O
nitroglycerin B-DRUG
but O
remained O
hypotensive O
once O
this O

 O
medication O
was O
stopped O
. O
Initially O
patient O
required O

 O
norepinephrine B-DRUG
which O
was O
quickly O
weaned O
. O
Given O
concern O
for O

 O
adrenal B-REA
insufficiency I-REA
stress O
dose O
steroids B-DRUG
were O
initiated O
at O

 O
50 B-STR
mg I-STR
IV B-ROU
hydrocortisone B-DRUG
Q6hrs B-FRE
. I-FRE
This O
was O
weaned O
to O
PO B-ROU

 I-ROU
hydrocrotisone B-DRUG
twice B-FRE
daily I-FRE
. I-FRE
Eventually O
, O
blood B-REA
pressures I-REA

 I-REA
stabilized O
and O
anti B-DRUG
hypertensive I-DRUG
agents O
were O
restarted O
. O

 O
. O

 O
5 O
) O
Chronic O
systolic O
CHF/ O
Dilated O
Cardiomyopathy O
: O
During O

 O
admission O
patient O
was O
thought O
to O
be O
slightly O
volume O
overloaded O

 O
despite O
an O
elevated O
BNP O
that O
was O
lower O
than O
prior O
admissions O
. O

 O
During O
his O
stay O
he O
was O
diuresed B-REA
with O
IV B-ROU
lasix B-DRUG
and O
then O
converted O

 O
to O
20 B-STR
mg I-STR
PO B-ROU
lasix B-DRUG
at O
the O
time O
of O
discharge O
. O
Patient O
was O
continued O

 O
on O
QOD B-FRE
digoxin B-DRUG
and O
while O
his O
beta B-DRUG
blocker I-DRUG
and O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
were O
initially O

 O
held O
these O
were O
restarted O
prior O
to O
discharge O
. O

 O
. O

 O
6 O
) O
Stage O
IV O
CKD O
: O
On O
admission O
Creatinine O
was O
not O
markedly O

 O
elevated O
from O
baseline O
. O
Throughout O
the O
hospitalization O

 O
creatinine O
fluctuated O
between O
1.3 O
- O
2 O
depending O
on O
the O
degree O
of O

 O
diuresis O
. O
Nephrotoxins O
were O
avoided O
when O
possible O
. O

 O
. O

 O
7 O
) O
AF B-REA
: I-REA
Patient O
is O
pacemaker O
dependent O
. O
Coumadin B-DRUG
was O
continued O

 O
while O
inpatient O
. O
During O
admission O
INR O
became O
supratherapeutic O

 O
and O
Coumadin B-DRUG
was O
held O
. O
During O
this O
time O
as O
noted O
below O
patient O

 O
developed O
GI O
Bleed O
which O
reguired O
reversal O
of O
INR O
and O
heparin B-DRUG

 I-DRUG
gtt B-ROU
. I-ROU
At O
discharge O
patient O
will O
continue O
coumadin B-DRUG
per O
home O

 O
regimen O
2.5 B-STR
mg I-STR
Daily B-FRE
, I-FRE
except O
Tuesdays O
when O
he O
will O
take O
1.5 B-STR
mg I-STR
. I-STR

 O
. O

 O
8) O
History O
of O
DVT B-REA
: I-REA
Continued O
coumadin B-DRUG

 I-DRUG
. O

 O
9 O
) O
Adrenal B-REA
Insufficiency I-REA
: I-REA
Initially O
patient O
was O
hypotensive O
so O

 O
stress B-DOS
dose I-DOS
steroids B-DRUG
were O
initiated O
as O
above O
. O
Once O
blood O

 O
pressures O
stabilized O
patient O
was O
transitioned O
to O
home O

 O
hydrocortisone B-DRUG
regimen O
. O

 O
. O

 O
10 O
) O
Chronic O
Anemia O
: O
Patient O
with O
chronic B-REA
anemia I-REA
thought O
to O
be O

 O
related O
to O
chronic O
kidney O
disease O
. O
As O
an O
outpatient O
patient O

 O
recieves O
EPO B-DRUG
injections B-ROU
Monthly B-FRE
. I-FRE
During O
admission O
patients O
HCT O

 O
trended O
down O
in O
the O
setting O
of O
supratherapeutic O
INR O
and O
GI O
bleed O

 O
as O
noted O
below O
. O
Patient O
was O
transfused O
two B-DOS
units B-FOR
pRBCs B-DRUG
when O

 O
HCT<21 O
. O
HCT O
will O
be O
followed O
as O
an O
outpatient O
and O
EPO B-DRUG
injections B-ROU

 I-ROU
will O
be O
continued O
. O

 O
. O


 O
11 O
) O
Recent O
Herpes O
Zoster O
: O
Pt O
received O
> O
7 O
days O
of O
therapy O
for O

 O
zoster O
and O
no O
active O
lesions O
. O
No O
vision O
changes O
or O
eye O

 O
involvement O
. O
Patient O
was O
continued O
on O
gabapentin B-DRUG
300 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O
Post B-REA

 I-REA
herpetic I-REA
neuralgias I-REA
continued O
to O
bother O
patient O
during O
the O

 O
hospitalization O
, O
patient O
reported O
[ O
* O
* O
12 O
- O
6 O
* O
* O
] O
pain O
, O
and O
gabapentin B-DRUG
was O

 O
increased O
to O
400 B-STR
mg I-STR
TID B-FRE
. I-FRE
The O
day O
following O
this O
change O
the O

 O
patient O
became O
increasingly O
somnolent B-ADE
as O
noted O
above O
. O
Gabapentin B-DRUG

 I-DRUG
at O
that O
time O
was O
stopped O
with O
improvement O
in O
mental O
status O
. O

 O
Scheduled O
tylenol B-DRUG
was O
continued O
for O
pain B-REA
. I-REA
Narcotics B-DRUG
and O

 O
neurontin B-DRUG
were O
avoided O
given O
the O
somnolence B-ADE
noted O
above O
. O

 O
. O

 O
12 O
) O
Hyperlipidemia B-REA
: I-REA
Continued O
rosuvastatin B-DRUG

 I-DRUG
. O

 O
13 O
) O
GI B-REA
Bleed I-REA
: I-REA
On O
[ O
* O
* O
5 O
- O
29 O
* O
* O
] O
, O
patient O
developed O
dark O
melenotic O
stool O
in O

 O
the O
setting O
of O
a O
supratherapeutic B-REA
INR I-REA
. I-REA
INR O
was O
reversed O
with O
Vit O

 O
K O
5 B-STR
mg I-STR
PO B-ROU
, I-ROU
GI O
was O
consulted O
, O
and O
IV B-ROU
PPI B-DRUG
40 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
was O
started O
. O

 O
HCT O
was O
followed O
and O
was O
relatively O
stable O
. O
GI O
deferred O

 O
endoscopy O
given O
the O
patient O
's O
stability O
and O
poor O
respiratory O

 O
status O
given O
concern O
the O
patient O
would O
reguire O
intubation O
for O

 O
the O
procedure O
. O
At O
discharge O
patient O
will O
continue O
Omeprazole B-DRUG

 I-DRUG
40 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
will O
arrange O
for O
further O
GI O
evaluation O
once O

 O
patient O
is O
optomized O
from O
a O
respiratory O
standpoint O
. O

 O
. O

 O
14 O
) O
Non O
Sustained O
Ventricular O
Tachycardia O
: O
Throughout O
the O

 O
hospitalization O
patient O
had O
NSVT O
. O
The O
longest O
run O
of O
NSVT O
was O
22 O

 O
beats O
during O
which O
patient O
was O
asymptomatic O
. O
Patient O
has O
BiV O
ICD O

 O
in O
place O
. O
Electrophysiology O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
6349 O
* O
* O
] O
pacemaker O
and O
it O
was O
found O

 O
to O
be O
functioning O
normally O
. O
EP O
noted O
that O
the O
patient O
's O

 O
pacemaker O
will O
pace O
patient O
out O
of O
this O
concerning O
rhythm O
if O

 O
rate O
exceeds O
140 O
bpm O
. O
Metoprolol B-DRUG
was O
uptitrated O
to O
25 B-STR
mg I-STR
Daily B-FRE

 I-FRE
with O
the O
hopes O
of O
decreasing O
the O
frequency O
of O
this O
rhythm O
. O



 O

Medications O
on O
Admission O
: O

 O
-ALBUTEROL B-DRUG
SULFATE I-DRUG
90 B-STR
mcg I-STR
2 B-DOS
puffs B-FOR
orally B-ROU
Q6 B-FRE
hours I-FRE
PRN I-FRE

 I-FRE
-DIGOXIN B-DRUG
125 B-STR
mcg I-STR
by B-ROU
mouth I-ROU
every B-FRE
other I-FRE
day I-FRE

 I-FRE
-FLUTICASONE-SALMETEROL B-DRUG
500 B-STR
mcg-50 I-STR
mcg I-STR
inhaled B-ROU
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
-FUROSEMIDE B-DRUG
10 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
-GABAPENTIN B-DRUG
300 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
-HYDROCORTISONE B-DRUG
10 B-STR
mg I-STR
QAM B-FRE
and O
5 B-STR
mg I-STR
QPM B-FRE
daily I-FRE

 I-FRE
-IPRATROPIUM-ALBUTEROL B-DRUG
18 B-STR
mcg-103 I-STR
mcg I-STR
2 B-DOS
puffs B-FOR
orally B-ROU
Q6hr B-FRE
: I-FRE
PRN I-FRE

 I-FRE
-METOPROLOL B-DRUG
SUCCINATE I-DRUG
25 B-STR
mg I-STR
by B-ROU
mouth I-ROU
DAILY B-FRE

 I-FRE
-NITROGLYCERIN B-DRUG
0.4 B-STR
mg I-STR
sublingually B-ROU
as B-FRE
needed I-FRE
for O
chest B-REA
pain I-REA
x3 B-DOS

 I-DOS
-ROSUVASTATIN B-DRUG
10 B-STR
mg I-STR
daily B-FRE

 I-FRE
-SPIRONOLACTONE B-DRUG
25 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
a I-FRE
day I-FRE

 I-FRE
-TIOTROPIUM B-DRUG
BROMIDE I-DRUG
18 B-STR
mcg I-STR
inhaled B-ROU
daily B-FRE

 I-FRE
-VALACYCLOVIR B-DRUG
1,000 B-STR
mg I-STR
by B-ROU
mouth I-ROU
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
-WARFARIN B-DRUG
2.5 B-STR
mg I-STR
by B-ROU
mouth I-ROU
daily B-FRE
on I-FRE
Mondays I-FRE

 I-FRE
-WARFARIN B-DRUG
5 B-STR
mg I-STR
by B-ROU
mouth I-ROU
daily B-FRE
on I-FRE
Tues-Sun I-FRE

 I-FRE
-ASCORBIC B-DRUG
ACID I-DRUG
500 B-STR
mg I-STR
by B-ROU
mouth I-ROU
daily B-FRE

 I-FRE
-ASPIRIN B-DRUG

 I-DRUG
-GLUCOSAMINE B-DRUG
1,000 B-STR
by B-ROU
mouth I-ROU
daily B-FRE

 I-FRE
-MULTIVITAMIN B-DRUG
one B-DOS
Tablet(s B-FOR
) O
by B-ROU
mouth I-ROU
daily B-FRE

 I-FRE
-SENNA B-DRUG


 I-DRUG
Discharge O
Medications O
: O

 O
1 O
. O
Furosemide B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O


 O
2 O
. O
Prednisone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O

 O
for B-DUR
3 I-DUR
days I-DUR
: I-DUR
LAST O
DAY O
[ O
* O
* O
6 O
- O
8 O
* O
* O
] O
. O

 O
3 O
. O
Warfarin B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Mon B-FRE
, I-FRE
Wed I-FRE
, I-FRE
Thurs I-FRE
, I-FRE

 I-FRE
Fri I-FRE
, I-FRE
Sat I-FRE
, I-FRE
Sun I-FRE
: I-FRE
Hold O
dose O
6/9 O
and O
restart O
on O
[ O
* O
* O
6 O
- O
6 O
* O
* O
] O
. O
. O

 O
4 O
. O
Fluticasone-Salmeterol B-DRUG
500 B-STR
- I-STR
50 I-STR
mcg/Dose I-STR
Disk B-FOR
with I-FOR
Device I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Disk B-FOR
with I-FOR
Device I-FOR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
5 O
. O
Rosuvastatin B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
6 O
. O
Ascorbic B-DRUG
Acid I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
7 O
. O
Aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR

 I-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
8 O
. O
Multivitamin B-DRUG
     O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O



 O
9 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
10 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( O
2 O
times O
a O
day O
) O
. O

 O
11 O
. O
Digoxin B-DRUG
125 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
EVERY B-FRE
OTHER I-FRE

 I-FRE
DAY I-FRE
( O
Every O
Other O
Day O
) O
. O

 O
12 O
. O
Guaifenesin B-DRUG
100 B-STR
mg/5 I-STR
mL I-STR
Syrup B-FOR
Sig O
: O
5 B-DOS
- I-DOS
10 I-DOS
MLs I-DOS
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
cough B-REA
. I-REA

 O
13 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( O
0.083 B-STR
% O
) O
Solution B-FOR
for O

 O
Nebulization B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Inhalation B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE

 I-FRE
needed I-FRE
for O
shortness B-REA
of I-REA
breath I-REA
or O
wheezing B-REA
. I-REA

 O
14 O
. O
Losartan B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O


 O
15 O
. O
Omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) O
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) O
PO B-ROU
BID B-FRE
( O
2 O
times O
a O
day O
) O
. O

 O
16 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
17 O
. O
Vitamin B-DRUG
D I-DRUG
50,000 B-STR
unit I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU

 I-ROU
1X/WEEK B-FRE
( O
WE O
) O
for B-DUR
8 I-DUR
weeks I-DUR
. I-DUR

 O
18 O
. O
Hydrocortisone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QAM B-FRE
( O
once O

 O
a O
day O
( O
in O
the O
morning O
) O
) O
. O

 O
19 O
. O
Hydrocortisone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QPM B-FRE
( O
once O

 O
a O
day O
( O
in O
the O
evening O
) O
) O
. O

 O
20 O
. O
Nitroglycerin B-DRUG
0.3 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Sublingual B-ROU
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Sublingual B-ROU
once B-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
chest B-REA
pain I-REA
: I-REA
Take O
if O
you O

 O
develop O
CP B-REA
, I-REA
if O
CP O
is O
not O
alleviated O
call O
911 O
. O
. O

 O
21 O
. O
Spiriva B-DRUG
with O
HandiHaler O
18 B-STR
mcg I-STR
Capsule B-FOR
, I-FOR
w/Inhalation B-FOR
Device I-FOR

 I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Inhalation B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
22 O
. O
Warfarin B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
[ O
* O
* O
12 O
- O
29 O
* O
* O
] O
tablet B-FOR
Tablet B-FOR
PO B-ROU
Tuesdays B-FRE
. I-FRE

 O
23 O
. O
Glucosamine B-DRUG
1,000 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE

 I-FRE
day I-FRE
. I-FRE

 O
24 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q B-FRE
8H I-FRE

 I-FRE
( I-FRE
Every I-FRE
8 I-FRE
Hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
537**]- O
[ O
* O
* O
Location O
( O
un O
) O
538 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
Congestive O
Heart O
Failure O

 O
[ O
* O
* O
Hospital O
2182 O
* O
* O
] O

 O
Hospital O
Acquired O
Pneumonia O

 O
Anemia O

 O
Atrial O
Fibrillation O


 O
Secondary O
: O

 O
Herpes O
Zoster O

 O
Hyperlipidemia O



 O

Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
requires O
assistance O
or O
aid O
( O
walker O

 O
or O
cane O
) O
. O



 O
Discharge O
Instructions O
: O

 O
Dear O
Mr. O
[ O
* O
* O
Known O
lastname O
14879 O
* O
* O
] O
, O


 O
It O
was O
a O
pleasure O
caring O
for O
you O
while O
you O
were O
admitted O
with O

 O
shortness O
of O
breath O
. O
During O
your O
stay O
we O
treated O
a O
pneumonia O
and O

 O
optimized O
your O
therapy O
for O
congestive O
heart O
failure O
and O
COPD O
. O

 O
You O
were O
also O
found O
to O
have O
a O
bleed O
in O
your O
GI O
tract O
which O

 O
resolved O
without O
intervention O
. O

 O
. O

 O
It O
will O
be O
important O
for O
you O
to O
follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
as O
an O

 O
outpatient O
for O
further O
evaluation O
and O
management O
. O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O

 O
will O
help O
arrange O
other O
follow O
up O
as O
necessary O
. O

 O
. O

 O
You O
should O
weigh O
yourself O
every O
morning O
, O
call O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
if O

 O
weight O
goes O
up O
more O
than O
3 O
lbs O
. O
Limit O
your O
salt O
intake O
to O
2 O

 O
Grams O
daily O
. O
Take O
all O
medications O
as O
prescribed O
. O

 O
. O

 O
The O
following O
changes O
were O
made O
to O
your O
medications O
: O

 O
- O
STOP O
: O
Valacyclovir B-DRUG

 I-DRUG
- O
STOP O
: O
Spironolactone B-DRUG
until O
instructed O
to O
restart O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O

 O
- O
STOP O
: O
Gabapentin B-DRUG

 I-DRUG
- O
CHANGE O
: O
Furosemide B-DRUG
to O
20 B-STR
mg I-STR
Daily B-FRE

 I-FRE
- O
START O
: O
Prednisone B-DRUG
5 B-STR
mg I-STR
Daily B-FRE
for B-DUR
3 I-DUR
more I-DUR
days I-DUR
, I-DUR
last O
day O
[ O
* O
* O
6 O
- O
8 O
* O
* O
] O

 O
- O
START O
: O
Vitamin B-DRUG
D I-DRUG
50,000 B-STR
Units I-STR
once B-FRE
weekly I-FRE
for B-DUR
8 I-DUR
weeks I-DUR
. I-DUR
First O

 O
Day O
[ O
* O
* O
6 O
- O
5 O
* O
* O
] O
. O

 O
. O

 O
Again O
it O
was O
a O
pleasure O
participating O
in O
your O
care O
. O


 O
Followup O
Instructions O
: O

 O
Department O
: O
[ O
* O
* O
Hospital3 O
249 O
* O
* O
] O

 O
When O
: O
WEDNESDAY O
[ O
* O
* O
2171 O
- O
6 O
- O
12 O
* O
* O
] O
at O
8:50AM O

 O
With O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
1980 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
1981 O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
250 O
* O
* O
] O

 O
Building O
: O
[ O
* O
* O
Hospital6 O
29 O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
895 O
* O
* O
] O

 O
Campus O
: O
EAST O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2144 O
- O
8 O
- O
10 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2090 O
- O
5 O
- O
20 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Penicillins B-DRUG
/ O
Bactrim B-DRUG
/ O
Prilosec B-DRUG
/ O
Heparin B-DRUG
Agents I-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
6088 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
cold O
, O
painful O
right O
foot O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
1 O
. O
Insertion O
of O
Gunther-Tulip O
IVC O
filter O
, O
jugular O
approach O
. O

 O
2 O
. O
Venous O
iliofemoral O
and O
femoral O
popliteal O
thrombectomy O
. O

 O
3 O
. O
Right O
groin O
AV O
fistula O
. O


 O
History O
of O
Present O
Illness O
: O

 O
54F O
s/p O
right O
total O
knee O
replacement O
[ O
* O
* O
2144 O
- O
7 O
- O
16 O
* O
* O
] O
. O
  O
Presented O
to O

 O
[ O
* O
* O
Hospital3 O
17031 O
* O
* O
] O
on O
[ O
* O
* O
2144 O
- O
7 O
- O
29 O
* O
* O
] O
with O
3 O
- O
4 O
day O
h/o O
shortness O
of O

 O
breath O
, O

 O
new O
RLE O
swelling O
, O
and O
right O
foot O
pain O
. O
  O
CTA O
chest O
at O
that O
time O

 O
demonstrated O
PE O
. O
  O
BLE O
US O
demonstrated O
DVT O
in O
right O
comomon O

 O
femoral O
vein O
, O
superficial O
femoral O
vein O
, O
and O
proximal O
greater O

 O
saphenous O
vein O
; O
popliteal O
vein O
was O
not O
assessed O
. O
  O
Prior O
to O

 O
presentation O
, O
she O
was O
on O
Lovenox B-DRUG
for O
DVT B-REA
prophylaxis I-REA
; I-REA
platelet O

 O
count O
was O
41,000 O
on O
presentation O
. O
  O
Given O
suspicion B-REA
of I-REA
HIT I-REA
, I-REA
she O

 O
was O
started O
on O
an O
argatroban B-DRUG
drip B-ROU
and O
coumadin B-DRUG
for O
her B-REA
DVT I-REA
. I-REA


 O
Since O
admission O
, O
her O
foot O
has O
become O
progressively O
more O

 O
cyanotic O
, O

 O
painful O
, O
and O
swollen O
. O
  O
Report O
from O
transferring O
ICU O
physician O

 O
was O

 O
that O
right O
foot O
DP O
and O
PT O
pulses O
were O
dopplerable O
. O
  O
She O
is O

 O
transferred O
here O
for O
further O
management O
. O



 O
Past O
Medical O
History O
: O

 O
OSA O
, O
fentanyl B-DRUG
usage O
, O
mitral O
regurgitation/valve O
prolapse O
, O

 O
HTN O
, O
obesity O
, O
hyperlipidemia O
, O
asthma O
, O
h/o O
palpitations O
and O

 O
unifocal O
premature O
ventricular O
beats O
( O
followed O
by O
cardiology O

 O
here O
) O
, O
GERD O



 O
Social O
History O
: O

 O
Denies O
EtOH O
and O
tobacco O
use O
. O
  O
Former O
nurse O
[ O
* O
* O
First O
Name O
( O
Titles O
) O
* O
* O
] O
[ O
* O
* O
Hospital3 O
* O
* O
] O
Hospital O
. O
  O
Currently O
disabled O
. O



 O
Family O
History O
: O

 O
family O
cardiovascular O
illness O
, O
o/w O
noncontributory O



 O
Physical O
Exam O
: O

 O
Vital O
: O
  O
Tm99.2 O
Tc98.9 O
P80 O
BP102/60 O
RR98%RA O


 O
Gen O
: O
NAD O
, O
AAOx3 O

 O
CV O
: O
RRR O
, O
+ O
s1,s2 O

 O
Lung O
: O
CTAB O

 O
Abd O
: O
+ O
BS O
, O
Soft O
, O
NT/ND O

 O
Right O
foot O
: O
no O
drainage O
, O
less O
edematous O
, O
dressed O
with O
silvadine O

 O
ointment O
and O
gauze O
. O

 O
Palpable O
pulses O
on O
right O
LE O



 O

Pertinent O
Results O
: O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
10 O
* O
* O
] O
05:35AM O
BLOOD O
WBC-6.1 O
RBC-3.45 O
* O
Hgb-9.4 O
* O
Hct-28.9 O
* O

 O
MCV-84 O
MCH-27.3 O
MCHC-32.6 O
RDW-15.2 O
Plt O
Ct-300 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
9 O
* O
* O
] O
05:33AM O
BLOOD O
WBC-5.3 O
RBC-3.39 O
* O
Hgb-9.1 O
* O
Hct-28.5 O
* O

 O
MCV-84 O
MCH-27.0 O
MCHC-32.1 O
RDW-15.2 O
Plt O
Ct-234 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
8 O
* O
* O
] O
06:07AM O
BLOOD O
WBC-6.2 O
RBC-3.41 O
* O
Hgb-9.2 O
* O
Hct-28.2 O
* O

 O
MCV-83 O
MCH-26.8 O
* O
MCHC-32.5 O
RDW-15.0 O
Plt O
Ct-213 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
7 O
* O
* O
] O
04:00AM O
BLOOD O
WBC-8.2 O
RBC-3.55 O
* O
Hgb-9.8 O
* O
Hct-29.2 O
* O

 O
MCV-82 O
MCH-27.5 O
MCHC-33.4 O
RDW-15.0 O
Plt O
Ct-194 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
6 O
* O
* O
] O
06:23AM O
BLOOD O
WBC-8.2 O
RBC-3.54 O
* O
Hgb-9.5 O
* O
Hct-29.3 O
* O

 O
MCV-83 O
MCH-26.9 O
* O
MCHC-32.5 O
RDW-15.5 O
Plt O
Ct-166 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
5 O
* O
* O
] O
03:24AM O
BLOOD O
WBC-10.2 O
RBC-3.56 O
* O
Hgb-9.9 O
* O
Hct-29.3 O
* O

 O
MCV-82 O
MCH-27.9 O
MCHC-33.8 O
RDW-15.6 O
* O
Plt O
Ct-128 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
4 O
* O
* O
] O
01:54AM O
BLOOD O
WBC-8.8 O
RBC-3.46 O
* O
Hgb-9.7 O
* O
Hct-28.6 O
* O

 O
MCV-83 O
MCH-28.1 O
MCHC-34.0 O
RDW-15.2 O
Plt O
Ct-112 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
06:02PM O
BLOOD O
WBC-9.8 O
RBC-3.60 O
* O
Hgb-10.2 O
* O
Hct-29.5 O
* O

 O
MCV-82 O
MCH-28.3 O
MCHC-34.5 O
RDW-15.4 O
Plt O
Ct-109 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
02:15AM O
BLOOD O
WBC-7.5 O
RBC-3.67 O
* O
Hgb-10.2 O
* O
Hct-30.4 O
* O

 O
MCV-83 O
MCH-27.8 O
MCHC-33.6 O
RDW-15.3 O
Plt O
Ct-89 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
04:57PM O
BLOOD O
WBC-6.6 O
RBC-3.85 O
* O
Hgb-10.8 O
* O
Hct-31.7 O
* O

 O
MCV-82 O
MCH-27.9 O
MCHC-33.9 O
RDW-15.2 O
Plt O
Ct-101 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
02:10PM O
BLOOD O
WBC-4.7 O
RBC-3.81 O
* O
Hgb-10.2 O
* O
Hct-31.0 O
* O

 O
MCV-81 O
* O
MCH-26.7 O
* O
MCHC-32.8 O
RDW-15.0 O
Plt O
Ct-119 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
09:27AM O
BLOOD O
Hct-30.6 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
03:07AM O
BLOOD O
WBC-5.5 O
RBC-3.27 O
* O
Hgb-8.8 O
* O
Hct-26.4 O
* O

 O
MCV-81 O
* O
MCH-27.0 O
MCHC-33.4 O
RDW-14.9 O
Plt O
Ct-120 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
01:11AM O
BLOOD O
Hct-28.2 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
1 O
* O
* O
] O
10:19AM O
BLOOD O
Hct-26.6 O
* O
Plt O
Ct-82 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
1 O
* O
* O
] O
04:44AM O
BLOOD O
WBC-7.3 O
RBC-3.41 O
* O
Hgb-9.1 O
* O
Hct-26.8 O
* O

 O
MCV-79 O
* O
MCH-26.8 O
* O
MCHC-34.0 O
RDW-15.2 O
Plt O
Ct-91 O
* O

 O
[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
01:20PM O
BLOOD O
WBC-11.1 O
* O
RBC-4.11 O
* O
Hgb-10.7 O
* O
Hct-33.6 O
* O

 O
MCV-82 O
MCH-26.1 O
* O
MCHC-31.9 O
RDW-15.3 O
Plt O
Ct-91 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
06:02PM O
BLOOD O
Neuts-87 O
* O
Bands-0 O
Lymphs-6.0 O
* O
Monos-5 O

 O
Eos-2 O
Baso-0 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
02:10PM O
BLOOD O
Neuts-67.5 O
Lymphs-18.8 O
Monos-7.0 O
Eos-6.4 O
* O

 O
Baso-0.4 O

 O

[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
01:20PM O
BLOOD O
Neuts-78 O
* O
Bands-2 O
Lymphs-7 O
* O
Monos-10 O

 O
Eos-3 O
Baso-0 O
Atyps-0 O
Metas-0 O
Myelos-0 O

 O
[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
01:20PM O
BLOOD O
Hypochr-NORMAL O
Anisocy-1 O
+ O

 O
Poiklo-OCCASIONAL O
Macrocy-OCCASIONAL O
Microcy-OCCASIONAL O

 O
Polychr-1 O
+ O
Ovalocy-OCCASIONAL O

 O
[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
01:20PM O
BLOOD O
Hypochr-NORMAL O
Anisocy-1 O
+ O

 O
Poiklo-OCCASIONAL O
Macrocy-OCCASIONAL O
Microcy-OCCASIONAL O

 O
Polychr-1 O
+ O
Ovalocy-OCCASIONAL O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
10 O
* O
* O
] O
05:35AM O
BLOOD O
Plt O
Ct-300 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
10 O
* O
* O
] O
05:35AM O
BLOOD O
PT-39.8 O
* O
PTT-54.3 O
* O
INR(PT)-4.3 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
9 O
* O
* O
] O
05:33AM O
BLOOD O
Plt O
Ct-234 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
9 O
* O
* O
] O
05:33AM O
BLOOD O
PT-41.9 O
* O
PTT-54.3 O
* O
INR(PT)-4.6 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
8 O
* O
* O
] O
12:15PM O
BLOOD O
PT-38.4 O
* O
PTT-52.1 O
* O
INR(PT)-4.1 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
8 O
* O
* O
] O
06:07AM O
BLOOD O
Plt O
Ct-213 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
8 O
* O
* O
] O
06:07AM O
BLOOD O
PT-36.4 O
* O
PTT-48.2 O
* O
INR(PT)-3.9 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
8 O
* O
* O
] O
02:58AM O
BLOOD O
PT-37.4 O
* O
PTT-52.2 O
* O
INR(PT)-4.0 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
7 O
* O
* O
] O
04:45PM O
BLOOD O
PT-34.7 O
* O
PTT-47.3 O
* O
INR(PT)-3.7 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
7 O
* O
* O
] O
12:47PM O
BLOOD O
PT-36.8 O
* O
PTT-67.7 O
* O
INR(PT)-3.9 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
7 O
* O
* O
] O
09:50AM O
BLOOD O
PT-39.4 O
* O
PTT-76.7 O
* O
INR(PT)-4.3 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
7 O
* O
* O
] O
04:00AM O
BLOOD O
Plt O
Ct-194 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
7 O
* O
* O
] O
04:00AM O
BLOOD O
PT-46.0 O
* O
PTT-91.3 O
* O
INR(PT)-5.2 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
6 O
* O
* O
] O
11:45PM O
BLOOD O
PT-44.1 O
* O
PTT-90.8 O
* O
INR(PT)-4.9 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
6 O
* O
* O
] O
04:55PM O
BLOOD O
PTT-85.9 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
6 O
* O
* O
] O
06:23AM O
BLOOD O
Plt O
Ct-166 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
5 O
* O
* O
] O
05:48PM O
BLOOD O
PT-34.2 O
* O
PTT-89.9 O
* O
INR(PT)-3.6 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
5 O
* O
* O
] O
03:24AM O
BLOOD O
Plt O
Ct-128 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
5 O
* O
* O
] O
03:24AM O
BLOOD O
PT-34.1 O
* O
PTT-99.6 O
* O
INR(PT)-3.6 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
4 O
* O
* O
] O
08:42AM O
BLOOD O
PT-32.8 O
* O
PTT-77.1 O
* O
INR(PT)-3.4 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
4 O
* O
* O
] O
01:54AM O
BLOOD O
Plt O
Ct-112 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
4 O
* O
* O
] O
01:54AM O
BLOOD O
PT-36.6 O
* O
PTT-107.5 O
* O
INR(PT)-3.9 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
08:07PM O
BLOOD O
PT-32.5 O
* O
PTT-81.5 O
* O
INR(PT)-3.4 O
* O

 O

[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
06:02PM O
BLOOD O
Plt O
Ct-109 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
02:56PM O
BLOOD O
PT-35.5 O
* O
PTT-90.4 O
* O
INR(PT)-3.8 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
08:55AM O
BLOOD O
PT-37.0 O
* O
PTT-82.6 O
* O
INR(PT)-4.0 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
02:15AM O
BLOOD O
Plt O
Ct-89 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
08:46PM O
BLOOD O
PTT-82.9 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
04:57PM O
BLOOD O
Plt O
Ct-101 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
04:57PM O
BLOOD O
PT-43.4 O
* O
PTT-103 O
* O
INR(PT)-4.8 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
02:10PM O
BLOOD O
Plt O
Ct-119 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
02:10PM O
BLOOD O
PT-42.8 O
* O
PTT-92.6 O
* O
INR(PT)-4.7 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
09:27AM O
BLOOD O
PTT-80.1 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
03:07AM O
BLOOD O
Plt O
Ct-120 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
03:07AM O
BLOOD O
PTT-95.1 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
12:04AM O
BLOOD O
PTT-81.5 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
1 O
* O
* O
] O
04:29PM O
BLOOD O
PT-34.1 O
* O
PTT-78.8 O
* O
INR(PT)-3.6 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
1 O
* O
* O
] O
10:19AM O
BLOOD O
Plt O
Ct-82 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
1 O
* O
* O
] O
10:19AM O
BLOOD O
PT-34.2 O
* O
PTT-87.8 O
* O
INR(PT)-3.6 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
1 O
* O
* O
] O
04:44AM O
BLOOD O
Plt O
Ct-91 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
1 O
* O
* O
] O
04:44AM O
BLOOD O
PT-31.7 O
* O
PTT-87.3 O
* O
INR(PT)-3.3 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
1 O
* O
* O
] O
12:00AM O
BLOOD O
PTT-94.6 O
* O

 O
[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
05:06PM O
BLOOD O
PT-33.1 O
* O
PTT-93.2 O
* O
INR(PT)-3.4 O
* O

 O
[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
01:20PM O
BLOOD O
Plt O
Smr-LOW O
Plt O
Ct-91 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
04:57PM O
BLOOD O
Fibrino-280 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
9 O
* O
* O
] O
05:33AM O
BLOOD O
Glucose-111 O
* O
UreaN-10 O
Creat-0.6 O
Na-142 O

 O
K-4.0 O
Cl-109 O
* O
HCO3 O
- O
25 O
AnGap-12 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
8 O
* O
* O
] O
06:07AM O
BLOOD O
Glucose-103 O
UreaN-9 O
Creat-0.6 O
Na-144 O

 O
K-4.0 O
Cl-111 O
* O
HCO3 O
- O
25 O
AnGap-12 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
7 O
* O
* O
] O
04:00AM O
BLOOD O
Glucose-114 O
* O
UreaN-10 O
Creat-0.7 O
Na-141 O

 O
K-3.9 O
Cl-107 O
HCO3 O
- O
26 O
AnGap-12 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
6 O
* O
* O
] O
06:23AM O
BLOOD O
Glucose-114 O
* O
UreaN-9 O
Creat-0.7 O
Na-141 O

 O
K-3.4 O
Cl-106 O
HCO3 O
- O
26 O
AnGap-12 O

 O

[ O
* O
* O
2144 O
- O
8 O
- O
5 O
* O
* O
] O
03:24AM O
BLOOD O
Glucose-104 O
UreaN-9 O
Creat-0.7 O
Na-141 O

 O
K-3.6 O
Cl-108 O
HCO3 O
- O
24 O
AnGap-13 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
4 O
* O
* O
] O
01:54AM O
BLOOD O
Glucose-120 O
* O
UreaN-8 O
Creat-0.7 O
Na-143 O

 O
K-4.4 O
Cl-113 O
* O
HCO3 O
- O
21 O
* O
AnGap-13 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
08:07PM O
BLOOD O
K-3.8 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
02:15AM O
BLOOD O
Glucose-117 O
* O
UreaN-7 O
Creat-0.7 O
Na-144 O

 O
K-4.0 O
Cl-114 O
* O
HCO3 O
- O
25 O
AnGap-9 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
04:57PM O
BLOOD O
Glucose-114 O
* O
UreaN-8 O
Creat-0.6 O
Na-140 O

 O
K-4.1 O
Cl-110 O
* O
HCO3 O
- O
23 O
AnGap-11 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
03:07AM O
BLOOD O
Glucose-308 O
* O
UreaN-10 O
Creat-0.7 O
Na-137 O

 O
K-4.0 O
Cl-103 O
HCO3 O
- O
26 O
AnGap-12 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
1 O
* O
* O
] O
04:44AM O
BLOOD O
Glucose-127 O
* O
UreaN-10 O
Creat-0.6 O
Na-137 O

 O
K-4.1 O
Cl-103 O
HCO3 O
- O
26 O
AnGap-12 O

 O
[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
01:20PM O
BLOOD O
Glucose-112 O
* O
UreaN-15 O
Creat-0.9 O
Na-138 O

 O
K-5.0 O
Cl-100 O
HCO3 O
- O
26 O
AnGap-17 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
8 O
* O
* O
] O
06:07AM O
BLOOD O
estGFR-Using O
this O

 O
[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
01:20PM O
BLOOD O
estGFR-Using O
this O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
02:15AM O
BLOOD O
CK(CPK)-865 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
04:57PM O
BLOOD O
CK(CPK)-929 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
03:07AM O
BLOOD O
CK(CPK)-716 O
* O
TotBili-0.7 O
DirBili-0.3 O

 O
IndBili-0.4 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
1 O
* O
* O
] O
04:44AM O
BLOOD O
CK(CPK)-87 O

 O
[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
01:20PM O
BLOOD O
CK(CPK)-53 O

 O
[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
01:20PM O
BLOOD O
CK-MB-NotDone O
cTropnT-<0.01 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
9 O
* O
* O
] O
05:33AM O
BLOOD O
Calcium-8.2 O
* O
Phos-3.7 O
Mg-2.4 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
8 O
* O
* O
] O
06:07AM O
BLOOD O
Calcium-8.4 O
Phos-3.6 O
Mg-2.2 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
7 O
* O
* O
] O
04:00AM O
BLOOD O
Calcium-8.2 O
* O
Phos-3.4 O
Mg-2.1 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
6 O
* O
* O
] O
06:23AM O
BLOOD O
Calcium-8.0 O
* O
Phos-3.5 O
Mg-2.1 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
5 O
* O
* O
] O
03:24AM O
BLOOD O
Calcium-8.4 O
Phos-3.8 O
Mg-1.9 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
4 O
* O
* O
] O
01:54AM O
BLOOD O
Calcium-8.8 O
Phos-3.7 O
Mg-2.2 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
02:15AM O
BLOOD O
Calcium-7.6 O
* O
Phos-3.4 O
Mg-2.1 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
04:57PM O
BLOOD O
Calcium-7.4 O
* O
Phos-4.2 O
Mg-2.1 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
03:07AM O
BLOOD O
Calcium-8.4 O
Phos-4.2 O
Mg-2.3 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
1 O
* O
* O
] O
04:44AM O
BLOOD O
Calcium-8.7 O
Phos-3.4 O
Mg-2.1 O

 O

[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
01:20PM O
BLOOD O
Calcium-9.9 O
Phos-4.3 O
Mg-2.5 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
03:07AM O
BLOOD O
Hapto-137 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
4 O
* O
* O
] O
07:55AM O
BLOOD O
Vanco-6.8 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
4 O
* O
* O
] O
02:25AM O
BLOOD O
Type-[**Last O
Name O
( O
un O
) O
* O
* O
] O
pH-7.42 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
10:22AM O
BLOOD O
Type-ART O
pO2 O
- O
91 O
pCO2 O
- O
43 O
pH-7.37 O

 O
calTCO2 O
- O
26 O
Base O
XS-0 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
09:08AM O
BLOOD O
Type-ART O
pO2 O
- O
82 O
* O
pCO2 O
- O
44 O
pH-7.39 O

 O
calTCO2 O
- O
28 O
Base O
XS-0 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
02:29AM O
BLOOD O
Type-ART O
pO2 O
- O
86 O
pCO2 O
- O
42 O
pH-7.42 O

 O
calTCO2 O
- O
28 O
Base O
XS-2 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
07:09PM O
BLOOD O
Type-ART O
pO2 O
- O
101 O
pCO2 O
- O
44 O
pH-7.40 O

 O
calTCO2 O
- O
28 O
Base O
XS-1 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
05:08PM O
BLOOD O
Type-ART O
pO2 O
- O
86 O
pCO2 O
- O
42 O
pH-7.39 O

 O
calTCO2 O
- O
26 O
Base O
XS-0 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
03:43PM O
BLOOD O
Type-ART O
Rates-/10 O
Tidal O
V-700 O
FiO2 O
- O
58 O

 O
pO2 O
- O
186 O
* O
pCO2 O
- O
41 O
pH-7.41 O
calTCO2 O
- O
27 O
Base O
XS-1 O
Intubat-INTUBATED O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
01:49PM O
BLOOD O
Type-ART O
Rates-/11 O
Tidal O
V-700 O
FiO2 O
- O
59 O

 O
pO2 O
- O
198 O
* O
pCO2 O
- O
36 O
pH-7.47 O
* O
calTCO2 O
- O
27 O
Base O
XS-3 O
Intubat-INTUBATED O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
11:06AM O
BLOOD O
Type-ART O
Rates-/10 O
Tidal O
V-700 O
FiO2 O
- O
86 O

 O
pO2 O
- O
235 O
* O
pCO2 O
- O
40 O
pH-7.46 O
* O
calTCO2 O
- O
29 O
Base O
XS-5 O
AADO2 O
- O
356 O
REQ O

 O
O2 O
- O
62 O
Intubat-INTUBATED O
Vent-CONTROLLED O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
03:10PM O
BLOOD O
K-3.8 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
09:08AM O
BLOOD O
Glucose-115 O
* O
K-3.5 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
01:49PM O
BLOOD O
Glucose-99 O
Lactate-0.9 O
Na-139 O
K-4.0 O

 O
Cl-106 O
calHCO3 O
- O
27 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
11:06AM O
BLOOD O
Glucose-104 O
Lactate-0.9 O
Na-139 O
K-4.6 O

 O
Cl-102 O
calHCO3 O
- O
29 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
10:22AM O
BLOOD O
O2 O
Sat-95 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
09:08AM O
BLOOD O
O2 O
Sat-94 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
07:09PM O
BLOOD O
O2 O
Sat-96 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
03:43PM O
BLOOD O
Hgb-11.0 O
* O
calcHCT-33 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
01:49PM O
BLOOD O
Hgb-10.4 O
* O
calcHCT-31 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
11:06AM O
BLOOD O
Hgb-11.0 O
* O
calcHCT-33 O

 O

[ O
* O
* O
2144 O
- O
8 O
- O
4 O
* O
* O
] O
02:25AM O
BLOOD O
freeCa-1.08 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
09:08AM O
BLOOD O
freeCa-1.12 O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
3 O
* O
* O
] O
02:29AM O
BLOOD O
freeCa-1.11 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
01:49PM O
BLOOD O
freeCa-1.10 O
* O

 O
[ O
* O
* O
2144 O
- O
8 O
- O
2 O
* O
* O
] O
11:06AM O
BLOOD O
freeCa-1.12 O

 O
[ O
* O
* O
2144 O
- O
7 O
- O
31 O
* O
* O
] O
01:20PM O
BLOOD O
HEPARIN B-DRUG
DEPENDENT O
ANTIBODIES- O


 O
Brief O
Hospital O
Course O
: O

 O
Patient O
is O
a O
54-year-old O
female O
who O
had O
a O
total O
knee O
repair O
2 O

 O
weeks O
ago O
and O
subsequently O
developed O
heparin B-DRUG
induced B-ADE

 I-ADE
thrombocytopenia I-ADE
with O
a O
large O
right O
iliofemoral O
DVT O
and O
over O
the O

 O
past O
3 O
days O
. O
Progressive O
signs O
of O
phlegmasia O

 O
cerulea O
dolens O
. O
Despite O
aggressive O
anticoagulation B-REA
with O
direct B-DRUG

 I-DRUG
thrombin I-DRUG
inhibitors I-DRUG
and O
elevation O
, O
the O
toes O
were O
progressively O

 O
gangrenous O
and O
venous O
thrombectomy O
was O
required O
to O
prevent O
limb O

 O
loss O
. O
She O
was O
not O
a O
candidate O
for O
thrombolysis B-DRUG
, I-DRUG
due O
to O
her O

 O
recent O
knee O
replacement O
. O
  O
Patient O
was O
admitted O
and O
placed O
on O

 O
argatroban B-DRUG
for O
anticoagulation B-REA
and O
diltiazem B-DRUG
. I-DRUG
  O
Patient O
was O

 O
transfused O
2units O
x2 O
for O
low O
hct O
. O
Patient O
was O
taken O
to O
the O
OR O

 O
venous O
thrombectomy O
to O
salvage O
limb O
. O
  O
In O
the O
OR O
the O
patient O
was O

 O
found O
to O
have O
a O
patent O
left O
iliac O
venous O
system O
and O
patent O

 O
inferior O
vena O
cava O
. O
Uneventful O
deployment O
of O
a O
Tulip O
IVC O
filter O
. O

 O
Successful O
thrombectomy O
of O
the O
femoral O
vein O
of O
the O
thigh O
and O

 O
profunda O
veins O
along O
with O
large O
amount O
of O
thrombus O
removed O
from O

 O
the O
right O
iliac O
system O
. O
The O
resultant O
clearing O
was O
quite O
good O
. O

 O
AV O
fistula O
was O
placed O
from O
the O
branch O
of O
the O
anterior O
saphenous O

 O
vein O
to O
the O
superficial O
femoral O
artery O
. O
  O
Patient O
tolerated O
the O

 O
procedure O
well O
and O
was O
transferred O
in O
stable O
condition O
to O
CVICU O

 O
intubated O
and O
given O
argatatroban B-DRUG
. I-DRUG


 O
POD1 O
: O
swelling O
on O
right O
leg O
was O
much O
improved O
. O
Patient O
was O

 O
extubated O
. O

 O
SW O
was O
consulted O
and O
saw O
the O
patient O
several O
times O
for O
emotional O

 O
suppor O
and O
to O
help O
cope O
with O
her O
illness O
. O
   O
Patient O
was O

 O
continued O
tx O
of O
vanco/flagyl B-DRUG
for O
prophylaxis B-REA
. I-REA


 O
POD2 O
: O
  O
Physical O
therapy O
cleared O
for O
rehab O
. O


 O
POD3 O
: O
  O
Patient O
was O
started O
on O
coumadin B-DRUG
anticoagulation B-REA
. I-REA
Was O

 O
encouraged O
to O
be O
OOB O
for O
short O
periods O
. O
  O
Physical O
therapy O
was O

 O
c/s O
for O
dx O
& O
tx O
. O


 O
POD4 O
: O
psychiatry O
was O
consulted O
for O
assessment O
and O
management O
of O

 O
anxiety O
. O
Pt O
was O
assessed O
with O
dx O
c/w O
adjustment B-REA
d/o I-REA
with I-REA
mixed I-REA

 I-REA
anxiety/depression I-REA
and O
recommended O
ativan B-DRUG
0.5 B-STR
mg I-STR
PO B-ROU
TID B-FRE
PRN I-FRE

 I-FRE
anxiety B-REA
. I-REA
  O
Psychiatry O
continued O
to O
follow O
during O
her O
stay O
. O



 O
POD5 O
: O
  O
Argatroban B-DRUG
was O
stopped O
( O
PTT O
was O
102.0 O
and O
INR O
was O
5.1 O
) O

 O
and O
INR O
checked O
four O
hours O
later O
to O
allow O
the O
effects O
of O

 O
argatroban B-DRUG
to O
wear O
off O
( O
PTT90.8 O
, O
INR4.9 O
at O
that O
time O
) O
. O
  O
Due O
to O

 O
therapeutic O
INR O
, O
  O
argatroban B-DRUG
remained O
off O
and O
patient O
was O

 O
anticoagulated B-REA
with O
coumadin B-DRUG
only O
with O
target O
INR O
[ O
* O
* O
3 O
- O
1 O
* O
* O
] O
. O

 O
Silvadine B-DRUG
was O
applied B-ROU
to O
right B-REA
foot I-REA
wound I-REA
. I-REA
And O
activity O
was O

 O
increased O
to O
touchdown O
weight O
bearing O
of O
right O
heel O
. O


 O
POD6 O
: O
  O
INR O
3.7 O
and O
PTT O
45.9 O
  O
and O
coumadin B-DRUG
7.5 B-STR
mg I-STR
given O
and O

 O
PTT/INR O
cont O
to O
followed O
. O

 O
POD8 O
: O
  O
INR O
4.3 O
and O
PTT O
54.3 O
, O
last O
INR O
prior O
to O
D/C O


 O
Medications O
on O
Admission O
: O

 O
Advair B-DRUG
, I-DRUG
Protonix B-DRUG
, I-DRUG
verapamil B-DRUG
240 B-STR
, I-STR
baby B-STR
aspirin B-DRUG
. I-DRUG



 O
Discharge O
Medications O
: O

 O
1 O
. O
Miconazole B-DRUG
Nitrate I-DRUG
2 B-STR
% I-STR
Powder B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU
TID B-FRE

 I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
2 O
. O
Fluticasone-Salmeterol B-DRUG
250 B-STR
- I-STR
50 I-STR
mcg/Dose I-STR
Disk B-FOR
with I-FOR
Device I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Disk B-FOR
with I-FOR
Device I-FOR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
3 O
. O
Aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Diltiazem B-DRUG
HCl I-DRUG
60 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1.5 B-DOS
Tablets B-FOR
PO B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
17 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Puff B-FOR
Inhalation B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
6 O
. O
Atorvastatin B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Albuterol B-DRUG
90 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
Four B-DOS
( I-DOS
4 I-DOS
) I-DOS
Puff B-FOR

 I-FOR
Inhalation B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
8 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( I-STR
0.083 I-STR
% I-STR
) I-STR
Solution B-FOR
for I-FOR

 I-FOR
Nebulization I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Inhalation B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE

 I-FRE
needed I-FRE
. I-FRE

 O
9 O
. O
Nystatin B-DRUG
100,000 B-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
QID B-FRE

 I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
0.02 B-STR
% I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Inhalation B-ROU

 I-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
11 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
13 O
. O
Menthol-Cetylpyridinium B-DRUG
3 B-STR
mg I-STR
Lozenge B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Lozenge B-FOR

 I-FOR
Mucous B-ROU
membrane I-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
. I-FRE

 O
14 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
15 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
16 O
. O
Silver B-DRUG
Sulfadiazine I-DRUG
1 B-STR
% I-STR
Cream B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
17 O
. O
Hydromorphone B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE

 I-FRE
4 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
18 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE

 I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O

19 O
. O
Lorazepam B-DRUG
0.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q8H B-FRE
( I-FRE
every I-FRE
8 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
20 O
. O
Magnesium B-DRUG
Hydroxide I-DRUG
400 B-STR
mg/5 I-STR
mL I-STR
Suspension B-FOR
Sig O
: O
Thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS

 I-DOS
ML I-DOS
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
21 O
. O
Warfarin B-DRUG
3 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Once B-FRE
Daily I-FRE
at I-FRE
4 I-FRE

 I-FRE
PM I-FRE
: I-FRE
goal O
INR O
[ O
* O
* O
3 O
- O
1 O
* O
* O
] O
. O

 O
22 O
. O
Bisacodyl B-DRUG
10 B-STR
mg I-STR
Suppository B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Suppository B-FOR
Rectal B-ROU

 I-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
23 O
. O
Insulin B-DRUG

 I-DRUG
Insulin B-DRUG
SC O
  O
( O
per O
Insulin B-DRUG
Flowsheet O
) O

       O
Sliding B-DOS
Scale I-DOS


 I-DOS
Fingerstick O
QACHSInsulin B-DRUG
SC B-ROU
Sliding B-DOS
Scale I-DOS

   I-DOS
Q6H B-FRE

 I-FRE
Regular O

 O
Glucose O
Insulin B-DRUG
Dose O

 O
0 B-REA
- I-REA
60 I-REA
   I-REA
mg/dL I-REA
[ O
* O
* O
1 O
- O
29 O
* O
* O
] O
amp B-FOR
D50 B-DRUG

 I-DRUG
61 O
- O
120 O
   O
mg/dL O
0 O
   O
Units O

 O
121 O
- O
140 O
   O
mg/dL O
2 O
   O
Units O

 O
141 O
- O
160 O
   O
mg/dL O
3 O
   O
Units O

 O
161 O
- O
180 O
   O
mg/dL O
4 O
   O
Units O

 O
181 O
- O
200 O
   O
mg/dL O
5 O
   O
Units O

 O
201 O
- O
220 O
   O
mg/dL O
6 O
   O
Units O

 O
221 O
- O
240 O
   O
mg/dL O
7 O
   O
Units O

 O
241 O
- O
260 O
   O
mg/dL O
8 O
   O
Units O

 O
261 O
- O
280 O
   O
mg/dL O
9 O
   O
Units O

 O
281 O
- O
300 O
   O
mg/dL O
10 O
   O
Units O

 O
301 O
- O
320 O
   O
mg/dL O
11 O
   O
Units O

 O
321 O
- O
340 O
   O
mg/dL O
12 O
   O
Units O

 O
341 O
- O
360 O
   O
mg/dL O
13 O
   O
Units O

 O
> O
360 O
   O
mg/dL O
Notify O
M.D. O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
* O
* O
] O
Hospital O
[ O
* O
* O
Hospital1 O
189 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Phlegmasia O
, O
venous O
gangrene O
R O
lower O
extremity O

 O
OSA O

 O
fentanyl B-DRUG
usage O
, O

 O
mitral O
regurgitation/valve O
prolapse O

 O
HTN O

 O
obesity O

 O
hyperlipidemia O

 O
asthma O

 O
h/o O
palpitations O
and O
unifocal O
premature O
ventricular O
beats O

 O
( O
followed O
by O
cardiology O
here O
) O

 O
GERD O



 O
Discharge O
Condition O
: O

 O
Good O



 O
Discharge O
Instructions O
: O

 O
- O
You O
had-Insertion O
of O
Gunther-Tulip O
IVC O
filter O
, O
jugular O

 O
approach O
, O

   O
Venous O
iliofemoral O
and O
femoral O
popliteal O
thrombectomy O
, O
Right O

 O
groin O

   O
AV O
fistula O
. O


 O
- O
You O
will O
resume O
activities O
per O
your O
prescribed O
activity O

 O
limitations O
. O


 O
- O
Your O
R O
foot O
wound O
care O
per O
orders O
. O


 O
- O
FU O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
as O
scheduled O
. O


 O
- O
Keep O
your O
other O
FU O
as O
scheduled O
. O



 O

Followup O
Instructions O
: O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
251 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
1490 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
1237 O
* O
* O
] O

 O
Date/Time:[**2144 O
- O
8 O
- O
19 O
* O
* O
] O
10:00 O

 O
Provider O
: O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
Phone:[**Telephone/Fax O
( O
1 O
) O
16827 O
* O
* O
] O
Date/Time:[**2144 O
- O
12 O
- O
2 O
* O
* O
] O
8:40 O




 O
Completed O
by:[**2144 O
- O
8 O
- O
10 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2126 O
- O
12 O
- O
4 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2127 O
- O
1 O
- O
12 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2080 O
- O
3 O
- O
28 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
3326 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
R O
basilic O
vein O
thrombosis O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
R O
heart O
catheterization O

 O
L O
internal O
jugular O
central O
venous O
line O

 O
L O
radial O
arterial O
line O


 O
History O
of O
Present O
Illness O
: O

 O
Ms. O
[ O
* O
* O
Known O
lastname O
28331 O
* O
* O
] O
is O
a O
46 O
year O
old O
woman O
with O
history O
of O
AML B-REA
s/p O

 O
allogeneic O
stem O

 O
cell O
transplant O
from O
an O
unrelated O
donor O
in O
[ O
* O
* O
2124 O
- O
10 O
- O
24 O
* O
* O
] O
, O
with O

 O
TBI B-DRUG
and O
Cytoxan B-DRUG
for O
conditioning O
regimen O
. O
  O
Her O
course O
was O

 O
complicated O
by O
graft O
versus O
host O
disease O
of O
the O
skin O
and O
lungs O
, O

 O
hypertension O
and O
numerous O
steroid-related B-DRUG
complications O
such O
as O

 O
diabetes B-ADE
, I-ADE
steroid B-DRUG
myopathy B-ADE
, I-ADE
and O
increased O
peripheral O
edema O
. O

 O
. O

 O
She O
presents O
today O
from O
clinic O
with O
right O
arm O
swelling O
( O
she O
had O

 O
a O
PICC O
in O
the O
arm O
) O
and O
was O
found O
to O
have O
a O
completely O
occluded O

 O
right O
basilic O
vein O
. O
  O
She O
has O
some O
pain O
in O
the O
right O
arm O
, O

 O
especially O
with O
movement O
. O
  O
The O
PICC O
line O
was O
pulled O
and O
she O
was O

 O
admitted O
for O
anticoagulation O
. O

 O
. O

 O
Of O
note O
, O
she O
was O
recently O
discharged O
after O
she O
was O
admitted O
with O

 O
Enterococcal B-REA
bacteremia I-REA
( O
vanco B-DRUG
sensitive O
) O
; O
she O
finished O
her O

 O
course O
of O
ampicillin B-DRUG
yesterday O
. O
  O
She O
has O
otherwise O
been O
doing O

 O
well O
at O
rehab-- O
she O
has O
been O
slowly O
diuresed O
and O
is O
making O
some O

 O
progress O
with O
PT O
. O


 O
Past O
Medical O
History O
: O

 O
PMH/PSH O
: O

 O
1 O
) O
Acute O
Myelogenous O
Leukemia O
type O
M2 O
s/p O
matched O
unrelated O

 O
donor O
stem O
cell O
transplant O
[ O
* O
* O
10 O
- O
29 O
* O
* O
] O
; O
complicated O
by O
GVHD O
of O
the O

 O
liver O
, O
skin O
and O
lungs O
. O

 O
2 O
) O
Bronchiolitis O
Obliterans O

 O
- O
PFTs O
[ O
* O
* O
2126 O
- O
6 O
- O
6 O
* O
* O
] O
showed O
FEV1 O
0.47 O
L/17 O
% O
of O
predicted O
, O
FEV1/FVC O
41 O
% O

 O
- O
developed O
due O
to O
GVHD O
[ O
* O
* O
6 O
- O
29 O
* O
* O
] O

 O
- O
at O
End O
Stage O
Lung O
Disease O
- O
severely O
limited O
functional O
status O


 O
40 O
( O
on O
prior O
admission O
) O

 O
3 O
) O
Right O
lung O
abscess O
, O
s/p O
resection O

 O
4 O
) O
Pulmonary O
nodules O
with O
geotrichum O

 O
5 O
) O
Diabetes O
Mellitus O
, O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
steroid O
treatment O

 O
6 O
) O
Hypertension O



 O

Social O
History O
: O

 O
Patient O
lives O
with O
mother O
, O
but O
has O
been O
at O
rehab O
since O
her O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O

 O
discharge O
one O
week O
ago O
. O
Currently O
unemployed O
. O
Previously O

 O
worked O
as O
stock O
clerk O
. O
Quit O
smoking O
2 O
years O
ago O
. O
Occasional O
EtOH O

 O
use O
. O


 O
Family O
History O
: O

 O
No O
history O
of O
oncologic O
diseases O
. O



 O
Physical O
Exam O
: O

 O
Vitals O
on O
arrival O
to O
the O
floor O
: O
97.7 O
, O
60 O
, O
120/92 O
, O
100 O
% O
3L O
NC O

 O
Gen O
: O
Obese O
cushingoid O
female O
pleasant O
, O
sitting O
up O
in O
bed O
. O
Wearin O

 O
oxygen O

 O
HEENT O
: O
+ O
mucous O
on O
eyelashes O
and O
injected O
conjunctivae O
b/l- O
old O

 O
per O
patient O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
GVHD O
. O
No O
scleral O
icterus O
. O

 O
Neck O
: O
No O
cervical O
LAD O
. O
JVP O
could O
not O
be O
appreciated O
. O

 O
CV O
: O
nml O
S1 O
, O
S2 O
, O
no O
m/r/g O

 O
Lungs O
: O
occ O
wheeze O
, O
but O
overall O
CTA O
b/l O

 O
Extremities O
: O
4 O
+ O
pitting O
edema O
of O
the O
legs O
, O
L O
+ O
R O
, O
to O
the O
thigh O
. O

 O
No O
areas O
of O
cellulitis O
on O
legs O
or O
arms O
. O
Some O
weeping O
of O
clear O

 O
fluid O
from O
anterior O
left O
leg O
and O
right O
arm O
( O
at O
sites O
where O
she O

 O
has O
scabs O
and O
scratches O
) O
. O
  O
Extremities O
somewhat O
cool O
to O
touch O
, O

 O
but O
2 O
+ O
DPP O
b/l O
and O
radial O
pulse O
. O

 O
Neuro O
: O
CN O
II- O
XII O
grossly O
intact O
. O
  O
Gait O
deferred O
. O

 O
Upper O
extremities O
: O
No O
increases O
tone O
. O
2 O
+ O
DTRs O
. O
4/5 O
strength O

 O
throughout O
. O

 O
Lower O
extremities O
: O
2/5 O
strength O
present O
in O
proximal O
muscles O
with O


 O
[ O
* O
* O
3 O
- O
29 O
* O
* O
] O
in O
distal O
muscles O
s/l O
. O
No O
reflexes O
elicited O
. O


 O
Pertinent O
Results O
: O

 O
ADMISSION O
LABS O
: O

 O
[ O
* O
* O
2126 O
- O
12 O
- O
4 O
* O
* O
] O
11:20AM O
BLOOD O
WBC-6.4 O
RBC-2.67 O
* O
Hgb-9.9 O
* O
Hct-30.7 O
* O

 O
MCV-115 O
* O
MCH-37.3 O
* O
MCHC-32.4 O
RDW-15.8 O
* O
Plt O
Ct-131 O
* O

 O
[ O
* O
* O
2126 O
- O
12 O
- O
4 O
* O
* O
] O
11:20AM O
BLOOD O
Neuts-86.2 O
* O
Lymphs-7.6 O
* O
Monos-5.3 O
Eos-0.7 O

 O
Baso-0.1 O

 O
[ O
* O
* O
2126 O
- O
12 O
- O
4 O
* O
* O
] O
11:20AM O
BLOOD O
Plt O
Ct-131 O
* O

 O
[ O
* O
* O
2126 O
- O
12 O
- O
4 O
* O
* O
] O
11:20AM O
BLOOD O
UreaN-37 O
* O
Creat-1.3 O
* O
Na-142 O
K-3.6 O
Cl-96 O

 O
HCO3 O
- O
40 O
* O
AnGap-10 O

 O
[ O
* O
* O
2126 O
- O
12 O
- O
4 O
* O
* O
] O
11:20AM O
BLOOD O
ALT-15 O
AST-16 O
LD(LDH)-255 O
* O
AlkPhos-669 O
* O

 O
TotBili-0.3 O
DirBili-0.2 O
IndBili-0.1 O

 O
[ O
* O
* O
2126 O
- O
12 O
- O
4 O
* O
* O
] O
11:20AM O
BLOOD O
Calcium-8.3 O
* O
Phos-3.5 O
Mg-1.8 O

 O
UricAcd-10.1 O
* O
Cholest-156 O


 O
DISCHARGE O
LABS O
: O


 O
RADIOLOGY O
: O

 O
[ O
* O
* O
2126 O
- O
12 O
- O
4 O
* O
* O
] O
RUE O
US O
: O
Basilic O
vein O
thrombosis O

 O
[ O
* O
* O
2126 O
- O
12 O
- O
4 O
* O
* O
] O
Bilateral O
LE O
US O
: O
No O
evidence O
of O
DVT O



 O
[ O
* O
* O
2126 O
- O
12 O
- O
11 O
* O
* O
] O
Renal O
US O
: O
Unremarkable O
renal O
ultrasound O
without O

 O
evidence O
of O
vascular O
abnormality O
. O



 O
Brief O
Hospital O
Course O
: O

 O
1 O
. O
Anasarca O
: O
The O
patient O
appeared O
to O
be O
total O
body O
overloaded O
by O

 O
intravascularly O
dry O
at O
admission O
. O
She O
[ O
* O
* O
Month/Day/Year O
1834 O
* O
* O
] O
right O
heart O

 O
catheterization O
on O
[ O
* O
* O
2126 O
- O
12 O
- O
6 O
* O
* O
] O
that O
showed O
pulmonary B-REA
hypertension I-REA

 I-REA
( O
systolic O
BP O
45 O
, O
diastolic O
BP O
20 O
, O
mean O
BP O
28 O
) O
. O
She O
was O
therefore O

 O
started O
on O
sildenafil B-DRUG
. I-DRUG
The O
nephrology O
service O
was O
consulted O
, O
and O

 O
she O
diuresed B-REA
well O
on O
a O
regimen O
on O
albumin B-DRUG
, I-DRUG
lasix B-DRUG
, I-DRUG
and O

 O
chlorthiazide B-DRUG
( O
then O
metolazone B-DRUG
) I-DRUG
. O
Her O
diuresis O
was O
discontinued O

 O
on O
[ O
* O
* O
1 O
- O
8 O
* O
* O
] O
because O
of O
development O
of O
hypotension O
occuring O
in O
the O

 O
setting O
of O
a O
urinary O
tract O
infection O
. O
Subsequently O
, O
she O
was O

 O
transferred O
to O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
for O
hypotension O
( O
see O
below O
) O
where O

 O
sildenafil B-DRUG
was O
d/c'd O
as O
the O
patient O
was O
unlikely O
benefiting O
from O

 O
it O
in O
the O
setting O
of O
relatively O
mild O
to O
moderate O
pulmonary O
HTN O

 O
and O
overall O
systemic O
hypotension O
. O


 O
2 O
. O
UTI B-REA
: I-REA
She O
developed O
a O
urinary O
tract O
infection O
with O
Pseudomonas O

 O
on O
[ O
* O
* O
12 O
- O
15 O
* O
* O
] O
and O
was O
treated O
with O
a O
two B-DUR
week I-DUR
course O
of O
levofloxacin B-DRUG

 I-DRUG
then O
ciprofloxacin B-DRUG
. I-DRUG
A O
repeat O
urine O
culture O
was O
obtained O
for O

 O
followup O
on O
[ O
* O
* O
1 O
- O
2 O
* O
* O
] O
although O
she O
was O
afebrile O
and O
had O
no O
urinary O

 O
complaints O
. O
This O
culture O
again O
grew O
out O
Pseudomonas O
, O
this O
time O

 O
quinolone B-DRUG
resistant O
. O
Her O
foley O
catheter O
was O
changed O
, O
as O
she O

 O
refused O
to O
have O
it O
removed O
. O
She O
subsequently O
developed O
a O
fever O

 O
to O
101.3 O
on O
[ O
* O
* O
1 O
- O
7 O
* O
* O
] O
and O
was O
started O
on O
cefepime B-DRUG
, I-DRUG
with O
addition O
of O

 O
vancomycin B-DRUG
and O
flagyl B-DRUG
on O
[ O
* O
* O
1 O
- O
8 O
* O
* O
] O
. O
Upon O
transfer O
to O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
for O

 O
hypotension O
and O
tachycardia O
( O
see O
below O
) O
, O
she O
was O
continued O
on O

 O
vancomycin B-DRUG
, I-DRUG
cefepime B-DRUG
, I-DRUG
and O
flagyl B-DRUG
. I-DRUG
A O
central O
venous O
line O
and O

 O
arterial O
line O
were O
placed O
under O
sterile O
conditions O
. O
After O
24 O

 O
hours O
in O
the O
ICU O
, O
the O
patient O
was O
on O
3 O
pressors B-DRUG
with O
the O

 O
differential O
diagnosis O
including O
septic O
vs. O
cardiogenic O
shock O
. O

 O
Meropenem B-DRUG
was O
added O
as O
for O
double B-REA
gram-negative I-REA
and I-REA
Psuedomonas I-REA

 I-REA
coverage I-REA
. I-REA
In O
spite O
of O
maximal O
medical O
therapy O
, O
the O
patient O

 O
remained O
maxed O
out O
on O
3 O
pressors B-DRUG
. I-DRUG
A O
repeat O
family O
meeting O
was O

 O
held O
with O
the O
pt O
's O
HCP O
and O
mother O
, O
who O
agreed O
to O
make O
the O

 O
patient O
CMO O
. O
She O
expired O
shortly O
thereafter O
. O
An O
autospy O
was O

 O
offered O
, O
but O
declined O
. O



 O
3 O
. O
Hypotension B-REA
and O
tachycardia B-REA
: I-REA
She O
developed O
hypotension O
to O
the O

 O
70 O
's O
sytolic O
on O
[ O
* O
* O
1 O
- O
8 O
* O
* O
] O
which O
responded O
initially O
to O
fluid B-DRUG
boluses B-DOS
. I-DOS

 O
Her O
hypotension O
was O
thought O
to O
reflect O
both O
aggressive O
diuresis O

 O
and O
possible O
urosepsis O
. O
She O
developed O
tachycardia B-REA
to I-REA
the I-REA
120 I-REA
's I-REA

 I-REA
on O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
with O
a O
new O
RBBB O
. O
She O
was O
transferred O
to O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
where O

 O
she O
was O
given O
adenosine B-DRUG
6 B-STR
mg I-STR
X O
2 B-DOS
with O
conversion O
to O
sinus O

 O
tachycaria O
after O
the O
second O
dose O
of O
adenosine B-DRUG
. I-DRUG
However O
, O
she O
went O

 O
back O
into O
a O
wide O
complex O
tachycardia O
with O
a O
RBBB O
pattern O
soon O

 O
thereafter O
. O
The O
cardiology O
team O
evaluated O
her O
and O
felt O
that O
this O

 O
rhythm O
was O
most O
likely O
an O
SVT O
with O
rate O
related O
aberancy O
; O

 O
however O
the O
following O
day O
, O
after O
reviewing O
the O
EKG O
strips O
with O

 O
the O
EP O
attending O
, O
the O
patient O
was O
determined O
to O
have O
a O
fasicular B-REA

 I-REA
ventricular I-REA
tachycardia I-REA
in O
the O
setting O
of O
no O
known O
prior O
CAD O
or O

 O
ischemic O
scar O
. O
The O
treatment O
of O
choice O
in O
this O
setting O
would O

 O
have O
been O
verapimil B-DRUG
; I-DRUG
however O
this O
was O
not O
feasible O
as O
the O

 O
patient O
was O
already O
on O
3 O
pressors B-REA
( O
neo B-DRUG
, I-DRUG
levophed B-DRUG
, I-DRUG
and O

 O
vasopressin B-DRUG
) I-DRUG
. O
The O
following O
day O
, O
a O
dose O
of O
verapimil B-DRUG
was O
tried O

 O
given O
concern O
for O
possibly O
worsening O
cardiogenic O
shock O
( O
however O

 O
the O
patient O
's O
extremities O
remained O
warm O
to O
palpation O
, O
which O

 O
suggested O
likely O
septic O
shock O
) O
with O
conversion O
back O
to O
sinus O

 O
tachycardia O
. O
She O
was O
not O
cardioverted O
secondary O
to O
the O
patient O
's O

 O
wishes O
to O
remain O
DNR/DNI O
. O
Given O
the O
patient O
's O
lack O
of O

 O
improvement O
in O
spite O
of O
maximal O
medical O
care O
, O
the O
patient O
was O

 O
made O
CMO O
after O
another O
family O
meeting O
and O
expired O
shortly O

 O
thereafter O
. O


 O
3 O
. O
C. B-REA
diff I-REA
colitis I-REA
: I-REA
She O
experienced O
loose O
stools O
after O
admission O

 O
and O
a O
stool O
sample O
was O
positive O
for O
C. O
diff O
toxin O
on O
[ O
* O
* O
12 O
- O
8 O
* O
* O
] O
; O
she O

 O
was O
subsequently O
treated O
with O
a O
14 B-DUR
day I-DUR
course O
of O
flagyl B-DRUG
. I-DRUG
This O

 O
was O
restarted O
on O
[ O
* O
* O
1 O
- O
8 O
* O
* O
] O
as O
noted O
above O
in O
the O
context O
of O
recurrent O

 O
fever O
and O
increased O
stooling O
. O


 O
4 O
. O
Right B-REA
basilic I-REA
vein I-REA
thrombosis I-REA
: I-REA
The O
patient O
's O
PICC O
line O
was O

 O
removed O
and O
she O
was O
started O
on O
IV B-ROU
heparin B-DRUG
and O
then O
coumadin B-DRUG
. I-DRUG
Her O

 O
anticoagulation B-DRUG
was O
discontinued O
in O
the O
setting O
of O
heme O
positive O

 O
stools O
and O
widely O
varying O
INR O
( O
thought O
likely O
to O
be O
due O
to O

 O
interactions O
with O
her O
many O
medications O
) O
. O
A O
repeat O
ultrasound O
of O

 O
the O
upper O
extremity O
showed O
no O
evidence O
of O
persistent O
thrombus O

 O
therefore O
she O
was O
not O
continued O
on O
further O
anticoagulation B-DRUG
. I-DRUG


 O
5 O
. O
AML B-REA
with I-REA
history I-REA
of I-REA
GVHD I-REA
: I-REA
She O
was O
continued O
on O
cyclosporine B-DRUG
, I-DRUG

 O
Cellcept B-DRUG
, I-DRUG
and O
her O
prednisone B-DRUG
was O
titrated O
down O
per O
BMT O

 O
recommendations O
. O



 O
6 O
. O
Elevated O
LFTs O
: O
Her O
transaminases O
, O
alkaline O
phosphatase O
, O
and O

 O
bilirubin O
were O
moderately O
elevated O
and O
thought O
to O
be O
secondary O

 O
to O
GVHD O
of O
the O
liver O
after O
review O
of O
her O
medication O
list O
and O

 O
right O
upper O
quadrant O
ultrasound O
revealed O
no O
other O
clear O
causes O

 O
of O
these O
findings O
. O
Her O
alkaline O
phosphatase O
elevation O
was O

 O
probably O
due O
at O
least O
in O
part O
to O
her O
bony O
disease O
as O
the O
bone O

 O
specific O
fraction O
was O
elevated O
as O
well O
. O


 O
7 O
. O
Acute O
renal O
failure O
: O
The O
patient O
's O
creatinine O
was O
1.3 O
at O

 O
admission O
peaking O
at O
1.9 O
. O
She O
was O
thought O
to O
be O
intravascularly O

 O
dry O
with O
prerenal O
failure O
. O
Her O
creatinine O
improved O
with O
addition O

 O
of O
albumin B-DRUG
to O
her O
diuretic O
regimen O
consistent O
with O
this O
. O


 O
8 O
. O
Pulmonary B-REA
hypertension I-REA
: I-REA
Ms. O
[ O
* O
* O
Known O
lastname O
28331 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Titles O
) O
1834 O
* O
* O
] O
right O
heart O

 O
catheterization O
on O
[ O
* O
* O
12 O
- O
7 O
* O
* O
] O
to O
assess O
whether O
pulmonary O

 O
hypertension O
might O
be O
contributing O
to O
her O
significant O
edema O
. O

 O
This O
study O
showed O
mean O
pulmonary O
pressures O
of O
28 O
and O
she O
was O

 O
subsequently O
started O
on O
sildenafil B-DRUG
, I-DRUG
which O
was O
subsequently O
d/c'd O

 O
upon O
transfer O
to O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
( O
see O
above O
) O
. O


 O
9 O
. O
Heme B-REA
positive I-REA
stools I-REA
: I-REA
As O
noted O
above O
, O
she O
had O
heme O
positive O

 O
stools O
in O
the O
setting O
of O
anticoagulation B-REA
with O
IV B-ROU
heparin B-DRUG
and O

 O
warfarin B-DRUG
and O
recent O
C. O
difficile O
colitis O
infectoin O
. O
In O
addition O
, O

 O
she O
had O
a O
prior O
history O
of O
gastritis O
on O
endoscopy O
and O
was O

 O
receiving O
steroids B-DRUG
for O
her O
GVHD B-REA
. I-REA
She O
was O
started O
on O
a O
PPI B-DRUG
and O

 O
her O
Hct O
was O
followed O
closely O
. O


 O
10 O
. O
Hyperparathyroidism B-REA
and O
vitamin B-REA
D I-REA
deficiency I-REA
: I-REA
The O
patient O
's O

 O
PTH O
was O
rechecked O
as O
the O
differential O
for O
her O
bone O
changes O
noted O

 O
on O
plain O
films O
included O
osteitis O
fibrosa O
. O
She O
was O
evaluated O
by O

 O
the O
endocrinology O
consult O
service O
who O
felt O
that O
her O

 O
hyperparathyroidism B-ADE
was O
likely O
secondary O
, O
perhaps O
due O
to O
renal O

 O
failure O
or O
steroid B-DRUG
use O
. O
Her O
vitamin O
D O
levels O
were O
rechecked O
and O

 O
found O
to O
be O
low O
. O
She O
was O
started O
on O
weekly B-FRE
vitamin B-DRUG
D I-DRUG
and O
daily B-FRE

 I-FRE
calcium B-DRUG
. I-DRUG
She O
will O
need O
repeat O
vitamin O
D O
studies O
and O
should O

 O
follow O
up O
with O
endocrinology O
for O
further O
management O
. O
She O
was O

 O
started O
on O
a O
bisphosphonate B-DRUG
per O
endocrine O
recs O
. O


 O
11 O
. O
Pulmonary O
osteoarthropathy O
: O
She O
complained O
of O
diffuse O
body O

 O
pains O
and O
aches O
. O
Imaging O
of O
her O
extremities O
was O
notable O
for O

 O
diffuse O
periosteal O
reaction O
. O
The O
endocrinology O
service O
reviewed O

 O
the O
films O
and O
felt O
the O
history O
and O
imaging O
were O
most O
consistent O

 O
with O
pulmonary O
osteoarthropathy O
. O
Her O
pain O
was O
treated O
with O
oral B-ROU

 I-ROU
dilaudid B-DRUG
as O
needed O
for O
pain B-REA
control I-REA
. I-REA



 O
12 O
. O
Eye B-REA
pains I-REA
: I-REA
Ms. O
[ O
* O
* O
Known O
lastname O
28331 O
* O
* O
] O
complained O
of O
eye O
soreness O
. O
This O
was O

 O
thought O
to O
be O
secondary O
to O
GVHD O
. O
She O
was O
started O
on O
cyclosporin B-DRUG

 I-DRUG
eye B-ROU
drops B-FOR
and O
artificial B-DRUG
tears I-DRUG
. I-DRUG
She O
was O
evaluated O
by O
the O

 O
opthalmology O
consult O
service O
who O
recommended O
addition O
of O
Refresh B-DRUG

 I-DRUG
eye B-ROU
drops B-FOR
which O
she O
continued O
with O
relief O
of O
her O
symptoms O
. O


 O
Medications O
on O
Admission O
: O

 O
Atenolol B-DRUG
100 B-STR
mg I-STR
qd B-FRE

 I-FRE
Cell B-DRUG
cept I-DRUG
[ O
* O
* O
Pager O
number O
* O
* O
] O
mg O
qam B-FRE

 I-FRE
Cellcept B-DRUG
[ O
* O
* O
Pager O
number O
* O
* O
] O
mg O
qpm B-FRE

 I-FRE
Hydralazine B-DRUG
25 B-STR
mg I-STR
q B-FRE
6 I-FRE
hrs I-FRE

 I-FRE
Neoral B-DRUG
50 B-STR
mg I-STR
qam B-FRE

 I-FRE
Neoral B-DRUG
25 B-STR
mg I-STR
qhs B-FRE

 I-FRE
Prednisone B-DRUG
15 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Valtrex B-DRUG
500 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
VFEND B-DRUG
200 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Benzonatate B-DRUG

 I-DRUG
Azithromycin B-DRUG
250 B-STR
mg I-STR
qod B-FOR

 I-FOR
Bactrim B-DRUG
DS B-STR
MWF B-FRE

 I-FRE
Lantus B-DRUG
12 B-DOS
U I-DOS
qd B-FRE

 I-FRE
HSSI B-DRUG

 I-DRUG
Zolpidem B-DRUG
10 B-STR
mg I-STR
qd B-FRE

 I-FRE
Oxycodone B-DRUG
5 B-STR
mg I-STR
prn B-FRE

 I-FRE
Odansetron B-DRUG
4 B-STR
mg I-STR
q B-FRE
8 I-FRE
hrs I-FRE
prn I-FRE

 I-FRE
Albuterol B-DRUG
prn B-FRE


 I-FRE
Discharge O
Medications O
: O

 O
n/a O


 O
Discharge O
Disposition O
: O

 O
Expired O


 O
Discharge O
Diagnosis O
: O

 O
Cardiorespiratory O
Arrest O

 O
Septic O
vs. O
cardiogenic O
shock O

 O
Psuedomonas O
UTI O

 O
Fasciular O
Ventricular O
Tachycardia O

 O
AML O
c/b O
GVHD O

 O
R O
basilic O
DVT O

 O
Acute O
renal O
failure O

 O
Anasarca O

 O
Pulmonary O
Hypertension O



 O
Discharge O
Condition O
: O

 O
expired O


 O
Discharge O
Instructions O
: O

 O
n/a O


 O
Followup O
Instructions O
: O

 O
n/a O



 O
Completed O
by:[**2127 O
- O
1 O
- O
13 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2104 O
- O
4 O
- O
10 O
* O
* O
] O
     O
Discharge O
Date O
: O
  O
[ O
* O
* O
2104 O
- O
4 O
- O
15 O
* O
* O
] O



 O
Service O
: O


 O
NOTE O
: O
  O
Day O
of O
discharge O
to O
be O
decided O
; O
possibly O
[ O
* O
* O
2104 O
- O
4 O
- O
15 O
* O
* O
] O
. O


 O
CHIEF O
COMPLAINT O
: O
  O
Melena O
. O


 O
HISTORY O
OF O
PRESENT O
ILLNESS O
: O
  O
The O
patient O
is O
an O
88-year-old O

 O
female O
with O
a O
history O
coronary O
artery O
disease O
and O
previous O

 O
colonoscopy O
in O
[ O
* O
* O
2101 O
* O
* O
] O
with O
multiple O
polyps O
presenting O
with O

 O
melena O
and O
hematemesis O
. O


 O
The O
patient O
presented O
to O
the O
Emergency O
Department O
for O

 O
evaluation O
of O
lower O
back O
and O
leg O
pain O
. O
  O
While O
there O
, O
she O

 O
developed O
melena O
and O
hematemesis O
. O
  O
The O
patient O
was O
recently O

 O
treated O
for O
a O
zoster B-REA
infection I-REA
with O
Motrin B-DRUG
times B-DUR
two I-DUR
weeks I-DUR

 I-DUR
per O
Emergency O
Department O
documentation O
. O


 O
Currently O
, O
she O
denies O
any O
fevers O
, O
chills O
, O
chest O
pain O
, O

 O
shortness O
of O
breath O
, O
or O
abdominal O
pain O
. O
  O
She O
reports O
diarrhea O

 O
today O
times O
five O
times O
. O
  O
She O
had O
not O
looked O
at O
her O
previous O

 O
stools O
. O


 O
The O
patient O
was O
hemodynamically O
stable O
in O
the O
Emergency O

 O
Department O
. O
  O
In O
the O
Emergency O
Department O
, O
a O
nasogastric B-ROU
tube I-ROU

 I-ROU
was O
placed O
and O
lavage O
did O
not O
clear O
with O
2 B-DOS
liters I-DOS
of O
lavage B-DRUG
. I-DRUG

 O
She O
received O
Kayexalate B-DRUG
for O
a O
potassium B-REA
of I-REA
6 I-REA
, I-REA
calcium B-DRUG
, I-DRUG

 I-DRUG
insulin B-DRUG
, I-DRUG
and O
D-50 B-DRUG
. I-DRUG
  O
Her O
electrocardiogram O
also O
showed O
peaked O

 O
T O
waves O
consistent O
with O
hyperkalemia O
. O



 O
PAST O
MEDICAL O
HISTORY O
: O

  O
1 O
. O
  O
Coronary O
artery O
disease O
; O
status O
post O
coronary O
artery O

 O
bypass O
graft O
in O
[ O
* O
* O
2097 O
* O
* O
] O
with O
saphenous O
vein O
graft O
to O
the O
first O

 O
obtuse O
marginal O
, O
saphenous O
vein O
graft O
to O
posterior O
descending O

 O
artery O
, O
and O
saphenous O
vein O
graft O
to O
the O
left O
anterior O

 O
descending O
artery O
. O
  O
She O
is O
status O
post O
multiple O
percutaneous O

 O
transluminal O
coronary O
angioplasties O
with O
brachy O
therapy O
. O

  O
2 O
. O
  O
Gastroesophageal O
reflux O
disease O
. O

  O
3 O
. O
  O
Depression O
. O

  O
4 O
. O
  O
Degenerative O
joint O
disease O
. O

  O
5 O
. O
  O
Irritable O
bowel O
syndrome O
. O

  O
6 O
. O
  O
B12 O
deficiency O
( O
pernicious O
anemia O
) O
. O

  O
7 O
. O
  O
Chronic O
renal O
insufficiency O
( O
with O
a O
baseline O
creatinine O

 O
of O
1.2 O
) O
. O

  O
8 O
. O
  O
Anemia O
( O
with O
a O
baseline O
hematocrit O
of O
26 O
to O
32 O
) O
. O

  O
9 O
. O
  O
Recent O
urinary O
tract O
infections O
. O

 O
10 O
. O
  O
Status O
post O
total O
abdominal O
hysterectomy O
and O
small-bowel O

 O
obstruction O
. O

 O
11 O
. O
  O
A O
2-D O
echocardiogram O
in O
[ O
* O
* O
2102 O
- O
9 O
- O
26 O
* O
* O
] O
showing O
an O

 O
ejection O
fraction O
of O
greater O
than O
70 O
% O
, O
moderate O
left O

 O
ventricular O
hypertrophy O
, O
normal O
right O
wall O
motion O
, O
1 O
+ O
aortic O

 O
insufficiency O
, O
and O
1 O
+ O
mitral O
regurgitation O
, O
and O
diastolic O

 O
dysfunction O
. O

 O
12 O
. O
  O
History O
of O
Kaposi O
sarcoma O
resected O
in O
[ O
* O
* O
2103 O
- O
5 O
- O
27 O
* O
* O
] O
. O


 O
ALLERGIES B-ADE
: I-ADE
  O
BACTRIM B-DRUG
, I-DRUG
CIPROFLOXACIN B-DRUG
, I-DRUG
and O
AMPICILLIN B-DRUG
. I-DRUG


 I-DRUG
MEDICATIONS O
ON O
ADMISSION O
: O

  O
1 O
. O
  O
Lisinopril B-DRUG
10 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE

  O
2 O
. O
  O
Lipitor B-DRUG
20 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE

  O
3 O
. O
  O
Imdur B-DRUG
45 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE

  O
4 O
. O
  O
Metoprolol B-DRUG
50 B-STR
mg I-STR
by B-ROU
mouth I-ROU
twice B-FRE
per I-FRE
day I-FRE
. I-FRE

  O
5 O
. O
  O
Plavix B-DRUG
75 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE

  O
6 O
. O
  O
Aspirin B-DRUG
325 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE

  O
7 O
. O
  O
Prilosec B-DRUG
20 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE

  O
8 O
. O
  O
Remeron B-DRUG
30 B-STR
mg I-STR
by B-ROU
mouth I-ROU
at B-FRE
hour I-FRE
of I-FRE
sleep I-FRE
. I-FRE

  O
9 O
. O
  O
Ferrous B-DRUG
sulfate I-DRUG
325 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE

 O
10 O
. O
  O
BuSpar B-DRUG
5 B-STR
mg I-STR
by B-ROU
mouth I-ROU
twice B-FRE
per I-FRE
day I-FRE
. I-FRE


 O
FAMILY O
HISTORY O
: O
  O
Sister O
with O
heart O
disease O
. O


 O
SOCIAL O
HISTORY O
: O
  O
Lives O
at O
the O
[ O
* O
* O
Hospital3 O
537 O
* O
* O
] O
. O
  O
She O
denies O

 O
tobacco O
or O
alcohol O
use O
. O
  O
She O
is O
a O
widow O
. O



 O
PHYSICAL O
EXAMINATION O
ON O
PRESENTATION O
: O
  O
Temperature O
was O
98.7 O

 O
degrees O
Fahrenheit O
, O
her O
blood O
pressure O
was O
136/70 O
, O
her O
pulse O

 O
was O
90 O
, O
her O
respiratory O
rate O
was O
16 O
, O
and O
she O
was O
saturating O

 O
98 O
% O
on O
room O
air O
. O
  O
In O
general O
, O
the O
patient O
is O
an O
elderly O

 O
female O
in O
no O
apparent O
distress O
. O
  O
She O
appeared O
pale O
and O

 O
fatigued O
. O
  O
Head O
, O
eyes O
, O
ears O
, O
nose O
, O
and O
throat O
examination O
the O

 O
oropharynx O
was O
clear O
. O
  O
The O
mucous O
membranes O
were O
dry O
. O

 O
Nasogastric O
tube O
with O
blood O
. O
  O
The O
neck O
was O
supple O
. O
  O
The O
lungs O

 O
were O
clear O
to O
auscultation O
bilaterally O
. O
  O
Heart O
was O
regular O
in O

 O
rate O
and O
rhythm O
plus O
a O
2/6 O
systolic O
ejection O
murmur O
at O
the O

 O
right O
upper O
sternal O
border O
. O
  O
The O
abdomen O
was O
soft O
, O
nontender O
, O

 O
and O
nondistended O
. O
  O
There O
were O
good O
bowel O
sounds O
. O

 O
Maroon-tinged O
stool O
. O
  O
Guaiac-positive O
. O
  O
No O
melena O
. O

 O
Extremities O
revealed O
needed O
. O
  O
Multiple O
bruise-like O
lesions O

 O
with O
central O
hardness O
on O
arms O
and O
legs O
. O
  O
No O
evidence O
of O

 O
rashes O
. O
  O
Neurologically O
, O
cranial O
nerves O
II O
through O
XII O
were O

 O
intact O
. O
  O
She O
followed O
commands O
. O


 O
PERTINENT O
LABORATORY O
VALUES O
ON O
PRESENTATION O
: O
  O
White O
blood O

 O
cell O
count O
was O
5.8 O
( O
with O
a O
differential O
of O
76 O
% O
neutrophils O
, O

 O
21 O
% O
lymphocytes O
, O
2 O
% O
monocytes O
, O
and O
1 O
% O
eosinophils O
) O
, O
her O

 O
hematocrit O
was O
27.4 O
( O
down O
from O
30 O
on O
admission O
to O
the O

 O
Emergency O
Department O
) O
, O
and O
her O
platelets O
were O
127 O
. O
  O
Her O
INR O

 O
was O
1.1 O
, O
her O
partial O
thromboplastin O
time O
was O
24.9 O
. O

 O
Chemistry-7 O
revealed O
her O
sodium O
was O
137 O
, O
potassium O
was O
6 O

 O
( O
repeat O
4.9 O
) O
, O
chloride O
was O
108 O
, O
bicarbonate O
was O
20 O
, O
blood O

 O
urea O
nitrogen O
was O
51 O
, O
creatinine O
was O
1.2 O
, O
and O
her O
blood O

 O
glucose O
was O
115 O
. O
  O
Urinalysis O
was O
straw O
colored O
, O
specific O

 O
gravity O
of O
0.018 O
, O
trace O
leukocyte O
esterase O
, O
pH O
of O
5 O
. O


 O
PERTINENT O
RADIOLOGY/IMAGING O
: O
  O
An O
electrocardiogram O
showed O
a O

 O
normal O
sinus O
rhythm O
at O
79 O
beats O
per O
minute O
, O
and O
primary O

 O
atrioventricular O
block O
. O
  O
Q O
wave O
in O
II O
, O
III O
, O
and O
F. O
  O
Normal O

 O
axis O
. O
  O
Peaked O
T O
waves O
in O
precordium O
. O


 O
ASSESSMENT O
: O
  O
The O
patient O
is O
an O
88-year-old O
female O
with O
a O

 O
gastrointestinal B-REA
bleed I-REA
after O
taking O
nonsteroidal B-DRUG

 I-DRUG
antiinflammatory I-DRUG
drugs I-DRUG
for B-DUR
the I-DUR
last I-DUR
two I-DUR
weeks I-DUR
for O
left O
leg O

 O
pain O
. O


 O
BRIEF O
SUMMARY O
OF O
HOSPITAL O
COURSE O
BY O
ISSUE/SYSTEM O
: O



 O
1 O
. O
  O
GASTROINTESTINAL O
BLEED O
ISSUES O
: O
  O
The O
patient O
had O
an O

 O
initial O
esophagogastroduodenoscopy O
on O
[ O
* O
* O
4 O
- O
11 O
* O
* O
] O
which O
showed O
a O

 O
big O
clot O
adherent O
to O
a O
large-sized O
hiatal O
hernia O
. O
  O
The O
clot O

 O
was O
too O
large O
to O
safely O
irrigate O
off O
. O
  O
Underneath O
the O
clot O

 O
could O
have O
been O
an O
ulcer O
erosion O
or O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
-[**Doctor O
Last O
Name O
* O
* O
] O
tear O
. O
  O
In O

 O
the O
stomach O
, O
there O
was O
diffuse O
atrophy O
of O
the O
mucosa O
with O
no O

 O
bleeding O
noted O
; O
compatible O
with O
chronic O
atrophic O
gastritis O
. O

 O
There O
was O
no O
bleeding O
in O
the O
duodenum O
. O


 O
The O
patient O
was O
kept O
on O
strict O
nothing O
by O
mouth O
and O

 O
intravenous B-ROU
fluids B-DRUG
, I-DRUG
and O
her O
hematocrit O
levels O
were O
followed O

 O
to O
keep O
her O
hematocrit O
above O
30 O
. O
  O
Her O
hematocrit O
dropped O

 O
initially O
from O
30.3 O
to O
27.4 O
and O
then O
to O
22.6 O
. O
  O
She O
was O

 O
transfused B-ROU
2 B-DOS
units I-DOS
of O
packed B-DRUG
red I-DRUG
blood I-DRUG
cells I-DRUG
, I-DRUG
and O
her O

 O
hematocrit O
has O
been O
stable O
since O
, O
ranging O
from O
30 O
to O
32 O
, O
with O

 O
no O
further O
episodes O
of O
bleeding O
since O
[ O
* O
* O
4 O
- O
12 O
* O
* O
] O
. O
  O
She O
has O

 O
remained O
on O
a B-DRUG
proton I-DRUG
pump I-DRUG
inhibitor I-DRUG
( I-DRUG
Protonix I-DRUG
) I-DRUG
twice B-FRE
per I-FRE
day I-FRE
. I-FRE


 O
A O
repeat O
esophagogastroduodenoscopy O
performed O
on O
[ O
* O
* O
4 O
- O
14 O
* O
* O
] O

 O
showed O
still O
adherent O
clot O
about O
8 O
cm O
in O
length O
and O
2 O
cm O
in O

 O
width O
, O
adherent O
to O
a O
2-cm O
length O
mucosa O
within O
the O
large O

 O
hiatal O
hernia O
. O
  O
There O
were O
no O
signs O
of O
active O
bleeding O
. O

 O
Electrocautery O
was O
applied O
to O
the O
base O
of O
the O
clot O
in O
an O

 O
attempt O
to O
dislodge O
it O
from O
the O
esophageal O
mucosa O
and O
for O

 O
hemostasis O
; O
however O
, O
despite O
the O
clot O
still O
remained O
adherent O

 O
to O
the O
esophageal O
mucosa O
. O
  O
It O
appeared O
that O
there O
may O
be O
an O

 O
ulceration O
and O
mucous O
in O
the O
area O
of O
the O
esophagus O
to O
which O

 O
the O
clot O
was O
adherent O
. O
  O
Otherwise O
, O
the O
stomach O
and O
the O

 O
duodenum O
were O
normal O
on O
the O
repeat O

 O
esophagogastroduodenoscopy O
. O


 O
The O
patient O
was O
kept O
nothing O
by O
mouth O
for O
the O
remaining O

 O
portion O
of O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
766 O
* O
* O
] O
, O
[ O
* O
* O
4 O
- O
14 O
* O
* O
] O
, O
and O
was O
continued O
on O
intravenous B-ROU

 I-ROU
fluids B-DRUG
. I-DRUG
  O
Since O
her O
hematocrit O
remained O
stable O
on O
the O

 O
following O
day O
( O
[ O
* O
* O
4 O
- O
15 O
* O
* O
] O
) O
, O
she O
was O
started O
on O
clear O
liquids O
in O

 O
the O
morning O
, O
and O
diet O
may O
be O
advanced O
to O
soft O
solids O
until O

 O
her O
repeat O
upper O
endoscopy O
next O
week O
which O
has O
already O
been O

 O
scheduled O
. O


 O
Since O
her O
hematocrit O
has O
been O
stable O
for O
the O
last O
several O

 O
days O
, O
the O
patient O
is O
safe O
to O
be O
discharged O
to O
home O
or O
to O

 O
rehabilitation O
. O



 O
An O
upper O
endoscopy O
followup O
has O
been O
scheduled O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
21140 O
* O
* O
] O

 O
and O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
2161 O
* O
* O
] O
at O
the O
Endoscopy O
Unit O
on O
the O
[ O
* O
* O
Location O
( O
un O
) O
448 O
* O
* O
] O
of O

 O
[ O
* O
* O
Hospital O
Ward O
Name O
1950 O
* O
* O
] O
One O
[ O
* O
* O
Hospital O
Ward O
Name O
516 O
* O
* O
] O
Building O
on O
[ O
* O
* O
2104 O
- O
5 O
- O
8 O
* O
* O
] O
at O
9:30 O

 O
a.m. O
  O
The O
patient O
should O
not O
have O
anything O
to O
eat O
after O

 O
midnight O
on O
[ O
* O
* O
2104 O
- O
5 O
- O
7 O
* O
* O
] O
and O
should O
not O
eat O
breakfast O
on O
the O

 O
morning O
of O
[ O
* O
* O
2104 O
- O
5 O
- O
8 O
* O
* O
] O
( O
on O
the O
morning O
of O
the O

 O
esophagogastroduodenoscopy O
) O
. O


 O
Her O
aspirin B-DRUG
and O
Plavix B-DRUG
should O
be O
held O
considering O
her O

 O
gastrointestinal O
bleed O
, O
and O
restarting O
of O
these O
two O

 O
medications O
will O
be O
made O
after O
her O
repeat O
endoscopy O
on O
[ O
* O
* O
5 O
- O
8 O
* O
* O
] O
. O
  O
The O
patient O
should O
remain O
on O
Protonix B-DRUG
40 B-STR
mg I-STR
by B-ROU
mouth I-ROU

 I-ROU
twice B-FRE
per I-FRE
day I-FRE
until O
her O
repeat O
endoscopy O
, O
and O
she O
should O

 O
avoid O
nonsteroidal B-DRUG
antiinflammatory I-DRUG
drugs I-DRUG
until O
her O

 O
procedure O
. O
  O
The O
patient O
will O
also O
probably O
benefit O
from O
a O

 O
colonoscopy O
as O
an O
outpatient O
. O
  O
Helicobacter O
pylori O
antibody O

 O
was O
still O
pending O
. O


 O
2 O
. O
  O
THROMBOCYTOPENIA B-ADE
ISSUES O
: O
  O
Heparin-induced B-DRUG

 O
thrombocytopenia B-ADE
antibody O
was O
positive O
, O
so O
the O
patient O
should O

 O
not O
receive O
any O
heparin B-DRUG
. I-DRUG
  O
The O
patient O
has O
a O
history O
of O
a O
mild O

 O
pancytopenia O
in O
the O
past O
, O
and O
this O
issue O
was O
discussed O

 O
between O
the O
patient O
and O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
410 O
* O
* O
] O
of O
Hematology/Oncology O
, O

 O
and O
it O
was O
decided O
that O
no O
bone O
marrow O
biopsy O
would O
be O

 O
performed O
. O
  O
The O
patient O
should O
follow O
up O
as O
an O
outpatient O

 O
with O
her O
primary O
care O
physician O
to O
insure O
that O
she O
has O
a O
rise O

 O
in O
her O
platelets O
. O


 O
3 O
. O
  O
HYPERKALEMIA O
ISSUES O
: O
  O
The O
patient O
had O
an O
initial O

 O
potassium O
value O
of O
6 O
with O
peaked O
T O
waves O
on O

 O
electrocardiogram O
. O
  O
This O
was O
thought O
to O
likely O
be O
due O
to O

 O
dehydration O
, O
and O
the O
blood O
sample O
was O
also O
moderately O

 O
hemolyzed O
. O
  O
Otherwise O
, O
her O
potassium O
has O
remained O
stable O
. O


 O
4 O
. O
  O
CONGESTIVE O
HEART O
FAILURE O
ISSUES O
: O
  O
The O
patient O
does O
have O

 O
an O
element O
of O
diastolic O
dysfunction O
, O
and O
so O
her O
fluid O
status O

 O
was O
carefully O
monitored O
a O
she O
was O
getting O
significant O
amounts O

 O
of O
fluids B-DRUG
and O
packed B-DRUG
red I-DRUG
blood I-DRUG
cells I-DRUG
. I-DRUG
  O
She O
has O
maintained O

 O
stable O
oxygenation O
, O
and O
good O
oxygen O
saturations O
, O
as O
well O
as O

 O
good O
urine O
output O
. O



 O
5 O
. O
  O
COAGULOPATHY O
ISSUES O
: O
  O
The O
patient O
developed O
an O
INR O
of O

 O
1.4 O
; O
likely O
secondary O
to O
being O
nothing O
by O
mouth O
for O
many O
days O

 O
and O
deficiency O
in O
vitamin O
K. O
  O
She O
has O
been O
given O
by B-ROU
mouth I-ROU

 I-ROU
vitamin B-DRUG
K I-DRUG
and O
should O
continue O
this O
for B-DUR
two I-DUR
more I-DUR
days I-DUR
. I-DUR
  O
Her O

 O
INR O
will O
likely O
decrease O
when O
she O
receives O
adequate O

 O
nutrition O
. O


 O
6 O
. O
  O
CORONARY O
ARTERY O
DISEASE O
ISSUES O
: O
  O
As O
mentioned O
above O
, O

 O
aspirin B-DRUG
and O
Plavix B-DRUG
were O
being O
held O
secondary O
to O
a O
large O

 O
gastrointestinal O
bleed O
. O
  O
The O
patient O
should O
continue O
to O
hold O

 O
these O
two O
medications O
until O
her O
repeat O
endoscopy O
on O
[ O
* O
* O
5 O
- O
8 O
* O
* O
] O
; O

 O
at O
which O
time O
the O
decision O
as O
to O
whether O
to O
restart O
these O

 O
medications O
can O
be O
made O
. O
  O
The O
patient O
has O
been O
restarted O
on O

 O
her O
beta B-DRUG
blocker I-DRUG
. I-DRUG
  O
She O
will O
continue O
with O
her O
statin B-DRUG
, I-DRUG
Imdur B-DRUG

 I-DRUG
beta B-DRUG
blocker I-DRUG
, I-DRUG
and O
ACE B-DRUG
inhibitor I-DRUG
. I-DRUG


 O
7 O
. O
  O
CHRONIC O
RENAL O
INSUFFICIENCY O
ISSUES O
: O
  O
The O
patient O
's O

 O
creatinine O
is O
at O
baseline O
. O
  O
Her O
blood O
urea O
nitrogen O
was O

 O
likely O
increased O
secondary O
to O
bleeding O
and O
has O
now O
returned O

 O
to O
[ O
* O
* O
Location O
213 O
* O
* O
] O
. O


 O
8 O
. O
  O
LEFT O
LEG O
PAIN O
ISSUES O
: O
  O
The O
patient O
had O
a O
previous O
zoster B-REA

 I-REA
infection I-REA
that O
was O
treated O
with O
Valtrex B-DRUG
. I-DRUG
  O
On O
admission O
, O
she O

 O
had O
no O
evidence O
of O
a O
zoster O
infection O
with O
no O
rashes O

 O
apparent O
. O
  O
The O
patient O
has O
multiple O
musculoskeletal O

 O
complaints O
that O
have O
been O
chronic O
. O
  O
She O
was O
continued O
on O
her O

 O
Neurontin B-DRUG
for O
neuropathic B-REA
pain I-REA
. I-REA
  O
The O
patient O
was O
also O
given O

 O
Tylenol B-DRUG
for O
pain B-REA
control I-REA
. I-REA
   O
She O
does O
not O
have O
an O
active O

 O
zoster O
infection O
. O


 O
9 O
. O
  O
PSYCHIATRIC O
ISSUES O
: O
  O
The O
patient O
was O
continued O
on O
her O

 O
BuSpar B-DRUG
. I-DRUG
  O
She O
has O
multiple O
somatic O
complaints O
; O
likely O
anxiety B-REA

 I-REA
related O
. O


 O
10 O
. O
  O
ACIDOSIS/FLUIDS/ELECTROLYTES/NUTRITION O
ISSUES O
: O
  O
The O

 O
patient O
's O
acidosis O
was O
improving O
as O
her O
diarrhea O
improved O
. O

 O
It O
will O
likely O
continue O
to O
improve O
as O
she O
maintains O
a O
normal O

 O
diet O
and O
her O
diarrhea O
continues O
to O
decrease O
. O
   O
She O
was O

 O
started O
on O
a O
clear O
diet O
on O
[ O
* O
* O
4 O
- O
15 O
* O
* O
] O
following O
her O

 O
esophagogastroduodenoscopy O
since O
her O
hematocrit O
has O
been O

 O
stable O
. O


 O
11 O
. O
  O
PROPHYLAXIS O
ISSUES O
: O
  O
The O
patient O
was O
maintained O
on O

 O
pneumatic O
boots O
and O
a B-DRUG
proton I-DRUG
pump I-DRUG
inhibitor I-DRUG
. I-DRUG
  O
The O
patient O

 O
should O
not O
receive O
any O
heparin B-DRUG
secondary O
to O
positive O

 O
heparin-induced B-DRUG
thrombocytopenia B-ADE
antibody O
. O


 O
12 O
. O
  O
ACCESS O
ISSUES O
: O
  O
The O
patient O
has O
difficult O
access O
issues O

 O
and O
two O
peripheral O
intravenous O
lines O
through O
most O
of O
her O

 O
stay O
. O


 O
13 O
. O
  O
CODE O
STATUS O
ISSUES O
: O
  O
The O
patient O
is O
a O
full O
code O
. O



 O
14 O
. O
  O
DISPOSITION O
ISSUES O
: O
  O
At O
the O
time O
of O
this O
dictation O
, O
a O

 O
Physical O
Therapy O
consultation O
has O
recommended O
benefit O
from O

 O
rehabilitation O
for O
maximum O
safety O
. O
  O
The O
patient O
is O
being O

 O
screened O
for O
rehabilitation O
at O
the O
time O
of O
this O
dictation O
. O


 O
DISCHARGE O
DIAGNOSES O
: O

 O
1 O
. O
  O
Gastrointestinal O
bleed O
. O

 O
2 O
. O
  O
Anemia O
. O

 O
3 O
. O
  O
Chronic O
renal O
insufficiency O
. O

 O
4 O
. O
  O
Coronary O
artery O
disease O
. O

 O
5 O
. O
  O
Anxiety/depression O
. O


 O
DISCHARGE O
STATUS O
: O
  O
To O
rehabilitation O
. O


 O
CONDITION O
AT O
DISCHARGE O
: O
  O
Stable O
. O


 O
MEDICATIONS O
ON O
DISCHARGE O
: O

  O
1 O
. O
  O
Protonix B-DRUG
40 B-STR
mg I-STR
by B-ROU
mouth I-ROU
twice B-FRE
per I-FRE
day I-FRE
. I-FRE

  O
2 O
. O
  O
Metoprolol B-DRUG
25 B-STR
mg I-STR
by B-ROU
mouth I-ROU
twice B-FRE
per I-FRE
day I-FRE
. I-FRE

  O
3 O
. O
  O
Nystatin B-DRUG
5 B-STR
mg I-STR
by B-ROU
mouth I-ROU
four B-FRE
times I-FRE
per I-FRE
day I-FRE
as I-FRE
needed I-FRE
( O
for O

 O
thrush B-REA
) I-REA
. O

  O
4 O
. O
  O
Gabapentin B-DRUG
300 B-STR
mg I-STR
by B-ROU
mouth I-ROU
twice B-FRE
per I-FRE
day I-FRE
. I-FRE

  O
5 O
. O
  O
Cepacol B-DRUG
one B-DOS
lozenge B-FOR
by B-ROU
mouth I-ROU
as B-FRE
needed I-FRE
. I-FRE

  O
6 O
. O
  O
Oxycodone B-DRUG
2.5 B-STR
mg I-STR
to I-STR
5 I-STR
mg I-STR
by B-ROU
mouth I-ROU
q.4 B-FRE
- I-FRE
6h I-FRE
. I-FRE
as I-FRE
needed I-FRE
. I-FRE

  O
7 O
. O
  O
Tylenol B-DRUG
1000 B-STR
mg I-STR
by B-ROU
mouth I-ROU
three B-FRE
times I-FRE
per I-FRE
day I-FRE
. I-FRE

  O
8 O
. O
  O
Ferrous B-DRUG
sulfate I-DRUG
325 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE

  O
9 O
. O
  O
BuSpar B-DRUG
5 B-STR
mg I-STR
by B-ROU
mouth I-ROU
twice B-FRE
per I-FRE
day I-FRE
. I-FRE

 O
10 O
. O
  O
Mirtazapine B-DRUG
30 B-STR
mg I-STR
by B-ROU
mouth I-ROU
at B-FRE
hour I-FRE
of I-FRE
sleep I-FRE
. I-FRE

 O
11 O
. O
  O
Isosorbide B-DRUG
mononitrate I-DRUG
extended I-DRUG
release I-DRUG
45 B-STR
mg I-STR
by B-ROU
mouth I-ROU

 I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE

 O
12 O
. O
  O
Atorvastatin B-DRUG
20 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
per I-FRE
day I-FRE
. I-FRE


 O
DISCHARGE O
INSTRUCTIONS/FOLLOWUP O
: O

 O
1 O
. O
  O
The O
patient O
was O
instructed O
to O
follow O
up O
with O
her O
primary O

 O
care O
physician O
in O
one O
to O
two O
weeks O
. O

 O
2 O
. O
  O
The O
patient O
has O
a O
follow-up O
esophagogastroduodenoscopy O

 O
scheduled O
for O
[ O
* O
* O
5 O
- O
8 O
* O
* O
] O
at O
9:30 O
a.m. O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
21140 O
* O
* O
] O
and O
Dr. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
2161 O
* O
* O
] O
at O
the O
Endoscopy O
Unit O
, O
[ O
* O
* O
Location O
( O
un O
) O
448 O
* O
* O
] O
of O
[ O
* O
* O
Hospital O
Ward O
Name O
1950 O
* O
* O
] O
One O
, O

 O
[ O
* O
* O
Hospital O
Ward O
Name O
516 O
* O
* O
] O
Building O
. O
  O
The O
patient O
should O
register O
in O
the O

 O
lobby O
of O
the O
[ O
* O
* O
Hospital O
Ward O
Name O
1826 O
* O
* O
] O
Building O
at O
8:30 O
a.m. O
and O
should O
not O

 O
have O
anything O
to O
eat O
after O
midnight O
on O
[ O
* O
* O
2104 O
- O
5 O
- O
7 O
* O
* O
] O
. O
  O
She O

 O
should O
not O
eat O
breakfast O
on O
the O
morning O
of O
[ O
* O
* O
2104 O
- O
5 O
- O
8 O
* O
* O
] O
. O

 O
3 O
. O
  O
Esophagogastroduodenoscopy O
reports O
have O
been O
sent O
with O

 O
the O
patient O
to O
rehabilitation O
, O
and O
the O
patient O
should O
bring O

 O
these O
papers O
with O
her O
to O
her O
esophagogastroduodenoscopy O

 O
appointment O
. O







                         O

[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
, O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
M.D. O
  O
[ O
* O
* O
MD O
Number(1 O
) O
1019 O
* O
* O
] O


 O
Dictated O
By:[**Name8 O
( O
MD O
) O
10397 O
* O
* O
] O


 O
MEDQUIST36 O


 O
D O
: O
  O
[ O
* O
* O
2104 O
- O
4 O
- O
15 O
* O
* O
] O
  O
13:01 O

 O
T O
: O
  O
[ O
* O
* O
2104 O
- O
4 O
- O
15 O
* O
* O
] O
  O
14:36 O

 O
JOB O
# O
: O
  O
[ O
* O
* O
Job O
Number O
101481 O
* O
* O
] O

 O

Admission O
Date O
: O
  O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2122 O
- O
7 O
- O
11 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2081 O
- O
7 O
- O
30 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Tessalon B-DRUG
Perles I-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
896 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Cough O
, O
SOB O
, O
fever O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
- O
None O


 O
History O
of O
Present O
Illness O
: O

 O
40 O
yo O
M O
with O
in O
his O
usual O
state O
of O
good O
health O
presents O
with O

 O
fever O
to O
103 O
, O
cough O
, O
and O
shortness O
of O
breath O
. O
His O
initial O

 O
symptoms O
were O
fever O
and O
myalgia O
, O
beginning O
abruptly O
on O
Friday O

 O
morning O
. O
He O
subsequently O
developed O
cough O
. O
On O
the O
morning O
of O
his O

 O
admission O
, O
he O
developed O
palpitations O
and O
presented O
to O
a O
hospital O

 O
in O
[ O
* O
* O
Location O
3615 O
* O
* O
] O
, O
where O
he O
was O
found O
to O
be O
in O
rapid O
atrial O

 O
fibrillation O
. O
From O
there O
, O
he O
was O
transported O
to O
[ O
* O
* O
Location O
( O
un O
) O
9101 O
* O
* O
] O
, O
where O

 O
he O
was O
treated O
with O
normal B-DRUG
saline I-DRUG
, I-DRUG
vancomycin B-DRUG
1 B-STR
gm I-STR
, I-STR
azithromycin B-DRUG

 I-DRUG
500 B-STR
mg I-STR
, I-STR
ceftriaxone B-DRUG
1 B-STR
gram I-STR
, I-STR
digoxin B-DRUG
0.25 B-STR
mg I-STR
, I-STR
ibuprofen B-DRUG
600 B-STR
mg I-STR
, I-STR

 O
acetaminophen B-DRUG
975 B-STR
mg I-STR
, I-STR
diltiazem B-DRUG
20 B-STR
mg I-STR
IV B-ROU
, I-ROU
and O
Cardizen B-DRUG
CD I-DRUG
120 B-STR

 I-STR
mg I-STR
. I-STR
His O
heart O
rate O
was O
controlled O
, O
but O
he O
developed O
a O
new O
oxygen O

 O
requirement O
and O
was O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
further O
management O
. O


 O
At O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
, O
CXR O
showed O
a O
right-sided O
pneumonia O
with O
parapneumonic O

 O
effusion O
. O
He O
was O
continued O
on O
a O
diltiazem B-DRUG
gtt B-ROU
at O
10 B-STR
mg/hr I-STR
. I-STR
Blood O

 O
and O
sputum O
cultures O
were O
sent O
. O
He O
was O
admitted O
to O
the O
ICU O
on O
a O

 O
non-rebreather O
. O



 O
Past O
Medical O
History O
: O

 O
- O
Right O
Knee O
Surgery O
with O
hardware O
in O
place O


 O
Social O
History O
: O

 O
- O
Works O
as O
an O
emergency O
medicine O
physician O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O

 O
- O
Married O
with O
two O
young O
children O

 O
- O
Tobacco O
: O
None O

 O
- O
EtOH O
: O
< O
1 O
drink/week O

 O
- O
Illicit O
drug O
use O
: O
None O


 O
Family O
History O
: O

 O
- O
Father O
: O
CABG O
in O
his O
50s O
. O

 O
- O
No O
family O
history O
of O
venous O
thrombosis O
. O



 O

Physical O
Exam O
: O

 O
ADMISSION O
PHYSICAL O
EXAM O
: O

 O
Vital O
signs O
: O

 O
T O
: O
100.6 O
  O
HR O
: O
89 O
  O
BP O
: O
150/94 O
  O
RR O
: O
16 O
  O
O2 O
Sat O
99%/NRB O

 O
Gen O
: O
No O
acute O
distress O
. O
Pale O
. O

 O
HEENT O
: O
NC/AT O
. O
Anicteric O
sclerae O
. O
Moist O
mucous O
membranes O
. O
OP O
with O

 O
mild O
erythema O
and O
no O
exudate O
. O

 O
Neck O
: O
Supple O
. O
No O
cervical O
or O
supraclavicular O
lymphadenopathy O
. O

 O
Resp O
: O
Normal O
respiratory O
effort O
. O
Dull O
to O
percussion O
at O
right O

 O
base O
. O
Bronchial O
breath O
sounds/egophony O
at O
bilateral O
bases O
R O
> O
L. O

 O
CV O
: O
RRR O
( O
converted O
to O
sinus O
during O
exam O
) O
. O
Normal O
s1 O
and O
s2 O
. O
No O

 O
M/G/R. O

 O
Abd O
: O
+ O
BS O
. O
Soft O
. O
NT/ND O
. O
No O
rebound O
or O
guarding O
. O

 O
Ext O
: O
Warm O
and O
well-perfused O
. O
Radial O
and O
DP O
pulses O
2 O
+ O

 O
bilaterally O
. O

 O
Neuro O
: O
A+Ox3 O
. O
PERRL O
. O
EOMI O
, O
with O
no O
nystagmus O
. O
Face O
symmetric O
. O

 O
Palate O
elevates O
symmetrically O
. O
Tongue O
protrudes O
in O
midline O
. O

 O
Strength O
5/5 O
throughout O
upper O
and O
lower O
extremities O
. O


 O
DISCHARGE O
EXAM O
: O

 O
GEN O
: O
WNWD O
male O
resting O
ambulating O
in O
room O
. O

 O
HEENT O
: O
EOMI O
. O
MMM O
. O

 O
NECK O
: O
Supple O
. O

 O
COR O
: O
+ O
S1S2 O
, O
RRR O
, O
no O
m/g/r O
. O

 O
PULM O
: O
Decreased O
bibalilar O
breath O
sounds O
with O
dullness O
to O

 O
percussion O
at O
right O
base O
. O
Inspiratory O
crackles O
at O
bases O
( O
right O

 O
worse O
than O
left O
) O
. O
  O
No O
wheeze O
. O

 O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
: O
+ O
NABS O
in O
4Q O
. O
Soft O
, O
NTND O
. O

 O
EXT O
: O
Warm O
, O
well-perfused O
. O
+ O
DP O
bilaterally O
. O

 O
NEURO O
: O
Awake O
, O
alert O
. O


 O
Pertinent O
Results O
: O

 O
ADMISSION O
LABS O
: O


 O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
07:24PM O
BLOOD O
WBC-9.1 O
RBC-4.09 O
* O
Hgb-12.1 O
* O
Hct-34.4 O
* O

 O
MCV-84 O
MCH-29.4 O
MCHC-35.1 O
* O
RDW-14.3 O
Plt O
Ct-200 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
07:24PM O
BLOOD O
Neuts-82.8 O
* O
Lymphs-13.5 O
* O
Monos-3.1 O

 O
Eos-0.2 O
Baso-0.4 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
07:24PM O
BLOOD O
PT-14.4 O
* O
PTT-26.1 O
INR(PT)-1.2 O
* O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
07:24PM O
BLOOD O
Glucose-110 O
* O
UreaN-6 O
Creat-0.7 O
Na-138 O

 O
K-3.7 O
Cl-108 O
HCO3 O
- O
22 O
AnGap-12 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
07:24PM O
BLOOD O
ALT-45 O
* O
AST-32 O
CK(CPK)-111 O
AlkPhos-64 O

 O
TotBili-0.3 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
07:24PM O
BLOOD O
CK-MB-2 O
cTropnT-0.02 O
* O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
07:14PM O
BLOOD O
Lactate-1.4 O


 O
Cardiac O
Markers O
Trend O
: O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
07:24PM O
BLOOD O
CK-MB-2 O
cTropnT-0.02 O
* O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
7 O
* O
* O
] O
12:49AM O
BLOOD O
CK-MB-2 O
cTropnT-0.01 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
7 O
* O
* O
] O
05:35AM O
BLOOD O
CK-MB-2 O
cTropnT-<0.01 O



 O
Lactate O
Trend O
: O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
07:14PM O
BLOOD O
Lactate-1.4 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
7 O
* O
* O
] O
07:48AM O
BLOOD O
Lactate-1.1 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
7 O
* O
* O
] O
04:09PM O
BLOOD O
Lactate-0.8 O


 O
Pertinent O
Other O
Labs O
: O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
7 O
* O
* O
] O
03:08PM O
BLOOD O
HIV O
Ab-NEGATIVE O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
11:47PM O
URINE O
Color-Straw O
Appear-Clear O
Sp O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
-1.010 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
6 O
* O
* O
] O
11:47PM O
URINE O
Blood-SM O
  O
Nitrite-NEG O
Protein-NEG O

 O
Glucose-NEG O
Ketone-40 O
Bilirub-NEG O
Urobiln-NEG O
pH-5.0 O
Leuks-NEG O

 O
Legionella O
negative O


 O
DISCHARGE O
LABS O
: O


 O
Imaging O
: O

 O
[ O
* O
* O
7 O
- O
6 O
* O
* O
] O
CXR O
: O
IMPRESSION O
: O
Findings O
concerning O
for O
right O
lower O
lobe O

 O
pneumonia O
and O
possible O
right O
pleural O
effusion O
with O
atelectasis O
. O

 O
Left O
base O
retrocardiac O
opacity O
could O
be O
due O
to O
atelectasis O

 O
although O
a O
second O
location O
of O
consolidation/infection O
not O

 O
excluded O
. O
Additionally O
, O
subtle O
opacity O
at O
the O
lateral O
left O
mid O

 O
lung O
, O
while O
could O
relate O
to O
overlying O
soft O
tissue O
, O
additional O

 O
focus O
of O
consolidation O
is O
not O
excluded O
. O


 O
[ O
* O
* O
7 O
- O
7 O
* O
* O
] O
: O
CXR O
: O
FINDINGS O
: O
As O
compared O
to O
the O
previous O
radiograph O
, O
the O

 O
extent O
of O
the O
pre-existing O
right O
pleural O
effusion O
is O
stable O
. O
On O

 O
the O
left O
, O
an O
area O
of O

 O
parenchymal O
opacity O
, O
previously O
qualified O
as O
potential O

 O
pneumonia O
, O
has O

 O
increased O
in O
extent O
. O
There O
is O
a O
newly O
occurred O
small O
reactive O

 O
left-sided O

 O
pleural O
effusion O
with O
subsequent O
left O
atelectasis O
. O
The O
diameter O

 O
of O
the O

 O
pulmonary O
vessels O
is O
minimally O
increased O
, O
potentially O
reflecting O

 O
mild O
fluid O
overload O
. O


 O
[ O
* O
* O
7 O
- O
7 O
* O
* O
] O
CTA O
: O
1 O
. O
Widespread O
rapidly O
evolving O
multilobar O
pneumonia O
, O

 O
possibly O
complicated O
by O
ARDS O
. O

 O
2 O
. O
Small O
bilateral O
simple O
layering O
pleural O
effusions O
. O


 O
[ O
* O
* O
2122 O
- O
7 O
- O
9 O
* O
* O
] O
03:31AM O
BLOOD O
WBC-8.7 O
RBC-4.12 O
* O
Hgb-11.7 O
* O
Hct-34.5 O
* O

 O
MCV-84 O
MCH-28.4 O
MCHC-33.9 O
RDW-14.4 O
Plt O
Ct-282 O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
9 O
* O
* O
] O
03:31AM O
BLOOD O
Glucose-94 O
UreaN-8 O
Creat-0.9 O
Na-143 O
K-3.6 O

 O
Cl-106 O
HCO3 O
- O
28 O
AnGap-13 O


 O
Brief O
Hospital O
Course O
: O

 O
PRIMARY O
REASON O
FOR O
ADMISSION O
: O

 O
40 O
yo O
M O
presents O
with O
fever O
, O
shortness O
of O
breath O
, O
and O
cough O
, O

 O
admitted O
to O
MICU O
for O
hypoxemia O
requiring O
NRB O
, O
found O
to O
have O

 O
trilobar O
PNA O
. O



 O
ACUTE O
DIAGNOSES O
: O

 O
# O
Multilobar O
Pneumonia O
, O
likely O
bacterial O
: O
CTA O
results O
showed O

 O
significant O
tri-lobar O
PNA O
which O
appeared O
significant O
enough O
for O

 O
shunting O
to O
explain O
his O
degree O
of O
hypoxia O
. O
His O
PNA B-REA
was O
treated O

 O
and O
oxygen B-DRUG
was O
weaned O
down O
and O
he O
tolerated O
walking O
around O
floor O

 O
with O
nasal B-ROU
cannula I-ROU
, I-ROU
though O
he O
wore O
face B-ROU
tent I-ROU
at O
baseline O
for O

 O
comfort O
. O
He O
was O
initially O
treated O
for O
CAP O
but O
because O
he O
works O

 O
in O
a O
health-care O
setting O
and O
considering O
the O
extent O
of O
PNA O
with O

 O
hypoxia O
he O
was O
treated O
for O
HCAP B-REA
coverage O
with O
IV B-ROU
vancomycin B-DRUG
, I-DRUG

 O
cefepime B-DRUG
, I-DRUG
and O
ciprofloxacin B-DRUG
. I-DRUG
On O
the O
floor O
he O
quickly O
weaned O
down O

 O
to O
room O
air O
and O
was O
breathing O
comfortably O
with O
occasionally O

 O
sputum O
tinged O
with O
blood O
. O
He O
was O
discharged O
on O
a O
10-day B-DUR
course O

 O
of O
levofloxacin B-DRUG
& O
linezolid B-DRUG
, I-DRUG
to O
cover O
ensure O
coverage O
of O
both O

 O
MSRA B-REA
and O
other O
usual O
CAP B-REA
organisms I-REA
. I-REA


 O
# O
Atrial B-REA
Fibrillation I-REA
with I-REA
RVR I-REA
: I-REA
Dr. O
[ O
* O
* O
Known O
lastname O
23 O
* O
* O
] O
initially O
presented O

 O
in O
new O
onset O
A.Fib O
with O
runs O
of O
RVR O
into O
160s O
with O
associated O

 O
hypotension O
. O
He O
was O
treated O
with O
a O
10mg/hr B-STR
Dilt B-DRUG
drip B-ROU
and O

 O
spontaneously O
converted O
to O
sinus O
and O
he O
remained O
in O
sinus O
rhythm O

 O
throughout O
the O
rest O
of O
his O
hospitalization O
. O
Although O
he O
has O
a O

 O
history O
of O
palpitations O
in O
the O
past O
( O
and O
has O
been O
on O
a O
Holter O

 O
monitor O
) O
, O
this O
is O
his O
first O
episode O
of O
atrial B-REA
fibrillation I-REA
. I-REA

 O
Given O
his O
CHADS2 O
score O
of O
0 O
- O
1 O
it O
was O
felt O
that O
he O
did O
not O

 O
require O
anything O
other O
than O
a O
daily B-FRE
aspirin B-DRUG
( O
which O
he O
has O
been O

 O
taking O
as O
an O
outpatient O
) O
. O
  O
The O
aspirin B-DRUG
was O
held O
due O
to O

 O
intermittent B-ADE
hemoptysis/blood I-ADE
streaked I-ADE
sputum I-ADE
, I-ADE
but O
Dr. O
[ O
* O
* O
Known O
lastname O
23 O
* O
* O
] O

 O
was O
advised O
to O
discuss O
reinitiation O
of O
aspirin B-DRUG
as O
an O
outpatient O
. O


 O
CHRONIC O
DIAGNOSES O
: O
None O
. O


 O
TRANSITIONAL O
ISSUES O
: O

 O
# O
Follow-Up O
: O
The O
patient O
was O
instructed O
to O
follow O
up O
with O
his O

 O
new O
primary O
care O
doctor O
within O
1 O
- O
2 O
weeks O
. O
  O
He O
was O
told O
to O

 O
discuss O
reinitation O
of O
aspirin B-DRUG
with O
his O
PCP O
when O
his O
hemoptysis B-ADE

 I-ADE
ceases O
. O
  O
He O
should O
also O
be O
screened O
for O
hypertension O
, O
as O
it O
was O

 O
noted O
that O
his O
blood O
pressure O
was O
elevated O
to O
the O
140s-150s O

 O
systolic O
while O
he O
was O
on O
the O
floor O
. O



 O
Medications O
on O
Admission O
: O

 O
- O
Aspirin B-DRUG
81 B-STR
mg I-STR
PO B-ROU
Daily B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
linezolid B-DRUG
600 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q12H B-FRE
( I-FRE
every I-FRE
12 I-FRE

 I-FRE
hours I-FRE
) I-FRE
for B-DUR
10 I-DUR
days I-DUR
. I-DUR

 O
Disp:*20 O
Tablet(s B-FOR
) I-FOR
* I-FOR
Refills:*0 O
* O

 O
2 O
. O
levofloxacin B-DRUG
750 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
for B-DUR
10 I-DUR
days I-DUR
. I-DUR

 O
Disp:*10 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
3 O
. O
codeine-guaifenesin B-DRUG
10 B-STR
- I-STR
100 I-STR
mg/5 I-STR
mL I-STR
Syrup B-FOR
Sig O
: O
5 B-DOS
- I-DOS
10 I-DOS
MLs I-DOS
PO B-ROU
Q6H B-FRE

 I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
cough B-REA
: I-REA
Do O
not O
drive O
while O
taking O

 O
this O
medication O
. O

 O
Disp:*500 O
ML(s O
) O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
PRIMARY O
DIAGNOSIS O
: O

 O
- O
Multifocal O
pneumonia O

 O
- O
Sepsis O


 O
SECONDARY O
DIAGNOSIS O
: O

 O
- O
Atrial O
fibrillation O
with O
rapid O
  O
ventricular O
response O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
Dr. O
[ O
* O
* O
Known O
lastname O
23 O
* O
* O
] O
, O
it O
was O
a O
pleasure O
to O
participate O
in O
your O
care O
while O

 O
you O
were O
hospital O
. O
You O
were O
initially O
admitted O
to O
the O
MICU O
on O
a O

 O
diltiazem B-DRUG
drip B-ROU
to O
control B-REA
your I-REA
rapid I-REA
atrial I-REA
fibrillation I-REA
. I-REA
  O
You O

 O
had O
an O
ongoing O
oxygen B-DRUG
requirement O
and O
it O
was O
discovered O
that O
you O

 O
had O
a B-REA
multifocal I-REA
pneumonia I-REA
. I-REA
  O
You O
were O
treated O
with O

 O
broad-spectrum B-DRUG
IV B-ROU
antibiotics I-DRUG
, I-DRUG
which O
were O
transitioned O
to O
PO B-ROU

 I-ROU
antibiotics B-DRUG
a O
day O
prior O
to O
your O
discharge O
. O


 O
MEDICATION O
CHANGES O
: O

 O
- O
Medications O
ADDED O
: O
Linezolid B-DRUG
600 B-STR
mg I-STR
Q12H B-FRE
for B-DUR
10 I-DUR
days I-DUR

 I-DUR
- O
Medications O
ADDED O
: O
Guaifenesin-CODEINE B-DRUG
cough B-FOR
syrup I-FOR
as B-FRE
needed I-FRE

 I-FRE
for O
cough B-REA

 I-REA
- O
Medications O
STOPPED O
: O
Aspirin B-DRUG

 I-DRUG
- O
Medications O
CHANGED O
: O
None O
. O


 O
Followup O
Instructions O
: O

 O
We O
are O
working O
on O
a O
follow O
up O
appointment O
in O
[ O
* O
* O
State O
* O
* O
] O
Group O
with O
your O
new O
primary O
care O
physician O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
. O

 O
The O
office O
will O
contact O
you O
at O
home O
with O
an O
appointment O
. O
If O
you O

 O
have O
not O
heard O
within O
2 O
business O
days O
or O
have O
any O
questions O

 O
please O
call O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2205 O
* O
* O
] O
. O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2137 O
- O
10 O
- O
31 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2061 O
- O
8 O
- O
17 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Lasix B-DRUG
/ O
Diuril B-DRUG
/ O
Keflex B-DRUG
/ O
Iodine B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
2712 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Dyspnea O
, O
Renal O
Failure O
, O
anemia O
, O
fluid O
overload O



 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Bronchoscopy O



 O
History O
of O
Present O
Illness O
: O

 O
76 O
year O
old O
female O
with O
h/o O
IPF B-REA
on O
chronic B-DUR
prednisone B-DRUG
, I-DRUG
COPD B-REA
with O

 O
trach O
, O
CHF O
, O
mechanical O
mitral O
valve O
, O
pacemaker O
, O
and O
anemia O
who O

 O
presents O
with O
several O
days O
of O
worsening O
dysypnea O
, O
peripheral O

 O
edema O
, O
and O
fatigue O
. O
She O
reports O
difficulty O
walking O
very O
short O

 O
distances O
due O
to O
SOB O
and O
lightheadness O
frequently O
. O
She O
reports O

 O
[ O
* O
* O
2 O
- O
28 O
* O
* O
] O
pillow O
orthopnea O
that O
remains O
unchanged O
from O
baseline O
. O
She O

 O
reports O
frequent O
productive O
cough O
that O
occasionally O
is O
bloody O
, O

 O
last O
bloody O
sputum O
was O
this O
morning O
. O
She O
reports O
frequency O
of O

 O
cough O
and O
sputum O
production O
is O
same O
as O
baseline O
. O
She O
believes O

 O
she O
has O
had O
an O
unknown O
amount O
of O
weight O
gain O
. O
  O
Peripheral O
edema O

 O
fluctuates O
in O
severity O
. O
She O
denies O
changes O
in O
bowel O
habits O
and O

 O
denies O
changes O
in O
urination O
. O
She O
denies O
changes O
in O
appetite O
, O

 O
denies O
fever O
, O
chills O
, O
chest O
pain O
, O
nausea O
, O
vomiting O
, O
abdominal O

 O
pain O
, O
melena O
, O
and O
BRBPR.She O
denies O
sick O
contacts O
and O
recent O

 O
travel O
. O


 O
In O
the O
ED O
, O
labs O
were O
significant O
for O
Hct O
14 O
, O
INR O
10 O
, O
creatinine O

 O
2.1 O
. O
  O
Had O
peripheral O
edema O
on O
exam O
. O
  O
She O
was O
ordered O
for O
2 B-DOS
units I-DOS

 I-DOS
PRBCs B-DRUG
( O
not O
given O
due O
to O
difficult O
crossmatch O
) O
, O
crossmatched O
4 O

 O
units O
. O
Also O
given O
5 B-STR
mg I-STR
po B-ROU
vitamin B-DRUG
K. I-DRUG
  O
She O
was O
not O
given O
lasix B-DRUG
or O

 O
FFP B-DRUG
. I-DRUG
  O
Most O
recent O
vitals O
85 O
113/49 O
23 O
100 O
% O
5L O
. O

 O
. O

 O
In O
the O
MICU O
, O
she O
was O
noted O
to O
be O
short O
of O
breath O
and O
had O
brown O
, O

 O
guaiac O
positive O
stool O
. O

 O
. O

 O
Review O
of O
systems O
: O

 O
( O
+ O
) O
Per O
HPI O

 O
( O
- O
) O
Denies O
fever O
, O
chills O
, O
night O
sweats O
, O
denies O
headache O
, O
sinus O

 O
tenderness O
, O
rhinorrhea O
or O
congestion O
. O
Denies O
chest O
pain O
, O
chest O

 O
pressure O
, O
palpitations O
, O
or O
weakness O
. O
Denies O
nausea O
, O
vomiting O
, O

 O
diarrhea O
, O
constipation O
, O
abdominal O
pain O
, O
or O
changes O
in O
bowel O

 O
habits O
. O
Denies O
dysuria O
, O
frequency O
, O
or O
urgency O
. O
Denies O

 O
arthralgias O
or O
myalgias O
. O



 O
Past O
Medical O
History O
: O

 O
- O
s/p O
mechanical O
mitral O
valve O
repair O
[ O
* O
* O
2125 O
* O
* O
] O

 O
-sinus O
node O
dysfunction O
s/p O
DDD O
pacemaker O
placement O
[ O
* O
* O
2125 O
* O
* O
] O

 O
- O
atrial O
flutter O
s/p O
ablation O
[ O
* O
* O
2-/2132 O
* O
* O
] O
and O
cardioversion O
[ O
* O
* O
11 O
- O
3 O
* O
* O
] O

 O
- O
congestive O
heart O
failure O
, O
Last O
echo O
[ O
* O
* O
2137 O
- O
9 O
- O
12 O
* O
* O
] O
LVEF= O
40 O
- O
45 O
% O

 O
Moderate O
to O
severe O
[ O
3 O
+ O
] O
tricuspid O
regurgitation O

 O
- O
chronic B-REA
obstructive I-REA
pulmonary I-REA
disease I-REA
: I-REA
4LO2 B-DRUG
trach O
at O
home O
at O

 O
rest O

 O
- O
idiopathic B-REA
pulmonary I-REA
fibrosis I-REA
on O
chronic O
prednisone B-DRUG

 I-DRUG
- O
chronic O
kidney O
disease O
; O
baseline O
creatinine O
1.3 O
- O
1.6 O
on O
[ O
* O
* O
2137 O
- O
9 O
- O
18 O
* O
* O
] O

 O
UreaN-40 O
* O
Creat-1.1 O

 O
- O
anemia O
due O
to O
mechanical O
valve O
and O
chronic O
kidney O
disease O

 O
- O
hypertension O

 O
- O
hypercholesterolemia O

 O
- O
hypothyroidism O

 O
- O
meniere??????s O
disease O
( O
HOH O
) O

 O
- O
spinal O
arthritis O

 O
- O
breast O
cancer O
radical O
mastectomy O
right O
breast O
[ O
* O
* O
2095 O
* O
* O
] O
. O
Partial O

 O
left O
[ O
* O
* O
2097 O
* O
* O
] O
. O

 O
- O
s/p O
hysterectomy O
[ O
* O
* O
2101 O
* O
* O
] O

 O
- O
s/p O
nasal O
embolization O
for O
refractory O
epistaxis O
[ O
* O
* O
6 O
- O
30 O
* O
* O
] O



 O
Social O
History O
: O

 O
-smoked O
36 O
years O
, O
quit O
in O
[ O
* O
* O
2111 O
* O
* O
] O
. O

 O
-denies O
alcohol O
use O
. O

 O
-no O
IVDU O
. O

 O
-requires O
assistance O
with O
all O
ADLs O
and O
IADLs O

 O
-uses O
walker O
at O
baseline O
. O

 O
-housekeeper O
2x O
/week O
in O
past O
. O

 O
-peapod O
for O
groceries O
. O

 O
-HHA O
twice O
a O
week O
and O
for O
assitance O
with O
showers O
. O

 O
-husband O
does O
[ O
* O
* O
Name2 O
( O
NI O
) O
14994 O
* O
* O
] O
. O

 O
-Husband O
[ O
* O
* O
Name O
( O
NI O
) O
9102 O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
15153 O
* O
* O
] O


 O
Family O
History O
: O

 O
Father O
had O
polymyositis O
and O
coronary O
artery O
disease O
; O
mother O
had O

 O
metastatic O
bone O
cancer O
. O
She O
has O
several O
cousins O
with O
breast O

 O
cancer O
. O



 O

Physical O
Exam O
: O

 O
Vitals O
: O
T:98.3 O
BP:119/51 O
P:86 O
R:13 O
  O
SpO2:100 O
% O

 O
General O
: O
Alert O
, O
oriented O
, O
short O
of O
breath O
, O
difficulty O
finishing O

 O
sentences O

 O
HEENT O
: O
Sclera O
anicteric O
, O
pale O
conjuctiva O
, O
no O
tenderness O
, O

 O
increased O
pigmentation O
bilateral O
cheeks O
, O
dry O
oral O
mucosa O
, O

 O
oropharynx O
clear O
, O
PERRL O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
CV O
: O
tachycardia O
, O
normal O
S1 O
loud O
mechanical O
S2 O
, O
no O
rubs O
, O
no O

 O
gallops O

 O
Lungs O
: O
slight O
use O
of O
accessory O
muscles O
, O
decreased O
breath O
sounds O

 O
bilaterally O
L O
> O
R O
, O
crackles O
in O
R O
Lung O
, O
large O
healed O
scar O
on O
R O

 O
chest O
in O
mammary O
region O
from O
radical O
mastectomy O

 O
Abdomen O
: O
refused O

 O
GU O
: O
foley O

 O
Rectal O
: O
refused O

 O
Ext O
: O
cap O
refill O
< O
2 O
sec O
, O
+ O
2 O
pitting O
edema O
upper O
and O
lower O

 O
extremities O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
02:24PM O
   O
WBC-13.6 O
* O
# O
RBC-1.49 O
* O
# O
HGB-4.6 O
* O
# O
HCT-14.2 O
* O
# O

 O
MCV-95 O
MCH-30.6 O
MCHC-32.1 O
RDW-17.5 O
* O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
02:24PM O
   O
PLT O
COUNT-240 O
# O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
02:24PM O
   O
NEUTS-92.1 O
* O
LYMPHS-4.3 O
* O
MONOS-2.0 O
EOS-1.4 O

 O
BASOS-0.1 O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
02:24PM O
   O
PT-86.1 O
* O
PTT-53.0 O
* O
INR(PT)-10.0 O
* O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
02:24PM O
   O
GLUCOSE-254 O
* O
UREA O
N-72 O
* O
CREAT-2.1 O
* O
SODIUM-138 O

 O
POTASSIUM-5.4 O
* O
CHLORIDE-97 O
TOTAL O
CO2 O
- O
29 O
ANION O
GAP-17 O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
02:24PM O
   O
cTropnT-0.13 O
* O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
03:20PM O
   O
IRON-13 O
* O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
03:20PM O
   O
calTIBC-329 O
HAPTOGLOB-122 O
FERRITIN-64 O
TRF-253 O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
03:20PM O
   O
CK-MB-3 O
proBNP-1495 O
* O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
03:20PM O
   O
ALT(SGPT)-20 O
AST(SGOT)-23 O
LD(LDH)-405 O
* O

 O
CK(CPK)-48 O
ALK O
PHOS-48 O
TOT O
BILI-0.3 O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
08:36PM O
   O
RET O
MAN-15.1 O
* O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
10:03PM O
URINE O
  O
RBC-0 O
WBC-1 O
BACTERIA-NONE O
YEAST-NONE O

 O
EPI-0 O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
10:03PM O
URINE O
  O
BLOOD-NEG O
NITRITE-NEG O
PROTEIN-TR O

 O
GLUCOSE-NEG O
KETONE-NEG O
BILIRUBIN-NEG O
UROBILNGN-NEG O
PH-6.0 O

 O
LEUK-NEG O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
10:03PM O
URINE O
  O
OSMOLAL-335 O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
7 O
* O
* O
] O
10:03PM O
URINE O
  O
HOURS-RANDOM O
UREA O
N-451 O
CREAT-71 O

 O
SODIUM-39 O
POTASSIUM-44 O
CHLORIDE-29 O

 O
. O

 O
Day O
of O
Discharge O
: O

 O
WBC O
   O
RBC O
   O
Hgb O
   O
Hct O
MCV O
MCH O
MCHC O
RDW O
Plt O
Ct O

 O
11.4 O
* O
3.32 O
* O
9.7 O
* O
30.1 O
* O
91 O
29.3 O
32.3 O
16.7 O
* O
169 O

 O
. O


    O
PT O
    O
PTT O
     O
INR(PT O
) O

   O
20.4 O
* O
47.3 O
* O
     O
1.9 O

 O
. O

 O
Glucose O
UreaN O
Creat O
  O
Na O
   O
K O
     O
Cl O
HCO3 O
AnGap O

   O
87 O
      O
76 O
* O
1.7 O
* O
  O
152 O
  O
3.1 O
* O
109 O
* O
  O
28 O
   O
18 O

 O
. O

 O
Anemia O
work-up O

 O
retic O
: O
6.6 O

 O
calTIBC O
Hapto O
Ferritn O
TRF O

  O
329 O
     O
122 O
    O
64 O
    O
253 O

 O
. O

 O
LFTs O
: O

 O
ALT O
AST O
     O
LD(LDH O
) O
CK(CPK O
) O
AlkPhos O
Amylase O
TotBili O
DirBili O

  O
30 O
   O
28 O
                      O
72 O
      O
492 O
* O
    O
0.4 O

 O
. O

 O
TFTs O

 O
TSH O
: O
12 O

 O
FT4 O
: O
1.1 O


 O
Images O
: O

 O
[ O
* O
* O
10 O
- O
7 O
* O
* O
] O
Chest O
AP O
: O
Low O
lung O
volumes O
with O
known O
idiopathic O
pulmonary O

 O
fibrosis O
. O
While O
a O
subtle O
superimposed O
acute O
consolidation O
in O
the O

 O
lung O
bases O
is O
difficult O
to O
exclude O
, O
it O
would O
be O
highly O

 O
coincidental O
and O
is O
felt O
less O
likely O
with O
the O
increased O
opacity O

 O
likely O
due O
to O
crowding O
. O


 O
CXR O
( O
[ O
* O
* O
10 O
- O
8 O
* O
* O
] O
) O
: O

 O
FINDINGS O
: O
As O
compared O
to O
the O
previous O
radiograph O
, O
there O
is O
no O

 O
relevant O

 O
change O
. O
Status O
post O
sternotomy O
, O
status O
post O
valvular O

 O
replacement O
. O
The O

 O
external O
and O
internal O
pacemaker O
with O
leads O
are O
visible O
. O

 O
Unchanged O
evidence O
of O
a O
right O
basal O
opacity O
with O
a O
predominantly O

 O
reticular O
pattern O
, O
that O
might O
, O
in O
part O
be O
, O
fibrotic O
. O
  O
These O
are O

 O
likely O
to O
be O
related O
to O
the O
known O
history O
of O
idiopathic O

 O
pulmonary O
fibrosis O
. O
There O
is O
no O
evidence O
of O
fluid O
overload O
on O

 O
the O
current O
image O
. O
No O
pleural O
effusions O
. O
No O
parenchymal O

 O
opacities O
have O
newly O
occurred O
. O

 O
. O

 O
CT O
Torso O
: O
[ O
* O
* O
10 O
- O
27 O
* O
* O
] O

 O
IMPRESSION O
: O

 O
1 O
. O
Emphysema O
and O
pulmonary O
fibrosis O
with O
mild O
bibasilar O

 O
consolidations O
, O
worse O
on O
the O
right O
than O
the O
left O
, O
likely O

 O
reflecting O
atelectasis O
, O
although O

 O
superimposed O
pneumonia O
can O
not O
be O
excluded O
. O

 O
2 O
. O
Status O
post O
right O
mastectomy O
. O

 O
3 O
. O
Cholelithiasis O
in O
a O
nondistended O
gallbladder O
with O
mild O
wall O

 O
edema/pericholecystic O
fluid O
likely O
reflects O
either O
CHF O
or O

 O
hypoproteinemia O
. O

 O
4 O
. O
Diverticulosis O
without O
diverticulitis O
. O

 O
5 O
. O
No O
evidence O
of O
intra-abdominal O
free O
air O
or O
organized O
fluid O

 O
collection O
. O

 O
6 O
. O
Indistinct O
pancreatic O
head O
; O
correlate O
with O
pancreatic O
enzymes O

 O
if O
clinical O
concern O
for O
pancreatitis O
. O

 O
. O

 O
RUQ O
US O
[ O
* O
* O
10 O
- O
25 O
* O
* O
] O

 O
1 O
. O
Sludge O
and O
stones O
in O
the O
gallbladder O
neck O
without O
other O

 O
findings O
to O

 O
suggest O
acute O
cholecystitis O
. O
If O
there O
is O
continued O
clinical O

 O
concern O
, O
a O
HIDA O
scan O
may O
be O
more O
definitive O
in O
the O
exclusion O
of O

 O
acute O
cholecystitis O
. O

 O
2 O
. O
Dilated O
hepatic O
veins O
consistent O
with O
diastolic O
dysfunction O

 O
. O


 O
CT O
Head O
[ O
* O
* O
10 O
- O
20 O
* O
* O
] O

 O
1 O
. O
No O
acute O
intracranial O
abnormality O
. O

 O
2 O
. O
Small O
vessel O
ischemic O
disease O
and O
diffuse O
cerebral O
atrophy O
. O


 O
. O

 O
Pathology O
: O

 O
Bronchial O
lavage O
: O

   O
ATYPICAL O
. O

   O
Atypical O
squamous O
cells O
. O

   O
Bronchial O
cells O
and O
inflammatory O
cells O
. O

 O
. O

 O
Colonic O
polyp O
, O
distal O
ascending/proximal O
transverse O
( O
biopsy O
) O
: O

 O
1 O
. O
  O
Fragments O
of O
adenoma O
with O
focal O
high O
grade O
dysplasia O
. O

 O
. O

 O
Micro O
: O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
28 O
* O
* O
] O
2:47 O
pm O
STOOL O
     O
CONSISTENCY O
: O
NOT O
APPLICABLE O

       O
Source O
: O
Stool O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2137 O
- O
10 O
- O
29 O
* O
* O
] O
* O
* O


    O
CLOSTRIDIUM O
DIFFICILE O
TOXIN O
A O
& O
B O
TEST O
( O
Final O
[ O
* O
* O
2137 O
- O
10 O
- O
29 O
* O
* O
] O
) O
: O

       O
Reported O
to O
and O
read O
back O
by O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
15154 O
* O
* O
] O
@ O
0550 O
ON O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
29 O
* O
* O
] O
. O

       O
CLOSTRIDIUM O
DIFFICILE O
. O

          O
FECES O
POSITIVE O
FOR O
C. O
DIFFICILE O
TOXIN O
BY O
EIA O
. O

 O
[ O
* O
* O
2137 O
- O
10 O
- O
27 O
* O
* O
] O
2:27 O
am O
SPUTUM O
      O
Source O
: O
Endotracheal O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2137 O
- O
10 O
- O
29 O
* O
* O
] O
* O
* O


    O
GRAM O
STAIN O
( O
Final O
[ O
* O
* O
2137 O
- O
10 O
- O
27 O
* O
* O
] O
) O
: O

       O
> O
25 O
PMNs O
and O
< O
10 O
epithelial O
cells/100X O
field O
. O

       O
4 O
+ O
   O
( O
> O
10 O
per O
1000X O
FIELD O
) O
: O
   O
GRAM O
POSITIVE O
COCCI O
. O

                                     O
IN O
PAIRS O
AND O
CLUSTERS O
. O

       O
3 O
+ O
  O
( O
5 O
- O
10 O
per O
1000X O
FIELD O
) O
: O
   O
GRAM O
NEGATIVE O
ROD(S O
) O
. O

       O
1 O
+ O
    O
( O
< O
1 O
per O
1000X O
FIELD O
) O
: O
   O
GRAM O
POSITIVE O
ROD(S O
) O
. O

       O
1 O
+ O
    O
( O
< O
1 O
per O
1000X O
FIELD O
) O
: O
   O
GRAM O
NEGATIVE O
DIPLOCOCCI O
. O

       O
1 O
+ O
    O
( O
< O
1 O
per O
1000X O
FIELD O
) O
: O
   O
BUDDING O
YEAST O
WITH O

 O
PSEUDOHYPHAE O
. O

       O
SMEAR O
REVIEWED O
; O
RESULTS O
CONFIRMED O
. O


    O
RESPIRATORY O
CULTURE O
( O
Final O
[ O
* O
* O
2137 O
- O
10 O
- O
29 O
* O
* O
] O
) O
: O

       O
MODERATE O
GROWTH O
Commensal O
Respiratory O
Flora O
. O


 O
[ O
* O
* O
2137 O
- O
10 O
- O
27 O
* O
* O
] O
1:09 O
am O
URINE O
      O
Source O
: O
Catheter O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2137 O
- O
10 O
- O
28 O
* O
* O
] O
* O
* O


    O
URINE O
CULTURE O
( O
Final O
[ O
* O
* O
2137 O
- O
10 O
- O
28 O
* O
* O
] O
) O
: O

       O
YEAST O
. O
    O
~7000/ML O
. O



 O
Brief O
Hospital O
Course O
: O

 O
76 O
y.o O
woman O
with O
PMH O
of O
IPF O
, O
COPD O
, O
anemia O
, O
mechanical O
mitral O

 O
valve O
, O
and O
pacemaker O
presents O
with O
worsening O
dyspnea O
, O
acute O
renal O

 O
failure O
, O
and O
fluid O
overload O
. O



 O
# O
. O
Anemia O
: O
On O
admission O
hemoglobin O
of O
4.6 O
and O
hematocrit O
of O
14.2 O

 O
from O
a O

 O
hgb O
10 O
and O
hct O
33.1 O
within O
the O
last O
several O
weeks O
. O
Hemolysis O

 O
labs O
negative O
, O
and O
rectal O
exam O
showed O
guiac O
positive O
brown O

 O
stool O
. O
Her O
anemia O
was O
believed O
to O
be O
secondary O
to O
a O
GI O
bleed O
. O

 O
She O
was O
transfused O
4 O
units O
total O
with O
appropriate O
hct O
response O
, O

 O
and O
her O
hct/hgb O
ramined O
stable O
. O
She O
underwent O
EGD/colonoscopy O

 O
which O
showed O
esophageal O
and O
fundal O
varices O
and O
a O
large O
polyp O
in O

 O
the O
colon O
, O
concerning O
for O
malignancy O
which O
was O
believed O
to O
be O

 O
the O
source O
of O
bleeding O
. O
  O
On O
biopsy O
, O
this O
lesion O
was O
found O
to O
be O

 O
an O
adenoma O
with O
high O
grade O
dysplasia O
. O
Gastroenterology O
believed O

 O
that O
it O
would O
be O
possible O
to O
perform O
a O
transluminal O
resection O

 O
but O
that O
the O
procedure O
would O
have O
high O
risk O
of O
perforation O
and O

 O
death O
. O
After O
a O
goals O
of O
care O
discussion O
with O
the O
[ O
* O
* O
Hospital O
228 O
* O
* O
] O

 O
health O
care O
proxy O
, O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
15155 O
* O
* O
] O
, O
and O
the O
gastroenterology O
team O

 O
it O
was O
decided O
that O
though O
the O
adenoma O
is O
high O
risk O
for O

 O
malignancy O
, O
she O
will O
likely O
succumb O
to O
her O
severe O
pulmonary O

 O
disease O
in O
the O
next O
1 O
- O
5 O
years O
and O
removal O
of O
the O
mass O
is O
not O
in O

 O
line O
with O
her O
goals O
of O
care O
. O
She O
was O
started O
on O
nadolol B-DRUG
for O

 O
esophageal B-REA
varaces I-REA
. I-REA

 O
OUTPATIENT O
ISSUES O
: O

 O
-- O
Obtain O
2x O
weekly O
HCTs O
and O
transfuse O
for O
HCT O
< O
21 O

 O
-- O
Continue O
Fe O
supplementation O
and O
epo O
administration O

 O
. O


 O
# O
. O
Hypoxemic O
respiratory O
failure O
: O
The O
patient O
presented O
on O
5L O

 O
trans-trach O
from O
a O
baseline O
of O
4L O
at O
home O
in O
the O
setting O
of O

 O
known O
IPF O
, O
COPD O
, O
and O
chronic O
heart O
failure O
. O
  O
Her O
dyspnea O
was O

 O
attributed O
to O
anemia O
vs O
fluid O
overload O
from O
CHF O
, O
and O
remained O

 O
stable O
in-house O
and O
gradually O
improved O
upon O
discharge O
from O
the O

 O
ICU O
. O
  O
There O
was O
low O
suspicion O
for O
a O
COPD O
or O
IPF O
exacerbation O
. O

 O
She O
was O
given O
IV B-ROU
Torsemide B-DRUG
for O
diuresis B-REA
with O
her O
packed B-DRUG
red I-DRUG
cell I-DRUG

 I-DRUG
transfusions B-ROU
, I-ROU
and O
her O
home O
Bumex B-DRUG
was O
held O
in-house O
. O
  O
Her O
home O

 O
prednisone B-DRUG
and O
nebulizers B-DRUG
were O
continued O
in-house O
. O
  O
Related O
to O

 O
her O
shortness O
of O
breath O
, O
she O
occassionally O
coughed O
up O
" O
blood O

 O
balls O
" O
, O
which O
she O
attributed O
to O
bloodly O
mucous O
originating O
at O

 O
her O
catheter O
site O
. O
  O
These O
were O
inconsistent O
, O
and O
associated O
with O

 O
epistaxis O
, O
and O
we O
believed O
that O
there O
was O
a O
component O
of O
bloody O

 O
post-nasal O
drip O
contributing O
, O
exacerbated O
by O
the O
fact O
that O
she O

 O
was O
on O
a O
heparin B-DRUG
gtt B-ROU
for O
her B-REA
heart I-REA
valve I-REA
. I-REA
  O
The O
total O
blood O
loss O

 O
from O
these O
episodes O
was O
essentially O
non-contributory O
. O
  O
On O
the O

 O
floor O
, O
she O
continued O
to O
be O
dyspneic O
at O
times O
. O
  O
She O
was O
found O
to O

 O
have O
evidence O
of O
a O
RUL B-REA
HAP I-REA
, I-REA
so O
she O
was O
started O
empirically O
on O

 O
vancomycin B-DRUG
and O
cefepime B-DRUG
. I-DRUG
She O
developed O
progressive O
respiratory O

 O
distress O
and O
returned O
the O
MICU O
where O
she O
was O
intubated O
. O
She O

 O
underwent O
broncheoalveolar O
lavage O
which O
was O
culture O
negative O
and O

 O
her O
antibiotics B-DRUG
were O
discontinued O
on O
[ O
* O
* O
10 O
- O
23 O
* O
* O
] O
. O
She O
continued O
to O
be O

 O
intermittently O
diuresed O
but O
it O
was O
stopped O
when O
her O
creatinine B-DRUG

 I-DRUG
bumped O
from O
1.8 O
to O
2.7 O
. O
She O
was O
extubated O
and O
returned O
to O
the O

 O
medical O
floor O
with O
o2 B-DRUG
sats O
95 O
% O
on O
2LNC O
The O
thought O
is O
that O
her O

 O
respiratory O
distress O
was O
likely O
due O
to O
a O
mucus O
plug O
and O

 O
pulmonary O
edema O
. O
After O
two O
days O
on O
the O
medical O
floor O
, O
she O
pulled O

 O
out O
a O
nasogastric O
tube O
which O
had O
been O
used O
for O
tubefeeds O
, O

 O
aspirated O
and O
developed O
respiratory O
distress O
with O
hypoxia O
and O

 O
acidemia O
. O
She O
was O
transferred O
to O
the O
MICU O
for O
a O
third O
time O
where O

 O
she O
was O
again O
intubated O
. O
Out O
of O
concern O
for O
HCAP B-REA
the O
pt O
was O

 O
started O
on O
vanc/[**Last B-DRUG
Name O
( O
un O
) O
2830 O
* O
* O
] O
. O
Due O
to O
increasing O
wbc O
and O
decreased O
stool O

 O
output O
there O
was O
also O
concern O
for O
c.diff B-REA
, I-REA
which O
ultimately O
was O

 O
positive O
, O
and O
the O
pt O
was O
started O
on O
flagyl/PO B-ROU
vanc B-DRUG
. I-DRUG
The O
pt O
's O

 O
respiratory O
status O
improved O
and O
she O
was O
successfully O
extubated O
. O

 O
Vancomycin B-DRUG
was O
discontinued O
on O
[ O
* O
* O
10 O
- O
30 O
* O
* O
] O
with O
plan O
to O
complete O
a O

 O
total O
of O
8d B-DUR
of O
meropenem B-DRUG
. I-DRUG

 O
OUTPATIENT O
ISSUES O
: O

 O
-- O
Continue O
meropenem B-DRUG
thru O
[ O
* O
* O
11 O
- O
3 O
* O
* O
] O
. O

 O
-- O
Ongoing O
discussion O
regarding O
replacement O
of O
transtracheal O

 O
catheter O
. O

 O
. O


 O
# O
Clostridium O
Difficile O
: O
The O
pt O
was O
found O
to O
have O
a O
rising O
WBC O
, O

 O
episodes O
of O
hypotension O
and O
decreased O
stool O
output O
. O
She O
was O

 O
empirically O
started O
on O
IV B-ROU
flagyl B-DRUG
and O
PO B-ROU
vanco B-DRUG
which O
were O

 O
continued O
when O
stool O
culture O
was O
positive O
for O
c.diff B-REA
. I-REA
Pt O
had O

 O
subsequent O
decreased O
in O
WBC O
to O
normal O
with O
improvement O
in O
loose O

 O
stools O
. O

 O
OUTPATIENT O
ISSUES O
: O

 O
-- O
Plan O
to O
complete O
PO B-ROU
vancomycin B-DRUG
125 B-STR
mg I-STR
PO B-ROU
Q6hrs B-FRE
as O
well O
as O

 O
Flagyl B-DRUG
500 B-STR
mg I-STR
Q8hrs B-FRE
; I-FRE
end O
date O
[ O
* O
* O
11 O
- O
9 O
* O
* O
] O
. O

 O
. O

 O
# O
Anticoagulation O
: O
Patient O
anticoagulated O
due O
to O
presence O
of O

 O
mechanical O
valve O
. O
Patient O
presented O
with O
an O
INR B-REA
of I-REA
10 I-REA
for O

 O
unclear O
reasons O
. O
  O
She O
received O
5 B-STR
mg I-STR
PO B-ROU
Vit B-DRUG
K I-DRUG
, I-DRUG
and O
her O
INR O

 O
down-trended O
to O
the O
sub-therapeutic O
range O
and O
she O
was O
started O
on O

 O
a O
Heparin B-DRUG
gtt B-ROU
for O
her O
mechanical B-REA
mitral I-REA
valve I-REA
. I-REA
  O
She O
experienced O

 O
epistaxis O
and O
coughed O
up O
bloody O
mucus O
in O
the O
setting O
of O
a O

 O
slightly O
supratherapeutic B-ADE
PTT I-ADE
which O
resolved O
with O
decreasing O
her O

 O
Heparin B-DRUG
gtt B-ROU
. I-ROU
  O
She O
was O
kept O
on O
a O
heparin B-DRUG
drip B-ROU
for O
bridging O
on O
the O

 O
medicine O
floor O
. O
  O
When O
the O
decision O
was O
made O
to O
pursue O

 O
endomucosal O
resection O
of O
her O
adenoma O
, O
her O
warfarin B-DRUG
was O

 O
discontinued O
, O
however O
given O
this O
was O
put O
on O
hold O
, O
the O
pt O
was O

 O
restarted O
on O
coumadin B-DRUG
[ O
* O
* O
10 O
- O
29 O
* O
* O
] O
. O
At O
time O
of O
discharge O
patient O

 O
remained O
on O
hep B-DRUG
gtt B-ROU
as O
well O
as O
coumadin B-DRUG
3 B-STR
mg I-STR
daily B-FRE
; I-FRE
INR O
on O
day O
of O

 O
discharge O
1.9 O

 O
OUTPATIENT O
ISSUES O
: O

 O
-- O
COntinue O
hep B-DRUG
gtt B-ROU
and O
coumadin B-DRUG
until O
INR O
therapeutic O
( O
2.5 O
- O

 O
3.5 O
) O
. O

 O
. O

 O
# O
Volume O
Status/Acute O
Renal O
Failure O
. O
Patient O
with O
oscillating O

 O
renal O
function O
in O
house O
. O
Peak O
   O
Cr O
2.8 O
from O
a O
baseline O
of O
~1.4 O
, O

 O
likely O
secondary O
to O
hypovolemia O
as O
well O
as O
renal O
hypoperfusion O

 O
[ O
* O
* O
2 O
- O
27 O
* O
* O
] O
anemia O
. O
  O
Urine O
lytes O
showed O
were O
consistent O
with O

 O
hypovolemia O
. O
Initially O
Bumex B-DRUG
was O
held O
and O
she O
was O
given O
IV B-ROU

 I-ROU
hydration B-DRUG
. I-DRUG
Creatinine O
increased O
from O
1.8 O
- O
2.7 O
in O
the O
setting O
of O

 O
diuresis O
( O
as O
above O
) O
and O
bumex B-DRUG
was O
held O
. O
During O
hospital O
stay O

 O
patient O
was O
intermittently O
diuresised O
and O
prior O
to O
discharge O

 O
restarted O
on O
PO B-ROU
Bumex B-DRUG
5 B-STR
mg I-STR
daily B-FRE
with O
creatinine O
of O
1.7 O
. O
Weight O

 O
at O
time O
of O
discharge O
: O
62.4 O
kg O
; O
sating O
> O
95 O
% O
on O
5L O
NC O
. O

 O
OUTPATIENT O
ISSUES O
: O

 O
-- O
Pleae O
continue O
Bumex B-DRUG
5 B-STR
mg I-STR
PO B-ROU
daily B-FRE
; I-FRE
monitor O
weights O
daily O
as O

 O
well O
as O
renal O
function O
; O
may O
consider O
increasing O
bumex B-DRUG
to O
[ O
* O
* O
Hospital1 O
* O
* O
] O
or O

 O
transitioning O
to O
IV B-ROU
if O
weight O
increases O
> O
3 O
lb O

 O
. O

 O
# O
Esophageal B-REA
Varices I-REA
. I-REA
Newly O
diagnosed O
. O
Patient O
placed O
on O
nadolol B-DRUG

 I-DRUG
10 B-STR
mg I-STR
daily B-FRE
. I-FRE

 O
. O


 O
# O
Hypertension B-REA
. I-REA
Patient O
largely O
hypotensive O
to O
normotensive O
in O

 O
house O
. O
Decision O
made O
to O
hold O
home O
amlodipine B-DRUG
5 B-STR
mg I-STR
daily B-FRE
as O
well O

 O
as O
spironolactone B-DRUG
50 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
at O
time O
of O
discharge O
. O

 O
OUTPATIENT O
ISSUES O
: O

 O
-- O
Close O
hemodynamic O
monitoring O
; O
plan O
to O
re-initiate O

 O
anti-hypertensives O
if O
needed O
. O

 O
. O

 O
# O
Pulmonary O
fibrosis O
. O
Patient O
with O
transtracheal O
O2 B-DRUG
catheter O
as O

 O
well O
as O
use O
of O
chronic O
steriods O
as O
an O
outpatient O
. O
During O
1st O

 O
intubation O
transtracheal O
cath O
was O
removed O
. O
In O
house O
patient O

 O
received O
stress B-DOS
dose I-DOS
steriods B-DRUG
which O
were O
weanted O
to O
home O

 O
prednisone B-DRUG
10 B-STR
mg I-STR
daily B-FRE
at O
time O
of O
discharge O
. O

 O
OUTPATIENT O
ISSUES O
: O

 O
-- O
Continue O
chronic B-DUR
prednisone B-DRUG
; I-DRUG
consider O
need O
for O
PCP O
[ O
* O
* O
Name9 O
( O
PRE O
) O
* O
* O
] O

 O
[ O
* O
* O
Name9 O
( O
PRE O
) O
* O
* O
] O
Continue O
discussion O
re O
replacement O
of O
transtracheal O
cath O

 O
. O

 O
# O
Hypernatremia O
. O
Patient O
noted O
to O
be O
intermittently O

 O
hypernatremic O
when O
NPO/intubated O
. O
Received O
free O
water O
boluses O

 O
thru O
NGT O
as O
well O
as O
IV B-ROU
D5 B-DRUG
with O
improvement O
. O
Na O
at O
time O
of O

 O
discharge O
152 O

 O
OUTPATIENT O

 O
-- O
Continue O
monitoring O
of O
electrolytes O
; O
encourage O
PO O
intake O
and O

 O
adminster O
D5W B-DRUG
if O
needed O
( O
however O
by O
cautious O
in O
setting O
of O
known O

 O
diastolic O
CHF O
) O
. O


 O
# O
Goals O
of O
Care O
: O
On O
[ O
* O
* O
2137 O
- O
10 O
- O
25 O
* O
* O
] O
a O
goals O
of O
care O
discussion O
was O
held O

 O
with O
the O
patient O
's O
HCP O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
15155 O
* O
* O
] O
. O
The O
decision O
was O
made O
to O

 O
forgo O
aggressive O
management O
of O
the O
colonic O
adenoma O
as O
her O
life O

 O
expectancy O
with O
idiopathic O
pulmonary O
fibrosis O
( O
which O
she O
has O

 O
suffered O
with O
for O
~8 O
years O
) O
is O
now O
less O
than O
5 O
years O
and O
likely O

 O
less O
than O
one O
. O
The O
family O
wanted O
the O
patient O
to O
remain O
full O
code O

 O
and O
to O
have O
aggressive O
management O
of O
her O
pulmonary O
disease O
. O


 O
# O
Code O
: O
Full O

 O
# O
HCP O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
15155 O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
15156 O
* O
* O
] O

 O
. O

 O
. O

 O
TRANSITIONAL O
ISSUES O

 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
Health B-REA
Care I-REA
Associated I-REA
Pneumonia I-REA
treatment O

 O
-- O
Continue O
on O
meropenem B-DRUG
for O
planned O
8d B-DUR
course I-DUR
, I-DUR
end O
date O
[ O
* O
* O
11 O
- O
3 O
* O
* O
] O

 O
. O

 O
C. B-REA
Difficile I-REA
infection I-REA

 I-REA
-- O
Continue O
on O
flagyl B-DRUG
and O
PO B-ROU
vanc B-DRUG
for O
planned O
10d B-DUR
course I-DUR
; I-DUR
end O

 O
date O
: O
[ O
* O
* O
11 O
- O
9 O
* O
* O
] O

 O
. O

 O
Congestive B-REA
Heart I-REA
Failure I-REA

 I-REA
-- O
Continue O
PO B-ROU
Bumex B-DRUG
5 B-STR
mg I-STR
daily B-FRE
; I-FRE
monitor O
weights O
as O
well O
as O
renal O

 O
function O
with O
weekly O
chem O
10 O
panel O

 O
. O


 O
Mitral B-REA
Valve I-REA
Replacement I-REA
; I-REA
goal O
INR O
2.5 O
- O
3.5 O

 O
-- O
Continue O
hep B-DRUG
gtt B-ROU
until O
bridged O
with O
coumadin B-DRUG
, I-DRUG
3 B-STR
mg I-STR
daily B-FRE
, I-FRE
to O
a O

 O
therapeutic O
INR O

 O
. O

 O
Colonic O
Polyp O
; O
GI O
bleed O

 O
-- O
Please O
check O
twice O
weekly O
hematocrit O
check O
with O
plan O
to O

 O
transfuse O
if O
< O
24 O

 O
. O

 O
Arrythmia B-REA

 I-REA
-- O
Restarting O
home O
dofetilide B-DRUG
on O
discharge O
; O
primary O
cardiologist O

 O
aware O
. O

 O
. O

 O
Hypernatremia O

 O
-- O
Patient O
with O
improved O
PO O
intake O
in O
days O
leading O
up O
to O

 O
discharge O
however O
sodiums O
borderine O
in O
140s-150s O
. O
Please O
monitor O

 O
closely O
to O
ensure O
patient O
does O
not O
need O
additional O
free O
water O
to O

 O
correction O
of O
electrolyte O
abnormality O
. O

 O
. O

 O
PCP O
[ O
* O
* O
Name O
Initial O
( O
PRE O
) O
* O
* O
] O
: O

 O
[ O
* O
* O
Month O
( O
only O
) O
116 O
* O
* O
] O
consider O
starting O
PCP O
prophylaxis O
given O
chronic B-DUR
steroid B-DRUG
use O
. O

  O
Discussed O
with O
the O
patient O
's O
pulmonologist O
, O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
. O
  O
Patient O

 O
has O
been O
on O
it O
in O
the O
past O
, O
but O
when O
she O
was O
on O
higher O
doses O
of O

 O
PO B-ROU
steroids B-DRUG
( O
~20 B-STR
mg I-STR
) I-STR
chronically O
. O


 O
Left O
kidney O
mass O
was O
seen O
on O
CT O
abdomen O
which O
is O
new O
since O
[ O
* O
* O
2134 O
* O
* O
] O

 O
and O
will O
need O
follow O
up O
ultrasound O
and O
monitoring O
. O



 O
Medications O
on O
Admission O
: O

 O
1.amlodipine B-DRUG
5 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
2.fexofenadine B-DRUG
60 B-STR
mg I-STR
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
3.levothyroxine B-DRUG
112 B-STR
mcg I-STR
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
4.omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
PO B-ROU
BID B-FRE

 I-FRE
5.multivitamin B-DRUG
  O
One B-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
6.tiotropium B-DRUG
bromide I-DRUG
18 B-STR
mcg I-STR
Capsule B-FOR
, I-FOR
w/Inhalation I-FOR
Device I-FOR
One B-DOS
Cap B-FOR

 I-FOR
Inhalation B-ROU
DAILY B-FRE

 I-FRE
7.atorvastatin B-DRUG
20 B-STR
mg I-STR
Tablet B-ROU
One B-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
8.docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
One B-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE

 I-FRE
9.dofetilide B-DRUG
125 B-STR
mcg I-STR
Capsule B-FOR
One B-DOS
Capsule B-FOR
PO B-ROU
Q12H B-FRE

 I-FRE
10.albuterol B-DRUG
sulfate I-DRUG
90 B-STR
mcg/Actuation I-STR
HFA B-FOR
Aerosol I-FOR
Inhaler I-FOR
Two B-DOS

 I-DOS
Puff B-FOR
Inhalation B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours)PRN I-FRE
dyspnea B-REA
. I-REA

 O
11.cholecalciferol B-DRUG
( I-DRUG
vitamin I-DRUG
D3 I-DRUG
) I-DRUG
1,000 B-STR
unit I-STR
Tablet B-FOR
Two B-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
DAILY B-FRE
12.fluticasone B-DRUG
110 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Two B-DOS
Puff B-FOR

 I-FOR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
13.morphine B-DRUG
15 B-STR
mg I-STR
Tablet B-FOR
Extended I-FOR
Release I-FOR
One B-DOS

 I-DOS
Tablet B-FOR

 I-FOR
14.morphine B-DRUG
10 B-STR
mg/5 I-STR
mL I-STR
Solution B-FOR
[ O
* O
* O
1 O
- O
28 O
* O
* O
] O
PO B-ROU
Q4H B-FRE
PRN I-FRE
dyspnea B-REA
. I-REA

 O
15.calcium B-DRUG
carbonate I-DRUG
200 B-STR
mg I-STR
calcium B-DRUG
( O
500 B-STR
mg I-STR
) I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
16.warfarin B-DRUG
5 B-STR
mg I-STR
One B-DOS
Tablet B-FOR
PO B-ROU
4X/WEEK B-FRE
( O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
, O
MO B-FRE
, I-FRE
WE I-FRE
, I-FRE
FR I-FRE
) I-FRE
. O

 O
17.warfarin B-DRUG
2 B-STR
mg I-STR
One B-DOS
Tablet B-FOR
PO B-ROU
3X/WEEK B-FRE
( O
TU B-FRE
, I-FRE
TH I-FRE
, I-FRE
SA I-FRE
) I-FRE
. O

 O
18.Epogen B-DRUG
20,000 B-STR
unit/mL I-STR
One B-DOS
Injection B-ROU
once B-FRE
a I-FRE
week I-FRE
. I-FRE

 O
19.guaifenesin B-DRUG
600 B-STR
mg I-STR
Tablet B-FOR
Extended I-FOR
Release I-FOR
One B-DOS

 I-DOS
Tablet B-FOR
Extended I-FOR
Release I-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
20.bumetanide B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
21.prednisone B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Please O
follow O
attached O
taper O

 O
instructions O
. O
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
: I-FRE
On O
[ O
* O
* O
8 O
- O
9 O
* O
* O
] O
, O
take O
40 B-STR
mg I-STR
( O
4 O

 O
tablets B-FOR
once B-FRE
daily I-FRE
) I-FRE
. O
On O
[ O
* O
* O
8 O
- O
11 O
* O
* O
] O
, O
take O
30 B-STR
mg I-STR
( O
3 B-DOS
tablets B-FOR
once B-FRE

 I-FRE
daily I-FRE
) I-FRE
. O
On O
[ O
* O
* O
8 O
- O
14 O
* O
* O
] O
, O
take O
20 B-STR
mg I-STR
( O
two B-DOS
tablets B-FOR
once B-FRE
daily I-FRE
) I-FRE
. O
On O

 O
[ O
* O
* O
9 O
- O
26 O
* O
* O
] O
and O
onwards O
, O
take O
10 B-STR
mg I-STR
per O
day O
( O
one B-DOS
tablet B-FOR
once B-FRE
daily I-FRE
) I-FRE
. O

 O
22.ferrous B-DRUG
sulfate I-DRUG
325 B-STR
mg I-STR
( O
65 B-STR
mg I-STR
iron B-DRUG
) I-DRUG
One B-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
23.spironolactone B-DRUG
50 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
added O
[ O
* O
* O
2137 O
- O
10 O
- O
5 O
* O
* O
] O



 O
Discharge O
Medications O
: O

 O
1 O
. O
Outpatient O
Lab O
Work O

 O
Please O
obtain O
twice O
weekly O
hematocrits O
, O
INR O
( O
INR O
goal O
2.5 O
- O
3.5 O
) O

 O
2 O
. O
Outpatient O
Lab O
Work O

 O
Please O
obtain O
twice O
weekly O
chemistry O
panels O
( O
sodium O
, O
potassium O
, O

 O
chloride O
, O
bicarb O
, O
BUN O
, O
creatinine O
, O
mag O
, O
calcium O
, O
phosp O
) O
to O

 O
monitor O
for O
hypernatremia O
and O
chronic O
kidney O
insufficiency O

 O
3 O
. O
bumetanide B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
4 O
. O
Sodium B-DRUG
Chloride I-DRUG
0.9 B-STR
% I-STR
  O
Flush B-FOR
10 B-DOS
mL I-DOS
IV B-ROU
PRN B-FRE
line B-REA
flush I-REA

 I-REA
Temporary O
Central O
Access-ICU O
: O
Flush O
with O
10mL B-DOS
Normal B-DRUG
Saline I-DRUG

 I-DRUG
daily B-FRE
and I-FRE
PRN I-FRE
. I-FRE

 O
5 O
. O
warfarin B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Once B-FRE
Daily I-FRE
at I-FRE
4 I-FRE

 I-FRE
PM I-FRE
: I-FRE
goal B-REA
inr I-REA
2.5 I-REA
- I-REA
3.5 I-REA
. I-REA

 O
6 O
. O
vancomycin B-DRUG
125 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE

 I-FRE
6 I-FRE
hours I-FRE
) I-FRE
: I-FRE
TO O
END O
[ O
* O
* O
2137 O
- O
11 O
- O
9 O
* O
* O
] O
. O

 O
7 O
. O
prednisone B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
8 O
. O
fexofenadine B-DRUG
60 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE


 O
9 O
. O
levothyroxine B-DRUG
112 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE

 I-FRE
day I-FRE
. I-FRE

 O
10 O
. O
omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
11 O
. O
multivitamin B-DRUG
     O
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE


 O
12 O
. O
tiotropium B-DRUG
bromide I-DRUG
18 B-STR
mcg I-STR
Capsule B-FOR
, I-FOR
w/Inhalation I-FOR
Device I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Inhalation B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
13 O
. O
atorvastatin B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE



 O
14 O
. O
dofetilide B-DRUG
125 B-STR
mcg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
twice B-FRE
a I-FRE

 I-FRE
day I-FRE
. I-FRE

 O
15 O
. O
albuterol B-DRUG
sulfate I-DRUG
90 B-STR
mcg/Actuation I-STR
HFA I-STR
Aerosol B-FOR
Inhaler I-FOR
Sig O
: O

 O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
  O
Inhalation B-ROU
every B-FRE
four I-FRE
( I-FRE
4 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
shortness B-REA

 I-REA
of I-REA
breath I-REA
or O
wheezing B-REA
. I-REA

 O
16 O
. O
cholecalciferol B-DRUG
( O
vitamin B-DRUG
D3 I-DRUG
) I-DRUG
1,000 B-STR
unit I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
17 O
. O
fluticasone B-DRUG
110 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Puff B-FOR

 I-FOR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
18 O
. O
morphine B-DRUG
15 B-STR
mg I-STR
Tablet B-FOR
Extended I-FOR
Release I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR

 I-FOR
Extended I-FOR
Release I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
: I-REA
hold O
for O

 O
sedation B-ADE
, I-ADE
RR B-ADE
< I-ADE
12 I-ADE
. I-ADE

 O
19 O
. O
morphine B-DRUG
10 B-STR
mg/5 I-STR
mL I-STR
Solution B-FOR
Sig O
: O
[ O
* O
* O
1 O
- O
28 O
* O
* O
] O
  O
PO B-ROU
every B-FRE
four I-FRE
( I-FRE
4 I-FRE
) I-FRE

 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
shortness B-REA
of I-REA
breath I-REA
or O
wheezing B-REA
. I-REA

 O
20 O
. O
calcium B-DRUG
carbonate I-DRUG
200 B-STR
mg I-STR
calcium B-DRUG
( O
500 B-STR
mg I-STR
) I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR

 I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
21 O
. O
Epogen B-DRUG
20,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Injection B-FOR
once B-FRE

 I-FRE
a I-FRE
week I-FRE
: I-FRE
Please O
administer O
on O
Monday O
. O

 O
22 O
. O
ferrous B-DRUG
sulfate I-DRUG
325 B-STR
mg I-STR
( O
65 B-STR
mg I-STR
iron B-DRUG
) I-DRUG
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
23 O
. O
metronidazole B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q8H B-FRE

 I-FRE
( O
every O
8 O
hours O
) O
: O
TO O
END O
[ O
* O
* O
2137 O
- O
11 O
- O
9 O
* O
* O
] O
. O

 O
24 O
. O
heparin B-DRUG
( I-DRUG
porcine I-DRUG
) I-DRUG
in I-DRUG
D5W I-DRUG
  O
Intravenous B-ROU

 I-ROU
25 O
. O
nadolol B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
26 O
. O
meropenem B-DRUG
500 B-STR
mg I-STR
Recon B-FOR
Soln I-FOR
Sig O
: O
Five B-DOS
Hundred I-DOS
( I-DOS
500 I-DOS
) I-DOS
mg I-DOS

 I-DOS
Intravenous B-ROU
every B-FRE
eight I-FRE
( I-FRE
8) I-FRE
hours I-FRE
for B-DUR
3 I-DUR
days I-DUR
: I-DUR
TO O
END O
[ O
* O
* O
2137 O
- O
11 O
- O
3 O
* O
* O
] O
. O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
459 O
* O
* O
] O
for O
the O
Aged O
- O
MACU O


 O
Discharge O
Diagnosis O
: O

 O
GI O
bleed O
secondary O
to O
colonic O
lesion O

 O
Health O
care O
associated O
pneumonia O

 O
Acute O
on O
chronic O
kidney O
insufficiency O

 O
COPD O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Out O
of O
Bed O
with O
assistance O
to O
chair O
or O

 O
wheelchair O
. O



 O
Discharge O
Instructions O
: O

 O
Dear O
Ms O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
it O
was O
a O
pleasure O
taking O
care O
of O
you O
. O


 O
You O
were O
admitted O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
evaluation O
of O
GI O
bleed O
and O
while O

 O
in O
house O
you O
developed O
respiratory O
compromise O
requiring O

 O
intubation O
. O

 O
. O


 O
Regarding O
the O
GI B-REA
bleed I-REA
, I-REA
you O
were O
seen O
by O
our O
team O
of O
GI O
doctors O

 O
who O
performed O
a O
colonscopy O
. O
During O
the O
procedure O
a O
colonic O

 O
lesion O
was O
seen O
and O
a O
plan O
was O
devised O
to O
proceed O
for O
excisional O

 O
biopsy O
. O
You O
were O
transfused B-ROU
RBCs B-DRUG
as B-FRE
needed I-FRE
and O
your O
blood O
counts O

 O
were O
monitored O
closely O
. O
After O
discussion O
with O
your O
family O
the O

 O
decision O
to O
undergo O
biopsy O
was O
deferred O
to O
the O
outpatient O

 O
setting O
. O

 O
. O

 O
While O
in O
house O
your O
breathing O
became O
labored O
on O
several O

 O
occassions O
which O
required O
intubation O
twice O
. O
The O
cause O
of O
the O

 O
distress O
included O
aspiration O
and O
possible O
pneumonia O
. O
You O
were O

 O
started O
on O
antibiotics B-DRUG
with O
a O
plan O
to O
complete O
an O
8d B-DUR
course O
. O

 O
Your O
transtracheal O
catheter O
was O
removed O
with O
plan O
to O
discuss O

 O
replacement O
as O
an O
outpatient O
. O
At O
time O
of O
discharge O
you O
were O

 O
oxygenating O
well O
using O
supplemental O
oxygen B-DRUG
delivered O
by O
nasal B-ROU

 I-ROU
cannula I-ROU
. I-ROU


 O
Also O
you O
were O
noted O
to O
have O
an O
infection B-REA
in I-REA
your I-REA
GI I-REA
tract I-REA
and O

 O
were O
started O
on O
antiobiotics B-DRUG
to O
eradicate O
this O
bacteria O
. O


 O
Prior O
to O
discharge O
you O
were O
feeling O
much O
improved O
and O
the O

 O
decision O
was O
made O
to O
transition O
to O
a O
nursing O
facility/rehab O

 O
where O
you O
can O
work O
to O
optimize O
strength O
, O
mobility O
and O
nutrition O
. O

 O
. O

 O
CHANGES O
TO O
YOUR O
MEDICATIONS O
: O

 O
START O
10 B-STR
mg I-STR
Nadolol B-DRUG
daily B-FRE
for O
gastric B-REA
varices I-REA

 I-REA
CONTINUE O
MEROPENEM B-DRUG
until O
[ O
* O
* O
2137 O
- O
11 O
- O
3 O
* O
* O
] O

 O
CONTINUE O
VANCOMYCIN B-DRUG
AND O
FLAGYL B-DRUG
until O
[ O
* O
* O
2137 O
- O
11 O
- O
9 O
* O
* O
] O

 O
STOP O
SPIRONOLACTONE B-DRUG
and O
AMLODIPINE B-DRUG
until O
told O
otherwise O

 O
CHANGE O
COUMADIN B-DRUG
to O
3 B-STR
mg I-STR
daily B-FRE
( O
goal B-REA
INR I-REA
2.5 I-REA
to I-REA
3.5 I-REA
) I-REA

 O
CHANGE O
BUMEX B-DRUG
to O
5 B-STR
mg I-STR
daily B-FRE
( O
previously O
5 B-STR
mg I-STR
twice B-FRE
a I-FRE
day I-FRE
) I-FRE


 O
Again O
it O
was O
a O
pleasure O
taking O
care O
of O
you O
. O
Please O
contact O
with O

 O
any O
questions O
or O
concerns O
. O


 O
Followup O
Instructions O
: O

 O
Department O
: O
WEST O
[ O
* O
* O
Hospital O
2002 O
* O
* O
] O
CLINIC O

 O
When O
: O
TUESDAY O
[ O
* O
* O
2137 O
- O
11 O
- O
26 O
* O
* O
] O
at O
8:45 O
AM O

 O
With O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
3020 O
* O
* O
] O

 O
Building O
: O
De O
[ O
* O
* O
Hospital1 O
* O
* O
] O
Building O
( O
[ O
* O
* O
Hospital O
Ward O
Name O
121 O
* O
* O
] O
Complex O
) O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
WEST O
     O
Best O
Parking O
: O
[ O
* O
* O
Street O
Address(1 O
) O
592 O
* O
* O
] O
Garage O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2195 O
- O
4 O
- O
22 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2115 O
- O
11 O
- O
6 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Erythromycin B-DRUG
Base O
/ O
Sulfa B-DRUG
( O
Sulfonamide B-DRUG
Antibiotics I-DRUG
) I-DRUG
/ O

 O
clindamycin B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
3918 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
chills O
, O
rigors O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
3 O
* O
* O
] O
- O
Colonoscopy O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
13 O
* O
* O
] O
- O
Colonoscopy O


 O
History O
of O
Present O
Illness O
: O

 O
EAST O
HOSPITAL O
MEDICINE O
ATTENDING O
ADMISSION O
NOTE O
. O

 O
Date O
: O
[ O
* O
* O
2195 O
- O
4 O
- O
2 O
* O
* O
] O

 O
Time O
: O
0130 O

 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

 O
PCP O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
1158 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
679 O
* O
* O
] O
. O
Onc O
: O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O

 O
. O

 O
CC:[**CC O
Contact O
Info O
93625 O
* O
* O
] O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

 O
HPI O
: O
79 O
yo O
F O
with O
MDS-- O
> O
AML O
, O
HTN O
, O
hyperlipidemia O
, O

 O
diverticulosis O
, O
h/o O
anal O
fissure O
, O
AVM O
s/p O
recent O
cauterization O

 O
who O
was O
recently O
admitted O
from O
[ O
* O
* O
Date O
range O
( O
1 O
) O
93626 O
* O
* O
] O
for O
decitabine B-DRUG
and O
was O

 O
in O
outpatient O
center O
today O
for O
platelet O
transfusion O
for O
dropping O

 O
plt O
count O
( O
22 O
) O
and O
nosebleeds O
. O
She O
tolerated O
the O
infusion O
but O
on O

 O
her O
way O
home O
, O
she O
developed O
rigors O
, O
chills O
and O
she O
returned O
to O

 O
the O
outpatient O
unit O
. O
Upon O
arrival O
, O
she O
was O
hypertensive O
and O
had O

 O
a O
temp O
to O
99.8 O
. O
She O
was O
given O
benadryl B-DRUG
, I-DRUG
demerol B-DRUG
, I-DRUG
tylenol B-DRUG
, I-DRUG

 O
hydrocortisone B-DRUG
. I-DRUG
She O
subsequently O
became O
hypotensive B-REA
to O
90/40 O
and O

 O
received O
IVF B-DRUG
bolus B-DOS
. I-DOS
She O
had O
intermittent O
, O
mild O
hypoxia O
93 O
- O
96 O
% O
. O

   O
She O
was O
thought O
to O
have O
a O
transfusion O
reaction O
( O
work-up O

 O
ordered O
) O
but O
her O
labs O
were O
notable O
for O
neutropenia O
and O
she O
was O

 O
referred O
to O
the O
ED O
for O
admission O
. O



 O
In O
ER O
: O
( O
Triage O
Vitals O
: O
99.1 O
85 O
118/50 O
18 O
93 O
% O
RA O
) O
CBC O
notable O
for O

 O
hct O
19.6 O
from O
24.9 O
earlier O
in O
the O
day O
. O
hemolysis O
labs O
negative O
. O

 O
CXR O
revealed O
mild O
interstitial O
edema O
. O
CT O
scan O
was O
performed O
to O

 O
r/o O
a O
RP O
bleed O
. O


 O
Currently O
, O
she O
feels O
completely O
well O
. O
She O
reports O
that O
she O
felt O

 O
while O
prior O
to O
the O
platelet O
infusion O
and O
denies O
any O
fever O
, O

 O
chills O
, O
abd O
pain O
, O
N/V/D O
, O
cough O
, O
headache O
. O
Her O
only O
concern O
is O
a O

 O
bruise/canker O
sore O
in O
her O
L O
mouth O
which O
is O
mildly O
tender O
. O

 O
. O

 O
PAIN O
SCALE O
: O
none O

 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

 O
REVIEW O
OF O
SYSTEMS O
: O

 O
CONSTITUTIONAL O
: O
        O
[ O
] O
All O
Normal O

 O
[ O
] O
Fever O
  O
[ O
x O
] O
Chills O
   O
[ O
] O
Sweats O
  O
[ O
] O
Fatigue O
   O
[ O
] O
Malaise O

 O
[ O
] O
Anorexia O
  O
[ O
] O
Night O
sweats O

 O
[ O
] O
_ O
_ O
_ O
_ O
_ O
lbs O
. O
    O
weight O
  O
loss/gain O
     O
over O
_ O
_ O
_ O
_ O
_ O
months O


 O
HEENT O
: O
          O
[ O
] O
All O
Normal O

 O
[ O
] O
Blurred O
vision O
   O
[ O
] O
Blindness O
  O
[ O
] O
Photophobia O

 O
[ O
] O
Decreased O
acuity O
[ O
] O
Dry O
mouth O
  O
[ O
x O
] O
Bleeding O
gums O

 O
[ O
] O
Oral O
ulcers O
  O
[ O
] O
Sore O
throat O
    O
[ O
x O
] O
Epistaxis O
  O
[ O
] O
Tinnitus O

 O
[ O
] O
Decreased O
hearing O
    O
[ O
] O
Tinnitus O
[ O
] O
Other O
: O


 O
RESPIRATORY O
: O
    O
[ O
x O
] O
All O
Normal O

 O
[ O
] O
SOB O
     O
[ O
] O
DOE O
    O
[ O
] O
Ca O
n't O
walk O
2 O
flights O
     O
[ O
] O
Cough O

 O
[ O
] O
Wheeze O
  O
[ O
] O
Purulent O
sputum O
    O
[ O
] O
Hemoptysis O
   O
[ O
] O
Pleuritic O

 O
pain O

 O
[ O
] O
Other O
: O


 O
CARDIAC O
: O
        O
[ O
x O
] O
  O
All O
Normal O

 O
[ O
] O
Angina O
    O
[ O
] O
Palpitations O
   O
[ O
] O
Edema O
   O
[ O
] O
PND O

 O
[ O
] O
Orthopnea O
    O
[ O
] O
Chest O
Pain O
[ O
] O
Other O
: O


 O
GI O
: O
             O
[ O
x O
] O
All O
Normal O

 O
[ O
] O
Blood O
in O
stool O
     O
[ O
] O
Hematemesis O
     O
[ O
] O
Odynophagia O

 O
[ O
] O
Dysphagia O
: O
   O
[ O
] O
Solids O
    O
[ O
] O
Liquids O

 O
[ O
] O
Anorexia O
    O
[ O
] O
Nausea O
  O
[ O
] O
Vomiting O
   O
[ O
] O
Reflux O

 O
[ O
] O
Diarrhea O
    O
[ O
] O
Constipation O
  O
[ O
] O
  O
Abd O
pain O
  O
[ O
] O
Other O
: O


 O
GU O
: O
             O
[ O
x O
] O
All O
Normal O

 O
[ O
] O
Dysuria O
      O
[ O
] O
Frequency O
    O
[ O
] O
Hematuria O
  O
[ O
] O
Discharge O

 O
[ O
] O
Menorrhagia O


 O
SKIN O
: O
           O
[ O
x O
] O
All O
Normal O

 O
[ O
] O
Rash O
        O
[ O
] O
Pruritus O



 O
MS O
: O
             O
[ O
x O
] O
All O
Normal O

 O
[ O
] O
Joint O
pain O
    O
[ O
] O
Jt O
swelling O
   O
[ O
] O
Back O
pain O
  O
[ O
] O
Bony O
pain O


 O
NEURO O
: O
          O
[ O
x O
] O
All O
Normal O

 O
[ O
] O
Headache O
    O
[ O
] O
Visual O
changes O
   O
[ O
] O
Sensory O
change O
[ O

 O
] O
Confusion O
[ O
] O
Numbness O
of O
extremities O

 O
[ O
] O
Seizures O
   O
[ O
] O
Weakness O
[ O
] O
Dizziness/Lightheaded O
[ O
] O
Vertigo O

 O
[ O
] O
Headache O


 O
ENDOCRINE O
: O
     O
[ O
x O
] O
All O
Normal O

 O
[ O
] O
Skin O
changes O
  O
[ O
] O
Hair O
changes O
   O
[ O
] O
Temp O
subjectivity O


 O
HEME/LYMPH O
: O
    O
[ O
] O
All O
Normal O

 O
[ O
] O
Easy O
bruising O
   O
[ O
x O
] O
Easy O
bleeding O
    O
[ O
] O
Adenopathy O


 O
PSYCH O
: O
         O
[ O
x O
] O
All O
Normal O

 O
[ O
] O
Mood O
change O
        O
[ O
] O
Suicidal O
Ideation O
  O
[ O
] O
Other O
: O


 O
[x]all O
other O
systems O
negative O
except O
as O
noted O
above O



 O
Past O
Medical O
History O
: O

 O
Past O
Oncologic O
history O
: O

 O
- O
MDS O
initially O
diagnosed O
in O
[ O
* O
* O
8-/2194 O
* O
* O
] O
during O
workup O
for O
anemia O
. O

 O
Initial O
BM O
biopsy O
with O
e/o O
hypercellular O
marrow O
with O
peripheral O

 O
blasts O
. O
  O
The O
patient O
was O
maintained O
with O
transfusion O
as O
needed O

 O
and O
aranesp B-DRUG
qweek B-FRE
. I-FRE
  O
In O
winter O
[ O
* O
* O
2194 O
* O
* O
] O
, O
pt O
was O
also O
found O
to O
have O

 O
increasing O
white O
count O
, O
as O
high O
as O
143 O
K O
on O
most O
recent O
BMT O

 O
admission O
, O
at O
which O
point O
repeat O
biopsy O
revealed O
blasts O

 O
consistent O
with O
acute O
myeloiod O
transformation O
. O

 O
. O

 O
PMH O
: O

 O
- O
diverticulosis O
complicated O
by O
bleeding O

 O
- O
bleeding O
anal O
fissures O

 O
- O
bleeding O
AVMs O
( O
[ O
* O
* O
2-/2195 O
* O
* O
] O
) O

 O
- O
GERD O

 O
- O
emphysema(mild O
) O

 O
- O
dental O
extraction O

 O
- O
myelodysplastic O
syndrome O
dx O
[ O
* O
* O
8-/2194 O
* O
* O
] O
with O
persistent O
blastemia O

 O
- O
hysterectomy O
at O
age O
39 O

 O
- O
hemorrhoidectomy O
x O
4 O

 O
- O
colon O
polyps O
, O
AVM O

 O
- O
bilateral O
bunion O
surgery O

 O
- O
hypertension O

 O
- O
hyperlipidemia O

 O
- O
proctalgia O
fugax O

 O
- O
TMJD O


 O
Social O
History O
: O

 O
The O
patient O
is O
married O
and O
lives O
with O
her O
husband O
. O
  O
She O
has O

 O
three O
grown O
children O
. O
  O
Has O
a O
twin O
sister O
. O
  O
Ex-[**Name2 O
( O
NI O
) O
1818 O
* O
* O
] O
, O
quit O
14 O

 O
year O
ago O
; O
has O
35 O
pack O
year O
history O
. O
  O
Denies O
any O
illicit O
drug O

 O
use O
. O
  O
Reports O
having O
a O
glass O
of O
wine O
nightly O
. O



 O
Family O
History O
: O

 O
No O
known O
fhx O
of O
MDS O
or O
leukemia O
. O



 O
Physical O
Exam O
: O

 O
Admission O
physical O
exam O
: O

 O
T O
95.9 O
P O
82 O
BP O
98/56 O
RR O
20 O
O2Sat O
96 O
% O
RA O

 O
GENERAL O
: O
  O
non-toxic O
, O
well-appearing O
, O
mentating O
clearly O

 O
Eyes O
: O
NC/AT O
, O
post-surgical O
pupils O
( O
cataracts O
) O
, O
EOMI O
, O
no O
scleral O

 O
icterus O
noted O

 O
Ears/Nose/Mouth/Throat O
: O
MMM O
, O
small O
purplish O
nodule O
on O
tongue O
, O

 O
bruising O
on O
inside O
of O
her O
mouth O
on O
left O
side O

 O
Neck O
: O
supple O
, O
no O
JVD O

 O
Respiratory O
: O
Lungs O
CTA O
bilaterally O
without O
R/R/W O

 O
Cardiovascular O
: O
Reg O
S1S2 O
, O
no O
M/R/G O
noted O

 O
Gastrointestinal O
: O
soft O
, O
NT/ND O
, O
+ O
bowel O
sounds O

 O
Genitourinary O
: O
  O
no O
flank O
tenderness O

 O
Skin O
: O
no O
rashes O
or O
lesions O
noted O
. O

 O
Extremities O
: O
No O
C/C/E O
bilaterally O
, O
2 O
+ O
radial O
, O
DP O
and O
PT O
pulses O

 O
b/l O
. O

 O
Lymphatics/Heme/Immun O
: O
No O
cervical O
, O
supraclavicular O

 O
lymphadenopathy O
noted O
. O

 O
Neurologic O
: O

 O
-mental O
status O
: O
Alert O
, O
oriented O
x O
3 O
. O
Able O
to O
relate O
history O

 O
without O
difficulty O
. O

 O
-cranial O
nerves O
: O
II-XII O
intact O

 O
-motor O
: O
normal O
bulk O
, O
strength O
and O
tone O
throughout O
. O
No O
abnormal O

 O
movements O
noted O
. O

 O
-sensory O
: O
No O
deficits O
to O
light O
touch O
throughout O
. O

 O
No O
foley O
catheter/tracheostomy/PEG/ventilator O
support/chest O

 O
tube/colostomy O

 O
Psychiatric O
: O
  O
pleasant O
and O
interactive O


 O
ACCESS O
: O
[x]PIV O

 O
. O

 O
Discharge O
PE O
: O

 O
VS O
: O
Tc O
97.2 O
Tmax O
97.8 O
BP O
118/68 O
( O
110 O
- O
130'/60 O
- O
80 O
' O
) O
HR O
76 O
( O
70 O
- O
80 O
' O
) O

 O
RR O
18 O
Sat O
99 O
RA O

 O
General O
: O
pleasant O
, O
well O
appearing O
elderly O
female O
, O
sitting O

 O
comforably O
in O
chair O
, O
NAD O
, O

 O
HEENT O
: O
EOMI O
, O
PERRL O
, O
OP O
clear O
, O
MM O
moist O

 O
neck O
: O
supple O

 O
CV O
: O
3/6 O
SEM O
loudest O
at O
RUSB O
, O
normal O
S1 O
, O
S2 O

 O
lungs O
: O
clear O
to O
auscultation O
b/l O
, O
no O
wheezes/rhonchi/crackles O

 O
abdomen O
: O
soft O
, O
mild O
tenderness O
at O
left O
lower O
quadrant O
and O

 O
minimal O
tenderness O
at O
right O
upper O
quadrant O
, O
no O
rebound O

 O
tenderness O
or O
guarding O
, O
nondistended O
, O
+ O
BS O

 O
extremities O
: O
warm O
, O
well O
perfused O
, O
no O
LE O
edema O
, O
2+DP O
pulses O

 O
Neuro O
: O
CN2 O
- O
12 O
grossly O
intact O
, O
normal O
muscle O
strength O
and O

 O
sensation O
throughout O



 O
Pertinent O
Results O
: O

 O
Admission O
labs O
: O

 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
WBC-2.2 O
* O
RBC-2.67 O
* O
HGB-8.4 O
* O
HCT-24.9 O
* O
MCV-94 O
MCH-31.5 O

 O
MCHC-33.7 O
RDW-18.4 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
NEUTS-30 O
* O
BANDS-0 O
LYMPHS-42 O
MONOS-8 O
EOS-0 O
BASOS-0 O

 O
ATYPS-1 O
* O
METAS-1 O
* O
MYELOS-1 O
* O
BLASTS-17 O
* O
NUC O
RBCS-2 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
PLT O
SMR-VERY O
LOW O
PLT O
COUNT-22 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
GRAN O
CT-704 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
WBC-3.7 O
* O
# O
RBC-2.21 O
* O
HGB-6.8 O
* O
HCT-19.6 O
* O
MCV-89 O
MCH-30.8 O

 O
MCHC-34.7 O
RDW-19.6 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
NEUTS-87 O
* O
BANDS-0 O
LYMPHS-2 O
* O
MONOS-1 O
* O
EOS-0 O
BASOS-0 O

 O
ATYPS-0 O
METAS-0 O
MYELOS-0 O
BLASTS-10 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
PLT O
SMR-VERY O
LOW O
PLT O
COUNT-21 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
PLT O
COUNT-31 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
ALT(SGPT)-12 O
AST(SGOT)-27 O
LD(LDH)-274 O
* O
ALK O
PHOS-67 O
TOT O

 O
BILI-1.8 O
* O
DIR O
BILI-0.6 O
* O
INDIR O
BIL-1.2 O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
HAPTOGLOB-197 O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
GLUCOSE-116 O
* O
UREA O
N-25 O
* O
CREAT-0.8 O
SODIUM-138 O

 O
POTASSIUM-4.3 O
CHLORIDE-103 O
TOTAL O
CO2 O
- O
26 O
ANION O
GAP-13 O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
URINE O
  O
BLOOD-SM O
  O
NITRITE-NEG O
PROTEIN-TR O
GLUCOSE-NEG O

 O
KETONE-NEG O
BILIRUBIN-NEG O
UROBILNGN-NEG O
PH-5.0 O
LEUK-NEG O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O
URINE O
  O
RBC-1 O
WBC-3 O
BACTERIA-FEW O
YEAST-NONE O
EPI-2 O
TRANS O

 O
EPI-<1 O

 O
. O

 O
Discharge O
labs O
: O

 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
19 O
* O
* O
] O
BLOOD O
ALT-8 O
AST-22 O
LD(LDH)-222 O
AlkPhos-51 O
TotBili-1.1 O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
22 O
* O
* O
] O
BLOOD O
WBC-1.8 O
* O
RBC-2.94 O
* O
Hgb-9.1 O
* O
Hct-27.3 O
* O
MCV-93 O

 O
MCH-31.0 O
MCHC-33.3 O
RDW-19.1 O
* O
Plt O
Ct-84 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
22 O
* O
* O
] O
BLOOD O
Neuts-53 O
Bands-0 O
Lymphs-33 O
Monos-0 O
Eos-0 O
Baso-0 O

 O
Atyps-0 O
Metas-0 O
Myelos-2 O
* O
Blasts-12 O
* O
NRBC-1 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
22 O
* O
* O
] O
BLOOD O
Plt O
Smr-LOW O
Plt O
Ct-84 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
22 O
* O
* O
] O
BLOOD O
PT-15.4 O
* O
INR(PT)-1.4 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
22 O
* O
* O
] O
BLOOD O
Gran O
Ct-979 O
* O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
22 O
* O
* O
] O
BLOOD O
Glucose-101 O
* O
UreaN-16 O
Creat-0.8 O
Na-137 O
K-3.8 O

 O
Cl-99 O
HCO3 O
- O
29 O
AnGap-13 O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
22 O
* O
* O
] O
BLOOD O
Calcium-8.6 O
Phos-4.0 O
Mg-1.9 O

 O
. O


 O
Microbiology O
: O

 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
Urine O
culture O
: O
mixed O
flora O

 O
Blood O
culture O
: O
no O
growth O

 O
MRSA O
screen O
: O
negative O

 O
. O

 O
Imaging O
: O

 O
= O
= O
= O
= O
= O
= O
= O
= O

 O
[ O
* O
* O
4 O
- O
1 O
* O
* O
] O
CHEST O
( O
PA O
& O
LAT O
) O
- O
Calcified O
pleural O
plaque O
is O
better O

 O
assessed O
on O
the O
prior O
CT O
. O
There O
is O
mild O
interstitial O
edema O
with O

 O
no O
large O
effusions O
or O
pneumothorax O
. O
No O
signs O
of O
pneumonia O
. O

 O
Cardiomediastinal O
silhouette O
is O
stable O
. O
Calcified O

 O
tracheobronchial O
tree O
noted O
. O
Bony O
structures O
are O
intact O

 O
. O

 O
[ O
* O
* O
4 O
- O
1 O
* O
* O
] O
CT O
ABD O
& O
PELVIS O
WITH O
CO O
- O
No O
acute O
intra-abdominal O
or O

 O
pelvic O
process O
. O
No O
evidence O
of O
retroperitoneal O
hemorrhage O
. O

 O
Stable O
gallbladder O
polyp O
. O
Stable O
gallbladder O
polyps O
versus O
a O

 O
focus O
of O
adenomyomatosis O
within O
the O
gallbladder O
fundus O
. O
Sigmoid O

 O
diverticulosis O
. O
Patchy O
bibasilar O
opacities O
within O
the O
lung O

 O
bases O
, O
with O
subpleural O
scar O
formations O
and O
bronchiectasis O
within O

 O
the O
lung O
bases O
. O

 O
. O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
8 O
* O
* O
] O
CT O
head O
without O
contrast O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
No O
evidence O
of O
acute O
intracranial O
hemorrhage O
or O
mass O
effect O
. O

 O
Slightly O

 O
dense O
appearance O
of O
the O
cortex O
lateral O
to O
the O
Sylvian O
fissure O
( O

 O
se O
2 O
, O
i O
m O
12 O
) O
is O
likely O
related O
to O
volume O
averaging O
rather O
than O

 O
hemorrhage O
; O
a O
follow O
up O
can O
be O
considered O
if O
necessary O
. O
No O
prior O

 O
CT O
studies O
are O
available O
. O

 O
2 O
. O
Bilateral O
mastoid O
opacification O
from O
fluid/mucosal O
thickening O


 O
. O

 O
CTA O
[ O
* O
* O
2195 O
- O
4 O
- O
18 O
* O
* O
] O
Abd-Pelvis O

 O
IMPRESSION O
: O

 O
1 O
. O
No O
contrast O
extravasation O
to O
suggest O
GI O
bleeding O
. O

 O
2 O
. O
Stable O
gallbladder O
polyp O
and O
fundal O
adenomyomatosis O
. O

 O
3 O
. O
Colonic O
diverticulosis O
without O
evidence O
of O
diverticulitis O
. O

 O
4 O
. O
Small O
left O
adrenal O
adenoma O
. O

 O
5 O
. O
Unchanged O
Focal O
celiac O
artery O
and O
aortic O
dilation O
as O

 O
described O
above O
. O

 O
. O

 O
Colonoscopy O
: O

 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
[ O
* O
* O
3 O
- O
1 O
* O
* O
] O
Colonoscopy O
prior O
to O
this O
admission O
: O

 O
Abnormal O
mucosa O
in O
the O
colon O
. O
Diverticulosis O
of O
the O
sigmoid O

 O
colon O
. O
A O
small O
posterior O
rectal O
fissure O
was O
noted O
in O
the O
anal O

 O
canal O
. O
This O
was O
not O
bleeding O
. O
Blood O
was O
noted O
throughout O
the O

 O
entire O
colon O
. O

 O
Otherwise O
normal O
colonoscopy O
to O
cecum O
. O

 O
. O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
3 O
* O
* O
] O
colonoscopy O
: O

 O
Non O
bleediong O
diverticulosis O
of O
the O
whole O
colon O
. O
Bleeding O

 O
angioectasias O
in O
the O
cecum O
treated O
with O
APC O
. O
Polyp O
in O
the O

 O
transverse O
colon O
. O
Blood O
and O
stool O
throughout O
colon O
. O
Non O
bleeding O

 O
posterior O
anal O
fissure O
. O

 O
. O


 O
[ O
* O
* O
2195 O
- O
4 O
- O
13 O
* O
* O
] O
colonoscopy O
: O

 O
Blood O
in O
the O
whole O
colon O
. O
Diverticulosis O
of O
the O
sigmoid O
colon O

 O
and O
descending O
colon O
. O
Ulcers O
in O
the O
cecum O
. O
A O
large O
adherent O

 O
blood O
clot O
was O
found O
in O
the O
cecum O
with O
surrounding O
oozing O
of O

 O
bright O
red O
blood O
. O
Given O
the O
risk O
of O
uncontrollable O
bleeding O
in O

 O
the O
setting O
of O
low O
platelets O
, O
the O
clot O
was O
not O
removed O
. O

 O
Otherwise O
normal O
colonoscopy O
to O
cecum O


 O
Brief O
Hospital O
Course O
: O

 O
Ms. O
[ O
* O
* O
Known O
lastname O
73078 O
* O
* O
] O
is O
79 O
year O
old O
pleasant O
woman O
with O
a O
Past O
medical O

 O
history O
significant O
for O
MDS O
with O
AML B-REA
transformation O
on O
Dacogen B-DRUG
, I-DRUG

 O
diverticulosis O
, O
known O
cecal O
AVMs O
admitted O
from O
clinic O
on O
[ O
* O
* O
2195 O
- O
4 O
- O
1 O
* O
* O
] O

 O
in O
the O
setting O
of O
a O
transfusion O
reaction O
to O
platelets B-DRUG
with O

 O
thrombocytopenia B-ADE
who O
was O
noted O
to O
develop O
bright O
red O
blood O
per O

 O
rectum O
with O
acute O
hematocrit O
drop O
who O
underwent O
repeat O

 O
colonoscopy O
showing O
non-bleeding O
diverticulosis O
of O
the O
entire O

 O
colon O
and O
bleeding O
angioectasias O
of O
the O
cecum O
treated O
with O
Argon O

 O
Plasma O
coagulation O
. O
She O
required O
a O
second O
colonoscopy O
for O

 O
repeated O
bloody O
bowel O
movements O
which O
showed O
a O
clot O
adherent O
to O

 O
the O
cecum O
. O
She O
remained O
stable O
for O
a O
while O
then O
had O
frequent O

 O
bloody B-REA
bowel I-REA
movements I-REA
again O
which O
was O
controlled O
by O
amicar B-DRUG
drip B-ROU

 I-ROU
for B-DUR
8 I-DUR
hours I-DUR
. I-DUR
Gradually O
her O
platelets O
started O
to O
increase O
. O
After O

 O
these O
events O
, O
she O
remained O
stable O
and O
was O
discharged O
home O
in O

 O
stable O
condition O
. O
She O
will O
require O
HLA O
matched O
platelet O

 O
transfusions O
in O
the O
future O
if O
needed O
. O

 O
. O


 O
# O
cecal O
AVMs O
: O
  O
She O
was O
transferred O
to O
the O
ICU O
twice O
for O
bright O

 O
red O
blood O
per O
rectum O
. O
The O
patient O
developed O
BRBPR O
, O
and O
was O
found O

 O
to O
have O
cecal O
AVMs O
on O
colonoscopy O
s/p O
APC O
. O
Specifically O
, O
repeat O

 O
colonoscopy O
demonstrated O
cecal O
angioectasias O
that O
were O
actively O

 O
bleeding O
, O
non-bleeding O
colonic O
diverticula O
and O
small O
polyp O
. O

 O
Hemostasis O
achieved O
with O
Argon O
Plasma O
coagulation O
therapy O
on O

 O
[ O
* O
* O
2195 O
- O
4 O
- O
3 O
* O
* O
] O
. O
  O
During O
her O
stay O
she O
required O
several B-DOS
units I-DOS
of O
PRBC B-DRUG
and O

 O
platelets B-DRUG
. I-DRUG
After O
remaining O
stable O
, O
she O
was O
transferred O
back O
to O

 O
the O
floor O
however O
she O
had O
the O
same O
situation O
again O
and O
was O

 O
transferred O
back O
to O
the O
ICU O
where O
she O
had O
her O
second O
colonoscopy O

 O
which O
showed O
a O
clot O
adherent O
to O
the O
cecum O
with O
oozing O
around O
the O

 O
clot O
. O
The O
clot O
was O
not O
removed O
( O
not O
amenable O
to O
endoscopic O

 O
management O
) O
. O
GI O
recommended O
surgical O
consult O
for O
possible O

 O
resection O
however O
given O
her O
underlying O
disease O
and O
low O
platelet O

 O
counts O
, O
they O
felt O
this O
will O
not O
be O
a O
favorable O
management O
. O
After O

 O
having O
stable O
H/H O
, O
she O
was O
transferred O
back O
to O
the O
floor O
. O
While O

 O
on O
the O
floor O
, O
she O
had O
a O
few O
bloody O
bowel O
movements O
however O
the O

 O
night O
of O
[ O
* O
* O
4 O
- O
17 O
* O
* O
] O
she O
had O
total O
of O
450 O
cc O
bloody B-REA
watery I-REA
stools I-REA
which O

 O
required O
amicar B-DRUG
drip B-ROU
for B-DUR
8 I-DUR
hours I-DUR
( O
her O
platelets O
were O
in O
the O

 O
40 O
- O
50 O
's O
) O
. O
CTA O
was O
negative O
. O
Following O
this O
, O
she O
did O
not O
have O
any O

 O
further O
significant O
bloody O
stools O
. O
She O
remained O
vitally O
stable O

 O
with O
stable O
H/H O
and O
gradually O
rising O
platelet O
count O
. O

 O
. O

 O
# O
thrombocytopenia B-ADE
: I-ADE
Secondary O
to O
chemotherapy B-DRUG
and O
MDS/AML O

 O
concerns O
. O
Concern O
for O
consumptive O
process O
following O
transfusion B-FOR

 I-FOR
of O
platelets B-DRUG
in O
the O
setting O
of O
possible O
ITP O
vs. O
TTP O
however O

 O
Hematologic O
smear O
was O
without O
schistocytes O
and O
there O
was O
no O

 O
evidence O
of O
renal O
failure O
or O
neurologic O
concerns O
; O
no O
fevers O
. O
The O

 O
patient O
also O
had O
two B-ADE
transfusion I-ADE
reactions I-ADE
to O
platelets B-DRUG
when O

 O
first O
admitted O
. O
She O
was O
premedicated O
with O
anti-histamines B-DRUG
. I-DRUG
While O

 O
the O
patient O
was O
actively O
bleeding O
, O
she O
was O
also O
given O
Amicar B-DRUG
( O
2 B-STR

 I-STR
grams I-STR
IV B-ROU
with O
1gram/hour B-STR
IV B-ROU
infusion B-FOR
overnight O
on O
[ O
* O
* O
2195 O
- O
4 O
- O
2 O
* O
* O
] O
) O
. O
This O

 O
was O
repeated O
over O
the O
night O
of O
[ O
* O
* O
4 O
- O
17 O
* O
* O
] O
as O
above O
. O
She O
was O
found O
to O

 O
have O
a O
positive B-REA
PRA I-REA
and O
required O
HLA B-DRUG
matched I-DRUG
platelets I-DRUG
for O
all O

 O
subsequent O
transfusions O
. O
Her O
twin O
sister O
was O
tested O
at O
Red O
Cross O

 O
for O
potential O
candidate O
to O
donate O
platelets O
for O
her O
sister O

 O
however O
since O
she O
takes O
aspirin B-DRUG
and O
plavix B-DRUG
, I-DRUG
this O
was O
not O
a O

 O
suitable O
option O
. O
Of O
note O
, O
her O
platelet O
count O
was O
improving O

 O
already O
and O
did O
not O
require O
further O
platelet B-DRUG
transfusions B-FOR
. I-FOR

 O
Platelet O
count O
was O
in O
the O
90 O
's O
upon O
discharge O
. O

 O
. O


 O
# O
transfusion B-ADE
reaction/PRA B-ADE
positive I-ADE
: I-ADE
The O
patient O
had O
transfusion O

 O
reaction O
to O
platelet B-DRUG
transfusion B-FOR
( O
once O
in O
clinic O
, O
and O
once O
while O

 O
on O
the O
floor O
) O
. O
She O
was O
premedicated O
with O
famotidine B-DRUG
, I-DRUG
benadryl B-DRUG
, I-DRUG

 O
and O
hydrocortisone B-DRUG
. I-DRUG
A O
blood O
bank O
work O
up O
was O
initiated O
, O
and O
the O

 O
patient O
was O
given O
group O
specific O
platelets B-DRUG
. I-DRUG
She O
was O
found O
to O
be O

 O
PRA B-REA
positive I-REA
and O
requires O
HLA B-DRUG
matched I-DRUG
platelets I-DRUG
. I-DRUG
However O
, O
during O

 O
her O
second O
episode O
of O
BRBPR O
on O
[ O
* O
* O
4 O
- O
12 O
* O
* O
] O
, O
it O
was O
found O
that O
there O
was O

 O
no O
more O
HLA B-DRUG
matched I-DRUG
platelets I-DRUG
available O
in O
[ O
* O
* O
Location O
( O
un O
) O
86 O
* O
* O
] O
area O
. O
Red O

 O
Cross O
was O
contact[**Name O
( O
NI O
) O
* O
* O
] O
for O
more O
HLA B-DRUG
matched I-DRUG
platelets I-DRUG
. I-DRUG
Sister O
was O
a O

 O
potential O
donor O
however O
it O
was O
n't O
suitable O
given O
her O

 O
anti-platelet O
therapy O
as O
above O
. O
She O
did O
not O
require O
further O

 O
platelet B-DRUG
transfusions B-FOR
once O
her O
platelet O
count O
started O
to O

 O
increase O
. O

 O
. O

 O
# O
MDS B-REA
with I-REA
AML I-REA
transformation I-REA
: I-REA
  O
While O
the O
patient O
was O
on O
the O

 O
floor O
, O
it O
was O
noticed O
that O
her O
blast O
count O
was O
trending O
up O
and O

 O
her O
neutrophil O
count O
was O
trending O
down O
. O
  O
It O
was O
then O
decided O
to O

 O
start O
her O
on O
second O
cycle O
of O
Dacogen B-DRUG
( O
day O
1 O
= O
[ O
* O
* O
2195 O
- O
4 O
- O
8 O
* O
* O
] O
) O
. O
  O
The O

 O
patient O
tolerated O
the O
Dacogen B-DRUG
well O
, O
with O
little O
side O
effects O
. O

 O
12 O
% O
blast O
cells O
on O
peripheral O
blood O
upon O
discharge O
. O

 O
. O

 O
# O
GERD B-REA
: I-REA
The O
patient O
was O
continued O
on O
her O
home O
PPI B-DRUG
. I-DRUG

 O
. O

 O
# O
constipation O
: O
  O
The O
patient O
has O
a O
history O
of O
severe O

 O
constipation O
, O
however O
, O
her O
home O
medications O
were O
held O
in O
the O

 O
setting O
of O
her O
BRBPR O
and O
then O
restarted O
upon O
discharge O
given O

 O
resolution O
of O
bloody O
bowel O
movements O
. O

 O
. O

 O
Transitional O
Issues O
: O

 O
- O
The O
patient O
had O
transfusion B-ADE
reaction I-ADE
to O
platelets B-DRUG
; I-DRUG
a O
blood O

 O
bank O
work O
up O
was O
initiated O
and O
she O
was O
found O
to O
be O
PRA B-REA
positive I-REA
; I-REA

 O
she O
will O
require O
HLA B-DRUG
matched I-DRUG
platelets I-DRUG
for O
all O
subsequent O

 O
transfusions O
. O


 O
Medications O
on O
Admission O
: O

 O
1 O
. O
loratadine B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
daily B-FRE
( O
) O
. O

 O
2 O
. O
omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
polyethylene B-DRUG
glycol I-DRUG
3350 I-DRUG
17 B-STR
gram I-STR
Powder B-FOR
in I-FOR
Packet I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Powder B-FOR
in I-FOR
Packet I-FOR
PO B-ROU
QHS B-FRE
( I-FRE
once I-FRE
a I-FRE
day I-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
magnesium B-DRUG
hydroxide I-DRUG
400 B-STR
mg/5 I-STR
mL I-STR
Suspension B-FOR
Sig O
: O
Thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS

 I-DOS
ML I-DOS
PO B-ROU
QHS B-FRE
( I-FRE
once I-FRE
a I-FRE
day I-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID O
( O
2 O



 O
times O
a O
day O
) O
. O

 O
6 O
. O
allopurinol B-DRUG
300 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O



 O
Discharge O
Medications O
: O

 O
1 O
. O
loratadine B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
daily B-FRE
( O
) O
. O

 O
2 O
. O
omeprazole B-DRUG
40 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
3 O
. O
Miralax B-DRUG
17 B-STR
gram I-STR
Powder B-FOR
in I-FOR
Packet I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
PO B-ROU
at B-FRE
bedtime I-FRE

 I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
4 O
. O
Milk B-DRUG
of I-DRUG
Magnesia I-DRUG
400 B-STR
mg/5 I-STR
mL I-STR
Suspension B-FOR
Sig O
: O
Thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS
ml I-DOS

 I-DOS
PO B-ROU
at B-FRE
bedtime I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
5 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
twice B-FRE

 I-FRE
a I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
myelodysplastic O
syndrome/acute O
myloid O
leukemia O

 O
cecal O
atriovenous O
malformations O

 O
Lower O
GI O
bleed O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
Dear O
Ms. O
[ O
* O
* O
Known O
lastname O
73078 O
* O
* O
] O
, O


 O
It O
was O
a O
pleasure O
taking O
care O
of O
you O
while O
you O
were O
hospitalized O

 O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
. O
  O
You O
were O
admitted O
to O
the O
hospital O
because O
you O
had O
a O

 O
transfusion B-ADE
reaction I-ADE
after O
getting O
platelets B-DRUG
at O
clinic O
. O
  O
We O
did O

 O
some O
tests O
and O
found O
that O
you O
will O
need O
specially O
screened O

 O
platelets O
from O
now O
on O
because O
your O
body O
reacts O
to O
normal O

 O
platelets O
. O


 O
While O
you O
were O
here O
, O
you O
also O
developed O
some O
bleeding O
from O
your O

 O
rectum O
. O
  O
You O
were O
transferred O
to O
the O
intensive O
care O
unit O
and O

 O
they O
gastrointestinal O
doctors O
looked O
into O
your O
intestines O
with O
a O

 O
camera O
and O
found O
some O
areas O
of O
bleeding O
called O
AV O
malformations O

 O
that O
were O
clipped O
. O
After O
this O
, O
you O
were O
sent O
to O
the O
floor O
then O

 O
sent O
back O
to O
the O
ICU O
when O
you O
had O
further O
bleeding O
. O
Second O

 O
colonoscopy O
was O
done O
which O
showed O
a O
large O
clot O
attached O
to O
your O

 O
colon O
in O
the O
same O
area O
where O
the O
AVM O
's O
were O
clipped O
. O
Your O
blood O

 O
level O
was O
stable O
as O
well O
as O
your O
blood O
pressure O
and O
you O
were O

 O
transferred O
to O
the O
floor O
. O


 O
While O
on O
the O
floor O
, O
you O
had O
a O
few O
loose O
bloody O
stools O
that O

 O
subsequently O
resolved O
. O
Your O
diet O
was O
gradually O
advanced O
and O
you O

 O
tolerated O
it O
well O
prior O
to O
discharge O
. O
Your O
platelets O
gradually O

 O
increased O
and O
it O
was O
in O
the O
80 O
's O
on O
your O
discharge O
day O
. O



 O
The O
surgeons O
evaluated O
you O
for O
possible O
surgical O
removal O
of O
part O

 O
of O
your O
colon O
, O
however O
they O
felt O
it O
is O
unsafe O
to O
do O
surgery O
for O

 O
the O
moment O
. O
We O
did O
not O
discharge O
you O
on O
Amicar B-DRUG
which O
is O
a O
clot B-REA

 I-REA
stabilizer I-REA
medication O
since O
you O
did O
not O
have O
further O
bloody O

 O
stools O
, O
your O
blood O
level O
was O
stable O
and O
your O
platelets O
were O

 O
gradually O
increasing O
. O


 O
We O
also O
noticed O
some O
changes O
in O
your O
blood O
work O
that O
made O
us O

 O
think O
that O
your O
leukemia O
was O
acting O
up O
again O
; O
because O
of O
that O
we O

 O
started O
you O
on O
another O
five B-FRE
day I-FRE
cycle O
of O
chemotherapy B-DRUG
. I-DRUG
  O
You O

 O
tolerated O
the O
chemo B-DRUG
well O
. O

 O
. O

 O
While O
in O
the O
hosiptal O
, O
it O
was O
noted O
that O
occasionally O
your O
blood O

 O
pressure O
was O
high O
and O
you O
were O
started O
on O
a O
medication O
for O
brief O

 O
time O
. O
However O
, O
given O
your O
GI O
bleeds O
, O
this O
was O
held O
. O
We O
will O
not O

 O
discharge O
you O
at O
the O
moment O
with O
anti-hypertensive B-DRUG
medication I-DRUG
. I-DRUG


 O
We O
did O
the O
following O
changes O
in O
your O
medication O
list O
: O

 O
- O
Please O
stop O
allopurinol B-DRUG


 I-DRUG
Please O
continue O
the O
rest O
of O
your O
home O
medications O
the O
same O
way O

 O
you O
were O
taking O
them O
at O
home O
prior O
to O
admission O
. O


 O
Your O
PICC O
line O
was O
removed O
prior O
to O
discharge O
. O


 O
It O
will O
be O
important O
for O
you O
to O
follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
. O


 O
Please O
follow O
with O
your O
appointments O
as O
illustrated O
below O
. O


 O
Followup O
Instructions O
: O

 O
Department O
: O
HEMATOLOGY/ONCOLOGY O

 O
When O
: O
MONDAY O
[ O
* O
* O
2195 O
- O
4 O
- O
27 O
* O
* O
] O
at O
12:30 O
PM O

 O
With O
: O
[ O
* O
* O
Name6 O
( O
MD O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
22 O
* O
* O
] O

 O
Building O
: O
[ O
* O
* O
Hospital6 O
29 O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O


 O
Department O
: O
HEMATOLOGY/ONCOLOGY O

 O
When O
: O
MONDAY O
[ O
* O
* O
2195 O
- O
4 O
- O
27 O
* O
* O
] O
at O
12:30 O
PM O

 O
With O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
2747 O
* O
* O
] O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
3983 O
* O
* O
] O
, O
NP O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
3237 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O



 O
Department O
: O
HEMATOLOGY/BMT O

 O
When O
: O
MONDAY O
[ O
* O
* O
2195 O
- O
4 O
- O
27 O
* O
* O
] O
at O
1 O
PM O

 O
With O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
539 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
9816 O
* O
* O
] O
, O
RN O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
3241 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O



                              O
[ O
* O
* O
Name6 O
( O
MD O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(2 O
) O
3922 O
* O
* O
] O


 O

Admission O
Date O
: O
  O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2175 O
- O
8 O
- O
17 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2132 O
- O
3 O
- O
23 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Zosyn B-DRUG


 I-DRUG
Attending:[**Known O
firstname O
30 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Fever O
of O
103 O
on O
HD O
, O
abd O
pain O
, O
N/V O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
ERCP O
on O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
with O
stent O
placement O

 O
ET O
Intubation O
on O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O

 O
ERCP O
on O
[ O
* O
* O
2175 O
- O
8 O
- O
14 O
* O
* O
] O
with O
stent O
placement O

 O
Extubation O
on O
[ O
* O
* O
2175 O
- O
8 O
- O
14 O
* O
* O
] O

 O
Hemodialysis O

 O
Central O
venous O
catheter O
- O
RIJ O

 O
Arterial O
line O

 O
Echocardiogram O


 O
History O
of O
Present O
Illness O
: O

 O
This O
is O
a O
43 O
yo O
man O
transferred O
from O
MICU O
[ O
* O
* O
Location O
( O
un O
) O
2452 O
* O
* O
] O
for O
ERCP O
in O
the O

 O
setting O
of O
presumed O
biliary O
sepsis O
. O
Patient O
was O
transferred O
on O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
7 O
* O
* O
] O
from O
[ O
* O
* O
Hospital3 O
* O
* O
] O
ED O
with O
fever O
found O
at O
HD O
[ O
* O
* O
2175 O
- O
8 O
- O
7 O
* O
* O
] O
to O

 O
103 O
. O
He O
reports O
symptoms O
started O
the O
evening O
of O
[ O
* O
* O
8 O
- O
6 O
* O
* O
] O
with O
sharp O

 O
abdominal O
pain O
, O
nausea O
, O
vomitting O
, O
and O
diarrhea O
. O
At O
HD O
he O
was O

 O
febrile B-REA
with I-REA
rigors I-REA
to I-REA
temp I-REA
of I-REA
103 I-REA
. I-REA
He O
had O
blood O
cultures O
and O

 O
was O
given O
vanco/ceftazidime B-DRUG
and O
sent O
to O
[ O
* O
* O
Hospital3 O
* O
* O
] O
. O
At O

 O
[ O
* O
* O
Hospital3 O
3583 O
* O
* O
] O
he O
was O
given O
benedryl B-DRUG
25 B-STR
mg I-STR
iv B-ROU
, I-ROU
reglan B-DRUG
10 B-STR
mg I-STR
iv B-ROU
, I-ROU

 O
morphine B-DRUG
6 B-STR
mg I-STR
iv B-ROU
, I-ROU
zosyn B-DRUG
2.25gm B-STR
iv B-ROU
. I-ROU
He O
had O
an O
abdomen/pelvis O
CT O

 O
that O
preliminarily O
showed O
gall O
bladder O
hypodensity O
without O
signs O

 O
of O
acute O
cholecysitis O
. O
He O
was O
transferred O
here O
for O
ERCP O
given O

 O
elevated O
amylase O
, O
lipase O
and O
transaminases O
. O
AT O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
he O
was O

 O
given O
3L B-DOS
IVF B-DRUG
for O
SBP B-REA
77 I-REA
- I-REA
111 I-REA
with O
HR B-REA
100 I-REA
's I-REA
with O
Tm B-REA
101.5 I-REA
. I-REA
He O
was O

 O
given O
tylenol B-DRUG
1gm B-STR
. I-STR
He O
was O
admitted O
to O
MICU O
[ O
* O
* O
Location O
( O
un O
) O
2452 O
* O
* O
] O
overnight O

 O
where O
a O
right B-ROU
IJ I-ROU
central I-ROU
line I-ROU
was O
placed O
and O
he O
received O
2L B-DOS
NS B-DRUG
, I-DRUG

 O
IV B-ROU
vancomycin B-DRUG
and O
zosyn B-DRUG
. I-DRUG
Patient O
was O
transferred O
to O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
for O

 O
planned O
ERCP O
intervention O
on O
the O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
. O



 O

Past O
Medical O
History O
: O

 O
CAD O
s/p O
stent O
[ O
* O
* O
1 O
- O
6 O
* O
* O
] O
at O
[ O
* O
* O
Hospital1 O
2177 O
* O
* O
] O
in O
the O
setting O
of O
pna O

 O
HTN O

 O
gout B-REA
: I-REA
no O
active O
symptoms O
for O
several O
years O
, O
does O
not O
take O
ppx B-DRUG

 I-DRUG
ESRD O
on O
HD O
x9 O
years O
, O
? O
[ O
* O
* O
12 O
- O
31 O
* O
* O
] O
post-strep O
infection O
as O
a O
child O
? O
, O
on O

 O
M/W/F O
schedule O
, O
last O
HD O
[ O
* O
* O
8 O
- O
7 O
* O
* O
] O
, O
at O
Forsinius O
in O
[ O
* O
* O
Location O
( O
un O
) O
3320 O
* O
* O
] O
where O
he O

 O
reportedly O
normally O
gets O
5 O
kg O
removed O

 O
OSA O
on O
CPAP O
, O
pressure O
17mmHg O
? O
, O
but O
is O
unable O
to O
tolerate O
at O
home O



 O
Social O
History O
: O

 O
Lives O
with O
children O
( O
age O
19 O
, O
22 O
) O
, O
denies O
past O
or O
current O

 O
tobacco O
, O
drinks O
etoh O
only O
on O
special O
occaisions O
( O
less O
than O

 O
once/month O
) O
but O
drank O
more O
heavily O
prior O
to O
HD O
, O
occaisional O
MJ O

 O
but O
no O
IVDU O
or O
cocaine O
. O


 O
Family O
History O
: O

 O
Father O
with O
hypertension O
, O
mother O
with O
DM O
, O
sibs O
healthy O
, O
children O

 O
healthy O
. O


 O
Physical O
Exam O
: O

 O
VS O
: O
T O
99.5 O
HR O
101 O
BP O
117/75 O
RR O
28 O
Sat O
93 O
% O
on O
4L O
NC O

 O
Gen O
: O
NAD O
, O
obese O
man O
, O
speaking O
in O
full O
sentances O
, O
mild O
labored O

 O
breathing O
, O
drowsy O
but O
arousable O
, O
witnessed O
apnic O
episodes O
while O

 O
sleeping O

 O
HEENT O
: O
PERRL O
, O
OP O
clear O
, O
MM O
dry O
, O
mild O
scleral O
icterus O

 O
Neck O
: O
Supple O
, O
Right O
IJ O
in O
place O
, O
no O
LAD O

 O
CV O
: O
Reg O
, O
Tachy O
, O
III/VI O
SEM O
best O
at O
RUSB O
, O
heard O
throughout O
, O
no O

 O
r/g O

 O
Resp O
: O
Decreased O
BS O
at O
both O
bases O
with O
scattered O
rales O
R O
base O

 O
Abdomen O
: O
Obese O
, O
distended O
but O
soft O
, O
NT O
, O
no O
obvious O
masses O
but O

 O
very O
protuberant O
, O
white O
striae O
, O
no O
fluid O
wave O
, O
tympanic O
to O

 O
percussion O
throughout O
, O
unable O
to O
palpate O
liver O
or O
spleen O
; O
no O

 O
periumbilical O
ecchymosis O

 O
Ext O
: O
1 O
+ O
PE O
to O
thigh O
bilaterally O
; O
2 O
+ O
DP O
's O
B O
, O
left O
UE O
fistula O

 O
+ O
palpable O
thrill O

 O
Neuro O
: O
A&Ox3 O
, O
CN O
II-XII O
intact O
, O
strength O
5/5 O
B O
UE/LE O
, O
sensation O

 O
intact O
to O
light O
touch O

 O
Skin O
: O
no O
rashes O
, O
lesions O
or O
ecchymoses O

 O
. O



 O

Pertinent O
Results O
: O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
10:22PM O
   O
TYPE-ART O
TEMP-38.2 O
RATES-20/1 O
TIDAL O
VOL-700 O

 O
PEEP-5 O
O2 O
- O
60 O
PO2 O
- O
79 O
* O
PCO2 O
- O
41 O
PH-7.42 O
TOTAL O
CO2 O
- O
28 O
BASE O
XS-1 O

 O
INTUBATED-INTUBATED O
VENT-CONTROLLED O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
10:22PM O
   O
LACTATE-1.2 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
10:22PM O
   O
O2 O
SAT-95 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
08:56PM O
   O
TYPE-ART O
TEMP-38.2 O
RATES-[**10 O
- O
30 O
* O
* O
] O
TIDAL O
VOL-700 O

 O
PEEP-5 O
O2 O
- O
60 O
PO2 O
- O
86 O
PCO2 O
- O
63 O
* O
PH-7.28 O
* O
TOTAL O
CO2 O
- O
31 O
* O
BASE O
XS-0 O

 O
INTUBATED-INTUBATED O
VENT-CONTROLLED O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
08:56PM O
   O
LACTATE-0.9 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
08:56PM O
   O
freeCa-1.03 O
* O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
08:49PM O
   O
GLUCOSE-101 O
UREA O
N-45 O
* O
CREAT-10.1 O
* O
SODIUM-140 O

 O
POTASSIUM-4.6 O
CHLORIDE-98 O
TOTAL O
CO2 O
- O
27 O
ANION O
GAP-20 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
08:49PM O
   O
CK(CPK)-534 O
* O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
08:49PM O
   O
CK-MB-5 O
cTropnT-0.29 O
* O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
08:49PM O
   O
CALCIUM-7.6 O
* O
PHOSPHATE-5.9 O
* O
MAGNESIUM-2.1 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
02:22PM O
   O
TYPE-MIX O
PO2 O
- O
44 O
* O
PCO2 O
- O
54 O
* O
PH-7.39 O
TOTAL O

 O
CO2 O
- O
34 O
* O
BASE O
XS-5 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
02:22PM O
   O
LACTATE-1.4 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
01:55PM O
   O
GLUCOSE-125 O
* O
UREA O
N-38 O
* O
CREAT-9.1 O
* O
SODIUM-139 O

 O
POTASSIUM-4.4 O
CHLORIDE-96 O
TOTAL O
CO2 O
- O
30 O
ANION O
GAP-17 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
01:55PM O
   O
ALT(SGPT)-70 O
* O
AST(SGOT)-50 O
* O
LD(LDH)-198 O
ALK O

 O
PHOS-200 O
* O
AMYLASE-241 O
* O
TOT O
BILI-4.5 O
* O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
01:55PM O
   O
LIPASE-236 O
* O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
01:55PM O
   O
ALBUMIN-3.5 O
CALCIUM-7.8 O
* O
PHOSPHATE-5.1 O
* O

 O
MAGNESIUM-2.1 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
01:55PM O
   O
WBC-6.9 O
RBC-3.60 O
* O
HGB-11.2 O
* O
HCT-33.2 O
* O
MCV-92 O

 O
MCH-31.2 O
MCHC-33.8 O
RDW-14.2 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
01:55PM O
   O
NEUTS-92.5 O
* O
LYMPHS-3.1 O
* O
MONOS-4.0 O
EOS-0.2 O

 O
BASOS-0.2 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
01:55PM O
   O
PLT O
COUNT-179 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
01:21PM O
   O
LACTATE-1.7 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
GLUCOSE-127 O
* O
UREA O
N-32 O
* O
CREAT-8.8 O
* O
SODIUM-140 O

 O
POTASSIUM-4.8 O
CHLORIDE-92 O
* O
TOTAL O
CO2 O
- O
32 O
ANION O
GAP-21 O
* O

 O

[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
ALT(SGPT)-87 O
* O
AST(SGOT)-66 O
* O
CK(CPK)-80 O
ALK O

 O
PHOS-213 O
* O
AMYLASE-376 O
* O
TOT O
BILI-3.7 O
* O
DIR O
BILI-2.3 O
* O
INDIR O
BIL-1.4 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
LIPASE-459 O
* O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
CK-MB-NotDone O
cTropnT-0.21 O
* O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
ALBUMIN-3.9 O
CALCIUM-7.6 O
* O
PHOSPHATE-4.4 O

 O
MAGNESIUM-1.2 O
* O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
TRIGLYCER-236 O
* O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
CORTISOL-34.3 O
* O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
VANCO-10.4 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
ASA-NEG O
ACETMNPHN-7.0 O
bnzodzpn-NEG O

 O
barbitrt-NEG O
tricyclic-NEG O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
WBC-10.3 O
RBC-3.63 O
* O
HGB-11.2 O
* O
HCT-32.5 O
* O
MCV-90 O

 O
MCH-30.9 O
MCHC-34.4 O
RDW-14.7 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
NEUTS-94 O
* O
BANDS-4 O
LYMPHS-1 O
* O
MONOS-1 O
* O
EOS-0 O

 O
BASOS-0 O
ATYPS-0 O
METAS-0 O
MYELOS-0 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
HYPOCHROM-NORMAL O
ANISOCYT-NORMAL O

 O
POIKILOCY-NORMAL O
MACROCYT-NORMAL O
MICROCYT-NORMAL O

 O
POLYCHROM-NORMAL O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
PLT O
COUNT-240 O

 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
04:10AM O
   O
PT-15.5 O
* O
PTT-28.7 O
INR(PT)-1.4 O
* O


 O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
ERCP O
FINDINGS O
: O
The O
common O
bile O
duct O
was O
adequately O

 O
opacified O
with O
contrast O
medium O
after O
the O
cannulation O
of O
the O

 O
biliary O
duct O
. O
No O
apparent O
extrahepatic O
or O
intrahepatic O
biliary O

 O
duct O
dilatation O
or O
irregularity O
is O
seen O
. O
No O
filling O
defects O

 O
consistent O
with O
stones O
were O
noted O
. O
As O
per O
report O
, O
in O
subsequent O

 O
images O
, O
biliary O
stent O
was O
successfully O
placed O
. O
IMPRESSION O
: O

 O
Successful O
placement O
of O
biliary O
stent O
. O



 O
[ O
* O
* O
2175 O
- O
8 O
- O
9 O
* O
* O
] O
Transthoracic O
Echo O
: O
The O
left O
atrium O
is O
moderately O

 O
dilated O
. O
There O
is O
moderate O
symmetric O
left O
ventricular O

 O
hypertrophy O
. O
The O
left O
ventricular O
cavity O
size O
is O
normal O
. O
Overall O

 O
left O
ventricular O
systolic O
function O
is O
normal O
( O
LVEF O
70 O
% O
) O
. O
Tissue O

 O
Doppler O
imaging O
suggests O
an O
increased O
left O
ventricular O
filling O

 O
pressure O
( O
PCWP>18mmHg O
) O
. O
Transmitral O
Doppler O
and O
tissue O
velocity O

 O
imaging O
are O
consistent O
with O
Grade O
II O
( O
moderate O
) O
LV O
diastolic O

 O
dysfunction O
. O
There O
is O
no O
ventricular O
septal O
defect O
. O
Right O

 O
ventricular O
chamber O
size O
and O
free O
wall O
motion O
are O
normal O
. O
The O

 O
aortic O
root O
is O
mildly O
dilated O
at O
the O
sinus O
level O
. O
The O
ascending O

 O
aorta O
is O
moderately O
dilated O
. O
There O
are O
three O
aortic O
valve O

 O
leaflets O
. O
The O
aortic O
valve O
leaflets O
are O
moderately O
thickened O
. O

 O
There O
is O
mild O
aortic O
valve O
stenosis O
. O
The O
mitral O
valve O
leaflets O

 O
are O
mildly O
thickened O
. O
Mild O
( O
1 O
+ O
) O
mitral O
regurgitation O
is O
seen O
. O

 O
[ O
Due O
to O
acoustic O
shadowing O
, O
the O
severity O
of O
mitral O
regurgitation O

 O
may O
be O
significantly O
UNDERestimated O
. O
] O
There O
is O
mild O
pulmonary O

 O
artery O
systolic O
hypertension O
. O
There O
is O
a O
trivial/physiologic O

 O
pericardial O
effusion O
. O
There O
are O
no O
echocardiographic O
signs O
of O

 O
tamponade O
. O


 O
[ O
* O
* O
2175 O
- O
8 O
- O
14 O
* O
* O
] O
ERCP O
FINDINGS O
: O
Comparison O
is O
made O
with O
CT O
from O
[ O
* O
* O
8 O
- O
12 O
* O
* O
] O
, O
[ O
* O
* O
2174 O
* O
* O
] O
and O
prior O
ERCP O
from O
[ O
* O
* O
2175 O
- O
8 O
- O
8 O
* O
* O
] O
. O
  O
There O
is O

 O
removal O
of O
a O
plastic O
stent O
. O
A O
retrograde O
cholangiogram O
shows O

 O
multiple O
filling O
defects O
, O
some O
of O
which O
likely O
represent O
stones O
, O

 O
within O
otherwise O
normal- O
appearing O
biliary O
tree O
. O
A O
biliary O
stent O

 O
was O
then O
placed O
. O



 O
Brief O
Hospital O
Course O
: O

 O
# O
Hypotension/Sepsis O
: O
On O
admission O
, O
patient O
met O
SIRS O
criteria O

 O
with O
fever O
, O
tachypnea O
, O
tachycardia O
and O
lactate O
of O
2.5 O
consistent O

 O
with O
sepsis O
. O
Infectious O
source O
was O
likely O
biliary O
tract O
vs. O
HD O

 O
line O
infection O
, O
however O
also O
considered O
was O
pulmonary O
source O
w/ O

 O
new O
O2 O
requirements O
although O
more O
likely O
from O
capillary O

 O
leak/CHF O
. O
Patient O
has O
remained O
fluid O
responsive O
intially O
without O

 O
need O
for O
pressors B-DRUG
. I-DRUG
The O
underlying O
infection B-REA
was O
treated O
with O
IV B-ROU

 I-ROU
vancomycin/unasyn/gentamycin B-DRUG
for O
synergy B-REA
until O
cultures O
at O
OSH O

 O
grew O
enterobacter B-REA
at O
which O
point O
only O
zosyn B-DRUG
was O
continued O
with O

 O
appropriate O
coverage O
. O
The O
patients O
lactate O
level O
, O
fevers O
and O
WBC O

 O
were O
trended O
and O
returned O
to O
[ O
* O
* O
Location O
213 O
* O
* O
] O
. O
Zosyn B-DRUG
was O
switched O
to O

 O
Ciprofloxacin B-DRUG
after O
the O
patient O
developed O
a O
drug B-ADE
rash I-ADE
. I-ADE

 O
. O


 O
# O
Mechanical O
ventilation O
: O
Patient O
came O
to O
the O
ICU O
intubated O
s/p O

 O
ERCP O
, O
on O
a O
propofol B-DRUG
drip B-ROU
. I-ROU
Initially O
he O
was O
hypotensive B-REA
which O
was O

 O
treated O
with O
IV B-ROU
fluids B-DRUG
and O
discontinued O
propofol B-DRUG
, I-DRUG
switching O
to O

 O
fentanyl/versed B-DRUG
for O
sedation B-REA
. I-REA
  O
Shortly O
thereafter O
the O
patient O

 O
became O
restless O
, O
agitated O
and O
continued O
to O
be O
hypotensive B-ADE
. I-ADE
He O

 O
was O
given O
10 B-STR
mg I-STR
vecuronium B-DRUG
and O
paralyzed B-REA
for I-REA
arterial I-REA
line I-REA

 I-REA
placement I-REA
and I-REA
foley I-REA
placement I-REA
. I-REA
His O
labile O
blood O
pressures O
also O

 O
exacerbated O
his O
already O
fluid-overloaded O
state O
, O
making O
it O

 O
difficult O
to O
wean O
off O
the O
vent O
. O
The O
initiation O
of O
hemodialysis O

 O
effectively O
controlled O
his O
BP O
and O
fluid O
status O
, O
and O
on O
day O
7 O
, O

 O
after O
his O
second O
ERCP O
, O
he O
was O
extubated O
and O
started O
on O
CPAP O

 O
overnight O
. O

 O
. O

 O
# O
Gallstone O
Pancreatitis O
: O
On O
admission O
the O
patient O
had O
elevated O

 O
LFTs O
, O
pancreatic O
enzymes O
, O
bilirubin O
and O
alk O
phos O
. O
His O
levels O

 O
slowly O
trended O
down O
post-ERCP O
except O
bilirubin O
and O
AP O
, O
which O

 O
continued O
to O
rise O
. O
The O
patient O
experienced O
intermittent O

 O
epigastric O
discomfort O
which O
prompted O
a O
RUQ O
US O
, O
which O
showed O
a O

 O
fatty O
liver O
but O
the O
common O
bile O
duct O
non-well O
visualised O
. O
CT O

 O
scan O
of O
abdomen O
showed O
no O
intrahepatic O
biliary O
dilatation O
, O

 O
cholelithiasis O
, O
and O
a O
subtle O
hypodensity O
in O
pancreatic O
head O
. O

 O
Hepatology O
and O
ERCP O
were O
consulted O
prompting O
a O
second-look O
ERCP O
, O

 O
which O
showed O
sludge O
drainage O
in O
the O
major O
papilla O
, O
stent O

 O
migrated O
to O
major O
papilla O
and O
several O
stones O
in O
the O
cystic O
duct O
. O

 O
The O
stent B-REA
was I-REA
replaced I-REA
, I-REA
antibiotics B-DRUG
were O
continued O
, O
and O
the O

 O
patient O
's O
enzymes O
and O
bilirubin O
were O
trended O
. O

 O
. O

 O
# O
ESRD O
: O
Initially O
the O
nephrology O
service O
felt O
HD O
was O
not O

 O
appropriate O
early O
during O
admission O
, O
in O
setting O
of O
patient O

 O
becoming O
hypertensive B-REA
to O
200s O
with O
volume O
resusitation O
for O

 O
pancreatitis O
. O
Beta-blockers B-DRUG
were O
started O
however O
the O
patient O
did O

 O
not O
respond O
and O
O2 O
sats O
started O
trending O
down O
with O
worsening O

 O
acidemia O
and O
low O
PaO2 O
. O
The O
following O
day O
HD O
was O
initiated O
with O

 O
good O
response O
in O
blood O
pressure O
. O
The O
patient O
received O
HD O

 O
throughout O
his O
course O
, O
with O
the O
day O
before O
D/c O
the O
final O
time O
. O

 O
. O

 O
# O
Hypoxia B-REA
: I-REA
Suspected O
capillary O
leak O
in O
the O
setting O
of O
sepsis O
vs. O

 O
CHF O
as O
pt O
with O
known O
CAD O
. O
The O
patient O
was O
weaned O
off O
his O
O2 B-DRUG

 I-DRUG
requirement O
prior O
to O
discharge O
. O

 O
. O

 O
# O
Drug B-ADE
Rash I-ADE
: I-ADE
Patient O
developed O
a O
diffuse O
petticheal/macular B-ADE
rash I-ADE

 I-ADE
on O
his O
chest O
and O
legs O
which O
was O
pruritic O
. O
  O
Dermatology O
was O

 O
consulted O
who O
felt O
consistent O
with O
a O
drug O
rash O
. O
  O
Offending O
[ O
* O
* O
Doctor O
Last O
Name O
360 O
* O
* O
] O

 O
was O
felt O
to O
be O
Zosyn B-DRUG
. I-DRUG
  O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
was O
discontinued O
and O
rash O
improved O
. O

 O
He O
will O
continue O
hydoxyzine O
, O
sarna O
and O
fluocinonide O
. O

 O
. O


 O
# O
CAD B-REA
: I-REA
An O
echo O
was O
performed O
to O
rule O
out O
endocarditis O
as O
a O
cause O

 O
of O
fever O
. O
This O
showed O
extensive O
calcification O
of O
cardiac O

 O
skeleton O
, O
mild O
calcific O
aortic O
stenosis O
, O
and O
no O
definite O

 O
vegetations O
. O
His O
ECG O
had O
some O
ischemic O
changes O
of O
unclear O

 O
duration O
, O
and O
the O
patient O
had O
no O
active O
symptoms O
. O
Cardiac O

 O
enzymes O
were O
stably O
elevated O
on O
admission O
and O
, O
in O
the O
setting O
of O

 O
ESRD O
, O
this O
was O
unlikely O
to O
be O
acute O
event O
. O
His O
aspirin B-DRUG
and O

 O
plavix B-DRUG
were O
continued O
and O
the O
patient O
remained O
on O
telemetry O
for O

 O
the O
duration O
of O
his O
stay O
. O

 O
. O

 O
# O
OSA O
: O
Witnessed O
apneic O
episodes O
while O
asleep O
. O
Known O
history O
of O

 O
OSA O
on O
CPAP O
as O
outpatient O
but O
has O
not O
been O
tolerating O
of O
recent O
. O

 O
Once O
patient O
was O
extubated O
he O
was O
started O
on O
CPAP O
overnight O
. O

 O
. O

 O
# O
Anemia O
: O
Normocytic O
with O
normal O
RDW O
. O
Unclear O
baseline O
. O
[ O
* O
* O
Month O
( O
only O
) O
116 O
* O
* O
] O
be O

 O
low O
related O
to O
ESRD O
( O
not O
on O
epo O
as O
outpatient O
that O
we O
know O
of O
) O
. O

 O
D. O
bili O
not O
consistent O
with O
hemolysis O
. O
Hematocrit O
was O
trended O

 O
and O
continued O
to O
improve O
with O
HD O
and O
management O
. O
Renal O
recs O
: O
use O

 O
epo O
during O
HD O
. O

 O
. O


 O
Medications O
on O
Admission O
: O

 O
fish B-DRUG
oil I-DRUG
daily B-STR

 I-STR
sensipar B-DRUG
120 B-STR
mg I-STR
daily B-FRE

 I-FRE
ativan B-DRUG
0.5 B-STR
mg I-STR
prn B-FRE
( O
rare O
) O

 O
percocet B-DRUG
prn B-FRE
( O
rare O
) O

 O
nifedipineER B-DRUG
90 B-STR
daily B-FRE
( O
last O
[ O
* O
* O
8 O
- O
7 O
* O
* O
] O
) O

 O
minoxidil-dose B-DRUG
unable O
to O
verify O
but O
pt O
states O
rx O
for O
2 B-DOS
tabs B-FOR
and O

 O
only O
takes O
1 B-DOS

 I-DOS
renagel B-DRUG
2400 B-STR
mg I-STR
tid B-FRE
ac I-FRE

 I-FRE
phoslo B-DRUG
1334 B-STR
mg I-STR
( O
? O
) O
tid B-FRE
ac I-FRE

 I-FRE
simvastatin B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
plavix B-DRUG
75 B-STR
mg I-STR
daily B-FRE

 I-FRE
aspirin B-DRUG
325 B-STR
mg I-STR
daily B-FRE

 I-FRE
toprolXL B-DRUG
50 B-STR
mg I-STR
daily B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Clopidogrel B-DRUG
75 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Simvastatin B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Metoprolol B-DRUG
Succinate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sustained I-FOR
Release I-FOR
24 I-FOR
hr I-FOR

 I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
Sustained I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Camphor-Menthol B-DRUG
0.5 B-STR
- I-STR
0.5 I-STR
% I-STR
Lotion B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU

 I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( B-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
Disp:*1 O
tube O
* O
Refills:*0 O
* O

 O
6 O
. O
Ciprofloxacin B-DRUG
750 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE

 I-FRE
for B-DUR
5 I-DUR
days I-DUR
: I-DUR
Take O
this O
at O
least O
one O
hour O
before O
you O
take O
Renagel B-DRUG
. I-DRUG

 O
Disp:*5 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
7 O
. O
Hydroxyzine B-DRUG
HCl I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
itching B-REA
: I-REA
Only O
take O
this O
as B-DUR
long I-DUR
as I-DUR

 I-DUR
your I-DUR
rash I-DUR
is I-DUR
itching I-DUR
. I-DUR

 O
Disp:*21 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
8 O
. O
Fluocinonide B-DRUG
0.05 B-STR
% I-STR
Cream B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( B-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
rash B-REA
for B-DUR
12 I-DUR
days I-DUR
: I-DUR
Only B-DUR
use I-DUR
while I-DUR
you I-DUR

 I-DUR
have I-DUR
the I-DUR
rash I-DUR
. I-DUR

 O
Disp:*1 O
tube O
* O
Refills:*0 O
* O

 O
9 O
. O
Cinacalcet B-DRUG
30 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Four B-DOS
( I-DOS
4 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Nifedipine B-DRUG
90 B-STR
mg I-STR
Tablet B-FOR
Sustained I-FOR
Release I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
Sustained I-FOR
Release I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Minoxidil B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Sevelamer B-DRUG
HCl I-DRUG
800 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE

 I-FRE
W/MEALS I-FRE
( I-FRE
3 I-FRE
TIMES I-FRE
A I-FRE
DAY I-FRE
WITH I-FRE
MEALS I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Calcium B-DRUG
Acetate I-DRUG
667 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
TID B-FRE

 I-FRE
W/MEALS I-FRE
( I-FRE
3 I-FRE
TIMES I-FRE
A I-FRE
DAY I-FRE
WITH I-FRE
MEALS I-FRE
) I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
Diagnoses O
: O

 O
Biliary O
Sepsis O

 O
Gallstone O
Pancreatitis O


 O
Secondary O
Diagnoses O
: O

 O
ESRD O
with O
hemodialysis O

 O
CAD O

 O
Drug O
rash O

 O
OSA O

 O
HTN O

 O
Anemia O



 O
Discharge O
Condition O
: O

 O
Good O
, O
tolerating O
regular O
diet O
, O
ambulating O
with O
walker O
for O

 O
deconditioning O
, O
able O
to O
climb O
a O
flight O
of O
stairs O
, O
no O
oxygen O

 O
requirement O
, O
VSS O



 O

Discharge O
Instructions O
: O

 O
You O
were O
seen O
and O
treated O
at O
the O
hopital O
for O
a O
blockage B-REA
in I-REA
the I-REA

 I-REA
area I-REA
of I-REA
your I-REA
gallbladder I-REA
, I-REA
which O
caused O
you O
to O
become O
infected B-REA
. I-REA

 O
You O
were O
treated O
with O
intravenous B-ROU
fluids B-DRUG
, I-DRUG
antibiotics B-DRUG
and O
ERCP O

 O
( O
Endoscopic O
Retrograde O
Cholangiopancreatography O
) O
twice O
. O
A O
small O

 O
tube O
called O
a O
stent O
was O
placed O
near O
your O
gallbladder O
so O
that O
it O

 O
will O
drain O
bile O
into O
your O
intestine O
. O


 O
Please O
take O
the O
antibiotics B-DRUG
( I-DRUG
Ciprofloxacin I-DRUG
) I-DRUG
until O
it O
is O

 O
finished O
. O
You O
may O
also O
use O
the O
skin O
cream O
for O
your O
rash O
as O
long O

 O
as O
you O
need O
it O
. O
You O
may O
take O
all O
of O
your O
home O
medications O
, O
and O

 O
none O
of O
the O
dosages O
were O
changed O
. O


 O
Call O
your O
doctor O
or O
come O
to O
the O
Emergency O
Department O
right O
away O

 O
if O
any O
of O
the O
following O
problems O
develop O
: O


 O
* O
If O
you O
are O
vomitting O
and O
can O
not O
keep O
in O
fluids O
or O
your O

 O
medications O
. O


 O
* O
You O
are O
getting O
dehydrated O
due O
to O
continued O
vomitting O
, O

 O
diarrhea O
or O
other O
reasons O
. O
  O
Signs O
of O
dehydration O
include O
dry O

 O
mouth O
, O
rapid O
heartbeat O
or O
feeling O
dizzy O
or O
faint O
when O
standing O
. O


 O
* O
You O
see O
blood O
or O
dark/black O
material O
when O
you O
vomit O
or O
have O
a O

 O
bowel O
movement O
. O


 O
* O
Your O
skin O
, O
or O
the O
whites O
of O
your O
eyes O
become O
yellow O
again O
. O


 O
* O
Your O
pain O
is O
not O
improving O
within O
8 O
- O
12 O
hours O
or O
not O
gone O

 O
within O
24 O
hours O
. O
  O
Call O
or O
return O
immediately O
if O
your O
pain O
is O

 O
getting O
worse O
or O
is O
changing O
location O
or O
moving O
to O
your O
chest O
or O

 O
back O
. O


 O
* O
You O
have O
shaking O
chills O
, O
or O
a O
fever O
greater O
than O
100.4 O
( O
F O
) O

 O
degrees O
or O
38(C O
) O
degrees O
. O


 O
* O
Any O
serious O
change O
in O
your O
symptoms O
, O
or O
any O
new O
symptoms O
that O

 O
concern O
you O
. O


 O
Followup O
Instructions O
: O

 O
Please O
make O
an O
appointment O
to O
follow O
up O
with O
your O
PCP O
: O

 O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
80088 O
* O
* O
] O
in O
the O
next O
week O
or O
two O
to O
further O

 O
evaluate O
your O
response O
to O
treatment O
. O


 O
You O
will O
also O
need O
to O
follow-up O
with O
the O
Gastroenterology O
team O

 O
to O
have O
a O
repeat O
ERCP O
6 O
weeks O
with O
Dr. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
. O
Please O

 O
call O
his O
office O
at O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2306 O
* O
* O
] O
M-F O
8:30am-4:30pm O
. O


 O
The O
Dermatologists O
would O
also O
like O
you O
to O
make O
an O
appointment O

 O
for O
some O
areas O
of O
skin O
that O
require O
follow-up O
. O
You O
may O
call O

 O
their O
office O
at O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
8132 O
* O
* O
] O
to O
schedule O
the O
appointment O
. O




 O
Completed O
by:[**2175 O
- O
8 O
- O
17 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2188 O
- O
2 O
- O
8 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2188 O
- O
3 O
- O
4 O
* O
* O
] O



 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Hydralazine B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
3151 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
" O
I O
could O
n't O
breathe O
" O
x O
1 O
day O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Angiogram O

 O
Embolization O
of O
L3 O
Lumbar O
Artery O



 O
History O
of O
Present O
Illness O
: O

    O
86-year-old O
woman O
w/ O
HTN O
, O
hypothyroidism O
, O
AAA O
presents O
w/ O

 O
shortness O
of O
breath O
x O
1 O
day O
. O
  O
She O
was O
in O
her O
USOH O
until O
3 O
days O

 O
ago O
, O
when O
she O
developed O
insidious O
onset O
of O
nasal O
congestion O
, O

 O
runny O
nose O
, O
and O
cough O
occasionally O
productive O
of O
scant O
yellow O

 O
sputum O
. O
  O
She O
reports O
minor O
subjective O
fever O
initially O
that O
has O

 O
resolved O
. O
  O
These O
symptoms O
have O
persisted O
until O
now O
. O
  O
Over O
the O

 O
past O
2 O
days O
, O
she O
has O
developed O
increased O
dyspnea O
on O
exertion O
. O

 O
There O
is O
no O
dyspnea O
at O
rest O
, O
orthopnea O
, O
or O
PND O
. O
  O
This O
morning O
, O

 O
she O
had O
a O
prolonged O
episode O
of O
coughing O
which O
caused O
significant O

 O
dyspnea O
, O
prompting O
her O
to O
call O
her O
PCP O
for O
advice O
. O
  O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
665 O
* O
* O
] O

 O
was O
concerned O
about O
her O
dyspnea O
and O
advised O
her O
to O
present O
to O

 O
the O
ED O
for O
evaluation O
. O
  O
She O
denies O
any O
weight O
loss O
, O
chills O
, O

 O
myalgias O
, O
abdominal O
pain O
, O
nausea O
, O
vomiting O
, O
diarrhea O
, O

 O
hematochezia O
, O
black O
stools O
, O
dysuria O
, O
chest O
pain O
, O
or O

 O
palpitations O
. O
  O
She O
does O
report O
difficulty O
w/ O
balance O
over O
past O

 O
months O
requiring O
her O
to O
use O
a O
cane O
for O
walking O
. O

    O
In O
the O
ED O
, O
she O
was O
observed O
to O
have O
a O
large O
melanic O
stool O

 O
without O
any O
associated O
symptoms O
. O
  O
Vital O
signs O
were O
stable O
. O
  O
She O

 O
was O
treated O
w/ O
ceftriaxone B-DRUG
1gm B-STR
and O
azithromycin B-DRUG
500 B-STR
mg I-STR
for O

 O
possible O
PNA B-REA
. I-REA


 O
Past O
Medical O
History O
: O

 O
1 O
. O
Pacemaker O
DDD O
for O
sick O
sinus O
syndrome O

 O
2 O
. O
Thoracic O
aortic O
aneurysm O
s/p O
aortic O
arch O
graft O
and O
AVR O

 O
3 O
. O
s/p O
AVR O
w/ O
St. O
Jude O
's O
valve O
[ O
* O
* O
2178 O
* O
* O
] O

 O
4 O
. O
Hypertension O

 O
5 O
. O
Hypothyroidism O

 O
6 O
. O
Lower O
back O
pain O

 O
7 O
. O
Colonic O
polyps O

 O
8 O
. O
Iron O
deficiency O
anemia O

 O
9 O
. O
Abdominal O
aortic O
aneurysm O

 O
10 O
. O
h/o O
gallstone O
pancreatitis O

 O
11 O
. O
s/p O
open O
cholecystectomy O
[ O
* O
* O
7-/2183 O
* O
* O
] O



 O
Social O
History O
: O

 O
Divorced O
; O
former O
stock O
broker O
, O
lives O
alone O
in O
apt O
in O
[ O
* O
* O
Hospital1 O
1426 O
* O
* O
] O

 O
Towers O
; O
smoked O
20 O
pack-years O
but O
quit O
years O
ago O
; O
no O
alcohol O
or O

 O
recreational O
drug O
use O
; O
walks O
w/ O
cane O
at O
baseline O
. O


 O
Family O
History O
: O

 O
1 O
. O
DM2 O
: O
brother O



 O
Physical O
Exam O
: O

 O
VS O
  O
T O
98.2F O
, O
BP O
119/58 O
, O
HR O
82 O
, O
RR O
18 O
, O
O2 O
sat O
99 O
% O
4L/m O


 O
Gen O
: O
awake O
, O
alert O
, O
NAD O

 O
HEENT O
: O
anicteric O
, O
EOMI O
, O
PERRL O
, O
pink O
conjunctivae O
, O
OP O
clear O
w/ O

 O
MMM O
, O
no O
JVD O
, O
neck O
supple O

 O
CV O
: O
reg O
s1/s2 O
, O
no O
s3/s4/m/r O

 O
Pulm O
: O
crackles O
at O
left O
base O
cleared O
w/ O
cough O
, O
no O
wheezes O

 O
Abd O
: O
+ O
BS O
, O
soft O
, O
NT O
, O
ND O

 O
Ext O
: O
warm O
, O
2 O
+ O
DP O
B O
, O
no O
edema O

 O
Neuro O
: O
alert O
and O
oriented O
x O
3 O
, O
CN O
2 O
- O
12 O
intact O
, O
strength O
5/5 O

 O
throughout O
UE/LE O
B O
, O
sensation O
to O
fine O
touch O
intact O
throughout O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2188 O
- O
2 O
- O
7 O
* O
* O
] O
06:30PM O
   O
WBC-4.5 O
RBC-3.98 O
* O
HGB-11.2 O
* O
HCT-32.9 O
* O
MCV-83 O
# O

 O
MCH-28.2 O
MCHC-34.0 O
RDW-14.9 O

 O
[ O
* O
* O
2188 O
- O
2 O
- O
7 O
* O
* O
] O
06:30PM O
   O
PLT O
COUNT-127 O
* O

 O
[ O
* O
* O
2188 O
- O
2 O
- O
7 O
* O
* O
] O
06:30PM O
   O
NEUTS-81.2 O
* O
LYMPHS-11.0 O
* O
MONOS-7.4 O
EOS-0.2 O

 O
BASOS-0.2 O


 O
[ O
* O
* O
2188 O
- O
2 O
- O
7 O
* O
* O
] O
06:30PM O
   O
GLUCOSE-86 O
UREA O
N-25 O
* O
CREAT-0.9 O
SODIUM-139 O

 O
POTASSIUM-3.8 O
CHLORIDE-100 O
TOTAL O
CO2 O
- O
29 O
ANION O
GAP-14 O

 O
[ O
* O
* O
2188 O
- O
2 O
- O
8 O
* O
* O
] O
08:15AM O
   O
CALCIUM-8.5 O
PHOSPHATE-3.0 O
MAGNESIUM-1.8 O


 O
[ O
* O
* O
2188 O
- O
2 O
- O
7 O
* O
* O
] O
06:30PM O
   O
CK(CPK)-221 O
* O

 O
[ O
* O
* O
2188 O
- O
2 O
- O
7 O
* O
* O
] O
06:30PM O
   O
CK-MB-6 O
cTropnT-<0.01 O

 O
[ O
* O
* O
2188 O
- O
2 O
- O
8 O
* O
* O
] O
08:15AM O
   O
CK(CPK)-372 O
* O

 O
[ O
* O
* O
2188 O
- O
2 O
- O
8 O
* O
* O
] O
08:15AM O
   O
CK-MB-7 O

 O
[ O
* O
* O
2188 O
- O
2 O
- O
8 O
* O
* O
] O
08:15AM O
   O
cTropnT-0.02 O
* O

 O
[ O
* O
* O
2188 O
- O
2 O
- O
8 O
* O
* O
] O
12:24PM O
   O
CK-MB-8 O

 O
[ O
* O
* O
2188 O
- O
2 O
- O
8 O
* O
* O
] O
12:24PM O
   O
cTropnT-0.03 O
* O


 O
[ O
* O
* O
2188 O
- O
2 O
- O
7 O
* O
* O
] O
06:30PM O
URINE O
  O
COLOR-Straw O
APPEAR-Clear O
SP O
[ O
* O
* O
Last O
Name O
( O
un O
) O
155**]-1.018 O

 O
[ O
* O
* O
2188 O
- O
2 O
- O
7 O
* O
* O
] O
06:30PM O
URINE O
  O
RBC-0 O
- O
2 O
WBC-0 O
- O
2 O
BACTERIA-FEW O
YEAST-NONE O

 O
EPI-0 O
- O
2 O


 O
CXR O
: O
Left O
basilar O
opacity O
that O
may O
represent O
atelectasis O
altho O

 O
pneumonia O
not O
excluded O
. O
Probable O
emphysema O
. O



 O
CTA O
chest O
: O

   O
1 O
. O
Slightly O
limited O
examination O
for O
evaluation O
for O
pulmonary O

 O
embolus O
, O
although O
no O
large O
central O
pulmonary O
embolus O
is O
present O

 O
and O
no O
definite O
evidence O
of O
more O
distal O
pulmonary O
embolus O
is O

 O
visualized O
. O

   O
2 O
. O
Mediastinal O
and O
hilar O
lymphadenopathy O
, O
including O
multiple O

 O
subcentimeter O
pretracheal O
and O
precarinal O
nodes O
, O
and O
enlarged O

 O
right O
hilar O
and O
subcarinal O
nodal O
masses O
. O

   O
3 O
. O
Four O
millimeter O
nodule O
within O
the O
left O
upper O
lobe O

 O
laterally O
. O
Comparison O
with O
any O
possibly O
available O
prior O
imaging O

 O
is O
recommended O
. O
Short-term O
CT O
follow-up O
is O
recommended O
. O

   O
4 O
. O
Bronchiectatic O
changes O
predominantly O
in O
the O
lower O
lobes O

 O
bilaterally O
. O

   O
5 O
. O
Large O
hiatal O
hernia O
. O


 O
[ O
* O
* O
2188 O
- O
2 O
- O
22 O
* O
* O
] O
: O
Angiogram O

 O
IMPRESSION O
: O

 O
1 O
. O
No O
evidence O
of O
active O
extravasation O
of O
the O
contrast O
material O

 O
as O
above O
. O

 O
2 O
. O
Embolization O
of O
the O
left O
L3 O
lumbar O
artery O
per O
surgical O
team O

 O
request O
. O



 O
Brief O
Hospital O
Course O
: O

 O
1 O
. O
Dyspnea O
: O
  O
she O
was O
admitted O
w/ O
dyspnea O
in O
setting O
of O
URI O

 O
symptoms O
that O
was O
most O
consistent O
w/ O
viral O
URI O
, O
as O
there O
was O
no O

 O
fever O
and O
no O
infiltrative O
process O
on O
chest O
CT O
. O
  O
She O
was O
tested O

 O
for O
influenza O
w/ O
DFA O
of O
nasal O
aspirate O
. O
  O
Meanwhile O
, O
she O
was O

 O
treated O
w/ O
ceftriaxone B-DRUG
and O
azithromycin B-DRUG
to O
cover O
possible O
CAP B-REA
. I-REA

 O
On O
HD#2 O
, O
DFA O
returned O
as O
positive O
for O
influenza O
A. O
  O
As O
the O
pt O

 O
had O
been O
afebrile O
w/ O
no O
signs O
of O
infxn O
, O
pneumonia O
was O
thought O
to O

 O
be O
unlikely O
and O
abx O
were O
d/c O
at O
that O
time O
. O
  O
She O
remained O
dyspnic O

 O
w/ O
upper O
and O
lower O
airway O
wheezing O
throughout O
her O
early O
hospital O

 O
course O
, O
which O
was O
thought O
to O
be O
[ O
* O
* O
2 O
- O
6 O
* O
* O
] O
viral O
bronchitis B-REA
. I-REA
  O
She O
was O

 O
treated O
w/ O
prednisone B-DRUG
taper O
and O
nebulized B-FOR
albuterol B-DRUG
and O

 O
atrovent B-DRUG
, I-DRUG
w/ O
good O
symptom O
control O
. O
  O
However O
, O
she O
required O

 O
continued O
O2 B-DRUG
by O
NC B-ROU
to O
maintain O
O2 O
sats O
> O
93 O
% O
throughout O
the O
first O

 O
half O
of O
her O
admission O
. O
  O
By O
d/c O
, O
she O
was O
weaned O
off O
O2 B-DRUG
and O
was O

 O
breathing O
comfortably O
on O
room O
air O
without O
requirement O
for O

 O
albuterol B-DRUG
or O
atrovent B-DRUG
. I-DRUG
  O
At O
d/c O
, O
she O
is O
maintaining O
good O
O2 O
sat O

 O
on O
room O
air O
and O
is O
not O
dyspnic O
. O



 O
2 O
. O
GI O
bleed O
: O
  O
she O
was O
observed O
to O
have O
melanic O
stool O
in O
the O
ED O
, O

 O
without O
any O
GI O
symptoms O
. O
  O
She O
was O
guaiac O
positive O
at O
that O
time O
. O

 O
This O
was O
most O
likely O
[ O
* O
* O
2 O
- O
6 O
* O
* O
] O
indolent O
upper O
GI O
bleed O
. O
  O
On O
admission O
, O

 O
coumadin B-DRUG
was O
held O
and O
heparin B-DRUG
was O
started O
for O
anticoagulation B-REA

 I-REA
given O
her O
AVR O
. O
  O
Treatment O
was O
started O
w/ O
IV B-ROU
protonix B-DRUG
. I-DRUG
  O
Plans O

 O
were O
made O
for O
EGD/colonoscopy O
to O
evaluate O
for O
source O
of O

 O
bleeding O
, O
but O
these O
procedures O
were O
delayed O
due O
to O
the O
pt O
's O

 O
dyspnea O
and O
relative O
risk O
of O
sedation O
. O
  O
Her O
HCT O
was O
observed O
to O

 O
drop O
significantly O
, O
which O
was O
likely O
[ O
* O
* O
2 O
- O
6 O
* O
* O
] O
retroperitoneal O
bleed O

 O
as O
below O
, O
and O
not O
related O
to O
GI O
bleed O
. O
  O
After O
her O
admission O
, O
she O

 O
had O
no O
further O
melena O
or O
hematochezia O
. O
  O
After O
stabilization O
of O

 O
retroperitoneal O
bleed O
, O
she O
underwent O
EGD O
and O
colonoscopy O
, O
which O

 O
demonstrated O
evidence O
of O
esophagitis O
w/ O
no O
active O
bleeding O
. O

 O
Protonix B-DRUG
was O
changed O
to O
oral B-ROU
formulation O
, O
and O
sucralfate B-DRUG
was O

 O
added O
for O
improved O
treatment O
of O
esophagitis B-REA
. I-REA
  O
She O
had O
no O
further O

 O
evidence O
of O
active O
GI O
bleeding O
during O
her O
admission O
. O
  O
Her O

 O
sucralfate B-DRUG
was O
stopped O
. O
She O
will O
need O
to O
continue O
protonix B-DRUG
twice B-FRE

 I-FRE
daily I-FRE
after O
d/c O
. O



 O
3 O
. O
Retroperitoneal O
hemorrhage O
: O
  O
on O
HD#4 O
, O
her O
HCT O
was O
observed O
to O

 O
have O
dropped O
overnight O
from O
27 O
to O
21 O
. O
  O
This O
was O
concerning O
for O

 O
active O
GI O
bleed O
. O
  O
She O
was O
transfused O
w/ O
2units B-DOS
PRBCs B-DRUG
, I-DRUG
w/ O

 O
appropriate O
HCT O
increase O
to O
29 O
after O
transfusion O
. O
  O
However O
, O
her O

 O
HCT O
again O
decreased O
overnight O
from O
29 O
to O
22 O
with O
no O
melena O
or O

 O
hematochezia O
to O
explain O
the O
blood O
loss O
. O
  O
Lab O
workup O
showed O
no O

 O
evidence O
of O
hemolysis O
. O
  O
Abd O
CT O
demonstrated O
large O
left O

 O
retroperitoneal O
hemorrhage O
, O
11x5 O
cm O
in O
size O
, O
w/ O
radiographic O

 O
evidence O
of O
acute O
on O
chronic O
bleeding O
. O
  O
Heparin B-DRUG
was O
d/c O
, O
she O
was O

 O
transfused O
w/ O
an O
additional O
2units B-DOS
PRBCs B-DRUG
, I-DRUG
and O
was O
transferred O
to O

 O
the O
MICU O
for O
close O
monitoring O
. O
  O
Surgery O
was O
consulted O
, O
and O

 O
recommended O
holding O
anticoagulation O
with O
close O
monitoring O
of O

 O
HCT O
. O
  O
The O
pt O
had O
appropriate O
response O
of O
HCT O
w/ O
PRBC B-DRUG

 I-DRUG
transfusion B-ROU
, I-ROU
and O
HCT O
remained O
stable O
for O
3 O
days O
off O

 O
anticoagulation O
. O
  O
As O
HCT O
had O
stabilized O
, O
she O
was O
transferred O

 O
back O
to O
the O
Medicine O
floor O
and O
Surgery O
recommended O
resuming O

 O
heparin B-DRUG
for O
anticoagulation B-REA
. I-REA
  O
Heparin B-DRUG
was O
resumed O
w/ O
close O

 O
monitoring O
of O
PTT O
, O
and O
HCT O
was O
monitored O
closely O
. O
  O
However O
, O

 O
after O
resuming O
heparin B-DRUG
the O
pt O
had O
another O
decrease O
in O
HCT O

 O
concerning O
for O
active O
bleeding O
. O
  O
Heparin B-DRUG
was O
stopped O

 O
immediately O
. O
  O
Repeat O
CT O
scan O
showed O
enlarging O
left O

 O
retroperitoneal O
bleed O
tracking O
down O
into O
pelvis O
and O
left O
thigh O
. O

 O
CTA O
was O
done O
to O
localize O
source O
of O
bleed O
, O
and O
showed O
active O

 O
contrast O
extravasation O
from O
the O
left O
L3 O
lumbar O
artery O
. O
  O
IR O
was O

 O
consulted O
, O
and O
performed O
embolization O
of O
left O
L3 O
lumbar O
artery O
, O

 O
though O
there O
was O
no O
evidence O
of O
active O
bleeding O
from O
the O
artery O

 O
at O
the O
time O
of O
the O
procedure O
. O
  O
She O
tolerated O
the O
procedure O
well O
. O

  O

HCT O
was O
follow O
closely O
after O
embolization O
, O
and O
remained O
stable O

 O
for O
3 O
days O
. O
  O
Repeat O
CTA O
showed O
no O
active O
bleeding O
from O
the O
L3 O

 O
lumbar O
artery O
, O
which O
indicated O
a O
successful O
embolization O
. O
  O
Given O

 O
this O
confirmation O
and O
stable O
HCT O
, O
heparin B-DRUG
was O
resumed O
w/ O
initial O

 O
goal O
PTT O
of O
40 O
. O
  O
HCT O
was O
stable O
on O
this O
level O
of O
heparin B-DRUG
, I-DRUG
so O

 O
heparin B-DRUG
was O
increased O
to O
goal O
PTT O
of O
60 O
- O
70 O
. O
  O
The O
pt O
received O
1 B-DOS

 I-DOS
dose O
of O
coumadin B-DRUG
5 B-STR
mg I-STR
to O
begin O
long-term O
anticoagulation B-REA
. I-REA
  O
A O
PTT O

 O
of O
60 O
was O
achieved O
and O
was O
stable O
for O
12 O
hours O
w/ O
stable O
HCT O
, O

 O
but O
the O
pt O
then O
developed O
abdominal O
distention O
and O
pain O
, O
w/ O

 O
significant O
LLQ/LUQ O
tenderness O
on O
exam O
. O
  O
This O
was O
concerning O
for O

 O
additional O
bleeding O
. O
  O
Heparin B-DRUG
was O
once O
again O
d/c O
, O
and O
repeat O
CT O

 O
showed O
markedly O
enlarged O
retroperitoneal O
bleed O
displacing O
the O

 O
left O
kidney O
and O
bowels O
to O
the O
right O
abdomen O
. O
  O
Surgery O
, O
IR O
, O
and O

 O
Vascular O
Surgery O
were O
all O
consulted O
for O
recommendations O
on O
how O

 O
to O
stop O
her O
bleeding O
. O
  O
The O
consulting O
services O
all O
agreed O
that O

 O
intervention O
was O
ill-advised O
, O
as O
surgical O
treatment O
was O
often O

 O
inneffective O
and O
repeated O
arterial O
embolization O
in O
this O
setting O

 O
might O
result O
in O
embolization O
of O
the O
wrong O
vessel O
, O
w/ O
possible O

 O
bowel O
infarction O
or O
other O
complication O
. O
  O
Thus O
, O
the O
pt O
was O
given O

 O
2units B-DOS
FFP B-DRUG
to O
reverse O
her O
INR O
of O
1.3 O
, O
and O
was O
transfused O
w/ O

 O
2units B-DOS
of O
PRBCs B-DRUG
. I-DRUG
  O
Her O
HCT O
did O
not O
respond O
appropriately O
to O
PRBC B-DRUG

 I-DRUG
transfusion O
, O
so O
she O
was O
transferred O
to O
the O
MICU O
for O
close O

 O
monitoring O
and O
continued O
transfusion O
. O
  O
While O
in O
MICU O
, O

 O
anticoagulation O
continued O
to O
be O
held O
, O
and O
patient O
remained O

 O
stable O
during O
MICU O
course O
. O
  O
Indeed O
, O
it O
was O
felt O
that O
risks O
of O

 O
bleeding O
outweighed O
need O
to O
anti-coagulation O
benefits O
. O
The O

 O
patient O
was O
transferred O
to O
the O
floor O
with O
no O
further O
episodes O
of O

 O
bleeding O
and O
a O
stable O
hematocrit O
for O
> O
72 O
hours O
by O
discharge O
. O


 O
4 O
. O
HTN O
: O
  O
BP O
was O
acceptable O
on O
admission O
. O
  O
BP O
meds O
were O
held O

 O
initially O
given O
concern O
for O
GI O
bleed O
and O
subsequent O

 O
retroperitoneal O
hemorrhage O
. O
  O
However O
, O
BP O
was O
elevated O
within O
a O

 O
few O
days O
of O
admission O
. O
  O
When O
retroperitoneal O
bleed O
had O
initially O

 O
stabilized O
, O
her O
outpt O
meds O
were O
resumed O
including O
diovan B-DRUG
, I-DRUG
HCTZ B-DRUG
, I-DRUG

 O
and O
clonidine B-DRUG
, I-DRUG
resulting O
in O
good O
BP B-REA
control I-REA
. I-REA
  O
When O
her O

 O
hematocrit O
began O
to O
drop O
for O
a O
second O
time O
and O
the O
patient O
was O

 O
transferred O
back O
to O
the O
MICU O
, O
her O
antihypertensives B-DRUG
were O
again O

 O
held O
. O
As O
her O
bleed O
stabilized O
, O
her O
blood O
pressures O
trended O

 O
upward O
and O
she O
was O
restarted O
on O
diovan B-DRUG
at O
1/2 O
her O
home O
dose O
. O
Her O

 O
blood O
pressures O
should O
be O
followed O
at O
rehab O
. O



 O
5 O
. O
Anemia O
: O
  O
she O
has O
h/o O
iron O
deficiency O
anemia O
, O
w/ O
prior O
EGD O

 O
showing O
gastritis O
. O
  O
HCT O
on O
admission O
was O
slightly O
below O
baseline O

 O
of O
32 O
- O
33 O
. O
  O
HCT O
remained O
stable O
for O
initial O
hospital O
days O
, O
but O

 O
dropped O
w/ O
retroperitoneal O
bleed O
as O
above O
. O
  O
Her O
HCT O
was O
labile O

 O
throughout O
her O
admission O
[ O
* O
* O
2 O
- O
6 O
* O
* O
] O
intermittent O
bleeding O
. O
At O
d/c O
, O

 O
there O
is O
no O
evidence O
of O
active O
bleeding O
. O
  O
She O
will O
require O
f/u O

 O
of O
HCT O
after O
d/c O
to O
watch O
for O
further O
bleeding O
. O


 O
6 O
. O
Hypothyroidism B-REA
: I-REA
  O
stable O
on O
synthroid B-DRUG
during O
her O
admission O
. O


 O
7 O
. O
AVR O
: O
  O
she O
has O
St. O
[ O
* O
* O
Male O
First O
Name O
( O
un O
) O
1525 O
* O
* O
] O
artificial O
aortic O
valve O
; O
requires O

 O
anticoagulation O
w/ O
goal O
INR O
2.5 O
- O
3.5 O
. O
  O
INR O
subtherapeutic O
on O

 O
admission O
. O
  O
Given O
melanic O
stool O
, O
we O
held O
coumadin B-DRUG
on O
admission O

 O
and O
started O
heparin B-DRUG
for O
anticoagulation B-REA
. I-REA
  O
She O
had O
intermittent O

 O
retroperitoneal O
bleeding O
during O
her O
admission O
, O
requiring O
d/c O
and O

 O
resumption O
of O
heparin B-DRUG
multiple O
times O
as O
above O
. O
  O
Given O
her O

 O
repeated O
spontaneous O
bleeding O
after O
embolization O
of O
L3 O
lumber O

 O
artery O
, O
we O
do O
not O
want O
to O
restart O
anticoagulation O
in O
the O
near O

 O
future O
as O
the O
risk O
of O
ongoing O
bleeding O
is O
too O
great O
. O


 O
8 O
. O
Mediastinal O
LAD O
: O
  O
she O
has O
mediastinal O
LAD O
, O
w/ O
largest O
node O
3 O

 O
x O
2 O
cm O
by O
CT O
. O
  O
This O
may O
represent O
lung O
CA O
given O
pulm O
nodule O
and O

 O
smoking O
history O
. O
  O
However O
, O
the O
pt O
wishes O
to O
defer O
further O

 O
evaluation O
until O
active O
issues O
resolved O
. O
  O
Will O
follow O
w/ O
repeat O

 O
CT O
2 O
months O
after O
d/c O
. O


 O
9 O
. O
Cystitis B-REA
: I-REA
  O
she O
developed O
cystitis O
from O
yeast O
while O
using O

 O
foley O
catheter O
, O
likely O
[ O
* O
* O
2 O
- O
6 O
* O
* O
] O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
564 O
* O
* O
] O
, O
as O
supported O
by O
pyuria O
and O

 O
yeast O
in O
ucx O
. O
  O
Foley O
catheter O
was O
changed O
on O
discovery O
of O
yeast B-REA

 I-REA
in I-REA
urine I-REA
, I-REA
and O
she O
was O
treated O
w/ O
7 B-DUR
day I-DUR
course O
of O
fluconazole B-DRUG
. I-DRUG

 O
At O
d/c O
, O
there O
is O
no O
evidence O
of O
active O
infection O
. O


 O
Medications O
on O
Admission O
: O

 O
1 O
. O
coumadin B-DRUG
6 B-STR
mg I-STR
6 B-FRE
days I-FRE
per I-FRE
week I-FRE
, I-FRE
7 B-STR
mg I-STR
1 B-FRE
day I-FRE
per I-FRE
week I-FRE

 I-FRE
2 O
. O
diovan B-DRUG
160 B-STR
mg I-STR
qam B-FRE

 I-FRE
3 O
. O
HCTZ B-DRUG
12.5 B-STR
mg I-STR
q B-FRE
day I-FRE

 I-FRE
4 O
. O
Prevacid B-DRUG

 I-DRUG
5 O
. O
Synthroid B-DRUG
175mcg B-STR
q B-FRE
day I-FRE

 I-FRE
6 O
. O
clonidine B-DRUG
0.1 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O



 O
Discharge O
Medications O
: O

 O
1 O
. O
Levothyroxine B-DRUG
Sodium I-DRUG
175 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
2 O
. O
Zolpidem B-DRUG
Tartrate I-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( O
at O

 O
bedtime O
) O
as O
needed O
. O

 O
3 O
. O
Valsartan B-DRUG
80 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
Disp:*30 O
Capsule(s O
) O
* O
Refills:*2 O
* O

 O
4 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q4 B-FRE
- I-FRE
6H I-FRE
( I-FRE
every I-FRE

 I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
fever B-REA
and O
pain B-REA
. I-REA

 O
5 O
. O
Pantoprazole B-DRUG
Sodium I-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q12H B-FRE
( O
every O
12 O
hours O
) O
. O


 O
6 O
. O
Simethicone B-DRUG
80 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Chewable I-FOR
PO B-ROU
QID B-FRE
( O
4 O
times O
a O
day O
) O
. O

 O
7 O
. O
Lidocaine B-DRUG
HCl I-DRUG
2 O
% O
Gel B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Urethral B-ROU
Q4 B-FRE
- I-FRE
6 I-FRE
PRN I-FRE
( O
) O

 O
as O
needed O
for O
rectal B-REA
discomfort I-REA
. I-REA



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
2558 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
1 O
. O
Retroperitoneal O
Bleed O
. O

 O
2 O
. O
Influenza O
A O

 O
3 O
. O
Mediastinal O
Lymphadenopathy O
. O

 O
4 O
. O
4 O
mm O
nodule O
within O
the O
left O
upper O
lobe O
laterally O
with O
hazy O

 O
spiculated O
margins O
. O

 O
5 O
. O
Bronchiectasis O
. O

 O
6 O
. O
Hiatal O
Hernia O
. O

 O
7 O
. O
GI O
bleed O
. O


 O
Secondary/PMH O
: O

 O
1 O
. O
Ascending O
thoracic O
aortic O
aneurysm O
s/p O
valve O
conduit O

 O
replacement O
with O
St. O
[ O
* O
* O
Male O
First O
Name O
( O
un O
) O
923 O
* O
* O
] O
MVR O
and O
hemi-Cabrol O
and O
hemi-Rhemi O

 O
arch O
replacement O
. O

 O
2 O
. O
Hypertension O
. O

 O
3 O
. O
Hypothyroidism O
. O

 O
4 O
. O
Iron O
Deficiency O
Anemia O
. O

 O
5 O
. O
Abdominal O
Aortic O
Aneurysm O
. O
3.1 O
x O
3.6 O
cm O

 O
6 O
. O
Gallstone O
Pancreatitis O
. O

 O
7 O
. O
Perforated O
hemorrhagic O
gallbladder O
s/p O
Cholecystectomy O
. O



 O
Discharge O
Condition O
: O

 O
Stable O
to O
go O
to O
[ O
* O
* O
Hospital3 O
2558 O
* O
* O
] O
. O
  O
No O
evidence O
of O
active O
bleeding O

 O
or O
infection O
. O
  O
Tolerating O
diet O
well O
. O


 O
Discharge O
Instructions O
: O

 O
You O
are O
being O
discharged O
after O
treatment O
for O
influenza O
, O
GI O

 O
bleed O
, O
and O
retroperitoneal O
bleeding O
. O
  O
Please O
take O
all O

 O
medications O
as O
prescribed O
. O


 O
We O
restarted O
your O
diovan B-DRUG
at O
half O
of O
your O
previous O
dose O
. O
Your O

 O
blood O
pressures O
should O
be O
followed O
closely O
at O
[ O
* O
* O
Hospital3 O
2558 O
* O
* O
] O
. O



 O
Call O
your O
doctor O
or O
present O
to O
the O
ED O
if O
you O
have O
shortness O
of O

 O
breath O
, O
dizziness O
, O
chest O
pain O
, O
confusion O
, O
abdominal O
pain O
, O
nausea O

 O
and O
vomiting O
, O
fever O
, O
bleeding O
, O
black O
stools O
, O
or O
other O
concerning O

 O
symptoms O
. O


 O
Followup O
Instructions O
: O

 O
Follow-up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
665 O
* O
* O
] O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
250 O
* O
* O
] O
) O
after O
you O
have O
been O

 O
discharged O
from O
[ O
* O
* O
Hospital3 O
2558 O
* O
* O
] O
. O
  O
Call O
to O
make O
an O
appointment O
. O


 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
1947**],[**Name11 O
( O
NameIs O
) O
3152 O
* O
* O
] O
[ O
* O
* O
Hospital O
1947 O
* O
* O
] O
CLINIC O
Where O
: O
CC-2 O
[ O
* O
* O
Hospital O
1947 O
* O
* O
] O

 O
UNIT O
Phone:[**Telephone/Fax O
( O
1 O
) O
3153 O
* O
* O
] O
Date/Time:[**2188 O
- O
4 O
- O
15 O
* O
* O
] O
2:10 O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2184 O
- O
10 O
- O
22 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2184 O
- O
11 O
- O
9 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2120 O
- O
5 O
- O
4 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
6169 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Word O
finding O
difficulty O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Craniotomy O
and O
drainage O



 O
History O
of O
Present O
Illness O
: O

 O
Pt O
is O
a O
64 O
y/o O
male O
with O
a O
h/o O
AML/MDS O
, O
DM2 O
, O
and O
COPD O
who O

 O
presented O
to O
clinic O
today O
for O
a O
routine O
visit O
with O
a O
complaint O

 O
of O
a O
difficulty O
finding O
words O
over O
the O
past O
week O
. O
He O
states O
this O

 O
came O
on O
suddenly O
. O
The O
primary O
trouble O
is O
with O
finding O
words O
to O

 O
describe O
what O
he O
wants O
to O
say O
, O
not O
actually O
articulating O
the O

 O
words O
. O
He O
denies O
any O
other O
neurologic O
symptoms O
, O
including O

 O
weakness O
( O
no O
stumbling O
, O
dropping O
items O
) O
, O
loss O
of O
sensation O
, O
or O

 O
other O
confusion O
. O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
displays O
understanding O
of O
his O

 O
current O
situation O
and O
location O
. O
He O
denies O
any O
specific O
symptoms O
, O

 O
including O
fever/chills O
, O
headache O
, O
shortness O
of O
breath O
, O
chest O

 O
pain/pressure O
, O
nausea/vomiting O
, O
diarrhea/constipation O
, O

 O
melena/hematochezia O
, O
dysuria/hematuria O
, O
nosebleeds O
, O
and O
rashes O
. O

 O
Hhis O
speech O
prompted O
the O
team O
in O
the O
clinic O
to O
investigate O
these O

 O
symptoms O
, O
and O
an O
MRI/MRA O
demonstrated O
a O
left O
parietal O
fluid O

 O
collection O
. O


 O
In O
terms O
of O
his O
AML B-REA
, I-REA
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
was O
treated O
with O
LODAC O
in O
[ O
* O
* O
2182 O
* O
* O
] O

 O
and O
subsequent O
to O
that O
has O
been O
on O
hydrea B-DRUG
and O
donazol B-DRUG
and O
has O

 O
been O
transfusion O
dependant O
. O
  O
He O
is O
currently O
on O
hydroxyurea B-DRUG

 I-DRUG
only O
. O


 O
Past O
Medical O
History O
: O

 O
1.)AML O
, O
converted O
from O
MDS O

 O
2.)DM-2 O

 O
3.)COPD O



 O
Social O
History O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
lives O
alone O
. O
  O
His O
sister O
lives O
about O
one O
block O
from O

 O
him O
and O
is O
very O
supportive O
. O
  O
He O
uses O
[ O
* O
* O
Company O
107361 O
* O
* O
] O
the O
ride O
to O
get O
to O

 O
his O
[ O
* O
* O
Hospital1 O
107362 O
* O
* O
] O
clinic O
visits O
. O
  O
He O
lived O
in O
[ O
* O
* O
State O
15946 O
* O
* O
] O
for O
many O
years O

 O
where O
he O
worked O
at O
a O
VA O
. O
  O
He O
also O
has O
worked O
as O
a O
taxi O
driver O
. O

 O
He O
smoked O
for O
many O
years O
but O
quit O
around O
30 O
years O
ago O
. O


 O
Family O
History O
: O

 O
Non-contributory O
. O



 O
Physical O
Exam O
: O

 O
t O
98.4 O
, O
bp O
114/68 O
, O
hr O
88 O
, O
rr O
14 O
, O
spo2 O
95%ra O

 O
gen- O
thin O
older O
male O
, O
appears O
frustrated O
and O
slightly O
confused O

 O
heent- O
anicteric O
sclera O
, O
op O
clear O
with O
mmm O

 O
neck- O
no O
jvd O
, O
no O
lad O
, O
no O
thyromegaly O

 O
cv- O
rrr O
, O
s1s2 O
, O
no O
m/r/g O

 O
pul- O
moves O
air O
well O
, O
occasional O
wheeze O
, O
no O
rales/rhonchi O

 O
abd- O
soft O
, O
nt O
, O
nad O
, O
nabs O
, O
no O
organomegaly O

 O
extrm- O
decreased O
bulk/normal O
tone O
, O
no O
c/c/e O
, O
warm O
dry O

 O
neuro- O
a&ox3 O
( O
knows O
situation O
, O
knows O
having O
trouble O
finding O

 O
words O
) O
; O
language O
: O
pt O
has O
naming O
difficulties O
, O
can O
not O
find O
name O

 O
for O
pen O
, O
chair O
; O
affect O
: O
approriately O
frustrated O
; O
cn O
: O
eomi O
, O

 O
perrl O
, O
facial O
motion/sensation O
intact/symmetric O
, O
tongue O
midline O

 O
and O
without O
fasiculations O
; O
motor O
: O
[ O
* O
* O
4 O
- O
21 O
* O
* O
] O
distal O
strength O
all O
extrm O
, O

 O
4+/5 O
in O
le O
with O
hip O
flexion O
, O
[ O
* O
* O
4 O
- O
21 O
* O
* O
] O
LE O
knee O
flexion/extension O
, O
ue O

 O
[ O
* O
* O
3 O
- O
22 O
* O
* O
] O
proximal O
strenght O
, O
[ O
* O
* O
4 O
- O
21 O
* O
* O
] O
distal O
, O
no O
pronator O
drift O
; O
sensation O

 O
intact O
to O
light O
touch O
throughout O
; O
reflexes O
+ O
2 O
and O
symmetric O

 O
patellar O
, O
ankle O
, O
biceps O
; O
finger O
to O
nose O
normal O
, O
rapid O

 O
alternating O
movements O
normal O
. O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2184 O
- O
10 O
- O
22 O
* O
* O
] O
09:05AM O
BLOOD O
WBC-22.4 O
* O
RBC-3.40 O
* O
Hgb-10.3 O
* O
Hct-30.0 O
* O

 O
MCV-88 O
MCH-30.2 O
MCHC-34.3 O
RDW-14.1 O
Plt O
Ct-6 O
* O
# O

 O
[ O
* O
* O
2184 O
- O
10 O
- O
29 O
* O
* O
] O
12:30AM O
BLOOD O
WBC-15.5 O
* O
RBC-3.20 O
* O
Hgb-9.8 O
* O
Hct-28.9 O
* O

 O
MCV-90 O
MCH-30.6 O
MCHC-33.8 O
RDW-14.4 O
Plt O
Ct-82 O
* O

 O
[ O
* O
* O
2184 O
- O
11 O
- O
9 O
* O
* O
] O
05:45AM O
BLOOD O
WBC-14.9 O
* O
RBC-2.87 O
* O
Hgb-8.7 O
* O
Hct-25.9 O
* O

 O
MCV-91 O
MCH-30.5 O
MCHC-33.7 O
RDW-14.7 O
Plt O
Ct-27 O
* O
# O

 O
[ O
* O
* O
2184 O
- O
11 O
- O
9 O
* O
* O
] O
05:45AM O
BLOOD O
Glucose-83 O
UreaN-29 O
* O
Creat-0.5 O
Na-140 O

 O
K-4.2 O
Cl-100 O
HCO3 O
- O
34 O
* O
AnGap-10 O

 O
[ O
* O
* O
2184 O
- O
11 O
- O
9 O
* O
* O
] O
05:45AM O
BLOOD O
Calcium-10.2 O
Phos-4.6 O
* O
Mg-2.3 O


 O
Brief O
Hospital O
Course O
: O

 O
64 O
y/o O
male O
with O
AML B-REA
progressed O
from O
MDS O
currently O
being O
treated O

 O
with O
hydroxyurea B-DRUG
who O
was O
admitted O
for O
a O
word O
finding O
difficulty O

 O
and O
was O
found O
to O
have O
a O
subdural O
bleed O
in O
the O
setting O
of O

 O
platelets O
of O
six O
. O



 O
1.)Subdural O
bleed O
-- O
The O
patient O
was O
initially O
brought O
up O
to O
a O

 O
platelet O
level O
of O
50 O
and O
observed O
in O
the O
bone O
marrow O
unit O
. O
  O
On O

 O
the O
second O
day O
of O
admission O
, O
he O
experienced O
a O
sudden O
, O
severe O

 O
headache O
and O
had O
a O
stat O
head O
CT O
, O
showing O
no O
definite O
change O
in O

 O
the O
size O
of O
the O
lesion O
or O
the O
degree O
of O
midline O
shift O
, O
yet O
due O

 O
to O
his O
symptoms O
, O
neurosurgery O
was O
consulted O
. O
  O
They O
felt O
it O

 O
appropriate O
to O
take O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
to O
the O
OR O
where O
the O
subdural O

 O
bleed O
was O
drained O
; O
subsequent O
pathology O
demonstrated O
clotted O

 O
blood O
. O
  O
He O
was O
kept O
in O
the O
neurosurgical O
ICU O
for O
two O
days O
where O

 O
he O
did O
well O
with O
no O
post-operative O
complications O
and O
was O
then O

 O
sent O
back O
to O
the O
bone O
marrow O
unit O
for O
further O
care O
. O
  O
By O
his O

 O
return O
to O
BMT O
, O
his O
speech O
and O
confusion O
had O
greatly O
improved O
, O

 O
and O
his O
family O
members O
agreed O
that O
he O
was O
back O
to O
his O
baseline O
. O

 O
Throughout O
the O
remainder O
of O
the O
admission O
, O
he O
continued O
to O

 O
experience O
a O
slight O
headache B-REA
, I-REA
much O
improved O
from O
admission O
, O
that O

 O
was O
well O
relieved O
by O
5 B-STR
mg I-STR
of O
oxycodone B-DRUG
. I-DRUG
  O
His O
word-finding O

 O
symptoms O
did O
not O
recur O
. O

 O
The O
main O
challenge O
was O
maintaining O
his O
platelets O
at O
a O
an O

 O
appropriate O
level O
due O
to O
his O
underlying O
myelodysplastic O

 O
syndrome O
. O
  O
Per O
the O
neurosurgery O
team O
, O
his O
goal O
for O
platelets O
was O

 O
around O
50 O
for O
three O
weeks O
; O
at O
the O
time O
of O
discharge O
, O
he O
will O

 O
require O
an O
additional O
week O
of O
platelets O
at O
this O
level O
, O
usually O

 O
achievable O
by O
giving O
two O
bags O
of O
platelets O
each O
morning O
, O

 O
checking O
a O
post O
transfusion O
count O
30 O
- O
60 O
minutes O
thereafter O
. O

 O
After O
this O
week O
has O
finished O
, O
he O
will O
be O
maintained O
at O
his O
prior O

 O
level O
, O
getting O
transfusion O
two O
to O
three O
times O
per O
week O
at O

 O
[ O
* O
* O
Hospital1 O
1388 O
* O
* O
] O
hematology O
clinic O
under O
the O
care O
of O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
1557 O
* O
* O
] O
. O
  O
He O
will O

 O
follow-up O
with O
his O
hematologist O
, O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
1557 O
* O
* O
] O
, O
for O
his O
AML O
in O
one O

 O
week O
and O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
739 O
* O
* O
] O
, O
a O
neurosurgeon O
, O
in O
two O
weeks O

 O
( O
he O
will O
get O
a O
repeat O
CT O
scan O
at O
that O
time O
) O
. O


 O
2.)AML B-REA
-- O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
is O
being O
treated O
with O
hydroxyurea B-DRUG
and O

 O
transfusions O
as O
needed O
. O
  O
His O
WBC O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ranged O
between O
12 O
and O

 O
28 O
, O
generally O
around O
14 O
. O
  O
His O
goal O
hematocrit O
was O
over O
25 O
, O
and O

 O
he O
generally O
required O
one B-DOS
unit I-DOS
of O
packed B-DRUG
RBC I-DRUG
's I-DRUG
every B-FRE
three I-FRE
to I-FRE

 I-FRE
four I-FRE
days I-FRE
. I-FRE
  O
Platelet O
requirements O
have O
been O
described O
above O
. O



 O
3.)Type B-REA
two I-REA
diabetes I-REA
-- O
The O
prednisone B-DRUG
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
takes O
makes O

 O
his O
blood O
sugars O
somewhat O
difficult O
to O
control O
, O
however O
, O
a O

 O
regimen O
of O
Humalog B-DRUG
75/25 B-STR
with O
45 B-DOS
units I-DOS
every B-FRE
morning I-FRE
and O
25 B-DOS

 I-DOS
units I-DOS
at B-FRE
night I-FRE
seemed O
to O
work O
the O
best O
. O
  O
He O
was O
also O
covered O

 O
with O
a O
routine O
regular B-DRUG
insulin I-DRUG
sliding B-DOS
scale I-DOS
for O
excessively O

 O
high O
values O
( O
usually O
starting O
at O
2 B-DOS
units I-DOS
of O
regular B-DRUG
insulin I-DRUG
for O

 O
a O
glucose O
of O
150 O
- O
200 O
, O
and O
going O
up O
by O
two B-DOS
units I-DOS
of O
insulin B-DRUG
for O

 O
every O
50mg/dl O
of O
blood O
glucose O
increase O
) O
. O


 O
4.)COPD B-REA
-- O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
was O
maintained O
on O
Advair B-DRUG
250/50 B-STR
, I-STR
one B-DOS

 I-DOS
puff B-FOR
twice B-FRE
a I-FRE
day I-FRE
. I-FRE
  O
He O
was O
also O
given O
an O
albuterol B-DRUG
inhaler B-FOR
for O

 O
shortness B-REA
of I-REA
breath/wheezing B-REA
that O
he O
rarely O
needed O
. O
  O
He O
became O

 O
wheezier O
in O
the O
middle O
of O
the O
admission O
, O
and O
was O
given O
twice B-FRE

 I-FRE
daily I-FRE
scheduled O
albuterol B-DRUG
nebs B-FOR
to O
which O
he O
responded O
well O
. O
  O
We O

 O
would O
recommend O
continuing O
these O
for O
two O
more O
days O
, O
then O

 O
stopping O
them O
, O
leaving O
him O
on O
only O
Advair B-DRUG
and O
as O
needed O

 O
albuterol B-DRUG
inhalers B-FOR
. I-FOR


 O
5.)Fever O
-- O
One O
week O
prior O
to O
discharge O
, O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
had O
a O

 O
temperature O
to O
101 O
. O
  O
His O
blood O
and O
urine O
cultures O
were O
negative O
. O

  O
Clinically O
and O
radiographically O
, O
his O
most O
likely O
source O
was O

 O
pulmonary O
, O
although O
the O
chest O
x-ray O
did O
not O
demonstrate O
an O

 O
obvious O
pneumonia B-REA
. I-REA
  O
He O
was O
treated O
with O
levofloxacin B-DRUG
, I-DRUG
and O
will O

 O
finish O
his O
course O
with O
seven B-DUR
more I-DUR
days I-DUR
of O
antibiotics B-DRUG
. I-DRUG


 O
Medications O
on O
Admission O
: O

 O
Humalog B-DRUG
75/25 B-STR
40 B-DOS
units I-DOS
sc B-ROU
every B-FRE
AM I-FRE
and I-FRE
PM I-FRE

 I-FRE
Furosemide B-DRUG
20 B-STR
mg I-STR
po B-ROU
daily B-FRE

 I-FRE
Advair B-DRUG
250/50 B-STR
one B-DOS
puff B-FOR
twice B-FRE
daily I-FRE

 I-FRE
Hydroxyurea B-DRUG
1000 B-STR
mg I-STR
po B-ROU
once B-FRE
daily I-FRE

 I-FRE
Pantoprazole B-DRUG
40 B-STR
mg I-STR
po B-ROU
daily B-FRE

 I-FRE
Prednisone B-DRUG
15 B-STR
mg I-STR
po B-ROU
daily B-FRE


 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Humalog B-DRUG
Mix O
75 B-STR
- I-STR
25 I-STR
75 I-STR
- I-STR
25 I-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Forty B-DOS
Five I-DOS

 I-DOS
( I-DOS
45 I-DOS
) I-DOS
Units I-DOS
Subcutaneous B-ROU
qAM B-FRE
. I-FRE

 O
2 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
0.083 B-STR
% I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Neb B-ROU

 I-ROU
Inhalation I-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*qs O
qs O
* O
Refills:*2 O
* O

 O
3 O
. O
Fexofenadine B-DRUG
HCl I-DRUG
60 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
4 O
. O
Levofloxacin B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q24H B-FRE
( O
every O

 O
24 O
hours O
) O
for B-DUR
7 I-DUR
days I-DUR
. I-DUR

 O
5 O
. O
Furosemide B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
6 O
. O
Fluticasone-Salmeterol B-DRUG
250 B-STR
- I-STR
50 I-STR
mcg/Dose I-STR
Disk B-FOR
with I-FOR
Device I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Puff B-ROU
Inhalation I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
7 O
. O
Hydroxyurea B-DRUG
500 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
8 O
. O
Pantoprazole B-DRUG
Sodium I-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE


 O
9 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
10 O
. O
Oxycodone B-DRUG
HCl I-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q4 B-FRE
- I-FRE
6H I-FRE

 I-FRE
( O
every O
4 O
to O
6 O
hours O
) O
as O
needed O
. O

 O
11 O
. O
Prednisone B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
12 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Heparin B-DRUG
Lock I-DRUG
Flush I-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
100 B-STR
unit/mL I-STR
Syringe B-FOR
Sig O
: O
Two B-DOS

 I-DOS
( I-DOS
2 I-DOS
) I-DOS
Ml I-DOS
Intravenous B-ROU
  O
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE
Ml O

 O
14 O
. O
Humalog B-DRUG
Mix I-DRUG
75 B-STR
- I-STR
25 I-STR
75 I-STR
- I-STR
25 I-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Twenty B-DOS
( I-DOS
20 I-DOS
) I-DOS

 I-DOS
Units I-DOS
Subcutaneous B-ROU
qPM B-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital1 O
700 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
701 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
Subdural O
hematomoa O

 O
Secondary O
: O

 O
Acute O
Myelogenous O
leukemia/Myelodysplastic O
syndrome O

 O
Diabetes O
-- O
type O
two O

 O
COPD O



 O
Discharge O
Condition O
: O

 O
Fair O
, O
with O
improved O
sx O
, O
stable O
hematoma O
, O
requiring O
frequent O

 O
platelet O
transfusions O
. O


 O
Discharge O
Instructions O
: O

 O
Please O
return O
to O
the O
emergency O
department O
for O
fevers/chills O
, O

 O
shortness O
of O
breath O
, O
chest O
pain O
, O
severe O
headaches O
, O
confusion O
, O

 O
speech O
difficulties O
. O


 O
Follow O
up O
as O
below O
. O


 O
Take O
medications O
as O
prescribed O
. O


 O
Followup O
Instructions O
: O

 O
You O
have O
an O
appointment O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
on O
[ O
* O
* O
11 O
- O
19 O
* O
* O
] O
at O
11:30 O
. O

 O
Please O
call O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
107363 O
* O
* O
] O
for O
questions O
. O


 O
Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
1730 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
6175 O
* O
* O
] O
, O
MD O
Where O
: O
[ O
* O
* O
Hospital6 O
29 O
* O
* O
] O

 O
HEMATOLOGY/BMT O
Phone:[**Telephone/Fax O
( O
1 O
) O
3237 O
* O
* O
] O
Date/Time:[**2184 O
- O
11 O
- O
15 O
* O
* O
] O
12:30 O



 O
Please O
call O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
739 O
* O
* O
] O
, O
your O
neurosurgeon O
, O
at O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1669 O
* O
* O
] O

 O
to O
be O
seen O
in O
two O
weeks O
. O
  O
When O
you O
call O
, O
please O
remind O
them O
you O

 O
will O
need O
another O
CT-scan O
of O
your O
head O
prior O
to O
the O
visit O
. O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2178 O
- O
6 O
- O
29 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2178 O
- O
6 O
- O
30 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2133 O
- O
6 O
- O
10 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Fish O
Product O
Derivatives O
/ O
Shellfish O
Derived O
/ O
Peanut O
/ O
Grass O

 O
Pollen-Bermuda O
, O
Standard O
/ O
Mold O
Extracts O
/ O
Cat O
Hair O
Std O
Extract O


 O
Attending:[**Last O
Name O
( O
NamePattern4 O
) O
290 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Dyspnea O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O



 O
History O
of O
Present O
Illness O
: O

 O
45yo O
M O
with O
PMHx O
of O
refractory O
asthma O
with O
> O
100 O
hospitalization O

 O
and O
17 O
past O
intubations O
now O
presenting O
with O
wheezing O
, O
SOB O
, O

 O
worsening O
over O
the O
past O
2 O
days O
. O

 O
Patient O
developed O
cough O
and O
shortness O
of O
breath O
for O
the O
past O

 O
week O
that O
he O
attributes O
to O
the O
hot O
weather O
. O
Over O
the O
past O
2 O

 O
days O
, O
patient O
has O
had O
worsening O
SOB O
and O
wheezing O
, O
not O
managed O

 O
with O
home O
nebulizers O
. O
Prior O
to O
presentation O
in O
the O
ED O
, O
the O

 O
patient O
used O
his O
nebulizers O
6 O
times O
on O
the O
AM O
of O
presentation O

 O
with O
no O
changes O
in O
symptoms O
. O
He O
reports O
that O
he O
increased O
his O

 O
prednisone B-DRUG
dose O
from O
30 B-STR
mg I-STR
daily B-FRE
to O
80 B-STR
mg I-STR
daily B-FRE
3 O
days O
ago O
. O
His O

 O
cough O
is O
productive O
of O
sputum O
, O
described O
as O
clear O
, O
thick O
and O

 O
yellow O
. O
He O
reports O
that O
he O
had O
fever O
of O
99.2 O
1 O
week O
ago O
. O
He O
has O

 O
also O
noticed O
DOE O
, O
which O
the O
patient O
does O
not O
experience O
at O

 O
baseline O
. O

 O
Of O
note O
, O
he O
reports O
that O
his O
wife O
has O
been O
ill O
with O
coughing O
and O

 O
runny O
nose O
. O

 O
Initial O
vitals O
upon O
arrival O
to O
the O
ED O
: O
98.0 O
103 O
153/98 O
22 O
97 O
% O

 O
RA O
. O
In O
the O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
verbal O
report O
, O
the O
patient O
is O
speaking O
in O

 O
full O
sentences O
though O
having O
difficulty O
completing O
full O

 O
sentences O
, O
but O
with O
no O
accessory O
muscle O
use O
and O
no O
tachypnea O
. O

 O
The O
patient O
had O
a O
CXR O
which O
showed O
no O
effusions O
or O

 O
consolidations O
concerning O
for O
PNA O
. O
The O
patient O
was O
given O
2 B-DOS

 I-DOS
Duo-Neb B-DRUG
treatments O
, O
IV B-ROU
magnesium B-DRUG
, I-DRUG
and O
IV B-ROU
solumedrol B-DRUG
125 B-STR
mg I-STR
ONCE B-FRE
. I-FRE



 O
On O
arrival O
to O
the O
MICU O
, O
the O
patient O
is O
feeling O
tired O
, O
but O
denies O

 O
chest O
pain O
, O
chest O
tightness O
, O
shortness O
of O
breath O
, O
abdominal O

 O
pain O
, O
nausea O
, O
or O
vomiting O
. O



 O
Past O
Medical O
History O
: O

 O
- O
Severe O
asthma O
with O
greater O
than O
100 O
hospitalizations O
, O
multiple O

 O
intubations O
( O
17 O
) O
, O
followed O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
in O
pulm O
, O
plan O
to O
refer O



 O
to O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
at O
[ O
* O
* O
Hospital1 O
112 O
* O
* O
] O

 O
- O
OSA O
on O
CPAP O
at O
night O

 O
- O
Avascular B-ADE
necrosis I-ADE
of O
the O
hip O
and O
shoulder O
from O
prolonged O

 O
steroid B-DRUG
use O
, O
status O
post O
hip O
replacement O
( O
[ O
* O
* O
2173 O
* O
* O
] O
) O

 O
- O
GERD O

 O
- O
H/o O
L O
Achilles O
tendon O
rupture O
s/p O
repair O



 O
Social O
History O
: O

 O
Works O
as O
school O
bus O
driver O
. O
Lives O
with O
wife O
and O
one O
of O
his O
three O

 O
children O
. O
Still O
smoking O
1ppd O
. O
Has O
on O
average O
a O
bottle O
of O

 O
wine/week O
when O
he O
can O
afford O
it O
. O
Denies O
ilicits O
. O


 O
Family O
History O
: O

 O
Two O
children O
with O
asthma O
as O
well O
as O
mother O
with O
asthma O
. O



 O
Physical O
Exam O
: O

 O
Admission O
: O

 O
General O
: O
Alert O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
MMM O
, O
oropharynx O
clear O
, O
EOMI O
, O
PERRL O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
CV O
: O
Regular O
rate O
and O
rhythm O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O

 O
gallops O

 O
Lungs O
: O
bilateral O
wheezes O
, O
no O
rales O
, O
ronchi O

 O
Abdomen O
: O
soft O
, O
non-tender O
, O
non-distended O
, O
bowel O
sounds O
present O
, O

 O
no O
organomegaly O

 O
GU O
: O
no O
foley O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
no O
clubbing O
, O
cyanosis O
or O

 O
edema O

 O
Neuro O
: O
CNII-XII O
intact O
, O
5/5 O
strength O
upper/lower O
extremities O
, O

 O
grossly O
normal O
sensation O
, O
2 O
+ O
reflexes O
bilaterally O
, O
gait O

 O
deferred O
, O
finger-to-nose O
intact O


 O
Discharge O
: O
same O
as O
above O
except O
: O

 O
VS O
: O
97 O
% O
RA O
with O
ambulation O

 O
Lungs O
: O
CTAB O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2178 O
- O
6 O
- O
29 O
* O
* O
] O
12:00PM O
BLOOD O
WBC-12.9 O
* O
# O
RBC-5.20 O
Hgb-15.6 O
Hct-47.5 O

 O
MCV-91 O
MCH-30.1 O
MCHC-32.9 O
RDW-13.5 O
Plt O
Ct-310 O

 O
[ O
* O
* O
2178 O
- O
6 O
- O
29 O
* O
* O
] O
12:00PM O
BLOOD O
Neuts-66.4 O
Lymphs-23.8 O
Monos-7.9 O
Eos-1.4 O

 O
Baso-0.6 O

 O
[ O
* O
* O
2178 O
- O
6 O
- O
29 O
* O
* O
] O
12:00PM O
BLOOD O
Glucose-91 O
UreaN-15 O
Creat-1.0 O
Na-140 O

 O
K-5.1 O
Cl-109 O
* O
HCO3 O
- O
21 O
* O
AnGap-15 O

 O
[ O
* O
* O
2178 O
- O
6 O
- O
29 O
* O
* O
] O
01:40PM O
URINE O
Color-Yellow O
Appear-Clear O
Sp O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
-1.027 O

 O
[ O
* O
* O
2178 O
- O
6 O
- O
29 O
* O
* O
] O
01:40PM O
URINE O
Blood-NEG O
Nitrite-NEG O
Protein-TR O

 O
Glucose-NEG O
Ketone-NEG O
Bilirub-NEG O
Urobiln-NEG O
pH-5.5 O
Leuks-NEG O

 O
[ O
* O
* O
2178 O
- O
6 O
- O
29 O
* O
* O
] O
01:40PM O
URINE O
RBC-1 O
WBC-1 O
Bacteri-NONE O
Yeast-NONE O
Epi-0 O

 O
TransE-<1 O

 O
[ O
* O
* O
2178 O
- O
6 O
- O
29 O
* O
* O
] O
01:40PM O
URINE O
CastHy-5 O
* O

 O
[ O
* O
* O
2178 O
- O
6 O
- O
29 O
* O
* O
] O
01:40PM O
URINE O
Mucous-MANY07/02/12 O
1:40 O
pm O
URINE O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2178 O
- O
6 O
- O
30 O
* O
* O
] O
* O
* O



    O
URINE O
CULTURE O
( O
Final O
[ O
* O
* O
2178 O
- O
6 O
- O
30 O
* O
* O
] O
) O
: O
    O
NO O
GROWTH O
. O


 O
CXR O
: O
FINDINGS O
: O
  O
Frontal O
and O
lateral O
views O
of O
the O
chest O
were O

 O
obtained O
. O
  O
The O
heart O
is O
of O
normal O
size O
with O
normal O

 O
cardiomediastinal O
contours O
. O
  O
Bilateral O
streaky O
linear O
perihilar O

 O
opacities O
are O
compatible O
with O
reactive O
airway O
disease O
, O

 O
progressed O
since O
[ O
* O
* O
2175 O
* O
* O
] O
and O
similar O
to O
[ O
* O
* O
2178 O
- O
5 O
- O
16 O
* O
* O
] O
. O
  O
The O
lungs O

 O
are O
otherwise O
clear O
. O
  O
No O
lobar O
consolidation O
, O
pleural O
effusion O
, O

 O
or O
pneumothorax O
. O
  O
The O
osseous O
structures O
are O
unremarkable O
. O
  O
No O

 O
radiopaque O
foreign O
bodies O
. O

 O
IMPRESSION O
: O
  O
Bilateral O
streaky O
perihilar O
opacities O
, O
compatible O

 O
with O
reactive O
airway O
disease O
, O
similar O
to O
[ O
* O
* O
2178 O
- O
5 O
- O
16 O
* O
* O
] O
though O

 O
progressed O
since O
[ O
* O
* O
2176 O
- O
9 O
- O
13 O
* O
* O
] O
. O



 O
Brief O
Hospital O
Course O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
was O
admitted O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
with O
an O
exacerbation O
of O
his O

 O
reactive B-REA
airway I-REA
disease I-REA
, I-REA
asthma O
vs O
COPD O
vs O
bronchiectasis O
. O
He O

 O
was O
started O
on O
standing O
bronchodilator B-DRUG
nebs B-FOR
and O
prednisone B-DRUG
60 B-STR
mg I-STR

 I-STR
daily B-FRE
and O
admitted O
to O
the O
ICU O
. O
His O
CXR O
showed O
no O
PNA O
. O
His O

 O
respiratory O
status O
improved O
dramatically O
in O
the O
next O
24h O
and O
his O

 O
oxygen O
sat O
was O
97 O
% O
RA O
with O
ambulation O
. O
He O
was O
encouraged O
to O
quit O

 O
smoking O
again O
and O
provided O
script O
for O
nicotine B-DRUG
lozenges B-FOR
. I-FOR
He O
was O

 O
discharged O
with O
a O
plan O
to O
taper O
prednisone B-DRUG
in O
the O
following O

 O
manner O
: O
take O
60 B-STR
mg I-STR
x O
4 B-DUR
days I-DUR
, I-DUR
50 B-STR
mg I-STR
x O
4 B-DUR
days I-DUR
, I-DUR
40 B-STR
mg I-STR
x O
4 B-DUR
days I-DUR
, I-DUR
then O

 O
return O
to O
usual O
dose O
of O
30 B-STR
mg I-STR
daily B-FRE
. I-FRE
He O
should O
likely O
have O
a O
high O

 O
res O
CT O
chest O
as O
an O
outpatient O
to O
eval O
for O
bronchiectasis O
. O
He O
may O

 O
also O
have O
an O
element O
of O
COPD O
contributing O
to O
this O
picture O
. O
He O

 O
will O
follow O
up O
with O
PCP O
in O
next O
few O
days O
, O
pulmonary O
next O
month O
. O



 O
Medications O
on O
Admission O
: O

 O
1 O
. O
DuoNeb B-DRUG
( I-DRUG
ipratropium-albuterol I-DRUG
) I-DRUG
0.5 B-STR
mg-3 I-STR
mg(2.5 I-STR
mg I-STR
base)/3 B-DOS
mL I-DOS

 I-DOS
Inhalation B-ROU
Q4H B-FRE
: I-FRE
PRN I-FRE
shortness B-REA
of I-REA
breath I-REA
or O
wheezing B-REA

 I-REA
2 O
. O
fluticasone B-DRUG
220 B-STR
mcg/actuation I-STR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
6 B-DOS
puffs B-ROU
twice B-FRE
a I-FRE

 I-FRE
day I-FRE

 I-FRE
3 O
. O
Fluticasone B-DRUG
Propionate I-DRUG
NASAL B-ROU
1 B-DOS
SPRY B-FOR
NU O
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
4 O
. O
Montelukast B-DRUG
Sodium I-DRUG
10 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
5 O
. O
Loratadine B-DRUG
10 B-STR
mg I-STR
Oral B-ROU
Daily B-FRE

 I-FRE
6 O
. O
Salmeterol B-DRUG
Xinafoate O
Diskus O
( O
50 B-STR
mcg I-STR
) I-STR
1 B-DOS
INH B-ROU
IH O
Q12H B-FRE

 I-FRE
7 O
. O
Omeprazole B-DRUG
20 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
8 O
. O
Tiotropium B-DRUG
Bromide I-DRUG
1 B-DOS
CAP B-FOR
IH B-ROU
DAILY B-FRE
RX O
* O
Spiriva B-DRUG
with O
HandiHaler O

 O
18 B-STR
mcg I-STR
1 B-DOS
cap B-FOR
IH B-ROU
daily B-FRE

 I-FRE
9 O
. O
ProAir B-DRUG
HFA I-DRUG
* I-DRUG
NF I-DRUG
* I-DRUG
( I-DRUG
albuterol I-DRUG
sulfate I-DRUG
) I-DRUG
90 B-STR
mcg/actuation I-STR

 I-STR
Inhalation B-ROU
Q4H B-FRE
: I-FRE
PRN I-FRE
shortness B-REA
of I-REA
breath I-REA
or O
wheezing B-REA

 I-REA
10 O
. O
Nicotine B-DRUG
Lozenge B-FOR
4 B-STR
mg I-STR
PO B-ROU
Q1H B-FRE
: I-FRE
PRN I-FRE
craving B-REA

 I-REA
11 O
. O
PredniSONE B-DRUG
30 B-STR
mg I-STR
PO B-ROU
daily B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
DuoNeb B-DRUG
* O
NF O
* O
( O
ipratropium-albuterol B-DRUG
) I-DRUG
0.5 B-STR
mg-3 I-STR
mg(2.5 I-STR
mg I-STR

 I-STR
base)/3 I-STR
mL I-STR
Inhalation B-ROU
Q4H B-FRE
: I-FRE
PRN I-FRE
shortness B-REA
of I-REA
breath I-REA
or O
wheezing B-REA

 I-REA
RX O
* O
DuoNeb B-DRUG
0.5 B-STR
mg-3 I-STR
mg I-STR
( I-STR
2.5 I-STR
mg I-STR
base)/3 I-STR
mL I-STR
1 B-DOS
nebulizer B-FOR
IH B-ROU
every B-FRE

 I-FRE
four I-FRE
( I-FRE
4 I-FRE
) I-FRE
hours I-FRE
Disp O
# O
* O
60 O
Vial O
Refills:*0 O

 O
2 O
. O
fluticasone B-DRUG
* O
NF O
* O
220 B-STR
mcg/actuation I-STR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
6 B-DOS
puffs B-FOR
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
RX O
* O
Flovent B-DRUG
HFA O
220 B-STR
mcg I-STR
6 B-DOS
puffs B-FOR
IH B-ROU
twice B-FRE
a I-FRE
day I-FRE
Disp O
# O
* O
1 O
Inhaler B-FOR

 I-FOR
Refills:*0 O

 O
3 O
. O
Fluticasone B-DRUG
Propionate I-DRUG
NASAL B-ROU
1 B-DOS
SPRY B-FOR
NU B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
4 O
. O
Montelukast B-DRUG
Sodium I-DRUG
10 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
RX O
* O
Singulair B-DRUG
10 B-STR
mg I-STR
1 B-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
daily B-FRE
Disp O
# O
* O
30 O
Tablet B-FOR

 I-FOR
Refills:*0 O

 O
5 O
. O
Loratadine B-DRUG
* O
NF O
* O
10 B-STR
mg I-STR
Oral B-ROU
Daily B-FRE
Reason O
for O
Ordering O
: O
Wish O
to O

 O
maintain O
preadmission O
medication O
while O
hospitalized O
, O
as O
there O
is O

 O
no O
acceptable O
substitute O
drug O
product O
available O
on O
formulary O
. O

 O
6 O
. O
Salmeterol B-DRUG
Xinafoate I-DRUG
Diskus B-FOR
( O
50 B-STR
mcg I-STR
) I-STR
1 B-DOS
INH B-ROU
IH B-ROU
Q12H B-FRE

 I-FRE
RX O
* O
Serevent B-DRUG
Diskus O
50 B-STR
mcg I-STR
1 B-DOS
discus B-FOR
IH B-ROU
every B-FRE
twelve I-FRE
( I-FRE
12 I-FRE
) I-FRE
hours I-FRE

 I-FRE
Disp O
# O
* O
1 O
Inhaler B-FOR
Refills:*0 O

 O
7 O
. O
Omeprazole B-DRUG
20 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
8 O
. O
Tiotropium B-DRUG
Bromide I-DRUG
1 B-DOS
CAP B-FOR
IH B-ROU
DAILY B-FRE

 I-FRE
RX O
* O
Spiriva B-DRUG
with O
HandiHaler O
18 B-STR
mcg I-STR
1 B-DOS
cap B-FOR
IH B-ROU
daily B-FRE
Disp O
# O
* O
1 O

 O
Inhaler B-FOR
Refills:*0 O

 O
9 O
. O
ProAir B-DRUG
HFA I-DRUG
* O
NF O
* O
( O
albuterol B-DRUG
sulfate I-DRUG
) I-DRUG
90 B-STR
mcg/actuation I-STR

 I-STR
Inhalation B-ROU
Q4H B-FRE
: I-FRE
PRN I-FRE
shortness B-REA
of I-REA
breath I-REA
or O
wheezing B-REA

 I-REA
RX O
* O
albuterol B-DRUG
sulfate I-DRUG
90 B-STR
mcg I-STR
2 B-DOS
puffs B-FOR
IH B-ROU
every B-FRE
four I-FRE
( I-FRE
4 I-FRE
) I-FRE
hours I-FRE

 I-FRE
Disp O
# O
* O
1 O
Inhaler B-FOR
Refills:*0 O

 O
10 O
. O
Nicotine B-DRUG
Lozenge B-FOR
4 B-STR
mg I-STR
PO B-ROU
Q1H B-FRE
: I-FRE
PRN I-FRE
craving B-REA

 I-REA
RX O
* O
nicotine B-DRUG
( I-DRUG
polacrilex I-DRUG
) I-DRUG
4 B-STR
mg I-STR
1 B-DOS
lozenge B-FOR
by B-ROU
mouth I-ROU
every B-FRE
hour I-FRE

 I-FRE
Disp O
# O
* O
120 O
Lozenge B-FOR
Refills:*0 O

 O
11 O
. O
PredniSONE B-DRUG
60 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE

 I-FRE
RX O
* O
prednisone B-DRUG
10 B-STR
mg I-STR
1 B-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
as O
directed O
Disp O
# O
* O
91 O

 O
Tablet B-FOR
Refills:*0 O

 O
RX O
* O
prednisone B-DRUG
10 B-STR
mg I-STR
1 B-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
as O
directed O
Disp O
# O
* O
100 O

 O
Tablet B-FOR
Refills:*0 O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
1 O
. O
Asthma/COPD O
exacerbation O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
hospital O
with O
difficulty O
breathing O
. O

 O
This O
was O
likely O
due O
to O
an O
exacerbation O
of O
your O
asthma O
. O
You O
may O

 O
also O
have O
COPD O
, O
another O
chronic O
lung O
disease O
. O
It O
is O
important O

 O
you O
take O
all O
of O
your O
breathing O
medications O
every O
day O
. O
You O
should O

 O
stop O
smoking O
to O
avoid O
having O
more O
of O
these O
episodes O
. O

 O
. O


 O
Some O
of O
your O
medications O
were O
changed O
during O
this O
admission O
: O

 O
START O
prednisone B-DRUG
taper B-DOS
, I-DOS
take O
60 B-STR
mg I-STR
daily B-FRE
for B-DUR
one I-DUR
week I-DUR
, I-DUR
then O
40 B-STR
mg I-STR

 I-STR
daily B-FRE
for B-DUR
one I-DUR
week I-DUR
, I-DUR
then O
20 B-STR
mg I-STR
daily B-FRE
for B-DUR
one I-DUR
week I-DUR
, I-DUR
then O
10 B-STR
mg I-STR

 I-STR
daily B-FRE
for B-DUR
one I-DUR
week I-DUR
. I-DUR

 O
. O

 O
You O
should O
continue O
to O
take O
all O
of O
your O
other O
medications O
as O

 O
prescribed O
. O


 O
Followup O
Instructions O
: O

 O
You O
should O
have O
a O
follow O
up O
appointment O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
within O

 O
the O
next O
3 O
days O
. O
Please O
call O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2010 O
* O
* O
] O
to O
schedule O
this O

 O
appointment O
when O
you O
get O
home O
today O
. O


 O
Department O
: O
PULMONARY O
FUNCTION O
LAB O

 O
When O
: O
WEDNESDAY O
[ O
* O
* O
2178 O
- O
8 O
- O
5 O
* O
* O
] O
at O
10:20 O
AM O

 O
With O
: O
PULMONARY O
FUNCTION O
LAB O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
609 O
* O
* O
] O

 O
Building O
: O
[ O
* O
* O
Hospital6 O
29 O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O


 O
Department O
: O
MEDICAL O
SPECIALTIES O

 O
When O
: O
WEDNESDAY O
[ O
* O
* O
2178 O
- O
8 O
- O
5 O
* O
* O
] O
at O
10:40 O
AM O

 O
With O
: O
[ O
* O
* O
Known O
firstname O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
, O
M.D. O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
612 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O


 O
Department O
: O
PFT O

 O
When O
: O
WEDNESDAY O
[ O
* O
* O
2178 O
- O
8 O
- O
5 O
* O
* O
] O
at O
10:40 O
AM O



                              O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(1 O
) O
292 O
* O
* O
] O


 O

Admission O
Date O
: O
  O
[ O
* O
* O
2194 O
- O
10 O
- O
16 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2194 O
- O
11 O
- O
13 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2119 O
- O
1 O
- O
20 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
668 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Right O
adrenal O
tumor O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Exploratory O
laparotomy O
, O
right O
adrenalectomy O
and O
right O
segment O
6 O

 O
resection O



 O
History O
of O
Present O
Illness O
: O

 O
The O
patient O
is O
a O
75 O
y/o O
female O
who O
presents O
with O
a O
right O
adrenal O

 O
mass O
. O
  O
The O
patient O
has O
been O
progressively O
feeling O
unwell O
since O

 O
[ O
* O
* O
Month O
( O
only O
) O
116 O
* O
* O
] O
. O
  O
After O
sustaining O
a O
fall O
, O
the O
patient O
started O
to O
have O

 O
worsening O
weakness O
and O
fatigue O
that O
she O
needed O
to O
start O
using O
a O

 O
walker O
to O
ambulate O
and O
had O
difficulty O
getting O
out O
of O
chairs O
. O

 O
She O
also O
reports O
increased O
facial O
hair O
in O
the O
past O
six O
months O
. O

 O
On O
imaging O
, O
the O
patient O
had O
a O
10 O
x O
7 O
cm O
right O
adrenal O
mass O
. O

 O
Further O
workup O
revealed O
that O
the O
patient O
had O
hypercortisolism O
. O

 O
On O
review O
of O
systems O
, O
the O
patient O
complains O
of O
pain O
and O

 O
increased O
difficulty O
in O
performing O
her O
activities O
of O
daily O

 O
living O
. O
  O
The O
patient O
denies O
weight O
loss O
or O
weight O
gain O
. O

 O
Although O
, O
her O
obesity O
has O
become O
more O
central O
in O
nature O
and O
she O

 O
has O
had O
loss O
of O
hair O
on O
her O
scalp O
, O
while O
having O
increased O
facial O

 O
hair O
. O
  O
She O
also O
reports O
increased O
bruising O
along O
her O

 O
extremities O
, O
some O
shortness O
of O
breath O
on O
exertion O
, O
thinning O
of O

 O
her O
skin O
, O
and O
decreased O
energy O
. O
  O
The O
patient O
denies O
fever O
, O

 O
chills O
, O
chest O
pain O
, O
palpitations O
, O
abdominal O
pain O
, O

 O
nausea/vomiting O
, O
diarrhea O
, O
constipation O
, O
or O
dysuria O
. O



 O
Past O
Medical O
History O
: O

 O
colon B-REA
Ca I-REA
s/p O
partial O
colectomy O
and O
adjuvant O
chemo B-DRUG
- O
8y O
ago O

 O
HTN O

 O
CCY O
[ O
* O
* O
2184 O
* O
* O
] O

 O
adrenal O
mass O

 O
mitral O
valve O
prolapse O


 O
Social O
History O
: O

 O
Lives O
alone O
in O
NJ O
, O
here O
living O
with O
daughter O
while O
undergoes O

 O
further O
evaluation O
and O
mgmt O
. O
  O
Denies O
tobacco O
( O
< O
100 O
lifetime O

 O
cigarettes O
) O
, O
social O
EtOH O
, O
no O
IVDU O
. O
  O
Has O
3 O
daughters O
and O
2 O
sons O



 O
Family O
History O
: O

 O
DM O
in O
both O
brothers O
and O
both O
parents O
; O
F O
- O
prostate O
and O
liver O
Ca O
; O

 O
uncle O
- O
gastric O
Ca O



 O
Physical O
Exam O
: O

 O
T O
96.3 O
  O
P O
66 O
  O
BP O
176/90 O
  O
R O
20 O
  O
SaO2 O
95 O
% O
RA O

 O
Gen O
- O
no O
acute O
distress O
, O
well-appearing O
, O
upper O
lip O
hirsutism O

 O
Heent O
- O
facial O
hirsutism O
, O
no O
scleral O
icterus O
, O
moist O
mucous O

 O
membranes O

 O
Lungs O
- O
clear O
to O
auscultation O
bilaterally O

 O
heart O
- O
regular O
rate O
and O
rhythm O

 O
abd O
- O
obese O
, O
soft O
, O
nontender O
, O
nondistended O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2194 O
- O
10 O
- O
16 O
* O
* O
] O
08:08PM O
URINE O
  O
COLOR-Yellow O
APPEAR-Clear O
SP O
[ O
* O
* O
Last O
Name O
( O
un O
) O
155**]-1.010 O

 O
[ O
* O
* O
2194 O
- O
10 O
- O
16 O
* O
* O
] O
08:08PM O
URINE O
  O
BLOOD-TR O
NITRITE-NEG O
PROTEIN-NEG O

 O
GLUCOSE-TR O
KETONE-NEG O
BILIRUBIN-NEG O
UROBILNGN-NEG O
PH-7.0 O

 O
LEUK-NEG O

 O
[ O
* O
* O
2194 O
- O
10 O
- O
16 O
* O
* O
] O
08:08PM O
URINE O
  O
RBC-0 O
- O
2 O
WBC-1 O
BACTERIA-RARE O
YEAST-NONE O

 O
EPI-0 O
- O
2 O

 O
[ O
* O
* O
2194 O
- O
10 O
- O
16 O
* O
* O
] O
08:08PM O
URINE O
  O
AMORPH-FEW O

 O
[ O
* O
* O
2194 O
- O
10 O
- O
16 O
* O
* O
] O
05:30PM O
   O
GLUCOSE-124 O
* O
UREA O
N-19 O
CREAT-0.4 O
SODIUM-142 O

 O
POTASSIUM-2.9 O
* O
CHLORIDE-98 O
TOTAL O
CO2 O
- O
33 O
* O
ANION O
GAP-14 O

 O
[ O
* O
* O
2194 O
- O
10 O
- O
16 O
* O
* O
] O
05:30PM O
   O
CALCIUM-9.2 O
PHOSPHATE-3.1 O
MAGNESIUM-1.8 O

 O
[ O
* O
* O
2194 O
- O
10 O
- O
16 O
* O
* O
] O
05:30PM O
   O
WBC-7.3 O
RBC-3.63 O
* O
HGB-11.8 O
* O
HCT-33.6 O
* O
MCV-93 O

 O
MCH-32.5 O
* O
MCHC-35.0 O
RDW-16.4 O
* O

 O
[ O
* O
* O
2194 O
- O
10 O
- O
16 O
* O
* O
] O
05:30PM O
   O
PLT O
COUNT-231 O

 O
[ O
* O
* O
2194 O
- O
10 O
- O
16 O
* O
* O
] O
05:30PM O
   O
PT-10.8 O
PTT-19.1 O
* O
INR(PT)-0.9 O



 O
Brief O
Hospital O
Course O
: O

 O
She O
was O
taken O
to O
the O
OR O
by O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
for O
exploratory O

 O
laparotomy O
, O
right O

 O
adrenalectomy O
and O
right O
hepatic O
segment O
6 O
resection O
. O
Please O
see O

 O
operative O
report O
for O
details O
. O
EBL O
was O
3 O
liters O
. O
An O
introp O
U/S O

 O
revealed- O
liver O
echogenicity O
appeared O
unremarkable O
. O
Within O
the O

 O
posterior O
segment O
of O
the O
right O
lobe O
of O
the O
liver O
, O
there O
was O
s O
a O

 O
5.5 O
x O
3.3 O
cm O
well- O
circumscribed O
, O
slightly O
hypoechoic O
lesion O

 O
that O
contained O
a O
degree O
of O
increased O
through O
transmission O

 O
suggesting O
at O
least O
some O
cystic O
components O
. O
The O
relationship O
of O

 O
this O
to O
the O
surrounding O
vasculature O
, O
particularly O
the O
posterior O

 O
branch O
of O
the O
right O
portal O
vein O
was O
demonstrated O
. O
No O
other O

 O
additional O
lesions O
were O
found O
. O
Two O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
drains O
were O
removed O
by O

 O
postop O
day O
5 O
. O
Pathology O
returned O
positive O
for O
1 O
. O
Right O
adrenal O

 O
mass O
, O
excision O
( O
A-F O
) O
: O

 O
Malignant O
neoplasm O
most O
consistent O
with O
adrenal O
cortical O

 O
carcinoma O
, O
see O
note O
. O

 O
2 O
. O
Liver O
segment O
six O
, O
resection O
( O
G-O O
) O
: O

 O
Malignant O
neoplasm O
most O
consistent O
with O
adrenal O
cortical O

 O
carcinoma O
, O
see O
note O
. O
Endocrinology O
was O
to O
follow O
and O
the O
plan O

 O
was O
to O
use O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
as O
an O
outpatient O
. O


 O
Postop O
she O
was O
in O
the O
SICU O
for O
fluid O
management O
and O
ATN O
. O

 O
Baseline O
creatinine O
was O
0.6 O
. O
Nephrology O
was O
consulted O
. O

 O
Creatinine O
trended O
down O
to O
1.1 O
by O
POD O
8 O
. O
Renal O
u/s O
was O
normal O
. O

 O
Stress O
dose O
steroids B-DRUG
were O
given O
preop O
and O
postop O
per O

 O
Endocrinology O
. O
Endocrinology O
preferred O
a O
slow O
6 B-DUR
month I-DUR
steroid B-DRUG

 I-DRUG
taper B-DOS
. I-DOS
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
tapered B-DOS
prednisone B-DRUG
after O
one B-DUR
week I-DUR
as O
she O

 O
developed O
an O
incision O
infection O
necessitating O
opening O
the O

 O
incision O
and O
using O
a O
wound O
vac O
. O
  O
A O
CT O
of O
the O
abd O
was O
done O
on O

 O
which O
demonstrated O
Two O
ill-defined O
fluid O
collections O

 O
post-surgical O
site O
that O
were O
extrahepatic O
and O
could O
represent O

 O
postoperative O
seromas O
, O
bilomas O
, O
or O
less O
likely O
abscesses O
. O

 O
Multiple O
scattered O
foci O
of O
air O
, O
likely O
postoperative O
. O
2 O
. O

 O
Increased O
stranding O
about O
the O
head O
of O
the O
pancreas O
, O
possibly O

 O
pancreatitis O
. O
3 O
. O
Bibasilar O
atelectasis O
and O
small O
right O
pleural O

 O
effusion O
. O
Amylase O
and O
lipase O
were O
normal O
. O
LFTs O
preop O
were O
ast O

 O
1298 O
, O
alt O
1308 O
, O
alk O
phos O
64 O
and O
tbili O
0.7 O
. O
These O
trended O
down O

 O
postop O
with O
the O
exception O
of O
the O
alk O
phos O
which O
increased O
to O
as O

 O
high O
as O
806 O
on O
HD O
20 O
. O
Subsequently O
, O
this O
has O
decreased O
some O
to O

 O
504 O
as O
of O
[ O
* O
* O
11 O
- O
13 O
* O
* O
] O
. O



 O
She O
required O
PICC O
line O
placement O
for O
IV B-ROU
antibiotics B-DRUG
and O
TPN O
as O

 O
her O
kcals O
were O
insufficient O
. O
Her O
appetite O
was O
diminished O
. O
She O

 O
appeared O
apathetic O
on O
many O
days O
and O
expressed O
feelings O
of O

 O
sadness O
. O
Psychiatry O
saw O
her O
and O
agreed O
with O
the O
team O
that O
she O

 O
was O
experiencing O
intermittent O
delerium O
. O
There O
was O
concern O
that O

 O
she O
was O
experiencing O
the O
effects O
of O
less O
cortisol O
. O
Neurology O

 O
recommended O
a O
CT O
and O
EEG O
. O
  O
A O
head O
CT O
was O
done O
for O
waxing/[**Doctor O
Last O
Name O
688 O
* O
* O
] O

 O
mental O
status O
. O
This O
was O
negative O
for O
bleed/mass O
on O
[ O
* O
* O
10 O
- O
29 O
* O
* O
] O
. O
An O
EEG O

 O
was O
performed O
which O
demonstrated O
mild O
encephalopathy O
. O
TSH O
was O

 O
3.4 O
. O
  O
Psychiatry O
did O
not O
recommend O
antidepressents B-DRUG
or O
stimulants O

 O
at O
the O
time O
. O


 O
On O
CT O
a O
right O
pleural O
effusion O
was O
noted O
. O
She O
experienced O
desats O

 O
and O
sob O
. O
Pleuracentesis O
was O
performed O
on O
[ O
* O
* O
11 O
- O
6 O
* O
* O
] O
( O
HD O
20)with O
a O

 O
negative O
culture O
. O
A O
f/u O
cxr O
was O
improved O
and O
without O

 O
pneumothorax O
. O


 O
She O
developed O
a O
Klebsiella B-REA
uti I-REA
which O
was O
treated O
with O
Cipro B-DRUG
and O

 O
Flagyl B-DRUG
for O
the O
wound B-REA
x O
4 B-DUR
days I-DUR
. I-DUR
These O
antibiotics O
were O
switched O

 O
to O
Vanco B-DRUG
and O
Meropenum B-DRUG
when O
a O
wound B-REA
culture I-REA
identified O
strep O

 O
veridans O
, O
sparse O
yeast O
, O
Klebsiella O
which O
was O
pan O
sensitive O
and O

 O
staph O
coag O
positive O
resistent O
to O
levo/oxicillin/penicillin B-DRUG
and O

 O
sensitive O
to O
vanco B-DRUG
. I-DRUG
Vanco B-DRUG
levels O
were O
monitored O
. O
Creatinine O

 O
remained O
stable O
. O
She O
developed O
a O
2nd O
UTI O
, O
yeast O
which O
was O
treated O

 O
with O
a O
GU O
Ampho O
bladder O
irrigant O
x3 O
days O
. O
This O
was O
due O
to O
finish O

 O
on O
[ O
* O
* O
11 O
- O
13 O
* O
* O
] O
pm O
. O
Repeat O
u/a O
and O
cx O
were O
sent O
on O
[ O
* O
* O
11 O
- O
13 O
* O
* O
] O
. O


 O
A O
repeat O
abd O
CT O
revealed O
stable O
appearance O
of O
hepatic O
fluid O

 O
collections O
with O
some O
debris O
and O
air O
in O
the O
surgical O
bed O
. O

 O
Bibasilar O
atelectasis O
with O
stable O
right O
pleural O
effusion O
. O

 O
Stable O
appearance O
of O
right O
abdominal O
wall O
defect O
overlying O

 O
surgical O
site O
. O
Interval O
development O
of O
nonocclusive O
thrombus O

 O
within O
the O
intrahepatic O
inferior O
vena O
cava O
. O
She O
was O
started O
on O

 O
coumadin B-DRUG
and O
IV B-ROU
heparin B-DRUG
until O
she O
was O
therapeutic O
. O
INR O
Goal O
was O

 O
[ O
* O
* O
1 O
- O
31 O
* O
* O
] O
. O
INR O
on O
[ O
* O
* O
11 O
- O
13 O
* O
* O
] O
was O
2.6 O



 O
On O
[ O
* O
* O
11 O
- O
12 O
* O
* O
] O
after O
taking O
off O
the O
vac O
and O
reviewing O
the O
CT O
, O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
406 O
* O
* O
] O

 O
drain O
was O
inserted O
thru O
the O
wound O
into O
a O
peri-hepatic O
collection O

 O
and O
placed O
to O
bulb O
suction O
. O
  O
Water O
soluble O
contrast O
was O

 O
administered O
at O
the O
bedside O
through O
this O
catheter O
. O
Contrast O
was O

 O
administered O
. O
Contrast O
was O
seen O
surrounding O
this O
wound O
and O

 O
draining O
along O
the O
right O
lateral O
aspect O
of O
the O
wound O
into O

 O
dressing O
, O
however O
, O
no O
definite O
communication O
into O
the O
abdominal O

 O
cavity O
noted O
. O
Midline O
chevron O
scar O
and O
multiple O
clips O
scattered O

 O
across O
the O
abdomen O
were O
seen O
. O
Remainder O
of O
abdomen O
was O
gasless O
. O

 O
Small O
amount O
of O
oral B-ROU
contrast B-DRUG
seen O
in O
the O
rectum O
. O
  O
She O
then O

 O
underwent O
successful O
drainage O
catheter O
placement O
in O
collection O

 O
in O
the O
subhepatic O
and O
hepatic O
areas O
on O
[ O
* O
* O
2194 O
- O
11 O
- O
12 O
* O
* O
] O
. O


 O
The O
plan O
is O
for O
her O
to O
go O
to O
[ O
* O
* O
Hospital O
100 O
* O
* O
] O
Rehab O
on O
TPN O
via O
a O
R O
picc O

 O
with O
a O
RUQ O
incision O
wound O
vac O
. O
She O
has O
2 O
hepatic O
drains O
to O

 O
gravity O
drainage O
and O
meropenum/vanco B-DRUG
will O
continue O
until O
next O

 O
week O
. O
She O
will O
follow O
up O
with O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
on O
[ O
* O
* O
11 O
- O
17 O
* O
* O
] O
and O

 O
with O
endocrinology O
as O
an O
outpatient O
. O


 O
Please O
schedule O
GYN O
follow O
up O
of O
postmenopausal O
bleeding O
noted O

 O
on O
POD O
# O
5.Pelvic O
U/S O
( O
prelim O
report O
) O
- O
Study O
v. O
limited O
as O

 O
patient O
was O
not O
able O
to O
achieve O
proper O
positioning O
; O
uterus O
8.0 O
x O

 O
4.4 O
x O
4.5 O
cm O
; O
endometrium O
is O
not O
well O
visualized O
; O
ovaries O
not O

 O
visualized O
. O
She O
experienced O
minimal O
spotting O
while O
hospitalized O
. O




 O
Medications O
on O
Admission O
: O

 O
hydralazine B-DRUG
25q8 B-FRE
, I-FRE
HCTZ B-DRUG
25 B-STR
, I-STR
KCl B-DRUG
40 B-STR
" I-STR


 O
Discharge O
Medications O
: O

 O
1 O
. O
Hydralazine B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q8H B-FRE
( I-FRE
every I-FRE
8 I-FRE

 I-FRE
hours I-FRE
) I-FRE
: I-FRE
hold O
for O
sbp O
< O
140 O
. O

 O
2 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( O
E.C. O
) O
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( O
E.C. O
) O
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Oxycodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
325 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU

 I-ROU
Q4 B-FRE
- I-FRE
6H I-FRE
( I-FRE
every I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
4 O
. O
Furosemide B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE



 O
5 O
. O
Ciprofloxacin B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q12H B-FRE

 I-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
for B-DUR
4 I-DUR
doses I-DUR
. I-DUR

 O
6 O
. O
Insulin B-DRUG
Lispro I-DRUG
( I-DRUG
Human I-DRUG
) I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
follow O

 O
sliding B-DOS
scale I-DOS
  O
Subcutaneous B-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
. I-FRE

 O
7 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q4 B-FRE
- I-FRE
6H I-FRE
( I-FRE
every I-FRE

 I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
8 O
. O
Bimatoprost B-DRUG
0.03 B-STR
% O
Drops B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Ophthalmic B-ROU
  O
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Prednisone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
10 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
2.5 B-DOS
Tablets B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Miconazole B-DRUG
Nitrate I-DRUG
2 O
% O
Powder B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU
  O
TID B-FRE

 I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
: I-FRE
peri O
area O
. O

 O
12 O
. O
Warfarin B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
: I-FRE

 O
check O
INR O
twice O
weekly O
. O
goal O
[ O
* O
* O
1 O
- O
31 O
* O
* O
] O
. O

 O
13 O
. O
Vancomycin B-DRUG
in I-DRUG
Dextrose I-DRUG
1 B-STR
g/200 I-STR
mL I-STR
Piggyback B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Intravenous B-ROU
  O
Q B-FRE
24H I-FRE
( I-FRE
Every I-FRE
24 I-FRE
Hours I-FRE
) I-FRE
: I-FRE
check O
vanco O
level O
twice O

 O
weekly O
. O

 O
14 O
. O
Meropenem B-DRUG
500 B-STR
mg I-STR
Recon B-FOR
Soln I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Recon B-FOR
Soln I-FOR

 I-FOR
Intravenous B-ROU
  O
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
15 O
. O
Heparin B-DRUG
Lock I-DRUG
Flush I-DRUG
( O
Porcine B-DRUG
) I-DRUG
100 B-STR
unit/mL I-STR
Syringe B-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
ML B-FOR
Intravenous B-ROU
  O
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
: I-FRE
per O
picc O
line O

 O
protocol O
. O

 O
16 O
. O
Outpatient O
Lab O
Work O

 O
Labs O
every O
Monday O
and O
Thursday O
for O
cbc O
, O
chem O
10 O
, O
ast O
, O
alt O
, O
alk O

 O
phos O
, O
t.bili O
, O
albumin O
and O
inr O
. O
Fax O
to O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
697 O
* O
* O
] O
attn O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
, O
RN O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
459 O
* O
* O
] O
for O
the O
Aged O
- O
MACU O


 O
Discharge O
Diagnosis O
: O

 O
R O
adrenal O
mass O

 O
Hepatic O
collections O

 O
IVC O
thrombus O

 O
malnutrition O

 O
UTI O
, O
yeast O

 O
pleural O
effusion O

 O
ARF O
, O
resolved O

 O
post O
menopausal O
bleeding O



 O
Discharge O
Condition O
: O

 O
good O



 O
Discharge O
Instructions O
: O

 O
Call O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
673 O
* O
* O
] O
if O
fevers O
, O
chills O
, O
nausea O
, O

 O
vomiting O
, O
incision O
red/bleeding O
or O
draining O
pus O
, O
wound O
drain O

 O
dislodges O
, O
foul O
smelling O
wound O
or O
increased O
wound O
drainage O
, O

 O
increased O
shortness O
of O
breath O
. O



 O
Followup O
Instructions O
: O

 O
weekProvider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
1330 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
673 O
* O
* O
] O

 O
Date/Time:[**2194 O
- O
11 O
- O
17 O
* O
* O
] O
11:30 O

 O
please O
schedule O
follow O
up O
with O
Dr O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
574 O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
6468 O
* O
* O
] O

 O
( O
Endocrinology O
) O
in O
1 O
week O
. O
Attempt O
Monday O
appointment O

 O
GYN O
follow O
up O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2664 O
* O
* O
] O
& O
schedule O
TVU/S O
as O
outpt O
prior O
to O

 O
apt O
. O




 O
Completed O
by:[**2194 O
- O
11 O
- O
13 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2159 O
- O
9 O
- O
24 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2159 O
- O
9 O
- O
29 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2114 O
- O
3 O
- O
15 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
OBSTETRICS/GYNECOLOGY O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
6743 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
dysgerminoma O
of O
the O
right O
ovary O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
diagnostic O
laparoscopy O

 O
total O
abdominal O
hysterectomy O

 O
left O
salpingoopherectomy O

 O
pelvic O
and O
para-aortic O
lymph O
node O
dissection O

 O
omentectomy O

 O
cystoscopy O



 O
History O
of O
Present O
Illness O
: O

 O
This O
is O
a O
45 O
yo O
P0 O
who O
presented O
following O
discovery O
of O

 O
disgerminoma O
of O
the O
right O
ovary O
. O
  O
Dr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
was O
in O

 O
her O
usual O
state O
of O
good O
health O
until O
[ O
* O
* O
2159 O
- O
6 O
- O
12 O
* O
* O
] O
. O
  O
She O

 O
presented O
at O
that O
time O
to O
[ O
* O
* O
Hospital O
1559 O
* O
* O
] O
Medical O
Center O
with O
acute O

 O
severe O
abdominopelvic O
pain O
. O
  O
She O
was O
found O
to O
have O
a O
torsion O
of O

 O
the O
right O
ovary O
and O
underwent O
an O
emergent O
exploratory O

 O
laparotomy O
, O

 O
right O
salpingo-oophorectomy O
. O
  O
Final O
pathology O
revealed O
a O
15 O
cm O

 O
serous O
cystadenoma O
of O
the O
ovary O
with O
a O
1 O
cm O
disgerminoma O
of O
the O

 O
ovary O
focussed O
within O
the O
center O
. O
  O
She O
had O
this O
surgery O
through O

 O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
22790 O
* O
* O
] O
incision O
and O
has O
healed O
well O
from O
that O
surgery O
. O

 O
Pathology O
has O
been O
read O
here O
at O
[ O
* O
* O
Hospital1 O
188 O
* O
* O
] O
. O
  O
The O
disgerminoma O
is O
identified O
as O
well O
as O
the O
serous O

 O
cyst O
. O
  O
The O
report O
was O
that O
the O
ovary O
was O
intact O
without O
surface O

 O
involvement O
. O
  O
The O
serous O
cyst O
was O
separate O
. O
  O
The O
patient O
has O
had O

 O
laboratory O
evaluations O
performed O
postoperatively O
and O
these O

 O
include O
an O
LDH O
level O
which O
is O
normal O
, O
an O
inhibin O
level O
which O

 O
evidently O
was O
normal O
, O
hCG O
level O
normal O
. O
  O
She O
had O
normal O
liver O

 O
function O
tests O
and O
blood O
counts O
as O
well O
. O
  O
She O
has O
been O
advised O

 O
after O
an O
evaluation O
at O
the O
[ O
* O
* O
Hospital O
1559 O
* O
* O
] O
Medical O
Center O
to O
undergo O
a O

 O
staging O
laparotomy O
including O
hysterectomy O
, O
left O



 O
Past O
Medical O
History O
: O

 O
PAST O
MEDICAL O
HISTORY O
: O
  O
She O
is O
relatively O
healthy O
. O
  O
She O
denies O

 O
any O

 O
history O
of O
asthma O
, O
hypertension O
, O
mitral O
valve O
prolapse O
, O
or O

 O
thromboembolic O
disorder O
. O
  O
With O
respect O
to O
screening O
evaluations O
, O

 O
she O
reports O
being O
up-to-date O
with O
respect O
to O
colonoscopy O
and O

 O
mammography O
. O
  O
She O
does O
suffer O
from O
GERD B-REA
, I-REA
for O
which O
she O
uses O

 O
Prilosec B-DRUG
. I-DRUG



 O
PAST O
SURGICAL O
HISTORY O
: O
  O
As O
above O
. O
  O
She O
also O
underwent O
an O

 O
appendectomy O
at O
the O
age O
of O
13 O
. O


 O
OB/GYN O
HISTORY O
: O
  O
She O
is O
a O
gravida O
0 O
. O
  O
She O
has O
two O
adopted O

 O
children O
. O
  O
She O
reports O
irregular O
menstrual O
cycles O
, O
which O
are O

 O
moderate O
to O
heavy O
in O
flow O
. O
  O
They O
last O
five O
days O
. O
  O
Her O
last O
was O

 O
on O

 O
[ O
* O
* O
7 O
- O
27 O
* O
* O
] O
. O
  O
She O
denies O
any O
history O
of O
pelvic O
infections O
or O
abnormal O

 O
Pap O

 O
smears O
and O
her O
last O
was O
obtained O
in O
12/[**2156 O
* O
* O
] O
. O
  O
She O
denies O
any O

 O
history O
of O
gynecological O
problems O
. O



 O
Social O
History O
: O

 O
Neurologist O
in O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
within O
the O
[ O
* O
* O
Hospital3 O
* O
* O
] O
system O
. O
  O
Denies O

 O
tobacco O
or O
illict O
drug O
use O
. O
  O
Occasional O
alcohol O
use O
. O
  O
She O
lives O

 O
with O
her O

 O
husband O
and O
two O
adopted O
children O
. O
  O
She O
denies O
any O
history O
of O

 O
verbal O
, O
physical O
, O
or O
sexual O
abuse O
. O


 O
Family O
History O
: O

 O
She O
reports O
her O
father O
had O
[ O
* O
* O
Name2 O
( O
NI O
) O
499 O
* O
* O
] O
cancer O
at O
the O

 O
age O
of O
59 O
. O
  O
There O
is O
no O
other O
family O
history O
of O
cancer O
. O



 O
Physical O
Exam O
: O

 O
At O
the O
time O
of O
preoperative O
visit O
: O


 O
GENERAL O
: O
  O
She O
appears O
her O
stated O
age O
, O
in O
no O
apparent O
distress O
. O

 O
HEENT O
: O
  O
Normocephalic O
, O
atraumatic O
. O
  O
Oral O
mucosa O
without O
evidence O

 O
of O
thrush O
or O
mucositis O
. O
  O
Eyes O
, O
sclerae O
are O
anicteric O
. O

 O
NECK O
: O
  O
Supple O
. O
  O
There O
are O
no O
masses O
. O

 O
LYMPHATICS O
: O
  O
Lymph O
node O
survey O
, O
negative O
cervical O
, O

 O
supraclavicular O
, O
axillary O
, O
or O
inguinal O
adenopathy O
. O

 O
CHEST O
: O
  O
Lungs O
clear O
. O

 O
HEART O
: O
  O
Regular O
rate O
and O
rhythm O
. O

 O
BACK O
: O
  O
No O
spinal O
or O
CVA O
tenderness O
. O

 O
ABDOMEN O
: O
  O
Soft O
, O
nontender O
, O
nondistended O
. O
  O
There O
are O
no O
palpable O

 O
masses O
. O
  O
There O
is O
no O
hepato O
or O
splenomegaly O
. O
  O
There O
is O
no O
fluid O

 O
wave O
. O
  O
A O
well-healed O
incision O
is O
noted O
. O

 O
EXTREMITIES O
: O
  O
There O
is O
no O
clubbing O
, O
cyanosis O
, O
or O
edema O
. O

 O
PELVIC O
: O
  O
Normal O
external O
genitalia O
. O
  O
Inner O
labia O
minora O
are O

 O
normal O
. O
  O
Urethral O
meatus O
normal O
. O
  O
Speculum O
is O
placed O
. O
  O
The O
walls O

 O
of O
the O
vagina O
are O
normal O
. O
  O
Apex O
is O
normal O
. O
  O
Cervix O
is O
normal O
. O

 O
Bimanual O
exam O
reveals O
no O
mass O
or O
lesion O
. O


 O
At O
the O
time O
of O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
transfer O
: O



 O
General O
Appearance O
: O
Well O
nourished O
, O
Overweight O
/ O
Obese O
, O
full O

 O
neck O

 O
Eyes O
/ O
Conjunctiva O
: O
PERRL O

 O
Head O
, O
Ears O
, O
Nose O
, O
Throat O
: O
Normocephalic O
, O
orbital O
edema O

 O
Lymphatic O
: O
Cervical O
WNL O
, O
Supraclavicular O
WNL O

 O
Cardiovascular O
: O
( O
S1 O
: O
Normal O
) O
, O
( O
S2 O
: O
Normal O
) O

 O
Peripheral O
Vascular O
: O
( O
Right O
radial O
pulse O
: O
Not O
assessed O
) O
, O
( O
Left O

 O
radial O
pulse O
: O
Not O
assessed O
) O
, O
( O
Right O
DP O
pulse O
: O
Present O
) O
, O
( O
Left O
DP O

 O
pulse O
: O
Present O
) O

 O
Abdominal O
: O
Midline O
incision O
, O
dressing O
in O
place O
, O
clean O
, O
dry O
, O

 O
intact O
with O
mild O
serosanguinous O
drainage O

 O
Extremities O
: O
Right O
lower O
extremity O
edema O
: O
Trace O
, O
Left O
lower O

 O
extremity O
edema O
: O
Trace O

 O
Skin O
: O
  O
Not O
assessed O
, O
No(t O
) O
Rash O
: O

 O
Neurologic O
: O
Attentive O
, O
Follows O
simple O
commands O
, O
Responds O
to O
: O
Not O

 O
assessed O
, O
Oriented O
( O
to O
) O
: O
person O
, O
place O
, O
time O
, O
Movement O
: O
Not O

 O
assessed O
, O
Tone O
: O
Not O
assessed O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2159 O
- O
9 O
- O
24 O
* O
* O
] O
02:20PM O
BLOOD O
WBC-9.3 O
RBC-3.93 O
* O
Hgb-8.3 O
* O
# O
Hct-27.5 O
* O

 O
MCV-70 O
* O
# O
MCH-21.1 O
* O
# O
MCHC-30.1 O
* O
# O
RDW-17.5 O
* O
Plt O
Ct-366 O

 O
[ O
* O
* O
2159 O
- O
9 O
- O
26 O
* O
* O
] O
07:15AM O
BLOOD O
WBC-10.1 O
RBC-3.53 O
* O
Hgb-8.1 O
* O
Hct-25.2 O
* O

 O
MCV-71 O
* O
MCH-23.0 O
* O
MCHC-32.2 O
RDW-19.4 O
* O
Plt O
Ct-243 O

 O
[ O
* O
* O
2159 O
- O
9 O
- O
24 O
* O
* O
] O
07:49PM O
BLOOD O
Neuts-85.2 O
* O
Lymphs-9.1 O
* O
Monos-5.2 O
Eos-0.3 O

 O
Baso-0.2 O

 O
[ O
* O
* O
2159 O
- O
9 O
- O
25 O
* O
* O
] O
05:10PM O
BLOOD O
Neuts-77.8 O
* O
Lymphs-14.5 O
* O
Monos-7.2 O

 O
Eos-0.5 O
Baso-0.1 O

 O
[ O
* O
* O
2159 O
- O
9 O
- O
24 O
* O
* O
] O
02:20PM O
BLOOD O
PT-13.0 O
PTT-21.5 O
* O
INR(PT)-1.1 O

 O
[ O
* O
* O
2159 O
- O
9 O
- O
26 O
* O
* O
] O
07:15AM O
BLOOD O
PT-13.2 O
PTT-25.1 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2159 O
- O
9 O
- O
24 O
* O
* O
] O
02:20PM O
BLOOD O
Glucose-168 O
* O
UreaN-7 O
Creat-0.7 O
Na-138 O

 O
K-4.6 O
Cl-104 O
HCO3 O
- O
28 O
AnGap-11 O

 O
[ O
* O
* O
2159 O
- O
9 O
- O
26 O
* O
* O
] O
07:15AM O
BLOOD O
Glucose-108 O
* O
UreaN-8 O
Creat-0.6 O
Na-133 O

 O
K-4.4 O
Cl-97 O
HCO3 O
- O
27 O
AnGap-13 O

 O
[ O
* O
* O
2159 O
- O
9 O
- O
24 O
* O
* O
] O
02:20PM O
BLOOD O
Calcium-7.8 O
* O
Phos-4.5 O
# O
Mg-2.1 O

 O
[ O
* O
* O
2159 O
- O
9 O
- O
25 O
* O
* O
] O
06:00AM O
BLOOD O
Calcium-7.7 O
* O
Phos-3.0 O
Mg-2.2 O

 O
[ O
* O
* O
2159 O
- O
9 O
- O
24 O
* O
* O
] O
03:07PM O
BLOOD O
Type-ART O
pO2 O
- O
163 O
* O
pCO2 O
- O
59 O
* O
pH-7.27 O
* O

 O
calTCO2 O
- O
28 O
Base O
XS-0 O
Intubat-NOT O
INTUBA O



 O
CT-A O

 O
IMPRESSION O
: O

 O
1 O
. O
Slightly O
limited O
exam O
secondary O
to O
motion O
and O
body O
habitus O

 O
however O
no O

 O
pulmonary O
embolus O
in O
the O
central O
or O
segmental O
pulmonary O

 O
arteries O
. O

 O
2 O
. O
Scattered O
upper O
lobe O
predominent O
bilateral O
peribronchiolar O

 O
nodular O

 O
opacities O
which O
may O
be O
due O
to O
an O
infectious/inflammatory O

 O
etiology O
or O

 O
aspiration O
. O
Bilateral O
lower O
lobes O
and O
lingular O
atelectasis O
. O

 O
3 O
. O
Diffuse O
low O
attenuation O
of O
the O
liver O
compatible O
with O
fatty O

 O
infiltration O
. O



 O
Brief O
Hospital O
Course O
: O

 O
On O
[ O
* O
* O
9 O
- O
24 O
* O
* O
] O
, O
she O
underwent O
diagnostic O
laparoscoy O
, O
converted O

 O
to O
open O
total O
abdominal O
hysterectomy O
, O
left O
salpingoopherectomy O
, O

 O
pelvic O
and O
para-aortic O
lymph O
node O
dissection O
, O
omentectomy O
, O
and O

 O
cystoscopy O
. O
  O
Procedure O
was O
converted O
due O
to O
difficulty O
accessing O

 O
the O
lymph O
nodes O
. O
  O
Please O
see O
Dr.[**Name O
( O
NI O
) O
27357 O
* O
* O
] O
operative O
note O
for O

 O
full O
details O
. O


 O
Postoperatively O
, O
the O
patient O
received O
a O
TAP O
block O
for O
pain O
in O

 O
the O
PACU O
. O
  O
She O
developed O
tachycardia O
to O
130s O
. O
  O
Preoperatively O
, O

 O
the O
patient O
had O
been O
tachycardic O
to O
110s O
. O
   O
The O
patient O
had O

 O
received O
6L B-DOS
IV B-ROU
fluids B-DRUG
and O
maintained O
good O
UOP O
. O
  O
She O
also O

 O
received O
13 B-STR
mg I-STR
IV B-ROU
morphine B-DRUG
and O
RR B-ADE
went I-ADE
down I-ADE
to I-ADE
8 I-ADE
. I-ADE
   O
Arterial O

 O
blood O
gas O
demonstrated O
hypercarbia O
with O
pCO2 O
to O
59 O
. O
  O
No O

 O
pre-operative O
Hct O
was O
drawn O
, O
but O
the O
post-op O
HCT O
was O
27.5 O
. O
  O
Her O

 O
02 O
sat O
was O
82 O
% O
on O
RA O
and O
up O
to O
mid O
90s O
on O
CPAP O
. O
  O
The O
decision O

 O
was O
made O
to O
transfer O
the O
patient O
to O
the O
[ O
* O
* O
Hospital O
Ward O
Name O
332 O
* O
* O
] O
ICU O
for O
further O

 O
management O
. O
  O
On O
arrival O
to O
the O
ICU O
the O
patient O
's O
02 O
sat O
99 O
% O
on O

 O
2L O
, O
she O
was O
alert O
, O
oriented O
and O
RR O
15 O
, O
not O
complaining O
of O
any O

 O
pain O
. O
  O
She O
had O
a O
one-night O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
stay O
. O


 O
The O
following O
were O
addressed O
during O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
stay O
: O


 O
1 O
) O
Hypoxia O
: O

 O
Her O
hypoxia B-ADE
was O
likely O
multifactorial O
, O
associated O
with O

 O
atelectasis B-ADE
and O
low B-ADE
RR I-ADE
in O
the O
setting O
of O
a O
high O
morphine B-DRUG
dose O
. O

 O
The O
CXR O
was O
consistent O
with O
atelectasis O
. O
  O
Patient O
also O
noted O
to O

 O
have O
some O
snoring O
and O
full O
neck O
likely O
associated O
with O
some O

 O
degree O
of O
sleep O
apnea O
. O
  O
She O
was O
ruled O
out O
for O
pulmonary O
embolism O

 O
with O
CT-A. O
The O
CT O
did O
suggest O
possible O
aspiration O
versus O

 O
infectious O
etiology O
with O
" O
scattered O
bilateral O

 O
peribronchovascular O
opacities O
. O
" O
  O
At O
the O
time O
of O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
call-out O
, O

 O
the O
patient O
was O
saturating O
98 O
% O
on O
2L B-DOS
oxygen B-DRUG
by O
nasal B-ROU
canula I-ROU
, I-ROU

 O
which O
was O
stable O
from O
her O
presentation O
to O
the O
ICU O
, O
mildly O

 O
improved O
. O



 O
2 O
) O
Sinus O
Tachycardia O
: O

 O
Her O
sinus O
tachycardia O
was O
of O
unclear O
etiology O
, O
though O
clearly O

 O
documented O
prior O
to O
going O
to O
the O
OR O
. O
  O
The O
patient O
clearly O
denied O

 O
pain O
, O
anxiety O
; O
her O
post-op B-REA
pain I-REA
was O
controlled O
with O
dilaudid B-DRUG

 I-DRUG
PCA B-FOR
. I-FOR
  O
She O
did O
describe O
some O
difficulty O
with O
bowel B-DRUG
prep I-DRUG
that O

 O
could O
have O
caused O
dehydration B-ADE
, I-ADE
but O
the O
tachycardia O
did O
not O

 O
resolve O
with O
6L B-DOS
IVFs B-DRUG
despite O
orbital O
edema O
. O
  O
Her O
post-operative O

 O
fever O
could O
have O
been O
contributing O
to O
the O
tachycardia O
as O
well O
. O

 O
Telemetry O
was O
discontinued O
upon O
transfer O
to O
the O
GYN O
oncology O

 O
service O
. O


 O
3 O
) O
Fever O
: O

 O
The O
patient O
spiked O
a O
fever O
to O
102.5 O
the O
evening O
of O
POD#0 O
. O
  O
CTA O

 O
was O
suggestive O
of O
possible O
aspiration O
pneumonia O
as O
an O
etiology O
. O


 O
4 O
) O
Anemia O
: O

 O
Hematocrit O
at O
time O
of O
transfer O
to O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
was O
24 O
. O
  O
She O
was O

 O
transfused O
1 B-DOS
unit I-DOS
of O
pRBCs B-DRUG
in O
the O
ICU O
in O
addition O
to O
2 B-DOS
units B-FOR
of O

 O
pRBCs B-DRUG
she O
had O
received O
intraoperatively O
in O
the O
PACU O
. O


 O
The O
patient O
was O
transferred O
to O
the O
gyn O
oncology O
service O
on O

 O
POD#1 O
. O
  O
The O
remainder O
of O
her O
hospital O
stay O
was O
notable O
for O
the O

 O
following O
: O


 O
1 O
) O
Apiration O
pneumonia O
: O

 O
The O
patient O
was O
successfully O
weaned O
to O
room O
air O
on O
gyn O
oncology O

 O
service O
. O
  O
Given O
that O
her O
temperature O
was O
still O
elevated O
to O
101.2 O

 O
at O
the O
time O
of O
transfer O
, O
she O
was O
started O
on O
IV B-ROU
clindamycin B-DRUG

 I-DRUG
empirically O
for O
treatment O
of O
aspiration B-REA
pneumonia I-REA
. I-REA
  O
Urine O

 O
culture O
was O
negative O
, O
and O
blood O
cultures O
were O
still O
pending O
at O

 O
the O
time O
of O
hospital O
discharge O
. O
  O
Following O
initiation O
of O

 O
clindamycin B-DRUG
, I-DRUG
she O
remained O
afebrile O
for O
over O
24 O
hours O
. O
  O
She O
then O

 O
respiked O
to O
a O
low O
grade O
temperature O
of O
100.6 O
. O
  O
Urinalysis O
was O

 O
negative O
. O
  O
CXR O
was O
repeated O
, O
demonstrating O
bibasilar O
opacities O

 O
concerning O
for O
ongoing O
aspiration B-REA
pneumonia I-REA
. I-REA
  O
The O
patient O

 O
spontaneously O
defervesced O
, O
and O
remained O
afebrile O
for O
the O

 O
remainder O
of O
her O
hospital O
stay O
. O
  O
Clindamycin B-DRUG
was O
discontinued O

 O
and O
levofloxacin B-DRUG
initiated O
. O
  O
The O
patient O
received O
24 B-DUR
hours I-DUR
of O
IV B-ROU

 I-ROU
levofloxacin B-DRUG
and O
was O
discharged O
home O
on O
po B-ROU
levofloxacin B-DRUG
. I-DRUG
  O
Within O

 O
24 O
hours O
of O
discharge O
, O
the O
patient O
called O
informing O
that O

 O
insurance O
would O
not O
cover O
po B-ROU
levofloxacin B-DRUG
. I-DRUG
  O
She O
was O
switched O
to O

 O
a O
10 B-DUR
day I-DUR
course O
of O
augmentin B-DRUG
and O
azithromycin B-DRUG
. I-DRUG


 O
2 O
) O
Nausea/emesis O

 O
The O
patient O
experienced O
an O
episode O
of O
nausea O
with O
small O
amount O

 O
of O
bilious O
emesis O
on O
POD#3 O
. O
  O
Diet O
was O
retracted O
from O
full O

 O
liquids O
back O
to O
NPO O
with O
resolution O
of O
symptoms O
. O
  O
Diet O
was O

 O
successfully O
advanced O
the O
following O
day O
. O


 O
She O
was O
discharged O
home O
on O
POD#5 O
in O
good O
condition O
: O
tolerating O
a O

 O
regular O
diet O
, O
ambulating O
and O
voiding O
without O
difficulty O
, O

 O
afebrile O
, O
saturating O
well O
on O
room O
air O
. O


 O
Medications O
on O
Admission O
: O

 O
prilosec B-DRUG



 I-DRUG
Discharge O
Medications O
: O

 O
1 O
. O
Levofloxacin B-DRUG
750 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE

 I-FRE
for B-DUR
10 I-DUR
days I-DUR
. I-DUR

 O
Disp:*10 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
2 O
. O
Omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) O
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) O
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
3 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
Disp:*60 O
Capsule(s O
) O
* O
Refills:*0 O
* O

 O
4 O
. O
Oxycodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
325 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU

 I-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
: I-REA
do O
not O
exceed O
12 O
pills O

 O
in O
any O
24 O
hour O
period O
. O

 O
Disp:*40 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
5 O
. O
Ibuprofen B-DRUG
600 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
Disp:*40 O
Tablet(s O
) O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
dysgerminoma O
of O
the O
ovary O



 O
Discharge O
Condition O
: O

 O
good O



 O
Discharge O
Instructions O
: O

 O
- O
Please O
call O
your O
doctor O
if O
you O
experience O
fever O
> O
100.4 O
, O

 O
chills O
, O
nausea O
and O
vomiting O
, O
worsening O
or O
severe O
abdominal O
pain O
, O


 O
heavy O
vaginal O
bleeding O
, O
chest O
pain O
, O
trouble O
breathing O
, O
or O
if O
you O


 O
have O
any O
other O
questions O
or O
concerns O
. O

 O
- O
Please O
call O
if O
you O
have O

 O
redness O
and O
warmth O
around O
the O
incision O
, O
if O
your O
incision O
is O

 O
draining O
pus-like O
or O
foul O
smelling O
discharge O
, O
or O
if O
your O

 O
incision O
reopens O
. O

 O
- O
No O
driving O
for O
two O
weeks O
and O
while O
taking O
narcotic B-DRUG
pain I-DRUG

 I-DRUG
medication I-DRUG
as O
it O
can O
make O
you O
drowsy B-ADE
. I-ADE

 O
- O
No O
heavy O
lifting O
or O
strenuous O
exercise O
for O
6 O
weeks O
to O
allow O

 O
your O
incision O
to O
heal O
adequately O
. O

 O
- O
Nothing O
per O
vagina O
( O
no O
tampons O
, O
intercourse O
, O
douching O
for O
6 O

 O
weeks O
. O

 O
- O
Please O
keep O
your O
follow-up O
appointments O
as O
outlined O
below O
. O



 O
Followup O
Instructions O
: O

 O
Provider O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
33326 O
* O
* O
] O
Phone:[**Telephone/Fax O
( O
1 O
) O
5777 O
* O
* O
] O

 O
Date/Time:[**2159 O
- O
10 O
- O
4 O
* O
* O
] O
10:10 O

 O
Provider O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
5777 O
* O
* O
] O

 O
Date/Time:[**2159 O
- O
10 O
- O
31 O
* O
* O
] O
1:00 O



                              O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(2 O
) O
6753 O
* O
* O
] O


 O
Completed O
by:[**2159 O
- O
10 O
- O
4 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2182 O
- O
4 O
- O
23 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2100 O
- O
2 O
- O
23 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Iodine B-DRUG
; I-DRUG
Iodine B-DRUG
Containing I-DRUG
/ O
Dust O
& O
Pollen O
Filter O
Mask O
/ O

 O
Hydralazine B-DRUG
/ O
Cyclophosphamide B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
689 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
BRBPR O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
EGD O

 O
Blood O
Transfusion O



 O

History O
of O
Present O
Illness O
: O

  O
82yo O
F O
with O
h/o O
renal O
artery O
stenosis O
, O
CKD O
stage O
III O
, O
pAF B-REA
on O

 O
coumadin B-DRUG
presents O
with O
BRBPR O
X O
3 O
yesterday O
. O
Patient O
presented O
to O

 O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
about O
1 O
month O
ago O
with O
increased O
creatinine O
to O
3 O
( O
from O

 O
1.6 O
) O
. O
A O
workup O
including O
renal O
biopsy O
revealed O
pauci-immune O

 O
P-ANCA B-ADE
positive I-ADE
glomerulonephritis I-ADE
thought O
secondary O
to O

 O
hydralazine B-DRUG
. I-DRUG
She O
was O
started O
on O
prednisone B-DRUG
and O
cyclophosphamide B-DRUG

 I-DRUG
at O
that O
point O
. O

 O
In O
addition O
, O
according O
to O
the O
patient O
and O
records O
from O
[ O
* O
* O
Hospital O
* O
* O
] O
she O
was O
also O
recently O
admitted O
to O
[ O
* O
* O
Hospital3 O
* O
* O
] O
after O
a O

 O
collapse O
one O
month O
ago O
. O
She O
was O
brought O
in O
and O
found O
to O
have O
AF B-REA

 I-REA
with I-REA
RVR I-REA
. I-REA
Was O
started O
on O
dilt B-DRUG
and O
metoprolol B-DRUG
with O
reportedly O

 O
good O
control O
. O
Further O
workup O
there O
included O
an O
EGD O
and O

 O
colonoscopy O
which O
revealed O
gastric O
ulcers O
and O
polyps O
as O
well O
as O

 O
candidiasis O
. O
She O
received O
2units B-STR
pRBCs B-DRUG
and O
her O
hct O
came O
up O
to O

 O
30 O
. O
While O
there O
she O
was O
noted O
to O
be O
neutropenic B-ADE
. I-ADE
They O
thought O

 O
this O
was O
possibly O
medication O
related O
. O
Cyclophosphamide B-DRUG
, I-DRUG
bactrim B-DRUG
, I-DRUG

 O
and O
fluconazole B-DRUG
were O
discontinued O
. O
She O
completed O
a O
course O
of O

 O
caspofungin B-DRUG
and O
a O
TTE O
was O
negative O
for O
vegetations O
. O
Her O
WBC O

 O
count O
came O
up O
. O
She O
was O
discharged O
to O
[ O
* O
* O
Hospital3 O
* O
* O
] O
. O

 O
Today O
was O
feeling O
weak O
and O
tired O
and O
then O
had O
3 O
episodes O
of O

 O
BRBPR O
so O
decided O
to O
come O
to O
Ed O
. O
Presented O
to O
ED O
in O
AF B-REA
with I-REA
RVR I-REA

 I-REA
to O
160s O
. O
Received O
10 B-STR
mg I-STR
Iv B-ROU
Dilt B-DRUG
with O
improvement O
in O
rate O
to O
high O

 O
90s/100 O
. O
Received O
then O
30 B-STR
mg I-STR
PO B-ROU
dilt B-DRUG
. I-DRUG
Stable O
HRs O
since O
. O
Also O

 O
received O
5 B-STR
mg I-STR
IV B-ROU
metoprolol B-DRUG
. I-DRUG

 O
Initial O
VS O
: O
97.8 O
137AF O
111/78 O
16 O
99 O
. O
No O
N/V/Abd O
pain O
. O
Just O
feels O

 O
tired O
. O
Rectal O
exam O
revealed O
guaiac B-REA
positive I-REA
dark I-REA
stool I-REA
. I-REA
Received O

 O
IVF B-DRUG
and O
40 B-STR
mg I-STR
IV B-ROU
protonix B-DRUG
. I-DRUG
Hct O
in O
ED O
is O
27 O
consistent O
with O

 O
baseline O
( O
25 O
- O
30 O
) O
here O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
. O
Were O
going O
to O
do O
NGL O
but O
decided O

 O
not O
to O
because O
did O
n't O
want O
her O
to O
go O
back O
into O
AF O
with O
RVR O
. O
GI O

 O
called O
in O
Ed O
and O
will O
see O
her O
on O
the O
floor O
. O

 O
. O

 O
On O
the O
floor O
, O
patient O
complained O
of O
being O
sick O
of O
being O
in O
the O

 O
hospital O
and O
dry O
mouth O
. O
Otherwise O
densies O
fevers O
, O
chills O
, O

 O
abdominal O
pain O
, O
diarrhea O
, O
constipation O
, O
nausea O
, O
and O
vomiting O
. O

 O
Has O
had O
some O
weight O
loss O
worked O
up O
in O
the O
past O
and O
possibly O

 O
related O
to O
depression O
( O
per O
the O
patient O
) O
after O
her O
friend O
died O

 O
recently O
. O
Complained O
of O
occasional O
flank O
pain O
at O
biopsy O
site O
and O

 O
a O
developing O
bed O
sore O
. O
Rest O
of O
ROS O
negative O
including O
no O
CP O
, O

 O
palps O
, O
sob O
, O
dysuria O
. O

 O
. O



 O

Past O
Medical O
History O
: O

 O
Past O
Medical O
History O
: O

 O
RAS O
, O
HTN O

 O
CKD O
III O
, O
baseline O
GFR~30 O
with O
Cr O
1.6 O

 O
paroxysmal B-REA
AFIB I-REA
on O
sotalol B-DRUG
for B-DUR
2 I-DUR
yrs I-DUR
and O
coumadin B-DRUG

 I-DRUG
Anemia O
of O
CKD O

 O
Nephrolithiasis O
( O
prior O
oxalate O
stone O
) O

 O
s/p O
appy O
, O
chole O
, O
and O
tubal O
ligation O


 O
Social O
History O
: O

 O
Lives O
alone O
, O
independent O
for O
ADLS O
, O
family O
lives O
in O
the O
area O
. O

 O
Denies O
ETOH O
, O
tobacco O
, O
and O
illicits O



 O
Family O
History O
: O

 O
HTN O
, O
colon O
CA O

 O
No O
DMII O
, O
no O
heritable O
kidney O
dz O


 O
Physical O
Exam O
: O

 O
Vitals O
: O
T O
: O
96.2 O
BP:137/83 O
P:110 O
R:18 O
O2 O
: O
97 O
% O
RA O

 O
General O
: O
Alert O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
dryMM O
, O
oropharynx O
clear O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O
rales O
, O

 O
ronchi O

 O
CV O
: O
irregularly O
irregular O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O

 O
gallops O

 O
Abdomen O
: O
soft O
, O
non-tender O
, O
non-distended O
, O
bowel O
sounds O
present O
, O

 O
no O
rebound O
tenderness O
or O
guarding O
, O
no O
organomegaly O
. O

 O
Rectal O
: O
external O
hemorrhoids O
, O
good O
rectal O
tone O
, O
grossly O
bloody O

 O
stool O
, O
guaiac O
positive O

 O
GU O
: O
no O
foley O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
no O
clubbing O
, O
cyanosis O
or O

 O
edema O



 O

Pertinent O
Results O
: O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
07:25PM O
   O
HCT-30.8 O
* O
# O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
07:25PM O
   O
PT-20.4 O
* O
PTT-26.0 O
INR(PT)-1.9 O
* O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
09:26AM O
   O
GLUCOSE-81 O
UREA O
N-69 O
* O
CREAT-2.2 O
* O
SODIUM-143 O

 O
POTASSIUM-4.3 O
CHLORIDE-105 O
TOTAL O
CO2 O
- O
27 O
ANION O
GAP-15 O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
09:26AM O
   O
CALCIUM-8.3 O
* O
PHOSPHATE-4.4 O
MAGNESIUM-1.7 O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
09:26AM O
   O
PT-25.1 O
* O
PTT-27.0 O
INR(PT)-2.4 O
* O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
09:25AM O
   O
HCT-24.0 O
* O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
05:30AM O
   O
GLUCOSE-106 O
* O
UREA O
N-73 O
* O
CREAT-2.2 O
* O
# O

 O
SODIUM-143 O
POTASSIUM-4.7 O
CHLORIDE-105 O
TOTAL O
CO2 O
- O
26 O
ANION O
GAP-17 O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
05:30AM O
   O
estGFR-Using O
this O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
05:30AM O
   O
cTropnT-0.01 O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
05:30AM O
   O
WBC-7.2 O
RBC-3.08 O
* O
HGB-8.9 O
* O
HCT-27.3 O
* O
MCV-89 O

 O
MCH-28.8 O
MCHC-32.6 O
RDW-18.3 O
* O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
05:30AM O
   O
NEUTS-80.7 O
* O
LYMPHS-15.4 O
* O
MONOS-3.5 O
EOS-0.1 O

 O
BASOS-0.3 O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
05:30AM O
   O
PLT O
COUNT-229 O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
05:30AM O
   O
PT-22.9 O
* O
PTT-25.3 O
INR(PT)-2.2 O
* O



 O
[ O
* O
* O
2182 O
- O
4 O
- O
13 O
* O
* O
] O
02:48AM O
BLOOD O
WBC-6.1 O
RBC-3.61 O
* O
Hgb-10.6 O
* O
Hct-31.0 O
* O

 O
MCV-86 O
MCH-29.4 O
MCHC-34.2 O
RDW-18.4 O
* O
Plt O
Ct-167 O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
14 O
* O
* O
] O
07:53AM O
BLOOD O
WBC-7.1 O
RBC-3.64 O
* O
Hgb-11.2 O
* O
Hct-31.6 O
* O

 O
MCV-87 O
MCH-30.7 O
MCHC-35.4 O
* O
RDW-19.1 O
* O
Plt O
Ct-146 O
* O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
15 O
* O
* O
] O
06:20AM O
BLOOD O
WBC-7.4 O
RBC-3.66 O
* O
Hgb-10.5 O
* O
Hct-32.3 O
* O

 O
MCV-88 O
MCH-28.7 O
MCHC-32.6 O
RDW-18.9 O
* O
Plt O
Ct-131 O
* O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
16 O
* O
* O
] O
06:25AM O
BLOOD O
WBC-8.4 O
RBC-3.88 O
* O
Hgb-10.8 O
* O
Hct-34.5 O
* O

 O
MCV-89 O
MCH-27.9 O
MCHC-31.4 O
RDW-17.9 O
* O
Plt O
Ct-145 O
* O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
07:25PM O
BLOOD O
PT-20.4 O
* O
PTT-26.0 O
INR(PT)-1.9 O
* O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
13 O
* O
* O
] O
02:48AM O
BLOOD O
PT-18.4 O
* O
PTT-25.5 O
INR(PT)-1.7 O
* O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
14 O
* O
* O
] O
07:53AM O
BLOOD O
PT-12.9 O
PTT-23.5 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
14 O
* O
* O
] O
07:53AM O
BLOOD O
Glucose-97 O
UreaN-53 O
* O
Creat-2.2 O
* O
Na-142 O

 O
K-3.7 O
Cl-102 O
HCO3 O
- O
29 O
AnGap-15 O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
15 O
* O
* O
] O
04:40PM O
BLOOD O
Glucose-165 O
* O
UreaN-38 O
* O
Creat-2.1 O
* O
Na-142 O

 O
K-4.2 O
Cl-106 O
HCO3 O
- O
24 O
AnGap-16 O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
16 O
* O
* O
] O
06:25AM O
BLOOD O
Glucose-159 O
* O
UreaN-35 O
* O
Creat-2.1 O
* O
Na-141 O

 O
K-4.3 O
Cl-105 O
HCO3 O
- O
26 O
AnGap-14 O

 O
[ O
* O
* O
2182 O
- O
4 O
- O
12 O
* O
* O
] O
05:23PM O
BLOOD O
ANCA-POSITIVE O
* O


 O
Brief O
Hospital O
Course O
: O

 O
82yo O
F O
with O
h/o O
PUD O
and O
CKD O
with O
recent O
acute B-ADE
renal I-ADE
failure I-ADE
from O

 O
hydralazine B-DRUG
induced O
pauci-immune B-ADE
glomerulonephritis I-ADE
admitted O

 O
with O
BRBPR O
and O
atrial O
fibrillation O
with O
RVR O
. O

 O
. O

 O
# O
GIB B-REA
: I-REA
Given O
significant O
orthostasis O
, O
hct O
down O
to O
24 O
( O
baseline O

 O
30 O
) O
and O
history O
of O
PUD O
, O
initially O
concerned O
about O
UGIB O
. O
  O
NG O

 O
lavage O
was O
negative O
which O
was O
reassuring O
. O
  O
She O
was O
given O
2u B-DOS
pRBC B-DRUG

 I-DRUG
with O
stable O
blood O
counts O
and O
hemodynamics O
. O
  O
She O
had O
an O
EGD O
on O

 O
[ O
* O
* O
4 O
- O
13 O
* O
* O
] O
without O
e/o O
active O
bleeding O
. O
  O
Per O
GI O
likely O
LGIB O
and O
will O

 O
need O
c-scope O
sometime O
during O
this O
admission O
. O
  O
She O
was O
also O
given O

 O
2u B-DOS
FFP B-DRUG
given O
coagulopathy B-REA
and O
concern O
for O
GIB B-REA
and O
need O
for O

 O
endoscopy O
. O
Bleeding O
ceased O
, O
however O
, O
colonoscopy O
deferred O

 O
secondary O
to O
difficult O
to O
control O
AFib O
with O
RVR O
. O
She O
should O

 O
follow-up O
as O
an O
outpatient O
for O
colonscopy O
. O

 O
. O


 O
# O
AF B-REA
with I-REA
RVR I-REA
: I-REA
She O
had O
been O
on O
sotolol B-DRUG
for O
several O
years O
until O

 O
her O
recent O
admission O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
when O
this O
was O
discontinued O
in O
the O

 O
setting O
of O
her O
worsening O
renal O
failure O
. O
  O
She O
was O
noted O
to O
have O

 O
AF O
with O
RVR O
to O
140s O
. O
  O
Initially O
felt O
to O
be O
worsened O
by O
volume O

 O
depletion O
with O
GIB O
. O
  O
However O
, O
despite O
blood O
products O
, O
she O

 O
remained O
tachycardic O
and O
thus O
nodal O
agents O
were O
resumed O
. O

 O
Anticoagulation O
was O
held O
in O
acute O
setting O
, O
with O
coagulopathy O

 O
reversed O
in O
the O
setting O
of O
GIB O
. O
She O
was O
uptitrated O
on O
her O
PO B-ROU

 I-ROU
regimen O
to O
Metoprolol B-DRUG
50 B-STR
mg I-STR
TID B-FRE
and O
Diltiazem B-DRUG
30 B-STR
mg I-STR
QID B-FRE
which O
kept O

 O
her B-REA
HR I-REA
in I-REA
reasonable I-REA
control I-REA
until O
she O
underwent O
a O
bowel O
prep O

 O
for O
her O
colonoscopy O
. O
On O
the O
morning O
of O
the O
scheduled O

 O
colonoscopy O
, O
she O
developed O
AFib O
with O
RVR O
in O
the O
setting O
of O

 O
dehydration O
evidence O
by O
alkalosis O
and O
hypernatremia O
. O
She O

 O
received O
agressive O
IV B-ROU
hydration B-DRUG
and O
multiple O
IV B-ROU
medications B-DRUG
to O

 O
help O
control O
rate O
. O
Her O
heart O
rate O
initially O
responded O
and O

 O
stabilized O
in O
the O
90 O
- O
100 O
's O
. O
However O
, O
the O
following O
evening O
, O
she O

 O
required O
another O
bowel O
prep O
and O
her O
heart B-REA
rate I-REA
escalated I-REA
to O
the O

 O
150 O
's O
. O
She O
received O
additional O
IV B-ROU
nodal B-DRUG
agents I-DRUG
and O
her O
PO O

 O
regimen O
was O
increased O
. O
An O
electrophysiology O
consult O
was O
obtained O

 O
and O
the O
recommendation O
was O
for O
rate O
control O
and O
uptitration O
with O

 O
her O
current O
medications O
. O
Rhythm O
control O
was O
deferred O
. O
She O
was O

 O
restarted O
on O
anti-coagulation B-REA
on O
HD#5 O
with O
a O
heparin B-DRUG
gtt B-ROU
. I-ROU
A O
TEE O

 O
showed O
no O
evidence O
of O
thrombus O
. O
A O
cardioversion O
was O
attempted O

 O
and O
was O
unsuccessful O
. O
The O
patient O
was O
loaded O
with O
amiodarone B-DRUG
and O

 O
the O
Metoprolol B-DRUG
was O
uptitrated O
to O
100 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
to O
achieve B-REA
adequate I-REA

 I-REA
rate I-REA
control I-REA
. I-REA
She O
was O
started O
on O
Diltiazem B-DRUG
which O
was O
uptitrated O

 O
to O
45 B-STR
mg I-STR
PO B-ROU
QID B-FRE
. I-FRE
  O
HR O
was O
in O
the O
80s O
on O
discharge O
. O
  O
Her O
coumadin B-DRUG

 I-DRUG
was O
re-started O
and O
heparin B-DRUG
gtt B-ROU
was O
continued O
until O
the O
INR O
was O

 O
therapeutic O
. O
  O
Her O
INR O
became O
supratherapeutic O
and O
Coumadin B-DRUG
was O

 O
held O
on O
discharge O
. O
  O
She O
should O
follow-up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
as O
an O

 O
outpatient O
. O
  O
She O
should O
have O
INR O
checked O
in O
2 O
days O
and O
coumadin B-DRUG

 I-DRUG
restarted O
. O
  O
If O
her O
Amiodarone B-DRUG
converts O
her O
to O
sinus B-REA
rhythm I-REA
or O

 O
drops O
her O
heart O
rate O
as O
she O
becomes O
therapeutic O
, O
she O
may O
need O
to O

 O
stop O
her O
Metoprolol B-DRUG
. I-DRUG

 O
. O


 O
# O
CHF B-REA
: I-REA
In O
the O
setting O
of O
Atrial O
Fibrillation O
with O
RVR O
, O
the O

 O
patient O
was O
noted O
to O
develop O
signs O
and O
symptoms O
concerning O
for O

 O
CHF O
, O
such O
as O
rales O
and O
O2 O
requirement O
. O
The O
patient O
was O
diuresed B-REA

 I-REA
adequately O
with O
Lasix B-DRUG
and O
symptoms O
improved O
. O
The O
patient O
was O

 O
weaned O
off O
supplemental O
oxygen O
and O
was O
staturating O
95 O
% O
on O
RA O
. O

 O
Her O
creatinine B-ADE
bumped I-ADE
and O
Lasix B-DRUG
was O
stopped O
. O
  O
Her O
peak O

 O
creatinine O
was O
2.8 O
on O
[ O
* O
* O
2182 O
- O
4 O
- O
21 O
* O
* O
] O
and O
came O
down O
to O
2.5 O
on O
[ O
* O
* O
2182 O
- O
4 O
- O
23 O
* O
* O
] O
. O

 O
Lasix B-DRUG
can O
be O
considered O
as O
an O
outpatient O
if O
she O
develops O
signs O

 O
and O
symptoms B-REA
of I-REA
congestive I-REA
heart I-REA
failure I-REA
. I-REA

 O
. O

 O
# O
CKD B-REA
: I-REA
Renal O
function O
improving O
. O
  O
Per O
renal O
, O
taper B-DOS
prednsione B-DRUG
to O

 O
40 B-STR
mg I-STR
and O
then O
to O
30 B-STR
mg I-STR
. I-STR
She O
remained O
on O
prednisone B-DRUG
3omg B-STR
Daily B-FRE

 I-FRE
and O
her O
creatinine O
remained O
stable O
. O
  O
Her O
steroid B-DRUG
ppx O
including O

 O
PCP O
[ O
* O
* O
Name9 O
( O
PRE O
) O
* O
* O
] O
, O
PPI B-DRUG
, I-DRUG
calcium B-DRUG
, I-DRUG
vit B-DRUG
D I-DRUG
were O
continued O
. O
  O
She O
was O
followed O

 O
by O
the O
renal O
consult O
service O
during O
her O
admission O
and O
Lasix B-DRUG
was O

 O
held O
when O
Creatinine B-ADE
was I-ADE
elevated I-ADE
. I-ADE
  O
She O
is O
on O
Atovaquone B-DRUG

 I-DRUG
Suspension B-FOR
1500 B-STR
mg I-STR
PO/NG B-ROU
DAILY B-FRE
for O
prophylaxis B-REA
. I-REA

 O
. O

 O
There O
are O
no O
pending O
studies O
at O
the O
time O
of O
discharge O
. O


 O
Medications O
on O
Admission O
: O

 O
Nystatin B-DRUG
S+S B-FOR
X B-DUR
7 I-DUR
days I-DUR
( O
day O
3 O
today O
) O

 O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
Ranitidine B-DRUG
150 B-STR
mg I-STR
daily B-FRE

 I-FRE
Diltiazem B-DRUG
SR I-DRUG
120 B-STR
mg I-STR
po B-ROU
daily B-FRE

 I-FRE
Coumadin B-DRUG
2.5 B-STR
mg I-STR
daily B-FRE

 I-FRE
Atovaquone B-DRUG
1500 B-STR
mg I-STR
daily B-FRE

 I-FRE
Vit B-DRUG
B12 I-DRUG
500mcg B-STR
daily B-FRE

 I-FRE
Folate B-DRUG
1 B-STR
mg I-STR
daily B-FRE

 I-FRE
Prilosec B-DRUG
40 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Toprol B-DRUG
XL I-DRUG
50 B-STR
mg I-STR
daily B-FRE

 I-FRE
Calcium/Vit B-DRUG
D I-DRUG
600 B-STR
- I-STR
400units I-STR
twice B-FRE
daily I-FRE

 I-FRE
Prednisone B-DRUG
50 B-STR
mg I-STR
daily B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Atovaquone B-DRUG
750 B-STR
mg/5 I-STR
mL I-STR
Suspension B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
  O
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Cyanocobalamin B-DRUG
500 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Folic B-DRUG
Acid I-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
4 O
. O
Cholecalciferol B-DRUG
( I-DRUG
Vitamin I-DRUG
D3 I-DRUG
) I-DRUG
400 B-STR
unit I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q12H B-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet O
, O
Delayed O
Release O
(E.C.)(s O
) O
* O
Refills:*0 O
* O

 O
6 O
. O
Prednisone B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Nystatin B-DRUG
100,000 B-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ml I-DOS
PO B-ROU
Q8H B-FRE

 I-FRE
( I-FRE
every I-FRE
8 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Menthol-Cetylpyridinium B-DRUG
3 B-STR
mg I-STR
Lozenge B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Lozenge B-FOR

 I-FOR
Mucous B-ROU
membrane I-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
sore B-REA
throat I-REA
. I-REA

 O
9 O
. O
Trazodone B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
as I-FRE

 I-FRE
needed I-FRE
for O
insomnia B-REA
. I-REA

 O
10 O
. O
Amiodarone B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
for B-DUR
2 I-DUR
days I-DUR
: I-DUR
on O
[ O
* O
* O
2182 O
- O
4 O
- O
25 O
* O
* O
] O
, O
please O
change O
to O
200 O
mg O
PO O
BID O
for O

 O
1 O
week O
, O
then O
on O
[ O
* O
* O
2182 O
- O
5 O
- O
2 O
* O
* O
] O
change O
to O
200 O
mg O
daily O
. O

 O
11 O
. O
Amiodarone B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
: I-FRE

 O
start O
on O
[ O
* O
* O
2182 O
- O
4 O
- O
25 O
* O
* O
] O
for B-DUR
1 I-DUR
week I-DUR
, I-DUR
then O
change O
to O
200 B-STR
mg I-STR
PO B-ROU
daily B-FRE
. I-FRE

 O
12 O
. O
Lorazepam B-DRUG
0.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE

 I-FRE
bedtime I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
insomnia B-REA
, I-REA
anxiety B-REA
. I-REA

 O
13 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE

 I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
14 O
. O
Calcium B-DRUG
Carbonate I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
15 O
. O
Diltiazem B-DRUG
HCl I-DRUG
30 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1.5 B-DOS
Tablets B-FOR
PO B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
16 O
. O
Outpatient O
Lab O
Work O

 O
Please O
check O
electrolytes O
( O
Na O
, O
K O
, O
Cl O
, O
HCO3 O
) O
and O
renal O
function O

 O
( O
BUN O
, O
CREAT O
) O
, O
and O
hematocrit O
in O
1 O
week O
. O

 O
17 O
. O
Outpatient O
Lab O
Work O

 O
Please O
check O
INR O
and O
Hematocrit O
in O
2 O
days O
. O
  O
Please O
restart O

 O
Coumadin B-DRUG
at O
2.5 B-STR
mg I-STR
daily B-FRE
if O
INR O
less O
than O
2.5 O
. O
  O
Recheck O
INR O
every O

 O
2 O
days O
. O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital O
* O
* O
] O
Healthcare O
Center O
- O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O



 O
Discharge O
Diagnosis O
: O

 O
Bright O
Red O
Blood O
Per O
rectum O

 O
Anemia O
requiring O
blood O
transfusion O

 O
Atrial O
Fibrillation O
with O
RVR O

 O
pauci-immune O
glomerulonephritis O
with O
p-anca O
positive O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Out O
of O
Bed O
with O
assistance O
to O
chair O
or O

 O
wheelchair O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
hospital O
for O
bleeding O
from O
your O
rectum O
. O

 O
You O
received O
a O
blood B-DRUG
transfusion I-DRUG
for O
anemia B-REA
. I-REA
You O
blood O
count O

 O
improved O
and O
your O
bleeding O
stopped O
. O


 O
The O
gatroenterologists O
performed O
an O
upper O
endoscopy O
which O
was O

 O
normal O
. O
You O
were O
continued O
on O
a O
antacid B-DRUG
. I-DRUG
The O
plan O
was O
for O
you O
to O

 O
undergo O
a O
colonoscopy O
. O


 O
While O
undergoing O
the O
prep O
for O
the O
colonoscopy O
, O
you O
developed O
a O

 O
very O
fast O
heart O
rate O
from O
your O
atrial O
fibrillation O
. O
Your O
blood O

 O
pressure O
medications O
were O
increased O
to O
help O
control O
our O
heart O

 O
rate O
. O
The O
cardiologists O
attempted O
to O
cardiovert O
you O
out O
of O

 O
atrial O
fibrillation O
, O
but O
were O
unsuccessful O
. O
You O
were O
started O
on O

 O
Amiodarone B-DRUG
and O
continued O
on O
metoprolol B-DRUG
. I-DRUG
  O
You O
were O
started O
on O

 O
Diltiazem B-DRUG
for O
heart B-REA
rate I-REA
control I-REA
. I-REA
You O
were O
given O
lasix B-DRUG
for O
heart B-REA

 I-REA
failure I-REA
but O
this O
was O
stopped O
prior O
to O
discharge O
. O


 O
When O
you O
came O
into O
the O
hospital O
, O
you O
were O
taking O
prednisone B-DRUG
. I-DRUG
The O

 O
nephrologists O
recommended O
that O
your O
prednisone B-DRUG
be O
decreased O
to O

 O
30 B-STR
mg I-STR
per B-FRE
day I-FRE
. I-FRE
You O
should O
continue O
to O
take O
Prednisone B-DRUG
30 B-STR
mg I-STR
Daily B-FRE
. I-FRE



 O
CHANGES O
IN O
YOUR O
MEDICATION O
; O

 O
1 O
. O
Amiodarone B-DRUG
200 B-STR
mg I-STR
Three B-FRE
times I-FRE
per I-FRE
day I-FRE
for B-DUR
1 I-DUR
week I-DUR
. I-DUR
  O
On O
[ O
* O
* O
2182 O
- O
4 O
- O
25 O
* O
* O
] O
, O

 O
change O
to O
200 B-STR
mg I-STR
2 B-FRE
times I-FRE
per I-FRE
day I-FRE
for B-DUR
1 I-DUR
week I-DUR
and O
then O
200 B-STR
mg I-STR
Daily B-FRE
. I-FRE

 O
2 O
. O
Metoprolol B-DRUG
100 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
3 O
. O
Prednisone B-DRUG
30 B-STR
mg I-STR
Daily B-FRE

 I-FRE
4 O
. O
STOP O
Prilosec B-DRUG
40 B-STR
mg I-STR
Daily B-FRE

 I-FRE
5 O
. O
START O
Protonix B-DRUG
40 B-STR
mg I-STR
Twice B-FRE
Daily I-FRE

 I-FRE
6 O
. O
CHANGE O
Diltiazem B-DRUG
to O
45 B-STR
mg I-STR
PO B-ROU
QID B-FRE


 I-FRE
Followup O
Instructions O
: O

 O
You O
need O
to O
schedule O
a O
follow-up O
appointment O
with O
the O
[ O
* O
* O
Hospital O
* O
* O
] O
clinic O
. O

 O
You O
can O
call O
them O
@ O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2233 O
* O
* O
] O
to O
schedule O
an O
appointment O

 O
and O
outpatient O
colonoscopy O
. O



 O
Name O
: O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name7 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Initial O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O

 O
Specialty O
: O
Cardiology O

 O
Address O
: O
[ O
* O
* O
Street O
Address(2 O
) O
2687**],STE O
7C O
, O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
Numeric O
Identifier O
822 O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
5768 O
* O
* O
] O

 O
When O
: O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
766 O
* O
* O
] O
, O
[ O
* O
* O
4 O
- O
29 O
* O
* O
] O
at O
11:30am O


 O
We O
are O
working O
on O
a O
follow O
up O
appointment O
with O
Dr O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
in O
the O

 O
Nephrology O
department O
in O
the O
next O
week O
. O
You O
will O
be O
called O
with O

 O
this O
appointment O
. O
If O
you O
have O
not O
heard O
or O
have O
questions O
, O

 O
please O
call O
: O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
10135 O
* O
* O
] O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2138 O
- O
8 O
- O
13 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2138 O
- O
8 O
- O
16 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2073 O
- O
3 O
- O
15 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Penicillins B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
695 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
abdominal O
pain O
and O
weakness O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O



 O
History O
of O
Present O
Illness O
: O

 O
65 O
M O
with O
history O
of O
HCV O
, O
HCC O
s/p O
left O
lateral O
segmentectomy O
in O

 O
[ O
* O
* O
2135 O
* O
* O
] O
who O
presents O
now O
with O
1 O
- O
2 O
weeks O
of O
abdominal O
pain O
and O

 O
overall O
weakness O
. O
He O
reports O
that O
~10 O
days O
ago O
he O
had O
a O
few O
days O

 O
of O
nausea O
and O
emesis O
; O
after O
this O
passed O
he O
began O
to O
feel O
very O

 O
weak O
with O
decreased O
energy O
and O
dyspnea O
on O
exertion O
. O
Over O
the O

 O
same O
time O
period O
he O
has O
begun O
to O
have O
sharp O
right B-REA
upper I-REA
quadrant I-REA

 I-REA
pain I-REA
, I-REA
described O
as O
under O
his O
ribs O
, O
worsening O
with O
deep O
breaths O

 O
in O
. O
He O
has O
been O
treating O
this O
with O
advil B-DRUG
, I-DRUG
he O
states O
that O
he O

 O
takes O
three B-DOS
pills B-FOR
( O
unk O
strength O
) O
once B-FRE
a I-FRE
day I-FRE
. I-FRE
He O
also O
endorses O

 O
involuntary O
20 O
lb O
weight O
loss O
over O
the O
past O
month O
. O
He O
denies O

 O
hematemesis O
, O
denies O
blood O
in O
his O
stool O
or O
dark O
stools O
, O
denies O

 O
changes O
in O
urinary O
frequency/urgency O
or O
color O
. O
He O
denies O
fevers O

 O
or O
chills O
at O
home O
. O
13 O
point O
review O
of O
systems O
is O
otherwise O

 O
negative O
. O


 O
Past O
Medical O
History O
: O

 O
PMHx O
: O

 O
perforated O
diverticulitis O

 O
Hepatitis O
C O
, O
diagnosed O
in O
[ O
* O
* O
7-/2135 O
* O
* O
] O
w/o O
antiviral O
therapy O

 O
h/o O
alcohol O
abuse O

 O
h/o O
tobacco O
abuse O

 O
glaucoma O

 O
cataracts O


 O
PSurgHx O
: O

 O
sigmoidectomy O
& O
diverting O
loop O
ileostomy O
[ O
* O
* O
2136 O
- O
8 O
- O
21 O
* O
* O
] O



 O
Social O
History O
: O

 O
Works O
as O
a O
painter O
, O
lives O
alone O
, O
tob O
1 O
ppd O
x40 O
years O
, O
EtOH O
one O

 O
pint/day O
vodka O
x O
20 O
years O
, O
abstinence O
since O
[ O
* O
* O
2136 O
- O
4 O
- O
7 O
* O
* O
] O
, O
remote O

 O
heroin O
use O
, O
current O
occasional O
MJ O
use O
. O



 O
Family O
History O
: O

 O
non-contributory O


 O
Physical O
Exam O
: O

 O
PHYSICAL O
EXAM O
: O

 O
98.7 O
95 O
100/61 O
16 O
100 O
% O

 O
Gen O
: O
AAOx3 O
, O
comfortable O
, O
NAD O
, O
cooperative O
and O
pleasant O

 O
HEENT O
: O
PERRL O
, O
sclera O
anicteric O
, O
oropharynx O
clear O

 O
CV O
: O
RRR O
, O
no O
m/r/g O

 O
Pulm O
: O
CTAB O

 O
Abd O
: O
BS(+ O
) O
, O
soft O
, O
ND O
, O
mild O
TTP O
at O
RUQ O
. O
Prior O
surgical O
incisions O

 O
consistent O
with O
previous O
segmentectomy O
well-healed O
, O

 O
non-indurated O
, O
non-erythematous O
, O
non-tender O
. O

 O
G/U O
: O
Deferred O

 O
MSK O
: O
No O
c/c/e O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2138 O
- O
8 O
- O
13 O
* O
* O
] O
04:00PM O
   O
GLUCOSE-122 O
* O
UREA O
N-19 O
CREAT-1.3 O
* O
SODIUM-132 O
* O

 O
POTASSIUM-4.6 O
CHLORIDE-97 O
TOTAL O
CO2 O
- O
25 O
ANION O
GAP-15 O

 O
[ O
* O
* O
2138 O
- O
8 O
- O
13 O
* O
* O
] O
04:00PM O
   O
ALT(SGPT)-34 O
AST(SGOT)-120 O
* O
LD(LDH)-537 O
* O
ALK O

 O
PHOS-472 O
* O
TOT O
BILI-0.9 O

 O
[ O
* O
* O
2138 O
- O
8 O
- O
13 O
* O
* O
] O
04:00PM O
   O
LIPASE-160 O
* O

 O
[ O
* O
* O
2138 O
- O
8 O
- O
13 O
* O
* O
] O
04:00PM O
   O
proBNP-251 O
* O

 O
[ O
* O
* O
2138 O
- O
8 O
- O
13 O
* O
* O
] O
04:00PM O
   O
ALBUMIN-3.5 O
IRON-19 O
* O


 O
Brief O
Hospital O
Course O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
was O
admitted O
to O
the O
Hepatobiliary O
Surgical O
Service O

 O
on O
[ O
* O
* O
2138 O
- O
8 O
- O
13 O
* O
* O
] O
with O
abdominal O
pain O
and O
weakness O
as O
described O
above O
. O

 O
His O
initial O
labs O
demonstrated O
a O
significant O
anemia O
, O
with O
a O

 O
hematocrit O
of O
19.7 O
. O
Further O
review O
of O
his O
history O
raised O
the O

 O
possibility O
of O
an O
upper B-ADE
GI I-ADE
bleed I-ADE
, I-ADE
as O
it O
was O
determined O
he O
had O

 O
been O
taking O
high O
doses O
of O
NSAIDs B-DRUG
for O
his O
abdominal B-REA
pain I-REA
, I-REA
and O
had O

 O
unclear O
history O
of O
melanotic O
stools O
and/or O
blood-tinged O
emesis O
. O

 O
He O
was O
initially O
admitted O
to O
the O
Surgical O
ICU O
, O
where O
he O
was O

 O
stabilized O
with O
2 B-STR
units I-STR
of O
packed B-DRUG
red I-DRUG
blood I-DRUG
cells I-DRUG
. I-DRUG
His O

 O
hematocrit O
then O
rose O
to O
23.4 O
, O
at O
which O
time O
he O
was O
transfused O
an O

 O
additional O
2 O
units O
. O
His O
hematocrit O
then O
stabilized O
at O
28.2 O
. O


 O
A O
CT O
of O
his O
abdomen O
performed O
shortly O
after O
admission O
on O
[ O
* O
* O
2138 O
- O
8 O
- O
13 O
* O
* O
] O

 O
revealed O
the O
following O
: O

 O
1 O
. O
  O
Extensive O
hepatic O
lesions O
( O
presumably O
HCC O
) O
with O
extensive O

 O
mesenteric O
root O
, O
porta O
hepatis O
lymphadenopathy O
, O
and O
mediastinal O

 O
lymphadenopathy O
as O
well O
as O
mesenteric/omental O
implants O
and O

 O
possible O
pancreatic O
and O
mesenteric O
vein O
invasion O
as O
described O

 O
above O
. O
  O
Nonhemorrhagic O
ascites O
. O
No O
areas O
of O
active O
hemorrhage O

 O
within O
the O
mass O
lesions O
or O
along O
the O
course O
of O
the O
bowel O
are O

 O
present O
. O

 O
2 O
. O
  O
Gastroesophageal O
varices O
. O

 O
3 O
. O
  O
Nonhemorrhagic O
right O
pleural O
effusion O
with O
associated O

 O
atelectasis O
. O
New O
bilateral O
pulmonary O
nodules O
concerning O
for O

 O
metastases O
. O



 O
Given O
the O
size O
and O
distribution O
of O
his O
hepatic O
lesions O
, O
Mr. O

 O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
was O
determined O
to O
be O
not O
eligible O
for O
surgical O

 O
resection O
. O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
also O
received O
an O
esophago-gastric O

 O
endoscopy O
to O
evaluate O
his O
suspected O
upper O
GI O
bleed O
, O
anemia O
, O
and O

 O
abdominal O
pain O
. O
This O
study O
revealed O
the O
following O
: O

 O
- O
[ O
* O
* O
Name O
Prefix O
( O
Prefixes O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Prefixes O
) O
* O
* O
] O
B O
distal O
esophagitis O
, O
2 O
cords O
of O
small O
esophageal O

 O
varices O
without O
red O
whale O
signs O
left O
undisturbed O
, O
irregular O
GEJ O

 O
with O
2 O
tongues O
of O
salmon O
like O
mucosa O
left O
undisturbed O
. O

 O
- O
Diffuse O
mild O
to O
modorate O
erythema O
with O
deformed O
antrum O
and O

 O
pyloric O
area O
. O
One O
small O
1 O
cm O
clean O
based O
ulcer O
with O
surrounding O

 O
edema O
and O
erythema O
left O
undisturbed O
. O
Retroflex O
view O
revealed O
a O

 O
moderate O
hiatal O
hernia O
, O
hiatus O
~3 O
cm O
. O

 O
- O
Duodenitis O
and O
one O
small O
< O
1 O
cm O
superficial O
clean O
based O
ulcer O
in O

 O
the O
duodenal O
bulb O
left O
undisturbed O
, O
normal O
second O
portion O
. O

 O
- O
Otherwise O
normal O
EGD O
to O
second O
part O
of O
the O
duodenum O
. O


 O
The O
etiology O
of O
his O
anemia O
was O
determined O
to O
be O
a O
combination O
of O

 O
hepatic O
lesions/HCC O
as O
well O
as O
upper B-ADE
GI I-ADE
bleed I-ADE
, I-ADE
possibly O

 O
secondary O
to O
NSAID B-DRUG
use O
. O
After O
hemodynamic O
and O
cardiovascular O

 O
stabilization O
with O
transfusions O
as O
above O
, O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
was O

 O
transferred O
out O
of O
the O
SICU O
to O
the O
surgical O
floor O
. O
His O
liver O

 O
lesions O
and O
clinical O
case O
was O
discussed O
during O
a O

 O
multi-disciplinary O
hepatic O
tumor O
conference O
. O
It O
was O
determined O

 O
he O
would O
benefit O
from O
biopsy O
of O
his O
lesions O
, O
with O
possible O

 O
systemic O
therapy O
to O
be O
determined O
as O
an O
outpatient O
. O
Mr. O

 O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
future O
outpatient O
care O
was O
coordinated O
with O
the O

 O
hematology-oncology O
service O
, O
and O
he O
was O
discharged O
on O
[ O
* O
* O
8 O
- O
16 O
* O
* O
] O
, O
[ O
* O
* O
2137 O
* O
* O
] O
. O


 O
Medications O
on O
Admission O
: O

 O
Occasional O
NSAID B-DRUG
use O
. O


 O
Discharge O
Medications O
: O

 O
1 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
PO B-ROU
Q12H B-FRE

 I-FRE
RX O
* O
pantoprazole B-DRUG
40 B-STR
mg I-STR
1 B-DOS
tablet(s B-FOR
) O
by B-ROU
mouth I-ROU
q12 B-FRE
hours I-FRE
Disp O
# O
* O
60 O

 O
Tablet O
Refills:*2 O

 O
2 O
. O
HYDROmorphone B-DRUG
( O
Dilaudid B-DRUG
) I-DRUG
2 B-STR
mg I-STR
PO B-ROU
Q4H B-FRE
: I-FRE
PRN I-FRE
Pain B-REA

 I-REA
RX O
* O
hydromorphone B-DRUG
[ O
Dilaudid B-DRUG
] I-DRUG
2 B-STR
mg I-STR
[ O
* O
* O
12 O
- O
9 O
* O
* O
] O
tablet(s B-FOR
) O
by B-ROU
mouth I-ROU
q B-FRE
4 I-FRE
- I-FRE
6 I-FRE

 I-FRE
hours I-FRE
PRN I-FRE
Disp O
# O
* O
40 O
Tablet O
Refills:*0 O

 O
3 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
RX O
* O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
1 B-DOS
capsule(s B-FOR
) O
by B-ROU
mouth I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
PRN B-FRE
Disp O

 O
# O
* O
60 O
Capsule O
Refills:*1 O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Extensive O
liver O
lesions O
( O
presumably O
recurrent O
hepatocellular O

 O
carcinoma O
) O



 O

Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
Please O
call O
Dr.[**Name O
( O
NI O
) O
1369 O
* O
* O
] O
office O
at O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
673 O
* O
* O
] O
for O
fever O
, O

 O
chills O
, O
nausea O
, O
vomiting O
, O
diarrhea O
, O
constipation O
, O
inability O
to O

 O
tolerate O
food O
, O
fluids O
or O
medications O
. O


 O
You O
will O
be O
following O
up O
with O
the O
oncologist O
Dr O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
1852 O
* O
* O
] O

 O
for O
possible O
liver O
biopsy O
and O
treatment O
discussions O
. O


 O
Please O
continue O
omeprazole B-DRUG
2 B-DOS
of O
the O
20 B-STR
mg I-STR
tablets B-FOR
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
due O
to O
the O
stomach B-ADE
and I-ADE
small I-ADE
intestine I-ADE
ulcers I-ADE
that O
developed O

 O
most O
likely O
due O
to O
the O
amount O
of O
advil B-DRUG
( O
ibuprofen B-DRUG
) I-DRUG
you O
were O

 O
taking O
. O
This O
prescription O
has O
been O
called O
into O
the O
[ O
* O
* O
Company O
4916 O
* O
* O
] O
at O

 O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
84701 O
* O
* O
] O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
84702 O
* O
* O
] O
) O
in O
[ O
* O
* O
Location O
( O
un O
) O
669 O
* O
* O
] O
. O
It O
should O
be O
covered O
by O

 O
your O
insurance O
. O
Please O
take O
2 B-DOS
of O
the O
20 B-STR
mg I-STR
tablets B-FOR
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
and O
avoid O
the O
use O
of O
ibuprofen B-DRUG
( O
advil B-DRUG
) I-DRUG
, O
aspirin B-DRUG
or O
any O
aspirin B-DRUG

 I-DRUG
containing I-DRUG
products I-DRUG
. I-DRUG


 O
Please O
see O
Dr O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
1852 O
* O
* O
] O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
8770 O
* O
* O
] O
) O
as O
soon O
as O
possible O

 O
for O
further O
evaluation O
and O
treatment O
options O
. O


 O
No O
driving O
if O
taking O
narcotic B-DRUG
pain I-DRUG
medication I-DRUG
. I-DRUG


 O
Followup O
Instructions O
: O

 O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
1852 O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
8770 O
* O
* O
] O
Oncologist O
  O
Call O
for O
appointment O
as O

 O
soon O
as O
possible O


 O
Dr. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
497 O
* O
* O
] O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
3618 O
* O
* O
] O
hepatology O
. O
Call O
to O
schedule O
an O

 O
appointment O
for O
2 O
weeks O
. O
Before O
your O
appointment O
, O
you O
will O
go O
to O

 O
the O
lab O
and O
get O
your O
blood O
drawn O
for O
a O
lab O
test O
. O
Please O
bring O

 O
the O
lab O
script O
that O
will O
be O
provided O
to O
you O
upon O
discharge O
so O

 O
they O
know O
what O
labs O
to O
draw O
. O



                              O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
707 O
* O
* O
] O
MD O
, O
[ O
* O
* O
MD O
Number(3 O
) O
709 O
* O
* O
] O


 O

Admission O
Date O
: O
  O
[ O
* O
* O
2177 O
- O
3 O
- O
10 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2177 O
- O
3 O
- O
12 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2122 O
- O
3 O
- O
1 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1711 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Pericardial O
effusion O
. O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Pericardiocentesis O
and O
pericardial O
drain O
placement O
. O



 O
History O
of O
Present O
Illness O
: O

 O
The O
patient O
is O
a O
52-year O
old O
female O
with O
a O
history O
of O
metastatic B-REA

 I-REA
breast I-REA
cancer I-REA
, I-REA
s/p O
lt O
. O
mastectomy O
now O
enrolled O
in O
clinical O
trial O

 O
" O
05 O
- O
395 O
" O
( O
lapatinib B-DRUG
monotherapy I-DRUG
1500 B-STR
mg I-STR
) I-STR
, O
who O
noted O
lt O
. O
arm O

 O
swelling O
[ O
* O
* O
2 O
- O
28 O
* O
* O
] O
. O
Doppler O
neg O
for O
clot O
, O
but O
CT O
( O
routine O
, O
restaging O
) O

 O
revealed O
pericardial O
effusion O
. O
Echo O
[ O
* O
* O
3 O
- O
3 O
* O
* O
] O
revealed O
: O
small O
to O

 O
moderate O
sized O
circumferential O
pericardial O
effusion O
, O
most O

 O
prominently O
inferolateral O
to O
the O
left O
ventricle O
and O
around O
the O

 O
right O
atrium O
, O
but O
~1 O
cm O
anterior O
to O
the O
right O
ventricle O
. O
There O
is O

 O
mild O
right O
ventricular O
diastolic O
collapse O
consistent O
with O

 O
increased O
pericardial O
pressure/early O
tamponade O
physiology O
. O

 O
. O

 O
[ O
* O
* O
3 O
- O
5 O
* O
* O
] O
: O
Compared O
with O
the O
prior O
study O
( O
images O
reviewed O
) O
of O

 O
[ O
* O
* O
2177 O
- O
3 O
- O
3 O
* O
* O
] O
, O
the O
pericardial O
effusion O
appears O
similar O
to O
slightly O

 O
larger O
. O
There O
is O
right O
ventricular O
diastolic O
collapse O
, O

 O
consistent O
with O
impaired O
fillling/tamponade O
physiology O
. O

 O
. O

 O
[ O
* O
* O
3 O
- O
7 O
* O
* O
] O
: O
There O
is O
subtle O
RV O
diastolic O
compression O
without O
collapse O

 O
( O
no O
overt O
tamponade O
) O
. O
Compared O
with O
the O
prior O
study O
( O
images O

 O
reviewed O
) O
of O
[ O
* O
* O
2177 O
- O
3 O
- O
5 O
* O
* O
] O
, O
there O
is O
slightly O
less O
pericardial O
fluid O

 O
anteriorly O
. O
Otherwise O
no O
change O
. O

 O
. O

 O
A O
pericardial O
drain O
was O
placed O
with O
return O
of O
approximately O
250 O

 O
cc O
of O
serosanginous O
fluid O
and O
normalization O
of O
right O
heart O

 O
pressures O
. O
She O
is O
admitted O
to O
the O
CCU O
for O
further O
monitoring O
. O



 O
Past O
Medical O
History O
: O

 O
ONCOLOGY O
HISTORY O
: O
She O
was O
initially O
diagnosed O
in O
[ O
* O
* O
2164 O
* O
* O
] O
with O
a O
3.5 O

 O
cm O
infiltrating O
ductal O
carcinoma O
, O
lymph O
node O
positive O
, O
LVI O

 O
positive O
, O
ER O
positive O
. O
She O
is O
status O
post O
left O
mastectomy O
with O

 O
reconstruction O
, O
CAF O
followed O
by O
tamoxifen B-DRUG
. I-DRUG
She O
recurred O
in O

 O
[ O
* O
* O
7-/2169 O
* O
* O
] O
, O
with O
metastasis O
to O
her O
left O
supraclavicular O
node O
and O

 O
lung O
. O
Biopsy O
documented O
HER-2/neu B-REA
over O
expression O
by O

 O
immunohistochemistry O
. O
ER O
positive O
. O
She O
was O
treated O
with O
Arimidex B-DRUG

 I-DRUG
for B-DUR
six I-DUR
months I-DUR
, I-DUR
which O
was O
followed O
by O
Taxol B-DRUG
and O
Herceptin B-DRUG
. I-DRUG
She O

 O
was O
then O
treated O
with O
high-dose B-DOS
chemo B-DRUG
and O
Herceptin B-DRUG
followed O
by O

 O
transplant O
as O
part O
of O
the O
clinical O
trial O
. O
This O
chemo B-DRUG
included O

 O
thiotepa B-DRUG
, I-DRUG
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
, O
and O
Taxol B-DRUG
. I-DRUG
In O
[ O
* O
* O
9-/2173 O
* O
* O
] O
, O
she O
was O
treated O
with O

 O
letrozole B-DRUG
and O
Herceptin B-DRUG
and O
was O
then O
switched O
to O
Aromasin B-DRUG
and O

 O
Herceptin B-DRUG
in O
11/[**2174 O
* O
* O
] O
. O
Upon O
progression O
[ O
* O
* O
Male O
First O
Name O
( O
un O
) O
* O
* O
] O
was O
switched O
to O
the O

 O
lapatinib B-DRUG
phase O
II O
trial O
in O
[ O
* O
* O
7 O
- O
28 O
* O
* O
] O
, O
and O
herceptin B-DRUG
was O

 O
discontinued O
. O
She O
has O
received O
8 B-DUR
cycles I-DUR
of O
lapatinib B-DRUG
. I-DRUG

 O
. O

 O
PAST O
MEDICAL O
HISTORY O
: O

 O
1 O
. O
Metastatic O
breast O
cancer O
as O
above O
. O

 O
2 O
. O
Autologous O
bone O
marrow O
transplant O
in O
[ O
* O
* O
2169 O
* O
* O
] O
. O

 O
3 O
. O
History O
of O
meningoceles O
. O

 O
4 O
. O
Hyperlipidemia O
. O



 O
Social O
History O
: O

 O
A O
single O
parent O
. O
She O
lives O
with O
her O
13-year-old O
daughter O
. O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O

 O
tobacco O
, O
alcohol O
, O
or O
drugs O
. O


 O
Family O
History O
: O

 O
Father O
has O
lymphoma O
. O


 O
Physical O
Exam O
: O

 O
Blood O
pressure O
was O
116/66 O
mm O
Hg O
while O
seated O
. O
Pulse O
was O
73 O

 O
beats/min O
and O
regular O
, O
respiratory O
rate O
was O
15 O
breaths/min O
. O

 O
Generally O
the O
patient O
was O
well O
developed O
, O
well O
nourished O
and O

 O
well O
groomed O
. O
The O
patient O
was O
oriented O
to O
person O
, O
place O
and O

 O
time O
. O
The O
patient O
's O
mood O
and O
affect O
were O
not O
inappropriate O
. O

 O
. O

 O
There O
was O
no O
xanthalesma O
and O
conjunctiva O
were O
pink O
with O
no O

 O
pallor O
or O
cyanosis O
of O
the O
oral O
mucosa O
. O
The O
neck O
was O
supple O
with O

 O
JVP O
of O
less O
than O
6 O
cm O
. O
The O
carotid O
waveform O
was O
normal O
. O
There O

 O
was O
no O
thyromegaly O
. O
The O
were O
no O
chest O
wall O
deformities O
, O

 O
scoliosis O
or O
kyphosis O
. O
The O
respirations O
were O
not O
labored O
and O

 O
there O
were O
no O
use O
of O
accessory O
muscles O
. O
The O
lungs O
were O
clear O
to O

 O
ascultation O
bilaterally O
with O
normal O
breath O
sounds O
and O
no O

 O
adventitial O
sounds O
or O
rubs O
. O

 O
. O


 O
Palpation O
of O
the O
heart O
revealed O
the O
PMI O
to O
be O
located O
in O
the O
5th O

 O
intercostal O
space O
, O
mid O
clavicular O
line O
. O
There O
were O
no O
thrills O
, O

 O
lifts O
or O
palpable O
S3 O
or O
S4 O
. O
The O
heart O
sounds O
revealed O
a O
normal O

 O
S1 O
and O
the O
S2 O
was O
normal O
. O
There O
were O
no O
rubs O
, O
clicks O
or O
gallops O
. O

 O
There O
was O
a O
slight O
[ O
* O
* O
1 O
- O
28 O
* O
* O
] O
HSM O
. O

 O
. O

 O
There O
is O
a O
pericardial O
drain O
in O
place O
in O
the O
sub-xiphoid O

 O
position O
. O
Drainage O
bag O
connected O
, O
contains O
approx O
10 O
cc O
of O

 O
serosanguinous O
fluid O
. O

 O
. O

 O
The O
abdominal O
aorta O
was O
not O
enlarged O
by O
palpation O
. O
There O
was O
no O

 O
hepatosplenomegaly O
or O
tenderness O
. O
The O
abdomen O
was O
soft O
nontender O

 O
and O
nondistended O
. O
The O
extremities O
had O
no O
pallor O
, O
cyanosis O
, O

 O
clubbing O
. O
There O
is O
slight O
( O
1 O
+ O
) O
, O
diffuse O
, O
Lt O
. O
UE O
edema O
. O
There O

 O
were O
no O
abdominal O
, O
femoral O
or O
carotid O
bruits O
. O
Inspection O
and/or O

 O
palpation O
of O
skin O
and O
subcutaneous O
tissue O
showed O
no O
stasis O

 O
dermatitis O
, O
ulcers O
, O
scars O
, O
or O
xanthomas O
. O

 O
. O

 O
Pulses O
: O

 O
Right O
: O
Carotid O
2 O
+ O
Femoral O
2 O
+ O
Popliteal O
2 O
+ O
DP O
2 O
+ O
PT O
2 O
+ O

 O
Left O
: O
Carotid O
2 O
+ O
Femoral O
2 O
+ O
Popliteal O
2 O
+ O
DP O
2 O
+ O
PT O
2 O
+ O


 O
Pertinent O
Results O
: O

 O
Labwork O
on O
admission O
: O

 O
[ O
* O
* O
2177 O
- O
3 O
- O
10 O
* O
* O
] O
04:15PM O
   O
WBC-4.2 O
RBC-3.40 O
* O
HGB-10.8 O
* O
HCT-31.0 O
* O
MCV-91 O

 O
MCH-31.9 O
MCHC-35.0 O
RDW-14.8 O

 O
[ O
* O
* O
2177 O
- O
3 O
- O
10 O
* O
* O
] O
04:15PM O
   O
PLT O
COUNT-161 O

 O
[ O
* O
* O
2177 O
- O
3 O
- O
10 O
* O
* O
] O
04:15PM O
   O
GLUCOSE-99 O
UREA O
N-12 O
CREAT-0.7 O
SODIUM-139 O

 O
POTASSIUM-3.9 O
CHLORIDE-106 O
TOTAL O
CO2 O
- O
25 O
ANION O
GAP-12 O

 O
. O

 O
Labwork O
on O
admission O
: O

 O
C.CATH O
Study O
Date O
of O
[ O
* O
* O
2177 O
- O
3 O
- O
10 O
* O
* O
] O



 O
* O
* O
* O
Not O
Signed O
Out O
* O
* O
* O


 O
BRIEF O
HISTORY O
: O

 O
This O
55 O
year O
old O
female O
with O
known O
diagnosis O
of O
metastatic O

 O
breast O
cancer O

 O
presented O
with O
pericardial O
effusion O
diagnosed O
on O
echocardiogram O

 O
with O

 O
significant O
respiratory O
mitral O
flow O
variation O
. O
Patient O
was O

 O
therefore O

 O
referred O
for O
pericardiocentesis O
. O


 O
INDICATIONS O
FOR O
CATHETERIZATION O
: O

 O
Pericardial O
effusion O
. O


 O
PROCEDURE O
: O

 O
Right O
Heart O
Catheterization O
: O
was O
performed O
by O
percutaneous O
entry O

 O
of O
the O

 O
right O
femoral O
vein O
, O
using O
a O
7 O
French O
pulmonary O
wedge O
pressure O

 O
catheter O
, O

 O
advanced O
to O
the O
PCW O
position O
through O
an O
8 O
French O
introducing O

 O
sheath O
. O

 O
Cardiac O
output O
was O
measured O
by O
the O
Fick O
method O
. O

 O
Pericardiocentesis O
: O
was O
performed O
via O
the O
subxyphoid O
approach O
, O

 O
using O
an O

 O
18 O
gauge O
thin-wall O
needle O
, O
a O
guide O
wire O
, O
and O
a O
drainage O

 O
catheter O
. O

 O
Conscious O
Sedation O
: O
  O
was O
provided O
with O
appropriate O
monitoring O

 O
performed O
by O

 O
a O
member O
of O
the O
nursing O
staff O
. O



 O
HEMODYNAMICS O
RESULTS O
BODY O
SURFACE O
AREA O
: O
  O
m2 O

   O
HEMOGLOBIN O
: O
gms O
% O

   O
FICK O

 O
* O
* O
PRESSURES O

 O
RIGHT O
ATRIUM O
{ O
a/v/m O
} O
14/12/10 O

 O
RIGHT O
VENTRICLE O
{ O
s/ed O
} O
35/12 O

 O
PULMONARY O
ARTERY O
{ O
s/d/m O
} O
35/15/21 O

 O
PULMONARY O
WEDGE O
{ O
a/v/m O
} O
16/16/12 O

 O
AORTA O
{ O
s/d/m O
} O
140/65/95 O

 O
PERICARDIUM O
{ O
m O
} O
12 O

 O
* O
* O
CARDIAC O
OUTPUT O

 O
HEART O
RATE O
{ O
beats/min O
} O
70 O

 O
RHYTHM O
SINUS O


 O
OTHER O
HEMODYNAMIC O
DATA O
: O
      O
The O
oxygen O
consumption O
was O
assumed O
. O






 O
TECHNICAL O
FACTORS O
: O

 O
Total O
time O
( O
Lidocaine B-DRUG
to O
test O
complete O
) O
= O
45 O
minutes O
. O

 O
Arterial O
time O
= O
45 O
minutes O
. O

 O
Fluoro O
time O
= O
2.3 O
minutes O
. O

 O
Contrast B-DRUG
injected O
: O

           O
Non-ionic O
low O
osmolar O
( O
isovue O
, O
optiray O
... O
) O
, O
vol O
20 O
ml O
, O

 O
Indications O
- O
Renal O

 O
Anesthesia B-REA
: I-REA

           O
1 B-STR
% I-STR
Lidocaine B-DRUG
subq B-ROU
. I-ROU

 O
Cardiac O
Cath O
Supplies O
Used O
: O

           O
- O
[ O
* O
* O
Company O
* O
* O
] O
, O
PERICARDIOSENTISIS O
SET O

           O
- O
ALLEGIANCE O
, O
CUSTOM O
STERILE O
PACK O



 O
COMMENTS O
: O

 O
1 O
. O
Resting O
hemodynamics O
were O
performed O
. O
The O
right O
sided O
filling O

 O
pressures O
were O
mildly O
elevated O
( O
mean O
RA O
pressure O
was O
12mmHg O
and O

 O
RVEDP O

 O
was O
12mmHg O
) O
. O
The O
pulmonary O
artery O
pressures O
were O
mildly O
elevated O


 O
measuring O
35/15mmHg O
. O
The O
left O
sided O
filling O
pressures O
were O

 O
equalized O
to O

 O
the O
right O
( O
mean O
PCW O
pressure O
was O
12mmHg O
) O
. O
There O
was O
significant O

 O
respiratory O
variation O
of O
systemic O
arterial O
pressure O
up O
to O

 O
20mmHg O
. O
There O

 O
was O
equalization O
of O
RA O
and O
pericardial O
pressures O
. O

 O
2 O
. O
Pericardiocentesis O
was O
performed O
under O
fluoroscopy O
guidance O
. O

 O
Pericardial O
drain O
was O
subsequently O
placed O
with O
240cc O

 O
serosanguinous O

 O
fluid O
removed O
. O
Repeat O
measurement O
of O
pericardial O
pressure O
and O
RA O


 O
pressure O
demonstrated O
clear O
seperation O
. O



 O
FINAL O
DIAGNOSIS O
: O

 O
1 O
. O
Elevated O
right O
sided O
filling O
pressures O
with O
equlization O
of O

 O
RA/LA/pericardial O
pressures O
. O

 O
2 O
. O
Successful O
placement O
of O
pericardial O
drain O
. O

 O
. O

 O
ECHO O
Study O
Date O
of O
[ O
* O
* O
2177 O
- O
3 O
- O
10 O
* O
* O
] O

 O
Conclusions O
: O

 O
Overall O
left O
ventricular O
systolic O
function O
is O
low O
normal O
( O
LVEF O

 O
50 O
- O
55 O
% O
) O
. O
There O
is O
a O
trivial/physiologic O
pericardial O
effusion O
. O

 O
Compared O
with O
the O
prior O
study O
( O
images O
reviewed O
) O
of O
[ O
* O
* O
2177 O
- O
3 O
- O
7 O
* O
* O
] O
, O

 O
there O
is O
now O
minimal O
residual O
pericardial O
effusion O
. O

 O
. O

 O
ECG O
Study O
Date O
of O
[ O
* O
* O
2177 O
- O
3 O
- O
10 O
* O
* O
] O
  O
1:00:10 O
PM O

 O
Sinus O
rhythm O

 O
Normal O
ECG O

 O
Since O
previous O
tracing O
, O
no O
significant O
change O

 O
. O


 O
CHEST O
( O
PORTABLE O
AP O
) O
  O
[ O
* O
* O
2177 O
- O
3 O
- O
11 O
* O
* O
] O

 O
IMPRESSION O
: O
AP O
chest O
, O
small O
right O
pleural O
effusion O
is O
present O
. O

 O
Right O
lower O
lobe O
atelectasis O
is O
new O
since O
[ O
* O
* O
2 O
- O
28 O
* O
* O
] O
. O
Consolidation O

 O
in O
the O
anterior O
segment O
of O
the O
right O
upper O
lobe O
and O
a O
right O

 O
apical O
paramediastinal O
mass O
are O
unchanged O
. O
Left O
lung O
is O
clear O
. O

 O
Several O
loops O
of O
pericardiocentesis O
catheter O
projecting O
over O
the O

 O
subxiphoid O
midline O
, O
the O
base O
of O
the O
heart O
and O
superiorly O
to O
the O

 O
level O
of O
the O
pulmonary O
outflow O
tract O
, O
are O
acutely O
coiled O
and O

 O
should O
be O
evaluated O
clinically O
to O
see O
if O
they O
are O
draining O

 O
properly O
. O
No O
pneumothorax O
. O

 O
. O

 O
ECHO O
Study O
Date O
of O
[ O
* O
* O
2177 O
- O
3 O
- O
11 O
* O
* O
] O

 O
Conclusions O
: O

 O
Left O
ventricular O
wall O
thickness O
, O
cavity O
size O
, O
and O
systolic O

 O
function O
are O
normal O
( O
LVEF>55 O
% O
) O
. O
Right O
ventricular O
chamber O
size O

 O
and O
free O
wall O
motion O
are O
normal O
. O
There O
is O
a O
small O

 O
circumferential O
pericardial O
effusion O
primarily O
inferolateral O
to O

 O
the O
left O
ventricle O
with O
minimal O
effusion O
anterior O
to O
the O
right O

 O
ventricle O
. O
No O
echocardiographic O
signs O
of O
tamponade O
physiology O

 O
are O
seen O
. O

 O
Compared O
with O
the O
prior O
study O
( O
images O
reviewed O
) O
of O
[ O
* O
* O
2177 O
- O
3 O
- O
10 O
* O
* O
] O
, O

 O
the O
  O
inferolateral O
effusion O
is O
more O
prominent O
. O

 O
. O

 O
Labwork O
on O
discharge O
: O

 O
[ O
* O
* O
2177 O
- O
3 O
- O
12 O
* O
* O
] O
09:25AM O
BLOOD O
WBC-5.6 O
RBC-3.67 O
* O
Hgb-11.9 O
* O
Hct-36.0 O

 O
MCV-98 O
# O
MCH-32.3 O
* O
MCHC-32.9 O
RDW-14.2 O
Plt O
Ct-185 O

 O
[ O
* O
* O
2177 O
- O
3 O
- O
12 O
* O
* O
] O
09:25AM O
BLOOD O
Glucose-108 O
* O
UreaN-8 O
Creat-0.7 O
Na-136 O

 O
K-3.7 O
Cl-104 O
HCO3 O
- O
21 O
* O
AnGap-15 O


 O
Brief O
Hospital O
Course O
: O

 O
55 O
year-old O
female O
with O
metastatic O
breast O
cancer O
presenting O
with O

 O
pericardial O
effusion O
. O

 O
. O

 O
1 O
. O
Pericardial O
effusion O
. O
Likely O
malignant O
. O
Pericardiocentesis O

 O
was O
performed O
with O
approximately O
250 O
cc O
of O
serosanguinous O
fluid O

 O
output O
and O
normalization O
of O
right O
heart O
pressures O
. O
A O
pericardial O

 O
drain O
was O
placed O
with O
320 O
cc O
of O
serosanguinous O
fluid O
output O
the O

 O
first O
12 O
hours O
, O
then O
75 O
cc O
over O
6 O
hours O
, O
then O
no O
output O
. O
A O

 O
repeat O
echocardiogram O
showed O
a O
small O
pericardial O
effusion O

 O
without O
evidence O
of O
tamponade O
as O
above O
. O
The O
pericardial O
drain O

 O
was O
removed O
. O
An O
echocardiogram O
the O
next O
morning O
showed O
stable O

 O
small O
pericardial O
effusion O
. O
Cultures O
were O
negative O
at O
the O
time O

 O
of O
discharge O
and O
cytology O
was O
pending O
. O
The O
patient O
will O
have O
a O

 O
repeat O
echocardiogram O
five O
days O
after O
discharge O
and O
will O

 O
follow-up O
with O
her O
oncologist O
. O
The O
patient O
may O
need O
a O

 O
pericardial O
window O
or O
balloon O
pericardiotomy O
procedure O
if O
the O

 O
effusion O
increases O
in O
size O
. O

 O
. O


 O
2 O
. O
Infectious O
disease O
. O
The O
patient O
had O
a O
temperature O
to O
100.8 O

 O
the O
second O
day O
of O
admission O
. O
The O
patient O
's O
only O
localizing O

 O
symptom O
was O
a O
nonproductive O
cough O
the O
patient O
has O
complained O
of O

 O
for O
the O
past O
three O
weeks O
, O
overall O
improved O
since O
that O
time O
. O

 O
Chest O
x-ray O
showed O
atelectasis O
but O
no O
new O
consolidations O
. O

 O
Urinalysis O
negative O
for O
infection O
. O
Urine O
, O
blood O
, O
and O
pericardial O

 O
fluid O
cultures O
without O
growth O
at O
the O
time O
of O
discharge O
. O
The O

 O
fever O
was O
likely O
secondary O
to O
atelectasis O
or O
the O
patient O
's O

 O
underlying O
malignancy O
. O

 O
. O

 O
3 O
. O
Breast B-REA
cancer I-REA
. I-REA
The O
patient O
is O
now O
off O
the O
lapatinib B-DRUG
study O
. O

 O
The O
patient O
is O
followed O
by O
oncology O
. O

 O
. O

 O
4 O
. O
Anemia O
. O
The O
patient O
's O
hematocrit O
remained O
stable O
at O
31 O
- O
36 O

 O
during O
admission O
. O
The O
patient O
's O
iron O
studies O
showed O
an O
iron O
to O

 O
TIBC O
ratio O
of O
5 O
% O
, O
although O
ferritin O
was O
within O
normal O
limits O
. O

 O
Folate O
and O
B12 O
were O
within O
normal O
limits O
. O
Further O
management O

 O
deferred O
to O
the O
patient O
's O
primary O
physician O
. O


 O
Medications O
on O
Admission O
: O

 O
Simvastatin B-DRUG
20 B-STR
mg I-STR
QD B-FRE


 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Simvastatin B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
Pericardial O
effusion O
status O
post O
pericardiocentesis O
and O

 O
pericardial O
drain O
placement/removal O

 O
. O

 O
Secondary O
: O

 O
1 O
. O
Metastatic O
breast O
cancer O

 O
2 O
. O
Autologous O
bone O
marrow O
transplant O
in O
[ O
* O
* O
2169 O
* O
* O
] O

 O
3 O
. O
History O
of O
meningoceles O

 O
4 O
. O
Hyperlipidemia O



 O
Discharge O
Condition O
: O

 O
Afebrile O
, O
vital O
signs O
stable O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
hospitalized O
after O
a O
procedure O
to O
remove O
fluid O
from O

 O
your O
pericardial O
sac O
. O
You O
will O
need O
a O
repeat O
echocardiogram O
to O

 O
assess O
for O
fluid O
reaccumulation O
. O
The O
office O
of O
your O
oncologist O
, O

 O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
contact O
you O
regarding O
scheduling O
of O
your O

 O
repeat O
echocardiogram O
and O
follow-up O
with O
oncology O
. O

 O
. O

 O
You O
spiked O
a O
fever O
during O
admission O
without O
any O
localizing O

 O
symptoms O
. O
Your O
oncologist O
should O
follow-up O
the O
urine O
, O
blood O
, O
and O

 O
pericardial O
fluid O
cultures O
drawn O
during O
this O
admission O
. O

 O
. O

 O
Please O
contact O
a O
physician O
if O
you O
experience O
fevers O
, O
chills O
, O

 O
chest O
pain O
, O
shortness O
of O
breath O
, O
palpitations O
, O
or O
any O
other O

 O
concerning O
symptoms O
. O

 O
. O

 O
Please O
take O
your O
medications O
as O
prescribed O
. O
There O
were O
no O

 O
changes O
made O
to O
your O
medications O
. O

 O
. O

 O
Please O
keep O
your O
follow-up O
appointments O
as O
below O
. O



 O
Followup O
Instructions O
: O

 O
The O
office O
of O
your O
oncologist O
, O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
contact O
you O

 O
regarding O
scheduling O
of O
your O
repeat O
echocardiogram O
and O
follow-up O

 O
with O
oncology O
on O
Monday O
, O
[ O
* O
* O
3 O
- O
17 O
* O
* O
] O
. O
Please O
call O
the O
office O
at O

 O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
21188 O
* O
* O
] O
with O
any O
questions O
or O
concerns O
or O
if O
you O
do O
not O

 O
hear O
from O
a O
representative O
by O
this O
Friday O
. O

 O
. O

 O
Previously O
scheduled O
appointments O
: O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
706 O
* O
* O
] O
Phone:[**Telephone/Fax O
( O
1 O
) O
327 O
* O
* O
] O
Date/Time:[**2177 O
- O
3 O
- O
17 O
* O
* O
] O
10:45 O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2159 O
- O
5 O
- O
15 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2083 O
- O
5 O
- O
13 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
2071 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Fatigue O
for O
one O
week O
. O
Transferred O
to O
CCU O
with O
hypoxic O
distress O

 O
in O
context O
of O
AF O
with O
RVR O
, O
developed O
PNA O
and O
transferred O
to O
MICU O

 O
with O
stabilized O
AF O
. O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O
. O


 O
History O
of O
Present O
Illness O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
70654 O
* O
* O
] O
is O
a O
75 O
M O
with O
a O
history O
of O
coronary O
artery O
disease O

 O
s/p O
CABG O
x3 O
( O
[ O
* O
* O
University/College O
* O
* O
] O
Presbyterian O
NY O
, O
[ O
* O
* O
2145 O
* O
* O
] O
) O
, O
PTCA O
x2 O
stents O

 O
( O
DES O
: O
proximal O
LAD O
and O
SVG O
to O
PDA O
, O
[ O
* O
* O
2156 O
* O
* O
] O
) O
as O
well O
as O

 O
assymptomatic O
PAF B-REA
on O
coumadin B-DRUG
who O
presented O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
on O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O

 O
with O
fatigue O
for O
the O
last O
5 O
days O
. O
He O
did O
not O
endorse O
shortness O

 O
of O
breath O
or O
chest O
pain O
, O
only O
generalized O
fatigue O
. O
Other O
ROS O

 O
were O
negative O
and O
notable O
for O
the O
absence O
of O
fevers O
, O
chills O
, O

 O
productive O
cough O
, O
sick O
contacts O
, O
recent O
travel O
or O
other O

 O
complaints O
. O



 O
In O
the O
ED O
, O
initial O
vitals O
: O
97.8 O
65 O
132/78 O
16 O
97 O
. O
CXR O
showed O
a O

 O
small O
new O
right O
pleural O
effusion O
. O
EKG O
showed O
atrial O
fibrillation O

 O
at O
a O
rate O
of O
114 O
, O
and O
ST O
depression O
II O
, O
III O
, O
AVf B-REA
, I-REA
V4-V6 O
. O
He O
was O

 O
given O
Aspirin B-DRUG
and O
placed O
on O
Oxygen B-DRUG
. I-DRUG
Cardiac O
biomarkers O
were O

 O
negative O
x O
3 O
. O
He O
was O
loaded O
with O
dofetilide B-DRUG
for O
chemical B-REA

 I-REA
cardioversion I-REA
of O
his O
a O
fib O
and O
went O
into O
NSR O
after O
the O
first O

 O
dose O
. O
The O
following O
morning O
he O
developed O
worsening O
dyspnea O
and O

 O
was O
found O
to O
be O
hypoxic O
with O
O2 O
sats O
in O
the O
70s O
on O
RA O
. O
He O

 O
triggerred O
for O
hypoxia O
and O
was O
found O
to O
have O
expiratory O
wheezes O

 O
and O
crackles O
at O
the O
base O
. O
Chest O
x-ray O
showed O
severe O
scoliosis O

 O
and O
opacities O
within O
both O
lower O
lobes O
. O
VBG O
showed O
pH O
7.42 O
, O
pO2 O

 O
53 O
, O
pCo2 O
30 O
. O
He O
was O
placed O
on O
a O
non-rebreather O
with O
O2 O
sats O
that O

 O
returned O
to O
92 O
% O
. O
The O
team O
felt O
that O
his O
symptoms O
were O
either O
CHF O

 O
versus O
pneumonia O
, O
with O
CHF O
more O
likely O
because O
he O
did O
not O
have O
a O

 O
white O
count O
or O
fever O
at O
the O
time O
. O
He O
was O
diuresed B-REA
with O
20 B-STR
mg I-STR
IV B-ROU

 I-ROU
lasix B-DRUG
x O
3 B-DOS
and O
had O
2 O
L O
of O
urine O
output O
. O
He O
remained O
on O
the O

 O
non-rebreather O
throughout O
the O
afternoon O
despite O
the O
diuresis O
. O
He O

 O
was O
given O
nebulizers B-DRUG
and O
ordered O
doxycycline B-DRUG
and O
augmentin B-DRUG
for O

 O
possible B-REA
community I-REA
acquired I-REA
pneumonia I-REA
( O
although O
he O
did O
not O

 O
receive O
antibiotics B-DRUG
) I-DRUG
. O
At O
6:30 O
pm O
nightfloat O
came O
to O
evaluate O
the O

 O
patient O
and O
was O
concerned O
. O
An O
ABG O
showed O
pH O
7.42 O
pO2 O
66 O
and O
pCO2 O

 O
54 O
. O
Vanc B-DRUG
and O
cefipime B-DRUG
were O
started O
and O
the O
CCU O
was O
called O
to O

 O
evaluate O
the O
patient O
. O


 O
The O
patient O
was O
found O
to O
be O
tachypneic O
and O
uncomfortable O
, O
using O

 O
increase O
work O
of O
breathing O
. O
He O
was O
sating O
92 O
% O
on O
the O

 O
non-rebreather O
. O
He O
was O
transferred O
for O
hypoxic O
respiratory O

 O
distress O
. O
In O
the O
CCU O
he O
endorsed O
chills O
, O
but O
denied O
fever O
, O
chest O

 O
pain O
, O
palpitations O
, O
nausea O
, O
cough O
, O
abdominal O
pain O
, O
HA O
, O
dysuria O
, O

 O
myalgias O
, O
melena O
. O


 O
Respiratory O
status O
continued O
to O
be O
tenuous O
in O
the O
CCU O
requiring O

 O
face O
mask O
during O
the O
day O
, O
and O
BiPap O
overnight O
. O
Patient O
was O
not O

 O
intubated O
due O
to O
concerns O
about O
ability O
to O
wean O
from O
the O
vent O
. O

 O
He O
was O
treated O
empirically O
with O
broad O
spectrum O
. O



 O
CCU O
course O
notable O
for O
increasing O
respiratory O
distress O
requiring O

 O
BiPap O
for O
comfort O
. O
Initially O
used O
overnight O
only O
with O
face O
mask O

 O
during O
the O
day O
but O
increasingly O
requiring O
BiPap O
. O
Was O
seen O
by O
his O

 O
outpatient O
pulmonologist O
who O
agreed O
with O
current O
plan O
, O
and O
felt O

 O
patient O
likely O
to O
be O
difficult O
to O
wean O
from O
the O
vent O
if O

 O
intubated O
. O
+ O
6L O
LOS O
( O
not O
counting O
insensible O
losses O
) O
. O
Admission O

 O
weight O
53.1 O
kg O
, O
currently O
weighs O
56.1 O
kg(but O
unreliable O
as O
bed O

 O
weight O
with O
sheets O
etc O
) O
. O
Patient O
had O
intermittent O
A. B-REA
Fib I-REA
with I-REA

 I-REA
RVR I-REA
requiring O
boluses B-DOS
of O
diltiazem B-DRUG
for O
rate B-REA
control I-REA
. I-REA



 O
Past O
Medical O
History O
: O

 O
1 O
. O
coronary O
artery O
disease O

 O
-CABG O
in O
[ O
* O
* O
2145 O
* O
* O
] O
: O
SVG O
to O
RPDA O
; O
SVG O
sequentially O
to O
diagonal O
and O
OM O
; O

 O
no O
LIMA O
graft O

 O
-Cath O
in O
[ O
* O
* O
2156 O
* O
* O
] O
notable O
for O
occlusion O
of O
a O
vein O
graft O
to O
the O
right O

 O
PDA O
treated O
with O
a O
DES O
and O
a O
subsequent O
elective O
native O
vessel O

 O
LAD O
PCI O

 O
2 O
. O
PAF B-REA
: I-REA
rate B-REA
controlled I-REA
with O
atenolol B-DRUG
and O
on O
warfarin B-DRUG

 I-DRUG
3 O
. O
Dyslipidemia O

 O
4 O
. O
Hypertension O

 O
5 O
. O
OSA O
on O
BiPAP O
11 O
cm O
insp O
and O
9 O
cm O
exp O
pressures O

 O
6 O
. O
Tuberculosis O
as O
a O
child O
, O
status O
post O
left O
upper O
lobe O

 O
lobectomy O

 O
7 O
. O
BPH O

 O
8 O
. O
Severe O
kyphoscoliosis O

 O
9 O
. O
Chronic O
sinususitis O


 O
Social O
History O
: O

 O
- O
Married O
, O
Lives O
in O
[ O
* O
* O
Location O
745 O
* O
* O
] O
with O
Wife O
, O
Three O
Children O

 O
- O
Holocaust O
survivor O

 O
- O
Retired O
child O
psychologist O
at O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
in O
NY O


 O
- O
Tobacco O
history O
: O
Denies O

 O
- O
ETOH O
: O
Denies O

 O
- O
Illicit O
drugs O
: O
Denies O



 O
Family O
History O
: O

 O
No O
family O
history O
of O
early O
MI O
, O
arrhythmia O
, O
cardiomyopathies O
, O
or O

 O
sudden O
cardiac O
death O
. O

 O
- O
Father O
: O
Killed O
during O
Holocaust O

 O
- O
Mother O
: O
Died O
in O
90s O
, O
no O
known O
medical O
history O

 O
- O
Sister O
: O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
3730 O
* O
* O
] O
, O
50s O
. O



 O

Physical O
Exam O
: O

 O
Gen O
: O
Pleasant O
. O
NAD O
. O
Oriented O
x3 O
. O
Mood O
, O
affect O
appropriate O
. O

 O
HEENT O
: O
Sclera O
anicteric O
. O
PERRL O
, O
EOMI O
. O
Conjunctiva O
were O
pink O
, O
no O

 O
pallor O
or O
cyanosis O
of O
the O
oral O
mucosa O
. O

 O
Neck O
: O
Supple O
with O
full O
EJ O
and O
JVP O
slightly O
above O
clavicle O

 O
CV O
: O
normal O
S1 O
, O
S2 O
. O
No O
m/r/g O
. O

 O
Chest O
: O
Sever O
Kyphoscoliosis O
. O
Patient O
appeared O
uncomfortable O

 O
breathing O
, O
increased O
work O
, O
+ O
accessory O
muscle O
use O
, O
+ O
expiratory O

 O
wheezes O
and O
decreased O
breath O
sounds O
on O
right O
and O
left O
bases O
. O
+ O

 O
egophony O
and O
+ O
fremitus O
on O
right O
base O
. O

 O
Abd O
: O
Soft O
, O
NTND O
. O
No O
HSM O
or O
tenderness O
. O

 O
Ext O
: O
1 O
+ O
Pedal/Ankle O
Edema O
Bilaterally O
. O

 O
Skin O
: O
No O
stasis O
dermatitis O
, O
ulcers O
, O
scars O
, O
or O
xanthomas O
. O



 O
Pertinent O
Results O
: O

 O
Lab O
Data O
on O
Admission O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
08:50AM O
BLOOD O
WBC-6.3 O
RBC-3.91 O
* O
Hgb-12.2 O
* O
Hct-36.9 O
* O

 O
MCV-94 O
MCH-31.2 O
MCHC-33.0 O
RDW-15.0 O
Plt O
Ct-141 O
* O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
08:50AM O
BLOOD O
Neuts-67.3 O
Lymphs-24.0 O
Monos-5.5 O
Eos-2.6 O

 O
Baso-0.6 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
08:50AM O
BLOOD O
PT-28.1 O
* O
PTT-37.9 O
* O
INR(PT)-2.8 O
* O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
08:50AM O
BLOOD O
Glucose-120 O
* O
UreaN-34 O
* O
Creat-1.2 O
Na-142 O

 O
K-4.3 O
Cl-102 O
HCO3 O
- O
33 O
* O
AnGap-11 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
08:50AM O
BLOOD O
ALT-41 O
* O
AST-36 O
LD(LDH)-211 O
CK(CPK)-70 O

 O
AlkPhos-140 O
* O
TotBili-0.4 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
08:50AM O
BLOOD O
CK-MB-NotDone O
cTropnT-<0.01 O
proBNP-3733 O
* O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
08:50AM O
BLOOD O
TSH-2.6 O


 O
Pertinent O
Labs O
from O
During O
the O
Admission O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
22 O
* O
* O
] O
05:30AM O
BLOOD O
Calcium-8.9 O
Phos-3.0 O
Mg-1.9 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
23 O
* O
* O
] O
03:43AM O
BLOOD O
VitB12 O
- O
728 O
Folate-19.0 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
23 O
* O
* O
] O
03:43AM O
BLOOD O
ASA-NEG O
Acetmnp-10.0 O
Bnzodzp-NEG O

 O
Barbitr-NEG O
Tricycl-NEG O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
22 O
* O
* O
] O
06:45PM O
BLOOD O
Lactate-1.2 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
23 O
* O
* O
] O
04:00AM O
BLOOD O
freeCa-1.13 O



 O
Blood O
Gas O
, O
Lactate O
, O
Cardiac O
Enzymes O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
08:50AM O
BLOOD O
CK-MB-NotDone O
cTropnT-<0.01 O
proBNP-3733 O
* O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
08:50AM O
BLOOD O
cTropnT-<0.01 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
01:07PM O
BLOOD O
CK-MB-NotDone O
cTropnT-<0.01 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
09:18PM O
BLOOD O
CK-MB-NotDone O
cTropnT-<0.01 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
22 O
* O
* O
] O
07:24PM O
BLOOD O
CK-MB-3 O
cTropnT-<0.01 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
23 O
* O
* O
] O
03:43AM O
BLOOD O
CK-MB-3 O
cTropnT-<0.01 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
23 O
* O
* O
] O
03:15PM O
BLOOD O
CK-MB-4 O
cTropnT-<0.01 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
24 O
* O
* O
] O
03:57AM O
BLOOD O
CK-MB-3 O
cTropnT-<0.01 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
27 O
* O
* O
] O
05:30AM O
BLOOD O
proBNP-4224 O
* O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
22 O
* O
* O
] O
01:13PM O
BLOOD O
Type-[**Last O
Name O
( O
un O
) O
* O
* O
] O
Temp-37.0 O
pO2 O
- O
30 O
* O
pCO2 O
- O
53 O
* O

 O
pH-7.37 O
calTCO2 O
- O
32 O
* O
Base O
XS-3 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
22 O
* O
* O
] O
06:45PM O
BLOOD O
Type-ART O
pO2 O
- O
66 O
* O
pCO2 O
- O
34 O
* O
pH-7.42 O

 O
calTCO2 O
- O
23 O
Base O
XS--1 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
23 O
* O
* O
] O
04:00AM O
BLOOD O
Type-[**Last O
Name O
( O
un O
) O
* O
* O
] O
Temp-38.4 O
pO2 O
- O
60 O
* O
pCO2 O
- O
59 O
* O

 O
pH-7.40 O
calTCO2 O
- O
38 O
* O
Base O
XS-8 O
Intubat-NOT O
INTUBA O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
23 O
* O
* O
] O
05:19PM O
BLOOD O
Type-[**Last O
Name O
( O
un O
) O
* O
* O
] O
Temp-36.3 O
Rates-/25 O
FiO2 O
- O
80 O
O2 O

 O
Flow-12 O
pO2 O
- O
42 O
* O
pCO2 O
- O
53 O
* O
pH-7.40 O
calTCO2 O
- O
34 O
* O
Base O
XS-5 O
AADO2 O
- O
495 O

 O
REQ O
O2 O
- O
81 O
Intubat-NOT O
INTUBA O
Comment-NEBULIZER O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
24 O
* O
* O
] O
02:14PM O
BLOOD O
Type-ART O
Temp-36.6 O
pO2 O
- O
51 O
* O
pCO2 O
- O
42 O

 O
pH-7.48 O
* O
calTCO2 O
- O
32 O
* O
Base O
XS-6 O
Intubat-NOT O
INTUBA O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
24 O
* O
* O
] O
03:37PM O
BLOOD O
Type-ART O
Temp-36.6 O
Rates-/26 O
O2 O
Flow-12 O

 O
pO2 O
- O
54 O
* O
pCO2 O
- O
43 O
pH-7.45 O
calTCO2 O
- O
31 O
* O
Base O
XS-4 O
Intubat-NOT O
INTUBA O

 O
Comment-NON-REBREA O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
26 O
* O
* O
] O
05:03PM O
BLOOD O
Type-[**Last O
Name O
( O
un O
) O
* O
* O
] O
pO2 O
- O
30 O
* O
pCO2 O
- O
57 O
* O
pH-7.33 O
* O

 O
calTCO2 O
- O
31 O
* O
Base O
XS-1 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
27 O
* O
* O
] O
05:33AM O
BLOOD O
Type-[**Last O
Name O
( O
un O
) O
* O
* O
] O
pO2 O
- O
49 O
* O
pCO2 O
- O
57 O
* O
pH-7.31 O
* O

 O
calTCO2 O
- O
30 O
Base O
XS-0 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
22 O
* O
* O
] O
06:45PM O
BLOOD O
Lactate-1.2 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
23 O
* O
* O
] O
04:00AM O
BLOOD O
Lactate-2.1 O
* O

 O

[ O
* O
* O
2159 O
- O
4 O
- O
23 O
* O
* O
] O
05:19PM O
BLOOD O
Lactate-1.4 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
24 O
* O
* O
] O
02:14PM O
BLOOD O
Lactate-1.6 O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
26 O
* O
* O
] O
05:03PM O
BLOOD O
Lactate-0.9 O


 O
Other O
Reports O


 O
EKG O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O

 O
Atrial O
fibrillation O
with O
premature O
ventricular O
contractions O
and O

 O
uncontrolled O
ventricular O
response O
. O
Compared O
to O
tracing O
# O
2 O
the O

 O
heart O
rate O
is O
faster O
. O

 O
Rate O
PR O
QRS O
QT/QTc O
P O
QRS O
T O

 O
114 O
0 O
104 O
330/424 O
0 O
16 O
-164 O


 O
CXR O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O

 O
COMPARISON O
: O
Multiple O
prior O
chest O
radiographs O
from O
[ O
* O
* O
2157 O
- O
1 O
- O
5 O
* O
* O
] O
, O

 O
[ O
* O
* O
2157 O
- O
3 O
- O
2 O
* O
* O
] O
, O
and O
[ O
* O
* O
2159 O
- O
1 O
- O
17 O
* O
* O
] O
. O
CTA O
chest O
was O
performed O
on O
[ O
* O
* O
2157 O
- O
3 O
- O
10 O
* O
* O
] O
. O

 O
CHEST O
RADIOGRAPH O
, O
PA O
AND O
LATERAL O
VIEWS O
: O
The O
patient O
is O
status O

 O
post O
median O
sternotomy O
, O
CABG O
, O
and O
coronary O
artery O
stenting O
. O

 O
Severe O
scoliosis O
of O
the O
thoracolumbar O
spine O
, O
with O
deformity O
of O

 O
the O
left O
rib O
cage O
, O
again O
limits O
evaluation O
. O
Left O
lung O
volume O
is O

 O
chronically O
small O
. O
Left O
pleural O
thickening O
with O
calcification O
is O

 O
as O
before O
. O
On O
the O
right O
, O
there O
is O
small O
pleural O
effusion O
which O

 O
is O
new O
since O
[ O
* O
* O
2159 O
- O
1 O
- O
17 O
* O
* O
] O
. O
There O
may O
be O
subtle O
ill-defined O
opacity O

 O
in O
the O
right O
lung O
base O
. O
No O
overt O
pulmonary O
edema O
is O
seen O
. O

 O
Cardiac O
enlargement O
is O
unchanged O
. O

 O
IMPRESSIONS O
: O
Evaluation O
limited O
by O
spine O
and O
ribcage O
deformity O
. O

 O
New O
small O
right O
pleural O
effusion O
and O
subtle O
opacity O
in O
the O
right O

 O
lung O
base O
, O
which O
could O
represent O
aspiration O
, O
atelectasis O
, O
and/or O

 O
developing O
consolidation O
. O



 O
Echo O
[ O
* O
* O
2159 O
- O
4 O
- O
23 O
* O
* O
] O

   O
The O
left O
atrium O
is O
mildly O
dilated O
. O
No O
atrial O
septal O
defect O
is O

 O
seen O
by O
2D O
or O
color O
Doppler O
. O
Left O
ventricular O
wall O
thicknesses O

 O
and O
cavity O
size O
are O
normal O
. O
There O
is O
mild O
regional O
left O

 O
ventricular O
systolic O
dysfunction O
with O
infero-lateral O

 O
hypokinesis O
. O
There O
is O
no O
ventricular O
septal O
defect O
. O
The O
right O

 O
ventricular O
cavity O
is O
mildly O
dilated O
with O
mild O
global O
free O
wall O

 O
hypokinesis O
. O
The O
aortic O
valve O
leaflets O
( O
3 O
) O
are O
mildly O
thickened O

 O
but O
aortic O
stenosis O
is O
not O
present O
. O
Trace O
aortic O
regurgitation O

 O
is O
seen O
. O
The O
mitral O
valve O
leaflets O
are O
mildly O
thickened O
. O
Mild O
to O

 O
moderate O
( O
[**1 O
- O
13**]+ O
) O
mitral O
regurgitation O
is O
seen O
. O
The O
tricuspid O

 O
valve O
leaflets O
are O
mildly O
thickened O
. O
There O
is O
mild O
pulmonary O

 O
artery O
systolic O
hypertension O
. O
There O
is O
no O
pericardial O
effusion O
. O

   O
Compared O
with O
the O
report O
of O
the O
prior O
study O
( O
images O

 O
unavailable O
for O
review O
) O
of O
[ O
* O
* O
2158 O
- O
6 O
- O
13 O
* O
* O
] O
, O
no O
definite O
change O
. O


 O
CARDIAC O
CATH O
performed O
on O
[ O
* O
* O
2156 O
- O
10 O
- O
4 O
* O
* O
] O
demonstrated O
: O

 O
1 O
. O
Coronary O
angiography O
in O
this O
right O
dominant O
system O

 O
demonstrated O
a O
normal O
LMCA O
with O
collaterals O
to O
RPL O
. O
The O
LAD O
had O

 O
a O
90 O
% O
proximal O
lesion O
with O
competitive O
flow O
. O
The O
LCX O
system O
had O

 O
an O
occluded O

 O
OM O
. O
The O
RCA O
was O
not O
selectively O
engaged O
. O

 O
2 O
. O
Graft O
angiography O
showed O
a O
patent O
SVG O
to O
diagonal O
and O
OM O
. O
The O

 O
SVG O
to O
RPDA O
had O
a O
99 O
% O
proximal O
stenosis O
. O

 O
3 O
. O
Limited O
resting O
hemodynamics O
as O
detailed O
above O
revealed O

 O
mildly O

 O
elevated O
filling O
pressures O
. O

 O
4 O
. O
PCI O
of O
SVG-RPDA O
with O
3.5 O
X O
28 O
mm O
Cypher O
DES O
and O
no O
residual O

 O
stenosis O
or O
complications O
( O
see O
PTCA O
comments O
for O
detail O
) O
. O

 O
FINAL O
DIAGNOSIS O
: O

 O
1 O
. O
Three O
vessel O
coronary O
artery O
disease O
. O

 O
2 O
. O
Patent O
SVG-diagonal-OM O
graft O
. O

 O
3 O
. O
Proximal O
stenosis O
of O
SVG-RCA O
, O
successful O
PCI O
with O
Cypher O

 O
drug-eluting O
stent O
. O


 O
CARDIAC O
CATH O
performed O
on O
[ O
* O
* O
2156 O
- O
10 O
- O
6 O
* O
* O
] O
demonstrated O
: O

 O
1 O
. O
Successful O
stenting O
of O
the O
proximal O
LAD O
with O
2.5 O
X O
13 O
Cypher O

 O
[ O
* O
* O
Name O
Prefix O
( O
Prefixes O
) O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
Prefixes O
) O
7930 O
* O
* O
] O
to O
3.0 O
with O
no O
residual O
stenosis O
. O

 O
2 O
. O
Distal O
LAD O
myocardial O
bridge O
with O
compression O
during O
systole O

 O
but O

 O
normal O
flow O
at O
diastole O
. O

 O
FINAL O
DIAGNOSIS O
: O

 O
1 O
. O
Two O
vessel O
coronary O
artery O
disease O
. O

 O
2 O
. O
Successful O
stenting O
of O
the O
proximal O
LAD O
with O
Cypher O
DES O
. O



 O
CXR O
[ O
* O
* O
2159 O
- O
4 O
- O
22 O
* O
* O
] O

 O
IMPRESSIONS O
: O
FINDINGS O
: O
Comparison O
is O
made O
to O
prior O
study O
from O

 O
[ O
* O
* O
2159 O
- O
4 O
- O
21 O
* O
* O
] O
. O
Study O
is O
markedly O
limited O
due O
to O
patient O

 O
positioning O
and O
the O
severe O
scoliosis O
. O
Allowing O
for O
this O
, O

 O
however O
, O
there O
appears O
to O
be O
opacities O
within O
both O
lower O
lobes O

 O
which O
are O
worrisome O
for O
consolidation O
or O
pneumonia O
. O
The O

 O
consolidations O
on O
the O
right O
side O
are O
much O
more O
apparent O
than O
on O

 O
the O
study O
from O
yesterday O
. O
Aspiration O
can O
not O
be O
excluded O
. O


 O
CXR O
[ O
* O
* O
2159 O
- O
4 O
- O
27 O
* O
* O
] O

 O
FINDINGS O
: O
As O
compared O
to O
the O
previous O
radiograph O
, O
the O
volume O
of O

 O
the O
right O
hemithorax O
has O
decreased O
. O
As O
a O
consequence O
, O
there O
is O

 O
increased O
crowding O
of O
the O
right O
perihilar O
vessels O
. O
However O
, O

 O
there O
is O
no O
clear O
evidence O
of O
pneumonia O
( O
the O
film O
strongly O

 O
resembles O
the O
examination O
performed O
on O
[ O
* O
* O
2159 O
- O
4 O
- O
24 O
* O
* O
] O
, O
8:03 O

 O
a.m. O
) O
. O
Unchanged O
marked O
asymmetry O
of O
the O
chest O
wall O
given O
the O

 O
extreme O
scoliosis O
. O
Unchanged O
size O
of O
the O
cardiac O
silhouette O
. O


 O
CT O
chest O
[ O
* O
* O
2159 O
- O
4 O
- O
28 O
* O
* O
] O

 O
1 O
. O
Moderate O
right O
pleural O
effusion O
with O
adjacent O

 O
telectasis/consolidation O
. O

 O
2 O
. O
Scattered O
ground-glass O
opacities O
with O
enlarged O
heart O
. O
These O

 O
findings O
are O
most O
likely O
representative O
of O
pulmonary O
edema O
. O

 O
3 O
. O
Calcified O
left O
pleural O
plaques O
consistent O
empyema O
. O

 O
4 O
. O
Prominent O
abdominal O
vessels O
are O
limited O
due O
to O
lack O
of O

 O
intravenous O

 O
contrast O
but O
suggestive O
of O
varices O
. O
Clinical O
correlation O
is O

 O
recommended O
. O

 O
5 O
. O
Marked O
thoracic O
cage O
distortion O
due O
to O
scoliosis O
. O


 O
Pleural O
fluid O
[ O
* O
* O
2159 O
- O
4 O
- O
29 O
* O
* O
] O

 O
NEGATIVE O
FOR O
MALIGNANT O
CELLS O
. O


 O
CXR O
[ O
* O
* O
2159 O
- O
5 O
- O
10 O
* O
* O
] O

 O
As O
compared O
to O
the O
previous O
radiograph O
, O
the O
lung O
volumes O
are O

 O
unchanged O
. O
Presence O
of O
a O
minimal O
right-sided O
pleural O
effusion O

 O
can O
not O
be O

 O
excluded O
. O
Minimally O
increased O
diameters O
of O
the O
pulmonary O
vessels O

 O
in O
the O
right O
upper O
lobe O
could O
indicate O
mild O
overhydration O
. O

 O
Unchanged O
size O
of O
the O
cardiac O
silhouette O
. O
Unchanged O
aspect O
of O

 O
the O
left O
lung O
. O


 O
DISCHARGE O
LABS O
: O

 O
[ O
* O
* O
2159 O
- O
5 O
- O
15 O
* O
* O
] O
WBC-7.7 O
RBC-3.72 O
* O
Hgb-11.2 O
* O
Hct-35.0 O
* O
MCV-94 O
Plt O
Ct-335 O

 O
[ O
* O
* O
2159 O
- O
5 O
- O
15 O
* O
* O
] O
PT-29.5 O
* O
PTT-37.2 O
* O
INR(PT)-2.9 O
* O

 O
[ O
* O
* O
2159 O
- O
5 O
- O
15 O
* O
* O
] O
Glucose-94 O
UreaN-44 O
* O
Creat-1.2 O
Na-142 O
K-4.1 O
Cl-96 O

 O
HCO3 O
- O
38 O
* O
[ O
* O
* O
2159 O
- O
5 O
- O
15 O
* O
* O
] O
Calcium-9.3 O
Phos-3.8 O
Mg-2.1 O



 O
Brief O
Hospital O
Course O
: O

 O
Brief O
Hospital O
Course O

 O
Professor O
[ O
* O
* O
Known O
lastname O
70654 O
* O
* O
] O
is O
a O
75 O
YOM O
with O
paroxysmal O
atrial O

 O
fibrillation O
and O
coronary O
artery O
disease O
who O
presented O
with O
5 O

 O
days O
of O
fatigue O
and O
was O
found O
to O
be O
in O
Atrial O
fibrillaton O
with O

 O
RVR O
. O
Patient O
was O
admitted O
to O
the O
cardiology O
service O
and O

 O
dofetilide B-DRUG
was O
initiated O
given O
atrial B-REA
fibrillation I-REA
. I-REA
On O
HD#1 O

 O
patient O
develope O
hypoxic O
respiratory O
distress O
reguiring O
transfer O

 O
to O
the O
CCU O
where O
he O
was O
treated O
for O
community B-REA
acquired I-REA
pneumonia I-REA

 I-REA
with O
Vancomycin B-DRUG
, I-DRUG
Cefepime B-DRUG
, I-DRUG
and O
Doxycycline B-DRUG
given O
concern O
for O
QT O

 O
prolongatoin O
. O
During O
his O
stay O
in O
the O
CCU O
he O
was O
intermittently O

 O
in O
atrial O
fibrillation O
with O
RVR O
and O
would O
intermittently O
develop O

 O
respiratory O
distress O
reguiring O
BiPap O
. O
  O
Patient O
was O
eventually O

 O
transferred O
to O
the O
MICU O
for O
more O
intensive O
management O
of O
his O

 O
pulmonary O
issues O
. O
There O
the O
patient O
completed O
his O
course O
of O

 O
antibiotics B-DRUG
and O
was O
diuresed O
. O
Slowly O
the O
patients O
breathing O

 O
improved O
and O
on O
[ O
* O
* O
5 O
- O
4 O
* O
* O
] O
was O
transfered O
to O
the O
general O
medical O

 O
floor O
. O



 O
Hypoxic O
Respiratory O
Distress O
: O

 O
On O
presentation O
to O
the O
hospital O
patient O
was O
at O
baseline O

 O
pulmonary O
status O
. O
Initial O
CXR O
with O
question O
of O
RLL O
opacity O
. O
On O

 O
HD#1 O
patient O
developed O
hypoxic O
respiratory O
failure O
which O

 O
[ O
* O
* O
Hospital O
70655 O
* O
* O
] O
transfer O
to O
the O
CCU O
and O
broad O
spectrum O
antibiotics B-DRUG
to O

 O
treat O
RLL B-REA
pneumonia I-REA
visualized O
on O
CXR O
. O
Further O
patient O
became O

 O
febrile O
prior O
to O
transfer O
. O
Initially O
patient O
was O
thought O
to O
have O

 O
RLL O
infiltrate O
c/w O
pneumonia O
and O
high O
fever O
. O
Patient O
was O
treated O

 O
for O
probable O
RLL B-REA
pneumonia I-REA
with O
Vancomycin B-DRUG
, I-DRUG
Cefepime B-DRUG
, I-DRUG
and O

 O
Doxycycline B-DRUG
completing O
an O
8 B-DUR
day I-DUR
course I-DUR
. I-DUR
On O
transfer O
to O
the O
MICU O

 O
the O
patient O
appeared O
to O
have O
superimposed O
pulmonary O
edema O
from O

 O
volume O
resuscitation O
as O
evidenced O
by O
LOS O
fluid O
balance O
, O
interval O

 O
weight O
, O
and O
clinical O
exam O
. O
  O
MICU O
attempted O
low O
dose O
lasix B-DRUG

 I-DRUG
overnight O
[ O
* O
* O
4 O
- O
27 O
* O
* O
] O
for O
diuresis B-REA
and O
monitored O
respiratory O
status O
, O

 O
with O
700cc O
out O
and O
no O
worsening O
in O
creatinine O
. O
  O
Non-contrast O
CT O

 O
showed O
moderate O
right O
sided O
pleural O
effusion O
. O
Based O
upon O

 O
patient O
's O
respiratory O
distress O
, O
he O
underwent O
a O
1.5L O

 O
thoracentesis O
on O
[ O
* O
* O
4 O
- O
29 O
* O
* O
] O
with O
interval O
improvement O
in O
respiratory O

 O
status O
. O
Patient O
has O
limited O
reserve O
given O
prior O
pneumonectomy O

 O
and O
severe O
kyphoscoliosis O
and O
may O
not O
tolerate O
small O
volumes O
of O

 O
fluid O
. O
A O
Urine O
legionella O
was O
negative O
. O
Blood O
cultures O
negative O

 O
( O
finalized O
) O
. O
Sputum O
cultures O
contaminated O
. O
Pleural O
fluid O

 O
appeared O
transudative O
and O
cultures O
NGTD O
. O
The O
patient O
was O

 O
maintained O
on O
nebulizers O
as O
needed O
. O
The O
patient O
underwent O

 O
aggressive O
diuresis B-REA
with O
IV B-ROU
lasix B-DRUG
and O
was O
negative O

 O
approximately O
6 O
liters O
for O
his O
MICU O
stay O
( O
though O
even O
from O

 O
admission O
weight O
) O
. O
The O
patient O
initially O
required O
BiPap O
around O

 O
the O
clock O
. O
  O
He O
was O
weaned O
to O
a O
shovel O
mask O
and O
eventually O
to O
a O

 O
nasal O
cannula O
with O
diuresis O
. O
  O
He O
continued O
on O
BiPap O
at O
night O

 O
with O
his O
home O
settings O
. O
Based O
upon O
radiographic O
images O
, O
there O

 O
was O
concern O
that O
patient O
may O
be O
aspirating O
. O
  O
He O
was O
evaluated O
by O

 O
speech O
and O
swallow O
who O
cleared O
the O
patient O
for O
solids O
and O
thin O

 O
liquids O
; O
pills O
whole O
with O
puree O
. O
After O
diuresis O
patient O

 O
continued O
to O
improve O
, O
no O
longer O
needing O
BiPAP O
during O
the O
day O
. O

 O
Patient O
was O
transferred O
to O
the O
general O
medical O
floor O
where O

 O
diuresis O
was O
continued O
. O
The O
patient O
was O
maintained O
on O
nasal O

 O
cannula O
1 O
- O
2L O
for O
a O
week O
, O
and O
finally O
weaned O
down O
to O
RA O
, O
satting O

 O
mid90s O
on O
discharge O
. O
The O
patient O
was O
discharged O
on O
Lasix B-DRUG
and O

 O
Aldactone B-DRUG
. I-DRUG



 O
Atrial B-REA
fibrillation I-REA
: I-REA

 O
On O
admission O
to O
the O
hospital O
patient O
was O
found O
to O
be O
in O
atrial O

 O
fibrillation O
. O
With O
therapeutic O
INRs O
for O
the O
past O
two O
months O
. O

 O
Decision O
was O
made O
to O
start O
dofetilide B-DRUG
. I-DRUG
Patient O
initially O

 O
converted O
to O
sinus O
rhythm O
prior O
to O
transfer O
to O
CCU O
. O
During O
CCU O

 O
stay O
patient O
was O
paroxysmally O
in O
atrial B-REA
fibrillation I-REA
which O
was O

 O
intermittently O
controlled O
with O
diltiazem B-DRUG
. I-DRUG
  O
The O
patient O
was O

 O
continued O
on O
dofetilide B-DRUG
per O
EP O
recommendations O
, O
and O
daily O
EKGs O

 O
were O
initially O
obtained O
to O
monitor O
for O
QT O
prolongation O
. O
  O
The O

 O
patient O
's O
diltiazem B-DRUG
was O
up-titrated O
as O
tolerated O
. O
  O
At O
the O
time O

 O
of O
leaving O
the O
MICU O
, O
he O
was O
on O
Diltiazem B-DRUG
Extended I-DRUG
Release I-DRUG
240 B-STR
mg I-STR

 I-STR
PO B-ROU
BID B-FRE
. I-FRE
  O
He O
was O
in O
sinus O
rhythm O
. O
On O
the O
floor O
, O
the O
patient O
was O

 O
intermittently O
in O
afib O
. O
He O
was O
started O
on O
Metoprolol B-DRUG
25 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
for O
better O
heart B-REA
rate I-REA
control I-REA
. I-REA
He O
was O
intermittently O
in O
afib O
and O

 O
junction O
rhythm O
( O
rate O
60s-80s O
) O
. O
Dofetilide B-DRUG
was O
discontinued O
on O

 O
[ O
* O
* O
5 O
- O
14 O
* O
* O
] O
. O
He O
was O
discharged O
on O
Dilt B-DRUG
240 B-STR
mg I-STR
PO B-ROU
BID B-FRE
, I-FRE
Metoprolol B-DRUG
25 B-STR
mg I-STR
PO B-ROU

 I-ROU
BID B-FRE
. I-FRE


 O
Metabolic B-ADE
alkalosis I-ADE
: I-ADE

 O
Thought O
to O
be O
secondary O
to O
aggressive O
diuresis B-REA
with O
lasix B-DRUG

 I-DRUG
( O
contraction O
alkalosis O
) O
. O
Correction O
may O
help O
respiratory O
status O

 O
by O
preventing O
compensatory O
hypoventilation O
. O
On O
his O
last O
day O
in O

 O
the O
MICU O
, O
he O
was O
started O
on O
acetazolamide B-DRUG
250 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O


 O
Junctional B-REA
Bradycardia I-REA
: I-REA

 O
Likely O
secondary O
to O
beta-blockers B-DRUG
. I-DRUG
  O
The O
patient O
was O
started O
on O

 O
Metoprolol B-DRUG
, I-DRUG
as O
recommended O
by O
EP O
. O
The O
patient O
was O
noted O
to O
be O
in O

 O
a O
junctional O
rhythm O
, O
but O
was O
not O
bradycardic O
. O


 O
Coronary B-REA
artery I-REA
disease I-REA
: I-REA

 O
post O
CABG O
and O
[ O
* O
* O
Name O
Prefix O
( O
Prefixes O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Prefixes O
) O
* O
* O
] O
2 O
. O
  O
ST O
depressions O
on O
EKG O
( O
stable O
, O
but O

 O
worsened O
with O
tachycardia O
to O
150s O
) O
. O
  O
No O
active O
chest O
pain O
. O

 O
Cardiac O
enzymes O
negative O
. O
The O
patient O
was O
continued O
on O
aspirin B-DRUG

 I-DRUG
81 B-STR
mg I-STR
and O
his O
home O
dose O
Lipitor B-DRUG
. I-DRUG


 O
Hypernatremia B-REA
: I-REA

 O
The O
patient O
was O
intermittently O
hypernatremic O
while O
in O
the O
MICU O
, O

 O
most O
recently O
with O
Na O
146 O
on O
[ O
* O
* O
5 O
- O
4 O
* O
* O
] O
free O
water O
deficit O
of O
1.4L O
. O
He O

 O
intermittently O
received O
D5W B-DRUG
X O
1000 B-DOS
cc I-DOS
and O
PO O
intake O
was O

 O
encouraged O
. O


 O
OSA O
: O
Continued O
Home O
BiPAP O


 O
Hyperlipidemia B-REA
: I-REA
Continued O
Atorvastatin B-DRUG



 I-DRUG

Medications O
on O
Admission O
: O

  O
( O
per O
DC O
Summary O
[ O
* O
* O
2159 O
- O
1 O
- O
18 O
* O
* O
] O
) O

 O
1 O
. O
Atenolol B-DRUG
50 B-STR
mg I-STR
Once B-FRE
Daily I-FRE

 I-FRE
2 O
. O
Atorvastatin B-DRUG
20 B-STR
mg I-STR
Once B-FRE
Daily I-FRE

 I-FRE
3 O
. O
Fluticasone B-DRUG
50 B-STR
mcg I-STR
One B-DOS
Nasal B-ROU
Spray B-FOR
Daily B-FRE

 I-FRE
4 O
. O
Lorazepam B-DRUG
0.5 B-STR
mg I-STR
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Once B-FRE
Daily I-FRE
PRN I-FRE
anxiety B-REA
, I-REA

 O
insomnia B-REA
. I-REA

 O
5 O
. O
Mirtazapine B-DRUG
7.5 B-STR
mg I-STR
PO B-ROU
HS B-FRE

 I-FRE
6 O
. O
Nifedipine B-DRUG
60 B-STR
mg I-STR
Once B-FRE
Daily I-FRE

 I-FRE
7 O
. O
Nitroglycerin B-DRUG
0.3 B-STR
mg I-STR
SL B-ROU
PRN B-FRE
Chest B-REA
Pain I-REA

 I-REA
8 O
. O
Risedronate B-DRUG
35 B-STR
mg I-STR
once B-FRE
weekly I-FRE

 I-FRE
9 O
. O
Warfarin B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Once B-FRE
Daily I-FRE

 I-FRE
10 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Once B-FRE
Daily I-FRE

 I-FRE
11 O
. O
Os-Cal B-DRUG
500 I-DRUG
+ I-DRUG
D I-DRUG
500 I-DRUG
mg(1,250 B-STR
mg I-STR
) I-STR
-400 B-DOS
unit I-DOS
, I-DOS
Twice B-FRE
Daily I-FRE

 I-FRE
12 O
. O
Lactobacillus B-DRUG
Rhamnosus I-DRUG
One B-DOS
Capsule B-FOR
PO B-ROU
Once B-FRE
a I-FRE
Day I-FRE

 I-FRE
13 O
. O
Bipap O



 O

Discharge O
Medications O
: O

 O
1 O
. O
Atorvastatin B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Fluticasone B-DRUG
50 B-STR
mcg/Actuation I-STR
Spray B-FOR
, I-FOR
Suspension I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Spray B-FOR
Nasal B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Lactobacillus B-DRUG
Rhamnosus I-DRUG
( I-DRUG
GG I-DRUG
) I-DRUG
10 B-STR
billion I-STR
cell I-STR
Capsule B-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
4 O
. O
Aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR

 I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Mirtazapine B-DRUG
15 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE

 I-FRE
bedtime I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
Insomnia/anxiety B-REA
. I-REA

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
6 O
. O
Diltiazem B-DRUG
HCl I-DRUG
120 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Sustained I-FOR
Release I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Sustained I-FOR
Release I-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*120 O
Capsule O
, O
Sustained O
Release(s O
) O
* O
Refills:*0 O
* O

 O
7 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
8 O
. O
Warfarin B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
2X/WEEK B-FRE

 I-FRE
( O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
, O
TU O
) O
. O

 O
9 O
. O
Warfarin B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
4X/WEEK B-FRE

 I-FRE
( I-FRE
MO I-FRE
, I-FRE
WE I-FRE
, I-FRE
TH I-FRE
, I-FRE
FR I-FRE
, I-FRE
SA I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Os-Cal B-DRUG
500 I-DRUG
+ I-DRUG
D I-DRUG
500 I-DRUG
mg(1,250 B-STR
mg I-STR
) I-STR
-400 B-DOS
unit I-DOS
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
11 O
. O
Miconazole B-DRUG
Nitrate I-DRUG
2 B-STR
% I-STR
Powder B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ADE
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
rash B-REA
for B-DUR
10 I-DUR
days I-DUR
. I-DUR

 O
Disp:*1 O
container O
* O
Refills:*0 O
* O

 O
12 O
. O
Furosemide B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
13 O
. O
Aldactone B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*15 O
Tablet(s O
) O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital O
119 O
* O
* O
] O
Homecare O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
Diastolic O
Heart O
Failure O

 O
Paroxysmal O
Atrial O
[ O
* O
* O
Hospital O
9343 O
* O
* O
] O

 O
Health O
care O
Associated O
Pneumonia O

 O
Restrictive O
Pulmonary O
Disease O
secondary O
to O
kyphoscoliosis O

 O
CAD O

 O
HTN O

 O
HLD O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
Dear O
Mr. O
[ O
* O
* O
Known O
lastname O
70654 O
* O
* O
] O
, O

 O
. O


 O
It O
was O
a O
pleasure O
caring O
for O
you O
while O
you O
were O
hospitalized O

 O
with O
fatigue O
and O
shortness O
of O
breath O
. O
During O
your O
stay O
your O

 O
breathing O
became O
extremely O
labored O
[ O
* O
* O
Hospital O
70656 O
* O
* O
] O
transfer O
to O
the O

 O
Intensive O
Care O
Unit O
were O
you O
were O
treated O
with O
antibiotics B-DRUG
for O

 O
pneumonia B-REA
. I-REA
While O
in O
the O
ICU O
your O
breathing O
was O
slow O
to O
improve O

 O
so O
you O
were O
also O
diuresed O
with O
IV B-ROU
diuretics B-DRUG
( O
lasix B-DRUG
) I-DRUG
. O
Slowly O
your O

 O
breathing O
improved O
and O
you O
were O
transfered O
to O
regular O
medical O

 O
floor O
. O
Throughout O
this O
time O
your O
heart O
rate O
was O
in O
and O
out O
of O

 O
atrial O
fibrillation O
. O
Electrophysiology O
recommended O
Diltiazem B-DRUG
and O

 O
Metoprolol B-DRUG
for O
good B-REA
rate I-REA
control I-REA
. I-REA
You O
were O
also O
on O
Dofetilide B-DRUG

 I-DRUG
which O
was O
stopped O
since O
it O
did O
not O
keep O
you O
in O
a O
normal O
heart O

 O
rhythm O
. O

 O
. O

 O
Please O
take O
all O
your O
medications O
as O
prescribed O
and O
keep O
all O
of O

 O
your O
follow O
up O
appointments O
. O
Weigh O
yourself O
every O
morning O
, O
and O

 O
call O
your O
physician O
if O
your O
weight O
goes O
up O
more O
than O
3 O
lbs O
. O
You O

 O
should O
also O
have O
lab O
work O
checked O
at O
your O
visit O
on O
[ O
* O
* O
2159 O
- O
5 O
- O
18 O
* O
* O
] O
to O

 O
ensure O
your O
kidney O
function O
and O
electrolytes O
are O
normal O
. O

 O
. O

 O
The O
following O
changes O
were O
made O
to O
your O
medication O
regimen O
: O

 O
# O
. O
CHANGE O
Atenolol B-DRUG
to O
Metoprolol B-DRUG
25 B-STR
mg I-STR
by B-ROU
mouth I-ROU
twice B-FRE
daily I-FRE

 I-FRE
# O
. O
STOP O
Nifedipine B-DRUG

 I-DRUG
# O
. O
START O
Diltiazem B-DRUG
240 B-STR
mg I-STR
by B-ROU
mouth I-ROU
twice B-FRE
daily I-FRE

 I-FRE
# O
. O
START O
Miconazole B-DRUG
powder B-FOR
twice B-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
you O
groin B-REA

 I-REA
rash I-REA

 I-REA
# O
. O
Start O
Lasix B-DRUG
20 B-STR
mg I-STR
daily B-FRE
on O
[ O
* O
* O
2159 O
- O
5 O
- O
17 O
* O
* O
] O
( O
Call O
PCP O
and O
stop O
if O
you O

 O
feel O
lightheaded O
or O
dizzy O
) O

 O
# O
. O
Start O
Aldactone B-DRUG
12.5 B-STR
mg I-STR
daily B-FRE
on O
[ O
* O
* O
2159 O
- O
5 O
- O
17 O
* O
* O
] O
) O
Call O
PCP O
and O
stop O
if O

 O
you O
feel O
lightheaded O
or O
dizzy O
) O

 O
# O
. O
We O
also O
increased O
your O
mirtazapine B-DRUG
to O
30 B-STR
mg I-STR
at B-FRE
nighttime I-FRE

 I-FRE
# O
. O
DECREASE O
your O
aspirin B-DRUG
to O
81 B-STR
mg I-STR
daily B-FRE


 I-FRE
Followup O
Instructions O
: O

 O
PCP O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
have O
been O
set O
up O
to O
see O
a O
Nurse O
Practitioner O
, O
as O
well O

 O
as O
your O
primary O
care O
physician O
in O
the O
next O
week O
: O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
FERN O
, O
RNC O

 O
Phone:[**Telephone/Fax O
( O
1 O
) O
250 O
* O
* O
] O

 O
Date/Time:[**2159 O
- O
5 O
- O
18 O
* O
* O
] O
9:00 O

 O
. O

 O
Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
7212 O
* O
* O
] O
, O
MD O

 O
Phone:[**Telephone/Fax O
( O
1 O
) O
250 O
* O
* O
] O

 O
Date/Time:[**2159 O
- O
5 O
- O
25 O
* O
* O
] O
10:30 O

 O
. O


 O
Cardiology O
: O
Please O
follow-up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O

 O
Date/Time O
: O
[ O
* O
* O
6 O
- O
15 O
* O
* O
] O
at O
2 O
pm O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
62 O
* O
* O
] O

 O
. O

 O
Other O
Appointments O
: O

 O
ORTHO O
XRAY O
( O
SCC O
2 O
) O

 O
Phone:[**Telephone/Fax O
( O
1 O
) O
1228 O
* O
* O
] O

 O
Date/Time:[**2159 O
- O
6 O
- O
14 O
* O
* O
] O
10:40 O

 O
. O

 O
DR O
. O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Initial O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
( O
ortho O
spine O
) O

 O
Phone:[**Telephone/Fax O
( O
1 O
) O
3736 O
* O
* O
] O

 O
Date/Time:[**2159 O
- O
6 O
- O
14 O
* O
* O
] O
11:00 O

 O
. O

 O
PULMONARY O
FUNCTION O
LAB O

 O
Phone:[**Telephone/Fax O
( O
1 O
) O
609 O
* O
* O
] O

 O
Date/Time:[**2159 O
- O
6 O
- O
15 O
* O
* O
] O
11:10 O

 O
. O

 O
DR O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
612 O
* O
* O
] O

 O
Date/Time:[**2159 O
- O
6 O
- O
15 O
* O
* O
] O
11:30 O



                              O
[ O
* O
* O
Name6 O
( O
MD O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
MD O
, O
[ O
* O
* O
MD O
Number(3 O
) O
2073 O
* O
* O
] O


 O

Admission O
Date O
: O
  O
[ O
* O
* O
2108 O
- O
8 O
- O
7 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2108 O
- O
10 O
- O
15 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2035 O
- O
11 O
- O
18 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
No O
Known O
Allergies O
/ O
Adverse O
Drug O
Reactions O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
3021 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Hypopharyngeal O
Mass O
, O
concern O
for O
proximal O
airway O
compression O
. O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
7 O
* O
* O
] O
Hypopharyngeal O
tumor O
biopsy O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
7 O
* O
* O
] O
G-tube O
placement O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
7 O
* O
* O
] O
Port O
placement O
. O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
10 O
* O
* O
] O
Tracheostomy O
. O


 O
History O
of O
Present O
Illness O
: O

 O
72 O
M O
was O
admitted O
for O
expedited O
workup O
of O
hypopharyngeal O
lesion O

 O
and O
biopsy O
that O
was O
compressing O
the O
proximal O
airway O
as O
seen O
on O

 O
PET/CT O
. O
After O
biopsy O
was O
performed O
with O
ENT O
service O
, O
patient O
was O

 O
admitted O
to O
the O
ENT O
service O
for O
further O
observation O
. O
Right O

 O
venous O
access O
port O
was O
placed O
as O
well O
as O
G-tube O
in O
preparation O

 O
for O
induction O
chemotherapy O
. O
Once O
patient O
was O
stable O
from O

 O
procedures O
, O
he O
was O
transferred O
to O
the O
oncology O
service O
for O

 O
preparation O
of O
starting O
chemotherapy O
. O


 O
He O
reports O
no O
acute O
complaints O
on O
admission O
to O
the O
ENT O
service O
. O


 O
Past O
Medical O
History O
: O

 O
NIDDM O
. O

 O
HTN O
. O

 O
BPH O
. O

 O
Cataracts O
. O

 O
CVA O
. O

 O
Pancreatitis O
. O

 O
Bilateral O
inguinal O
hernia O
repair O
. O

 O
Bilateral O
knee O
surgery O
. O

 O
Hypopharyngeal O
squamous O
cell O
cancer O
dx O
7/[**2108 O
* O
* O
] O
. O


 O
Social O
History O
: O

 O
He O
used O
to O
work O
as O
a O
brick O
layer O
, O
but O
is O
currently O
not O
working O
. O

 O
He O
lives O
alone O
and O
has O
never O
been O
married O
. O
  O
He O
does O
not O
smoke O

 O
and O
never O
smoked O
. O
  O
He O
used O
to O
drink O
, O
but O
quit O
six O
years O
ago O

 O
after O
having O
been O
quite O
a O
heavy O
drinker O
. O


 O
Family O
History O
: O

 O
No O
history O
of O
cancer O
in O
his O
family O
. O



 O
Physical O
Exam O
: O

 O
Exam O
on O
admission O
to O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
: O

 O
General O
: O
Lethargic O
, O
oriented O
x O
2 O
( O
person O
, O
place O
) O
, O
no O
acute O

 O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
MM O
dry O
, O
oropharynx O
clear O
without O
noted O

 O
lesions O
, O
PERRL O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
CV O
: O
Regular O
rate O
and O
rhythm O
, O
distant O
heart O
sounds O
, O
normal O
S1 O
+ O

 O
S2 O
, O
no O
murmurs O
, O
rubs O
, O
gallops O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
on O
anterior O
exam O
, O
no O

 O
wheezes O
, O
rales O
, O
rhonchi O

 O
Abdomen O
: O
soft O
, O
non-distended O
, O
bowel O
sounds O
present O
but O

 O
hypoactive O
, O
G-tube O
in O
place O
with O
minimal O
yellow O
bilious O

 O
drainage O
, O
no O
tenderness O
to O
palpation O
, O
no O
rebound O
or O
guarding O

 O
GU O
: O
Foley O
in O
place O
, O
scrotal O
erythema O
noted O
, O
no O
penile O
lesions O

 O
Ext O
: O
Warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
no O
clubbing O
, O
cyanosis O
or O

 O
edema O

 O
Neuro O
: O
AOx2 O
, O
moving O
all O
four O
extremities O


 O
Pertinent O
Results O
: O

 O
ADMISSION O
LABS O
: O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
8 O
* O
* O
] O
WBC O
10.4 O
, O
Hb O
11.5 O
, O
HCT O
33.1 O
, O
PLT O
100 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
8 O
* O
* O
] O
PT O
11.6 O
, O
INR O
1.1 O
, O
PTT O
28.1 O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
8 O
* O
* O
] O
Na O
134 O
, O
K O
4.4 O
, O
CL O
98 O
, O
CO2 O
30 O
, O
BUN O
24 O
, O
creat O
0.9 O
, O
glucose O

 O
223 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
8 O
* O
* O
] O
Albumin O
3.6 O
, O
Ca O
9.1 O
, O
Phos O
2.7 O
, O
Mg O
2.1 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
8 O
* O
* O
] O
ALT O
16 O
, O
AST O
22 O
, O
ALK O
70 O
, O
T O
BILI O
0.6 O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
7 O
- O
19 O
* O
* O
] O
CT O
NECK O
: O
IMPRESSION O
: O

 O
1 O
. O
Exophytic O
polypoid O
, O
hyperenhancing O
mucosal O
mass O
lesion O
in O
the O

 O
posterior O
hypopharynx O
protruding O
into O
the O
airway O
lumen O
at O
the O

 O
level O
of O
the O
piriform O
sinuses O
without O
obstruction O
. O
  O
This O
, O
in O

 O
combination O
with O
enlarged O
left O
level O
II O
and O
level O
V O
lymph O
nodes O
, O

 O
one O
of O
which O
is O
necrotic O
, O
is O
concerning O
for O
malignancy O
. O
Direct O

 O
visualization O
is O
recommended O
. O

 O
2 O
. O
Nonenhancing O
, O
cystic-appearing O
lesion O
is O
noted O
on O
the O
right O

 O
retropharyngeal O
and O
right O
masticator O
space O
, O
causing O
mild O
mass O

 O
effect O
in O
the O
right O
carotid O
space O
, O
correlation O
with O
MRI O
of O
the O

 O
neck O
with O
and O
without O
contrast O
is O
recommended O
for O
further O

 O
characterication O
. O

 O
3 O
. O
  O
Hyperdense O
secretions O
in O
the O
left O
maxillary O
sinus O
may O

 O
represent O
fungal O
or O
inspissated O
secretions O
, O
incompletely O

 O
evaluated O
on O
this O
study O
. O

 O
4 O
. O
  O
Patulous O
upper O
esophagus O
. O

 O
. O


 O
[ O
* O
* O
2108 O
- O
8 O
- O
3 O
* O
* O
] O
PET/CT O
: O
IMPRESSION O
: O

 O
1 O
. O
FDG-avid O
hypopharyngeal O
mass O
and O
cervical O
lymphadenopathy O
. O

 O
2 O
. O
FDG-avid O
right O
7th O
rib O
sclerotic O
focus O
, O
concerning O
for O

 O
metastasis O
. O

 O
3 O
. O
Airway O
narrowing O
. O
This O
finding O
was O
discussed O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
11925 O
* O
* O
] O

 O
with O
the O
clinical O
team O
at O
the O
time O
of O
completion O
of O
the O
study O
. O

 O
4 O
. O
Tree O
in O
[ O
* O
* O
Male O
First O
Name O
( O
un O
) O
239 O
* O
* O
] O
and O
ground O
glass O
opacities O
in O
the O
right O
middle O

 O
lobe O
, O
which O
are O
non-specific O
but O
concerning O
for O
aspiration O
in O

 O
the O
setting O
of O
pharyngeal O
obstruction O
. O

 O
5 O
. O
Ascending O
aortic O
dilation O
. O

 O
6 O
. O
Calcified O
splenic O
artery O
aneurysm O
. O

 O
7 O
. O
Tiny O
lung O
nodules O
. O
Follow O
up O
is O
recommended O
within O
one O
year O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
8 O
* O
* O
] O
RIGHT O
RIB O
X-RAY O
: O
IMPRESSION O
: O

 O
1 O
. O
  O
Large O
amount O
of O
free O
air O
underneath O
the O
hemidiaphragms O
. O

 O
Subcutaneous O
air O
. O
This O
should O
be O
correlated O
with O
the O
recent O

 O
surgery O
and O
if O
it O
can O
not O
be O
explained O
by O
the O
surgery O
, O
further O

 O
evaluation O
with O
CT O
can O
be O
performed O
to O
assess O
for O
perforation O
. O

 O
2 O
. O
  O
Sclerotic O
right O
seventh O
lateral O
rib O
lesion O
concerning O
for O

 O
metastasis O
is O
best O
evaluated O
on O
the O
PET-CT O
examination O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
9 O
* O
* O
] O
MRI O
BRAIN O
: O
IMPRESSION O
: O

 O
1 O
. O
  O
Unchanged O
bilateral O
retropharyngeal O
and O
masticator O
space O

 O
lesions O
, O
with O
cystic/necrotic O
changes O
on O
the O
right O
side O
, O

 O
previously O
demonstrated O
by O
neck O
CT O
on O
[ O
* O
* O
2108 O
- O
7 O
- O
19 O
* O
* O
] O
, O
likely O

 O
related O
with O
a O
history O
of O
hypopharyngeal O
cancer O
. O

 O
2 O
. O
  O
Intracranially O
there O
is O
no O
evidence O
of O
abnormal O
enhancement O

 O
to O
suggest O
metastasis O
or O
leptomeningeal O
disease O
. O

 O
3 O
. O
  O
Chronic O
lacunar O
ischemic O
changes O
are O
demonstrated O
in O
the O

 O
cerebellar O
hemispheres O
. O
Subcortical O
and O
periventricular O
areas O
of O

 O
chronic O
small O
vessel O
disease O
. O
No O
acute O
or O
subacute O
ischemic O

 O
changes O
are O
identified O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
9 O
* O
* O
] O
VIDEO O
SWALLOW O
: O
IMPRESSION O
: O
Aspiration O
of O
thin O
and O
nectar O

 O
thick O
liquids O
after O
the O
swallow O
in O
patient O
with O
hypopharyngeal O

 O
mass O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
20 O
* O
* O
] O
CXR O
: O
CONCLUSION O
: O
There O
is O
a O
pneumonia O
at O
the O
left O
lung O

 O
base O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
20 O
* O
* O
] O
KUB O
: O
IMPRESSION O
: O
No O
obvious O
signs O
of O
free O
air O
. O
  O
Exam O

 O
somewhat O
limited O
by O
image O
quality O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
21 O
* O
* O
] O
CXR O
FINDINGS O
: O
CONCLUSION O
: O
Progression O
of O
the O
pneumonia O

 O
at O
the O
left O
lung O
base O
. O

 O
. O


 O
[ O
* O
* O
2108 O
- O
8 O
- O
23 O
* O
* O
] O
Wound O
Cx O
: O
[ O
* O
* O
2108 O
- O
8 O
- O
23 O
* O
* O
] O
11:34 O
am O
SWAB O
      O
Source O
: O
G-tube O

 O
site O
. O

 O
GRAM O
STAIN O
( O
Final O
[ O
* O
* O
2108 O
- O
8 O
- O
23 O
* O
* O
] O
) O
: O
mixed O
bacterial O
types O
( O
> O
=3 O
) O
. O

       O
1 O
+ O
    O
( O
< O
1 O
per O
1000X O
FIELD O
) O
: O
   O
POLYMORPHONUCLEAR O

 O
LEUKOCYTES O
. O

       O
4 O
+ O
   O
( O
> O
10 O
per O
1000X O
FIELD O
) O
: O
   O
GRAM O
POSITIVE O
COCCI O
. O

                                     O
IN O
PAIRS O
, O
CHAINS O
, O
AND O

 O
CLUSTERS O
. O

       O
2 O
+ O
   O
( O
1 O
- O
5 O
per O
1000X O
FIELD O
) O
: O
   O
GRAM O
NEGATIVE O
ROD(S O
) O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
26 O
* O
* O
] O
CXR O
: O
COMPARISON O
: O
Chest O
radiograph O
from O
[ O
* O
* O
8 O
- O
20 O
* O
* O
] O
and O
[ O
* O
* O
8 O
- O
21 O
* O
* O
] O
, O
[ O
* O
* O
2108 O
* O
* O
] O
. O
There O
is O
gradual O
progression O
of O
multifocal O

 O
consolidations O
, O
currently O
extensively O
involving O
left O
lower O
lobe O
, O

 O
left O
upper O
lobe O
and O
right O
lower O
lobe O
. O
  O
In O
addition O
, O
there O
is O

 O
interval O
development O
of O
pulmonary O
edema O
and O
bilateral O
pleural O

 O
effusions O
. O
  O
No O
pneumothorax O
is O
seen O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
28 O
* O
* O
] O
CT O
HEAD O
: O
IMPRESSION O
: O

 O
1 O
. O
  O
No O
definite O
acute O
intracranial O
process O
. O

 O
2 O
. O
  O
No O
major O
vascular O
territorial O
infarct O
. O
  O
If O
clinical O

 O
suspicion O
is O
high O
, O
MRI O
could O
be O
considered O
. O

 O
3 O
. O
  O
Left O
basal O
ganglia O
lacunes O
, O
age-related O
involution O
and O
mild O

 O
small O
vessel O
ischemic O
disease O
. O

 O
4 O
. O
  O
Re-demonstration O
of O
cystic O
mass O
in O
the O
right O
retropharynx O
. O

 O
5 O
. O
  O
Longstanding O
left O
maxillary O
sinus O
disease O
with O
atelectatic O

 O
appearance O
of O
the O
sinus O
and O
bony O
sclerosis O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
28 O
* O
* O
] O
MRI/MRA O
BRAIN O
: O
IMPRESSION O
: O

 O
1 O
. O
  O
Multiple O
small O
acute O
infarcts O
in O
bilateral O
cerebral O

 O
hemispheres O
, O
right O
pons O
, O
and O
bilateral O
cerebellar O
hemispheres O
, O

 O
suggesting O
a O
central O
embolic O
source O
. O
  O
This O
was O
discussed O
with O

 O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
from O
neurology O
between O
4:30 O
and O
4:45 O
pm O
on O
[ O
* O
* O
2108 O
- O
8 O
- O
28 O
* O
* O
] O
. O

 O
2 O
. O
  O
No O
evidence O
of O
intracranial O
metastatic O
disease O
. O

 O
3 O
. O
  O
Partially O
visualized O
bilateral O
retropharyngeal O
and O
right O

 O
masticator O
space O
masses O
, O
related O
to O
the O
patient O
's O
known O

 O
hypopharyngeal O
cancer O
. O

 O
4 O
. O
  O
Unremarkable O
head O
MRA O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
29 O
* O
* O
] O
ECHO O
: O
IMPRESSION O
: O
LIMITED O
VIEWS O
. O
Suboptimal O
image O

 O
quality O
. O
Preserved O
global O
left O
ventricular O
systolic O
function O
. O

 O
Can O
not O
assess O
right O
ventricular O
function O
, O
aortic O
valve O

 O
structure/function O
, O
or O
tricuspid O
valve O
structure/function O
. O

 O
. O


 O
[ O
* O
* O
2108 O
- O
9 O
- O
2 O
* O
* O
] O
CXR O
: O
IMPRESSION O
: O
There O
are O
bilateral O
layering O
pleural O

 O
effusions O
and O
residual O
patchy O
airspace O
opacity O
in O
the O
left O
upper O

 O
lobe O
, O
left O
middle O
lung O
and O
at O
both O
bases O
. O
  O
These O
findings O
may O

 O
reflect O
pneumonia O
. O
  O
There O
is O
likely O
a O
superimposed O
component O
of O

 O
mild O
interstitial O
edema O
as O
well O
. O
  O
Right O
Port-A-Cath O
is O
unchanged O

 O
in O
position O
. O
  O
No O
pneumothorax O
is O
seen O
. O
  O
Overall O
, O
cardiac O
and O

 O
mediastinal O
contours O
are O
likely O
stable O
, O
although O
the O
left O
heart O

 O
border O
is O
somewhat O
obscured O
by O
the O
overlying O
effusion O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
3 O
* O
* O
] O
ECHO O
: O
No O
thrombus/mass O
. O
  O
Compared O
with O
the O
prior O
study O

 O
( O
images O
reviewed O
) O
of O
[ O
* O
* O
2108 O
- O
8 O
- O
29 O
* O
* O
] O
, O
a O
PFO O
is O
now O
detected O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
3 O
* O
* O
] O
LE O
DOPPLER O
U/S O
: O
IMPRESSION O
: O

 O
1 O
. O
Non-occlusive O
deep O
venous O
thrombosis O
within O
a O
short O
segment O

 O
of O
the O
right O
peroneal O
vein O
. O

 O
2 O
. O
No O
deep O
venous O
thrombosis O
within O
the O
left O
lower O
extremity O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
10 O
* O
* O
] O
CXR O
: O
IMPRESSION O
: O
  O
No O
change O
from O
9:54 O
a.m. O
in O

 O
pneumomediastinum O
and O
bibasilar O
opacities O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
15 O
* O
* O
] O
RUE O
DOPPLER O
U/S O
: O
IMPRESSION O
: O
  O
No O
right O
upper O
extremity O

 O
deep O
venous O
thrombosis O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
20 O
* O
* O
] O
CTA O
NECK O
IMPRESSION O
: O

 O
1 O
. O
  O
Status O
post O
tracheostomy O
placement O
with O
tip O
terminating O

 O
within O
the O
intrathoracic O
proximal O
trachea O
. O
  O
Thickening O
of O
the O

 O
pretracheal O
soft O
tissues O
at O
the O
level O
of O
the O
tracheostomy O
entry O

 O
likely O
post-surgical O
in O
nature O
. O
No O
evidence O
of O
erosions O
into O

 O
adjacent O
vessels O
by O
the O
tumor O
or O
active O
bleeding O
. O
interval O

 O
decreased O
size O
of O
level O
5 O
abnormal O
lymph O
node O
and O
right O

 O
parapharyngeal O
cystic O
mass O
. O

 O
2 O
. O
  O
Hypopharyngeal O
mass O
as O
described O
, O
smaller O
since O
the O
prior O

 O
examination O
. O

 O
3 O
. O
  O
Blurring O
of O
the O
fat O
planes O
of O
the O
anterior O
neck O
as O
it O
could O

 O
be O
seen O
with O
radiation O
. O

 O
4 O
. O
  O
Enlarged O
lymph O
nodes O
in O
the O
AP O
window O
and O
pretracheal O

 O
spaces O
. O

 O
5 O
. O
  O
Worsening O
pleural O
effusions O
and O
parenchymal O
opacities O
that O

 O
could O
be O
seen O
with O
volume O
overload O
. O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
27 O
* O
* O
] O
pCXR O
FINDINGS O
: O
  O
As O
compared O
to O
the O
previous O
radiograph O
, O

 O
there O
is O
an O
unchanged O
right O
basilar O
opacity O
. O
  O
The O
extent O
and O

 O
severity O
of O
the O
parenchymal O
opacity O
is O
similar O
to O
the O
previous O

 O
examination O
. O
  O
Tracheostomy O
and O
right-sided O
Port-A-Cath O
are O

 O
unchanged O
. O
  O
Unchanged O
mild O
retrocardiac O
atelectasis O
. O
  O
No O

 O
pneumothorax O
. O

 O
. O


 O
[ O
* O
* O
2108 O
- O
9 O
- O
25 O
* O
* O
] O
CXR O
FINDINGS O
: O
Analysis O
is O
performed O
in O
direct O
comparison O

 O
with O
the O
next O
preceding O
similar O
study O
of O
[ O
* O
* O
2108 O
- O
9 O
- O
10 O
* O
* O
] O
. O
  O
The O

 O
tracheal O
cannula O
is O
in O
midline O
position O
, O
seen O
to O
terminate O
in O

 O
the O
trachea O
. O
  O
Termination O
point O
is O
similar O
as O
it O
was O
before O
. O

 O
The O
on O
previous O
examination O
identified O
paratracheal O
air O
and O

 O
subcutaneous O
air O
in O
the O
left O
lower O
neck O
region O
, O
indicative O
of O

 O
pneumomediastinum O
at O
that O
time O
, O
can O
not O
be O
seen O
anymore O
. O
  O
No O

 O
pneumothoraces O
present O
. O
  O
Heart O
size O
unchanged O
. O
  O
The O
previously O

 O
existing O
pulmonary O
congestive O
pattern O
and O
bilateral O
basal O

 O
parenchymal O
infiltrates O
have O
regressed O
markedly O
. O
  O
No O
new O

 O
abnormalities O
are O
seen O
. O
  O
A O
remaining O
diffuse O
haze O
on O
the O
left O

 O
base O
is O
indicative O
for O
some O
pleural O
effusion O
layering O

 O
posteriorly O
. O
IMPRESSION O
: O
  O
Stable O
position O
of O
tracheostomy O

 O
cannula O
, O
previously O
identified O
pneumomediastinum O
has O

 O
disappeared O
. O
  O
No O
pneumothorax O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
10 O
- O
2 O
* O
* O
] O
pCXR O
: O
FINDINGS O
: O
  O
As O
compared O
to O
the O
previous O
radiograph O
, O

 O
there O
is O
no O
relevant O
change O
. O
  O
Tracheostomy O
tube O
in O
constant O

 O
position O
, O
right O
pectoral O
Port-A-Cath O
. O
  O
Constant O
elevation O
of O
the O

 O
right O
hemidiaphragm O
with O
minimal O
blunting O
of O
the O
costophrenic O

 O
sinuses O
. O
  O
Borderline O
size O
of O
the O
cardiac O
silhouette O
. O
  O
No O
newly O

 O
appeared O
parenchymal O
opacities O
. O
  O
No O
pulmonary O
edema O
. O

 O
. O

 O
[ O
* O
* O
2108 O
- O
10 O
- O
12 O
* O
* O
] O
CXR O
: O
IMPRESSION O
: O
Tracheostomy O
tube O
is O
in O
standard O

 O
position O
. O
  O
Right O
subclavian O
infusion O
port O
ends O
in O
the O
mid O
to O
low O

 O
SVC O
. O
  O
No O
mediastinal O
widening O
or O
pneumothorax O
. O
  O
Lungs O
are O

 O
essentially O
clear O
. O
  O
Small O
right O
pleural O
effusion O
unchanged O
. O

 O
. O


 O
DISCHARGE O
LABS O
: O

 O
[ O
* O
* O
2108 O
- O
10 O
- O
15 O
* O
* O
] O
06:30AM O
BLOOD O
WBC-4.1 O
RBC-2.63 O
* O
Hgb-9.1 O
* O
Hct-25.1 O
* O

 O
MCV-96 O
MCH-34.8 O
* O
MCHC-36.4 O
* O
RDW-17.3 O
* O
Plt O
Ct-108 O
* O

 O
[ O
* O
* O
2108 O
- O
10 O
- O
10 O
* O
* O
] O
09:23AM O
BLOOD O
Neuts-71.4 O
* O
Lymphs-11.4 O
* O
Monos-8.5 O

 O
Eos-8.5 O
* O
Baso-0.3 O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
22 O
* O
* O
] O
06:00AM O
BLOOD O
PT-11.0 O
PTT-30.8 O
INR(PT)-1.0 O

 O
[ O
* O
* O
2108 O
- O
10 O
- O
15 O
* O
* O
] O
06:30AM O
BLOOD O
Glucose-158 O
* O
UreaN-27 O
* O
Creat-0.7 O
Na-131 O
* O

 O
K-4.5 O
Cl-94 O
* O
HCO3 O
- O
35 O
* O
AnGap-7 O
* O

 O
[ O
* O
* O
2108 O
- O
10 O
- O
10 O
* O
* O
] O
09:23AM O
BLOOD O
ALT-20 O
AST-19 O
LD(LDH)-163 O
AlkPhos-82 O

 O
TotBili-0.2 O

 O
[ O
* O
* O
2108 O
- O
10 O
- O
6 O
* O
* O
] O
06:00AM O
BLOOD O
Albumin-2.8 O
* O
Calcium-8.3 O
* O
Phos-3.8 O
Mg-2.0 O

 O
[ O
* O
* O
2108 O
- O
10 O
- O
13 O
* O
* O
] O
06:00AM O
BLOOD O
Calcium-9.0 O
Phos-4.4 O
Mg-1.9 O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
9 O
* O
* O
] O
05:45AM O
BLOOD O
% O
HbA1c-7.0 O
* O
eAG-154 O
* O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
28 O
* O
* O
] O
05:32AM O
BLOOD O
Triglyc-52 O
HDL-16 O
CHOL/HD-2.8 O
LDLcalc-19 O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
10 O
* O
* O
] O
10:21AM O
BLOOD O
Osmolal-324 O
* O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
15 O
* O
* O
] O
03:54AM O
BLOOD O
TSH-3.7 O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
16 O
* O
* O
] O
06:00AM O
BLOOD O
25VitD-26 O
* O



 O
Brief O
Hospital O
Course O
: O

 O
72yo O
man O
with O
h/o O
EtOH O
abuse O
, O
DM O
, O
recently O
diagnosed O

 O
hypopharyngeal B-REA
SCC I-REA
admitted O
[ O
* O
* O
2108 O
- O
8 O
- O
7 O
* O
* O
] O
to O
ENT O
service O
for O
biopsy O
of O

 O
pharyngeal O
mass O
, O
G-tube O
and O
port O
placement O
. O
  O
Then O
transferred O
to O

 O
the O
oncology O
service O
on O
[ O
* O
* O
8 O
- O
8 O
* O
* O
] O
for O
initiation O
of O
chemotherapy B-DRUG
. I-DRUG
  O
His O

 O
hospital O
course O
was O
significant O
for O
initiation O
of O
tube O
feeds O

 O
after O
failing O
a O
swallow O
evaluation O
. O
  O
Chemotherapy B-DRUG
with O

 O
docetaxel B-DRUG
, I-DRUG
cisplatin B-DRUG
, I-DRUG
5FU B-DRUG
was O
initiated O
[ O
* O
* O
2108 O
- O
8 O
- O
11 O
* O
* O
] O
, O
complicated O
by O

 O
diarrhea O
, O
severe O
cytopenias O
, O
? O
leaking O
G O
tube O
, O
severe O

 O
nausea/vomiting O
. O
  O
On O
[ O
* O
* O
2108 O
- O
8 O
- O
19 O
* O
* O
] O
, O
he O
received O
10 B-STR
mg I-STR
olanzapine B-DRUG
for O

 O
nausea B-REA
and O
subsequently O
became O
very O
lethargic O
and O
developed O

 O
fever O
, O
hypotension O
, O
acute O
kidney O
injury O
, O
and O
ultimately O

 O
transfered O
to O
the O
ICU O
[ O
* O
* O
2108 O
- O
8 O
- O
20 O
* O
* O
] O
for O
sepsis O
and O
neutropenic B-ADE
fever I-ADE
. I-ADE

 O
His O
ICU O
course O
was O
significant O
for O
diagnosis O
of O
LLL O
pneumonia O
, O

 O
hypotension O
attributed O
to O
hypovolemia O
[ O
* O
* O
3 O
- O
8 O
* O
* O
] O
limited O
PO O

 O
intake/diarrhea O
vs. O
sepsis O
, O
improvement O
in O
acute O
renal O
failure O
, O

 O
hypernatremia O
. O
  O
He O
has O
had O
frequent O
atrial O
ectopy O
and O
PVCs O
and O

 O
electrolyte O
abnormalities O
. O
  O
ENT O
planned O
for O
tracheostomy O
[ O
* O
* O
2108 O
- O
8 O
- O
28 O
* O
* O
] O

 O
for O
airway O
protection O
during O
therapy O
, O
but O
on O
[ O
* O
* O
2108 O
- O
8 O
- O
28 O
* O
* O
] O
early O
AM O
, O

 O
he O
was O
found O
to O
have O
left O
facial O
droop O
. O
  O
MRI O
confirmed O
CVA O

 O
suggestive O
of O
thromboembolism O
. O
  O
TTE O
showed O
no O
evidence O
of O
clot O
. O

 O
Neuro O
recommended O
starting O
heparin B-DRUG
ggt B-ROU
, I-ROU
which O
was O
started O

 O

[ O
* O
* O
2108 O
- O
8 O
- O
29 O
* O
* O
] O
. O
  O
TEE O
could O
not O
be O
done O
given O
size/location O
of O

 O
hypopharyngeal O
mass O
. O
  O
Repeat O
TTE O
with O
bubble O
study O
revealed O
a O

 O
PFO O
and O
LE O
doppler O
U/S O
showed O
a O
RLE O
DVT O
. O
  O
The O
tracheostomy O
was O

 O
eventually O
placed O
[ O
* O
* O
2108 O
- O
9 O
- O
10 O
* O
* O
] O
. O
  O
However O
, O
this O
was O
complicated O
by O

 O
bleeding O
over O
one O
week O
. O
  O
Anticoagulation O
was O
stopped O
as O
a O

 O
result O
. O
  O
A O
rechallenge O
with O
anticoagulation O
failed O
a O
second O
time O

 O
due O
to O
bleeding O
from O
his O
tumor O
and O
trach O
site O
. O
  O
He O
has O

 O
subsequently O
been O
managed O
with O
venodynes O
and O
prophylactic O

 O
heparin B-DRUG
5,000 B-STR
units I-STR
SC B-ROU
TID B-FRE
. I-FRE
  O
On O
[ O
* O
* O
2108 O
- O
9 O
- O
24 O
* O
* O
] O
he O
coughed O
out O
his O

 O
tracheostomy O
cannula O
. O
  O
Replacement O
was O
complicated O
by O
bleeding O

 O
and O
hemoptysis O
requiring O
ENT O
evaluation O
. O
  O
Bleeding/hemoptysis O

 O
resolved O
gradually O
over O
next O
4 O
days O
. O
  O
He O
again O
developed O

 O
aspiration B-REA
pneumonia I-REA
[ O
* O
* O
2108 O
- O
9 O
- O
28 O
* O
* O
] O
and O
was O
started O
on O
cefepime B-DRUG
and O

 O
vancomycin B-DRUG
. I-DRUG
  O
His O
respiratory O
status O
was O
stable O
and O
actually O

 O
improved O
rather O
quickly O
. O
  O
Antibiotics B-DRUG
were O
stopped O
[ O
* O
* O
2108 O
- O
10 O
- O
3 O
* O
* O
] O
. O

 O
Combination O
XRT O
and O
cetuximab B-DRUG
was O
planned O
. O
  O
A O
loading O
dose O

 O
( O
400mg/m2 O
) O
of O
cetuximab B-DRUG
was O
given O
[ O
* O
* O
2108 O
- O
10 O
- O
3 O
* O
* O
] O
and O
radiation O
started O

 O
[ O
* O
* O
2108 O
- O
10 O
- O
10 O
* O
* O
] O
and O
will O
continue O
for O
6 O
weeks O
total O
. O

 O
. O

 O
MICU O
COURSE O
: O

 O
Mr. O
O O
' O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
was O
admitted O
to O
MICU O
For O
airway O
monitoring O
after O

 O
trach O
placement O
. O
  O
Trach O
placement O
was O
uncomplicated O
. O
  O
On O

 O
admission O
, O
he O
was O
breathing O
comfortably O
and O
in O
no O
distress O
. O

 O
Post-op O
CXR O
was O
performed O
, O
which O
showed O
pneumomediastinum O
; O
this O

 O
was O
not O
unexpected O
given O
recent O
open O
procedure O
. O
  O
Repeat O
CXR O

 O
showed O
no O
change O
in O
pneumomediastinum O
. O
  O
Post-op O
trach O
care O
was O

 O
administered O
including O
airway O
suctioning O
as O
needed O
. O
  O
Tube O
feeds O

 O
were O
re-initiated O
with O
additional O
boluses O
of O
free O
water O
given O

 O
hypernatremia O
. O
  O
Enoxaparin B-DRUG
was O
held O
overnight O
on O
day O
1 O
of O
MICU O

 O
course O
because O
of O
bleeding O
from O
suction O
. O
  O
However O
, O
bleeding O
was O

 O
limited O
, O
so O
enoxaparin B-DRUG
was O
restarted O
in O
the O
morning O
of O
MICU O
day O

 O
2 O
. O
  O
Ophthalmology O
was O
consulted O
for O
continuing O
care O
of O
VZV B-REA
; I-REA
they O

 O
recommended O
continuing O
acyclovir B-DRUG
. I-DRUG
  O
He O
remained O
hemodynamically O

 O
stable O
and O
returned O
to O
the O
primary O
team O
. O

 O
. O

 O
OTHER O
DETAILS O
: O

 O
# O
Cough O
: O
CXR O
negative O
. O
  O
Cough O
may O
be O
due O
to O
XRT O
. O
  O
Continued O

 O
suction O
and O
humidified O
air O
via O
trach O
. O

 O
. O


 O
# O
Recurrent O
aspiration O
pneumonia/sepsis O
: O
Resolved O
. O
  O
Episode O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
20 O
* O
* O
] O
required O
transfer O
to O
ICU O
with O
relative O
hypotension O
, O

 O
tachycardia O
, O
fever O
, O
hypoxia O
, O
and O
tachypnea O
. O
  O
LLL B-REA
pneumonia I-REA
on O

 O
CXR O
treated O
initially O
with O
vancomycin B-DRUG
, I-DRUG
cefepime B-DRUG
, I-DRUG
and O

 O
metronidazole B-DRUG
due O
to O
concern O
for O
aspiration O
. O
  O
CXR O
[ O
* O
* O
2108 O
- O
8 O
- O
21 O
* O
* O
] O
and O

 O
[ O
* O
* O
2108 O
- O
8 O
- O
26 O
* O
* O
] O
showed O
worsening O
infiltrate O
, O
so O
abx O
changed O
to O
meropenem B-DRUG

 I-DRUG
with O
vancomycin B-DRUG
[ O
* O
* O
2108 O
- O
8 O
- O
26 O
* O
* O
] O
, O
finished O
[ O
* O
* O
2108 O
- O
9 O
- O
3 O
* O
* O
] O
. O
Concern O
for O
another O

 O
episode O
of O
PNA B-REA
prompted O
use O
of O
vanco B-DRUG
and O
cefepime B-DRUG
[ O
* O
* O
2108 O
- O
9 O
- O
28 O
* O
* O
] O
- O

 O
[ O
* O
* O
2108 O
- O
10 O
- O
3 O
* O
* O
] O
. O
  O
Continued O
to O
have O
secretions O
and O
rhonchi O
. O
  O
Guaifenesin B-DRUG

 I-DRUG
PRN O
cough B-REA
. I-REA
  O
Aspiration O
precautions O
. O
  O
AVOID O
sedating B-DRUG
meds I-DRUG
. I-DRUG

 O
. O

 O
# O
Eye B-REA
pain I-REA
: I-REA
Due O
to O
post-herpetic O
neuralgia O
+ O
/- O
stye O
. O

 O
Ophthalmology O
consulted O
. O
  O
Started O
on O
lubrigel B-DRUG
to O
maintain B-REA

 I-REA
hydration I-REA
to I-REA
eye I-REA
surface I-REA
. I-REA
  O
Tramadol B-DRUG
and O
acetaminophen B-DRUG
PRN O
. O

 O
. O

 O
# O
Left B-REA
eye I-REA
lens I-REA
implant I-REA
( O
for O
? O
glaucoma O
) O
: O
Outpatient O

 O
bacitracin/polymyxin B-DRUG
B I-DRUG
used O
initially O
; O
stopped O
per O

 O
Ophthalmology O
. O

 O
. O

 O
# O
Zoster B-REA
: I-REA
VZV B-REA
culture O
positive O
. O
  O
Started O
on O
acyclovir B-DRUG
treatment O

 O
dose O
x10d B-DUR
, I-DUR
then O
changed O
to O
prophylaxis O
dose O
. O
  O
Ophthalmology O

 O
consulted O
; O
no O
ocular O
involvement O
initially O
, O
then O
filamentary O

 O
keratopathy O
seen O
[ O
* O
* O
2108 O
- O
10 O
- O
4 O
* O
* O
] O
. O
  O
Pain B-REA
initially O
controlled O
with O

 O
gabapentin B-DRUG
, I-DRUG
titrated O
off O
[ O
* O
* O
2108 O
- O
9 O
- O
15 O
* O
* O
] O
to O
avoid O
somnolence O
. O
  O
Restarted O

 O
gabapentin B-DRUG
given O
increased O
pain B-REA
; I-REA
will O
titrate O
up O
dose O
. O

 O
Acetaminophen B-DRUG
and O
tramadol B-DRUG
PRN O
. O

 O
. O

 O
# O
S/P O
trach O
[ O
* O
* O
2108 O
- O
9 O
- O
10 O
* O
* O
] O
: O
Complicated O
by O
bleeding O
, O
resolved O
off O

 O
anticoagulation B-REA
, I-REA
now O
on O
heparin B-DRUG
SC B-ROU
. I-ROU
  O
Cuff O
deflated O
[ O
* O
* O
2108 O
- O
9 O
- O
14 O
* O
* O
] O
. O

 O
Routine O
trach O
change O
to O
uncuffed O
trach O
[ O
* O
* O
2108 O
- O
9 O
- O
17 O
* O
* O
] O
. O
  O
CTA O
[ O
* O
* O
2108 O
- O
9 O
- O
20 O
* O
* O
] O

 O
showed O
soft-tissue O
swelling O
around O
the O
trach O
, O
but O
no O
active O

 O
bleed O
. O
  O
Coughed O
out O
trach O
tube O
[ O
* O
* O
2108 O
- O
9 O
- O
24 O
* O
* O
] O
, O
re-bled O
then O
, O
now O

 O
resolved O
. O
  O
Airway O
suctioning O
PRN O
. O
  O
Continued O
telemetry O
for O

 O
continuous O
O2 O
monitoring O
( O
hospital O
policy O
for O
trach O
patients O
) O
. O

 O
. O


 O
# O
Hemoptysis O
: O
As O
above O
. O
  O
ENT O
consulted O
. O
  O
No O
bleeding O
from O
tumor O
, O

 O
likely O
source O
is O
mild O
trauma O
from O
trach O
replacement O
. O
  O
Resolved O
. O

 O
- O
Change O
trach O
tube O
as O
needed O
or O
recommended O
by O
ENT/resp O
care O

 O
team O
. O

 O
. O

 O
# O
Hypopharyngeal O
squamous O
cell O
CA O
: O
T1N2bMx O
stage O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
. O
  O
Started O

 O
cycle O
# O
1 O
TCF O
chemo O
[ O
* O
* O
2108 O
- O
8 O
- O
11 O
* O
* O
] O
complicated O
by O
N/V O
, O
severe O
cytopenias O
, O

 O
sepsis O
, O
and O
CVA O
. O
  O
Per O
ENT O
, O
the O
mass O
initially O
was O
filling O
the O

 O
hypopharynx O
and O
likely O
affecting O
his O
ability O
to O
handle O

 O
secretions O
though O
the O
airway O
was O
open O
. O
  O
Trach O
postponed O
due O
to O

 O
acute O
CVA O
, O
initially O
planned O
for O
[ O
* O
* O
2108 O
- O
8 O
- O
28 O
* O
* O
] O
. O
  O
Per O
ENT O
( O
via O

 O
laryngoscopy O
) O
, O
excellent O
response O
to O
chemotherapy O
with O
a O
~90 O
% O

 O
reduction O
in O
tumor O
size O
. O
  O
Unable O
to O
continue O
with O
TCF O
given O

 O
life-threatening O
complications O
, O
his O
treatment O
was O
changed O
to O
XRT O

 O
with O
concurrent O
cetuximab B-DRUG
as O
a O
radio-sensitizer O
. O
  O
Loading O
dose O

 O
cetuximab B-DRUG
400mg/m2 B-STR
given O
[ O
* O
* O
2108 O
- O
10 O
- O
3 O
* O
* O
] O
. O
  O
2nd O
weekly O
dose O
delayed O
due O

 O
to O
insurance O
issues O
; O
given O
250mg/m2 B-STR
[ O
* O
* O
2108 O
- O
10 O
- O
12 O
* O
* O
] O
. O
  O
Anti-emetics B-DRUG
PRN O
. O

 O
Caphasol B-DRUG
, I-DRUG
Maalox/diphenhydramine/lidocaine B-DRUG
PRN O
mouth B-REA
pain I-REA
. I-REA

 O
Continue O
daily O
XRT O
with O
weekly O
cetuximab B-DRUG
for B-DUR
six I-DUR
weeks I-DUR
total O
. O

 O
. O

 O
# O
CVA/PFO O
: O
Left O
face O
drooping O
seen O
[ O
* O
* O
2108 O
- O
8 O
- O
28 O
* O
* O
] O
; O
MRI O
positive O
for O

 O
CVA B-REA
, I-REA
likely O
embolic O
. O
  O
Neurology O
consulted O
and O
heparin B-DRUG
gtt B-ROU

 I-ROU
started O
. O
  O
Aspirin B-DRUG
started O
[ O
* O
* O
2108 O
- O
8 O
- O
28 O
* O
* O
] O
, O
but O
stopped O
when O
heparin B-DRUG

 I-DRUG
started O
. O
  O
MRA O
brain O
unremarkable O
. O
  O
TTE O
negative O
for O
clot O
. O
  O
No O

 O
TEE O
given O
location O
of O
tumor O
. O
  O
Repeat O
TTE O
with O
bubble O
study O

 O
showed O
a O
PFO O
. O
  O
LE O
doppler O
U/S O
showed O
a O
RLE O
DVT O
, O
possible O
  O
source O

 O
of O
CVA O
and O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
( O
paradoxical O
emboli O
) O
. O
  O
Heparin B-DRUG
gtt B-ROU
changed O
to O

 O
enoxaparin B-DRUG
. I-DRUG
  O
Then O
stopped O
for O
post-trach B-ADE
bleeding I-ADE
complications I-ADE
. I-ADE

  O
Restarted O
heparin B-DRUG
gtt B-ROU
[ O
* O
* O
2108 O
- O
9 O
- O
19 O
* O
* O
] O
and O
stopped O
[ O
* O
* O
2108 O
- O
9 O
- O
20 O
* O
* O
] O
due O
to O

 O
recurrent O
trach O
bleed O
. O
  O
Continue O
heparin B-DRUG
5000U B-STR
SC B-FOR
TID B-FRE
. I-FRE
  O
PT/OT O
. O

 O
. O

 O
# O
RLE B-REA
DVT I-REA
: I-REA
Anticoagulation B-DRUG
stopped O
due O
to O
trach B-ADE
bleeding I-ADE
. I-ADE
  O
IVC O

 O
filter O
considered O
, O
but O
decided O
against O
. O
  O
Continued O
heparin B-DRUG
SC B-ROU

 I-ROU
PPx O
and O
venodynes O
. O

 O
. O


 O
# O
Acute O
renal O
failure O
: O
Baseline O
creatinine O
0.7 O
, O
peak O
1.6 O
, O
now O

 O
back O
to O
baseline O
. O
  O
Furosemide/metolazone B-DRUG
given O
for O
anasarca B-REA
, I-REA
now O

 O
euvolemic B-REA
. I-REA
  O
Maintain O
adequate O
hydration O
with O
tube O
feeds/flushes O
. O

 O
. O

 O
# O
Paraphimosis O
: O
Urology O
successfully O
reduced O
it O
[ O
* O
* O
2108 O
- O
9 O
- O
14 O
* O
* O
] O
. O

 O
. O

 O
# O
Diarrhea B-REA
: I-REA
Intermittent O
. O
  O
C. O
diff O
negative O
x2 O
. O
  O
Loperamide B-DRUG
PRN O
. O

 O
. O

 O
# O
Thrombocytopenia O
: O
Chronic O
. O
  O
Suspected O
due O
to O
alcoholic O
liver O

 O
disease/hypersplenism O
. O
  O
Severe O
post-chemo O
, O
now O
back O
to O
baseline O
. O

 O
. O

 O
# O
Anemia O
: O
Chronic O
anemia O
but O
sub-acute O
drop O
due O
to O
chemo B-DRUG
, I-DRUG
then O

 O
post-trach O
bleeding O
. O
  O
Transfused O
1U O
RBC O
[ O
* O
* O
2108 O
- O
8 O
- O
31 O
* O
* O
] O
, O
[ O
* O
* O
2108 O
- O
9 O
- O
3 O
* O
* O
] O
, O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
10 O
* O
* O
] O
, O
2U O
[ O
* O
* O
2108 O
- O
9 O
- O
12 O
* O
* O
] O
, O
1U O
[ O
* O
* O
2108 O
- O
9 O
- O
14 O
* O
* O
] O
, O
[ O
* O
* O
2108 O
- O
9 O
- O
18 O
* O
* O
] O
, O
[ O
* O
* O
2108 O
- O
10 O
- O
1 O
* O
* O
] O
, O
[ O
* O
* O
2108 O
- O
10 O
- O
9 O
* O
* O
] O
. O

 O
. O

 O
# O
Hx O
Anasarca B-REA
: I-REA
Resolved O
. O
  O
Due O
to O
hypoalbuminemia O
. O
  O
Albumin B-DRUG

 I-DRUG
infusions B-FOR
with O
furosemide/metolazone B-DRUG
effectively O
diuresed O
. O

 O
. O

 O
# O
NIDDM O
: O
HbA1c O
7.0 O
on O
[ O
* O
* O
2108 O
- O
8 O
- O
9 O
* O
* O
] O
. O
  O
Endocrine O
following O
. O
  O
Insulin B-DRUG

 I-DRUG
glargine I-DRUG
dose O
at O
6U B-FOR
daily B-FRE
. I-FRE
  O
Cover O
with O
insulin B-DRUG
sliding B-DOS
scale I-DOS
. I-DOS

 O
. O

 O
# O
Hypertension O
: O
Decreased O
amlodipine B-DRUG
10 B-STR
to O
5 B-STR
mg I-STR
daily B-FRE
[ O
* O
* O
2108 O
- O
8 O
- O
30 O
* O
* O
] O
and O

 O
discontinued O
[ O
* O
* O
2108 O
- O
9 O
- O
13 O
* O
* O
] O
to O
change O
to O
metoprolol B-DRUG
given O
ectopy O
. O

 O
Metoprolol B-DRUG
dose O
increased O
from O
12.5 B-STR
to O
25 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O
  O
Added O
back O

 O
amlodipine B-DRUG
5 B-STR
mg I-STR
daily B-FRE
[ O
* O
* O
2108 O
- O
9 O
- O
20 O
* O
* O
] O
. O
  O
Trigger O
for O
hypertensive O
urgency O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
21 O
* O
* O
] O
, O
so O
amlodipine B-DRUG
increased O
to O
10 B-STR
mg I-STR
daily B-FRE
. I-FRE
  O
Started O

 O
lisinopril B-DRUG
5 B-STR
mg I-STR
daily B-FRE
[ O
* O
* O
2108 O
- O
9 O
- O
30 O
* O
* O
] O
for O
SBPs O
in O
160s O
for O
several O
days O
. O

  O
Increased O
lisinopril B-DRUG
to O
10 B-STR
mg I-STR
daily B-FRE
[ O
* O
* O
2108 O
- O
10 O
- O
12 O
* O
* O
] O
for O
continued O

 O
uncontrolled B-REA
HTN I-REA
. I-REA

 O
. O

 O
# O
Non-sustained O
ventricular O
tachycardia O
: O
Frequent B-REA
PVCs I-REA
, I-REA
atrial B-REA

 I-REA
ectopy I-REA
. I-REA
  O
Resolved O
with O
addition O
of O
metoprolol B-DRUG
12.5 B-STR
mg I-STR
PO B-ROU
BID B-FRE
. I-FRE

 O
. O

 O
# O
Hyperlipidemia B-REA
: I-REA
Stable O
. O
  O
Continued O
statin B-DRUG
. I-DRUG

 O
. O


 O
# O
Anxiety/PTSD/depression O
: O
New O
depression O
. O
  O
Increased O
outpatient O

 O
citalopram B-DRUG
from O
20 B-STR
to O
30 B-STR
mg I-STR
on O
[ O
* O
* O
2108 O
- O
10 O
- O
7 O
* O
* O
] O
. O

 O
. O

 O
# O
Nasal B-REA
congestion I-REA
: I-REA
Saline B-DRUG
nasal B-ROU
spray B-FOR
. I-FOR

 O
. O

 O
# O
Scrotal B-REA
erythema I-REA
: I-REA
Miconazole B-DRUG
powder B-FOR
to O
skin B-ROU
. I-ROU

 O
. O

 O
# O
Pain B-REA
( O
Port O
site O
, O
G-tube O
site O
, O
left O
forehead O
zoster O
) O
: O
Restarted O

 O
gabapentin B-DRUG
for O
left O
forehead O
zoster O
pain O
. O
  O
Acetaminophen B-DRUG
PRN O
. O

 O
- O
TITRATE O
UP O
GABAPENTIN B-DRUG
FOR O
ZOSTER B-REA
PAIN I-REA
. I-REA

 O
. O

 O
# O
Hypernatremia O
: O
Improved O
after O
stopping O
furosemide B-DRUG
and O

 O
increasing O
tube O
feed O
flushes O
. O
  O
Decreased O
tube O
feed O
flushes O
as O

 O
sodium O
levels O
declined O
. O

 O
. O

 O
# O
Hyponatremia B-ADE
: I-ADE
Mild O
. O
SIADH O
vs O
recent O
HCTZ/hypovol B-DRUG
( O
hctz O
dc'd O

 O
[ O
* O
* O
2108 O
- O
9 O
- O
28 O
* O
* O
] O
) O
. O
  O
Decreased O
free O
water O
intake O
. O
  O
Salt O
tablets O
PRN O
. O

 O
. O

 O
# O
Severe O
weakness/lethargy O
: O
Severe O
deconditioning O
. O
  O
TSH O
normal O
. O

 O
Stopped O
gabapentin B-DRUG
[ O
* O
* O
2108 O
- O
9 O
- O
15 O
* O
* O
] O
to O
avoid O
sedation O
. O
  O
Slowly O
improving O
. O

  O
PT O
reconsulted O
. O

 O
. O

 O
# O
FEN O
: O
NPO O
and O
continuous O
tube O
feeds O
with O
water O
flushes O
. O

 O
Repleted O
hypokalemia O
. O
  O
Repleting O
low O
vitamin O
D. O
  O
Improved O

 O
alkalosis O
after O
gentle O
IVFs B-DRUG
and O
blood B-DRUG
transfusion B-FOR
. I-FOR

 O
. O

 O
# O
GI B-REA
PPx I-REA
: I-REA
Lansoprazole B-DRUG
via O
G-tube B-ROU
. I-ROU
  O
Bowel O
regimen O
restarted O
for O

 O
constipation B-REA
. I-REA

 O
. O

 O
# O
DVT B-REA
PPx I-REA
: I-REA
Heparin B-DRUG
SC B-ROU
5,000U B-STR
TID B-FRE
. I-FRE

 O
. O

 O
# O
IV O
access O
: O
Port O
placed O
[ O
* O
* O
2108 O
- O
8 O
- O
7 O
* O
* O
] O
. O

 O
. O

 O
# O
Precautions O
: O
Fall O
, O
MRSA O
( O
positive O
screen O
) O
, O
aspiration O
. O

 O
. O

 O
# O
CODE O
STATUS O
: O
FULL O
. O


 O
Medications O
on O
Admission O
: O

 O
bacitracin B-DRUG
polymixin B-DRUG

 I-DRUG
citalopram B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
glimepiride B-DRUG
1 B-STR
mg I-STR
daily B-FRE

 I-FRE
lisinopril B-DRUG
5 B-STR
mg I-STR
daily B-FRE

 I-FRE
omeprazole B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
oxycodone B-DRUG
5 B-STR
mg I-STR
Q4H B-FRE
prn O
pain B-REA

 I-REA
simvistatin B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
asa B-DRUG
81 B-STR
mg I-STR
daily B-FRE

 I-FRE
colace B-DRUG
100 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
MVI B-DRUG
one B-DOS
daily B-FRE

 I-FRE
Glucerna B-DRUG
8 B-STR
oz I-STR
three B-FRE
times I-FRE
daily I-FRE

 I-FRE
NaCl B-DRUG
nasal B-ROU
spray B-FOR
2 B-DOS
sprays B-FOR
ea B-ROU
nostril I-ROU
prn O



 O

Discharge O
Medications O
: O

 O
1 O
. O
lansoprazole B-DRUG
30 B-STR
mg I-STR
Rapid B-FOR
Dissolve I-FOR
, I-FOR
DR I-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
DAILY B-FRE
. I-FRE

 O
Disp:*30 O
Tablet O
, O
Rapid O
Dissolve O
, O
DR(s O
) O
* O
Refills:*2 O
* O

 O
2 O
. O
prochlorperazine B-DRUG
maleate I-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
q6HR B-FRE

 I-FRE
PRN I-FRE
nausea B-REA
. I-REA

 O
Disp:*20 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
3 O
. O
ondansetron B-DRUG
HCl I-DRUG
4 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
q8HR B-FRE
PRN I-FRE

 I-FRE
nausea B-REA
. I-REA

 O
Disp:*20 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
4 O
. O
amlodipine B-DRUG
10 B-STR
mg I-STR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
5 O
. O
nystatin B-DRUG
100,000 B-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Five O
( O
5 O
) O
ML B-FOR
PO B-ROU
QID B-FRE
. I-FRE

 O
6 O
. O
simvastatin B-DRUG
10 B-STR
mg I-STR
tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
tablet B-FOR
PO B-ROU
DAILY B-FRE
. I-FRE

 O
7 O
. O
fluticasone B-DRUG
50 B-STR
mcg/actuation I-STR
Spray B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Spray B-FOR
Nasal B-ROU

 I-ROU
DAILY B-FRE
. I-FRE

 O
8 O
. O
dextromethorphan-guaifenesin B-DRUG
10 B-STR
- I-STR
100 I-STR
mg/5 I-STR
mL I-STR
Syrup B-FOR
Sig O
: O
5ML O
PO B-ROU

 I-ROU
Q6H B-FRE
PRN I-FRE
cough B-REA
. I-REA

 O
9 O
. O
bisacodyl B-DRUG
10 B-STR
mg I-STR
tablet B-FOR
, I-FOR
delayed I-FOR
release I-FOR
( I-FOR
DR/EC I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
PRN I-FRE

 I-FRE
constipation B-REA
. I-REA

 O
10 O
. O
miconazole B-DRUG
nitrate I-DRUG
2 O
% O
Powder B-FOR
Sig O
: O
Appl B-FOR
Topical B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
PRN O

 O
scrotal O
irritation B-REA
. I-REA

 O
11 O
. O
lidocaine-diphenhyd-[**Doctor B-DRUG
Last O
Name O
* O
* O
] O
-mag-[**Doctor O
Last O
Name O
* O
* O
] O
200 B-STR
- I-STR
25 I-STR
- I-STR
400 I-STR
- I-STR
40 I-STR
mg/30 I-STR
mL I-STR

 I-STR
Mouthwash B-FOR
Sig O
: O
Fifteen B-DOS
( I-DOS
15 I-DOS
) I-DOS
mL B-FOR
Mucous B-ROU
membrane I-ROU
QID B-FRE
PRN I-FRE
pain B-REA
. I-REA

 O
12 O
. O
loperamide B-DRUG
2 B-STR
mg I-STR
PO B-ROU
QID B-FRE
PRN I-FRE
loose B-REA
stool I-REA
. I-REA

 O
13 O
. O
folic B-DRUG
acid I-DRUG
1 B-STR
mg I-STR
PO B-ROU
DAILY B-FRE
. I-FRE

 O
14 O
. O
cholecalciferol B-DRUG
( O
vitamin O
D3 O
) O
400 B-STR
unit I-STR
tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
tablet B-FOR
PO B-ROU
DAILY B-FRE
. I-FRE

 O
15 O
. O
chlorhexidine B-DRUG
gluconate I-DRUG
0.12 B-STR
% O
Mouthwash B-FOR
Sig O
: O
Fifteen B-DOS
( I-DOS
15 I-DOS
) I-DOS

 I-DOS
ML O
Mucous B-ROU
membrane I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O

 O
16 O
. O
ipratropium B-DRUG
bromide I-DRUG
0.02 B-STR
% O
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Neb B-FOR
Inh B-ROU
Q6H B-FRE

 I-FRE
PRN I-FRE
wheezes B-REA
. I-REA

 O
17 O
. O
acyclovir B-DRUG
400 B-STR
mg I-STR
tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
PO B-ROU
Q8H B-FRE
. I-FRE

 O
18 O
. O
heparin B-DRUG
( I-DRUG
porcine I-DRUG
) I-DRUG
5,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
1mL O
Injection B-FOR

 I-FOR
TID B-FRE
. I-FRE

 O
19 O
. O
acetaminophen B-DRUG
325 B-STR
mg I-STR
tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
PO B-ROU
Q6H B-FRE
PRN I-FRE

 I-FRE
pain B-REA
. I-REA

 O
20 O
. O
metoprolol B-DRUG
tartrate I-DRUG
25 B-STR
mg I-STR
tablet B-FOR
Sig O
: O
0.5 B-DOS
tablet B-FOR
PO B-ROU
BID B-FRE
. I-FRE

 O
21 O
. O
white B-DRUG
petrolatum-mineral I-DRUG
oil I-DRUG
56.8 B-STR
- I-STR
42.5 I-STR
% I-STR
Ointment B-FOR
Sig O
: O
Appl B-FOR

 I-FOR
Ophthalmic B-ROU
Q2 B-FRE
- I-FRE
3HR I-FRE
. I-FRE

 O
22 O
. O
tramadol B-DRUG
50 B-STR
mg I-STR
PO B-ROU
BID B-FRE
PRN I-FRE
left B-REA
eye I-REA
pain I-REA
. I-REA

 O
23 O
. O
citalopram B-DRUG
20 B-STR
mg I-STR
tablet B-FOR
Sig O
: O
1.5 B-DOS
tablets B-FOR
PO B-ROU
DAILY B-FRE
. I-FRE

 O
24 O
. O
lisinopril B-DRUG
10 B-STR
mg I-STR
tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
tablet B-FOR
PO B-ROU
DAILY B-FRE
. I-FRE

 O
25 O
. O
senna B-DRUG
8.8 B-STR
mg/5 I-STR
mL I-STR
Syrup B-FOR
Sig O
: O
Five O
( O
5 O
) O
mL O
PO B-ROU
BID B-FRE
. I-FRE

 O

26 O
. O
magnesium B-DRUG
hydroxide I-DRUG
400 B-STR
mg/5 I-STR
mL I-STR
Sig O
: O
30ML O
PO B-ROU
Q6H B-FRE
PRN I-FRE

 I-FRE
Constipation B-REA
. I-REA

 O
27 O
. O
gabapentin B-DRUG
100 B-STR
mg I-STR
capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
capsule B-FOR
PO B-ROU
TID B-FRE
. I-FRE

 O
28 O
. O
docusate B-DRUG
sodium I-DRUG
50 B-STR
mg/5 I-STR
mL I-STR
Liquid B-FOR
Sig O
: O
10mL O
PO B-ROU
TID B-FRE
. I-FRE

 O
29 O
. O
polyethylene B-DRUG
glycol I-DRUG
3350 I-DRUG
17 B-STR
gram I-STR
Powder B-FOR
in O
Packet B-FOR
PO B-ROU
DAILY B-FRE
. I-FRE

 O
30 O
. O
acetaminophen B-DRUG
650 B-STR
mg I-STR
PO B-ROU
: I-ROU
Give O
30 O
minutes O
prior O
to O
cetuximab B-DRUG
. I-DRUG

 O
31 O
. O
diphenhydramine B-DRUG
HCl I-DRUG
50 B-STR
mg/mL I-STR
Sig O
: O
1mL O
Injection B-FOR
: I-FOR
Give O
30 O

 O
minutes O
prior O
to O
cetuximab B-DRUG
. I-DRUG

 O
32 O
. O
insulin B-DRUG
glargine I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
6U O
SC B-ROU
qHS B-FRE
. I-FRE

 O
33 O
. O
insulin B-DRUG
regular I-DRUG
human I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
As O
directed O

 O
Units O
Injection O
QID B-FRE
: I-FRE
Per O
sliding B-DOS
scale I-DOS
. I-DOS

 O
34 O
. O
cetuximab B-DRUG
100mg/50mL B-STR
Solution B-FOR
Sig O
: O
250mg/m2 B-DOS
IV B-ROU
once B-FRE
a I-FRE
week I-FRE

 I-FRE
for B-DUR
4 I-DUR
weeks I-DUR
: I-DUR
Continue O
until O
radiation O
is O
complete O
. O


 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital O
* O
* O
] O
HOSPITAL O
[ O
* O
* O
Hospital1 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
1 O
. O
Hypopharyngeal O
squamous O
cell O
carcinoma O
( O
throat O
cancer O
) O
. O

 O
2 O
. O
Cycle O
# O
1 O
TCF O
( O
docetaxel B-DRUG
, I-DRUG
cisplatin B-DRUG
, I-DRUG
5FU B-DRUG
) I-DRUG
chemotherapy O
. O

 O
3 O
. O
Aspiration O
. O

 O
4 O
. O
Hypertension O
( O
high O
blood O
pressure O
) O
. O

 O
5 O
. O
Thrombocytopenia O
( O
low O
platelet O
count O
) O
. O

 O
6 O
. O
Hypokalemia O
( O
low O
potassium O
level O
) O
. O

 O
7 O
. O
Diarrhea O
. O

 O
8 O
. O
Arrhythmia O
. O

 O
9 O
. O
Mucositis O
. O

 O
10 O
. O
Pneumonia O
. O

 O
11 O
. O
Neutropenia O
( O
low O
white O
blood O
count O
) O
. O

 O
12 O
. O
Anemia O
( O
low O
red O
blood O
cell O
count O
) O
. O

 O
13 O
. O
Diabetes O
. O

 O
14 O
. O
Stroke O
. O

 O
15 O
. O
Acute O
kidney O
failure O
. O

 O
16 O
. O
DVT O
( O
deep O
vein O
thrombosis O
, O
blood O
clot O
in O
right O
leg O
) O
. O

 O
17 O
. O
Patent O
foramen O
ovale O
( O
hole O
in O
heart O
) O
. O

 O
18 O
. O
Hemorrhage O
from O
tracheostomy O
. O

 O
19 O
. O
Zoster O
( O
shingles O
) O
. O

 O
20 O
. O
Arrhythmia O
. O

 O
21 O
. O
Generalized O
weakness O
. O

 O
22 O
. O
Radiation O
therapy O
and O
cetuximab B-DRUG
chemotherapy O
. O


 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Out O
of O
Bed O
with O
assistance O
to O
chair O
or O

 O
wheelchair O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
hospital O
for O
a O
biopsy O
of O
a O
tumor O
in O

 O
your O
throat O
( O
hypopharynx O
) O
. O
  O
A O
G-tube O
for O
tube O
feeding O
and O
a O
port O

 O
for O
chemotherapy O
were O
placed O
. O
  O
The O
tumor O
biopsy O
confirmed O

 O
squamous O
cell O
carcinoma O
( O
cancer O
) O
and O
you O
were O
transferred O
to O
the O

 O
Oncology O
floor O
to O
start O
chemotherapy B-DRUG
. I-DRUG
  O
MRI O
of O
the O
brain O
did O
not O

 O
show O
any O
cancer O
in O
the O
brain O
. O
  O
Video O
swallow O
evaluation O
showed O

 O
severe O
aspiration O
of O
food O
and O
liquids O
. O
  O
You O
can O
not O
eat O
or O
drink O

 O
until O
this O
is O
re-evaluated O
. O
  O
All O
of O
your O
nutrition O
must O
come O

 O
through O
tube O
feeds O
. O
  O
Tube O
feeds O
were O
started O
and O
you O
developed O

 O
high B-REA
blood I-REA
sugars I-REA
managed O
with O
insulin B-DRUG
. I-DRUG

 O
. O

 O
Chemotherapy B-DRUG
was O
difficult O
to O
tolerate O
. O
  O
You O
needed O
several O

 O
different O
types O
of O
anti-nausea O
medications O
. O
  O
All O
of O
your O
blood O

 O
counts O
became O
very O
low O
from O
the O
chemotherapy B-DRUG
. I-DRUG
  O
You O
developed O

 O
fevers O
and O
pneumonia O
that O
were O
treated O
in O
the O
Intensive O
Care O

 O
Unit O
with O
IV B-ROU
antibiotics B-DRUG
. I-DRUG
  O
You O
also O
developed O
a O
stroke O
with O

 O
left-sided O
weakness O
. O
  O
The O
stroke O
likely O
originated O
from O
a O
blood O

 O
clot O
in O
the O
right O
leg O
that O
traveled O
in O
the O
blood O
stream O
and O

 O
passed O
through O
a O
hole O
in O
the O
heart O
( O
patent O
foramen O
ovale O
) O
and O

 O
then O
into O
the O
brain O
and O
kidney O
also O
causing O
some O
kidney O
damage O
. O

 O
You O
were O
started O
on O
a O
blood B-DRUG
thinner I-DRUG
for O
this O
. O
  O
To O
prevent O

 O
difficulty O
breathing O
from O
future O
radiation O
therapy O
, O
a O

 O
tracheostomy O
was O
placed O
. O
  O
However O
, O
this O
was O
complicated O
by O

 O
bleeding B-ADE
and O
the O
blood B-DRUG
thinner I-DRUG
was O
not O
able O
to O
be O
restarted O
. O

 O
You O
also O
developed O
a O
rash O
on O
your O
left O
forehead O
. O
  O
Culture O

 O
confirmed O
this O
was O
shingles B-REA
. I-REA
  O
You O
were O
treated O
with O
an O

 O
anti-viral O
drug O
acyclovir B-DRUG
and O
a O
pain B-REA
medicine O
gabapentin B-DRUG
for O
it O
. O

 O
. O

 O
You O
developed O
recurrent O
pneumonia B-REA
and O
were O
started O
on O
IV B-ROU

 I-ROU
antibiotics B-DRUG
. I-DRUG
  O
You O
coughed O
out O
your O
trach O
tube O
, O
but O
this O
was O

 O
replaced O
. O
  O
You O
started O
daily O
radiation O
treatment O
[ O
* O
* O
10 O
- O
10 O
* O
* O
] O
, O

 O
Monday O
through O
Friday O
for O
6 O
weeks O
. O
  O
You O
will O
also O
be O
treated O

 O
with O
weekly O
cetuximab B-DRUG
immunotherapy O
during O
your O
radiation O
. O
  O
Your O

 O
first O
dose O
was O
on O
[ O
* O
* O
2108 O
- O
10 O
- O
3 O
* O
* O
] O
. O
  O
As O
radiation O
therapy O
continues O
, O
your O

 O
cough O
may O
worsen O
and O
require O
more O
suctioning O
. O


 O
TRANSITION O
ISSUES O
: O

 O
1 O
. O
You O
will O
return O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
daily O
radiation O
therapy O
, O
Monday O

 O
to O
Friday O
, O
for O
6 O
weeks O
. O

 O
2 O
. O
You O
will O
receive O
weekly O
cetuximab B-DRUG
infusion B-FOR
therapy O
weekly O

 O
until O
radiation O
therapy O
is O
completed O
. O

 O
3 O
. O
You O
will O
be O
going O
to O
a O
rehab O
center O
for O
physical O
therapy O
. O



 O
Followup O
Instructions O
: O

 O
YOU O
WILL O
NEED O
TO O
FOLLOW-UP O
WITH O
YOUR O
ONCOLOGIST O
DR O
. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
3150 O
* O
* O
] O
IN O
1 O
MONTH O
. O
  O
We O
are O
working O
on O
a O
follow O
up O
appt O
with O

 O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
in O
30 O
days O
. O
You O
will O
be O
called O
at O
home O
with O
the O

 O
appointment O
. O
   O
If O
you O
have O
not O
heard O
or O
have O
questions O
, O
please O

 O
call O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
45687 O
* O
* O
] O
. O



 O

Admission O
Date O
: O
  O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2182 O
- O
7 O
- O
4 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2113 O
- O
2 O
- O
28 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Doxycycline B-DRUG


 I-DRUG
Attending:[**Last O
Name O
( O
NamePattern4 O
) O
290 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Weakness O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
none O


 O
History O
of O
Present O
Illness O
: O

 O
69 O
M O
PMH O
ESRD O
on O
HD O
, O
DM O
, O
MIx2 O
, O
CHF O
, O
s/p O
CABG O
, O
p/w O
fall O
at O
home O

 O
[ O
* O
* O
2 O
- O
4 O
* O
* O
] O
weakness O
and O
lack O
of O
strength O
. O
Recent O
admit O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
early O

 O
[ O
* O
* O
2 O
- O
6 O
* O
* O
] O
with O
fall O
, O
found O
to O
be O
febrile O
and O
confused O
, O
with O
pus O

 O
expressed O
near O
the O
AV O
fistula O
. O
AV O
graft O
felt O
to O
be O
infected O
and O

 O
thrombosed O
, O
blood O
cultures O
+ O
for O
MSSA B-REA
. I-REA
Admitted O
to O
ICU O
, O

 O
vancomycin B-DRUG
then O
oxacillin B-DRUG
, I-DRUG
with O
course O
complicated O
by O
decr O
O2 O

 O
sat O
. O
TEE O
neg O
, O
MRI O
+ O
cellulitis O
, O
- O
osteo O
. O
A O
MRI O
of O
the O
L O
shoulder O

 O
was O
- O
for O
osteo O
but O
? O
for O
septic O
emboli O
in O
lungs O
. O
AV O
graft O
was O

 O
partially O
removed O
. O
During O
this O
time O
, O
the O
pt O
also O
experienced O
a O

 O
TC B-REA
seizure I-REA
. I-REA
LP O
, O
CT O
EEG O
were O
all O
negative O
. O
He O
was O
loaded O
on O

 O
dilantin B-DRUG
and O
d/c'd O
per O
neuro O
. O
While O
septic O
, O
he O
also O
experienced O

 O
an O
NSTEMI O
, O
incr B-REA
INR I-REA
to I-REA
4 I-REA
with O
neg O
DIC O
panel O
that O
was O
responsive O

 O
to O
Vit B-DRUG
K I-DRUG
, I-DRUG
and O
increased O
LFT/GGT O
with O
neg O
US O
. O
He O
was O
d/c'd O
on O
4 O

 O
weeks O
of O
cefazolin B-DRUG
. I-DRUG
He O
then O
returned O
on O
[ O
* O
* O
2-/2107 O
* O
* O
] O
with O
f/c O
, O
cough O
and O

 O
SOB O
. O
He O
developed O
resp O
distress O
and O
was O
intubated O
, O

 O
vanco/ceft-->ox/ceft B-DRUG
for O
PNA B-REA
. I-REA
BAL O
with O
2 O
+ O
poly O
but O
cx O
neg O
. O
He O

 O
had O
pleural O
effusion O
, O
which O
when O
tapped O
revealed O
transudate O
. O
On O

 O
this O
admission O
, O
he O
denied O
LOC O
, O
f/c O
, O
cough O
, O
CP O
. O


 O
Past O
Medical O
History O
: O

 O
ESRD O
-- O
HD O

 O
Kyrle O
's O
dz O

 O
DM O

 O
CHF O
, O
EF O
20 O
% O

 O
CABG O
[ O
* O
* O
2164 O
* O
* O
] O

 O
MI O
x O
2 O
- O
-[**2173 O
* O
* O
] O
, O
[ O
* O
* O
2180 O
* O
* O
] O

 O
Afib O

 O
Anemia O

 O
PVD O

 O
CVA O

 O
? O
protein O
S O
def O

 O
Sz O
in O
setting O
of O
sepsis O

 O
septic O
AV O
graft O


 O
Social O
History O
: O

 O
+ O
tobacco O
for O
50 O
years O


 O
Family O
History O
: O

 O
NC O



 O
Physical O
Exam O
: O

 O
V O
: O
T O
100.4 O
HR O
122 O
AF O
   O
BP O
119/75 O
( O
dop/levo O
) O
  O
AC O
600x12 O
1.0 O
  O
Sat O

 O
93 O
% O
PEEP O
5 O

 O
G O
: O
Intubated O
, O
sedated O

 O
HEENT O
: O
Intubated O
, O
anicteric O
sclerae O
, O
MM O
dry O
, O
PERRL O

 O
Lungs O
: O
CTA O
BL O

 O
CV O
: O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
S1S2 O
, O
III/VI O
SM O
loudest O
at O
apex O
, O
no O
radiation O

 O
Abd O
: O
Soft O
, O
NT O
, O
ND O
, O
No O
rebound O

 O
Ext O
: O
BL O
blue O
toes O
, O
chronic O
vascular O
changes O
, O
BL O
pulses O
by O

 O
doppler O
, O
L O
forearm O
erythema O
, O
AV O
fistula O

 O
Neuro O
: O
withdraws O
to O
pain O
B O
, O
Babinski O
neg O
BL O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
4 O
* O
* O
] O
03:42AM O
BLOOD O
WBC-21.4 O
* O
RBC-4.66 O
Hgb-15.0 O
Hct-46.6 O

 O
MCV-100 O
* O
MCH-32.1 O
* O
MCHC-32.1 O
RDW-15.5 O
Plt O
Ct-127 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
06:07PM O
BLOOD O
WBC-19.1 O
* O
RBC-4.46 O
* O
Hgb-14.4 O
Hct-44.0 O

 O
MCV-99 O
* O
MCH-32.2 O
* O
MCHC-32.6 O
RDW-15.6 O
* O
Plt O
Ct-141 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
08:14AM O
BLOOD O
WBC-20.2 O
* O
RBC-4.66 O
Hgb-14.9 O
Hct-45.4 O

 O
MCV-97 O
MCH-31.9 O
MCHC-32.7 O
RDW-15.7 O
* O
Plt O
Ct-121 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
01:25AM O
BLOOD O
WBC-20.5 O
* O
RBC-4.63 O
Hgb-14.7 O
Hct-46.0 O

 O
MCV-99 O
* O
MCH-31.7 O
MCHC-31.9 O
RDW-15.7 O
* O
Plt O
Ct-138 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
08:00PM O
BLOOD O
WBC-18.1 O
* O
RBC-4.71 O
Hgb-14.8 O
Hct-46.4 O

 O
MCV-99 O
* O
MCH-31.3 O
MCHC-31.8 O
RDW-15.6 O
* O
Plt O
Ct-115 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
02:43PM O
BLOOD O
WBC-14.2 O
* O
RBC-4.10 O
* O
# O
Hgb-13.3 O
* O
# O
Hct-40.3 O
# O

 O
MCV-99 O
* O
MCH-32.6 O
* O
MCHC-33.1 O
RDW-15.8 O
* O
Plt O
Ct-90 O
* O
# O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
02:43PM O
BLOOD O
Neuts-72 O
* O
Bands-10 O
* O
Lymphs-16 O
* O
Monos-0 O

 O
Eos-0 O
Baso-0 O
Atyps-1 O
* O
Metas-1 O
* O
Myelos-0 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
4 O
* O
* O
] O
03:42AM O
BLOOD O
Plt O
Ct-127 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
06:07PM O
BLOOD O
Plt O
Ct-141 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
08:14AM O
BLOOD O
Plt O
Ct-121 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
01:25AM O
BLOOD O
Plt O
Ct-138 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
01:25AM O
BLOOD O
PT-14.3 O
* O
PTT-32.4 O
INR(PT)-1.4 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
08:00PM O
BLOOD O
Plt O
Ct-115 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
08:00PM O
BLOOD O
PT-15.5 O
* O
PTT-31.3 O
INR(PT)-1.6 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
02:43PM O
BLOOD O
Plt O
Smr-LOW O
Plt O
Ct-90 O
* O
# O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
02:43PM O
BLOOD O
PT-26.5 O
* O
PTT-36.1 O
* O
INR(PT)-4.6 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
08:00PM O
BLOOD O
Fibrino-378 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
4 O
* O
* O
] O
03:42AM O
BLOOD O
Glucose-151 O
* O
UreaN-64 O
* O
Creat-8.5 O
* O
Na-133 O

 O
K-6.8 O
* O
Cl-95 O
* O
HCO3 O
- O
16 O
* O
AnGap-29 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
06:07PM O
BLOOD O
Glucose-132 O
* O
UreaN-55 O
* O
Creat-8.1 O
* O
Na-134 O

 O
K-5.4 O
* O
Cl-95 O
* O
HCO3 O
- O
17 O
* O
AnGap-27 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
02:43PM O
BLOOD O
Glucose-90 O
UreaN-35 O
* O
Creat-7.0 O
* O
# O
Na-134 O

 O
K-4.8 O
Cl-97 O
HCO3 O
- O
21 O
* O
AnGap-21 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
08:00PM O
BLOOD O
ALT-17 O
AST-27 O
LD(LDH)-263 O
* O
AlkPhos-153 O
* O

 O
TotBili-0.9 O

 O

[ O
* O
* O
2182 O
- O
7 O
- O
4 O
* O
* O
] O
03:42AM O
BLOOD O
Calcium-6.9 O
* O
Phos-9.6 O
* O
# O
Mg-1.6 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
08:14AM O
BLOOD O
Calcium-7.4 O
* O
Phos-8.0 O
* O
Mg-1.4 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
01:25AM O
BLOOD O
Calcium-7.0 O
* O
Phos-6.9 O
* O
Mg-1.4 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
08:00PM O
BLOOD O
Albumin-3.0 O
* O
Calcium-7.1 O
* O
Phos-5.9 O
* O

 O
Mg-1.3 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
06:07PM O
BLOOD O
Cortsol-24.6 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
05:42PM O
BLOOD O
Cortsol-19.6 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
01:25AM O
BLOOD O
Cortsol-23.1 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
08:14AM O
BLOOD O
Vanco-10.0 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
4 O
* O
* O
] O
03:58AM O
BLOOD O
Type-MIX O
pO2 O
- O
42 O
* O
pCO2 O
- O
51 O
* O
pH-7.13 O
* O

 O
calHCO3 O
- O
18 O
* O
Base O
XS--13 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
07:40PM O
BLOOD O
Type-MIX O
pO2 O
- O
48 O
* O
pCO2 O
- O
44 O
pH-7.26 O
* O

 O
calHCO3 O
- O
21 O
Base O
XS--6 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
06:06PM O
BLOOD O
Type-ART O
pO2 O
- O
115 O
* O
pCO2 O
- O
34 O
* O
pH-7.34 O
* O

 O
calHCO3 O
- O
19 O
* O
Base O
XS--6 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
08:30AM O
BLOOD O
Type-MIX O
Temp-38.0 O
Rates-[**12 O
- O
13 O
* O
* O
] O
Tidal O

 O
V-500 O
PEEP-5 O
O2 O
- O
40 O
pO2 O
- O
46 O
* O
pCO2 O
- O
46 O
* O
pH-7.29 O
* O
calHCO3 O
- O
23 O
Base O

 O
XS--4 O
-ASSIST/CON O
Intubat-INTUBATED O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
02:38AM O
BLOOD O
Type-ART O
Temp-37.4 O
Rates-[**12 O
- O
11 O
* O
* O
] O
Tidal O
V-500 O

 O
PEEP-5 O
O2 O
- O
50 O
pO2 O
- O
189 O
* O
pCO2 O
- O
33 O
* O
pH-7.36 O
calHCO3 O
- O
19 O
* O
Base O
XS--5 O

 O
-ASSIST/CON O
Intubat-INTUBATED O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
01:34AM O
BLOOD O
Type-MIX O
Temp-37.4 O
Rates-[**12 O
- O
11 O
* O
* O
] O
Tidal O
V-500 O

 O
PEEP-5 O
O2 O
- O
50 O
pO2 O
- O
42 O
* O
pCO2 O
- O
45 O
pH-7.29 O
* O
calHCO3 O
- O
23 O
Base O
XS--4 O

 O
-ASSIST/CON O
Intubat-INTUBATED O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
05:33PM O
BLOOD O
Type-MIX O
pO2 O
- O
37 O
* O
pCO2 O
- O
46 O
* O
pH-7.35 O

 O
calHCO3 O
- O
26 O
Base O
XS-0 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
4 O
* O
* O
] O
03:58AM O
BLOOD O
Glucose-168 O
* O
Lactate-7.1 O
* O
Na-133 O
* O
K-6.8 O
* O

 O
Cl-97 O
* O
calHCO3 O
- O
18 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
08:30AM O
BLOOD O
Lactate-2.1 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
02:38AM O
BLOOD O
Lactate-1.8 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
01:34AM O
BLOOD O
Lactate-1.9 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
12:20AM O
BLOOD O
Lactate-1.8 O

 O

[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
06:18PM O
BLOOD O
Lactate-1.9 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
02:44PM O
BLOOD O
Lactate-2.8 O
* O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
4 O
* O
* O
] O
03:58AM O
BLOOD O
Hgb-15.6 O
calcHCT-47 O
O2 O
Sat-60 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
08:30AM O
BLOOD O
O2 O
Sat-72 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
3 O
* O
* O
] O
01:34AM O
BLOOD O
O2 O
Sat-69 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
2 O
* O
* O
] O
05:33PM O
BLOOD O
O2 O
Sat-66 O

 O
[ O
* O
* O
2182 O
- O
7 O
- O
4 O
* O
* O
] O
03:58AM O
BLOOD O
freeCa-1.05 O
* O


 O
Brief O
Hospital O
Course O
: O

 O
Pt O
admitted O
to O
ICU O
. O
Intubated O
. O

 O
1 O
. O
Septic B-REA
shock I-REA
: I-REA
GPC O
thought O
to O
be O
from O
line O
infection O
vs O
a O

 O
pulmonary O
source O
. O
  O
He O
was O
started O
on O
Vanco B-DRUG
CTX B-DRUG
, I-DRUG
and O
Gent B-DRUG
, I-DRUG
with O

 O
requirement O
of O
pressor B-DRUG
support O
for O
hypotension B-REA
. I-REA
Renal O
was O

 O
consulted O
and O
a O
decision O
was O
made O
to O
attempt O
to O
treat O
without O

 O
pulling O
the O
line O
. O
  O
The O
patient O
was O
weaned O
off O
of O
pressors O
. O

 O
Discussion O
with O
the O
patient O
's O
girlfriend O
revealed O
that O
he O
had O

 O
been O
having O
large O
volume O
diarrhea O
prior O
to O
being O
found O
on O
the O

 O
floor O
. O
Further O
discussion O
with O
surgery O
ensued O
and O
pt O
was O
slated O

 O
to O
go O
to O
the O
OR O
on O
[ O
* O
* O
7 O
- O
4 O
* O
* O
] O
for O
evaluation O
of O
the O
infected O
graft O

 O
stump O
. O


 O
In O
early O
AM O
on O
[ O
* O
* O
7 O
- O
4 O
* O
* O
] O
, O
pt O
found O
to O
be O
in O
asystole O
. O
Immediately O

 O
started O
on O
pressors B-DRUG
and O
IVF B-DRUG
for O
hypotension B-REA
. I-REA
  O
Rhythm O
changed O
to O

 O
Vtach O
, O
labs O
sent O
and O
pt O
found O
to O
have O
hyperkalemia B-REA
, I-REA
started O
on O

 O
Bicarb B-DRUG
, I-DRUG
Insulin B-DRUG
, I-DRUG
glucose B-DRUG
. I-DRUG
  O
Rhythm O
returned O
to O
asystole O
, O
code O

 O
called O
, O
pt O
pronounced O
deceased O
at O
4:10AM O
. O


 O
Medications O
on O
Admission O
: O

 O
Plavix B-DRUG
, I-DRUG
oxycontin B-DRUG
, I-DRUG
lisinopril B-DRUG
, I-DRUG
Imdur B-DRUG
, I-DRUG
Metoprolol B-DRUG
, I-DRUG
Lipitor B-DRUG
, I-DRUG

 O
Protonix B-DRUG
, I-DRUG
Neurontin B-DRUG
, I-DRUG
Amiodarone B-DRUG



 I-DRUG
Discharge O
Medications O
: O

 O
none O


 O
Discharge O
Disposition O
: O

 O
Expired O


 O
Discharge O
Diagnosis O
: O

 O
Sepsis O


 O
Discharge O
Condition O
: O

 O
deceased O


                              O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(1 O
) O
292 O
* O
* O
] O


 O

Admission O
Date O
: O
  O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2179 O
- O
1 O
- O
9 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2111 O
- O
4 O
- O
12 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
148 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Abdominal O
pain O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
: O

 O
1 O
. O
Exploratory O
laparotomy O
. O

 O
2 O
. O
Reduction O
of O
internal O
volvulus O
of O
the O
small O
bowel O
. O

 O
3 O
. O
Small-bowel O
resection O
with O
primary O
anastomosis O
. O



 O
History O
of O
Present O
Illness O
: O

 O
67 O
year O
old O
man O
with O
[ O
* O
* O
Hospital O
100256 O
* O
* O
] O
medical O
problems O
including O
DM O

 O
type O
2 O
, O
[ O
* O
* O
Hospital3 O
9642 O
* O
* O
] O
mechanical O
[ O
* O
* O
Hospital3 O
1291 O
* O
* O
] O
, O
Ascending O
aorta O
repair O
with O

 O
graft O
CAD O
s/p O
CABG O
, O
hx O
of O
VF O
arrest O
s/p O
AICD O
[ O
* O
* O
2175 O
* O
* O
] O
who O
presents O

 O
with O
acute O
onset O
severe O
abdominal O
pain O
at O
10 O
am O
yesterday O
AM O
. O

 O
States O
was O
previosly O
feeling O
well O
, O
tolerating O
POs O
and O
having O

 O
regular O
BMs O
when O
this O
started O
. O
  O
Never O
had O
pain O
like O
this O
before O
, O

 O
[ O
* O
* O
10 O
- O
3 O
* O
* O
] O
diffuse O
, O
crampy O
. O
+ O
nausea O
, O
no O
vomiting O
. O
  O
Last O
BM O

 O
yesterday O
, O
normal O
, O
no O
blood O
. O
Denies O
Diarrhea O
. O
  O
No O
fevers O
or O

 O
chills O
. O
In O
the O
Emergency O
Department O
, O
he O
was O
noted O
to O
be O

 O
hypotensive O
, O
started O
on O
vasopressors O
, O
received O
3L O
IVF O
with O

 O
labored O
breathing O
and O
thus O
intubated O
in O
ED O
. O
He O
was O
admitted O
to O

 O
to O
the O
SICU O
. O



 O

Past O
Medical O
History O
: O

 O
CAD O
s/p O
CABGx3 O
[ O
* O
* O
2168 O
* O
* O
] O

 O
- O
h/o O
VF O
arrest O
[ O
* O
* O
6 O
- O
30 O
* O
* O
] O
s/p O
ICD O
placement O
; O
required O
explantation O

 O
for O
MRSA O
pocket O
infection O
with O
reimplantation O
[ O
* O
* O
10 O
- O
31 O
* O
* O
] O
, O
s/p O
lead O

 O
removal O
[ O
* O
* O
4 O
- O
2 O
* O
* O
] O

 O
- O
mechanical O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
1291 O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
. O
[ O
* O
* O
Male O
First O
Name O
( O
un O
) O
1525 O
* O
* O
] O
, O
[ O
* O
* O
2168 O
* O
* O
] O

 O
- O
ascending O
aorta O
repair O
c O
graft O
[ O
* O
* O
4-/2169 O
* O
* O
] O

 O
- O
CHF O
( O
EF O
20 O
% O
per O
TTE O
[ O
* O
* O
2178 O
- O
8 O
- O
19 O
* O
* O
] O
) O

 O
- O
high O
grade O
CoNS O
bacteremia B-REA
in O
[ O
* O
* O
2 O
- O
2 O
* O
* O
] O
c/b O
high O
grade O
CoNS O
, O
VRE O

 O
bactermia B-REA
while O
on O
vancomycin B-DRUG
[ O
* O
* O
3 O
- O
2 O
* O
* O
] O
, O
s/p O
4 B-DUR
weeks I-DUR
daptomycin B-DRUG
and O

 O
explantation O
of O
ICD O
leads O

 O
- O
pseudomonas B-REA
UTI I-REA
[ O
* O
* O
6 O
- O
2 O
* O
* O
] O
s/p O
cefepime B-DRUG
x O
14 B-DUR
days I-DUR
, I-DUR
now O
pseudomonas B-REA

 I-REA
UTI I-REA
[ O
* O
* O
8 O
- O
2 O
* O
* O
] O
s/p O
meropenem B-DRUG
x O
14 B-DUR
days I-DUR

 I-DUR
- O
R O
lateral O
foot O
ulcer O
s/p O
debridement O
s/p O
zosyn B-DRUG
x O
14 B-DUR
days I-DUR

 I-DUR
- O
DM2 O
c/b O
neuropathy O

 O
- O
Hep B-REA
C I-REA
( O
dx O
[ O
* O
* O
4 O
- O
2 O
* O
* O
] O
, O
2.38 O
million O
IU/ml O
. O
Seen O
by O
Hepatology O
, O
[ O
* O
* O
2178 O
- O
7 O
- O
30 O
* O
* O
] O

 O
note O
emphasizes O
deferring O
IFN/ribavirin B-DRUG
tx O
for O
now O
given O

 O
infections O
, O
etc O
. O
) O

 O
- O
HTN O

 O
- O
HLP O

 O
- O
PVD O
s/p O
L O
BKA O
[ O
* O
* O
7 O
- O
27 O
* O
* O
] O

 O
- O
hypothyroidism O

 O
- O
h/o O
opiate B-DRUG
dependence O
, O
? O
benzo B-DRUG
dependence O

 O
- O
acute O
on O
chronic O
SDH O
, O
[ O
* O
* O
8 O
- O
30 O
* O
* O
] O

 O
- O
h/o O
R O
scapula O
fx O

 O
- O
h/o O
MRSA O
elbow O
bursitis O
, O
[ O
* O
* O
5 O
- O
1 O
* O
* O
] O

 O
- O
h/o O
closed O
bimalleolar O
fx O
s/p O
repair O
, O
removal O
of O
hardware O
[ O
* O
* O
6 O
- O
26 O
* O
* O
] O


 O
Social O
History O
: O

 O
Lives O
in O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
though O
has O
been O
in O
rehab O
for O
much O
of O
the O

 O
past O
few O
months O
. O
Former O
cab O
driver O
. O
Social O
history O
is O

 O
significant O
for O
the O
current O
tobacco O
use O
of O
40 O
pack O
years O
. O
There O

 O
is O
no O
history O
of O
alcohol O
abuse O
or O
recreational O
drug O
use O
. O
Lives O

 O
with O
common-law O
wife O
of O
35 O
years O
who O
is O
a O
home O
health O
aid O
. O



 O
Family O
History O
: O

 O
No O
family O
history O
of O
early O
MI O
, O
arrhythmia O
, O
cardiomyopathies O
, O
or O

 O
sudden O
cardiac O
death O
; O
otherwise O
non-contributory O
. O



 O
Physical O
Exam O
: O

 O
On O
Admission O
: O

 O
VS O
: O
T96.0 O
66 O
80/50 O
24 O
100 O
% O
facemask O

 O
GEN O
: O
ill O
appearing O
man O
, O
sleepy O
, O
answering O
questions O
with O

 O
difficulty O

 O
HEENT O
: O
Sclera O
anicteric O
. O
MMdry O

 O
CV O
: O
irregular O
irregular O

 O
LUNGS O
: O
Labored O
breathing O
. O
Diffuse O
bilateral O
rales O

 O
ABDOMEN O
: O
distended O
, O
diffusely O
tender O
with O
rebound O
and O
guarding O

 O
RECTAL O
: O
trace O
guaiac O
pos O

 O
. O

 O
At O
Discharge O
: O

 O
AVSS/afebrile O
. O

 O
GEN O
: O
Well O
in O
NAD O
. O

 O
HEENT O
: O
Sclerae O
anicteric O
. O
O-P O
clear O
. O

 O
NECK O
: O
Supple O
. O

 O
LUNGS O
: O
CTA(B O
) O

 O
COR O
: O
Irregularly O
irregular O

 O
ABD O
: O
Midline O
incision O
with O
steri-strips O
c/d/i O
. O
Lower O
aspect O

 O
incisional O
wound O
5 O
cm O
x O
3 O
cm O
x O
2 O
cm O
granulating O
, O
clean O
. O
Wet-to-dry O

 O
packing O
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O
BSX4 O
. O
Appopriately O
tender O
to O
palpation O
along O
wound O
, O

 O
otherwise O
soft/NT/ND O
. O

 O
EXTREM O
: O
No O
c/c/e O
. O

 O
NEURO O
: O
A+Ox3 O
. O



 O
Pertinent O
Results O
: O

 O
On O
Admission O
: O



 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
12:15AM O
   O
PT-48.6 O
* O
PTT-61.5 O
* O
INR(PT)-5.2 O
* O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
12:15AM O
   O
PLT O
COUNT-158 O
# O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
12:15AM O
   O
NEUTS-90.2 O
* O
LYMPHS-5.2 O
* O
MONOS-4.0 O
EOS-0.4 O

 O
BASOS-0.2 O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
12:15AM O
   O
WBC-8.2 O
RBC-3.68 O
* O
HGB-8.5 O
* O
HCT-28.7 O
* O
MCV-78 O
* O

 O
MCH-23.1 O
* O
MCHC-29.7 O
* O
RDW-19.7 O
* O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
12:15AM O
URINE O
  O
GR O
HOLD-HOLD O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
12:15AM O
   O
CALCIUM-6.7 O
* O
PHOSPHATE-2.6 O
* O
MAGNESIUM-1.7 O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
12:15AM O
   O
LIPASE-15 O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
12:15AM O
   O
ALT(SGPT)-25 O
AST(SGOT)-33 O
LD(LDH)-196 O
ALK O

 O
PHOS-59 O
TOT O
BILI-0.4 O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
12:15AM O
   O
GLUCOSE-228 O
* O
UREA O
N-40 O
* O
CREAT-1.2 O
SODIUM-139 O

 O
POTASSIUM-3.6 O
CHLORIDE-106 O
TOTAL O
CO2 O
- O
22 O
ANION O
GAP-15 O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
12:44AM O
   O
LACTATE-2.2 O
* O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
04:30AM O
   O
PT-21.6 O
* O
PTT-41.8 O
* O
INR(PT)-2.0 O
* O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
04:38AM O
   O
LACTATE-2.9 O
* O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
04:45AM O
   O
PT-24.2 O
* O
PTT-43.7 O
* O
INR(PT)-2.3 O
* O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
06:11AM O
   O
freeCa-1.04 O
* O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
06:11AM O
   O
HGB-9.2 O
* O
calcHCT-28 O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
06:11AM O
   O
GLUCOSE-223 O
* O
LACTATE-3.9 O
* O
NA+-137 O
K+-4.2 O

 O
CL--103 O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
07:58AM O
   O
PT-19.1 O
* O
PTT-42.3 O
* O
INR(PT)-1.7 O
* O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
07:58AM O
   O
PLT O
COUNT-212 O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
07:58AM O
   O
WBC-14.8 O
* O
# O
RBC-3.85 O
* O
HGB-9.3 O
* O
HCT-30.6 O
* O

 O
MCV-80 O
* O
MCH-24.1 O
* O
MCHC-30.4 O
* O
RDW-19.2 O
* O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
07:58AM O
   O
CALCIUM-7.6 O
* O
PHOSPHATE-2.4 O
* O
MAGNESIUM-2.2 O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
07:58AM O
   O
CK-MB-NotDone O
cTropnT-0.03 O
* O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
07:58AM O
   O
GLUCOSE-230 O
* O
UREA O
N-43 O
* O
CREAT-1.6 O
* O
SODIUM-140 O

 O
POTASSIUM-3.6 O
CHLORIDE-106 O
TOTAL O
CO2 O
- O
21 O
* O
ANION O
GAP-17 O

 O
. O

 O
Prior O
to O
Discharge O
: O



 O
[ O
* O
* O
2179 O
- O
1 O
- O
7 O
* O
* O
] O
06:29AM O
BLOOD O
WBC-4.4 O
RBC-3.21 O
* O
Hgb-9.0 O
* O
Hct-27.7 O
* O

 O
MCV-86 O
MCH-28.0 O
MCHC-32.5 O
RDW-22.5 O
* O
Plt O
Ct-119 O
* O

 O
[ O
* O
* O
2179 O
- O
1 O
- O
7 O
* O
* O
] O
06:29AM O
BLOOD O
Plt O
Ct-119 O
* O

 O
[ O
* O
* O
2179 O
- O
1 O
- O
7 O
* O
* O
] O
06:29AM O
BLOOD O
Glucose-157 O
* O
UreaN-16 O
Creat-0.8 O
Na-132 O
* O

 O
K-4.3 O
Cl-91 O
* O
HCO3 O
- O
34 O
* O
AnGap-11 O

 O
[ O
* O
* O
2179 O
- O
1 O
- O
7 O
* O
* O
] O
06:29AM O
BLOOD O
Calcium-8.4 O
Phos-2.8 O
Mg-1.8 O

 O
[ O
* O
* O
2179 O
- O
1 O
- O
8 O
* O
* O
] O
04:20AM O
BLOOD O
PT-26.4 O
* O
PTT-48.8 O
* O
INR(PT)-2.6 O
* O

 O
. O

 O
IMAGING O
: O

 O
[ O
* O
* O
12 O
- O
17 O
* O
* O
] O
CXR O
Interval O
worsening O
of O
mild O
pulmonary O
edema O
. O
Moderate O

 O
bibasilar O
atelectasis O
in O
the O
setting O
of O
low O
lung O
volumes O
. O

 O
[ O
* O
* O
12 O
- O
17 O
* O
* O
] O
CT O
abd O
: O
Findings O
concerning O
for O
mesenteric O
ischemia O
with O

 O
portal O
venous O
air O
, O
with O
focus O
of O
air O
seen O
in O
mesentery O
centered O

 O
about O
loops O
of O
small O
bowel O
in O
the O
right O
mid O
abdomen O
with O
air O

 O
circumferentially O
surrounding O
the O
lumen O
suggestive O
of O

 O
pneumatosis O
and O
associated O
mesenteric O
stranding O
( O
301B:18 O
- O
27 O
) O
. O

 O
Vascular O
event O
may O
represent O
etiology O
, O
though O
swirling O

 O
configuration O
suggests O
internal O
hernia O
. O

 O
[ O
* O
* O
12 O
- O
18 O
* O
* O
] O
CXR O
improved O
basilar O
aeration O
. O
CVl O
well O
placed O

 O
[ O
* O
* O
12 O
- O
20 O
* O
* O
] O
CXR O
New O
b/l O
poorly O
defined O
pulmonary O
opacities O
, O
some O
w/ O

 O
nodular O
configuration O
. O

 O
[ O
* O
* O
12 O
- O
20 O
* O
* O
] O
CXR O
Interval O
increase O
in O
diffuse O
widespread O
airspace O

 O
consolidation O
, O
? O
ARDS O
. O

 O
[ O
* O
* O
12 O
- O
21 O
* O
* O
] O
multifocal O
pneumonia O
. O
Co-existing O
ARDS O
is O
also O
possible O
. O

 O
[ O
* O
* O
12 O
- O
21 O
* O
* O
] O
lung O
CT O

 O
[ O
* O
* O
12 O
- O
21 O
* O
* O
] O
Head O
CT O

 O
[ O
* O
* O
12 O
- O
28 O
* O
* O
] O
: O
Echo O
: O
EF O
20 O
- O
25 O
% O
, O
PCWP>18 O
, O
[**12 O
- O
26**]+ O
MR O
, O
dilated O
LV O
, O
global O

 O
hypokinesis O

 O
[ O
* O
* O
1 O
- O
2 O
* O
* O
] O
CXR O
: O
Worsening O
pulmonary O
edema O
. O
Evidence O
for O
bilateral O

 O
pleural O

 O
effusions O
, O
which O
may O
have O
increased O
as O
well O
. O

 O
[ O
* O
* O
1 O
- O
4 O
* O
* O
] O
CXR O
: O
Mild-to-moderate O
pulmonary O
edema O
has O
improved O
since O

 O
[ O
* O
* O
1 O
- O
2 O
* O
* O
] O

 O
[ O
* O
* O
1 O
- O
5 O
* O
* O
] O
CXR O
: O
Cardiomegaly O
, O
bilateral O
pleural O
effusions O
and O

 O
atelectasis O
, O

 O
overall O
appearing O
minimally O
changed O
. O

 O
. O


 O
MICROBIOLOGY O
: O

 O
[ O
* O
* O
12 O
- O
17 O
* O
* O
] O
Sputum O
MRSA O
Mod O
growth O
. O

 O
[ O
* O
* O
12 O
- O
18 O
* O
* O
] O
Bcx O
: O
Staph O
coag O
neg O
1/2 O
bottles O

 O
[ O
* O
* O
12 O
- O
19 O
* O
* O
] O
BAL O
MRSA O

 O
[ O
* O
* O
12 O
- O
20 O
* O
* O
] O
Sputum O
: O
MRSA O
, O
sparse O
GNR O

 O
[ O
* O
* O
12 O
- O
23 O
* O
* O
] O
BAL O
: O
MRSA O

 O
[ O
* O
* O
12 O
- O
24 O
* O
* O
] O
BAL O
: O
Negative O

 O
[ O
* O
* O
12 O
- O
26 O
* O
* O
] O
C O
diff O
neg O

 O
[ O
* O
* O
12 O
- O
30 O
* O
* O
] O
Catheter O
tip O
neg O

 O
. O

 O
PATHOLOGY O
: O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
SPECIMEN O
SUBMITTED O
: O
ILEUM O
. O


 O
DIAGNOSIS O
: O


 O
Ileum O
, O
Segmental O
resection O
: O

 O
1 O
. O
  O
Ischemic O
enteritis O
with O
focally O
transmural O
necrosis O
and O

 O
associated O
serositis O
. O

 O
2 O
. O
  O
One O
unremarkable O
resection O
margin O
; O
opposite O
resection O
margin O

 O
with O
mucosal O
ischemic O
changes O
and O
acute O
inflammation O
of O
the O

 O
superficial O
submucosa O
. O


 O
Clinical O
: O
  O
Ischemic O
bowel O
, O
acute O
abdomen O
. O

 O
Gross O
: O


 O
The O
specimen O
is O
received O
fresh O
labeled O
with O
the O
patient O
's O
name O
, O

 O
" O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
, O
[ O
* O
* O
Known O
firstname O
* O
* O
] O
" O
, O
the O
medical O
record O
number O
and O
" O
ileum O
. O
" O
It O

 O
consists O
of O
a O
segment O
of O
small O
bowel O
measuring O
92 O
cm O
in O
length O

 O
and O
3 O
cm O
in O
average O
diameter O
. O
  O
A O
portion O
of O
mesentery O
is O

 O
attached O
to O
the O
small O
bowel O
that O
measures O
2 O
x O
4 O
x O
3 O
cm O
. O
The O

 O
specimen O
is O
not O
oriented O
. O
  O
The O
mesentery O
is O
unremarkable O
. O
The O

 O
serosa O
of O
the O
bowel O
is O
focally O
erythematous O
and O
dusky O
looking O
. O

 O
There O
are O
two O
staples O
measuring O
3.7 O
and O
5.2 O
cm O
. O
  O
The O
specimen O
is O

 O
opened O
along O
the O
antimesenteric O
surface O
to O
reveal O
fecal O
material O

 O
and O
blood O
within O
the O
lumen O
. O
The O
mucosa O
in O
the O
central O
portion O
of O

 O
the O
bowel O
measuring O
34 O
cm O
in O
length O
is O
erythematous O
, O
brown O
and O

 O
dusky O
looking O
. O
No O
masses O
or O
polyps O
are O
identified O
. O
  O
No O

 O
perforation O
site O
is O
identified O
. O
  O
The O
bowel O
wall O
within O
the O

 O
affected O
area O
measures O
up O
to O
0.2 O
cm O
in O
thickness O
. O
  O
Normal O

 O
looking O
bowel O
measures O
up O
to O
0.4 O
cm O
in O
thickness O
. O
  O
The O
specimen O

 O
is O
represented O
in O
cassettes O
as O
follows O
: O
  O
A O
= O
5.2 O
cm O
stapled O

 O
margin O
, O
B O
= O
3.7 O
cm O
staple O
margin O
, O
C O
= O
section O
of O
affected O
bowel O
, O

 O
D O
= O
transition O
between O
effected O
and O
normal O
bowel O
, O
E-G O
= O
fat O
. O



 O
Brief O
Hospital O
Course O
: O

 O
The O
patient O
with O
multiple O
medical O
problems O
was O
admitted O
to O
the O

 O
General O
Surgical O
Service O
on O
[ O
* O
* O
2178 O
- O
12 O
- O
17 O
* O
* O
] O
for O
evaluation O
of O
an O
acute O

 O
abdomen O
likely O
from O
ischemic B-REA
bowel I-REA
. I-REA
  O
He O
was O
admitted O
to O
the O

 O
SICU O
. O
He O
was O
made O
NPO O
, O
started O
on O
IV B-ROU
fluids B-DRUG
, I-DRUG
a O
foley O
catheter O

 O
and O
CVL O
were O
placed O
, O
empiric O
IV B-ROU
Vancomycin B-DRUG
and O
Zosyn B-DRUG
were O

 O
started O
, O
and O
he O
was O
given O
Fentanyl B-DRUG
IV B-ROU
PRN B-FRE
for O
pain B-REA
and O
Valium B-DRUG

 I-DRUG
for O
sedation B-REA
. I-REA
He O
was O
emergently O
brought O
to O
the O
Operating O
Room O
, O

 O
where O
he O
underwent O
exploratory O
laparotomy O
, O
reduction O
of O
internal O

 O
volvulus O
of O
the O
small O
bowel O
, O
and O
small-bowel O
resection O
with O

 O
primary O
anastomosis(reader O
referred O
to O
the O
Operative O
Note O
for O

 O
details O
) O
. O
He O
was O
found O
to O
have O
ischemic O
bowel O
with O
obstruction O
, O

 O
peritonitis O
, O
and O
an O
internal O
volvulus O
of O
the O
small O
bowel O
. O

 O
He O
was O
returned O
to O
the O
SICU O
for O
post-operative O
care O
. O

 O
. O

 O
SICU/TICU O
EVENTS O
[ O
* O
* O
2178 O
- O
1 O
- O
17 O
* O
* O
] O
- O
[ O
* O
* O
2178 O
- O
12 O
- O
29 O
* O
* O
] O
: O

 O
[ O
* O
* O
12 O
- O
17 O
* O
* O
] O
1 O
u O
PRBC O
, O
750 O
LR O
intraop O
, O
to O
ICU O
post O
op O
. O
On O
neo O
and O
epi O
. O

 O
Transfused O
1 O
u O
for O
hct O
28 O
. O
Febrile O
to O
101 O
. O

 O
[ O
* O
* O
12 O
- O
17 O
* O
* O
] O
pm O
- O
spike O
to O
101.2 O
, O
decreasing O
pressor O
requirements O
and O

 O
lactate O
. O
Pan-Cxs O
sent O
. O

 O
[ O
* O
* O
12 O
- O
18 O
* O
* O
] O
Left O
subclavian O
placed O
. O
Bloody O
guiac O
+ O
BM O
overnight O
. O
HCT O

 O
drifting O
down O
. O
GPC O
on O
blood O
culture O
1/2 O
bottles O
[ O
* O
* O
12 O
- O
18 O
* O
* O
] O
. O

 O
[ O
* O
* O
12 O
- O
19 O
* O
* O
] O
: O
Bronch O
and O
BAL.Abx O
started O
after O
BAL O

 O
[ O
* O
* O
12 O
- O
20 O
* O
* O
] O
: O
Low O
uop O
. O
Large O
heparin B-DRUG
requirement O
given O
FFP B-DRUG
2 B-DOS
untis I-DOS
for O

 O
? O
atIII O
def O
. O
PS O
trial O
failed O
changed O
back O
to O
rate O
. O
TPN O
started O
. O



 O
[ O
* O
* O
12 O
- O
21 O
* O
* O
] O
: O
Concern O
for O
depressed O
mental O
status O
in O
AM O
. O
Concern O
for O

 O
septic O
emboli O
to O
brain/eyes/lungs O
. O
Mental O
status O
improved O
in O
PM O

 O
w/o O
intervention O
except O
for O
holding O
of O
propofol B-DRUG
. I-DRUG
Also O
concern O

 O
for O
pt O
's O
high O
need O
of O
heparin B-DRUG
to O
stay O
in O
therapeutic O
level O
. O

 O
Peripheral O
smear O
sent O
. O
LENI O
negative O
. O

 O
[ O
* O
* O
2178 O
- O
12 O
- O
22 O
* O
* O
] O
: O
Bedside O
TTE O
w/ O
hyperdynamic O
LV O
, O
FeNa O
0.2 O
% O
, O
given O
3 O

 O
Unit O
of O
Blood O
, O
He O
Had O
melanotic O
stool O
, O
but O
HD O
stable O
, O
started O
on O

 O
D5W B-DRUG
at O
30cc/h B-STR
, I-STR
Creatine O
improving O
. O
acutely O
became O
diaphoretic O

 O
sat O
down O
to O
88 O
% O
pt O
labored O
and O
desynchronous O
with O
ventilator O
, O

 O
tachycadic O
high O
BP O
w/ O
Map O
110 O
, O
tachycardic O
120 O
, O
CVP O
26 O
. O
Patient O

 O
had O
flush O
PE O
lasix B-DRUG
bolus B-DOS
given O
, O
patient O
sedated O
, O
ABG O
improved O

 O
[ O
* O
* O
12 O
- O
27 O
* O
* O
] O
- O
Extubated O
[ O
* O
* O
12 O
- O
26 O
* O
* O
] O
PM O
, O
started O
on O
BiPAP O
. O
Back O
on O
Lasix B-DRUG
gtt B-ROU
, I-ROU

 O
started O
Carvedilol B-DRUG
, I-DRUG
started O
bridge O
to O
Coumadin B-DRUG
. I-DRUG
Re-intubated O
due O

 O
to O
fluid O
reaccumulation O

 O
[ O
* O
* O
12 O
- O
29 O
* O
* O
] O
: O
Extubated O
. O
Doing O
well O
. O

 O
[ O
* O
* O
12 O
- O
30 O
* O
* O
] O
PICC O
placed O

 O
[ O
* O
* O
1 O
- O
2 O
* O
* O
] O
: O
to O
TICU O
for O
resp O
distress O
, O
Bipap O
responsive O
, O
cardiac O
diet O

 O
now O
, O
restarted O
carvedilol B-DRUG
, I-DRUG
ace B-DRUG
, I-DRUG
aldactone B-DRUG
, I-DRUG
required O
bipap O
o/n O

 O
after O
brief O
desat O

 O
[ O
* O
* O
1 O
- O
3 O
* O
* O
] O
Bipap O
during O
the O
day O
and O
extra O
Lasix B-DRUG
20 B-STR
mg I-STR
IV B-ROU
x1 B-DOS
, I-DOS
negative O

 O
for O
the O
day O
, O
Bipap O
overnight O
, O
held O
coumadin B-DRUG
x O
1 B-DOS
for O
INR O
5.8 O

 O
[ O
* O
* O
1 O
- O
4 O
* O
* O
] O
: O
Opening O
of O
abdominal O
wound O
. O
Held O
coumadin B-DRUG
for O
INR O
5.7 O
. O

 O
[ O
* O
* O
1 O
- O
5 O
* O
* O
] O
: O
started O
glargine B-DRUG
, I-DRUG
removed O
foley O
, O
restarted O
coumadin B-DRUG
3 B-STR
mg I-STR
. I-STR

 O
[ O
* O
* O
1 O
- O
6 O
* O
* O
] O
: O
Coumadin B-DRUG
reduced O
to O
2 B-STR
mg I-STR
. I-STR

 O
. O

 O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
9 O
EVENTS O
: O

 O
On O
[ O
* O
* O
2179 O
- O
1 O
- O
6 O
* O
* O
] O
, O
the O
patient O
was O
transfered O
to O
the O
inpatient O
floor O
. O

 O
He O
arrived O
on O
a O
Diabetic/low O
sodium O
regular O
diet O
, O
oral O

 O
medications O
, O
voiding O
without O
assitance O
, O
with O
IV B-ROU
Linezolid B-DRUG
and O

 O
Meropenem B-DRUG
continued O
. O
Coumadin B-DRUG
was O
continued O
, O
and O
monitored O

 O
closely O
to O
maintain O
a O
therapeutic O
goal O
range O
of O
2.5 O
- O
3.5 O
. O
The O
INR O

 O
on O
[ O
* O
* O
2179 O
- O
1 O
- O
8 O
* O
* O
] O
was O
2.6 O
. O

 O
. O


 O
During O
this O
hospitalization O
, O
the O
patient O
ambulated O
early O
and O

 O
frequently O
, O
was O
adherent O
with O
respiratory O
toilet O
and O
incentive O

 O
spirrometry O
, O
and O
actively O
participated O
in O
the O
plan O
of O
care O
. O
The O

 O
patient O
's O
blood O
sugar O
was O
monitored O
regularly O
throughout O
the O

 O
stay O
; O
Lantus B-DRUG
and O
sliding B-DOS
scale I-DOS
insulin B-DRUG
was O
administered O
as O

 O
indicated O
. O
Labwork O
was O
routinely O
followed O
; O
electrolytes O
were O

 O
repleted O
when O
indicated O
. O

 O
. O

 O
At O
the O
time O
of O
discharge O
on O
, O
the O
patient O
was O
doing O
well O
, O

 O
afebrile O
with O
stable O
vital O
signs O
. O
  O
The O
patient O
was O
tolerating O
a O

 O
diabetic/low O
sodium O
regular O
diet O
, O
ambulating O
with O
assistance O
, O

 O
voiding O
without O
assistance O
, O
and O
pain O
was O
well O
controlled O
. O
  O
He O

 O
was O
discharged O
to O
an O
extended O
care O
facility O
for O
rehabilitation O

 O
and O
nursing O
care O
. O
The O
patient O
received O
discharge O
teaching O
and O

 O
follow-up O
instructions O
with O
understanding O
verbalized O
and O

 O
agreement O
with O
the O
discharge O
plan O
. O

 O
. O

 O
Services O
Consulted O
during O
admission O
: O
Infectious O
Disease O
, O

 O
Otolaryngology O
, O
Cardiology O
, O
Pulmonary O
, O
Social O
Work O
, O
Physical O

 O
Therapy O
, O
and O
Occupational O
Therapy O
. O


 O
Medications O
on O
Admission O
: O

 O
Amiodarone B-DRUG
200 B-STR
mg I-STR
DAILY B-FRE

 I-FRE
Atorvastatin B-DRUG
40 B-STR
mg I-STR
DAILY B-FRE

 I-FRE
Polyethylene B-DRUG
Glycol I-DRUG
3350 I-DRUG
17 B-STR
gram/dose I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Amitriptyline B-DRUG
10 B-STR
mg I-STR
HS B-FRE

 I-FRE
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Senna B-DRUG
8.6 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Captopril B-DRUG
25 B-STR
mg I-STR
TID B-FRE

 I-FRE
Lactulose B-DRUG
30 B-STR
Q8H B-FRE
( I-FRE
every I-FRE
8 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
Aspirin B-DRUG
81 B-STR
mg I-STR
Daily B-FRE

 I-FRE
Lorazepam B-DRUG
0.5 B-STR
mg I-STR
Q4H B-FRE
as I-FRE
needed I-FRE
for O
anxiety B-REA

 I-REA
Levetiracetam B-DRUG
500 B-STR
mg I-STR
QHS B-FRE

 I-FRE
Gabapentin B-DRUG
400 B-STR
mg I-STR
Q8H B-FRE
( O

 O
Warfarin B-DRUG
5 B-STR
mg I-STR
Daily B-FRE

 I-FRE
Oxycodone B-DRUG
5 B-STR
mg I-STR
Q4H B-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
Acetaminophen B-DRUG
500 B-STR
mg I-STR
q8 B-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA

 I-REA
Bisacodyl B-DRUG
10 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
prn B-FRE

 I-FRE
Albuterol B-DRUG
Sulfate I-DRUG
90 B-STR
mcg I-STR
2 B-DOS
Puffs B-FOR
IH B-ROU
Q6H B-FRE
prn I-FRE

 I-FRE
Ipratropium B-DRUG
Bromide I-DRUG
17 B-STR
mcg/Actuation I-STR
QID B-FRE
( O

 O
Meropenem B-DRUG
500 B-STR
mg I-STR
q6 B-FRE

 I-FRE
Spironolactone B-DRUG
25 B-STR
mg I-STR
DAILY B-FRE

 I-FRE
Torsemide B-DRUG
20 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Metolazone B-DRUG
5 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Metoprolol B-DRUG
12.5 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Potassium B-DRUG
Chloride I-DRUG
20 B-STR
mEq I-STR
once B-FRE
a I-FRE
day I-FRE

 I-FRE
Insulin B-DRUG
Glargine I-DRUG
40 B-DOS
units I-DOS
Subcutaneous B-ROU
at B-FRE
bedtime I-FRE

 I-FRE
Insulin B-DRUG
Lispro I-DRUG
per O
sliding B-DOS
scale I-DOS



 I-DOS
Discharge O
Medications O
: O

 O
1 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
fever B-REA
or O
pain B-REA
. I-REA

 O
2 O
. O
Spironolactone B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
4 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
5 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( I-STR
0.083 I-STR
% I-STR
) I-STR
Solution B-FOR
for I-FOR

 I-FOR
Nebulization I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
neb B-FOR
Inhalation B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE

 I-FRE
needed I-FRE
for O
shortness B-REA
of I-REA
breath I-REA
or O
wheezing B-REA
. I-REA

 O
6 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
0.02 B-STR
% O
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
neb B-FOR

 I-FOR
Inhalation B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
shortness B-REA
of I-REA
breath I-REA

 I-REA
or O
wheezing B-REA
. I-REA

 O
7 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Warfarin B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
at I-FRE
16:00 I-FRE
: I-FRE

 O
St. O
[ O
* O
* O
Male O
First O
Name O
( O
un O
) O
1525 O
* O
* O
] O
mechanical O
[ O
* O
* O
Male O
First O
Name O
( O
un O
) O
1291 O
* O
* O
] O
; O
INR O
goal O
2.5 O
- O
3.5 O
. O

 O
9 O
. O
Ondansetron B-DRUG
4 B-STR
mg I-STR
IV B-ROU
Q8H B-FRE
: I-FRE
PRN I-FRE
nausea B-REA

 I-REA
10 O
. O
Oxycodone B-DRUG
5 B-STR
mg/5 I-STR
mL I-STR
Solution B-FOR
Sig O
: O
5 B-DOS
- I-DOS
10 I-DOS
mg I-DOS
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
11 O
. O
Ativan B-DRUG
0.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
[ O
* O
* O
12 O
- O
26 O
* O
* O
] O
Tablet(s B-FOR
) I-FOR
( O
give O
SL B-ROU
) I-ROU
PO B-ROU
every B-FRE

 I-FRE
6 I-FRE
- I-FRE
8 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
Anxiety B-REA
. I-REA

 O
12 O
. O
Atorvastatin B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE
bedtime I-FRE
. I-FRE


 O
13 O
. O
Torsemide B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
14 O
. O
Metolazone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
15 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE

 I-FRE
day I-FRE
. I-FRE

 O
16 O
. O
Potassium B-DRUG
Chloride I-DRUG
10 B-STR
mEq I-STR
Tablet B-FOR
Sustained I-FOR
Release I-FOR
Sig O
: O
Two B-DOS

 I-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
Sustained I-FOR
Release I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
17 O
. O
Levetiracetam B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE

 I-FRE
bedtime I-FRE
. I-FRE

 O
18 O
. O
Neurontin B-DRUG
400 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
three B-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
. I-FRE

 O
19 O
. O
Amiodarone B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE



 O
20 O
. O
Amitriptyline B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE

 I-FRE
bedtime I-FRE
. I-FRE

 O
21 O
. O
Captopril B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
three B-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
. I-FRE

 O
22 O
. O
Insulin B-DRUG
Lispro I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
4 B-DOS
- I-DOS
22 I-DOS
units I-DOS

 I-DOS
Subcutaneous B-ROU
As B-FRE
directed I-FRE
per O
Humalog B-DRUG
Insulin I-DRUG
Sliding B-DOS
Scale I-DOS
. I-DOS

 O
23 O
. O
Lantus B-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
Forty B-DOS
( I-DOS
40 I-DOS
) I-DOS
units I-DOS

 I-DOS
Subcutaneous B-ROU
at B-FRE
bedtime I-FRE
. I-FRE

 O
24 O
. O
Medication O
: O

 O
Morphine B-DRUG
Sulfate I-DRUG
2 B-STR
- I-STR
4 I-STR
mg I-STR
IV B-ROU
Q6H B-FRE
: I-FRE
PRN I-FRE
Breakthrough B-REA
Pain I-REA
Only O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
7 O
* O
* O
] O
& O
Rehab O
Center O
- O
[ O
* O
* O
Hospital1 O
8 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
1 O
. O
Ischemic O
bowel O
. O

 O
2 O
. O
Bowel O
obstruction O
. O

 O
3 O
. O
Peritonitis O
. O

 O
4 O
. O
Internal O
volvulus O
of O
small O
bowel O
. O

 O
5 O
. O
Multifocal O
pneumonia O

 O
. O

 O
Secondary O
: O

 O
1 O
. O
CAD O

 O
2 O
. O
History O
of O
VF O
arrest O
[ O
* O
* O
6 O
- O
30 O
* O
* O
] O
s/p O
ICD O
placement O

 O
3 O
. O
Mechanical O
St. O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
1525 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
1291 O
* O
* O
] O
on O
Coumadin B-DRUG
prophylaxis B-REA
INR O
Goal O

 O
2.5 O
- O
3.5 O
) O

 O
4 O
. O
CHF O
( O
EF O
20 O
% O
) O


 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O

 O
Activity O
Status O
: O
Ambulatory O
- O
requires O
assistance O
or O
aid O
( O
walker O

 O
or O
cane O
) O



 O
Discharge O
Instructions O
: O

 O
Weigh O
yourself O
every O
morning O
, O
[ O
* O
* O
Name8 O
( O
MD O
) O
138 O
* O
* O
] O
MD O
if O
weight O
goes O
up O
more O

 O
than O
3 O
lbs O
. O

 O
. O

 O
Please O
resume O
all O
regular O
home O
medications O
, O
unless O
specifically O

 O
advised O
not O
to O
take O
a O
particular O
medication O
. O
  O
Also O
, O
please O
take O

 O
any O
new O
medications O
as O
prescribed O
. O


 O
Please O
get O
plenty O
of O
rest O
, O
continue O
to O
ambulate O
several O
times O

 O
per O
day O
, O
and O
drink O
adequate O
amounts O
of O
fluids O
. O
  O
Avoid O
lifting O

 O
weights O
greater O
than O
[ O
* O
* O
5 O
- O
3 O
* O
* O
] O
lbs O
until O
you O
follow-up O
with O
your O

 O
surgeon O
, O
who O
will O
instruct O
you O
further O
regarding O
activity O

 O
restrictions O
. O


 O
Avoid O
driving O
or O
operating O
heavy O
machinery O
while O
taking O
pain O

 O
medications O
. O


 O
Please O
follow-up O
with O
your O
surgeon O
and O
Primary O
Care O
Provider O

 O
( O
PCP O
) O
as O
advised O
. O


 O
Incision O
Care O
: O


 O
* O
Please O
call O
your O
doctor O
or O
nurse O
practitioner O
if O
you O
have O

 O
increased O
pain O
, O
swelling O
, O
redness O
, O
or O
drainage O
from O
the O
incision O

 O
site O
. O

 O
* O
Avoid O
swimming O
and O
baths O
until O
your O
follow-up O
appointment O
. O

 O
* O
You O
may O
shower O
, O
and O
wash O
surgical O
incisions O
with O
a O
mild O
soap O

 O
and O
warm O
water O
. O
  O
Gently O
pat O
the O
area O
dry O
. O

 O
* O

If O
you O
have O
steri-strips O
, O
they O
will O
fall O
off O
on O
their O
own O
. O

 O
Please O
remove O
any O
remaining O
strips O
7 O
- O
10 O
days O
after O
surgery O
. O

 O
* O
The O
lower O
incision O
wound O
will O
be O
cared O
for O
by O
your O
nurse O
. O
Car O

 O
is O
a O
wet-to-dry O
dressing O
changed O
twice B-FRE
daily I-FRE
. I-FRE

 O
. O

 O
Coumadin B-DRUG
( O
Warfarin B-DRUG
) I-DRUG
: O


 O
What O
is O
this O
medicine O
used O
for O
? O

 O
This O
medicine O
is O
used O
to O
thin B-REA
the I-REA
blood I-REA
so O
that O
clots O
will O
not O

 O
form O
. O


 O
How O
does O
it O
work O
? O

 O
Warfarin B-DRUG
changes O
the O
body O
's O
clotting O
system O
. O
It O
thins B-REA
the I-REA
blood I-REA

 I-REA
to O
prevent O
clots O
from O
forming O
. O


 O
What O
you O
should O
contact O
your O
healthcare O
provider O
[ O
* O
* O
Name O
Initial O
( O
PRE O
) O
* O
* O
] O
: O

 O
Signs O
of O
a O
life-threatening O
reaction O
. O
These O
include O
wheezing O
; O

 O
chest O
tightness O
; O
fever O
; O
itching O
; O
bad O
cough O
; O
blue O
skin O
color O
; O

 O
fits O
; O
or O
swelling O
of O
face O
, O
lips O
, O
tongue O
, O
or O
throat O
, O
severe O

 O
dizziness O
or O
passing O
out O
, O
falls O
or O
accidents O
, O
especially O
if O
you O

 O
hit O
your O
head O
. O
Talk O
with O
healthcare O
provider O
even O
if O
you O
feel O

 O
fine O
, O
significant O
change O
in O
thinking O
clearly O
and O
logically O
, O

 O
severe O
headache O
, O
severe O
back O
pain O
, O
severe O
belly O
pain O
, O
black O
, O

 O
tarry O
, O
or O
bloody O
stools O
, O
blood O
in O
the O
urine O
, O
nosebleeds O
, O

 O
coughing O
up O
blood O
, O
vomiting O
blood O
, O
unusual O
bruising O
or O
bleeding O
, O

 O
severe O
menstrual O
bleedin O
, O
or O
rash O
. O


 O
Call O
your O
doctor O
if O
you O
are O
unable O
to O
eat O
for O
several O
days O
, O
for O

 O
whatever O
reason O
. O
Also O
call O
if O
you O
have O
stomach O
problems O
, O

 O
vomiting O
, O
or O
diarrhea O
that O
lasts O
more O
than O
1 O
day O
. O
These O
problems O

 O
could O
affect O
your O
Coumadin??????/warfarin B-DRUG
dosage O
. O


 O
Coumadin B-DRUG
( O
Warfarin B-DRUG
) I-DRUG
and O
diet O
: O

 O
Certain O
foods O
and O
beverages O
can O
impair O
the O
effect O
of O
warfarin B-DRUG
. I-DRUG

 O
For O
this O
reason O
, O
it O
's O
important O
to O
pay O
attention O
to O
what O
you O
eat O

 O
while O
taking O
this O
medication O
. O


 O
Until O
recently O
, O
doctors O
advised O
[ O
* O
* O
Name5 O
( O
PTitle O
) O
* O
* O
] O
taking O
warfarin B-DRUG
to O
avoid O

 O
foods O
high O
in O
vitamin B-DRUG
K. I-DRUG
This O
is O
because O
large O
amounts O
of O

 O
vitamin B-DRUG
K I-DRUG
can O
counteract O
the O
benefits O
of O
warfarin B-DRUG
. I-DRUG
However O
, O

 O
recent O
research O
shows O
that O
rather O
than O
eliminating O
vitamin B-DRUG
K I-DRUG

 I-DRUG
from O
your O
diet O
, O
it O
is O
more O
important O
to O
be O
consistent O
in O
your O

 O
dietary O
vitamin B-DRUG
K I-DRUG
intake O
. O



 O
These O
foods O
contain O
vitamin B-DRUG
K I-DRUG
: I-DRUG

 O
Fruits O
and O
vegetables O
, O
such O
as O
: O
Kiwi O
, O
Blueberries O
, O
Broccoli O
, O

 O
Cabbage O
, O
[ O
* O
* O
Location O
( O
un O
) O
2831 O
* O
* O
] O
sprouts O
, O
Green O
onions O
, O
Asparagus O
, O
Cauliflower O
, O

 O
Peas O
, O
Lettuce O
, O
Spinach O
, O
Turnip O
, O
collard O
, O
and O
mustard O
greens O
, O

 O
Parsley O
, O
Kale O
, O
Endive O
. O
Meats O
, O
such O
as O
: O
Beef O
liver O
, O
Pork O
liver O
. O

 O
Other O
: O
Mayonnaise O
, O
Margarine O
, O
Canola O
oil O
, O
Soybean O
oil O
, O
Vitamins O
, O

 O
Soybeans O
and O
Cashews O
. O


 O
Limit O
alcohol O
. O
Alcohol O
can O
affect O
your O
Coumadin??????/warfarin B-DRUG
dosage O

 O
but O
it O
does O
not O
mean O
you O
must O
avoid O
all O
alcohol O
. O
Serious O

 O
problems O
can O
occur O
with O
alcohol O
and O
Coumadin??????/warfarin B-DRUG
when O
you O

 O
drink O
more O
than O
2 O
drinks O
a O
day O
or O
when O
you O
change O
your O
usual O

 O
pattern O
. O
Binge O
drinking O
is O
not O
good O
for O
you O
. O
Be O
careful O
on O

 O
special O
occasions O
or O
holidays O
, O
and O
drink O
only O
what O
you O
usually O

 O
would O
on O
any O
regular O
day O
of O
the O
week O
. O


 O
Monitoring O
: O

 O
The O
doctor O
decides O
how O
much O
Coumadin??????/warfarin B-DRUG
you O
need O
by O

 O
testing O
your O
blood O
. O
The O
test O
measures O
how O
fast O
your O
blood O
is O

 O
clotting O
and O
lets O
the O
doctor O
know O
if O
your O
dosage O
should O
change O
. O

 O
If O
your O
blood O
test O
is O
too O
high O
, O
you O
might O
be O
at O
risk O
for O

 O
bleeding O
problems O
. O
If O
it O
is O
too O
low O
, O
you O
might O
be O
at O
risk O
for O

 O
forming O
clots O
. O
Your O
doctor O
has O
decided O
on O
a O
range O
on O
the O
blood O

 O
test O
that O
is O
right O
for O
you O
. O
The O
blood O
test O
used O
for O
monitoring O

 O
is O
called O
an O
INR O
. O


 O
Use O
of O
Other O
medications O
: O

 O
When O
Coumadin??????/warfarin B-DRUG
is O
taken O
with O
other O
medicines O
it O
can O

 O
change O
the O
way O
other O
medicines O
work O
. O
Other O
medicines O
can O
also O

 O
change O
the O
way O
Coumadin??????/warfarin B-DRUG
works O
. O
It O
is O
very O
important O
to O

 O
talk O
with O
your O
doctor O
about O
all O
of O
the O
other O
medicines O
that O
you O

 O
are O
taking O
, O
including O
over-the-counter O
medicines O
, O
antibiotics B-DRUG
, I-DRUG

 O
vitamins O
, O
or O
herbal O
products O
. O


 O
Followup O
Instructions O
: O

 O
Please O
call O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2828 O
* O
* O
] O
to O
schedule O
a O
follow-up O
appointment O

 O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
( O
Surgery O
) O
in O
2 O
weeks O
. O

 O
. O


 O
Provider O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
3688 O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
2422 O
* O
* O
] O

 O
Date/Time:[**2179 O
- O
1 O
- O
27 O
* O
* O
] O
1:10 O

 O
Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
544 O
* O
* O
] O
, O
M.D. O
( O
PCP O
) O
Date/Time:[**2179 O
- O
1 O
- O
29 O
* O
* O
] O
11:50 O

 O
Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
1244 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
1237 O
* O
* O
] O

 O
Date/Time:[**2179 O
- O
2 O
- O
23 O
* O
* O
] O
10:15 O




 O
Completed O
by:[**2179 O
- O
1 O
- O
8 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2180 O
- O
10 O
- O
15 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2180 O
- O
11 O
- O
10 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2145 O
- O
7 O
- O
4 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Compazine B-DRUG
/ O
Zosyn B-DRUG


 I-DRUG
Attending:[**Last O
Name O
( O
NamePattern1 O
) O
1167 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Nausea O
, O
labored O
breathing O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
cardiac O
catheterization O

 O
endocardial O
biopsy O



 O
History O
of O
Present O
Illness O
: O

 O
35yF O
with O
multiple O
medical O
problems O
( O
including O
SLE O
, O
restrictive O

 O
lung O
disease O
, O
global O
cardiomyopathy O
with O
severely O
depressed O

 O
systolic O
function O
, O
nephrotic O
syndrome O
) O
, O
with O
recent O
admission O

 O
[ O
* O
* O
Date O
range O
( O
1 O
) O
68983 O
* O
* O
] O
for O
nausea O
, O
vomiting O
, O
and O
diarrhea O
, O
re-admitted O
with O

 O
shortness O
of O
breath O
, O
tachycardia O
, O
and O
persistent O
nausea O
. O



 O
Her O
symptoms O
began O
in O
[ O
* O
* O
Month O
( O
only O
) O
* O
* O
] O
( O
after O
a O
recent O

 O
hospitalization O
) O
, O
when O
she O
developed O
diarrhea B-ADE
( O
which O
she O
relates O

 O
to O
her O
metoprolol B-DRUG
) I-DRUG
. O
The O
diarrhea O
( O
multiple O
times O
daily O
, O

 O
non-bloody O
, O
brown O
in O
color O
) O
initially O
improved O
but O
then O
worsened O

 O
again O
. O
She O
then O
developed O
nausea O
, O
vomiting O
, O
and O
dry O
heaves O
, O

 O
without O
abdominal O
pain O
, O
and O
was O
admitted O
on O
[ O
* O
* O
10 O
- O
10 O
* O
* O
] O
. O
She O
also O

 O
reported O
worsening O
shortness O
of O
breath O
, O
3 O
pillow O
orthopnea O
, O
and O

 O
episodes O
of O
paroxysmal O
nocturnal O
dyspnea O
. O
She O
was O
felt O
to O
be O

 O
intravascularly B-REA
dry I-REA
, I-REA
so O
she O
was O
given O
IV B-ROU
fluids B-DRUG
. I-DRUG
She O
had O
a O

 O
thorough O
workup O
for O
causes O
of O
her O
diarrhea O
( O
infectious O
, O

 O
structural O
, O
medication O
related O
etc O
. O
) O
and O
was O
scheduled O
for O
GI O

 O
follow O
up O
on O
[ O
* O
* O
10 O
- O
16 O
* O
* O
] O
. O
During O
the O
admission O
, O
an O
echocardiogram O
was O

 O
performed O
, O
demonstrating O
worsening O
systolic O
function O
( O
EF O

 O
15 O
- O
20 O
% O
) O
, O
but O
she O
was O
felt O
to O
be O
intravascularly O
dry O
, O
so O
her O

 O
Lasix B-DRUG
was O
held O
. O
Given O
the O
patient O
's O
concern O
that O
her O
diarrhea O

 O
started O
at O
the O
same O
time O
as O
metoprolol B-DRUG
( O
75 B-STR
mg I-STR
daily B-FRE
) I-FRE
, O
this O

 O
medication O
was O
also O
stopped O
( O
and O
switched O
to O
carvedilol B-DRUG
3.125 B-STR
mg I-STR

 I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
) O
. O
She O
was O
to O
have O
close O
follow O
up O
with O
her O
cardiologist O
. O
She O

 O
had O
acute B-REA
on I-REA
chronic I-REA
renal I-REA
failure I-REA
which O
returned O
to O
close O
to O

 O
baseline O
( O
1.5 O
) O
with O
IV B-ROU
fluids B-DRUG
; I-DRUG
she O
had O
a O
renal O
biopsy O
during O

 O
that O
admission O
, O
the O
results O
of O
which O
are O
still O
pending O
. O
Her O

 O
Imuran B-DRUG
was O
initially O
held O
during O
the O
last O
hospitalization O
but O

 O
was O
restarted O
after O
a O
conversation O
with O
her O
[ O
* O
* O
Hospital1 O
112 O
* O
* O
] O
rheumatologist O
. O

 O
During O
that O
hospitalization O
, O
her O
nausea O
was O
not O
fully O
explained O
, O

 O
but O
there O
was O
a O
possibility O
that O
restarting O
her O
Imuran B-DRUG
may O
have O

 O
contributed O
. O


 O
Her O
presentation O
today O
is O
similar O
. O
She O
has O
nausea O
and O
dry O
heaves O

 O
( O
non-bloody O
, O
non-bilious O
) O
, O
along O
with O
worsening O
shortness O
of O

 O
breath/PND/orthopnea O
. O
Her O
husband O
( O
who O
follows O
her O
vitals O

 O
closely O
) O
has O
noted O
increased O
blood O
pressures O
and O
heart O
rates O

 O
since O
she O
was O
discharged O
from O
the O
hospital O
. O
Given O
her O
worsened O

 O
nausea O
and O
tachycardia O
to O
the O
120 O
's O
, O
he O
brought O
her O
to O
the O

 O
hospital O
. O
She O
denies O
any O
history O
of O
blood O
clot O
( O
but O
had O
IUFD O
at O

 O
21wks O
recently O
) O
. O



 O
In O
the O
ED O
, O
triage O
vitals O
were O
T97.6F O
, O
HR O
124 O
, O
BP O
126/109 O
, O
RR O
18 O
, O

 O
Sat O
100 O
% O
. O
She O
was O
given O
4 B-STR
mg I-STR
IV B-ROU
ondansteron B-DRUG
x O
2 B-DOS
, I-DOS
in O
addition O
to O

 O
ceftriaxone B-DRUG
and O
azithromycin B-DRUG
given O
an O
equivocal O
chest O
x-ray O
. O
She O

 O
was O
transferred O
to O
the O
floor O
for O
further O
evaluation O
. O
Her O

 O
respiratory O
rate O
was O
noted O
to O
be O
as O
high O
as O
33 O
. O


 O
On O
review O
of O
systems O
, O
she O
reports O
nausea O
and O
vomiting O
, O
as O
well O

 O
as O
shortness O
for O
breath O
and O
orthopnea O
as O
above O
. O
Diarrhea O
is O

 O
unchanged O
. O
She O
denies O
fevers O
, O
chills O
, O
chest O
pain O
( O
but O
perhaps O

 O
some O
chest O
" O
heaviness O
" O
) O
, O
palpitations O
, O
pleuritic O
chest O
pain O
, O

 O
cough O
, O
weakness O
, O
numbness O
, O
tingling O
, O
abdominal O
pain O
, O

 O
constipation O
, O
hematemesis O
, O
hematochezia O
, O
urinary O
symptoms O
. O


 O
Past O
Medical O
History O
: O

 O
- O
SLE O
: O
diagnosed O
in O
[ O
* O
* O
2168 O
* O
* O
] O
, O
manifested O
by O
kidney O
disease O

 O
( O
membranous O
nephropathy O
by O
report O
of O
biopsy O
) O
, O
facial O
rash O
, O

 O
Sjogren O
's O
syndrome O
, O
Raynaud O
's O
phenomenon O
, O
and O
pleuritis O

 O
- O
Gastritis O

 O
- O
Restrictive O
lung O
disease O
: O
followed O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
, O
noted O
to O

 O
be O
moderate O
to O
severe O
on O
PFTs O
completed O
5/[**2179 O
* O
* O
] O
. O

 O
- O
History O
of O
pancytopenia O
associated O
with O
varicella O
zoster O

 O
infection O

 O
- O
History O
of O
persistent O
thrombocytopenia O

 O
- O
Baseline O
proteinuria O
( O
Cr O
0.8 O
- O
0.9 O
pre-pregnancy O
) O

 O
- O
Intrauterine O
fetal O
demise O
[ O
* O
* O
7-/2180 O
* O
* O
] O
( O
at O
gestational O
age O
~21wks O
) O

 O
- O
Right- O
and O
left-sided O
cardiomyopathy O
( O
EF O
estimated O
15 O
- O
20 O
% O
in O

 O
[ O
* O
* O
9-/2180 O
* O
* O
] O
) O



 O
Social O
History O
: O

 O
Patient O
is O
a O
computer O
programer O
in O
[ O
* O
* O
Location O
( O
un O
) O
745 O
* O
* O
] O
and O
married O
. O
She O
was O

 O
accompanied O
at O
presentation O
by O
her O
husband O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
and O
sister O
. O
She O

 O
denies O
tobacco O
or O
EtOH O
. O



 O
Family O
History O
: O

 O
Adopted O


 O
Physical O
Exam O
: O

 O
Vitals O
: O
T94.5F O
( O
oral O
, O
repeat O
axillary O
temp O
was O
95.4F O
) O
, O
BP O

 O
120/94 O
, O
HR O
120 O
, O
RR O
40 O
, O
Sat O
95%RA O

 O
General O
: O
Moon O
facies O
, O
chronically O
ill-appearing O
, O
tachypneic O
, O
in O

 O
mild O
respiratory O
distress O
; O
malar O
rash O
present O

 O
HEENT O
: O
EOMI O
, O
PERRL O
, O
anicteric O
, O
OP O
clear O

 O
Heart O
: O
Tachycardic O
without O
murmurs O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
crackles O

 O
appreciated O

 O
Back O
: O
No O
CVA O
tenderness O
, O
no O
spinal O
tenderness O

 O
Abd O
: O
Soft O
, O
non-tender O
, O
non-distended O
, O
+ O
bowel O
sounds O
, O
no O

 O
hepatosplenomegaly O

 O
Extremities O
: O
No O
clubbing O
, O
cyanosis O
; O
1 O
+ O
DP O
pulses O
bilaterally O
; O
2 O
+ O

 O
pitting O
edema O
in O
feet O
to O
mid-shin O
bilaterally O
( O
L O
> O
R O
) O

 O
Neuro O
: O
A&O O
x O
3 O



 O
Pertinent O
Results O
: O

 O
Urine O
: O
Yellow O
, O
Hazy O
, O
SpecGr O
1.022 O
, O
pH O
6.0 O
, O
Sm O
leuk O
, O
Sm O
blood O
, O

 O
500 O
prot O
, O
[ O
* O
* O
1 O
- O
20 O
* O
* O
] O
RBC O
, O
few O
bacteria O
, O
0 O
- O
2 O
epi O


 O
Na O
133 O
   O
K O
4.3 O
   O
Cl O
101 O
   O
HCO3 O
18 O
   O
BUN O
33 O
   O
Creat O
1.4 O
   O
Gluc O

 O
100 O


 O
CK O
: O
13 O
  O
MB O
: O
Notdone O
  O
Trop-T O
: O
0.04 O


 O
ALT O
: O
29 O
   O
AST O
: O
34 O
   O
AP O
: O
121 O
   O
Tbili O
: O
0.3 O

 O
Lip O
: O
64 O


 O
proBNP O
: O
[ O
* O
* O
Numeric O
Identifier O
68984 O
* O
* O
] O


 O
WBC O
5.6 O

 O
N:81.3 O
L:12.8 O
M:5.3 O
E:0.4 O
Bas:0.2 O

 O
Hgb O
12.1 O

 O
Hct O
37.5 O

 O
Plt O
137 O

 O
MCV O
96 O


 O
PT O
: O
11.7 O
  O
PTT O
: O
24.4 O
  O
INR O
: O
1.0 O


 O
CXR O
[ O
* O
* O
10 O
- O
15 O
* O
* O
] O
PA/Lat O
( O
prelim O
) O
: O
Retrocardiac O
opacification O
which O
may O

 O
represent O
atelectasis O
vs. O
pneumonia O
; O
bibasilar O
effusions O
and O

 O
increased O
hilar O
infiltrates O
suggestive O
of O
volume O
overload O
; O

 O
stable O
moderate O
cardiomegaly O
. O


 O
ECG O
[ O
* O
* O
10 O
- O
15 O
* O
* O
] O
: O
Sinus O
tachycardia O
. O
Leftward O
axis O
, O
normal O
intervals O
. O

 O
TWF O
in O
I O
, O
II O
, O
V5-V6 O
( O
interpreted O
as O
pseudonormalization O
in O
ED O
, O

 O
but O
unimpressive O
) O
. O


 O
[ O
* O
* O
Month/Year O
( O
2 O
) O
* O
* O
] O
[ O
* O
* O
10 O
- O
11 O
* O
* O
] O
: O
The O
left O
atrium O
is O
elongated O
. O
No O
atrial O
septal O

 O
defect O
is O
seen O
by O
2D O
or O
color O
Doppler O
. O
The O
right O
atrial O
pressure O

 O
is O
indeterminate O
. O
Left O
ventricular O
wall O
thicknesses O
are O
normal O
. O

 O
The O
left O
ventricular O
cavity O
is O
mildly O
dilated O
. O
There O
is O
severe O

 O
global O
left O
ventricular O
hypokinesis O
( O
LVEF O
= O
15 O
- O
20 O
% O
) O
. O
No O
masses O

 O
or O
thrombi O
are O
seen O
in O
the O
left O
ventricle O
. O
There O
is O
no O

 O
ventricular O
septal O
defect O
. O
RV O
with O
severe O
global O
free O
wall O

 O
hypokinesis O
. O
There O
is O
no O
aortic O
valve O
stenosis O
. O
No O
aortic O

 O
regurgitation O
is O
seen O
. O
The O
mitral O
valve O
leaflets O
are O

 O
structurally O
normal O
. O
There O
is O
no O
mitral O
valve O
prolapse O
. O
Moderate O

 O
( O
2 O
+ O
) O
mitral O
regurgitation O
is O
seen O
. O
There O
is O
mild O
pulmonary O

 O
artery O
systolic O
hypertension O
. O
There O
is O
no O
pericardial O
effusion O
. O

 O
Compared O
with O
the O
prior O
study O
( O
images O
reviewed O
) O
of O
[ O
* O
* O
2180 O
- O
7 O
- O
24 O
* O
* O
] O
, O
the O

 O
LV O
cavity O
size O
has O
increased O
and O
the O
LVEF O
is O
slightly O
lower O

 O
( O
LVEF O
OVERestimated O
on O
prior O
study O
) O
. O
RV O
dysfunction O
is O
now O
more O

 O
prominent O
. O

 O
. O


 O
The O
left O
atrium O
is O
elongated O
. O
Left O
ventricular O
wall O
thicknesses O

 O
and O
cavity O
size O
are O
normal O
. O
There O
is O
moderate O
global O
left O

 O
ventricular O
hypokinesis O
. O
Quantitative O
( O
biplane O
) O
LVEF O
= O
33 O
% O
. O

 O
Right O
ventricular O
chamber O
size O
is O
normal O
with O
borderline O
normal O

 O
free O
wall O
systolic O
function O
. O
The O
diameters O
of O
aorta O
at O
the O

 O
sinus O
, O
ascending O
and O
arch O
levels O
are O
normal O
. O
The O
aortic O
valve O

 O
leaflets O
( O
3 O
) O
appear O
structurally O
normal O
with O
good O
leaflet O

 O
excursion O
and O
no O
aortic O
regurgitation O
. O
The O
mitral O
valve O
leaflets O

 O
are O
structurally O
normal O
. O
There O
is O
no O
mitral O
valve O
prolapse O
. O

 O
Moderate O
( O
2 O
+ O
) O
mitral O
regurgitation O
is O
seen O
. O
There O
is O
mild O

 O
pulmonary O
artery O
systolic O
hypertension O
. O
There O
is O
no O
pericardial O

 O
effusion O
. O


 O
. O

 O
[ O
* O
* O
Year O
( O
4 O
digits O
) O
* O
* O
] O
[ O
* O
* O
2180 O
- O
11 O
- O
6 O
* O
* O
] O

 O
Left O
ventricular O
wall O
thicknesses O
are O
normal O
. O
The O
left O

 O
ventricular O
cavity O
is O
mildly O
dilated O
. O
There O
is O
moderate O
to O

 O
severe O
global O
left O
ventricular O
hypokinesis O
( O
LVEF O
= O
30 O
% O
) O
. O
Right O

 O
ventricular O
chamber O
size O
is O
normal O
. O
with O
borderline O
normal O
free O

 O
wall O
function O
. O
The O
aortic O
valve O
leaflets O
( O
3 O
) O
appear O
structurally O

 O
normal O
with O
good O
leaflet O
excursion O
and O
no O
aortic O
regurgitation O
. O

 O
The O
mitral O
valve O
leaflets O
are O
mildly O
thickened O
. O
There O
is O
no O

 O
mitral O
valve O
prolapse O
. O
There O
is O
moderate O
thickening O
of O
the O

 O
mitral O
valve O
chordae O
. O
Moderate O
to O
severe O
( O
3 O
+ O
) O
mitral O

 O
regurgitation O
is O
seen O
. O
Moderate O
[ O
2 O
+ O
] O
tricuspid O
regurgitation O
is O

 O
seen O
. O
There O
is O
moderate O
pulmonary O
artery O
systolic O
hypertension O
. O

 O
Significant O
pulmonic O
regurgitation O
is O
seen O
. O
There O
is O
no O

 O
pericardial O
effusion O
. O


 O
[ O
* O
* O
Month/Day/Year O
* O
* O
] O
[ O
* O
* O
2180 O
- O
11 O
- O
9 O
* O
* O
] O

 O
Compared O
with O
the O
prior O
study O
( O
images O
reviewed O
) O
of O
[ O
* O
* O
2180 O
- O
11 O
- O
6 O
* O
* O
] O
, O

 O
left O
ventricular O
cavity O
size O
is O
smaller O
, O
global O
systolic O

 O
function O
is O
improved O
( O
quantitative O
biplane O
LVEF O
30 O
% O
on O
review O
of O

 O
prior O
study O
) O
, O
and O
the O
severity O
of O
mitral O
regurgitation O
and O

 O
estimated O
pulmonary O
artery O
systolic O
pressure O
are O
reduced O
. O



 O
Brief O
Hospital O
Course O
: O

 O
35yF O
with O
multiple O
medical O
problems O
( O
including O
SLE O
, O
restrictive O

 O
lung O
disease O
, O
global O
cardiomyopathy O
with O
severely O
depressed O

 O
systolic O
function O
, O
nephrotic O
syndrome O
) O
, O
with O
recent O
admission O

 O
[ O
* O
* O
Date O
range O
( O
1 O
) O
68983 O
* O
* O
] O
for O
nausea O
, O
vomiting O
, O
and O
diarrhea O
, O
admitted O
with O

 O
shortness O
of O
breath O
, O
tachycardia O
, O
and O
persistent O
nausea O
. O

 O
. O


 O
# O
) O
Cardiomyopathy O
: O
Pt O
was O
initially O
admitted O
to O
the O
hospitalist O

 O
service O
but O
transferred O
for O
cath O
and O
endocardial O
biopsy O
in O
the O

 O
setting O
of O
worsening O
EF O
. O
  O
Her O
cardiomyopathy O
was O
thought O
to O
be O

 O
due O
to O
lupus O
. O
  O
Peripartum O
cardiomyopathy O
was O
also O
considered O

 O
however O
given O
the O
timing O
of O
onset O
and O
biopsy O
showing O
immune O

 O
complexes O
seen O
on O
endocardial O
biopsy O
, O
lupus B-REA
cardiomyopathy I-REA
was O

 O
thought O
to O
be O
more O
likely O
. O
  O
She O
was O
treated O
with O
steroids B-DRUG
, I-DRUG

 O
cytoxan B-DRUG
, I-DRUG
plasmaphoresis B-DRUG
, I-DRUG
IVIG B-DRUG
and O
supportive O
care O
, O
and O
improved O

 O
from O
an O
EF O
of O
15 O
to O
33 O
% O
. O
  O
It O
is O
unclear O
which O
therapy O
led O
to O

 O
improvement O
. O
  O
She O
did O
require O
temporary O
CCU O
transfer O
for O

 O
milrinone B-DRUG
given O
worsening O
EF O
, O
however O
was O
weaned O
after O
a O
few O

 O
days O
and O
transferred O
back O
to O
the O
floor O
in O
stable O
condition O
. O
  O
Her O

 O
mitral O
regurgitation O
and O
hypertension O
also O
contributed O
to O
her O

 O
poor O
forward O
flow O
, O
and O
htn B-REA
improved O
with O
diuresis O
, O
hydralazine B-DRUG
, I-DRUG

 O
lisinopril B-DRUG
and O
amlodipine B-DRUG
. I-DRUG

 O
. O

 O
# O
) O
sCHF B-REA
, I-REA
volume B-REA
overload I-REA
: I-REA
On O
admission O
, O
pt O
was O
clearly O

 O
tachypneic O
but O
satting O
well O
on O
room O
air O
. O
Reported O
3 O
pillow O

 O
orthopnea O
and O
paroxysmal O
noctural O
dyspnea O
, O
in O
the O
setting O
of O

 O
recent O
d/c O
Lasix B-DRUG
and O
IVF B-DRUG
resuscitation B-REA
, I-REA
LE O
edema O
also O
suggested O

 O
fluid O
overload O
. O
  O
BNP O
extremely O
elevated O
at O
65,187 O
. O
  O
She O
also O
had O

 O
non-specific O
sxs O
concerning O
for O
HF O
including O
throat O
tightness O

 O
and O
GI O
sxs O
. O
  O
Her O
sxs O
improved O
with O
diuresis O
and O
symptomatic O

 O
management O
and O
she O
was O
discharged O
on O
oral B-ROU
torsemide B-DRUG
. I-DRUG
  O
She O
was O

 O
also O
treated O
with O
BP B-REA
control I-REA
and O
bblocker B-DRUG
therapy O
. O
  O
Given O
her O

 O
SOB O
and O
LE O
edema O
R O
> O
L O
, O
a O
LE O
US O
was O
performed O
and O
showed O
no O
LE O

 O
clot O
, O
therefore O
PE O
was O
thought O
to O
be O
unlikely O
. O

 O
. O


 O
# O
) O
SLE B-REA
. I-REA
Pt O
diagnosed O
in O
[ O
* O
* O
2168 O
* O
* O
] O
, O
manifested O
by O
kidney O
disease O

 O
previously O
membranous O
nephropathy O
, O
facial O
rash O
, O
Sjogren O
's O

 O
syndrome O
, O
Raynaud O
's O
phenomenon O
, O
and O
pleuritis O
. O
  O
Previously O

 O
followed O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
68981 O
* O
* O
] O
at O
B&W O
, O
however O
has O
requested O
to O
transfer O

 O
her O
care O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
after O
this O
admission O
. O
  O
Initially O
contined O
on O

 O
Plaquenil B-DRUG
and O
Imuran B-DRUG
, I-DRUG
as O
well O
as O
prednisone B-DRUG
. I-DRUG
  O
Plaquenil B-DRUG
dc'd O
per O

 O
rheumatology O
recs O
. O
  O
Cardiomyopathy O
and O
renal O
failure O
on O
current O

 O
admission O
were O
felt O
to O
be O
manifestation O
of O
underlying O
lupus B-REA
. I-REA

 O
Rheumatology O
was O
consulted O
and O
recommended O
aggressive O
therapy O

 O
with O
steriods B-DRUG
, I-DRUG
cytoxan B-DRUG
and O
plasmapheresis B-DRUG
. I-DRUG
  O
Received O
solumedrol B-DRUG

 I-DRUG
1 B-STR
g I-STR
daily B-FRE
x I-FRE
3 I-FRE
followed O
by O
solumedrol B-DRUG
30 B-STR
mg I-STR
IV B-ROU
q12hrs B-FRE
, I-FRE
which O
was O

 O
uptitrated O
to O
60 B-STR
q B-FRE
12 I-FRE
hrs I-FRE
and O
subseuquently O
tapered B-DOS
and O
she O
was O

 O
ultimately O
discharged O
on O
prednisone B-DRUG
60 B-STR
mg I-STR
orally B-ROU
daily B-FRE
. I-FRE
  O
She O
was O

 O
also O
placed O
on O
atovaquone B-DRUG
PCP B-REA
prophylaxis I-REA
in O
the O
setting O
of O

 O
immunosuppression O
. O
  O
She O
recieved O
1 B-DOS
dose I-DOS
of O
cytoxan B-DRUG
750 B-STR
mg I-STR
on O
[ O
* O
* O
10 O
- O
20 O
* O
* O
] O

 O
with O
mesna B-DRUG
, I-DRUG
cell O
counts O
with O
nadir B-DRUG
on O
[ O
* O
* O
11 O
- O
5 O
* O
* O
] O
. O
  O
Prior O
to O
cytoxan B-DRUG
, I-DRUG

 O
she O
received O
7.5 B-STR
mg I-STR
Lupron B-DRUG
for O
ovarian B-REA
protection I-REA
with O
plans O
to O

 O
pursue O
egg O
harvesting O
for O
fertility O
as O
an O
outpatient O
. O
  O
Received O

 O
5 B-DOS
cycles I-DOS
of O
plasmapheresis B-DRUG
. I-DRUG
  O
3 B-DOS
doses O
of O
IVIG B-DRUG
was O
also O

 O
administered O
given O
that O
pts O
HF O
continued O
to O
worsen O
during O
the O

 O
hospital O
stay O
. O
  O
Additional O
plasmaphoreis B-DRUG
was O
considered O
but O
held O

 O
due O
to O
her O
continued O
improvement O
. O

 O
. O

 O
# O
) O
Nausea/diarrhea B-ADE
. I-ADE
Initially O
thought O
secondary O
to O
restarting O

 O
Imuran B-DRUG
, I-DRUG
however O
pt O
and O
husband O
attributed O
to O
bblocker B-DRUG
therapy O
. O

 O
Most O
likely O
due O
to O
gut O
edema O
in O
the O
setting O
of O
right O
HF O
. O
  O
GI O
was O

 O
consulted O
and O
agreed O
however O
recommended O
ruling O
out O
infectious O

 O
etiology O
given O
her O
immunosuppression O
; O
w/u O
was O
negative O
. O
She O

 O
improved O
with O
symptomatic O
tx O
and O
treatment O
of O
her O
HH O
. O

 O
. O


 O
# O
) O
thrombocytopenia B-REA
: I-REA
Pt O
bleeding O
from O
HD O
site O
[ O
* O
* O
10 O
- O
21 O
* O
* O
] O
, O
improved O

 O
with O
Cryo B-DRUG
, I-DRUG
Platelets B-DRUG
, I-DRUG
and O
Surgicel B-DRUG
. I-DRUG
Patient O
developed O

 O
thrombocytopenia O
with O
nadir O
of O
68 O
, O
likely O
multifactorial O
related O

 O
to O
dilution O
, O
imunnosupression O
, O
and O
possibly O
pheresis O
. O
  O
Heme O

 O
consulted O
and O
recommended O
removing O
ASA B-DRUG
, I-DRUG
NSAIDs B-DRUG
, I-DRUG
all O
heparin B-DRUG

 I-DRUG
products O
, O
f/u O
LFTs O
, O
fibrinogen B-DRUG
. I-DRUG
  O
Platelet O
drop O
was O
too O
quick O
to O

 O
be O
related O
to O
Cytoxan B-DRUG
and O
likelihood O
of O
developping O
4 O
T O
score O
is O

 O
3 O
. O
HIT O
ab O
negative O
. O
Fibrinogen B-DRUG
nomralized O
. O
Thrombocytopenia O

 O
quickly O
improved O
, O
however O
then O
fluctuated O
in O
the O
setting O
of O

 O
cytoxan B-DRUG
use O
. O
  O
IgG O
and O
IgM O
ACA O
negative O
, O
so O
unlikely O
to O
have O

 O
prothrombotic O
state O
. O

 O
. O

 O
# O
) O
Acute O
on O
chronic O
RF O
: O
Pt O
with O
h/o O
SLE O
Nephritis O
. O
Pt O
previously O

 O
with O
membranous O
nephropathy O
on O
prior O
biopsy O
. O
  O
She O
had O
repeat O

 O
biopsy O
showing O
type O
3,4,5 O
lupus O
nephritis O
. O
  O
Worsening O
renal O

 O
failure O
with O
creatinine O
increased O
to O
3.7 O
up O
from O
1.4 O
on O

 O
admission O
. O
  O
Urine O
lytes O
indicative O
of O
prerenal O
ischemia O
( O
FeUrea O

 O
< O
0.02 O
% O
) O
+ O
/- O
evolving O
ATN O
  O
likely O
from O
poor O
cardiac O
output/ O

 O
cardiorenal O
syndrome O
. O
  O
renal O
U/S O
show O
's O
no O
obstruction O
. O
   O
While O

 O
her O
renal O
function O
showed O
some O
initial O
worsening O
with O
diuresis O
, O

 O
diuresis O
was O
continued O
due O
to O
continued O
volume O
overload O
, O
and O

 O
creatinine O
remained O
stable O
. O

 O
. O

 O
# O
HTN B-REA
: I-REA
BPs O
improved O
with O
uptitration O
of O
hydralazine B-DRUG
and O
addition O

 O
of O
lisinopril B-DRUG
. I-DRUG
  O
Pt O
concerned O
that O
hydralazine B-DRUG
may O
be O
causing O

 O
joint B-ADE
pain I-ADE
. I-ADE
  O
Given O
this O
and O
her O
improved O
renal O
function O
, O

 O
lisinopril B-DRUG
was O
uptitrated O
and O
hydralazine B-DRUG
discontinued O
. O
  O
Blood O

 O
pressures O
stable O

 O
. O

 O
# O
Anemia B-REA
: I-REA
  O
Likely O
due O
to O
acute O
renal O
disease O
, O
cytoxan B-DRUG
therapy O
. O

 O
Pt O
was O
given O
one B-DOS
unit I-DOS
of O
PRBCs B-DRUG
while O
in O
patient O
and O
started O
on O

 O
epo O
with O
good O
improvement O
in O
her O
crit O
. O

 O
. O

 O
# O
Joint B-REA
pain I-REA
: I-REA
? O
medication O
side O
effect O
( O
IVIG B-DRUG
, I-DRUG
hydralazine B-DRUG
) I-DRUG
vs O

 O
lupus O
flare O
, O
however O
pt O
has O
never O
had O
joint O
pain O
with O
lupus O

 O
flares O
in O
the O
past O
. O
  O
Hydralazine B-DRUG
was O
discontinued O
, O
symptomatic O

 O
relief O
with O
tylenol B-DRUG
, I-DRUG
PT O
. O



 O
Medications O
on O
Admission O
: O

 O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
po B-ROU
BID B-FRE

 I-FRE
Prednisone B-DRUG
15 B-STR
mg I-STR
qam B-FRE
and O
5 B-STR
mg I-STR
qpm B-FRE

 I-FRE
Vitamin B-DRUG
D I-DRUG
400 B-STR
units I-STR
daily B-FRE

 I-FRE
Calcium B-DRUG
500 B-STR
mg I-STR
twice B-FRE
daily I-FRE

 I-FRE
Ferrous B-DRUG
sulfate I-DRUG
325 B-STR
mg I-STR
once B-FRE
daily I-FRE
( O
not O
continued O
last O
admission O
) O

 O
Multivitamin B-DRUG
one B-DOS
tablet B-FOR
once B-FRE
daily I-FRE
( O
not O
continued O
last O

 O
admission O
) O

 O
Cyanocobalamin B-DRUG
1000 B-STR
mcg I-STR
injection B-FOR
once B-FRE
a I-FRE
month I-FRE
( O
not O
listed O
at O

 O
last O
admission O
) O

 O
Folic B-DRUG
acid I-DRUG
1 B-STR
mg I-STR
daily B-FRE

 I-FRE
Furosemide B-DRUG
40 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
daily I-FRE
( O
held O
after O
admission O
) O

 O
Plaquenil B-DRUG
200 B-STR
mg I-STR
by B-ROU
mouth I-ROU
once B-FRE
daily I-FRE

 I-FRE
Metoprolol B-DRUG
75 B-STR
mg I-STR
XL I-DRUG
by B-ROU
mouth I-ROU
daily B-FRE
at I-FRE
bedtime I-FRE
( O
changed O
to O

 O
carvedilol B-DRUG
) I-DRUG

 O
Carvedilol B-DRUG
3.125 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Imuran B-DRUG
50 B-STR
mg I-STR
daily B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Folic B-DRUG
Acid I-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
2 O
. O
Calcium B-DRUG
Carbonate I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Cholecalciferol B-DRUG
( I-DRUG
Vitamin I-DRUG
D3 I-DRUG
) I-DRUG
400 B-STR
unit I-STR
Tablet B-FOR
Sig O
: O
2.5 B-DOS
Tablets B-FOR

 I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE

 I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
: I-REA
please O
do O
not O
exceed O
3000mg/day O
. O

 O
5 O
. O
Atovaquone B-DRUG
750 B-STR
mg/5 I-STR
mL I-STR
Suspension B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
5ml I-DOS
teaspoons I-DOS

 I-DOS
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*300 O
ml O
* O
Refills:*2 O
* O

 O
6 O
. O
Ferrous B-DRUG
Sulfate I-DRUG
325 B-STR
mg I-STR
( O
65 B-STR
mg I-STR
Iron B-DRUG
) I-DRUG
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
7 O
. O
Epoetin B-DRUG
Alfa I-DRUG
4,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
injection B-FOR

 I-FOR
Injection B-FOR
QMOWEFR B-FRE
( O
[ O
* O
* O
Hospital1 O
766 O
* O
* O
] O
-Wednesday-Friday O
) O
. O

 O
Disp:*12 O
injections O
* O
Refills:*2 O
* O

 O
8 O
. O
Carvedilol B-DRUG
12.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*120 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
9 O
. O
Nystatin B-DRUG
100,000 B-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
BID B-FRE

 I-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*300 O
ML(s O
) O
* O
Refills:*2 O
* O

 O
10 O
. O
Amlodipine B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
11 O
. O
Spironolactone B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
12 O
. O
Prednisone B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*90 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
13 O
. O
Hydrocortisone B-DRUG
2.5 B-STR
% I-STR
Cream B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-ROU
Rectal I-ROU
Q B-FRE
DAY I-FRE

 I-FRE
( O
) O
. O

 O
Disp:*1 O
tube O
* O
Refills:*2 O
* O

 O
14 O
. O
Lisinopril B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
15 O
. O
Torsemide B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*2 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Primary O

 O
Systemic O
Lupus O
Erythematosus O
Associated O
Cardiomyopathy O
. O

 O
. O

 O
Secondary O

 O
Systemic O
Lupus O
Erythematosus O

 O
Hypertension O

 O
Persistent O
Thrombocytopenia O



 O
Discharge O
Condition O
: O

 O
stable O
, O
good O
, O
baseline O
ambulatory O
and O
mental O
status O



 O

Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
hospital O
because O
you O
were O
having O
nausea O

 O
shortness O
of O
breath O
. O
You O
were O
found O
to O
have O
a O
lupus O
induced O

 O
cardiomyopathy O
causing O
heart O
failure O
. O
You O
received O

 O
immunosuppressive O
medications O
to O
control O
your O
immune O
system O
and O

 O
your O
heart O
function O
improved O
as O
shown O
on O
serial O
echos O
. O
You O

 O
received O
diuretics O
to O
remove O
the O
fluid O
that O
accumulated O
due O
to O

 O
the O
heart O
failure O
, O
and O
medications O
to O
control O
your O
blood O

 O
pressure O
. O

 O
. O

 O
The O
following O
changes O
were O
made O
to O
your O
medications O
. O

 O
We O
STOPPED O
: O

 O
plaquenil B-DRUG

 I-DRUG
. O

 O
We O
changed O
to O
: O

 O
carvedilol B-DRUG
25 B-STR
mg I-STR
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
vitamin B-DRUG
D I-DRUG
1000 B-STR
mg I-STR
daily B-FRE

 I-FRE
. O

  O
We O
added O
: O

 O
lisinopril B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
torsemide B-DRUG
20 B-STR
mg I-STR
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
hydrocortisone B-DRUG
2.5 B-STR
% I-STR
rectal B-ROU
cream B-FOR
1 B-DOS
application B-FOR
per B-ROU
rectum I-ROU
daily B-FRE

 I-FRE
with O
rectal B-REA
pain I-REA

 I-REA
spironolactone B-DRUG
25 B-STR
mg I-STR
daily B-FRE

 I-FRE
amlodipine B-DRUG
10 B-STR
mg I-STR
daily B-FRE

 I-FRE
ferrous B-DRUG
sulphate I-DRUG
325 B-STR
mg I-STR
daily B-FRE

 I-FRE
erythropoeitin B-DRUG
Alfa I-DRUG
4000 B-STR
unit I-STR
SC B-ROU
injection B-FOR
MWF B-FRE

 I-FRE
atovaquone B-DRUG
suspension B-FOR
1500 B-STR
mg I-STR
daily B-FRE
while O
on O
prednisone B-DRUG

 I-DRUG
nyastatin B-DRUG
5ml B-DOS
p.o B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
as B-FRE
needed I-FRE
for O
oral B-REA
thrush I-REA

 I-REA
. O

 O
Weigh O
yourself O
every O
morning O
, O
[ O
* O
* O
Name8 O
( O
MD O
) O
138 O
* O
* O
] O
MD O
if O
weight O
goes O
up O
more O

 O
than O
3 O
lbs O
. O


 O
Followup O
Instructions O
: O

 O
1.Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
4900 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
2226 O
* O
* O
] O

 O
Date/Time:[**2180 O
- O
11 O
- O
13 O
* O
* O
] O
8:00 O

 O
. O

 O
2.MD O
: O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
5700 O
* O
* O
] O

 O
Specialty O
: O
PCP O

 O
[ O
* O
* O
Name O
Initial O
( O
PRE O
) O
2897**]/ O
Time O
: O
Thursday O
, O
[ O
* O
* O
11 O
- O
24 O
* O
* O
] O
at O
3:15pm O

 O
Location O
: O
[ O
* O
* O
Apartment O
Address(1 O
) O
68985 O
* O
* O
] O
, O
[ O
* O
* O
Location O
( O
un O
) O
583 O
* O
* O
] O
, O
MA O

 O
Phone O
number O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
31923 O
* O
* O
] O

 O
. O

 O
3.Cardiology O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
* O
* O
] O
Lab O

 O
Specialty O
: O
Cardiology O

 O
Date/ O
Time O
: O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
766 O
* O
* O
] O
, O
[ O
* O
* O
11 O
- O
21 O
* O
* O
] O
at O
3:00pm O

 O
Location O
: O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Bldg O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
Location O
( O
un O
) O
86 O
* O
* O
] O
, O
MA O

 O
Phone O
number O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
62 O
* O
* O
] O

 O
. O


 O
4.MD O
: O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
449 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
437 O
* O
* O
] O

 O
Specialty O
: O
Cardiology O

 O
Date/ O
Time O
: O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
766 O
* O
* O
] O
, O
[ O
* O
* O
11 O
- O
21 O
* O
* O
] O
at O
4:00pm O

 O
Location O
: O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Bldg O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
Location O
( O
un O
) O
86 O
* O
* O
] O
, O
MA O

 O
Phone O
number O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
62 O
* O
* O
] O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2148 O
- O
7 O
- O
1 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2148 O
- O
7 O
- O
9 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2074 O
- O
1 O
- O
3 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
ORTHOPAEDICS O


 O
Allergies O
: O

 O
No O
Known O
Allergies O
/ O
Adverse O
Drug O
Reactions O


 O
Attending:[**First O
Name8 O
( O
NamePattern2 O
) O
1103 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
AMS O
, O
low O
urine O
output O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
1 O
* O
* O
] O
: O
s/p O
Right O
knee O
replacement O



 O
History O
of O
Present O
Illness O
: O

 O
74 O
yo O
male O
with O
h/o O
DM2 O
, O
HTN O
, O
CAD O
with O
stent O
placement O
, O
one O

 O
kidney O
, O
Parkinson O
's O
dz O
. O
End-stage O
tricompartmental O
OA O
, O
presented O

 O
for O
right O
TKR O
. O


 O
After O
surgery O
, O
patient O
was O
somnolent O
and O
with O
low B-REA
urine I-REA
output I-REA
. I-REA

 O
In O
OR/PACU O
patient O
received O
4L B-DOS
liters O
fluids B-DRUG
+ O
500 B-DOS
cc I-DOS
5 B-STR
% I-STR

 O
albumin B-DRUG
, I-DRUG
with O
UOP O
376cc O
( O
10 O
- O
20 O
cc/hr O
) O
. O
  O
Patient O
developed O

 O
increasing O
somnolence O
throughout O
the O
day O
. O
  O
Received O
total O
1.5 B-STR
mg I-STR

 I-STR
dilaudid B-DRUG
per O
PCA B-ROU
in O
PACU O
. O
  O
He O
also O
received O
1 B-STR
g I-STR
tylenol B-DRUG
and O
4U B-DOS

 I-DOS
insulin B-DRUG
SC B-ROU
. I-ROU
  O
Creatinine O
was O
1.3 O
( O
baseline O
1.0 O
- O
1.2 O
) O
. O
  O
Hematocrit O

 O
25 O
at O
5 O
pm O
, O
subsequently O
23 O
( O
baseline O
30 O
- O
33 O
) O
. O
  O
ABG O
7.42/44/64/30 O
. O



 O
Vitals O
in O
PACU O
: O

 O
T O
96.8 O
- O
97.4 O
HR O
50 O
- O
100 O
BP O
120s/50s O
RR O
15 O
- O
20 O
O2Sa O
98 O
- O
99 O
% O
on O
2L O


 O
Vitals O
on O
arrival O
to O
the O
MICU O
: O

 O
T O
100.1 O
HR O
102 O
BP O
141/62 O
RR O
22 O
SaO2 O
96 O
% O
on O
2L O
NC O


 O
Upon O
transfer O
to O
the O
MICU O
he O
was O
transfused O
1U B-DOS
RBC B-DRUG
followed O
by O

 O
20 B-STR
mg I-STR
Lasix B-DRUG
, I-DRUG
after O
which O
UOP O
rose O
to O
~100cc/hr O
. O



 O

Past O
Medical O
History O
: O

 O
1)3VCAD O

  O
- O
s/p O
STEMI O
and O
PTCA O
of O
LAD O
[ O
* O
* O
2141 O
* O
* O
] O
at O
[ O
* O
* O
Hospital1 O
2177 O
* O
* O
] O

  O
- O
s/p O
PTCA O
& O
DES O
to O
OM1 O
[ O
* O
* O
2146 O
- O
2 O
- O
18 O
* O
* O
] O

  O
- O
s/p O
DES O
to O
prox/mid-LAD O
& O
OM1 O
[ O
* O
* O
2147 O
- O
2 O
- O
16 O
* O
* O
] O

  O
- O
s/p O
stent O
& O
balloon O
angioplasty O
to O
LAD O
[ O
* O
* O
2147 O
- O
12 O
- O
20 O
* O
* O
] O

  O
- O
ECG O
[ O
* O
* O
2148 O
- O
6 O
- O
26 O
* O
* O
] O
: O
notable O
for O
SR O
, O
PR O
214 O
, O
poor O
R O
wave O
progression O
, O

    O
nonspecific O
lateral O
lead O
ST-T O
wave O
abnormalities O

 O
2)Hypertension O

 O
3)Dyslipidemia O

 O
4)BPH O

 O
5)Type O
2 O
diabetes O
with O
peripheral O
neuropathy O

 O
6)s/p O
R O
nephrectomy O
~10 O
years O
ago O
at O
[ O
* O
* O
Hospital1 O
2177 O
* O
* O
] O
- O
path O
benign O
per O

 O
patient O

 O
7)Parkinson B-REA
's I-REA
disease I-REA
: I-REA

  O
- O
diagnosed O
age O
70 O

  O
- O
followed O
as O
outpatient O
by O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
951 O
* O
* O
] O
. O

  O
- O
Carbidopa/levodopa B-DRUG

 I-DRUG
8)Bells B-REA
' I-REA
palsy I-REA
( O
[ O
* O
* O
2 O
- O
1 O
* O
* O
] O
HTN O
) O
[ O
* O
* O
6 O
- O
8 O
* O
* O
] O
s/p O
valtrex B-DRUG

 I-DRUG
9)CKD O
Stage O
II O
baseline O
1.0 O
- O
1.2 O

 O
10)Depression O

 O
11)Microcytic O
anemia-stable O
all O
his O
life-?thalassemia O
. O
neg O
, O

 O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
-egd O
in O
past O

 O
12)Elevated O
PSA O

 O
13)Urinary O
frequency O
and O
incomplete O
emptying O
on O
UDS O

 O
14)Knee O
arthritis O




 O
Social O
History O
: O

 O
Lives O
with O
his O
wife O
and O
son O
. O
Retired O
[ O
* O
* O
Name2 O
( O
NI O
) O
13222 O
* O
* O
] O
at O
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O
No O

 O
smoking O
, O
drinking O
or O
illicit O
drug O
use O
. O
  O
Does O
work O
part-time O
now O

 O
at O
a O
gun O
and O
rifle O
club O
. O
  O
Notes O
that O
his O
diet O
is O
not O
good O
-- O
> O

 O
pizza O
, O
sandwiches O
. O



 O
Family O
History O
: O

 O
No O
family O
history O
of O
early O
MI O
, O
arrhythmia O
, O
cardiomyopathies O
, O
or O

 O
sudden O
cardiac O
death O
. O




 O
Physical O
Exam O
: O

 O
Well O
appearing O
in O
no O
acute O
distress O

 O
Afebrile O
with O
stable O
vital O
signs O

 O
Pain O
well-controlled O

 O
Respiratory O
: O
CTAB O

 O
Cardiovascular O
: O
RRR O

 O
Gastrointestinal O
: O
NT/ND O

 O
Genitourinary O
: O
Foley O
catheter O
, O
remove O
[ O
* O
* O
2148 O
- O
7 O
- O
13 O
* O
* O
] O
at O
6 O
am O

 O
Neurologic O
: O
Intact O
with O
no O
focal O
deficits O

 O
Psychiatric O
: O
Pleasant O
, O
A&O O
x3 O

 O
Musculoskeletal O
Lower O
Extremity O
: O

 O
* O
Incision O
healing O
well O
with O
staples O

 O
* O
Sanguinous O
drainage O
from O
proximal B-REA
wound I-REA
, I-REA
dressed O
with O
silver B-DRUG

 I-DRUG
nitrate I-DRUG
and O
steristrips O
placed O
on O
[ O
* O
* O
7 O
- O
6 O
* O
* O
] O
, O
good O
effect O

 O
* O
Eccymosis O
medial/lateral O
knee O
and O
shin O

 O
* O
Thigh O
full O
but O
soft O

 O
* O
No O
calf O
tenderness O

 O
* O
SILT O
, O
NVI O
distally O

 O
* O
Toes O
warm O

 O
* O
+ O
cap O
refill O

 O
* O
WEAK O
PT O
, O
-AT O



 O
Pertinent O
Results O
: O

 O
CXR O
[ O
* O
* O
2148 O
- O
7 O
- O
1 O
* O
* O
] O
: O
Low O
lung O
volumes O
. O
Interval O
appearance O
of O
mild O

 O
interstitial O
edema O
and O
engorged O
pulmonary O
vasculature O
. O
Heart O

 O
size O
is O
increased O
. O
Bibasilar O
opacities O
likely O
atelectasis O
. O

 O
Stomach O
is O
distended O
with O
gas O
. O



 O
[ O
* O
* O
2148 O
- O
7 O
- O
9 O
* O
* O
] O
07:30AM O
BLOOD O
WBC-9.9 O
RBC-3.66 O
* O
Hgb-9.2 O
* O
Hct-28.6 O
* O

 O
MCV-78 O
* O
MCH-25.1 O
* O
MCHC-32.1 O
RDW-17.6 O
* O
Plt O
Ct-331 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
8 O
* O
* O
] O
07:05AM O
BLOOD O
WBC-8.6 O
RBC-3.62 O
* O
Hgb-9.5 O
* O
Hct-28.2 O
* O

 O
MCV-78 O
* O
MCH-26.3 O
* O
MCHC-33.7 O
RDW-16.9 O
* O
Plt O
Ct-268 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
8 O
* O
* O
] O
01:00AM O
BLOOD O
WBC-8.4 O
RBC-3.53 O
* O
Hgb-9.3 O
* O
# O
Hct-27.0 O
* O

 O
MCV-76 O
* O
MCH-26.2 O
* O
MCHC-34.3 O
RDW-16.9 O
* O
Plt O
Ct-262 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
7 O
* O
* O
] O
05:30AM O
BLOOD O
WBC-6.6 O
RBC-2.99 O
* O
Hgb-7.3 O
* O
Hct-22.6 O
* O

 O
MCV-76 O
* O
MCH-24.4 O
* O
MCHC-32.2 O
RDW-16.9 O
* O
Plt O
Ct-205 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
6 O
* O
* O
] O
08:00AM O
BLOOD O
WBC-7.8 O
RBC-3.26 O
* O
Hgb-7.9 O
* O
Hct-24.3 O
* O

 O
MCV-75 O
* O
MCH-24.2 O
* O
MCHC-32.4 O
RDW-16.8 O
* O
Plt O
Ct-187 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
5 O
* O
* O
] O
08:00AM O
BLOOD O
WBC-8.4 O
RBC-3.54 O
* O
Hgb-8.8 O
* O
Hct-26.4 O
* O

 O
MCV-75 O
* O
MCH-24.8 O
* O
MCHC-33.2 O
RDW-16.6 O
* O
Plt O
Ct-145 O
* O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
4 O
* O
* O
] O
07:55AM O
BLOOD O
WBC-10.0 O
RBC-3.36 O
* O
Hgb-7.9 O
* O
Hct-24.5 O
* O

 O
MCV-73 O
* O
MCH-23.4 O
* O
MCHC-32.2 O
RDW-16.6 O
* O
Plt O
Ct-116 O
* O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
3 O
* O
* O
] O
07:35AM O
BLOOD O
WBC-11.7 O
* O
RBC-3.60 O
* O
Hgb-8.3 O
* O
Hct-25.5 O
* O

 O
MCV-71 O
* O
MCH-23.2 O
* O
MCHC-32.7 O
RDW-15.3 O
Plt O
Ct-130 O
* O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
2 O
* O
* O
] O
03:22AM O
BLOOD O
WBC-9.6 O
RBC-4.06 O
* O
Hgb-9.4 O
* O
Hct-28.8 O
* O

 O
MCV-71 O
* O
MCH-23.1 O
* O
MCHC-32.6 O
RDW-15.6 O
* O
Plt O
Ct-119 O
* O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
1 O
* O
* O
] O
05:30PM O
BLOOD O
WBC-9.8 O
RBC-3.58 O
* O
# O
Hgb-7.9 O
* O
# O
Hct-25.2 O
* O
# O

 O
MCV-70 O
* O
MCH-22.0 O
* O
MCHC-31.4 O
RDW-15.7 O
* O
Plt O
Ct-145 O
* O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
1 O
* O
* O
] O
05:30PM O
BLOOD O
Neuts-78.4 O
* O
Lymphs-15.8 O
* O
Monos-5.0 O

 O
Eos-0.5 O
Baso-0.3 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
8 O
* O
* O
] O
07:05AM O
BLOOD O
PT-11.5 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
9 O
* O
* O
] O
07:30AM O
BLOOD O
Glucose-184 O
* O
UreaN-23 O
* O
Creat-0.9 O
Na-133 O

 O
K-4.2 O
Cl-98 O
HCO3 O
- O
26 O
AnGap-13 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
8 O
* O
* O
] O
07:05AM O
BLOOD O
Glucose-204 O
* O
UreaN-28 O
* O
Creat-0.9 O
Na-134 O

 O
K-3.9 O
Cl-97 O
HCO3 O
- O
27 O
AnGap-14 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
7 O
* O
* O
] O
05:30AM O
BLOOD O
Glucose-168 O
* O
UreaN-33 O
* O
Creat-1.1 O
Na-134 O

 O
K-3.6 O
Cl-98 O
HCO3 O
- O
26 O
AnGap-14 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
8 O
* O
* O
] O
07:05AM O
BLOOD O
Calcium-8.1 O
* O
Phos-2.5 O
* O
Mg-2.0 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
7 O
* O
* O
] O
05:30AM O
BLOOD O
Calcium-7.7 O
* O
Phos-2.5 O
* O
Mg-2.3 O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
6 O
* O
* O
] O
08:00AM O
BLOOD O
Calcium-7.8 O
* O
Phos-2.4 O
* O
Mg-2.4 O

 O

[ O
* O
* O
2148 O
- O
7 O
- O
1 O
* O
* O
] O
07:37PM O
BLOOD O
Type-ART O
O2 O
Flow-2 O
pO2 O
- O
64 O
* O
pCO2 O
- O
44 O

 O
pH-7.42 O
calTCO2 O
- O
30 O
Base O
XS-3 O
Intubat-NOT O
INTUBA O

 O
[ O
* O
* O
2148 O
- O
7 O
- O
1 O
* O
* O
] O
07:37PM O
BLOOD O
Hgb-7.8 O
* O
calcHCT-23 O
O2 O
Sat-91 O


 O
Brief O
Hospital O
Course O
: O

 O
The O
patient O
was O
admitted O
to O
the O
orthopaedic O
surgery O
service O
and O

 O
was O
taken O
to O
the O
operating O
room O
for O
above O
described O
procedure O
. O

 O
Please O
see O
separately O
dictated O
operative O
report O
for O
details O
. O
The O

 O
surgery O
was O
uncomplicated O
and O
the O
patient O
tolerated O
the O

 O
procedure O
well O
. O
Patient O
received O
perioperative O
IV B-ROU
antibiotics B-DRUG
. I-DRUG


 O
Postoperative O
course O
was O
remarkable O
for O
the O
following O
: O


 O
1 O
. O
Admit O
to O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
for O
post O
op O
medical O
management O
. O
  O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
course O
as O

 O
below O
. O
  O
transferred O
to O
the O
floor O
late O
in O
the O
evening O
on O
POD1 O


 O
2 O
. O
Geriatric O
c/s O
for O
medical O
co-management O


 O
3 O
. O
Post-op O
anemia O
- O
POD2 O
Hct O
25.5 O
- O
> O
1u O
PRBC O
, O
POD3 O
Hct O
24.5 O
, O

 O
asymptomatic O
- O
> O
Transfused O
additional O
1u O
PRBCs O
. O
  O
POD5 O
HCT O
24.3 O

 O
- O
> O
1u O
PRBCs O
, O
POD6 O
- O
> O
HCT O
22.6 O
- O
> O
2u O
PRBCs O


 O
4 O
. O
Neuro O
consult O
for O
R O
foot O
motor O
deficit O
- O
incomplete O
study O
, O

 O
but O
no O
obvious O
nerve O
compression O
. O


 O
5 O
. O
Hematuria O
and O
urinary B-REA
retention I-REA
- O
Started O
on O
Bactrim B-DRUG

 I-DRUG
prophylactically B-REA
. I-REA
Hematura O
cleared O
spontaneously O
. O
Patient O
was O

 O
unable B-REA
to I-REA
void I-REA
, I-REA
straight O
cathed O
x O
many O
, O
when O
urine O
culture O

 O
confirmed O
negative O
, O
stopped O
Bactrim B-DRUG
and O
foley O
placed O
[ O
* O
* O
7 O
- O
5 O
* O
* O
] O
. O
Foley O

 O
removed O
[ O
* O
* O
2148 O
- O
7 O
- O
9 O
* O
* O
] O
at O
6 O
am O
but O
patient O
failed O
voising O
trial O
, O
bladder O

 O
scanned O
> O
400cc O
after O
6 O
hrs O
. O
Foley O
replaced O
, O
increased O
terazosin B-DRUG

 I-DRUG
15 B-STR
mg I-STR
daily B-FRE
, I-FRE
repeat O
voiding O
trial O
[ O
* O
* O
2148 O
- O
7 O
- O
13 O
* O
* O
] O
at O
6 O
am O
. O


 O
Otherwise O
, O
pain B-REA
was O
initially O
controlled O
with O
IV B-ROU
pain B-DRUG
meds I-DRUG

 I-DRUG
followed O
by O
a O
transition O
to O
oral O
pain O
medications O
on O
POD#1 O
. O
  O
The O

 O
patient O
received O
lovenox B-DRUG
for O
DVT B-REA
prophylaxis I-REA
starting O
on O
the O

 O
morning O
of O
POD#1 O
. O
The O
surgical O
dressing O
was O
changed O
on O
POD#2 O
and O

 O
the O
surgical O
incision O
was O
found O
to O
be O
clean O
and O
intact O
without O

 O
erythema O
or O
abnormal O
drainage O
. O
The O
patient O
was O
seen O
daily O
by O

 O
physical O
therapy O
. O
Labs O
were O
checked O
throughout O
the O
hospital O

 O
course O
and O
repleted O
accordingly O
. O
At O
the O
time O
of O
discharge O
the O

 O
patient O
was O
tolerating O
a O
regular O
diet O
and O
feeling O
well O
. O
  O
The O

 O
patient O
was O
afebrile O
with O
stable O
vital O
signs O
. O
  O
The O
patient O
's O

 O
hematocrit O
was O
acceptable O
and O
pain O
was O
adequately O
controlled O
on O

 O
an O
oral O
regimen O
. O
The O
operative O
extremity O
was O
neurovascularly O

 O
intact O
and O
the O
wound O
was O
benign O
. O



 O
The O
patient O
's O
weight-bearing O
status O
is O
weight O
bearing O
as O

 O
tolerated O
on O
the O
operative O
extremity O
. O


 O
Mr. O
[ O
* O
* O
Known O
lastname O
17922 O
* O
* O
] O
is O
discharged O
to O
rehab O
in O
stable O
condition O
. O


 O
[ O
* O
* O
Hospital O
Unit O
Name O
13533 O
* O
* O
] O
: O


 O
74 O
M O
with O
DM O
, O
HTN O
, O
CAD O
, O
Parkinson O
's O
s/p O
R O
TKR O
experienced O
low O
UOP O

 O
and O
AMS O
in O
PACU O
and O
transferred O
to O
MICU O
. O
AMS B-ADE
likely O
secondary O
to O

 O
narcotics B-DRUG
, I-DRUG
low O
urine O
output O
secondary O
to O
under-rescuscitation O
. O


 O
ACUTE O
ISSUES O
: O


 O
# O
Anemia B-REA
: I-REA
Received O
4L B-DOS
crystalloid B-DRUG
+ O
0.5L B-DOS
colloid B-DRUG
in O
the O
OR O

 O
during O
the O
procedure O
. O
He O
also O
received O
1 B-DOS
unit I-DOS
PRBCs B-DRUG
. I-DRUG
He O
was O

 O
given O
another O
1 B-DOS
un I-DOS
PRBCs B-DRUG
with O
lasix B-DRUG
upon O
arrival O
to O
the O
ICU O
. O
His O

 O
Hct O
responded O
appropriately O
with O
an O
increase O
from O
25.2 O
to O
28.8 O
. O


 O
# O
AMS B-ADE
: I-ADE
Pt O
was O
very O
somnolent B-ADE
on O
arrival O
but O
was O
arousable O
. O

 O
Attributed O
to O
a O
combination O
of O
narcotics B-DRUG
and O
underlying O

 O
Parkinson O
's O
disease O
. O
The O
patient O
had O
no O
focal O
neurologic O

 O
deficits O
so O
further O
imaging O
of O
the O
head O
was O
not O
obtained O
. O
He O

 O
became O
significantly O
more O
interactive O
throughout O
his O
course O
and O

 O
on O
transfer O
was O
at O
baseline O
. O


 O
# O
CAD/hyperlipidemia O
: O
Requires O
antiplatelet O
therapy O
s/p O
stents O
. O

 O
The O
patient O
's O
[ O
* O
* O
Hospital O
Unit O
Name O
* O
* O
] O
and O
[ O
* O
* O
Hospital O
Unit O
Name O
4532 O
* O
* O
] O
were O
restarted O
after O
consulting O

 O
with O
orthopedics O
. O


 O
# O
s/p O
TKR O
: O
Patient O
was O
in O
repositiong O
device O
during O
stay O
. O

 O
Started O
on O
Lovenox B-DRUG
for O
DVT B-REA
prophylaxis I-REA
. I-REA


 O
STABLE O
ISSUES O
: O


 O
# O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
/low O
UOP O
: O
Cr O
on O
admission O
was O
slightly O
higher O
than O
baseline O

 O
( O
1.3 O
vs O
1.0 O
- O
1.2 O
) O
. O
  O
The O
patient O
is O
s/p O
nephrectomy O
, O
which O

 O
combined O
with O
intraop O
blood O
loss O
probably O
contributed O
to O
his O

 O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
. O
Urine B-REA
output I-REA
responded O
to O
lasix B-DRUG


 I-DRUG
# O
DM2 B-REA
: I-REA
Patient O
was O
placed O
back O
on O
home O
insulin B-DRUG
at O
40 B-DOS
units I-DOS
of O

 O
70/30 B-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
and O
sliding B-DOS
scale I-DOS
. I-DOS
Sugars O
remained O
well O
controlled O
. O


 O
# O
HTN B-REA
: I-REA
SBPs O
were O
up O
to O
160s O
in O
MICU O
. O
The O
patient O
was O
restarted O

 O
on O
home O
metoprolol B-DRUG
dose O
. O
His O
home O
valsartan B-DRUG
and O
HCTZ B-DRUG
were O
held O

 O
pending O
followup O
creatinine O
. O
Cr O
remained O
stable O
at O
1.3 O
at O
the O

 O
time O
of O
transfer O
. O


 O
# O
Parkinson B-REA
's I-REA
: I-REA
Stable O
. O
Continued O
on O
home O
carbidopa-levodopa B-DRUG
. I-DRUG


 O
# O
BPH B-REA
: I-REA
Stable O
, O
home O
finasteride B-DRUG
and O
terazosin B-DRUG
continued O
. O


 O
TRANSITIONAL O
ISSUES O
: O
F/u O
outpatient O
as O
per O
ortho O
. O


 O
Medications O
on O
Admission O
: O

 O
[ O
* O
* O
Hospital1 O
* O
* O
] O
, O
diovan B-DRUG
, I-DRUG
HCTZ B-DRUG
, I-DRUG
insulin B-DRUG
, I-DRUG
carbidopa B-DRUG
, I-DRUG
levodopa B-DRUG
, I-DRUG
finasteride B-DRUG
, I-DRUG

 O
mirtazapine B-DRUG
, I-DRUG
clopidogrel B-DRUG
, I-DRUG
pravachol B-DRUG
, I-DRUG
hytrin B-DRUG
, I-DRUG
metoprolol B-DRUG



 I-DRUG

Discharge O
Medications O
: O

 O
1 O
. O
carbidopa-levodopa B-DRUG
25 B-STR
- I-STR
100 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
pravastatin B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
3 O
. O
metoprolol B-DRUG
succinate I-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Extended I-FOR
Release I-FOR
24 I-FOR
hr I-FOR

 I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
Extended I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
4 O
. O
clopidogrel B-DRUG
75 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
5 O
. O
omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
6 O
. O
acetaminophen B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q8H B-FRE
( I-FRE
every I-FRE

 I-FRE
8 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
7 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
bisacodyl B-DRUG
10 B-STR
mg I-STR
Suppository B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Suppository B-FOR
Rectal B-ROU

 I-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
10 O
. O
finasteride B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
11 O
. O
mirtazapine B-DRUG
7.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE
bedtime I-FRE

 I-FRE
as I-FRE
needed I-FRE
for O
insomnia B-REA
. I-REA

 O
12 O
. O
polyethylene B-DRUG
glycol I-DRUG
3350 I-DRUG
17 B-STR
gram I-STR
Powder B-FOR
in I-FOR
Packet I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Powder B-FOR
in I-FOR
Packet I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
13 O
. O
enoxaparin B-DRUG
40 B-STR
mg/0.4 I-STR
mL I-STR
Syringe B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
syringe B-FOR

 I-FOR
Subcutaneous B-ROU
once B-FRE
a I-FRE
day I-FRE
for B-DUR
4 I-DUR
weeks I-DUR
: I-DUR
Restart O
: O
[ O
* O
* O
2148 O
- O
7 O
- O
10 O
* O
* O
] O

 O
Last O
dose O
: O
[ O
* O
* O
2148 O
- O
7 O
- O
29 O
* O
* O
] O
. O

 O
14 O
. O
aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR

 I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
: I-FRE
[ O
* O
* O
Month O
( O
only O
) O
116 O
* O
* O
] O
resume O
325 B-STR
mg I-STR
daily B-FRE
after O
Lovenox B-DRUG
completed O
. O

 O
15 O
. O
oxycodone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
: I-REA
Hold O
for O
sedation B-ADE
or O
confusion B-ADE
. I-ADE

 O
Disp:*50 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
16 O
. O
insulin B-DRUG
NPH I-DRUG
& I-DRUG
regular I-DRUG
human I-DRUG
100 B-STR
unit/mL I-STR
( I-STR
70 I-STR
- I-STR
30 I-STR
) I-STR
Suspension B-FOR

 I-FOR
Sig O
: O
Forty B-DOS
( I-DOS
40 I-DOS
) I-DOS
units I-DOS
Subcutaneous B-ROU
twice B-FRE
a I-FRE
day I-FRE
: I-FRE
Home O
dose O
, O
but O

 O
has O
been O
held O
while O
inpatient O
[ O
* O
* O
2 O
- O
1 O
* O
* O
] O
poor O
appetite O
. O

 O

17 O
. O
terazosin B-DRUG
5 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE

 I-FRE
bedtime I-FRE
) I-FRE
: I-FRE
Dose O
increased O
from O
10 B-STR
mg I-STR
daily B-FRE
[ O
* O
* O
2 O
- O
1 O
* O
* O
] O
urinary B-REA
retention I-REA
. I-REA




 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
2558 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Right O
knee O
osteoarthritis O

 O
Urinary O
retention O

 O
Post-op O
anemia O
due O
to O
blood O
loss O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Out O
of O
Bed O
with O
assistance O
to O
chair O
or O

 O
wheelchair O
. O



 O
Discharge O
Instructions O
: O

 O
1 O
. O
Please O
return O
to O
the O
emergency O
department O
or O
notify O
your O

 O
physician O
if O
you O
experience O
any O
of O
the O
following O
: O
severe O
pain O

 O
not O
relieved O
by O
medication O
, O
increased O
swelling O
, O
decreased O

 O
sensation O
, O
difficulty O
with O
movement O
, O
fevers O
greater O
than O
101.5 O
, O

 O
shaking O
chills O
, O
increasing O
redness O
or O
drainage O
from O
the O
incision O

 O
site O
, O
chest O
pain O
, O
shortness O
of O
breath O
or O
any O
other O
concerns O
. O


 O
2 O
. O
Please O
follow O
up O
with O
your O
primary O
physician O
regarding O
this O

 O
admission O
and O
any O
new O
medications O
and O
refills O
. O


 O
3 O
. O
Resume O
your O
home O
medications O
unless O
otherwise O
instructed O
. O


 O
4 O
. O
You O
have O
been O
given O
medications O
for O
pain O
control O
. O
Please O
do O

 O
not O
drive O
, O
operate O
heavy O
machinery O
, O
or O
drink O
alcohol O
while O

 O
taking O
these O
medications O
. O
As O
your O
pain O
decreases O
, O
take O
fewer O

 O
tablets O
and O
increase O
the O
time O
between O
doses O
. O
This O
medication O
can O

 O
cause O
constipation B-REA
, I-REA
so O
you O
should O
drink O
plenty O
of O
water O
daily O

 O
and O
take O
a O
stool B-DRUG
softener I-DRUG
( O
such O
as O
colace B-DRUG
) I-DRUG
as O
needed O
to O
prevent O

 O
this O
side O
effect O
. O
  O
Call O
your O
surgeons O
office O
3 O
days O
before O
you O

 O
are O
out O
of O
medication O
so O
that O
it O
can O
be O
refilled O
. O
  O
These O

 O
medications O
can O
not O
be O
called O
into O
your O
pharmacy O
and O
must O
be O

 O
picked O
up O
in O
the O
clinic O
or O
mailed O
to O
your O
house O
. O
  O
Please O
allow O

 O
an O
extra O
2 O
days O
if O
you O
would O
like O
your O
medication O
mailed O
to O
your O

 O
home O
. O


 O
5 O
. O
You O
may O
not O
drive O
a O
car O
until O
cleared O
to O
do O
so O
by O
your O

 O
surgeon O
. O


 O
6 O
. O
Please O
keep O
your O
wounds O
clean O
. O
You O
may O
shower O
starting O
five O

 O
( O
5 O
) O
days O
after O
surgery O
, O
but O
no O
tub O
baths O
or O
swimming O
for O
at O

 O
least O
four O
( O
4 O
) O
weeks O
. O
No O
dressing O
is O
needed O
if O
wound O
continues O

 O
to O
be O
non-draining O
. O
Any O
stitches O
or O
staples O
that O
need O
to O
be O

 O
removed O
will O
be O
taken O
out O
at O
your O
follow-up O
visit O
in O
three O
( O
3 O
) O

 O
weeks O
after O
your O
surgery O
. O


 O
7 O
. O
Please O
call O
your O
surgeon O
's O
office O
to O
schedule O
or O
confirm O
your O

 O
follow-up O
appointment O
in O
three O
( O
3 O
) O
weeks O
. O



 O
8 O
. O
Please O
DO O
NOT O
take O
any O
non-steroidal O
anti-inflammatory O

 O
medications O
( O
NSAIDs O
such O
as O
celebrex B-DRUG
, I-DRUG
ibuprofen B-DRUG
, I-DRUG
advil B-DRUG
, I-DRUG
aleve B-DRUG
, I-DRUG

 O
motrin B-DRUG
, I-DRUG
etc O
) O
. O


 O
9 O
. O
ANTICOAGULATION B-REA
: I-REA
Please O
continue O
your O
lovenox B-DRUG
for B-DUR
four I-DUR
( I-DUR
4 I-DUR
) I-DUR

 I-DUR
weeks I-DUR
to O
help O
prevent B-REA
deep I-REA
vein I-REA
thrombosis I-REA
( I-REA
blood I-REA
clots I-REA
) I-REA
. I-REA
  O
If O

 O
you O
were O
taking O
aspirin B-DRUG
prior O
to O
your O
surgery O
, O
it O
is O
OK O
to O

 O
continue O
at O
your O
previous O
dose O
while O
taking O
this O
medication O
. O

 O
[ O
* O
* O
Male O
First O
Name O
( O
un O
) O
* O
* O
] O
STOCKINGS O
x O
6 O
WEEKS O
. O


 O
10 O
. O
WOUND O
CARE O
: O
Please O
keep O
your O
incision O
clean O
and O
dry O
. O
It O
is O

 O
okay O
to O
shower O
five O
days O
after O
surgery O
but O
no O
tub O
baths O
, O

 O
swimming O
, O
or O
submerging O
your O
incision O
until O
after O
your O
four O
( O
4 O
) O

 O
week O
checkup O
. O
Please O
place O
a O
dry O
sterile O
dressing O
on O
the O
wound O

 O
each O
day O
if O
there O
is O
drainage O
, O
otherwise O
leave O
it O
open O
to O
air O
. O

 O
Check O
wound O
regularly O
for O
signs O
of O
infection O
such O
as O
redness O
or O

 O
thick O
yellow O
drainage O
. O
Staples O
will O
be O
removed O
at O
your O
follow-up O

 O
visit O
in O
three O
( O
3 O
) O
weeks O
. O


 O
11 O
. O
VNA O
( O
once O
at O
home O
) O
: O
Home O
PT/OT O
, O
dressing O
changes O
as O

 O
instructed O
, O
and O
wound O
checks O
. O


 O
12 O
. O
ACTIVITY O
: O
Weight O
bearing O
as O
tolerated O
on O
the O
operative O

 O
extremity O
. O
Mobilize O
. O
CPM/ROM O
as O
tolerated O
. O
No O
strenuous O
exercise O

 O
or O
heavy O
lifting O
until O
follow O
up O
appointment O
. O
Left O
foot O
AFO O
at O

 O
all O
times O
when O
ambulating O
. O


 O
Physical O
Therapy O
: O

 O
RLE O
WBAT O

 O
Intensive O
ROM O

 O
CPM O
2 O
- O
3x/day O
for O
2hr O
sessions O
, O
maximum O
flexion O
as O
tolerated O

 O
Left O
foot O
AFO O
AAT O
when O
ambulating O

 O
Mobilize O
frequently O


 O
Treatments O
Frequency O
: O

 O
Dry O
sterile O
dressing O
daily O
as O
needed O
for O
drainage O

 O
Wound O
checks O

 O
Ice O
and O
elevation O

 O
TEDs O

 O
D/c O
foley O
catheter O
[ O
* O
* O
2148 O
- O
7 O
- O
13 O
* O
* O
] O
at O
6 O
am O
and O
repeat O
voiding O
trial O

 O
* O
Staples O
will O
be O
removed O
at O
follow-up O
appointment O
in O
3 O
weeks O
* O


 O
Followup O
Instructions O
: O

 O
Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Initial O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
, O
[ O
* O
* O
MD O
Number(3 O
) O
3261**]:[**Telephone/Fax O
( O
1 O
) O
1228 O
* O
* O
] O

 O
Date/Time:[**2148 O
- O
7 O
- O
23 O
* O
* O
] O
3:00 O


 O
Provider O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
396 O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
M.D. O
Phone:[**Telephone/Fax O
( O
1 O
) O
31415 O
* O
* O
] O

 O
Date/Time:[**2148 O
- O
11 O
- O
12 O
* O
* O
] O
4:00 O



 O
Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
2908 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
62 O
* O
* O
] O

 O
Date/Time:[**2149 O
- O
2 O
- O
5 O
* O
* O
] O
4:00 O




 O
Completed O
by:[**2148 O
- O
7 O
- O
9 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2120 O
- O
8 O
- O
30 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2120 O
- O
9 O
- O
15 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2051 O
- O
9 O
- O
25 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
CARDIOTHORACIC O


 O
Allergies O
: O

 O
aspirin B-DRUG
/ O
Codeine B-DRUG
/ O
Penicillins B-DRUG
/ O
Iodine B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
165 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Chest O
Pain O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
2 O
* O
* O
] O
Cardiac O
Cath O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
5 O
* O
* O
] O
Urgent O
coronary O
artery O
bypass O
graft O
x5 O
: O
  O
Left O
internal O

 O
mammary O
artery O
to O
left O
anterior O
descending O
artery O
and O
saphenous O

 O
vein O
grafts O
to O
diagonal O
ramus O
obtuse O
marginal O
and O
posterior O

 O
descending O
arteries O


 O
History O
of O
Present O
Illness O
: O

 O
68 O
year O
old O
male O
with O
insulin B-DRUG
dependent O
DM B-REA
, I-REA
HTN O
, O
obesity O

 O
admitted O
to O
CCU O
for O
aspirin B-DRUG
desensitization O
in O
setting O
of O
chest O

 O
pain O
with O
exertion O
over O
past O
week O
. O
Symptoms O
started O
1 O
week O
ago O

 O
with O
substernal O
chest O
pain O
while O
carying O
luggage O
to O
cruise O
ship O

 O
- O
substernal/dull O
, O
radiates O
to O
abdomen O
" O
like O
ruler O
" O
, O
occurs O

 O
during O
exertion O
. O
Resolved O
with O
rest O
. O
Then O
tried O
to O
exert O
himself O

 O
again O
throughout O
week O
, O
but O
developed O
same O
chest O
pain O
. O
He O
has O

 O
been O
" O
taking O
it O
slowly O
" O
, O
however O
, O
still O
gets O
symptoms O
with O

 O
decreasing O
amount O
of O
exertion O
. O
New O
symptom O
for O
him O
. O
Denies O

 O
peripheral O
edema O
, O
palpitations O
, O
syncope O
. O
Came O
to O
ED O
for O
eval O
. O
He O

 O
was O
found O
to O
have O
multivessel O
disease O
upon O
cardiac O

 O
catheterization O
and O
is O
now O
being O
referred O
to O
cardiac O
surgery O
for O

 O
revascularization O
. O


 O
Past O
Medical O
History O
: O

 O
Diabetes O

 O
Hypertension O

 O
Arthritis O

 O
Kidney O
Stones O

 O
Bullet O
wound O
to O
right O
leg O

 O
s/p O
Back O
surgery O

 O
s/p O
Right O
rotator O
cuff O
repair O


 O
Social O
History O
: O

 O
Race O
: O
Caucasian O

 O
Last O
Dental O
Exam:3 O
- O
4 O
months O
ago O

 O
Lives O
with O
: O
family O

 O
Contact:[**Name O
( O
NI O
) O
* O
* O
] O
( O
daughter O
) O

 O
Occupation O
: O
Retired O
prison O
crew O
manager O

 O
Cigarettes O
: O
Smoked O
no O
[ O
x O
] O
yes O
[ O
] O

 O
Other O
Tobacco O
use O
: O
denies O

 O
ETOH O
: O
< O
1 O
drink/week O
[ O
x O
] O
  O
[ O
* O
* O
1 O
- O
15 O
* O
* O
] O
drinks/week O
[ O
] O
> O
8 O
drinks/week O
[ O
] O

 O
Illicit O
drug O
use O
: O
denies O


 O
Family O
History O
: O

 O
Premature O
coronary O
artery O
disease- O
Brother O
deceased O
from O
sudden O

 O
cardiac O
death O
at O
58 O
. O
Father O
with O
MI O
in O
mid-70 O
's O


 O
Physical O
Exam O
: O

 O
Pulse:65 O
Resp:15 O
  O
O2 O
sat O
: O
99/RA O

 O
B/P O
  O
Right:176/103 O
    O
Left:147/71 O

 O
Height:6 O
' O
     O
Weight:260 O
lbs O



 O
General O
: O

 O
Skin O
: O
Dry O
[ O
x O
] O
intact O
[ O
x O
] O

 O
HEENT O
: O
PERRLA O
[ O
x O
] O
EOMI O
[ O
x O
] O

 O
Neck O
: O
  O
Supple O
[ O
x O
] O
Full O
ROM O
[ O
x O
] O

 O
Chest O
: O
Lungs O
clear O
bilaterally O
[ O
x O
] O

 O
Heart O
: O
RRR O
[ O
x O
] O
  O
Irregular O
[ O
] O
  O
Murmur O
[ O
] O
grade O
_ O
_ O
_ O
_ O
_ O
_ O

 O
Abdomen O
: O
Soft O
[ O
x O
] O
non-distended O
[ O
x O
] O
non-tender O
[ O
x O
] O
  O
bowel O
sounds O

 O
+ O
[ O
x O
] O

 O
Extremities O
: O
Warm O
[ O
x O
] O
, O
well-perfused O
[ O
x O
] O
  O
Edema O
[ O
] O
_ O
_ O
_ O
_ O
_ O

 O
Varicosities O
: O
None O
[ O
x O
] O

 O
Neuro O
: O
Grossly O
intact O
[ O
x O
] O

 O
Pulses O
: O

 O
Femoral O
      O
Right O
: O
palp O
  O
Left O
: O
palp O

 O
DP O
           O
Right O
: O
dop O
  O
Left O
: O
dop O

 O
PT O
           O
[ O
* O
* O
Name O
( O
NI O
) O
167 O
* O
* O
] O
: O
palp O
  O
Left O
: O
palp O

 O
Radial O
       O
Right O
: O
   O
Left O
: O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
9 O
* O
* O
] O
05:10AM O
BLOOD O
WBC-10.4 O
RBC-3.45 O
* O
Hgb-10.7 O
* O
Hct-30.2 O
* O

 O
MCV-88 O
MCH-31.0 O
MCHC-35.5 O
* O
RDW-13.2 O
Plt O
Ct-230 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
5 O
* O
* O
] O
01:04PM O
BLOOD O
PT-13.8 O
* O
PTT-33.7 O
INR(PT)-1.2 O
* O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
9 O
* O
* O
] O
05:10AM O
BLOOD O
Glucose-156 O
* O
UreaN-32 O
* O
Creat-1.3 O
* O
Na-136 O

 O
K-4.0 O
Cl-95 O
* O
HCO3 O
- O
31 O
AnGap-14 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
11 O
* O
* O
] O
06:24AM O
BLOOD O
WBC-8.1 O
RBC-3.52 O
* O
Hgb-10.6 O
* O
Hct-31.9 O
* O

 O
MCV-91 O
MCH-30.1 O
MCHC-33.3 O
RDW-12.8 O
Plt O
Ct-337 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
10 O
* O
* O
] O
12:50PM O
BLOOD O
WBC-9.9 O
RBC-3.62 O
* O
Hgb-10.8 O
* O
Hct-33.3 O
* O

 O
MCV-92 O
MCH-29.8 O
MCHC-32.5 O
RDW-13.1 O
Plt O
Ct-341 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
11 O
* O
* O
] O
06:24AM O
BLOOD O
Glucose-92 O
UreaN-34 O
* O
Creat-1.3 O
* O
Na-135 O

 O
K-4.0 O
Cl-95 O
* O
HCO3 O
- O
29 O
AnGap-15 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
10 O
* O
* O
] O
12:50PM O
BLOOD O
Glucose-140 O
* O
UreaN-33 O
* O
Creat-1.4 O
* O
Na-135 O

 O
K-4.2 O
Cl-94 O
* O
HCO3 O
- O
28 O
AnGap-17 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
9 O
* O
* O
] O
05:10AM O
BLOOD O
Glucose-156 O
* O
UreaN-32 O
* O
Creat-1.3 O
* O
Na-136 O

 O
K-4.0 O
Cl-95 O
* O
HCO3 O
- O
31 O
AnGap-14 O



 O
Findings O

 O
LEFT O
ATRIUM O
: O
No O
spontaneous O
echo O
contrast O
or O
thrombus O
in O
the O

 O
body O
of O
the O
[ O
* O
* O
Name O
Prefix O
( O
Prefixes O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Prefixes O
) O
* O
* O
] O
LAA O
. O
Good O
( O
> O
20 O
cm/s O
) O
LAA O
ejection O
velocity O
. O

 O
RIGHT O
ATRIUM/INTERATRIAL O
SEPTUM O
: O
PFO O
is O
present O
. O
Left-to-right O

 O
shunt O
across O
the O
interatrial O
septum O
at O
rest O
. O

 O
LEFT O
VENTRICLE O
: O
Normal O
LV O
wall O
thickness O
and O
cavity O
size O
. O

 O
Overall O
normal O
LVEF O
( O
> O
55 O
% O
) O
. O

 O
RIGHT O
VENTRICLE O
: O
Normal O
RV O
systolic O
function O
. O

 O
AORTA O
: O
Normal O
aortic O
diameter O
at O
the O
sinus O
level O
. O
Simple O

 O
atheroma O
in O
aortic O
arch O
. O
Simple O
atheroma O
in O
descending O
aorta O
. O

 O
AORTIC O
VALVE O
: O
Three O
aortic O
valve O
leaflets O
. O
No O
AS O
. O
No O
AR O
. O

 O
MITRAL O
VALVE O
: O
Mildly O
thickened O
mitral O
valve O
leaflets O
. O
Trivial O

 O
MR O
. O

 O
TRICUSPID O
VALVE O
: O
Normal O
tricuspid O
valve O
leaflets O
with O
trivial O

 O
TR O
. O

 O
PULMONIC O
VALVE/PULMONARY O
ARTERY O
: O
Pulmonic O
valve O
not O
visualized O
. O

 O
No O
PS O
. O
Physiologic O
PR O
. O

 O
PERICARDIUM O
: O
No O
pericardial O
effusion O
. O

 O
Conclusions O

 O
PRE-BYPASS O
: O

 O
-No O
spontaneous O
echo O
contrast O
or O
thrombus O
is O
seen O
in O
the O
body O
of O

 O
the O
left O
atrium O
or O
left O
atrial O
appendage O
. O

 O
-A O
small O
patent O
foramen O
ovale O
is O
present O
. O
A O
slight O
left-to-right O

 O
shunt O
across O
the O
interatrial O
septum O
is O
seen O
. O

 O
- O
Left O
ventricular O
wall O
thicknesses O
and O
cavity O
size O
are O
normal O
. O

 O
Overall O
left O
ventricular O
systolic O
function O
is O
normal O
( O
LVEF>55 O
% O
) O

 O
with O
normal O
free O
wall O
contractility O
. O

 O
-There O
are O
simple O
atheroma O
in O
the O
aortic O
arch O
. O
There O
are O
simple O

 O
atheroma O
in O
the O
descending O
thoracic O
aorta O
. O

 O
-There O
are O
three O
aortic O
valve O
leaflets O
. O
There O
is O
no O
aortic O
valve O

 O
stenosis O
. O
No O
aortic O
regurgitation O
is O
seen O
. O

 O
-The O
mitral O
valve O
leaflets O
are O
mildly O
thickened O
. O
Trivial O
mitral O

 O
regurgitation O
is O
seen O
. O

 O
-There O
is O
no O
pericardial O
effusion O
. O

 O
POSTBYPASS O
: O

 O
The O
patient O
is O
AV B-REA
paced I-REA
on O
low O
dose O
phenylephrine B-DRUG
infusion B-FOR
. I-FOR

 O
Biventricular O
funtion O
is O
maintained O
. O
The O
valves O
remain O

 O
unchanged O
. O
The O
aorta O
remains O
intact O
. O


 O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
CSURG O
FA6A O
[ O
* O
* O
2120 O
- O
9 O
- O
13 O
* O
* O
] O
10:28 O
AM O

 O
CHEST O
( O
PA O
& O
LAT O
) O
   O
Clip O
# O
[ O
* O
* O
Clip O
Number O
( O
Radiology O
) O
91676 O
* O
* O
] O

 O
Reason O
: O
eval O
for O
effusion O

  O
Final O
Report O

 O
PA O
LATERAL O
VIEWS O
OF O
THE O
CHEST O


 O
REASON O
FOR O
EXAM O
: O
Status O
post O
CABG O
. O



 O
Comparison O
is O
made O
with O
prior O
study O
performed O
the O
day O
earlier O
. O

 O
Mediastinal O
widening O
has O
improved O
. O
Cardiac O
size O
is O
top O
normal O
. O

 O
Right O
basilar O

 O
atelectasis O
has O
resolved O
. O
Small O
atelectasis O
in O
the O
left O
lower O

 O
lobe O
remain O
. O

 O
Bilateral O
pleural O
effusions O
are O
small O
. O
There O
is O
no O
evidence O
of O

 O
pneumothorax O
. O


 O
[ O
* O
* O
Hospital O
93 O
* O
* O
] O
MEDICAL O
CONDITION O
: O

    O
68 O
year O
old O
man O
with O
ileus/obstruction O

 O
REASON O
FOR O
THIS O
EXAMINATION O
: O

    O
eval O
ileus O


 O
Final O
Report O

 O
INDICATION O
: O
Question O
ileus O
or O
obstruction O
. O


 O
COMPARISON O
: O
Abdominal O
radiographs O
on O
[ O
* O
* O
2120 O
- O
9 O
- O
12 O
* O
* O
] O
. O


 O
FINDINGS O
: O
Six O
frontal O
views O
of O
the O
abdomen O
were O
obtained O
. O
Again O

 O
seen O
is O

 O
small O
bowel O
dilation O
, O
similar O
to O
yesterday O
's O
study O
, O
with O
air O

 O
again O
seen O
in O
the O
transverse O
colon O
. O
There O
is O
no O
evidence O
of O
free O

 O
air O
. O
There O
are O
scattered O
air-fluid O
levels O
seen O
. O
Again O
seen O
is O

 O
hyperostosis O
of O
the O
lumbar O
spine O
, O
consistent O
with O
DISH O
. O
Again O

 O
seen O
is O
a O
cluster O
of O
calcifications O
within O
the O
region O
of O
the O

 O
prostate O
likely O
representing O
prostate O
calcifications O
. O
There O
are O

 O
sternotomy O
wires O
in O
place O
. O


 O
IMPRESSION O
: O
Some O
small O
bowel O
dilation O
with O
air O
in O
the O
colon O
, O

 O
consistent O
with O

 O
ileus O
. O



 O
[ O
* O
* O
2120 O
- O
8 O
- O
30 O
* O
* O
] O
12:40PM O
BLOOD O
WBC-7.7 O
RBC-4.50 O
* O
Hgb-13.9 O
* O
Hct-40.2 O

 O
MCV-90 O
MCH-30.8 O
MCHC-34.5 O
RDW-12.6 O
Plt O
Ct-239 O

 O
[ O
* O
* O
2120 O
- O
8 O
- O
31 O
* O
* O
] O
05:18AM O
BLOOD O
WBC-6.4 O
RBC-4.39 O
* O
Hgb-13.2 O
* O
Hct-38.1 O
* O

 O
MCV-87 O
MCH-30.1 O
MCHC-34.6 O
RDW-13.2 O
Plt O
Ct-189 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
1 O
* O
* O
] O
05:55AM O
BLOOD O
WBC-7.2 O
RBC-4.43 O
* O
Hgb-13.4 O
* O
Hct-39.9 O
* O

 O
MCV-90 O
MCH-30.4 O
MCHC-33.7 O
RDW-13.0 O
Plt O
Ct-185 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
2 O
* O
* O
] O
06:45AM O
BLOOD O
WBC-7.4 O
RBC-4.41 O
* O
Hgb-13.9 O
* O
Hct-39.3 O
* O

 O
MCV-89 O
MCH-31.5 O
MCHC-35.4 O
* O
RDW-13.3 O
Plt O
Ct-201 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
3 O
* O
* O
] O
02:40AM O
BLOOD O
WBC-9.1 O
RBC-4.16 O
* O
Hgb-12.6 O
* O
Hct-36.6 O
* O

 O
MCV-88 O
MCH-30.3 O
MCHC-34.4 O
RDW-13.2 O
Plt O
Ct-200 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
4 O
* O
* O
] O
07:15AM O
BLOOD O
WBC-11.0 O
RBC-4.25 O
* O
Hgb-13.3 O
* O
Hct-37.6 O
* O

 O
MCV-89 O
MCH-31.4 O
MCHC-35.5 O
* O
RDW-13.3 O
Plt O
Ct-192 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
6 O
* O
* O
] O
02:05AM O
BLOOD O
WBC-12.2 O
* O
RBC-3.70 O
* O
Hgb-11.0 O
* O
Hct-32.9 O
* O

 O
MCV-89 O
MCH-29.9 O
MCHC-33.6 O
RDW-13.2 O
Plt O
Ct-171 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
8 O
* O
* O
] O
05:29AM O
BLOOD O
WBC-13.4 O
* O
RBC-3.46 O
* O
Hgb-10.6 O
* O
Hct-29.8 O
* O

 O
MCV-86 O
MCH-30.6 O
MCHC-35.6 O
* O
RDW-13.3 O
Plt O
Ct-213 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
10 O
* O
* O
] O
12:50PM O
BLOOD O
WBC-9.9 O
RBC-3.62 O
* O
Hgb-10.8 O
* O
Hct-33.3 O
* O

 O
MCV-92 O
MCH-29.8 O
MCHC-32.5 O
RDW-13.1 O
Plt O
Ct-341 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
11 O
* O
* O
] O
06:24AM O
BLOOD O
WBC-8.1 O
RBC-3.52 O
* O
Hgb-10.6 O
* O
Hct-31.9 O
* O

 O
MCV-91 O
MCH-30.1 O
MCHC-33.3 O
RDW-12.8 O
Plt O
Ct-337 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
12 O
* O
* O
] O
05:50AM O
BLOOD O
WBC-7.2 O
RBC-3.44 O
* O
Hgb-10.6 O
* O
Hct-30.1 O
* O

 O
MCV-88 O
MCH-30.7 O
MCHC-35.0 O
RDW-12.7 O
Plt O
Ct-308 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
13 O
* O
* O
] O
09:34AM O
BLOOD O
WBC-7.2 O
RBC-3.76 O
* O
Hgb-11.1 O
* O
Hct-34.7 O
* O

 O
MCV-92 O
MCH-29.6 O
MCHC-32.1 O
RDW-12.8 O
Plt O
Ct-396 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
14 O
* O
* O
] O
07:15AM O
BLOOD O
WBC-7.8 O
RBC-3.41 O
* O
Hgb-10.1 O
* O
Hct-30.5 O
* O

 O
MCV-90 O
MCH-29.8 O
MCHC-33.3 O
RDW-12.2 O
Plt O
Ct-323 O

 O
[ O
* O
* O
2120 O
- O
8 O
- O
30 O
* O
* O
] O
12:40PM O
BLOOD O
Neuts-55.1 O
Lymphs-36.0 O
Monos-5.6 O
Eos-2.6 O

 O
Baso-0.7 O

 O
[ O
* O
* O
2120 O
- O
8 O
- O
30 O
* O
* O
] O
12:40PM O
BLOOD O
PT-11.1 O
PTT-22.3 O
INR(PT)-0.9 O

 O
[ O
* O
* O
2120 O
- O
8 O
- O
30 O
* O
* O
] O
12:40PM O
BLOOD O
Plt O
Ct-239 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
14 O
* O
* O
] O
07:15AM O
BLOOD O
Plt O
Ct-323 O

 O
[ O
* O
* O
2120 O
- O
8 O
- O
30 O
* O
* O
] O
12:40PM O
BLOOD O
Glucose-96 O
UreaN-30 O
* O
Creat-1.1 O
Na-141 O

 O
K-4.6 O
Cl-106 O
HCO3 O
- O
27 O
AnGap-13 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
9 O
* O
* O
] O
05:10AM O
BLOOD O
Glucose-156 O
* O
UreaN-32 O
* O
Creat-1.3 O
* O
Na-136 O

 O
K-4.0 O
Cl-95 O
* O
HCO3 O
- O
31 O
AnGap-14 O

 O

[ O
* O
* O
2120 O
- O
9 O
- O
10 O
* O
* O
] O
12:50PM O
BLOOD O
Glucose-140 O
* O
UreaN-33 O
* O
Creat-1.4 O
* O
Na-135 O

 O
K-4.2 O
Cl-94 O
* O
HCO3 O
- O
28 O
AnGap-17 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
11 O
* O
* O
] O
06:24AM O
BLOOD O
Glucose-92 O
UreaN-34 O
* O
Creat-1.3 O
* O
Na-135 O

 O
K-4.0 O
Cl-95 O
* O
HCO3 O
- O
29 O
AnGap-15 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
12 O
* O
* O
] O
05:50AM O
BLOOD O
Glucose-98 O
UreaN-29 O
* O
Creat-1.2 O
Na-139 O

 O
K-4.1 O
Cl-99 O
HCO3 O
- O
29 O
AnGap-15 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
13 O
* O
* O
] O
09:34AM O
BLOOD O
Glucose-70 O
UreaN-21 O
* O
Creat-1.2 O
Na-138 O

 O
K-4.1 O
Cl-99 O
HCO3 O
- O
27 O
AnGap-16 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
14 O
* O
* O
] O
07:15AM O
BLOOD O
Glucose-73 O
UreaN-18 O
Creat-1.1 O
Na-140 O

 O
K-4.1 O
Cl-104 O
HCO3 O
- O
25 O
AnGap-15 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
15 O
* O
* O
] O
07:10AM O
BLOOD O
UreaN-17 O
Creat-1.0 O
Na-138 O
K-4.1 O
Cl-102 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
10 O
* O
* O
] O
12:50PM O
BLOOD O
ALT-19 O
AST-30 O
LD(LDH)-266 O
* O
AlkPhos-51 O

 O
Amylase-23 O
TotBili-0.8 O

 O
[ O
* O
* O
2120 O
- O
8 O
- O
30 O
* O
* O
] O
12:40PM O
BLOOD O
cTropnT-<0.01 O

 O
[ O
* O
* O
2120 O
- O
8 O
- O
30 O
* O
* O
] O
10:38PM O
BLOOD O
cTropnT-<0.01 O

 O
[ O
* O
* O
2120 O
- O
8 O
- O
31 O
* O
* O
] O
05:18AM O
BLOOD O
cTropnT-<0.01 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
5 O
* O
* O
] O
05:50PM O
BLOOD O
cTropnT-0.46 O
* O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
6 O
* O
* O
] O
02:05AM O
BLOOD O
CK-MB-18 O
* O
MB O
Indx-4.6 O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
6 O
* O
* O
] O
02:06AM O
BLOOD O
cTropnT-0.34 O
* O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
7 O
* O
* O
] O
04:08AM O
BLOOD O
cTropnT-0.31 O
* O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
9 O
* O
* O
] O
05:10AM O
BLOOD O
cTropnT-0.27 O
* O

 O
[ O
* O
* O
2120 O
- O
9 O
- O
3 O
* O
* O
] O
02:40AM O
BLOOD O
% O
HbA1c-6.7 O
* O
eAG-146 O
* O

 O
[ O
* O
* O
2120 O
- O
8 O
- O
31 O
* O
* O
] O
05:18AM O
BLOOD O
Triglyc-168 O
* O
HDL-44 O
CHOL/HD-3.6 O

 O
LDLcalc-80 O
LDLmeas-96 O



 O
Brief O
Hospital O
Course O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
4281 O
* O
* O
] O
presented O
to O
the O
ED O
with O
chest O
pain O
. O
He O
was O

 O
appropriately O
medically O
managed O
and O
admitted O
for O
further O

 O
work-up O
. O
He O
underwent O
a O
cardiac O
cath O
on O
[ O
* O
* O
9 O
- O
2 O
* O
* O
] O
which O
revealed O

 O
severe O
three O
vessel O
coronary B-REA
artery I-REA
disease I-REA
. I-REA
He O
underwent O

 O
pre-operative O
work-up O
and O
on O
[ O
* O
* O
9 O
- O
5 O
* O
* O
] O
was O
brought O
to O
the O
operating O

 O
room O
where O
he O
underwent O
a O
coronary O
artery O
bypass O
graft O
x O
5 O
( O
Left O

 O
internal O
mammary O
artery O
to O
left O
anterior O
descending O
artery O
and O

 O
saphenous O
vein O
grafts O
to O
diagonal O
ramus O
obtuse O
marginal O
and O

 O
posterior O
descending O
arteries O
) O
. O
Please O
see O
operative O
report O
for O

 O
surgical O
details O
. O
Following O
surgery O
he O
was O
transferred O
to O
the O

 O
CVICU O
for O
invasive O
monitoring O
intubated O
and O
sedated O
in O
stable O

 O
condition O
. O
Later O
this O
day O
he O
was O
weaned O
from O
sedation O
, O
awoke O

 O
neurologically O
intact O
and O
extubated O
. O
On O
post-op O
day O
one O
he O
was O

 O
started O
on O
beta-blockers/ B-DRUG
statin/aspirin/diuretics B-DRUG
and O
gently O

 O
diuresed O
towards O
his O
pre-op O
weight O
. O
Chest O
tubes O
and O
epicardial O

 O
pacing O
wires O
were O
removed O
per O
protocol O
. O
Later O
on O
this O
day O
he O
was O

 O
transferred O
to O
the O
step-down O
floor O
for O
further O
care O
. O
Physical O

 O
Therapy O
was O
consulted O
for O
evaluation O
of O
strength O
and O
mobility O

 O
and O
cleared O
him O
safe O
to O
return O
to O
home O
with O
VNA O
services O
when O

 O
ready O
. O
He O
did O
have O
some O
abdominal O
pain O
, O
nausea O
and O
abdominal O

 O
distention O
on O
post O
operative O
day O
4 O
. O
A O
KUB O
showed O
marked O
small O

 O
bowel O
dilation O
with O
air-fluid O
levels O
concerning O
for O
small O
bowel O

 O
obstruction O
. O
  O
All O
liver O
function O
tests O
and O
amylase/ O
lipase O
were O

 O
essentially O
normal O
. O
  O
His O
Lasix B-DRUG
was O
stopped O
, O
IVF B-DRUG
was O
given O
and O

 O
his O
abdominal O
pain O
slowly O
resolved O
. O
Repeat O
KUB O
showed O
ileus O
. O
  O
At O

 O
the O
time O
of O
discharge O
he O
was O
ambulating O
without O
difficulty O
, O

 O
passing O
flatus O
and O
stool O
, O
tolerating O
a O
regular O
oral O
diet O
and O
his O

 O
incisions O
were O
healing O
well O
. O
  O
The O
remainder O
of O
his O
hospital O

 O
course O
was O
essentially O
uneventful O
. O
He O
continued O
to O
progress O
and O

 O
was O
cleared O
for O
discharge O
to O
home O
with O
VNA O
on O
POD O
17 O
. O
All O
follow O

 O
up O
appointments O
were O
advised O
. O



 O
Medications O
on O
Admission O
: O

 O
- O
Metformin B-DRUG
1000 B-STR
mg I-STR
qam B-FRE

 I-FRE
- O
Humalin-N B-DRUG
30 B-DOS
units I-DOS
daily B-FRE

 I-FRE
- O
Humalin-R B-DRUG
30 B-DOS
units I-DOS
daily B-FRE

 I-FRE
- O
Lisinopril B-DRUG
20 B-DOS
daily B-FRE

 I-FRE
- O
paroxetine B-DRUG
20 B-DOS
daily B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
atorvastatin B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s B-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O

 O
2 O
. O
paroxetine B-DRUG
HCl I-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s B-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O

 O
3 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Capsule(s B-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O

 O
4 O
. O
aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
(E.C.)(s I-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O

 O
5 O
. O
omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C.)(s I-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O

 O
6 O
. O
metformin B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s B-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O

 O
7 O
. O
acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE

 I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
, I-REA
fever B-REA
. I-REA

 O
8 O
. O
metoprolol B-DRUG
tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s B-FOR
) I-FOR
* I-FOR
Refills:*2 O
* O

 O
9 O
. O
senna B-DRUG
8.6 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
: I-FRE

 O
hold O
for O
loose O
stools O
. O

 O
10 O
. O
glucometer O
  O
Sig O
: O
One O
( O
1 O
) O
   O
four O
times O
a O
day O
: O
Glucometer O
for O

 O
home O
monitoring O
. O

 O
Disp:*1 O
meter O
* O
Refills:*0 O
* O

 O
11 O
. O
test O
strips O
  O
Sig O
: O
One O
( O
1 O
) O
   O
four O
times O
a O
day O
. O

 O
Disp:*1 O
box O
* O
Refills:*2 O
* O

 O
12 O
. O
insulin B-DRUG
regular I-DRUG
human I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
Fifteen B-DOS
( I-DOS
15 I-DOS
) I-DOS

 I-DOS
units I-DOS
Injection B-ROU
every B-FRE
morning I-FRE
: I-FRE
[ O
* O
* O
Month O
( O
only O
) O
116 O
* O
* O
] O
need O
to O
increase O
to O
30 B-DOS
units I-DOS

 I-DOS
when O
oral O
intake O
better O
. O

 O
13 O
. O
Humulin B-DRUG
N I-DRUG
100 B-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Fifteen B-DOS
( I-DOS
15 I-DOS
) I-DOS
units I-DOS

 I-DOS
Subcutaneous B-ROU
every B-FRE
  I-FRE
morning I-FRE
: I-FRE
[ O
* O
* O
Month O
( O
only O
) O
116 O
* O
* O
] O
need O
to O
increase O
to O
30 B-DOS
units I-DOS

 I-DOS
when O
oral O
intake O
back O
to O
normal O
. O

 O
14 O
. O
furosemide B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE

 I-FRE
for B-DUR
5 I-DUR
days I-DUR
. I-DUR

 O
Disp:*5 O
Tablet(s B-FOR
) I-FOR
* I-FOR
Refills:*0 O
* O

 O
15 O
. O
potassium B-DRUG
chloride I-DRUG
10 B-STR
mEq I-STR
Tablet B-FOR
Extended I-FOR
Release I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
Extended I-FOR
Release I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
for B-DUR
5 I-DUR
days I-DUR
. I-DUR

 O
Disp:*5 O
Tablet B-FOR
Extended I-FOR
Release(s I-FOR
) I-FOR
* I-FOR
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O



 O
Facility O
: O

 O
Community O
Nurse O
[ O
* O
* O
First O
Name O
( O
Titles O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Titles O
) O
* O
* O
] O
Care O
, O
Inc O


 O
Discharge O
Diagnosis O
: O

 O
Coronary O
artery O
disease O
s/p O
coronary O
artery O
bypass O
graft O
x O
5 O

 O
Past O
medical O
history O
: O

 O
Diabetes O

 O
Hypertension O

 O
Arthritis O

 O
Kidney O
Stones O

 O
Bullet O
wound O
to O
right O
leg O

 O
s/p O
Back O
surgery O

 O
s/p O
Right O
rotator O
cuff O
repair O


 O
Discharge O
Condition O
: O

 O
Alert O
and O
oriented O
x3 O
nonfocal O

 O
Ambulating O
with O
steady O
gait O

 O
Incisional B-REA
pain I-REA
managed O
with O
oral B-ROU
analgesia B-DRUG

 I-DRUG
Incisions O
: O

 O
Sternal O
- O
healing O
well O
, O
no O
erythema O
or O
drainage O

 O
Leg O
Left O
- O
healing O
well O
, O
no O
erythema O
or O
drainage O
. O

 O
Trace O
Edema O



 O
Discharge O
Instructions O
: O

 O
Please O
shower O
daily O
including O
washing O
incisions O
gently O
with O
mild O

 O
soap O
, O
no O
baths O
or O
swimming O
until O
cleared O
by O
surgeon O
. O
Look O
at O

 O
your O
incisions O
daily O
for O
redness O
or O
drainage O

 O
Please O
NO O
lotions O
, O
cream O
, O
powder O
, O
or O
ointments O
to O
incisions O

 O
Each O
morning O
you O
should O
weigh O
yourself O
and O
then O
in O
the O
evening O

 O
take O
your O
temperature O
, O
these O
should O
be O
written O
down O
on O
the O
chart O


 O
No O
driving O
for O
approximately O
one O
month O
and O
while O
taking O

 O
narcotics O
, O
will O
be O
discussed O
at O
follow O
up O
appointment O
with O

 O
surgeon O
when O
you O
will O
be O
able O
to O
drive O

 O
No O
lifting O
more O
than O
10 O
pounds O
for O
10 O
weeks O

 O
Please O
call O
with O
any O
questions O
or O
concerns O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O


 O
* O
* O
Please O
call O
cardiac O
surgery O
office O
with O
any O
questions O
or O

 O
concerns O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O
. O
Answering O
service O
will O
contact O
on O
call O

 O
person O
during O
off O
hours O
* O
* O


 O
Followup O
Instructions O
: O

 O
You O
are O
scheduled O
for O
the O
following O
appointments O

 O
Surgeon O
: O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
Phone:[**Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O
Date/Time:[**2120 O
- O
10 O
- O
7 O
* O
* O
] O
at O

 O
1:30pm O
in O
the O
[ O
* O
* O
Hospital O
* O
* O
] O
Medical O
office O
building O
[ O
* O
* O
Hospital O
Unit O
Name O
* O
* O
] O

 O
Cardiologist O
: O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
8098 O
* O
* O
] O
on O
[ O
* O
* O
10 O
- O
7 O
* O
* O
] O
at O
1:15pm O

 O
WOUND O
CARE O
NURSE O
Phone:[**Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O
Date/Time:[**2120 O
- O
9 O
- O
17 O
* O
* O
] O
at O
10:15 O

 O
at O
[ O
* O
* O
Last O
Name O
( O
un O
) O
2577 O
* O
* O
] O
building O
[ O
* O
* O
Hospital O
Unit O
Name O
* O
* O
] O


 O
Please O
call O
to O
schedule O
appointments O
with O
your O

 O
Primary O
Care O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
39008 O
* O
* O
] O
in O
[ O
* O
* O
12 O
- O
10 O
* O
* O
] O
weeks O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
57082 O
* O
* O
] O


 O
* O

* O
Please O
call O
cardiac O
surgery O
office O
with O
any O
questions O
or O

 O
concerns O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O
. O
Answering O
service O
will O
contact O
on O
call O

 O
person O
during O
off O
hours O
* O
* O



                              O
[ O
* O
* O
Name6 O
( O
MD O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(2 O
) O
173 O
* O
* O
] O


 O
Completed O
by:[**2120 O
- O
9 O
- O
15 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2147 O
- O
5 O
- O
6 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2147 O
- O
5 O
- O
11 O
* O
* O
] O



 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1828 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
low O
HCT O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
EGD O
with O
epinephrine B-DRUG
and O
clipping O
, O
[ O
* O
* O
2147 O
- O
5 O
- O
8 O
* O
* O
] O



 O
History O
of O
Present O
Illness O
: O

 O
Pt O
is O
a O
85 O
yo O
female O
with O
a O
Hx O
significant O
for O
A-fib B-REA
on O
aspirin B-DRUG

 I-DRUG
325BID B-FRE
, I-FRE
who O
presented O
to O
OSH O
with O
a O
HCT O
of O
16 O
and O
report O
per O
son O

 O
that O
patient O
had O
experienced O
increased O
fatigue O
and O
unsteady O
gait O

 O
yesterday O
. O
with O
two O
episodes O
of O
near O
syncope O
since O
than O
. O
NP O
saw O

 O
pt O
and O
had O
discovered O
low O
BP O
and O
recommended O
transfer O
to O
ED O

 O
given O
her O
low O
BP O
and O
weakness O
. O
No O
other O
complains O
or O
symptoms O

 O
had O
been O
endorsed O
. O
She O
was O
taken O
to O
[ O
* O
* O
Hospital1 O
2025 O
* O
* O
] O
and O
was O
transfered O

 O
without O
prior O
transfusion O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
based O
on O
family O
request O
. O

 O
. O

 O
ROS O
: O
pt O
denies O
categorically O
any O
complain O



 O
Past O
Medical O
History O
: O

 O
[ O
* O
* O
Name O
( O
NI O
) O
17584 O
* O
* O
] O
, O
unclear O
why O
not O
on O
anticoagulation O
, O
no O
history O
of O
falls O

 O
Dementia O

 O
Incontinence O

 O
Arthritis O

 O
. O



 O
Social O
History O
: O

  O
lives O
with O
husband O
at O
assisted O
[ O
* O
* O
First O
Name9 O
( O
NamePattern2 O
) O
62680 O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
walks O
with O

 O
walker O
, O
no O
tobacco O
or O
alcohol O
abuse O


 O
Physical O
Exam O
: O

 O
T O
99.4 O
BP O
: O
108/33 O
HR O
77 O
SPO2 O
100 O
% O
3L O

 O
General O
: O
pale O
appearing O
female O
in O
NAD O
, O
AOx1 O
, O
flat O
affect O

 O
HEENT O
: O
pale O
conjunctiva O
, O
dry O
MM O
, O
no O
dentition O

 O
Neck O
: O
supple O
, O
no O
LAD O

 O
Lungs O
: O
CTA O
bilaterally O

 O
Heart O
: O
RRR O
, O
no O
m/r/g O

 O
Abdomen O
: O
obese O
, O
soft O
, O
epigastric O
tenderness O

 O
Extremities O
: O
cool O
, O
without O
clubbing O
or O
edema O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2147 O
- O
5 O
- O
6 O
* O
* O
] O
03:45PM O
   O
WBC-17.5 O
* O
# O
RBC-1.92 O
* O
# O
HGB-5.9 O
* O
# O
HCT-18.5 O
* O
# O

 O
MCV-96 O
MCH-30.7 O
MCHC-31.9 O
RDW-14.7 O

 O
[ O
* O
* O
2147 O
- O
5 O
- O
6 O
* O
* O
] O
03:45PM O
   O
NEUTS-82.0 O
* O
LYMPHS-14.7 O
* O
MONOS-2.8 O
EOS-0.3 O

 O
BASOS-0.3 O

 O
[ O
* O
* O
2147 O
- O
5 O
- O
6 O
* O
* O
] O
08:30PM O
   O
GLUCOSE-113 O
* O
UREA O
N-73 O
* O
CREAT-1.2 O
* O
SODIUM-140 O

 O
POTASSIUM-4.3 O
CHLORIDE-111 O
* O
TOTAL O
CO2 O
- O
20 O
* O
ANION O
GAP-13 O

 O
. O


 O
EGD O
( O
[ O
* O
* O
2147 O
- O
5 O
- O
8 O
* O
* O
] O
) O

 O
Esophagus O
: O

 O
Lumen O
: O
A O
complex O
, O
sliding O
, O
medium O
paraesophageal O
hernia O
was O

 O
seen O
. O

 O
Stomach O
: O
Normal O
stomach O
. O

 O
Duodenum O
: O
Excavated O
Lesions O
. O
A O
single O
cratered O
ulcer O
was O
found O

 O
in O
the O
duodenal O
bulb O
. O
A O
clot O
suggested O
recent O
bleeding O
. O
4 O

 O
cc O
. O
Epinephrine B-DRUG
1/[**Numeric O
Identifier O
961 O
* O
* O
] O
hemostasis B-REA
with O
success O
. O
[ O
* O
* O
Hospital1 O
* O
* O
] O
-CAP O

 O
Electrocautery O
was O
applied O
for O
hemostasis O
successfully O
. O
A O
single O

 O
superficial O
ulcer O
was O
found O
in O
the O
distal O
bulb O
. O
A O
visible O
vessel O

 O
suggested O
recent O
bleeding O
. O
4 O
cc O
. O
Epinephrine B-DRUG
1/[**Numeric O
Identifier O
961 O
* O
* O
] O
hemostasis B-REA

 I-REA
with O
success O
. O
A O
hemoclip O
was O
then O
applied O
to O
the O
visible O
vessel O
. O



 O
Brief O
Hospital O
Course O
: O

 O
MICU O
course O
: O
2 O
large-bore O
IVs O
were O
placed O
. O
The O
pt O
's O
ASA B-DRUG
, I-DRUG
BB B-DRUG
, I-DRUG

 O
ACEi B-DRUG
and O
Lasix B-DRUG
were O
held O
. O
She O
had O
no O
further O
BMs O
or O
melena O
. O
She O

 O
remained O
HD O
stable O
with O
SBP O
in O
110s O
and O
HR O
in O
70s O
after O
initial O

 O
2L B-DOS
NS B-DRUG
bolus B-DOS
. I-DOS
She O
was O
transiently O
on O
a O
PPI B-DRUG
drip B-ROU
and O
was O

 O
transfused O
a O
total O
of O
4U O
with O
HCT O
coming O
up O
to O
27 O
from O
18 O
. O
Her O

 O
HCT O
remained O
stable O
after O
these O
initial O
4 O
units O
. O

 O
. O

 O
GI O
did O
not O
feel O
that O
the O
pt O
was O
still O
actively O
bleeding O
, O
thus O
no O

 O
urgent O
scope O
was O
performed O
in O
the O
MICU O
. O
She O
was O
switched O
to O
PPI B-DRUG

 I-DRUG
IV B-ROU
bid B-FRE
and O
started O
on O
clears O
which O
she O
tolerated O
well O
. O
The O
pt O

 O
was O
transferred O
to O
the O
medicine O
floor O
for O
further O
management O
. O

 O
. O

 O
Floor O
Course O
: O

 O
# O
GI B-REA
bleed I-REA
: I-REA
The O
pt O
required O
a O
total O
of O
7 B-DOS
units I-DOS
pRBCs B-DRUG
to O
maintain O

 O
her O
HCT O
over O
her O
hospital O
course O
. O
She O
had O
an O
EGD O
performed O
by O
GI O

 O
which O
demonstrated O
a O
single O
cratered O
ulcer O
in O
the O
duodenal O
bulb O

 O
with O
stigmata O
of O
recent O
bleeding O
. O
This O
was O
injected B-FOR
with O

 O
epinephrine B-DRUG
and O
clipped O
; O
GI O
indicated O
that O
a O
risk O
of O
rebleeding O

 O
remained O
. O
The O
pt O
was O
treated O
with O
a O
Protonix B-DRUG
gtt B-ROU
for O
> B-DUR
48 I-DUR
hours I-DUR

 I-DUR
and O
then O
transitioned O
to O
PO B-ROU
therapy O
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O
The O
pt O
's O
HCT O
was O
stable O

 O
for O
the O
remainder O
of O
her O
[ O
* O
* O
Hospital O
62681 O
* O
* O
] O
hospital O
stay O
at O

 O
around O
27 O
to O
28 O
. O
The O
pt O
's O
antihypertensives B-DRUG
were O
held O
in O
this O

 O
setting O
and O
her O
blood B-REA
pressure I-REA
was O
well-controlled O
with O
only O

 O
diltiazem B-DRUG
. I-DRUG
The O
pt O
's O
home O
aspirin B-DRUG
was O
held O
. O

 O
. O


 O
# O
A-fib/SVT B-REA
: I-REA
At O
the O
time O
of O
admission O
, O
the O
pt O
was O
taking O
ASA B-DRUG
325 B-STR

 I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
for O
her O
prior O
history O
of O
PAF O
; O
this O
was O
stopped O
at O
the O
time O

 O
of O
admission O
. O
In O
the O
setting O
of O
having O
her O
beta B-DRUG
blocker I-DRUG
held O
, O

 O
the O
pt O
was O
noted O
to O
have O
several O
episodes O
of O
AF O
with O
RVR O
( O
HR O
to O

 O
the O
140s O
) O
, O
as O
well O
as O
two O
episodes O
of O
SVT O
( O
HR O
again O
to O
140s O
) O

 O
that O
was O
thought O
to O
likely O
represent O
AVNRT O
. O
All O
of O
these O

 O
episodes O
were O
asymptomatic O
for O
her O
and O
she O
remained O
HD O
stable O
. O
A O

 O
TSH O
and O
CXR O
were O
checked O
and O
were O
unremarkable O
. O
Although O
the O

 O
pt O
's O
HR O
responded O
well O
to O
re-initiation O
of O
her O
beta B-DRUG
blocker I-DRUG
, I-DRUG

 O
this O
did O
not O
suppress O
her O
SVT B-REA
, I-REA
and O
thus O
her O
beta B-DRUG
blocker I-DRUG
was O

 O
transitioned O
to O
PO B-ROU
diltiazem B-DRUG
. I-DRUG
At O
the O
time O
of O
discharge O
, O
she O
had O

 O
not O
had O
any O
SVT B-REA
for O
24 O
hours O
. O
We O
would O
suggest O
possible O

 O
up-titration O
of O
her O
diltiazem B-DRUG
as O
allowed O
by O
her O
HR O
and O
BP O
, O
and O

 O
eventual O
conversion O
to O
the O
long-acting O
form O
of O
the O
medication O
. O

 O
. O

 O
# O
Diastolic B-REA
dysfunction I-REA
: I-REA
The O
pt O
appeared O
euvolemic O
throughout O

 O
her O
stay O
. O
A O
chest O
x-ray O
after O
several O
days O
without O
Lasix B-DRUG
did O
not O

 O
demonstrate O
any O
evidence O
of O
failure O
. O
A O
echo O
in O
[ O
* O
* O
2145 O
* O
* O
] O
demonstrated O

 O
preserved O
EF O
and O
mild O
AR O
. O
As O
above O
, O
the O
pt O
's O
ACEi B-DRUG
, I-DRUG
beta B-DRUG
blocker I-DRUG

 I-DRUG
and O
lasix B-DRUG
were O
held O
at O
admission O
; O
* O
* O
* O
these O
may O
need O
to O
be O

 O
restarted O
in O
the O
future O
. O
* O
* O
* O

 O
. O

 O
# O
CAD O
: O
The O
pt O
had O
a O
negative O
stress-MIBI O
in O
[ O
* O
* O
2145 O
* O
* O
] O
. O
Her O
ASA B-DRUG
was O

 O
held O
throughout O
her O
hospital O
stay O
as O
described O
above O
. O
When O
her O

 O
HR O
was O
elevated O
, O
the O
pt O
was O
noted O
to O
have O
fairly O
diffuse O
ST O

 O
depressions O
which O
resolved O
with O
better O
HR O
control O
, O
thus O

 O
continued O
aspirin B-DRUG
therapy O
, O
likely O
at O
325 B-STR
mg I-STR
daily B-FRE
, I-FRE
would O
be O

 O
ideal O
. O
This O
was O
deferred O
at O
the O
time O
of O
discharge O
so O
that O
the O

 O
pt O
's O
HCT O
could O
be O
followed O
for O
another O
1 O
- O
2 O
weeks O
. O

 O
. O

 O
# O
Dementia O
: O
The O
pt O
remained O
pleasantly O
and O
mildly O
demented O

 O
throughout O
her O
hospital O
course O
. O
There O
was O
no O
evidence O
of O

 O
delirium O
. O


 O
Medications O
on O
Admission O
: O

 O
Aspirin B-DRUG
325 B-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Lasix B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
Metoprolol B-DRUG
25 B-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Lisinopril B-DRUG
2.5 B-STR

 I-STR
Citalopram B-DRUG
20 B-STR
mg I-STR
QHS B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q12H B-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Diltiazem B-DRUG
HCl I-DRUG
30 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QID B-FRE
( I-FRE
4 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Citalopram B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE
bedtime I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
[ O
* O
* O
Hospital1 O
* O
* O
] O
[ O
* O
* O
Hospital1 O
1501 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
upper O
GI O
bleeding O

 O
atrial O
fibrillation O

 O
other O
SVT O
( O
suspected O
AVNRT O
) O

 O
. O

 O
Secondary O
: O

 O
coronary O
artery O
disease O

 O
diastolic O
dysfunction O



 O
Discharge O
Condition O
: O

 O
Improved O
. O
Vital O
signs O
and O
HCT O
stable O
. O
Pt O
moderately O

 O
deconditioned O
. O



 O
Discharge O
Instructions O
: O

 O
-You O
were O
admitted O
with O
bleeding O
in O
your O
GI O
tract O
that O
was O

 O
caused O
by O
an O
ulcer O
. O
We O
have O
treated O
you O
with O
blood O
transfusions O
, O

 O
applied O
clips O
to O
the O
blood O
vessels O
in O
your O
ulcer O
and O
are O
giving O

 O
you O
medications O
to O
help O
prevent O
a O
recurrence O
. O
You O
are O
being O

 O
discharged O
to O
rehab O
before O
going O
home O
to O
help O
regain O
your O

 O
strength O
. O

 O
-It O
is O
important O
that O
you O
continue O
to O
take O
your O
medications O
as O

 O
directed O
. O
We O
made O
the O
following O
changes O
to O
your O
medications O

 O
during O
this O
admission O
: O

 O
-- O
> O
Aspirin B-DRUG
was O
held O
because O
of O
bleeding O
. O
Talk O
with O
your O
doctor O

 O
about O
when O
or O
if O
to O
restart O
this O
. O

 O
-- O
> O
Your O
home O
metoprolol B-DRUG
was O
changed O
to O
diltiazem B-DRUG
. I-DRUG
This O
is O
a O

 O
similar O
medicine O
that O
we O
think O
will O
do O
a O
better O
job O
of O

 O
controlling B-REA
your I-REA
heart I-REA
rate I-REA
. I-REA

 O
-- O
> O
Your O
Lasix B-DRUG
was O
stopped O
because O
your O
blood O
pressure O
was O

 O
normal O
. O
Please O
talk O
with O
your O
doctor O
about O
when O
to O
restart O
this O
. O

 O
-- O
> O
Your O
lisinopril B-DRUG
was O
stopped O
because O
your O
blood O
pressure O
was O

 O
normal O
. O
Please O
talk O
with O
your O
doctor O
about O
when O
to O
restart O
this O
. O

 O
-Contact O
your O
doctor O
or O
come O
to O
the O
Emergency O
Room O
should O
your O

 O
symptoms O
return O
. O
Also O
seek O
medical O
attention O
if O
you O
develop O
any O

 O
new O
fever O
, O
chills O
, O
trouble O
breathing O
, O
chest O
pain O
, O
nausea O
, O

 O
vomiting O
or O
unusual O
stools O
. O


 O
Followup O
Instructions O
: O

 O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
5351 O
* O
* O
] O
is O
aware O
that O
you O
have O
been O
discharged O
from O
the O

 O
hospital O
. O
Her O
office O
will O
contact O
you O
to O
arrange O
follow-up O
in O

 O
the O
next O
few O
days O
. O
Please O
call O
her O
office O
at O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
608 O
* O
* O
] O
if O
you O

 O
have O
not O
heard O
from O
them O
by O
then O
. O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2135 O
- O
2 O
- O
14 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2052 O
- O
1 O
- O
30 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Bactrim B-DRUG


 I-DRUG
Attending:[**Doctor O
First O
Name O
2080 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
shortness O
of O
breath O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
thoracentesis O


 O
History O
of O
Present O
Illness O
: O

 O
Reason O
for O
MICU O
Admission O
: O
hypoxia O
respiratory O
distress O

 O
. O

 O
Primary O
Care O
Physician O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
585**],[**Name11 O
( O
NameIs O
) O
586 O
* O
* O
] O
[ O
* O
* O
Name O
Initial O
( O
NameIs O
) O
* O
* O
] O
. O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
589 O
* O
* O
] O

 O
. O

 O
CC O
: O
cough O
, O
shortness O
of O
breath O

 O
. O

 O
HPI O
: O
83yo O
female O
Russian O
with O
history O
of O
CLL O
presenting O
with O

 O
respiratory O
distress O
. O

 O
. O

 O
Per O
patient O
she O
reports O
6 O
days O
of O
productive O
cough O
and O

 O
progressive O
dyspnea O
. O
She O
reports O
associated O
fevers O
up O
to O
100.2 O

 O
and O
sore O
throat O
. O
Two O
days O
prior O
to O
admission O
prescribed O
bactrim B-DRUG

 I-DRUG
by O
her O
son O
who O
is O
a O
physician O
. O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
[ O
* O
* O
Name11 O
( O
NameIs O
) O
3010 O
* O
* O
] O
worsened O
and O
she O

 O
presented O
to O
her O
PCP O
[ O
* O
* O
Name O
Initial O
( O
PRE O
) O
3011 O
* O
* O
] O
. O
There O
vital O
signs O
notable O
for O
O2 B-DRUG
sat O

 O
89 O
% O
RA O
, O
improved O
to O
92 O
% O
on O
2L B-DOS
NC B-ROU
. I-ROU
CXR O
with O
right O
increased O

 O
effusion O
and O
possible O
left O
sided O
infiltrate O
. O
She O
was O
referred O
to O

 O
ED O
for O
further O
eval O
. O

 O
. O

 O
In O
the O
ED O
, O
initial O
VS O
: O
99.3 O
81 O
118/46 O
20 O
96 O
% O
NRB O
. O
Labs O
notable O

 O
for O
WBC O
of O
33.2 O
, O
61 O
% O
lymphocytes O
; O
K O
: O
5.2 O
, O
creatinine O
2.7 O
, O

 O
lactate O
1.3 O
. O
Blood O
cultures O
obtained O
. O
CXR O
performed O
which O

 O
demonstrated O
interval O
increase O
in O
moderate O
- O
large O
right O
pleural B-REA

 I-REA
effusion I-REA
as O
well O
as O
opacity B-REA
lateral I-REA
to I-REA
left I-REA
hilum I-REA
. I-REA
Patient O

 O
received O
PO B-ROU
Tylenol B-DRUG
650 B-STR
mg I-STR
x1 B-DOS
, I-DOS
IV B-ROU
Ceftriaxone B-DRUG
and O
Levofloxacin B-DRUG
. I-DRUG

 O
The O
patient O
was O
attempted O
to O
be O
weaned O
to O
NC O
, O
but O
desated O
to O

 O
90 O
% O
. O
  O
She O
was O
placed O
back O
on O
a O
NRB O
and O
transferred O
to O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
for O

 O
further O
evaluation O
and O
management O
. O

 O
. O

 O
In O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
the O
patient O
states O
that O
her O
breathing O
has O
improved O
. O


 O
. O


 O
ROS O
: O

 O
+ O
: O
as O
per O
HPI O

 O
- O
: O
denies O
any O
chills O
, O
weight O
change O
, O
nausea O
, O
vomiting O
, O
abdominal O

 O
pain O
, O
diarrhea O
, O
constipation O
, O
melena O
, O
hematochezia O
, O
chest O
pain O
, O

 O
orthopnea O
, O
PND O
, O
lower O
extremity O
edema O
, O
urinary O
frequency O
, O

 O
urgency O
, O
dysuria O
, O
lightheadedness O
, O
gait O
unsteadiness O
, O
focal O

 O
weakness O
, O
vision O
changes O
, O
headache O
, O
rash O
or O
skin O
changes O
. O



 O
Past O
Medical O
History O
: O

 O
Past O
Medical O
History O
: O

 O
# O
Oncologic O
History O

 O
Chronic B-REA
Lymphocytic I-REA
Leukemia I-REA

 I-REA
- O
Diagnosed O
in O
[ O
* O
* O
2125 O
* O
* O
] O
: O
Rai O
stage O
0 O
in O
[ O
* O
* O
2125 O
* O
* O
] O

 O
- O
s/p O
5 B-DUR
cycles I-DUR
of O
fludarabine B-DRUG
ending O
in O
[ O
* O
* O
2130 O
- O
5 O
- O
29 O
* O
* O
] O
. O

 O
- O
recurrent O
anemia O
and O
advancing O
peripheral O
blood O
lymphocytosis O

 O
and O
lymphadenopathy O
, O
prompted O
4 O
additional O
3-day O
cycles O
of O

 O
fludarabine B-DRUG
from O
[ O
* O
* O
3 O
- O
9 O
* O
* O
] O
to O
[ O
* O
* O
6 O
- O
6 O
* O
* O
] O
. O

 O
# O
PMH O

 O
1 O
. O
  O
Macular O
degeneration O
; O
legally O
blind O
. O

 O
2 O
. O
  O
Chronic O
renal O
failure O
: O
baseline O
creatinine O
1.5 O

 O
3 O
. O
  O
Hypothyroidism O
secondary O
to O
hemithyroidectomy O
on O
[ O
* O
* O
2121 O
- O
2 O
- O
26 O
* O
* O
] O

 O
4 O
. O
  O
Diabetes O
: O
last O
HgA1c O
: O
7.0 O

 O
5 O
. O
  O
Hypertension O
. O

 O
6 O
. O
  O
In O
[ O
* O
* O
2133 O
- O
6 O
- O
29 O
* O
* O
] O
, O
she O
was O
admitted O
to O
hospital O
with O
respiratory O

 O
infection O
due O
to O
H1N1 B-REA
influenza I-REA
A. I-REA
She O
received O
6 B-DUR
days I-DUR
of O

 O
Tamiflu B-DRUG

 I-DRUG
and O
Levaquin B-DRUG
with O
improvement O
in O
symptoms O
. O
Myelosuppression O

 O
during O
her O
viral O
illness O
improved O
. O

 O
. O

 O
SURGICAL O
HISTORY O
: O

 O
Hysterectomy O
at O
age O
43 O
. O

 O
Appendectomy O
. O

 O
Right O
thyroidectomy O



 O
Social O
History O
: O

 O
Lives O
with O
her O
husband O
. O
  O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
two O
children O
. O
  O
Retired O
teacher O
. O

 O
Originally O
from O
[ O
* O
* O
Country O
532 O
* O
* O
] O

 O
Tob O
: O
  O
none O

 O
EtOH O
: O
  O
none O



 O
Family O
History O
: O

 O
Father O
- O
h/o O
esophageal O
cancer O

 O
Mother O
- O
h/o O
skin O
cancer O

 O
Sister O
- O
h/o O
breast O
cancer O



 O
Physical O
Exam O
: O

 O
On O
Admission O
: O

 O
GEN O
: O
Well-appearing O
, O
well-nourished O
, O
no O
acute O
distress O

 O
HEENT O
: O
EOMI O
, O
PERRL O
, O
sclera O
anicteric O
, O
no O
epistaxis O
or O

 O
rhinorrhea O
, O
MMM O
, O
OP O
Clear O

 O
NECK O
: O
No O
JVD O
, O
carotid O
pulses O
brisk O
, O
no O
bruits O
, O
no O
cervical O

 O
lymphadenopathy O
, O
trachea O
midline O

 O
COR O
: O
RRR O
, O
II/ O
VI O
SEM O
, O
no O
M/G/R O
, O
normal O
S1 O
S2 O
, O
radial O
pulses O
+ O
2 O

 O
PULM O
: O
diminished O
BS O
at O
the O
right O
base O
, O
otherwise O
no O
W/R/R O

 O
ABD O
: O
Soft O
, O
NT O
, O
ND O
, O
+ O
BS O
, O
no O
HSM O
, O
no O
masses O

 O
EXT O
: O
No O
C/C/E O
, O
no O
palpable O
cords O

 O
NEURO O
: O
alert O
, O
oriented O
to O
person O
, O
place O
, O
and O
time O
. O
CN O
II O
? O
? O
? O
? O
? O
? O
XII O

 O
grossly O
intact O
. O
Moves O
all O
4 O
extremities O
. O
Strength O
5/5 O
in O
upper O

 O
and O
lower O
extremities O
. O
Patellar O
DTR O
+ O
1 O
. O
Plantar O
reflex O

 O
downgoing O
. O
No O
gait O
disturbance O
. O
No O
cerebellar O
dysfunction O
. O

 O
SKIN O
: O
No O
jaundice O
, O
cyanosis O
, O
or O
gross O
dermatitis O
. O
No O
ecchymo O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
05:30PM O
   O
WBC-33.2 O
* O
RBC-4.31 O
HGB-12.5 O
HCT-36.5 O
MCV-85 O

 O
MCH-29.1 O
MCHC-34.3 O
RDW-15.9 O
* O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
05:30PM O
   O
PLT O
SMR-NORMAL O
PLT O
COUNT-164 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
05:30PM O
   O
NEUTS-34 O
* O
BANDS-0 O
LYMPHS-61 O
* O
MONOS-5 O
EOS-0 O

 O
BASOS-0 O
ATYPS-0 O
METAS-0 O
MYELOS-0 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
05:30PM O
   O
HYPOCHROM-NORMAL O
ANISOCYT-NORMAL O

 O
POIKILOCY-NORMAL O
MACROCYT-NORMAL O
MICROCYT-NORMAL O

 O
POLYCHROM-NORMAL O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
05:30PM O
   O
GLUCOSE-134 O
* O
UREA O
N-48 O
* O
CREAT-2.7 O
* O
# O

 O
SODIUM-136 O
POTASSIUM-5.2 O
* O
CHLORIDE-102 O
TOTAL O
CO2 O
- O
20 O
* O
ANION O

 O
GAP-19 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
10:28PM O
   O
PT-13.6 O
* O
PTT-28.0 O
INR(PT)-1.2 O
* O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
05:30PM O
   O
CK(CPK)-89 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
05:30PM O
   O
cTropnT-<0.01 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
05:35PM O
   O
LACTATE-1.3 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
10:28PM O
   O
PT-13.6 O
* O
PTT-28.0 O
INR(PT)-1.2 O
* O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
05:30PM O
   O
CK-MB-4 O
proBNP-1345 O
* O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
11:09PM O
URINE O
  O
HOURS-RANDOM O
UREA O
N-390 O
CREAT-52 O

 O
SODIUM-37 O
POTASSIUM-30 O
CHLORIDE-16 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
11:09PM O
URINE O
  O
OSMOLAL-270 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
11:09PM O
URINE O
  O
COLOR-Yellow O
APPEAR-Clear O
SP O
[ O
* O
* O
Last O
Name O
( O
un O
) O
155**]-1.008 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
11:09PM O
URINE O
  O
BLOOD-NEG O
NITRITE-NEG O
PROTEIN-NEG O

 O
GLUCOSE-NEG O
KETONE-NEG O
BILIRUBIN-NEG O
UROBILNGN-NEG O
PH-5.0 O

 O
LEUK-NEG O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
11:09PM O
URINE O
  O
RBC-<1 O
WBC-1 O
BACTERIA-NONE O
YEAST-NONE O

 O
EPI-<1 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
11:09PM O
URINE O
  O
MUCOUS-RARE O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
11:09PM O
URINE O
  O
EOS-NEGATIVE O

 O
. O

                     O
IgG O
IgA O
IgM O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
10 O
* O
* O
] O
05:57 O
    O
963 O
  O
52 O
* O
66 O

 O
. O

 O
Micro O
: O

 O
Legionella O
Urinary O
Antigen O
  O
( O
Final O
[ O
* O
* O
2135 O
- O
2 O
- O
9 O
* O
* O
] O
) O
: O

       O
NEGATIVE O
FOR O
LEGIONELLA O
SEROGROUP O
1 O
ANTIGEN O
. O


 O
[ O
* O
* O
2135 O
- O
2 O
- O
9 O
* O
* O
] O
2:33 O
pm O
PLEURAL O
FLUID O


    O
GRAM O
STAIN O
( O
Final O
[ O
* O
* O
2135 O
- O
2 O
- O
9 O
* O
* O
] O
) O
: O

       O
1 O
+ O
    O
( O
< O
1 O
per O
1000X O
FIELD O
) O
: O
   O
POLYMORPHONUCLEAR O

 O
LEUKOCYTES O
. O

       O
NO O
MICROORGANISMS O
SEEN O
. O


    O
FLUID O
CULTURE O
( O
Preliminary O
) O
: O
    O
NO O
GROWTH O
. O



    O
ANAEROBIC O
CULTURE O
( O
Final O
[ O
* O
* O
2135 O
- O
2 O
- O
11 O
* O
* O
] O
) O
: O
    O
NO O
GROWTH O
. O

 O
URINE O
CULTURE O
( O
Final O
[ O
* O
* O
2135 O
- O
2 O
- O
10 O
* O
* O
] O
) O
: O
    O
< O
10,000 O
organisms/ml O

 O
Pleural O

 O
Pathology O
: O
pending O

 O
CT O
chest O
: O

 O
FINDINGS O
: O
Bulky O
lymphadenopathy O
is O
present O
in O
the O
imaged O
portion O

 O
of O
the O
lower O
neck O
, O
superior O
mediastinum O
, O
throughout O
the O

 O
intrathoracic O
mediastinum O
, O
bilateral O
hila O
, O
and O
to O
a O
lesser O

 O
extent O
within O
the O
axillary O
regions O
. O
Large O
right O
pleural O
effusion O

 O
is O
dependent O
in O
location O
and O
measures O
simple O
fluid O
density O
. O
A O

 O
small O
amount O
of O
loculated O
fluid O
is O
also O
present O
within O
the O
major O

 O
fissure O
and O
in O
the O
anterolateral O
portion O
of O
the O
right O
lower O

 O
chest O
. O
Extensive O
consolidation O
is O
present O
within O
the O
right O
lower O

 O
and O
right O
middle O
lobes O
. O
  O
Peribronchiolar O
abnormalities O
are O

 O
present O
in O
both O
upper O
lobes O
with O
a O
combination O
of O
ground O
glass O

 O
and O
consolidation O
accompanied O
by O
bronchial O
wall O
thickening O
and O

 O
small O
peribronchial O
nodules O
. O
A O
dominant O
peribronchial O
nodule O
in O

 O
the O
left O
upper O
lobe O
measures O
2.2 O
cm O
and O
is O
surrounded O
by O
a O
halo O

 O
of O
ground-glass O
opacity O
( O
26 O
, O
series O
3A O
) O
. O
This O
corresponds O
to O
a O

 O
rapidly O
growing O
focal O
opacity O
on O
serial O
chest O
x-rays O
between O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
8 O
* O
* O
] O
and O
[ O
* O
* O
2135 O
- O
2 O
- O
10 O
* O
* O
] O
. O
Additional O

 O
peribronchiolar O
abnormalities O
are O
present O
to O
a O
lesser O
extent O

 O
within O
the O
left O
lower O
lobe O
. O


 O
Exam O
was O
not O
tailored O
to O
evaluate O
the O
subdiaphragmatic O
region O
, O

 O
but O
note O
is O

 O
made O
of O
retroperitoneal O
or O
intra-abdominal O
lymphadenopathy O
as O

 O
well O
as O

 O
incompletely O
imaged O
splenomegaly O
. O


 O
Lucent O
spine O
lesions O
within O
the O
lower O
thoracic O
spine O
( O
image O
53 O
, O

 O
series O
3A O
and O
image O
48 O
, O
series O
3A O
) O
are O
probably O
hemangiomas O
. O

 O
Degenerative O
changes O
are O
also O
noted O
at O
multiple O
levels O

 O
throughout O
the O
spine O
. O


 O
IMPRESSION O
: O

 O
1 O
. O
Multifocal O
lung O
abnormalities O
most O
suggestive O
of O
a O
widespread O

 O
infectious O
process O
. O
Nodular O
opacity O
with O
ground-glass O
halo O
in O

 O
left O
upper O
lobe O
is O
nonspecific O
, O
but O
this O
appearance O
may O
be O

 O
associated O
with O
angioinvasive O
Aspergillus O
infection O
in O
the O

 O
setting O
of O
neutropenic O
fever O
. O

 O
2 O
. O
Large O
simple O
right O
pleural O
effusion O
. O

 O
3 O
. O
Extensive O
lymphadenopathy O
, O
likely O
related O
to O
the O
provided O

 O
history O
of O
CLL O
. O
  O
Splenomegaly O
is O
also O
in O
keeping O
with O
this O

 O
diagnosis O
. O

 O
4 O
. O
Two O
lucent O
thoracic O
vertebral O
body O
lesions O
in O
the O
lower O

 O
thoracic O
spine O

 O
which O
probably O
reflect O
hemangiomas O
. O

 O
. O


 O
TTE O

 O
The O
left O
atrium O
is O
normal O
in O
size O
. O
No O
atrial O
septal O
defect O
is O

 O
seen O
by O
2D O
or O
color O
Doppler O
. O
The O
estimated O
right O
atrial O
pressure O

 O
is O
0 O
- O
10mmHg O
. O
Left O
ventricular O
wall O
thickness O
, O
cavity O
size O
and O

 O
regional/global O
systolic O
function O
are O
normal O
( O
LVEF O
> O
55 O
% O
) O
. O
Tissue O

 O
Doppler O
imaging O
suggests O
a O
normal O
left O
ventricular O
filling O

 O
pressure O
( O
PCWP<12mmHg O
) O
. O
Right O
ventricular O
chamber O
size O
and O
free O

 O
wall O
motion O
are O
normal O
. O
The O
aortic O
valve O
leaflets O
are O
moderately O

 O
thickened O
. O
There O
is O
no O
aortic O
valve O
stenosis O
. O
Trace O
aortic O

 O
regurgitation O
is O
seen O
. O
The O
mitral O
valve O
leaflets O
are O
mildly O

 O
thickened O
. O
Trivial O
mitral O
regurgitation O
is O
seen O
. O
There O
is O

 O
borderline O
pulmonary O
artery O
systolic O
hypertension O
. O
There O
is O
no O

 O
pericardial O
effusion O
. O


 O
IMPRESSION O
: O
Normal O
left O
ventricular O
cavity O
size O
and O
wall O

 O
thickness O
with O
preserved O
global O
and O
regional O
biventricular O

 O
systolic O
function O
. O
No O
clinically O
significant O
valvular O

 O
regurgitation O
. O
Borderline O
pulmonary O
artery O
systolic O

 O
hypertension O
. O
An O
area O
of O
echodensity O
measuring O
7.4 O
cm O
x O
4.9 O
cm O

 O
( O
clip O
[ O
* O
* O
Clip O
Number O
( O
Radiology O
) O
* O
* O
] O
) O
is O
seen O
that O
appears O
to O
be O
contained O
within O
a O
small O

 O
right O
pleural O
effusion O
. O
Clinical O
correlation O
and O
consideration O

 O
of O
a O
chest O
CT O
for O
further O
characterization O
suggested O
. O

 O
. O

 O
LENI O
: O

 O
FINDINGS O
: O
Color O
and O
[ O
* O
* O
Doctor O
Last O
Name O
352**]-scale O
son[**Name O
( O
NI O
) O
* O
* O
] O
was O
performed O
on O
the O

 O
bilateral O
lower O
extremities O
. O
The O
bilateral O
common O
femoral O
, O

 O
superficial O
femoral O
and O
popliteal O
veins O
are O
normal O
in O

 O
compressibility O
, O
augmentation O
, O
and O
Doppler O
waveforms O
. O
The O
calf O

 O
veins O
are O
patent O
and O
compressible O
. O
There O
is O
no O
deep O
vein O

 O
thrombosis O
in O
either O
lower O
extremity O
. O

 O
. O


 O
Brief O
Hospital O
Course O
: O

 O
This O
is O
a O
83 O
year-old O
female O
with O
a O
history O
of O
CLL O
who O
presents O

 O
with O
respiratory O
distress O
. O

 O
. O


 O
# O
Respiratory O
Distress O
. O
Etiology O
likely O
secondary O
to O
worsening O

 O
effusion O
as O
well O
as O
new O
infiltrates O
concerning O
for O
multifocal O

 O
pneumonia O
. O
Patient O
with O
known O
malignancy O
and O
therefore O
at O
risk O

 O
for O
hypercoagulable O
state O
. O
[ O
* O
* O
Doctor O
Last O
Name O
3012 O
* O
* O
] O
score O
appears O
to O
be O
low O
-1 O
( O
+ O
1 O

 O
for O
malignancy O
, O
-2 O
for O
other O
cause O
of O
dyspnea O
) O
. O
LENIs O
negative O
. O

 O
Biomarkers O
flat O
. O
TTE O
with O
normal O
systolic O
and O
diastolic O

 O
function O
. O
Patient O
underwent O
uncomplicated O
thoracentitis O
on O
[ O
* O
* O
2 O
- O
9 O
* O
* O
] O
, O

 O
500cc O
was O
removed O
. O
Fluid O
largely O
transudative O
. O
Gram O
stain O
with O

 O
no O
growth O
. O
Cytology O
pending O
. O
  O
CXR O
with O
LUL O
infiltrate O
. O
Urine O

 O
legionella O
negative O
. O
Blood O
cx O
: O
NGTD O
. O
CT O
scan O
consistent O
with O

 O
multifocal B-REA
pneumonia I-REA
; I-REA
though O
question O
of O
fungal O
per O
radiology O
, O

 O
clinical O
suspicion O
higher O
for O
pneumococcal B-REA
pathogen O
. O
Patient O

 O
continued O
on O
Ceftriaxone B-DRUG
and O
Levofloxacin B-DRUG
with O
plan O
for B-DUR
8 I-DUR
- I-DUR
10day I-DUR

 I-DUR
course O
. O
Patient O
's O
respiratory O
status O
improved O
on O
these O

 O
antibiotics B-DRUG
and O
O2 B-DRUG
was O
weaned O
as O
tolerated O
. O
At O
time O
of O
transfer O

 O
to O
floor O
on O
[ O
* O
* O
2 O
- O
11 O
* O
* O
] O
, O
oxygen O
saturation O
was O
> O
94 O
% O
on O
3L B-DOS
NC B-ROU
. I-ROU
  O
Narrowed O

 O
to O
Levofloxacin B-DRUG
alone O
prior O
to O
discharge O

 O
. O

 O
PENDING O
CYTOLOGY O
NEEDS O
FOLLOW O
UP O
. O
  O
ALSO O
RECOMMEND O
CT O
CHEST O
AFTER O

 O
TREATMENT O
COMPLETED O
. O

 O
. O

 O
# O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
. O
Patient O
with O
history O
of O
chronic O
renal O
insufficiency O
with O

 O
baseline O
creatinine O
1.5 O
. O
Creatinine O
on O
admission O
2.7 O
. O
Etiology O

 O
pre-renal B-ADE
, I-ADE
AIN I-ADE
in O
setting O
of O
recent O
bactrim B-DRUG
usage O
. O
UA O
and O
urine O

 O
culture O
without O
sign O
of O
infection O
. O
Urine O
eosinophils O
negative O
. O

 O
FeNa O
: O
1.3 O
. O
Creatinine B-REA
slowly O
improved O
with O
IVF B-DRUG
and O
was O
2.3 O
. O
at O

 O
time O
of O
transfer O
to O
the O
medical O
floor O
. O
Trending O
daily O
. O
  O
It O
was O

 O
lowered O
to O
1.7 O
prior O
to O
discharge O
. O

 O
. O

 O
# O
CLL B-REA
. I-REA
Patient O
diagnosed O
in O
[ O
* O
* O
2125 O
* O
* O
] O
. O
Patient O
last O
treated O
with O

 O
fludarabine B-DRUG
in O
[ O
* O
* O
2133 O
- O
5 O
- O
29 O
* O
* O
] O
. O
Labs O
notable O
for O
elevated O
WBC O
> O
20 O
since O

 O
4/[**2134 O
* O
* O
] O
. O
Patient O
without O
anemia O
or O
thrombocytopenia O
. O
IgG O
levels O

 O
checked O
. O
IgG O
level O
wnl O
. O
Dr O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
followed O
patient O
closely O
. O
No O

 O
plan O
for O
IVIG B-DRUG
infusion B-ROU
. I-ROU

 O
. O

 O
# O
Diabetes B-REA
. I-REA
Last O
HgA1c O
: O
9.0 O
. O
Patient O
states O
she O
does O
not O
take O

 O
any O
meds O
for O
diabetes O
and O
her O
daughter O
said O
she O
eats O
whatever O

 O
she O
wants O
. O
Monitoring O
QID B-FRE
FS O
, O
ISS B-DRUG
. I-DRUG

 O
. O

 O
# O
Hypothyroid B-REA
. I-REA
Continued O
Synthroid B-DRUG

 I-DRUG
. O

 O
# O
FEN B-REA
: I-REA
IVF B-DRUG
, I-DRUG
replete O
prn O
, O
diabetic/cardiac O
diet O

 O
. O

 O
# O
Access O
: O
PIV O

 O
. O

 O
# O
PPx B-REA
: I-REA
subQ B-ROU
heparin B-DRUG
, I-DRUG
home O
PPI B-DRUG

 I-DRUG
. O



 O
Medications O
on O
Admission O
: O

 O
See O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
admission O
note O


 O
Discharge O
Medications O
: O

 O
1 O
. O
omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
Q12H B-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
tramadol B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
levothyroxine B-DRUG
100 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
lipase-protease-amylase B-DRUG
12,000 B-STR
- I-STR
38,000 I-STR
-60,000 I-STR
unit I-STR
Capsule B-FOR
, I-FOR

 I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Cap B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
albuterol B-DRUG
sulfate I-DRUG
90 B-STR
mcg/Actuation I-STR
HFA B-FOR
Aerosol I-FOR
Inhaler I-FOR
Sig O
: O

 O
1 B-DOS
- I-DOS
2 I-DOS
puffs B-FOR
Inhalation B-ROU
every B-FRE
4 I-FRE
- I-FRE
6 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
shortness B-REA
of I-REA

 I-REA
breath I-REA
or O
wheezing B-REA
. I-REA

 O
Disp:*1 O
inhaler O
* O
Refills:*0 O
* O

 O
6 O
. O
levofloxacin B-DRUG
750 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q48H B-FRE
( I-FRE
every I-FRE

 I-FRE
48 I-FRE
hours I-FRE
) I-FRE
for O
2 B-DUR
doses I-DUR
. I-DUR

 O
Disp:*2 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
7 O
. O
Home O
Oxygen B-DRUG

 I-DRUG
2 B-DOS
liters I-DOS
continuous O
pulse O
dose O
for O
portability O
. O

 O
dx O
: O
pleural B-REA
effusion I-REA

 I-REA
8 O
. O
metformin B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Extended I-FOR
Rel I-FOR
24 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
Extended I-FOR
Rel I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital1 O
* O
* O
] O
Family O
& O
[ O
* O
* O
Hospital1 O
1926 O
* O
* O
] O
Services O


 O
Discharge O
Diagnosis O
: O

 O
Community O
acquired O
pneumonia O
with O
parapneumonic O
effusion O

 O
Chronic O
kidney O
disease O
stage O
III O

 O
CLL O

 O
Hypothyroidism O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
for O
treatment O
for O
severe B-REA
pneumonia I-REA
as O
well O
as O

 O
fluid O
in O
the O
lung O
. O
  O
The O
fluid O
in O
the O
lung O
was O
sampled O
. O
  O
You O
were O

 O
started O
on O
antibiotics B-DRUG
with O
improvement O
in O
your O
symptoms O
. O

 O
Please O
continue O
your O
antibiotics B-DRUG
to O
complete O
the O
full O
course O
. O

 O
Please O
take O
all O
other O
medications O
as O
prescribed O
. O


 O
You O
need O
to O
see O
you O
PCP O
in O
close O
follow O
up O
. O
  O
Lung O
fluid O
cytology O

 O
is O
PENDING O
at O
discharge O
and O
will O
need O
to O
be O
followed O
up O
. O
  O
Also O
, O

 O
we O
recommend O
a O
follow O
up O
CT O
scan O
of O
the O
chest O
once O
your O
symptoms O

 O
resolve O
. O


 O
START O
: O

 O
Levofloxacin B-DRUG
750 B-STR
mg I-STR
every B-FRE
48 I-FRE
hours I-FRE

 I-FRE
Albuterol B-DRUG
inhaler B-FOR
as B-FRE
needed I-FRE


 I-FRE
Followup O
Instructions O
: O

 O
Please O
follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
as O
soon O
as O
possible O



 O
Department O
: O
[ O
* O
* O
Hospital3 O
1935 O
* O
* O
] O
CENTER O

 O
When O
: O
WEDNESDAY O
[ O
* O
* O
2135 O
- O
2 O
- O
23 O
* O
* O
] O
at O
8:20 O
AM O

 O
With O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
354 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
3013 O
* O
* O
] O
, O
M.D. O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
253 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O


 O
Department O
: O
HEMATOLOGY/ONCOLOGY O

 O
When O
: O
TUESDAY O
[ O
* O
* O
2135 O
- O
3 O
- O
22 O
* O
* O
] O
at O
1:30 O
PM O

 O
With O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
3014 O
* O
* O
] O
, O
RN O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
22 O
* O
* O
] O

 O
Building O
: O
[ O
* O
* O
Hospital6 O
29 O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
24 O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O


 O
Department O
: O
MEDICAL O
SPECIALTIES O

 O
When O
: O
THURSDAY O
[ O
* O
* O
2135 O
- O
5 O
- O
19 O
* O
* O
] O
at O
9:30 O
AM O

 O
With O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
312 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
3015 O
* O
* O
] O
, O
M.D. O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1803 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2169 O
- O
1 O
- O
19 O
* O
* O
] O



 O
Service O
: O
EMERGENCY O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
2565 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Altered O
Mental O
Status O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
PICC O
Line O

 O
Bronchoscopy O
[ O
* O
* O
1 O
- O
15 O
* O
* O
] O
and O
[ O
* O
* O
1 O
- O
16 O
* O
* O
] O


 O
History O
of O
Present O
Illness O
: O

 O
Ms. O
[ O
* O
* O
Known O
lastname O
84119 O
* O
* O
] O
is O
an O
85 O
year-old O
woman O
with O
resp O
failure/vent O

 O
dependent O
s/p O
trach O
, O
recent O
PEs O
, O
sCHF O
( O
EF O
25 O
% O
) O
, O
AF O
, O
and O
PVD O
who O

 O
is O
transferred O
from O
rehab O
because O
of O
unresponsiveness O
and O
low O

 O
tidal O
volumes O
and O
is O
admitted O
to O
MICU O
for O
further O
management O
. O

 O
. O

 O
She O
was O
discharged O
on O
[ O
* O
* O
2169 O
- O
1 O
- O
13 O
* O
* O
] O
from O
the O
thoracics O
service O
after O

 O
presenting O
from O
an O
OSH O
with O
tracheal O
laceration O
in O
the O
setting O

 O
of O
traumatic O
intubation O
and O
sub-cutaneous O
emphysema O

 O
post-intubation O
. O
  O
Her O
recent O
history O
prior O
to O
that O
includes O
a O

 O
fall O
on O
[ O
* O
* O
10 O
- O
31 O
* O
* O
] O
with O
a O
C2 O
odontoid O
fracture O
and O
diagnosis O
of O
PEs O

 O
in O
the O
setting O
of O
dyspnea O
on O
[ O
* O
* O
2168 O
- O
12 O
- O
10 O
* O
* O
] O
requiring O
intubation O

 O
( O
complicated O
by O
trach O
injury O
) O
for O
hypercapnea O
. O
  O
On O
the O
thoracics O

 O
service O
, O
she O
[ O
* O
* O
Date O
Range O
1834 O
* O
* O
] O
multiple O
bronchoscopies O
and O
trach O

 O
placement O
( O
( O
# O
7 O
[ O
* O
* O
Last O
Name O
( O
un O
) O
295 O
* O
* O
] O
) O
and O
revisions O
with O
clot O
demonstrated O
in O

 O
posterior O
trachea O
and O
trach O
dislodgement O
. O
  O
She O
was O
discharged O
on O

 O
trach O
cpap O
with O
cmv O
onvernight O
. O
  O
She O
was O
transitioned O
from O
CMV O

 O
ventilation O
to O
CPAP O
, O
and O
was O
able O
to O
tolerate O
trach O
collar O
for O

 O
unspecified O
periods O
of O
time O
. O

 O
. O

 O
At O
rehab O
, O
she O
had O
AMS/unresponsiveness O
which O
is O
different O
from O

 O
her O
baseline O
, O
and O
low O
tidal O
volumes O
on O
pressure O
support O
and O
was O

 O
transferred O
to O
the O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
further O
management O
. O
  O
ABG O
7.24/44/91 O

 O
( O
? O
may O
be O
an O
error O
) O
and O
98.6 O
74 O
26 O
95/61 O
92 O
% O
on O
fio2 O
40 O
% O
per O

 O
rehab O
notes O
. O

 O
. O


 O
In O
the O
ED O
, O
vital O
signs O
were O
initially O
: O
99 O
61 O
  O
106/49 O
100 O
% O
on O

 O
vent O
. O
CXR O
showed O
  O
pleural O
effusions O
but O
no O
acute O
findings O
and O
IP O

 O
was O
consulted O
and O
felt O
trach O
was O
in O
good O
position O
and O
she O
did O

 O
not O
need O
urgent O
intervention O
. O
  O
Thoracics O
was O
also O
notified O
and O

 O
will O
follow O
the O
patient O
. O
  O
Head O
CT O
neg O
. O
  O
UA B-REA
was I-REA
grossly I-REA
positive I-REA

 I-REA
and O
cipro B-DRUG
was O
started O
. O
  O
She O
was O
also O
on O
a O
heparin B-DRUG
gtt B-ROU
on O
arrival O

 O
and O
this O
was O
stopped O
when O
coags O
returned O
within O
INR O
6 O
. O
  O
She O
was O

 O
then O
admitted O
for O
further O
management O
. O



 O
Past O
Medical O
History O
: O

 O
1 O
. O
Possible O
CAD O

 O
2 O
. O
Congestive O
heart O
failure O
, O
possible O
EF O
of O
25 O
% O
( O
per O
report O
) O

 O
3 O
. O
COPD O

 O
4 O
. O
Atrial O
fibrillation O

 O
5 O
. O
LBBB O

 O
6 O
. O
PVD O

 O
7 O
. O
Arthritis O

 O
8 O
. O
MRSA O
infection O
in O
the O
pasy O

 O
9 O
. O
squamous O
cell O
carcinoma O
of O
right O
arm O

 O
10 O
. O
dementia O

 O
11 O
. O
Odontoid O
fracture O
in O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
collar O

 O
12 O
. O
Hyperlipidemia O


 O
Social O
History O
: O

 O
+ O
tobacco O
, O
recently O
quit O
. O
No O
illicits O
or O
EtOH O
per O
report O
. O

 O
Widowed O
, O
lives O
with O
son O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
. O
Healthcare O
proxy O
is O
son O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
. O


 O
Family O
History O
: O

 O
No O
CAD O
or O
arrhythmia O


 O
Physical O
Exam O
: O

 O
Tmax O
: O
37.7 O
? O
? O
? O
? O
? O
? O
C O
( O
99.8 O
? O
? O
? O
? O
? O
? O
F O
) O

 O
Tcurrent O
: O
37.6 O
? O
? O
? O
? O
? O
? O
C O
( O
99.6 O
? O
? O
? O
? O
? O
? O
F O
) O

 O
HR O
: O
65 O
( O
48 O
- O
82 O
) O
bpm O

 O
BP O
: O
99/41(56 O
) O
{ O
90/21(39 O
) O
- O
135/71(82 O
) O
} O
mmHg O

 O
RR O
: O
18 O
( O
13 O
- O
22 O
) O
insp/min O

 O
SpO2 O
: O
100 O
% O

 O
Heart O
rhythm O
: O
AF O
( O
Atrial O
Fibrillation O
) O

 O
Height O
: O
61 O
Inch O



 O
General O
Appearance O
: O
No O
acute O
distress O
, O
Thin O

 O
Eyes O
/ O
Conjunctiva O
: O
PERRL O

 O
Head O
, O
Ears O
, O
Nose O
, O
Throat O
: O
Normocephalic O
, O
trach O

 O
Cardiovascular O
: O
( O
S1 O
: O
Normal O
) O
, O
( O
S2 O
: O
Normal O
) O

 O
Peripheral O
Vascular O
: O
( O
Right O
radial O
pulse O
: O
Not O
assessed O
) O
, O
( O
Left O

 O
radial O
pulse O
) O
Not O
assessed O
) O
, O
( O
Right O
DP O
pulse O
: O
Not O
assessed O
) O
, O

 O
( O
Left O
DP O
pulse O
: O
Not O
assessed O
) O

 O
Respiratory O
/ O
Chest O
: O
( O
Expansion O
: O
Symmetric O
) O
, O
( O
Breath O
Sounds O
: O

 O
Clear O
: O
) O

 O
Extremities O
: O
Right O
lower O
extremity O
edema O
: O
3 O
+ O
, O
Left O
lower O

 O
extremity O
edema O
: O
3 O
+ O
( O
bilaterally O
to O
the O
thighs O
) O

 O
Skin O
: O
  O
Not O
assessed O
, O
No(t O
) O
Rash O
: O

 O
Neurologic O
: O
Minimally O
Responds O
to O
: O
Verbal O
stimuli O
, O
Movement O
: O

 O
Spontaneous O
, O
Tone O
: O
Not O
assessed O
, O
PERRL O
, O
withdraws O
to O
painful O

 O
stimuli O
, O
Upgoing O
toesNeurologic O
: O
Responds O
to O
: O
Not O
assessed O
, O

 O
Movement O
: O
Not O
assessed O
, O
Tone O
: O
Not O
assessed O



 O
Pertinent O
Results O
: O

 O
Admission O
: O


 O
[ O
* O
* O
2169 O
- O
1 O
- O
13 O
* O
* O
] O
02:18AM O
BLOOD O
WBC-8.0 O
RBC-2.95 O
* O
Hgb-9.4 O
* O
Hct-30.2 O
* O

 O
MCV-102 O
* O
MCH-31.8 O
MCHC-31.0 O
RDW-16.7 O
* O
Plt O
Ct-218 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
12:15PM O
BLOOD O
Neuts-92.7 O
* O
Lymphs-3.7 O
* O
Monos-3.3 O
Eos-0.2 O

 O
Baso-0.1 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
13 O
* O
* O
] O
02:18AM O
BLOOD O
PT-16.3 O
* O
PTT-55.8 O
* O
INR(PT)-1.4 O
* O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
13 O
* O
* O
] O
02:18AM O
BLOOD O
Glucose-153 O
* O
UreaN-24 O
* O
Creat-0.3 O
* O
Na-143 O

 O
K-3.7 O
Cl-115 O
* O
HCO3 O
- O
24 O
AnGap-8 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
12:15PM O
BLOOD O
ALT-21 O
AST-24 O
LD(LDH)-188 O
CK(CPK)-16 O
* O

 O
AlkPhos-44 O
TotBili-0.2 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
10:30AM O
BLOOD O
Lipase-29 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
13 O
* O
* O
] O
02:18AM O
BLOOD O
Calcium-9.3 O
Phos-3.4 O
Mg-2.2 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
12:15PM O
BLOOD O
VitB12 O
- O
471 O
Folate-GREATER O
TH O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
12:15PM O
BLOOD O
TSH-1.0 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
12:15PM O
BLOOD O
Free O
T4 O
- O
1.1 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
10:30AM O
BLOOD O
Ethanol-NEG O
Acetmnp-NEG O
Bnzodzp-NEG O

 O
Barbitr-NEG O
Tricycl-NEG O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
12:15PM O
BLOOD O
ASA-NEG O
Ethanol-NEG O
Acetmnp-NEG O

 O
Bnzodzp-NEG O
Barbitr-NEG O
Tricycl-NEG O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
12:39PM O
BLOOD O
Type-[**Last O
Name O
( O
un O
) O
* O
* O
] O
pO2 O
- O
87 O
pCO2 O
- O
52 O
* O
pH-7.26 O
* O

 O
calTCO2 O
- O
24 O
Base O
XS--4 O
Comment-GREEN O
TOP O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
11:17AM O
BLOOD O
Glucose-158 O
* O
Lactate-2.0 O
Na-145 O
K-4.5 O

 O
Cl-112 O
calHCO3 O
- O
24 O


 O
Discharge O
: O



 O
[ O
* O
* O
2169 O
- O
1 O
- O
19 O
* O
* O
] O
04:22AM O
BLOOD O
WBC-4.5 O
RBC-2.65 O
* O
Hgb-8.7 O
* O
Hct-25.7 O
* O

 O
MCV-97 O
MCH-33.0 O
* O
MCHC-34.0 O
RDW-16.8 O
* O
Plt O
Ct-129 O
* O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
19 O
* O
* O
] O
04:22AM O
BLOOD O
PT-17.2 O
* O
PTT-30.3 O
INR(PT)-1.5 O
* O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
19 O
* O
* O
] O
04:22AM O
BLOOD O
Glucose-114 O
* O
UreaN-26 O
* O
Creat-0.5 O
Na-139 O

 O
K-3.7 O
Cl-107 O
HCO3 O
- O
25 O
AnGap-11 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
18 O
* O
* O
] O
02:50PM O
BLOOD O
LD(LDH)-194 O
TotBili-0.5 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
12:15PM O
BLOOD O
Lipase-27 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
15 O
* O
* O
] O
03:17AM O
BLOOD O
CK-MB-NotDone O
cTropnT-0.03 O
* O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
14 O
* O
* O
] O
12:15PM O
BLOOD O
cTropnT-0.03 O
* O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
19 O
* O
* O
] O
04:22AM O
BLOOD O
Calcium-8.5 O
Phos-2.7 O
Mg-2.1 O

 O
[ O
* O
* O
2169 O
- O
1 O
- O
18 O
* O
* O
] O
02:50PM O
BLOOD O
Hapto-168 O


 O
[ O
* O
* O
2169 O
- O
1 O
- O
18 O
* O
* O
] O
11:00 O
am O
SPUTUM O
      O
Source O
: O
Endotracheal O
. O


    O
GRAM O
STAIN O
( O
Final O
[ O
* O
* O
2169 O
- O
1 O
- O
18 O
* O
* O
] O
) O
: O

       O
[ O
* O
* O
10 O
- O
16 O
* O
* O
] O
PMNs O
and O
< O
10 O
epithelial O
cells/100X O
field O
. O

       O
1 O
+ O
    O
( O
< O
1 O
per O
1000X O
FIELD O
) O
: O
   O
MULTIPLE O
ORGANISMS O

 O
CONSISTENT O
WITH O

                                     O
OROPHARYNGEAL O
FLORA O
. O

       O
3 O
+ O
  O
( O
5 O
- O
10 O
per O
1000X O
FIELD O
) O
: O
   O
GRAM O
NEGATIVE O
ROD(S O
) O
. O


    O
RESPIRATORY O
CULTURE O
( O
Preliminary O
) O
: O

       O
Further O
incubation O
required O
to O
determine O
the O
presence O
or O

 O
absence O
of O

       O
commensal O
respiratory O
flora O
. O

       O
GRAM O
NEGATIVE O
ROD(S O
) O
. O
    O
MODERATE O
GROWTH O
. O


 O
[ O
* O
* O
2169 O
- O
1 O
- O
16 O
* O
* O
] O
8:30 O
pm O
URINE O
      O
Source O
: O
Catheter O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2169 O
- O
1 O
- O
19 O
* O
* O
] O
* O
* O


    O
URINE O
CULTURE O
( O
Final O
[ O
* O
* O
2169 O
- O
1 O
- O
19 O
* O
* O
] O
) O
: O

       O
ESCHERICHIA O
COLI O
. O
    O
> O
100,000 O
ORGANISMS/ML O
.. O

          O
PRESUMPTIVE O
IDENTIFICATION O
. O

          O
WARNING O
! O
This O
isolate O
is O
an O
extended-spectrum O

 O
beta-lactamase O

          O
( O
ESBL O
) O
producer O
and O
should O
be O
considered O
resistant O
to O

 O
all O

          O
penicillins B-DRUG
, I-DRUG
cephalosporins B-DRUG
, I-DRUG
and O
aztreonam B-DRUG
. I-DRUG
Consider O

 O
Infectious O

          O
Disease O
consultation O
for O
serious O
infections O
caused O
by O

          O
ESBL-producing O
species O
. O


                               O
SENSITIVITIES O
: O
MIC O
expressed O
in O

 O
MCG/ML O



 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

                              O
ESCHERICHIA O
COLI O

                              O
| O

 O
AMPICILLIN------------ B-DRUG
  O
= O
> O
32 O
R O

 O
AMPICILLIN/SULBACTAM-- B-DRUG
  O
= O
> O
32 O
R O

 O
CEFAZOLIN------------- B-DRUG
  O
= O
> O
64 O
R O

 O
CEFEPIME-------------- B-DRUG
  O
= O
> O
64 O
R O

 O
CEFTAZIDIME----------- B-DRUG
       O
R O

 O
CEFTRIAXONE----------- B-DRUG
  O
= O
> O
64 O
R O

 O
CIPROFLOXACIN--------- B-DRUG
   O
= O
> O
4 O
R O

 O
GENTAMICIN------------ B-DRUG
     O
4 O
S O

 O
MEROPENEM-------------<=0.25 B-DRUG
S O

 O
NITROFURANTOIN-------- B-DRUG
    O
64 O
I O

 O
PIPERACILLIN/TAZO----- B-DRUG
    O
32 O
I O

 O
TOBRAMYCIN------------ B-DRUG
     O
4 O
S O

 O
TRIMETHOPRIM/SULFA---- B-DRUG
  O
= O
> O
16 O
R O


 O
URINE O
CULTURE O
( O
Final O
[ O
* O
* O
2169 O
- O
1 O
- O
18 O
* O
* O
] O
) O
: O

       O
ESCHERICHIA O
COLI O
. O
    O
> O
100,000 O
ORGANISMS/ML O
.. O

          O
WARNING O
! O
This O
isolate O
is O
an O
extended-spectrum O

 O
beta-lactamase O

          O
( O
ESBL O
) O
producer O
and O
should O
be O
considered O
resistant O
to O

 O
all O

          O
penicillins B-DRUG
, I-DRUG
cephalosporins B-DRUG
, I-DRUG
and O
aztreonam B-DRUG
. I-DRUG
Consider O

 O
Infectious O

          O
Disease O
consultation O
for O
serious O
infections O
caused O
by O

          O
ESBL-producing O
species O
. O

       O
KLEBSIELLA O
PNEUMONIAE O
. O
    O
10,000 O
- O
100,000 O
ORGANISMS/ML O
.. O


                               O
SENSITIVITIES O
: O
MIC O
expressed O
in O

 O
MCG/ML O


 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

                              O
ESCHERICHIA O
COLI O

                              O
| O
          O
KLEBSIELLA O
PNEUMONIAE O

                              O
| O
          O
| O

 O
AMPICILLIN------------ B-DRUG
  O
= O
> O
32 O
R O

 O
AMPICILLIN/SULBACTAM-- B-DRUG
  O
= O
> O
32 O
R O
      O
< O
= O
2 O
S O

 O
CEFAZOLIN------------- B-DRUG
  O
= O
> O
64 O
R O
      O
< O
= O
4 O
S O

 O
CEFEPIME-------------- B-DRUG
    O
32 O
R O
      O
< O
= O
1 O
S O

 O
CEFTAZIDIME----------- B-DRUG
       O
R O
      O
< O
= O
1 O
S O

 O
CEFTRIAXONE----------- B-DRUG
  O
= O
> O
64 O
R O
      O
< O
= O
1 O
S O

 O
CIPROFLOXACIN--------- B-DRUG
   O
= O
> O
4 O
R O
   O
< O
= O
0.25 O
S O

 O
GENTAMICIN------------ B-DRUG
     O
2 O
S O
      O
< O
= O
1 O
S O

 O
MEROPENEM-------------<=0.25 B-DRUG
S O
   O
< O
= O
0.25 O
S O

 O
NITROFURANTOIN-------- B-DRUG
    O
64 O
I O
     O
< O
= O
16 O
S O

 O
PIPERACILLIN/TAZO----- B-DRUG
    O
32 O
I O
      O
< O
= O
4 O
S O

 O
TOBRAMYCIN------------ B-DRUG
     O
4 O
S O
      O
< O
= O
1 O
S O

 O
TRIMETHOPRIM/SULFA---- B-DRUG
  O
= O
> O
16 O
R O
      O
< O
= O
1 O
S O


 O
Blood O
Cultures O
: O
NGTD O


 O
CT O
Head O
[ O
* O
* O
1 O
- O
14 O
* O
* O
] O

 O
IMPRESSION O
: O


 O
1 O
. O
No O
definite O
acute O
intracranial O
pathology O
. O
No O
bleed O
or O

 O
evidence O
for O
acute O

 O
vascular O
territorial O
infarction O
. O
However O
, O
if O
there O
is O
concern O

 O
for O
acute O

 O
infarct O
, O
MRI O
with O
diffusion- O
weighted O
imaging O
, O
if O
feasible O
, O
is O

 O
more O
sensitive O
. O



 O
2 O
. O
Chronic O
small O
vessel O
microvascular O
infarction O
and O
global O

 O
parenchymal O

 O
atrophy O
. O


 O
3 O
. O
Secretions O
within O
bilateral O
sphenoid O
and O
right O
mastoid O
apical O

 O
air O
cells O
, O

 O
some O
of O
which O
may O
relate O
to O
the O
( O
reported O
) O
presence O
of O

 O
tracheostomy O
. O


 O
CXR O
[ O
* O
* O
1 O
- O
18 O
* O
* O
] O
: O

 O
The O
ET O
tube O
tip O
is O
4 O
cm O
above O
the O
carina O
. O
Cardiomediastinal O

 O
silhouette O
is O

 O
unchanged O
. O
There O
is O
slight O
interval O
improvement O
in O
vascular O

 O
engorgement O
. O
No O

 O
change O
in O
bibasal O
left O
more O
than O
right O
atelectasis O
is O
seen O
. O



 O
Brief O
Hospital O
Course O
: O

 O
# O
Acute O
on O
Chronic O
respiratory O
failure O
: O
  O
The O
patient O
was O

 O
admitted O
due O
to O
altered O
mental O
status O
and O
low O
tidal O
volumes O
. O

 O
The O
patient O
with O
known O
traumatic O
intubation O
at O
OSH O
c/b O
tracheal O

 O
injury O
, O
and O
trached O
here O
requiring O
multiple O
revisions O
. O
  O
Also O

 O
with O
COPD O
. O
Patient O
went O
into O
respiratory O
distress O
with O
hypoxia O

 O
and O
hypotension B-REA
. I-REA
  O
She O
was O
started O
on O
levophed B-DRUG
and O
[ O
* O
* O
Month/Year O
( O
2 O
) O
1834 O
* O
* O
] O

 O
emergent O
bronch O
. O
  O
The O
bronch O
showed O
granulation O
tissue O

 O
obstructing O
95 O
% O
of O
her O
tube O
. O
  O
The O
tube O
was O
passed O
farther O
down O

 O
past O
the O
site O
of O
obstruction O
and O
the O
patient O
's O
respiratory O

 O
status O
improved O
and O
was O
weaned O
off O
levophed B-DRUG
. I-DRUG
  O
The O
patient O
then O

 O
[ O
* O
* O
Month/Year O
( O
2 O
) O
1834 O
* O
* O
] O
repeat O
bronch O
the O
following O
day O
on O
[ O
* O
* O
1 O
- O
15 O
* O
* O
] O
that O
showed O

 O
the O
tube O
to O
be O
patent O
and O
the O
tracheal O
laceration O
to O
be O
healing O

 O
well O
. O
  O
The O
patient O
's O
respiratory O
status O
remained O
stable O
and O
her O

 O
ventilator O
settings O
at O
the O
time O
of O
dicharge O
were O
: O
CMV O
, O
Vt O

 O
(Set):450 O
, O
RR O
( O
Set O
) O
: O
14 O
, O
PEEP O
: O
5 O
cmH2O O
, O
and O
FiO2 O
: O
40 O
% O
. O
  O
The O

 O
patient O
was O
also O
treated O
for O
a O
VAP B-REA
based O
on O
CXR O
( O
left O

 O
retrocardiac O
opcaity O
and O
increasing O
sputum O
) O
. O
  O
She O
was O
started O
on O

 O
Vanco/Cefepime B-DRUG
on O
[ O
* O
* O
1 O
- O
16 O
* O
* O
] O
for O
presumed O
VAP B-REA
. I-REA
  O
She O
was O
then O
changed O

 O
to O
Vanco/Meropenem B-DRUG
given O
her O
ESBL B-REA
urine I-REA
cx I-REA
results I-REA
. I-REA
  O
Her O
sputum O

 O
subsequently O
grew O
out O
GNR B-REA
and O
she O
will O
continue O
vancomycin B-DRUG
and O

 O
meropenem B-DRUG
for B-DUR
a I-DUR
planned I-DUR
8 I-DUR
day I-DUR
course I-DUR
( O
last O
day:[**1 O
- O
24 O
* O
* O
] O
) O
. O
  O
A O
PICC O

 O
line O
was O
placed O
on O
[ O
* O
* O
1 O
- O
18 O
* O
* O
] O
. O
  O
The O
patient O
did O
have O
a O
low O
grade O
temp O

 O
of O
100.5 O
at O
the O
time O
of O
discharge O
. O
  O
This O
was O
discussed O
with O
Dr. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
84121 O
* O
* O
] O
at O
[ O
* O
* O
Hospital1 O
* O
* O
] O
and O
is O
aware O
. O



 O
# O
. O
VAP B-REA
: I-REA
See O
above O
for O
respiratory O
course O
. O
  O
Patient O
with O
planned O

 O
8 B-DUR
day I-DUR
course O
of O
meropenem B-DRUG
with O
final O
day O
being O
[ O
* O
* O
2169 O
- O
1 O
- O
24 O
* O
* O
] O
. O
  O
Sputum O

 O
is O
currently O
growing O
GNR O
and O
needs O
to O
be O
followed O
up O
for O
final O

 O
speciation O
and O
sensitivities O
. O


 O
# O
UTI B-REA
: I-REA
The O
patient O
was O
intially O
treated O
with O
ciprofloxacin B-DRUG
on O

 O
admission O
for O
a O
positive B-REA
UA I-REA
. I-REA
  O
She O
was O
then O
broadened O
to O

 O
Vanco/Cefepime B-DRUG
given O
she O
was O
at O
rehab O
for O
resistant B-REA
organisms I-REA
. I-REA

 O
The O
UCx O
returned O
ESBL B-REA
E. I-REA
Coli I-REA
and O
was O
switched O
to O
meropenem B-DRUG
for O

 O
a O
planned O
8 B-DUR
day I-DUR
course O
( O
last O
day O
[ O
* O
* O
2169 O
- O
1 O
- O
24 O
* O
* O
] O
) O
. O


 O
# O
Altered O
mental O
status O
: O
  O
The O
patient O
came O
in O
minimally O
reactive O

 O
which O
was O
a O
change O
from O
her O
baseline O
per O
the O
family O
. O
  O
Her O
change O

 O
in O
mental O
status O
was O
attributed O
to O
her O
infection O
and O
after O

 O
treatment O
for O
her O
VAP O
and O
UTI O
her O
mental O
status O
returned O
to O

 O
baseline O
. O
  O
She O
is O
able O
to O
follow O
very O
simple O
commands O
and O
answer O

 O
some O
simple O
yes/no O
questions O
. O


 O
# O
CHF B-REA
: I-REA
  O
The O
patient O
had O
an O
EF O
25 O
% O
per O
report O
. O
  O
Her O
metoprolol B-DRUG

 I-DRUG
and O
lisinopril B-DRUG
was O
held O
given O
her O
infection O
and O
normal O
blood O

 O
pressure O
. O
Additionally O
, O
her O
lasix B-DRUG
was O
initially O
held O
. O
  O
The O

 O
patient O
was O
restarted O
on O
her O
metoprolol B-DRUG
at O
12.5 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
, O
but O

 O
several O
doses O
were O
held O
secondary O
to O
hypotension O
and O

 O
bradycardia O
. O
  O
Her O
blood O
pressure O
and O
heart O
rate O
should O
be O

 O
monitored O
at O
rehab O
and O
titrate O
metoprolol B-DRUG
accordingly O
. O
  O
The O

 O
patient O
was O
restarted O
on O
her O
lasix B-DRUG
20 B-STR
mg I-STR
po B-ROU
BID B-FRE
given O
her O
volume B-REA

 I-REA
overload I-REA
. I-REA
Her O
weight O
, O
respirtory O
status O
and O
I/O O
should O
be O

 O
monitored O
and O
lasix B-DRUG
titrated O
at O
rehab O
. O


 O
# O
Anemia O
: O
The O
patient O
admission O
Hct O
was O
26 O
and O
slowly O
trended O

 O
down O
to O
Hct O
21 O
. O
  O
Her O
hemolysis O
labs O
were O
negative O
and O
there O
were O

 O
no O
signs O
of O
active O
bleeding O
. O
  O
Her O
guaiac O
was O
negative O
. O
  O
She O
was O

 O
trnasfused O
one O
unit O
[ O
* O
* O
1 O
- O
18 O
* O
* O
] O
and O
her O
Hct O
remained O
stable O
. O
  O
Upon O

 O
discharge O
her O
Hct O
was O
25.7 O
. O


 O
# O
PEs B-REA
: I-REA
  O
Patient O
with O
recent O
diagnosis O
in O
[ O
* O
* O
11 O
- O
30 O
* O
* O
] O
. O
  O
The O
patient O
was O

 O
continued O
on O
coumadin B-DRUG
3 B-STR
mg I-STR
daily B-FRE
and O
brdiged O
with O
lovenox B-DRUG
60 B-STR
mg I-STR

 I-STR
q12 B-FRE
for O
a O
subtherapeutic B-REA
INR I-REA
. I-REA
  O
Upon O
discharge O
her O
coumadin B-DRUG
was O

 O
increased O
to O
5 B-STR
mg I-STR
daily B-FRE
and O
continued O
on O
lovenox B-DRUG
60 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
until O

 O
INR O
> O
2.0 O
. O



 O
# O
C2 O
fracture O
: O
  O
Patient O
with O
C2 O
fracture O
after O
a O
fall O
on O
[ O
* O
* O
10 O
- O
31 O
* O
* O
] O
. O

 O
She O
was O
maintained O
on O
a O
[ O
* O
* O
Location O
( O
un O
) O
2848 O
* O
* O
] O
J-collar O
. O
  O
The O
patient O
should O
have O

 O
follow-up O
with O
neurosurgery O
as O
an O
outpatient O
. O


 O
# O
AFib B-REA
: I-REA
  O
Patient O
's O
metoprolol B-DRUG
was O
initially O
held O
due O
to O
ongoing O

 O
infection O
. O
  O
Her O
metoprolol B-DRUG
was O
restarted O
on O
12.5 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
and O

 O
continued O
on O
systemic O
coagulation O
. O


 O
Medications O
on O
Admission O
: O

 O
1 O
. O
Chlorhexidine B-DRUG
Gluconate I-DRUG
0.12 B-STR
% O
Mouthwash B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML I-DOS

 I-DOS
Mucous B-ROU
membrane I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
2 O
. O
Therapeutic B-DRUG
Multivitamin I-DRUG
     O
Liquid B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
DAILY B-FRE


 I-FRE
3 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
90 B-STR
mcg/Actuation I-STR
HFA B-FOR
Aerosol I-FOR
Inhaler I-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O

 O
Six B-DOS
( I-DOS
6 I-DOS
) I-DOS
Puff B-FOR
Inhalation B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
17 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Six B-DOS
( I-DOS
6 I-DOS
) I-DOS

 I-DOS
Puff B-FOR
Inhalation B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
6 O
. O
Furosemide B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
7 O
. O
Potassium B-DRUG
Chloride I-DRUG
20 B-STR
mEq I-STR
Packet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
packet B-FOR
PO B-ROU
twice O



 O
a O
day O
: O
adjust O
as O
labs O
or O
lasix B-DRUG
adjusted O
. O

 O
8 O
. O
Oxycodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
325 I-STR
mg/5 I-STR
mL I-STR
Solution B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS

 I-DOS
ML I-DOS
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
9 O
. O
Acetylcysteine B-DRUG
20 B-STR
% I-STR
( I-STR
200 I-STR
mg/mL I-STR
) I-STR
Solution B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
ML I-DOS

 I-DOS
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
10 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( I-STR
0.083 I-STR
% I-STR
) I-STR
Solution B-FOR
for I-FOR

 I-FOR
Nebulization I-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
ml O
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
11 O
. O
Warfarin B-DRUG
3 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE
bedtime I-FRE
: I-FRE
goal B-REA

 I-REA
INR I-REA
for I-REA
afib I-REA
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
. O
rehab O
MD O
to O
adjust O
coumadin B-DRUG
dose O
based O
on O
INR O
. O

 O
stop O
heparin B-DRUG
gtt B-ROU
once O
INR O
> O
2.0 O
. O

 O
12 O
. O
Lansoprazole B-DRUG
30 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
, I-FOR
DR I-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
PO B-ROU

 I-ROU
DAILY B-FRE

 I-FRE
13 O
. O
Sodium B-DRUG
Chloride I-DRUG
0.9 B-STR
% I-STR
  O
Flush B-FOR
10 B-DOS
mL I-DOS
IV B-ROU
PRN B-FRE
line B-REA
flush I-REA

 I-REA
14 O
. O
Lisinopril B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
daily B-FRE

 I-FRE
15 O
. O
Simvastatin B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE
bedtime I-FRE
. I-FRE


 O
16 O
. O
Heparin B-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
in I-DRUG
D5W I-DRUG
25,000 B-STR
unit/250 I-STR
mL I-STR
Parenteral B-FOR

 I-FOR
Solution I-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
Seven B-DOS
Hundred I-DOS
( I-DOS
700 I-DOS
) I-DOS
units B-FOR
Intravenous B-ROU
ASDIR B-FRE
( I-FRE
AS I-FRE

 I-FRE
DIRECTED I-FRE
) I-FRE
: I-FRE
adjust O
for O
PTT O
60 O
- O
80 O
. O
check O
q O
6 O
hrs O
or O
per O
protocol O

 O
if O
stable O
> O
24 O
hrs O
. O
stop O
when O
INR O
> O
2.0 O
. O



 O

Discharge O
Medications O
: O

 O
1 O
. O
Bisacodyl B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( O
E.C. O
) O
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O

 O
Constipation B-REA
. I-REA

 O
2 O
. O
Docusate B-DRUG
Sodium I-DRUG
50 B-STR
mg/5 I-STR
mL I-STR
Liquid B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
17 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
Six B-DOS
( I-DOS
6 I-DOS
) I-DOS

 I-DOS
Puff B-FOR
Inhalation B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Simvastatin B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Oxycodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
325 I-STR
mg/5 I-STR
mL I-STR
Solution B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS

 I-DOS
ML I-DOS
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
6 O
. O
Chlorhexidine B-DRUG
Gluconate I-DRUG
0.12 B-STR
% O
Mouthwash B-FOR
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
ML B-FOR

 I-FOR
Mucous B-ROU
membrane I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
mouthcare B-REA
. I-REA

 O
7 O
. O
Cholecalciferol B-DRUG
( O
Vitamin B-DRUG
D3 I-DRUG
) I-DRUG
400 B-STR
unit I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Calcium B-DRUG
Carbonate I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Therapeutic B-DRUG
Multivitamin I-DRUG
     O
Liquid B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML B-FOR
PO B-ROU
daily B-FRE

 I-FRE
( O
) O
. O

 O
10 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Acetylcysteine B-DRUG
20 B-STR
% I-STR
( I-STR
200 I-STR
mg/mL I-STR
) I-STR
Solution B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
ML B-FOR

 I-FOR
Miscellaneous O
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
thick B-REA

 I-REA
secretions I-REA
. I-REA

 O
12 O
. O
Enoxaparin B-DRUG
60 B-STR
mg/0.6 I-STR
mL I-STR
Syringe B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Subcutaneous B-ROU

 I-ROU
Q12H B-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
90 B-STR
mcg/Actuation I-STR
HFA B-FOR
Aerosol I-FOR
Inhaler I-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O

 O
Six B-DOS
( I-DOS
6 I-DOS
) I-DOS
Puff B-FOR
Inhalation B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O

 O
wheezes B-REA
. I-REA

 O
14 O
. O
Furosemide B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O

15 O
. O
Warfarin B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Once B-FRE
Daily I-FRE
at I-FRE
4 I-FRE

 I-FRE
PM I-FRE
. I-FRE

 O
16 O
. O
Famotidine B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q12H B-FRE
( I-FRE
every I-FRE

 I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
17 O
. O
Meropenem B-DRUG
500 B-STR
mg I-STR
Recon B-FOR
Soln I-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Recon B-FOR
Soln I-FOR

 I-FOR
Intravenous B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
18 O
. O
Vancomycin B-DRUG
1,000 B-STR
mg I-STR
Recon B-FOR
Soln I-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Intravenous B-ROU
Q O

 O
24H O
( O
Every O
24 O
Hours O
) O
. O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital1 O
700 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
701 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Urinary O
tract O
Infection- O
E.coli O
( O
ESBL O
) O

 O
Pneumonia O



 O
Discharge O
Condition O
: O

 O
Level O
of O
Consciousness O
: O
Lethargic O
but O
arousable O

 O
Activity O
Status O
: O
Bedbound O

 O
Mental O
Status O
: O
Patient O
has O
trach O
, O
arousable O
but O
not O
following O
any O

 O
commands O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
hospital O
for O
concerns O
of O
a O
urinary B-REA

 I-REA
traction I-REA
infection I-REA
and O
pneumonia B-REA
. I-REA
You O
were O
treated O
with O

 O
antibiotics B-DRUG
and O
will O
need O
to O
complete O
this O
course O
while O
at O

 O
rehab O
. O


 O
Followup O
Instructions O
: O




 O
Completed O
by:[**2169 O
- O
1 O
- O
19 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2185 O
- O
11 O
- O
15 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2185 O
- O
11 O
- O
24 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2126 O
- O
1 O
- O
11 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Keflex B-DRUG
/ O
Ciprofloxacin B-DRUG
/ O
Ertapenem B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
943 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
altered O
mental O
status O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Status O
post O
airway O
intubation O
( O
performed O
at O
outside O
hospital O
, O

 O
extubated O
here O
) O

 O
PICC O
placement O
[ O
* O
* O
2185 O
- O
11 O
- O
17 O
* O
* O
] O



 O
History O
of O
Present O
Illness O
: O

 O
Hepatologist O
: O
  O
Dr. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
497 O
* O
* O
] O

 O
PCP O
: O
  O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O

 O
. O

 O
Ms. O
[ O
* O
* O
Known O
lastname O
92101 O
* O
* O
] O
is O
a O
59yo O
woman O
with O
h/o O
Hepatitic O
C O
Cirrhosis O
with O

 O
portal O
hypertension O
s/p O
TIPS O
, O
MELD O
score O
23 O
, O
who O
presented O
to O
an O

 O
OSH O
with O
altered O
mental O
status O
. O

 O
. O

 O
Her O
father O
found O
her O
on O
the O
morning O
of O
admission O
with O
her O
legs O

 O
hanging O
over O
the O
side O
of O
the O
bed O
. O
  O
She O
was O
unresponsive O
. O
  O
The O

 O
family O
reports O
that O
she O
had O
been O
feeling O
well O
at O
home O
but O

 O
becoming O
increasingly O
confused O
. O
  O
They O
admit O
that O
she O
often O

 O
fights O
against O
taking O
lactulose B-DRUG
, I-DRUG
though O
they O
feel O
she O
is O
largely O

 O
compliant O
with O
it O
. O
  O
She O
may O
have O
spit O
out O
her O
lactulose B-DRUG
dose O

 O
last O
night O
. O
  O
Otherwise O
, O
ROS O
significant O
for O
some O
nausea O
. O
  O
She O

 O
has O
nevertheless O
been O
eating O
and O
drinking O
well O
. O
  O
No O
diarrhea O
. O

 O
No O
fevers O
. O

 O
. O

 O
When O
EMS O
arrived O
, O
her O
blood O
sugar O
was O
146 O
. O
  O
She O
was O
noted O
to O
be O

 O
incontinent O
of O
urine O
. O

 O
. O


 O
Upon O
arrival O
to O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Hospital3 O
6783 O
* O
* O
] O
, O
her O
VS O
were O
129/60 O
   O
117 O
   O
21 O

 O
98 O
% O
RA O
. O
  O
She O
was O
intubated O
because O
of O
failure O
to O
protect O
her O

 O
airway O
. O
  O
Although O
the O
lowest O
recorded O
temp O
was O
96.2 O
rectally O
, O

 O
she O
was O
noted O
as O
being O
hypothermic O
and O
a O
bair O
hugger O
was O
placed O
. O

  O
Labs O
were O
notable O
for O
K O
of O
6.2 O
and O
non-gap O
acidosis O
with O
HCO3 O

 O
of O
14 O
. O
  O
Lactate O
was O
elevated O
at O
5.6 O
. O
  O
WBC O
elevated O
at O
16 O
with O

 O
Hct O
and O
Cr O
at O
baseline O
. O
  O
UA O
significant O
for O
large O
leukocytes O
and O

 O
negative O
nitrites O
. O
  O
CT O
Head O
without O
contrast O
revealed O
vague O
area O

 O
of O
low O
attenuation O
in O
the O
lft O
frontal O
region O
, O
? O
related O
to O
small O

 O
vessel O
ischemia O
. O
  O
There O
was O
no O
evidence O
of O
bleed O
, O
mass O
, O
or O

 O
midline O
shift O
. O
  O
CXR O
revealed O
vascular O
congestion O
. O
  O
She O
was O

 O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
further O
care O
. O

 O
. O

 O
Upon O
arrival O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
MICU O
, O
she O
was O
intubated O
. O
  O
Further O
history O

 O
was O
obtained O
via O
phone O
call O
through O
the O
patient O
's O
son O
. O

 O
. O

 O
ROS O
: O
  O
unable O
to O
obtain O



 O
Past O
Medical O
History O
: O

 O
Hepatitis O
C O
, O
Genotype O
1 O
: O
Diagnosed O
in O
[ O
* O
* O
2185 O
- O
1 O
- O
8 O
* O
* O
] O
with O
last O

 O
VL O
263,000 O
in O
[ O
* O
* O
8-/2185 O
* O
* O
] O

 O
Cirrhosis B-ADE
( O
Methotrexate B-DRUG
and O
Hepatitis O
C O
Induced O
) O

 O
Portal O
Hypertension O

 O
Chronic O
Kidney O
Disease O
with O
baseline O
Cr O
1.8 O
- O
2.0 O

 O
Diastolic O
CHF O
: O
Grade O
I O
diastolic O
dysfunction O
[ O
* O
* O
7 O
- O
17 O
* O
* O
] O
, O
EF O
75 O
% O

 O
Ascites O
Diuretic-Resistant O

 O
Esophageal O
Varices O
per O
report O
; O
however O
, O
EGD O
[ O
* O
* O
7-/2185 O
* O
* O
] O
reports O

 O
normal O
esophagus O

 O
Psoriasis B-REA
with I-REA
Arthropathy I-REA
- O
s/p O
Methotrexate B-DRUG
x B-DUR
15 I-DUR
years I-DUR
( O
MTX B-DRUG

 I-DRUG
d/c O
in O
12.07 O
when O
patient O
developed O
ascites B-ADE
and O
now O
uses O

 O
halobetasol B-DRUG
cream B-FOR
) I-FOR

 O
Anemia O
with O
baseline O
Hct O
25 O
- O
30 O

 O
Thyroid O
nodule O
2.2 O
cm O
identified O
on O
ultrasound O
[ O
* O
* O
9 O
- O
16 O
* O
* O
] O
, O
needs O
Bx O

 O
( O
has O
f/u O
in O
Thyroid O
nodule O
clinic O
) O

 O
Admission O
[ O
* O
* O
Date O
range O
( O
1 O
) O
92102 O
* O
* O
] O
: O
  O
for O
elective O
TIPS O
, O
also O
had O
UTI O

 O
Admission O
[ O
* O
* O
Date O
range O
( O
1 O
) O
92103 O
* O
* O
] O
: O
  O
for O
hyponatremia O
and O
ARF O

 O
Foot O
drop O
from O
peroneal O
nerve O
injury O
during O
TIPS O
procedure O
( O
per O

 O
DC O
summary O
) O

 O
Hyponatremia O
with O
baseline O
Na O
128 O
- O
130 O

 O
. O



 O
Social O
History O
: O

 O
Quit O
smoking O
in O
[ O
* O
* O
2184 O
* O
* O
] O
. O
  O
No O
alcohol O
problems O
, O
no O
drugs O
. O

 O
Lives O
with O
her O
son O
and O
her O
father O
. O

 O
Uses O
a O
cane O
and O
walker O
. O



 O

Family O
History O
: O

 O
no O
FH O
of O
liver O
disease O


 O
Physical O
Exam O
: O

 O
vitals O
: O
97.7 O
   O
131 O
    O
122/72 O
    O
26 O
    O
100 O
% O
on O
AC O
100 O
% O
  O
500/16 O

 O
PEEP O
+ O
5 O
. O

 O
Gen O
: O
Intubated O
, O
not O
responsive O
to O
voice O
but O
does O
move O
upon O
touch O

 O
and O
withdraw O
from O
painful O
stimuli O
( O
not O
on O
sedating O
meds O
) O

 O
HEENT O
: O
Eyelids O
closed O
, O
eyes O
are O
often O
gazing O
to O
the O
right O
but O

 O
she O
will O
move O
her O
eyes O
to O
midline O
to O
look O
toward O
examiner O
. O

 O
Pupils O
equally O
reactive O
, O
not O
pinpoint O
. O

 O
Face O
symmetric O
, O
mucous O
membranes O
moist O
. O

 O
Neck O
: O
supple O
, O
small O
thyroid O
nodule O
in O
mid-left O
thyroid O
. O

 O
CV O
: O
S1 O
, O
S2 O
, O
regular O
tachycardia O
with O
I/VI O
systolic O
murmur O
at O

 O
LUSB O
, O
non-radiating O
. O

 O
Lungs O
: O
clear O
b/l O
, O
no O
crackles O
appreciated O
. O

 O
Abd O
: O
obese O
with O
ascites O
, O
BS O
present O
. O
  O
umbilical O
veins O
prominent O
. O

  O
Soft O
and O
she O
does O
not O
flinch O
with O
palpation O
. O

 O
Hepatosplenomegaly O
. O

 O
Skin O
: O
Flaking O
, O
dry O
skin O
on O
scalp O
and O
LE O
b/l O
. O
  O
Large O
skin O
tear O
on O

 O
right O
calf O
. O
  O
Violaceous O
plaques O
on O
chest O
and O
raised O
subcutaneous O

 O
areas O
on O
her O
right O
arm O
. O

 O
Ext O
: O
Erythema O
of O
LE O
, O
L O
> O
R O
, O
but O
not O
particularly O
warm O
. O
  O
2 O
+ O
edema O

 O
of O
LE O
b/l O
. O
  O
Distal O
pulses O
+ O
1 O
b/l O
. O

 O
Neuro O
: O
No O
asterixis O
when O
hands O
are O
extended O
at O
wrists O
. O

 O
. O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
24 O
* O
* O
] O
06:27AM O
BLOOD O
WBC-9.8 O
RBC-2.74 O
* O
Hgb-8.4 O
* O
Hct-25.3 O
* O

 O
MCV-92 O
MCH-30.7 O
MCHC-33.3 O
RDW-17.3 O
* O
Plt O
Ct-164 O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
23 O
* O
* O
] O
05:00AM O
BLOOD O
WBC-9.2 O
RBC-2.75 O
* O
Hgb-8.7 O
* O
Hct-25.2 O
* O

 O
MCV-92 O
MCH-31.7 O
MCHC-34.6 O
RDW-17.5 O
* O
Plt O
Ct-149 O
* O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
16 O
* O
* O
] O
06:00AM O
BLOOD O
Neuts-77.3 O
* O
Lymphs-15.9 O
* O
Monos-5.1 O

 O
Eos-1.5 O
Baso-0.2 O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
24 O
* O
* O
] O
06:27AM O
BLOOD O
PT-19.9 O
* O
PTT-46.1 O
* O
INR(PT)-1.9 O
* O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
23 O
* O
* O
] O
05:00AM O
BLOOD O
PT-21.2 O
* O
PTT-48.8 O
* O
INR(PT)-2.0 O
* O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
24 O
* O
* O
] O
06:27AM O
BLOOD O
Glucose-146 O
* O
UreaN-23 O
* O
Creat-1.5 O
* O
Na-129 O
* O

 O
K-3.7 O
Cl-103 O
HCO3 O
- O
19 O
* O
AnGap-11 O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
23 O
* O
* O
] O
05:00AM O
BLOOD O
Glucose-156 O
* O
UreaN-22 O
* O
Creat-1.4 O
* O
Na-131 O
* O

 O
K-3.8 O
Cl-106 O
HCO3 O
- O
21 O
* O
AnGap-8 O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
24 O
* O
* O
] O
06:27AM O
BLOOD O
ALT-19 O
AST-29 O
LD(LDH)-239 O
AlkPhos-94 O

 O
TotBili-1.7 O
* O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
24 O
* O
* O
] O
06:27AM O
BLOOD O
Albumin-2.9 O
* O
Calcium-9.7 O
Phos-3.1 O
Mg-1.9 O

 O
. O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
16 O
* O
* O
] O
CT O
Head O
without O
constrast O
: O
  O
No O
acute O
intracranial O

 O
process O

 O
. O


 O
[ O
* O
* O
2185 O
- O
11 O
- O
16 O
* O
* O
] O
MR O
[ O
* O
* O
Name13 O
( O
STitle O
) O
430 O
* O
* O
] O
and O
Brain O
without O
contrast O
: O
  O
Limited O
study O
due O

 O
to O
motion O
artifact O
. O
No O
contrast O
was O
administered O
due O
to O
the O

 O
patient O
's O
inability O
to O
further O
cooperate O
and O
the O
marginal O
renal O

 O
status O
. O
There O
is O
no O
evidence O
of O
infarction O
. O
The O
MRA O
demonstrates O

 O
a O
dominant O
and O
patent O
right O
vertebral O
artery O
with O
a O
tiny O
, O
but O

 O
apparently O
patent O
left O
vertebral O
artery O
, O
and O
patent O
internal O

 O
carotid O
arteries O
bilaterally O
. O
The O
remainder O
of O
the O
study O
, O

 O
although O
limited O
, O
demonstrates O
no O
evidence O
of O
hemorrhage O
or O

 O
other O
abnormalities O
. O

 O
. O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
17 O
* O
* O
] O
CT O
abd O
and O
pelvis O
w/o O
contrast O
: O
1 O
. O
No O
evidence O
of O

 O
hemoperitoneum O
or O
retroperitoneal O
hemorrhage O
. O

 O
2 O
. O
Cirrhotic O
liver O
, O
with O
signs O
for O
portal O
hypertension O
with O
a O

 O
large O
amount O
of O
ascites O
. O

 O
3 O
. O
Consolidation O
within O
the O
lower O
lobes O
of O
the O
lungs O

 O
bilaterally O
, O
most O
likely O
represents O
atelectasis O
. O
However O
, O

 O
superimposed O
infection O
can O
not O
be O
excluded O
. O

 O
4 O
. O
Cholelithiasis O
. O

 O
5 O
. O
Anasarca O
. O

 O
. O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
22 O
* O
* O
] O
Liver O
, O
gallbladder O
u/s O
: O
1 O
. O
Patent O
TIPS O
with O
abnormally O

 O
high O
velocities O
within O
the O
mid O
and O
distal O
aspects O
of O
the O
shunt O
, O

 O
similar O
to O
the O
previous O
exam O
. O
Findings O
remain O
compatible O
with O

 O
TIPS O
malfunction O
. O

 O
2 O
. O
Limited O
evaluation O
of O
the O
left O
and O
anterior O
right O
portal O
vein O

 O
although O

 O
suggestion O
of O
abnormal O
directionality O
of O
flow O
within O
the O
left O

 O
portal O
vein O

 O
is O
compatible O
with O
shunt O
dysfunction O
. O

 O
3 O
. O
Cirrhotic O
liver O
with O
moderate-to-severe O
perihepatic O
ascites O

 O
and O

 O
cholelithiasis O
. O

 O
. O

 O
[ O
* O
* O
2185 O
- O
11 O
- O
24 O
* O
* O
] O
TTE O
: O
The O
left O
atrium O
is O
moderately O
dilated O
. O
Left O

 O
ventricular O
wall O
thickness O
, O
cavity O
size O
and O
regional/global O

 O
systolic O
function O
are O
normal O
( O
LVEF O
70 O
% O
) O
. O
There O
is O
no O
ventricular O

 O
septal O
defect O
. O
Right O
ventricular O
chamber O
size O
and O
free O
wall O

 O
motion O
are O
normal O
. O
The O
aortic O
valve O
leaflets O
( O
3 O
) O
are O
mildly O

 O
thickened O
but O
aortic O
stenosis O
is O
not O
present O
. O
No O
masses O
or O

 O
vegetations O
are O
seen O
on O
the O
aortic O
valve O
. O
The O
mitral O
valve O

 O
leaflets O
are O
mildly O
thickened O
. O
There O
is O
no O
mitral O
valve O

 O
prolapse O
. O
No O
mass O
or O
vegetation O
is O
seen O
on O
the O
mitral O
valve O
. O

 O
Trivial O
mitral O
regurgitation O
is O
seen O
. O
The O
estimated O
pulmonary O

 O
artery O
systolic O
pressure O
is O
normal O
. O
No O
vegetation/mass O
is O
seen O

 O
on O
the O
pulmonic O
valve O
. O
There O
is O
no O
pericardial O
effusion O
. O

 O
. O

 O
Compared O
with O
the O
findings O
of O
the O
prior O
study O
( O
images O
reviewed O
) O

 O
of O
[ O
* O
* O
2185 O
- O
10 O
- O
27 O
* O
* O
] O
, O
no O
major O
change O
is O
evident O
. O

 O
. O

 O
IMPRESSION O
: O
no O
obvious O
vegetations O
seen O



 O

Brief O
Hospital O
Course O
: O

 O
Ms. O
[ O
* O
* O
Known O
lastname O
92101 O
* O
* O
] O
is O
a O
59yo O
woman O
who O
presented O
w/ O
altered O
mental O

 O
status O
in O
the O
setting O
of O
Hep O
C O
cirrhosis O
. O


 O
# O
Altered O
Mental O
Status O
: O
Given O
her O
hx O
of O
hep O
C O
cirrhosis O
and O

 O
recent O
TIPs O
procedure O
, O
her O
AMS O
was O
thought O
to O
be O
most O
likely O
due O

 O
to O
hepatic B-REA
encephalopathyy I-REA
. I-REA
She O
was O
reported O
to O
have O
a O
hx O
of O

 O
poor O
compliance O
with O
lactulose B-DRUG
at O
home O
. O
  O
Of O
note O
, O
she O
has O
not O

 O
had O
other O
episodes O
of O
hepatic O
encephalopathy O
prior O
to O
this O
. O

 O
Head O
CT O
at O
OSH O
was O
negative O
. O
  O
Given O
her O
leukocytosis O
on O

 O
admission O
, O
infection O
, O
particularly O
SBP O
or O
pneumonia O
, O
were O
also O

 O
considered O
. O
Overdose O
was O
also O
a O
possibility O
, O
although O
family O

 O
denies O
drug O
use O
. O
Upon O
arrival O
in O
the O
MICU O
she O
was O
started O
on O

 O
lactulose B-DRUG
and O
rifaximine B-DRUG
. I-DRUG
She O
underwent O
a O
paracentesis O
to O
eval O

 O
for O
SBP O
, O
which O
had O
a O
negative O
gram O
stain O
and O
culture O
. O
Given O
her O

 O
AMS O
, O
she O
was O
considered O
high O
risk O
for O
aspiration O
, O
and O
she O
was O

 O
started O
on O
empiric O
treatment O
with O
vanc/aztreonam/azithromycin B-DRUG

 I-DRUG
( O
allergic B-ADE
to O
cipro B-DRUG
and O
keflex B-DRUG
) I-DRUG
for O
nosocomial B-REA
or I-REA
aspiration I-REA
PNA I-REA

 I-REA
vs O
SBP O
. O
While O
there O
was O
no O
known O
hx O
of O
EtOH O
abuse O
, O
thiamine B-DRUG
IV B-ROU

 I-ROU
was O
administered O
. O
On O
exam O
the O
pt O
had O
some O
focal O
findings O
of O

 O
persistent O
right-[**Hospital1 O
* O
* O
] O
and O
downward O
deviation O
of O
her O
eyes O
, O
with O

 O
inability O
to O
track O
past O
midline O
. O
She O
had O
a O
repeat O
head O
CT O
and O
an O

 O
MRI/MRA O
which O
were O
both O
without O
evidence O
of O
significant O

 O
pathology O
. O
Following O
extubation O
and O
decreased O
sedation O
, O
her O

 O
mental O
status O
improved O
and O
the O
focal O
eye O
findings O
resolved O
. O

 O
While O
not O
back O
at O
her O
baseline O
, O
pt O
was O
awake O
, O
alert O
, O
and O

 O
oriented O
x3 O
when O
she O
was O
transferred O
to O
the O
floor O
. O
Pt O
seen O
by O

 O
Neurology O
, O
but O
had O
already O
had O
significant O
improvement O
and O
no O

 O
focal O
findings O
. O
On O
the O
floor O
, O
her O
mental O
status O
continued O
to O

 O
improve O
. O
At O
time O
of O
discharge O
, O
she O
is O
back O
to O
baseline O
, O

 O
conversational O
, O
oriented O
x3 O
but O
at O
times O
is O
tearful O
. O
She O
is O

 O
being O
discharged O
on O
Rifaximin B-DRUG
and O
furosemide B-DRUG
. I-DRUG

 O
. O


 O
# O
Respiratory O
failure O
: O
Patient O
was O
intubated O
for O
airway O

 O
protection O
at O
OSH O
. O
  O
Her O
CXR O
here O
suggested O
a O
possible O
aspiration O

 O
pneumonia O
, O
which O
could O
have O
been O
[ O
* O
* O
3 O
- O
12 O
* O
* O
] O
to O
her O
AMS O
. O
  O
It O
is O
unclear O

 O
if O
she O
received O
IVF B-DRUG
at O
OSH O
. O
She O
was O
weaned O
off O
of O
the O
vent O

 O
quickly O
as O
she O
required O
minimal O
pressure O
support O
and O
had O
good O

 O
RSBIs O
. O
She O
was O
extubated O
on O
[ O
* O
* O
2185 O
- O
11 O
- O
17 O
* O
* O
] O
was O
satting O
well O
on O
room O
air O

 O
at O
the O
time O
of O
transfer O
to O
the O
floor O
. O
On O
discharge O
, O
she O

 O
continues O
to O
have O
oxygen O
saturations O
in O
the O
high O
90 O
's O
on O
room O

 O
air O
. O

 O
. O

 O
# O
Rash O
: O
Pt O
arrived O
in O
the O
MICU O
with O
three O
skin O
findings O
. O
Bullae O
, O

 O
blisters/breakdown O
, O
and O
a O
  O
diffuse O
maculopapular O
rash O
on O

 O
proximal O
legs O
and O
trunk O
. O
Dermatology O
was O
consulted O
. O
The O
blisters O

 O
and O
bullae O
were O
thought O
to O
be O
[ O
* O
* O
3 O
- O
12 O
* O
* O
] O
trauma O
in O
the O
setting O
of O

 O
coagulopathy O
due O
to O
liver O
disease O
and O
thinned O
skin O
. O
Urine O

 O
Porphobilinogens O
were O
checked O
to O
rule O
out O
porphyria O
in O
the O

 O
setting O
of O
Hep O
C O
liver O
disease O
and O
were O
negative O
. O
The O
diffuse O

 O
maculopapular B-ADE
rash I-ADE
appeared O
to O
be O
new O
, O
and O
looks O
more O
like O
a O

 O
hypersensitivity B-ADE
reaction I-ADE
, I-ADE
likely O
to O
ertapenem B-DRUG
. I-DRUG
Pt O
has O
known O

 O
allergies B-ADE
to O
Keflex B-DRUG
ad O
Cipro B-DRUG
, I-DRUG
and O
had O
received O
ertapenem B-DRUG
at O
the O

 O
OSH O
. O
She O
was O
treated O
with O
topical B-ROU
clobetasol B-DRUG
cream B-FOR
to O
the O
rash B-REA

 I-REA
on O
abdomen O
and O
lower O
extremities O
( O
avoiding O
folds O
) O
, O
and O

 O
hydrocortisone B-DRUG
2.5 B-STR
% I-STR
cream B-FOR
to O
rash B-REA
in O
folds O
of O
abdomen O
and O
groin O
. O

 O
Also O
, O
the O
bullae O
over O
time O
evolved O
into O
ulcerations O
on O
the O
pt O
's O

 O
legs O
, O
arms O
and O
left O
shoulder O
which O
were O
treated O
with O
wound O
care O

 O
as O
recommended O
by O
our O
wound O
care O
team O
and O
plastics O
. O

 O
. O

 O
# O
Cirrhosis B-REA
[ O
* O
* O
3 O
- O
12 O
* O
* O
] O
Hep O
C O
: O
Pt O
was O
treated O
as O
described O
above O
with O

 O
lactulose B-DRUG
and O
rifaximine B-DRUG
as O
well O
as O
a O
PPI B-DRUG
, I-DRUG
and O
was O
followed O
by O

 O
Hepatology O
. O
  O
She O
had O
a O
RUQ O
ultrasound O
on O
[ O
* O
* O
11 O
- O
16 O
* O
* O
] O
and O
again O
on O
[ O
* O
* O
11 O
- O
23 O
* O
* O
] O

 O
which O
showed O
her O
TIPS O
was O
patent O
. O
She O
should O
have O
a O
repeats O
TIPS O

 O
ultrasound O
in O
1 O
month O
. O
She O
had O
a O
5L O
paracentesis O
on O
[ O
* O
* O
11 O
- O
20 O
* O
* O
] O
which O

 O
was O
negative O
for O
increased O
WBC O
and O
culture O
was O
sterile O
. O

 O
. O


 O
# O
VRE B-REA
: I-REA
Pt O
had O
blood O
culture O
[ O
* O
* O
11 O
- O
16 O
* O
* O
] O
which O
grew O
VRE O
sensitive O
to O

 O
daptomycin B-DRUG
and O
linezolid B-DRUG
in O
[ O
* O
* O
2 O
- O
11 O
* O
* O
] O
bottles O
. O
Daptomycin B-DRUG
was O
started O

 O
on O
[ O
* O
* O
11 O
- O
17 O
* O
* O
] O
. O
  O
ID O
was O
consulted O
in O
house O
. O
TTE O
showed O
no O
vegetations O

 O
on O
[ O
* O
* O
11 O
- O
24 O
* O
* O
] O
. O
  O
The O
pt O
should O
be O
continued O
on O
IV B-ROU
daptomycin B-DRUG
to O

 O
complete O
a O
14 B-DUR
day I-DUR
course O
on O
[ O
* O
* O
2185 O
- O
12 O
- O
2 O
* O
* O
] O
. O

 O
. O

 O
# O
Sinus O
tachycardia O
: O
Pt O
was O
likely O
intravascularly O
dry O
on O

 O
admission O
given O
Hct O
above O
baseline O
, O
poor O
urine O
output O
, O
and O

 O
tachycardia O
above O
baseline O
, O
although O
some O
level O
of O
tachyardia O

 O
appears O
to O
be O
chronic O
in O
her O
. O
  O
Also O
may O
be O
exacerbated O
by O
acute O

 O
illness O
. O
She O
received O
albumin B-DRUG
25 B-STR
g I-STR
in I-STR
500cc I-STR
NS I-STR
x2 B-DOS
and O
her O
HR O
and O

 O
urine O
output O
were O
followed O
. O
Her O
diuretics O
were O
held O
until O
the O

 O
next O
morning O
. O
At O
discharge O
, O
her O
HR O
remains O
in O
the O
80 O
's O
to O
90 O
's O
. O

 O
. O

 O
# O
Chronic O
diastolic O
heart O
failure O
: O
Appeared O
hypovolemic O

 O
admission O
, O
her O
diuretics O
were O
held O
as O
above O
. O
Her O
diuretics O
were O

 O
gradually O
restarted O
on O
the O
floor O
. O
She O
is O
not O
accumulating O

 O
ascited O
at O
the O
time O
of O
discharge O
. O

 O
. O

 O
# O
Chronic O
Kidney O
Disease O
: O
  O
baseline O
Cr O
1.8 O
- O
2.0 O
, O
Cr O
on O
discharge O

 O
1.5 O
, O
urine O
output O
initially O
poor O
on O
admission O
, O
but O
improved O

 O
after O
fluid O
challenge O
. O

 O
. O

 O
# O
Thyroid O
nodule O
: O
Should O
be O
followed O
up O
as O
outpatient O
. O

 O
. O

 O
# O
Hyponatremia O
: O
Pt O
has O
chronic O
hyponatremia O
seen O
on O
past O

 O
admission O
with O
baseline O
128 O
- O
130 O
. O
As O
diuretics O
were O
increased O
, O

 O
her O
sodium O
gradually O
decreased O
to O
129 O
on O
day O
of O
discharge O
. O

 O
Treatment O
ongoing O
for O
this O
condition O
should O
include O
ongoing O

 O
fluid O
restriction O
to O
approximately O
1500cc/day O
. O

 O
. O

 O
# O
Hypercalcemia B-ADE
: I-ADE
Pt O
had O
transient O
hypercalcemia O
to O
10.8 O
this O

 O
admission O
thought O
to O
be O
[ O
* O
* O
3 O
- O
12 O
* O
* O
] O
Calcium B-DRUG
and O
vitamin B-DRUG
D I-DRUG
use O
at O
home O
. O

 O
These O
were O
stopped O
and O
Ca O
is O
now O
9.9 O
at O
time O
of O
discharge O
. O

 O
Recommend O
not O
restarting O
these O
medications O
at O
this O
time O
. O

 O
. O

 O
# O
[ O
* O
* O
Name O
( O
NI O
) O
1867 O
* O
* O
] O
Pt O
with O
thrombocytopenia O
this O
admission O

 O
thought O
[ O
* O
* O
3 O
- O
12 O
* O
* O
] O
chronic O
liver O
disease O
. O
Plt O
at O
discharge O
are O
164 O
. O



 O

Medications O
on O
Admission O
: O

 O
Metoclopramide B-DRUG
5 B-STR
mg I-STR
TID B-FRE

 I-FRE
Pantoprazole B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
Clobetasol B-DRUG
0.05 B-STR
% I-STR
Cream B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Ergocalciferol B-DRUG
( I-DRUG
Vitamin I-DRUG
D2 I-DRUG
) I-DRUG
50,000 B-STR
unit I-STR
QWednesday B-FRE

 I-FRE
Calcium-Cholecalciferol B-DRUG
( I-DRUG
D3 I-DRUG
) I-DRUG
500 B-STR
(1,250)-400 I-STR
mg-unit I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Nystatin B-DRUG
100,000 B-STR
unit/mL I-STR
5ml B-DOS
QID B-FRE

 I-FRE
Lactulose B-DRUG
30ml B-DOS
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Furosemide B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
Spironolactone B-DRUG
25 B-STR
mg I-STR
daily B-FRE

 I-FRE
. O



 O
Discharge O
Medications O
: O

 O
1 O
. O
Heparin B-DRUG
Flush B-FOR
( O
10 B-STR
units/ml I-STR
) I-STR
2 B-DOS
mL I-DOS
IV B-ROU
PRN B-FRE
line B-REA
flush I-REA

 I-REA
PICC O
, O
heparin B-DRUG
dependent O
: O
Flush O
with O
10mL B-DOS
Normal B-DRUG
Saline I-DRUG
followed O

 O
by O
Heparin B-DRUG
as O
above O
daily B-FRE
and O
PRN B-FRE
per O
lumen O
. O

 O
2 O
. O
Daptomycin B-DRUG
500 B-STR
mg I-STR
Recon B-FOR
Soln I-FOR
Sig O
: O
Four B-DOS
Hundred I-DOS
( I-DOS
400 I-DOS
) I-DOS
mg I-DOS

 I-DOS
Intravenous B-ROU
Q48H B-FRE
( I-FRE
every I-FRE
48 I-FRE
hours I-FRE
) I-FRE
: I-FRE
Please O
continue O
for B-DUR
9 I-DUR
days I-DUR
. I-DUR

 O
Please O
NOTE O
: O
patient O
has O
changing O
renal O
function O
. O
Currently O
GFR O

 O
is O
less O
than O
50 O
, O
so O
should O
dose O
q48 O
hours O
. O
If O
GFR>50 O
, O
please O

 O
change O
to O
q24 O
hour O
dosing O
. O

 O
3 O
. O
Clobetasol B-DRUG
0.05 B-STR
% I-STR
Cream B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl I-DOS
Topical B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( B-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
psoriasis B-REA
. I-REA

 O
4 O
. O
Furosemide B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
5 O
. O
Spironolactone B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
Lactulose B-DRUG
10 B-STR
gram/15 I-STR
mL I-STR
Syrup B-FOR
Sig O
: O
Thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
twice B-FRE
a I-FRE

 I-FRE
day I-FRE
. I-FRE

 O
7 O
. O
Metoclopramide B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Nystatin B-DRUG
100,000 B-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
QID B-FRE

 I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Rifaximin B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Hydrocortisone B-DRUG
2.5 B-STR
% I-STR
Cream B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl I-DOS
Rectal B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 O

 O
times O
a O
day O
) O
. O

 O
11 O
. O
Thiamine B-DRUG
HCl I-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE

 I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
Vancomycin B-DRUG
Resistant O
Enterococcus B-REA
Bacteremia I-REA

 I-REA
Encephalopathy O

 O
Traumatic O
Skin O
Rash O

 O
Hyponatremia O


 O
Secondary O
: O

 O
Hepatitis O
C O
Cirrhosis O

 O
Chronic O
Kidney O
Disease O



 O

Discharge O
Condition O
: O

 O
Afebrile O
, O
stable O
, O
ambulatory O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
after O
you O
were O
found O
passed O
out O
at O
home O
. O
This O

 O
was O
likely O
due O
to O
encephalopathy B-REA
which O
cleared O
with O
lactulose B-DRUG
, I-DRUG

 O
and O
an O
infection O
that O
was O
found O
in O
your O
blood O
. O
You O
will O
continue O

 O
on O
an O
antibiotic O
, O
Daptomycin B-DRUG
, I-DRUG
intravenously B-ROU
for B-DUR
a I-DUR
total I-DUR
of I-DUR
14 I-DUR

 I-DUR
days I-DUR
, I-DUR
finishing O
on O
[ O
* O
* O
12 O
- O
2 O
* O
* O
] O
. O
Please O
be O
sure O
to O
renally O
dose O

 O
this O
medication O
: O
once O
daily O
if O
GFR>50 O
or O
once O
every O
other O
day O
if O

 O
GFR<50 O
. O

 O
. O

 O
Continuing O
issues O
include O
hyponatremia O
, O
which O
should O
be O
managed O

 O
initially O
with O
fluid O
restriction O
. O
She O
has O
had O
chronic O

 O
hyponatremia O
with O
baseline O
128 O
- O
130 O
on O
previous O
admission O
here O
. O

 O
Please O
monitor O
sodium O
levels O
while O
at O
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O

 O
. O

 O
Her O
course O
has O
also O
been O
complicated O
by O
easy O
bruising O
and O

 O
blistering O
which O
has O
necessitated O
a O
dermatology O
consult O
. O
It O
was O

 O
felt O
these O
were O
traumatically O
induced O
. O
They O
are O
being O
cared O
for O

 O
currently O
with O
wound O
care O
. O

 O
. O

 O
Of O
note O
, O
the O
patient O
was O
hypercalcemic B-ADE
, I-ADE
and O
found O
to O
have O

 O
elevated O
PTH O
level O
. O
She O
had O
been O
taking O
ergocalciferol B-DRUG
and O

 O
cholecalciferol B-DRUG
both O
of O
which O
were O
stopped O
, O
and O
the O
calcium O

 O
normalized O
. O
Please O
continue O
to O
hold O
these O
medications O
, O
to O
be O

 O
restarted O
at O
the O
discretion O
of O
her O
primary O
care O
physician O
and O

 O
[ O
* O
* O
Hospital1 O
* O
* O
] O
physician O
. O

 O
. O


 O
Followup O
Instructions O
: O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
THYROID O
NODULE O
CENTER O
Phone:[**Telephone/Fax O
( O
1 O
) O
26555 O
* O
* O
] O

 O
Date/Time:[**2185 O
- O
12 O
- O
1 O
* O
* O
] O
10:30 O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
[ O
* O
* O
Hospital O
1389 O
* O
* O
] O
CLINIC O
Phone:[**Telephone/Fax O
( O
1 O
) O
673 O
* O
* O
] O

 O
Date/Time:[**2185 O
- O
12 O
- O
7 O
* O
* O
] O
8:40 O




 O
Completed O
by:[**2185 O
- O
11 O
- O
24 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2115 O
- O
5 O
- O
15 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2115 O
- O
5 O
- O
23 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2050 O
- O
5 O
- O
19 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
CARDIOTHORACIC O


 O
Allergies O
: O

 O
Penicillins B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
5790 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
pericardial O
effusion O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2115 O
- O
5 O
- O
15 O
* O
* O
] O
- O
Left O
video O
assisted O
thoracoscopic O
surgery O
, O
pericardial O

 O
window O
. O
( O
Dr O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O



 O
History O
of O
Present O
Illness O
: O

 O
Ms O
[ O
* O
* O
Known O
lastname O
101562 O
* O
* O
] O
is O
a O
64 O
year O
old O
woman O
with O
multiple O
medical O
problems O

 O
who O
was O
referred O
to O
our O
clinic O
for O
a O
pericardial O
window O
. O
She O
was O

 O
being O
evaluated O
by O
ENT O
( O
Dr O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
this O
spring O
for O
excision O

 O
of O
leukoplakia O
of O
the O
vocal O
cords O
when O
a O
moderate O
pericardial O

 O
effusion O
was O
discovered O
on O
pre-operative O
testing O
. O
Her O

 O
ENT O
procedure O
was O
postponed O
pending O
management O
of O
the O
effusion O
. O

 O
Of O
note O
, O
she O
is O
a O
poor O
historian O
and O
is O
unsure O
of O
her O
medical O

 O
issues O
or O
surgical O
plans O
. O
She O
had O
a O
pericardiocentesis O
performed O

 O
six O
months O
ago O
which O
drained O
1L O
. O
She O
denies O
prior O
thoracic O
or O

 O
major O
abdominal O
surgery O
. O
She O
was O
recently O
placed O
on O
coumadin B-DRUG
for O

 O
A-fib B-REA
, I-REA
she O
has O
held O
that O
for O
2 O
days O
. O
Last O
INR O
available O
was O
2.6 O

 O
on O
[ O
* O
* O
2115 O
- O
2 O
- O
27 O
* O
* O
] O
, O
then O
rechecked O
at O
1.2 O
on O
[ O
* O
* O
2115 O
- O
5 O
- O
15 O
* O
* O
] O
. O


 O
Past O
Medical O
History O
: O

 O
1 O
. O
CARDIAC O
RISK O
FACTORS O
: O
Hypertension O
, O
Hyperlipidemia O

 O
2 O
. O
CARDIAC O
HISTORY O
: O

 O
- O
CABG O
: O
None O

 O
- O
PERCUTANEOUS O
CORONARY O
INTERVENTIONS O
: O
  O
None O

 O
3 O
. O
OTHER O
PAST O
MEDICAL O
HISTORY O
: O

 O
Pericardial O
effusion O

 O
COPD O

 O
Vocal O
chord O
abnormality O

 O
Carotid O
artery O
disease O

 O
s/p O
bilateral O
carotid O
endarterectomies-left O
[ O
* O
* O
2106 O
* O
* O
] O
, O
right O
[ O
* O
* O
2111 O
* O
* O
] O

 O
Peripheral O
arterial O
disease O

 O
Esophageal O
reflux O

 O
Gastric B-ADE
ulcer I-ADE
related O
to O
NSAIDS B-DRUG

 I-DRUG
Hypothyroidism O

 O
Atrial O
fibrillation O

 O
Current O
smoking->[**12 O
- O
2 O
* O
* O
] O
pack O
per O
day O

 O
Right O
ACL O
repair O

 O
Cholecystectomy O

 O
Bladder O
suspension O
x O
3 O

 O
Right O
rotator O
cuff O
repair O

 O
Shingles O

 O
Depression O

 O
PVD O
: O

 O
Successful O
stenting O
of O
left O
common O
iliac O
stenosis O

 O
followed O
by O
covered O
stenting O
for O
dissection O
and O
possible O

 O
extravasation O
[**5 O
- O
8**].Occluded O
superficial O
femoral O
artery O
with O

 O
reconstitution O
of O
heavily O
diseased O
above-knee O
popliteal O
artery O
. O



 O
Social O
History O
: O

 O
Married O
but O
husband O
in O
nursing O
home O
. O
Has O
two O
sons O
. O
80 O
pk O
yr O
hx O

 O
of O
smokign O

 O
Former O
ETOH O
abuse O
, O
not O
current O
. O
No O
illicit O
drug O
use O


 O
Family O
History O
: O

 O
Both O
parents O
with O
CAD O
, O
her O
mother O
had O
MI O
at O
unknown O
age O
. O

 O
Brother O
had O
MI O
at O
age O
51 O
. O
  O
She O
also O
CAD O
in O
multiple O
other O
family O

 O
members O



 O
Physical O
Exam O
: O

 O
VS O
: O
T O
97.6 O
  O
HR O
: O
70 O
AF O
  O
BP O
: O
100 O
- O
120/72 O
Sats O
: O
96 O
% O
RA O
@ O
rest O

 O
activtiy O
89 O
- O
95 O
% O
RA O

 O
General O
: O
65 O
year-old O
female O
in O
no O
apparent O
distress O

 O
HEENT O
: O
normocephalic O
, O
mucus O
membranes O
moist O

 O
Neck O
: O
supple O

 O
Card O
: O
RRR O

 O
Resp O
: O
decreased O
breath O
sounds O
no O
crackles O
or O
wheezes O

 O
GI O
: O
obese O
, O
benign O

 O
Extr O
: O
warm O
no O
edema O

 O
Incision O
: O
L O
VATs O
clean O
, O
dry O
intact O
. O
no O
erythema O

 O
Neuro O
: O
Awake O
, O
alert O
oriented O
. O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2115 O
- O
5 O
- O
22 O
* O
* O
] O
WBC-13.7 O
* O
RBC-4.99 O
Hgb-14.0 O
Hct-41.1 O
Plt O
Ct-488 O
* O

 O
[ O
* O
* O
2115 O
- O
5 O
- O
22 O
* O
* O
] O
Glucose-134 O
* O
UreaN-9 O
Creat-0.6 O
Na-142 O
K-3.5 O
Cl-101 O

 O
HCO3 O
- O
32 O

 O
[ O
* O
* O
2115 O
- O
5 O
- O
22 O
* O
* O
] O
Calcium-9.1 O
Phos-4.1 O
Mg-2.0 O


 O
[ O
* O
* O
2115 O
- O
5 O
- O
21 O
* O
* O
] O
CXR O
: O

 O
FINDINGS O
: O
In O
comparison O
with O
the O
study O
of O
[ O
* O
* O
5 O
- O
20 O
* O
* O
] O
, O
there O
is O
little O

 O
overall O

 O
change O
. O
Continued O
enlargement O
of O
the O
cardiac O
silhouette O
with O

 O
mild O
elevation O
of O
pulmonary O
venous O
pressure O
. O
Atelectatic O
changes O

 O
are O
seen O
at O
the O
bases O
, O
especially O
on O
the O
left O
with O
small O

 O
bilateral O
pleural O
effusions O
. O


 O
[ O
* O
* O
2115 O
- O
5 O
- O
17 O
* O
* O
] O
Echo O
: O
IMPRESSION O
: O
Normal O
biventricular O
cavity O
sizes O
with O

 O
preserved O
global O
biventricular O
systolic O
function O
. O
Moderate O

 O
mitral O
regurgitation O
. O
Pulmonary O
artery O
systolic O
hypertension O
. O
No O

 O
significant O
pericardial O
effusion O
. O



 O

Brief O
Hospital O
Course O
: O

 O
Ms O
[ O
* O
* O
Known O
lastname O
101562 O
* O
* O
] O
was O
admitted O
to O
the O
Thoracic O
Surgery O
service O
on O
the O

 O
day O
of O
her O
scheduled O
surgery O
, O
[ O
* O
* O
2115 O
- O
5 O
- O
15 O
* O
* O
] O
. O
INR O
was O
checked O
that O
day O

 O
( O
1.2 O
) O
. O
She O
underwent O
left O
video O
assisted O
thoracoscopic O
surgery O

 O
with O
pericardial O
window O
under O
Dr O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
. O
The O
surgery O
was O

 O
uneventful O
and O
went O
as O
planned O
, O
but O
she O
remained O
intubated O

 O
overnight O
given O
her O
very O
high O
oxygen O
requirement O
. O
She O
was O

 O
transferred O
to O
the O
ICU O
intubated O
and O
an O
urgent O
pulmonology O

 O
consult O
was O
requested O
. O
Our O
pulmonology O
colleagues O
agreed O
with O
us O

 O
that O
she O
was O
retaining O
fluid O
leading O
to O
pulmonary B-REA
edema I-REA
so O
we O

 O
removed O
all O
IV B-ROU
fluid B-DRUG
and O
began O
diuresis B-REA
with O
furosemide B-DRUG
IV B-ROU
. I-ROU
She O

 O
responded O
well O
and O
she O
was O
extubated O
in O
the O
afternoon O
of O
POD O
1 O
. O

 O
By O
POD O
2 O
, O
she O
had O
resumed O
most O
of O
her O
home O
medications O
and O
was O

 O
beginning O
a O
regular O
diet O
. O
Her O
Coumadin B-DRUG
was O
resumed O
and O

 O
pericardial O
drain O
was O
removed O
( O
total O
output O
) O
on O
POD O
3 O
. O
She O

 O
remained O
in O
the O
ICU O
until O
POD O
4 O
, O
the O
primary O
indication O
being O

 O
increased O
oxygen O
demand O
, O
requiring O
face O
tent O
most O
of O
the O
day O
. O

 O
Chest O
x-rays O
and O
daily O
weights O
indicated O
she O
was O
no O
longer O
fluid O

 O
overloaded O
, O
but O
her O
oxygenation O
continued O
to O
be O
poor O
. O
On O
the O

 O
floor O
, O
we O
were O
unable O
to O
keep O
her O
oxygen B-DRUG
saturation O
above O
90 O
% O

 O
with O
less O
than O
4L B-DOS
nasal B-ROU
canula I-ROU
. I-ROU
She O
reports O
this O
as O
her O
baseline O

 O
pulmonary O
status O
, O
though O
denies O
being O
on O
home O
oxygen B-DRUG
. I-DRUG
She O
was O

 O
seen O
and O
evaluated O
by O
physical O
therapy O
who O
initially O
recommended O

 O
rehab O
due O
to O
risk O
of O
fall O
. O
She O
also O
required O
4L B-DOS
NC B-ROU
desaturating O

 O
to O
84 O
% O
on O
2L B-DOS
NC B-ROU
. I-ROU
Over O
the O
next O
few O
days O
she O
improved O
. O
  O
Physical O

 O
therapy O
re-evaluated O
her O
and O
deemed O
her O
safe O
for O
home O
with O
PT O
. O


 O
While O
in O
house O
some O
mild O
confusion O
which O
improved O
over O
the O

 O
course O
of O
her O
hospital O
stay O
. O
  O
On O
discharge O
she O
was O
awake O
, O
alert O
, O

 O
oriented O
and O
walked O
independently O
. O


 O
Heme O
: O
Warfarin B-DRUG
was O
restarted O
for O
atrial B-REA
fibrillation I-REA
and O
she O

 O
will O
follow-up O
with O
her O
PCP O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
17143 O
* O
* O
] O
as O
an O
outpatient O
. O



 O
By O
the O
time O
of O
discharge O
on O
[ O
* O
* O
2115 O
- O
5 O
- O
23 O
* O
* O
] O
, O
she O
was O
tolerating O
a O

 O
regular O
diet O
, O
voiding O
without O
difficulty O
, O
hemodynamically O

 O
stable O
, O
taking O
her O
home O
medications O
and O
ambulating O
independently O

 O
without O
oxygen O
, O
saturating O
94 O
% O
RA O
. O
   O
She O
was O
discharged O
to O
home O

 O
with O
[ O
* O
* O
Location O
( O
un O
) O
86 O
* O
* O
] O
Care O
Group O
VNA O
and O
Physical O
therapy O
. O
  O
She O
will O

 O
follow-up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
as O
an O
outpatient O
. O


 O
Medications O
on O
Admission O
: O

 O
ALBUTEROL B-DRUG
90mcg B-STR
2pf B-ROU
q6prn B-FRE
, I-FRE
ADVAIR B-DRUG
250 B-STR
- I-STR
50 I-STR
" I-STR
, I-STR
AMLODIPINE B-DRUG
10 B-STR
' I-STR
, I-STR

 O
ARIPIPRAZOLE B-DRUG
20 B-STR
' I-STR
, I-STR
EZETIMIBE-SIMVASTATIN B-DRUG
[ O
* O
* O
9 O
- O
19 O
* O
* O
] O
' O
, O
FUROSEMIDE B-DRUG
40 B-STR
' I-STR
, I-STR

 O
LEVOTHYROXINE B-DRUG
100 B-STR
' I-STR
, I-STR
LORAZEPAM B-DRUG
2qhs B-FRE
, I-FRE
METOPROLOL B-DRUG
100 B-STR
' I-STR
, I-STR
OMEPRAZOLE B-DRUG

 I-DRUG
40 B-STR
' I-STR
, I-STR
QUETIAPINE B-DRUG
25 B-STR
' I-STR
' I-STR
' I-STR
, O
QUETIAPINE B-DRUG
200qhs B-FRE
PRN I-FRE
, I-FRE
RANITIDINE B-DRUG
300qhs B-FRE
, I-FRE

 O
WARFARIN B-DRUG
2 B-STR
' I-STR
, I-STR
D3 B-DRUG
1000 B-STR
' I-STR



 I-STR
Discharge O
Medications O
: O

 O
1 O
. O
fluticasone-salmeterol B-DRUG
250 B-STR
- I-STR
50 I-STR
mcg/dose I-STR
Disk B-FOR
with I-FOR
Device I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Disk B-FOR
with I-FOR
Device I-FOR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( B-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
albuterol B-DRUG
sulfate I-DRUG
90 B-STR
mcg/Actuation I-STR
HFA B-FOR
Aerosol I-FOR
Inhaler I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Puff B-FOR
Inhalation B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O

 O
wheezes B-REA
, I-REA
sob B-REA
. I-REA

 O
3 O
. O
amlodipine B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
4 O
. O
aripiprazole B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE



 O
5 O
. O
levothyroxine B-DRUG
100 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
quetiapine B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
quetiapine B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QHS B-FRE
( I-FRE
once I-FRE
a I-FRE

 I-FRE
day I-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
insomnia B-REA
. I-REA

 O
9 O
. O
ranitidine B-DRUG
HCl I-DRUG
150 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE

 I-FRE
bedtime I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
nicotine B-DRUG
21 B-STR
mg/24 I-STR
hr I-STR
Patch B-FOR
24 B-DUR
hr I-DUR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Patch B-FOR
24 I-FOR
hr I-FOR

 I-FOR
Transdermal B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
12 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
oxycodone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
every B-FRE
4 I-FRE
- I-FRE
6 I-FRE
hours I-FRE

 I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
Disp:*20 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
14 O
. O
furosemide B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
15 O
. O
warfarin B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Once B-FRE
Daily I-FRE
at I-FRE
4 I-FRE

 I-FRE
PM I-FRE
: I-FRE
INR O
Goal O
2.0 O
- O
2.5 O
for O
Afib B-REA
. I-REA

 O
16 O
. O
metoprolol B-DRUG
succinate I-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Extended I-FOR
Release I-FOR
24 I-FOR
hr I-FOR

 I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
Extended I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
17 O
. O
Vytorin B-DRUG
[ O
* O
* O
9 O
- O
19 O
* O
* O
] O
10 B-STR
- I-STR
20 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE

 I-FRE
bedtime I-FRE
. I-FRE

 O
18 O
. O
Vitamin B-DRUG
D-3 I-DRUG
1,000 B-STR
unit I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Chewable I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
19 O
. O
potassium B-DRUG
chloride I-DRUG
8 B-STR
mEq I-STR
Tablet B-FOR
Extended I-FOR
Release I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
Extended I-FOR
Release I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet O
Extended O
Release(s O
) O
* O
Refills:*2 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Location O
( O
un O
) O
86 O
* O
* O
] O
VNA O


 O
Discharge O
Diagnosis O
: O

 O
Pericardial O
effusion O

 O
Hypertension O

 O
Hyperlipidemia O

 O
COPD O

 O
Vocal O
chord O
abnormality O

 O
Carotid O
artery O
disease O

 O
Peripheral O
arterial O
disease O

 O
Esophageal O
reflux O

 O
Gastric B-ADE
ulcer I-ADE
related O
to O
NSAIDS B-DRUG
, I-DRUG

 O
Hypothyroidism O

 O
Atrial B-REA
fibrillation I-REA
( O
on O
coumadin B-DRUG
) I-DRUG

 I-DRUG
Shingles O

 O
Depression O

 O
Peripheral O
vascular O
disease O



 O
PSH O
: O
bilateral O
carotid O
endarterectomies-left O
[ O
* O
* O
2106 O
* O
* O
] O
, O
right O
[ O
* O
* O
2111 O
* O
* O
] O
; O

 O
Right O
ACL O
repair O
, O
lap O
CCY O
, O
Bladder O
suspension O
x O
3 O
, O
Right O
rotator O

 O
cuff O
repair O
; O
covered O
stenting O
for O
dissection O
and O
possible O

 O
extravasation O
left O
common O
iliac O
[ O
* O
* O
5 O
- O
8 O
* O
* O
] O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
independent O



 O
Discharge O
Instructions O
: O

 O
Call O
Dr.[**Name O
( O
NI O
) O
2347 O
* O
* O
] O
office O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2348 O
* O
* O
] O
if O
you O
experience O
: O

 O
-Fevers O
greater O
than O
101 O
or O
chills O

 O
-Increased O
shortness O
of O
breath O
or O
cough O
or O
chest O
pain O

 O
-Left O
chest O
incision O
develops O
drainage O
. O
Your O
left O
incisions O
are O

 O
covered O
with O
glue O
. O
This O
will O
come O
off O
over O
a O
couple O
weeks O
. O


 O
Pain O
: O

 O
-Acetaminophen B-DRUG
650 B-STR
every B-FRE
6 I-FRE
hours I-FRE
for O
pain B-REA

 I-REA
-Oxycodone B-DRUG
5 B-STR
mg I-STR
every B-FRE
4 I-FRE
- I-FRE
6 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA


 I-REA
Activity O

 O
-Shower O
daily O
. O
Wash O
incision O
with O
mild O
soap O
& O
water O
, O
rinse O
, O
pat O

 O
dry O

 O
-No O
tub O
bathing O
or O
swimming O
until O
incisions O
healed O

 O
-Walk O
4 O
- O
5 O
times O
a O
day O
increase O
you O
time O
and O
distance O

 O
-Continue O
incentive O
spirometry O


 O
Followup O
your O
coumadin B-DRUG
dosing O
with O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
16258 O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
19196 O
* O
* O
] O

 O
on O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2974 O
* O
* O
] O
[ O
* O
* O
2115 O
- O
5 O
- O
24 O
* O
* O
] O
. O
VNA O
should O
draw O
your O
INR O
[ O
* O
* O
Month/Day/Year O
2974 O
* O
* O
] O
. O



 O
Followup O
Instructions O
: O

 O
Follow-up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
0 O
- O
0- O
* O
* O
] O
Date/Time:[**2115 O
- O
5 O
- O
30 O
* O
* O
] O

 O
4:00 O
in O
the O
[ O
* O
* O
Hospital O
Ward O
Name O
516 O
* O
* O
] O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Center O
, O
[ O
* O
* O
Location O
( O
un O
) O
24 O
* O
* O
] O


 O
Chest O
X-Ray O
[ O
* O
* O
Location O
( O
un O
) O
861 O
* O
* O
] O
Radiology O
30 O
minutes O
before O
your O

 O
appointment O


 O
INR O
[ O
* O
* O
2115 O
- O
5 O
- O
24 O
* O
* O
] O
. O
Followup O
coumadin B-DRUG
dosing O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
16258 O
* O
* O
] O
on O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
2974 O
* O
* O
] O

 O
[ O
* O
* O
2115 O
- O
5 O
- O
24 O
* O
* O
] O
. O




 O
Completed O
by:[**2115 O
- O
5 O
- O
23 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2181 O
- O
6 O
- O
17 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2181 O
- O
6 O
- O
21 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2118 O
- O
3 O
- O
10 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Bactrim B-DRUG
DS I-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
12131 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Chief O
Complaint O
: O
  O
acute O
SOB O


 O
Reason O
for O
MICU O
transfer O
: O
  O
suspected O
PE O
, O
sepsis O
[ O
* O
* O
3 O
- O
8 O
* O
* O
] O
UTI O



 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O


 O
History O
of O
Present O
Illness O
: O

 O
63F O
w/ O
recurrent B-REA
stage I-REA
IIIC I-REA
papillary I-REA
serous I-REA
ovarian I-REA
CA I-REA
on O
cycle O

 O
8 O
day O
14 O
of O
carboplatin B-DRUG
, I-DRUG
gemcitabine B-DRUG
, I-DRUG
bevacizumab B-DRUG
( O
avastin B-DRUG
) I-DRUG
, O

 O
complicated O
by O
ureter O
obstruction O
requiring O
left O
ureteral O
stent O

 O
and O
right O
nephrostomy O
tube O
. O
She O
had O
a O
week O
of O
SOB O
PTA O
but O
on O

 O
[ O
* O
* O
6 O
- O
16 O
* O
* O
] O
had O
acute O
onset O
of O
SOB O
when O
at O
home O
, O
with O
fever O
, O
without O

 O
cough O
, O
and O
no O
abd O
pain O
, O
no O
dysuria O
. O
Oncologic O
course O
has O
been O

 O
complicated O
by O
b/l O
hydronephrosis O
thought O
to O
be O
[ O
* O
* O
3 O
- O
8 O
* O
* O
] O
malignancy O
, O

 O
as O
well O
as O
utereral O
obstructions O
requiring O
right O
nephrostomy O

 O
tube O
. O


 O
In O
the O
ED O
, O
initial O
VS O
were O
: O
  O
101 O
108 O
158/67 O
24 O
100 O
% O
2L O
( O
highest O

 O
temp O
was O
102.3 O
) O
. O
EKG O
showed O
ST O
106 O
incomplete O
RB O
on O
previous O
, O

 O
incomplete O
L O
bundle O
. O
  O
CTA O
was O
deferred O
due O
to O
elevated O
Cr O
. O

 O
Non-con O
belly O
scan O
was O
ordered O
and O
bedside O
u/s O
showed O
normal O

 O
fast O
, O
no O
pericardial O
effusion O
, O
no O
right O
heart O
strain O
, O
mild O
left O

 O
hydronephrosis O
, O
normal O
right O
kidney O
. O
She O
was O
started O
on O

 O
Vanc/Cefepime B-DRUG
and O
given O
APAP B-DRUG
. I-DRUG
Urine O
from O
nephrostomy O
was O
cloudy O
; O

 O
Foley'd O
urine O
was O
the O
second O
drawn O
. O
Heparin B-DRUG
gtt B-ROU
was O
commenced O

 O
for O
suspected O
PE B-REA
. I-REA
She O
had O
an O
elevated O
pro-BNP O
but O
normal O
trop O
, O

 O
and O
no O
right O
axis O
deviation O
on O
ECG O
or O
on O
u/s O
: O
was O
not O
a O

 O
candidate O
for O
TPA B-DRUG
. I-DRUG


 O
On O
arrival O
to O
the O
MICU O
, O
she O
does O
not O
c/o O
any O
pain O
, O
but O
is O
still O

 O
feeling O
SOB O
, O
better O
when O
supine O
as O
opposed O
to O
sitting O
up O
. O
  O
She O

 O
denies O
CP O
, O
HA O
, O
abdom O
pain O
, O
pain O
upon O
deep O
inspiration O
, O
pain O
in O

 O
calves/thighs O
. O
Adds O
that O
on O
day O
of O
admission O
, O
she O
felt O
more O
SOB O

 O
fairly O
abruptly O
while O
sitting O
outside O
; O
at O
baseline O
, O
has O
no O
h/o O

 O
heart O
problems O
or O
SOB O
when O
walking O
. O
She O
still O
urinates O
and O
also O

 O
has O
UOP O
through O
the O
nephrostomy O
tube O
; O
is O
maintaining O
PO O
intake O

 O
and O
says O
she O
still O
made O
urine O
at O
home O
today O
. O


 O
Review O
of O
systems O
: O

 O
Per O
HPI O



 O

Past O
Medical O
History O
: O

 O
ONCOLOGIC O
HISTORY O
: O

 O
-- O
[ O
* O
* O
2180 O
- O
2 O
- O
7 O
* O
* O
] O
diagnosed O
with O
epithelial O
ovarian O
cancer O
at O
the O
time O

 O
of O

 O
exploratory O
laparotomy O
performed O
by O
Dr O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
2028 O
* O
* O
] O
. O
Pathology O

 O
revealed O

 O
stage O
IIIC O
poorly O
differentiated O
( O
G3 O
) O
papillary O
serous O

 O
carcinoma O
. O

 O
Two O
pelvic O
lymph O
nodes O
and O
one O
groin O
node O
were O
involved O
. O
There O

 O
was O
no O
visible O
disease O
at O
the O
end O
of O
the O
operation O
. O

 O
-- O
[ O
* O
* O
2180 O
- O
2 O
- O
28 O
* O
* O
] O
C1D1 O
IP O
Cis/Taxol B-DRUG
as O
per O
GOG O
172 O

 O
-- O
[ O
* O
* O
2180 O
- O
3 O
- O
20 O
* O
* O
] O
C2D1 O
IP O
Cis/Taxol B-DRUG
as O
per O
GOG O
172 O

 O
-- O
[ O
* O
* O
2180 O
- O
4 O
- O
10 O
* O
* O
] O
  O
C3D1 O
IP O
Cis/Taxol B-DRUG
as O
per O
GOG O
172 O

 O
-- O
[ O
* O
* O
2180 O
- O
5 O
- O
1 O
* O
* O
] O
C4D1 O
IP O
Cis/Taxol B-DRUG
as O
per O
GOG O
172 O

 O
-- O
[ O
* O
* O
2180 O
- O
5 O
- O
23 O
* O
* O
] O
C5D1 O
IP O
Cis/Taxol B-DRUG
as O
per O
GOG O
172 O

 O
-- O
[ O
* O
* O
2180 O
- O
6 O
- O
12 O
* O
* O
] O
  O
C6D1 O
IP O
Cis/Taxol B-DRUG
as O
per O
GOG O
172 O

 O
. O

 O
Past O
Medical O
History O
: O

 O
HTN O
. O

 O
orthostatic O
hypotension O
. O

 O
Right O
femoral O
hernia O
repair O
[ O
* O
* O
2153 O
* O
* O
] O
. O

 O
Cesarean O
section O
. O

 O
. O

 O
OB/GYN O
History O
: O
  O
G3P3 O
. O
  O
2 O
spontaneous O
vaginal O
deliveries O
and O
one O

 O
cesarean O
section O
. O

 O
No O
h/o O
pelvic O
infections O
. O

 O
No O
h/o O
abnormal O
pap O
smears O
. O

 O
Menopause O
five O
years O
ago O
without O
complication O
and O
no O

 O
postmenopausal O
bleeding O
. O


 O
Social O
History O
: O

 O
Tobacco O
: O
Denies O
. O

 O
Alcohol O
: O
Occasional O
. O

 O
Drugs O
: O
Denies O
. O

 O
She O
lives O
with O
her O
husband O
in O
[ O
* O
* O
Name O
( O
NI O
) O
5176 O
* O
* O
] O
, O
who O
is O
an O
optometrist O
at O

 O
the O
[ O
* O
* O
Hospital O
* O
* O
] O
Clinic O
. O



 O
Family O
History O
: O

 O
Father O
: O
colon O
cancer O
in O
his O
50s O
. O

 O
Son O
: O
testicular O
cancer O
at O
19 O
, O
with O
no O
evidence O
of O
recurrence O
. O

 O
No O
other O
family O
history O
of O
cancer O
. O



 O
Physical O
Exam O
: O

 O
Admission O
Physical O
Exam O
: O

 O
Vitals O
: O
  O
T O
: O
100 O
  O
HR O
: O
94 O
  O
BP O
: O
118/39 O
  O
100 O
% O
2L O
NC O

 O
General O
: O
Alert O
, O
oriented O
x3 O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
MMM O
, O
oropharynx O
clear O
, O
EOMI O
, O
PERRL O

 O
Neck O
: O
supple O
, O
JVP O
7 O
- O
8 O
cm O
, O
no O
LAD O

 O
CV O
: O
Regular O
rate O
and O
rhythm O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O

 O
gallops O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O
rales O
, O

 O
ronchi O

 O
Abdomen O
: O
soft O
, O
non-distended O
, O
bowel O
sounds O
present O
, O
no O

 O
organomegaly O
, O
no O
tenderness O
to O
palpation O
, O
no O
rebound O
or O

 O
guarding O
. O
Right O
nephrostomy O
tube O
draining O
yellow O
urine O
with O
some O

 O
white O
clots O
; O
entry O
site O
is O
w/o O
erythema O
or O
drainage O
. O

 O
GU O
: O
foley O

 O
Ext O
: O
Warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
no O
clubbing O
, O
cyanosis O
or O

 O
edema O
; O
no O
erythema O
or O
swelling O
or O
tenderness O
in O
calves O

 O
Neuro O
: O
CNII-XII O
intact O
, O
5/5 O
strength O
upper/lower O
extremities O
, O

 O
grossly O
normal O
sensation O
, O
2 O
+ O
reflexes O
bilaterally O
. O

 O
Discharge O
Physical O
Exam O
: O

 O
Vitals O
: O
98.8 O
, O
136/82 O
, O
73 O
, O
20 O
, O
100 O
% O
RA O

 O
General O
: O
Alert O
, O
oriented O
x3 O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
MMM O
, O
oropharynx O
clear O
, O
EOMI O
, O
PERRL O

 O
Neck O
: O
supple O
, O
JVP O
7 O
- O
8 O
cm O
, O
no O
LAD O

 O
CV O
: O
Regular O
rate O
and O
rhythm O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O

 O
gallops O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O
rales O
, O

 O
ronchi O

 O
Abdomen O
: O
soft O
, O
non-distended O
, O
bowel O
sounds O
present O
, O
no O

 O
organomegaly O
, O
no O
tenderness O
to O
palpation O
, O
no O
rebound O
or O

 O
guarding O
. O
Right O
nephrostomy O
tube O
draining O
clear O
yellow O
urine O
; O

 O
entry O
site O
is O
w/o O
erythema O
or O
drainage O
. O

 O
GU O
: O
foley O

 O
Ext O
: O
Warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
no O
clubbing O
, O
cyanosis O
or O

 O
edema O
; O
no O
erythema O
or O
swelling O
or O
tenderness O
in O
calves O

 O
Neuro O
: O
CNII-XII O
intact O
, O
5/5 O
strength O
upper/lower O
extremities O
, O

 O
grossly O
normal O
sensation O
, O
2 O
+ O
reflexes O
bilaterally O
. O



 O
Pertinent O
Results O
: O

 O
ADMISSION O
LABS O
: O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
09:50PM O
BLOOD O
WBC-7.9 O
RBC-2.45 O
* O
Hgb-7.8 O
* O
Hct-24.9 O
* O

 O
MCV-102 O
* O
MCH-31.9 O
MCHC-31.3 O
RDW-18.6 O
* O
Plt O
Ct-65 O
* O
# O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
09:50PM O
BLOOD O
Neuts-90.8 O
* O
Lymphs-6.5 O
* O
Monos-2.6 O
Eos-0.1 O

 O
Baso-0.1 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
09:50PM O
BLOOD O
PT-11.7 O
PTT-28.1 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
17 O
* O
* O
] O
06:41AM O
BLOOD O
Ret O
Aut-0.2 O
* O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
09:50PM O
BLOOD O
Glucose-150 O
* O
UreaN-23 O
* O
Creat-1.9 O
* O
Na-140 O

 O
K-4.3 O
Cl-104 O
HCO3 O
- O
22 O
AnGap-18 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
09:50PM O
BLOOD O
ALT-15 O
AST-16 O
LD(LDH)-184 O
CK(CPK)-34 O

 O
AlkPhos-94 O
TotBili-0.3 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
09:50PM O
BLOOD O
CK-MB-1 O
cTropnT-<0.01 O
proBNP-788 O
* O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
17 O
* O
* O
] O
04:18AM O
BLOOD O
CK-MB-1 O
cTropnT-<0.01 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
09:50PM O
BLOOD O
Albumin-4.3 O
Calcium-9.8 O
Phos-0.7 O
* O
# O
Mg-2.0 O

 O
UricAcd-6.6 O
* O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
09:50PM O
BLOOD O
D-Dimer-2249 O
* O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
17 O
* O
* O
] O
04:18AM O
BLOOD O
Hapto-225 O
* O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
09:50PM O
BLOOD O
Lactate-3.0 O
* O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
17 O
* O
* O
] O
07:05AM O
BLOOD O
Lactate-1.0 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
11:20PM O
URINE O
Color-Straw O
Appear-Cloudy O
Sp O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
-1.009 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
11:20PM O
URINE O
Blood-MOD O
Nitrite-NEG O
Protein-300 O

 O
Glucose-NEG O
Ketone-NEG O
Bilirub-NEG O
Urobiln-NEG O
pH-8.0 O
Leuks-LG O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
11:20PM O
URINE O
RBC-27 O
* O
WBC->182 O
* O
Bacteri-MOD O
Yeast-NONE O

 O
Epi-0 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
17 O
* O
* O
] O
12:15AM O
URINE O
Hours-RANDOM O
Creat-67 O
Na-44 O
K-36 O
Cl-40 O

 O
. O


 O
DISCHARGE O
LABS O
: O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
21 O
* O
* O
] O
06:00AM O
BLOOD O
WBC-10.2 O
RBC-2.51 O
* O
Hgb-8.1 O
* O
Hct-24.5 O
* O

 O
MCV-98 O
MCH-32.5 O
* O
MCHC-33.3 O
RDW-18.2 O
* O
Plt O
Ct-54 O
* O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
21 O
* O
* O
] O
06:00AM O
BLOOD O
Neuts-80.9 O
* O
Lymphs-12.2 O
* O
Monos-6.0 O

 O
Eos-0.7 O
Baso-0.1 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
21 O
* O
* O
] O
06:00AM O
BLOOD O
Plt O
Ct-54 O
* O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
20 O
* O
* O
] O
05:51AM O
BLOOD O
Fibrino-470 O
* O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
20 O
* O
* O
] O
05:51AM O
BLOOD O
Ret O
Aut-1.6 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
21 O
* O
* O
] O
06:00AM O
BLOOD O
Glucose-95 O
UreaN-14 O
Creat-1.2 O
* O
Na-143 O

 O
K-3.9 O
Cl-108 O
HCO3 O
- O
28 O
AnGap-11 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
21 O
* O
* O
] O
06:00AM O
BLOOD O
ALT-26 O
AST-19 O
LD(LDH)-182 O
AlkPhos-115 O
* O

 O
TotBili-0.2 O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
21 O
* O
* O
] O
06:00AM O
BLOOD O
Calcium-8.7 O
Phos-4.1 O
Mg-2.0 O


 O
MICROBIOLOGY O
: O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
10:30 O
pm O
BLOOD O
CULTURE O
      O
2 O
OF O
2 O
. O

    O
Blood O
Culture O
, O
Routine O
( O
Preliminary O
) O
: O

       O
GRAM O
NEGATIVE O
ROD(S O
) O
. O

    O
Aerobic O
Bottle O
Gram O
Stain O
( O
Final O
[ O
* O
* O
2181 O
- O
6 O
- O
17 O
* O
* O
] O
) O
: O

       O
GRAM O
NEGATIVE O
ROD(S O
) O
. O

    O
Anaerobic O
Bottle O
Gram O
Stain O
( O
Final O
[ O
* O
* O
2181 O
- O
6 O
- O
17 O
* O
* O
] O
) O
: O

       O
GRAM O
NEGATIVE O
ROD(S O
) O
. O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
URINE O
CULTURE O
( O
Preliminary O
) O
: O

       O
STAPH O
AUREUS O
COAG O
+ O
. O
    O
> O
100,000 O
ORGANISMS/ML O
. O

 O
. O

 O
IMAGING O
: O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
CXR O
: O
IMPRESSION O
: O
  O
No O
acute O
cardiopulmonary O
abnormality O
. O


 O
[ O
* O
* O
2181 O
- O
6 O
- O
17 O
* O
* O
] O
CT O
abd/pelvis O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Worsened O
left O
sided O
hydronephrosis O
with O
ureteral O
stent O
in O

 O
unchanged O

 O
position O
. O
  O
New O
stranding O
around O
the O
left O
kidney O
is O
noted O
which O

 O
may O
represent O
new O
inflammation O
versus O
forniceal O
rupture O
. O

 O
Contiued O
stranding O
is O
noted O
along O
the O
course O
of O
the O
left O
ureter O
. O


 O
3 O
. O
Urothelial O
thickening O
is O
noted O
on O
the O
right O
, O
with O
increase O
in O

 O
renal O
pelvis O
dilation O
but O
no O
gross O
hydronephrosis O
. O

 O
4 O
. O
Right O
groin O
mass O
( O
series O
2 O
, O
image O
78 O
) O
previously O
identified O

 O
as O
local O

 O
recurrence O
is O
unchanged O
in O
size O
compared O
to O
the O
prior O

 O
examination O
. O

 O
. O

 O
-[**6 O
- O
17 O
* O
* O
] O
b/l O
LENIs O
: O

 O
IMPRESSION O
: O
  O
No O
evidence O
of O
deep O
vein O
thrombosis O
either O
the O

 O
right O
or O
left O

 O
lower O
extremity O
. O

 O
. O

 O
-[**6 O
- O
17 O
* O
* O
] O
VQ O
scan O
: O
Very O
low O
likelihood O
ratio O
for O
recent O
pulmonary O

 O
embolism O
. O



 O
MICROBIOLOGY O

 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
10:30 O
pm O
BLOOD O
CULTURE O
      O
2 O
OF O
2 O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2181 O
- O
6 O
- O
19 O
* O
* O
] O
* O
* O


    O
Blood O
Culture O
, O
Routine O
( O
Final O
[ O
* O
* O
2181 O
- O
6 O
- O
19 O
* O
* O
] O
) O
: O

       O
ESCHERICHIA B-REA
COLI I-REA
. I-REA
    O
FINAL O
SENSITIVITIES O
. O

          O
Cefazolin B-DRUG
interpretative O
criteria O
are O
based O
on O
a O
dosage O

 O
regimen O
of O

          O
2 B-STR
g I-STR
every B-FRE
8h I-FRE
. I-FRE

          O
Piperacillin/Tazobactam B-DRUG
sensitivity O
testing O
performed O

 O
by O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
3077 O
* O
* O
] O

          O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
3060 O
* O
* O
] O
. O


                               O
SENSITIVITIES O
: O
MIC O
expressed O
in O

 O
MCG/ML O


 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

                              O
ESCHERICHIA O
COLI O

                              O
| O

 O
AMPICILLIN------------ O
   O
< O
= O
2 O
S O

 O
AMPICILLIN/SULBACTAM-- O
   O
< O
= O
2 O
S O

 O
CEFAZOLIN------------- O
   O
< O
= O
4 O
S O

 O
CEFEPIME-------------- O
   O
< O
= O
1 O
S O

 O
CEFTAZIDIME----------- O
   O
< O
= O
1 O
S O

 O
CEFTRIAXONE----------- O
   O
< O
= O
1 O
S O

 O
CIPROFLOXACIN---------<=0.25 O
S O

 O
GENTAMICIN------------ O
   O
< O
= O
1 O
S O

 O
MEROPENEM-------------<=0.25 O
S O

 O
PIPERACILLIN/TAZO----- O
       O
S O

 O
TOBRAMYCIN------------ O
   O
< O
= O
1 O
S O

 O
TRIMETHOPRIM/SULFA---- O
   O
< O
= O
1 O
S O


    O
Aerobic O
Bottle O
Gram O
Stain O
( O
Final O
[ O
* O
* O
2181 O
- O
6 O
- O
17 O
* O
* O
] O
) O
: O

       O
Reported O
to O
and O
read O
back O
by O
NIDHI O
SUKUL,5/13/12,10:40AM O
. O

       O
GRAM O
NEGATIVE O
ROD(S O
) O
. O


    O
Anaerobic O
Bottle O
Gram O
Stain O
( O
Final O
[ O
* O
* O
2181 O
- O
6 O
- O
17 O
* O
* O
] O
) O
: O

       O
Reported O
to O
and O
read O
back O
by O
NIDHI O
SUKUL,5/13/12,10:40AM O
. O

       O
GRAM O
NEGATIVE O
ROD(S O
) O
. O


 O
[ O
* O
* O
2181 O
- O
6 O
- O
16 O
* O
* O
] O
11:20 O
pm O
URINE O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2181 O
- O
6 O
- O
19 O
* O
* O
] O
* O
* O


    O
URINE O
CULTURE O
( O
Final O
[ O
* O
* O
2181 O
- O
6 O
- O
19 O
* O
* O
] O
) O
: O

       O
STAPH O
AUREUS O
COAG O
+ O
. O
    O
> O
100,000 O
ORGANISMS/ML O
.. O

          O
Staphylococcus O
species O
may O
develop O
resistance O
during O

 O
prolonged O

          O
therapy O
with O
quinolones O
. O
   O
Therefore O
, O
isolates O
that O
are O

 O
initially O

          O
susceptible O
may O
become O
resistant O
within O
three O
to O
four O

 O
days O
after O

          O
initiation O
of O
therapy O
. O
  O
Testing O
of O
repeat O
isolates O
may O

 O
be O

          O
warranted O
. O


                               O
SENSITIVITIES O
: O
MIC O
expressed O
in O

 O
MCG/ML O



 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

                              O
STAPH O
AUREUS O
COAG O
+ O

                              O
| O

 O
GENTAMICIN------------ O
< O
= O
0.5 O
S O

 O
LEVOFLOXACIN----------<=0.12 O
S O

 O
NITROFURANTOIN-------- O
    O
32 O
S O

 O
OXACILLIN-------------<=0.25 O
S O

 O
TRIMETHOPRIM/SULFA---- O
< O
= O
0.5 O
S O


 O
Brief O
Hospital O
Course O
: O

 O
Ms. O
[ O
* O
* O
Known O
lastname O
18573 O
* O
* O
] O
is O
a O
63F O
w/ O
recurrent B-REA
stage I-REA
IIIC I-REA
papillary I-REA

 I-REA
serous I-REA
ovarian I-REA
CA I-REA
on O
cycle O
8 O
day O
14 O
of O
carboplatin B-DRUG
, I-DRUG
gemcitabine B-DRUG
, I-DRUG

 O
bevacizumab B-DRUG
( O
avastin B-DRUG
) I-DRUG
, O
and O
b/l O
hydronephrosis O
[ O
* O
* O
3 O
- O
8 O
* O
* O
] O
ureter O

 O
obstruction O
requiring O
left O
ureteral O
stent O
and O
right O
nephrostomy O

 O
tube O
. O
She O
p/w O
acute O
onset O
SOB O
in O
the O
setting O
of O
one O
week O
of O

 O
dyspnea O
and O
fatigue O
, O
which O
was O
initially O
concerning O
for O
PE O
. O

 O
Further O
w/u O
ended O
up O
ruling O
out O
PE O
, O
and O
her O
SOB O
was O
likely O
in O

 O
the O
context O
of O
her O
fever O
and O
GNR O
bacteremia O
, O
which O
were O
likely O

 O
[ O
* O
* O
3 O
- O
8 O
* O
* O
] O
urinary O
source O
. O

 O
. O

 O
ACTIVE O
ISSUES O
: O

 O
. O

 O
# O
Dyspnea O
: O
Pt O
p/w O
acute O
onset O
SOB O
, O
and O
was O
found O
to O
be O
in O
sinus O

 O
tach O
with O
elevated O
d-dimer O
and O
BNP O
in O
setting O
of O
malignancy O
, O

 O
although O
bedside O
u/s O
showed O
no O
e/o O
R O
heart O
strain O
. O
She O
did O
not O

 O
undergo O
CTA O
due O
to O
elevated O
Cr O
, O
but O
was O
started O
on O
a O
heparin B-DRUG
gtt B-ROU

 I-ROU
in O
the O
ED O
. O
Upon O
admission O
to O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
, O
she O
had O
no O
Si/Sx O
of O

 O
hemodynamic O
or O
respiratory O
collapse O
. O
ACS O
, O
PNA O
or O
pulmonary O
edema O

 O
were O
r/o O
. O
LENIs O
were O
obtained O
, O
which O
were O
negative O
. O
A O
VQ O
scan O

 O
was O
subsequently O
performed O
, O
and O
it O
was O
low O
probability O
for O
PE O

 O
and O
the O
heparin B-DRUG
was O
d/c'd O
. O
In O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
her O
SOB O
vastly O
improved O

 O
without O
further O
intervention O
. O
Her O
dyspnea O
was O
most O
likely O
due O
to O

 O
her O
anemia B-REA
as O
she O
significantly O
improved O
after O
transfusion O
of O
2 B-DOS

 I-DOS
units B-FOR
pRBCs B-DRUG
for O
a O
HCT B-REA
of I-REA
18 I-REA
. I-REA

 O
. O


 O
# O
Fevers O
and O
UTI B-REA
: I-REA
UTI O
was O
likely O
cause O
for O
her O
fevers O
to O
102.3 O

 O
and O
diff O
with O
91 O
% O
PMNs O
. O
Pt O
has O
a O
h/o O
b/l O
hydronephrosis O
[ O
* O
* O
3 O
- O
8 O
* O
* O
] O

 O
ureter O
obstruction O
requiring O
left O
ureteral O
stent O
and O
right O

 O
nephrostomy O
tube O
, O
and O
all O
UA O
's O
have O
been O
positive O
with O
pyuria O

 O
and O
hematuria O
since O
[ O
* O
* O
2 O
- O
15 O
* O
* O
] O
. O
Upon O
admission O
, O
she O
again O
had O
positive O

 O
UA O
's O
from O
both O
foley O
and O
nephrostomy O
tube O
. O
She O
received O

 O
vanc/cefepime B-DRUG
in O
the O
ED O
; O
her O
past O
urine O
Cx O
's O
have O
grown O
E O
coli O

 O
sensitive O
to O
cefepime B-DRUG
. I-DRUG
Per O
past O
urology O
notes O
, O
her O
R O
kidney O
is O

 O
not O
functioning O
as O
well O
as O
the O
left O
, O
and O
no O
other O
urological O

 O
interventions O
were O
necessary O
; O
she O
is O
scheduled O
for O
a O
left O
stent O

 O
change O
in O
[ O
* O
* O
7 O
- O
17 O
* O
* O
] O
. O

 O
While O
in O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
, O
GNRs O
grew O
out O
of O
her O
blood O
Cx O
from O
[ O
* O
* O
6 O
- O
16 O
* O
* O
] O
, O
and O

 O
she O
was O
continued O
on O
cefepime B-DRUG
( O
d1=[**6 O
- O
16 O
* O
* O
] O
) O
, O
and O
continued O
on O
vanc O

 O
( O
d1=[**6 O
- O
16 O
* O
* O
] O
) O
given O
that O
she O
has O
a O
port O
. O
Her O
urine O
culture O
grew O
coag O

 O
+ O
staph O
and O
per O
Urology O
, O
it O
was O
recommended O
to O
continue O
treating O

 O
the O
UTI O
w/o O
indication O
for O
stent O
removal O
at O
this O
time O
. O
Her O
urine O

 O
culture O
eventually O
speciated O
as O
pansensitive O
staphylococcus B-REA

 I-REA
aureus I-REA
, I-REA
and O
she O
was O
transitioned O
to O
oral B-ROU
augmentin B-DRUG
to O
compelte O
a O

 O
total O
14 B-DUR
day I-DUR
course O
following O
discharge O
. O
  O
Her O
blood O
cultures O

 O
speciated O
as O
pansensitive O
E. B-REA
coli I-REA
and O
she O
was O
transitined O
to O

 O
oral B-ROU
ciprofloxacin B-DRUG
, I-DRUG
also O
to O
complete O
a O
14 B-DUR
day I-DUR
course O
, O
priro O
to O

 O
dishcarge O
. O
  O
She O
remained O
afebrile O
and O
stable O
on O
oral B-ROU
antibiotics B-DRUG

 I-DRUG
for O
24 O
hours O
prior O
to O
discharge O
. O

 O
. O

 O
# O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
: O
Baseline O
Cr O
is O
about O
1.2 O
- O
1.3 O
; O
pt O
initially O
p/w O
Cr O
1.9 O
. O

 O
Likely O
prerenal O
etiology O
given O
fever O
and O
UTI O
and O
FeNa O
of O
0.9 O
% O
. O

 O
She O
has O
a O
h/o O
obstruction O
, O
but O
had O
been O
maintaining O
good O
UOP O

 O
from O
urethra O
and O
nephrostomy O
. O
Her O
Cr O
improved O
in O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
to O
1.4 O

 O
after O
2 B-DOS
units B-FOR
pRBCs B-DRUG
, I-DRUG
and O
subsequently O
improved O
further O
to O
1.2 O
by O

 O
the O
time O
of O
discharge O
. O

 O
. O


 O
# O
Anemia B-REA
: I-REA
Macrocytic O
anemia O
with O
Hct O
24.9 O
and O
MCV O
102 O
on O

 O
admission O
; O
baseline O
Hct O
is O
in O
high O
20 O
's O
. O
She O
had O
no O
Si/Sx O
of O

 O
active O
bleeding O
upon O
admission O
, O
although O
the O
pt O
endorses O
small O

 O
amts O
of O
blood O
in O
stool O
while O
on O
avastin B-DRUG
, I-DRUG
known O
to O
heme-onc O
. O
She O

 O
had O
a O
6-point O
Hct O
drop O
after O
admission O
to O
the O
[ O
* O
* O
Hospital O
Unit O
Name O
153 O
* O
* O
] O
with O
no O

 O
identified O
source O
; O
her O
Hct O
bumped O
appropriately O
after O
2U B-FOR
PRBC B-DRUG
's I-DRUG
. I-DRUG

 O
Her O
stool O
was O
guaiac O
negative O
. O

 O
. O

 O
CHRONIC O
OR O
INACTIVE O
ISSUES O
: O

 O
. O

 O
# O
Thrombocytopenia B-ADE
: I-ADE
Most O
likely O
[ O
* O
* O
3 O
- O
8 O
* O
* O
] O
chemo B-DRUG
per O
her O
primary O

 O
oncologist O
, O
as O
per O
hx O
of O
similar O
s/p O
chemo B-DRUG
and O
is O
unlikely O
HIT O

 O
as O
her O
platelets O
were O
decreased O
upon O
admission O
and O
before O
the O

 O
initiation O
of O
the O
heparin B-DRUG
gtt B-ROU
. I-ROU

 O
. O

 O
# O
Recurrent B-REA
stage I-REA
IIIC I-REA
papillary I-REA
serous I-REA
ovarian I-REA
CA I-REA
on O
cycle O
8 O

 O
day O
14 O
of O
carboplatin B-DRUG
, I-DRUG
gemcitabine B-DRUG
, I-DRUG
bevacizumab B-DRUG
( O
avastin B-DRUG
) I-DRUG
. O

 O
. O

 O
# O
HTN B-REA
: I-REA
initially O
held O
home O
lisinopril B-DRUG
5 B-STR
mg I-STR
daily B-FRE
given O
fevers O
, O

 O
UTI O
, O
and O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
. O
Once O
her O
creatinine O
decreased O
to O
1.4 O
, O
her O
home O

 O
lisinopril B-DRUG
was O
re-started O
. O


 O
Medications O
on O
Admission O
: O

 O
Home O
Medications O
: O

 O
Lisinopril B-DRUG
5 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Vitamin B-DRUG
D I-DRUG

 I-DRUG
Colace B-DRUG



 I-DRUG
Discharge O
Medications O
: O

 O
1 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
lisinopril B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
3 O
. O
Vitamin B-DRUG
D3 I-DRUG
  O
Oral B-ROU

 I-ROU
4 O
. O
ciprofloxacin B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q12H B-FRE

 I-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
for B-DUR
11 I-DUR
days I-DUR
: I-DUR
last O
day O
[ O
* O
* O
2181 O
- O
7 O
- O
1 O
* O
* O
] O
. O

 O
Disp:*22 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
5 O
. O
amoxicillin-pot B-DRUG
clavulanate I-DRUG
875 B-STR
- I-STR
125 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
Q12H B-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
for B-DUR
11 I-DUR
days I-DUR
: I-DUR
last O
day O
[ O
* O
* O
2181 O
- O
7 O
- O
1 O
* O
* O
] O
. O

 O
Disp:*22 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
6 O
. O
senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
7 O
. O
polyethylene B-DRUG
glycol I-DRUG
3350 I-DRUG
17 B-STR
gram I-STR
Powder B-FOR
in I-FOR
Packet I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Powder B-FOR
in I-FOR
Packet I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O

 O
constipation B-REA
. I-REA

 O
Disp:*30 O
Powder O
in O
Packet(s O
) O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
Eschirichia O
coli O
bactermeia O

 O
Methicillin O
sensitive O
staphylococcus O
aureus O
urinary O
tract O

 O
infection O

 O
Anemia O

 O
Thrombocytopenia O



 O
Secondary O
: O

 O
Stage O
IIIC O
papillary O
serous O
ovarian O
carcinoma O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
Ms. O
[ O
* O
* O
Known O
lastname O
18573 O
* O
* O
] O
, O


 O
It O
was O
a O
pleasure O
taking O
care O
of O
you O
at O
the O
[ O
* O
* O
Hospital1 O
771 O
* O
* O
] O
. O
  O
You O
were O
admitted O
with O
shortness O
of O

 O
breath O
and O
fevers O
. O
  O
You O
were O
initially O
admitted O
to O
our O
intensive O

 O
care O
unit O
, O
where O
you O
were O
treated O
with O
antibiotics B-DRUG
. I-DRUG
  O
Your O
blood O

 O
counts O
were O
found O
to O
be O
low O
, O
and O
you O
were O
given O
blood B-DRUG

 I-DRUG
transfusions I-DRUG
. I-DRUG
You O
were O
initally O
started O
on O
a O
blood B-DRUG
thinner I-DRUG
to O

 O
treat O
you O
for O
a B-REA
potential I-REA
blood I-REA
clot I-REA
in I-REA
your I-REA
lungs I-REA
, I-REA
but O

 O
subsequent O
studies O
showed O
that O
you O
were O
unlikely O
to O
have O

 O
developed O
a O
blood B-REA
clot I-REA
, I-REA
and O
the O
blood B-DRUG
thinner I-DRUG
was O
stopped O
. O
  O
Your O

 O
breathing O
improved O
after O
blood B-DRUG
transfusion B-FOR
. I-FOR


 O
We O
found O
that O
you O
have O
an O
infection B-REA
in O
your O
blood O
and O
urine O
. O

 O
You O
were O
treated O
initially O
with O
intravenous B-ROU
antibiotics B-DRUG
, I-DRUG
and O

 O
eventually O
switched O
to O
oral B-ROU
antibiotics B-DRUG
. I-DRUG
  O
You O
will O
need O
to O

 O
compelte O
a O
course O
of O
oral B-ROU
antibiotics B-DRUG
as O
an O
outpatient O
. O
  O
Please O

 O
followup O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
in O
clinic O
. O


 O
We O
made O
the O
following O
changes O
to O
your O
medications O
: O

 O
STARTED O

 O
-Augmentin B-DRUG
until O
[ O
* O
* O
2181 O
- O
7 O
- O
1 O
* O
* O
] O

 O
-Ciprofloxacin B-DRUG
until O
[ O
* O
* O
2181 O
- O
7 O
- O
1 O
* O
* O
] O

 O
-Senna B-DRUG
and O
Polyethylene B-DRUG
glycol I-DRUG
to O
help O
you O
move B-REA
your I-REA
bowels I-REA


 I-REA
Please O
continue O
taking O
your O
other O
medications O
as O
usual O
. O


 O
Please O
followup O
with O
your O
doctors O
, O
see O
below O
. O


 O
Followup O
Instructions O
: O

 O
Department O
: O
HEMATOLOGY/ONCOLOGY O

 O
When O
: O
MONDAY O
[ O
* O
* O
2181 O
- O
6 O
- O
25 O
* O
* O
] O
at O
9:30 O
AM O

 O
With O
: O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
22 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
24 O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O



 O
Department O
: O
HEMATOLOGY/ONCOLOGY O

 O
When O
: O
MONDAY O
[ O
* O
* O
2181 O
- O
6 O
- O
25 O
* O
* O
] O
at O
11:00 O
AM O

 O
With O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
14688 O
* O
* O
] O
, O
RN O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
22 O
* O
* O
] O

 O
Building O
: O
[ O
* O
* O
Hospital6 O
29 O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
24 O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O


 O
Department O
: O
RADIOLOGY O
CARE O
UNIT O

 O
When O
: O
WEDNESDAY O
[ O
* O
* O
2181 O
- O
7 O
- O
11 O
* O
* O
] O
at O
9:00 O
AM O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
446 O
* O
* O
] O

 O
Building O
: O
De O
[ O
* O
* O
Hospital1 O
* O
* O
] O
Building O
( O
[ O
* O
* O
Hospital O
Ward O
Name O
121 O
* O
* O
] O
Complex O
) O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
WEST O
     O
Best O
Parking O
: O
[ O
* O
* O
Street O
Address(1 O
) O
592 O
* O
* O
] O
Garage O




 O
Completed O
by:[**2181 O
- O
6 O
- O
23 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2105 O
- O
7 O
- O
27 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2105 O
- O
7 O
- O
28 O
* O
* O
] O



 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
330 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Hypotension O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Central O
Venous O
line O
( O
Right O
IJ O
) O

 O
Arterial O
line O
( O
Left O
) O


 O
History O
of O
Present O
Illness O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
is O
a O
[ O
* O
* O
Age O
over O
90 O
* O
* O
] O
year O
old O
male O
with O
a O
history O
of O
atrial O

 O
fibrillation O
, O
systolic O
heart O
failure O
, O
chronic O
kidney O
disease O
who O

 O
presents O
from O
NH O
with O
altered O
mental O
status O
. O
  O
Per O
report O
, O
pt O
was O

 O
noted O
by O
staff O
at O
NH O
yesterday O
to O
be O
difficult O
to O
arouse O
and O

 O
having O
labored O
breathing O
. O
  O
His O
vitals O
at O
the O
time O
included O
BP O

 O
112/57 O
, O
and O
O2 O
sats O
and O
temperature O
were O
not O
obtainable O
due O

 O
likely O
to O
hypothermia O
. O
  O
He O
was O
sent O
to O
the O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
for O
further O

 O
revaluation O
. O
  O
Of O
note O
, O
per O
his O
daughter O
, O
he O
was O
recently O

 O
hospitalized O
( O
[ O
* O
* O
2015 O
- O
7 O
- O
16 O
* O
* O
] O
) O
from O
[ O
* O
* O
Hospital3 O
* O
* O
] O
Hospital O
with O
congestive O

 O
heart O
failure O
. O
  O
During O
this O
hospitalization O
he O
was O
noted O
to O
have O

 O
deteriorating O
mental O
status O
and O
delirium O
, O
which O
is O
why O
he O
had O

 O
been O
discharged O
to O
NH O
. O

 O
In O
the O
ED O
, O
VS O
T O
92.1 O
axillary O
, O
BP O
100/50 O
, O
HR O
50 O
, O
RR O
21 O
88 O
% O
6L O

 O
initially O
then O
placed O
99 O
% O
NRB O
. O
  O
He O
received O
vancomycin B-DRUG
, I-DRUG

 O
ceftriaxone B-DRUG
, I-DRUG
and O
flagyl B-DRUG
for O
aspiration B-REA
pneumonia I-REA
. I-REA
  O
Also O
received O

 O
vitamin B-DRUG
K I-DRUG
IV B-ROU
10 B-STR
mg I-STR
for O
coagulopathy B-REA
with O
INR O
to O
7.2 O
. O
  O
With O
CT O

 O
head O
negative O
for O
acute O
intracranial O
process O
. O
  O
Also O
received O
1 B-DOS
L I-DOS

 I-DOS
IVF B-DRUG
total O
in O
ED O
. O

 O
On O
arrival O
to O
MICU O
, O
he O
was O
noteedd O
to O
be O
bradycardic B-REA
to O
HRs O
to O

 O
30s O
and O
hypotensive O
to O
SBP O
80s O
with O
MAPS O
50s O
. O
  O
He O
was O
given O
1 B-STR
mg I-STR

 I-STR
atropine B-DRUG
with O
HR O
to O
50s O
. O
  O
He O
was O
given O
500 B-DOS
cc I-DOS
fluid B-DRUG
bolus B-DOS
x O
2 B-DOS

 I-DOS
and O
SBP O
came O
up O
to O
90s O
. O


 O
Past O
Medical O
History O
: O

 O
Systolic O
Heart O
Failure O
with O
EF O
30 O
% O

 O
Hypertension O

 O
Atrial O
Fibrillation O

 O
Hypothyrodism O

 O
Chronic O
kidney O
disease O
, O
stage O
III O

 O
Dysphagia O

 O
Dementia O
? O


 O
Social O
History O
: O

 O
Currently O
lives O
in O
a O
nursing O
home O
. O
  O
Has O
a O
daughter O
and O
son O
. O

 O
[ O
* O
* O
Name O
( O
NI O
) O
3003 O
* O
* O
] O
to O
being O
in O
the O
nursing O
home O
, O
he O
lived O
with O
his O
daugther O
. O


 O
Family O
History O
: O

 O
NC O



 O
Physical O
Exam O
: O

 O
VS O
: O
HR O
46 O
  O
96/49 O
RR O
18 O
100 O
% O
NRB O

 O
GEN O
: O
On O
NRB O
, O
difficult O
to O
arouse O
, O
non-verbal O
, O
opens O
eyes O
to O

 O
painful O
stimuli O
, O
unable O
to O
follow O
commands O

 O
HEENT O
: O
AT O
, O
NC O
, O
  O
EOMI O
, O
no O
conjuctival O
injection O
, O
anicteric O
, O
MM O

 O
dry O
, O
right O
pupil O
reactive O
3 O
to O
2 O
mm O
, O
left O
pupil O
unreactive O

 O
CV O
: O
Irreg O
irreg O
, O
nl O
s1 O
s2 O

 O
PULM O
: O
Diffuse O
crackles O
anteriorly O

 O
ABD O
: O
soft O
, O
mild O
distension O
, O
+ O
BS O
, O
no O
HSM O

 O
EXT O
: O
cool O
, O
b/l O
lateral O
malleolus O
venous O
stasis O
ulcers O

 O
NEURO O
: O
Unable O
to O
assess O
due O
to O
mental O
status O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
26 O
* O
* O
] O
10:40PM O
BLOOD O
WBC-4.8 O
RBC-3.30 O
* O
Hgb-10.5 O
* O
Hct-32.1 O
* O

 O
MCV-98 O
MCH-32.0 O
MCHC-32.8 O
RDW-17.6 O
* O
Plt O
Ct-124 O
* O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
27 O
* O
* O
] O
05:10PM O
BLOOD O
WBC-5.9 O
RBC-3.06 O
* O
Hgb-10.0 O
* O
Hct-30.5 O
* O

 O
MCV-100 O
* O
MCH-32.7 O
* O
MCHC-32.8 O
RDW-17.2 O
* O
Plt O
Ct-100 O
* O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
26 O
* O
* O
] O
10:40PM O
BLOOD O
Neuts-85.0 O
* O
Bands-0 O
Lymphs-9.2 O
* O
Monos-4.7 O

 O
Eos-0.6 O
Baso-0.5 O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
26 O
* O
* O
] O
10:40PM O
BLOOD O
PT-60.4 O
* O
PTT-67.9 O
* O
INR(PT)-7.2 O
* O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
27 O
* O
* O
] O
04:49AM O
BLOOD O
Fibrino-405 O
* O
D-Dimer-686 O
* O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
26 O
* O
* O
] O
10:40PM O
BLOOD O
Glucose-61 O
* O
UreaN-50 O
* O
Creat-2.0 O
* O
Na-137 O

 O
K-4.8 O
Cl-100 O
HCO3 O
- O
27 O
AnGap-15 O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
26 O
* O
* O
] O
10:40PM O
BLOOD O
ALT-23 O
AST-40 O
CK(CPK)-175 O
* O
AlkPhos-164 O
* O

 O
TotBili-0.8 O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
26 O
* O
* O
] O
10:40PM O
BLOOD O
CK-MB-17 O
* O
MB O
Indx-9.7 O
* O
cTropnT-0.12 O
* O

 O
proBNP-5749 O
* O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
27 O
* O
* O
] O
03:32AM O
BLOOD O
Albumin-2.8 O
* O
Calcium-7.5 O
* O
Phos-4.1 O
Mg-1.9 O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
27 O
* O
* O
] O
03:32AM O
BLOOD O
TSH-20 O
* O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
27 O
* O
* O
] O
04:55PM O
BLOOD O
T4 O
- O
5.9 O
calcTBG-0.82 O
TUptake-1.22 O

 O
T4Index-7.2 O

 O
[ O
* O
* O
2105 O
- O
7 O
- O
26 O
* O
* O
] O
11:01PM O
BLOOD O
Lactate-1.4 O


 O
Relevant O
Imaging O
: O


 O
CT O
Head O

 O
FINDINGS O
: O
There O
is O
no O
intra- O
or O
extra-axial O
hemorrhage O
, O
mass O

 O
effect O
, O
or O
shift O
of O
normally O
midline O
structures O
. O
Extensive O

 O
bilateral O
periventricular O
as O
well O
as O
subcortical O
white O
matter O

 O
hypoattenuation O
related O
to O
chronic O

 O
microangiopathic O
ischemic O
changes O
is O
evident O
. O



 O
The O
ventricles O
and O
sulci O
are O
moderately O
prominent O
, O
appropriate O

 O
for O
age- O

 O
associated O
involutionary O
changes O
. O
Bilateral O
basal O
ganglia O

 O
calcification O
and O
extensive O
calcification O
along O
the O
tentorium O

 O
and O
falx O
cerebri O
are O
evident O
. O
The O
osseous O
and O
soft O
tissue O

 O
structures O
are O
unremarkable O
. O
A O
nonspecific O
focus O
of O
hyperdense O

 O
focus O
is O
noted O
in O
the O
left O
pre-zygomatic O
soft O
tissue O
. O
Clinical O

 O
correlation O
is O
advised O
. O


 O
IMPRESSION O
: O
No O
acute O
intracranial O
process O
. O
A O
small O
hyperdense O

 O
focus O
in O
the O

 O
left O
pre-zygomatic O
soft O
tissue O
could O
represent O
calcification O
and O

 O
clinical O
correlation O
is O
advised O
. O


 O
ECHO O

 O
The O
left O
atrium O
is O
moderately O
dilated O
. O
The O
right O
atrium O
is O

 O
markedly O
dilated O
. O
There O
is O
mild O
symmetric O
left O
ventricular O

 O
hypertrophy O
with O
normal O
cavity O
size O
. O
There O
is O
mild O
regional O
left O

 O
ventricular O
systolic O
dysfunction O
with O
severe O
hypokinesis O
of O
the O

 O
basal O
half O
of O
the O
inferior O
and O
inferolateral O
walls O
. O
The O

 O
remaining O
segments O
contract O
normally O
( O
LVEF O
= O
40 O
% O
) O
. O
Right O

 O
ventricular O
chamber O
size O
and O
free O
wall O
motion O
are O
normal O
. O
The O

 O
ascending O
aorta O
is O
dilated O
at O
the O
sinus O
level O
. O
The O
descending O

 O
thoracic O
aorta O
is O
mildly O
dilated O
. O
The O
aortic O
valve O
leaflets O
are O

 O
severely O
thickened/deformed O
. O
Significant O
aortic O
stenosis O
is O

 O
present O
( O
not O
quantified O
) O
. O
No O
aortic O
regurgitation O
is O
seen O
. O
The O

 O
mitral O
valve O
leaflets O
are O
mildly O
thickened O
. O
Mild O
( O
1 O
+ O
) O
mitral O

 O
regurgitation O
is O
seen O
. O
The O
tricuspid O
valve O
leaflets O
are O
mildly O

 O
thickened O
. O
There O
is O
mild O
pulmonary O
artery O
systolic O
hypertension O
. O

 O
There O
is O
no O
pericardial O
effusion O
. O


 O
IMPRESSION O
: O
Mild O
symmetric O
left O
ventricular O
hypertrophy O
with O

 O
regional O
systolic O
dysfunction O
c/w O
CAD O
. O
Aortic O
stenosis O
. O
Dilated O

 O
ascending O
aorta O
. O

 O
If O
clinically O
indicated O
, O
a O
follow-up O
study O
to O
assess O
aortic O

 O
stenosis O
is O
suggested O
when O
the O
patient O
can O
be O
transported O
to O
the O

 O
Echo O
laboratory O
. O



 O
Brief O
Hospital O
Course O
: O

 O
[ O
* O
* O
Age O
over O
90 O
* O
* O
] O
year O
old O
male O
with O
a O
history O
of O
systolic O
congestive O
heart O

 O
failure O
, O
atrial O
fibrillation O
, O
who O
presented O
with O
hypoxia O
, O

 O
hypotension O
, O
and O
hypothermia O
. O


 O
Upon O
admission O
to O
the O
MICU O
, O
agressive O
therapy O
was O
initiated O

 O
keeping O
a O
broad O
differential O
diagnosis O
. O
Patient O
however O

 O
continued O
to O
deteriorate O
and O
abruptly O
became O
profoundly O

 O
bradycardic B-REA
, I-REA
unresponsive O
to O
atropine B-DRUG
or O
increasing O
doses O
of O

 O
pressors B-DRUG
, I-DRUG
culminating O
in O
asystole O
; O
patient O
was O
pronounced O
dead O

 O
at O
1:05am O
on O
[ O
* O
* O
2105 O
- O
7 O
- O
28 O
* O
* O
] O
. O
Below O
are O
the O
details O
leading O
to O
these O

 O
events O
, O
arranged O
by O
problem O
: O



 O
1)Hypotension O
/ O
Hypothermia O
: O
On O
initial O
presentation O
on O
the O

 O
floor O
SBP B-REA
80s I-REA
, I-REA
given O
500cc B-DOS
fluid B-DRUG
bolus B-DOS
x O
2 B-DOS
with O
SBP O
to O
90s O
. O

 O
Meets O
SIRS O
criteria O
with O
hypothermia O
and O
tachpnea O
and O

 O
hypotension O
concerning O
for O
sepsis O
, O
with O
pneumonia O
as O
the O
most O

 O
likely O
source O
. O
  O
Also O
on O
differential O
was O
hypovolemic O
hypotension O

 O
for O
occult O
blood O
loss O
, O
cardiogenic O
shock O
, O
adrenal O
insuffiency O

 O
and O
myxedema O
coma O
. O
Cooling O
blanket O
placed O
on O
patient O
upon O

 O
arrival O
. O


 O
Patient O
was O
given O
fluid B-DRUG
boluses B-DOS
and O
central O
access O
was O
obtained O
. O

 O
Echocardiogram O
was O
obtained O
and O
revealed O
mildly O
depressed O

 O
ejection O
fraction O
( O
40 O
% O
) O
with O
inferolateral O
wall O
hypokinesis O
and O

 O
moderate O
tricuspid O
regurgitation O
. O
Central O
venous O
pressure O
was O

 O
measured O
and O
found O
to O
be O
elvated O
to O
24mmHg O
, O
which O
even O
in O
the O

 O
setting O
of O
TR O
was O
felt O
to O
rule O
out O
hypovolemia O
. O
Patient O
was O

 O
initiated O
on O
Dopamine B-DRUG
in O
hopes O
of O
supporting B-REA
both I-REA
blood I-REA
pressure I-REA

 I-REA
and I-REA
heart I-REA
rate I-REA
. I-REA
Arterial O
line O
was O
placed O
for O
accurate O
assessment O

 O
of O
arterial O
pressure O
. O
Hematocrit O
remained O
stable O
and O
pressure O

 O
responded O
to O
pressor B-DRUG
support O
. O


 O
Patient O
started O
on O
stress B-DOS
dose I-DOS
steroids B-DRUG
for O
possible O
adrenal B-REA

 I-REA
insufficiency I-REA
. I-REA


 O
2)Hypoxia O
: O
With O
bilateral O
infiltrates O
and O
likely O
superimposed O

 O
fluid O
overlaod O
. O
  O
Given O
recent O
hospitalization O
and O
extent O
of O
O2 O

 O
requirement O
, O
high O
suspicion O
for O
Hospital B-REA
Acquired I-REA
Pneumonia I-REA

 I-REA
( I-REA
HAP I-REA
) I-REA
with O
vancomycin B-DRUG
and O
zosyn B-DRUG
. I-DRUG
This O
was O
later O
changed O
to O

 O
Vancomycin B-DRUG
and O
Cefepime B-DRUG
. I-DRUG
Patients O
blood O
gas O
was O
concerning O
for O

 O
hypercarbia O
, O
and O
after O
re-discussing O
goals O
of O
care O
with O
family O

 O
and O
confirming O
patient O
did O
not O
want O
to O
be O
intubated O
, O
non O

 O
invasive O
ventillation O
was O
initiated O
. O
Patient O
tolerated O
NIPPV O

 O
well O
and O
hypoxia O
/ O
hypercarbia O
/ O
respiratory O
acidosis O
improved O

 O
until O
his O
sudden O
decompensation O
. O


 O
3)Bradycardia B-REA
: I-REA
With O
baseline O
bradycardia O
per O
history O
, O
unclear O

 O
etiology O
. O
  O
On O
arrival O
to O
MICU O
, O
bradycardic O
to O
HR O
in O
30s O
, O
gave O
1 O

 O
mg O
atropine B-DRUG
with O
HR O
to O
50s O
. O
  O
All O
nodal O
agents O
were O
stopped O
and O

 O
heart O
rate O
improved O
with O
Dopamine B-DRUG
administration O
. O


 O
4)Meningitis B-REA
: I-REA
Given O
patients O
poor O
baseline O
mental O
status O
and O

 O
findings O
of O
significant O
nuchal O
rigidity O
, O
concern O
for O
meningitis O

 O
was O
raised O
. O
Given O
patients O
decompensated O
status O
, O
lumbar O
puncture O

 O
was O
not O
pursued O
and O
empiric O
coverage O
with O
Ampicillin B-DRUG
for O

 O
listeria B-REA
, I-REA
Vancomycin/Cefepime B-DRUG
for O
Staph/Strep B-REA
were O
initiated O
. O


 O
5)Hypothyroidism B-REA
: I-REA
TSH O
of O
20 O
, O
difficult O
to O
interpret O
in O
this O

 O
setting O
as O
sick O
euthyroid O
may O
have O
impacted O
laboratory O
results O
. O

 O
Given O
decompensated O
state O
, O
endocrine O
consult O
was O
placed O
and O

 O
thyroid B-DRUG
hormone I-DRUG
was O
supplemented O
intravenously B-ROU
at O
higher O
doses O

 O
than O
per O
outpatient O
regimen O
. O
Free O
T3 O
, O
T4 O
and O
Thyroid O
binding O

 O
protein O
were O
ordered O
but O
were O
not O
available O
before O
patient O

 O
decompensated O
. O
Per O
endocrine O
team O
recommendations O
, O
T3 O
was O
not O

 O
given O
due O
to O
concerns O
for O
arrythmia O
and O
cardiac O
side O
effects O
, O

 O
and O
given O
very O
poor O
level O
of O
evidence O
for O
its O
efficacy O
. O



 O
6)Coagulopathy B-REA
: I-REA
INR O
7.2 O
on O
admission O
in O
setting O
of O

 O
anticoagulation B-DRUG
. I-DRUG
  O
Given O
vitamin B-DRUG
K I-DRUG
and O
FFP B-DRUG
. I-DRUG
DIC O
labs O
negative O
. O


 O
7)Chronic O
kidney O
disease O
: O
With O
known O
baseline O
CKD O
stage O
III O
, O

 O
likely O
exacerbated O
in O
the O
setting O
of O
hypotension O
. O


 O
Medications O
on O
Admission O
: O

 O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
PRN B-FRE

 I-FRE
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
Milk B-DRUG
of I-DRUG
Magnesia I-DRUG
PRN B-FRE

 I-FRE
Dulcolax B-DRUG
10 B-STR
mg I-STR
Rectal B-ROU
Suppository B-FOR
PRN B-FRE

 I-FRE
Fleet B-DRUG
Enema I-DRUG
PRN B-FRE

 I-FRE
Albuterol B-DRUG
INH B-ROU
PRN B-FRE

 I-FRE
Coumadin B-DRUG
2.5 B-STR
mg I-STR
DAILY B-FRE

 I-FRE
Flomax B-DRUG
0.4 B-STR
mg I-STR
DAILY B-FRE

 I-FRE
Ferrous B-DRUG
Sulfate I-DRUG
325 B-STR
mg I-STR
DAILY B-FRE

 I-FRE
Levothyroxine B-DRUG
125 B-STR
mcg I-STR
DAILY B-FRE

 I-FRE
Lasix B-DRUG
20 B-STR
mg I-STR
DAILY B-FRE

 I-FRE
Lisinopril B-DRUG
2.5 B-STR
mg I-STR
DAILY B-FRE

 I-FRE
Magnesium B-DRUG
Oxide I-DRUG
400 B-STR
mg I-STR
DAILY B-FRE

 I-FRE
Calcium B-DRUG
500 B-STR
with O
Vitamin B-DRUG
D I-DRUG
DAILY B-FRE

 I-FRE
Proscar B-DRUG
5 B-STR
mg I-STR
DAILY B-FRE

 I-FRE
Ranitidine B-DRUG
150 B-STR
mg I-STR
DAILY B-FRE

 I-FRE
Zyprexa B-DRUG
2.5 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O


 O
Discharge O
Disposition O
: O

 O
Expired O


 O
Discharge O
Diagnosis O
: O

 O
Patient O
expired O


 O
Discharge O
Condition O
: O

 O
Patient O
expired O


 O
Discharge O
Instructions O
: O

 O
Patient O
expired O


 O
Followup O
Instructions O
: O

 O
Patient O
expired O



 O

Admission O
Date O
: O
  O
[ O
* O
* O
2194 O
- O
6 O
- O
24 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2194 O
- O
6 O
- O
27 O
* O
* O
] O



 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Aspirin B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
425 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Transfer O
from O
OSH O
for O
STEMI O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
cardiac O
catheterization O



 O
History O
of O
Present O
Illness O
: O

 O
87-year-old O
M O
with O
h/o O
HTN O
, O
hyperlipidemia O
presented O
to O
OSH O
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
[ O
* O
* O
Location O
( O
un O
) O
620 O
* O
* O
] O
with O
SSCP O
. O
Patient O
woke O
up O
in O
the O
morning O
and O
went O
for O

 O
walk/gardening O
then O
started O
to O
feel O
very O
badly O
around O
10 O
am O
, O

 O
nauseas O
, O
profuse O
sweating O
and O
feeling O
as O
though O
his O
chest O
was O

 O
going O
to O
" O
explode O
" O
. O
He O
went O
home O
and O
tried O
to O
vomit O
but O
could O
n't O

 O
so O
presented O
to O
the O
[ O
* O
* O
Hospital1 O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
620 O
* O
* O
] O
. O
At O
baseline O
he O
is O
very O
active O

 O
and O
can O
do O
30 O
minutes O
on O
the O
stationary O
bike O
or O
20 O
minutes O
of O

 O
rowing O
. O
He O
has O
never O
had O
similar O
symptoms O
in O
the O
past O
. O

 O
. O

 O
At O
OSH O
, O
VS O
97.2 O
63 O
135/78 O
20 O
97 O
% O
RA O
. O
EKG O
showing O
STE B-REA
in I-REA
inferior I-REA

 I-REA
leads I-REA
. I-REA
Treated O
with O
heparin B-DRUG
bolus B-DOS
of O
4200 B-STR
units I-STR
no O
gtt O
, O

 O
Integrillin B-DRUG
bolus B-DOS
6.8 O
ml O
with O
no O
drip O
, O
2 B-DOS
sublinqual B-ROU
gtt I-ROU
then O

 O
stopped O
, O
and O
2 B-STR
mg I-STR
of O
Morphine B-DRUG
IV B-ROU
and O
2L B-DOS
NS B-DRUG
. I-DRUG
Attempted O
to O
give O

 O
Lopressor B-DRUG
IV B-ROU
but O
after O
1 B-STR
mg I-STR
pt O
's O
b/p B-ADE
dropped I-ADE
to I-ADE
96/48 I-ADE
so O
not O

 O
given O
. O
Patient O
transferred O
for O
cath O
. O

 O
. O

 O
Cath O
here O
showed O
a O
proximal O
RCA O
occlusion O
with O
placement O
of O
3 O

 O
BMS O
. O
Transferred O
to O
ICU O
for O
hemodynamic O
instability O
, O
started O
on O

 O
Integrilin B-DRUG
gtt B-ROU
and O
Dopamine B-DRUG
gtt B-ROU
for O
hypotension B-REA
although O
AO O

 O
137/75 O
during O
cath O
. O
Upon O
arrival O
to O
the O
ICU O
patient O
is O
totally O

 O
CP O
free O
. O
He O
c/o O
feeling O
cold O
and O
thirsty/dry O
mouth O
. O
ROS O
negative O

 O
for O
h/o O
stroke O
, O
GI/GU O
complaints O
. O



 O
Past O
Medical O
History O
: O

 O
- O
HTN O

 O
- O
Hyperlipidemia O

 O
- O
h/o O
hematuria O
with O
renal O
stone O
s/p O
? O
lithotripsy O



 O
Social O
History O
: O

 O
Patient O
lives O
alone O
, O
wife O
recently O
put O
in O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
for O
advanced O

 O
Alzheimer O
's O
, O
previously O
looked O
after O
her O
at O
home O
x O
1 O
yr O
. O
He O
is O

 O
independent O
with O
ADL O
's O
, O
very O
active O
as O
described O
above O
. O
Never O

 O
smoked O
, O
never O
drinks O
, O
no O
OTC B-DRUG
meds I-DRUG
, I-DRUG
no O
illicit O
drugs O
. O
Has O
several O

 O
children O
in O
the O
area O
. O


 O
Family O
History O
: O

 O
No O
early O
CAD O
. O
Brother O
died O
of O
hemorrhagic O
stroke O
. O



 O
Physical O
Exam O
: O

 O
VS O
: O
T O
95.6 O
BP O
151/79 O
HR O
76 O
RR O
14 O
O2 B-DRUG
97 O
% O
4L O

 O
Gen O
: O
elderly O
male O
lying O
flat O
, O
NAD O
. O
Oriented O
x3 O
. O
Mood O
, O
affect O

 O
appropriate O
. O

 O
HEENT O
: O
NCAT O
. O
Sclera O
anicteric O
. O
PERRL O
, O
EOMI O
. O
Conjunctiva O
were O

 O
pink O
, O
no O
pallor O
or O
cyanosis O
of O
the O
oral O
mucosa O
. O
No O
xanthalesma O
. O


 O
Neck O
: O
Supple O
with O
JVP O
of O
7 O
cm O
. O

 O
CV O
: O
PMI O
located O
in O
5th O
intercostal O
space O
, O
midclavicular O
line O
. O

 O
RR O
, O
normal O
S1 O
, O
S2 O
. O
No O
m/r/g O
. O
No O
thrills O
, O
lifts O
. O
No O
S3 O
or O
S4 O
. O

 O
Chest O
: O
No O
chest O
wall O
deformities O
, O
scoliosis O
or O
kyphosis O
. O
Resp O

 O
were O
unlabored O
, O
no O
accessory O
muscle O
use O
. O
CTAB O
, O
no O
crackles O
, O

 O
wheezes O
or O
rhonchi O
. O

 O
Abd O
: O
Soft O
, O
NTND O
. O
No O
HSM O
or O
tenderness O
. O
Abd O
aorta O
not O
enlarged O
by O

 O
palpation O
. O
No O
abdominial O
bruits O
. O

 O
Ext O
: O
No O
c/c/e O
. O
No O
femoral O
bruits O
. O
Left O
groin O
sheat O
in O
place O
, O

 O
c/d/i O
, O
2 O
+ O
pulses O
, O
2 O
+ O
dp O
pulses O
b/l O

 O
Skin O
: O
No O
stasis O
dermatitis O
, O
ulcers O
, O
scars O
, O
or O
xanthomas O
. O



 O
Pertinent O
Results O
: O

 O
EKG O
[ O
* O
* O
2194 O
- O
6 O
- O
24 O
* O
* O
] O
10:51 O
: O
NSR O
at O
70 O
, O
4 O
mm O
STE O
II O
, O
III O
, O
F O
, O
RBBB O
, O
PR O
192 O
, O

 O
nl O
axis O

 O
Post O
intervention O
: O
1 O
- O
2 O
mm O
STE O
inferior O
leads O
, O
RBBB O

 O
. O

 O
140 O
  O
107 O
  O
18 O

 O
------------- O
< O
161 O

 O
4.2 O
  O
25 O
  O
0.9 O

 O
PT O
: O
11.9 O
  O
PTT O
: O
81.0 O
  O
INR O
: O
1.0 O

 O
. O

 O
trends O
: O

 O
[ O
* O
* O
2194 O
- O
6 O
- O
24 O
* O
* O
] O
WBC-10.3 O
RBC-3.79 O
* O
Hgb-12.6 O
* O
Hct-37.6 O
* O
Plt O
Ct-250 O

 O
[ O
* O
* O
2194 O
- O
6 O
- O
24 O
* O
* O
] O
12:00PM O
BLOOD O
CK(CPK)-217 O
* O

 O
[ O
* O
* O
2194 O
- O
6 O
- O
24 O
* O
* O
] O
09:12PM O
BLOOD O
CK(CPK)-1042 O
* O

 O
[ O
* O
* O
2194 O
- O
6 O
- O
25 O
* O
* O
] O
06:24AM O
BLOOD O
CK(CPK)-873 O
* O

 O
[ O
* O
* O
2194 O
- O
6 O
- O
24 O
* O
* O
] O
12:00PM O
BLOOD O
CK-MB-10 O
MB O
Indx-4.6 O
cTropnT-0.04 O
* O

 O
[ O
* O
* O
2194 O
- O
6 O
- O
24 O
* O
* O
] O
09:12PM O
BLOOD O
CK-MB-153 O
* O
MB O
Indx-14.7 O
* O
cTropnT-4.03 O
* O

 O
[ O
* O
* O
2194 O
- O
6 O
- O
25 O
* O
* O
] O
06:24AM O
BLOOD O
CK-MB-117 O
* O
MB O
Indx-13.4 O
* O

 O
. O


 O
[ O
* O
* O
6 O
- O
24 O
* O
* O
] O
: O
Cath O
: O

 O
1 O
. O
Selective O
coronary O
angiography O
of O
this O
right O
dominant O
system O

 O
revealed O

 O
single O
vessel O
coronary O
artery O
disease O
. O
The O
LMCA O
had O
no O

 O
angiographically O

 O
apparent O
flow O
limiting O
stenosis O
. O
The O
LAD O
had O
mild O
diffuse O

 O
disease O
. O
The O

 O
LCX O
had O
no O
angiographically O
apparent O
flow O
limiting O
stenosis O
. O
The O

 O
RCA O
was O

 O
a O
dominant O
vessel O
and O
was O
totally O
occluded O
proximally O
. O

 O
2 O
. O
Limited O
resting O
hemodynamics O
revealed O
normal O
systemic O

 O
pressure O
. O

 O
3 O
. O
Left O
ventriculography O
was O
deferred O
. O

 O
FINAL O
DIAGNOSIS O
: O

 O
1 O
. O
One O
vessel O
coronary O
artery O
disease O
. O

 O
2 O
. O
Normal O
systemic O
pressure O
. O

 O
3 O
. O
Acute O
inferior O
myocardial O
infarction O
, O
managed O
by O
acute O
ptca O
. O

  O
3 O
bare O
metal O
stents O
placed O
in O
the O
RCA O
vessel O
. O

 O
. O

 O
[ O
* O
* O
6 O
- O
26 O
* O
* O
] O
: O
ECHO O
: O
EF O
45 O
- O
50 O
% O
. O
  O
The O
left O
atrium O
is O
normal O
in O
size O
. O
The O

 O
estimated O
right O
atrial O
pressure O
is O
> O
20 O
mmHg O
. O
The O
left O

 O
ventricular O
cavity O
size O
is O
normal O
. O
Overall O
left O
ventricular O

 O
systolic O
function O
is O
mildly O
depressed O
with O
inferior O

 O
akinesis/hypokinesis O
and O
inferolateral O
hypokinesis O
. O
Right O

 O
ventricular O
chamber O
size O
is O
normal O
. O
Right O
ventricular O
systolic O

 O
function O
appears O
depressed O
. O
There O
is O
abnormal O
septal O

 O
motion/position O
consistent O
with O
right O
ventricular O

 O
pressure/volume O
overload O
. O
The O
aortic O
valve O
leaflets O
( O
3 O
) O
are O

 O
mildly O
thickened O
. O
No O
aortic O
regurgitation O
is O
seen O
. O
The O
mitral O

 O
valve O
appears O
structurally O
normal O
with O
trivial O
mitral O

 O
regurgitation O
. O
There O
is O
a O
trivial/physiologic O
pericardial O

 O
effusion O
. O
At O
least O
moderate O
pulmonary O
artery O
systolic O

 O
hypertension O
. O



 O
Brief O
Hospital O
Course O
: O

 O
ASSESSMENT O
AND O
PLAN O
, O
AS O
REVIEWED O
AND O
DISCUSSED O
IN O

 O
MULTIDISCIPLINARY O
ROUNDS O
: O

 O
Pt O
is O
an O
87 O
yo O
M O
with O
h/o O
HTN O
, O
hyperlipidemia O
who O
presents O
with O

 O
IMI O
s/p O
3x O
BMS O
to O
proximal O
RCA O
lesion O
. O

 O
. O

 O
# O
) O
CAD B-REA
: I-REA
IMI O
with O
proximal O
RCA O
occlusion O
, O
CK O
here O
217 O
Trop O
0.04 O

 O
- O
trend O
CK O
to O
peak O

 O
- O
monitor O
on O
tele O

 O
- O
start O
ASA B-DRUG
desensitization O
protocol O
given O
allergy O

 O
- O
Plavix B-DRUG

 I-DRUG
- O
high O
dose O
statin B-DRUG

 I-DRUG
- O
Integrilin B-DRUG
x B-DUR
18 I-DUR
hrs I-DUR

 I-DUR
- O
wean O
dopamine B-DRUG
given O
elevated B-REA
SBP I-REA
, I-REA
low O
dose O
beta B-DRUG
blocker I-DRUG
once O

 O
off O
dopamine B-DRUG

 I-DRUG
- O
echo O
in O
AM O
to O
evaluate O
EF O

 O
- O
daily O
EKG O

 O
- O
bolus B-DOS
IVF B-DRUG
for O
hypotension B-REA

 I-REA
- O
start O
ACEI B-DRUG
once O
hemodynamically O
stable O

 O
- O
going O
check O
, O
PM O
Hct O
, O
plts O

 O
. O

 O
# O
) O
Hypotension B-REA
. I-REA
Transient O
, O
likely O
in O
setting O
of O
vasodilators B-DRUG
at O

 O
OSH O
. O
Started O
on O
dopamine B-DRUG
--wean O
as O
SBP O
tolerates O
. O

 O
- O
bolus B-DOS
IVF B-DRUG
for O
hypotension B-REA

 I-REA
- O
low O
dose O
beta B-DRUG
blocker I-DRUG

 I-DRUG
. O

 O
# O
) O
Rhythm O
: O
NSR O
, O
RBBB O
, O
? O
old O

 O
- O
contact O
PCP O
for O
old O
EKG O

 O
- O
monitor O
on O
tele O
for O
PR O
prolongation O
, O
LAFB O

 O
- O
low O
dose O
beta B-DRUG
blocker I-DRUG

 I-DRUG
. O


 O
# O
) O
Pump O
: O
echo O
in O
AM O

 O
. O

 O
# O
) O
Hyperlipidemia B-REA
: I-REA
high O
dose O
statin B-DRUG

 I-DRUG
. O

 O
# O
) O
HTN B-REA
: I-REA
holding O
hctz B-DRUG
, I-DRUG
low O
dose O
beta B-DRUG
blocker I-DRUG
as O
tolerated O

 O
. O

 O
# O
) O
FEN B-REA
: I-REA
bolus B-DOS
IVF B-DRUG
prn B-FRE
, I-FRE
cardiac O
diet O
, O
replete O
lytes O
prn O

 O
. O

 O
# O
) O
PPX B-REA
: I-REA
PPI B-DRUG
, I-DRUG
bowel O
reg O
prn O

 O
. O

 O
# O
) O
Access O
: O
PIV O
x O
2 O

 O
. O

 O
# O
) O
Dispo O
: O
ICU O
level O
of O
care O
pending O
hemodynamic O
stability O

 O
. O

 O
# O
) O
Code O
: O
full O



 O
Medications O
on O
Admission O
: O

 O
ALLERGIES O
: O
ASA B-DRUG
-->facial B-ADE
swelling/itching B-ADE

 I-ADE
. O

 O
CURRENT O
MEDICATIONS O
: O

 O
- O
Hctz B-DRUG
? O
dose O
( O
[ O
* O
* O
1 O
- O
14 O
* O
* O
] O
pill B-FOR
) I-FOR

 O
- O
Simvastatin B-DRUG
? O
dose O
( O
[ O
* O
* O
1 O
- O
14 O
* O
* O
] O
pill B-FOR
) I-FOR



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
- O
Acute O
STEMI O
, O
inferior O
MI O
with O
CA O
occlusion O

 O
- O
HTN O

 O
- O
Hyperlipidemia O

 O
- O
ASA B-DRUG
allergy O
s/p O
successful O
desensitization O



 O
Discharge O
Condition O
: O

 O
well O



 O
Discharge O
Instructions O
: O

 O
You O
came O
in O
after O
experiencing O
a O
heart O
attack O
. O
  O
You O
underwent O

 O
cardiac O
catheterization O
and O
had O
three O
stents O
placed O
in O
your O

 O
right O
coronary O
artery O
. O
  O
You O
tolerated O
the O
procedure O
well O
. O
  O
We O

 O
performed O
an O
aspirin B-DRUG
desentizitation O
protocol O
to O
start O
aspirin B-DRUG
. I-DRUG

 O
. O

 O
Please O
take O
all O
of O
your O
medications O
as O
instucted O
. O
  O
We O
made O
the O

 O
following O
adjustments O
: O

 O
1 O
. O
  O
Plavix B-DRUG
: I-DRUG
you O
MUST O
take O
this O
medication O
every B-FRE
day I-FRE
for B-DUR
the I-DUR
next I-DUR

 I-DUR
month I-DUR
. I-DUR
  O
We O
recommend O
you O
take O
it O
for B-DUR
at I-DUR
least I-DUR
1 I-DUR
year I-DUR
or O

 O
otherwise O
as O
pe O
your O
cardiologist O

 O
2 O
. O
  O
Toprol B-DRUG
XL I-DRUG
once B-FRE
daily I-FRE

 I-FRE
3 O
. O
  O
Atorvastatin B-DRUG
80 B-STR
mg I-STR
daily B-FRE
( O
stop O
you O
simvastatin B-DRUG
) I-DRUG

 O
4 O
. O
  O
Stop O
your O
hydrochlorothiazide B-DRUG
. I-DRUG

 O
5 O
. O
  O
Aspirin B-DRUG
325 B-STR
mg I-STR
daily B-FRE

 I-FRE
6 O
. O
  O
Lisinopril B-DRUG
5 B-STR
mg I-STR
daily B-FRE

 I-FRE
. O

 O
Please O
contact O
your O
PCP O
or O
come O
to O
the O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
if O
you O
experience O

 O
chest O
pain O
, O
shortness O
of O
breath O
, O
abdominal O
pain O
. O
  O
Please O

 O
followup O
with O
your O
PCP O
within O
the O
next O
1 O
- O
2 O
weeks O
. O


 O
Followup O
Instructions O
: O

 O
You O
have O
an O
appointment O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
on O
[ O
* O
* O
7 O
- O
11 O
* O
* O
] O
at O
11:00AM O
. O

 O
Please O
call O
his O
office O
@ O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
30419 O
* O
* O
] O
if O
any O
changes O
need O
to O
be O

 O
made O
. O

 O
. O


 O
A O
follow O
up O
appointment O
has O
been O
made O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
of O

 O
Cardiology O
at O
the O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
in O
[ O
* O
* O
Location O
( O
un O
) O
620 O
* O
* O
] O
, O
MA O
. O
His O
office O
number O
is O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
4105 O
* O
* O
] O
. O
The O
appointment O
is O
on O
[ O
* O
* O
7 O
- O
17 O
* O
* O
] O
@ O
3:30pm O
. O
Please O

 O
call O
if O
any O
changes O
are O
needed O
to O
be O
made O
. O




 O
Completed O
by:[**2194 O
- O
6 O
- O
27 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2196 O
- O
1 O
- O
2 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2128 O
- O
11 O
- O
8 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1055 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Nausea/vomiting O
, O
abdominal O
pain O
. O
Transferred O
from O
OSH O
. O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
ERCP O
with O
stent O
placed O
in O
CBD O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O

 O
Endotracheal O
intubation O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
; O
extubated O
[ O
* O
* O
2195 O
- O
12 O
- O
29 O
* O
* O
] O



 O
History O
of O
Present O
Illness O
: O

 O
67 O
yo O
male O
, O
h/o O
3vd O
, O
[ O
* O
* O
Month/Day/Year O
* O
* O
] O
s/p O
ablation O
in O
[ O
* O
* O
4 O
- O
27 O
* O
* O
] O
at O
[ O
* O
* O
Hospital1 O
2025 O
* O
* O
] O
, O
RA O
, O

 O
diastolic O
dysfunction O
, O
who O
presented O
from O
[ O
* O
* O
Hospital O
1263 O
* O
* O
] O
hospital O
with O

 O
? O
biliary O
sepsis O
. O
  O
Pt O
reports O
that O
on O
day O
of O
admission O
, O
he O
woke O

 O
up O
with O
malaise O
, O
nausea O
, O
vomiting O
, O
fevers O
, O
and O
rigors O
. O
  O
He O
went O

 O
to O
[ O
* O
* O
Doctor O
Last O
Name O
1263 O
* O
* O
] O
ED O
, O
found O
to O
be O
febrile B-REA
with O
abnormal O
LFT O
's O
, O
was O

 O
started O
on O
antibiotics B-DRUG
  O
( O
clinda/ceftaz B-DRUG
) I-DRUG
and O
IVF B-DRUG
, I-DRUG
and O
was O

 O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
presumed O
biliary B-REA
sepsis I-REA
and O
further O

 O
management O
. O
  O
On O
transfer O
, O
he O
was O
started O
on O
zosyn/levo/flagyl B-DRUG
, I-DRUG

 O
was O
hemodynamically O
unstable O
, O
was O
intubated O
prior O
to O
ERCP O
. O
  O
ERCP O

 O
showed O
no O
obstruction O
, O
no O
stones O
, O
some O
biliary O
sludging O
only O

 O
( O
normal O
cholangiogram O
) O
. O
  O
A O
stent O
was O
placed O
in O
the O
CBD O
. O
  O
He O

 O
continued O
to O
by O
hypotensive/unstable O
post O
ERCP O
, O
was O
found O
to O

 O
have O
an O
evolving O
NSTEMI O
( O
tnt O
leak O
, O
2 O
mm O
ST O
depre O
in O
v3-v6 O
; O
peak O

 O
tnt O
1.8 O
, O
now O
trended O
down O
) O
. O
  O
He O
remained O
intubated O
. O
  O
SWAN O
on O

 O
[ O
* O
* O
12 O
- O
24 O
* O
* O
] O
showed O
PCWP O
35 O
, O
BP O
95/43 O
, O
FA=22 O
, O
and O
the O
next O
warning O
, O
he O

 O
went O
into O
rapid B-REA
afib I-REA
with I-REA
decompensation I-REA
requiring O
single O
200 O
J O

 O
shock O
. O
  O
He O
was O
on O
3 O
pressors B-DRUG
at O
the O
time O
( O
levophed B-DRUG
, I-DRUG
vasopressin B-DRUG
, I-DRUG

 O
dopa B-DRUG
) I-DRUG
, O
converted O
into O
NSR O
temporarily O
, O
was O
started O
on O
amio B-DRUG
. I-DRUG
He O

 O
had O
recurrence O
of O
afib O
. O
  O
DCCV O
was O
repeated O
2 O
times O
without O

 O
success O
; O
he O
spontaneously O
reverted O
to O
NSR O
( O
? O
s/p O
DCCV O
on O
[ O
* O
* O
12 O
- O
26 O
* O
* O
] O
) O

 O
has O
remained O
in O
this O
rhythm O
, O
and O
is O
on O
an O
amio B-DRUG
taper B-DOS
( O
drip B-ROU
) I-ROU
. O

 O
Cardiology O
is O
following O
. O
  O
Etiology O
of O
this O
new O
onset O
afib O
was O

 O
thought O
to O
be O
in O
the O
setting O
of O
volume O
resuscitation O
and O
acute O

 O
illness O
. O



 O
With O
respect O
to O
his O
sepsis B-REA
, I-REA
he O
required O
3 O
pressors B-DRUG
as O
above O
, O
was O

 O
on O
vanco/zosyn/lev/flagyl B-DRUG
. I-DRUG
  O
Blood O
cultures O
from O
[ O
* O
* O
Doctor O
Last O
Name O
1263 O
* O
* O
] O
grew O
out O

 O
[ O
* O
* O
4 O
- O
26 O
* O
* O
] O
E. O
coli O
( O
with O
E. O
coli O
also O
in O
urine O
) O
resistant O
to O

 O
amp/pip/sulbactam B-DRUG
. I-DRUG
  O
Ciprofloxacin B-DRUG
was O
added O
to O
regimen O
on O
[ O
* O
* O
12 O
- O
26 O
* O
* O
] O
. O

 O
He O
is O
currently O
just O
on O
cipro B-DRUG
and O
is O
to O
complete O
a O
14 B-DUR
day I-DUR
course O

 O
for O
E. B-REA
coli I-REA
. I-REA
  O
He O
continued O
to O
improve O
clinically O
, O
was O
extubated O

 O
on O
[ O
* O
* O
12 O
- O
29 O
* O
* O
] O
, O
and O
he O
was O
transferred O
to O
the O
floor O
on O
[ O
* O
* O
12 O
- O
30 O
* O
* O
] O
( O
stable O
, O

 O
mentating O
) O
. O
  O
Other O
MICU O
events O
include O
a O
drop B-ADE
in I-ADE
platelets I-ADE

 I-ADE
following O
48 O
hours O
of O
heparin B-DRUG
therapy O
( O
HIT O
negative O
, O
Hep O
d/c'ed O
, O

 O
and O
platelets O
recovering O
) O
. O
  O
He O
had O
a O
bump O
in O
his O
creatinine O
to O

 O
3.0 O
( O
baseline O
1.3 O
- O
1.5 O
as O
per O
PCP O
) O
which O
is O
resolving O
( O
? O
ATN O
[ O
* O
* O
2 O
- O
23 O
* O
* O
] O

 O
hypotension O
but O
no O
muddy O
brown O
casts O
on O
sediment O
) O
. O
  O
Renal O
US O
was O

 O
obtained O
that O
did O
not O
show O
hydronephrosis O
or O
cause O
or O
ARF O
. O
  O
Hct O

 O
has O
been O
stable O
, O
but O
he O
has O
been O
guaiac O
positive O
on O
exam O
. O
  O
Pt O

 O
was O
stable O
on O
transfer O
to O
the O
floor O
. O


 O
Past O
Medical O
History O
: O

 O
Cardiac O
: O

 O
1 O
. O
  O
Severe O
3vd O
by O
report O
; O
apparently O
not O
a O
surgical O
candidate O
. O

 O
Cardiologist O
is O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
59998 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
at O
[ O
* O
* O
Hospital1 O
2025 O
* O
* O
] O
, O
recent O
P-MIBI O
on O
[ O
* O
* O
5 O
- O
26 O
* O
* O
] O

 O
2 O
. O
History O
of O
[ O
* O
* O
Month/Year O
( O
2 O
) O
* O
* O
] O
/SVT O
, O
s/p O
ablation O
in O
[ O
* O
* O
5 O
- O
26 O
* O
* O
] O

 O
3 O
. O
  O
MI O
[ O
* O
* O
6 O
- O
29 O
* O
* O
] O
yrs O
ago O
; O
few O
episodes O
of O
angina O
since O
that O
time O


 O
Other O
PMH O
: O

 O
1 O
. O
  O
RA B-REA
x O
30 O
yrs O
, O
on O
remicaide B-DRUG
and O
MTX B-DRUG
, I-DRUG
symptoms O
stable O
; O
usually O

 O
has O
sx O
in O
shoulders O
and O
knees O
; O
Rheum O
: O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
STitle O
) O
* O
* O
] O
in O
[ O
* O
* O
Hospital1 O
392 O
* O
* O
] O

 O
2 O
. O
  O
? O
h/o O
HBV O

 O
3 O
. O
  O
GERD O

 O
4 O
. O
  O
Pilonidal O
cyst O
in O
20 O
's O



 O
Meds O
on O
transfer O
: O

 O
Ciprofloxacin B-DRUG
500 B-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
d4/14 O
; O
d1=[**12 O
- O
26 O
* O
* O
] O
) O

 O
Amiodarone B-DRUG
taper B-DOS

 I-DOS
Oxybutynin B-DRUG
5 B-STR
mg I-STR
TID B-FRE

 I-FRE
SSI B-DRUG

 I-DRUG
ASA B-DRUG
325 B-STR

 I-STR
Lansoprazole B-DRUG

 I-DRUG
Ativan B-DRUG
PRN B-FRE

 I-FRE
MsO4 B-DRUG
PRN B-FRE

 I-FRE
Nystatin B-DRUG
suspension B-FOR


 I-FOR
ALL O
: O
NKDA O


 O
Social O
History O
: O

 O
Quit O
smoking O
30 O
yrs O
ago O
; O
smoked O
[ O
* O
* O
1 O
- O
23 O
* O
* O
] O
ppd O
prior O
to O
this O

 O
Social O
EtOH O

 O
No O
drugs/IVDU O
ever O

 O
Homosexual O
, O
lives O
with O
partner O
; O
had O
neg O
HIV O
test O
3 O
yrs O
ago O
, O
has O

 O
been O
monogamous O
with O
his O
partner O
since O
that O
time O



 O
Family O
History O
: O

 O
Mother O
died O
lung O
ca O
age O
76 O
( O
smoker O
) O

 O
Uncle-CABG O


 O
Physical O
Exam O
: O

 O
VS O
: O
98.4 O
    O
57 O
    O
129/62 O
    O
15 O
   O
98 O
% O
RA O
     O
wt=132 O
kg O
; O
admission O

 O
118.7 O
kg O

 O
Gen O
: O
very O
pleasant O
male O
, O
nad O
, O
sitting O
in O
bed O
, O
comfortable O
, O
A&Ox3 O

 O
HEENT O
: O
PERRL O
, O
EOM O
grossly O
intact O
, O
OP O
clear O

 O
Neck O
: O
no O
JVD O
appreciated O
, O
no O
LAD O
, O
no O
bruits O

 O
CV O
: O
RRR O
, O
nl O
S1/S2 O
, O
no O
m/r/g O

 O
Lungs O
: O
CTA O
B O
from O
anterior O
exam O
, O
no O
w/r/r O

 O
Abd O
: O
soft O
, O
nt/nd O
, O
nabs O

 O
Extr O
: O
[**2 O
- O
24**]+ O
edema O
in O
UE O
and O
LE O
( O
with O
pneumoboots O
on O
UE/LE O
) O
; O
still O

 O
with O
foley O
and O
rectal O
tube O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
10:10PM O
   O
HGB-12.7 O
* O
calcHCT-38 O
O2 O
SAT-77 O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
10:09PM O
   O
TYPE-ART O
TEMP-37.6 O
PO2 O
- O
195 O
* O
PCO2 O
- O
36 O
PH-7.28 O
* O

 O
TOTAL O
CO2 O
- O
18 O
* O
BASE O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
10:09PM O
   O
O2 O
SAT-98 O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
07:27PM O
   O
LACTATE-3.3 O
* O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
05:03PM O
   O
freeCa-1.11 O
* O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
04:50PM O
   O
GLUCOSE-130 O
* O
UREA O
N-34 O
* O
CREAT-2.6 O
* O
SODIUM-140 O

 O
POTASSIUM-4.8 O
CHLORIDE-109 O
* O
TOTAL O
CO2 O
- O
16 O
* O
ANION O
GAP-20 O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
04:50PM O
   O
CK-MB-49 O
* O
MB O
INDX-7.7 O
* O
cTropnT-0.51 O
* O



 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
03:18AM O
   O
FIBRINOGE-654 O
* O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
03:18AM O
   O
ALT(SGPT)-181 O
* O
AST(SGOT)-191 O
* O
CK(CPK)-405 O
* O

 O
ALK O
PHOS-175 O
* O
AMYLASE-55 O
TOT O
BILI-4.5 O
* O
DIR O
BILI-3.8 O
* O
INDIR O

 O
BIL-0.7 O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
03:18AM O
   O
LIPASE-13 O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
03:18AM O
   O
ALBUMIN-3.1 O
* O
CALCIUM-7.5 O
* O
PHOSPHATE-3.1 O

 O
MAGNESIUM-1.0 O
* O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
03:18AM O
   O
HBsAg-NEGATIVE O
HBs O
Ab-POSITIVE O
HAV O

 O
Ab-NEGATIVE O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
03:18AM O
   O
HCV O
Ab-NEGATIVE O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
03:18AM O
   O
WBC-33.7 O
* O
RBC-4.30 O
* O
HGB-14.2 O
HCT-42.0 O
MCV-98 O

 O
MCH-33.0 O
* O
MCHC-33.8 O
RDW-15.4 O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
03:18AM O
   O
NEUTS-78 O
* O
BANDS-6 O
* O
LYMPHS-3 O
* O
MONOS-11 O
EOS-0 O

 O
BASOS-0 O
ATYPS-0 O
METAS-2 O
* O
MYELOS-0 O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
03:18AM O
   O
HYPOCHROM-NORMAL O
ANISOCYT-1 O
+ O
POIKILOCY-NORMAL O

 O
MACROCYT-1 O
+ O
MICROCYT-NORMAL O
POLYCHROM-NORMAL O

 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
03:18AM O
   O
PLT O
COUNT-250 O


 O
[ O
* O
* O
2195 O
- O
12 O
- O
29 O
* O
* O
] O
3:59 O
PM O

 O
PORTABLE O
RENAL O
ULTRASOUND O
: O
Limited O
views O
of O
both O
kidneys O
were O

 O
obtained O
. O
The O
right O
kidney O
measures O
11.7 O
cm O
. O
The O
left O
kidney O

 O
measures O
11.2 O
cm O
. O
There O
is O
no O
evidence O
of O
renal O
stones O
, O

 O
hydronephrosis O
, O
or O
perinephric O
fluid O
collections O
. O


 O
IMPRESSION O
: O

 O
Limited O
portable O
exam O
shows O
no O
significant O
abnormalities O
. O


 O
CHEST O
( O
PORTABLE O
AP O
) O
  O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
3:21 O
AM O

 O
An O
AP O
portable O
study O
of O
the O
chest O
was O
obtained O
. O
No O
prior O
studies O

 O
available O
for O
comparison O
. O
There O
is O
poor O
inspiratory O
effort O
. O
The O

 O
lungs O
are O
clear O
of O
an O
active O
congestion O
or O
infiltration O
. O
No O

 O
evidence O
of O
pleural O
effusion O
or O
pneumothoraces O
. O
The O
cardiac O
size O

 O
can O
not O
be O
evaluated O
on O
this O
AP O
portable O
study O
of O
the O
chest O
. O
A O

 O
left O
subclavian O
CVP O
line O
is O
in O
place O
the O
tip O
is O
entering O
the O

 O
superior O
vena O
cava O
. O


 O
IMPRESSION O
: O
No O
evidence O
of O
active O
diseases O
in O
the O
lungs O
or O

 O
heart O
. O


 O
ABDOMEN O
( O
SUPINE O
ONLY O
) O
PORT O
  O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
6:44 O
PM O
: O
There O
are O
multiple O

 O
mildly O
gas O
distended O
loops O
of O
small O
bowel O
and O
gas O
present O
in O
the O

 O
colon O
. O
A O
plastic O
biliary O
stent O
is O
present O
in O
the O
right O
upper O

 O
quadrant O
. O
The O
diaphragms O
are O
not O
included O
on O
the O
film O
. O


 O
IMPRESSION O
: O
Mildly O
gas O
distended O
loops O
of O
small O
bowel O
, O

 O
nonspecific O
. O



 O
LIVER O
OR O
GALLBLADDER O
US O
( O
SINGLE O
ORGAN O
) O
PORT O
  O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
3:53 O
AM O
: O

 O
FINDINGS O
: O
Examination O
is O
limited O
due O
to O
patient O
body O
habitus O
. O

 O
Allowing O
for O
this O
, O
liver O
appears O
echogenic O
, O
consistent O
with O

 O
fatty O
infiltration O
. O
No O
focal O
masses O
are O
identified O
. O
There O
is O
no O

 O
intrahepatic O
or O
extrahepatic O
ductal O
dilatation O
. O
The O
common O
bile O

 O
duct O
measures O
6 O
mm O
in O
diameter O
. O
The O
gallbladder O
contains O
sludge O
, O

 O
but O
there O
are O
no O
secondary O
signs O
of O
cholecystitis O
. O
Specifically O
, O

 O
there O
is O
no O
wall O
edema O
, O
pericholecystic O
fluid O
, O
or O
gallbladder O

 O
distention O
. O
Normal O
color O
flow O
is O
identified O
within O
the O
main O

 O
portal O
and O
hepatic O
veins O
. O
There O
is O
no O
ascites O
. O
Note O
is O
made O
of O
a O

 O
markedly O
atrophic O
right O
kidney O
, O
with O
evidence O
of O
cortical O

 O
thinning O
. O


 O
IMPRESSION O
: O


 O
1 O
) O
Echogenic O
liver O
consistent O
with O
fatty O
infiltration O
. O
Please O

 O
note O
that O
more O
severe O
forms O
of O
liver O
disease O
, O
including O

 O
significant O
hepatic O
fibrosis O
and O
cirrhosis O
, O
can O
not O
be O
excluded O

 O
on O
the O
basis O
of O
this O
study O
. O


 O
2 O
) O
Gallbladder O
sludge O
but O
no O
secondary O
signs O
of O
cholecystitis O
. O


 O
3 O
) O
No O
evidence O
of O
biliary O
obstruction O
. O


 O
4 O
) O
Patent O
portal O
and O
hepatic O
veins O


 O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
ECG O
: O
Sinus O
rhythm O
Premature O
ventricular O
contractions O

 O
Inferior/lateral O
ST-T O
changes O
are O
nonspecific O

 O
Since O
pervious O
tracing O
, O
no O
significant O
change O

 O
Intervals O
: O
Rate O
93 O
PR O
148 O
QRS O
86 O
  O
QT/QTc O
378/428 O
Axis O
: O
P O
43 O
QRS O

 O
0 O
T O
-16 O


 O
Read O
by O
: O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
2889**],[**First O
Name3 O
( O
LF O
) O
2890 O
* O
* O
] O
K. O


 O
Cardiology O
Report O
ECHO O
Study O
Date O
of O
[ O
* O
* O
2195 O
- O
12 O
- O
25 O
* O
* O
] O




 O
PATIENT/TEST O
INFORMATION O
: O

 O
Indication O
: O
Left O
ventricular O
function O
. O
Myocardial O
infarction O
. O

 O
Height O
: O
( O
in O
) O
68 O

 O
Weight O
( O
lb O
) O
: O
300 O

 O
BSA O
( O
m2 O
) O
: O
2.43 O
m2 O

 O
BP O
( O
mm O
Hg O
) O
: O
74/60 O

 O
HR O
( O
bpm O
) O
: O
66 O

 O
Status O
: O
Inpatient O

 O
Date/Time O
: O
[ O
* O
* O
2195 O
- O
12 O
- O
25 O
* O
* O
] O
at O
10:55 O

 O
Test O
: O
Portable O
TTE O
( O
Complete O
) O

 O
Doppler O
: O
Full O
doppler O
and O
color O
doppler O

 O
Contrast O
: O
None O

 O
Tape O
Number O
: O
2004W487 O
- O
1:24 O

 O
Test O
Location O
: O
West O
MICU O

 O
Technical O
Quality O
: O
Suboptimal O





 O
REFERRING O
DOCTOR O
: O
DR O
. O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Initial O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O



 O
MEASUREMENTS O
: O

 O
Left O
Atrium O
- O
Long O
Axis O
Dimension O
: O
* O
4.8 O
cm O
( O
nl O
< O
= O
4.0 O
cm O
) O

 O
Left O
Atrium O
- O
Four O
Chamber O
Length O
: O
* O
5.8 O
cm O
( O
nl O
< O
= O
5.2 O
cm O
) O

 O
Right O
Atrium O
- O
Four O
Chamber O
Length O
: O
5.0 O
cm O
( O
nl O
< O
= O
5.0 O
cm O
) O

 O
Left O
Ventricle O
- O
Septal O
Wall O
Thickness O
: O
* O
1.2 O
cm O
( O
nl O
0.6 O
- O
1.1 O

 O
cm O
) O

 O
Left O
Ventricle O
- O
Inferolateral O
Thickness O
: O
0.9 O
cm O
( O
nl O
0.6 O
- O
1.1 O

 O
cm O
) O

 O
Left O
Ventricle O
- O
Diastolic O
Dimension O
: O
* O
5.7 O
cm O
( O
nl O
< O
= O
5.6 O
cm O
) O

 O
Left O
Ventricle O
- O
Ejection O
Fraction O
: O
* O
< O
= O
25 O
% O
( O
nl O
> O
= O
55 O
% O
) O

 O
Aorta O
- O
Valve O
Level O
: O
3.6 O
cm O
( O
nl O
< O
= O
3.6 O
cm O
) O

 O
Aorta O
- O
Ascending O
: O
* O
3.5 O
cm O
( O
nl O
< O
= O
3.4 O
cm O
) O

 O
Aortic O
Valve O
- O
Peak O
Velocity O
: O
1.0 O
m/sec O
( O
nl O
< O
= O
2.0 O
m/sec O
) O

 O
Mitral O
Valve O
- O
E O
Wave O
: O
0.7 O
m/sec O

 O
Mitral O
Valve O
- O
E O
Wave O
Deceleration O
Time O
: O
148 O
msec O

 O
TR O
Gradient O
( O
+ O
RA O
= O
PASP O
) O
: O
* O
25 O
to O
30 O
mm O
Hg O
( O
nl O
< O
= O
25 O
mm O
Hg O
) O


 O
INTERPRETATION O
: O


 O
Findings O
: O


 O
LEFT O
ATRIUM O
: O
Mild O
LA O
enlargement O
. O


 O
RIGHT O
ATRIUM/INTERATRIAL O
SEPTUM O
: O
Normal O
RA O
size O
. O
A O
catheter O
or O

 O
pacing O
wire O
is O

 O
seen O
in O
the O
RA O
and/or O
RV O
. O


 O
LEFT O
VENTRICLE O
: O
Mildly O
dilated O
LV O
cavity O
. O
Severe O
global O
LV O

 O
hypokinesis O
. O

 O
Severely O
depressed O
LVEF O
. O


 O
RIGHT O
VENTRICLE O
: O
RV O
not O
well O
seen O
. O


 O
AORTA O
: O
Normal O
aortic O
root O
diameter O
. O


 O
AORTIC O
VALVE O
: O
Mildly O
thickened O
aortic O
valve O
leaflets O
( O
3 O
) O
. O
No O
AR O
. O



 O
MITRAL O
VALVE O
: O
Mildly O
thickened O
mitral O
valve O
leaflets O
. O
Mild O
( O
1 O
+ O
) O

 O
MR O
. O


 O
TRICUSPID O
VALVE O
: O
Normal O
tricuspid O
valve O
leaflets O
with O
trivial O

 O
TR O
. O


 O
PERICARDIUM O
: O
No O
pericardial O
effusion O
. O


 O
GENERAL O
COMMENTS O
: O
Suboptimal O
image O
quality O
- O
poor O
echo O
windows O
. O



 O
Conclusions O
: O

 O
1 O
. O
The O
left O
atrium O
is O
mildly O
dilated O
. O

 O
2 O
. O
The O
left O
ventricular O
cavity O
is O
mildly O
dilated O
. O
There O
is O

 O
severe O
global O
left O

 O
ventricular O
hypokinesis O
. O
Overall O
left O
ventricular O
systolic O

 O
function O
is O

 O
difficult O
to O
assess O
but O
is O
probably O
severely O
depressed O
. O

 O
3 O
. O
The O
aortic O
valve O
leaflets O
( O
3 O
) O
are O
mildly O
thickened O
. O

 O
4 O
. O
The O
mitral O
valve O
leaflets O
are O
mildly O
thickened O
. O
Mild O
( O
1 O
+ O
) O

 O
mitral O

 O
regurgitation O
is O
seen O
. O


 O
Electronically O
signed O
by O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
1445 O
* O
* O
] O
, O
MD O
on O
[ O
* O
* O
2195 O
- O
12 O
- O
25 O
* O
* O
] O
11:19 O
. O



 O
Date O
: O
Thursday O
, O
[ O
* O
* O
2195 O
- O
12 O
- O
24 O
* O
* O
] O
Endoscopist(s O
) O
: O
[ O
* O
* O
Name6 O
( O
MD O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O

 O
MD O

 O
[ O
* O
* O
First O
Name O
( O
Titles O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Titles O
) O
59820 O
* O
* O
] O
, O
MD O
( O
fellow O
) O


 O
Patient O
: O
[ O
* O
* O
Known O
firstname O
* O
* O
] O
[ O
* O
* O
Known O
lastname O
* O
* O
] O

  O
Ref O
. O
Phys O
. O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
, O
MD O

 O
Birth O
Date O
: O
[ O
* O
* O
2128 O
- O
11 O
- O
8 O
* O
* O
] O
( O
67 O
years O
) O
Instrument O
: O
TJF O
160 O

 O
ID O
# O
: O
[ O
* O
* O
Numeric O
Identifier O
59999 O
* O
* O
] O
ASA O
Class O
: O
P2 O

 O
Medications O
: O
General O
anesthesia O


 O
Indications O
: O
67 O
y O
o O
male O
with O
nausea O
, O
vomiting O
, O
epigastric O
pain O
, O

 O
elevated O
LFT O
and O
hypotension O
. O
ERCP O
to O
evaluate O
for O
biliary O

 O
obstruction O
. O
Level O
3 O
consult O
was O
performed O
. O


 O
Procedure O
: O
The O
procedure O
, O
indications O
, O
preparation O
and O
potential O

 O
complications O
were O
explained O
to O
the O
patient O
, O
who O
indicated O
his O

 O
understanding O
and O
signed O
the O
corresponding O
consent O
forms O
. O
The O

 O
patient O
was O
placed O
in O
the O
prone O
position O
and O
an O
endoscope O
was O

 O
introduced O
through O
the O
mouth O
and O
advanced O
under O
direct O

 O
visualization O
until O
the O
second O
part O
of O
the O
duodenum O
was O
reached O
. O

 O
Careful O
visualization O
was O
performed O
. O
The O
procedure O
was O
not O

 O
difficult O
. O
The O
quality O
of O
the O
preparation O
was O
good O
. O
The O
patient O

 O
tolerated O
the O
procedure O
well O
. O
There O
were O
no O
complications O
. O

 O
Findings O
: O
Esophagus O
: O
Limited O
exam O
of O
the O
esophagus O
was O
normal O

 O
Stomach O
: O
Limited O
exam O
of O
the O
stomach O
was O
normal O

 O
Duodenum O
: O
Limited O
exam O
of O
the O
duodenum O
was O
normal O

 O
Major O
Papilla O
: O
Major O
papilla O
was O
located O
inside O
a O
diverticulum O
. O


 O
Cannulation O
: O
  O
Cannulation O
of O
the O
biliary O
duct O
was O
successful O
and O

 O
deep O
with O
a O
sphincterotome O
using O
a O
free-hand O
technique O
. O
Contrast O

 O
medium O
was O
injected O
resulting O
in O
complete O
opacification O
. O
The O

 O
procedure O
was O
not O
difficult O
. O
An O
additional O
cannulation O
attempt O

 O
of O
the O
biliary O
duct O
was O
successful O
and O
superficial O
with O
a O

 O
sphincterotome O
using O
a O
free-hand O
technique O
. O
Contrast O
medium O
was O

 O
injected O
resulting O
in O
partial O
opacification O
. O
The O
procedure O
was O

 O
not O
difficult O
. O

 O
Biliary O
Tree O
: O
Normal O
cholangiogram O
without O
biliary O
obstruction O
. O

 O
Small O
stone O
in O
CBD O
ca O
n't O
be O
ruled O
out O
. O
  O
Opacified O
portion O
of O

 O
pancreatic O
duct O
in O
the O
head O
was O
normal O
. O

 O
Procedures O
: O
A O
9 O
cm O
by O
10 O
fr O
Cotton-[**Doctor O
Last O
Name O
* O
* O
] O
biliary O
stent O
was O

 O
placed O
successfully O
in O
the O
CBD O
. O

 O
Impression O
: O
1 O
. O
Major O
papilla O
was O
located O
inside O
a O
diverticulum O
. O



 O
2 O
. O
Normal O
cholangiogram O
without O
biliary O
obstruction O
. O
Small O
stone O

 O
in O
CBD O
ca O
n't O
be O
ruled O
out O
. O


 O
3 O
. O
Given O
sepsis O
of O
unclear O
source O
and O
the O
fact O
that O
a O
small O

 O
stone O
could O
not O
be O
ruled O
out O
, O
a O
  O
9 O
cm O
by O
10 O
fr O
Cotton-[**Doctor O
Last O
Name O
* O
* O
] O

 O
biliary O
stent O
was O
placed O
successfully O
in O
the O
CBD O
. O


 O
4 O
. O
Opacified O
portion O
of O
pancreatic O
duct O
in O
the O
head O
was O
normal O
. O


 O
Additional O
notes O
: O
The O
procedure O
was O
performed O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O

 O
( O
attending O
physician O
) O
and O
ERCP O
fellow O
. O







 O
Brief O
Hospital O
Course O
: O

 O
A/P O
: O
67 O
yo O
male O
, O
h/o O
severe O
3vd O
, O
RA O
, O
presenting O
from O
OSH O
with O

 O
? O
biliary O
sepsis O
, O
s/p O
ERCP O
with O
stent O
placed O
, O
being O
treated O
for O

 O
urosepsis O
vs O
biliary O
sepsis O
, O
extubated O
and O
doing O
well O
. O


 O
1 O
. O
Sepsis O
: O
The O
patient O
's O
initial O
picture O
was O
consistent O
with O

 O
septic O
+ O
cardiogenic O
shock O
. O
Initial O
SG O
numbers O
revealed O
high O

 O
SVR O
, O
low O
CO O
, O
and O
high O
PCWP O
. O
He O
remained O
hypotensive B-REA
despite O
IVF B-DRUG
, I-DRUG

 O
and O
pressors B-DRUG
were O
continued O
, O
with O
eventual O
triple O
pressor B-DRUG

 I-DRUG
therapy O
( O
Levo B-DRUG
, I-DRUG
Dopamine B-DRUG
and O
Vasopressin B-DRUG
) I-DRUG
required O
for O

 O
hemodynamic B-REA
support I-REA
. I-REA
A O
random O
cortisol O
was O
20 O
, O
and O
29 O

 O
post-cosyntropin O
. O
Despite O
appropriate O
response O
, O
the O
low B-REA
random I-REA

 I-REA
cortisol I-REA
prompted O
initiation O
of O
steroid B-DRUG
therapy O
, O
initially O

 O
Dexamethasone B-DRUG
, I-DRUG
then O
hydrocortisone B-DRUG
and O
Fludrocortisone B-DRUG
with O
plan O

 O
to O
complete O
7 B-DUR
days I-DUR
of O
Rx O
( O
completed O
) O
. O
His O
lactate O
, O
elevated O
on O

 O
admission O
, O
came O
down O
. O
He O
was O
successfully O
weaned O
off O
Levo B-DRUG
and O

 O
Vasopressin B-DRUG
on O
[ O
* O
* O
2195 O
- O
12 O
- O
28 O
* O
* O
] O
, O
then O
off O
Dopamine B-DRUG
on O
[ O
* O
* O
2195 O
- O
12 O
- O
29 O
* O
* O
] O
. O
ERCP O
did O

 O
not O
show O
obstruction O
, O
? O
biliary O
sludge O
. O
  O
He O
was O
initially O
on O

 O
vanco/zosyn/flagyl-->cipro/vanco/flagyl B-DRUG
. I-DRUG
  O
Vanco/flagyl B-DRUG
were O

 O
discontinued O
on O
[ O
* O
* O
12 O
- O
27 O
* O
* O
] O
( O
c. O
diff O
neg O
x O
3 O
) O
, O
and O
he O
will O
continue O
a O

 O
course O
of O
cipro B-DRUG
for O
? O
urosepsis B-REA
. I-REA
  O
All O
cultures O
here O
have O
been O

 O
NGTD O
, O
but O
he O
is O
being O
treated O
for O
[ O
* O
* O
4 O
- O
26 O
* O
* O
] O
E. O
coli O
blood O
culture O

 O
bottles O
at O
[ O
* O
* O
Doctor O
Last O
Name O
1263 O
* O
* O
] O
. O
  O
Ciprofloxacin B-DRUG
was O
continued O
for O
the O
14 B-DUR
day I-DUR

 I-DUR
course O
( O
until O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
) O
. O
  O
He O
was O
hemodynamically O
stable O
throughout O

 O
hospitalization O
. O
  O
Blood B-DRUG
pressure I-DRUG
medications I-DRUG
were O
initially O
held O

 O
[ O
* O
* O
2 O
- O
23 O
* O
* O
] O
hypotension O
. O
  O
Lisinopril B-DRUG
was O
restarted O
prior O
to O
discharge O

 O
after O
renal O
function O
improved O
. O
  O
Atenolol B-DRUG
was O
held O
given O
patient O

 O
was O
still O
on O
amiodarone B-DRUG
taper B-DOS
. I-DOS
  O
This O
should O
be O
restarted O
after O

 O
he O
follows O
up O
with O
his O
PCP/cardiologist O
. O



 O
2 O
. O
NSTEMI O
: O
The O
[ O
* O
* O
Hospital O
228 O
* O
* O
] O
hospital O
course O
was O
complicated O
by O

 O
troponin O
elevation O
felt O
secondary O
to O
demand O
in O
the O
setting O
of O

 O
acute O
illness O
( O
peak O
troponin O
1.86 O
) O
. O
He O
received O
48 B-DUR
hours I-DUR
of O

 O
intravenous B-ROU
heparin B-DRUG
, I-DRUG
D/C'd O
in O
the O
setting O
of O
thrombocytopenia B-ADE
. I-ADE

 O
An O
echo O
was O
performed O
on O
[ O
* O
* O
12 O
- O
25 O
* O
* O
] O
, O
which O
revealed O
severe O
global O
LV O

 O
hypokinesis O
with O
EF<25 O
% O
. O
Cardiology O
followed O
in-house O
. O

 O
Lisinopril B-DRUG
, I-DRUG
ASA B-DRUG
, I-DRUG
were O
continued O
. O
Lipitor B-DRUG
was O
added O
upon O

 O
discharge O
at O
a O
lower O
dose O
, O
and O
atenolol B-DRUG
was O
held O
. O
  O
This O
should O

 O
be O
restarted O
when O
amiodarone B-DRUG
taper B-DOS
is O
completed O
and O
he O
follows O

 O
up O
with O
his O
primary O
cardiologist O
. O
  O
He O
also O
had O
an O
echo O
in-house O

 O
showing O
a O
very O
depressed O
EF O
( O
< O
25 O
% O
) O
, O
likely O
[ O
* O
* O
2 O
- O
23 O
* O
* O
] O
myocardial O

 O
suppression O
from O
sepsis O
. O
  O
He O
should O
have O
a O
follow O
up O
TTE O
after O

 O
discharge O
from O
rehab O
. O


 O
3 O
. O
Afib B-REA
: I-REA
Patient O
went O
into O
atrial O
fibrillation O
on O
[ O
* O
* O
12 O
- O
25 O
* O
* O
] O
with O
RVR O

 O
and O
hypotension O
. O
Cardioversion O
was O
attempted O
without O
success O
. O
He O

 O
was O
loaded O
with O
amiodarone B-DRUG
IV B-ROU
and O
an O
amiodarone B-DRUG
drip B-ROU
was O

 O
initiated O
. O
He O
converted O
to O
NSR O
in O
PM O
. O
Then O
, O
he O
reverted O
back O

 O
into O
afib B-REA
on O
[ O
* O
* O
12 O
- O
26 O
* O
* O
] O
after O
an O
increase O
in O
dopamine B-DRUG
dose O
to O
3 B-DOS

 I-DOS
( O
? O
true-true O
and O
unrelated O
? O
) O
. O
Given O
low O
cardiac O
output O
and O

 O
ongoing O
hypotension B-REA
requiring O
3 O
pressors B-DRUG
, I-DRUG
cardioversion O
was O

 O
performed O
with O
conversion O
to O
NSR O
after O
a O
single O
200J O
shock O
. O
The O

 O
patient O
was O
switched O
to O
PO B-ROU
amiodarone B-DRUG
on O
[ O
* O
* O
12 O
- O
26 O
* O
* O
] O
, O
to O
be O
continued O

 O
TID B-FRE
until O
[ O
* O
* O
1 O
- O
2 O
* O
* O
] O
, O
then O
[ O
* O
* O
Hospital1 O
* O
* O
] O
for B-DUR
1 I-DUR
week I-DUR
, I-DUR
then O
QD B-FRE
for B-DUR
1 I-DUR
week I-DUR
, I-DUR
then O

 O
200 B-STR
mg I-STR
PO B-ROU
QD B-FRE
until O
cardiology O
follow-up O
. O
He O
remained O
in O
NSR O

 O
throughout O
hospitalization O
after O
transfer O
out O
of O
the O
unit O
. O
  O
His O

 O
atenolol B-DRUG
was O
held O
and O
should O
be O
restarted O
after O
he O
finishes O
his O

 O
amiodarone B-DRUG
taper B-DOS
and O
follows O
up O
with O
his O
cardiologist O
, O
Dr. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
. O
  O
He O
was O
started O
on O
fondaparinux/coumadin B-DRUG
for O

 O
anticoagulation B-REA
( O
afib O
and O
low O
EF O
) O
. O
  O
Goal O
INR O
is O
[ O
* O
* O
2 O
- O
24 O
* O
* O
] O
, O

 O
fondaparinux B-DRUG
can O
be O
d/c'ed O
when O
INR=1.8 O
. O



 O
4 O
. O
ARF O
on O
CRF O
: O
Per O
patient O
's O
PCP O
( O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
, O
baseline O

 O
creatinine O
around O
1.3 O
- O
1.5 O
. O
Peak O
creatinine O
3.0 O
at O
OSH O
. O
Mr. O
[ O
* O
* O
Known O
lastname O
* O
* O
] O

 O
was O
initially O
oliguric O
on O
admission O
. O
His O
urine O
output O
slowly O

 O
improved O
with O
better O
hemodynamics O
, O
with O
slowly O
improving O

 O
creatinine O
. O
Urine O
lytes O
suggestive O
of O
renal O
etiology O
( O
likely O
ATN O

 O
[ O
* O
* O
2 O
- O
23 O
* O
* O
] O
hypotension O
from O
sepsi O
) O
, O
and O
urine O
sediment O
bland O
. O
Currently O

 O
2.1 O
, O
and O
auto-diuresing O
and O
mobilising O
fluid O
. O
RUS O
without O

 O
evidence O
of O
hydronephrosis O
or O
other O
abnormality O
. O
  O
His O
creatinine O

 O
returned O
to O
baseline O
( O
1.3 O
) O
and O
was O
stable O
on O
discharge O
. O
  O
He O

 O
diuresed B-REA
very O
well O
on O
IV B-ROU
lasix B-DRUG
( O
goal O
2L/d O
) O
. O
  O
He O
was O
discharge O
on O

 O
PO B-ROU
bumex B-DRUG
1 B-STR
mg I-STR
daily B-FRE
. I-FRE
  O
This O
should O
be O
continued O
until O
he O
is O

 O
clinically O
euvolemic O
and O
his O
peripheral O
edema O
is O
resolved O
. O


 O
5 O
. O
Transaminitis O
: O
s/p O
ERCP O
with O
stent O
placement O
, O
but O
only O

 O
finding O
of O
sludge O
. O
Query O
transaminitis O
in O
setting O
of O
sepsis O
. O

 O
LFT O
's O
were O
back O
to O
normal O
at O
time O
of O
discharge O
. O
  O
They O
should O
be O

 O
checked O
within O
a O
week O
of O
discharge O
. O
  O
Lipitor B-DRUG
was O
restarted O
at O

 O
lower O
dose O
upon O
discharge O
and O
can O
be O
titrated O
up O
. O


 O
7 O
. O
Thrombocytopenia B-ADE
: I-ADE
While O
in O
ICU O
, O
platelets O
were O
noted O
to O
drop O

 O
to O
a O
nadir O
in O
the O
80s O
. O
Concern O
for O
HIT B-ADE
was O
raised O
and O
Heparin B-DRUG

 I-DRUG
was O
discontinued O
after O
48 B-DUR
hours I-DUR
of O
therapy O
. O
HIT O
screen O
negative O
. O

 O
Picture O
no O
c/w O
DIC O
. O
Ultimately O
, O
thrombocytopenia B-ADE
was O
felt O

 O
medication-induced O
, O
query O
direct O
effect O
of O
Heparin B-DRUG
versus O

 O
antibiotics B-DRUG
( O
vanco B-DRUG
, I-DRUG
Flagyl B-DRUG
) I-DRUG
. O
Now O
slowly O
rising O
. O
  O
This O
was O
likley O

 O
multifactorial O
in O
the O
setting O
of O
sepsis O
, O
medications O
, O
pressors B-DRUG

 I-DRUG
and O
not O
[ O
* O
* O
2 O
- O
23 O
* O
* O
] O
heparin B-DRUG
. I-DRUG
  O
Platelets O
continued O
to O
go O
up O
and O
were O

 O
stable O
at O
time O
of O
discharge O
. O


 O
8 O
. O
  O
? O
Glucose B-REA
intolerance I-REA
: I-REA
continue O
on O
SSI B-DRUG
, I-DRUG
no O
history O
of O
DM O
, O

 O
likely O
in O
setting O
of O
steroids B-DRUG
for O
sepsis B-REA
. I-REA
  O
SSI B-DRUG
should O
be O

 O
continued O
as O
long O
as O
pt O
has O
abnormal O
blood O
sugars O
. O
  O
If O
this O

 O
intolerance O
persists O
, O
PCP O
should O
recommend O
further O
therapy O
. O


 O
9 O
. O
  O
Code O
: O
Full O


 O
10 O
. O
  O
Dispo O
: O
Patient O
was O
seen O
by O
physical O
therapy O
in O
house O
and O

 O
was O
thought O
to O
require O
acute O
level O
rehabilitation O
for O

 O
deconditioning O
. O
He O
was O
discharged O
to O
[ O
* O
* O
Hospital1 O
* O
* O
] O
Rehabiliation O
for O

 O
physical O
therapy O
and O
diuresis O
. O



 O
Medications O
on O
Admission O
: O

 O
Aspirin B-DRUG
325 B-STR
po B-ROU
daily B-FRE

 I-FRE
Lipitor B-DRUG
80 B-STR
daily B-FRE

 I-FRE
Protonix B-DRUG
40 B-STR
daily B-FRE

 I-FRE
Folate B-DRUG
1 B-STR
mg I-STR
po B-ROU
daily B-FRE

 I-FRE
Zestril B-DRUG
10 B-STR
po B-ROU
daily B-FRE

 I-FRE
atenolol B-DRUG
25 B-STR
daily B-FRE

 I-FRE
remicaid B-DRUG
q B-FRE
weeks I-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Nystatin B-DRUG
100,000 B-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML B-FOR
PO B-ROU
QID B-FRE

 I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
3 O
. O
Insulin B-DRUG
Regular I-DRUG
Human I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
sliding B-DOS
scale I-DOS

  I-DOS
Injection B-ROU
ASDIR B-FRE
( I-FRE
AS I-FRE
DIRECTED I-FRE
) I-FRE
: I-FRE
for O
BS O
150 O
- O
200 O
, O
give O
2 O
U O
, O
for O
BS O

 O
201 O
- O
250 O
, O
give O
4 O
U O
, O
for O
BS O
251 O
- O
300 O
, O
give O
6U O
, O
for O
BS O
301 O
- O
350 O
, O
give O

 O
8U O
, O
for O
BS O
351 O
- O
400 O
, O
give O
10 O
U. O

 O
4 O
. O
Oxybutynin B-DRUG
Chloride I-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
5 O
. O
Ciprofloxacin B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q12H B-FRE

 I-FRE
( O
every O
12 O
hours O
) O
for B-DUR
7 I-DUR
days I-DUR
: I-DUR
Continue O
until O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
. O

 O
6 O
. O
Amiodarone B-DRUG
HCl I-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
for B-DUR
7 I-DUR
days I-DUR
: I-DUR
Continue O
[ O
* O
* O
Date O
range O
( O
1 O
) O
60000 O
* O
* O
] O
. O

 O
7 O
. O
Amiodarone B-DRUG
HCl I-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
: I-FRE
Continue O
until O
you O
follow O
up O
with O
cardiology O
. O

 O
8 O
. O
Pantoprazole B-DRUG
Sodium I-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE


 O
9 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
10 O
. O
Zolpidem B-DRUG
Tartrate I-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE

 I-FRE
bedtime I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
11 O
. O
Fondaparinux B-DRUG
Sodium I-DRUG
2.5 B-STR
mg/0.5 I-STR
mL I-STR
Syringe B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Subcutaneous B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
: I-FRE
Continue O
until O
therapeutic O
on O

 O
coumadin B-DRUG
. I-DRUG
  O
Overlap O
therapy O
for O
2 O
days O
with O
therapeutic O
coumadin B-DRUG

 I-DRUG
dosing O
. O

 O
12 O
. O
Morphine B-DRUG
Sulfate I-DRUG
2 B-STR
- I-STR
4 I-STR
mg I-STR
IV B-ROU
Q4H B-FRE
: I-FRE
PRN I-FRE

 I-FRE
13 O
. O
Lorazepam B-DRUG
0.5 B-STR
- I-STR
2 I-STR
mg I-STR
IV B-ROU
Q4H B-FRE
: I-FRE
PRN I-FRE

 I-FRE
14 O
. O
Warfarin B-DRUG
Sodium I-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( O
at O

 O
bedtime O
) O
: O
Please O
ck O
INR O
every O
other O
day O
for O
goal O
INR O
[ O
* O
* O
2 O
- O
24 O
* O
* O
] O
. O

 O
Adjust O
coumadin B-DRUG
dosing O
accordingly O
. O

 O
15 O
. O
Lisinopril B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE



 O
16 O
. O
Bumex B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
17 O
. O
Lipitor B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
18 O
. O
Cyanocobalamin B-DRUG
1,000 B-STR
mcg I-STR
Tablet B-FOR
Sustained I-FOR
Release I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
Sustained I-FOR
Release I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
7 O
* O
* O
] O
& O
Rehab O
Center O
- O
[ O
* O
* O
Hospital1 O
8 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
diagnoses O

 O
1 O
. O
  O
Sepsis O

 O
2 O
. O
  O
Biliary O
stenting O
( O
ERCP O
) O
, O
? O
biliary O
sepsis O

 O
3 O
. O
  O
Respiratory O
failure O

 O
Secondary O
diagnoses O

 O
1 O
. O
  O
New O
onset O
Atrial O
fibrillation O
in O
setting O
of O
illness O

 O
2 O
. O
  O
NSTEMI O
in O
setting O
of O
acute O
illness O

 O
3 O
. O
  O
Acute O
renal O
failure/ATN O

 O
4 O
. O
  O
Thrombocytopenia O

 O
5 O
. O
  O
3 O
vessel O
coronary O
artery O
disease O

 O
6 O
. O
  O
CHF O
with O
diastolic O
dysfunction O



 O
Discharge O
Condition O
: O

 O
Stable O
-- O
afebrile O
, O
all O
blood O
cultures O
negative O
, O
breathing O

 O
comfortably O
on O
room O
air O
, O
requires O
further O
diuresis O
and O
physical O

 O
therapy O
. O


 O
Discharge O
Instructions O
: O

 O
1 O
. O
  O
Please O
take O
all O
your O
medications O
as O
described O
in O
the O

 O
discharge O
instructions O
. O
  O
We O
made O
a O
few O
changes O
to O
your O

 O
medication O
regimen O
. O


 O
-We O
added O
Bumex B-DRUG
1 B-STR
mg I-STR
PO B-ROU
qam B-FRE
, I-FRE
for O
diuresis B-REA
. I-REA
  O
Goal O
is O
2L O
neg/day O

 O
until O
you O
are O
clinically O
euvolemic O
, O
peripheral O
edema O
is O

 O
resolved O
. O

 O
- O
You O
should O
finish O
a O
course O
of O
antibiotics B-DRUG
( O
ciprofloxacin B-DRUG
) I-DRUG
; O

 O
continue O
until O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
, O
for O
positive O
blood O
cultures O

 O
- O
You O
can O
continue O
the O
oxybutynin B-DRUG
for O
bladder B-REA
spasms I-REA
if O
you O

 O
continue O
to O
requires O
this O

 O
- O
We O
started O
you O
on O
Fondaparinux B-DRUG
and O
coumadin B-DRUG
( O
anticoagulation B-REA

 I-REA
for O
your O
atrial B-REA
fibrillation I-REA
and O
low B-REA
ejection I-REA
fraction I-REA
) I-REA
. O
  O
The O

 O
Fondaparinux B-DRUG
will O
only O
be O
continued O
until O
you O
are O
therapeutic O
on O

 O
your O
coumadin B-DRUG
. I-DRUG

 O
- O
You O
should O
finish O
amiodarone B-DRUG
taper B-DOS
as O
outlined O
in O
medications O

 O
section O
. O

 O
- O
We O
are O
holding O
your O
beta O
blocker O
( O
you O
were O
on O
atenolol B-DRUG
25 B-STR
mg I-STR

 I-STR
daily B-FRE
) I-FRE
for O
now O
until O
you O
complete O
the O
amiodarone B-DRUG
taper B-DOS
and O

 O
follow O
up O
with O
your O
cardiologist O
. O

 O
- O
We O
are O
also O
holding O
your O
rheumatoid B-REA
arthritis I-REA
medications O
at O

 O
this O
time O
( O
MTX B-DRUG
, I-DRUG
Remicaide B-DRUG
) I-DRUG
. O
  O
These O
should O
be O
restarted O
after O
you O

 O
leave O
rehab O
and O
follow O
up O
with O
your O
primary O
rheumatologist O
. O

 O
- O
We O
also O
decreased O
your O
lipitor B-DRUG
to O
40 B-STR
qd B-FRE
. I-FRE
  O
You O
should O
increase O

 O
this O
after O
having O
your O
LFT O
's O
rechecked O
by O
your O
PCP O
. O



 O
2 O
. O
  O
Follow O
up O
with O
your O
PCP O
, O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
, O
within O
1 O
week O
of O

 O
leaving O
rehab O
. O
  O
He O
may O
want O
to O
make O
adjustments O
to O
your O

 O
medication O
regimen O
at O
this O
time O
. O
  O
You O
should O
also O
follow O
up O
with O

 O
the O
cardiology O
clinic O
here O
and O
your O
rheumatologist O
upon O
leaving O

 O
rehab O
. O


 O
3 O
. O
  O
Call O
your O
physician O
if O
you O
experience O
chest O
pain O
, O
shortness O

 O
of O
breath O
, O
fevers O
> O
101 O
. O
Take O
your O
medications O
as O
prescribed O
. O

 O
Weigh O
yourself O
daily O
and O
record O
your O
weight O
. O
Call O
your O
physician O

 O
if O
your O
weight O
increases O
by O
3 O
lbs O
. O


 O
Followup O
Instructions O
: O

 O
1 O
. O
  O
Follow O
up O
with O
your O
PCP O
, O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
60001 O
* O
* O
] O
) O
, O
within O

 O
1 O
week O
of O
leaving O
rehab O
. O
  O
He O
may O
want O
to O
make O
adjustments O
to O

 O
your O
medication O
regimen O
at O
this O
time O
. O
  O
He O
can O
consider O
stopping O

 O
your O
bumex B-DRUG
at O
this O
time O
, O
restart O
your O
beta B-DRUG
blocker I-DRUG
and O
your O

 O
rheumatoid B-DRUG
arthritis I-DRUG
medications I-DRUG
. I-DRUG


 O
2 O
. O
  O
You O
should O
also O
follow O
up O
with O
your O
cardiologist O
, O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
59998 O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
, O
at O
[ O
* O
* O
Hospital1 O
2025 O
* O
* O
] O
. O
  O
You O
will O
be O
on O
an O
amiodarone B-DRUG
taper B-DOS
until O
this O

 O
time O
. O
  O
She O
should O
consider O
restarting O
your O
atenolol B-DRUG
at O
this O
time O

 O
and O
monitor O
your O
coumadin B-DRUG
therapy O
. O
  O
She O
should O
also O
consider O

 O
titrating O
up O
your O
Lisinopril B-DRUG
to O
your O
usual O
dose O
( O
10 B-STR
mg I-STR
daily B-FRE
) I-FRE
at O

 O
this O
time O
. O
  O
We O
are O
discharging O
you O
on O
2.5 B-STR
mg I-STR
daily B-FRE
. I-FRE


 O
3 O
. O
  O
Follow O
up O
with O
Liver O
clinic O
, O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
STitle O
) O
* O
* O
] O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
60002 O
* O
* O
] O
) O
, O
in O
2 O
months O
for O
removal O
of O
your O
biliary O
stent O
. O
  O
Call O

 O
to O
make O
this O
appointment O
as O
soon O
as O
possible O


 O
3 O
. O
  O
Follow O
up O
with O
your O
rheumatologist O
upon O
leaving O
rehab O
. O
  O
She O

 O
may O
decide O
when O
to O
restart O
your O
Methotrexate B-DRUG
and O
Remicaide B-DRUG


 I-DRUG
BRING O
THIS O
DISCHARGE O
PAPERWORK O
WITH O
YOU O
AT O
TIME O
OF O
ALL O
FOLLOW O
UP O

 O
APPOINTMENTS O




 O

Admission O
Date O
: O
[ O
* O
* O
2121 O
- O
11 O
- O
3 O
* O
* O
] O
        O
Discharge O
Date O
: O
[ O
* O
* O
2121 O
- O
11 O
- O
17 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2048 O
- O
1 O
- O
11 O
* O
* O
] O
        O
Sex O
: O
  O
F O


 O
Service O
: O
  O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O



 O
ADMISSION O
DIAGNOSIS O
: O
  O
Incarcerated O
parastomal O
hernia O
. O


 O
DISCHARGE O
DIAGNOSES O
: O
  O
Incarcerated O
parastomal O
hernia O
. O


 O
Status O
post O
reduction O
of O
hernia O
, O
re-siting O
of O
colostomy O
. O


 O
Aspiration O
pneumonia O
. O


 O
ETOH O
withdrawal O
. O


 O
Respiratory O
failure O
. O


 O
Status O
post O
tracheostomy O
. O


 O
HISTORY O
OF O
PRESENT O
ILLNESS O
: O
  O
The O
patient O
is O
a O
73-year-old O

 O
woman O
who O
has O
a O
history O
of O
parastomal O
hernias O
and O
has O
had O

 O
these O
hernias O
repaired O
times O
four O
or O
five O
. O
She O
now O
presents O

 O
with O
acute O
onset O
of O
abdominal O
distention O
, O
nausea O
and O

 O
vomiting O
, O
as O
well O
as O
a O
mass O
in O
the O
parastomal O
region O
. O


 O
PAST O
MEDICAL O
HISTORY O
: O
  O
ETOH O
( O
one O
bottle O
of O
wine O
per O
day O
) O
. O


 O
Hypertension O
. O


 O
Gastroesophageal O
reflux O
disease O
. O


 O
Hepatitis O
C. O


 O
Anxiety O
. O


 O
Depression O
. O


 O
Etiopathic O
splenomegaly O
. O


 O
Etiopathic O
thrombocytopenia O
. O


 O
Heparin B-DRUG
induced O
thrombocytopenia O
negative O
. O


 O
PAST O
SURGICAL O
HISTORY O
: O
  O
Status O
post O
[ O
* O
* O
Month O
( O
only O
) O
* O
* O
] O
. O


 O
Parastomal O
hernia O
repair O
times O
four O
or O
five O
. O


 O
Total O
abdominal O
hysterectomy O
. O


 O
Breast O
biopsy O
. O


 O
Cataract O
surgery O
. O


 O
MEDICATIONS O
AT O
HOME O
: O

 O
1 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR
once B-FRE
daily I-FRE
. I-FRE

 O
2 O
. O
Hydrochlorothiazide B-DRUG
25 B-STR
mg I-STR
once B-FRE
daily I-FRE
. I-FRE

 O
3 O
. O
Zoloft B-DRUG
50 B-STR
mg I-STR
once B-FRE
daily I-FRE
. I-FRE

 O
4 O
. O
Lisinopril B-DRUG
10 B-STR
mg I-STR
once B-FRE
daily I-FRE
. I-FRE

 O
5 O
. O
Ibuprofen B-DRUG
600 B-STR
mg I-STR
once B-FRE
daily I-FRE
p.r.n O
. O

 O
6 O
. O
Serax B-DRUG
15 B-STR
mg I-STR
t.i.d B-FRE
. I-FRE



 O
ALLERGIES O
: O
  O
No O
known O
drug O
allergies O
. O


 O
PHYSICAL O
EXAMINATION O
: O
  O
On O
admission O
, O
the O
patient O
is O
afebrile O
. O

 O
Vital O
signs O
are O
stable O
. O
Generally O
, O
she O
is O
in O
some O
distress O
. O

 O
Chest O
is O
clear O
to O
auscultation O
bilaterally O
. O
Cardiovascular O
is O

 O
regular O
rate O
and O
rhythm O
without O
murmur O
, O
rub O
or O
gallop O
. O

 O
Abdomen O
is O
soft O
, O
mildly O
distended O
and O
tender O
to O
palpation O
. O

 O
Tenderness O
is O
localized O
to O
the O
lower O
abdomen O
and O
more O
so O
in O

 O
the O
parastomal O
region O
. O
There O
is O
a O
large O
bulge O
around O
the O

 O
ostomy O
. O
Stoma O
itself O
is O
fairly O
pink O
and O
healthy O
. O
Extremities O

 O
are O
warm O
and O
well O
perfused O
with O
minimal O
edema O
. O


 O
HOSPITAL O
COURSE O
: O
  O
The O
patient O
was O
admitted O
for O
repair O
of O
her O

 O
incarcerated O
parastomal O
hernia O
. O
She O
was O
taken O
to O
the O

 O
Operating O
Room O
on O
[ O
* O
* O
2121 O
- O
11 O
- O
3 O
* O
* O
] O
for O
reduction O
, O
as O
well O
as O

 O
colostomy O
re-siting O
into O
the O
left O
upper O
quadrant O
. O
For O
details O

 O
of O
this O
, O
please O
see O
the O
previously O
dictated O
operative O
note O
. O



 O
Postoperatively O
, O
the O
patient O
's O
course O
was O
complicated O
by O
what O

 O
was O
thought O
to O
be O
an O
aspiration O
event O
on O
the O
evening O
of O

 O
postoperative O
day O
number O
two O
. O
She O
had O
acute O
respiratory O

 O
distress O
, O
as O
well O
as O
change O
in O
mental O
status O
, O
which O
is O

 O
different O
from O
her O
baseline O
. O
She O
was O
maintained O
with O
Lasix B-DRUG

 I-DRUG
diuresis B-REA
and O
face O
mask O
for O
approximately O
8 O
- O
12 O
hours O
but O
then O

 O
was O
subsequently O
intubated O
and O
transferred O
to O
the O
Intensive O

 O
Care O
Unit O
for O
worsening O
respiratory O
status O
. O
She O
was O
initially O

 O
only O
intubated O
for O
about O
24 O
hours O
and O
met O
all O
criteria O
for O

 O
extubation O
. O
Chest O
x-ray O
did O
confirm O
that O
she O
had O
bilateral O

 O
upper O
zone O
infiltrates O
and O
the O
patient O
was O
empirically O

 O
treated O
with O
a O
seven B-DUR
day I-DUR
course O
of O
vancomycin B-DRUG
and O
Levaquin B-DRUG
. I-DRUG

 O
After O
the O
patient O
met O
her O
respiratory O
extubation O
criteria O
, O

 O
she O
was O
extubated O
. O
She O
continued O
to O
do O
fairly O
well O
but O
had O

 O
change O
in O
mental O
status O
, O
which O
could O
not O
be O
attributed O
to O

 O
anything O
other O
than O
alcohol O
withdrawal O
. O
TSH O
, O
B-12 O
and O
folate O

 O
levels O
were O
checked O
, O
which O
were O
normal O
. O
CT O
scan O
of O
the O
head O

 O
was O
obtained O
on O
[ O
* O
* O
2121 O
- O
11 O
- O
10 O
* O
* O
] O
, O
which O
did O
not O
show O
any O
evidence O

 O
of O
acute O
injury O
. O
There O
was O
some O
evidence O
of O
old O
lacunar O

 O
infarcts O
. O
MR O
of O
the O
head O
was O
completed O
on O
[ O
* O
* O
2121 O
- O
11 O
- O
12 O
* O
* O
] O
, O
which O

 O
confirmed O
the O
above O
. O
In O
addition O
, O
the O
Neurology O
service O
was O

 O
consulted O
for O
her O
change B-ADE
in I-ADE
mental I-ADE
status I-ADE
and O
they O
felt O
it O

 O
was O
best O
attributed O
also O
to O
her O
alcohol O
withdrawal O
, O
as O
well O

 O
as O
withdrawal O
from O
her O
Serax B-DRUG
. I-DRUG
These O
were O
restarted O
per O
their O

 O
recommendations O
and O
the O
patient O
gradually O
improved O
some O
of O

 O
her O
mental O
status O
. O


 O
On O
[ O
* O
* O
2121 O
- O
11 O
- O
10 O
* O
* O
] O
, O
the O
patient O
was O
re-intubated O
( O
postoperative O

 O
day O
number O
seven O
) O
for O
worsening O
respiratory O
status O
. O
She O
was O

 O
maintained O
and O
ventilated O
during O
this O
time O
and O
had O
a O

 O
bronchoscopy O
performed O
on O
[ O
* O
* O
2121 O
- O
11 O
- O
13 O
* O
* O
] O
, O
which O
proved O
to O
be O

 O
negative O
for O
any O
significant O
pluggings O
or O
other O
bronchial O

 O
disease O
. O
The O
patient O
was O
extubated O
later O
that O
day O
on O

 O
[ O
* O
* O
2121 O
- O
11 O
- O
13 O
* O
* O
] O
, O
but O
then O
quickly O
failed O
her O
extubation O
trial O

 O
within O
approximately O
six O
hours O
. O
She O
was O
emergently O
re- O

 O
intubated O
and O
there O
was O
seen O
to O
be O
a O
fair O
amount O
of O
tracheal O

 O
and O
laryngeal O
edema O
at O
that O
time O
. O
The O
decision O
was O
then O
made O

 O
to O
give O
the O
patient O
a O
surgical O
airway O
and O
percutaneous O

 O
tracheostomy O
was O
performed O
on O
[ O
* O
* O
2121 O
- O
11 O
- O
14 O
* O
* O
] O
. O
This O
was O
done O
in O

 O
accordance O
and O
consent O
with O
her O
son O
, O
who O
was O
the O
healthcare O

 O
proxy O
during O
her O
change O
in O
mental O
status O
. O



 O
Ultimately O
, O
the O
patient O
was O
discharged O
on O
postoperative O
day O

 O
number O
fourteen O
to O
a O
[ O
* O
* O
Hospital O
4820 O
* O
* O
] O
rehabilitation O
facility O
for O

 O
ventilatory O
weaning O
, O
as O
well O
as O
allowing O
clearance O
of O
her O

 O
mental O
status O
. O
The O
Neurology O
service O
had O
seen O
the O
patient O
on O

 O
the O
day O
of O
discharge O
and O
agreed O
with O
the O
above O
and O
to O

 O
continue O
present O
management O
. O
The O
patient O
had O
a O
post-pyloric O

 O
feeding O
tube O
placed O
in O
Interventional O
Radiology O
on O
the O
day O
of O

 O
discharge O
in O
order O
to O
decrease O
the O
risk O
of O
aspiration O

 O
pneumonia O
. O
The O
patient O
was O
tolerating O
tube O
feeds O
adequate O
and O

 O
had O
good O
function O
with O
occasional O
tracheostomy O
mask O
trials O

 O
from O
the O
vent O
. O


 O
DISPOSITION O
: O
  O
To O
[ O
* O
* O
Hospital O
4820 O
* O
* O
] O
rehabilitation O
facility O
. O


 O
DIET O
: O
  O
Tube O
feedings O
: O
  O
Impact O
with O
fiber O
( O
or O
other O

 O
immunogenic O
tube O
feed O
formulation O
) O
at O
75 O
cc/hr O
. O


 O
DISCHARGE O
MEDICATIONS O
: O

 O
1 O
. O
Albuterol B-DRUG
nebulizers B-FOR
q B-FRE
6 I-FRE
hours I-FRE
p.r.n O
. O

 O
2 O
. O
Lopressor B-DRUG
5 B-STR
mg I-STR
intravenously B-ROU
q B-FRE
6 I-FRE
hours I-FRE
, I-FRE
hold O
for O
heart O

    O
rate O
less O
than O
60 O
or O
systolic O
blood O
pressure O
of O
less O
than O

    O
100 O
. O

 O
3 O
. O
Zyprexa B-DRUG
5 B-STR
mg I-STR
p.o B-ROU
. I-ROU
or O
per O
nasogastric B-ROU
tube I-ROU
daily B-FRE
. I-FRE

 O
4 O
. O
Roxicet B-DRUG
elixir B-FOR
5 B-DOS
- I-DOS
10 I-DOS
cc B-FOR
p.o B-ROU
. I-ROU
or O
nasogastric B-ROU
tube I-ROU
q B-FRE
4 I-FRE
hours I-FRE

    I-FRE
p.r.n O
. O
for O
pain B-REA
. I-REA

 O
5 O
. O
Serax B-DRUG
15 B-STR
mg I-STR
p.o B-ROU
. I-ROU
or O
per O
nasogastric B-ROU
tube I-ROU
t.i.d B-FRE
. I-FRE

 O
6 O
. O
Heparin B-DRUG
5,000 B-STR
units I-STR
subcutaneously B-ROU
t.i.d B-FRE
. I-FRE

 O
7 O
. O
Dilaudid B-DRUG
0.5 B-STR
- I-STR
2.0 I-STR
mg I-STR
intravenously B-ROU
or O
subcutaneously B-ROU
q B-FRE
4 I-FRE

    I-FRE
hours I-FRE
p.r.n I-FRE
. I-FRE
for O
pain B-REA
. I-REA

 O
8 O
. O
Insulin B-DRUG
sliding B-DOS
scale I-DOS
to O
cover O
blood B-REA
sugars I-REA
. I-REA
This O
should O

    O
begin O
at O
120 O
and O
advance O
every O
40 O
points O
of O
a O
blood O
sugar O
. O

    O
The O
beginning O
scale O
should O
start O
at O
two O
and O
increase O
two O

    O
units O
of O
insulin B-DRUG
per O
40 O
points O
of O
blood O
sugar O
. O

 O
9 O
. O
Atrovent B-DRUG
nebulizers B-FOR
inhaled B-ROU
q B-FRE
6 I-FRE
hours I-FRE
p.r.n O
. O

 O
10 O
. O
      O
Ativan B-DRUG
0.5 B-STR
- I-STR
1.0 I-STR
mg I-STR
intravenously B-ROU
q B-FRE
6 I-FRE
hours I-FRE
p.r.n O
. O

 O
11 O
. O
      O
Prevacid B-DRUG
30 B-STR
mg I-STR
per O
nasogastric B-ROU
tube I-ROU
q B-FRE
24 I-FRE
hours I-FRE
. I-FRE

 O
12 O
. O
      O
Zoloft B-DRUG
100 B-STR
mg I-STR
p.o B-ROU
. I-ROU
or O
per O
nasogastric B-ROU
tube I-ROU
daily B-FRE
. I-FRE



 O
DISCHARGE O
INSTRUCTIONS O
: O
  O
The O
patient O
is O
to O
follow-up O
with O
Dr. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
in O
four O
weeks O
' O
time O
. O
The O
patient O
should O
continue O

 O
receiving O
tube O
feeds O
of O
an O
immunogenic O
formula O
at O

 O
approximately O
75 O
cc/hour O
. O
The O
patient O
should O
continue O
all O
of O

 O
her O
medications O
as O
described O
above O
. O
In O
particular O
, O
it O
is O

 O
important O
to O
continue O
the O
Serax B-DRUG
and O
give O
Ativan B-DRUG
p.r.n O
. O
for O

 O
withdrawal B-REA
symptoms I-REA
. I-REA
The O
patient O
should O
have O
ventilatory O

 O
weaning O
with O
tracheostomy O
mask O
trials O
everyday O
until O
the O

 O
patient O
can O
be O
weaned O
off O
of O
mechanical O
ventilation O
. O
The O

 O
patient O
should O
have O
ostomy O
care O
per O
standard O
protocol O
. O




                         O

[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
1286 O
* O
* O
] O
, O
MD O
[ O
* O
* O
MD O
Number(1 O
) O
11126 O
* O
* O
] O


 O
Dictated O
By:[**Last O
Name O
( O
NamePattern1 O
) O
23688 O
* O
* O
] O

 O
MEDQUIST36 O

 O
D O
: O
  O
[ O
* O
* O
2121 O
- O
11 O
- O
17 O
* O
* O
] O
14:48:09 O

 O
T O
: O
  O
[ O
* O
* O
2121 O
- O
11 O
- O
17 O
* O
* O
] O
15:25:35 O

 O
Job O
# O
: O
  O
[ O
* O
* O
Job O
Number O
111143 O
* O
* O
] O

 O

Admission O
Date O
: O
  O
[ O
* O
* O
2153 O
- O
9 O
- O
18 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2153 O
- O
10 O
- O
4 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2079 O
- O
3 O
- O
29 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Percocet B-DRUG
/ O
Codeine B-DRUG
/ O
Demerol B-DRUG
/ O
Nafcillin B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
689 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Cellulitis O
, O
troponin O
leak O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Bedside O
debridement O
of O
eschar O
on O
right O
foot O



 O
History O
of O
Present O
Illness O
: O

 O
74 O
yo O
M O
with O
MM O
including O
PVD O
, O
DM O
, O
HTN O
, O
CAD O
, O
CRI O
transferred O

 O
from O
NWH O
for O
cellulitis/LE O
pain O
because O
pt O
's O
podiatric O
surgeon O

 O
is O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
. O
Initally O
presented O
to O
NWH O
because O
of O
increasing O

 O
right O
foot O
pain O
and O
redness O
. O
At O
NWH O
, O
found O
to O
have O
EKG O
changes O

 O
with O
STD O
in O
V2-V4 O
, O
though O
patient O
was O
asymptomatic O
and O
said O
he O

 O
never O
had O
chest O
pain O
. O
Unclear O
if O
he O
received O
abx O
from O
there O
per O

 O
records O
available O
. O
Patient O
was O
transferred O
here O
for O
further O

 O
management O
. O

 O
. O

 O
Of O
note O
, O
patient O
was O
recently O
hospitalized O
[ O
* O
* O
Date O
range O
( O
1 O
) O
91344 O
* O
* O
] O
in O
the O
ICU O

 O
at O
NWH O
when O
he O
was O
found O
at O
home O
unresponsive O
- O
was O
hypoglycemic O

 O
and O
in O
ARF O
. O
Patient O
states O
he O
does O
not O
remember O
' O
anything O
' O
about O

 O
that O
hospital O
stay O
, O
the O
medications O
he O
was O
on O
or O
any O
events O
that O

 O
occurred O
then O
. O
Per O
report O
, O
he O
was O
discharged O
on O
lovenox B-DRUG
for O
DVT B-REA

 I-REA
but O
when O
NWH O
ED O
was O
[ O
* O
* O
Name O
( O
NI O
) O
653 O
* O
* O
] O
, O
records O
there O
indicated O
that O
he O

 O
was O
started O
on O
Lovenox B-DRUG
ppx B-REA
because O
he O
was O
immobile O
and O
was O

 O
supposed O
to O
continue O
taking O
it O
until O
he O
was O
able O
to O
consistently O

 O
walk O
> O
100 O
feet O
. O
Unclear O
if O
patient O
has O
been O
administering O
the O

 O
lovenox B-DRUG
himself O
as O
he O
stated O
that O
he O
no O
longer O
gives O
himself O

 O
insulin B-DRUG
because O
' O
it O
's O
just O
too O
complicated O
' O
. O

 O
. O

 O
On O
past O
hospitalization O
at O
NWH O
, O
also O
had O
a O
troponin O
has O
high O
as O

 O
8.8 O
thought O
be O
due O
to O
demand B-REA
ischemia I-REA
in I-REA
the I-REA
setting I-REA
of I-REA

 I-REA
hypoglycemia I-REA
. I-REA
During O
that O
admission O
, O
he O
never O
had O
chest O
pain O
and O

 O
a O
stable O
percent O
MB O
fraction O
at O
0.7 O
. O
He O
was O
started O
on O
aspirin B-DRUG
, I-DRUG

 O
beta B-DRUG
blocker I-DRUG
and O
statin B-DRUG
. I-DRUG
An O
ACEi B-DRUG
was O
held O
due O
to O
intolerance B-ADE
in O

 O
the O
past O
. O

 O
. O

 O
In O
the O
ED O
here O
VS O
: O
AF O
, O
hr:67 O
, O
bp:130/70 O
, O
rr:16 O
98 O
% O
on O
RA O
. O

 O
Received O
fentanyl B-DRUG
for O
pain B-REA
, I-REA
cards O
and O
vascular O
were O
c/s O
. O
Blood O

 O
cx O
were O
drawn O
. O
Vascular O
recommended O
vanc/zosyn B-DRUG
given O
their O

 O
concern O
for O
osteo O
which O
he O
received O
. O
He O
received O
50 B-STR
mg I-STR
iv B-ROU

 I-ROU
fentanyl B-DRUG
for O
pain B-REA
. I-REA

 O
. O


 O
Upon O
transfer O
to O
the O
floor O
, O
patient O
c/o O
of O
persistent O
right O
foot O

 O
pain O
. O
Denies O
fever O
or O
chills O
, O
CP O
, O
SOB O
, O
N/V/D O
, O
constipation O
, O
HA O

 O
or O
vision O
changes O
. O

 O
. O

 O
The O
patient O
is O
not O
a O
competent O
historian O
. O
On O
review O
of O
systems O
, O

 O
he O
denies O
any O
prior O
history O
of O
stroke O
, O
TIA O
, O
deep O
venous O

 O
thrombosis O
, O
pulmonary O
embolism O
, O
bleeding O
at O
the O
time O
of O
surgery O
, O

 O
myalgias O
, O
joint O
pains O
, O
cough O
, O
hemoptysis O
, O
black O
stools O
or O
red O

 O
stools O
. O
He O
denies O
recent O
fevers O
, O
chills O
or O
rigors O
. O
He O
denies O

 O
exertional O
buttock O
or O
calf O
pain O
. O
All O
of O
the O
other O
review O
of O

 O
systems O
per O
HPI O
. O

 O
. O

 O
Cardiac O
review O
of O
systems O
is O
notable O
for O
absence O
of O
chest O
pain O
, O

 O
dyspnea O
on O
exertion O
, O
paroxysmal O
nocturnal O
dyspnea O
, O
orthopnea O
, O

 O
ankle O
edema O
, O
palpitations O
, O
syncope O
or O
presyncope O
. O


 O
Past O
Medical O
History O
: O

 O
1 O
. O
CARDIAC O
RISK O
FACTORS O
: O
(+)Diabetes O
, O
(+)Dyslipidemia O
, O
(+)HTN O

 O
2 O
. O
CARDIAC O
HISTORY O
: O

 O
-CABG O
: O
[ O
* O
* O
2137 O
* O
* O
] O
LIMA->LAD O
. O
SVG->dRCA O
and O
SVG->D1/OM O
. O

 O
-PERCUTANEOUS O
CORONARY O
INTERVENTIONS O
: O
[ O
* O
* O
2150 O
* O
* O
] O
( O
no O
report O

 O
available O
) O
, O
[ O
* O
* O
2147 O
* O
* O
] O
: O
3VD O
, O
patent O
LIMA-->LAD O
, O
patnet O
SVG-- O
> O
dRCA O
and O

 O
D1/OM O
, O
severe O
native O
vessel O
disease O

 O
. O

 O
-PACING/ICD O
: O
None O

 O
. O

 O
3 O
. O
OTHER O
PAST O
MEDICAL O
HISTORY O
: O
Per O
OMR O
notes O
, O
patient O
states O
he O

 O
does O
not O
know O
his O
full O
medical O
history O

 O
PVD O

 O
CAD O
s/p O
MI O
in O
' O
[ O
* O
* O
49 O
* O
* O
] O

 O
HTN O

 O
Hyperlipidemia O

 O
DM2 B-REA
on O
Insulin B-DRUG

 I-DRUG
Diastolic O
CHF O

 O
CRI O
( O
baseline O
1.8 O
- O
2 O
) O

 O
h/o O
GI O
bleed O

 O
Bladder O
carcinoma O

 O
Cervical O
stenosis O

 O
Anemia O

 O
Gastroparesis O

 O
. O

 O
PAST O
SURGICAL O
HISTORY O
: O

 O
- O
Debridement O
of O
osteomyelitis O
with O
L. O
5th O
metatarsal O
head O

 O
resection O
[ O
* O
* O
2153 O
- O
4 O
- O
19 O
* O
* O
] O

 O
- O
L O
CFA O
to O
BK O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
bypass O
with O
left O
arm O
vein O
[ O
* O
* O
9 O
- O
27 O
* O
* O
] O

 O
- O
L4 O
- O
5 O
laminectomies O
bilat O
w/ O
resection O
of O
large O
disk O
herniation O

 O
[ O
* O
* O
4 O
- O
24 O
* O
* O
] O

 O
- O
R O
2nd O
second O
toe O
amp O
[ O
* O
* O
5 O
- O
24 O
* O
* O
] O

 O
- O
R O
CFA O
to O
AK O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
bypass O
using O
[ O
* O
* O
Doctor O
Last O
Name O
4726**]-Tex O
[ O
* O
* O
4 O
- O
23 O
* O
* O
] O

 O
- O
L O
CEA O
[ O
* O
* O
2-/2140 O
* O
* O
] O
, O
4 O
vessel O
CABG O
[ O
* O
* O
1-/2138 O
* O
* O
] O

 O
- O
Aorta-bifemoral O
bypass O
at O
NWH O
in O
[ O
* O
* O
2147 O
* O
* O
] O
? O



 O

Social O
History O
: O

 O
HISTORY O
: O
Unwilling O
to O
give O
. O
Per O
prior O
records O
, O
married O
twice O
, O

 O
but O
recently O
separated O
. O
He O
has O
two O
children O
. O
H/o O
EtOH O
abuse O
in O

 O
AA O
35 O
yrs O
; O
tobacco O
45 O
pack O
year O
history O


 O
Family O
History O
: O

 O
Non-contributory O


 O
Physical O
Exam O
: O

 O
ADMISSION O
PHYSICAL O
EXAMINATION O
: O

 O
VS O
: O
T=97.9 O
BP=140/60 O
HR=72 O
RR=20 O
O2 B-DRUG
sat=93 O
on O
2L% O

 O
GENERAL O
: O
elderly O
male O
lying O
in O
bed O
. O
Oriented O
x3 O
. O
Mood O

 O
appropriate O
. O

 O
HEENT O
: O
NCAT O
. O
Sclera O
anicteric O
. O
PERRL O
, O
EOMI O
. O
dry O
mmm O
. O
Poor O

 O
dentition O

 O
NECK O
: O
Supple O
. O
No O
JVD O
. O

 O
CARDIAC O
: O
RRR O
. O
s1/s2 O
. O
III/VI O
systolic O
murmur O
heard O
best O
at O
LLSB O
. O


 O
LUNGS O
: O
clear O
anteriorly O
. O
patient O
unwilling O
to O
fully O
sit O
up O
for O

 O
posterior O
thorax O
exam O
, O
so O
limited O
. O
Heard O
scattered O
wheezes O
and O

 O
crackles O
at O
bases O
posteriorly O
. O

 O
ABDOMEN O
: O
Soft O
, O
NTND O
. O
+ O
bs O

 O
EXTREMITIES O
: O
chronic O
venous O
statis O
changes O
bilaterlly O
. O
warm O
to O

 O
touch O
, O
DP O
pulses O
dopplerable O
. O

 O
RLE O
: O
2 O
eshcars O
- O
one O
on O
medial O
aspect O
of O
foot O
and O
one O
on O
plantar O

 O
aspect O
of O
foot O
. O
Area O
of O
erythema O
on O
anterior/medial O
aspect O
of O

 O
foot O
with O
increased O
warmth O
. O
? O
collection O
under O
foot O
? O

 O
SKIN O
: O
as O
above O



 O
Pertinent O
Results O
: O

 O
Admission O
laboratories O
: O

 O
COMPLETE O
BLOOD O
COUNT O
( O
[ O
* O
* O
9 O
- O
18 O
* O
* O
] O
) O
WBC O
: O
9.2 O
RBC O
: O
3.45 O
* O
Hgb O
: O
8.3 O
* O
# O

 O
Hct:27.6 O
* O
MCV:80 O
* O
MCH:23.9 O
* O
MCHC:30.0 O
* O
RDW:24.4 O
* O
Plt O
Ct O
: O
300 O

 O
DIFFERENTIAL O
Neuts O
87.1 O
* O
Bands O
Lymphs O
6.3 O
* O
Monos O
4.8 O
Eos O
1.4 O

 O
Baso O
0.5 O

 O
[ O
* O
* O
2153 O
- O
9 O
- O
18 O
* O
* O
] O
07:01PM O

 O
BASIC O
COAGULATION O
( O
PT O
, O
PTT O
, O
PLT O
, O
INR O
) O
PT O
15.0*PTT O
41.8*Plt O
Ct O

 O
INR(PT)1.3 O
* O


 O
Chemistry O

 O
RENAL O
& O
GLUCOSE O
Glucose O
278 O
* O
UreaN O
69 O
* O
Creat O
2.0 O
* O
Na O
132 O
* O
K O
4.6 O

 O
Cl O
98 O
  O
HCO3 O
22 O


 O
EKG O
( O
[ O
* O
* O
9 O
- O
20 O
* O
* O
] O
) O
: O
Sinus O
rhythm O
. O
Right O
axis O
deviation O
. O
Incomplete O
right O

 O
bundle O
branch O
block O
. O
One O
to O
two O
millimeter O
downsloping O
ST O

 O
segment O
depression O
in O
the O
anterior O
leads O
extending O
from O
leads O

 O
V3-V6 O
. O
Consider O
myocardial O
ischemia O
. O
Compared O
to O
the O
previous O

 O
tracing O
of O
[ O
* O
* O
2153 O
- O
9 O
- O
19 O
* O
* O
] O
the O
ST-T O
wave O
changes O
are O
pretty O
similar O

 O
except O
that O
the O
lead O
placement O
is O
slightly O
different O
. O


 O
Rate O
PR O
QRS O
QT/QTc O
P O
QRS O
T O

 O
72 O
126 O
114 O
440/461 O
71 O
121 O
113 O



 O
WOUND O
CULTURE O
( O
Final O
[ O
* O
* O
2153 O
- O
9 O
- O
25 O
* O
* O
] O
) O
: O

       O
KLEBSIELLA O
OXYTOCA O
. O
    O
SPARSE O
GROWTH O
. O

       O
STAPH O
AUREUS O
COAG O
+ O
. O
    O
SPARSE O
GROWTH O
. O

          O
Oxacillin B-DRUG
RESISTANT O
Staphylococci O
MUST O
be O
reported O
as O

 O
also O

          O
RESISTANT O
to O
other O
penicillins B-DRUG
, I-DRUG
cephalosporins O
, O

 O
carbacephems B-DRUG
, I-DRUG

          O
carbapenems B-DRUG
, I-DRUG
and O
beta-lactamase B-DRUG
inhibitor I-DRUG
combinations I-DRUG
. I-DRUG


          O
Rifampin B-DRUG
should O
not O
be O
used O
alone O
for O
therapy O
. O

          O
Please O
contact O
the O
Microbiology O
Laboratory O
( O
[ O
* O
* O
6-/2450 O
* O
* O
] O
) O

 O
immediately O
if O

          O
sensitivity O
to O
clindamycin B-DRUG
is O
required O
on O
this O

 O
patient O
's O
isolate O
. O


                               O
SENSITIVITIES O
: O
MIC O
expressed O
in O

 O
MCG/ML O


 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

                              O
KLEBSIELLA O
OXYTOCA O

                              O
| O
          O
STAPH O
AUREUS O
COAG O
+ O

                              O
| O
          O
| O

 O
AMPICILLIN/SULBACTAM-- B-DRUG
     O
8 O
S O

 O
CEFAZOLIN------------- B-DRUG
     O
8 O
S O

 O
CEFEPIME-------------- B-DRUG
   O
< O
= O
1 O
S O

 O
CEFTAZIDIME----------- B-DRUG
   O
< O
= O
1 O
S O

 O
CEFTRIAXONE----------- B-DRUG
   O
< O
= O
1 O
S O

 O
CEFUROXIME------------ B-DRUG
     O
4 O
S O

 O
CIPROFLOXACIN---------<=0.25 B-DRUG
S O

 O
ERYTHROMYCIN---------- B-DRUG
              O
= O
> O
8 O
R O

 O
GENTAMICIN------------ O
   O
< O
= O
1 O
S O
    O
< O
= O
0.5 O
S O

 O
LEVOFLOXACIN---------- B-DRUG
              O
= O
> O
8 O
R O

 O
MEROPENEM-------------<=0.25 B-DRUG
S O

 O
OXACILLIN------------- B-DRUG
              O
= O
> O
4 O
R O

 O
PIPERACILLIN/TAZO----- B-DRUG
   O
< O
= O
4 O
S O

 O
RIFAMPIN-------------- B-DRUG
            O
< O
= O
0.5 O
S O

 O
TETRACYCLINE---------- B-DRUG
              O
< O
= O
1 O
S O

 O
TOBRAMYCIN------------ B-DRUG
   O
< O
= O
1 O
S O

 O
TRIMETHOPRIM/SULFA---- B-DRUG
   O
< O
= O
1 O
S O
    O
< O
= O
0.5 O
S O

 O
VANCOMYCIN------------ B-DRUG
              O
< O
= O
1 O
S O


    O
ANAEROBIC O
CULTURE O
( O
Final O
[ O
* O
* O
2153 O
- O
9 O
- O
24 O
* O
* O
] O
) O
: O
    O
NO O
ANAEROBES O
ISOLATED O
. O


 O
Imaging O
: O


 O
Xray O
of O
right O
foot O
( O
[ O
* O
* O
9 O
- O
19 O
* O
* O
] O
) O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Erosive O
bony O
destructions O
at O
the O
first O
distal O
phalanx O
and O
at O

 O
the O
stump O
of O
the O
second O
proximal O
phalanx O
consistent O
with O

 O
osteomyelitis O
. O

 O
2 O
. O
Severe O
degenerative O
changes O
in O
the O
tarsometatarsal O
joints O
and O

 O
fracture O
at O
the O
3rd O
metatarsal O
, O
suggesting O
early O
Charcot O
joint O

 O
disease O
. O

 O
3 O
. O
Significant O
small O
vessel O
disease O
. O



 O
2D-ECHOCARDIOGRAM O
( O
[ O
* O
* O
9 O
- O
20 O
* O
* O
] O
) O
: O
  O
The O
left O
atrium O
is O
mildly O
dilated O
. O

 O
The O
right O
atrium O
is O
markedly O
dilated O
. O
Left O
ventricular O
wall O

 O
thickness O
, O
cavity O
size O
and O
regional/global O
systolic O
function O
are O

 O
normal O
( O
LVEF O
> O
55 O
% O
) O
. O
There O
is O
no O
left O
ventricular O
outflow O

 O
obstruction O
at O
rest O
or O
with O
Valsalva O
. O
The O
right O
ventricular O

 O
cavity O
is O
markedly O
dilated O
with O
moderate O
global O
free O
wall O

 O
hypokinesis O
. O
There O
is O
abnormal O
septal O
motion/position O
consistent O

 O
with O
right O
ventricular O
pressure/volume O
overload O
. O
The O
ascending O

 O
aorta O
is O
moderately O
dilated O
. O
The O
aortic O
valve O
leaflets O
( O
3 O
) O
are O

 O
mildly O
thickened O
. O
There O
is O
mild O
aortic O
valve O
stenosis O
( O
valve O

 O
area O
1.2 O
- O
1.9cm2 O
) O
. O
Trace O
aortic O
regurgitation O
is O
seen O
. O
The O
mitral O

 O
valve O
leaflets O
are O
mildly O
thickened O
. O
There O
is O
no O
mitral O
valve O

 O
prolapse O
. O
Mild O
to O
moderate O
( O
[**12 O
- O
22**]+ O
) O
mitral O
regurgitation O
is O
seen O
. O

 O
The O
tricuspid O
valve O
leaflets O
are O
mildly O
thickened O
. O
Moderate O
to O

 O
severe O
[ O
3 O
+ O
] O
tricuspid O
regurgitation O
is O
seen O
. O
There O
is O
severe O

 O
pulmonary O
artery O
systolic O
hypertension O
. O
There O
is O
no O
pericardial O

 O
effusion O
. O


 O
Compared O
with O
the O
prior O
study O
( O
images O
reviewed O
) O
of O
[ O
* O
* O
2151 O
- O
12 O
- O
16 O
* O
* O
] O
, O

 O
the O
detected O
pulmonary O
hypertension O
has O
increased O
. O
There O
is O
no O

 O
change O
in O
the O
left O
ventricular O
systolic O
function O
. O


 O
ETT O
: O

 O
[ O
* O
* O
4-/2151 O
* O
* O
] O
: O

 O
This O
72 O
yo O
man O
with O
IDDM O
, O
mild O
AS O
s/p O
multiple O
cadiac O

 O
interventions O
was O
referred O
to O
the O
lab O
for O
evaluation O
as O
a O
part O

 O
of O
the O
Spinal O
Cord O
Stimulation O
study O
. O
The O
patient O
exercised O
for O

 O
2.5 O
minutes O
on O
a O
modified O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
protocol O
and O
stopped O
due O
a O

 O
marked O
drop O
in O
systolic O

 O
blood O
pressure O
. O
This O
represents O
a O
very O
limited O
exercise O

 O
tolerance O
for O

 O
his O
age O
. O
The O
patient O
denied O
any O
neck O
, O
chest O
, O
arm O
or O
back O

 O
discomfort O

 O
throughout O
the O
study O
. O
In O
the O
setting O
of O
baseline O
abnormalities O
, O

 O
an O

 O
additional O
0.5 O
mm O
of O
ST O
segment O
depression O
was O
noted O
in O
V4-V5 O
at O

 O
peak O

 O
exercise O
. O
These O
changes O
returned O
to O
baseline O
by O
minute O
3 O

 O
post-exercise O
. O
The O
rhythm O
was O
sinus O
with O
a O
single O
VPB O
in O
late O

 O
recovery O
period O
. O
Marked O
drop O
in O
blood O
pressure O
with O
exercise O

 O
( O
136/60mmHg O
at O
rest O
to O
98/50mmHg O
at O
peak O
) O
. O
Post-exercise O

 O
hypertension O
was O
noted O
( O
172/60mmHg O
at O
10 O
minutes O
of O
recovery O
) O
. O

 O
. O

 O
IMPRESSION O
: O
Marked O
drop O
in O
blood O
pressure O
with O
exercise O
. O

 O
Non-specific O
EKG O
changes O
without O
anginal O
type O
symptoms O
. O

 O
. O


 O
CARDIAC O
CATH O
: O

 O
[ O
* O
* O
2147 O
* O
* O
] O
: O

 O
COMMENTS O
: O

 O
1 O
. O
Coronary O
angiography O
of O
this O
right O
dominant O
circulation O

 O
revealed O

 O
severe O
native O
three O
vessel O
disease O
. O
The O
LMCA O
had O
a O
30 O
% O

 O
narrowing O
. O
The O

 O
LAD O
had O
diffuse O
luminal O
irregularities O
and O
a O
70 O
% O
proximal O

 O
stenosis O
. O
The O
mid O
vessel O
was O
diffusely O
diseased O
but O
the O
distal O

 O
vessel O
filled O
via O
a O
patent O
LIMA->dLAD O
. O
The O
LAD O
supplied O
a O
large O

 O
S2 O
that O
had O
an O
80 O
% O
lesion O
at O
its O
ostium O
. O
The O
LAD O
supplied O
two O

 O
moderate O
sized O
diagonal O
branches O
which O
had O
diffuse O
luminal O

 O
irregularities O
. O
The O
LCX O
tapered O
quickly O
and O
was O
totally O
occluded O

 O
in O
the O
proximal O
vessel O
after O
a O
small O
OM O
branch O
. O
The O
RCA O
was O

 O
diffusely O
diseased O
and O
totally O
occluded O
proximally O
. O

 O
2 O
. O
Selective O
vein O
graft O
angiography O
revealed O
a O
widely O
patent O

 O
SVG->dRCA O
and O
a O
widely O
patent O
SVG->D1/OM O
. O

 O
3 O
. O
Selective O
arterial O
conduit O
arteriography O
demonstrated O
a O

 O
widely O
patent O
LIMA->LAD O
. O

 O
4 O
. O
Resting O
hemodynamics O
revealed O
markedly O
elevated O
right O
and O

 O
left O

 O
ventricular O
filling O
pressures O
with O
an O
LVEDP O
of O
29 O
mmHg O
and O
a O

 O
mean O
PCW O

 O
pressure O
of O
22 O
mmHg O
. O
In O
addition O
, O
there O
were O
V-waves O
to O
50 O
mmHg O


 O
suggesting O
significant O
mitral O
regurgitation O
. O
There O
was O
evidence O

 O
of O

 O
moderate O
to O
severe O
pulmonary O
hypertension O
with O
PA O
pressures O
of O

 O
62/21/39 O
mmHg O
and O
a O
pulmonary O
vascular O
resistance O
of O
209 O

 O
dynes-sec/cm5 O
. O
The O
cardiac O
output O
was O
preserved O
at O
6.9 O
L/min O
. O

 O
Note O
was O
made O
of O
a O
10 O
mmHg O
gradient O
across O
the O
aortic O
valve O
. O

 O
5 O
. O
Left O
ventriculography O
was O
not O
performed O
due O
to O
the O
patient O
's O


 O
underlying O
renal O
insufficiency O
and O
recent O
non-invasive O
testing O

 O
documenting O
a O
preserved O
LV O
systolic O
function O
. O

 O
. O

 O
FINAL O
DIAGNOSIS O
: O

 O
1 O
. O
Severe O
native O
three O
vessel O
disease O
. O

 O
2 O
. O
Patent O
LIMA->LAD O
. O

 O
3 O
. O
Patent O
SVG->dRCA O
and O
SVG->D1/OM O
. O

 O
4 O
. O
Moderate O
to O
severe O
left O
ventricular O
diastolic O
dysfunction O
. O

 O
5 O
. O
Moderate O
to O
severe O
pulmonary O
hypertension O
. O


 O
CT O
head O
( O
[ O
* O
* O
9 O
- O
24 O
* O
* O
] O
) O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
No O
acute O
intracranial O
process O
. O

 O
2 O
. O
Sequelae O
of O
chronic O
infarction O
involving O
the O
left O

 O
parieto-occipital O

 O
region O
. O


 O
Renal O
U/S O
( O
[ O
* O
* O
9 O
- O
27 O
* O
* O
] O
) O
: O

 O
IMPRESSION O
: O


 O
Absent O
diastolic O
flow O
seen O
in O
the O
bilateral O
interlobar O
arteries O

 O
of O
the O

 O
kidneys O
. O
The O
findings O
are O
nonspecific O
, O
but O
indicate O
renal O

 O
parenchymal O

 O
disease O
. O
There O
is O
limited O
evaluation O
of O
the O
main O
renal O
arteries O
, O

 O
but O
there O
is O
no O
clear O
evidence O
of O
renal O
artery O
stenosis O
. O
There O

 O
is O
no O
hydronephrosis O
. O


 O
Brief O
Hospital O
Course O
: O

 O
Summary O
: O
74 O
yo O
M O
transferred O
from O
NWH O
with O
EKG O
changes O
, O
trop O

 O
here O
to O
0.87 O
( O
baseline O
0.2 O
) O
and O
RLE O
cellulitis O
, O
right O
foot O

 O
osteomyelitis O
, O
worsening O
acute O
on O
chronic O
renal O
failure O



 O
# O
Right O
lower O
extremity O
cellulitis O
and O
right O
foot O
osteomyelitis O
: O

 O
The O
patient O
presented O
with O
right O
lower O
extremity O
cellulitis O
and O

 O
was O
found O
to O
have O
osteomyelitis O
in O
the O
right O
foot O
. O
Vascular O

 O
surgery O
evaluated O
the O
patient O
and O
thought O
that O
treatment O
for O
the O

 O
infection B-REA
and O
ischemia O
would O
be O
a O
below O
the O
knee O
amputation O
, O

 O
though O
given O
the O
patient O
's O
poor O
cardiac O
status O
, O
he O
would O
not O
be O

 O
a O
good O
candidate O
for O
surgery O
. O
The O
patient O
was O
empirically O

 O
started O
on O
Vancomycin B-DRUG
and O
Zosyn B-DRUG
. I-DRUG
A O
wound O
culture O
grew O
Klebsiella O

 O
oxytoca O
and O
MRSA O
and O
continued O
on O
those O
antibiotics O
. O
Since O

 O
vascular O
surgery O
would O
be O
high O
risk O
, O
podiatry O
was O
consulted O
for O

 O
local O
debridement O
. O
They O
debrided O
the O
area O
locally O
, O
yet O
erythema O

 O
of O
the O
right O
foot O
existed O
. O
It O
remained O
unclear O
whether O
the O

 O
erythema O
was O
due O
to O
ischemia O
vs. O
a O
subcutaneous O
abscess O
, O
so O
they O

 O
recommended O
a O
MRI O
of O
the O
foot O
. O
The O
MRI O
was O
never O
performed O

 O
because O
after O
discussion O
with O
the O
family O
and O
primary O
care O

 O
physician O
, O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
was O
decided O
for O
the O
patient O
to O
become O
CMO O
. O
His O

 O
antibiotics O
were O
withdrawn O
and O
wound O
care O
applied O
to O
the O
area O
. O


 O
# O
Acute O
on O
chronic O
renal O
failure O
: O
The O
patient O
presented O
with O
a O

 O
creatinine O
close O
to O
his O
baseline O
, O
however O
, O
after O
periods O
of O

 O
hypotension O
, O
likely O
due O
to O
a O
peri-septic O
state O
, O
his O
creatinine O

 O
starting O
to O
rise O
. O
He O
was O
given O
fluid O
boluses O
of O
500 B-DOS
cc I-DOS
of O
normal B-DRUG

 I-DRUG
saline I-DRUG
as O
needed O
because O
his O
urine O
lytes O
showed O
a O
FeUrea~20 O
- O
25 O
% O
. O

 O
Renal O
was O
consulted O
and O
thought O
his O
creatinine O
rise O
was O
likely O

 O
due O
to O
acute O
tubular O
necrosis O
secondary O
to O
a O
pre-renal O
state O
. O

 O
The O
patient O
was O
offered O
aluminium O
hydroxide O
for O
high O
phosphate O

 O
levels O
, O
but O
the O
patient O
refused O
it O
. O
A O
renal O
ultrasound O
showed O
no O

 O
hydronephrosis O
. O
The O
patient O
became O
progressively O
oliguric O
with O

 O
UOP O
less O
than O
20 O
cc/hour O
. O
Renal O
thought O
his O
kidneys O
would O

 O
unlikely O
recover O
( O
his O
creatinine O
rose O
to O
5.3 O
despite O

 O
interventions O
) O
. O
The O
patient O
and O
his O
family O
felt O
that O
they O
did O

 O
not O
want O
to O
pursue O
dialysis O
as O
an O
option O
. O



 O
# O
Increased O
troponins O
: O
The O
patient O
was O
noted O
to O
have O
high O

 O
troponins O
and O
excentuated O
ST O
wave O
depressions O
in O
V3-V5 O
. O

 O
Cardiology O
was O
consulted O
and O
recommended O
medical O
management O
with O

 O
a O
beta B-DRUG
blocker I-DRUG
, I-DRUG
ACE B-DRUG
inhibitor I-DRUG
, I-DRUG
statin O
, O
and O
aspirin B-DRUG
. I-DRUG
The O
patient O

 O
was O
started O
on O
these O
medications O
, O
though O
became O
persistently O

 O
hyperkalemic O
, O
and O
therefore O
, O
the O
ACEi O
was O
discontinued O
. O
Also O
, O

 O
his O
CK O
and O
LFTs O
were O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
28645 O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
the O
statin O
dose O
of O
80 O
mg O
was O

 O
lowered O
to O
20 O
mg O
and O
eventually O
discontinued O
due O
to O
persistently O

 O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
28645 O
* O
* O
] O
LFTs O
. O
An O
echocardiogram O
revealed O
no O
acute O
wall O
motion O

 O
abnormality O
, O
though O
it O
did O
show O
worsening O
tricuspid O

 O
regurgitation O
and O
increased O
pulmonary O
artery O
pressure O
. O

 O
Throughout O
his O
stay O
, O
the O
patient O
did O
not O
have O
any O
chest O
pain O
. O


 O
# O
Increased O
LFTs O
: O
The O
patient O
has O
a O
known O
history O
of O
alcohol O

 O
abuse O
and O
increased O
LFTs O
in O
the O
past O
. O
During O
his O
peri-septic O

 O
period O
, O
the O
patient O
was O
noted O
to O
have O
increased O
LFTs O
, O
likely O

 O
multifactorial O
due O
to O
low O
perfusion O
to O
the O
liver O
and O
also O

 O
congestion O
secondary O
to O
tricuspid O
regurgitation O
. O
The O
patient O
did O

 O
not O
have O
any O
complaints O
of O
abdominal O
pain O
, O
though O
, O
he O
had O

 O
hepatomegaly O
on O
exam O
. O


 O
# O
Gastrointestinal B-ADE
bleed I-ADE
: I-ADE
The O
patient O
has O
a O
history O
of O
a O
GI O
bleed O

 O
and O
was O
guiaic O
positive O
in O
the O
ER O
. O
In O
addition O
, O
he O
had O
a O

 O
persistently O
elevated O
PT/PTT O
, O
likely O
due O
to O
either O
underlying O

 O
liver O
or O
hematologic O
disease O
. O
The O
patient O
's O
hematocrit O
remained O

 O
stable O
until O
[ O
* O
* O
9 O
- O
26 O
* O
* O
] O
when O
his O
hematocrit O
dropped O
from O
29.0 O
to O
25.6 O

 O
and O
was O
noted O
to O
have O
melenic O
stools O
. O
He O
continued O
to O
have O

 O
melenic O
stools O
, O
so O
he O
was O
transfused O
one O
unit O
of O
blood O
and O

 O
transferred O
to O
the O
MICU O
. O
His O
aspirin B-DRUG
was O
discontinued O
. O
His O

 O
hematocrit O
remained O
stable O
in O
the O
MICU O
and O
transferred O
to O
the O

 O
floors O
where O
there O
were O
no O
signs O
of O
any O
GI O
bleeding O
. O


 O
Altered O
mental O
status O
: O
The O
patient O
had O
periods O
where O
he O
had O

 O
altered O
mental O
status O
, O
mostly O
at O
night O
. O
His O
AMS O
was O
likely O

 O
multifactorial O
due O
to O
infection O
, O
pain O
and O
uremia O
. O
He O
had O

 O
significant O
altered O
mental O
status O
on O
one O
day O
when O
he O
appeared O

 O
more O
somnolent O
with O
respirations=10/min O
after O
a O
dose O
of O
Morphine B-DRUG

 I-DRUG
2 B-STR
mg I-STR
IV B-ROU
. I-ROU
Narcane O
was O
given O
with O
some O
effect O
. O
A O
head O
CT O
showed O
no O

 O
acute O
pathology O
. O
He O
continued O
to O
have O
periods O
of O
delirium O
mostly O

 O
at O
night O
. O



 O
# O
Pruritis B-ADE
: I-ADE
The O
patient O
has O
been O
complaining O
of O
pruritis O
, O

 O
especially O
on O
his O
back O
, O
since O
admission O
. O
A O
variety O
of O
remedies O

 O
were O
tried O
for O
wound O
care O
. O
According O
to O
his O
son O
, O
the O
pruritis O

 O
has O
been O
long-standing O
. O
It O
might O
be O
exacerbated O
by O
his O
renal O

 O
failure O
. O
A O
side O
effect O
of O
Morphine B-DRUG
is O
a O
possibility O
, O
but O
he O

 O
still O
had O
the O
itching B-REA
even O
before O
the O
morphine B-DRUG
. I-DRUG
He O
is O
being O

 O
treated O
with O
skin O
care O
, O
sarna B-DRUG
lotion B-FOR
, I-FOR
hydrocortisone B-DRUG
and O

 O
doxepin B-DRUG
. I-DRUG


 O
Goals O
of O
care O
: O
The O
patient O
entered O
the O
hospital O
as O
full O
code O
. O

 O
After O
the O
renal O
and O
GI O
bleeding O
complications O
from O
his O
illness O
, O

 O
the O
patient O
and O
his O
family O
decided O
to O
become O
DNR/DNI O
. O
After O
a O

 O
meeting O
with O
the O
PCP O
and O
the O
family O
, O
they O
thought O
the O
best O
route O

 O
would O
be O
to O
become O
comfort O
measures O
only O
instead O
of O
pursuing O

 O
dialysis O
and O
being O
chronically O
cared O
for O
in O
a O
nursing O
home O
. O
At O

 O
first O
, O
it O
was O
thought O
that O
his O
beta B-DRUG
blocker I-DRUG
, I-DRUG
aspirin B-DRUG
, I-DRUG
and O

 O
antibiotics B-DRUG
would O
be O
continued O
, O
however O
, O
after O
further O

 O
conversation O
, O
these O
medications O
were O
discontinued O
and O
only O

 O
palliative O
measures O
for O
insomnia O
, O
anxiety O
, O
pain O
and O
constipation O

 O
were O
ordered O
. O


 O
Medications O
on O
Admission O
: O

 O
MEDICATIONS O
( O
from O
NWH O
D/C O
summary O
on O
[ O
* O
* O
9 O
- O
11 O
* O
* O
] O
) O

 O
acetaminophen B-DRUG
1 B-STR
g I-STR
q8hr B-FRE

 I-FRE
ASA B-DRUG
325 B-STR
Daily B-FRE

 I-FRE
Erythropoietin B-DRUG
4000 B-DOS
units I-DOS
SC B-ROU
weekly B-FRE

 I-FRE
Ferrous B-DRUG
sulfate I-DRUG
325 B-STR
mg I-STR
Daily B-FRE

 I-FRE
Furosemide B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
Lovenox B-DRUG
30 B-STR
mg I-STR
SC B-ROU
daily B-FRE
until O
ambulatory O

 O
NPH B-DRUG
( O
8 B-DOS
units I-DOS
before O
breakfast O
and O
dinner O

 O
Regular B-DRUG
insulin I-DRUG
( O
5 B-DOS
units I-DOS
before O
breakfast O
and O
dinner O

 O
Metoprolol B-DRUG
12.5 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
MVT O
daily O

 O
Miralax B-DRUG
17 B-STR
g I-STR
Daily B-FRE

 I-FRE
Nystain B-DRUG
triamcinolone I-DRUG
cream B-FOR
topically B-ROU
twice B-FRE
daily I-FRE

 I-FRE
omeprazole B-DRUG
29 B-STR
mg I-STR
daily B-FRE

 I-FRE
Sarna B-DRUG
lotion B-FOR
to O
affected O
area O
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
senokot B-DRUG
qHs B-FRE

 I-FRE
Sertraline B-DRUG
50 B-STR
mg I-STR
daily B-FRE

 I-FRE
simvastatin B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
flomax B-DRUG
0.4 B-STR
mg I-STR
daily B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Sertraline B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
2 O
. O
Camphor-Menthol B-DRUG
0.5 B-STR
- I-STR
0.5 I-STR
% O
Lotion B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU

 I-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
itching B-REA
. I-REA

 O
3 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
fever B-REA
, I-REA
pain B-REA
. I-REA

 O
4 O
. O
Quetiapine B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QHS B-FRE
( I-FRE
once I-FRE
a I-FRE

 I-FRE
day I-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Trazodone B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE

 I-FRE
as I-FRE
needed I-FRE
for O
insomnia B-REA
. I-REA

 O
6 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
7 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
as O
needed O
for O
constipation B-REA
. I-REA

 O
8 O
. O
Morphine B-DRUG
10 B-STR
mg/5 I-STR
mL I-STR
Solution O
Sig O
: O
[ O
* O
* O
4 O
- O
29 O
* O
* O
] O
mL B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
, I-REA
respiratory B-REA
distress I-REA
. I-REA

 O
9 O
. O
Hydrocortisone B-DRUG
2.5 B-STR
% I-STR
Cream B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Rectal B-ROU
TID B-FRE
( I-FRE
3 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
itching B-REA
. I-REA

 O
10 O
. O
Doxepin B-DRUG
25 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O

 O
day O
) O
. O

 O
11 O
. O
Quetiapine B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
anxiety B-REA
. I-REA

 O
12 O
. O
Zofran B-DRUG
2 B-STR
mg/mL I-STR
Solution B-FOR
Sig O
: O
Four B-STR
( I-STR
4 I-STR
) I-STR
mg I-STR
Intravenous B-ROU
every B-FRE

 I-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
. I-REA



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
Cape O
Code O
Nursing O
& O
Rehabilitation O
Center O
- O
[ O
* O
* O
Location O
( O
un O
) O
10072 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O

 O
-cellulitis O
of O
lower O
extremity O

 O
-osteomyelitis O

 O
-coronary O
artery O
disease O

 O
. O

 O
Secondary O

 O
-Hypotension O

 O
-Type O
II O
diabetes O
Mellitus O



 O
Discharge O
Condition O
: O

 O
Stable O
. O
Patient O
breathing O
on O
room O
air O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
transferred O
to O
the O
hospital O
with O
right O
foot O
cellulitis O

 O
and O
osteomyelitis O
. O
You O
were O
started O
on O
antibiotics O
. O
Vascular O

 O
surgery O
evaluated O
the O
foot O
and O
were O
cautious O
to O
pursue O
surgical O

 O
intervention O
because O
you O
have O
a O
poor O
cardiac O
reserve O
. O
Podiatry O

 O
evaluated O
you O
and O
they O
.... O

 O
. O

 O
You O
should O
come O
back O
to O
the O
hospital O
or O
call O
your O
primary O
care O

 O
doctor O
if O
you O
have O
chest O
pain O
, O
shortness O
of O
breath O
, O
weight O
gain O
, O

 O
fevers/chills O
or O
increasing O
pain O
in O
your O
right O
foot O
. O


 O
Followup O
Instructions O
: O

 O
PRN O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2133 O
- O
9 O
- O
17 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2133 O
- O
9 O
- O
22 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2084 O
- O
5 O
- O
25 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Penicillins B-DRUG
/ O
Codeine B-DRUG


 I-DRUG
Attending:[**Doctor O
First O
Name O
5188 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Abdominal O
pain O
, O
vomiting O



 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Right O
Chest O
tube O
placement O
at O
bedside O



 O
History O
of O
Present O
Illness O
: O

 O
49 O
year O
old O
female O
with O
history O
of O
cervical O
cancer O
status O
post O

 O
multiple O
( O
? O
26 O
) O
abdominal O
surgeries O
for O
TAH/BSO O
and O
complications O

 O
resulting O
in O
colostomy O
and O
urostomy O
presented O
to O
OSH O
on O
[ O
* O
* O
2133 O
- O
9 O
- O
17 O
* O
* O
] O

 O
with O
one O
day O
of O
abdominal O
pain O
and O
vomiting O
. O
Per O
OSH O
report O
, O

 O
also O
experienced O
chills O
, O
fevers O
, O
and O
decreased O
colostomy O
output O
. O

 O
Noted O
to O
have O
WBC O
count O
13.5 O
. O
Abdominal O
CT O
was O
consistent O
with O

 O
obstruction O
. O
In O
OSH O
received O
NS B-DRUG
1L B-DOS
, O
cipro B-DRUG
IV B-ROU
, I-ROU
and O
narcotics B-DRUG
for O

 O
pain B-REA
control I-REA
. I-REA
Received O
Narcan B-DRUG
and O
was O
intubated O
" O
due O
to O
airway O

 O
concern O
" O
- O
overdose B-REA
on O
narcotic B-DRUG
analgesics I-DRUG
; I-DRUG
ABG O
7.20/73/77 O
on O
NC O

 O
4 O
LPM O
, O
anion O
gap O
17 O
. O
Also O
had O
R O
subclavian O
, O
NG O
tube O
placed O
. O

 O
. O

 O
In O
the O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
, O
T O
98.4 O
, O
HR O
126 O
, O
BP O
137/100 O
, O
RR O
14 O
, O
99 O
% O
on O
AC O

 O
ventilation O
. O
Received O
propofol B-DRUG
gtt B-FOR
, I-FOR
flagyl B-DRUG
500 B-STR
mg I-STR
IV B-ROU
x1 B-DOS
, I-DOS
and O

 O
morphine B-DRUG
4 B-STR
mg I-STR
IV B-ROU
. I-ROU



 O
Past O
Medical O
History O
: O

 O
Past O
Medical O
History O
: O

 O
- O
Cervical O
CA O
s/p O
TAH/BSO O
w/incidental O
appy O
and O
damaged O
bladder O

 O
( O
[ O
* O
* O
2106 O
* O
* O
] O
) O
, O
s/p O
mult O
procedures O
repair O
ending O
in O
urostomy O
and O

 O
colostomy O

 O
- O
Depression O

 O
- O
? O
Hepatitis O

 O
. O



 O
Social O
History O
: O

 O
Lives O
with O
boyfriend O
. O
On O
Disability O
due O
to O
multiple O
abdominal O

 O
surgeries/complications O
. O
  O
Denies O
alcohol O
, O
drug O
, O
or O
tobacco O
use O
. O




 O
Family O
History O
: O

 O
Noncontributory O


 O
Physical O
Exam O
: O

 O
Tmax O
: O
37.7 O
? O
? O
? O
? O
? O
? O
C O
( O
99.9 O
? O
? O
? O
? O
? O
? O
F O
) O

 O
Tcurrent O
: O
36.1 O
? O
? O
? O
? O
? O
? O
C O
( O
97 O
? O
? O
? O
? O
? O
? O
F O
) O

 O
HR O
: O
106 O
( O
105 O
- O
118 O
) O
bpm O

 O
BP O
: O
145/91(105 O
) O
{ O
113/56(70 O
) O
- O
156/104(115 O
) O
} O
mmHg O

 O
RR O
: O
19 O
( O
14 O
- O
28 O
) O
insp/min O

 O
SpO2 O
: O
98 O
% O



 O
GEN O
: O
Well-appearing O
, O
well-nourished O
, O

 O
HEENT O
: O
EOMI O
, O
sclera O
anicteric O
, O
no O
epistaxis O
or O
rhinorrhea O
, O
MMM O

 O
NECK O
: O
No O
JVD O
, O
trachea O
midline O

 O
CV O
: O
RRR O
, O
no O
M/G/R O
, O
normal O
S1 O
S2 O
, O
radial O
pulses O
+ O
2 O

 O
PULM O
: O
Coarse O
breath O
sounds O
diffusely O

 O
ABD O
: O
Multiple O
surgical O
incision O
scars O
; O
colostomy O
and O
urostomy O

 O
bags O
in O
place O
; O
hypoactive O
bowel O
sounds O
; O
soft O
, O
not O
distended O
; O

 O
difficult O
to O
assess O
for O
tenderness O

 O
EXT O
: O
No O
C/C/E O

 O
NEURO O
: O
responds O
to O
few O
questions O
( O
e.g. O
Are O
you O
in O
pain O
? O
) O
; O
Moves O

 O
all O
4 O
extremities O
. O

 O
SKIN O
: O
R O
subclavian O
in O
place O
and O
dressed O
; O
no O
jaundice O
, O
cyanosis O
, O

 O
or O
gross O
dermatitis O
. O
No O
ecchymoses O
. O

 O
. O

 O
At O
Discharge O
: O

 O
Vitals O
: O
98.9 O
, O
81 O
, O
107/53 O
, O
18 O
, O
96 O
% O
on O
RA O

 O
GEN O
: O
NAD O
, O
A/Ox3 O

 O
CV O
: O
RRR O
, O
no O
m/r/g O

 O
RESP O
: O
CTAB O

 O
ABD O
: O
Soft O
, O
ND O
, O
slightly O
tender O
to O
palpation O
. O
+ O
BS O
, O
passing O

 O
flatus O
, O
+ O
Stool O

 O
Ostomy O
: O
stoma O
beefy O
red O
, O
viable O
with O
liquid O
yellow O
effluence O

 O
Urostomy O
: O
conduit O
intact O
with O
clear O
yellow O
urine O

 O
Extrem O
: O
no O
c/c/e O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2133 O
- O
9 O
- O
19 O
* O
* O
] O
04:32AM O
BLOOD O
WBC-9.7 O
RBC-3.35 O
* O
Hgb-11.8 O
* O
Hct-33.9 O
* O

 O
MCV-101 O
* O
MCH-35.3 O
* O
MCHC-34.9 O
RDW-13.6 O
Plt O
Ct-223 O

 O
[ O
* O
* O
2133 O
- O
9 O
- O
17 O
* O
* O
] O
07:24PM O
BLOOD O
Neuts-81.9 O
* O
Lymphs-14.2 O
* O
Monos-3.3 O

 O
Eos-0.3 O
Baso-0.3 O

 O
[ O
* O
* O
2133 O
- O
9 O
- O
19 O
* O
* O
] O
04:32AM O
BLOOD O
PT-12.8 O
PTT-25.8 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2133 O
- O
9 O
- O
19 O
* O
* O
] O
04:32AM O
BLOOD O
Glucose-95 O
UreaN-10 O
Creat-0.7 O
Na-144 O

 O
K-3.3 O
Cl-106 O
HCO3 O
- O
29 O
AnGap-12 O

 O
[ O
* O
* O
2133 O
- O
9 O
- O
19 O
* O
* O
] O
04:32AM O
BLOOD O
ALT-43 O
* O
AST-39 O
LD(LDH)-216 O
AlkPhos-143 O
* O

 O
TotBili-1.1 O

 O
[ O
* O
* O
2133 O
- O
9 O
- O
19 O
* O
* O
] O
04:32AM O
BLOOD O
Calcium-8.7 O
Phos-2.3 O
* O
Mg-1.9 O

 O
[ O
* O
* O
2133 O
- O
9 O
- O
18 O
* O
* O
] O
12:17AM O
BLOOD O
Type-ART O
Rates-/14 O
pO2 O
- O
124 O
* O
pCO2 O
- O
50 O
* O

 O
pH-7.33 O
* O
calTCO2 O
- O
28 O
Base O
XS-0 O
Intubat-INTUBATED O
Vent-CONTROLLED O

 O
[ O
* O
* O
2133 O
- O
9 O
- O
17 O
* O
* O
] O
07:32PM O
BLOOD O
Lactate-1.3 O

 O
[ O
* O
* O
2133 O
- O
9 O
- O
21 O
* O
* O
] O
04:50AM O
BLOOD O
WBC-6.6 O
RBC-3.02 O
* O
Hgb-10.9 O
* O
Hct-30.4 O
* O

 O
MCV-101 O
* O
MCH-36.1 O
* O
MCHC-35.8 O
* O
RDW-13.3 O
Plt O
Ct-232 O

 O
[ O
* O
* O
2133 O
- O
9 O
- O
22 O
* O
* O
] O
05:34AM O
BLOOD O
Glucose-92 O
UreaN-5 O
* O
Creat-0.7 O
Na-140 O

 O
K-3.9 O
Cl-106 O
HCO3 O
- O
28 O
AnGap-10 O

 O
[ O
* O
* O
2133 O
- O
9 O
- O
22 O
* O
* O
] O
05:34AM O
BLOOD O
Calcium-9.0 O
Phos-3.3 O
# O
Mg-2.1 O

 O
. O



 O

Brief O
Hospital O
Course O
: O

 O
49 O
year-old O
female O
with O
history O
of O
cervical O
cancer O
and O
many O

 O
abdominal O
surgeries O
s/p O
colostomy O
and O
[ O
* O
* O
Hospital O
80011 O
* O
* O
] O
transferred O
from O

 O
OSH O
for O
further O
management O
of O
suspected O
small O
bowel O
obstruction O
. O

 O
Admitted O
to O
Medical O
ICU O
. O

 O
. O

 O
# O
Abdominal O
pain O
, O
nausea O
? O
? O
? O
? O
? O
? O
Surgery O
involved O
. O
At O
this O
time O

 O
diagnosis O
of O
SBO O
suspected O
, O
although O
surgeons O
are O
waiting O
to O
see O

 O
CT O
abdomen O
from O
OSH O
to O
solidify O
diagnosis O
. O
Supported O
by O
large O

 O
number O
of O
abdominal O
surgeries O
patient O
has O
had O
( O
- O
> O
risk O
for O

 O
adhesions O
) O
. O
Also O
with O
mildly O
elevated O
transaminases O
and O
alk O

 O
phos O
. O
Differential O
also O
includes O
gastroenteritis O
, O
cholecystitis O
, O

 O
cholangitis O
. O
Mildly O
febrile O
and O
with O
leukocytosis O
. O
Given O
history O

 O
of O
possibile O
pneumobilia O
on O
CT O
at O
OSH O
hospital O
, O
ddx O
also O

 O
includes O
biliary-enteric O
anastomosis O
or O
fistula O
. O
? O
history O
of O

 O
hepatitis O
. O

 O
- O
intially O
NPO O

 O
- O
NGT O
to O
low O
continuous O
suction O
, O
removed O
[ O
* O
* O
9 O
- O
20 O
* O
* O
] O
and O
started O
on O

 O
sips O

 O
- O
Hydrate O
with O
IVF B-DRUG
until O
adequate O
PO O

 O
- O
Pain B-REA
control I-REA
( O
minimize O
narcotics B-DRUG
) I-DRUG

 O
. O

 O
# O
Pneumothorax O
: O
Pt O
had O
PTX O
most O
likely O
[ O
* O
* O
1 O
- O
3 O
* O
* O
] O
line O
placement O
at O
OSH O
. O

  O
Chest-tube O
was O
placed O
and O
almost O
complete O
resolution O
of O
PTX O
. O

 O
-chest O
tube O
to O
suction O
until O
[ O
* O
* O
9 O
- O
20 O
* O
* O
] O
- O
placed O
to O
waterseal O

 O
-chest O
tube O
removed O
[ O
* O
* O
9 O
- O
21 O
* O
* O
] O
without O
complication O

 O
. O

 O
# O
Respiratory B-ADE
failure I-ADE
? O
? O
? O
? O
? O
? O
Pt O
previously O
intubated O
for O
hypercarbic O

 O
respiratory O
failure O
. O
Likely O
secondary O
to O
narcotics B-DRUG
. I-DRUG
Pt O

 O
successfully O
extubated O
and O
on O
4L O
NC O
on O
[ O
* O
* O
9 O
- O
18 O
* O
* O
] O

 O
. O

 O
# O
[ O
* O
* O
Name O
( O
NI O
) O
3674 O
* O
* O
] O
pt O
with O
Hct O
of O
33.9 O
down O
from O
38.1 O
. O
  O
Likely O
dilutional O

 O
from O
fluids O
and O
blood O
loss O
from O
chest O
tube O
placment O
. O

 O
. O

 O
# O
Acute O
renal O
failure O
? O
? O
? O
? O
? O
? O
Creatinine O
0.7 O
today O
, O
much O
improved O
from O

 O
admission O
. O
History O
of O
vomiting O
and O
poor O
PO O
intake O
, O
this O
may O
be O

 O
secondary O
to O
dehydration O
. O
Urine O
output O
  O
> O
30 O
cc O
per O
hour O
. O

 O
- O
Continue O
to O
hydrate O

 O
- O
Maintain O
UOP O
> O
30cc/hr O

 O
. O

 O
# O
UTI B-REA
- O
UA O
with O
positive O
nitrite O
, O
trace O
ketones O
, O
> O
50 O
WBCs O
, O
and O

 O
many O
bacteria O
. O
Given O
one B-DOS
dose O
of O
ciprofloxacin B-DRUG
in O
ED O
. O
Given O
that O

 O
patient O
has O
ileostomy O
, O
she O
will O
likely O
always O
have O
a O
' O
dirty O
' O
UA O
. O


 O
- O
Hold O
off O
on O
treating O
at O
this O
time O
as O
may O
just O
be O
a O
contaminant O

 O
- O
Follow O
urine O
culture O

 O
. O


 O
Patient O
was O
successfully O
extubated O
in O
ICU O
. O
Continued O
with O

 O
confusion O
. O
Restraints O
applied O
. O
Remained O
NPO O
with O
IVF B-DRUG
. I-DRUG
Mental O

 O
status O
cleared O
slowly O
. O
Transferred O
to O
Stone O
5 O
for O
further O

 O
management O
on O
[ O
* O
* O
9 O
- O
20 O
* O
* O
] O
. O

 O
. O

 O
[ O
* O
* O
9 O
- O
20 O
* O
* O
] O
-Pt O
pulled O
NGT O
out O
due O
to O
agitation B-ADE
r/t O
naroctic B-DRUG

 I-DRUG
medications O
. O
Maintained O
in O
2 O
point O
restraints O
overnight O
. O
Mental O

 O
status O
much O
improved O
in O
morning O
. O
Ostomy O
with O
gas O
but O
no O
stool O
. O

 O
KUB O
repeated-resolving O
ileus O
. O

 O
. O

 O
[ O
* O
* O
9 O
- O
21 O
* O
* O
] O
-Abdomen O
slightly O
distened O
. O
Started O
on O
clear O
liquids O
. O

 O
Tolerating O
well O
. O
No O
N/V. O
Right O
chest O
tube O
removed O
at O
bedside O
, O

 O
uncomplicated O
. O
CXR O
completed O
2 O
hours O
after O
, O
lungs O
clear O
, O
no O

 O
evidence O
of O
pneumothorax O
. O
Ostomy O
RN O
contact[**Name O
( O
NI O
) O
* O
* O
] O
to O
assist O
with O

 O
management O
of O
leaking O
ostomy O
and O
urostomy O
. O
Assisted O
OOB O
with O

 O
nursing O
. O
Ambulated O
without O
assist O
. O
Lives O
independently O
with O

 O
boyfriend O
. O
Diet O
advanced O
to O
regular O
food O
in O
evening O
. O
Tolerated O

 O
well O
. O

 O
. O

 O
[ O
* O
* O
9 O
- O
22 O
* O
* O
] O
-Continues O
to O
tolerate O
Regular O
food O
. O
Ostomy O
and O
Urostomy O

 O
putting O
out O
adequate O
amounts O
of O
urine/stool O
. O
Pain O
well O

 O
controlled O
with O
oral O
medication O
. O
Abdominal O
pain O
decreased O
. O

 O
Ostomy O
continues O
to O
leak O
even O
with O
efforts O
of O
Ostomy O
RN O
due O
to O

 O
patient O
's O
anatomy O
. O
Plan O
for O
discharge O
home O
today O
with O
VNA O
for O

 O
continued O
management O
of O
Ostomy O
appliance O
and O
skin O
assessment O
. O


 O
Medications O
on O
Admission O
: O

 O
Seroquel B-DRUG
25 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
Zantac B-DRUG
150 B-STR
mg I-STR
PO B-ROU
QHS B-FRE

 I-FRE
Cymbalta B-DRUG
60 B-STR
mg I-STR
PO B-ROU
BID B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Quetiapine B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O

 O
day O
) O
. O

 O
2 O
. O
Ranitidine B-DRUG
HCl I-DRUG
150 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( O
at O

 O
bedtime O
) O
. O

 O
3 O
. O
Duloxetine B-DRUG
30 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O
day O
) O
. O

 O
4 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
fever B-REA
or O
pain B-REA
: I-REA
Not O
to O
exceed O
4gm O
per O
day O
. O

 O
. O


 O
5 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
as O
needed O
for O
constipation B-REA
for B-DUR
1 I-DUR
months I-DUR
: I-DUR
Take O
with O

 O
Hydrocodone B-DRUG
. I-DRUG

 O
Disp:*60 O
Capsule(s O
) O
* O
Refills:*0 O
* O

 O
6 O
. O
Hydrocodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
500 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU

 I-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
for B-DUR
2 I-DUR
weeks I-DUR
: I-DUR
Do O
not O

 O
exceed O
4000 B-STR
mg I-STR
of O
Acetaminophen B-DRUG
in O
24hrs O
. O

 O
Disp:*45 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
7 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O

 O
day O
) O
as O
needed O
for O
constipation B-REA
: I-REA
Take O
with O
Hydrocodone B-DRUG
. I-DRUG

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
Nursing O
Services O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
Small O
bowel O
obstruction O

 O
Post-extubation O
confused O
related O
to O
medications O

 O
Right O
pneumothorax-Chest O
tube O
inserted O
. O

 O
UTI O

 O
Acute O
renal O
failure O

 O
. O

 O
Secondary O
: O

 O
Depression O
, O
hepatitis O
C O
, O
cervical O
CA O
, O
  O
TAH/BSO-Bladder O
injury O

 O
( O
urostomy O
& O
Colostomy O
) O



 O
Discharge O
Condition O
: O

 O
Stable O

 O
Tolerating O
a O
regular O
diet O

 O
Adequate O
pain O
control O
with O
oral O
medication O



 O
Discharge O
Instructions O
: O

 O
Please O
call O
your O
doctor O
or O
return O
to O
the O
ER O
for O
any O
of O
the O

 O
following O
: O

 O
* O
You O
experience O
new O
chest O
pain O
, O
pressure O
, O
squeezing O
or O

 O
tightness O
. O

 O
* O
New O
or O
worsening O
cough O
or O
wheezing O
. O

 O
* O
If O
you O
are O
vomiting O
and O
can O
not O
keep O
in O
fluids O
or O
your O

 O
medications O
. O

 O
* O
You O
are O
getting O
dehydrated O
due O
to O
continued O
vomiting O
, O

 O
diarrhea O
or O
other O
reasons O
. O
Signs O
of O
dehydration O
include O
dry O

 O
mouth O
, O
rapid O
heartbeat O
or O
feeling O
dizzy O
or O
faint O
when O
standing O
. O

 O
* O
You O
see O
blood O
or O
dark/black O
material O
when O
you O
vomit O
or O
have O
a O

 O
bowel O
movement O
. O

 O
* O
Your O
pain O
is O
not O
improving O
within O
8 O
- O
12 O
hours O
or O
not O
gone O

 O
within O
24 O
hours O
. O
Call O
or O
return O
immediately O
if O
your O
pain O
is O

 O
getting O
worse O
or O
is O
changing O
location O
or O
moving O
to O
your O
chest O
or O


 O
back O
. O

 O
* O
Avoid O
driving O
or O
operating O
heavy O
machinery O
while O
taking O
pain O

 O
medications O
. O

 O
* O
You O
have O
shaking O
chills O
, O
or O
a O
fever O
greater O
than O
101.5 O
( O
F O
) O

 O
degrees O
or O
38(C O
) O
degrees O
. O

 O
* O
Any O
serious O
change O
in O
your O
symptoms O
, O
or O
any O
new O
symptoms O
that O

 O
concern O
you O
. O

 O
* O
Please O
resume O
all O
regular O
home O
medications O
and O
take O
any O
new O

 O
meds O

 O
as O
ordered O
. O

 O
* O
Continue O
to O
ambulate O
several O
times O
per O
day O
. O

 O
. O


 O
Monitoring O
Ostomy O
output/Prevention O
of O
Dehydration O
: O

 O
-Keep O
well O
hydrated O
. O

 O
-Replace O
fluid O
loss O
from O
ostomy O
daily O
. O

 O
-Avoid O
only O
drinking O
plain O
water O
. O
Include O
Gatorade O
and/or O
other O

 O
vitamin O
drinks O
to O
replace O
fluid O
. O

 O
-Try O
to O
maintain O
ostomy O
output O
between O
1000mL O
to O
1500mL O
per O
day O
. O

 O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
MD O
if O
output O
greater O
than O
2 O
liters O
or O
under O
500ml O
in O
24 O

 O
hours O
. O

 O
. O

 O
Urostomy O
: O

 O
-Continue O
with O
urostomy O
managment O
prior O
to O
admission O
. O

 O
. O

 O
Diet O
: O

 O
-Continue O
with O
a O
low O
residue O
diet O
until O
your O
follow-up O

 O
appointment O
with O
your O
PCP O
. O

 O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
to O
Hand O
out O
provided O
to O
you O
by O
nursing O
for O
guidance O
. O



 O
Followup O
Instructions O
: O

 O
1 O
. O
Follow-up O
with O
PCP O
, O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
48826 O
* O
* O
] O
in O
1 O
week O
and O

 O
as O
needed O
. O



                              O
[ O
* O
* O
Name6 O
( O
MD O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
MD O
, O
[ O
* O
* O
MD O
Number(3 O
) O
5190 O
* O
* O
] O


 O
Completed O
by:[**2133 O
- O
9 O
- O
22 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2166 O
- O
5 O
- O
5 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2166 O
- O
5 O
- O
19 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2083 O
- O
4 O
- O
14 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
3984 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Epigastric O
pain O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
ERCP O


 O
History O
of O
Present O
Illness O
: O

 O
PCP O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
, O
[ O
* O
* O
Name11 O
( O
NameIs O
) O
1575 O
* O
* O
] O
[ O
* O
* O
Name O
Initial O
( O
NameIs O
) O
* O
* O
] O
. O

 O
Address O
: O
[ O
* O
* O
Street O
Address(2 O
) O
* O
* O
] O
[ O
* O
* O
Apartment O
Address(1 O
) O
86397 O
* O
* O
] O
, O
[ O
* O
* O
Location O
86398**],[**Numeric O
Identifier O
86399 O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
54195 O
* O
* O
] O

 O
Fax O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
86400 O
* O
* O
] O


 O
83 O
yo O
gentleman O
with O
little O
PMHx O
was O
admitted O
from O
ERCP O
suite O

 O
with O
history O
epigastric O
pain O
. O



 O
He O
was O
initially O
admitted O
to O
[ O
* O
* O
Hospital6 O
204 O
* O
* O
] O
( O
LGH O
) O
10 O

 O
days O
ago O
with O
acute O
on O
chronic O
epigastric O
pain O
and O
diagnosed O

 O
with O
pancreatitis O
. O
Additional O
review O
of O
systems O
is O
notable O
for O

 O
the O
following O
: O
intermittent O
epigastric O
pain O
and O
anorexia O
over O

 O
last O
3 O
- O
4 O
months O
. O
He O
denies O
fevers O
or O
jaundice O
. O
At O
LGH O
, O
labs O
were O

 O
notable O
for O
leukocytosis O
with O
WBC O
> O
20,000 O
, O
increasing O
serum O
and O

 O
fluid O
amylase O
levels O
with O
serial O
fluid O
amylase O
readings O
of O

 O
[**2156**]-3600s O
. O
Imaging O
was O
notable O
for O
the O
following O
: O
abdominal O
CT O

 O
with O
peripancreatic O
and O
ascitic O
fluid O
; O
MRI O
which O
revealed O
an O

 O
amorphous O
pancreatic O
head O
suggestive O
of O
hemorrhagic O

 O
pancreatitis O
. O
A O
paracentesis O
was O
performed O
on O
[ O
* O
* O
2166 O
- O
4 O
- O
28 O
* O
* O
] O
, O
and O
fluid O

 O
total O
protein O
was O
elevated O
, O
a O
SAAG O
was O
near O
zero O
, O
and O
fluid O
cell O

 O
count O
revealed O
WBC O
1700 O
with O
neutrophilic O
predominance O
. O
For O

 O
treatment O
, O
he O
was O
started O
empirically B-REA
on O
Unasyn B-DRUG
on O
[ O
* O
* O
2166 O
- O
4 O
- O
26 O
* O
* O
] O
and O

 O
then O
changed O
to O
Zosyn B-DRUG
on O
[ O
* O
* O
2166 O
- O
4 O
- O
29 O
* O
* O
] O
. O
He O
also O
had O
a O
drain O
placed O

 O
into O
one O
of O
his O
abdominal O
fluid O
collections O
. O
Additional O
issues O

 O
include O
the O
following O
: O

 O
- O
malnutrition O
- O
He O
was O
started O
on O
TPN B-DRUG
in O
the O
setting O
of O
being O

 O
NPO O
and O
with O
marked O
hypoalbuminemia O
with O
Alb O
1.5 O
. O

 O
- O
anemia B-REA
- O
He O
received O
1 B-DOS
unit I-DOS
pRBCs B-DRUG
. I-DRUG

 O
- O
Atrial B-REA
Fibrillation I-REA
- O
He O
developed O
rapid O
afib O
on O
[ O
* O
* O
2166 O
- O
4 O
- O
29 O
* O
* O
] O
. O
He O

 O
was O
initially O
started O
on O
diltiazem B-DRUG
with O
minimal O
improvement O
, O
and O

 O
he O
was O
then O
transitioned O
to O
amiodarone B-DRUG
. I-DRUG
  O
A O
pigtail O
drain O
was O

 O
placed O
[ O
* O
* O
2166 O
- O
5 O
- O
1 O
* O
* O
] O
to O
drain O
ascitic O
fluid O
. O

 O
He O
was O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
Assessment O
for O
ERCP O
and O
possible O

 O
transpapillary O
drainage O
with O
stenting O
. O
  O
Finger O
stick O
glucose O
was O

 O
elevated O
to O
225 O
this O
afternoon O
. O



 O
ROS O
: O

 O
Constitutional O
: O
No O
weight O
loss O
, O
fatigue O
, O
fevers O
, O
chills O
, O
night O

 O
sweats O
, O
(+)anorexia O
for O
3 O
- O
4 O
months O

 O
Neuro O
: O
No O
headaches O
, O
confusion O
, O
numbness O
of O
extremities O
, O

 O
dizziness O
or O
light-headedness O
, O
vertigo O
, O
weakness O
of O
extremities O
, O

 O
tremor O
, O
parasthesias O

 O
Psychiatric O
: O
no O
depression O
, O
no O
suicidal O
ideation O

 O
Eyes O
: O
No O
blurry O
vision O
, O
diplopia O
, O
loss O
of O
vision O
, O
photophobia O

 O
ENT O
: O
No O
dry O
mouth O
, O
oral O
ulcers O
, O
bleeding O
nose O
or O
gums O
, O
tinnitus O
, O

 O
sinus O
pain O
, O
sore O
throat O

 O
Cardiac O
: O
no O
chest O
pain O
, O
DOE O
, O
syncope O
, O
PND O
, O
orthopnea O
, O

 O
palpitations O
, O
( O
+ O
) O
chronic O
bilat O
LExt O
peripheral O
edema O

 O
Pulmonary O
: O
No O
shortness O
of O
breath O
, O
cough O
, O
hemoptysis O
, O
pleuritic O

 O
pain O

 O
GI O
: O
( O
+ O
) O
intermittent O
epigastric O
abd O
pain O
especially O
last O
10 O

 O
days O
, O
none O
now O
. O
no O
nausea O
, O
vomiting O
, O
diarrhea O
, O
constipation O
, O

 O
hematemesis O
, O
melena O
, O
hematochezia O
, O

 O
Heme O
: O
no O
easy O
bleeding O
, O
bruising O
, O
lymphadenopathy O

 O
GU O
: O
no O
dysuria O
, O
hematuria O
, O
( O
+ O
) O
increased O
frequency O
, O
urgency O

 O
chronically O
, O
but O
no O
incontinence O

 O
Endocrine O
: O
no O
changes O
in O
hair O
, O
skin O
, O
heat O
or O
cold O
intolerance O
, O

 O
change O
in O
hat O
or O
glove O
size O
, O
weight O
changes O
, O
change O
in O
energy O

 O
Skin O
: O
( O
+ O
) O
new O
rash O
mild O
today O
, O
no O
pruritis O
or O
lacerations O
, O

 O
Musculoskeletal O
: O
no O
myalgias O
, O
arthralgias O
, O
back O
pain O

 O
Allergy O
: O
no O
seasonal O
allergies O
; O
drug O
allergies O
as O
above O



 O
Past O
Medical O
History O
: O

 O
1 O
. O
Cirrhosis O

 O
- O
by O
recent O
MRI O
( O
no O
known O
prior O
eval O
/ O
pt O
not O
aware O
) O

 O
2 O
. O
New O
onset O
Rapid B-REA
Afib I-REA

 I-REA
- O
recently O
at O
LGH O
in O
setting O
of O
fluid O
overload O
, O
started O
on O

 O
amiodarone B-DRUG
, I-DRUG
now O
resolved O

 O
3 O
. O
Chronic O
Diastolic O
Congestive O
Heart O
Failure O

 O
4 O
. O
Benign O
Hypertension O

 O
5 O
. O
BPH O

 O
- O
prior O
prostate O
biopsy O
negative O
for O
Cancer O
per O
pt O
, O
has O

 O
urgency/frequency O
, O
no O
incontinence O
, O
no O
recent O
hydro O



 O
Social O
History O
: O

 O
Home O
: O
Lives O
alone O
downstairs O
from O
brother O
in O
law O
and O
nieces O
. O

 O
Childless O
widower O
. O
Was O
in O
the O
service O
. O

 O
Occupation O
: O
Former O
shipping O
department O
worker O
for O
box O
company O
. O

 O
Tobacco O
: O
Never O
smoked O
. O

 O
EtOH O
: O
Occasional O
ETOH O
in O
past O

 O
Drugs O
: O
Denies O



 O
Family O
History O
: O

 O
No O
cancers O
or O
genetic O
diseases O



 O
Physical O
Exam O
: O

 O
Elderly O
gentleman O
, O
pleasant O
, O
slightly O
hard O
of O
hearing O
in O
no O

 O
distress O

 O
T O
96.6 O
, O
BP O
118/50 O
, O
HR O
75 O
regular O
, O
RR O
22 O
SpO2 O
95%RA O

 O
HEENT O
: O
anicteric O
, O
OP O
mildly O
dry O
, O
no O
thrush O
, O
no O
lesions O

 O
Neck O
: O
JVP O
not O
elevated O
, O
no O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
, O
neck O
is O
supple O

 O
COR O
: O
RRR O
, O
nl O
s1/S2 O
, O
no O
MRG O
, O
normal O
PMI O

 O
LUNGS O
: O
scant O
crackles O
at O
bases O
, O
otherwise O
CTA O
bilaterallly O

 O
ABD O
: O
Distended O
with O
ascites O
, O
non-tender O
, O
no O
guarding O
, O
can O
not O

 O
evaluate O
for O
organomegaly O
given O
fluid O

 O
EXT O
: O
chronic O
venous O
stasis O
hemosiderosis O
, O
+ O
+ O
bilat O
symmetric O

 O
LExt O
edema O

 O
NEURO O
: O
alert/oriented O
x O
3 O
, O
mild O
sensory O
hearing O
loss O
, O
no O
focal O

 O
abnormalitis O

 O
SKIN O
: O
mild O
blanching O
rash O
on O
chest/back O
arms O
. O


 O
Pertinent O
Results O
: O

 O
OSH O
LABS O
: O

 O
[ O
* O
* O
2166 O
- O
4 O
- O
26 O
* O
* O
] O

 O
Na O
133 O
/ O
K O
5.1 O
/ O
Cl O
96 O
/ O
CO2 O
27 O
/ O
BUN O
46 O
/ O
Cr O
.18 O
/ O
BG O
192 O

 O
Alb O
2.6 O

 O
Ca O
8.2 O
/ O
TB O
1.2 O
/ O
Alk O
Phos O
230 O

 O
AST O
31 O
/ O
ALT O
38 O
/ O
Amylase O
157 O
/ O
Lipase O
1803 O

 O
WBC O
25.6 O
/ O
hct O
34 O
/ O
Plt O
700 O

 O
N O
94 O
/ O
L O
4 O
/ O
M O
2 O

 O
ESR O
75 O


 O
[ O
* O
* O
2166 O
- O
4 O
- O
28 O
* O
* O
] O

 O
WBC O
28.4 O
/ O
Hct O
31 O
/ O
Plt O
589 O

 O
CA O
[**75**]-9 O
- O
44 O


 O
[ O
* O
* O
2166 O
- O
4 O
- O
29 O
* O
* O
] O

 O
WBC O
22 O
/ O
Hct O
28.4 O
/ O
Plt O
578 O

 O
N O
87 O
/ O
Bands O
8 O
/ O
L O
0 O
/ O
M O
5 O

 O
Na O
140 O
/ O
K O
4.3 O
/ O
Cl O
107 O
/ O
CO2 O
24 O
/ O
BUN O
47 O
/ O
Cr O
1.4 O
/ O
BG O
198 O

 O
ALT O
19 O
/ O
AST O
18 O
/ O
Alk O
Phos O
120 O
/ O
Amylase O
185 O
/ O
Lipase O
1456 O

 O
BNP O
159 O


 O
[ O
* O
* O
2166 O
- O
4 O
- O
30 O
* O
* O
] O

 O
WBC O
18.2 O
/ O
Hct O
28.2 O
/ O
Plt O
489 O

 O
N O
77 O
/ O
Bands O
4 O
/ O
L O
10 O
/ O
M O
7 O
/ O
E O
2 O

 O
Na O
125 O
/ O
K O
3.8 O
/ O
Cl O
93 O
/ O
CO2 O
26 O
/ O
BUN O
38 O
/ O
Cr O
1.9 O

 O
Alb O
1.6 O

 O
TB O
.5 O
/ O
DB O
.4 O
/ O
Alk O
Phos O
96 O
/ O
ALT O
14 O
/ O
AST O
15 O
/ O
Amylase O
124 O
/ O

 O
Lipase O
827 O


 O
[ O
* O
* O
2166 O
- O
5 O
- O
4 O
* O
* O
] O

 O
Na O
136 O
/ O
K O
3.8 O
/ O
Cl O
102 O
/ O
CO2 O
30 O
/ O
BUN O
19 O
/ O
Cr O
.9 O

 O
Ca O
6.8 O
/ O
Phos O
2.6 O
/ O
Mg O
2.1 O

 O
Alb O
1.5 O

 O
Alk O
Phos O
128 O
/ O
TB O
.8 O
/ O
AST O
28 O
/ O
ALT O
23 O
/ O
Amylase O
149 O
/ O
Lipase O

 O
952 O

 O
INR O
1.2 O

 O
WBC O
16.1 O
/ O
Hct O
27.6 O
/ O
Plt O
386 O



 O
[ O
* O
* O
2166 O
- O
4 O
- O
28 O
* O
* O
] O
  O
Peritoneal O
fluid O

 O
WBC O
1774 O
/ O
RBC O
10,000 O
/ O
Alb O
1.9 O
/ O
Amylase O
1640 O
/ O
Glucose O
31 O

 O
- O
no O
malignant O
cells O
. O
  O
Increased O
PMNs O
with O
fibrinopurlent O
debris O


 O
MICROBIOLOGY O
: O

 O
[ O
* O
* O
2166 O
- O
4 O
- O
26 O
* O
* O
] O
Blood O
Cx O
x O
2 O
pending O
-- O
> O
negative O

 O
[ O
* O
* O
2166 O
- O
4 O
- O
28 O
* O
* O
] O
Ascites O
Fluid O
Cx O
pending O
-- O
> O
negative O

 O
[ O
* O
* O
2166 O
- O
4 O
- O
28 O
* O
* O
] O
AFB O
Smear O
- O
negative O


 O
OSH O
STUDIES O
: O

 O
Peritoneal O
Fluid O
- O
no O
malignant O
cells O


 O
CT O
abd O
[ O
* O
* O
2166 O
- O
4 O
- O
26 O
* O
* O
] O
: O

 O
1 O
. O
cirrhosis O
with O
moderate O
ascites O

 O
2 O
. O
high O
density O
soft O
tissue O
pancreatic O
head O
abnormality O
c/w O

 O
hemorrhagic O
fluid O

 O
3 O
. O
no O
air O
within O
the O
focus O
to O
suggest O
perforation O
. O
  O
Fluid O

 O
collection O
within O
central O
mesentary O
. O

 O
4 O
. O
Probable O
ileus O

 O
5 O
. O
marked O
enlarged O
prostate O

 O
6 O
. O
hiatal O
hernia O


 O
KUB O
[ O
* O
* O
2166 O
- O
4 O
- O
27 O
* O
* O
] O
: O
moderat O
ileus O
, O
no O
obstruction O


 O
CXR O
[ O
* O
* O
2166 O
- O
4 O
- O
29 O
* O
* O
] O
: O
low O
lung O
volumes O
with O
atelectasis O
and O
small O
bilat O

 O
effusions O
. O


 O
MRCP O
[ O
* O
* O
2166 O
- O
4 O
- O
28 O
* O
* O
] O
: O

 O
1 O
. O
Pancreatic O
head O
mass O
secondary O
to O
acute O
hemorrhagic O

 O
pancreatitis O
, O
need O
to O
r/o O
underlying O
mass O
. O

 O
2 O
. O
Secondary O
mild O
diation O
of O
main O
PD O
6 O
mm O
, O
unchanged O
from O
prior O

 O
CT O
, O
no O
intra/extra O
hepatic O
biliary O
dilation O
. O

 O
3 O
. O
Mild O
GB O
distention O
w/o O
stones O
. O

 O
4 O
. O
Cirrhosis O
and O
moderate O
ascites O
. O


 O
U/S O
[ O
* O
* O
2166 O
- O
4 O
- O
28 O
* O
* O
] O
: O
Abdominal O
ascites O
with O
septations O
. O
Heterogeneous O

 O
liver O
, O
nl O
spleen O
, O
no O
hydronephrosis O
, O
small O
bilat O
effusions O
. O


 O
ECHO O
[ O
* O
* O
2166 O
- O
4 O
- O
29 O
* O
* O
] O
: O
Mild O
LVH O
, O
nl O
LV O
size O
, O
EF O
65 O
% O
, O
grade O
1 O
diastolic O

 O
dysfunction O
, O
nl O
RV O
, O
mod O
LAE O
, O
minimal O
Aortic O
stenosis O
w/ O
peak O

 O
grad O
15mmHg O
, O
tr O
TR O
, O
no O
pericardial O
effusion O


 O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
LABS O
: O

 O
ADMISSION O
LABS O
[ O
* O
* O
2166 O
- O
5 O
- O
6 O
* O
* O
] O

 O
WBC O
17.7 O
/ O
Hct O
32.1 O
/ O
Plt O
401 O

 O
Na O
138 O
/ O
K O
3.5 O
/ O
Cl O
102 O
/ O
CO2 O
30 O
/ O
BUN O
17 O
/ O
Cr O
.8 O
/ O
BG O
67 O

 O
Ca O
7.1 O
/ O
Mg O
1.9 O
/ O
Phos O
2.9 O

 O
ALT O
24 O
/ O
AST O
29 O
/ O
Amylase O
212 O
/ O
Lipase O
166 O
/ O
Alk O
Phos O
151 O
/ O
LDH O

 O
227 O
/ O
TB O
1 O
/ O
Alb O
2.1 O

 O
IgG O
1527 O

 O
HBsAg O
negative O
/ O
HBsAb O
negative O
/ O
HBcAb O
negative O

 O
Hepatitis O
A O
antibody O
- O
negative O

 O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
negative O

 O
Hepatitis O
C O
Antibody O
negative O



 O
DISCHARGE O
LABS O
: O


 O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
MICROBIOLOGY O
: O

 O
[ O
* O
* O
2166 O
- O
5 O
- O
7 O
* O
* O
] O
C.diff O
Toxin O
- O
positive O

 O
[ O
* O
* O
2166 O
- O
5 O
- O
7 O
* O
* O
] O
Urine O
Cx O
negative O

 O
[ O
* O
* O
2166 O
- O
5 O
- O
7 O
* O
* O
] O
Blood O
Cx O
[ O
* O
* O
3 O
- O
6 O
* O
* O
] O
- O
Prelim O
GPC O
in O
clusters O


 O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
STUDIES O
: O

 O
[ O
* O
* O
2166 O
- O
5 O
- O
5 O
* O
* O
] O
ERCP O

 O
1 O
. O
Edematous O
major O
papilla O

 O
2 O
. O
The O
bile O
duct O
was O
not O
dilated O
. O
The O
distal O
bile O
duct O
filled O

 O
poorly O
, O
most O
likely O
due O
to O
extrinsic O
compression O
from O
the O

 O
pathology O
at O
the O
pancreatic O
head O
. O
No O
filling O
defects O
were O
noted O
. O


 O
3 O
. O
Contrast O
was O
injected O
into O
the O
pancreatic O
duct O
, O
which O

 O
appeared O
to O
terminate O
abruptly O
in O
the O
pancreatic O
head O
, O
with O
no O

 O
filling O
beyond O
that O
point O
. O
  O
This O
is O
in O
keeping O
with O
the O
reported O

 O
MRCP O
findings O
and O
is O
concerning O
for O
an O
obstructing O
pancreatic O

 O
mass O
. O


 O
[ O
* O
* O
2166 O
- O
5 O
- O
6 O
* O
* O
] O
Endoscopic O
Ultrasound O

 O
1 O
. O
A O
3.2 O
cm O
X O
4.1 O
cm O
discrete O
anechoic O
lesion O
, O
consistent O
with O
a O

 O
cyst O
was O
noted O
in O
the O
head O
of O
the O
pancreas O
. O

 O
2 O
. O
The O
walls O
of O
the O
cyst O
were O
thick O
measuring O
0.22 O
cm O
. O

 O
3 O
. O
Layering O
debris O
was O
noted O
in O
the O
dependent O
part O
of O
the O
cyst O
. O

 O
4 O
. O
A O
pseudoaneurysm O
was O
noted O
on O
the O
lateral O
wall O
of O
the O
cyst O
. O

 O
5 O
. O
The O
cyst O
appeared O
to O
obstruct O
the O
main O
pancreatic O
duct O
, O
which O

 O
was O
dilated O
distally O
. O
The O
cyst O
was O
also O
noted O
to O
compress O
the O

 O
portal O
vein O
. O

 O
6 O
. O
  O
A O
single O
perigastric O
lymph O
node O
was O
noted O
, O
which O
measured O

 O
1.8 O
x O
0.8 O
cm O
. O

 O
Otherwise O
normal O
EGD O
to O
third O
part O
of O
the O
duodenum O


 O
[ O
* O
* O
2166 O
- O
5 O
- O
7 O
* O
* O
] O
CTA O
Abd/Pelvis O

 O
1 O
. O
Multiple O
areas O
of O
fluid O
collection O
throughout O
the O
abdomen O

 O
including O
the O

 O
large O
bilobed O
pseudocyst O
above O
and O
below O
the O
pancreas O
, O
in O
the O

 O
right O
paracolic O
gutter O
, O
transverse O
mesentery O
, O
and O
within O

 O
anterior O
abdominal O
wall O
. O

 O
2 O
. O
6-mm O
pseudoaneurysm O
located O
within O
the O
pseudocyst O
at O
the O

 O
level O
of O
the O

 O
pancreas O
. O
There O
is O
also O
a O
10-mm O
aneurysm O
at O
the O
origin O
of O
the O

 O
common O
hepatic O
artery O
. O

 O
3 O
. O
Dilatation O
of O
the O
main O
pancreatic O
duct O
due O
to O
compressive O

 O
effect O
of O
the O

 O
pseudocyst O
. O




 O

Brief O
Hospital O
Course O
: O

 O
83yo O
male O
with O
history O
of O
BPH O
was O
transferred O
from O
an O
OSH O
for O

 O
evaluation O
of O
pancreatitis O
. O
Evaluation O
was O
notable O
for O
large O

 O
pancreatic O
pseudocyst O
with O
multiple O
intra-abdominal O
fluid O

 O
collections O
thought O
related O
to O
his O
pseudocyst O
. O
His O
course O
was O

 O
complicated O
by O
unexplained O
PEA O
arrest O
. O
The O
patient O
had O
an O
ICU O

 O
course O
s/p O
resuscitation O
wherein O
he O
did O
not O
regain O
mental O

 O
faculties O
or O
responsiveness O
. O
His O
family O
chose O
comfort O
measures O

 O
and O
Mr. O
[ O
* O
* O
Known O
lastname O
59996 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Titles O
) O
* O
* O
] O
on O
[ O
* O
* O
2166 O
- O
5 O
- O
19 O
* O
* O
] O
. O


 O
# O
PEA O
arrest O
- O
unclear O
precipitant O
. O
Patient O
never O
regained O

 O
mental O
faculties O
. O


 O
1 O
. O
Pancreatititis O
, O
Pancreatic O
Pseudocysts O
, O
Intra-abdominal O
fluid O

 O
Collections O

 O
On O
ERCP O
, O
patient O
was O
found O
to O
have O
bile O
duct O
filling O
defect O
, O

 O
suggestive O
of O
external O
compression O
. O
He O
underwent O
follow-up O
EUS O

 O
which O
revealed O
a O
large O
pancreatic O
pseudocyst O
. O
CTA O
Pancreas O
was O

 O
also O
performed O
, O
which O
confirmed O
the O
large O
pseudocysts O
but O
also O

 O
noted O
multiple O
large O
abdominal O
fluid O
collections O
. O
He O
was O

 O
evaluated O
by O
our O
general O
surgery O
team O
, O
who O
thought O
his O
abdominal O

 O
process O
of O
pancreatic O
pseudocyst O
and O
associated O
inflammation O
was O

 O
relatively O
immature O
, O
and O
that O
surgical O
intervention O
or O
drainage O

 O
at O
this O
time O
was O
not O
indicated O
. O
He O
developed O
a O
bleeding O
GDA O

 O
aneurysm O
and O
was O
taken O
to O
IR O
for O
embolization O
before O
which O
he O

 O
developed O
PEA O
arrest O
. O
This O
GDA O
was O
ultimately O
embolized O
. O


 O
2 O
. O
Clostridium B-REA
difficile I-REA
infection I-REA

 I-REA
Within O
48 O
hours O
of O
admission O
, O
patient O
developed O
increased O

 O
diarrhea B-REA
and O
marked O
leukocytosis O
from O
17 O
to O
26 O
. O
He O
was O
C. B-REA
diff I-REA

 I-REA
positive O
and O
started O
on O
flagyl B-DRUG
on O
[ O
* O
* O
2166 O
- O
5 O
- O
7 O
* O
* O
] O
with O
improvement O
in O
his O

 O
diarrhea O
. O
He O
was O
recommended O
to O
continue O
flagyl B-DRUG
for B-DUR
2 I-DUR
weeks I-DUR
from O

 O
4/7 O
- O
20/10 O
. O


 O
3 O
. O
Hepatic O
Cirrhosis O

 O
Imaging O
from O
abdominal O
CT O
and O
MRCP O
revealed O
hepatic O
cirrhosis O
, O

 O
although O
patient O
has O
no O
history O
of O
this O
in O
the O
past O
. O


 O
4 O
. O
Atrial B-REA
Fibrillation I-REA

 I-REA
Patient O
was O
diagnosed O
with O
atrial O
fibrillation O
at O
the O
OSH O
and O

 O
was O
started O
on O
diltiazem B-DRUG
before O
being O
transitioned O
to O

 O
amiodarone B-DRUG
. I-DRUG
Upon O
transfer O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
, O
his O
PICC O
line O
was O
noted O
to O

 O
be O
advanced O
into O
the O
right O
atrium O
, O
and O
it O
was O
thought O
that O
this O

 O
may O
have O
been O
triggering O
his O
atrial O
fibrillation O
. O
During O
his O

 O
hospitalization O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
, O
he O
remained O
in O
sinus O
rhythm O
and O
with O

 O
excellent O
rate O
control O
. O
His O
amiodarone B-DRUG
was O
discontinued O
. O


 O
5 O
. O
Acute O
Renal O
Failure O

 O
During O
his O
admission O
at O
the O
OSH O
, O
his O
creatinine B-DRUG
was O
as O
high O
as O

 O
1.9 O
and O
then O
remained O
stable O
between O
.[**8 O
- O
31 O
* O
* O
] O
. O



 O
6 O
. O
Malnutrition O

 O
Patient O
was O
started O
on O
TPN O
at O
the O
OSH O
and O
was O
continued O
on O
this O

 O
during O
his O
hospitalization O
. O
He O
was O
NPO O
during O
this O

 O
hospitalization O
and O
was O
NPO O
on O
discharge O
. O
At O
rehab O
, O
we O
recommend O

 O
that O
he O
remain O
NPO O
for O
the O
first O
week O
. O
He O
could O
take O
sips O
for O

 O
comfort O
after O
this O
time O
. O


 O
7 O
. O
Anemia O

 O
Unknown O
baseline O
. O
His O
hematocrit O
has O
remained O
stable O
during O
this O

 O
admission O
from O
27 O
- O
30 O
. O


 O
8 O
. O
Hyperglycemia B-REA

 I-REA
He O
was O
started O
on O
insulin B-DRUG
during O
his O
hospitalization O
at O
[ O
* O
* O
Hospital3 O
25354 O
* O
* O
] O
and O
was O
continued O
on O
insulin B-DRUG
during O
his O

 O
hospitalization O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
. O


 O
9 O
. O
Family O
Contact O

 O
Patient O
's O
family O
contact O
is O
the O
patient O
's O
niece O
[ O
* O
* O
Name O
( O
NI O
) O
86401 O
* O
* O
] O

 O
[ O
* O
* O
Name O
( O
NI O
) O
86402 O
* O
* O
] O
. O
Her O
home O
number O
is O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
86403 O
* O
* O
] O
; O
work O
number O
is O

 O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
86404 O
* O
* O
] O
; O
cell O
number O
is O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
86405 O
* O
* O
] O
. O




 O
Medications O
on O
Admission O
: O

 O
TRANSFER O
MEDICATIONS O
: O

 O
1 O
. O
Amiodarone B-DRUG
400 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
2 O
. O
Nitroglycerin B-DRUG
ointment B-FOR
SS O
QID B-FRE
( O
SBP O
> O
120 O
2 O
in O
, O
110 O
- O
119 O
1.5 O
in O
, O

 O
100 O
- O
109 O
1 O
in O
, O
< O
100 O
wipe O
off O

 O
3 O
. O
Octreotide B-DRUG
100mcg B-STR
IV B-ROU
q8hr B-FRE

 I-FRE
4 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
PO B-ROU
q B-FRE
24 I-FRE

 I-FRE
5 O
. O
Zosyn B-DRUG
3.375 B-STR
IV B-ROU
q6hr B-FRE
( O
Day O
1 O
- O
[ O
* O
* O
2166 O
- O
4 O
- O
28 O
* O
* O
] O
) O

 O
6 O
. O
Tamsulosin B-DRUG
.4 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
7 O
. O
Neutra-Phos B-DRUG
2pack B-DOS
PO B-ROU
BID B-FRE

 I-FRE
8 O
. O
Bacitracin B-DRUG
ointment B-FOR
TOP B-ROU
daily B-FRE
prn I-FRE

 I-FRE
9 O
. O
Demerol B-DRUG
50 B-STR
mg I-STR
IM B-ROU
q4h B-FRE
prn I-FRE
pain B-REA

 I-REA
10 O
. O
Demerol B-DRUG
75 B-STR
mg I-STR
IM B-ROU
q B-FRE
4hr I-FRE

 I-FRE
11 O
. O
Zoldipem B-DRUG
10 B-STR
mg I-STR
qhs B-FRE
prn I-FRE

 I-FRE
12 O
. O
TPN B-DRUG
per O
nutrition O


 O
HOME O
MEDICATIONS O
: O

 O
1 O
. O
Lasix B-DRUG

 I-DRUG
2 O
. O
Tamsulosin B-DRUG


 I-DRUG
Discharge O
Medications O
: O

 O
deceased O


 O
Discharge O
Disposition O
: O

 O
[ O
* O
* O
Month/Day/Year O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
deceased O


 O
Discharge O
Condition O
: O

 O
deceased O


 O
Discharge O
Instructions O
: O

 O
deceased O


 O
Followup O
Instructions O
: O

 O
deceased O


                              O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
2437 O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(1 O
) O
2438 O
* O
* O
] O


 O
Completed O
by:[**2166 O
- O
5 O
- O
21 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2100 O
- O
9 O
- O
20 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2100 O
- O
9 O
- O
28 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2022 O
- O
11 O
- O
12 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
NEUROSURGERY O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
3227 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Metastatic O
brain O
lesions O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
9 O
- O
23 O
* O
* O
] O
: O
Right O
parietal O
Craniotomy O
for O
Mass O
resection O



 O
History O
of O
Present O
Illness O
: O

 O
Patient O
is O
a O
77 O
yo O
woman O
with O
PMHx O
sig O
. O
for O
breast O
cancer O

 O
diagnosed O
in O
[ O
* O
* O
11/2098 O
* O
* O
] O
s/p O
chemotherapy B-DRUG
followed O
by O
Herceptin B-DRUG
who O

 O
presented O
to O
[ O
* O
* O
Hospital O
* O
* O
] O
Hospital O
with O
seizures O
, O
was O
found O
to O
have O

 O
metastatic O
brain O
lesion O
, O
and O
transferred O
for O
XRT O
of O
metastatic O

 O
brain O
lesions O
. O


 O
Patient O
had O
a O
PET O
scan O
in O
[ O
* O
* O
8 O
- O
20 O
* O
* O
] O
that O
was O
normal O
except O
a O
low O

 O
attenuation O
lesion O
in O
R O
parietal O
lobe O
. O
  O
Outpatient O
brain O
MRI O
on O

 O
[ O
* O
* O
2100 O
- O
9 O
- O
17 O
* O
* O
] O
showed O
1.2 O
cm O
right O
parietal O
mass O
with O
extensive O
edema O

 O
c/w O
sole O
metastasis O
. O


 O
On O
Sunday O
evening O
, O
she O
presented O
with O
new O
seizures O
. O
  O
The O

 O
patient O
's O
son O
was O
sitting O
with O
her O
when O
she O
began O
to O
have O

 O
jerking O
of O
her O
left O
arm O
. O
  O
She O
recalls O
that O
her O
arm O
was O

 O
" O
trembling O
" O
and O
then O
she O
can O
not O
recall O
any O
further O
events O
. O
  O
She O

 O
then O
developed O
slurred O
speech O
and O
L O
facial O
droop O
. O
  O
She O
was O
taken O

 O
to O
the O
ED O
, O
where O
she O
was O
agitated O
and O
confused O
. O
  O
She O
received O

 O
ativan B-DRUG
4 B-STR
mg I-STR
, I-STR
phenytoin B-DRUG
loading B-DOS
, I-DOS
and O
dexamethason B-DRUG
6 B-STR
mg I-STR
IV B-ROU
. I-ROU
  O
She O

 O
was O
seen O
by O
Neurology O
and O
Oncology O
, O
who O
felt O
that O
the O
patient O

 O
would O
be O
candidate O
for O
gamma O
knife O
or O
neurosurgical O
removal O

 O
followed O
by O
XRT O
. O
  O
She O
is O
transferred O
for O
evaluation O
of O
these O

 O
treatments O
. O
  O
She O
has O
had O
no O
seizures O
since O
being O
hospitalized O
at O

 O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
. O
  O
She O
did O
receive O
at O
8 O
AM O
on O
[ O
* O
* O
2100 O
- O
9 O
- O
20 O
* O
* O
] O
for O
agitation B-REA
. I-REA

 O
She O
also O
received O
dilantin B-DRUG
IV B-ROU
and O
Decadron B-DRUG
IV B-ROU
. I-ROU
  O
Vitals O
prior O
to O

 O
transfer O
were O
: O
  O
97.4 O
124/66 O
65 O
20 O
100 O
% O
on O
5L O
. O


 O
History O
was O
confirmed O
by O
her O
HCP/son O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
88500 O
* O
* O
] O
. O



 O
Review O
of O
Systems O
: O

 O
( O
+ O
) O
Per O
HPI O

 O
( O
- O
) O
Denies O
fever O
, O
chills O
, O
night O
sweats O
, O
recent O
weight O
loss O
or O

 O
gain O
. O
Denies O
headache O
, O
vision O
problems O
, O
gait O
problems O

 O
dysarthria O
. O
  O
Denies O
sinus O
tenderness O
, O
rhinorrhea O
or O
congestion O
. O

 O
Denies O
chest O
pain O
or O
tightness O
, O
palpitations O
. O
Denies O
cough O
, O

 O
shortness O
of O
breath O
. O
Denies O
nausea O
, O
vomiting O
, O
diarrhea O
, O

 O
constipation O
, O
or O
abdominal O
pain O
. O
No O
dysuria O
, O
urinary O
frequency O
. O

 O
All O
other O
review O
of O
systems O
negative O
. O


 O
Past O
Medical O
History O
: O

 O
- O
Breast O
cancer O
, O
stage O
IIIb O
( O
T3N3M0 O
) O
, O
diagnosed O
in O
[ O
* O
* O
11/2098 O
* O
* O
] O
, O

 O
right O
breast O
mass O
with O
positive O
supraclavicular O
and O
axillary O

 O
nodes O
, O
ER O
neg O
, O
PR O
neg O
, O
HER-2/Neu O
positive O
, O
s/p O
chemotherapy B-DRUG
with O

 O
6 O
cycles O
of O
Taxotere B-DRUG
, I-DRUG
carboplatin B-DRUG
, I-DRUG
and O
Herceptin B-DRUG
followed O
by O

 O
Herceptin B-DRUG
completed O
3 O
weeks O
ago O
by O
Dr. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O

 O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
88501 O
* O
* O
] O
) O
. O


 O
Social O
History O
: O

 O
Patient O
lives O
with O
her O
husband O
, O
has O
4 O
grown O
children O
. O

 O
Tobacco O
: O
  O
none O

 O
ETOH O
: O
none O



 O
Family O
History O
: O

 O
No O
history O
of O
cancer O
. O


 O
Physical O
Exam O
: O

 O
Vitals O
: O
  O
96.7 O
, O
140/80 O
, O
62 O
, O
18 O
, O
100 O
% O
on O
4L O

 O
Gen O
: O
NAD O
, O
lethargic O
but O
arousable O
, O
oriented O
to O
self O
, O
" O
Monday O
, O
" O

 O
[ O
* O
* O
2099 O
* O
* O
] O
( O
not O
to O
month O
) O
, O
thought O
she O
was O
at O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
HEENT O
: O
PERRL O
, O
not O
cooperative O
for O
EOMI O
, O
MM O
slightly O
dry O
, O
sclera O

 O
anicteric O
, O
not O
injected O

 O
Neck O
: O
no O
LAD O
, O
no O
JVD O

 O
Cardiovascular O
: O
RRR O
normal O
s1 O
, O
s2 O
, O
no O
murmurs O
appreciated O

 O
Respiratory O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O

 O
rales O
or O
rhonchi O

 O
Abd O
: O
normoactive O
bowel O
sounds O
, O
soft O
, O
non-tender O
, O
non O
distended O

 O
Extremities O
: O
  O
sig O
. O
chronic O
lymphedema O
on O
RUE O
, O
no O
pedal O
edema O
, O
2 O
+ O

 O
DP O
pulses O

 O
Neurological O
: O
CN O
sig O
. O
for O
uncooperative O
EOMI O
and O
slight O

 O
nasolabial O
flattening O
on O
left O
, O
sensation O
normal O
, O
speech O
fluent O
, O

 O
slightly O
hyperreflexive O
LUE O
compared O
to O
RUE O
, O
upgoing O
Babinksi O
on O

 O
L O
and O
downgoing O
on O
R O
, O
MS O
[ O
* O
* O
1 O
- O
15 O
* O
* O
] O
in O
LUE O
, O
[ O
* O
* O
3 O
- O
15 O
* O
* O
] O
in O
RUE O
, O
4-/5 O
in O
LLE O
, O

 O
4+/5 O
in O
RLE O

 O
Integument O
: O
Warm O
, O
moist O

 O
Psychiatric O
: O
lethargic O
but O
arousable O
, O
pleasant O
, O
not O
anxious O



 O
PE O
UPON O
DISCHARGE O
: O

 O
awake O
, O
a+ox3 O

 O
PERRL O
, O
EOMI O

 O
face O
symmetric O
, O
tongue O
midline O

 O
full O
strengths O
R O
UE O
and O
LE O

 O
L O
tricep O
[ O
* O
* O
3 O
- O
15 O
* O
* O
] O
otherwise O
5/5 O

 O
L O
AT/[**Last O
Name O
( O
un O
) O
938 O
* O
* O
] O
0/5 O
G O
[ O
* O
* O
2 O
- O
12 O
* O
* O
] O

 O
left O
neglect O

 O
following O
all O
commands O


 O
Pertinent O
Results O
: O

 O
OSH O
labs O
, O
[ O
* O
* O
2100 O
- O
9 O
- O
19 O
* O
* O
] O
: O

      O
12.5 O

 O
5.4>-------<196 O

       O
37.5 O


 O
143 O
         O
15 O

 O
---------------- O
< O
132 O

 O
3.1 O
         O
1.4 O


 O
CK O
221 O
, O
CKMB O
2.1 O
, O
Trop O
I O
0.02 O
at O
[ O
* O
* O
2100 O
- O
9 O
- O
20 O
* O
* O
] O
11:57 O

 O
Phenytoin B-DRUG
level O
21.6 O
at O
[ O
* O
* O
2100 O
- O
9 O
- O
20 O
* O
* O
] O
5:15 O


 O
BCxs O
from O
[ O
* O
* O
9 O
- O
19 O
* O
* O
] O
NGTD O

 O
UCx O
form O
[ O
* O
* O
9 O
- O
19 O
* O
* O
] O
NGTD O


 O
OSH O
Imaging O
: O

 O
[ O
* O
* O
2100 O
- O
9 O
- O
7 O
* O
* O
] O
, O
PET O
CT O
: O
  O
No O
abnormal O
FDG-Avid O
abnormalities O
to O
suggest O

 O
recurrent O
or O
metastatic O
idsease O
. O
  O
Not O
previously O
localized O
focus O

 O
of O
low O
attenuation O
which O
is O
partially O
seen O
in O
the O
high O
posterior O

 O
right O
parietal O
lobe O
. O


 O
[ O
* O
* O
2100 O
- O
9 O
- O
17 O
* O
* O
] O
, O
MRI O
brain O
with O
or O
without O
contrast O
: O
  O
1.2 O
cm O
R O
parietal O

 O
intraparenchymal O
enhancing O
mass O
with O
extensive O
vasogenic O
edema O

 O
is O
hgih O
suspicious O
for O
metastatic O
neoplasm O
. O
  O
The O
lesion O
is O

 O
located O
with O
the O
post O
central O
gyrus O
and O
edema O
extends O
to O
the O

 O
motor O
cortex O
. O
  O
There O
is O
no O
associated O
sig O
. O
midline O
shift O
or O

 O
downward O
herniation O
. O


 O
[ O
* O
* O
2100 O
- O
9 O
- O
19 O
* O
* O
] O
, O
head O
CT O
without O
contrast O
: O
  O
Area O
of O
hypoattenuation O
in O

 O
the O
R O
post O
central O
gyrus O
with O
a O
nodular O
focus O
of O
hyperdensity O
. O


 O
[ O
* O
* O
2100 O
- O
9 O
- O
19 O
* O
* O
] O
, O
CXR O
: O
  O
Limited O
study O
not O
including O
portions O
of O
the O

 O
lower O
lobes O
with O
suggestion O
of O
cardiomegaly O
without O
failure O
. O


 O
MRI O
Brain O
[ O
* O
* O
9 O
- O
24 O
* O
* O
] O

 O
Right O
posterior O
frontal/parietal O
2-cm O
lesion O
at O
the O
surface O
of O

 O
the O
brain O
, O
likely O
dural-based O
metastatic O
lesions O
. O
Surrounding O

 O
edema O
is O
seen O
. O
  O
No O
midline O
shift O
or O
hydrocephalus O
. O
No O
change O
in O

 O
appearance O


 O
[ O
* O
* O
9 O
- O
25 O
* O
* O
] O
Head O
CT O
: O
IMPRESSION O
: O
Right O
frontoparietal O
post-surgical O

 O
changes O
with O
small O
amount O
of O
blood O
products O
and O
focus O
of O
air O

 O
within O
the O
post-surgical O
cavity O
with O
surrounding O
vasogenic O

 O
edema O
. O
Pneumocephalus O
over O
the O
right O
frontal O
lobe O
. O
  O
Mild O
right O

 O
cerebral O
hemispheric O
edema O
with O
effacement O
of O
the O
sulci O
. O
No O

 O
midline O
shift O
. O



 O
[ O
* O
* O
9 O
- O
25 O
* O
* O
] O
Head O
MRI O
: O
IMPRESSION O
: O
Limited O
study O
with O
no O

 O
post-gadolinium O
T1 O
images O
obtained O
for O
assessment O
of O
residual O

 O
mass O
. O
No O
diffusion O
images O
. O
Blood O
products O
and O
postoperative O

 O
changes O
in O
the O
right O
parietal O
region O
are O
as O
expected O
. O
For O
better O

 O
assessment O
, O
consider O
repeat O
gadolinium O
study O
. O


 O
[ O
* O
* O
9 O
- O
27 O
* O
* O
] O
Head O
CT O
/c O
contrast O
: O
IMPRESSION O
: O

 O
1 O
. O
Post-surgical O
changes O
, O
similar O
in O
appearance O
with O
small O

 O
amount O
of O

 O
hemorrhagic O
products O
, O
edema O
and O
pneumocephalus O
as O
expected O
. O
No O

 O
new O
hemorrhage O
or O
shift O
of O
normally O
midline O
structures O
. O
2 O
. O
No O

 O
definite O
abnormal O
enhancement O
. O
Please O
note O
that O
MRI O
is O
more O

 O
sensitive O
for O
detection O
of O
residual O
disease O
. O



 O
Brief O
Hospital O
Course O
: O

 O
77 O
yo O
woman O
with O
PMHx O
sig O
. O
for O
breast O
cancer O
diagnosed O
in O

 O
[ O
* O
* O
11/2098 O
* O
* O
] O
s/p O
chemotherapy B-DRUG
followed O
by O
Herceptin B-DRUG
who O
presented O
to O

 O
[ O
* O
* O
Hospital O
* O
* O
] O
Hospital O
with O
seizures O
, O
was O
found O
to O
have O
metastatic O

 O
brain O
lesion O
, O
and O
transferred O
for O
XRT O
of O
metastatic O
brain O

 O
lesions O
. O

 O
. O

 O
# O
Metastatic B-REA
breast I-REA
cancer I-REA
to I-REA
the I-REA
brain/Seizure B-REA
: I-REA
The O
patient O
was O

 O
continued O
on O
decadron B-DRUG
and O
phenytoin B-DRUG
with O
a O
therapeutic O
level O
. O

 O
She O
was O
seen O
by O
the O
neuro-oncology O
service O
, O
neurosurgery O

 O
service O
, O
and O
the O
radiation O
oncology O
service O
. O
After O
long O

 O
discussion O
with O
her O
two O
sons O
, O
the O
patient O
opted O
for O

 O
neurosurgical O
treatment O
of O
her O
solitary O
brain O
metastasis O
and O
was O

 O
transferred O
on O
the O
neurosurgery O
service O
on O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
on O
[ O
* O
* O
9 O
- O
23 O
* O
* O
] O
. O

 O
An O
initial O
speech O
and O
swallowing O
study O
obtained O
while O
the O

 O
patient O
was O
recommended O
soft O
solids O
. O

 O
. O

 O
# O
Encephalopathy B-ADE
, I-ADE
metabolic O
: O
  O
The O
patient O
was O
initially O

 O
extremely O
lethargic O
, O
although O
arousable O
and O
able O
to O
follow O

 O
commands O
, O
which O
was O
thought O
to O
be O
secondary O
to O
the O
large O
doses O

 O
of O
ativan B-DRUG
that O
she O
received O
for O
her B-REA
seizure I-REA
. I-REA
By O
the O
second O

 O
hospital O
day O
the O
patient O
's O
mental O
status O
was O
completely O
back O
to O

 O
baseline O
and O
she O
remained O
oriented O
and O
interactive O
. O

 O
. O

 O
# O
Acute O
renal O
failure O
: O

 O
- O
IVFs B-DRUG

 I-DRUG
- O
monitor O
Cr O



 O
The O
patient O
was O
trasnferred O
to O
the O
neurosurgery O
service O
on O
the O

 O
evening O
of O
[ O
* O
* O
9 O
- O
23 O
* O
* O
] O
from O
the O
[ O
* O
* O
Hospital O
Ward O
Name O
516 O
* O
* O
] O
in O
order O
to O
undergo O

 O
surgical O
resection O
of O
her O
brain O
mass O
. O
She O
had O
an O
MRI O
WAND O
study O

 O
overnight O
on O
[ O
* O
* O
9 O
- O
23 O
* O
* O
] O
for O
surgical O
planning O
with O
plan O
for O
OR O
[ O
* O
* O
9 O
- O
24 O
* O
* O
] O

 O
am O
. O
On O
the O
morning O
of O
[ O
* O
* O
9 O
- O
24 O
* O
* O
] O
she O
was O
brought O
to O
the O
pre-op O
area O

 O
however O
her O
case O
had O
to O
be O
reshceduled O
for O
the O
evening O
. O
  O
She O

 O
remained O
stable O
on O
the O
floor O
while O
awaiting O
her O
operation O
. O

 O
Surgery O
was O
performed O
without O
complication O
. O
She O
was O
admitted O
to O

 O
the O
ICU O
post O
op O
for O
close O
neurological O
monitoring O
. O
The O
patient O
's O

 O
post-operative O
neurologic O
examination O
remained O
unchanged O
. O

 O
Post-op O
MRI O
revealed O
no O
evidence O
of O
new O
CVA O
or O
residual O
tumor O
. O


 O
On O
[**9 O
- O
25**]- O
[ O
* O
* O
9 O
- O
27 O
* O
* O
] O
she O
was O
neurologically O
stable O
. O
She O
was O
cleared O

 O
for O
transfer O
to O
the O
floor O
. O
Post O
operative O
imaging O
was O
performed O

 O
which O
revealed O
post O
operative O
changes O
and O
no O
hemorrhage O
. O
PT O
and O

 O
OT O
were O
consulted O
and O
recommended O
discharge O
to O
a O
rehab O
facility O
. O


 O
On O
[ O
* O
* O
9 O
- O
28 O
* O
* O
] O
she O
was O
cleared O
for O
discharge O
to O
rehab O
facility O
pending O

 O
bed O
availability O
. O


 O
Medications O
on O
Admission O
: O

 O
Home O
medications O
: O

 O
Per O
OSH O
records O
( O
via O
pharmacy O
phone O
call O
) O
, O
ativan B-DRUG
0.5 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
prn O

 O
anxiety B-REA


 I-REA
Medications O
on O
transfer O
: O

 O
Phenytoin B-DRUG
100 B-STR
mg I-STR
TID B-FRE

 I-FRE
Dexamethasone B-DRUG
4 B-STR
mg I-STR
q6 B-FRE
hrs I-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
atenolol B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
fever/pain B-REA
. I-REA

 O
4 O
. O
bisacodyl B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
insulin B-DRUG
lispro I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Subcutaneous B-ROU
ASDIR B-FRE
( O
AS O
DIRECTED O
) O
. O

 O
8 O
. O
phenytoin B-DRUG
sodium I-DRUG
extended I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR

 I-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
levetiracetam B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
dexamethasone B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1.5 B-DOS
Tablets B-FOR
PO B-ROU
q6hrs B-FRE
( O
) O
for O
3 O

 O
days O
. O

 O
11 O
. O
dexamethasone B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
q6hrs B-FRE
( O
) O

 O
for O
3 B-DUR
days I-DUR
. I-DUR

 O
12 O
. O
dexamethasone B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
q6hrs B-FRE
( O
) O
for O
3 O

 O
days O
. O

 O
13 O
. O
heparin B-DRUG
( I-DRUG
porcine I-DRUG
) I-DRUG
5,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Injection B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
14 O
. O
butalbital-acetaminophen-caff B-DRUG
50 B-STR
- I-STR
325 I-STR
- I-STR
40 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
[ O
* O
* O
12 O
- O
12 O
* O
* O
] O

 O
Tablets B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
15 O
. O
heparin B-DRUG
, I-DRUG
porcine I-DRUG
( I-DRUG
PF I-DRUG
) I-DRUG
10 B-STR
unit/mL I-STR
Syringe B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML B-FOR

 I-FOR
Intravenous B-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
line B-REA
flush I-REA
. I-REA

 O
16 O
. O
heparin B-DRUG
lock I-DRUG
flush I-DRUG
( I-DRUG
porcine I-DRUG
) I-DRUG
100 B-STR
unit/mL I-STR
Syringe B-FOR
Sig O
: O
Five B-DOS

 I-DOS
( I-DOS
5 I-DOS
) I-DOS
ML I-DOS
Intravenous B-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
DE-ACCESSING B-REA

 I-REA
port I-REA
. I-REA



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
1107 O
* O
* O
] O
[ O
* O
* O
Hospital O
* O
* O
] O
Hospital O
- O
[ O
* O
* O
Location O
( O
un O
) O
38 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Right O
parietal O
brain O
mass O



 O

Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Confused O
- O
sometimes O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
requires O
assistance O
or O
aid O
( O
walker O

 O
or O
cane O
) O
. O



 O
Discharge O
Instructions O
: O

 O
? O
? O
? O
? O
? O
? O
	 O
Have O
a O
friend/family O
member O
check O
your O
incision O
daily O
for O

 O
signs O
of O
infection O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Take O
your O
pain B-REA
medicine O
as O
prescribed O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Exercise O
should O
be O
limited O
to O
walking O
; O
no O
lifting O
, O
straining O
, O

 O
or O
excessive O
bending O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
may O
wash O
your O
hair O
only O
after O
sutures O
and/or O
staples O
have O

 O
been O
removed O
. O
If O
your O
wound O
closure O
uses O
dissolvable O
sutures O
, O

 O
you O
must O
keep O
that O
area O
dry O
for O
10 O
days O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
may O
shower O
before O
this O
time O
using O
a O
shower O
cap O
to O
cover O

 O
your O
head O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Increase O
your O
intake O
of O
fluids O
and O
fiber O
, O
as O
narcotic B-DRUG
pain I-DRUG

 I-DRUG
medicine I-DRUG
can O
cause O
constipation O
. O
We O
generally O
recommend O
taking O

 O
an O
over B-DRUG
the I-DRUG
counter I-DRUG
stool I-DRUG
softener I-DRUG
, I-DRUG
such O
as O
Docusate B-DRUG
( I-DRUG
Colace I-DRUG
) I-DRUG

 I-DRUG
while O
taking O
narcotic B-DRUG
pain I-DRUG
medication I-DRUG
. I-DRUG

 O
? O
? O
? O
? O
? O
? O
	 O
Unless O
directed O
by O
your O
doctor O
, O
do O
not O
take O
any O

 O
anti-inflammatory O
medicines O
such O
as O
Motrin B-DRUG
, I-DRUG
Aspirin B-DRUG
, I-DRUG
Advil B-DRUG
, I-DRUG
and O

 O
Ibuprofen B-DRUG
etc O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
If O
you O
have O
been O
prescribed O
Dilantin B-DRUG
( I-DRUG
Phenytoin I-DRUG
) I-DRUG
for O

 O
anti-seizure B-REA
medicine O
, O
take O
it O
as O
prescribed O
and O
follow O
up O
with O

 O
laboratory O
blood O
drawing O
in O
one O
week O
. O
  O
This O
can O
be O
drawn O
at O
your O

 O
PCP??????s O
office O
, O
but O
please O
have O
the O
results O
faxed O
to O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
87 O
* O
* O
] O
. O

 O
If O
you O
have O
been O
discharged O
on O
Keppra B-DRUG
( O
Levetiracetam O
) O
, O
you O
will O

 O
not O
require O
blood O
work O
monitoring O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Clearance O
to O
drive O
and O
return O
to O
work O
will O
be O
addressed O
at O

 O
your O
post-operative O
office O
visit O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Make O
sure O
to O
continue O
to O
use O
your O
incentive O
spirometer O
while O

 O
at O
home O
, O
unless O
you O
have O
been O
instructed O
not O
to O
. O


 O
CALL O
YOUR O
SURGEON O
IMMEDIATELY O
IF O
YOU O
EXPERIENCE O
ANY O
OF O
THE O

 O
FOLLOWING O



 O
? O
? O
? O
? O
? O
? O
	 O
New O
onset O
of O
tremors O
or O
seizures O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Any O
confusion O
or O
change O
in O
mental O
status O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Any O
numbness O
, O
tingling O
, O
weakness O
in O
your O
extremities O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Pain O
or O
headache O
that O
is O
continually O
increasing O
, O
or O
not O

 O
relieved O
by O
pain O
medication O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Any O
signs O
of O
infection O
at O
the O
wound O
site O
: O
redness O
, O
swelling O
, O

 O
tenderness O
, O
or O
drainage O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Fever O
greater O
than O
or O
equal O
to O
101 O
? O
? O
? O
? O
? O
? O
F. O



 O
Followup O
Instructions O
: O

 O
FOLLOW O
UP O
APPOINTMENT O
INSTRUCTIONS O


 O
? O
? O
? O
? O
? O
? O
You O
have O
an O
appointment O
in O
the O
Brain O
[ O
* O
* O
Hospital O
341 O
* O
* O
] O
Clinic O
on O
[ O
* O
* O
2100 O
- O
10 O
- O
4 O
* O
* O
] O

 O
at O
4 O
pm O

 O
. O
  O
The O
Brain O
[ O
* O
* O
Hospital O
341 O
* O
* O
] O
Clinic O
is O
located O
on O
the O
[ O
* O
* O
Hospital O
Ward O
Name O
516 O
* O
* O
] O
of O

 O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
, O
in O
the O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Building O
, O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
. O
This O
is O
a O

 O
multi-disciplinary O
appointment O
. O
Their O
phone O
number O
is O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1844 O
* O
* O
] O
. O
Please O
call O
if O
you O
need O
to O
change O
your O

 O
appointment O
, O
or O
require O
additional O
directions O
. O


 O
Please O
call O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1669 O
* O
* O
] O
if O
you O
have O
questions O
or O
problems O

 O
related O
to O
your O
surgery O
. O




 O
Completed O
by:[**2100 O
- O
9 O
- O
28 O
* O
* O
] O

Name O
: O
  O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
, O
[ O
* O
* O
Known O
firstname O
* O
* O
] O
V. O
                   O
Unit O
No O
: O
   O
[ O
* O
* O
Numeric O
Identifier O
11193 O
* O
* O
] O


 O
Admission O
Date O
: O
  O
[ O
* O
* O
2122 O
- O
4 O
- O
15 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2122 O
- O
8 O
- O
19 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2075 O
- O
12 O
- O
28 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Penicillins B-DRUG
/ O
Benzocaine B-DRUG



 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
2648 O
* O
* O
] O

 O
Addendum O
: O

 O
He O
remained O
in O
hospital O
after O
discovering O
that O
liver B-REA
abscesses I-REA

 I-REA
grew I-REA
sparse I-REA
mucor I-REA
. I-REA
ID O
recommended O
posoconazole B-DRUG
in O
addition O
to O

 O
ambisone B-DRUG
. I-DRUG
This O
was O
started O
and O
he O
continued O
on O
this O
for O
the O

 O
remainder O
of O
hospital O
course O
. O
The O
decision O
was O
made O
to O
keep O
him O

 O
hospitalized O
until O
re-transplanted O
. O

      O
Psychiatry O
was O
consulted O
for O
depression B-REA
. I-REA
Dextroamphetamine B-DRUG

 I-DRUG
was O
recommended O
as O
first O
choice O
with O
zoloft B-DRUG
being O
an O
alternative O

 O
[ O
* O
* O
Doctor O
Last O
Name O
932 O
* O
* O
] O
. O
Zoloft B-DRUG
was O
started O
and O
dose O
increase O
during O
remainder O
of O

 O
hospital O
stay O
with O
some O
improvement O
in O
mood O
. O

      O
2 B-DOS
units I-DOS
of O
PRBC B-DRUG
were O
given O
for O
a O
hct B-REA
of I-REA
22 I-REA
on O
[ O
* O
* O
6 O
- O
4 O
* O
* O
] O
. O
Epogen B-DRUG

 I-DRUG
was O
continued O
. O
On O
[ O
* O
* O
6 O
- O
5 O
* O
* O
] O
an O
abd O
ct O
revealed O
mod O
ascites O
for O
which O

 O
hepatology O
was O
consulted O
. O
A O
paracentesis O
was O
performed O
. O
He O
was O

 O
cultured O
for O
a O
temp O
of O
101.7 O
on O
[ O
* O
* O
6 O
- O
7 O
* O
* O
] O
for O
which O
the O
c-line O
was O

 O
changed O
. O
The O
tip O
was O
neg O
for O
growth O
as O
well O
as O
urine O
and O
blood O
. O

      O
On O
[ O
* O
* O
6 O
- O
9 O
* O
* O
] O
he O
grew O
gram B-REA
+ I-REA
cocci I-REA
( I-REA
VRE-enterococcus I-REA
faecium)only I-REA

 I-REA
sensitive O
to O
linezolid B-DRUG
. I-DRUG
Given O
past O
h/o O
myelosuppression B-REA
, I-REA
he O
was O

 O
started O
on O
Tigecycline B-DRUG
. I-DRUG
Tigecycline B-DRUG
continued O
for B-DUR
16 I-DUR
days I-DUR
. I-DUR
He O

 O
spiked O
a O
temp O
on O
[ O
* O
* O
6 O
- O
12 O
* O
* O
] O
and O
again O
the O
c-line O
was O
changed O
over O
a O

 O
wire O
. O
A O
rpt O
ABD O
CT O
revealed O
two O
fluid O
collections O
within O
the O

 O
left O
and O
right O
lobes O
of O
the O
liver O
. O
The O
collection O
within O
the O

 O
right O
lobe O
of O
the O
liver O
appeared O
to O
have O
increased O
in O
size O
, O

 O
measuring O
5.6 O
x O
4.1 O
cm O
. O
The O
left O
liver O
lobe O
collection O
was O

 O
essentially O
unchanged O
. O
Bilateral O
pleural O
effusions O
, O
greater O
on O

 O
the O
left O
, O
were O
decreased O
slightly O
and O
a O
large O
amount O
of O
ascites O
, O

 O
which O
was O
decreased O
slightly O
. O
There O
was O
evidence O
of O
peritoneal O

 O
enhancement O
. O
The O
fluid O
extended O
into O
the O
inguinal O
canals O
, O
and O

 O
was O
loculated O
on O
the O
right O
side O
. O
Ceftriaxone B-DRUG
which O
was O
used O
for O

 O
E.coli B-REA
was O
stopped O
after O
18 B-DUR
days I-DUR
and O
  O
Meropenum B-DRUG
was O
started O
for O

 O
E.coli B-REA
& O
Strep B-REA
veridins I-REA
to O
broaden O
coverage O
. O
Dapto B-DRUG
was O
stopped O
. O

 O
He O
remained O
on O
meromenum B-DRUG
for B-DUR
38 I-DUR
days I-DUR
. I-DUR
He O
continued O
to O
spike O

 O
temps O
. O

      O

Repeat O
paracentesis O
was O
done O
on O
[ O
* O
* O
6 O
- O
15 O
* O
* O
] O
. O
Cultures O
were O

 O
negative O
. O
On O
[ O
* O
* O
6 O
- O
18 O
* O
* O
] O
, O
he O
was O
removed O
from O
the O
Transplant O
list O
given O

 O
multidrug O
resistant O
multifocal O
liver O
abscesses O
, O
poor O
nutritional O

 O
status O
despite O
J O
tube O
feedings O
, O
debilitation O
and O
poor O
prior O

 O
outcomes O
in O
other O
patients O
with O
similar O
setting O
. O
On O
[ O
* O
* O
6 O
- O
16 O
* O
* O
] O
blood O

 O
cultures O
grew O
yeast O
. O
Ambisone B-DRUG
was O
started O
[ O
* O
* O
6 O
- O
19 O
* O
* O
] O
. O
Repeat O
blood O
and O

 O
drain O
cultures O
were O
sent O
. O
A O
TTE O
was O
done O
to O
r/o O
vegetations O
. O

 O
This O
was O
negative O
. O
An O
Ophthalmology O
exam O
was O
negative O
as O
well O
. O

 O
On O
[ O
* O
* O
6 O
- O
23 O
* O
* O
] O
a O
repeat O
abd O
CT O
revealed O
two O
large O
fluid O
collections O

 O
within O
the O
left O
and O
right O
lobes O
of O
the O
liver O
. O
The O
left O
lobe O

 O
fluid O
collection O
had O
decreased O
in O
size O
, O
whereas O
the O
right O
lobe O

 O
fluid O
collection O
had O
increased O
in O
size O
. O
A O
large O
well O

 O
circumscribed O
fluid O
collection O
extending O
down O
the O
right O
inguinal O

 O
canal O
into O
the O
right O
scrotum O
was O
seen O
. O
A O
head O
CT O
was O
done O
to O
r/o O

 O
infection O
. O
This O
was O
negative O
. O

      O
On O
[ O
* O
* O
6 O
- O
24 O
* O
* O
] O
an O
8 O
Fr O
catheter O
was O
repostitioned O
in O
RLQ O
. O
Culure O
of O

 O
the O
fluid O
grew O
ENTEROCOCCUS O
SP O
, O
CITROBACTER O
FREUNDII O
COMPLEX O
. O

 O
SPARSE O
GROWTH O
, O
NON-FERMENTER O
, O
NOT O
PSEUDOMONAS O
AERUGINOSA O
. O

 O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
* O
* O
] O
( O
TORULOPSIS O
) O
GLABRATA.MODERATE O
GROWTH O
and O
CITROBACTER O

 O
FREUNDII O
COMPLEX O
. O
Blood O
cultures O
from O
[ O
* O
* O
6 O
- O
23 O
* O
* O
] O
continued O
to O
grow O

 O
yeast O
and O
VRE O
. O
Blood O
cultures O
were O
done O
q O
3 O
days O
. O
  O
On O
[ O
* O
* O
7 O
- O
1 O
* O
* O
] O
CT O

 O
findings O
showed O
new O
area O
of O
decreased O
enhancement O
in O
segment O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O

 O
of O
the O
liver O
, O
worrisome O
for O
a O
new O
area O
of O
ischemia/infarction O
. O

 O
Internal O
air O
bubbles O
were O
present O
, O
and O
superinfection O
of O
this O

 O
area O
could O
not O
be O
excluded O
. O
The O
area O
did O
not O
appear O
to O
have O

 O
adequate O
liquification O
for O
percutaneous O
catheter O
drainage O
. O
Two O

 O
collections O
in O
left O
lobe O
of O
the O
liver O
had O
appropriately O

 O
positioned O
drainage O
catheters O
appeared O
slightly O
smaller O
and O
a O

 O
collection O
in O
right O
lobe O
of O
the O
liver O
, O
which O
contained O
an O

 O
appropriately O
positioned O
catheter O
was O
unchanged O
in O
size O
. O
On O
[ O
* O
* O
6 O
- O
30 O
* O
* O
] O

 O
Dapto B-DRUG
was O
restarted O
as O
well O
as O
gentamycin B-DRUG
for O
synergy O
to O
attempt O

 O
to O
clear O
VRE B-REA
. I-REA

 O

Ambisone B-DRUG
was O
changed O
to O
Caspo B-DRUG
on O
[ O
* O
* O
7 O
- O
3 O
* O
* O
] O
. O
On O
[**7 O
- O
7**],the O
catheter O
in O

 O
right O
lobe O
of O
liver O
was O
advanced O
several O
centimeters O
with O

 O
aspiration O
of O
approximately O
20 O
cc O
of O
purulent O
material O
. O
This O

 O
appeared O
in O
continuity O
with O
multiple O
bilomas/dilated O
ducts O
, O

 O
which O
were O
slightly O
more O
prominent O
than O
on O
the O
previous O
study O
. O

 O
ID O
recommended O
a O
TTE O
to O
r/o O
vegetation O
, O
but O
the O
patient O
refused O

 O
TTE O
. O

      O
Synercid B-DRUG
was O
started O
perioperatively O
for O
VRE B-REA
coverage I-REA
. I-REA
On O

 O
[ O
* O
* O
7 O
- O
17 O
* O
* O
] O
he O
was O
taken O
to O
the O
OR O
for O
irrigation O
and O
debridement O
of O

 O
hepatic O
abscess O
, O
right O
lobe O
by O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
. O
40 O
- O
50cc O
of O

 O
purulent O
, O
bile O
stained O
drainage O
was O
removed O
. O
A O
large O
drain O
was O

 O
left O
in O
place O
and O
placed O
to O
suction O
. O
He O
tolerated O
this O
procedure O

 O
well O
. O
Blood O
cultures O
and O
cline O
tip O
on O
[ O
* O
* O
7 O
- O
7 O
* O
* O
] O
were O
negative O
. O

 O
Cultures O
were O
negative O
until O
[ O
* O
* O
7 O
- O
14 O
* O
* O
] O
. O
He O
was O
relisted O
for O
liver O

 O
transplantation O
. O
Subsequent O
cultures O
grew O
  O
enterococcus O
faeceum O
. O

 O
Repeat O
cultures O
were O
negative O
, O
but O
then O
reculture O
grew O

 O
enterococcus O
faeceum O
and O
presumed O
torulopsis O
glabrata O
( O
per O

 O
ID).Levaquin B-DRUG
was O
added O
for O
additional O
gram B-REA
negative I-REA
coverage I-REA
. I-REA

        O
Repeat O
Abd O
CT O
showed O
interval O
placement O
of O
JP O
drain O
into O

 O
the O
right O
lobe O
of O
the O
liver O
with O
associated O
focal O
subcutaneous O

 O
air/surgical O
emphysema O
. O
Air O
containing O
abscess O
in O
the O
right O
lobe O

 O
superior O
to O
this O
appeared O
to O
have O
increased O
in O
size O
. O

 O
Splenomegaly O
and O
ascites O
were O
again O
noted O
. O
On O
[ O
* O
* O
7 O
- O
21 O
* O
* O
] O
, O
he O
underwent O

 O
successful O
CT-guided O
pigtail O
cath O
placement O
in O
enlarging O
fluid O

 O
collection O
at O
the O
junction O
of O
segments O
8 O
and O
4A O
. O



      O
On O
[ O
* O
* O
7 O
- O
29 O
* O
* O
] O
abd O
CT O
revealed O
1 O
) O
S/p O
multiple O
drains O
. O
Confluent O

 O
biloma/abscess O
involving O
segment O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
and O
VIII O
of O
the O
liver O
, O
the O

 O
component O
in O
the O
right O
lobe O
is O
smaller O
compared O
to O
the O
CT O
of O

 O
[ O
* O
* O
2122 O
- O
7 O
- O
21 O
* O
* O
] O
. O

 O
2 O
) O
Small O
bilateral O
pleural O
effusions O
. O

 O
3 O
) O
Persisting O
ascites O
, O
predominantly O
left-sided O
and O
partially O

 O
loculated O
. O

 O
4 O
) O
Nonvisualized O
proper O
hepatic O
artery O
, O
likely O
occluded O
. O
Partial O

 O
SMV O
occlusion O
. O

 O
5 O
) O
Prominent O
right-sided O
hydrocele O
. O

 O
6 O
) O
Splenomegaly O
. O

      O
Abscess O
cultures O
persistently O
grew O
VRE O
and O
[ O
* O
* O
Female O
First O
Name O
( O
un O
) O
* O
* O
] O

 O
( O
TORULOPSIS O
) O
GLABRATA O
. O
P. O

      O
On O
[ O
* O
* O
7 O
- O
31 O
* O
* O
] O
  O
Caspofungin B-DRUG
and O
meropenum B-DRUG
was O
stopped O
. O
The O
2 O

 O
drains O
in O
the O
left O
lobe O
were O
removed O
. O
A O
repeat O
CT O
on O
[ O
* O
* O
8 O
- O
3 O
* O
* O
] O

 O
revealed O
collection O
in O
left O
lobe O
and O
a O
drain O
was O
placed O
into O

 O
this O
site O
and O
10cc O
was O
sent O
for O
culture O
. O
Results O
are O
pending O
. O

      O
On O
[ O
* O
* O
8 O
- O
6 O
* O
* O
] O
the O
capped O
PTC O
drain O
fell O
out O
with O
no O
adverse O

 O
effects O
. O
Developed O
diarrhea O
after O
tube O
feed O
formula O
changed O
. O

 O
Stool O
was O
sent O
for O
c.diff O
. O
Stool O
neg O
on O
[ O
* O
* O
8 O
- O
5 O
* O
* O
] O
and O
pending O
for O

 O
[ O
* O
* O
8 O
- O
6 O
* O
* O
] O

      O
On O
[ O
* O
* O
8 O
- O
14 O
* O
* O
] O
the O
right O
liver O
abscess O
catheter O
fell O
out O
. O
This O

 O
area O
was O
then O
loosely O
packed O
with O
normal B-DRUG
saline I-DRUG
moist O
gauze O
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O

 O
Potassium O
was O
consistently O
running O
high O
. O
A O
renal O
consult O
was O

 O
obtained O
. O
Bactrim B-DRUG
and O
synercid B-DRUG
were O
felt O
to O
be O
contributing O
to O

 O
hyperkalemia B-ADE
. I-ADE
Bactrim B-DRUG
SS O
was O
decreased O
to O
3x/week B-FRE
and O
the O
tube O

 O
feeding O
was O
changed O
back O
to O
1/2 B-STR
strength O
Nepro B-DRUG
. I-DRUG
Potassium O

 O
decreased O
within O
the O
normal O
range O
. O

      O
In O
summary O
, O
this O
hospital O
course O
was O
extremely O
long O
and O

 O
complicated O
. O
He O
has O
remained O
afebrile O
for O
last O
few O
weeks O
. O

 O

Posoconazole B-DRUG
, I-DRUG
Levaquin B-DRUG
, I-DRUG
Synercid B-DRUG
will O
continue O
. O
Rifaximin B-DRUG
is O
to O

 O
prevent B-REA
encephalopathy I-REA
. I-REA
Bactrim B-DRUG
is O
for O
pcp B-REA
[ O
* O
* O
Name O
Initial O
( O
PRE O
) O
2515 O
* O
* O
] O
. O
The O
plan O

 O
is O
to O
send O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
to O
[ O
* O
* O
Hospital O
* O
* O
] O
Rehab O
Hospital O
with O
the O
hope O
of O

 O
building O
him O
up O
nutritionally O
and O
increasing O
his O
physical O

 O
strength O
and O
independence O
with O
the O
hope O
of O
keeping O
him O
afebrile O

 O
while O
awaiting O
re-transplantation O
of O
a O
second O
liver O
. O
  O
He O
will O
be O

 O
followed O
by O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
( O
Transplant O
Surgeon O
) O
and O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
25 O
* O
* O
] O
( O
ID O
) O
. O





 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
polymicrobial O
liver O
abscesses-ecoli O
, O
mucor O
, O
yeast O
, O
vre O
[ O
* O
* O
12 O
- O
18 O
* O
* O
] O

 O
ischemic O
biliary O
ducts O


 O
Pertinent O
Results O
: O

 O
Hematology O

   O
COMPLETE O
BLOOD O
COUNT O
WBC O
RBC O
Hgb O
Hct O
MCV O
MCH O
MCHC O
RDW O
Plt O
Ct O

 O
[ O
* O
* O
2122 O
- O
8 O
- O
17 O
* O
* O
] O
05:15AM O
    O
2.4 O
* O
3.14 O
* O
9.0 O
* O
26.4 O
* O
84 O
28.7 O
34.2 O
20.7 O
* O

 O
68 O
* O

   O
DIFFERENTIAL O
Neuts O
Bands O
Lymphs O
Monos O
Eos O
Baso O
Atyps O
Metas O

 O
Myelos O

 O
[ O
* O
* O
2122 O
- O
5 O
- O
2 O
* O
* O
] O
06:36PM O
    O
87 O
* O
3 O
3 O
* O
4 O
1 O
0 O
1 O
* O
1 O
* O
0 O

   O
RED O
CELL O
MORPHOLOGY O
Hypochr O
Anisocy O
Poiklo O
Macrocy O
Microcy O

 O
Polychr O
Ovalocy O
Schisto O

 O
[ O
* O
* O
2122 O
- O
5 O
- O
2 O
* O
* O
] O
06:36PM O
    O
1 O
+ O
1 O
1 O
+ O
OCCASIONAL O
NORMAL O
2 O
+ O
OCCASIONAL O


 O
1 O
1 O
+ O

 O
MANUAL O


   O
BASIC O
COAGULATION O
( O
PT O
, O
PTT O
, O
PLT O
, O
INR O
) O
PT O
PTT O
Plt O
Smr O
Plt O
Ct O

 O
INR(PT O
) O

 O
[ O
* O
* O
2122 O
- O
8 O
- O
17 O
* O
* O
] O
05:15AM O
          O
68 O
* O

   O
BASIC O
COAGULATION O
( O
FIBRINOGEN O
, O
DD O
, O
TT O
, O
REPTILASE O
, O
BT O
) O
Fibrino O

 O
[ O
* O
* O
2122 O
- O
5 O
- O
17 O
* O
* O
] O
04:17AM O
    O
523 O
* O


 O
Chemistry O

   O
RENAL O
& O
GLUCOSE O
Glucose O
UreaN O
Creat O
Na O
K O
Cl O
HCO3 O
AnGap O

 O
[ O
* O
* O
2122 O
- O
8 O
- O
17 O
* O
* O
] O
05:15AM O
    O
162 O
* O
34 O
* O
0.7 O
133 O
4.4 O
99 O
29 O
9 O

   O
ENZYMES O
& O
BILIRUBIN O
ALT O
AST O
LD(LDH O
) O
CK(CPK O
) O
AlkPhos O
Amylase O

 O
TotBili O
DirBili O

 O
[ O
* O
* O
2122 O
- O
8 O
- O
18 O
* O
* O
] O
06:00AM O
          O
18 O
* O
1 O

 O
1 O
VERIFIED O
BY O
REPLICATE O
ANALYSIS O




 O

Discharge O
Medications O
: O

 O
1 O
. O
Heparin B-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
5,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Injection B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
2 O
. O
Albuterol B-DRUG
90 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Puff B-FOR

 I-FOR
Inhalation B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
3 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Epoetin B-DRUG
Alfa I-DRUG
10,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Injection B-FOR

 I-FOR
QMOWEFR B-FRE
( I-FRE
Monday I-FRE
-Wednesday-Friday I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Posaconazole B-DRUG
  O
Sig O
: O
Two B-STR
Hundred I-STR
( I-STR
200 I-STR
) I-STR
mg I-STR
  O
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE


 O
6 O
. O
Rifaximin B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Sertraline B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
8 O
. O
Nifedipine B-DRUG
10 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Furosemide B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Psyllium B-DRUG
     O
Packet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Packet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Sirolimus B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
12 O
. O
Trimethoprim-Sulfamethoxazole B-DRUG
80 B-STR
- I-STR
400 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
3X/WEEK B-FRE
( I-FRE
MO I-FRE
, I-FRE
WE I-FRE
, I-FRE
FR I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Heparin B-DRUG
Lock I-DRUG
Flush I-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
100 B-STR
unit/mL I-STR
Syringe B-FOR
Sig O
: O
Two B-DOS

 I-DOS
( I-DOS
2 I-DOS
) I-DOS
ML I-DOS
Intravenous B-ROU
  O
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
: I-FRE
picc B-REA
line I-REA
care I-REA
. I-REA

 O
14 O
. O
Levofloxacin B-DRUG
in I-DRUG
D5W I-DRUG
500 B-STR
mg/100 I-STR
mL I-STR
Piggyback B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Intravenous B-ROU
  O
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
15 O
. O
Quinupristin-Dalfopristin B-DRUG
500 B-STR
mg I-STR
Recon B-FOR
Soln I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Recon B-FOR
Soln I-FOR
Intravenous B-ROU
  O
Q12H B-FRE
( I-FRE
every I-FRE
12 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
16 O
. O
Hydromorphone B-DRUG
2 B-STR
mg/mL I-STR
Syringe B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
mg I-DOS
Injection B-FOR
prn B-FRE
: I-FRE

 I-FRE
q4 I-FRE
- I-FRE
6 I-FRE
. I-FRE

 O
17 O
. O
Insulin B-DRUG
Glargine I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
Twenty B-DOS
One I-DOS
( I-DOS
21 I-DOS
) I-DOS

 I-DOS
units I-DOS
Subcutaneous B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
18 O
. O
Insulin B-DRUG
Regular I-DRUG
Human I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
follow O

 O
sliding B-DOS
scale I-DOS
  O
Injection B-FOR
four B-FRE
times I-FRE
a I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
14 O
* O
* O
] O
& O
Rehab O
Center O
- O
[ O
* O
* O
Hospital1 O
15 O
* O
* O
] O


                              O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
2649 O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(2 O
) O
2650 O
* O
* O
] O



 O
Completed O
by:[**2122 O
- O
8 O
- O
19 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2132 O
- O
1 O
- O
30 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2132 O
- O
2 O
- O
2 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2077 O
- O
2 O
- O
8 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Sulfa B-DRUG
( I-DRUG
Sulfonamides I-DRUG
) I-DRUG
/ O
Procardia B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
1257 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
GI O
Bleed O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Colonoscopy O

 O
Right O
femoral O
line O



 O
History O
of O
Present O
Illness O
: O

 O
54 O
year O
old O
woman O
with O
past O
medical O
history O
significant O
for O

 O
diverticulosis O
, O
hypertension O
, O
hyperlipidemia O
, O
rhythm O
controlled O

 O
afib O
not O
on O
coumadin B-DRUG
and O
chronic O
diastolic O
CHF O
who O
now O
presents O

 O
with O

 O
bright O
red O
blood O
per O
rectum O
for O
the O
past O
12 O
hours O
. O

 O
. O

 O
Patient O
states O
her O
symptoms O
began O
last O
night O
about O
8:15pm O
. O
She O

 O
had O
lower O
abd O
cramps O
and O
an O
episode O
of O
dark O
colored O
stool O
. O
She O

 O
had O
nausea O
with O
no O
emesis O
. O
Since O
then O
has O
had O
about O
20 O
bloody O

 O
BMs O
, O
dark O
red O
in O
color O
, O
with O
some O
clots O
. O
She O
states O
she O
had O

 O
undercooked O
red O
meat O
and O
steamed O
vegatable O
for O
dinner O
last O
night O

 O
at O
Friend O
's O
home O
. O
Her O
friend O
had O
severe O
diarrhea O
overnight O
, O
but O

 O
no O
rectal O
bleeding O
. O
Pt O
denies O
fever/chill O
, O
NSAIDs B-DRUG
use O
, O
but O
she O

 O
is O
on O
ASA B-DRUG
81 B-STR
mg I-STR
daily B-FRE
. I-FRE
She O
complaints O
of O
dizziness O
last O
night O
. O

 O
Pt O
's O
abdominal O
pain O
is O
much O
improved O
now O
. O

 O
. O

 O
In O
the O
ED O
, O
initial O
vs O
were O
: O
T O
96.4 O
P O
97 O
BP O
82/27 O
R O
15 O
O2 O
sat O

 O
100 O
% O
RA O
. O
Patient O
was O
given O
1 B-DOS
liter I-DOS
NS B-DRUG
and O
her O
BP O
improved O
. O
On O

 O
exam O
she O
had O
lower O
abdominal O
tenderness O
. O
She O
has O
dark O
red O
blood O

 O
on O
rectal O
exam O
but O
no O
more O
BMs O
in O
ER O
. O
GI O
and O
surgery O
were O

 O
called O
. O
NG O
lavage O
was O
negative O
for O
blood O
. O
Hct B-REA
was I-REA
26 I-REA
from O

 O
baseline O
of O
43 O
, O
so O
she O
was O
given O
2 B-DOS
unit I-DOS
of O
blood B-DRUG
( O
emergency O

 O
unit O
) O
and O
6 O
units O
were O
cross O
matched O
. O
She O
was O
alert O
during O
these O

 O
encounter O
. O
Intravenous B-ROU
Protonix B-DRUG
given O
and O
Cipro B-DRUG
and O
flagyl B-DRUG
were O

 O
also O
given O
. O
Access O
of O
PIV O
18 O
gauge O
x O
2 O
was O
established O
. O
At O
the O

 O
time O
of O
transfer O
to O
the O
ICU O
were O
73 O
97/52 O
15 O
100%2L O
. O

 O
. O


 O
During O
her O
MICU O
course O
, O
GI O
and O
Surgery O
followed O
. O
She O
received O

 O
total O
of O
6 B-DOS
U I-DOS
PRBC B-DRUG
( O
last O
one O
at O
8 O
AM O
today O
) O
1 B-DOS
U I-DOS
FFP B-DRUG
and O
her O
last O

 O
Bloody O
BM O
was O
4:30 O
PM O
on O
[ O
* O
* O
1 O
- O
30 O
* O
* O
] O
. O
Access O
was O
difficult O
, O
so O
despite O

 O
having O
2 O
18 O
G O
, O
a O
femoral O
line O
was O
placed O
and O
will O
be O
kept O
until O

 O
the O
morning O
. O
GI O
convinced O
her O
to O
have O
colonoscopy O
and O
so O
started O

 O
bowel O
prep O
tonight O
. O

 O
. O

 O
REVIEW O
OF O
SYSTEMS O
: O

 O
No O
fevers O
, O
chills O
, O
weight O
loss O
, O
headache O
, O
visual O
changes O
, O
sore O

 O
throat O
, O
chest O
pain O
, O
shortness O
of O
breath O
, O
nausea O
, O
vomiting O
, O

 O
abdominal O
pain O
, O
constipation O
, O
pruritis O
, O
easy O
bruising O
, O
dysuria O
, O

 O
skin O
changes O
, O
pruritis O
. O


 O
Past O
Medical O
History O
: O

 O
# O
. O
pAfib B-REA
- O
maintained O
on O
Propafenone B-DRUG

 I-DRUG
- O
CHADS1 B-REA
, I-REA
on O
aspirin B-DRUG

 I-DRUG
# O
. O
Chronic O
Diastolic O
CHF O
, O
EF O
55 O
% O

 O
# O
. O
Diverticulosis O

 O
# O
. O
Adrenal O
Adenoma O

 O
# O
. O
Chronic O
rhinitis O

 O
# O
. O
Bladder O
cancer O

 O
- O
dx'ed O
3 O
yrs O
ago O
s/p O
resection O
, O
no O
chemo B-DRUG

 I-DRUG
- O
Single O
papillary O
tumor O
at O
the O
left O
dome O
. O

 O
# O
. O
Hypertension O

 O
# O
. O
Chronic O
bronchitis O
( O
normal O
spirometry O
in O
[ O
* O
* O
2129 O
* O
* O
] O
) O

 O
# O
. O
Hyperlipidemia O

 O
# O
. O
Osteoarthritis O

 O
# O
. O
Tenosynovitis O

 O
# O
. O
Low O
Back O
Pain O



 O
Social O
History O
: O

 O
The O
patient O
currently O
lives O
in O
[ O
* O
* O
Location O
* O
* O
] O
alone O
. O
She O
is O
single O
, O
1 O

 O
son O
. O
The O
patient O
has O
no O
HCP O
. O
The O
patient O
is O
currently O
on O

 O
disability O
for O
arthritis O
. O
She O
previously O
worked O
in O
food O

 O
services O
, O
bartending O
, O
catering O
. O
Tobacco O
: O
[ O
* O
* O
1 O
- O
5 O
* O
* O
] O
PPD O
x O
40 O
years O

 O
ETOH O
: O
Prior O
heavy O
use O
, O
has O
since O
quit O
Illicits O
: O
None O



 O
Family O
History O
: O

 O
Mother O
with O
DM O
, O
HTN O
, O
diverticulitis O
, O
angina O
at O
the O
age O
of O
38 O
and O

 O
CVA O
at O
age O
48 O
from O
which O
she O
passed O
away O
. O



 O
Physical O
Exam O
: O

 O
On O
transfer O
out O
of O
MICU O
to O
floor O
: O

 O
VS O
: O
T96.7 O
HR86 O
BP124/88 O
RR18 O
98 O
% O
RA O

 O
GEN O
: O
No O
apparent O
distress O
, O
alert O
and O
oriented O
, O
comfortable O

 O
SKIN O
: O
Erythema O
and O
excoriations O
of O
bilateral O
upper O
extremities O

 O
HEENT O
: O
EOMI O
, O
normal O
oro/nasopharynx O
, O
moist O
mucus O
membranes O
, O
no O

 O
JVD/LAD O
. O
Neck O
soft O
and O
supple O
. O

 O
PULM O
: O
CTAB O
, O
no O
wheezing/rhonchi/rales O

 O
CARDIAC O
: O
Regular O
rate O
and O
rhythm O
; O
no O
murmurs/gallops/rubs O

 O
ABDOMEN O
: O
No O
apparent O
scars O
. O
Non-distended O
, O
non-distended O
, O
soft O
, O

 O
+ O
BS O
( O
slightly O
hyperactive O
) O

 O
EXTREMITIES O
: O
Trace O
peripheral O
edema O
, O
warm O
and O
well O
perfuse O
, O

 O
+ O
DP/PT O
pulses O
, O
right O
femoral O
line O
in O
place O
- O
c/d/i O



 O
Pertinent O
Results O
: O

 O
Chem O
10 O

 O
141 O
		 O
111 O
		 O
28 O
		 O
93 O
	   O
AGap=13 O

 O
4.1 O
		 O
21 O
		 O
1.0 O
	
 O
Ca O
: O
7.7 O
Mg O
: O
1.5 O
P O
: O
3.6 O

 O
ALT O
: O
	 O
AP O
: O
	 O
Tbili O
: O
	 O
Alb O
: O

 O
AST O
: O
	 O
LDH O
: O
129 O
	 O
Dbili O
: O
	 O
TProt O
: O

 O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
: O
	 O
Lip O
: O
	 	
 O
. O

 O
FDP O
: O
0 O
- O
10 O

 O
. O

 O
CBC O

 O
11.7 O
	 O
9.8 O
	 O
175 O

	 O
28.8 O
	
	 O
N:72.7 O
L:22.1 O
M:3.4 O
E:1.5 O
Bas:0.2 O

 O
. O

 O
PT O
: O
12.6 O
 	 O
PTT O
: O
26.7 O
 	 O
INR O
: O
1.1 O

 O
Fibrinogen O
: O
259 O

 O
. O

 O
Trop-T O
: O
< O
0.01 O

 O
. O

 O
ECHO O
( O
[ O
* O
* O
2130 O
- O
11 O
- O
10 O
* O
* O
] O
) O

 O
The O
left O
atrium O
is O
mildly O
dilated O
. O
Left O
ventricular O
wall O

 O
thickness O
, O
cavity O
size O
and O
regional/global O
systolic O
function O
are O

 O
normal O
( O
LVEF O
> O
55 O
% O
) O
. O
Right O
ventricular O
chamber O
size O
and O
free O
wall O

 O
motion O
are O
normal O
. O
The O
aortic O
valve O
leaflets O
( O
3 O
) O
are O
mildly O

 O
thickened O
but O
aortic O
stenosis O
is O
not O
present O
. O
Trace O
aortic O

 O
regurgitation O
is O
seen O
. O
The O
mitral O
valve O
appears O
structurally O

 O
normal O
with O
trivial O
mitral O
regurgitation O
. O
There O
is O
mild O

 O
pulmonary O
artery O
systolic O
hypertension O
. O
There O
is O
an O
anterior O

 O
space O
which O
most O
likely O
represents O
a O
fat O
pad O
. O

 O
IMPRESSION O
: O
Normal O
global O
and O
regional O
biventricular O
systolic O

 O
function O
. O
Mild O
pulmonary O
hypertension O
. O

 O
Compared O
with O
the O
prior O
study O
( O
images O
reviewed O
) O
of O
[ O
* O
* O
2129 O
- O
4 O
- O
22 O
* O
* O
] O
, O

 O
the O
patient O
is O
now O
in O
atrial O
fibrillation O
. O
Mild O
pulmonary O

 O
hypertension O
is O
identified O
. O
The O
other O
findings O
appear O
largely O

 O
similar O
. O
LV O
function O
is O
difficult O
to O
compare O
directly O
between O

 O
the O
studies O
given O
the O
current O
degree O
of O
tachycardia O
. O

 O
. O

 O
COLONOSCOPY O
: O

 O
Findings O
: O
( O
[ O
* O
* O
2131 O
- O
1 O
- O
12 O
* O
* O
] O
) O

 O
Contents O
: O
Red O
blood O
was O
seen O
in O
the O
rectum O
and O
sigmoid O
colon O
. O

 O
Excavated O
Lesions O
Multiple O
diverticula O
were O
seen O
in O
the O
sigmoid O

 O
colon O
. O
Diverticulosis O
appeared O
to O
be O
severe O
, O
with O
no O

 O
identifiable O
single O
bleeding O
diverticulum O
. O

 O
Impression O
: O
Blood O
in O
the O
rectum O
and O
sigmoid O
colon O
Diverticulosis O

 O
of O
the O
sigmoid O
colon O
Otherwise O
normal O
colonoscopy O
to O
proximal O

 O
sigmoid O
colon O

 O
Recommendations O
: O
Unable O
to O
pass O
sigmoid O
due O
to O
spasm O
, O
dicomfort O

 O
and O
blood O
contents O
. O
No O
identifiable O
bleeding O
lesion O
in O
this O

 O
limited O
exam O
. O
If O
bleeding O
persists O
, O
please O
obtain O
bleeding O
scan O
, O

 O
contact O
IR O
. O
Consider O
surgical O
consult O
. O

 O
. O

 O
[ O
* O
* O
2132 O
- O
2 O
- O
1 O
* O
* O
] O
: O
Mutiple O
diverticuli O
throughout O
the O
colon O
. O
Able O
to O
get O

 O
to O
ileocecal O
valve O
this O
time O
with O
general O
sedation O
. O



 O
Brief O
Hospital O
Course O
: O

 O
54 O
year O
old O
woman O
with O
past O
medical O
history O
of O
diverticulosis O

 O
with O
past O
GI O
bleeds O
, O
atrial O
fibrillation O
( O
CHADS1 O
, O
not O
on O

 O
coumadin B-DRUG
) I-DRUG
who O
presented O
with O
acute O
bright O
red O
blood O
per O
rectum O
, O

 O
hypotension O
and O
20 O
point O
hematocrit O
drop O
. O
Patient O
was O
initially O

 O
in O
the O
MICU O
and O
then O
transferred O
to O
the O
floor O
where O
she O

 O
tolerated O
bowel O
preparation O
and O
underwent O
colonoscopy O
showing O

 O
diffuse O
diverticular O
disease O
but O
no O
more O
active O
bleeding O
. O

 O
. O

 O
# O
Bright B-REA
red I-REA
blood I-REA
per I-REA
rectum I-REA
: I-REA
Gastroenterology O
and O
General O

 O
Surgery O
followed O
the O
patient O
closely O
in-house O
. O
Hematocrit O

 O
stabilized O
after O
6 B-DOS
units I-DOS
pRBC B-DRUG
, I-DRUG
1 B-DOS
unit I-DOS
FFP B-DRUG
. I-DRUG
Etiology O
likely O

 O
diverticular B-REA
bleed I-REA
given O
her O
long-standing O
history O
of O

 O
constipation O
and O
history O
of O
significant O
diverticular O
bleeds O
. O

 O
Also O
on O
the O
differential O
but O
lower O
include O
ischemic O
colitis O

 O
given O
atrial O
fibrillation O
( O
without O
coumadin B-DRUG
) I-DRUG
and O
lactate O
4.2 O

 O
initially O
. O
Repeat O
colonoscopy O
revealed O
extensive O
diverticular O

 O
disease O
throughotu O
patient O
's O
colon O
. O
Her O
IV B-ROU
pantoprazole B-DRUG
was O

 O
discontinued O
and O
patient O
started O
on O
clears O
diet O
which O
she O

 O
tolerated O
well O
; O
her O
diet O
was O
eventually O
advanced O
. O
Patient O
was O

 O
educated O
on O
dietary/bowel O
management O
for O
diverticuli O
and O

 O
discharged O
with O
close O
follow-up O
in O
GI O
and O
Gen O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
clinics O
. O

 O
Patient O
is O
to O
discuss O
surgical O
option O
, O
such O
as O
bowel O
resection O
, O

 O
given O
her O
significant O
history O
of O
dangerous O
diverticular O
bleeds O

 O
in O
the O
past O
( O
X3 O
- O
4 O
? O
) O

 O
. O

 O
# O
PRURITIC B-REA
RASH I-REA
: I-REA
Slightly O
erythematous O
and O
excoriated O
. O
Responded O

 O
to O
Sarna B-DRUG
lotion B-FOR
. I-FOR
Patient O
felt O
the O
IV B-ROU
pantoprazole B-DRUG
caused O
her O

 O
rash B-ADE
. I-ADE

 O
. O

 O
# O
PAROXYSMAL B-REA
ATRIAL I-REA
FIBRILLATION I-REA
: I-REA
Patient O
remained O
in O
sinus O

 O
rhythm O
. O
Given O
her O
GI B-ADE
bleed I-ADE
, I-ADE
aspirin B-DRUG
was O
held O
, O
to O
be O
restarted O

 O
upon O
discharge O
. O
She O
was O
continued O
on O
Propafenon B-DRUG
short O
acting O
, O
to O

 O
resume O
her O
home O
long O
acting O
version O
upon O
discharge O
. O

 O
. O

 O
# O
CHRONIC B-REA
DIASTOLIC I-REA
HEART I-REA
FAILURE I-REA
: I-REA
Well O
compensated O
, O
although O

 O
likely O
tolerates O
rapid O
ventricular O
response O
very O
poorly O
. O
No O

 O
crackles O
and O
trace O
lower O
extremity O
edema O
on O
exam O
. O
After O
her O

 O
colonoscopy O
, O
patient O
's O
home O
Diltiazem B-DRUG
dose O
was O
restarted O
in O

 O
short-acting O
form O
. O
Her O
enalapril B-DRUG
was O
held O
to O
be O
restarted O
when O

 O
patient O
was O
discharged O
home O
. O

 O
. O

 O
# O
OSTEOARTHRITIS B-REA
: I-REA
Stable O
and O
pain B-REA
well O
controlled O
with O
tylenol B-DRUG

 I-DRUG
and O
oxycodone B-DRUG
PRN B-FRE

 I-FRE
. O

 O
# O
BLADDER O
TUMOR O
: O
No O
clinical O
evidence O
of O
recurrence O
and O
was O

 O
stable O
. O

 O
. O

 O
# O
Right O
Femoral O
line O
: O
Difficult O
access O
and O
initial O
IJ O
was O

 O
attempted O
unsuccessfully O
. O
Patient O
had O
two O
peripheral O
IVs O
as O
well O

 O
and O
after O
colonoscopy O
, O
had O
the O
right O
femoral O
line O
removed O

 O
without O
issues O
. O
Site O
remained O
clean O
, O
dry O
and O
intact O
until O
after O

 O
discharge O
. O

 O
. O

 O
# O
CODE O
: O
Full O
, O
discussed O
and O
confirmed O
in O
ICU O



 O
Medications O
on O
Admission O
: O

 O
DILTIAZEM B-DRUG
HCL I-DRUG
- O
240 B-STR
mg I-STR
Capsule B-FOR

 I-FOR
ENALAPRIL B-DRUG
MALEATE I-DRUG
- O
  O
20 B-STR
mg I-STR
Tablet B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
FUROSEMIDE B-DRUG
- O
  O
40 B-STR
mg I-STR
Tablet B-FOR
daily B-FRE

 I-FRE
OXYCODONE-ACETAMINOPHEN B-DRUG
- O
5 B-STR
mg-325 I-STR
mg I-STR
q6H B-FRE
: I-FRE
PRN I-FRE
Pain B-REA

 I-REA
PROPAFENONE B-DRUG
[ I-DRUG
RYTHMOL I-DRUG
SR I-DRUG
] I-DRUG
- O
225 B-STR
mg I-STR
Capsule B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
DOCUSATE B-DRUG
SODIUM I-DRUG
- O
100 B-STR
mg I-STR
Capsule B-FOR

 I-FOR
ASPIRIN B-DRUG
81 B-STR
mg I-STR
daily B-FRE


 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Oxycodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
325 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR

 I-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
back B-REA
pain I-REA
. I-REA

 O
2 O
. O
Propafenone B-DRUG
225 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Sust I-FOR
. I-FOR
Release I-FOR
12 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Sust I-FOR
. I-FOR
Release I-FOR
12 I-FOR
hr I-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
3 O
. O
Cartia B-DRUG
XT I-DRUG
240 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Sust I-FOR
. I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Sust I-FOR
. I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
4 O
. O
Docusate B-DRUG
Sodium I-DRUG
250 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
twice B-FRE

 I-FRE
a I-FRE
day I-FRE
. I-FRE

 O
5 O
. O
Aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
6 O
. O
Enalapril B-DRUG
Maleate I-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE

 I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O
Diverticular O
bleed O

 O
Secondary O
: O
Paroxysmal O
atrial O
fibrillation O
, O
chronic O
diastolic O

 O
CHF O
, O
hypertension/hyperlipidemia O
, O
osteoarthritis O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O



 O
Discharge O
Instructions O
: O

 O
-You O
were O
admitted O
with O
bright B-REA
red I-REA
blood I-REA
in I-REA
your I-REA
bowel I-REA

 I-REA
movements O
. O
You O
were O
briefly O
in O
the O
ICU O
but O
stabilized O
well O
with O

 O
6 B-DOS
units I-DOS
of O
red B-DRUG
blood I-DRUG
cells I-DRUG
. I-DRUG
Colonoscopy O
showed O
you O
likely O
had O
a O

 O
bleed O
from O
the O
many O
diverticuli O
( O
outpouchings O
) O
you O
have O
in O
your O

 O
colon O
. O

 O
. O

 O
-It O
is O
important O
that O
you O
continue O
to O
take O
your O
medications O
as O

 O
directed O
. O
We O
made O
the O
following O
changes O
to O
your O
medications O

 O
during O
this O
admission O
: O

 O
-- O
> O
HOLD O
Furosemide B-DRUG
40 B-STR
mg I-STR
daily B-FRE
until O
you O
discuss O
with O
your O

 O
primary O
care O
doctor O

 O
-- O
> O
RESUME O
Aspirin B-DRUG
81 B-STR
mg I-STR
daily B-FRE

 I-FRE
-- O
> O
RESUME O
Rhythmol B-DRUG
SR I-DRUG
225 B-STR
mg I-STR
twice B-FRE
daily I-FRE

 I-FRE
-- O
> O
RESUME O
Enalapril B-DRUG
20 B-STR
mg I-STR
twice B-FRE
daily I-FRE

 I-FRE
. O

 O
-Contact O
your O
doctor O
or O
come O
to O
the O
Emergency O
Room O
should O
your O

 O
symptoms O
return O
. O
Also O
seek O
medical O
attention O
if O
you O
develop O
any O

 O
new O
fever O
, O
chills O
, O
trouble O
breathing O
, O
chest O
pain O
, O
nausea O
, O

 O
vomiting O
or O
unusual O
stools O
. O


 O
Followup O
Instructions O
: O

 O
Appointments O
: O

 O
. O

 O
* O

* O
Please O
call O
the O
General O
Surgery O
Clinic O
to O
make O
an O
appointment O

 O
to O
  O
be O
seen O
in O
[ O
* O
* O
1 O
- O
5 O
* O
* O
] O
weeks O
. O
You O
should O
discuss O
with O
them O
surgical O

 O
options O
for O
managing O
your O
significant O
diverticulosis O
. O
Their O

 O
phone O
number O
: O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
30009 O
* O
* O
] O

 O
. O

 O
* O
Please O
follow O
up O
with O
your O
PCP O
, O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
on O
[ O
* O
* O
2 O
- O
6 O
* O
* O
] O

 O
at O
11 O
am O
. O
Her O
number O
is O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
17826 O
* O
* O
] O
if O
you O
need O
to O
reschedule O
. O

 O
She O
should O
check O
your O
blood O
counts O
and O
blood O
pressure O
. O
Please O

 O
discuss O
with O
her O
about O
re-starting O
Furosemide B-DRUG
( I-DRUG
aka I-DRUG
Lasix I-DRUG
) I-DRUG
. I-DRUG

 O
. O

 O
* O
Gastroenteroloy O
- O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
STitle O
) O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
463 O
* O
* O
] O

 O
Date/Time:[**2132 O
- O
2 O
- O
12 O
* O
* O
] O
2:00pm O

 O
. O

 O
* O
Urology O
- O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
4653 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
5727 O
* O
* O
] O

 O
Date/Time:[**2132 O
- O
2 O
- O
14 O
* O
* O
] O
3:20pm O

 O
. O

 O
* O
Cardiology O
- O
DR O
. O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
275 O
* O
* O
] O
[ O
* O
* O
Initial O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
Phone:[**Telephone/Fax O
( O
1 O
) O
62 O
* O
* O
] O

 O
Date/Time:[**2132 O
- O
10 O
- O
2 O
* O
* O
] O
10:40am O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2124 O
- O
9 O
- O
25 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2124 O
- O
9 O
- O
29 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2047 O
- O
2 O
- O
17 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
NEUROSURGERY O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
3227 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
: O
" O
s/p O
unwitnessed O
fall O
on O
coumadin B-DRUG
" I-DRUG



 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O



 O
History O
of O
Present O
Illness O
: O

 O
This O
is O
a O
77 O
year O
old O
female O
with O
history O
of O
dementia O
, O

 O
hypertension O
, O
and O
atrial B-REA
fibrilation I-REA
on O
coumadin B-DRUG
who O
is O
status O

 O
post O
unwitnessed O
fall O
at O
home O
. O
There O
was O
unknown O
loss O
of O

 O
consiousness O
. O
The O
report O
from O
[ O
* O
* O
Hospital6 O
17032 O
* O
* O
] O

 O
states O
that O
the O
patient O
was O
seen O
on O
[ O
* O
* O
9 O
- O
24 O
* O
* O
] O
at O
920 O
pm O
and O
had O

 O
fallen O

 O
at O
home O
24 O
hours O
prior O
. O
  O
The O
patients O
husband O
is O
not O
present O
for O

 O
interview O
but O
reportedly O
heard O
a O
" O
thud O
" O
and O
found O
the O
patient O
on O

 O
the O
floor O
. O
  O
She O
was O
able O
to O
get O
up O
, O
ambulate O
into O
a O
chair O
and O

 O
then O
into O
bed O
. O
The O
patient O
is O
non O
verbal O
at O
the O
time O
of O
this O

 O
exam O

 O
and O
there O
is O
no O
family O
to O
provide O
history O
. O
  O
The O
husband O
was O

 O
called O
at O
home O
by O
Neurosurgery O
Service O
x O
2 O
and O
was O
not O

 O
successfully O
reached O
. O
At O
baseline O
, O
the O
patient O
is O
alert O
x2 O
. O



 O
Past O
Medical O
History O
: O

 O
dementia O
, O
HTN O
, O
afib O



 O
Social O
History O
: O

 O
lives O
at O
home O
with O
husband O


 O
Family O
History O
: O

 O
unknown O



 O
Physical O
Exam O
: O

 O
O O
: O
T:97.8 O
BP O
: O
148/62 O
HR:66 O
R:20 O
O2Sats O
: O
97 O
% O

 O
Gen O
: O
comfortable O
, O
NAD O
. O

 O
HEENT O
: O
hard O
cervical O
collar O
on O
Pupils O
: O
      O
EOMs O
: O
patient O
does O

 O
not O
participate O
, O
appears O
grossly O
intact O

 O
Neck O
: O
hard O
cervical O
collar O
on O

 O
Extrem O
: O
Warm O
and O
well-perfused O
. O

 O
Neuro O
: O

 O
Mental O
status O
: O
Awake O
and O
alert O
, O
cooperative O
with O
exam O
, O
normal O

 O
affect O
. O

 O
Orientation O
: O
  O
not O
oriented O
to O
person O
, O
place O
, O
and O
date O
. O

 O
Recall/Language O
: O
non O
verbal O


 O
Cranial O
Nerves O
: O

 O
I O
: O
Not O
tested O

 O
II O
: O
Pupils O
equally O
round O
and O
reactive O
to O
light O
, O
3 O
to O
2 O

 O
mm O
bilaterally O
. O
Visual O
fields O
unable O
to O
test O

 O
III O
, O
IV O
, O
VI O
: O
Extraocular O
movements O
unable O
to O
test O

 O
V O
, O
VII O
: O
Facial O
strength O
and O
sensation O
intact O
and O
symmetric O
. O

 O
VIII O
: O
Hearing O
grossly O
intact O

 O
IX O
, O
X O
: O
Palatal O
elevation O
-patient O
does O
not O
participate O

 O
[ O
* O
* O
Doctor O
First O
Name O
81 O
* O
* O
] O
: O
Sternocleidomastoid O
and O
trapezius O
normal O
bilaterally O
. O

 O
XII O
: O
Tongue O
midline O
without O
fasciculations O
. O



 O
Motor O
: O
Normal O
bulk O
and O
tone O
bilaterally O
. O
No O
abnormal O
movements O
, O

 O
tremors O
. O
Strength O
full O
power O
[ O
* O
* O
5 O
- O
3 O
* O
* O
] O
throughout O
. O
No O
pronator O
drift O


 O
Sensation O
: O
patient O
unable O
to O
participate O
in O
exam O


 O
Toes O
downgoing O
bilaterally O


 O
Coordination O
: O
patient O
unable O
to O
participate O


 O
DISCHARGE O
EXAM O
: O

 O
Confused O
but O
interactive O
. O
Non-focal O
. O
  O
Moves O
all O
extremities O
x O
4 O


 O
Pertinent O
Results O
: O

 O
CT O
HEAD O
W/O O
CONTRAST O
[ O
* O
* O
2124 O
- O
9 O
- O
25 O
* O
* O
] O

 O
Bifrontal O
intraparenchymal O
hemorrhage O
, O
left O
greater O
than O
right O

 O
with O
extension O
into O
the O
subarachnoid O
and O
subdural O
spaces O
. O
Small O

 O
amount O
of O
blood O
seen O
layering O
posteriorly O
within O
the O
ventricles O
. O

 O
No O
midline O
shift O
or O
herniation O
. O


 O
[ O
* O
* O
9 O
- O
25 O
* O
* O
] O
CT O
Head O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Unchanged O
foci O
of O
hemorrhage O
in O
the O
bifrontal O
parenchymal O

 O
region O
, O
left O

 O
greater O
than O
the O
right O
, O
with O
extension O
into O
the O
subarachnoid O
, O

 O
subdural O
, O
and O
intraventricular O
spaces O
. O

 O
2 O
. O
No O
new O
shift O
of O
the O
normally O
midline O
structures O
or O

 O
herniation O
. O


 O
[ O
* O
* O
9 O
- O
28 O
* O
* O
] O
CT O
Head O
: O

 O
Impression O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Unchanged O
large O
bifrontal O
hemorrhagic O
contusions O
, O

 O
subarachnoid O
hemorrhage O
, O
parafalcine O
subdural O
hemorrhage O
, O
and O

 O
intraventricular O
hemorrhage O
. O

 O
2 O
. O
Right O
occipital O
fracture O
extending O
into O
the O
foramen O
magnum O
. O

 O
If O
there O
is O
a O
clinical O
concern O
for O
transverse O
sinus O
injury O
, O
CTV O

 O
could O
be O
performed O



 O
Brief O
Hospital O
Course O
: O

 O
77 O
y/o O
F O
with O
baseline O
dementia O
and O
on O
coumadin B-DRUG
for O
a-fib B-REA
is O
s/p O

 O
unwitnessed O
fall O
with O
unknown O
LOC O
presents O
to O
OSH O
. O
She O
presented O

 O
with O
an O
INR O
of O
4.3 O
and O
was O
given O
one B-DOS
dose O
of O
vitamin B-DRUG
K I-DRUG
and O
a O

 O
dilantin B-DRUG
load O
. O
Head O
CT O
showed O
bilateral O
frontal O
IPH O
and O
SAH O
. O
She O

 O
was O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
further O
neurosurgical O
workup O
. O
Upon O

 O
arrival O
to O
[ O
* O
* O
Hospital1 O
* O
* O
] O
, O
patient O
was O
given O
2 B-STR
units I-STR
of O
FFP B-DRUG
and O
profiline B-DRUG
in O

 O
the O
ED O
for O
an O
INR O
of O
5 O
. O
She O
was O
admitted O
to O
the O
ICU O
for O

 O
neurosurgical O
observation O
. O
  O
Her O
exam O
was O
nonverbal O
and O
confused O
, O

 O
but O
full O
strength O
. O
She O
was O
cleared O
by O
the O
trauma O
service O
of O

 O
further O
injuries O
. O
On O
[ O
* O
* O
9 O
- O
25 O
* O
* O
] O
, O
patient O
's O
exam O
much O
improved O
, O
she O
is O

 O
alert O
to O
self O
and O
full O
strength O
. O
Repeat O
head O
CT O
stable O
and O

 O
patient O
's O
INR O
was O
1.3 O
. O
While O
in O
the O
ICU O
she O
went O
in O
to O
rapid O

 O
afib O
with O
heart O
rate O
in O
the O
140 O
's O
and O
she O
was O
started O
on O
a O

 O
diltiazem B-DRUG
iv B-ROU
drip B-ROU
with O
plan O
to O
wean O
to O
PO B-ROU
diltiazem B-DRUG
. I-DRUG



 O
On O
[ O
* O
* O
9 O
- O
26 O
* O
* O
] O
pt O
had O
a O
repeat O
CT O
head O
that O
showed O
no O
change O
from O
her O

 O
previous O
scan O
. O
Her O
INR O
remained O
below O
1.3 O
. O
She O
remained O
in O
the O

 O
ICU O
to O
continue O
her O
diltiazem B-DRUG
IV B-ROU
drip B-ROU
for O
treatment O
of O
her O

 O
atrial B-REA
fibrilation I-REA
. I-REA
Cardiology O
was O
consulted O
for O
further O

 O
management O
and O
felt O
it O
was O
safe O
to O
discontinue O
her O
IV B-ROU
and O
PO B-ROU

 I-ROU
diltiazem B-DRUG
and O
remain O
on O
her O
amiodarone B-DRUG
PO B-ROU
. I-ROU
Her O
lopressor B-DRUG
was O

 O
increased O
per O
their O
recommendations O
to O
50 B-STR
mg I-STR
twice B-FRE
daily I-FRE
. I-FRE
Her O

 O
heart O
rate O
remained O
stable O
and O
had O
no O
further O
episodes O
of O
rapid O

 O
atrial O
fibrilation O
. O


 O
[ O
* O
* O
Date O
range O
( O
1 O
) O
80149 O
* O
* O
] O
Pt O
transfered O
to O
the O
floor O
in O
stable O
condition O
. O
Repeat O

 O
head O
ct O
showed O
no O
change O
in O
size O
of O
contusions O
and O
was O
stable O

 O
when O
compared O
to O
previous O
exams O
. O
Her O
blood O
pressure O
was O
noted O
to O

 O
be O
in O
the O
170s O
, O
and O
cardiology O
recommended O
adding O
HCTZ B-DRUG
to O
her O

 O
current O
regimen O
. O
She O
was O
seen O
by O
physical O
therapy O
and O
plan O
was O

 O
for O
discharge O
to O
her O
extended O
care O
facility O
. O
The O
patient O
's O

 O
neurologic O
examination O
remained O
unchanged O
throughout O
the O
entire O

 O
hospitalization O
. O


 O
Medications O
on O
Admission O
: O

 O
metformin B-DRUG
500 B-STR
mg I-STR
po B-ROU
BID B-FRE
, I-FRE

 O
amiodarone(pacerone B-DRUG
) I-DRUG
100 B-STR
mg I-STR
po B-ROU
qd B-FRE
, I-FRE
diltiazem B-DRUG
hcl I-DRUG

 I-DRUG
ext-release(cartia B-DRUG
XT)120 B-STR
mg I-STR
poqd B-FRE
, I-FRE
simvastatin B-DRUG
4- B-STR
mg I-STR
po B-ROU
qd B-FRE
, I-FRE

 O
zetia B-DRUG

 I-DRUG
10 B-STR
po B-ROU
qd B-FRE
, I-FRE
lopressor B-DRUG
25 B-STR
mg I-STR
po B-ROU
bid B-FRE
, I-FRE
coumadin B-DRUG
4 B-STR
mg I-STR
po B-ROU
qd B-FRE
, I-FRE
aricept B-DRUG
5 O

 O
mg O
po B-ROU
  O
qd B-FRE
, I-FRE
celexa B-DRUG
10 B-STR
mg I-STR
po B-ROU
qd B-FRE
, I-FRE
pravachol B-DRUG
80 B-STR
po B-ROU
qd B-FRE
, I-FRE
zestril B-DRUG
40 B-STR
po B-ROU

 I-ROU
qd B-FRE
, I-FRE
ciprofloxacin B-DRUG
250 B-STR
po B-ROU
bid B-FRE
, I-FRE
ativan B-DRUG
1 B-STR
mg I-STR
po B-ROU
PRN B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE

 I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain/fever B-REA
. I-REA

 O
2 O
. O
Amiodarone B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
3 O
. O
Donepezil B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( O
at O
bedtime O
) O
. O


 O
4 O
. O
Citalopram B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
5 O
. O
Pravastatin B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Four B-DOS
( I-DOS
4 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
6 O
. O
Lisinopril B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O



 O
7 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O

 O
day O
) O
. O

 O
8 O
. O
Docusate B-DRUG
Sodium I-DRUG
50 B-STR
mg/5 I-STR
mL I-STR
Liquid B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
9 O
. O
Bisacodyl B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
10 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( O
2 O
times O
a O
day O
) O
. O

 O
11 O
. O
Insulin B-DRUG
Regular I-DRUG
Human I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Injection B-ROU
ASDIR B-FRE
( O
AS O
DIRECTED O
) O
. O

 O
12 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( O
2 O
times O
a O
day O
) O
. O

 O
13 O
. O
Hydrochlorothiazide B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
14 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
5 B-STR
mg I-STR
IV B-ROU
Q4H B-FRE
: I-FRE
PRN I-FRE
for O
hear B-REA
rate I-REA
> I-REA
100 I-REA

 I-REA
15 I-REA
. I-REA
Famotidine(PF B-DRUG
) O
in O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
( O
Iso-os O
) O
20 B-STR
mg/50 I-STR
mL I-STR
Piggyback B-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Intravenous B-ROU
Q12H B-FRE
( O
every O
12 O
hours O
) O
. O

 O
16 O
. O
Hydralazine B-DRUG
20 B-STR
mg/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Injection B-FOR
Q6H B-FRE

 I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
SBP>160 B-REA
. I-REA



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
25759 O
* O
* O
] O
& O
Rehab O
Center O
- O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
b/l O
frontal O
IPH O
, O
IVH O
, O
SAH O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Confused O
- O
always O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O



 O

Discharge O
Instructions O
: O

 O
? O
? O
? O
? O
? O
? O
	 O
Take O
your O
pain B-DRUG
medicine I-DRUG
as O
prescribed O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Exercise O
should O
be O
limited O
to O
walking O
; O
no O
lifting O
, O
straining O
, O

 O
or O
excessive O
bending O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Increase O
your O
intake O
of O
fluids O
and O
fiber O
, O
as O
narcotic B-DRUG
pain I-DRUG

 I-DRUG
medicine I-DRUG
can O
cause O
constipation B-ADE
. I-ADE
We O
generally O
recommend O
taking O

 O
an O
over O
the O
counter O
stool B-REA
softener I-REA
, I-REA
such O
as O
Docusate B-DRUG
( O
Colace O
) O

 O
while O
taking O
narcotic O
pain O
medication O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Unless O
directed O
by O
your O
doctor O
, O
do O
not O
take O
any O

 O
anti-inflammatory B-REA
medicines O
such O
as O
Motrin B-DRUG
, I-DRUG
Aspirin B-DRUG
, I-DRUG
Advil B-DRUG
, I-DRUG
or O

 O
Ibuprofen B-DRUG
etc O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
If O
you O
were O
on O
a O
medication O
such O
as O
Coumadin B-DRUG
( O
Warfarin O
) O
, O
or O

 O
Plavix B-DRUG
( O
clopidogrel O
) O
prior O
to O
your O
injury O
, O
you O
may O
safely O
resume O

 O
taking O
this O
in O
4 O
weeks O

 O
? O
? O
? O
? O
? O
? O
	 O
If O
you O
have O
been O
prescribed O
Dilantin B-DRUG
( O
Phenytoin O
) O
for O

 O
anti-seizure B-REA
medicine I-REA
, I-REA
take O
it O
as O
prescribed O
and O
follow O
up O
with O

 O
laboratory O
blood O
drawing O
in O
one O
week O
. O
  O
This O
can O
be O
drawn O
at O
your O

 O
PCP??????s O
office O
, O
but O
please O
have O
the O
results O
faxed O
to O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
87 O
* O
* O
] O
. O

 O
If O
you O
haven O
been O
discharged O
on O
Keppra B-DRUG
( O
Levetiracetam O
) O
, O
you O
will O

 O
not O
require O
blood O
work O
monitoring O
. O


 O
CALL O
YOUR O
SURGEON O
IMMEDIATELY O
IF O
YOU O
EXPERIENCE O
ANY O
OF O
THE O

 O
FOLLOWING O


 O
? O
? O
? O
? O
? O
? O
	 O
New O
onset O
of O
tremors O
or O
seizures O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Any O
confusion O
, O
lethargy O
or O
change O
in O
mental O
status O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Any O
numbness O
, O
tingling O
, O
weakness O
in O
your O
extremities O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Pain O
or O
headache O
that O
is O
continually O
increasing O
, O
or O
not O

 O
relieved O
by O
pain O
medication O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
New O
onset O
of O
the O
loss O
of O
function O
, O
or O
decrease O
of O
function O
on O

 O
one O
whole O
side O
of O
your O
body O
. O



 O
Followup O
Instructions O
: O

 O
Follow-Up O
Appointment O
Instructions O


 O
? O
? O
? O
? O
? O
? O
Please O
call O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
88 O
* O
* O
] O
to O
schedule O
an O
appointment O
with O
Dr. O

 O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
, O
to O
be O
seen O
in O
4 O
weeks O
. O

 O
? O
? O
? O
? O
? O
? O
You O
will O
need O
a O
CT O
scan O
of O
the O
brain O
without O
contrast O
prior O
to O

 O
your O
appointment O
. O
This O
can O
be O
scheduled O
when O
you O
call O
to O
make O

 O
your O
office O
visit O
appointment O
. O




 O
Completed O
by:[**2124 O
- O
9 O
- O
29 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2145 O
- O
9 O
- O
7 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2145 O
- O
9 O
- O
12 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2090 O
- O
7 O
- O
16 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Cefepime B-DRUG
/ O
Cipro B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
3913 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Hypotension O
, O
cough O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O


 O
History O
of O
Present O
Illness O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
47367 O
* O
* O
] O
is O
a O
55 O
yo O
male O
s/p O
allogeneic O
stem O
cell O
transplant O

 O
for O
AML O
[ O
* O
* O
6-/2143 O
* O
* O
] O
with O
chronic B-REA
GVHD I-REA
on O
long-term B-DUR
steroids B-DRUG
, I-DRUG
DM O
, O
hx B-REA

 I-REA
of I-REA
PE I-REA
on O
coumadin B-DRUG
. I-DRUG

 O
. O

 O
He O
presents O
to O
his O
[ O
* O
* O
Hospital O
3242 O
* O
* O
] O
clinic O
with O
fatigue O
for O
several O
days O
, O
and O

 O
anorexia O
, O
with O
about O
12 O
- O
16 O
hours O
of O
worsening O
shortness O
of O

 O
breath O
. O

 O
. O

 O
Endorses O
increased O
cough O
with O
yellow O
sputum O
production O
and O

 O
chills O
, O
but O
no O
fever O
. O
This O
morning O
, O
he O
reported O
an O
acute O
episode O

 O
of O
dyspnea O
that O
did O
not O
rapidly O
improved O
, O
and O
occured O
with O

 O
little O
amounts O
of O
activity O
and O
somewhat O
improved O
with O
rest O
. O
No O

 O
PND/orthopnea O
. O
No O
hemoptysis O
. O

 O
. O

 O
He O
has O
had O
no O
new O
rashes O
, O
and O
has O
not O
had O
documented O
fevers O
. O
He O

 O
has O
no O
diarrhea O
, O
but O
has O
been O
nauseated O
without O
vomiting O
. O
He O

 O
reports O
mild O
epigastric O
pain O
. O
He O
has O
a O
mild O
headache O
made O

 O
somewhat O
worse O
with O
light O
, O
but O
he O
feels O
that O
this O
is O
very O

 O
consistent O
with O
flares O
of O
GVH O
and O
not O
different O
( O
has O
occured O
he O

 O
estimates O
about O
8 O
times O
) O
. O

 O
. O

 O
In O
clinic O
SBP O
70 O
's O
, O
and O
he O
was O
given O
saline O
with O
improvement O
, O

 O
but O
then O
the O
BP O
decreased O
down O
to O
the O
80 O
's O
. O
Labs O
from O
clinic O

 O
showed O
that O
Cr O
increased O
to O
2.9 O
( O
baseline O
1.1 O
) O
. O
WBC O
increased O

 O
somewhat O
. O
He O
was O
transferred O
to O
the O
ED O
for O
further O
evaluation O
. O

 O
. O

 O
In O
the O
ED O
, O
initial O
vs O
were O
: O
4 O
97.6 O
72 O
105/73 O
18 O
99 O
% O
  O
He O
was O

 O
given O
total O
of O
3L O
of O
saline O
, O
and O
recent O
vital O
signs O
were O
98.8 O

 O
129/85 O
80 O
16 O
96 O
% O
on O
2L O
at O
time O
of O
transfer O
. O
A O
bedside O
" O
shock O
" O

 O
ultrasound O
US O
in O
ED O
showed O
no O
cardiac O
effusion O
, O
no O
evidence O
of O

 O
gross O
RV O
overload O
. O
EKG O
was O
not O
significantly O
changed O
. O
Her O
INR O

 O
was O
3.0 O
. O
Of O
note O
, O
he O
was O
also O
complaining O
of O
left O
sided O

 O
shoulder/neck O
pain O
associated O
with O
shortness O
of O
breath O
and O

 O
diaphoresis O
. O

 O
. O


 O
For O
interventions O
, O
he O
received O
1 B-STR
gm I-STR
vanc B-DRUG
and O
1gm B-STR
aztreonam B-DRUG
, I-DRUG
40 B-STR

 I-STR
mg I-STR
medrol B-DRUG
, I-DRUG
and O
2 B-DOS
L I-DOS
IVF B-DRUG
in O
clinic O
, O
and O
another O
liter B-DOS
in O
the O
ED O
. O


 O
Past O
Medical O
History O
: O

 O
- O
AML-M7 O
: O
s/p O
matched O
unrelated O
allogenic O
transplant O
on O

 O
[ O
* O
* O
2143 O
- O
6 O
- O
24 O
* O
* O
] O

 O
- O
Chronic O
extensive O
GVHD O
of O
skin O
and O
liver O
, O
liver O
biopsy O
[ O
* O
* O
4 O
- O
23 O
* O
* O
] O

 O
consistent O
with O
GVHD B-REA
, I-REA
managed O
with O
cyclosporine B-DRUG
, I-DRUG
steroids B-DRUG
, I-DRUG

 O
periodic O
CellCept B-DRUG
, I-DRUG
and O
has O
received O
1 B-DUR
cycle I-DUR
of O
Rituxan B-DRUG
. I-DRUG

 O
- O
Type O
2 O
DM O

 O
- O
Hyperlipidemia O

 O
- O
H/o O
AVN O
bilateral O
hips O

 O
- O
HTN O

 O
- O
H/o O
nephrolithiasis O
, O
lithotripsy O
and O
previous O
nephrostomy O
tube O

 O
and O
emergent O
surgery O
to O
repair O
ureteral O
damage O

 O
- O
h/o O
left O
interpolar O
renal O
lesion O
, O
followed O
with O
MRs O

 O
- O
h/o O
BCC O
s/p O
excision O

 O
- O
h/o O
SCC O
left O
cheek O
, O
s/p O
Mohs O
' O
[ O
* O
* O
5-/2144 O
* O
* O
] O

 O
- O
h/o O
multiple O
back O
surgeries O
: O
Lumbar O
L5-S1 O
surgery O
x O
3 O
, O
and O

 O
cervical O
spine O
fusion O
( O
bone O
graft O
, O
no O
hardware O
) O

 O
- O
h/o O
anterior O
cervical O
diskectomy O
and O
instrument O
arthrodesis O
at O

 O
C5-C6 O
and O
C6-C7 O
for O
degenerative O
cervical O
spondylitic O
disease O

 O
with O
spinal O
cord O
compression O
and O
foraminal O
stenosis O
at O
C5-C6 O
and O

 O
C6-C7 O
[**2-/2144**]- O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
548 O
* O
* O
] O

 O
- O
Chronic O
numbness O
, O
neuropathic O
pain O
in O
left O
upper O
extremity O
. O

 O
- O
Multilevel O
compression O
fractures O
T11 O
, O
T12 O
, O
L1 O
and O
mild O

 O
compression O
L3 O
and O
L4 O
. O

 O
- O
h/o O
pulmonary O
embolism O
[ O
* O
* O
11/2144 O
* O
* O
] O
on O
anticoagulated O
from O

 O
[**11/2144**]-present O

 O
- O
h/o O
RSV O
[ O
* O
* O
11/2144 O
* O
* O
] O
requiring O
ICU O
admission O

 O
- O
h/o O
OSA O
, O
planned O
BIPAP O
, O
followed O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
4507 O
* O
* O
] O


 O
Social O
History O
: O

 O
Lives O
with O
his O
wife O
, O
and O
one O
of O
children O
, O
worked O
as O
a O
[ O
* O
* O
Company O
22957 O
* O
* O
] O

 O
technician O
until O
[ O
* O
* O
Month O
( O
only O
) O
547 O
* O
* O
] O
when O
he O
took O
early O
retirement O
and O
he O
is O

 O
no O
longer O
working O
. O
  O
Tob O
: O
previously O
smoked O
1ppd O
for O
many O
years O

 O
but O
quit O
2.5 O
years O
ago O

 O
EtOH O
: O
h/o O
social O
use O
; O
none O
recently O


 O
Family O
History O
: O

 O
Mother O
died O
suddenly O
in O
her O
70s O
. O
Father O
died O
of O
unknown O
cancer O

 O
with O
tumors O
visible O
across O
body O
. O
One O
sister O
has O
thyroid O
cancer O
. O

 O
One O
brother O
has O
diabetes O
and O
kidney O
stones O
. O
One O
sister O
has O

 O
[ O
* O
* O
Name O
( O
NI O
) O
5895 O
* O
* O
] O
. O



 O

Physical O
Exam O
: O

 O
Tmax O
: O
36.7 O
? O
? O
? O
? O
? O
? O
C O
( O
98.1 O
? O
? O
? O
? O
? O
? O
F O
) O

 O
Tcurrent O
: O
36.7 O
? O
? O
? O
? O
? O
? O
C O
( O
98.1 O
? O
? O
? O
? O
? O
? O
F O
) O

 O
HR O
: O
85 O
( O
85 O
- O
85 O
) O
bpm O

 O
BP O
: O
101/66(75 O
) O
{ O
101/66(75 O
) O
- O
101/66(75 O
) O
} O
mmHg O

 O
RR O
: O
11 O
( O
11 O
- O
11 O
) O
insp/min O

 O
SpO2 O
: O
97 O
% O

 O
Heart O
rhythm O
: O
SR O
( O
Sinus O
Rhythm O
) O

 O
. O

 O
General O
: O
Alert O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
MMM O
, O
oropharynx O
clear O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O
rales O
, O

 O
ronchi O

 O
CV O
: O
Regular O
rate O
and O
rhythm O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O

 O
gallops O

 O
Abdomen O
: O
mild O
RUQ->mid O
epigastrium O
tenderness O

 O
GU O
: O
no O
foley O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
no O
clubbing O
, O
cyanosis O
or O

 O
edema O
. O
No O
calf O
or O
thigh O
tenderness O
. O

 O
Skin O
: O
depigmentation O
on O
hands O
, O
redness O
of O
neck O
, O
but O
no O
notable O

 O
skin O
changes O
otherwise O
. O
No O
rashes O
. O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
9 O
- O
9 O
* O
* O
] O
CT O
chest O
without O
contrast O

 O
IMPRESSION O
: O

 O
1 O
. O
Mostly O
resolved O
parenchymal O
opacities O
, O
leaving O
several O

 O
parenchymal O
bands O
which O
are O
felt O
most O
likely O
to O
represent O

 O
residua O
of O
a O
prior O
infectious O
or O
inflammatory O
process O
. O

 O
2 O
. O
Subacute O
to O
chronic O
rib O
fractures O
, O
including O
along O
the O
right O

 O
posterior O

 O
seventh O
rib O
, O
where O
there O
is O
faint O
but O
suspicious O
sclerosis O

 O
extending O
further O
laterally O
than O
would O
usually O
be O
expected O
in O

 O
the O
setting O
of O
an O
uncomplicated O
rib O
fracture O
. O
In O
the O
setting O
of O

 O
prior O
treated O
hematological O
malignancy O
, O
the O
finding O
of O
vague O

 O
sclerosis O
raises O
concern O
for O
a O
bone O
marrow O
abnormality O
such O
as O

 O
myelofibrosis O
or O
potentially O
a O
form O
of O
disease O
recurrence O
. O

 O
Mostly O
, O
however O
, O
the O
bones O
appear O
within O
normal O
limits O
. O

 O
. O

 O
[ O
* O
* O
9 O
- O
9 O
* O
* O
] O
PFT O
's O

 O
SPIROMETRY O

        O
Pre O
drug O
                 O
Post O
drug O

        O
Actual O
Pred O
% O
Pred O
        O
Actual O
% O
Pred O
% O
chg O

 O
FVC O
    O
3.86 O
   O
5.05 O
   O
76 O
         O
3.83 O
     O
76 O
   O
-1 O

 O
FEV1 O
   O
2.83 O
   O
3.60 O
   O
79 O
         O
2.69 O
     O
75 O
   O
-5 O

 O
FEV1/FVC O
73 O
   O
71 O
     O
103 O
        O
70 O
       O
98 O
   O
-4 O

 O
. O

 O
[ O
* O
* O
9 O
- O
8 O
* O
* O
] O
RUQ O
US O

 O
IMPRESSION O
: O

 O
1 O
. O
Polyp O
at O
neck O
of O
gallbladder O
( O
1.2 O
cm O
) O
, O
which O
was O
also O
seen O
on O

 O
prior O

 O
ultrasound O
scan O
[ O
* O
* O
2145 O
- O
2 O
- O
9 O
* O
* O
] O
. O
This O
has O
not O
changed O
significantly O

 O
since O
prior O

 O
ultrasound O
scan O
, O
but O
followup O
imaging O
is O
advised O
. O

 O
. O


 O
[ O
* O
* O
9 O
- O
8 O
* O
* O
] O
Echo O

 O
The O
left O
atrium O
is O
mildly O
dilated O
. O
Left O
ventricular O
wall O

 O
thickness O
, O
cavity O
size O
, O
and O
global O
systolic O
function O
are O
normal O

 O
( O
LVEF>55 O
% O
) O
. O
Due O
to O
suboptimal O
technical O
quality O
, O
a O
focal O
wall O

 O
motion O
abnormality O
can O
not O
be O
fully O
excluded O
. O
Tissue O
Doppler O

 O
imaging O
suggests O
a O
normal O
left O
ventricular O
filling O
pressure O

 O
( O
PCWP<12mmHg O
) O
. O
Right O
ventricular O
chamber O
size O
and O
free O
wall O

 O
motion O
are O
normal O
. O
The O
aortic O
root O
is O
mildly O
dilated O
at O
the O

 O
sinus O
level O
. O
The O
aortic O
valve O
leaflets O
( O
3 O
) O
appear O
structurally O

 O
normal O
with O
good O
leaflet O
excursion O
and O
no O
aortic O
regurgitation O
. O

 O
The O
mitral O
valve O
appears O
structurally O
normal O
with O
trivial O
mitral O

 O
regurgitation O
. O
There O
is O
no O
mitral O
valve O
prolapse O
. O
There O
is O

 O
borderline O
pulmonary O
artery O
systolic O
hypertension O
. O
There O
is O
an O

 O
anterior O
space O
which O
most O
likely O
represents O
a O
fat O
pad O
. O

 O
. O

 O
Micro O
: O

 O
[ O
* O
* O
9 O
- O
8 O
* O
* O
] O
CMV O
VL O
negative O

 O
[ O
* O
* O
9 O
- O
8 O
* O
* O
] O
sputum O
: O
oropharyngeal O
flora O

 O
[ O
* O
* O
9 O
- O
8 O
* O
* O
] O
urine O
cx O
negative O

 O
[ O
* O
* O
9 O
- O
8 O
* O
* O
] O
viral O
screen O
and O
cx O
negative O

 O
[ O
* O
* O
9 O
- O
7 O
* O
* O
] O
blood O
cx O
negative O

 O
. O

 O
ON O
ADMISSION O
: O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
7 O
* O
* O
] O
01:05PM O
BLOOD O
WBC-11.1 O
* O
RBC-4.39 O
* O
Hgb-16.0 O
Hct-49.0 O

 O
MCV-112 O
* O
MCH-36.5 O
* O
MCHC-32.7 O
RDW-14.9 O
Plt O
Ct-264 O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
7 O
* O
* O
] O
01:05PM O
BLOOD O
Neuts-85.1 O
* O
Lymphs-7.0 O
* O
Monos-5.2 O
Eos-2.5 O

 O
Baso-0.3 O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
7 O
* O
* O
] O
01:05PM O
BLOOD O
PT-30.5 O
* O
INR(PT)-3.0 O
* O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
7 O
* O
* O
] O
01:05PM O
BLOOD O
UreaN-28 O
* O
Creat-2.9 O
* O
# O
Na-140 O
K-4.4 O
Cl-101 O

 O
HCO3 O
- O
29 O
AnGap-14 O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
7 O
* O
* O
] O
01:05PM O
BLOOD O
ALT-24 O
AST-20 O
LD(LDH)-201 O
CK(CPK)-37 O
* O

 O
AlkPhos-155 O
* O
TotBili-0.3 O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
7 O
* O
* O
] O
01:05PM O
BLOOD O
cTropnT-0.05 O
* O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
7 O
* O
* O
] O
01:05PM O
BLOOD O
Albumin-4.2 O
Calcium-9.3 O
Phos-2.6 O
* O
Mg-2.4 O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
7 O
* O
* O
] O
08:13PM O
BLOOD O
Lactate-1.9 O

 O
. O


 O
ON O
DISCHARGE O
: O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
12 O
* O
* O
] O
05:40AM O
BLOOD O
WBC-7.2 O
RBC-3.45 O
* O
Hgb-12.5 O
* O
Hct-38.3 O
* O

 O
MCV-111 O
* O
MCH-36.2 O
* O
MCHC-32.7 O
RDW-15.0 O
Plt O
Ct-211 O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
12 O
* O
* O
] O
05:40AM O
BLOOD O
Neuts-68.8 O
Lymphs-17.2 O
* O
Monos-7.9 O

 O
Eos-5.7 O
* O
Baso-0.4 O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
12 O
* O
* O
] O
05:40AM O
BLOOD O
Plt O
Ct-211 O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
12 O
* O
* O
] O
05:40AM O
BLOOD O
Glucose-80 O
UreaN-18 O
Creat-0.9 O
Na-143 O

 O
K-3.7 O
Cl-104 O
HCO3 O
- O
30 O
AnGap-13 O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
12 O
* O
* O
] O
05:40AM O
BLOOD O
ALT-25 O
AST-18 O
LD(LDH)-181 O
AlkPhos-112 O

 O
TotBili-0.2 O

 O
[ O
* O
* O
2145 O
- O
9 O
- O
12 O
* O
* O
] O
05:40AM O
BLOOD O
Calcium-9.0 O
Phos-2.8 O
Mg-2.1 O
UricAcd-4.6 O


 O
Brief O
Hospital O
Course O
: O

 O
55 O
y/o O
male O
with O
? O
viral O
syndrome O
vs. O
other O
atypical O
infection O

 O
with O
hypotension O
that O
is O
suspected O
to O
be O
hypovolemia O
or O
adrenal O

 O
insufficiency O
, O
with O
acute O
renal O
failure O
. O

 O
. O

 O
# O
Lethargy O
: O
concern O
for O
viral O
syndrome O
, O
including O
activation O
of O

 O
CMV O
, O
or O
a O
respiratory O
virus O
. O
He O
has O
been O
known O
EBV+ O
in O
the O
past O
. O

 O
This O
could O
also O
be O
related O
to O
sensation O
of O
dyspnea O
that O
he O
has O

 O
been O
having O
, O
and O
warranted O
further O
cardiovascular O
and O
pulmonary O

 O
work-up O
in O
parallel O
with O
the O
infectious O
work-up O
. O
In O
the O
ICU O
, O

 O
continued O
broad O
spectrum O
antibiotics B-DRUG
of O
vancomycin B-DRUG
and O
aztreonam B-DRUG

 I-DRUG
( O
given O
allergy O
) O
. O
  O
Infectious O
workup O
largely O
negative O
including O

 O
CMV O
VL O
, O
respiratory O
panel O
, O
EBV O
VL O
, O
fungal O
markers O
, O
blood O

 O
cultures O
, O
urine O
cultures O
, O
CT O
chest O
. O
Pt O
's O
lethargy O
improved O
with O

 O
IVFs B-DRUG
, I-DRUG
antibiotics B-DRUG
, I-DRUG
and O
stress B-DOS
dose I-DOS
steroids B-DRUG
. I-DRUG
Did O
not O
ever O
need O

 O
pressors B-DRUG
. I-DRUG

 O
. O

 O
# O
Dyspnea/Cough O
: O
Concern O
for O
infectious O
process O
. O
Regarding O
VTE O
, O

 O
his O
risk O
should O
be O
reduced O
with O
therapeutic O
INR O
, O
though O
the O

 O
concern O
for O
coumadin B-DRUG
failure O
merits O
consideration O
, O
though O
would O

 O
be O
unlikely O
and O
he O
has O
no O
other O
signs O
and O
symptoms O
of O
DVT O
. O
PFTs O

 O
completed O
[ O
* O
* O
9 O
- O
9 O
* O
* O
] O
, O
with O
official O
report O
pending O
at O
time O
of O
this O

 O
summary O
. O
CT O
chest O
showing O
resolving O
parenchymal O
processes O
, O

 O
resolving O
infectious/inflammatory O
process O
. O
Continued O
broad O

 O
spectrum O
antibiotics B-DRUG
initially O
. O
When O
no O
infiltrate O
noted O
on O
CXR O
, O

 O
decreased O
ABX B-DRUG
to O
5 B-DUR
days I-DUR
of O
azithromycin B-DRUG
for O
treatment O
of O

 O
bronchitis B-REA
. I-REA

 O
. O

 O
# O
Hypotension B-REA
: I-REA
A O
bedside O
" O
shock O
" O
ultrasound O
US O
in O
ED O
showed O
no O

 O
cardiac O
effusion O
, O
no O
evidence O
of O
gross O
RV O
overload O
. O
EKG O

 O
unchanged O
. O
Patient O
's O
hypotension O
was O
fluid/stress O
dose O
steroids B-DRUG

 I-DRUG
responsive O
. O
Initially O
given O
stress O
dose O
steroids B-DRUG
with O
plans O
to O

 O
resume O
home O
dose O
. O
  O
Also O
given O
IVF B-DRUG
repletion O
. O
BPs O
normalized O
. O

 O
Likely O
etiology O
was O
slight O
adrenal O
insufficiency O
in O
setting O
of O

 O
viral O
syndrome O
despite O
negative O
infectious O
workup O
. O
Patient O

 O
discharged O
with O
prednisone B-DRUG
7.5 B-STR
mg I-STR
daily B-FRE
. I-FRE

 O
. O


 O
# O
Acute B-REA
Renal I-REA
Failure I-REA
: I-REA
Likely O
pre-renal O
azotemia O
. O
Improved O
with O

 O
IVFs B-DRUG
. I-DRUG
Cr O
0.9 O
on O
discharge O
. O

 O
. O

 O
# O
Mild O
epigastric/RUQ O
tenderness O
: O
No O
laboratory O
e/o O
hepatitis O
. O

 O
RUQ O
US O
showing O
polyp O
at O
neck O
of O
gallbladder O
( O
1.2 O
cm O
) O
, O
which O
was O

 O
also O
seen O
on O
prior O
ultrasound O
scan O
[ O
* O
* O
2145 O
- O
2 O
- O
9 O
* O
* O
] O
. O
No O
other O
findings O

 O
to O
explain O
epigastric O
pain O
. O
This O
pain O
has O
resolved O
on O
discharge O
. O

 O
. O

 O
# O
Pulmonary B-REA
Embolism I-REA
[ O
* O
* O
11 O
- O
23 O
* O
* O
] O
: O
continued O
coumadin B-DRUG
with O
INR O
goal O

 O
[ O
* O
* O
1 O
- O
19 O
* O
* O
] O
. O


 O
# O
Diabetes B-REA
: I-REA
Continued O
NPH B-DRUG
12 B-DOS
units I-DOS
[ O
* O
* O
Hospital1 O
* O
* O
] O
, O
with O
close O
sugar O

 O
monitoring O
and O
diabetic O
diet O
. O



 O
Medications O
on O
Admission O
: O

 O
ACYCLOVIR B-DRUG
- O
400 B-STR
mg I-STR
Tablet B-FOR
- O
1 B-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
three B-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE

 I-FRE
BUDESONIDE B-DRUG
[ O
ENTOCORT B-DRUG
EC I-DRUG
] I-DRUG
- O
  O
( O
Dose O
adjustment O
- O
no O
new O
Rx O
) O
- O
3 B-STR
mg I-STR

 I-STR
Capsule B-FOR
, I-FOR
Sust I-FOR
. I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
- O
1 B-DOS
( I-DOS
One I-DOS
) I-DOS
Capsule(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
twice B-FRE

 I-FRE
a I-FRE
day I-FRE

 I-FRE
FOLIC B-DRUG
ACID I-DRUG
- O
  O
( O
Dose O
adjustment O
- O
no O
new O
Rx O
) O
- O
1 B-STR
mg I-STR
Tablet B-FOR
- O
1 B-DOS

 I-DOS
( I-DOS
One I-DOS
) I-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
once B-FRE
a I-FRE
day I-FRE

 I-FRE
HYDROMORPHONE B-DRUG
- O
2 B-STR
mg I-STR
Tablet B-FOR
- O
[ O
* O
* O
12 O
- O
18 O
* O
* O
] O
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
every B-FRE
[ I-FRE
* I-FRE
* I-FRE
3 I-FRE
- I-FRE
22 I-FRE
* I-FRE
* I-FRE
] I-FRE

 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA

 I-REA
INSULIN B-DRUG
LISPRO I-DRUG
[ O
HUMALOG B-DRUG
] I-DRUG
- O
SS O

 O
LISINOPRIL B-DRUG
- O
  O
( O
Dose O
adjustment O
- O
no O
new O
Rx O
) O
- O
5 B-STR
mg I-STR
Tablet B-FOR
- O
1 B-DOS

 I-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
once B-FRE
a I-FRE
day I-FRE

 I-FRE
METOPROLOL B-DRUG
TARTRATE I-DRUG
- O
25 B-STR
mg I-STR
Tablet B-FOR
- O
1 B-DOS
( I-DOS
One I-DOS
) I-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU

 I-ROU
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
OXYCODONE B-DRUG
- O
20 B-STR
mg I-STR
Tablet B-FOR
Sustained I-FOR
Release I-FOR
12 I-FOR
hr I-FOR
- O
3 B-DOS
( I-DOS
Three I-DOS
) I-DOS

 I-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
every B-FRE
morning I-FRE
( O
60 B-STR
mg I-STR
) I-STR
, O
1 B-DOS
tablet B-FOR
every B-FRE
2 I-FRE
pm I-FRE
( O
20 B-STR

 I-STR
mg I-STR
) I-STR
and O
3 B-DOS
tablets B-FOR
every B-FRE
evening I-FRE
( O
60 B-STR
mg I-STR
) I-STR

 O
PANTOPRAZOLE B-DRUG
[ O
PROTONIX B-DRUG
] I-DRUG
- O
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
- O

 O
1 B-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
once B-FRE
day I-FRE

 I-FRE
PREDNISONE B-DRUG
- O
2.5 B-STR
mg I-STR
Tablet B-FOR
- O
2 B-DOS
( I-DOS
Two I-DOS
) I-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
once B-FRE
a I-FRE

 I-FRE
day I-FRE

 I-FRE
RISEDRONATE B-DRUG
[ O
ACTONEL B-DRUG
] I-DRUG
- O
35 B-STR
mg I-STR
Tablet B-FOR
q B-FRE
Saturday I-FRE

 I-FRE
TESTOSTERONE B-DRUG
[ O
ANDROGEL B-DRUG
] I-DRUG
- O
50 B-STR
mg/5 I-STR
gram I-STR
( I-STR
1 I-STR
% I-STR
) I-STR
Gel B-FOR
in I-FOR
Packet I-FOR
- O

 O
Apply O
to O
upper B-ROU
torso I-ROU
once B-FRE
daily I-FRE

 I-FRE
WARFARIN B-DRUG
[ O
COUMADIN B-DRUG
] I-DRUG
- O
  O
( O
Dose O
adjustment O
- O
no O
new O
Rx O
) O
- O
2.5 B-STR
mg I-STR

 I-STR
Tablet B-FOR
- O
2 B-DOS
( I-DOS
Two I-DOS
) I-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
once B-FRE
a I-FRE
day I-FRE
or I-FRE
as I-FRE
directed I-FRE

 I-FRE
CHOLECALCIFEROL B-DRUG
( O
VITAMIN B-DRUG
D3 I-DRUG
) I-DRUG
[ O
DELTA B-DRUG
D3 I-DRUG
] I-DRUG
- O
  O
( O
Dose O
adjustment O
- O
no O

 O
new O
Rx O
) O
- O
400 B-STR
unit I-STR
Tablet B-FOR
- O
1 B-DOS
Tablet(s B-FOR
) I-FOR
by B-ROU
mouth I-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE

 I-FRE
INSULIN B-DRUG
NPH I-DRUG
HUMAN I-DRUG
RECOMB I-DRUG
- O
  O
( O
Prescribed O
by O
Other O
Provider O
) O
- O
100 B-STR

 I-STR
unit/mL I-STR
Suspension B-FOR
- O
12 B-DOS
units I-DOS
twice B-FRE
a I-FRE
day I-FRE
Please O
take O
first O
dose O

 O
in O
the O
morning O
and O
the O
second O
dose O
at O
bedtime O


 O
Discharge O
Medications O
: O

 O
1 O
. O
Azithromycin B-DRUG
250 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE

 I-FRE
24 I-FRE
hours I-FRE
) I-FRE
for B-DUR
2 I-DUR
days I-DUR
. I-DUR

 O
Disp:*2 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
2 O
. O
Acyclovir B-DRUG
200 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
Q8H B-FRE
( I-FRE
every I-FRE
8 I-FRE

 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Folic B-DRUG
Acid I-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
4 O
. O
Hydromorphone B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
5 O
. O
OxyContin B-DRUG
60 B-STR
mg I-STR
Tablet B-FOR
Sustained I-FOR
Release I-FOR
12 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
Sustained I-FOR
Release I-FOR
12 I-FOR
hr I-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
: I-FRE
QAM I-FRE
and I-FRE
QPM I-FRE
. I-FRE

 O
6 O
. O
OxyContin B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sustained I-FOR
Release I-FOR
12 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
Sustained I-FOR
Release I-FOR
12 I-FOR
hr I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
: I-FRE
at I-FRE
1400 I-FRE
every I-FRE
day I-FRE
. I-FRE


 O
7 O
. O
Warfarin B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Once B-FRE
Daily I-FRE
at I-FRE
4 I-FRE

 I-FRE
PM I-FRE
. I-FRE

 O
8 O
. O
Budesonide B-DRUG
3 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Sust I-FOR
. I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Sust I-FOR
. I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
9 O
. O
Prednisone B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
: I-FRE
For O
total O
7.5 B-STR
mg I-STR
daily B-FRE
. I-FRE

 O
10 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Cholecalciferol B-DRUG
( O
Vitamin B-DRUG
D3 I-DRUG
) I-DRUG
400 B-STR
unit I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Actonel B-DRUG
35 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
week I-FRE
: I-FRE
On I-FRE

 I-FRE
Saturdays I-FRE
. I-FRE

 O
13 O
. O
AndroGel B-DRUG
1 B-STR
% I-STR
( I-STR
50 I-STR
mg/5 I-STR
gram I-STR
) I-STR
Gel B-FOR
in I-FOR
Packet I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
packet B-FOR

 I-FOR
Transdermal B-ROU
once B-FRE
a I-FRE
day I-FRE
: I-FRE
Apply O
to O
upper O
torso O
once B-FRE
daily I-FRE
as I-FRE

 I-FRE
directed I-FRE
. I-FRE

 O
14 O
. O
Insulin B-DRUG
NPH I-DRUG
Human I-DRUG
Recomb I-DRUG
100 B-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Twelve B-DOS

 I-DOS
( I-DOS
12 I-DOS
) I-DOS
units I-DOS
Subcutaneous B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
15 O
. O
Insulin B-DRUG
Lispro I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
Varied O
units O

 O
Subcutaneous B-ROU
four B-FRE
times I-FRE
a I-FRE
day I-FRE
: I-FRE
As O
per O
home O
sliding B-DOS
scale I-DOS
. I-DOS


 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
diagnosis O
: O

 O
Hypotension/adrenal O
insufficiency O

 O
Bronchitis O

 O
Acute O
renal O
failure O

 O
. O

 O
Secondary O
diagnosis O
: O

 O
AML O
s/p O
MUD O
allogeneic O
SCT O
[ O
* O
* O
6-/2143 O
* O
* O
] O

 O
Chronic O
GVHD O
of O
skin/liver O

 O
h/o O
PE O

 O
Diabetes O
mellitus O



 O
Discharge O
Condition O
: O

 O
Stable O
, O
afebrile O
, O
BP O
113/76 O
, O
RR O
16 O
, O
sats O
96 O
% O
on O
RA O
, O
INR O
1.8 O
. O



 O

Discharge O
Instructions O
: O

 O
You O
were O
admitted O
with O
fatigue O
, O
shortness O
of O
breath O
, O
cough O
, O
low O

 O
blood O
pressure O
and O
acute O
renal O
failure O
. O
We O
were O
concerned O
for O

 O
early O
sepsis B-REA
and O
you O
were O
in O
the O
ICU O
initially O
. O
You O
received O

 O
broad O
spectrum O
antibiotics B-DRUG
and O
stress O
dose O
steroids B-DRUG
, I-DRUG
but O
a O
full O

 O
workup O
( O
including O
viral O
swabs O
, O
cultures O
, O
ECHO O
, O
and O
CT O
chest O
) O

 O
were O
unrevealing O
. O
CT O
chest O
showed O
resolving O
infiltrates O
and O
your O

 O
symptoms O
improved O
so O
the O
antibiotics B-DRUG
were O
switched O
to O

 O
azithromycin B-DRUG
for O
presumed B-REA
bronchitis I-REA
. I-REA
Your O
prednisone B-DRUG
was O

 O
increased O
due O
to O
presumed O
mild B-REA
adrenal I-REA
insufficiency I-REA
. I-REA

 O
. O

 O
The O
following O
medication O
changes O
were O
made O
: O

 O
1 O
) O
Prednisone B-DRUG
increased O
to O
7.5 B-STR
mg I-STR
daily B-FRE

 I-FRE
2 O
) O
Azithromycin B-DRUG
( O
antibiotic O
) O
started O
, O
to O
be O
completed O
as O

 O
outpatient O

 O
3 O
) O
Your O
lisinopril B-DRUG
( O
blood B-DRUG
pressure I-DRUG
medication I-DRUG
) I-DRUG
and O
metoprolol B-DRUG

 I-DRUG
were O
discontinued O
. O
Do O
NOT O
resume O
these O
medications O
until O

 O
speaking O
to O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
. O

 O
. O

 O
You O
need O
to O
have O
your O
INR O
checked O
on O
Tuesday O
, O
[ O
* O
* O
2145 O
- O
9 O
- O
14 O
* O
* O
] O
. O
You O
also O

 O
need O
to O
follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
and O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
3235 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
3236 O
* O
* O
] O
within O
the O

 O
next O
week O
. O
Please O
call O
their O
office O
tomorrow O
to O
make O
this O

 O
appointment O
. O

 O
. O

 O
of O
the O
following O
symptoms O
: O
fever O
, O
chills O
, O
shortness O
of O
breath O
, O

 O
difficulty O
breathing O
, O
abdominal O
pain O
, O
cough O
, O
flu O
symptoms O
, O
or O

 O
any O
other O
worrisome O
symptoms O
. O



 O
Followup O
Instructions O
: O

 O
You O
need O
to O
have O
your O
INR O
checked O
on O
Tuesday O
, O
[ O
* O
* O
2145 O
- O
9 O
- O
14 O
* O
* O
] O
. O

 O
. O

 O
Please O
call O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
and O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
3235 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
72254 O
* O
* O
] O
office O
to O
make O
an O

 O
appointment O
to O
be O
seen O
later O
this O
week O
. O
They O
can O
be O
reached O
at O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
3241 O
* O
* O
] O
. O




 O
Completed O
by:[**2145 O
- O
9 O
- O
17 O
* O
* O
] O

Name O
: O
  O
[ O
* O
* O
Known O
lastname O
14279**],[**Known O
firstname O
511 O
* O
* O
] O
                  O
Unit O
No O
: O
   O
[ O
* O
* O
Numeric O
Identifier O
14280 O
* O
* O
] O


 O
Admission O
Date O
: O
  O
[ O
* O
* O
2129 O
- O
12 O
- O
5 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2129 O
- O
12 O
- O
28 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2062 O
- O
5 O
- O
24 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Nitrofurantoin B-DRUG
/ O
Yellow O
Dye O
/ O
Iron B-DRUG
/ O
Calcium B-DRUG



 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
3149 O
* O
* O
] O

 O
Addendum O
: O

 O
The O
patient O
was O
ready O
to O
go O
home O
with O
VNA O
services O
on O
[ O
* O
* O
2129 O
- O
12 O
- O
22 O
* O
* O
] O
. O

 O
Approximately O
at O
11 O
am O
, O
patient O
developed O
severe O
nausea O
and O
she O

 O
vomited O
x O
3 O
. O
She O
was O
started O
on O
IV B-ROU
fluids B-DRUG
and O
her O
discharge O
was O

 O
put O
on O
hold O
. O
The O
patient O
was O
stable O
, O
afebrile O
with O
vital O
signs O

 O
within O
normal O
limits O
. O
Approximately O
at O
3 O
pm O
, O
patient O
was O
found O

 O
to O
have O
rigors O
, O
her O
vital O
signs O
revealed O
hypotension O
with O
SBP O
to O

 O
the O
70s O
, O
and O
hyperglycemia B-REA
with I-REA
FS I-REA
470s I-REA
and O
altered O
mental O

 O
status O
. O
The O
patient O
received O
IV B-ROU
fluid B-DRUG
bolus B-FOR
( O
2L B-DOS
LR B-DRUG
) I-DRUG
, O
SC B-ROU
insulin B-DRUG

 I-DRUG
and O
was O
transferred O
to O
ICU O
for O
further O
management O
. O
Her O
blood O

 O
revealed O
increased O
leukocytosis O
, O
hyponatremia O
, O
hyperkalemia O
and O

 O
Cre O
1.7 O
( O
0.4 O
- O
0.6 O
baseline O
) O
. O
The O
patient O
was O
started O
on O
broad O

 O
spectrum O
antibiotics B-DRUG
, I-DRUG
levophed B-DRUG
gtt B-FOR
to O
maintain B-REA
BP I-REA
and O
agressive O

 O
fluid O
resuscitation O
, O
NGT O
was O
placed O
. O
Abdominal O
CT O
scan O
revealed O

 O
LLL O
consolidations O
, O
persistent O
2.9 O
x O
1.3 O
cm O
rim O
enhancing O

 O
aortocaval O
fluid O
collection O
near O
the O
liver O
hilum O
and O
was O
grossly O

 O
stable O
compare O
with O
CT O
from O
[ O
* O
* O
12 O
- O
15 O
* O
* O
] O
. O
With O
interventions O
patient O

 O
continue O
to O
improve O
. O
Her O
BP O
stabalized O
and O
pressors B-DRUG
were O
weaned O

 O
off O
, O
hyperglycemia B-REA
improved O
with O
insulin B-DRUG
, I-DRUG
Cre O
started O
to O

 O
downward O
with O
fluids O
. O
WBC O
started O
to O
downward O
26->19.8->12.6 O

 O
with O
abx B-DRUG
treatment O
. O
Her O
blood O
, O
urine O
and O
stool O
samples O
were O
sent O

 O
for O
culture O
. O
Patient O
received O
2 B-STR
units I-STR
of O
pRBC B-DRUG
and O
HCT O
improved O

 O
( O
24->30.2 O
) O
, O
and O
her O
mental O
status O
returned O
to O
her O
baseline O
. O
The O

 O
patient O
returned O
to O
the O
floor O
on O
[ O
* O
* O
2129 O
- O
12 O
- O
24 O
* O
* O
] O
. O
Her O
urine O
and O
stool O

 O
cultures O
were O
negative O
, O
last O
blood O
cultures O
still O
pendind O
. O

 O
Patient O
's O
Cre O
returned O
back O
to O
normal O
, O
her O
Bactrim B-DRUG
and O

 O
Fluconazole B-DRUG
were O
restarted O
. O
The O
patient O
's O
Coumadin B-DRUG
was O
hold O

 O
since O
[ O
* O
* O
2129 O
- O
12 O
- O
23 O
* O
* O
] O
for O
INR O
4.4 O
. O
The O
patient O
still O
to O
have O

 O
supratherapeutic O
INR O
on O
discharge O
( O
3.6 O
) O
, O
her O
INR O
will O
be O

 O
followed O
daily O
by O
VNA O
and O
her O
Coumadin B-DRUG
will O
be O
restarted O
when O

 O
INR O
therapeutic O
( O
[ O
* O
* O
3 O
- O
17 O
* O
* O
] O
) O
. O
Patient O
's O
PCP O
will O
be O
notify O
by O
VNA O
about O

 O
INR O
level O
and O
he O
will O
adjust O
patient O
's O
daily O
Warfarin B-DRUG
base O
on O

 O
INR O
result O
. O

 O

At O
the O
time O
of O
discharge O
, O
the O
patient O
was O
doing O
well O
, O
afebrile O

 O
with O
stable O
vital O
signs O
. O
The O
patient O
was O
tolerating O
a O
regular O

 O
diet O
, O
ambulating O
, O
voiding O
without O
assistance O
, O
and O
pain O
was O
well O

 O
controlled O
. O
The O
patient O
received O
discharge O
teaching O
and O

 O
follow-up O
instructions O
with O
understanding O
verbalized O
and O

 O
agreement O
with O
the O
discharge O
plan O
. O





 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
Northeast O
Clinical O
Services O


                              O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
2000 O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(2 O
) O
3151 O
* O
* O
] O


 O
Completed O
by:[**2129 O
- O
12 O
- O
29 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2178 O
- O
3 O
- O
25 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2178 O
- O
3 O
- O
28 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2094 O
- O
5 O
- O
27 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
No O
Known O
Allergies O
/ O
Adverse O
Drug O
Reactions O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
3326 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
altered O
mental O
status O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O


 O
History O
of O
Present O
Illness O
: O

 O
83-year-old O
woman O
with O
a O
history O
of O
tongue B-REA
cancer I-REA
on O

 O
chemoradiation O
, O
most O
recent O
cisplatin B-DRUG
dose O
on O
[ O
* O
* O
2178 O
- O
3 O
- O
13 O
* O
* O
] O
, O
presents O

 O
with O
altered B-ADE
mental I-ADE
status I-ADE
. I-ADE
Per O
his O
wife O
, O
the O
patient O
took O
his O

 O
oxycodone-acetaminophen B-DRUG
for O
the O
first O
time O
the O
night O
before O

 O
admission O
, O
[ O
* O
* O
2178 O
- O
3 O
- O
24 O
* O
* O
] O
. O
He O
woke O
up O
the O
morning O
of O
admission O
, O

 O
[ O
* O
* O
2178 O
- O
3 O
- O
25 O
* O
* O
] O
, O
confused B-ADE
and O
somnolent B-ADE
. I-ADE
No O
other O
complaint O
. O
Patient O
was O

 O
brought O
to O
the O
ED O
. O

 O
. O

 O
Of O
note O
, O
patient O
has O
been O
hyponatremic O
lately O
, O
per O
Atrius O

 O
records O
: O

 O
. O

 O
Date O
   O
Na O

 O
[ O
* O
* O
2 O
- O
20 O
* O
* O
] O
   O
115 O

 O
[ O
* O
* O
2 O
- O
22 O
* O
* O
] O
   O
126 O

 O
[ O
* O
* O
2 O
- O
24 O
* O
* O
] O
   O
133 O

 O
[ O
* O
* O
3 O
- O
5 O
* O
* O
] O
   O
130 O

 O
[ O
* O
* O
3 O
- O
19 O
* O
* O
] O
   O
124 O

 O
. O

 O
In O
the O
ED O
, O
T O
98.9 O
, O
HR O
95 O
, O
BP O
142/59 O
, O
RR O
18 O
, O
97%RA O
. O
His O
neuro O

 O
exam O
was O
nonfocal O
. O
Head O
CT O
showed O
no O
acute O
abnormality O
. O
CXR O
and O

 O
urinalysis O
unremarkable O
. O
His O
labs O
were O
notable O
for O
Na O
117 O
, O
Cr O

 O
0.8 O
, O
WBC O
2.3 O
with O
66 O
% O
neutrophils O
, O
Hct O
22.0 O
, O
plt O
194 O
. O
He O

 O
reportedly O
became O
more O
awake O
and O
mental O
status O
almost O
returned O

 O
to O
baseline O
after O
some O
hydration O
in O
the O
ED O
. O
Admitted O
for O
further O

 O
management O
. O

 O
. O

 O
On O
the O
floor O
, O
patient O
was O
oriented O
to O
name O
, O
date O
, O
and O
US O

 O
president O
, O
but O
not O
location O
. O
He O
was O
unable O
to O
name O
months O

 O
backwards O
. O

 O
. O

 O
Review O
of O
Systems O
: O
not O
obtainable O
due O
to O
patient O
's O
mental O
status O


 O
Past O
Medical O
History O
: O

 O
ONCOLOGIC O
HISTORY O
: O

 O
# O
Stage O
[ O
* O
* O
Doctor O
First O
Name O
690 O
* O
* O
] O
T4aN2cM0 O
squamous B-REA
cell I-REA
carcinoma I-REA
of I-REA
the I-REA
tongue I-REA
: I-REA

 O
diagnosed O
in O
[ O
* O
* O
2177 O
- O
12 O
- O
10 O
* O
* O
] O
. O
Started O
on O
radiation O
and O

 O
chemotherapy B-DRUG
with O
cisplatin B-DRUG
on O
[ O
* O
* O
2178 O
- O
2 O
- O
12 O
* O
* O
] O
. O

 O
. O


 O
OTHER O
MEDICAL O
HISTORY O
: O

 O
HTN O

 O
DM2 O

 O
Hyperlipidemia O

 O
BPH O


 O
Social O
History O
: O

 O
Quit O
smoking O
in O
[ O
* O
* O
2155 O
* O
* O
] O
after O
20 O
pack-years O
. O
Rare O
alcohol O
. O
used O
to O

 O
work O
in O
the O
gun O
business O
then O
in O
a O
sporting O
goods O
store O
. O
Has O
5 O

 O
children O
, O
15 O
grandchildren O
, O
and O
2 O
great-grandchildren O
. O


 O
Family O
History O
: O

 O
Mother O
had O
a O
[ O
* O
* O
Last O
Name O
* O
* O
] O
problem O
. O
Father O
had O
alcoholism O
. O
Son O
had O
a O

 O
kidney O
transplant O
. O
One O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
died O
of O
lung O
cancer O
. O
A O
maternal O

 O
uncle O
had O
leukemia O
, O
and O
another O
maternal O
uncle O
had O
lung O
cancer O
. O


 O
Physical O
Exam O
: O

 O
VS O
: O
T O
99.8 O
, O
BP O
160/70 O
, O
HR O
102 O
, O
RR O
16 O
, O
95%RA O

 O
GEN O
: O
Elderly O
man O
sleeping O
in O
bed O
but O
easily O
arousable O
, O
in O
NAD O

 O
HEENT O
: O
EOMI O
, O
sclera O
anicteric O
, O
conjunctivae O
clear O

 O
NECK O
: O
Supple O

 O
CV O
: O
Regular O
, O
slightly O
tachycardic O
, O
normal O
S1 O
, O
S2 O
. O
No O
m/r/g O
. O

 O
CHEST O
: O
Resp O
unlabored O
, O
no O
accessory O
muscle O
use O
. O
CTAB O
, O
no O

 O
crackles O
, O
wheezes O
or O
rhonchi O
. O

 O
ABD O
: O
Soft O
, O
NT O
, O
ND O
, O
no O
HSM O
, O
bowel O
sounds O
present O

 O
MSK O
: O
normal O
muscle O
tone O
and O
bulk O

 O
EXT O
: O
No O
c/c/e O
, O
2 O
+ O
DP/PT O
bilaterally O

 O
SKIN O
: O
No O
rash O
, O
warm O
skin O

 O
NEURO O
: O
oriented O
to O
name O
, O
date O
, O
US O
president O
but O
not O
location O
, O

 O
unable O
to O
name O
months O
backwards O
. O
CN O
II-XII O
intact O
, O
5/5 O
strength O

 O
throughout O
, O
intact O
sensation O
to O
light O
touch O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2178 O
- O
3 O
- O
25 O
* O
* O
] O
01:12PM O
   O
GLUCOSE-202 O
* O
UREA O
N-22 O
* O
CREAT-0.8 O
SODIUM-117 O
* O

 O
POTASSIUM-3.7 O
CHLORIDE-77 O
* O
TOTAL O
CO2 O
- O
31 O
ANION O
GAP-13 O

 O
[ O
* O
* O
2178 O
- O
3 O
- O
25 O
* O
* O
] O
01:12PM O
   O
WBC-2.3 O
* O
RBC-2.36 O
* O
HGB-8.1 O
* O
HCT-22.0 O
* O
# O
MCV-93 O

 O
MCH-34.4 O
* O
MCHC-37.0 O
* O
RDW-15.4 O

 O
[ O
* O
* O
2178 O
- O
3 O
- O
25 O
* O
* O
] O
01:12PM O
   O
NEUTS-66 O
BANDS-2 O
LYMPHS-11 O
* O
MONOS-18 O
* O
EOS-3 O

 O
BASOS-0 O
ATYPS-0 O
METAS-0 O
MYELOS-0 O

 O
[ O
* O
* O
2178 O
- O
3 O
- O
25 O
* O
* O
] O
01:12PM O
   O
PLT O
SMR-NORMAL O
PLT O
COUNT-194 O

 O
[ O
* O
* O
2178 O
- O
3 O
- O
25 O
* O
* O
] O
01:12PM O
   O
PT-12.9 O
PTT-24.2 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2178 O
- O
3 O
- O
27 O
* O
* O
] O
06:28PM O
BLOOD O
Type-ART O
pO2 O
- O
86 O
pCO2 O
- O
71 O
* O
pH-7.31 O
* O

 O
calTCO2 O
- O
37 O
* O
Base O
XS-5 O


 O
IMAGING O
: O

 O
Head O
CT O
[ O
* O
* O
2178 O
- O
3 O
- O
25 O
* O
* O
] O
: O

 O
1 O
. O
No O
acute O
intracranial O
process O
. O
No O
evidence O
of O
intracranial O

 O
hemorrhage O
. O

 O
2 O
. O
Small O
vessel O
ischemic O
disease O
. O
Prominent O
sulci O
and O

 O
ventricles O
, O
most O
likely O
age-related O
involutionary O
changes O
. O

 O
3 O
. O
Sinus O
disease O
, O
as O
detailed O
above O
. O



 O
CXR O
[ O
* O
* O
2178 O
- O
3 O
- O
25 O
* O
* O
] O
: O

 O
1 O
. O
Left O
lower O
lobe O
opacity O
could O
be O
atelectasis O
; O
however O
, O
can O
not O

 O
exclude O

 O
superinfection O
. O

 O
2 O
. O
Possible O
bilateral O
small O
pleural O
effusions O
. O

 O
3 O
. O
Cardiac O
silhouette O
top O
normal O
. O


 O
CTA O
chest O
[ O
* O
* O
2178 O
- O
3 O
- O
27 O
* O
* O
] O
: O
( O
prelim O
) O

 O
1 O
. O
No O
PE O
or O
acute O
aortic O
pathology O
. O

 O
2 O
. O
Moderate-to-large O
bilateral O
pleural O
effusions O
, O
with O
subtotal O

 O
atelectasis O
of O
the O
lower O
lobes O
. O

 O
3 O
. O
No O
PNA O
. O

 O
4 O
. O
Mild O
septal O
thickening O
compatible O
with O
mild O
pulmonary O
edema O
. O


 O
CXR O
[ O
* O
* O
2178 O
- O
3 O
- O
27 O
* O
* O
] O
: O
( O
prelim O
) O

 O
Bilateral O
moderate O
sized O
pleural O
effusions O
. O
No O
pneumothorax O
. O

 O
Pulmonary O
edema O
, O
cardiomegaly O
. O
Bibasal O
atelectasis O
. O
Findings O

 O
similar O
to O
earlier O
CT O
chest O
. O


 O
Brief O
Hospital O
Course O
: O

 O
83-year-old O
man O
with O
squamous B-REA
cell I-REA
carcinoma I-REA
of I-REA
the I-REA
tongue I-REA
, I-REA

 O
ongoing O
chemoradiation B-DRUG
, I-DRUG
presents O
with O
altered O
mental O
status O
. O


 O
1 O
. O
Hypoxic B-REA
respiratory I-REA
failure I-REA
: I-REA
Patient O
had O
been O
in O
sinus O

 O
tachycardia O
to O
~120 O
since O
admission O
despite O
2L B-DOS
IVF B-DRUG
and O
2 B-DOS
units I-DOS

 I-DOS
pRBC B-DRUG
. I-DRUG
Given O
this O
and O
his O
2L B-DOS
O2 B-DRUG
requirement O
, O
he O
went O
for O
CTA O

 O
chest O
, O
which O
showed O
no O
PE O
, O
but O
large O
bilateral O
pleural O
effusions O

 O
with O
atelectasis O
. O
He O
was O
agitated O
since O
the O
CTA O
, O
and O
around O
6 O
pm O
, O

 O
he O
looked O
cyanotic O
and O
had O
a O
desaturation O
to O
60 O
% O
on O
2L O
, O
improved O

 O
to O
93 O
% O
on O
NRB B-ROU
. I-ROU
He O
was O
given O
20 B-STR
mg I-STR
lasix B-DRUG
IV B-ROU
with O
brisk O
urine O

 O
output O
, O
as O
well O
as O
0.5 B-STR
mg I-STR
IV B-ROU
haloperidol B-DRUG
and O
10 B-STR
mg I-STR
IV B-ROU
hydralazine B-DRUG

 I-DRUG
( O
BP B-REA
~180/90 I-REA
) I-REA
and O
transferred O
to O
the O
ICU O
. O
Stat O
CXR O
showed O
diffuse O

 O
pulmonary O
edema O
, O
and O
with O
his O
concurrent O
hypertension B-REA
, I-REA
he O
was O

 O
started O
on O
a O
nitroglycerin B-DRUG
drip B-ROU
. I-ROU
His O
BP O
improved O
and O
overshot O

 O
transiently O
down O
to O
70/30 O
, O
but O
rapidly O
improved O
to O
~130s/80s O

 O
with O
cessation O
of O
drip O
. O
His O
O2 O
sats O
remained O
in O
the O
90s O
on O

 O
high-flow O
oxygen O
mask O
. O
He O
was O
sent O
for O
CT O
head O
given O
his O
altered O

 O
mental O
status O
and O
possibly O
new O
anisocoria O
. O
While O
being O

 O
transported O
, O
he O
developed O
bradycardia O
down O
to O
20 O
, O
desaturation O
, O

 O
and O
apnea O
requiring O
bag O
ventilation O
. O
On O
evaluation O
, O
there O
were O

 O
no O
palpable O
pulses O
and O
no O
obtainable O
blood O
pressure O
. O
Given O
his O

 O
confirmed O
DNR O
status O
, O
he O
was O
not O
resuscitated O
and O
expired O
. O

 O
Post-mortem O
exam O
was O
declined O
. O



 O
2 O
. O
Altered B-ADE
mental I-ADE
status I-ADE
: I-ADE
Cause O
not O
entirely O
clear O
, O
but O
possible O

 O
contribution O
from O
opioids B-DRUG
at O
home O
, O
as O
well O
as O
hyponatremia O
. O
He O

 O
was O
also O
treated O
with O
levofloxacin B-DRUG
for O
a O
possible O
pneumonia B-REA
, I-REA

 O
given O
left O
basilar O
opacity O
, O
mild O
hypoxia O
( O
93 O
% O
RA O
) O
, O
low O
grade O

 O
temps O
( O
99.7 O
) O
and O
cough O
. O
When O
the O
patient O
became O
agitated B-REA
as O

 O
noted O
in O
the O
events O
described O
above O
, O
he O
was O
treated O
with O
0.5 B-STR
mg I-STR

 I-STR
IV B-ROU
haloperidol B-DRUG
prn B-FRE
( O
total O
1.5 B-STR
mg I-STR
given O
) O
with O
good O
effect O
. O
CT O
head O

 O
with O
no O
acute O
process O
on O
admission O
and O
was O
planned O
to O
be O

 O
repeated O
given O
anisocoria O
, O
but O
aborted O
given O
above O
events O
. O


 O
3 O
. O
Hyponatremia B-REA
: I-REA
Treated O
with O
IV B-ROU
fluids B-DRUG
with O
improvement O
from O

 O
117 O
to O
127 O
. O


 O
4 O
. O
Tongue B-REA
cancer I-REA
: I-REA
On O
cisplatin B-DRUG
and O
radiation O
, O
with O
radiation O

 O
received O
during O
this O
admission O
. O


 O
5 O
. O
Anemia B-REA
: I-REA
Hct O
22 O
on O
admission O
. O
Transfused O
2 B-DOS
units I-DOS
PRBCs B-DRUG
with O

 O
improvement O
to O
30.7 O
. O


 O
Medications O
on O
Admission O
: O

 O
terazosin B-DRUG
5 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
omeprazole B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
morphine B-DRUG
10 B-STR
mg I-STR
oral B-ROU
solution B-FOR
q3h B-FRE
prn I-FRE
pain B-REA

 I-REA
ondansetron B-DRUG
prn B-FRE

 I-FRE
prochlorperazine B-DRUG
prn B-FRE

 I-FRE
lorazepam B-DRUG
1 B-STR
mg I-STR
q8h B-FRE
prn I-FRE
anxiety/insomnia B-REA

 I-REA
metformin B-DRUG
500 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
glipizide B-DRUG
10 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
aspirin B-DRUG
325 B-STR
mg I-STR
daily B-FRE


 I-FRE
Discharge O
Medications O
: O

 O
Expired O


 O
Discharge O
Disposition O
: O

 O
Expired O


 O
Discharge O
Diagnosis O
: O

 O
Expired O


 O
Discharge O
Condition O
: O

 O
Expired O


 O
Discharge O
Instructions O
: O

 O
Expired O


 O
Followup O
Instructions O
: O

 O
Expired O



 O
Completed O
by:[**2178 O
- O
3 O
- O
28 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2107 O
- O
6 O
- O
3 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2107 O
- O
6 O
- O
9 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2028 O
- O
1 O
- O
5 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
CARDIOTHORACIC O


 O
Allergies O
: O

 O
Codeine B-DRUG
/ O
Iodine-Iodine B-DRUG
Containing O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1505 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Chest O
pain O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
3 O
* O
* O
] O
Coronary O
artery O
bypass O
graft O
x O
2 O
( O
Left O
internal O
mammary O

 O
artery O
to O
left O
anterior O
descending O
, O
Saphenous O
vein O
graft O
to O

 O
diagonal O
) O


 O
History O
of O
Present O
Illness O
: O

 O
79 O
year O
old O
male O
with O
known O
coronary O
artery O
disease O
s/p O
cypher O

 O
stent O
to O
RCA O
in O
[ O
* O
* O
2098 O
* O
* O
] O
who O
has O
been O
complaining O
of O
chronic O
angina O

 O
with O
minimal O
exertion O
. O
In O
addition O
, O
notes O
difficulty O
breathing O
, O

 O
severe O
fatigue O
and O
chest O
pressure O
with O
light O
ADLs O
, O
such O
as O

 O
showering O
and O
picking O
up O
leaves O
. O
Despite O
maximal O
medical O
therapy O

 O
he O
is O
still O
complaining O
of O
recurrent O
angina O
and O
was O
referred O
for O

 O
elective O
catheterization O
. O
Catheterization O
revealed O
diffuse O
left O

 O
anterior O
descending O
narrowing O
with O
new O
narrowing O
at O
branching O
of O

 O
ostium O
which O
is O
not O
amenable O
to O
stenting O
without O
stenting O
over O

 O
circumflex O
. O
He O
presents O
today O
for O
surgical O
evaluation O
. O


 O
Past O
Medical O
History O
: O

 O
Coronary O
artery O
disease O
s/p O
cypher O
stent O
to O
RCA O
[ O
* O
* O
2098 O
* O
* O
] O

 O
Diabetes O

 O
Dyslipidemia O

 O
Hypertension O

 O
Chronic O
Renal O
Insufficiency O
( O
b/l O
cre O
1.5- O
1.9 O
) O

 O
GERD/PUD O

 O
Hiatal O
hernia O

 O
Spinal O
Stenosis O

 O
Benign O
prostatic O
hypertrophy O

 O
" O
Infection O
" O
of O
RLE O
foot-knee O
from O
a O
cut O
on O
his O
toe O
as O
a O
child O

 O
Past O
Surgical O
History O
: O

 O
s/p O
Posterior O
cervical O
laminectomy O
, O
[ O
* O
* O
2076 O
* O
* O
] O
( O
by O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
) O

 O
Lumbar O
laminectomy O
[ O
* O
* O
2104 O
* O
* O
] O

 O
Left O
hip- O
removal O
of O
fat O
tumor O

 O
Herniorrhaphy O
[ O
* O
* O
2075 O
* O
* O
] O

 O
Left O
Cataract O


 O
Social O
History O
: O

 O
Race O
: O
Immigrant O
from O
[ O
* O
* O
Country O
1684 O
* O
* O
] O

 O
Lives O
with O
: O
Wife O

 O
Occupation O
: O
Retired O
mechanic O

 O
Tobacco O
: O
remote O
history O
as O
a O
teenager O

 O
ETOH O
: O
Denies O


 O
Family O
History O
: O

 O
Brother O
died O
of O
MI O
at O
age O
47 O


 O
Physical O
Exam O
: O

 O
Pulse O
: O
80 O
Resp O
: O
18 O
  O
O2 O
sat O
: O
98 O
% O

 O
B/P O
  O
Right O
: O
109/66 O
   O
Left O
: O
105/61 O

 O
Height O
: O
5'8 O
" O
   O
Weight O
: O
84 O
kg O



 O
General O
: O
NAD O

 O
Skin O
: O
Dry O
[ O
X O
] O
intact O
[ O
X O
] O

 O
HEENT O
: O
PERRLA O
[ O
] O
EOMI O
[ O
x O
] O
pupils O
fixed O
( O
cataracts O
) O

 O
Neck O
: O
Supple O
[ O
x O
] O
Full O
ROM O
[ O
x O
] O

 O
Chest O
: O
Lungs O
clear O
bilaterally O
[ O
x O
] O

 O
Heart O
: O
RRR O
[ O
x O
] O
Irregular O
[ O
] O
Murmur O

 O
Abdomen O
: O
Soft O
[ O
x O
] O
non-distended O
[ O
x O
] O
non-tender O
[ O
x O
] O
bowel O
sounds O

 O
+ O

 O
[ O
x O
] O

 O
Extremities O
: O
Warm O
[ O
x O
] O
, O
well-perfused O
[ O
x O
] O

 O
Edema O
none O

 O
Varicosities O
: O
moderate O
varicosities O

 O
well-healed O
scar O
medial O
right O
leg- O
~3inches O
below O
knee O
( O
s/p O

 O
surgery O
for O
" O
infection O
" O
) O

 O
Neuro O
: O
Grossly O
intact O

 O
Pulses O
: O

 O
Femoral O
      O
Right O
: O
2 O
+ O
  O
Left:2 O
+ O

 O
DP O
           O
Right O
: O
2 O
+ O
  O
Left:2 O
+ O

 O
PT O
           O
[ O
* O
* O
Name O
( O
NI O
) O
167 O
* O
* O
] O
: O
2 O
+ O
  O
Left:2 O
+ O

 O
Radial O
       O
Right O
: O
2 O
+ O
  O
Left:2 O
+ O


 O
Carotid O
Bruit O
       O
no O
bruits O
appreciated O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
3 O
* O
* O
] O
Echo O
: O
PREBYPASS O
: O
No O
atrial O
septal O
defect O
is O
seen O
by O
2D O
or O

 O
color O
Doppler O
. O
Left O
ventricular O
wall O
thicknesses O
and O
cavity O
size O

 O
are O
normal O
. O
Regional O
left O
ventricular O
wall O
motion O
is O
normal O
. O

 O
Overall O
left O
ventricular O
systolic O
function O
is O
normal O
( O
LVEF>55 O
% O
) O
. O

 O
Right O
ventricular O
chamber O
size O
and O
free O
wall O
motion O
are O
normal O
. O

 O
The O
ascending O
aorta O
is O
mildly O
dilated O
. O
There O
are O
complex O
( O
> O
4 O
mm O
) O

 O
atheroma O
in O
the O
descending O
thoracic O
aorta O
. O
The O
aortic O
valve O

 O
leaflets O
( O
3 O
) O
are O
mildly O
thickened O
. O
Mild O
( O
1 O
+ O
) O
aortic O

 O
regurgitation O
is O
seen O
. O
The O
mitral O
valve O
leaflets O
are O
mildly O

 O
thickened O
. O
Physiologic O
mitral O
regurgitation O
is O
seen O
( O
within O

 O
normal O
limits O
) O
. O

 O
POSTBYPASS O
: O
There O
is O
preserved O
biventricular O
systolic O
function O
. O

 O
The O
study O
is O
otherwise O
unchanged O
from O
the O
prebypass O
period O
. O


 O
[ O
* O
* O
6 O
- O
8 O
* O
* O
] O
CXR O
: O
The O
lungs O
are O
low O
in O
volume O
but O
clear O
. O
The O
cardiac O

 O
silhouette O
is O
enlarged O
. O
The O
mediastinal O
silhouette O
and O
hilar O

 O
contours O
are O
normal O
. O
No O
pleural O
effusion O
or O
pneumothorax O
is O

 O
present O
. O
Sternal O
wires O
are O
intact O
. O



 O
[ O
* O
* O
2107 O
- O
6 O
- O
9 O
* O
* O
] O
10:47AM O
BLOOD O
WBC-5.6 O
RBC-3.73 O
* O
Hgb-11.8 O
* O
Hct-34.5 O
* O

 O
MCV-93 O
MCH-31.5 O
MCHC-34.1 O
RDW-15.0 O
Plt O
Ct-137 O
* O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
8 O
* O
* O
] O
05:00AM O
BLOOD O
WBC-4.4 O
RBC-3.66 O
* O
Hgb-11.2 O
* O
Hct-31.8 O
* O

 O
MCV-87 O
MCH-30.6 O
MCHC-35.2 O
* O
RDW-15.0 O
Plt O
Ct-95 O
* O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
6 O
* O
* O
] O
04:35AM O
BLOOD O
WBC-2.6 O
* O
# O
RBC-2.65 O
* O
Hgb-8.2 O
* O
Hct-23.4 O
* O

 O
MCV-88 O
MCH-31.0 O
MCHC-35.0 O
RDW-15.0 O
Plt O
Ct-73 O
* O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
3 O
* O
* O
] O
04:32PM O
BLOOD O
WBC-5.6 O
RBC-2.60 O
* O
# O
Hgb-8.2 O
* O
# O
Hct-23.0 O
* O
# O

 O
MCV-88 O
MCH-31.6 O
MCHC-35.7 O
* O
RDW-14.8 O
Plt O
Ct-67 O
* O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
9 O
* O
* O
] O
10:47AM O
BLOOD O
Plt O
Ct-137 O
* O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
7 O
* O
* O
] O
09:30AM O
BLOOD O
PT-12.0 O
PTT-23.0 O
INR(PT)-1.0 O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
3 O
* O
* O
] O
04:32PM O
BLOOD O
Plt O
Smr-VERY O
LOW O
Plt O
Ct-67 O
* O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
3 O
* O
* O
] O
04:32PM O
BLOOD O
PT-13.9 O
* O
PTT-26.7 O
INR(PT)-1.2 O
* O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
3 O
* O
* O
] O
04:32PM O
BLOOD O
Fibrino-198 O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
9 O
* O
* O
] O
10:47AM O
BLOOD O
Glucose-166 O
* O
UreaN-34 O
* O
Creat-1.7 O
* O
Na-136 O

 O
K-3.9 O
Cl-98 O
HCO3 O
- O
27 O
AnGap-15 O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
6 O
* O
* O
] O
04:35AM O
BLOOD O
Glucose-173 O
* O
UreaN-43 O
* O
Creat-2.3 O
* O
Na-133 O

 O
K-5.0 O
Cl-98 O
HCO3 O
- O
27 O
AnGap-13 O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
3 O
* O
* O
] O
05:41PM O
BLOOD O
UreaN-31 O
* O
Creat-1.4 O
* O
Na-136 O
K-4.8 O
Cl-107 O

 O
HCO3 O
- O
22 O
AnGap-12 O

 O
[ O
* O
* O
2107 O
- O
6 O
- O
6 O
* O
* O
] O
04:35AM O
BLOOD O
TotBili-1.6 O
* O


 O
[ O
* O
* O
2107 O
- O
6 O
- O
7 O
* O
* O
] O
1:31 O
pm O
SPUTUM O
     O
Site O
: O
EXPECTORATED O

       O
Source O
: O
Expectorated O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2107 O
- O
6 O
- O
9 O
* O
* O
] O
* O
* O


    O
GRAM O
STAIN O
( O
Final O
[ O
* O
* O
2107 O
- O
6 O
- O
7 O
* O
* O
] O
) O
: O

       O
> O
25 O
PMNs O
and O
< O
10 O
epithelial O
cells/100X O
field O
. O

       O
3 O
+ O
  O
( O
5 O
- O
10 O
per O
1000X O
FIELD O
) O
: O
   O
MULTIPLE O
ORGANISMS O

 O
CONSISTENT O
WITH O

                                     O
OROPHARYNGEAL O
FLORA O
. O

       O
2 O
+ O
   O
( O
1 O
- O
5 O
per O
1000X O
FIELD O
) O
: O
   O
BUDDING O
YEAST O
. O


    O
RESPIRATORY O
CULTURE O
( O
Final O
[ O
* O
* O
2107 O
- O
6 O
- O
9 O
* O
* O
] O
) O
: O

       O
SPARSE O
GROWTH O
Commensal O
Respiratory O
Flora O
. O

       O
GRAM O
NEGATIVE O
ROD(S O
) O
. O



 O
Brief O
Hospital O
Course O
: O

 O
Admitted O
same O
day O
surgery O
and O
was O
brought O
to O
the O
operating O
room O

 O
for O
coronary O
artery O
bypass O
graft O
surgery O
. O
  O
Please O
see O
operative O

 O
report O
for O
surgical O
details O
. O
He O
received O
cefazolin B-DRUG
for O

 O
perioperative B-REA
antibiotics B-DRUG
and O
was O
transferred O
to O
the O
intensive O

 O
care O
unit O
for O
post O
operative O
management O
. O
  O
That O
evening O
he O
was O

 O
weaned O
from O
sedation O
, O
awoke O
neurologically O
intact O
, O
and O
was O

 O
extubated O
without O
complications O
. O
  O
On O
post-op O
day O
one O
he O
was O

 O
started O
on O
beta-blockers B-DRUG
, I-DRUG
diuretics B-DRUG
and O
metformin B-DRUG
. I-DRUG
Later O
that O

 O
day O
he O
was O
transferred O
to O
the O
floor O
. O
  O
Physical O
therapy O
worked O

 O
with O
him O
on O
strength O
and O
mobility O
. O
  O
On O
post O
operative O
day O
two O
he O

 O
had O
episodes O
of O
nausea B-REA
treated O
with O
antiemtics B-DRUG
and O
then O
short O

 O
episode O
of O
confusion B-ADE
so O
his O
narcotics B-DRUG
were O
stopped O
and O
he O
was O

 O
placed O
on O
ultram B-DRUG
for O
pain B-REA
management I-REA
with O
good O
effect O
. O
  O
Due O
to O

 O
increased O
creatinine O
to O
2.1 O
his O
lasix B-DRUG
and O
metformin B-DRUG
were O

 O
stopped O
, O
and O
lantus B-DRUG
was O
increased O
for O
blood B-REA
glucose I-REA
management I-REA
. I-REA

 O
Over O
the O
next O
few O
days O
his O
creatinine O
peaked O
at O
2.3 O
on O
[ O
* O
* O
6 O
- O
6 O
* O
* O
] O
and O

 O
trended O
down O
to O
1.7 O
at O
discharge O
. O
  O
He O
was O
resumed O
on O
lasix B-DRUG
for O

 O
diuresiss B-REA
with O
lower B-REA
extremity I-REA
edema I-REA
. I-REA
  O
Additionally O
he O
had O

 O
decreased B-REA
hematocrit I-REA
requiring O
transfusions B-DRUG
, I-DRUG
and O
restarted O
on O

 O
home O
iron B-DRUG
. I-DRUG
  O
Hematocrits O
were O
trended O
daily O
and O
they O
remained O

 O
stable O
. O
  O
Also O
his O
white O
blood O
cell O
count O
dropped O
but O
no O
fever O

 O
and O
differential O
was O
normal O
, O
he O
was O
pan O
cultured O
and O
to O
date O

 O
only O
grew O
on O
gram O
negative O
rods O
from O
sputum O
and O
was O
placed O
on O

 O
levaquin B-DRUG
. I-DRUG
  O
He O
continued O
to O
improve O
and O
was O
ready O
for O
discharge O

 O
to O
rehab O
on O
post O
operative O
day O
six O
to O
Newbridge O
on O
the O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O

 O
with O
plan O
for O
follow O
up O
wound O
check O
next O
week O
for O
evaluation O
of O

 O
right O
leg O
. O


 O
Medications O
on O
Admission O
: O

 O
Doxazosin B-DRUG
4 B-STR
mg I-STR
daily B-FRE

 I-FRE
Finasteride B-DRUG
5 B-STR
mg I-STR
daily B-FRE

 I-FRE
Isosorbide B-DRUG
mononitrate I-DRUG
10 B-STR
mg I-STR
daily B-FRE

 I-FRE
Pantoprazole B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
Simvastatin B-DRUG
80 B-STR
mg I-STR
daily B-FRE

 I-FRE
Tramadol B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
every B-FRE
eight I-FRE
hours I-FRE
PRN I-FRE

 I-FRE
Metoprolol B-DRUG
succinate I-DRUG
50 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Betamethasone B-DRUG
valerate I-DRUG
0.1 B-STR
% O
Cream B-FOR
, I-FOR
apply O
to O
affected O
area O
twice B-FRE

 I-FRE
daily I-FRE

 I-FRE
Lorazepam B-DRUG
0.5 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
prn B-FRE
for O
anxiety B-REA

 I-REA
Metformin B-DRUG
1,000 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Nitrostat B-DRUG
0.4 B-STR
mg I-STR
Sublingual B-ROU
PRN B-FRE
for O
chest B-REA
pain I-REA

 I-REA
Travatan B-DRUG
Z I-DRUG
0.004 B-STR
% O
Drops B-FOR
Ophthalmic B-ROU

 I-ROU
Brimonidine B-DRUG
0.15 B-STR
% O
Drops B-FOR
Ophthalmic B-ROU

 I-ROU
Aspirin B-DRUG
81 B-STR
mg I-STR
daily B-FRE

 I-FRE
Amlodipine B-DRUG
2.5 B-STR
mg I-STR
daily B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
2 O
. O
simvastatin B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
3 O
. O
Colace B-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
4 O
. O
Ultram B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
every B-FRE
four I-FRE
( I-FRE
4 I-FRE
) I-FRE

 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
5 O
. O
doxazosin B-DRUG
4 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
6 O
. O
finasteride B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
7 O
. O
Protonix B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
8 O
. O
carvedilol B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
9 O
. O
ferrous B-DRUG
sulfate I-DRUG
325 B-STR
mg I-STR
( O
65 B-STR
mg I-STR
iron B-DRUG
) I-DRUG
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
10 O
. O
ascorbic B-DRUG
acid I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE

 I-FRE
day I-FRE
. I-FRE

 O
11 O
. O
levofloxacin B-DRUG
250 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q24H B-FRE

 I-FRE
( O
every O
24 O
hours O
) O
for B-DUR
7 I-DUR
days I-DUR
. I-DUR

 O
12 O
. O
chlorhexidine B-DRUG
gluconate I-DRUG
0.12 B-STR
% I-STR
Mouthwash B-FOR
Sig O
: O
Fifteen B-DOS
( I-DOS
15 I-DOS
) I-DOS

 I-DOS
ML I-DOS
Mucous B-ROU
membrane I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
13 O
. O
Mucinex B-DRUG
1,200 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
ER I-FOR
Multiphase I-FOR
12 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
ER I-FOR
Multiphase I-FOR
12 I-FOR
hr I-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
14 O
. O
albuterol B-DRUG
sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( O
0.083 B-STR
% O
) O
Solution B-FOR
for I-FOR

 I-FOR
Nebulization I-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
ml I-DOS
Inhalation B-ROU
Q2H B-FRE
( I-FRE
every I-FRE
2 I-FRE
hours I-FRE
) I-FRE
as I-FRE

 I-FRE
needed I-FRE
for O
wheezing B-REA
. I-REA

 O
15 O
. O
ipratropium-albuterol B-DRUG
18 B-STR
- I-STR
103 I-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
Two B-DOS

 I-DOS
( I-DOS
2 I-DOS
) I-DOS
Puff B-FOR
Inhalation B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
16 O
. O
lorazepam B-DRUG
0.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
: I-FRE
0.25 B-STR

 I-STR
mg I-STR
twice B-FRE
a I-FRE
day I-FRE
. O

 O
17 O
. O
cyanocobalamin B-DRUG
( I-DRUG
vitamin I-DRUG
B-12 I-DRUG
) I-DRUG
1,000 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
Six B-DOS
( I-DOS
6 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
: I-FRE
6000 B-STR
mcg I-STR
. O

 O
18 O
. O
sliding B-DOS
scale I-DOS
insulin B-DRUG

 I-DRUG
Insulin B-DRUG
SC B-ROU
Sliding B-DOS
Scale I-DOS

   I-DOS
Breakfast B-FRE
Lunch I-FRE
Dinner I-FRE
Bedtime I-FRE

 I-FRE
Regular O
Regular O
Regular O
Regular O

 O
Glucose O
Insulin B-DRUG
Dose O
Insulin B-DRUG
Dose O
Insulin B-DRUG
Dose O
Insulin B-DRUG
Dose O

 O
0 O
- O
70 O
   O
mg/dL O
Proceed O
with O
hypoglycemia O
protocol O
Proceed O
with O

 O
hypoglycemia O
protocol O
Proceed O
with O
hypoglycemia O
protocol O
Proceed O

 O
with O
hypoglycemia O
protocol O

 O

71 O
- O
90 O
   O
mg/dL O
0 O
   O
Units O
0 O
   O
Units O
0 O
   O
Units O
0 O
   O
Units O

 O
91 O
- O
140 O
   O
mg/dL O
3 O
   O
Units O
3 O
   O
Units O
3 O
   O
Units O
0 O
   O
Units O

 O
141 O
- O
180 O
   O
mg/dL O
6 O
   O
Units O
6 O
   O
Units O
6 O
   O
Units O
2 O
   O
Units O

 O
181 O
- O
220 O
   O
mg/dL O
9 O
   O
Units O
9 O
   O
Units O
9 O
   O
Units O
4 O
   O
Units O

 O
221 O
- O
280 O
   O
mg/dL O
12 O
   O
Units O
12 O
   O
Units O
12 O
   O
Units O
6 O
   O
Units O


 O
19 O
. O
insulin B-DRUG
glargine I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
Thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS
units I-DOS

 I-DOS
Subcutaneous B-ROU
at B-FRE
bedtime I-FRE
. I-FRE

 O
20 O
. O
furosemide B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
21 O
. O
potassium B-DRUG
chloride I-DRUG
20 B-STR
mEq I-STR
Tablet B-FOR
, I-FOR
ER I-FOR
Particles/Crystals I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
ER I-FOR
Particles/Crystals I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
Newbridge O
on O
the O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
1411 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Coronary O
artery O
disease O
s/p O
CABG O

 O
Anemia O

 O
Diabetes O
Mellitus O

 O
Dyslipidemia O

 O
Hypertension O

 O
Chronic O
Renal O
Insufficiency O
( O
creatinine O
1.5- O
1.9 O
) O

 O
Gastroesophageal O
reflux O
disease O

 O
Hiatal O
hernia O

 O
Spinal O
Stenosis O

 O
Benign O
prostatic O
hypertrophy O



 O
Discharge O
Condition O
: O

 O
Alert O
and O
oriented O
x3 O
nonfocal O

 O
Ambulating O
with O
steady O
gait O

 O
Incisional B-REA
pain I-REA
managed O
with O
Ultram B-DRUG
as B-FRE
needed I-FRE

 I-FRE
Incisions O
: O

 O
Sternal O
- O
healing O
well O
, O
no O
erythema O
or O
drainage O

 O
Leg O
Right O
- O
healing O
well O
, O
no O
erythema O
or O
drainage O
, O
significant O

 O
ecchymosis O
knee O
up O
through O
thigh O
no O
warmth O

 O
Edema O
+ O
1 O
pitting O
bilateral O
lower O
extremities O



 O
Discharge O
Instructions O
: O

 O
Please O
shower O
daily O
including O
washing O
incisions O
gently O
with O
mild O

 O
soap O
, O
no O
baths O
or O
swimming O
until O
cleared O
by O
surgeon O
. O
Look O
at O

 O
your O
incisions O
daily O
for O
redness O
or O
drainage O

 O
Please O
NO O
lotions O
, O
cream O
, O
powder O
, O
or O
ointments O
to O
incisions O

 O
Each O
morning O
you O
should O
weigh O
yourself O
and O
then O
in O
the O
evening O

 O
take O
your O
temperature O
, O
these O
should O
be O
written O
down O
on O
the O
chart O


 O
No O
driving O
for O
approximately O
one O
month O
and O
while O
taking O

 O
narcotics B-DRUG
, I-DRUG
will O
be O
discussed O
at O
follow O
up O
appointment O
with O

 O
surgeon O
when O
you O
will O
be O
able O
to O
drive O

 O
No O
lifting O
more O
than O
10 O
pounds O
for O
10 O
weeks O

 O
Please O
call O
with O
any O
questions O
or O
concerns O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O


 O
* O
* O
Please O
call O
cardiac O
surgery O
office O
with O
any O
questions O
or O

 O
concerns O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O
. O
Answering O
service O
will O
contact O
on O
call O

 O
person O
during O
off O
hours O
* O
* O



 O
Followup O
Instructions O
: O

 O
You O
are O
scheduled O
for O
the O
following O
appointments O

 O
Wound O
check O
Cardiac O
surgery O
office O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O
on O
[ O
* O
* O
6 O
- O
15 O
* O
* O
] O
at O
11 O
am O

 O
Surgeon O
: O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O
on O
[ O
* O
* O
6 O
- O
30 O
* O
* O
] O
at O
1:00pm O

 O
Cardiologist O
: O
Dr. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
919 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
911 O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
62 O
* O
* O
] O
on O
[ O
* O
* O
7 O
- O
6 O
* O
* O
] O
at O
3:00pm O


 O
Please O
call O
to O
schedule O
appointments O
with O
your O

 O
Primary O
Care O
Dr. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
172 O
* O
* O
] O
in O
[ O
* O
* O
3 O
- O
1 O
* O
* O
] O
weeks O


 O
* O
* O
Please O
call O
cardiac O
surgery O
office O
with O
any O
questions O
or O

 O
concerns O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O
. O
Answering O
service O
will O
contact O
on O
call O

 O
person O
during O
off O
hours O
* O
* O




 O
Completed O
by:[**2107 O
- O
6 O
- O
9 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2106 O
- O
7 O
- O
4 O
* O
* O
] O
       O
Discharge O
Date O
: O
  O
[ O
* O
* O
2106 O
- O
7 O
- O
13 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
   O
[ O
* O
* O
2056 O
- O
12 O
- O
21 O
* O
* O
] O
       O
Sex O
: O
  O
M O


 O
Service O
: O
  O
Cardiothoracic O
Surgery O


 O
HISTORY O
OF O
PRESENT O
ILLNESS O
: O
  O
This O
is O
a O
49-year-old O
gentleman O

 O
with O
a O
known O
history O
of O
ischemic O
cardiomyopathy O
with O
an O

 O
estimated O
ejection O
fraction O
of O
approximately O
20 O
% O
. O
  O
He O
had O

 O
been O
accepted O
by O
the O
[ O
* O
* O
Hospital O
4415 O
* O
* O
] O
heart O

 O
transplant O
service O
and O
was O
at O
home O
listed O
as O
a O
status O
2 O

 O
awaiting O
cardiac O
transplantation O
. O


 O
On O
[ O
* O
* O
2106 O
- O
7 O
- O
4 O
* O
* O
] O
the O
patient O
had O
new O
onset O
chest O
pain O
and O
was O

 O
admitted O
to O
the O
hospital O
where O
he O
ruled O
in O
for O
myocardial O

 O
infarction O
. O


 O
PAST O
MEDICAL O
HISTORY O
: O
  O
1 O
. O
Type O
1 O
diabetes O
. O
  O
2 O
. O
Known O
coronary O

 O
artery O
disease O
status O
post O
multiple O
cardiac O
catheterizations O
. O

 O
He O
is O
status O
post O
automatic O
implantable O

 O
cardioverter-defibrillator O
placement O
. O
  O
He O
has O
ischemic O

 O
cardiomyopathy O
. O
  O
3 O
. O
Hypothyroidism O
. O


 O
MEDICATIONS O
ON O
ADMISSION O
: O
  O
1 O
. O
Coreg B-DRUG
25 B-STR
mg I-STR
p.o B-ROU
. I-ROU
q.d B-FRE
. I-FRE
  O
2 O
. O

 O
Toprol B-DRUG
25 B-STR
mg I-STR
p.o B-ROU
. I-ROU
q.d B-FRE
. I-FRE
  O
3 O
. O
Plavix B-DRUG
75 B-STR
mg I-STR
p.o B-ROU
. I-ROU
q.d B-FRE
. I-FRE
  O
4 O
. O
Aspirin B-DRUG

 I-DRUG
325 B-STR
mg I-STR
p.o B-ROU
. I-ROU
q.d B-FRE
. I-FRE
  O
5 O
. O
Aldactone B-DRUG
12 B-STR
mg I-STR
p.o B-ROU
. I-ROU
q.d B-FRE
. I-FRE
  O
6 O
. O
Synthroid B-DRUG

 I-DRUG
0.125 B-STR
p.o B-ROU
. I-ROU
q.d B-FRE
. I-FRE
  O
7 O
. O
Lantus B-DRUG
insulin I-DRUG
25 B-STR
q.d B-FRE
. I-FRE
  O
8 O
. O
Humalog B-DRUG

 I-DRUG
sliding B-DOS
scale I-DOS
subcutaneous B-ROU
insulin B-DRUG
coverage O
. O


 O
ALLERGIES O
: O
  O
ACE B-DRUG
inhibitor I-DRUG
cause O
a O
cough B-ADE
. I-ADE


 O
HOSPITAL O
COURSE O
: O
  O
The O
patient O
was O
taken O
to O
the O
cardiac O

 O
catheterization O
laboratory O
where O
he O
was O
found O
to O
have O

 O
significant O
multivessel O
coronary O
artery O
disease O
including O
a O

 O
30 O
% O
left O
main O
and O
99 O
% O
left O
anterior O
descending O
coronary O

 O
artery O
, O
totally O
occluded O
left O
circumflex O
and O
totally O
occluded O

 O
right O
coronary O
. O
  O
His O
left O
ventricular O
ejection O
fraction O
was O

 O
estimated O
at O
13 O
% O
at O
cardiac O
catheterization O
. O
  O
The O
patient O
was O

 O
then O
referred O
to O
the O
cardiothoracic O
surgery O
service O
for O

 O
assessment O
for O
coronary O
artery O
bypass O
grafting O
. O



 O
The O
patient O
subsequently O
preoperatively O
was O
managed O
on O
the O

 O
cardiology O
service O
approximately O
[ O
* O
* O
2106 O
- O
7 O
- O
8 O
* O
* O
] O
, O
was O
noted O
to O
have O

 O
a O
dropping O
hematocrit O
and O
was O
sent O
for O
an O
urgent O
CT O
scan O
of O

 O
his O
abdomen O
and O
pelvis O
to O
rule O
out O
a O
source O
of O
hematocrit O

 O
drop O
. O
  O
He O
was O
found O
to O
have O
no O
intra-abdominal O
nor O

 O
retroperitoneal O
hematoma O
at O
that O
time O
however O
it O
was O
noted O

 O
that O
he O
had O
a O
pericardial O
effusion O
. O
  O
The O
patient O
also O
on O

 O
[ O
* O
* O
2106 O
- O
7 O
- O
8 O
* O
* O
] O
underwent O
a O
myocardial O
viability O
study O
which O
showed O

 O
diffuse O
uptake O
consistent O
with O
diffuse O
viability O
of O
left O

 O
ventricular O
wall O
. O
  O
The O
patient O
remained O
on O
the O
cardiology O

 O
service O
and O
was O
taken O
to O
the O
operating O
room O
on O
[ O
* O
* O
2106 O
- O
7 O
- O
12 O
* O
* O
] O
where O

 O
he O
underwent O
coronary O
artery O
bypass O
grafting O
x O
4 O
by O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
Prefixes O
) O
* O
* O
] O
. O
  O
He O
had O
a O
LIMA O
to O
the O
LAD O
, O
saphenous O
vein O
to O
the O

 O
RPL O
, O
saphenous O
vein O
to O
the O
D1 O
, O
to O
the O
OM O
. O
  O
The O
patient O
had O
a O

 O
preoperative O
intra-aortic O
balloon O
pump O
placed O
at O
the O

 O
beginning O
of O
the O
case O
prophylactically O
due O
to O
his O
poor O

 O
ejection O
fraction O
. O
  O
The O
patient O
did O
wean O
from O
cardiopulmonary O

 O
bypass O
and O
his O
chest O
was O
being O
closed O
when O
he O
was O
noted O
to O

 O
have O
significant O
problems O
with O
hypotension O
. O
  O
At O
that O
time O
it O

 O
was O
felt O
appropriate O
to O
place O
him O
on O
a O
left O
ventricular O

 O
assist O
device O
. O
  O
He O
was O
also O
placed O
on O
vasopressin B-DRUG
, I-DRUG

 O
epinephrine B-DRUG
, I-DRUG
Levophed B-DRUG
, I-DRUG
and O
milrinone B-DRUG
drips B-ROU
. I-ROU
  O
With O
the O
support O

 O
of O
the O
left O
ventricular O
assist O
device O
and O
the O
pressors B-DRUG
and O

 O
inotropic B-DRUG
agents I-DRUG
the O
patient O
was O
successfully O
transported O

 O
from O
the O
operating O
room O
to O
the O
cardiac B-REA
surgery I-REA
recovery O
unit O

 O
in O
the O
evening O
of O
[ O
* O
* O
2106 O
- O
7 O
- O
12 O
* O
* O
] O
where O
he O
proceeded O
to O
wake O
up O
from O

 O
general B-DRUG
anesthesia I-DRUG
. I-DRUG
  O
He O
required O
some O
fluid O
resuscitation O

 O
with O
blood B-DRUG
products I-DRUG
over O
the O
course O
of O
the O
first O
few O

 O
postoperative O
hours O
and O
remained O
relatively O
stable O
on O
the O

 O
support O
. O



 O
On O
physical O
examination O
at O
this O
time O
, O
neurologically O
the O

 O
patient O
is O
sedated B-REA
on O
propofol B-DRUG
but O
is O
easily O
awoken O
, O
follows O

 O
commands O
, O
nods O
his O
head O
appropriately O
and O
moves O
all O

 O
extremities O
. O
  O
From O
a O
cardiac O
standpoint O
the O
patient O
has O
a O

 O
blood O
pressure O
from O
90 O
to O
110s O
systolic O
with O
a O
mean O
arterial O

 O
pressure O
of O
65 O
to O
70 O
, O
presently O
on O
vasopressin B-DRUG
, I-DRUG
epinephrine B-DRUG
, I-DRUG

 O
Levophed B-DRUG
and O
milrinone B-DRUG
drips B-ROU
. I-ROU
  O
He O
is O
on O
an O
left O
ventricular O

 O
assist O
device O
, O
Abiomed O
BVAD O
5000 O
I O
, O
with O
liter O
flows O
between O

 O
5 O
and O
5.6 O
liters O
per O
minute O
. O
  O
His O
thermodilution O
cardiac O

 O
output O
has O
also O
been O
in O
the O
5 O
to O
6 O
liter O
per O
minute O
range O

 O
with O
an O
SvO2 B-DRUG
of O
approximately O
70 O
% O
. O
  O
The O
patient O
's O
lungs O
are O

 O
rhonchorous O
. O
  O
The O
patient O
has O
adequate O
oxygenation O
at O
this O

 O
time O
. O
  O
His O
abdomen O
is O
soft O
, O
nontender O
. O
  O
His O
extremities O
are O

 O
warm O
with O
minimal O
edema O
and O
he O
has O
positive O
Doppler O
signals O

 O
in O
both O
of O
his O
feet O
. O
  O
Immediately O
postoperatively O
the O

 O
patient O
's O
intra-aortic O
balloon O
pump O
was O
removed O
at O
the O

 O
bedside O
. O
  O
Manual O
pressure O
was O
held O
for O
35 O
minutes O
. O
  O
The O
groin O

 O
looks O
good O
without O
signs O
of O
bleeding O
or O
hematoma O
and O
the O

 O
pulse O
remains O
audible O
by O
Doppler O
in O
his O
balloon O
foot O
, O
which O

 O
is O
the O
right O
. O


 O
CURRENT O
MEDICATIONS O
: O
  O
1 O
. O
IV B-ROU
vasopressin B-DRUG
drip B-FOR
at O
0.8 B-DOS
units I-DOS
per I-DOS

 I-DOS
minute I-DOS
. I-DOS
  O
2 O
. O
Epinephrine B-DRUG
0.025 B-STR
mcg I-STR
per I-STR
kg I-STR
per I-STR
minute I-STR
. I-STR
  O
3 O
. O

 O
Levophed B-DRUG
0.02 B-STR
mcg I-STR
per I-STR
kg I-STR
per I-STR
minute I-STR
. I-STR
  O
4 O
. O
Milrinone B-DRUG
0.5 B-STR
mcg I-STR

 I-STR
per I-STR
kg I-STR
per I-STR
minute I-STR
. I-STR
  O
5 O
. O
Propofol B-DRUG
30 B-STR
. I-STR
  O
6 O
. O
Vancomycin B-DRUG
1 B-STR
gram I-STR
q. B-FRE

 I-FRE
12 I-FRE
hours I-FRE
. I-FRE
  O
7 O
. O
Carafate B-DRUG
1 B-STR
gram I-STR
q. B-FRE
6 I-FRE
hours I-FRE
. I-FRE
  O
8 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR

 I-STR
q.d B-FRE
. I-FRE
  O
9 O
. O
Ranitidine B-DRUG
150 B-STR
mg I-STR
b.i.d B-FRE
. I-FRE
  O
10 O
. O
Insulin B-DRUG
drip B-ROU
at O
29 B-STR

 I-STR
units I-STR
per B-FRE
hour I-FRE
, I-FRE
maintaining B-REA
a I-REA
blood I-REA
sugar I-REA
in I-REA
the I-REA
120 I-REA
- I-REA
140 I-REA

 I-REA
range I-REA
at O
this O
time O
. O


 O
MOST O
RECENT O
LABORATORY O
DATA O
: O
  O
White O
blood O
cell O
count O
10.4 O
, O

 O
hematocrit O
30.6 O
, O
platelet O
count O
167 O
. O
  O
Sodium O
138 O
, O
potassium O

 O
3.7 O
, O
chloride O
103 O
, O
CO2 O
17 O
, O
BUN O
16 O
, O
creatinine O
0.9 O
, O
glucose O

 O
131 O
. O
  O
His O
most O
recent O
prothrombin O
time O
is O
15.1 O
with O
an O
INR O
of O

 O
1.5 O
, O
PTT O
is O
42.6 O
. O
  O
Blood O
gas O
from O
this O
morning O
is O
pH O
7.42 O
, O

 O
PaCO2 O
32 O
, O
PaO2 O
116 O
, O
bicarbonate O
21 O
, O
base O
deficit O
-2 O
. O

 O
Initially O
postoperatively O
the O
patient O
had O
a O
significant O

 O
metabolic B-REA
acidosis I-REA
which O
resolved O
with O
a O
total O
of O
[ B-DOS
* I-DOS
* I-DOS
3 I-DOS
- I-DOS
1 I-DOS
* I-DOS
* I-DOS
] I-DOS
amps I-DOS
of O

 O
bicarbonate B-DRUG
over O
the O
course O
of O
the O
night O
, O
blood O
products O
and O

 O
fluid O
resuscitation O
. O



 O
DISCHARGE O
DIAGNOSES O
: O
  O
Ischemic O
cardiomyopathy O
with O
left O

 O
ventricular O
assist O
device O
placement O
status O
post O
coronary O

 O
artery O
bypass O
grafting O
x O
4 O
. O


 O
CONDITION O
: O
  O
His O
condition O
remains O
critical O
. O


 O
DISPOSITION O
: O
  O
He O
is O
being O
transported O
to O
the O
[ O
* O
* O
Hospital O
8503 O
* O
* O
] O
under O
the O
care O
of O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
36737 O
* O
* O
] O
for O
assessment O

 O
for O
heart O
transplant O
as O
well O
as O
possible O
HeartMate O
left O

 O
ventricular O
assist O
device O
placement O
in O
the O
next O
few O
days O
. O






                             O
[ O
* O
* O
Doctor O
Last O
Name O
412 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Prefixes O
) O
413 O
* O
* O
] O
, O
M.D. O
  O
[ O
* O
* O
MD O
Number(1 O
) O
414 O
* O
* O
] O


 O
Dictated O
By:[**Name8 O
( O
MD O
) O
964 O
* O
* O
] O

 O
MEDQUIST36 O


 O
D O
: O
  O
[ O
* O
* O
2106 O
- O
7 O
- O
13 O
* O
* O
] O
  O
09:36 O

 O
T O
: O
  O
[ O
* O
* O
2106 O
- O
7 O
- O
13 O
* O
* O
] O
  O
10:06 O

 O
JOB O
# O
: O
  O
[ O
* O
* O
Job O
Number O
36738 O
* O
* O
] O

 O

Admission O
Date O
: O
  O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2172 O
- O
12 O
- O
7 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2126 O
- O
2 O
- O
28 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Zosyn B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
603 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Hemoptysis O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Rigid O
bronchoscopy O
with O
embolization O

 O
Endotracheal O
intubation O



 O
History O
of O
Present O
Illness O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
88527 O
* O
* O
] O
is O
a O
46-year-old O
man O
with O
no O
significant O
PMH O
who O

 O
presented O
on O
[ O
* O
* O
2172 O
- O
11 O
- O
20 O
* O
* O
] O
to O
an O
OSH O
with O
a O
chief O
complaint O
of O

 O
hemoptysis O
. O
He O
reported O
that O
on O
[ O
* O
* O
2172 O
- O
11 O
- O
19 O
* O
* O
] O
he O
was O
woken O
up O
by O

 O
coughing O
and O
coughed O
up O
about O
half O
a O
cup O
of O
bright O
red O
blood O
. O
He O

 O
had O
a O
second O
episode O
of O
hemoptysis O
on O
[ O
* O
* O
2172 O
- O
11 O
- O
20 O
* O
* O
] O
and O
presented O
to O

 O
OSH O
ED O
. O
Because O
the O
pt O
had O
several O
episodes O
of O
hemoptysis O
( O
and O

 O
one O
in O
the O
ED O
) O
the O
pt O
was O
admitted O
for O
bronchoscopy O
. O
On O
[ O
* O
* O
2172 O
- O
11 O
- O
20 O
* O
* O
] O

 O
the O
pt O
was O
taken O
for O
bronchoscopy O
which O
was O
unable O
to O
be O

 O
performed O
due O
to O
difficulties O
with O
sedation O
, O
and O
a O
significant O

 O
amount O
of O
periglottic O
edema O
. O
The O
pt O
was O
then O
taken O
to O
the O
OR O
for O

 O
bronchoscopy O
under O
genearal O
anesthesia O
and O
endotracheal O

 O
intubation O
, O
and O
during O
the O
procedure O
a O
fresh O
clot O
was O
visualized O

 O
in O
the O
left O
lingula O
, O
which O
, O
when O
gently O
disturbed O
, O
produced O

 O
brisk O
bleeding O
. O
Due O
to O
the O
extent O
of O
bleeding O
patient O
was O
left O

 O
intubated O
and O
transfered O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
further O
evaluation O
. O


 O
Past O
Medical O
History O
: O

 O
None O
. O


 O
Social O
History O
: O

 O
Common O
law O
wife O
of O
25 O
[ O
* O
* O
Name2 O
( O
NI O
) O
1686 O
* O
* O
] O
. O
Works O
installing O
security O
systems O
. O
No O

 O
drug O
use O
, O
pets O
, O
travel O
, O
hobby O
exposures O
. O
  O
Tobacco O
: O
1.5pack/d O
x O

 O
5yrs O
, O
previously O
had O
quit O
for O
20yrs O
. O
  O
EtOH O
: O
one O
6 O
pack O
per O
day O

 O
plus O
vodka O
. O



 O
Family O
History O
: O

 O
Unable O
to O
obtain O



 O
Physical O
Exam O
: O

 O
Admission O
: O

 O
VS O
: O
Temp O
: O
afebrile O
BP:114/69 O
HR O
: O
52 O
RR O
: O
18 O
O2sat O
96 O
% O
on O
A/c O

 O
GEN O
: O
intubated O
, O
appears O
comfortable O

 O
HEENT O
: O
PERRL O
, O
anicteric O
, O
MMM O
, O
op O
without O
lesions O
, O
no O

 O
supraclavicular O
or O
cervical O
lymphadenopathy O
, O
no O
jvd O
, O
no O
carotid O

 O
bruits O
, O
no O
thyromegaly O
or O
thyroid O
nodules O

 O
RESP O
: O
CTA O
b/l O
with O
good O
air O
movement O
anteriorly O

 O
CV O
: O
RRR O
, O
S1 O
and O
S2 O
wnl O
, O
no O
m/r/g O

 O
ABD O
: O
nd O
, O
+ O
b/s O
, O
soft O
, O
nt O
, O
no O
masses O
or O
hepatosplenomegaly O

 O
EXT O
: O
no O
c/c/e O

 O
SKIN O
: O
no O
rashes/no O
jaundice/no O
splinters O

 O
NEURO O
: O
Intubated O
, O
moving O
all O
extremities O


 O
Discharge O
: O

 O
VS:99.4 O
84 O
120/62 O
18 O
99%RA O

 O
GA O
: O
AOx3 O
, O
NAD O

 O
HEENT O
: O
  O
PERRLA O
. O
MMM O
. O
no O
LAD O
. O
no O
JVD O
. O
neck O
supple O
. O

 O
Cards O
: O
PMI O
palpable O
at O
5/6th O
IC O
space O
. O
No O
RVH O
. O
RRR O
S1/S2 O
heard O
. O

 O
no O
murmurs/gallops/rubs O
. O

 O
Pulm O
: O
CTAB O
no O
crackles O
or O
wheezes O

 O
Abd O
: O
soft O
, O
NT O
, O
+ O
BS O
. O
no O
g/rt O
. O
neg O
HSM O
. O
neg O
[ O
* O
* O
Doctor O
Last O
Name O
515 O
* O
* O
] O
sign O
. O

 O
Extremities O
: O
wwp O
, O
1 O
+ O
edema O
b/l O
ankles O
. O
DPs O
, O
PTs O
2 O
+ O
. O

 O
Skin O
: O
maculopapular O
rash O
on O
extremities O
, O
back O
and O
chest O

 O
Neuro/Psych O
: O
CNs O
II-XII O
intact O
. O
5/5 O
strength O
in O
U/L O
extremities O
. O

 O
DTRs O
2 O
+ O
BL O
( O
biceps O
, O
achilles O
, O
patellar O
) O
. O
sensation O
intact O
to O
LT O
, O

 O
pain O
, O
temperature O
, O
vibration O
, O
proprioception O
. O
cerebellar O
fxn O

 O
intact O
( O
FTN O
, O
HTS O
) O
. O
gait O
deffered O
. O
Mildly O
confused O
but O
oriented O
. O



 O

Pertinent O
Results O
: O

 O
Admission O
labs O
: O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
01:19PM O
   O
HCT-39.0 O
* O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
10:41AM O
URINE O
  O
COLOR-Yellow O
APPEAR-Clear O
SP O
[ O
* O
* O
Last O
Name O
( O
un O
) O
155**]-1.024 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
10:41AM O
URINE O
  O
BLOOD-TR O
NITRITE-NEG O
PROTEIN-NEG O

 O
GLUCOSE-NEG O
KETONE-NEG O
BILIRUBIN-NEG O
UROBILNGN-NEG O
PH-5.0 O

 O
LEUK-NEG O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
10:41AM O
URINE O
  O
RBC-[**2 O
- O
14 O
* O
* O
] O
* O
WBC-0 O
- O
2 O
BACTERIA-FEW O
YEAST-NONE O

 O
EPI-0 O
- O
2 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
10:41AM O
URINE O
  O
MUCOUS-MOD O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
05:38AM O
   O
GLUCOSE-133 O
* O
UREA O
N-11 O
CREAT-1.0 O
SODIUM-139 O

 O
POTASSIUM-4.5 O
CHLORIDE-106 O
TOTAL O
CO2 O
- O
23 O
ANION O
GAP-15 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
05:38AM O
   O
ALT(SGPT)-50 O
* O
AST(SGOT)-23 O
ALK O
PHOS-51 O
TOT O

 O
BILI-0.6 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
05:38AM O
   O
CALCIUM-9.5 O
PHOSPHATE-3.8 O
MAGNESIUM-2.1 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
05:38AM O
   O
WBC-12.7 O
* O
RBC-4.72 O
HGB-15.1 O
HCT-42.3 O
MCV-92 O

 O
MCH-31.9 O
MCHC-34.7 O
RDW-12.7 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
05:38AM O
   O
NEUTS-92.1 O
* O
LYMPHS-5.4 O
* O
MONOS-2.3 O
EOS-0.1 O

 O
BASOS-0.2 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
05:38AM O
   O
PLT O
COUNT-270 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
05:38AM O
   O
PT-12.5 O
PTT-22.3 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
02:40AM O
   O
TYPE-ART O
PO2 O
- O
81 O
* O
PCO2 O
- O
42 O
PH-7.36 O
TOTAL O
CO2 O
- O
25 O

 O
BASE O
XS--1 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
02:40AM O
   O
LACTATE-1.3 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
12:52AM O
   O
TYPE-ART O
PO2 O
- O
64 O
* O
PCO2 O
- O
60 O
* O
PH-7.27 O
* O
TOTAL O

 O
CO2 O
- O
29 O
BASE O
XS-0 O

 O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
12:52AM O
   O
LACTATE-1.5 O


 O
Discharge O
labs O
: O

 O
[ O
* O
* O
2172 O
- O
12 O
- O
7 O
* O
* O
] O
08:30AM O
BLOOD O
WBC-8.5 O
RBC-3.74 O
* O
Hgb-11.9 O
* O
Hct-32.2 O
* O

 O
MCV-86 O
MCH-31.9 O
MCHC-37.0 O
* O
RDW-12.5 O
Plt O
Ct-687 O
* O

 O
[ O
* O
* O
2172 O
- O
12 O
- O
7 O
* O
* O
] O
08:30AM O
BLOOD O
Glucose-98 O
UreaN-20 O
Creat-1.1 O
Na-138 O

 O
K-4.1 O
Cl-104 O
HCO3 O
- O
23 O
AnGap-15 O

 O
[ O
* O
* O
2172 O
- O
12 O
- O
7 O
* O
* O
] O
08:30AM O
BLOOD O
ALT-54 O
* O
AST-35 O

 O
[ O
* O
* O
2172 O
- O
12 O
- O
7 O
* O
* O
] O
08:30AM O
BLOOD O
Lipase-637 O
* O

 O
[ O
* O
* O
2172 O
- O
12 O
- O
6 O
* O
* O
] O
06:00AM O
BLOOD O
VitB12 O
- O
1259 O
* O

 O
[ O
* O
* O
2172 O
- O
12 O
- O
6 O
* O
* O
] O
06:00AM O
BLOOD O
TSH-2.5 O



 O
Imaging O
: O

 O
Radiology O
report O
[ O
* O
* O
2172 O
- O
11 O
- O
22 O
* O
* O
] O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Aortogram O
and O
left O
bronchial O
arteriogram O
demonstrating O
the O

 O
anatomy O
. O

 O
2 O
. O
Left O
bronchial O
arteriogram O
demonstrated O
active O
contrast O

 O
extravasation O
from O
both O
superior O
and O
inferior O
branches O
. O
These O

 O
branches O
were O
successfully O

 O
catheterized O
with O
a O
microcatheter O
and O
embolized O
using O
500 O
- O
700 O

 O
micron O

 O
Embospheres O
. O
No O
spinal O
arterial O
contribution O
was O
noted O
from O

 O
either O
branch O
of O
the O
left O
bronchial O
artery O
. O
Post O
embolization O

 O
arteriogram O
showed O
satisfactory O
angiographic O
result O
. O

 O
3 O
. O
Deployment O
of O
Angio-Seal O
closure O
device O
for O
the O
right O
common O

 O
femoral O

 O
arterial O
access O
site O
. O


 O
CT O
head O
[ O
* O
* O
12 O
- O
6 O
* O
* O
] O
: O

 O
No O
acute O
intracranial O
pathology O
. O
MRI O
scanning O
is O
more O
sensitive O

 O
than O
CT O
imaging O
in O
detecting O
numerous O
brain O
parenchymal O

 O
abnormalities O
, O

 O
including O
acute O
brain O
ischemia O
. O


 O
12/26 O
L O
ankle O
xray O
: O
no O
frx O


 O
[ O
* O
* O
12 O
- O
5 O
* O
* O
] O
CXR O
: O
As O
compared O
to O
the O
previous O
radiograph O
, O
the O
patient O

 O
has O
been O

 O
extubated O
. O
The O
nasogastric O
tube O
and O
the O
right O
internal O
jugular O

 O
vein O
catheter O
have O
also O
been O
removed O
. O
There O
is O
a O
marked O

 O
improvement O
in O
ventilation O
of O
the O
right O
lung O
base O
. O
At O
the O
left O
, O

 O
some O
small O
areas O
of O
retrocardiac O
atelectasis O
persist O
. O
No O
newly O

 O
appeared O
focal O
parenchymal O
opacities O
suggesting O
pneumonia O
. O


 O
[ O
* O
* O
12 O
- O
1 O
* O
* O
] O
LENI O
: O
IMPRESSION O
: O

 O
No O
evidence O
of O
DVT O
. O


 O
Micro O
: O





 O
[ O
* O
* O
2172 O
- O
12 O
- O
2 O
* O
* O
] O
4:22 O
pm O
SPUTUM O
      O
Source O
: O
Endotracheal O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2172 O
- O
12 O
- O
4 O
* O
* O
] O
* O
* O


    O
GRAM O
STAIN O
( O
Final O
[ O
* O
* O
2172 O
- O
12 O
- O
2 O
* O
* O
] O
) O
: O

       O
> O
25 O
PMNs O
and O
< O
10 O
epithelial O
cells/100X O
field O
. O

       O
1 O
+ O
    O
( O
< O
1 O
per O
1000X O
FIELD O
) O
: O
   O
GRAM O
POSITIVE O
COCCI O
. O

                                     O
IN O
PAIRS O
. O


    O
RESPIRATORY O
CULTURE O
( O
Final O
[ O
* O
* O
2172 O
- O
12 O
- O
4 O
* O
* O
] O
) O
: O

       O
Commensal O
Respiratory O
Flora O
Absent O
. O

       O
STAPH O
AUREUS O
COAG O
+ O
. O
    O
SPARSE O
GROWTH O
. O

          O
Oxacillin O
RESISTANT O
Staphylococci O
MUST O
be O
reported O
as O

 O
also O

          O
RESISTANT O
to O
other O
penicillins O
, O
cephalosporins O
, O

 O
carbacephems O
, O

          O
carbapenems O
, O
and O
beta-lactamase O
inhibitor O
combinations O
. O


          O
Rifampin O
should O
not O
be O
used O
alone O
for O
therapy O
. O


                               O
SENSITIVITIES O
: O
MIC O
expressed O
in O

 O
MCG/ML O



 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

                              O
STAPH O
AUREUS O
COAG O
+ O

                              O
| O

 O
CLINDAMYCIN-----------<=0.25 O
S O

 O
ERYTHROMYCIN---------- O
   O
= O
> O
8 O
R O

 O
GENTAMICIN------------ O
< O
= O
0.5 O
S O

 O
LEVOFLOXACIN---------- O
     O
4 O
R O

 O
OXACILLIN------------- O
   O
= O
> O
4 O
R O

 O
RIFAMPIN-------------- O
< O
= O
0.5 O
S O

 O
TETRACYCLINE---------- O
   O
< O
= O
1 O
S O

 O
TRIMETHOPRIM/SULFA---- O
< O
= O
0.5 O
S O

 O
VANCOMYCIN------------ O
     O
1 O
S O



 O
Brief O
Hospital O
Course O
: O

 O
Hospital O
Course O
: O

 O
46 O
yo O
M O
with O
history O
of O
ETOH O
abuse O
transferred O
to O
MICU O
from O
OSH O

 O
for O
hemoptysis O
, O
now O
s/p O
lingular O
AVM O
bleed O
and O
IR O
embolization O
, O

 O
with O
ICU O
course O
complicated O
by O
MICU O
[ O
* O
* O
Hospital O
16630 O
* O
* O
] O
transferred O
to O
floor O

 O
with O
resolving O
fever O
and O
confusion O
. O


 O
Active O
Issues O
: O


 O
# O
Hemoptysis O
: O
  O
PE O
ruled O
out O
on O
CTA O
at O
OSH O
. O
Fungal O
markers O

 O
negative O
. O
Evidence O
of O
bleeding O
on O
bronch O
after O
two O
evaluations O

 O
thought O
[ O
* O
* O
1 O
- O
14 O
* O
* O
] O
AVM O
. O
Pt O
is O
s/p O
IR O
embolization O
of O
left O
bronchial O

 O
artery O
without O
hemopytysis O
since O
the O
[ O
* O
* O
11 O
- O
23 O
* O
* O
] O
. O
[ O
* O
* O
Hospital1 O
1562 O
* O
* O
] O
rheum O

 O
testing O
: O
all O
negative O
( O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O
, O
ANCA O
, O
ESR O
, O
CRP O
) O
. O
Anti O
GBM O
negative O
. O

 O
He O
was O
transferred O
to O
the O
floor O
on O
[ O
* O
* O
12 O
- O
5 O
* O
* O
] O
. O
  O
He O
will O
need O
to O
have O

 O
IP O
follow O
up O
in O
1 O
month O
. O


 O
# O
Respiratory O
distress/MRSA O
VAP O
: O
Patient O
transferred O
intubated O

 O
because O
of O
hemoptysis O
. O
Patient O
self-extubated O
on O
[ O
* O
* O
2172 O
- O
11 O
- O
25 O
* O
* O
] O
and O

 O
continued O
to O
oxygenate O
well O
, O
but O
on O
morning O
rounds O
[ O
* O
* O
11 O
- O
26 O
* O
* O
] O
pt O

 O
tachypneic O
, O
with O
pO2 O
on O
gas O
74 O
on O
6L B-DOS
NC B-ROU
O2 B-DRUG
and O
required O

 O
reintubation O
. O
Concern O
for O
multifocal B-REA
pneumonia I-REA
on O
CT O
. O
Patient O

 O
was O
initially O
covered O
with O
Vanc/Zosyn B-DRUG
. I-DRUG
The O
zosyn B-DRUG
was O
changed O
to O

 O
Aztreonam B-DRUG
given O
rash B-ADE
. I-ADE
Scopalamine B-DRUG
patch B-FOR
trialed O
on O
[ O
* O
* O
11 O
- O
30 O
* O
* O
] O
for O

 O
copious O
oral O
secretions O
, O
but O
this O
was O
ineffective O
. O
Sputum O

 O
culture O
+ O
for O
MRSA O
. O
Successfully O
extubated O
on O
[ O
* O
* O
12 O
- O
3 O
* O
* O
] O
. O
  O
Vancomycin B-DRUG

 I-DRUG
course O
completed O
in O
[ O
* O
* O
2172 O
- O
12 O
- O
7 O
* O
* O
] O
after O
14 B-DUR
days I-DUR
. I-DUR



 O
# O
Delirium O
: O
Active O
in O
MICU O
, O
out O
of O
window O
for O
ETOH O
withdrawal O
. O

 O
Two O
days O
after O
extubation O
, O
there O
was O
no O
evidence O
of O
withdrawal O

 O
but O
still O
had O
mild O
confusion O
with O
confabulation O
. O
Pt O
continued O
on O

 O
thiamine B-DRUG
. I-DRUG
CT O
head O
, O
TSH O
, O
B12 O
, O
RPR O
normal O
. O
He O
continued O
to O
perform O

 O
poorly O
on O
his O
mental O
status O
examination O
, O
however O
this O
was O
felt O

 O
most O
likely O
secondary O
to O
his O
long O
and O
heavy O
alcohol O
abuse O
. O


 O
# O
Diarrhea O
: O
Started O
in O
MICU O
in O
setting O
of O
abx B-DRUG
, I-DRUG
cdiff O
negative O
, O

 O
resolved O
on O
own O
. O


 O
# O
Maculopapular B-ADE
rash I-ADE
: I-ADE
over O
extremities O
, O
chest O
and O
back O
, O
thought O

 O
[ O
* O
* O
1 O
- O
14 O
* O
* O
] O
zosyn B-DRUG
which O
has O
been O
discontinued O
, O
mother O
with O
[ O
* O
* O
Name2 O
( O
NI O
) O
* O
* O
] O
allergy O
, O

 O
consider O
[ O
* O
* O
Name2 O
( O
NI O
) O
* O
* O
] O
an O
allergy O
. O


 O
# O
Thrombocytosis O
: O
Likely O
reaction O
to O
infection O
. O


 O
# O
Alcoholism B-REA
: I-REA
drinks O
6 O
beers/day O
, O
did O
not O
withdrawl O
, O
no O
desire O

 O
to O
quit O
, O
started O
on O
mvi B-DRUG
, I-DRUG
folate B-DRUG
, I-DRUG
thiamine B-DRUG
. I-DRUG


 O
# O
elevated O
INR O
: O
Likely O
in O
setting O
of O
poor O
nutrition O
, O
improved O
to O

 O
1.3 O
on O
discharge O
. O


 O
# O
. O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
: O
Likely O
secondary O
to O
dye O
load O
received O
with O
IR O
for O

 O
embolization O
. O
Improved O
throughout O
hospitalization O
with O
IVF B-DRUG
. I-DRUG


 O
# O
Anemia O
: O
Likely O
[ O
* O
* O
1 O
- O
14 O
* O
* O
] O
to O
blood O
loss O
from O
hemoptysis O
, O
should O
be O

 O
followed O
as O
outpatient O


 O
# O
ALT O
elevation O
: O
Likely O
chronic O
, O
outpatient O
f/u O
. O


 O
* O
* O
* O
* O
* O
* O
* O
* O
* O
* O
* O

 O
Inactive O
Issues O
: O

 O
# O
Smoking O
: O
cessation O
counseling O
performed O
, O
patient O
does O
not O

 O
desire O
to O
quit O

 O
* O
* O
* O
* O
* O
* O
* O
* O
* O
* O
* O
* O


 O
Faxed O
discharge O
summary O
to O
PCP O
. O


 O
Transitional O
Care O
: O

 O
1 O
) O
Anemia/Thrombocytosis O
: O
recheck O
CBC O
as O
outpt O

 O
2 O
) O
Elevated O
Lipase O
: O
No O
clinical O
signs O
of O
pancreatits O
but O
at O
risk O

 O
bc O
of O
alcohol O
, O
if O
abd O
pain O
develops O
consider O
CT O
abd/pel O

 O
3 O
) O
Elevated O
ALT O
: O
Likely O
chronic O
from O
ETOH O
vs O
NASH O
, O
consider O
w/u O

 O
as O
outpatient O


 O
Medications O
on O
Admission O
: O

 O
Propofol B-DRUG
gtt B-FOR

 I-FOR
Fentanyl B-DRUG
gtt B-FOR

 I-FOR
Protonix B-DRUG
40 B-STR
IV B-ROU
daily B-FRE

 I-FRE
MVI B-DRUG
daily B-FRE

 I-FRE
Thiamine B-DRUG
100 B-STR
mg I-STR
daily B-FRE

 I-FRE
Senna B-DRUG
1 B-DOS
tab B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Artificial B-DRUG
tears I-DRUG



 I-DRUG

Discharge O
Medications O
: O

 O
1 O
. O
Outpatient O
Physical O
Therapy O

 O
Please O
assess O
and O
treat O
for O
deconditioning O
from O
hospitalization O

 O
and O
left O
ankle O
pain O
. O
  O
Diagnosis O
: O
Pneumonia O
. O
Please O
give O
results O

 O
to O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
88528 O
* O
* O
] O
R. O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
39876 O
* O
* O
] O
. O
Ok O
to O
sign O
off O
. O

 O
2 O
. O
multivitamin B-DRUG
     O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
3 O
. O
folic B-DRUG
acid I-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
4 O
. O
thiamine B-DRUG
HCl I-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
Diagnosis O
: O

 O
Hemoptysis O
, O
? O
AVM O
in O
lingula O

 O
Ventilator-associated O
pneumonia O

 O
Anemia O

 O
Confusion O
possibly O
from O
Wernicke O
's O


 O
Secondary O
Diagnosis O
: O

 O
Alcohol O
Abuse O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
requires O
assistance O
or O
aid O
( O
walker O

 O
or O
cane O
) O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
to O
the O
ICU O
after O
coughing O
up O
blood O
. O
  O
You O

 O
needed O
to O
have O
a O
breathing O
tube O
placed O
in O
[ O
* O
* O
Hospital1 O
1562 O
* O
* O
] O
in O
order O
to O

 O
protect O
your O
airway O
. O
  O
You O
were O
then O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
. O
  O
You O

 O
underwent O
a O
procedure O
in O
the O
OR O
to O
stop O
the O
bleeding O
, O
called O

 O
embolization O
. O
  O
Following O
the O
procedure O
, O
you O
were O
monitored O
in O

 O
the O
ICU O
for O
recurrent O
episodes O
of O
bleeding O
, O
which O
you O
did O
not O

 O
have O
. O
  O
You O
developed O
a O
pneumonia O
while O
in O
the O
hospital O
, O
and O

 O
received O
antiobiotics B-DRUG
to O
treat O
the O
pneumonia B-REA
. I-REA
  O
You O
improved O
and O

 O
were O
transferred O
to O
the O
floor O
. O
On O
the O
floor O
, O
you O
had O
some O
low O

 O
grade O
fevers O
that O
improved O
on O
their O
own O
. O
  O
You O
also O
had O
some O

 O
confusion O
that O
was O
improving O
upon O
discharge O
. O
You O
were O
seen O
by O

 O
the O
physical O
therapist O
who O
felt O
you O
were O
safe O
to O
go O
home O
. O


 O
Medication O
changes O
: O

 O
1)We O
started O
you O
on O
a O
multivitamin B-DRUG
, I-DRUG
folic B-DRUG
acid I-DRUG
, I-DRUG
and O
thiamine B-DRUG
to O

 O
take O
every B-FRE
day I-FRE
. I-FRE


 O
Followup O
Instructions O
: O

 O
Please O
call O
to O
schedule O
an O
appointment O
with O
the O
interventional O

 O
pulmonologists O
within O
the O
next O
month O
. O
Phone O
: O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
17398 O
* O
* O
] O



 O
Name O
: O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name7 O
( O
NamePattern1 O
) O
1955 O
* O
* O
] O
[ O
* O
* O
Initial O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O

 O
Location O
: O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
FAMILY O
MEDICINE O

 O
Address O
: O
5 O
INDUSTRIAL O
DR O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
, O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
Numeric O
Identifier O
84441 O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
56653 O
* O
* O
] O

 O
Fax O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
88529 O
* O
* O
] O

 O
Appt O
: O
This O
Thursday O
, O
[ O
* O
* O
12 O
- O
10 O
* O
* O
] O
at O
1:45pm O




 O
Completed O
by:[**2172 O
- O
12 O
- O
7 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2202 O
- O
10 O
- O
17 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2202 O
- O
10 O
- O
22 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2143 O
- O
12 O
- O
3 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
NEUROLOGY O


 O
Allergies O
: O

 O
Vicodin B-DRUG
/ O
Roxicet B-DRUG
/ O
Sirolimus B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
1032 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Mental O
status O
changes O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Endotracheal O
intubation O

 O
Lumbar O
puncture O
with O
moderate O
sedation O

 O
Radial O
arterial O
line O
insertion O


 O
History O
of O
Present O
Illness O
: O

 O
58y/o O
RHM O
with O
history O
of O
liver O
transplant O
, O
Hepatitis O
C O
, O
chronic O

 O
renal O
disease O
and O
multiple O
asymptomatic O
strokes O
, O
presented O
with O

 O
sudden O
decline O
in O
his O
mental O
status O
. O
His O
wife O
witnessed O
him O
be O

 O
struggling O
get O
out O
from O
bed O
, O
decline O
in O
his O

 O
awareness O
. O
His O
wife O
spoke O
to O
him O
with O
appropriate O
condition O

 O
around O
6:05PM O
. O
Around O
6:25PM O
, O
she O
heard O
that O
the O
patient O
started O

 O
to O
say O
non-sence O
, O
act O
inappropriately O
, O
unable O
to O
exchange O

 O
conversation O
. O
His O
wife O
recalled O
some O
" O
shaking O
" O
at O
the O
right O
arm O
. O

 O
He O
was O
brought O
into O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
above O
time O
and O
Neurology O
was O

 O
consulted O
for O
code O
stroke O
. O


 O
In O
ED O
, O
while O
Neurology O
was O
examining O
patient O
, O
he O
developed O
right O

 O
arm O
, O
leg O
clonic O
seizure O
with O
head O
deviation O
and O
gaze O
deviation O

 O
toward O
to O
left O
. O
He O
responded O
with O
moan O
when O
his O
name O
was O
called O
, O

 O
then O
developed O
left O
arm O
clonic B-REA
seizure I-REA
( O
secondary O

 O
generalization O
) O
and O
became O
unresponsive O
. O
Ativan B-DRUG
2 B-STR
mg I-STR
IV B-ROU
was O
given O

 O
to O
stop O
. O
Patient O
was O
intubated O
subsequently O
to O
have O
further O

 O
neuroradiological O
evaluation O
. O



 O
HPI O
ADDENDUM O
: O

 O
Further O
history O
was O
obtained O
from O
the O
patient O
's O
wife O
the O
morning O

 O
following O
his O
admission O
. O
She O
reports O
the O
patient O
was O
well O
until O

 O
returning O
from O
a O
same-day-surgical O
procedure O
on O
[ O
* O
* O
10 O
- O
14 O
* O
* O
] O
for O
repair O

 O
of O
left O
eye O
retinal O
detachment O
. O
The O
patient O
was O
vague O
with O
his O

 O
reported O
symptoms O
, O
but O
complained O
of O
" O
feeling O
lousy O
" O
with O
poor O

 O
appetite O
and O
fatigue O
. O
He O
did O
not O
eat O
or O
drink O
very O
much O
Friday O

 O
or O
Saturday O
following O
. O
On O
Saturday O
evening O
he O
began O
to O
vomit O

 O
quite O
frequently O
. O
They O
had O
a O
small O
breakfast O
Sunday O
morning O
and O

 O
the O
patient O
was O
still O
feeling O
unwell O
, O
but O
altogether O
normal O
per O

 O
his O
wife O
. O
She O
left O
for O
a O
few O
hours O
during O
the O
day O
, O
returned O
home O

 O
and O
heard O
him O
yelling O
out O
of O
frustration O
after O
having O
dropped O

 O
something O
in O
his O
room O
, O
however O
the O
yelling O
continued O
and O
she O

 O
went O
to O
see O
him O
and O
noted O
that O
he O
had O
a O
great O
amount O
of O

 O
difficulty O
getting O
himself O
upright O
to O
the O
edge O
of O
his O
bed O
. O
She O

 O
then O
noted O
his O
right O
arm O
was O
shaking O
. O
He O
was O
brought O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O

 O
where O
the O
above O
described O
event O
occurred O
. O



 O
Past O
Medical O
History O
: O

 O
- O
ETOH/HCV O
cirrhosis O
s/p O
Liver O
Transplant O
[ O
* O
* O
2195 O
* O
* O
] O
on O

 O
immunosuppression O
. O
  O
Course O
c/b O
recurrent O
hep O
C O
viremia O
, O
CRI O
, O
LFT O

 O
abnl O
, O
acute O
rejection O
and O
hepatic O
artery O
thrombosis O
( O
[ O
* O
* O
2196 O
* O
* O
] O
) O

 O
- O
Polymyositis O
- O
diagnosed O
in O
[ O
* O
* O
2196 O
* O
* O
] O
after O
hepatic O
artery O

 O
thrombosis O
, O
Bx O
showed O
inflammatory O
myositis O

 O
- O
HTN O

 O
- O
CRI O
( O
baseline O
2.0 O
) O

 O
- O
DM B-REA
on O
insulin B-DRUG
- O
post-transplant O
, O
related O
to O
steroid B-DRUG
treatment O

 O
- O
IVDU O

 O
- O
Multiple O
strokes O
- O
[ O
* O
* O
2195 O
* O
* O
] O
prior O
to O
transplant O
left O
corona O

 O
radiata O

 O
and O
posterior O
putaminal O
infarct O
, O
periventricular O
white O
matter O

 O
disease O
. O
  O
[ O
* O
* O
8 O
- O
12 O
* O
* O
] O
MRI O
with O
evidence O
of O
chronic O
cerebellar O
infarcts O
. O

 O
- O
Seizure O
- O
single O
event O
3 O
days O
prior O
to O
transplant O
while O
in O

 O
hospital O
. O
However O
chart O
review O
reveals O
pt O
may O
have O
had O
seizures O

 O
associated O
with O
prior O
infarcts O
in O
[ O
* O
* O
2195 O
* O
* O
] O
. O



 O
Social O
History O
: O

 O
Lives O
with O
his O
wife O
. O
Does O
not O
smoke O
. O
Quit O
ETOH O
use O
several O
years O

 O
prior O
to O
transplant O
. O


 O
Family O
History O
: O

 O
No O
FH O
of O
stroke O
or O
neurological O
disease O



 O
Physical O
Exam O
: O

 O
Vitals O
: O
T O
? O
  O
HR O
64 O
, O
reg O
  O
BP O
243/123 O
RR O
17 O
  O
SO2 O
97 O
% O
r/a O

 O
Gen O
: O
NAD O
. O

 O
HEENT O
: O
MMM O
. O
Sclera O
clear O
. O
OP O
clear O
. O
Extra O
ear O
canals O
, O
ear O
drums O

 O
clear O
. O

 O
Neck O
: O
No O
Carotid O
bruits O

 O
CV O
: O
RRR O
, O
Nl O
S1 O
and O
S2 O
, O
no O
murmurs/gallops/rubs O

 O
Lung O
: O
Clear O
to O
auscultation O
bilaterally O

 O
Abd O
: O
Horizontal O
surgical O
scar O
. O
Soft O
, O
flat O
, O
no O
tenderness O

 O
Ext O
: O
No O
arthralgia O
, O
no O
deformities O
, O
no O
edema O


 O
Neurologic O
examination O
: O

 O
MS- O
Opening O
eyes O
to O
voice O
. O
Non-verbal O
. O
Vocalize O
non O
identifiable O

 O
sound O
. O
No O
following O
command O
. O


 O
CN- O
Pupils O
left O
sclera O
injected O
, O
surgical O
. O
Right O
pupil O
also O

 O
surgical O
. O
Left O
gaze O
preference O
. O
Left O
head O
turning O
. O
No O
facial O

 O
droop O
with O
grimacing O
. O
Gag+ O
. O
Cough+ O
. O


 O
Motor/Sensory- O
Normal O
bulk O
. O
R O
foot O
clonus O
x7 O
- O
9 O
beats O
. O
Left O

 O
negative O
. O
No O

 O
withdrawal O
at O
R O
arm O
, O
leg O
, O
L O
leg O
. O
Withdrawal O
at O
R O
arm O
. O

 O
Response O
to O
the O
noxious O
stimuli O
at O
left O
arm O
. O
None O
at O
right O
arm O
, O

 O
leg O
and O
left O
leg O
. O


 O
Reflexes O
: O
B O
T O
Br O
Pa O
Ankle O

 O
Right O
     O
2 O
2 O
2 O
  O
3 O
   O
3 O

 O
Left O
      O
2 O
2 O
2 O
  O
2 O
   O
2 O


 O
Toes O
were O
upgoing O
at O
the O
right O
, O
down O
at O
the O
left O
. O


 O
Coordination O
: O
Unable O
to O
examine O
due O
to O
inattention O
. O

 O
Meningeal O
sign O
: O
Negative O
Brudzinski O
sign O
. O
No O
nuchal O
rigidity O
. O



 O
Pertinent O
Results O
: O

 O
ADMISSION O
LABS O
: O

 O
138 O
  O
99 O
  O
42 O
  O
AGap=18 O

  O
------------<140 O

 O
3.9 O
  O
25 O
  O
2.3 O


 O
estGFR O
: O
29/36 O
( O
click O
for O
details O
) O


 O
11.2 O
  O
> O
15.9/46.6 O
< O
  O
127 O

 O
N:64.7 O
L:24.7 O
M:9.9 O
E:0.6 O
Bas:0.2 O


 O
PT O
: O
11.7 O
  O
PTT O
: O
31.0 O
  O
INR O
: O
1.0 O


 O
Head O
CT O
: O

 O
No O
hemorrhage O
. O


 O
Head O
MRI/MRA O
: O
MRA O
: O
The O
intracranial O
vertebral O
and O
internal O

 O
carotid O
arteries O
and O
their O
major O
branches O
appear O
normal O
with O
no O

 O
evidence O
of O
significant O
stenosis O
, O
occlusion O
, O
or O
aneurysms O
. O
MRI O
: O

 O
Unchanged O
appearance O
of O
punctate O
hemorrhagic O
areas O
in O
bilateral O

 O
cerebral O
hemispheres O
and O
brainstem O
suggestive O
of O
chronic O

 O
process O
. O
Amyloid O
angiopathy O
is O
one O
of O
the O
conditions O
that O
can O

 O
predispose O
to O
tiny O
punctate O
hemorrhages O
. O
No O
acute O
hemorrhage O
, O

 O
masses O
, O
infarct O
. O



 O

Brief O
Hospital O
Course O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
2809 O
* O
* O
] O
is O
a O
58 O
year O
old O
gentleman O
s/p O
liver O
transplant O

 O
related O
to O
chronic O
HCV O
infection O
, O
myopathy B-ADE
( O
? O
steroid B-DRUG
induced O
) O
, O

 O
history O
of O
prior O
multiple O
asymptomatic O
embolic O
infarcts O
prior O
to O

 O
transplantation O
, O
who O
presents O
with O
three O
day O
prodrome O
of O
general O

 O
malaise O
, O
poor O
appetite O
, O
nausea/vomiting O
, O
followed O
by O
acute O

 O
change O
in O
mental O
status O
with O
witnessed O
partial O
complex O
seizure O

 O
in O
the O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
. O


 O
1 O
) O
Neuro O
: O

 O
* O
SEIZURE O
- O
Initially O
a O
code O
stroke O
was O
called O
in O
the O
ED O
, O
but O
CT O

 O
imaging O
and O
later O
, O
MRI O
, O
showed O
no O
evidence O
of O
acute O
infarction O
. O

 O
Initial O
labs O
notable O
for O
presence O
of O
only O
serum O
benzodiazepines B-DRUG

 I-DRUG
on O
tox O
screening O
and O
acute O
on O
chronic O
renal O
failure O
. O
Etiology O
of O

 O
seizure O
was O
thought O
to O
be O
areas O
of O
prior O
cortical O
infarcts O
in O

 O
setting O
of O
gastrointestinal O
illness O
. O
The O
patient O
was O
intubated O

 O
in O
the O
emergency O
department O
and O
promptly O
extubated O
at O
2 O
am O
in O
the O

 O
Neuro O
ICU O
the O
same O
evening O
. O
The O
morning O
following O
admission O
the O

 O
patient O
's O
examination O
was O
notable O
for O
marked O
encephalopathy O
. O
He O

 O
was O
changed O
from O
phenytoin B-DRUG
to O
oxcarbazepine B-DRUG
( O
Trileptal B-DRUG
) I-DRUG
given O

 O
multiple O
long O
term O
side O
effects O
of O
phenytoin B-DRUG
, I-DRUG
and O
with O
normal O

 O
hepatic O
function O
, O
but O
renal O
impairment O
and O
keppra B-DRUG
did O
not O
seem O
a O

 O
wise O
choice O
. O
Lumbar O
puncture O
was O
attempted O
with O
light O
sedation O

 O
without O
success O
. O
It O
was O
re-attempted O
with O
fentanyl B-DRUG
and O
midazolam B-DRUG

 I-DRUG
for O
monitored B-REA
conscious I-REA
sedation I-REA
and O
revealed O
1 O
WBC O
, O
0 O
RBC O
, O

 O
normal O
protein O
and O
glucose O
. O
He O
was O
transferred O
to O
the O
floor O

 O
after O
an O
EEG O
done O
on O
the O
[ O
* O
* O
7 O
- O
18 O
* O
* O
] O
revealed O
no O

 O
abnormalities O
and O
showed O
a O
normal O
background O
. O

 O
* O
ENCEPHALOPATHY O
- O
On O
the O
floor O
, O
the O
patient O
's O
exam O
was O
notable O

 O
for O
continued O
encephalopathy O
, O
but O
he O
was O
evidently O
not O

 O
delerious O
. O
His O
main O
abnormalities O
were O
frontal O
dysfunction O
( O
as O

 O
exhibited O
by O
impulsiveness O
, O
stimulus-bound O
behaviors O
, O

 O
desinhibition O
, O
bilateral O
grasp O
and O
palmomental O
reflexes O
, O
a O

 O
marked O
inability O
to O
switch O
mindset O
) O
and O
memory O
( O
as O
exhibited O
by O

 O
anososgnosia O
, O
orientation O
to O
place O
and O
time O
, O
as O
well O
as O
not O

 O
imprinting O
new O
information O
, O
and O
working O
memory O
( O
the O
patient O

 O
stayed O
in-task O
, O
and O
had O
sufficent O
attention O
to O
perform O
, O
but O

 O
could O
n't O
complete O
the O
tasks O
) O
. O
Clinically O
he O
continued O
to O
improve O

 O
slowly O
but O
surely O
, O
an O
EEG O
done O
on O
[ O
* O
* O
10 O
- O
21 O
* O
* O
] O
showed O
7 O
Hz O
background O
, O

 O
but O
otherwise O
normal O
. O
Per O
his O
wife O
, O
his O
level O
of O
cognitive O

 O
functioning O
at O
home O
was O
high O
, O
as O
for O
example O
he O
was O
able O
to O

 O
discuss O
politics O
. O


 O
2 O
) O
Cardio O
: O

 O
* O

NSTEMI B-REA
- O
Patient O
was O
noted O
to O
have O
elevated O
troponin O
enzymes O

 O
to O
0.31 O
with O
EKG O
without O
ischemic O
changes O
. O
He O
was O
started O
on O

 O
aspirin B-DRUG
, I-DRUG
beta B-DRUG
blocker I-DRUG
, I-DRUG
atorvastatin B-DRUG
. I-DRUG
Cardiology O
consultation O
was O

 O
obtained O
and O
additionally O
recommended O
echocardiogram O
which O

 O
revealed O
moderate O
symmetric O
left O
ventricular O
hypertrophy O
, O
no O

 O
focal O
wall O
motion O
abnormalities O
( O
poor O
data O
quality O
though O
) O
, O

 O
LVEF>55 O
% O
, O
mild O
aortic O
valve O
stenosis O
. O
His O
NSTEMI O
was O
thought O

 O
related O
to O
demand O
related O
ischemia O
in O
the O
setting O
of O

 O
catecholamine O
surge O
associated O
with O
seizure O
. O
He O
should O
be O

 O
scheduled O
for O
an O
exercise O
stress O
test O
as O
an O
outpatient O
. O


 O
3 O
) O
FEN O

 O
* O
Acute B-REA
Renal I-REA
Failure I-REA
- O
Patient O
's O
has O
prior O
hepato-renal O

 O
syndrome O
now O
with O
baseline O
creatinine O
of O
1.9 O
- O
2 O
. O
Admission O

 O
creatinine O
notable O
for O
2.4 O
. O
He O
was O
noted O
to O
have O
low O
urine O

 O
output O
. O
He O
received O
vigorous O
IV B-ROU
hydration B-DRUG
with O
improved O
Cr O
to O

 O
1.6 O
, O
however O
this O
was O
likely O
a O
sampling O
error O
because O
all O
the O

 O
lines O
of O
his O
cellcount O
were O
down O
on O
this O
blooddraw O
as O
well O
, O

 O
repeat O
labs O
showed O
a O
creat O
of O
2.0 O
and O
his O
[ O
* O
* O
Hospital1 O
* O
* O
] O
back O
to O
the O
old O

 O
values O
. O
His O
medications O
were O
renally O
dosed O
. O
He O
was O
started O
on O

 O
Thiamine B-DRUG
, I-DRUG
Folate B-DRUG
and O
MVI B-DRUG
. I-DRUG


 O
4 O
) O
Liver B-REA
transplantation I-REA

 I-REA
Transaminase O
levels O
on O
admission O
were O
WNL O
. O
Hepatology O

 O
consultation O
was O
obtained O
and O
recommended O
continuing O
with O
his O

 O
prior O
regimen O
of O
immunosuppressive B-DRUG
agents I-DRUG
. I-DRUG
No O
changes O
were O
made O
. O



 O
5 O
) O
ID O

 O
A O
broad O
spectrum O
of O
CSF O
studies O
were O
sent O
despite O
the O
normal O

 O
cell O
count O
. O
Varicella O
PCR O
and O
CMV O
PCR O
negative O
, O
remainder O

 O
pending O
. O
MRSA O
isolation O
negative O
. O
VRE O
swab O
negative O
. O

 O
Cryptococcal O
antigen O
GRAM O
STAIN O
, O
FLUID O
CULTURE O
, O
FUNGAL O

 O
CULTURE-PRELIMINARY O
, O
ACID O
FAST O
CULTURE O
, O
VIRAL O
CULTURE O
were O
all O

 O
( O
preliminary O
) O
negative O
. O


 O
6 O
) O
PPx O
, O
reactivation O
and O
reconditioning O

 O
For O
prophylaxis B-REA
, I-REA
he O
was O
put O
on O
Heparin B-DRUG
, I-DRUG
pneumoboots O
, O
TEDs O
, O
and O

 O
PT O
and O
OT O
were O
consulted O
to O
evaluate O
and O
treat O
him O
. O



 O
Medications O
on O
Admission O
: O

 O
Prograf B-DRUG
1 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Imuran B-DRUG
50 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Cellcept B-DRUG
( O
mycophenidate B-DRUG
mofetil I-DRUG
) I-DRUG
1000 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
bactrim B-DRUG

 I-DRUG
metoprolol B-DRUG
50 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Clindagel B-DRUG

 I-DRUG
asa B-DRUG
81 B-STR
mg I-STR
daily B-FRE

 I-FRE
fosamax B-DRUG
35 B-STR
mg I-STR
q B-FRE
fri I-FRE

 I-FRE
marinol B-DRUG
5 B-STR
mg I-STR
qpm B-FRE
and I-FRE
qhs I-FRE

 I-FRE
simethicone B-DRUG
80 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
calcum B-DRUG
500 I-DRUG
mg I-DRUG
+ I-DRUG
D I-DRUG
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Ambien B-DRUG
( O
zolpidem B-DRUG
) I-DRUG
5 B-STR
mg I-STR
qhs B-FRE

 I-FRE
doxazosin B-DRUG
1.5 B-STR
mg I-STR
qhs B-FRE

 I-FRE
hydroxyzine B-DRUG
hcl I-DRUG
50 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
ritalin B-DRUG
15 B-STR
mg I-STR
qam B-FRE

 I-FRE
remeron B-DRUG
7.5 B-STR
qhs B-FRE

 I-FRE
prilosec B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
Effexor B-DRUG
37.5 B-STR
mg I-STR
daily B-FRE

 I-FRE
Florinef B-DRUG
0.1 B-STR
mg I-STR
daily B-FRE

 I-FRE
Lasix B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
Kayexylate B-DRUG

 I-DRUG
Lipitor B-DRUG
10 B-STR
mg I-STR
daily B-FRE

 I-FRE
Lisinopril B-DRUG
5 B-STR
mg I-STR
daily B-FRE

 I-FRE
Percocet B-DRUG
one B-DOS
tab B-FOR
qid B-FRE
prn I-FRE

 I-FRE
Cosopt B-DRUG
one B-DOS
drop B-FOR
to O
left B-ROU
eye I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Alphagan B-DRUG
0.15 B-STR
% I-STR
to O
left B-ROU
eye I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Ofloxacin B-DRUG
0.3 B-STR
% I-STR
eye B-ROU
drop B-FOR
to O
left B-ROU
eye I-ROU
qid B-FRE

 I-FRE
Prednisolone B-DRUG
1 B-STR
% I-STR
eye B-ROU
drop B-FOR
to O
left B-ROU
eye I-ROU
qid B-FRE

 I-FRE
Homatropine B-DRUG
5 B-STR
% I-STR
eye B-ROU
drop B-FOR
to O
left B-ROU
eye I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O



 O

Discharge O
Medications O
: O

 O
1 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Bisacodyl B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
3 O
. O
Tacrolimus B-DRUG
1 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Mycophenolate B-DRUG
Mofetil I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
5 O
. O
Colace B-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
6 O
. O
Alendronate B-DRUG
35 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QFRI B-FRE
( I-FRE
every I-FRE

 I-FRE
Friday I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Doxazosin B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1.5 B-DOS
Tablets B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Hydroxyzine B-DRUG
HCl I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Venlafaxine B-DRUG
37.5 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Sust I-FOR
. I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Sust I-FOR
. I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Fludrocortisone B-DRUG
0.1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Heparin B-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
5,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Injection B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
12 O
. O
Trimethoprim-Sulfamethoxazole B-DRUG
160 B-STR
- I-STR
800 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
MWF B-FRE
( I-FRE
Monday-Wednesday-Friday I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
ppx B-REA
. I-REA

 O
13 O
. O
Oxcarbazepine B-DRUG
300 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
14 O
. O
Dorzolamide-Timolol B-DRUG
2 B-STR
- I-STR
0.5 I-STR
% I-STR
Drops B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Drop B-FOR

 I-FOR
Ophthalmic B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
15 O
. O
Brimonidine B-DRUG
0.15 B-STR
% I-STR
Drops B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Drop B-FOR
Ophthalmic B-ROU
Q B-FRE
12H I-FRE

 I-FRE
( I-FRE
Every I-FRE
12 I-FRE
Hours I-FRE
) I-FRE
. I-FRE

 O
16 O
. O
Ofloxacin B-DRUG
0.3 B-STR
% I-STR
Drops B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Ophthalmic B-ROU
four B-FRE
times I-FRE

 I-FRE
daily I-FRE
( O
) O
. O

 O
17 O
. O
Prednisolone B-DRUG
Acetate I-DRUG
1 B-STR
% I-STR
Drops B-FOR
, I-FOR
Suspension I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Drop B-FOR

 I-FOR
Ophthalmic B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
18 O
. O
Homatropine B-DRUG
HBr I-DRUG
5 B-STR
% I-STR
Drops B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Ophthalmic B-ROU
twice B-FRE

 I-FRE
daily I-FRE
( O
) O
. O

 O
19 O
. O
Famotidine B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE

 I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
20 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O

21 O
. O
Atorvastatin B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
22 O
. O
Hexavitamin B-DRUG
     O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Cap B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
23 O
. O
Thiamine B-DRUG
HCl I-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
24 O
. O
Folic B-DRUG
Acid I-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE




 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
1107 O
* O
* O
] O
[ O
* O
* O
Hospital O
* O
* O
] O
[ O
* O
* O
Hospital O
1108 O
* O
* O
] O
Rehab O
Unit O
at O

 O
[ O
* O
* O
Hospital6 O
1109 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
1110 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Complex O
partial O
seizure O
with O
secondary O
generalization O
. O


 O
Discharge O
Condition O
: O

 O
Stable O
, O
improving O
cognitively O
. O


 O
Discharge O
Instructions O
: O

 O
You O
have O
been O
admitted O
with O
an O
epileptic O
seizure O
, O
most O
likely O

 O
related O
to O
small O
scars O
in O
your O
brain O
from O
old O
small O
strokes O
, O

 O
possibly O
in O
the O
setting O
mild O
dehydration O
. O
After O
this O
you O
have O

 O
been O
confused O
for O
a O
while O
, O
which O
is O
not O
unusual O
with O
a O
fragile O

 O
brain O
, O
a O
post-seizure O
state O
and O
a O
lot O
of O
medications O
on O
board O
. O

 O
Your O
medications O
such O
as O
Remeron B-DRUG
and O
Methylphenidate B-DRUG
have O
been O

 O
temporarily O
discontinued O
- O
please O
follow O
up O
with O
your O
doctor O
to O

 O
perhaps O
reverse O
these O
changes O
when O
you O
are O
back O
to O
your O

 O
baseline O
. O


 O
Please O
take O
all O
medications O
as O
directed O
, O
and O
attend O
all O
your O

 O
follow-up O
appointments O
. O
If O
you O
experience O
any O
signs O
or O
symptoms O

 O
of O
concern O
, O
please O
contact O
your O
doctor O
immediately O
, O
or O
in O
case O

 O
of O
urgency O
go O
directly O
to O
the O
emergency O
room O
- O
for O
example O
in O

 O
case O
of O
recurrence O
of O
seizures O
. O


 O
Followup O
Instructions O
: O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
673 O
* O
* O
] O

 O
Date/Time:[**2202 O
- O
11 O
- O
17 O
* O
* O
] O
8:40 O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
XRAY O
( O
SCC O
2 O
) O
Phone:[**Telephone/Fax O
( O
1 O
) O
1228 O
* O
* O
] O

 O
Date/Time:[**2202 O
- O
12 O
- O
14 O
* O
* O
] O
4:10 O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
8741 O
* O
* O
] O
[ O
* O
* O
Name11 O
( O
NameIs O
) O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
1228 O
* O
* O
] O
Date/Time:[**2202 O
- O
12 O
- O
14 O
* O
* O
] O

 O
4:30 O


 O
Provider O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
539 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
540 O
* O
* O
] O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
541 O
* O
* O
] O

 O
Date/Time:[**2202 O
- O
11 O
- O
17 O
* O
* O
] O
2:30 O



                              O

[ O
* O
* O
First O
Name5 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
MD O
, O
[ O
* O
* O
MD O
Number(3 O
) O
1041 O
* O
* O
] O


 O

Admission O
Date O
: O
  O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2133 O
- O
8 O
- O
25 O
* O
* O
] O



 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Flagyl B-DRUG
/ O
Proton B-DRUG
Pump I-DRUG
Inhibitors I-DRUG
( O
Benzimidazole B-DRUG
) I-DRUG


 O
Attending:[**First O
Name3 O
( O
LF O
) O
99 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Dyspnea O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
none O


 O
History O
of O
Present O
Illness O
: O

 O
This O
is O
an O
85 O
year O
old O
male O
with O
history O
of O
diastolic O
heart O

 O
failure O
, O
copmlete O
heart O
block O
( O
now O
s/p O
PPM O
[ O
* O
* O
6 O
- O
7 O
* O
* O
] O
) O
ESRD O
on O
HDHD O
, O

 O
h/o O
MRSA O
bacteremia O
and O
thrombocytopenia B-ADE
, I-ADE
likely O
secondary O
to O

 O
drug O
reaction O
( O
PPI B-DRUG
? I-DRUG
) O
who O
presents O
from O
[ O
* O
* O
Hospital O
100 O
* O
* O
] O
rehab O
with O

 O
dyspnea O
. O
  O
Patient O
reports O
SOB O
x O
1 O
day O
. O
  O
He O
denies O
any O
chest O

 O
pain O
, O
palpitations O
, O
N/V O
, O
abdominal O
pain O
, O
diarrhea O
, O
fevers O
, O

 O
chills O
or O
recent O
cough O
. O
  O
Patient O
states O
he O
was O
walking O
with O

 O
PT/OT O
and O
became O
SOB O
and O
dizzy O
. O
  O
Per O
ED O
report O
patient O
felt O

 O
better O
after O
HD O
yesterday O
, O
but O
continued O
with O
SOB O
today O
along O

 O
with O
AMS O
. O
  O
ABG O
done O
at O
[ O
* O
* O
Hospital O
100 O
* O
* O
] O
Rehab O
which O
showed O
increased O
CO2 O

 O
and O
decreased O
PaO2 O
from O
baseline O
so O
he O
was O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O

 O
for O
further O
care O
. O




 O
In O
the O
ED O
: O
  O
Temp O
97 O
, O
  O
HR O
71 O
, O
  O
BP O
122/53 O
, O
  O
RR O
15 O
  O
88 O
% O
on O
RA O
99 O
% O

 O
on O
NRB O
and O
then O
on O
CPAP O
. O
  O
CXR O
done O
which O
showed O
worsening O

 O
bilateral B-REA
pleural I-REA
effusions I-REA
. I-REA
  O
He O
was O
given O
CTX B-DRUG
1gm B-STR
x O
1 B-DOS
, I-DOS
Levaquin B-DRUG

 I-DRUG
500 B-STR
mg I-STR
IV B-ROU
x O
1 B-DOS
, I-DOS
Vanco B-DRUG
1gm B-STR
IV B-ROU
x O
1 B-DOS
and O
was O
transferred O
to O
MICU O
. O




 O
On O
arrival O
, O
patient O
stated O
he O
was O
feeling O
well O
. O
  O
+ O
mild O
SOB O
. O

 O
CPAP O
was O
removed O
and O
patient O
was O
with O
98 O
% O
O2 B-DRUG
saturation O
on O
2LNC B-ROU
. I-ROU

 O
ABG O
: O
  O
7.21 O
// O
77 O
// O
149 O
// O
32 O





 O
Past O
Medical O
History O
: O

 O
Diastolic O
Congestive O
Heart O
Failure O
: O
ECHO O
[ O
* O
* O
3 O
- O
7 O
* O
* O
] O
EF O
of O
50 O
% O
& O

 O
severe O
LVH O


  O
Atrial B-REA
fibrillation I-REA
previously O
on O
Coumadin B-DRUG
( O
until O
GI B-ADE
bleed I-ADE

 I-ADE
[ O
* O
* O
6 O
- O
7 O
* O
* O
] O
) O
, O
failed O
cardioversion O


 O
s/p O
Pacemaker O
placement O
[ O
* O
* O
6 O
- O
7 O
* O
* O
] O
for O
complete O
heart O
block O


 O
Peripheral O
vascular O
disease O
s/p O
right O
lower O
extremity O
bypass O


 O
Hiatal O
hernia O
with O
intrathoracic O
stomach O
( O
confirmed O
by O
[ O
* O
* O
2133 O
- O
6 O
- O
16 O
* O
* O
] O

 O
CT O
) O


 O
Hypertension O


 O
Gout O


 O
? O
Prostate O
followed O
by O
Urology O
( O
denies O
symptoms O
of O
BPH O
) O


 O
Chronic O
Kidney O
Disease O
on O
HD O



 O

Social O
History O
: O

 O
Patient O
has O
an O
insurance O
business O
and O
worked O
daily O
until O
recent O

 O
sicknesses O
. O
No O
current O
tobacco O
use O
. O
There O
is O
no O
history O
of O

 O
alcohol O
abuse O
. O

 O
Occupation O
: O
Owns O
Insurance O
business O


 O
Drugs O
: O
None O


 O
Tobacco O
: O
None O


 O
Alcohol O
: O
None O


 O
Other O
: O



 O
Family O
History O
: O

 O
There O
is O
no O
family O
history O
of O
premature O
coronary O
artery O
disease O

 O
or O
sudden O
death O
. O
Patient O
's O
daughter O
had O
" O
kidney O
disease O
" O
and O
is O

 O
now O
s/p O
renal O
transplant O
. O
2 O
sons O
and O
1 O
daughter O
. O


 O
Physical O
Exam O
: O

 O
Tmax O
: O
36.8 O
? O
? O
? O
? O
? O
? O
C O
( O
98.2 O
? O
? O
? O
? O
? O
? O
F O
) O

 O
Tcurrent O
: O
36.8 O
? O
? O
? O
? O
? O
? O
C O
( O
98.2 O
? O
? O
? O
? O
? O
? O
F O
) O

 O
HR O
: O
70 O
( O
70 O
- O
76 O
) O
bpm O

 O
BP O
: O
107/53(64 O
) O
{ O
82/16(37 O
) O
- O
112/93(97 O
) O
} O
mmHg O

 O
RR O
: O
27 O
( O
14 O
- O
27 O
) O
insp/min O

 O
SpO2 O
: O
100 O
% O

 O
Heart O
rhythm O
: O
AV O
Paced O

 O
Height O
: O
65 O
Inch O


 O
General O
Appearance O
: O
Well O
nourished O
, O
No O
acute O
distress O
, O

 O
Overweight O
/ O
Obese O
, O
No(t O
) O
Thin O
, O
Anxious O
, O
No(t O
) O
Diaphoretic O


 O
Eyes O
/ O
Conjunctiva O
: O
PERRL O
, O
No(t O
) O
Pupils O
dilated O
, O
No(t O
) O

 O
Conjunctiva O
pale O
, O
No(t O
) O
Sclera O
edema O


 O
Head O
, O
Ears O
, O
Nose O
, O
Throat O
: O
Normocephalic O
, O
No(t O
) O
Poor O
dentition O
, O

 O
No(t O
) O
Endotracheal O
tube O
, O
No(t O
) O
NG O
tube O


 O
Lymphatic O
: O
Cervical O
WNL O
, O
Supraclavicular O
WNL O
, O
No(t O
) O
Cervical O

 O
adenopathy O


 O
Cardiovascular O
: O
( O
PMI O
Normal O
, O
No(t O
) O
Hyperdynamic O
) O
, O
( O
S1 O
: O
Normal O
, O

 O
No(t O
) O
Absent O
) O
, O
( O
S2 O
: O
Normal O
, O
No(t O
) O
Distant O
, O
No(t O
) O
Loud O
, O
No(t O
) O

 O
Widely O
split O
, O
No(t O
) O
Fixed O
) O
, O
No(t O
) O
S3 O
, O
No(t O
) O
S4 O
, O
No(t O
) O
Rub O
, O

 O
( O
Murmur O
: O
No(t O
) O
Systolic O
, O
No(t O
) O
Diastolic O
) O


 O
Peripheral O
Vascular O
: O
( O
Right O
radial O
pulse O
: O
Present O
) O
, O
( O
Left O
radial O

 O
pulse O
: O
Present O
) O
, O
( O
Right O
DP O
pulse O
: O
Present O
) O
, O
( O
Left O
DP O
pulse O
: O

 O
Present O
) O


 O
Respiratory O
/ O
Chest O
: O
( O
Expansion O
: O
Symmetric O
, O
No(t O
) O
Paradoxical O
) O
, O

 O
( O
Percussion O
: O
No(t O
) O
Resonant O
: O
, O
No(t O
) O
Hyperresonant O
: O
) O
, O
( O
Breath O

 O
Sounds O
: O
No(t O
) O
Clear O
: O
, O
Crackles O
: O
midway O
up O
posterior O
lung O

 O
fields O
, O
No(t O
) O
Bronchial O
: O
, O
No(t O
) O
Wheezes O
: O
, O
Diminished O
: O

 O
bilateral O
bases O
) O


 O
Abdominal O
: O
Soft O
, O
Non-tender O
, O
Bowel O
sounds O
present O
, O
No(t O
) O

 O
Distended O
, O
No(t O
) O
Tender O
: O
, O
No(t O
) O
Obese O


 O
Extremities O
: O
Right O
: O
2 O
+ O
, O
Left O
: O
2 O
+ O
, O
to O
ankles O
bilaterally O


 O
Musculoskeletal O
: O
No(t O
) O
Muscle O
wasting O


 O
Skin O
: O
  O
Not O
assessed O
, O
Rash O
: O



 O
Neurologic O
: O
Follows O
simple O
commands O
, O
Responds O
to O
: O
Not O
assessed O
, O

 O
Oriented O
( O
to O
) O
: O
person O
, O
place O
, O
time O
, O
Movement O
: O
Not O
assessed O
, O

 O
Tone O
: O
Not O
assessed O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
01:21PM O
   O
PT-14.5 O
* O
PTT-31.3 O
INR(PT)-1.3 O
* O

 O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
01:21PM O
   O
PLT O
SMR-VERY O
LOW O
PLT O
COUNT-61 O
* O

 O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
01:21PM O
   O
NEUTS-68 O
BANDS-0 O
LYMPHS-13 O
* O
MONOS-9 O
EOS-10 O
* O

 O
BASOS-0 O
ATYPS-0 O
METAS-0 O
MYELOS-0 O

 O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
01:21PM O
   O
WBC-6.9 O
RBC-3.30 O
* O
# O
HGB-10.8 O
* O
HCT-36.9 O
* O
# O

 O
MCV-112 O
* O
MCH-32.7 O
* O
MCHC-29.2 O
* O
RDW-17.3 O
* O

 O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
01:21PM O
   O
CALCIUM-9.5 O
PHOSPHATE-3.8 O
MAGNESIUM-2.4 O

 O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
01:21PM O
   O
CK(CPK)-28 O
* O

 O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
01:21PM O
   O
GLUCOSE-106 O
* O
UREA O
N-20 O
CREAT-3.8 O
* O
# O
SODIUM-140 O

 O
POTASSIUM-4.7 O
CHLORIDE-100 O
TOTAL O
CO2 O
- O
31 O
ANION O
GAP-14 O

 O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
01:30PM O
   O
cTropnT-0.23 O
* O

 O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
01:31PM O
   O
LACTATE-0.9 O

 O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
01:31PM O
   O
TYPE-ART O
PO2 O
- O
149 O
* O
PCO2 O
- O
77 O
* O
PH-7.21 O
* O
TOTAL O

 O
CO2 O
- O
32 O
* O
BASE O
XS-0 O
INTUBATED-NOT O
INTUBA O

 O
[ O
* O
* O
2133 O
- O
8 O
- O
20 O
* O
* O
] O
03:59PM O
   O
TYPE-ART O
PO2 O
- O
95 O
PCO2 O
- O
58 O
* O
PH-7.30 O
* O
TOTAL O

 O
CO2 O
- O
30 O
BASE O
XS-0 O


 O
Brief O
Hospital O
Course O
: O

 O
Pt O
is O
an O
85 O
year O
old O
male O
with O
history O
of O
diastolic O
heart O

 O
failure O
, O
copmlete O
heart O
block O
( O
s/p O
PPM O
[ O
* O
* O
6 O
- O
7 O
* O
* O
] O
) O
ESRD O
on O
HDHD O
, O
h/o O

 O
MRSA O
bacteremia O
and O
thrombocytopenia B-ADE
, I-ADE
likely O
secondary O
to O
drug O

 O
reaction O
( O
PPI B-DRUG
? I-DRUG
) O
who O
presented O
from O
[ O
* O
* O
Hospital O
100 O
* O
* O
] O
rehab O
with O
dyspnea O
. O

 O
Initially O
admitted O
to O
MICU O
with O
dyspnea O
and O
? O
CO2 O
retention O

 O
requiring O
BiPAP O
. O
Pt O
was O
called O
out O
to O
the O
floor O
and O
did O
well O
for O

 O
several O
days O
. O
  O
He O
was O
then O
noted O
to O
be O
hypoxic O
at O
dialysis O
. O
  O
he O

 O
also O
underwent O
therapeutic O
thoracentesis O
on O
right O
side O
with O
good O

 O
relief O
. O
  O
The O
following O
morning O
, O
he O
was O
found O
to O
be O
somnolent O

 O
with O
myoclonic O
jerking O
. O
  O
ABG O
demonstrated O
7.24/70/89 O
on O
3 O
L/min O
. O

  O
He O
was O
transferred O
back O
to O
the O
MICU O
for O
? O
bipap O
. O
  O
He O
was O
noted O

 O
to O
be O
continually O
hypercarbic O
throughout O
his O
admission O
. O



 O
Pt O
's O
BPs O
continued O
to O
drop O
and O
he O
became O
unable O
to O
tolerate O
HD O
. O

 O
On O
the O
day O
prior O
to O
death O
, O
dialysis O
had O
to O
be O
stopped O

 O
prematurely O
( O
removed O
2.2L O
) O
due O
to O
hypoxia O
and O
hypotension O
. O
  O
The O

 O
morning O
of O
his O
death O
, O
he O
was O
noted O
to O
be O
acutely O
hypoxic O
and O

 O
hypercarbic O
. O
  O
CXR O
revealed O
a O
collapsed O
left O
lung O
and O
increase O
in O

 O
right O
sided O
pleural O
effusion O
. O
  O
Discussed O
situation O
with O
family O

 O
and O
it O
was O
decided O
to O
not O
escalate O
care O
( O
had O
been O
decided O
upon O

 O
to O
make O
him O
DNR/DNI O
the O
night O
before O
) O
. O
  O
Over O
the O
course O
of O
the O

 O
day O
, O
he O
became O
increasinly O
hypoxic O
, O
hypercarbic O
, O
acidotic O
, O
and O

 O
hypotensive O
. O
  O
He O
was O
pronounced O
deat O
at O
17:25 O
on O
[ O
* O
* O
2133 O
- O
8 O
- O
25 O
* O
* O
] O
. O

 O
Family O
was O
present O
and O
declined O
autopsy O
. O

 O
. O

 O
# O
. O
  O
Dyspnea O
: O
  O
Patient O
presented O
from O
rehab O
with O
acute O
dyspnea O

 O
and O
SOB O
with O
walking O
the O
day O
of O
admission O
likley O
from O
increasing O

 O
pleural B-REA
effusions I-REA
. I-REA
Patient O
had O
been O
afebrile O
, O
without O

 O
leukocytosis O
, O
bandemia O
or O
cough O
making O
PNA O
very O
unlikely O
. O
Given O

 O
that O
CTX/Levaquin/Vanco B-DRUG
started O
in O
the O
ED O
were O
D/Ced O
. O
Nephrology O

 O
was O
notified O
that O
the O
patient O
was O
admitted O
and O
Pt O
was O
sent O
to O
HD O

 O
for O
ultrafiltration O
on O
the O
day O
of O
transfer O
off O
of O
the O
MICU O
. O
CEs O

 O
were O
negative O
. O


 O
# O
. O
End O
Stage O
Renal O
Disease O
: O
  O
Patient O
on O
MWF O
HD O
treatments O
. O
Pt O

 O
continued O
HD O
as O
an O
in O
patient O
with O
removal O
of O
excess O
fluid O
. O


 O
# O
. O
C B-REA
Diff I-REA
colitis I-REA
: I-REA
Patient O
with O
( O
+ O
) O
C O
diff O
tox O
x O
3 O
during O

 O
admission O
in O
[ O
* O
* O
Month O
( O
only O
) O
205 O
* O
* O
] O
. O
  O
On O
Vanco B-DRUG
at O
[ O
* O
* O
Hospital O
100 O
* O
* O
] O
rehab O
until O
[ O
* O
* O
2133 O
- O
8 O
- O
24 O
* O
* O
] O
. O

 O
Vanco B-DRUG
250 B-STR
mg I-STR
PO B-ROU
QID B-FRE
was O
continued O
as O
an O
in O
patient O
. O


 O
# O
. O
Diastolic O
heart O
failure O
: O
Last O
ECHO O
[ O
* O
* O
2133 O
- O
7 O
- O
17 O
* O
* O
] O
with O
EF O
> O
55 O
% O
and O

 O
mild O
mitral O
regurgitation O
. O
HD O
was O
done O
as O
above O
. O


 O
# O
. O
Atrial B-REA
Fibrillation I-REA
: I-REA
Patient O
is O
currently O
V-paced O
. O
We O

 O
continued O
outpatient O
amiodarone B-DRUG
. I-DRUG
Anticoagulation B-DRUG
was O
held O
given O

 O
recent O
history O
of O
GI O
bleed O
. O


 O
# O
. O
Thrombocytopenia B-ADE
: I-ADE
Thought O
to O
be O
[ O
* O
* O
1 O
- O
31 O
* O
* O
] O
to O
drug O
reaction O
one O

 O
month O
ago O
( O
PPI B-DRUG
) I-DRUG
, O
currently O
at O
61 O
, O
down O
from O
113 O
at O
last O

 O
admisstion O
. O
This O
suggests O
the O
possibility O
of O
MDS O
. O
Follow O
up O
with O

 O
a O
hematologist O
may O
be O
indicate O
in O
the O
future O
as O
an O
outpatient O
, O

 O
but O
since O
the O
remainder O
of O
his O
counts O
are O
WNL O
no O
H/O O
consult O
was O

 O
called O
. O


 O
Medications O
on O
Admission O
: O

 O
Amiodarone B-DRUG
200 B-STR
mg I-STR
daily B-FRE


 I-FRE
Calcium B-DRUG
Gluconate I-DRUG
650 B-STR
mg I-STR
TID B-FRE



 I-FRE
Midodrine B-DRUG
5 B-STR
mg I-STR
TID B-FRE


 I-FRE
Simethicone B-DRUG
80 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O


 O
Vanco B-DRUG
250 B-STR
mg I-STR
PO B-ROU
QID B-FRE


 I-FRE
Vit B-DRUG
B/Vit B-DRUG
C/Folic B-DRUG
Acid I-DRUG



 I-DRUG
Discharge O
Medications O
: O

 O
Expired O


 O
Discharge O
Disposition O
: O

 O
Expired O


 O
Discharge O
Diagnosis O
: O

 O
Expired O


 O
Discharge O
Condition O
: O

 O
Expired O


 O
Discharge O
Instructions O
: O

 O
Expired O


 O
Followup O
Instructions O
: O

 O
Expired O



 O
Completed O
by:[**2133 O
- O
8 O
- O
25 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2114 O
- O
2 O
- O
28 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2114 O
- O
3 O
- O
2 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2046 O
- O
11 O
- O
11 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Furosemide B-DRUG
/ O
Klor-Con B-DRUG
/ O
ZPACK B-DRUG
/ O
Atrovent B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
983 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
BRBRP O
hematuria O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
none O


 O
History O
of O
Present O
Illness O
: O

 O
67 O
YOM O
who O
presents O
with O
worsening O
B O
BRBPR O
and O
hematuria O
. O
  O
He O

 O
reports O
developing O
BRBPR B-ADE
8 O
- O
9 O
months O
ago O
after O
starting O
pradaxa B-DRUG

 I-DRUG
for O
afib B-REA
. I-REA
  O
It O
remained O
stable O
, O
but O
over O
the O
past O
4 O
- O
5 O
days O
there O

 O
has O
been O
increasing O
blood O
and O
rectal O
pain O
along O
with O
hematuria O

 O
and O
dysuria O
. O
  O
He O
reports O
this O
was O
in O
the O
setting O
of O
cold O

 O
symptoms O
. O
  O
He O
denies O
melena O
, O
abdominal O
pain O
, O
nausea O
or O
vomiting O
. O

 O
He O
had O
some O
mild O
shortness O
of O
breath O
and O
fatigue O
yesterday O
and O

 O
today O
, O
but O
no O
CP O
. O

 O
. O

 O
In O
the O
ED O
, O
initial O
VS O
were O
ED O
97.2 O
57 O
82/58 O
16 O
96 O
% O
, O
and O
he O

 O
triggered O
for O
hypotension O
. O
  O
EKG O
showed O
sinus O
60 O
na O
ni O
qtc O
496 O
. O

 O
WBC O
was O
20.6 O
and O
Hct O
was O
37.7 O
. O
  O
INR O
was O
1.3 O
. O
  O
Cr O
was O
2.0 O
but O

 O
improved O
to O
1.5 O
. O
  O
Lactate O
1.7 O
. O
  O
UA O
showed O
108 O
wbc O
and O
many O

 O
bacteria O
. O
  O
He O
had O
a O
CT O
a/p O
which O
showed O
cystitis B-REA
but O
no O
major O

 O
bleed O
. O
  O
He O
received O
cipro/flagyl B-DRUG
. I-DRUG
  O
2 O
PIVs O
were O
placed O
and O

 O
received O
2L B-DOS
NS B-DRUG
. I-DRUG
  O
He O
did O
not O
receive O
blood O
. O

 O
. O

 O
He O
was O
seen O
by O
GI O
who O
felt O
that O
he O
may O
warrant O
a O
colonoscopy O

 O
initially O
, O
but O
decided O
given O
his O
stable O
picture O
to O
defer O
for O

 O
now O
. O

 O
. O

 O
On O
arrival O
to O
the O
MICU O
, O
he O
is O
comfortable O
and O
without O
any O

 O
complaints O
. O
  O
VS O
98.3 O
  O
97/58 O
  O
66 O
  O
16 O
  O
94 O
% O
RA O


 O
Review O
of O
systems O
: O

 O
( O
+ O
) O
Per O
HPI O

 O
( O
- O
) O
Denies O
headache O
, O
sinus O
tenderness O
, O
rhinorrhea O
or O
congestion O
. O

 O
Denies O
cough O
, O
shortness O
of O
breath O
, O
or O
wheezing O
. O
Denies O
chest O

 O
pain O
, O
chest O
pressure O
, O
palpitations O
, O
or O
weakness O
. O
Denies O
nausea O
, O

 O
vomiting O
, O
diarrhea O
, O
constipation O
, O
abdominal O
pain O
. O
Denies O
rashes O

 O
or O
skin O
changes O
. O

 O
. O



 O
Past O
Medical O
History O
: O

 O
Atrial O
fibrillation O

 O
ED O

 O
Gout O

 O
HTN O

 O
Hypothyroid O

 O
OSA O

 O
Asthma O

 O
Venous O
stasis O
ulcers O



 O

Social O
History O
: O

 O
lives O
alone O
in O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
. O
  O
recently O
separated O
. O
  O
drinks O
3 O

 O
scotches/night O
. O
  O
No O
hx O
of O
withdrawals O
. O
  O
smokes O
4 O
cigars/night O
. O

 O
no O
illicits O

 O
. O



 O
Family O
History O
: O

 O
NC O



 O
Physical O
Exam O
: O

 O
On O
admission O
: O

 O
Vitals O
: O
98.3 O
  O
97/58 O
  O
66 O
  O
16 O
  O
94 O
% O
RA O

 O
General O
: O
Alert O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
Sclera O
anicteric O
, O
pale O
conjunctiva O
. O
  O
MMM O
, O
oropharynx O

 O
clear O
, O
EOMI O
, O
PERRL O

 O
Neck O
: O
supple O
, O
JVP O
not O
elevated O
, O
no O
LAD O

 O
CV O
: O
Regular O
rate O
and O
rhythm O
, O
normal O
S1 O
+ O
S2 O
, O
no O
murmurs O
, O
rubs O
, O

 O
gallops O

 O
Lungs O
: O
diffuse O
wheezes O
. O
  O
No O
crackles O

 O
Abdomen O
: O
obese O
soft O
, O
non-tender O
, O
non-distended O
, O
bowel O
sounds O

 O
present O
, O
no O
organomegaly O

 O
Rectal O
( O
in O
ED O
) O
: O
Guiac O
+ O
brown O
stool O
, O
external O
hemorroids O
, O
no O

 O
obvious O
fissues O

 O
GU O
: O
no O
foley O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
1 O
+ O
edema O
. O
  O
Multiple O
leg O

 O
scars O

 O
Neuro O
: O
CNII-XII O
intact O
, O
5/5 O
strength O
upper/lower O
extremities O
, O

 O
grossly O
normal O
sensation O
, O
2 O
+ O
reflexes O
bilaterally O
, O
gait O

 O
deferred O
, O
finger-to-nose O
intact O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2114 O
- O
2 O
- O
28 O
* O
* O
] O
10:58AM O
BLOOD O
WBC-20.6 O
* O
# O
RBC-3.81 O
* O
Hgb-12.1 O
* O
# O
Hct-37.7 O
* O

 O
MCV-99 O
* O
MCH-31.9 O
MCHC-32.2 O
# O
RDW-13.5 O
Plt O
Ct-139 O
* O

 O
[ O
* O
* O
2114 O
- O
2 O
- O
28 O
* O
* O
] O
10:58AM O
BLOOD O
Neuts-73 O
* O
Bands-5 O
Lymphs-14 O
* O
Monos-7 O

 O
Eos-1 O
Baso-0 O
Atyps-0 O
Metas-0 O
Myelos-0 O

 O
[ O
* O
* O
2114 O
- O
2 O
- O
28 O
* O
* O
] O
10:58AM O
BLOOD O
PT-14.7 O
* O
PTT-34.7 O
INR(PT)-1.4 O
* O

 O
[ O
* O
* O
2114 O
- O
2 O
- O
28 O
* O
* O
] O
10:58AM O
BLOOD O
Glucose-128 O
* O
UreaN-36 O
* O
Creat-2.0 O
* O
Na-139 O

 O
K-5.8 O
* O
Cl-103 O
HCO3 O
- O
25 O
AnGap-17 O

 O
[ O
* O
* O
2114 O
- O
3 O
- O
1 O
* O
* O
] O
03:13AM O
BLOOD O
ALT-67 O
* O
AST-39 O
LD(LDH)-275 O
* O
AlkPhos-74 O

 O
TotBili-0.5 O

 O
[ O
* O
* O
2114 O
- O
2 O
- O
28 O
* O
* O
] O
10:58AM O
BLOOD O
Calcium-7.9 O
* O
Phos-5.2 O
* O
# O
Mg-1.8 O

 O
[ O
* O
* O
2114 O
- O
2 O
- O
28 O
* O
* O
] O
12:34PM O
BLOOD O
Lactate-1.7 O

 O
[ O
* O
* O
2114 O
- O
2 O
- O
28 O
* O
* O
] O
01:56PM O
URINE O
Color-Yellow O
Appear-Hazy O
Sp O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
-1.016 O

 O
[ O
* O
* O
2114 O
- O
2 O
- O
28 O
* O
* O
] O
01:56PM O
URINE O
RBC-10 O
* O
WBC-108 O
* O
Bacteri-MANY O
Yeast-NONE O

 O
Epi-0 O

 O
[ O
* O
* O
2114 O
- O
2 O
- O
28 O
* O
* O
] O
01:56PM O
URINE O
CastHy-27 O
* O



 O
CXR O
: O

 O
FINDINGS O
: O
Frontal O
and O
lateral O
views O
of O
the O
chest O
are O
compared O
to O

 O
previous O

 O
exam O
from O
[ O
* O
* O
2113 O
- O
3 O
- O
14 O
* O
* O
] O
. O
Compared O
to O
prior O
, O
there O
is O
new O

 O
central O
pulmonary O
vascular O
engorgement O
with O
mild O
cephalization O

 O
of O
the O
pulmonary O
vasculature O
. O
  O
There O
is O
no O
confluent O

 O
consolidation O
or O
effusion O
. O
Cardiomediastinal O
silhouette O
is O

 O
stable O
, O
as O
are O
the O
osseous O
and O
soft O
tissue O
structures O
. O

 O
IMPRESSION O
: O
Findings O
suggestive O
of O
mild O
pulmonary O
vascular O

 O
congestion O
without O
frank O
pulmonary O
edema O
. O


 O
CT O
Abd/Pelvis O
: O

 O
1 O
. O
Thickened O
bladder O
wall O
with O
surrounding O
stranding O
potentially O

 O
secondary O
to O
cystitis O
and O
correlation O
with O
UA O
suggested O
. O

 O
2 O
. O
There O
is O
no O
retroperitoneal O
hematoma O
. O

 O
3 O
. O
Hypodense O
lesions O
in O
each O
kidney O
likely O
represent O
cysts O
, O

 O
however O
, O
not O

 O
fully O
characterized O
on O
nonenhanced O
CT O
scan O
. O
If O
desired O
US O
could O

 O
help O

 O
characterize O
. O

 O
4 O
. O
Enlarged O
prostate O
. O



 O
Brief O
Hospital O
Course O
: O

 O
67 O
yom O
with O
history B-REA
of I-REA
a.fib I-REA
, I-REA
on O
pradaxa B-DRUG
, I-DRUG
now O
presenting O
with O

 O
worsening O
BRBPR B-ADE
and O
hematuria B-ADE

 I-ADE
. O

 O
# O
GI O
Bleed O
: O
Patient O
was O
monitored O
in O
the O
MICU O
overnight O
for O
GIB B-ADE

 I-ADE
given O
pradaxa B-DRUG
use O
. O
  O
He O
remained O
normotensive O
throughout O
his O
MICU O

 O
stay O
without O
drop O
in O
Hct O
. O
  O
He O
was O
evaluated O
by O
GI O
who O
felt O
no O

 O
urgent O
colonoscopy O
was O
needed O
, O
and O
symptoms O
were O
likely O

 O
secondary O
hemorrhoidal O
and O
exacerbated O
by O
anticoagulation O
. O
  O
He O

 O
was O
transferred O
to O
the O
medical O
floor O
where O
he O
remained O
stable O

 O
o/n O
. O
  O
After O
discussion O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
the O
patient O
's O
out- O
patient O

 O
cardiologist O
, O
given O
the O
fact O
that O
he O
has O
been O
in O
sinus O
for O
the O

 O
better O
part O
of O
a O
year O
and O
has O
not O
flipped O
into O
AFIB O
he O
was O
d/c'd O

 O
on O
full B-DOS
dose I-DOS
ASA B-DRUG
with O
GI O
f/u O
scheduled O
. O

 O
. O

 O
# O
UTI O
: O
Patient O
was O
started O
on O
ciprofloxacin B-DRUG
for O
UTI B-REA
as O
evidenced O

 O
by O
UA O
and O
dysuria O
. O
  O
He O
was O
subsequently O
switched O
to O
cefpodoxime B-DRUG

 I-DRUG
given O
concern O
for O
prolonged O
QTc O
in O
combination O
with O
amiodarone B-DRUG
. I-DRUG

 O
Micro O
showed O
a O
sensitive O
E. O
Coli O
. O

 O
. O

 O
# O
Afib B-REA
: I-REA
Patient O
remained O
in O
sinus O
rhythm O
. O
  O
Anticoagulation B-DRUG
was O

 O
initially O
held O
, O
then O
switched O
to O
ASA B-DRUG
as O
above O
. O


 O
# O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
: O
Creatinine O
was O
2.0 O
on O
admission O
, O
improving O
to O
1.2 O
the O

 O
following O
day O
and O
1.0 O
on O
the O
day O
of O
discharge O
. O
  O
Thought O
to O
be O

 O
secondary O
to O
volume O
depletion O
. O


 O
# O
Wheezing O
: O
Patine O
twas O
initially O
slightly O
wheezy O
on O
exam O

 O
thoguht O
to O
be O
sedcondary O
to O
mild O
volume O
overload O
. O
  O
The O
following O

 O
day O
pulmonary O
exam O
had O
improved O
, O
patient O
was O
comfortable O
on O
room O

 O
air O
. O
  O
He O
refused O
scripts O
for O
inhalers O
at O
home O
, O
saying O
he O
only O

 O
needs O
them O
when O
he O
is O
sick O
. O


 O
. O


 O
# O
Hypertension O
: O
Home O
medications O
initially O
held O
in O
the O
MICU O
, O

 O
were O
restarted O
after O
patient O
demonstrated O
hemodynamic O
stability O

 O
and O
transferred O
to O
the O
floor O
. O
  O
Did O
well O
from O
this O
standpoint O

 O
until O
discharge O
. O



 O
Medications O
on O
Admission O
: O

 O
albuterol B-DRUG
prn B-FRE

 I-FRE
alprazolam B-DRUG
prn B-FRE
' I-FRE

 O
amiodarone B-DRUG
200 B-STR
mg I-STR
po B-ROU
daily B-FRE

 I-FRE
atenolol B-DRUG
50 B-STR
mg I-STR
po B-ROU
daily B-FRE

 I-FRE
clobetasol B-DRUG
0.05 B-STR
% I-STR
prn B-FRE

 I-FRE
dabigatran B-DRUG
150 B-STR
mg I-STR
po B-ROU
bid B-FRE

 I-FRE
flovent B-DRUG
110 B-STR
2 B-DOS
puffs B-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
levoxyl B-DRUG
100mcg B-STR
daily B-FRE

 I-FRE
lisinopril B-DRUG
40 B-STR
mg I-STR
po B-ROU
daily B-FRE

 I-FRE
percocet B-DRUG
prn B-FRE

 I-FRE
cialis B-DRUG

 I-DRUG
triamterene/hctz B-DRUG
37.5/25 B-STR

 I-STR
ca/Vit B-DRUG
D I-DRUG

 I-DRUG
fish B-DRUG
oil I-DRUG

 I-DRUG
MTV B-DRUG



 I-DRUG
Discharge O
Medications O
: O

 O
1 O
. O
amiodarone B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
levothyroxine B-DRUG
100 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
alprazolam B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1.5 B-DOS
Tablets B-FOR
PO B-ROU
QHS B-FRE
( I-FRE
once I-FRE
a I-FRE
day I-FRE

 I-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
insomnia B-REA
. I-REA

 O
4 O
. O
cholecalciferol B-DRUG
( I-DRUG
vitamin I-DRUG
D3 I-DRUG
) I-DRUG
400 B-STR
unit I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
calcium B-DRUG
carbonate I-DRUG
200 B-STR
mg I-STR
calcium B-DRUG
( O
500 B-STR
mg I-STR
) I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR

 I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
multivitamin B-DRUG
     O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
7 O
. O
cefpodoxime B-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q12H B-FRE
( I-FRE
every I-FRE

 I-FRE
12 I-FRE
hours I-FRE
) I-FRE
for B-DUR
5 I-DUR
days I-DUR
. I-DUR

 O
Disp:*20 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
8 O
. O
phenazopyridine B-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
for B-DUR
2 I-DUR
days I-DUR
. I-DUR

 O
Disp:*6 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
9 O
. O
atenolol B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
lisinopril B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
triamterene-hydrochlorothiazid B-DRUG
37.5 B-STR
- I-STR
25 I-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Cap B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
13 O
. O
Cialis B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
prn B-FRE
as I-FRE
needed I-FRE
for O

 O
intercourse B-REA
. I-REA

 O
14 O
. O
Fish B-DRUG
Oil I-DRUG
1,000 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
once B-FRE
a I-FRE

 I-FRE
day I-FRE
. I-FRE

 O
15 O
. O
Flovent B-DRUG
HFA B-FOR
110 B-STR
mcg/actuation I-STR
Aerosol B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
puffs B-FOR

 I-FOR
Inhalation B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Lower B-ADE
GI I-ADE
bleeding I-ADE
c/b O
anticoagulation B-DRUG



 I-DRUG

Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
Dear O
Mr. O
[ O
* O
* O
Known O
lastname O
9861 O
* O
* O
] O
, O

    O
It O
has O
been O
a O
pleasure O
taking O
care O
of O
you O
in O
the O
hospital O
. O

 O
You O
were O
admitted O
after O
you O
saw O
some O
blood O
with O
your O
bowel O

 O
movements O
. O
  O
You O
were O
observed O
overnight O
in O
the O
ICU O
and O
did O
quite O

 O
well O
. O
  O
We O
discussed O
your O
pradaxa B-DRUG
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
who O
agreed O
that O

 O
you O
should O
switch O
to O
full B-DOS
dose I-DOS
aspirin B-DRUG
. I-DRUG

 O
. O

 O
Please O
START O
Asiprin B-DRUG
325 B-STR
mg I-STR
daily B-FRE

 I-FRE
Please O
STOP O
Dabigatran(Pradaxa B-DRUG
) I-DRUG

 I-DRUG
Please O
START O
Cefpodoxime B-DRUG
200 B-STR
mg I-STR
twice B-FRE
per I-FRE
day I-FRE
for B-DUR
5 I-DUR
more I-DUR
days I-DUR

 I-DUR
Please O
START O
Pyridium B-DRUG
to O
treat O
you O
urinary B-REA
symptoms I-REA



 I-REA
Followup O
Instructions O
: O

 O
Department O
: O
[ O
* O
* O
State O
* O
* O
] O
When O
: O
FRIDAY O
[ O
* O
* O
2114 O
- O
3 O
- O
9 O
* O
* O
] O
at O
9:30 O
AM O

 O
With O
: O
[ O
* O
* O
Name6 O
( O
MD O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
9862 O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
2205 O
* O
* O
] O

 O
Building O
: O
[ O
* O
* O
State O
* O
* O
] O
( O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
MA O
) O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
OFF O
CAMPUS O
     O
Best O
Parking O
: O
On O
Street O
Parking O

 O
. O

 O
DR O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
9863 O
* O
* O
] O
IS O
WORKING O
ON O
GETTING O
YOU O
AN O
EARLIER O
APPOINTMENT O

 O
AND O
WILL O
CALL O
YOU O
WITH O
IT O

 O
. O

 O
Department O
: O
DIV O
. O
OF O
GASTROENTEROLOGY O

 O
When O
: O
TUESDAY O
[ O
* O
* O
2114 O
- O
4 O
- O
10 O
* O
* O
] O
at O
3:30 O
PM O

 O
With O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
9864 O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
463 O
* O
* O
] O

 O
Building O
: O
Ra O
[ O
* O
* O
Hospital O
Unit O
Name O
1825 O
* O
* O
] O
( O
[ O
* O
* O
Hospital O
Ward O
Name O
1826**]/[**Hospital O
Ward O
Name O
1827 O
* O
* O
] O
Complex O
) O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
Main O
Garage O

 O
. O


 O
Department O
: O
WEST O
PROCEDURAL O
CENTER O

 O
When O
: O
TUESDAY O
[ O
* O
* O
2114 O
- O
5 O
- O
8 O
* O
* O
] O
at O
12:30 O
PM O

 O
With O
: O
WPC O
ROOM O
THREE O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
5072 O
* O
* O
] O

 O
Building O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
121 O
* O
* O
] O
Building O
( O
[ O
* O
* O
Hospital O
Ward O
Name O
121 O
* O
* O
] O
Complex O
) O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
WEST O
     O
Best O
Parking O
: O
[ O
* O
* O
Street O
Address(1 O
) O
592 O
* O
* O
] O
Garage O




 O
Completed O
by:[**2114 O
- O
3 O
- O
4 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2137 O
- O
9 O
- O
19 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2137 O
- O
10 O
- O
12 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2075 O
- O
12 O
- O
7 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
CARDIOTHORACIC O


 O
Allergies O
: O

 O
Penicillins B-DRUG
/ O
Iodine B-DRUG
; I-DRUG
Iodine B-DRUG
Containing O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
922 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
chest O
pain O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
s/p O
CABGx5(LIMA->LAD O
, O
SVG-.pLAD O
, O
Ramus O
, O
PDA O
, O
LCX O
) O
[ O
* O
* O
2137 O
- O
9 O
- O
19 O
* O
* O
] O

 O
Reexploration O
for O
bleeding O
. O

 O
Cardiac O
catherization O



 O
History O
of O
Present O
Illness O
: O

 O
61 O
year O
old O
male O
with O
angina O
over O
last O
year O
relieved O
with O
rest O
. O

 O
Presented O
to O
OSH O
when O
angina O
did O
not O
relieve O
with O
rest O
and O
ruled O

 O
in O
for O
NSTEMI O
. O
  O
Transferred O
for O
cardiac O
catherization O


 O
Past O
Medical O
History O
: O

 O
Hypertension O

 O
Angina O

 O
Heart O
Failure O

 O
Atrial O
Fibrillation O

 O
Skin O
Cancer O


 O
Social O
History O
: O

 O
Works O
at O
[ O
* O
* O
Company O
* O
* O
] O
globe O
, O
is O
married O

 O
Tobacco O
- O
denies O

 O
ETOH O
- O
[**2 O
- O
16**]/day O


 O
Family O
History O
: O

 O
Non O
contributory O


 O
Physical O
Exam O
: O

 O
Discharge O

 O
Neuro O
: O
alert O
, O
oriented O
x3 O
, O
strength O
R O
= O
L O
[ O
* O
* O
3 O
- O
20 O
* O
* O
] O
, O
no O
vision O
left O
eye O
, O

 O
normal O
vision O
right O
eye O

 O
Pulmonary O
: O
lungs O
clear O
to O
auscultation O
bilaterally O

 O
Cardiac O
: O
RRR O
+ O
murmur O
2/6 O
SEM O
, O
no O
rub/gallop O

 O
Sternal O
incision O
: O
healing O
no O
erythema O
, O
no O
drainage O
, O
sternum O

 O
stable O

 O
Abdomen O
: O
soft O
, O
nontender O
, O
nondistended O
, O
+ O
bowel O
sounds O
last O
BM O

 O
[ O
* O
* O
10 O
- O
12 O
* O
* O
] O

 O
Extremeties O
: O
warm O
, O
edema O
+ O
1 O
nonpitting O
, O
pulses O
palpable O

 O
Leg O
incision O
: O
endovascular O
harvest O
, O
healing O
, O
no O
drainage O
, O
no O

 O
erythema O



 O
Pertinent O
Results O
: O

 O
RENAL O
U.S. O
; O
DUPLEX O
DOP O
ABD/PEL O
LIMITED O


 O
Reason O
: O
r/o O
RAS O


 O
[ O
* O
* O
Hospital O
93 O
* O
* O
] O
MEDICAL O
CONDITION O
: O

 O
61 O
year O
old O
man O
s/p O
CABGx5 O
with O
acutely O
increased O
creatinine O

 O
REASON O
FOR O
THIS O
EXAMINATION O
: O

 O
r/o O
RAS O

 O
INDICATION O
: O
Status O
post O
CABG O
with O
acutely O
increased O
creatinine O
. O

 O
Rule O
out O
renal O
artery O
stenosis O
. O


 O
RENAL O
ULTRASOUND O
: O
No O
prior O
examinations O
. O
The O
kidneys O
are O
normal O

 O
in O
size O
and O
appearance O
. O
The O
right O
kidney O
measures O
13.6 O
cm O
and O

 O
left O
kidney O
measures O
13.2 O
cm O
. O
There O
are O
normal O
arterial O

 O
waveforms O
in O
the O
parenchyma O
bilaterally O
. O
The O
maximum O
RI O
on O
the O

 O
right O
is O
0.76 O
and O
on O
the O
left O
is O
0.8 O
( O
both O
of O
which O
are O

 O
minimally O
elevated O
) O
. O
There O
is O
no O
evidence O
of O
renal O
artery O

 O
stenosis O
. O
No O
hydronephrosis O
, O
stone O
, O
or O
mass O
. O
The O
bladder O
is O

 O
filled O
with O
fluid O
and O
shows O
no O
wall O
thickening O
or O
focal O
masses O
. O



 O
IMPRESSION O
: O
Minimally O
elevated O
resistive O
indices O
in O
both O

 O
kidneys O
, O
with O
no O
evidence O
of O
renal O
artery O
stenosis O
. O


 O
The O
study O
and O
the O
report O
were O
reviewed O
by O
the O
staff O
radiologist O
. O

 O
DR O
. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
18394 O
* O
* O
] O
[ O
* O
* O
Name O
( O
STitle O
) O
18395 O
* O
* O
] O


 O
CHEST O
( O
PA O
& O
LAT O
) O
  O
[ O
* O
* O
2137 O
- O
10 O
- O
11 O
* O
* O
] O
6:30 O
PM O


 O
CHEST O
( O
PA O
& O
LAT O
) O


 O
Reason O
: O
evaluate O
pleural O
effusion O


 O
[ O
* O
* O
Hospital O
93 O
* O
* O
] O
MEDICAL O
CONDITION O
: O

 O
61 O
year O
old O
man O
s/p O
CABG O

 O
REASON O
FOR O
THIS O
EXAMINATION O
: O

 O
evaluate O
pleural O
effusion O

 O
INDICATION O
: O
Status O
post O
CABG O
, O
evaluate O
pleural O
effusion O
. O


 O
PA O
AND O
LATERAL O
CHEST O
: O
Compared O
to O
[ O
* O
* O
2137 O
- O
10 O
- O
10 O
* O
* O
] O
. O
Left-sided O
PICC O
line O

 O
is O
unchanged O
in O
position O
with O
its O
tip O
in O
the O
distal O
SVC O
. O
There O

 O
is O
no O
pneumothorax O
. O
There O
remains O
a O
small O
left O
pleural O
effusion O

 O
not O
significantly O
changed O
and O
a O
small O
amount O
of O
linear O

 O
atelectasis O
at O
the O
left O
mid O
lung O
base O
. O
Calcified O
left O
hilar O

 O
adenopathy O
again O
seen O
. O
Heart O
remains O
upper O
limits O
of O
normal O
in O

 O
size O
. O
No O
significant O
short O
interval O
change O
. O


 O
The O
study O
and O
the O
report O
were O
reviewed O
by O
the O
staff O
radiologist O
. O

 O
DR O
. O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Initial O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O


 O
GENERAL O
COMMENTS O
: O
Suboptimal O
image O
quality O
- O
poor O
echo O
windows O
. O



 O
Conclusions O
: O

 O
The O
left O
atrium O
is O
mildly O
dilated O
. O
There O
is O
mild O
symmetric O
left O

 O
ventricular O

 O
hypertrophy O
with O
normal O
cavity O
size O
. O
Overall O
left O
ventricular O

 O
systolic O

 O
function O
is O
moderately O
depressed O
( O
EF O
35 O
- O
40 O
% O
) O
. O
Due O
to O
the O

 O
suboptimal O
image O

 O
quality O
, O
a O
regional O
wall O
motion O
abnormality O
can O
not O
be O
excluded O
. O

 O
Right O

 O
ventricular O
chamber O
size O
is O
normal O
. O
There O
is O
mild O
global O
right O

 O
ventricular O

 O
free O
wall O
hypokinesis O
. O
The O
ascending O
aorta O
is O
mildly O
dilated O
. O

 O
The O
aortic O
valve O

 O
leaflets O
( O
3 O
) O
are O
mildly O
thickened O
but O
aortic O
stenosis O
is O
not O

 O
present O
. O
Mild O

 O
( O
1 O
+ O
) O
aortic O
regurgitation O
is O
seen O
. O
The O
mitral O
valve O
leaflets O
are O

 O
mildly O

 O
thickened O
. O
There O
is O
a O
small O
pericardial O
effusion O
. O
The O
effusion O

 O
is O
echo O
dense O
, O

 O
consistent O
with O
blood O
, O
inflammation O
or O
other O
cellular O
elements O
. O

 O
There O
are O
no O

 O
echocardiographic O
signs O
of O
tamponade O
. O


 O
IMPRESSION O
: O
Small O
echodense O
pericardial O
effusion O
without O

 O
echocardiographic O

 O
signs O
of O
tamponade O
. O
Moderate O
left O
ventricular O
systolic O

 O
dysfunction O
. O
Mild O

 O
aortic O
regurgitation O
. O



 O
Compared O
with O
the O
prior O
study O
( O
images O
reviewed O
) O
of O
[ O
* O
* O
2137 O
- O
10 O
- O
3 O
* O
* O
] O
, O

 O
the O
pericardial O

 O
effusion O
is O
smaller O
. O
The O
other O
findings O
are O
similar O
. O


 O
Electronically O
signed O
by O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
171 O
* O
* O
] O
, O
MD O
on O
[ O
* O
* O
2137 O
- O
10 O
- O
10 O
* O
* O
] O
14:51 O
. O


 O
MRA O
head O

 O
IMPRESSION O
: O

 O
1 O
. O
No O
evidence O
of O
orbital O
abnormality O
on O
limited O
sections O

 O
through O
the O
orbits O
. O


 O
2 O
. O
Evidence O
of O
atherosclerotic O
disease O
, O
but O
without O
marked O

 O
stenoses O
or O
occlusion O
among O
the O
major O
arteries O
of O
the O
circle O
of O

 O
[ O
* O
* O
Location O
( O
un O
) O
431 O
* O
* O
] O
. O
Because O
of O
the O
limitations O
of O
the O
study O
, O
the O
ophthalmic O

 O
arteries O
are O
not O
well O
visualized O
on O
either O
side O
. O


 O
3 O
. O
Multiple O
small O
foci O
of O
T2 O
hyperintensity O
suggestive O
of O
prior O

 O
tiny O
infarcts O
in O
the O
cerebral O
white O
matte O
bilaterally O
. O
A O
few O
of O

 O
these O
demonstrate O
faintly O
increased O
signal O
also O
on O

 O
diffusion-weighted O
imaging O
, O
suggesting O
that O
they O
may O
be O
either O

 O
subacute O
or O
chronic O
. O



 O

Brief O
Hospital O
Course O
: O

 O
Transferred O
in O
from O
OSH O
and O
underwent O
cardiac O
catherization O
that O

 O
resulted O
in O
intra O
aortic O
balloon O
pump O
placement O
and O
transferred O

 O
to O
operating O
room O
emergently O
[ O
* O
* O
9 O
- O
19 O
* O
* O
] O
. O
  O
Please O
see O
catherization O

 O
report O
for O
further O
details O
. O
  O
He O
underwent O
coronary B-REA
artery I-REA
bypass I-REA

 I-REA
graft I-REA
x5 O
, O
please O
see O
operative O
report O
for O
further O
details O
. O
  O
He O

 O
was O
transferred O
to O
the O
CSRU O
on O
Neo B-DRUG
and O
propofol B-DRUG
with O
IABP O
. O
  O
He O

 O
received O
FFP B-DRUG
, I-DRUG
protamine B-DRUG
, I-DRUG
and O
platlets B-DRUG
for O
post B-REA
operative I-REA

 I-REA
bleeding I-REA
, I-REA
and O
then O
returned O
to O
operating O
room O
for O
reexploration O
, O

 O
please O
see O
operative O
report O
for O
further O
details O
. O
  O
He O
was O

 O
transferred O
to O
CSRU O
for O
continued O
management O
. O
  O
He O
continued O
with O

 O
tachycardia B-REA
not O
responsive O
to O
esmolol B-DRUG
was O
changed O
to O
cardizem B-DRUG

 I-DRUG
with O
better O
control O
, O
required O
vasopressors B-DRUG
for O
hypotension B-REA
. I-REA
  O
On O

 O
postoperative O
day O
[ O
* O
* O
1 O
- O
16 O
* O
* O
] O
the O
IABP O
was O
weaned O
and O
removed O
, O
he O

 O
continued O
on O
vasopressors B-DRUG
, I-DRUG
cardizem B-DRUG
was O
discontinued O
and O
he O
was O

 O
started O
on O
beta B-DRUG
blockers I-DRUG
. I-DRUG
  O
He O
remained O
intubated O
due O
to O

 O
hemodynamics O
and O
agitation O
. O
  O
Agitation O
continued O
with O
weaning O
of O

 O
sedation B-DRUG
, I-DRUG
diuresed B-DRUG
, I-DRUG
and O
betablocker B-DRUG
increased O
. O
  O
Postoperative O

 O
day O
[ O
* O
* O
4 O
- O
18 O
* O
* O
] O
tolerated O
CPAP O
and O
was O
extubated O
but O
was O
confused O
moving O

 O
all O
extremeties O
. O
Blood B-REA
pressure I-REA
and I-REA
heart I-REA
rate I-REA
labile I-REA
, I-REA
labetolol B-DRUG

 I-DRUG
started O
. O
  O
Postoperative O
[ O
* O
* O
6 O
- O
20 O
* O
* O
] O
he O
went O
into O
atrial B-REA
fibrillation I-REA
and O

 O
treated O
with O
Amiodarone B-DRUG
and O
beta B-DRUG
blockers I-DRUG
. I-DRUG
He O
remained O
in O
the O

 O
CSRU O
due O
to O
agitation B-REA
on O
CIWA O
d/t O
ETOH O
withdrawal O
, O
hemodynamic O
, O

 O
and O
respiratory O
management O
. O
  O
Psychiatry O
consulted O
due O
to O

 O
continued O
delirium O
and O
medications O
adjusted O
. O
  O
Anticoagulation O

 O
was O
started O
for O
atrial B-REA
fibrillation I-REA
with O
coumadin B-DRUG
on O
POD O
[ O
* O
* O
11 O
- O
25 O
* O
* O
] O
. O

 O
On O
postoperative O
14/13 O
he O
was O
ready O
for O
transfer O
to O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
2 O
with O

 O
a O
sitter O
, O
he O
continued O
with O
confusion O
at O
times O
, O
in/out O
atrial O

 O
fibrillation O
. O
  O
He O
continued O
to O
progress O
and O
physical O
activity O

 O
increased O
, O
he O
became O
more O
oriented O
, O
and O
was O
able O
to O
wean O
off O

 O
ativan B-DRUG
and O
sitter O
. O
  O
On O
posterative O
day O
20/19 O
he O
complained O
of O

 O
not O
being O
able O
to O
see O
out O
of O
left O
eye O
- O
opthamology O
evaluated O

 O
with O
question O
of O
posterior O
ischemic O
optic O
neuropathy O
which O
is O

 O
diagnosis O
by O
exclusion O
and O
he O
underwent O
MRI O
. O
  O
Plan O
for O
follow O
up O

 O
with O
opthamology O
in O
clinic O
no O
medical O
intervention O
at O
this O
time O
. O

  O
On O
postoperative O
day O
21/20 O
creatinine O
elevated O
with O
decreased O

 O
sodium O
. O
Fluid O
intake O
was O
increased O
, O
renal O
consulted O
, O

 O
echocardiogram O
( O
EF O
35 O
- O
40 O
% O
) O
. O
  O
All O
diuretics B-DRUG
, I-DRUG
ACE B-DRUG
inhibitors I-DRUG
, I-DRUG
and O

 O
NSAID B-DRUG
discontinued O
. O
  O
Creatinine O
decreased O
on O
Postoperative O
day O

 O

23/22 O
but O
sodium O
remained O
decreased O
and O
placed O
on O
free O
water O

 O
restriction O
with O
plan O
for O
chemistry O
to O
be O
rechecked O
[ O
* O
* O
10 O
- O
14 O
* O
* O
] O
at O

 O
rehab O
. O
  O
He O
was O
ready O
for O
discharge O
to O
rehab O
with O
plan O
for O
lab O

 O
checks O
. O


 O
Medications O
on O
Admission O
: O

 O
lopressor B-DRUG
, I-DRUG
lipitor B-DRUG
, I-DRUG
ASA B-DRUG
, I-DRUG
pepcid B-DRUG
, I-DRUG
Solumedrol B-DRUG
, I-DRUG
Plavix B-DRUG
, I-DRUG


 O
Discharge O
Medications O
: O

 O
1 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE

 I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE

 I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
5 O
. O
Atorvastatin B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
Hexavitamin B-DRUG
     O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Cap B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Folic B-DRUG
Acid I-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
9 O
. O
Thiamine B-DRUG
HCl I-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Fluticasone B-DRUG
110 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Puff B-FOR

 I-FOR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
11 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
17 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Puff B-FOR
Inhalation B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Amiodarone B-DRUG
200 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Diltiazem B-DRUG
HCl I-DRUG
180 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Sustained I-FOR
Release I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Sustained I-FOR
Release I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
14 O
. O
Haloperidol B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( O
at O

 O
bedtime O
) O
. O

 O
15 O
. O
Ferrous B-DRUG
Gluconate I-DRUG
300 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( O
2 O
times O
a O
day O
) O
. O

 O
16 O
. O
Outpatient O
Lab O
Work O

 O
please O
check O
SMA O
7 O
and O
HCT O
[ O
* O
* O
10 O
- O
14 O
* O
* O
] O

 O
17 O
. O
Warfarin B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
: I-FRE

 O
please O
give O
0.5 B-STR
mg I-STR
[ O
* O
* O
10 O
- O
13 O
* O
* O
] O
and O
check O
INR O
[ O
* O
* O
10 O
- O
14 O
* O
* O
] O
. O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
459 O
* O
* O
] O
for O
the O
Aged O
- O
[ O
* O
* O
Location O
( O
un O
) O
550 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Coronary O
artery O
disease O
. O

 O
HTN O

 O
Delirium O
. O



 O
Discharge O
Condition O
: O

 O
Good O



 O
Discharge O
Instructions O
: O

 O
Follow O
medications O
on O
discharge O
instructions O
. O

 O
Do O
not O
drive O
for O
4 O
weeks O
. O

 O
Do O
not O
lift O
more O
than O
10 O
lbs O
for O
2 O
months O
. O

 O
Shower O
daily O
, O
let O
water O
flow O
over O
wounds O
, O
pat O
dry O
with O
a O
towel O
. O

 O
Do O
not O
use O
lotions O
, O
powders O
, O
or O
creams O
on O
wounds O
. O

 O
Call O
our O
office O
for O
sternal O
drainage O
, O
temp>101.5 O
. O

 O
Please O
have O
SMA O
7 O
, O
HCT O
, O
INR O
checked O
[ O
* O
* O
10 O
- O
14 O
* O
* O
] O

 O
Free O
water O
restriction O
for O
hyponatremia O



 O
Followup O
Instructions O
: O

 O
Make O
an O
appointment O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
131 O
* O
* O
] O
for O
1 O
- O
2 O
weeks O
. O

 O
Make O
an O
appointment O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
4469 O
* O
* O
] O
for O
2 O
- O
3 O
weeks O
. O

 O
Make O
an O
appointment O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
914 O
* O
* O
] O
for O
4 O
weeks O
. O

 O
Make O
an O
appointment O
to O
see O
your O
local O
opthamologist O
after O

 O
discharge O
. O

 O
Make O
an O
appointment O
to O
see O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
22897 O
* O
* O
] O
with O
Neuro-opthamology O

 O
after O
discharge O
. O
Phone O
# O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
253 O
* O
* O
] O
. O

 O
Please O
have O
SMA O
7 O
, O
HCT O
, O
and O
INR O
drawn O
[ O
* O
* O
10 O
- O
14 O
* O
* O
] O



 O
Completed O
by:[**2137 O
- O
10 O
- O
12 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2135 O
- O
2 O
- O
17 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2135 O
- O
2 O
- O
24 O
* O
* O
] O



 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Horse O
Blood O
Extract O


 O
Attending:[**Doctor O
First O
Name O
1402 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
lightheadedness O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
right O
groin O
hematoma O
evacuation O
and O
repair O



 O
History O
of O
Present O
Illness O
: O

 O
Mr. O
[ O
* O
* O
Known O
firstname O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
7518 O
* O
* O
] O
is O
an O
85 O
y/o O
male O
with O
COPD O
, O
HTN O
, O
AF B-REA
on O

 O
coumadin B-DRUG
admitted O
to O
NEBH O
[ O
* O
* O
2 O
- O
8 O
* O
* O
] O
with O
atrial O
fibrillation O
s/p O
CV O

 O
developed O
tachy/brady O
syndrome O
s/p O
AF O
ablation O
on O
[ O
* O
* O
2 O
- O
14 O
* O
* O
] O

 O
discharged O
on O
CCB B-DRUG
, I-DRUG
metoprolol B-DRUG
and O
dofetilide B-DRUG
now O
presents O
with O

 O
presyncope O
and O
sinus O
bradycardia O
. O
On O
[ O
* O
* O
2 O
- O
14 O
* O
* O
] O
patient O
underwent O
EP O

 O
study O
which O
showed O
several O
atrial O
tachycardias O
and O
two O
were O

 O
ablated O
. O
The O
plan O
was O
for O
cardioversion O
following O
ablation O
but O

 O
patient O
converted O
to O
NSR O
and O
remained O
in O
NSR O
with O
only O
2 O
brief O

 O
episodes O
of O
AF O
on O
telemetry O
. O
Since O
discharge O
from O
the O
hospital O

 O
on O
[ O
* O
* O
2 O
- O
15 O
* O
* O
] O
the O
patient O
has O
been O
feeling O
well O
. O
He O
has O
not O
had O
any O

 O
chest O
pain O
, O
lightheadedness O
or O
dizziness O
until O
this O
morning O
. O

 O
This O
AM O
had O
minimal O
appetite O
at O
breakfast O
. O
Then O
attempted O
to O

 O
have O
a O
bowel O
movement O
several O
times O
with O
straining O
and O
each O
time O

 O
felt O
lightheaded O
and O
dizzy O
with O
associated O
diaphoresis O
. O
He O
has O

 O
been O
constipated O
over O
the O
past O
four O
days O
. O
His O
children O
were O
with O

 O
him O
, O
helped O
him O
back O
to O
bed O
and O
called O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
who O
referred O
him O

 O
to O
the O
Emergency O
Room O
. O
The O
patient O
did O
not O
ever O
lose O

 O
consciousness O
. O
He O
reports O
that O
he O
has O
been O
complaint O
with O
all O
of O

 O
his O
medications O
. O
He O
denies O
any O
associated O
chest O
pain O
or O

 O
shortness O
of O
breath O
. O
Patient O
has O
history O
of O
bradycardia B-ADE
in O
past O

 O
when O
on O
metoprolol B-DRUG
and O
cardizem B-DRUG
( O
HR O
ranging O
from O
40 O
- O
100 O
bpm O
) O
. O

 O
. O

 O
During O
the O
patient O
's O
last O
hospitalization O
he O
underwent O
AF O

 O
ablation O
however O
according O
to O
d/c O
summary O
only O
2 O
of O
4 O

 O
arrhythmias O
were O
ablated O
. O
He O
was O
in O
sinus O
rhythm O
prior O
to O

 O
discharge O
and O
was O
discharged O
on O
lopressor B-DRUG
, I-DRUG
cardizem B-DRUG
and O

 O
dofetilide B-DRUG
. I-DRUG

 O
. O

 O
In O
the O
ED O
, O
initial O
vitals O
were O
HR O
: O
45 O
- O
55 O
BP O
: O
78/39 O
, O
O2sat O
96 O
% O
on O

 O
RA O
. O
Exam O
notable O
for O
patient O
with O
good O
mentation O
. O
EKG O
was O

 O
initially O
sinus O
bradycardia O
. O
Patient O
received O
2 B-STR
g I-STR
Calcium B-DRUG

 I-DRUG
gluconate I-DRUG
and O
1L B-DOS
IVF B-DRUG
. I-DRUG
Symptoms O
and O
EKG O
changes O
felt O
to O
be O

 O
consistent O
with O
too O
much O
medication O
. O

 O
. O


 O
On O
arrival O
to O
the O
CCU O
, O
the O
patient O
feels O
" O
better O
" O
. O
He O
is O

 O
fatigued O
but O
overall O
improved O
from O
this O
afternoon O
. O
HR O
50s O
. O
BP O

 O
111/70 O
. O
He O
denies O
chest O
pain O
, O
shortness O
of O
breath O
, O
palpitations O
, O

 O
cough O
, O
abdominal O
pain O
, O
orthopnea O
, O
ankle O
edema O
and O
PND O
. O
He O
does O

 O
report O
some O
persistent O
groin O
pain O
, O
R O
> O
L O
which O
has O
improved O
over O

 O
the O
past O
several O
days O
. O



 O
Past O
Medical O
History O
: O

 O
Atrial B-REA
fibrillation I-REA
s/p O
CV O
[ O
* O
* O
2126 O
* O
* O
] O
on O
coumadin B-DRUG

 I-DRUG
hypertension O

 O
COPD/Bronchiectasis O

 O
congestive O
heart O
failure O
( O
unknown O
ef O
) O

 O
gastroesophageal O
reflux O
disease O
, O

 O
benign O
prostatic O
hypertrophy O
, O
, O

 O
anemia O
, O

 O
status O
post O
bilateral O
total O
knee O
replacements O
, O

 O
shoulder O
arthroplasty O

 O
. O

 O
Cardiac O
Risk O
Factors O
: O
- O
Diabetes O
, O
- O
Dyslipidemia O
, O
+ O
Hypertension O




 O
Social O
History O
: O

 O
Social O
history O
is O
significant O
for O
the O
absence O
of O
current O
tobacco O

 O
use O
. O
Former O
smoker O
but O
quit O
in O
[ O
* O
* O
2095 O
* O
* O
] O
with O
40 O
pack O
yr O
hx O
. O
There O
is O

 O
no O
history O
of O
alcohol O
abuse O
. O
No O
illicit O
drug O
use O
. O
Widowed O
. O
Lives O

 O
alone O
in O
[ O
* O
* O
Location O
( O
un O
) O
2312 O
* O
* O
] O
and O
completes O
all O
his O
ADLs O
. O
Former O

 O
fire-fighter O
but O
retired O
30 O
years O
. O
Has O
4 O
children O
and O
4 O

 O
grandkids O
. O



 O
Family O
History O
: O

 O
Significant O
for O
heart O
disease O
in O
father O
( O
mi O
[ O
* O
* O
89 O
* O
* O
] O
yo O
) O
, O
mother O
( O
mi O

 O
[ O
* O
* O
08 O
* O
* O
] O
yo O
) O
, O
and O
brother O
( O
mi O
[ O
* O
* O
67 O
* O
* O
] O
yo O
) O
. O
No O
diabetes O
in O
the O
family O
. O


 O
Physical O
Exam O
: O

 O
VS O
: O
HR O
56 O
, O
BP O
111/52 O
, O
100 O
% O
on O
2L O

 O
Gen O
: O
Elderly O
male O
NAD O
. O
Oriented O
x3 O
. O
Mood O
, O
affect O
appropriate O
. O

 O
HEENT O
: O
NCAT O
. O
Sclera O
anicteric O
. O
EOMI O
. O
Conjunctiva O
were O

 O
pink O
, O
no O
pallor O
or O
cyanosis O
of O
the O
oral O
mucosa O
. O
No O
xanthalesma O
. O


 O
Neck O
: O
Supple O
with O
no O
appreciable O
JVP O
. O

 O
CV O
: O
Bradycardic O
. O
s1 O
, O
s2 O
. O
No O
m/r/g O
. O
No O
thrills O
, O
lifts O
. O
No O
S3 O
or O

 O
S4 O
. O
Soft O
2/6 O
systolic O
ejection O
murmur O
at O
USB O
. O

 O
Chest O
: O
No O
chest O
wall O
deformities O
, O
scoliosis O
or O
kyphosis O
. O
Resp O

 O
were O
unlabored O
, O
no O
accessory O
muscle O
use O
. O
CTAB O
, O
no O
crackles O
, O

 O
wheezes O
or O
rhonchi O
. O
Resonant O
to O
percussion O
. O

 O
Abd O
: O
Soft O
, O
NTND O
. O
No O
HSM O
or O
tenderness O
. O
Abd O
aorta O
not O
enlarged O
by O


 O
palpation O
. O
No O
abdominial O
bruits O
. O

 O
Ext O
: O
Bilateral O
groin O
hematomas O
, O
right O
side O
is O
firm O
without O
ooze O
, O

 O
nontender O
to O
palpation O
, O
no O
bruit O
. O
Left O
side O
is O
soft O
, O
less O

 O
ecchymotic O
. O
Trace O
edema O
bilaterally O
. O
No O
femoral O
bruits O
b/l O
. O

 O
. O


 O
Pulses O
: O

 O
Right O
: O
Carotid O
2 O
+ O
Femoral O
2 O
+ O
Popliteal O
2 O
+ O
DP O
2 O
+ O
PT O
2 O
+ O

 O
Left O
: O
Carotid O
2 O
+ O
Femoral O
2 O
+ O
Popliteal O
2 O
+ O
DP O
2 O
+ O
PT O
2 O
+ O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
17 O
* O
* O
] O
10:10PM O
   O
GLUCOSE-194 O
* O
UREA O
N-22 O
* O
CREAT-1.0 O
SODIUM-137 O

 O
POTASSIUM-4.4 O
CHLORIDE-103 O
TOTAL O
CO2 O
- O
27 O
ANION O
GAP-11 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
17 O
* O
* O
] O
10:10PM O
   O
CK(CPK)-139 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
17 O
* O
* O
] O
10:10PM O
   O
cTropnT-0.09 O
* O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
17 O
* O
* O
] O
10:10PM O
   O
CK-MB-3 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
17 O
* O
* O
] O
10:10PM O
   O
WBC-6.9 O
RBC-2.77 O
* O
HGB-8.2 O
* O
HCT-23.8 O
* O
MCV-86 O

 O
MCH-29.4 O
MCHC-34.3 O
RDW-15.2 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
17 O
* O
* O
] O
10:10PM O
   O
NEUTS-92 O
* O
BANDS-0 O
LYMPHS-6 O
* O
MONOS-2 O
EOS-0 O

 O
BASOS-0 O
ATYPS-0 O
METAS-0 O
MYELOS-0 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
17 O
* O
* O
] O
10:10PM O
   O
HYPOCHROM-NORMAL O
ANISOCYT-1 O
+ O
POIKILOCY-NORMAL O

 O
MACROCYT-NORMAL O
MICROCYT-NORMAL O
POLYCHROM-NORMAL O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
17 O
* O
* O
] O
10:10PM O
   O
PLT O
SMR-NORMAL O
PLT O
COUNT-197 O

 O
[ O
* O
* O
2135 O
- O
2 O
- O
17 O
* O
* O
] O
10:10PM O
   O
PT-16.4 O
* O
PTT-32.0 O
INR(PT)-1.5 O
* O

 O
. O

 O
[ O
* O
* O
2 O
- O
18 O
* O
* O
] O

 O
Large O
bilateral O
groin O
hematomas O
demonstrated O
, O
without O
evidence O

 O
of O

 O
pseudoaneurysm O
seen O
. O

 O
. O

 O
[ O
* O
* O
2 O
- O
20 O
* O
* O
] O
Femoral O
U/S O
: O

 O
1 O
. O
Increase O
in O
size O
of O
large O
right O
groin O
hematoma O
extending O
into O

 O
the O
medial O
thigh O
. O
No O
evidence O
for O
pseudoaneurysm O
or O

 O
arteriovenous O
fistula O
. O

 O
2 O
. O
Small O
left O
groin O
hematoma O
. O



 O
Brief O
Hospital O
Course O
: O

 O
Patient O
is O
an O
85 O
year O
old O
male O
with O
history O
of O
AF O
s/p O
CV O
at O
OSH O

 O
with O
resultant O
tachy/brady O
s/p O
AF O
ablation O
on O
[ O
* O
* O
2 O
- O
14 O
* O
* O
] O
started O
on O

 O
dofetilide B-DRUG
, I-DRUG
CCB B-DRUG
and O
beta B-DRUG
blocker I-DRUG
now O
presents O
with O
presyncope B-ADE

 I-ADE
and O
bradycardia B-ADE
likely O
related O
to O
medication O
. O
Now O
off O
dilt B-DRUG
and O

 O
metoprolol B-DRUG
and O
on O
dofetilide B-DRUG
and O
acebutolol B-DRUG
with O
symptomatic O

 O
improvement O
. O
This O
hospitalization O
is O
complicated O
by O
ongoing O
fall O

 O
in O
HCT O
with O
expansion O
of O
his O
bilat O
groin O
hematomas O
R O
> O
L O
now O
s/p O
r O

 O
hematoma O
evacuation O
. O

 O
. O


 O
# O
# O
Bilateral O
groin O
hematomas O
: O
He O
had O
bilateral O
groin O
hematomas O
, O

 O
and O
had O
a O
hematocrit O
drop O
betwee O
his O
ablation O
and O
this O
admission O

 O
from O
about O
30 O
-- O
> O
24 O
. O
He O
had O
groin O
ultrasound O
that O
showed O

 O
bilateral O
hematomas O
but O
no O
pseudoaneurysm O
. O
S/p O
drainage O
and O

 O
hematoma O
evacuation O
by O
vascular O
surgery O
[ O
* O
* O
2135 O
- O
2 O
- O
20 O
* O
* O
] O
. O
Now O
with O
one O
JP O

 O
drain O
in O
place O
. O
Pt O
denies O
pain O
. O
No O
transfusions O
since O
[ O
* O
* O
2 O
- O
21 O
* O
* O
] O
. O

 O
Following O
vascular O
recs O
, O
he O
will O
follow O
up O
in O
2 O
weeks O
with O
Dr. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
. O
HCT O
remained O
stable O
at O
time O
of O
discharge O
. O

 O
. O

 O
# O
# O
Rhythm O
: O
He O
does O
have O
AF O
s/p O
CV O
c/b O
bradycardia O
and O

 O
tachycardia O
recently O
here O
for O
AF O
ablation O
on O
[ O
* O
* O
2 O
- O
14 O
* O
* O
] O
with O
2 O
of O
4 O

 O
atrial O
arrhythmias O
ablated O
. O
Discharged O
on O
[ O
* O
* O
2 O
- O
15 O
* O
* O
] O
on O
Dofetelide B-DRUG
, I-DRUG

 O
Cardizem B-DRUG
and O
Metoprolol B-DRUG
in O
normal O
sinus O
rhythm O
. O
Returns O
with O

 O
near O
syncopal O
episodes O
and O
sinus B-ADE
bradycardia I-ADE
, I-ADE
likely O
medication O

 O
related O
. O
Symptoms O
are O
likely O
exacerbated O
in O
setting O
of O
anemia O
. O

 O
Cardizem B-DRUG
and O
metoprolol B-DRUG
discontinued O
and O
he O
was O
discahrged O
on O

 O
acebutolol B-DRUG
and O
dofetilide B-DRUG
for O
rate B-REA
and I-REA
rhythm I-REA
control I-REA
which O
he O

 O
tolerated O
. O
HOLD O
coumadin B-DRUG
with O
lovenox B-DRUG
for O
now O
pending O
HCT O

 O
stabilization O
. O
Should O
be O
restarted O
at O
follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O

 O
of O
vascular O
surgery O
. O
He O
was O
monitored O
on O
telemetry O
. O

 O
. O

 O
# O
# O
Pump O
: O
Patient O
with O
known O
history O
of O
CHF O
per O
chart O
. O
Euvolemic O

 O
on O
exam O
. O
  O
Monitored O
I/Os O
, O
goal O
even O
. O

 O
. O

 O
# O
# O
CAD O
: O
No O
known O
CAD O
. O
No O
ischemic O
sxs O
currently O
. O

 O
. O

 O
# O
# O
Cellulitis B-REA
: I-REA
Pt O
had O
mild O
erythema O
R O
groin O
near O
well-healing O

 O
incision O
. O
had O
low O
grade O
fever O
with O
pancultures O
sent O
. O
  O
He O
was O

 O
started O
on O
cephalexin B-DRUG
to O
complete O
10 B-DUR
day I-DUR
course O
. O
His O
culture O

 O
data O
had O
no O
growth O
at O
time O
of O
discharge O
and O
he O
remained O

 O
afebrile>48 O
hours O
prior O
to O
discharge O
. O

 O
. O

 O
# O
# O
Anemia O
: O
Likely O
related O
to O
blood O
loss O
in O
groin O
based O
on O
exam O

 O
findings O
of O
bilateral O
hematomas O
. O
Baseline O
approximately O
30 O
. O

 O
Tranfused O
total O
6 O
units O
. O
Last O
transfused O
[ O
* O
* O
2135 O
- O
2 O
- O
21 O
* O
* O
] O
. O
  O
Continue O
iron B-DRUG

 I-DRUG
supplementation O
, O
B12 B-DRUG
. I-DRUG
Mgmt O
as O
above O
for O
hematomas O
. O

 O
. O

 O
# O
# O
GERD B-REA
: I-REA
Continued O
ppi B-DRUG

 I-DRUG
. O

 O
# O
# O
COPD O
: O
Continued O
inhalers O

 O
. O


 O
# O
# O
General O
Care O
: O
pneumoboots O
, O
ppi B-DRUG
, I-DRUG
Code O
status O
: O
FULL O
CODE O

 O
confirmed O
with O
patient O
, O
Communication O
: O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
( O
son O
) O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
111656 O
* O
* O
] O
. O
Discharged O
when O
cleared O
by O
PT O
. O



 O
Medications O
on O
Admission O
: O

 O
Dofetilide B-DRUG
500 B-STR
mcg I-STR
PO B-ROU
Q12H B-FRE

 I-FRE
Fluticasone-Salmeterol B-DRUG
250 B-STR
- I-STR
50 I-STR
mcg/Dose I-STR
Disk B-FOR
with I-FOR
Device I-FOR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Fluticasone B-DRUG
50 B-STR
mcg/Actuation I-STR
Spray B-FOR
daily B-FRE

 I-FRE
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
PO B-ROU
Q24H B-FRE

 I-FRE
Ferrous B-DRUG
Sulfate I-DRUG
325 B-STR
mg I-STR
daily B-FRE

 I-FRE
Cyanocobalamin B-DRUG
100 B-STR
mcg I-STR
Tablet B-FOR
5 B-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
Warfarin B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
PO B-ROU
Once O
Daily B-FRE
at I-FRE
4PM I-FRE

 I-FRE
Metoprolol B-DRUG
Tartrate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
Cardizem B-DRUG
CD I-DRUG
120 B-STR
mg I-STR
1 B-DOS
capsule B-FOR
daily B-FRE

 I-FRE
Lovenox B-DRUG
80 B-STR
mg/0.8 I-STR
mL I-STR



 I-STR
Discharge O
Medications O
: O

 O
1 O
. O
Ferrous B-DRUG
Sulfate I-DRUG
325 B-STR
mg I-STR
( O
65 O
mg O
Iron O
) O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
2 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
3 O
. O
Fluticasone-Salmeterol B-DRUG
250 B-STR
- I-STR
50 I-STR
mcg/Dose I-STR
Disk B-FOR
with I-FOR
Device I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Disk B-FOR
with I-FOR
Device I-FOR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
4 O
. O
Fluticasone B-DRUG
50 B-STR
mcg/Actuation I-STR
Spray I-STR
, I-STR
Suspension B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Spray B-FOR
Nasal B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
5 O
. O
Cyanocobalamin B-DRUG
100 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
6 O
. O
Dofetilide B-DRUG
500 B-STR
mcg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
Q12H B-FRE

 I-FRE
( O
every O
12 O
hours O
) O
. O

 O
7 O
. O
Acebutolol B-DRUG
200 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
Disp:*60 O
Capsule(s O
) O
* O
Refills:*2 O
* O

 O
8 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( O
every O
24 O
hours O
) O
. O

 O
9 O
. O
Cephalexin B-DRUG
250 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
three B-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
for B-DUR
8 I-DUR
days I-DUR
. I-DUR

 O
Disp:*24 O
Capsule(s O
) O
* O
Refills:*0 O
* O

 O
10 O
. O
Hydrocodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
500 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR

 I-FOR
PO B-ROU
Q4 B-FRE
- I-FRE
6H I-FRE
( O
) O
as O
needed O
for O
pain B-REA
. I-REA



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital O
119 O
* O
* O
] O
Homecare O


 O
Discharge O
Diagnosis O
: O

 O
Acute O
Blood O
Loss O
Anemia O

 O
Bilateral O
groin O
Hematomas O

 O
Chronic O
Congestive O
Heart O
Failure O

 O
Atrial O
Fibrillation O
s/p O
Ablation O

 O
Hypertension O



 O
Discharge O
Condition O
: O

 O
stable O
. O



 O

Discharge O
Instructions O
: O

 O
You O
had O
bleeding O
from O
the O
right O
groin O
site O
that O
required O
surgery O

 O
and O
evacuation O
of O
the O
blood O
. O
A O
drain O
was O
placed O
and O
will O
stay O
in O

 O
until O
you O
see O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
3407 O
* O
* O
] O
on O
[ O
* O
* O
3 O
- O
8 O
* O
* O
] O
. O
You O
can O
walk O
with O
this O
drain O

 O
but O
do O
not O
take O
a O
shower O
or O
bath O
until O
after O
you O
see O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
3407 O
* O
* O
] O
. O

 O
Please O
keep O
the O
dressing O
clean O
and O
dry O
. O
You O
were O
started O
on O
an O

 O
antibiotic B-DRUG
because O
the O
right O
groin O
site O
was O
warm O
and O
red O
, O
please O

 O
take O
this O
antibiotic B-DRUG
for O
a O
total O
of O
10 B-DUR
days I-DUR
. I-DUR
The O
visiting O
nurse O

 O
will O
help O
with O
the O
drain O
. O

 O
New O
medicines O
: O

 O
1 O
. O
Ceflexin B-DRUG
: I-DRUG
an O
antibiotic O
to O
treat O
the O
local B-REA
skin I-REA
infection I-REA

 I-REA
near O
the O
surgery O
site O
. O

 O
2 O
. O
Acebutalol B-DRUG
: I-DRUG
a O
beta B-DRUG
blocker I-DRUG
to O
take O
instead O
of O
the O
metoprolol B-DRUG

 I-DRUG
. O

 O
1 O
. O
Do O
not O
take O
any O
coumadin B-DRUG
or O
Lovenox B-DRUG
until O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
3407 O
* O
* O
] O
or O
Dr. O

 O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
tells O
you O
it O
is O
OK O
. O

 O
2 O
. O
Stop O
taking O
Cartia B-DRUG
XT I-DRUG
and O
metoprolol B-DRUG

 I-DRUG
. O

 O
Weigh O
yourself O
every O
morning O
, O
[ O
* O
* O
Name8 O
( O
MD O
) O
138 O
* O
* O
] O
MD O
if O
weight O
> O
3 O
lbs O
. O

 O
Adhere O
to O
2 O
gm O
sodium O
diet O

 O
. O

 O
Please O
call O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
or O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
3407 O
* O
* O
] O
if O
you O
have O
any O
further O

 O
bleeding O
, O
increasing O
swelling O
, O
pain O
or O
redness O
, O
fevers O
or O
any O

 O
other O
concerning O
symptoms O
. O


 O
Followup O
Instructions O
: O

 O
Vascular O
Surgery O
: O

 O
Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
1244 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
1237 O
* O
* O
] O

 O
Date/Time:[**2135 O
- O
3 O
- O
8 O
* O
* O
] O
10:30 O

 O
Cardiology O
: O

 O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name3 O
( O
LF O
) O
* O
* O
] O
J. O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
7960 O
* O
* O
] O
Date/Time O
: O




 O

Name O
: O
  O
[ O
* O
* O
Known O
lastname O
2170 O
* O
* O
] O
, O
[ O
* O
* O
Known O
firstname O
* O
* O
] O
                       O
Unit O
No O
: O
  O
[ O
* O
* O
Numeric O
Identifier O
2171 O
* O
* O
] O


 O
Admission O
Date O
: O
  O
[ O
* O
* O
2105 O
- O
11 O
- O
20 O
* O
* O
] O
     O
Discharge O
Date O
: O
  O
[ O
* O
* O
2105 O
- O
11 O
- O
27 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
   O
[ O
* O
* O
2030 O
- O
11 O
- O
10 O
* O
* O
] O
     O
Sex O
: O
  O
M O


 O
Service O
: O


 O
ADDENDUM O
TO O
HOSPITAL O
COURSE O
: O
  O
It O
was O
felt O
that O
the O
patient O
's O

 O
seizures B-ADE
were O
caused O
by O
the O
combination O
of O
Ritalin B-DRUG
and O

 O
thalidomide B-DRUG
. I-DRUG
  O
These O
medications O
were O
discontinued O
and O
as O

 O
stated O
previously O
, O
the O
patient O
was O
started O
on O
Phenytoin B-DRUG
for O

 O
prophylaxis B-REA
. I-REA




                           O
[ O
* O
* O
Name6 O
( O
MD O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
M.D. O
  O
[ O
* O
* O
MD O
Number(1 O
) O
2172 O
* O
* O
] O


 O
Dictated O
By:[**Last O
Name O
( O
NamePattern1 O
) O
866 O
* O
* O
] O


 O
MEDQUIST36 O


 O
D O
: O
  O
[ O
* O
* O
2105 O
- O
11 O
- O
27 O
* O
* O
] O
  O
14:35 O

 O
T O
: O
  O
[ O
* O
* O
2105 O
- O
11 O
- O
28 O
* O
* O
] O
  O
04:39 O

 O
JOB O
# O
: O
  O
[ O
* O
* O
Job O
Number O
2173 O
* O
* O
] O

 O

Admission O
Date O
: O
  O
[ O
* O
* O
2183 O
- O
10 O
- O
10 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2183 O
- O
10 O
- O
15 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2103 O
- O
6 O
- O
11 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Codeine B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
11040 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
shortness O
of O
breath O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
intubation O
, O
arterial O
line O
placement O


 O
History O
of O
Present O
Illness O
: O

 O
This O
is O
an O
80 O
year O
old O
female O
with O
history O
of O
bronchiectasis O
and O

 O
COPD O
as O
well O
as O
cardiomyopathy O
secondary O
to O
cardiac O
contusion O

 O
and O
atrial O
fibrillation O
who O
was O
transferred O
for O
persistent O

 O
hypoxic O
respiratory O
failure O
after O
an O
admission O
to O
[ O
* O
* O
Hospital O
* O
* O
] O

 O
Hospital O
. O



 O
The O
patient O
's O
history O
this O
year O
has O
been O
marked O
for O
starting O

 O
amioadarone B-DRUG
in O
[ O
* O
* O
Month O
( O
only O
) O
958 O
* O
* O
] O
for O
persistent B-REA
atrial I-REA
fibrilllation I-REA
( O
also O

 O
had O
TEE O
and O
cardioversion O
) O
and O
had O
stayed O
in O
sinus O
rhythm O
. O

 O
Unfortunately O
, O
in O
[ O
* O
* O
Month O
( O
only O
) O
* O
* O
] O
the O
patient O
developed O
worsening O

 O
cough O
and O
dyspnea O
and O
her O
amiodarone B-DRUG
was O
stopped O
due O
to O
concern O

 O
for O
early O
pulmonary B-ADE
toxicity I-ADE
. I-ADE
  O
On O
[ O
* O
* O
9 O
- O
23 O
* O
* O
] O
the O
patient O
was O
admitted O

 O
to O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
Hospial O
with O
worsening O
respiratory O
symptoms O
, O

 O
including O
dyspnea O
, O
cough O
, O
and O
hypoxia O
. O
  O
She O
had O
a O
chest O
CT O
on O

 O
[ O
* O
* O
9 O
- O
25 O
* O
* O
] O
that O
revealed O
diffuse O
GGO O
on O
a O
background O
of O

 O
bronchiectasis B-REA
and O
emphysema B-REA
. I-REA
  O
She O
started O
empiric O
treatment O

 O
with O
abx B-DRUG
and O
steroids B-DRUG
for O
concern O
of O
AIP B-REA
. I-REA
  O
Given O
progressive O

 O
respiratory O
failure O
she O
was O
intubated O
. O
  O
At O
the O
time O
of O

 O
bronchoscopy O
she O
had O
bloody O
secretions O
and O
there O
was O
concern O
for O

 O
pulmonary B-ADE
hemorrhage I-ADE
. I-ADE
  O
Therefore O
she O
was O
taken O
off O

 O
anticoagulation B-DRUG
. I-DRUG
  O
She O
was O
continued O
on O
antibiotics B-DRUG

 I-DRUG
( O
amp-sublactam B-DRUG
and O
azithromycin B-DRUG
) I-DRUG
and O
steroids B-DRUG
, I-DRUG
her O

 O
anticoagulation B-DRUG
was O
stopped O
, O
and O
she O
was O
also O
diuresed O
gently O
to O

 O
keep O
steadily O
negative O
fluid O
balances O
. O
  O
She O
had O
mild O

 O
improvements O
and O
was O
extubated O
on O
[ O
* O
* O
10 O
- O
2 O
* O
* O
] O
. O
  O
Unfortunately O
, O
since O

 O
extubation O
she O
had O
progressive O
supplementary B-FOR
O2 B-DRUG
requirements O
and O

 O
spent O
the O
last O
few O
days O
prior O
to O
transfer O
bouncing O
between O
100 O
% O

 O
NRB B-ROU
mask I-ROU
and O
CPAP B-ROU
. I-ROU
She O
has O
had O
no O
positive O
cultures O
and O

 O
bronchoscopy O
revealed O
no O
organisms O
and O
no O
pathognomonic O
findings O

 O
for O
a O
particular O
diagnosis O
. O
  O
OSH O
course O
was O
also O
notable O
for O

 O
persistent O
and O
difficult O
to O
control O
afib B-REA
with I-REA
RVR I-REA
so O
that O
on O

 O
transfer O
she O
was O
on O
high B-DOS
doses I-DOS
of O
diltiazem B-DRUG
, I-DRUG
metoprolol B-DRUG
, I-DRUG
and O

 O
digoxin B-DRUG
. I-DRUG
  O
Given O
her O
? O
pulmonary O
hemorrhage O
the O
patient O
's O
primary O

 O
pulmonologist O
strongly O
felt O
she O
should O
not O
be O
anticoagulated B-DRUG

 I-DRUG
again O
and O
wanted O
transfer O
partially O
to O
pursue O
AV O
nodal O
ablation O

 O
or O
other O
more O
advanced O
RVR O
management O
by O
our O
EP O
service O
. O


 O
On O
arrival O
, O
vital O
signs O
were O
96.1 O
( O
axillary O
) O
, O
HR O
88 O
( O
afib O
) O
, O

 O
131/65 O
, O
and O
satting O
95 O
% O
on O
non-rebreather O
. O
The O
patient O
was O

 O
awake O
, O
alert O
, O
responding O
appropriately O
to O
questioning O
. O
Reports O

 O
that O
her O
breathing O
is O
" O
a O
little O
labored O
, O
" O
but O
feels O
better O
than O

 O
she O
had O
at O
the O
OSH O
. O



 O
Past O
Medical O
History O
: O

 O
- O
Cardiomyopathy O
after O
chest O
contusion O
with O
former O
EF O
30 O
% O
, O
now O

 O
normalized O
at O
55 O
% O

 O
- O
CAD O
, O
s/p O
BMS O
to O
RCA O
in O
[ O
* O
* O
10/2181 O
* O
* O
] O

 O
- O
Upper O
lobe O
bronchiectasis O
attributed O
to O
severe O
pneumonias O
in O

 O
the O
[ O
* O
* O
2132 O
* O
* O
] O
. O
Typically O
has O
2 O
- O
3 O
episodes O
of O
exacerbation O

 O
bronchiectasis O
each O
year O
. O

 O
- O
COPD O
with O
moderately O
severe O
centrilobular O
emphysema O
on O
CT O

 O
- O
Hypertension O

 O
- O
T2DM O

 O
- O
Mitral O
Valve O
Prolapse O

 O
- O
R O
breast O
nodularites O
( O
stable O
on O
subsequent O
mammograms O
) O

 O
- O
Plantar O
Fasciitis O

 O
- O
s/p O
partial O
hysterectomy O
in O
[ O
* O
* O
2142 O
* O
* O
] O

 O
- O
Bladder O
suspension O

 O
- O
GERD O

 O
- O
Multinodular O
goiter O


 O
Social O
History O
: O

 O
Former O
smoker O
, O
x O
30 O
years O
at O
about O
two O
packs/day O
. O
Stopped O
seven O

 O
years O
ago O
. O
Occasional O
social O
alcohol O
. O
Lives O
at O
home O
alone O
, O
is O

 O
independent O
in O
ADLs O
. O
Two O
children O
are O
involved O
in O
her O
health O

 O
care O
. O


 O
Family O
History O
: O

 O
There O
is O
a O
family O
history O
of O
premature O
coronary O
artery O
disease O

 O
or O
sudden O
death O
( O
three O
brothers O
who O
died O
of O
CAD O
and O
one O
sister O

 O
with O
CHF O
) O
. O


 O
Physical O
Exam O
: O

 O
VS O
: O
Temp:96.1 O
BP:131/65 O
HR:88 O
( O
afib O
) O
RR:28 O
O2sat O
: O
95 O
% O
on O
NRB O

 O
GEN O
: O
pleasant O
, O
speaking O
in O
[ O
* O
* O
3 O
- O
17 O
* O
* O
] O
word O
sentences O
with O
NRB O
in O
place O
. O

 O
Not O
using O
accessory O
neck O
muscles O
. O
Awake O
, O
alert O
, O
oriented O
, O

 O
responding O
appropriately O
. O

 O
HEENT O
: O
PERRL O
, O
EOMI O
, O
anicteric O
, O
MMM O
, O
op O
without O
lesions O
, O
no O

 O
supraclavicular O
or O
cervical O
lymphadenopathy O
, O
no O
jvd O
, O
+ O
mild O

 O
thyromegaly O

 O
RESP O
: O
Bibasilar O
crackles O
bilaterally O
, O
no O
wheeze O

 O
CV O
: O
RR O
, O
S1 O
and O
S2 O
wnl O
, O
no O
m/r/g O

 O
ABD O
: O
nd O
, O
+ O
b/s O
, O
soft O
, O
nt O
, O
no O
masses O
or O
hepatosplenomegaly O

 O
EXT O
: O
no O
c/c/e O

 O
SKIN O
: O
no O
rashes/no O
jaundice/no O
splinters O

 O
NEURO O
: O
AAOx3 O
. O
4/5 O
strength O
throughout O
, O
with O
limited O
effort O
. O
No O

 O
sensory O
deficits O
to O
light O
touch O
appreciated O


 O
Pertinent O
Results O
: O

 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
LABORATORY O
RESULTS O

 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
On O
Admission O
: O

 O
WBC-12.0 O
* O
RBC-5.29 O
# O
Hgb-13.3 O
Hct-39.4 O
MCV-75 O
* O
RDW-17.7 O
* O
Plt O

 O
Ct-274 O

 O
---Neuts-91.0 O
* O
Lymphs-6.8 O
* O
Monos-1.1 O
* O
Eos-0.7 O
Baso-0.4 O

 O
PT-11.8 O
PTT-23.9 O
INR(PT)-1.0 O

 O
Glucose-150 O
* O
UreaN-33 O
* O
Creat-0.5 O
Na-139 O
K-5.9 O
* O
Cl-103 O
HCO3 O
- O
27 O

 O
Calcium-8.5 O
Phos-3.5 O
Mg-2.4 O

 O
ABG O
: O
7.49/ O
38 O
/ O
61 O



 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
OTHER O
STUDIES O

 O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O
= O

 O
Admission O
ECG O
: O


 O
Chest O
Radiograph O
[ O
* O
* O
2183 O
- O
10 O
- O
10 O
* O
* O
] O
: O

 O
IMPRESSION O
: O

 O
Dense O
bilateral O
reticular O
opacities O
. O
This O
may O
represent O
an O
acute O

 O
process O

 O
superimposed O
on O
background O
chronic O
changes O
. O
The O
differential O

 O
diagnosis O

 O
includes O
drug-related O
pneumonitis B-ADE
( O
by O
report O
, O
the O
patient O
is O
on O

 O
amiodarone B-DRUG
) I-DRUG
, O
interstitial O
edema O
, O
and O
interstitial O
infection O
. O

 O
Edema O
is O
considered O
less O
likely O
given O
the O
absence O
of O
effusions O
. O


 O
Bilateral O
Lower O
Extremity O
Ultrasounds O
[ O
* O
* O
2183 O
- O
10 O
- O
11 O
* O
* O
] O
: O

 O
IMPRESSION O
: O
Bilateral O
lower O
extremity O
DVTs O
, O
more O
extensive O
on O

 O
the O
right O

 O
involving O
the O
common O
femoral O
vein O
, O
proximal O
and O
distal O

 O
superficial O
femoral O

 O
veins O
and O
posterior O
tibial O
and O
peroneal O
veins O
. O
Partially O

 O
occlusive O
thrombus O

 O
within O
the O
distal O
left O
superficial O
femoral O
vein O
. O


 O
Brief O
Hospital O
Course O
: O

  O
80 O
y/o O
F O
with O
likely O
emphysema O
and O
bronchiectasis O
as O
well O
as O

 O
Afib O
w/ O
RVR O
and O
history O
of O
cardiomyopathy O
presenting O
with O

 O
worsening O
respiratory O
symptoms O
and O
hypoxia O
in O
the O
context O
of O

 O
bilateral O
ground O
glass O
infiltrates O
of O
uncertain O
etiology O
. O


 O
Hypoxic B-REA
respiratory I-REA
failure I-REA
: I-REA
The O
patient O
presented O
with O
very O

 O
high O
oxygen B-DRUG
requirements O
and O
desatting O
with O
minimal O
exertion O
or O

 O
very O
short O
periods O
off O
the O
high B-FOR
flow I-FOR
oxygen B-DRUG
masks B-ROU
. I-ROU
Unclear O

 O
ultimate O
etiology O
though O
diffuse O
findings O
on O
CT O
were O
thought O
to O

 O
be O
concerning O
for O
AIP O
on O
baseline O
lung O
disease O
with O
pulmonary O

 O
hemorrhage O
thought O
much O
less O
likely O
given O
reports O
of O
bleeding O
. O

 O
Patient O
had O
already O
received O
a O
fairly O
high B-DOS
pulse I-DOS
of O
steroids B-DRUG

 I-DRUG
leaving O
the O
benefit O
of O
another O
course O
questionable O
but O
given O

 O
tenuous O
respiratory O
status O
limiting O
ability O
to O
perform O
further O

 O
diagnostic O
work-up O
( O
particular O
any O
attempts O
to O
pursue O
tissue O

 O
diagnosis O
) O
a O
dose O
of O
1 B-STR
gram I-STR
methylprednisolone B-DRUG
daily B-FRE
was O

 O
initiated O
for B-DUR
three I-DUR
days I-DUR
followed O
by O
1 B-STR
mg/kg I-STR
daily B-FRE
. I-FRE
She O
was O
also O

 O
started O
on O
vancomycin B-DRUG
and O
cefepime B-DRUG
given O
neither O
vancomycin B-DRUG
nor O

 O
psuedomonas O
had O
been O
covered O
by O
here O
previous O
antibiotics B-DRUG
and O

 O
those O
could O
be O
established O
in O
her O
altered O
airways O
as O
a O
not O

 O
uncommon O
cause O
of O
pneumonia B-REA
. I-REA
  O
Also O
patient O
was O
found O
to O
have O

 O
DVT O
's O
as O
described O
elsewhere O
, O
which O
were O
treated O
in O
hopes O
of O

 O
helping O
hypoxia B-REA
. I-REA
  O
Patient O
received O
levalbuterol B-DRUG
and O
ipratroprium B-DRUG

 I-DRUG
nebulizers B-FOR
. I-FOR
  O
Eventually O
a O
bronchoscopy O
was O
done O
and O
did O
not O
show O

 O
evidence O
of O
pulmonary O
hemorrhage O
. O
  O
However O
, O
the O
patient O
's O

 O
oxygenation O
became O
more O
and O
more O
problem[**Name O
( O
NI O
) O
115 O
* O
* O
] O
and O
she O
was O

 O
intubated O
for O
hypoxemic O
respiratory O
failure O
. O
  O
Her O
ventilator O

 O
requirements O
continued O
to O
escalate O
. O



 O
Intracranial B-ADE
hemorrage I-ADE
: I-ADE
  O
While O
on O
a O
heparin B-DRUG
drip B-ROU
for O
DVT B-REA
, I-REA
the O

 O
patient O
was O
noted O
to O
have O
anisocoria O
. O
  O
Head O
CT O
revealed O
large O

 O
parenchymal O
hemorrhage O
apparently O
centered O
in O
the O
right O
corona O

 O
radiata O
or O
that O
caudate O
nucleus O
, O
with O
transependymal O
dissection O

 O
into O
both O
lateral O
ventricles O
, O
and O
the O
third O
and O
fourth O

 O
ventricles O
. O
  O
The O
patient O
's O
  O
poor O
prognosis O
was O
explained O
to O
her O

 O
family O
. O
  O
The O
decision O
was O
made O
to O
pursue O
comfort O
measures O
only O
. O


 O
Deep O
Vein O
Thromboses O
: O
On O
presentation O
given O
patient O
's O
refractory O

 O
hypoxia O
an O
lack O
of O
good O
options O
decision O
was O
made O
to O
pursue O
some O

 O
work O
up O
for O
VTE O
given O
she O
was O
thought O
to O
be O
too O
unstable O
for O
CT O

 O
Scan O
but O
this O
could O
contribute O
to O
hypoxia O
. O
  O
Lower O
extremity O

 O
ultrasounds O
revealed O
DVT B-REA
and O
she O
was O
started O
on O
heparin B-DRUG
gtt B-ROU
. I-ROU

 O
Presumably O
, O
DVT O
's O
were O
developed O
during O
OSH O
course O
after O

 O
warfarin B-DRUG
was O
stopped O
. O


 O
Atrial B-REA
fibrillation I-REA
: I-REA
Patient O
was O
well O
rate O
controlled O
at O
arrival O

 O
on O
dilt B-DRUG
90 B-STR
QID B-FRE
, I-FRE
metoprolol B-DRUG
tartrate I-DRUG
50 B-STR
TID B-FRE
and O
dig B-DRUG
, I-DRUG
given O
some O

 O
pauses O
( O
2 O
- O
2.5 O
seconds O
) O
on O
the O
night O
after O
admission O
and O

 O
generally O
good O
rate O
control O
. O
Later O
in O
her O
course O
her O
rate B-REA
became I-REA

 I-REA
more I-REA
rapid I-REA
and O
she O
briefly O
requiring O
diltiazem B-DRUG
gtt B-ROU
. I-ROU
  O
Heparin B-DRUG

 I-DRUG
drip B-ROU
was O
continued O
as O
above O
. O


 O
CAD B-REA
, I-REA
Cardiomyopathy O
: O
Patient O
had O
an O
EF O
of O
30 O
with O
a O
cardiac O

 O
contusion O
per O
past O
reports O
but O
now O
normalized O
to O
55 O
. O
  O
Echo O

 O
showed O
normal O
biventricular O
cavity O
sizes O
with O
preserved O
global O

 O
and O
regional O
biventricular O
systolic O
function O
and O
biatrial O

 O
enlargement O
. O
Pulmonary O
artery O
systolic O
hypertensionShe O
was O

 O
continued O
on O
her O
aspirin B-DRUG
, I-DRUG
simvastatin B-DRUG
, I-DRUG
and O
beta B-DRUG
blocker I-DRUG
for O
her O

 O
history O
of O
CAD B-REA
. I-REA

 O
. O

 O
Hypotension B-REA
: I-REA
Initially O
normotensive O
on O
rate B-DRUG
control I-DRUG
agents I-DRUG
. I-DRUG
Also O

 O
on O
daily B-FRE
furosemide B-DRUG
. I-DRUG
  O
On O
the O
day O
of O
intubation O
, O
she O
also O
became O

 O
hypotensive B-REA
requiring O
initiation O
of O
norepinephrine B-DRUG

 I-DRUG
. O

 O
Diabetes B-REA
Mellitus I-REA
Type I-REA
II I-REA
: I-REA
Mildly O
hyperglycemic B-REA
on O
arrival O
. O
On O

 O
oral O
agents O
at O
home O
, O
fingersticks O
with O
ISS B-DRUG
at O
OSH O
. O
  O
SS O
insulin B-DRUG

 I-DRUG
was O
continued O
. O

 O
. O

 O
Code O
status O
: O
  O
initially O
full O
, O
later O
comfort O
measures O
only O


 O
Medications O
on O
Admission O
: O

 O
- O
Metformin B-DRUG
1000 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
- O
Zocor B-DRUG
10 B-STR
mg I-STR
PO B-ROU
QHS B-FRE

 I-FRE
- O
Aspirin B-DRUG
81 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
- O
Amiodarone B-DRUG
200 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
- O
Warfarin B-DRUG
3 B-STR
mg I-STR
alternating O
with O
6 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
- O
Amlodipine B-DRUG
10 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
- O
Ca++/Vit B-DRUG
D I-DRUG

 I-DRUG
- O
HCTZ B-DRUG
25 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
- O
Glimepiride B-DRUG
2 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
- O
Metoprolol B-DRUG
50 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
- O
Prilosec B-DRUG
20 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
. O


 O
Meds O
on O
transfer O
: O

 O
simvastatin B-DRUG
10 B-STR
mg I-STR
PO B-ROU
QHS B-FRE

 I-FRE
senna B-DRUG
10 B-DOS
ml I-DOS
PO B-ROU
QHS B-FRE

 I-FRE
Aspirin B-DRUG
325 B-STR
po B-ROU
daily B-FRE

 I-FRE
docusate B-DRUG
100 B-STR
mg I-STR
po B-ROU
BID B-FRE

 I-FRE
guaifenesin B-DRUG
1200 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
omeprazole B-DRUG
40 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
digoxin B-DRUG
0.25 B-STR
po B-ROU
daily B-FRE

 I-FRE
diltiazem B-DRUG
90 B-STR
po B-ROU
q6H B-FRE

 I-FRE
metoprolol B-DRUG
50 B-STR
mg I-STR
po B-ROU
tid B-FRE

 I-FRE
SCH B-DRUG
5000 B-DOS
units I-DOS
Q8 B-FRE

 I-FRE
insulin B-DRUG
glargine I-DRUG
10 B-STR
units I-STR
daily B-FRE
& O
SS O

 O
levalbuterol B-DRUG
NEB B-FOR
QID B-FRE

 I-FRE
methylprednisolone B-DRUG
40 B-STR
mg I-STR
IV B-ROU
daily B-FRE

 I-FRE
ipratropium B-DRUG
neb B-FOR
QID B-FRE

 I-FRE
furosemide B-DRUG
40 B-STR
mg I-STR
iv B-ROU
daily B-FRE

 I-FRE
acetaminophen B-DRUG
650 B-STR
mg I-STR
PO B-ROU
Q4H B-FRE
prn I-FRE

 I-FRE
polyethylene B-DRUG
glycol I-DRUG
po B-ROU
daily B-FRE

 I-FRE
diphenhydramine B-DRUG
25 B-STR
mg I-STR
PO B-ROU
HS B-FRE
MR1 I-FRE
PRN I-FRE

 I-FRE
metoclopramide B-DRUG
10 B-STR
mg I-STR
IV B-ROU
Q6H B-FRE
PRN I-FRE

 I-FRE
ondansetron B-DRUG
4 B-STR
mg I-STR
IV B-ROU
Q6H B-FRE
PRN I-FRE

 I-FRE
metoprolol B-DRUG
5 B-STR
mg I-STR
IV B-ROU
Q6H B-FRE
PRN I-FRE

 I-FRE
bisacodyl B-DRUG
10 B-STR
mg I-STR
PR B-ROU
daily B-FRE
PRN I-FRE

 I-FRE
lorazepam B-DRUG
1 B-STR
mg I-STR
IV B-ROU
Q6H B-FRE
PRN I-FRE

 I-FRE
morphine B-DRUG
2 B-STR
mg I-STR
IV B-ROU
Q4H B-FRE
PRN I-FRE

 I-FRE
miconazole B-DRUG
topical B-ROU
TID B-FRE
PRN I-FRE


 I-FRE
Discharge O
Medications O
: O

 O
expired O


 O
Discharge O
Disposition O
: O

 O
Expired O


 O
Discharge O
Diagnosis O
: O

 O
respiratory O
failure O


 O
Discharge O
Condition O
: O

 O
expired O


 O
Discharge O
Instructions O
: O

 O
expired O


 O
Followup O
Instructions O
: O

 O
expired O



 O
Completed O
by:[**2183 O
- O
10 O
- O
17 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2123 O
- O
1 O
- O
25 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2123 O
- O
1 O
- O
31 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2061 O
- O
9 O
- O
28 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1936 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
SOB O
; O
Transfer O
from O
OSH O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Intubation O

 O
A-line O



 O
History O
of O
Present O
Illness O
: O

 O
61 O
year O
old O
female O
with O
history O
of O
COPD B-REA
on O
3L B-DOS
home O
O2 B-DRUG
( O
FEV1/FVC O

 O
33 O
FEV1 O
41%predicted O
) O
, O
and O
newly O
diagnosed O
LUL O
mass O
with O

 O
negative O
cytology O
on O
trans-bronch O
bx O
, O
brushing O
, O
and O
BAL O
[ O
* O
* O
2122 O
- O
12 O
- O
9 O
* O
* O
] O

 O
recently O
admitted O
[ O
* O
* O
Date O
range O
( O
1 O
) O
82788 O
* O
* O
] O
for O
COPD B-REA
exacerbation I-REA
presents O
with O

 O
SOB O
. O
She O
has O
had O
trouble O
breathing O
over O
past O
3 O
days O
but O
then O

 O
acutely O
worse O
at O
3 O
am O
when O
she O
reports O
the O
coughing O
began O
and O

 O
persisted O
for O
14 O
hours O
staright O
. O
She O
went O
to O
[ O
* O
* O
Hospital O
* O
* O
] O
Hospital O
, O

 O
gave O
her O
nebs B-DRUG
, I-DRUG
Solumedrol B-DRUG
and O
Toradol B-DRUG
  O
and O
transferred O
here O
. O


 O
She O
was O
transferred O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
given O
her O
care O
has O
been O
here O
. O

 O
On O
arrival O
to O
ED O
, O
vitals O
: O
96.5 O
HR O
82 O
BP O
108/58 O
RR O
18 O
98%2L O
. O
She O

 O
was O
oxygenating O
fine O
but O
uncomfortable O
per O
their O
report O
. O
CXR O

 O
showed O
no O
new O
infiltrate O
, O
stable O
LUL O
mass O
. O
  O
ABG O
7.39/57/189 O
. O

 O
She O
was O
given O
nebs B-DRUG
and O
azithromycin B-DRUG
; I-DRUG
but O
due O
to O
her O
discomfort O

 O
she O
was O
started O
on O
BIPAP O
which O
she O
did O
not O
tolerate O
well O
. O
  O
She O

 O
was O
given O
ativan B-DRUG
which O
improved O
her O
coughing/discomfort B-REA
and O
was O

 O
able O
to O
remain O
on O
NC O
alone O
. O
She O
was O
subsequently O
transferred O
to O

 O
the O
MICU O
. O

 O
. O

 O
On O
arrival O
to O
the O
unit O
, O
Patient O
was O
in O
mild O
distress O
with O

 O
coughing O
and O
increased O
work O
of O
breathing O
, O
she O
was O
given O

 O
albuterol B-DRUG
nebs B-FOR
and O
0.5 B-STR
mg I-STR
ativan B-DRUG
wtih O
marked O
improvement O
. O
  O
She O

 O
reports O
as O
above O
, O
worsening O
SOB O
over O
past O
3 O
- O
4 O
days O
that O
worsened O

 O
this O
AM O
. O
She O
denies O
fevers/chills O
, O
N/V O
, O
CP O
, O
or O
increased O
sputum O

 O
production O
. O
Denies O
new O
myalgias O
( O
has O
h/o O
fibromyalgia O
and O

 O
reports O
close O
to O
baseline O
pain O
) O
. O
Denies O
sick O
contacts O
. O

 O
. O

 O
. O


 O
( O
+ O
) O
Per O
HPI O

 O
( O
- O
) O
Denies O
fever O
, O
chills O
, O
night O
sweats O
, O
recent O
weight O
loss O
or O

 O
gain O
. O
Denies O
headache O
, O
sinus O
tenderness O
, O
rhinorrhea O
or O

 O
congestion O
. O
  O
Denies O
chest O
pain O
, O
chest O
pressure O
, O
palpitations O
, O
or O

 O
weakness O
. O
Denies O
nausea O
, O
vomiting O
, O
diarrhea O
, O
constipation O
, O

 O
abdominal O
pain O
, O
or O
changes O
in O
bowel O
habits O
. O
Denies O
dysuria O
, O

 O
frequency O
, O
or O
urgency O
. O
Denies O
arthralgias O
or O
myalgias O
. O
Denies O

 O
rashes O
or O
skin O
changes O
. O



 O
Past O
Medical O
History O
: O

 O
1 O
. O
LUL O
Lung O
Mass O

 O
-- O
s/p O
bronch O
w/brushings O
, O
BAL O
, O
and O
lymph O
nodes O
EBUS O
TBNA O
( O
neg O

 O
for O
malignancy O
) O

 O
2 O
. O
Severe O
emphysema O
on O
3L B-DOS
home O
O2 B-DRUG
; I-DRUG
FEV1/FVC O
33 O
, O
FEV1 O

 O
41%predicted O

 O
3 O
. O
Recent O
Pneumonia B-REA
- O
treated O
with O
azithromycin B-DRUG

 I-DRUG
4 O
. O
Diastolic O
heart O
failure O

 O
5 O
. O
Fibromyalgia O

 O
6 O
. O
Tobacco O
Abuse O

 O
. O

 O
Past O
Surgical O
History O

 O
[ O
* O
* O
2122 O
- O
12 O
- O
9 O
* O
* O
] O
: O
Status O
post O
electromagnetic O
navigational O
bronchoscopy O

 O
with O
radial O
endobronchial O
ultrasound O
, O
transbronchial O
biopsy O
, O

 O
bronchoalveolar O
lavage O
, O
and O
brushing O
of O
the O
left O
upper O
lobe O
mass O

 O
as O
well O
as O
placement O
of O
fiducials O
x4 O
into O
the O
left O
upper O
lobe O

 O
lung O
mass O
. O


 O
Social O
History O
: O

 O
lives O
home O
alone O
, O
has O
two O
daughters O
, O
widowed O
x O

 O
2 O
. O
Quit O
smoking O
last O
month O
when O
diagnosed O
with O
new O
lung O
mass O
, O

 O
prior O
smoked O
for O
50 O
years O
. O
Retired O
. O
No O
ETOH O
in O
17 O
years O
, O
no O
drug O


 O
use O
. O


 O
Family O
History O
: O

 O
brother O
with O
lung O
CA O


 O
Physical O
Exam O
: O

 O
Temp O
96.0 O
  O
141/72 O
  O
80 O
  O
29 O
  O
96 O
% O
NRB O
@15L O


 O
General O
Appearance O
: O
Anxious O
, O
slight O
respiratory O
distress O

 O
coughing O

 O
Eyes O
/ O
Conjunctiva O
: O
PERRL O
, O
Pupils O
dilated O

 O
Head O
, O
Ears O
, O
Nose O
, O
Throat O
: O
Normocephalic O

 O
Lymphatic O
: O
Cervical O
WNL O
, O
Supraclavicular O
WNL O

 O
Cardiovascular O
: O
( O
S1 O
: O
Normal O
) O
, O
( O
S2 O
: O
Normal O
) O

 O
Peripheral O
Vascular O
: O
( O
Right O
radial O
pulse O
: O
Present O
) O
, O
( O
Left O
radial O

 O
pulse O
: O
Present O
) O
, O
( O
Right O
DP O
pulse O
: O
Present O
) O
, O
( O
Left O
DP O
pulse O
: O

 O
Present O
) O

 O
Respiratory O
/ O
Chest O
: O
( O
Expansion O
: O
Symmetric O
) O
, O
( O
Breath O
Sounds O
: O

 O
Bronchial O
: O
, O
Wheezes O
: O
, O
Diminished O
: O
) O
, O
poor O
air O
movement O

 O
throughout O

 O
Abdominal O
: O
Soft O
, O
Non-tender O
, O
Bowel O
sounds O
present O

 O
Extremities O
: O
Right O
lower O
extremity O
edema O
: O
Absent O
, O
Left O
lower O

 O
extremity O
edema O
: O
Absent O

 O
Skin O
: O
  O
Not O
assessed O

 O
Neurologic O
: O
Responds O
to O
: O
Not O
assessed O
, O
Movement O
: O
Not O
assessed O
, O

 O
Tone O
: O
Not O
assessed O



 O
Pertinent O
Results O
: O

 O
Admission O
: O



 O
[ O
* O
* O
2123 O
- O
1 O
- O
25 O
* O
* O
] O
03:15PM O
BLOOD O
WBC-10.3 O
RBC-3.54 O
* O
Hgb-10.4 O
* O
Hct-31.4 O
* O

 O
MCV-89 O
MCH-29.3 O
MCHC-33.0 O
RDW-14.1 O
Plt O
Ct-189 O

 O
[ O
* O
* O
2123 O
- O
1 O
- O
25 O
* O
* O
] O
03:15PM O
BLOOD O
Glucose-157 O
* O
UreaN-21 O
* O
Creat-0.7 O
Na-138 O

 O
K-4.8 O
Cl-98 O
HCO3 O
- O
30 O
AnGap-15 O

 O
[ O
* O
* O
2123 O
- O
1 O
- O
25 O
* O
* O
] O
03:15PM O
BLOOD O
proBNP-89 O

 O
[ O
* O
* O
2123 O
- O
1 O
- O
25 O
* O
* O
] O
03:15PM O
BLOOD O
Calcium-8.4 O
Phos-3.2 O
Mg-2.2 O

 O
[ O
* O
* O
2123 O
- O
1 O
- O
25 O
* O
* O
] O
04:29PM O
BLOOD O
Type-ART O
PEEP-6 O
O2 O
Flow-50 O
pO2 O
- O
198 O
* O

 O
pCO2 O
- O
57 O
* O
pH-7.39 O
calTCO2 O
- O
36 O
* O
Base O
XS-8 O


 O
CXR O
: O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O

 O
IMPRESSION O
: O

 O
1 O
. O
No O
acute O
cardiopulmonary O
process O
. O

 O
2 O
. O
Unchanged O
left O
upper O
lobe O
spiculated O
mass O
. O


 O
CT O
CHEST O
: O
[ O
* O
* O
1 O
- O
26 O
* O
* O
] O

 O
FINDINGS O
: O
6.6 O
x O
1.6 O
cm O
left O
upper O
lobe O
lesion O
is O
less O
dense O
and O

 O
has O
slightly O
decreased O
in O
size O
since O
[ O
* O
* O
2122 O
- O
12 O
- O
2 O
* O
* O
] O
when O
it O
measured O

 O
6.6 O
x O
3 O
cm O
. O
There O
is O
stable O
mild O
left O
upper O
lung O
traction O

 O
bronchiectasis O
. O
There O
is O
near O
complete O
resolution O
of O
a O
right O

 O
middle O
lobe O
( O
4:106 O
) O
opacity O
measuring O
under O
5 O
mm O
. O
2.8 O
x O
5 O
mm O

 O
consolidation O
near O
the O
left O
upper O
lobe O
fissure O
is O
unchanged O

 O
since O
[ O
* O
* O
2122 O
- O
12 O
- O
2 O
* O
* O
] O
. O
Severe O
centrilobular O
emphysema O
is O
unchanged O
since O

 O
[ O
* O
* O
2122 O
- O
12 O
- O
2 O
* O
* O
] O
. O
There O
is O
no O
pleural O
effusion O
. O
ET O
tube O
tip O
is O
1 O
cm O
above O

 O
the O
carina O
. O
An O
NG O
tube O
courses O
through O
the O
esophagus O
and O
stomach O

 O
with O
its O
tip O
outside O
the O
plane O
of O
imaging O
. O

 O
Heart O
size O
is O
normal O
. O
The O
main O
pulmonary O
artery O
measures O
3.2 O
cm O

 O
in O
diameter O
. O
Scattered O
enlarged O
mediastinal O
nodes O
measuring O
up O

 O
to O
1.2 O
cm O
in O
diameter O
are O
little O
change O
since O
[ O
* O
* O
2122 O
- O
12 O
- O
2 O
* O
* O
] O
. O

 O
Although O
this O
exam O
was O
not O
tailored O
for O
subdiaphragmatic O

 O
diagnosis O
, O
the O
imaged O
intra-abdominal O
organs O
are O
unremarkable O
. O

 O
Bone O
windows O
demonstrate O
no O
lesion O
concerning O
for O
metastasis O
or O

 O
infection O
. O

 O
IMPRESSION O
: O

 O
1 O
. O
Given O
minimal O
improvement O
and O
benign O
histology O
of O
spiculated O

 O
left O
upper O

 O
lobe O
mass O
followup O
in O
6 O
months O
can O
be O
obtained O
. O

 O
2 O
. O
Resolution O
of O
opacity O
in O
the O
right O
lung O
at O
the O
junction O
of O

 O
the O
major O
and O
minor O
fissure O
. O

 O
3 O
. O
Stable O
severe O
centrilobular O
emphysema O
. O

 O
4 O
. O
ET O
tube O
tip O
is O
just O
above O
the O
carina O
in O
this O
study O
, O
but O
is O
in O

 O
satisfactory O
position O
on O
chest O
radiograph O
performed O
6 O
hours O

 O
after O
and O
thus O
does O
not O
need O
to O
be O
repositioned O
. O



 O

Brief O
Hospital O
Course O
: O

 O
61 O
year O
old O
female O
with O
COPD B-REA
on O
3L B-DOS
home O
O2 B-DRUG
s/p O
recent O
admission O

 O
[ O
* O
* O
12 O
- O
2 O
* O
* O
] O
for O
COPD O
exacerbation O
and O
newly O
diganosed O
LUL O
mass O
now O

 O
admitted O
with O
respiratory O
distress O
. O

 O
. O

 O
# O
. O
Acute O
hypercarbic O
respiratory O
distress/Cough O
: O
On O
admission O
, O

 O
the O
patient O
was O
complaining O
of O
3 O
days O
of O
cough O
and O
SOB O
that O

 O
acutely O
worsened O
overnight O
. O
She O
presented O
to O
an O
OSH O
and O
was O

 O
transferred O
to O
the O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
for O
further O
managment O
. O
  O
She O
was O

 O
placed O
on O
BiPAP O
in O
the O
ED O
and O
transferred O
to O
the O
MICU O
. O
She O
had O

 O
hypercapneia O
with O
a O
PCO2 O
of O
57 O
initially O
, O
and O
was O
placed O
on O
non O

 O
rebreather O
mask O
with O
little O
improvement O
, O
and O
was O
then O
started O
on O

 O
non O
invasive O
positive O
pressure O
ventilation O
. O
Patient O
however O

 O
tolerated O
this O
poorly O
and O
required O
intubation O
for O
severe O

 O
respiratory O
distress O
. O

 O
During O
acute O
decompensation O
, O
It O
was O
noted O
that O
patient O
was O

 O
taking O
very O
high O
frequency O
shallow O
breaths O
with O
a O
constant O
cough O

 O
like O
sound O
generated O
in O
the O
upper O
airway O
. O
Patient O
was O
relatively O

 O
easy O
to O
ventilate O
and O
this O
raised O
question O
of O
paradoxycal O
vocal O

 O
cord O
dysfunction O
, O
phrenic O
nerve O
injury O
, O
etc O
. O
During O
intubation O

 O
however O
, O
vocal O
cords O
were O
noted O
to O
be O
normal O
in O
appearance O
and O

 O
during O
serial O
imaging O
diaphragms O
remained O
symmetrical O
. O

 O
Patient O
was O
treated O
with O
pulse O
dose O
steroids B-DRUG
and O
started O
on O

 O
Azithromicyn B-DRUG
. I-DRUG
Given O
known O
left O
upper O
lobe O
nodule O
, O
a O
CT O
scan O
of O

 O
the O
chest O
was O
performed O
and O
did O
not O
show O
any O
significant O

 O
interval O
change O
. O
Patient O
was O
sucessfully O
extubated O
on O
[ O
* O
* O
1 O
- O
28 O
* O
* O
] O
with O

 O
short O
NIVPPV O
bridge O
. O
Patient O
was O
transfered O
to O
medical O
floor O
on O

 O
[ O
* O
* O
1 O
- O
28 O
* O
* O
] O
. O
  O
She O
had O
an O
uneventful O
course O
and O
was O
discharged O
in O
stable O

 O
condition O
. O

 O
Pt O
has O
been O
having O
financial O
problems O
and O
has O
not O
been O
able O
to O

 O
afford O
Tiotropium B-DRUG
( I-DRUG
Spiriva I-DRUG
) I-DRUG
. I-DRUG
  O
Social O
work O
was O
consulted O
and O
she O

 O
was O
given O
Ipratropium B-DRUG
instead O
. O

 O
Patient O
was O
slowly O
weaned O
off O
steroids B-DRUG
with O
taper B-DOS
over O
the O
next O

 O
2 B-DUR
- I-DUR
3 I-DUR
weeks I-DUR
. I-DUR


 O
# O
. O
Fibromyalgia B-REA
: I-REA
Difficult O
to O
control O
, O
with O
overt O
anxiety O
in O

 O
spite O
of O
[ O
* O
* O
Hospital O
17073 O
* O
* O
] O
medical O
regimen O
. O
We O
continued O
regimen O
with O

 O
fentanyl B-DRUG
patch B-FOR
, I-FOR
gabapentin B-DRUG
, I-DRUG
SOMA B-DRUG
, I-DRUG
darvocet B-DRUG
, I-DRUG
amitryptline B-DRUG
and O

 O
Propoxyphene B-DRUG


 I-DRUG
# O
. O
Anxiety O
: O
Patient O
with O
many O
social O
stressors O
and O
difficult O
to O

 O
control O
anxiety O
. O
Given O
progression O
of O
symptoms O
inspite O
of O

 O
agressive O
therapy O
, O
she O
was O
to O
follow O
up O
her O
outpatient O

 O
psychiatrist O
to O
address O
her O
anxiety O
. O


 O
# O
Anemia O
: O
During O
admission O
noted O
to O
be O
near O
baseline O
of O
31 O
. O

 O
There O
was O
no O
overt O
bleeding O
or O
hemolysis O
. O



 O

Medications O
on O
Admission O
: O

 O
Amitriptyline B-DRUG
150 B-STR
mg I-STR
qhs B-FRE

 I-FRE
aspirin B-DRUG
81 B-STR
daily B-FRE

 I-FRE
Darvocet B-DRUG
A[**Telephone/Fax O
( O
3 O
) O
* O
* O
] O
q6 B-FRE
prn I-FRE

 I-FRE
duonebs B-DRUG

 I-DRUG
valium B-DRUG
5 B-STR
mg I-STR
TID B-FRE

 I-FRE
fentanyl B-DRUG
patch B-FOR
25mcg B-STR
q72 B-FRE
hr I-FRE

 I-FRE
flurbiprofen B-DRUG
100 B-STR
mg I-STR
TID B-FRE

 I-FRE
lasix B-DRUG
80 B-STR
mg I-STR
daily B-FRE

 I-FRE
gabapentin B-DRUG
900 B-STR
mg I-STR
TID B-FRE

 I-FRE
hydrocodone-acetaminophen B-DRUG
5 B-STR
- I-STR
500 I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
prn B-FRE
pain B-REA

 I-REA
Potassium B-DRUG
Chloride I-DRUG
8mEQ B-STR
QID B-FRE

 I-FRE
Pulmicort B-DRUG

 I-DRUG
Soma B-DRUG
350 B-STR
mg I-STR
TID B-FRE

 I-FRE
MVI B-DRUG

 I-DRUG
Omega B-DRUG
3 I-DRUG



 I-DRUG

Discharge O
Medications O
: O

 O
1 O
. O
Carisoprodol B-DRUG
350 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Lorazepam B-DRUG
0.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
anxiety B-REA
. I-REA

 O
3 O
. O
Diazepam B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Amitriptyline B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE

 I-FRE
bedtime I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR

 I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
Darvocet B-DRUG
A[**Telephone/Fax O
( O
3 O
) O
* O
* O
] O
mg O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
every B-FRE

 I-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
fever B-REA
or O
pain B-REA
. I-REA

 O
7 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
2.5 B-STR
mg I-STR
/3 I-STR
mL I-STR
( I-STR
0.083 I-STR
% I-STR
) I-STR
Solution B-FOR
for I-FOR

 I-FOR
Nebulization I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
neb B-ROU
Inhalation B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE

 I-FRE
needed I-FRE
for O
SOB B-REA
. I-REA

 O
8 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
0.02 B-STR
% I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
neb B-FOR

 I-FOR
Inhalation B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
SOB B-REA
. I-REA

 O
9 O
. O
Fentanyl B-DRUG
50 B-STR
mcg/hr I-STR
Patch B-FOR
72 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Patch B-FOR
72 I-FOR
hr I-FOR

 I-FOR
Transdermal B-ROU
Q72H B-FRE
( I-FRE
every I-FRE
72 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Furosemide B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Gabapentin B-DRUG
300 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Pulmicort B-DRUG
  O
Inhalation B-ROU

 I-ROU
13 O
. O
Omega-3 B-DRUG
Fatty I-DRUG
Acids I-DRUG
     O
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU

 I-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
14 O
. O
Multivitamin B-DRUG
     O
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
15 O
. O
Flurbiprofen B-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
three B-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
. I-FRE

 O
16 O
. O
Azithromycin B-DRUG
250 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q24H B-FRE

 I-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
for B-DUR
3 I-DUR
days I-DUR
. I-DUR

 O
Disp:*6 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
17 O
. O
Prednisone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
see O
directions O
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE

 I-FRE
day I-FRE
for B-DUR
2 I-DUR
weeks I-DUR
: I-DUR
take O
8 B-DOS
pills B-FOR
on O
[ O
* O
* O
2123 O
- O
1 O
- O
31 O
* O
* O
] O
, O
then O
take O
6 B-DOS

 I-DOS
pills B-FOR
on O
[ O
* O
* O
2 O
- O
26 O
* O
* O
] O
, O
then O
take O
4 B-DOS
pills B-FOR
on O
[ O
* O
* O
2123 O
- O
2 O
- O
7 O
* O
* O
] O
, O

 O
then O
take O
2 B-DOS
pills B-FOR
on O
[ O
* O
* O
3 O
- O
6 O
* O
* O
] O
, O
then O
take O
1 B-DOS
pills B-FOR
on O

 O
[ O
* O
* O
3 O
- O
10 O
* O
* O
] O
. O

 O
Disp:*84 O
Tablet(s O
) O
* O
Refills:*0 O
* O



 O

Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Company O
1519 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
COPD O
exacerbation O

 O
Fibromyalgia O

 O
Lung O
mass O

 O
Possible O
h/o O
diastolic O
heart O
failure O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O



 O
Discharge O
Instructions O
: O

 O
You O
came O
to O
the O
hospital O
with O
shortness O
of O
breath O
that O
is O
likely O

 O
due O
to O
COPD O
exacerbation O
. O
  O
As O
you O
were O
tiring O
out O
, O
we O
put O
you O

 O
temporarily O
on O
a O
ventilator O
to O
help O
you O
breath O
. O
  O
You O
recovered O

 O
after O
one O
day O
and O
returned O
to O
your O
baseline O
functional O
status O
. O

 O
We O
found O
on O
CT O
scan O
a O
lung O
nodule O
that O
needs O
to O
be O
followed O
up O
. O

 O
Please O
see O
f/u O
appointments O
. O
  O
You O
were O
discharged O
in O
stable O

 O
condition O
. O

 O
. O

 O
Please O
follow O
up O
with O
your O
doctors O
, O
see O
below O
. O


 O
Followup O
Instructions O
: O

 O
Please O
follow O
up O
with O
Chest O
CT O
scan O
for O
the O
lung O
nodule O
in O
6 O

 O
month O
. O

 O
Provider O
: O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
83672 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
2664 O
* O
* O
] O

 O
Date/Time:[**2123 O
- O
2 O
- O
19 O
* O
* O
] O
10:30 O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2135 O
- O
7 O
- O
2 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2135 O
- O
8 O
- O
23 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2081 O
- O
3 O
- O
20 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Nafcillin B-DRUG
/ O
Vancomycin B-DRUG


 I-DRUG
Attending:[**Doctor O
First O
Name O
3290 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Back O
pain O
due O
to O
epidural O
abscesses O
complicated O
by O
bacteremia O

 O
and O
acute O
respiratory O
distress O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
1 O
. O
[ O
* O
* O
2135 O
- O
7 O
- O
3 O
* O
* O
] O
. O
Cervical O
decompression O
via O
laminectomies O
C2-C6 O

     O
bilaterally O
, O
insertion O
of O
2 O
epidural O
drains O
. O
Laminectomy O

 O
T12-L1-L2 O
, O
  O
insertion O
of O
2 O
drains O

 O
2 O
. O
[ O
* O
* O
2135 O
- O
7 O
- O
5 O
* O
* O
] O
Right O
knee O
arthrocentesis O
and O
washout O

 O
3 O
. O
[ O
* O
* O
2135 O
- O
7 O
- O
13 O
* O
* O
] O
Anterior O
cervical O
discectomy O
and O
fusion O
as O
well O
as O

 O
epidural O
abscess O
evacuation O
. O

 O
4 O
. O
[ O
* O
* O
2135 O
- O
7 O
- O
25 O
* O
* O
] O
IR-guided O
paraspinal O
abscess O
drainage O





 O
History O
of O
Present O
Illness O
: O

 O
54 O
yo O
F O
presents O
to O
ED O
w/ O
1 O
week O
of O
worsening O
back O
pain O
. O

 O
Pain O
reportedly O
started O
while O
riding O
a O
bike O
. O
Began O
in O

 O
lower O
back O
and O
has O
steadily O
risen O
up O
to O
her O
neck O
over O
the O
past O

 O
week O
. O
Also O
reports O
some O
shooting O
pain O
down O
right O
leg O
. O
+ O
fevers O

 O
and O
chills O
. O
For O
the O
past O
3 O
days O
, O
her O
legs O
have O
been O
feeling O

 O
weak O
, O
she O
has O
had O
difficulty O
urinating O
. O
Fevers O
and O
chills O
have O

 O
resolved O
. O
Reports O
tremors O
starting O
two O
days O
ago O
. O

 O
She O
denies O
fecal O
incontinence O
although O
this O
was O
reportedly O

 O
endorsed O
to O
ED O
staff O
. O
Denies O
any O
numbness O
or O
tingling O
in O
her O

 O
extremities O
. O



 O
Past O
Medical O
History O
: O

 O
None O


 O
Social O
History O
: O

 O
Works O
for O
a O
mission O
network O
. O
No O
IVDA O
. O
Social O
EtOH O


 O
Family O
History O
: O

 O
N/C O



 O
Physical O
Exam O
: O

 O
ADMISSION O
PHYSICAL O
EXAM O
: O

 O
T:98.7 O
  O
BP O
: O
155/100 O
HR:140 O
- O
150s O
   O
RR O
: O
20 O
     O
O2Sats O
100 O
% O
on O
NRB O

 O
Gen O
: O
Anxious O
, O
Uncomfortable O

 O
HEENT O
: O
Pupils O
: O
4->3 O
        O
EOMs O
- O
Full O

 O
Abd O
: O
Soft O
, O
NT O

 O
Extrem O
: O
Warm O
and O
well-perfused O
. O

 O
Neuro O
: O

 O
Mental O
status O
: O
Awake O
and O
alert O
, O
cooperative O
with O
exam O
, O
normal O

 O
affect O
. O

 O
Orientation O
: O
Oriented O
to O
person O
, O
place O
, O
and O
date O
. O

 O
Motor O
: O

       O
D O
    O
B O
     O
T O
    O
WE O
   O
WF O
    O
IP O
    O
Q O
  O
H O
     O
AT O
    O
[ O
* O
* O
Last O
Name O
( O
un O
) O
938 O
* O
* O
] O
    O
G O

 O
R O
     O
5 O
    O
5 O
     O
5 O
               O
5 O
     O
5 O
  O
5 O
     O
5 O
      O
5 O
     O
5- O

 O
L O
     O
5 O
    O
5 O
     O
5 O
               O
5 O
     O
5 O
  O
5 O
     O
5 O
      O
5 O
     O
5- O


 O
Sensation O
: O
Intact O
to O
light O
touch O
, O
propioception O
, O
pinprick O
and O

 O
vibration O
bilaterally O
. O


 O
Reflexes O
: O
Pa O
   O
Ac O

 O
Right O
     O
2 O
+ O
  O
Mute O

 O
Left O
      O
2 O
+ O
   O
Mute O


 O
Rectal O
exam O
- O
normal O
sphincter O
control O
, O
normal O
perianal O

 O
sensation O


 O
DISCHARGE O
PHYSICAL O
EXAM O
( O
[ O
* O
* O
8 O
- O
17 O
* O
* O
] O
) O
: O

 O
VS O
: O
Afebrile O
> O
36hr O
, O
Tc O
: O
98.1 O
  O
BP O
: O
130/76 O
( O
140 O
- O
170/80 O
- O
92 O
) O
94 O
% O
2L O

 O
02 O
saturation O
yesterday O
: O
97 O
- O
-100 O
% O
on O
1 O
- O
2L O
; O
94 O
% O
RA O

 O
GEN O
: O
Sleeping O
but O
arousable O
, O
oriented O
, O
no O
acute O
distress O

 O
HEENT O
: O
non-icteric O
sclera O
, O
MMM O

 O
NECK O
: O
Gauze O
and O
tegaderm O
in O
place O
over O
former O
RIJ O
, O
no O
tenderness O

 O
HEART O
: O
RRR O
, O
nl O
S1 O
S2 O
, O
3/6 O
systolic O
murmur O
, O
heard O
best O
at O
LUSB O
, O

 O
radiating O
to O
neck O
bilaterally O
, O
no O
rubs O

 O
LUNGS O
: O
anterior O
lung O
fields O
clear O
, O
slightly O
decreased O
bs O
at O

 O
bases O
, O
no O
wheezes O

 O
ABD O
: O
ecchymoses O
on O
lower O
abdomen O
, O
+ O
NABS O
, O
soft O
, O
non-distended O
, O

 O
non-tender O
, O
without O
rebound O
or O
guarding O

 O
EXT O
: O
warm O
, O
1 O
+ O
edema O
to O
ankle O
b/l O
, O
right O
knee O
with O
healed O

 O
surgical O
scar O

 O
T/L/D O

  O
- O
Left O
PICC O
line O
in O
place O
; O
no O
surrounding O
tenderness O
, O
erythema O



 O
Pertinent O
Results O
: O

 O
ADMISSION O
LABS O
: O



 O
[ O
* O
* O
2135 O
- O
7 O
- O
2 O
* O
* O
] O
01:45PM O
URINE O
  O
RBC-[**5 O
- O
5 O
* O
* O
] O
* O
WBC->50 O
BACTERIA-MANY O

 O
YEAST-NONE O
EPI-0 O
- O
2 O

 O
[ O
* O
* O
2135 O
- O
7 O
- O
2 O
* O
* O
] O
01:50PM O
   O
WBC-21.2 O
* O
RBC-4.70 O
HGB-14.2 O
HCT-43.9 O
MCV-93 O

 O
MCH-30.2 O
MCHC-32.4 O
RDW-14.4 O

 O
[ O
* O
* O
2135 O
- O
7 O
- O
2 O
* O
* O
] O
01:50PM O
   O
GLUCOSE-287 O
* O
UREA O
N-51 O
* O
CREAT-1.7 O
* O
SODIUM-136 O

 O
POTASSIUM-3.6 O
CHLORIDE-96 O
TOTAL O
CO2 O
- O
21 O
* O
ANION O
GAP-23 O
* O

 O
[ O
* O
* O
2135 O
- O
7 O
- O
2 O
* O
* O
] O
02:17PM O
   O
LACTATE-2.9 O
* O


 O
DISCHARGE O
LABS O
( O
[ O
* O
* O
8 O
- O
17 O
* O
* O
] O
) O

 O
WBC O
    O
RBC O
  O
Hgb O
   O
Hct O
  O
MCV O
MCH O
  O
MCHC O
RDW O
Plt O
Ct O

 O
16.6 O
* O
2.87 O
* O
8.0 O
* O
24.4 O
* O
85 O
  O
27.8 O
32.7 O
17.9 O
* O
227 O

 O
DIFF O
Neuts O
Bands O
Lymphs O
Monos O
Eos O
Baso O
Atyps O
Metas O
Myelos O

 O
Promyel O
NRBC O

       O
59 O
    O
9 O
* O
    O
8 O
* O
     O
21 O
* O
   O
0 O
    O
0 O
    O
1 O
* O
    O
2 O
* O
    O
0 O

 O
Glucose O
UreaN O
Creat O
  O
Na O
    O
K O
   O
Cl O
  O
HCO3 O
AnGap O

  O
96 O
      O
22 O
* O
   O
0.5 O
  O
141 O
   O
3.7 O
  O
102 O
  O
32 O
   O
11 O

 O
Inflammatory O
Markers O
( O
[ O
* O
* O
8 O
- O
16 O
* O
* O
] O
) O

 O
ESR O
: O
    O
115 O
* O

 O
CRP O
: O
    O
30.9 O

 O
. O

 O
MICRO O
: O

 O
Micro O
: O

 O
[ O
* O
* O
7 O
- O
2 O
* O
* O
] O
- O
Blood O
Cx O
- O
[ O
* O
* O
2 O
- O
27 O
* O
* O
] O
MSSA O

 O
[ O
* O
* O
7 O
- O
3 O
* O
* O
] O
- O
Epidural O
Swab O
- O
MSSA O

 O
[ O
* O
* O
7 O
- O
5 O
* O
* O
] O
- O
Joint O
Fluid O
+ O
Swab O
- O
MSSA O

 O
[ O
* O
* O
7 O
- O
13 O
* O
* O
] O
- O
Epidural O
Swab O
- O
MSSA O

 O
[ O
* O
* O
7 O
- O
25 O
* O
* O
] O
Abscess O
- O
MSSA O

 O
. O

 O
C. O
diff O
- O
[ O
* O
* O
8 O
- O
1 O
* O
* O
] O
( O
- O
) O
, O
[ O
* O
* O
7 O
- O
30 O
* O
* O
] O
( O
- O
) O
, O
[ O
* O
* O
7 O
- O
26 O
* O
* O
] O
( O
- O
) O
, O
[ O
* O
* O
8 O
- O
16 O
* O
* O
] O
( O
- O
) O

 O
. O


 O
Antimicrobial O
History O
: O

 O
Vanco+Cefepime B-DRUG
[**7 O
- O
10**]->[**7 O
- O
15 O
* O
* O
] O

 O
Vanco B-DRUG
[ O
* O
* O
7 O
- O
10 O
* O
* O
] O
- O
> O
[ O
* O
* O
7 O
- O
15 O
* O
* O
] O

 O
Nafcillin B-DRUG
[ O
* O
* O
7 O
- O
15 O
* O
* O
] O
- O
> O
[ O
* O
* O
7 O
- O
19 O
* O
* O
] O

 O
Vanco B-DRUG
[ O
* O
* O
7 O
- O
19 O
* O
* O
] O
- O
> O
[ O
* O
* O
8 O
- O
8 O
* O
* O
] O

 O
Cefepime B-DRUG
[ O
* O
* O
7 O
- O
26 O
* O
* O
] O
- O
> O
[ O
* O
* O
8 O
- O
2 O
* O
* O
] O

 O
Meropenem B-DRUG
1000 B-STR
mg I-STR
IV B-ROU
Q8 B-FRE
( O
[ O
* O
* O
8 O
- O
8 O
* O
* O
] O
- O
[ O
* O
* O
8 O
- O
14 O
* O
* O
] O
) O

 O
Daptomycin B-DRUG
600 B-STR
mg I-STR
IV B-ROU
Q24 B-FRE
( O
[ O
* O
* O
8 O
- O
8 O
* O
* O
] O
- O
present O
) O



 O
[ O
* O
* O
2135 O
- O
8 O
- O
17 O
* O
* O
] O
10:22 O
am O
STOOL O
     O
CONSISTENCY O
: O
NOT O
APPLICABLE O

       O
Source O
: O
Stool O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2135 O
- O
8 O
- O
18 O
* O
* O
] O
* O
* O


    O
CLOSTRIDIUM O
DIFFICILE O
TOXIN O
A O
& O
B O
TEST O
( O
Final O
[ O
* O
* O
2135 O
- O
8 O
- O
18 O
* O
* O
] O
) O
: O

       O
Feces O
negative O
for O
C.difficile O
toxin O
A O
& O
B O
by O
EIA O
. O

            O
( O
Reference O
Range-Negative O
) O
. O


 O
IMAGING O
: O

 O
MRI O
Spine O
[ O
* O
* O
7 O
- O
3 O
* O
* O
] O
: O

 O
1 O
. O
Cervical O
anterior O
epidural O
collection O
, O
with O
severe O
narrowing O

 O
of O
the O
thecal O
sac O
from O
C2 O
through O
C5 O
, O
without O
evidence O
of O
spinal O

 O
cord O
edema O
. O
Sagittal O
post-contrast O
images O
suggest O
that O
this O

 O
collection O
contains O
fluid O
at O
the O
level O
of O
C2 O
, O
which O
would O

 O
indicate O
an O
abscess O
rather O
than O
a O
phlegmon O
. O
However O
, O
axial O

 O
post-contrast O
images O
suggest O
that O
the O
central O
hypoenhancing O

 O
portion O
of O
the O
collection O
at O
C2 O
may O
not O
be O
fully O
liquefied O
, O
or O

 O
that O
the O
fluid O
may O
be O
highly O
viscous O
. O

 O
2 O
. O
Anterior O
epidural O
collection O
from O
T11 O
through O
the O
upper O

 O
sacrum O
, O

 O
compressing O
the O
thecal O
sac O
and O
crowding O
the O
cauda O
equina O
. O
This O

 O
collection O

 O
appears O
to O
contain O
fluid O
from O
T12 O
through O
L3 O
, O
indicative O
of O
an O

 O
abscess O
rather O
than O
a O
phlegmon O
. O

 O
3 O
. O
No O
evidence O
of O
discitis O
or O
osteomyelitis O
. O

 O
4 O
. O
Bilateral O
posterior O
paravertebral O
muscle O
phlegmon O
at O
the O

 O
level O
of O
L4 O
- O
5 O

 O
with O
a O
possible O
5 O
mm O
abscess O
on O
the O
right O
. O
Contrast O
enhancement O

 O
surrounding O
the O
L4 O
- O
5 O
facet O
joints O
may O
represent O
inflammation O

 O
secondary O
to O
the O
severe O
degenerative O
facet O
arthropathy O
, O
but O

 O
septic O
facet O
arthropathy O
can O
not O
be O
excluded O


 O
Echo O
[ O
* O
* O
7 O
- O
4 O
* O
* O
] O
: O

 O
IMPRESSION O
: O
Suboptimal O
image O
quality O
. O
Mild O
mitral O
leaflet O

 O
thickening O
but O
without O
discrete O
vegetation O
or O
pathologic O
flow O
. O

 O
Mild O
pulmonary O
artery O
systolic O
hypertension O
. O
Normal O
left O

 O
ventricular O
cavity O
size O
with O
preserved O
global O
and O
regional O

 O
systolic O
function O



 O
MRI O
Spine O
[ O
* O
* O
7 O
- O
4 O
* O
* O
] O
: O

 O
1 O
. O
Cervical O
region O
: O
No O
STIR O
signal O
abnormality O
in O
the O
cord O
. O
No O

 O
evidence O
of O

 O
cord O
compression O
. O
Expected O
post-op O
changes O
. O

 O
2 O
. O
Lumbar O
region O
: O
Small O
epidural O
signal O
abnormality O
, O
could O

 O
represent O
residual O
abscess O
collection O
from O
debridement O
or O

 O
post-surgical O
changes O
. O


 O
XRAY-Knee O

 O
IMPRESSION O
: O
Small O
to O
moderate-sized O
knee O
joint O
effusion O
. O


 O
CTA O
[ O
* O
* O
7 O
- O
9 O
* O
* O
] O

 O
IMPRESSION O
: O

 O
1 O
. O
No O
pulmonary O
embolism O
or O
acute O
aortic O
pathology O
. O

 O
2 O
. O
Moderate O
bilateral O
pleural O
effusions O
with O
subtotal O
lower O
lobe O

 O
collapse O
. O

 O
Evidence O
of O
loculated O
pleural O
effusions O
tracking O
up O
in O
the O
right O

 O
upper O
lateral O
pleural O
space O
. O

 O
3 O
. O
Multiple O
lung O
nodules O
likely O
infectious O
in O
this O
cl O

 O
inical O
setting O
. O
Follow- O

 O
up O
to O
resolution O
is O
recommended O

 O
4 O
. O
No O
pneumothorax O
. O


 O
MR O
[ O
* O
* O
Name13 O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
8 O
- O
12 O
* O
* O
] O

 O
Significant O
increase O
in O
volume O
of O
the O
epidural O
fluid O

 O
collection/abscess O

 O
extending O
from O
the O
uppermost O
C1 O
epidural O
space O
to O
the O
inferior O

 O
aspect O
of O
the O
study O
at O
L1 O
, O
largest O
at O
the O
upper O
cervical O
spine O

 O
where O
it O
measures O

 O
approximately O
1 O
cm O
in O
greatest O
thickness O
. O
The O
patient O
is O
status O

 O
post O
cervical O
laminectomy O
from O
approximately O
C2-C6 O
but O
the O

 O
epidural O
collection O
displaces O
the O
cervical O
cord O
posteriorly O
and O

 O
the O
cervical O
cord O
appears O
compressed O
against O
the O
posterior O
ring O

 O
of O
C1 O
. O
There O
is O
increased O
signal O
within O
the O
cervical O
cord O
from O

 O
the O
medulla O
to O
C3 O
. O

 O
2 O
. O
The O
epidural O
collection/abscess O
within O
the O
thoracic O
spine O

 O
mildly O

 O
displaces O
the O
thoracic O
cord O
without O
evidence O
of O
cord O
signal O

 O
abnormality O
. O


 O
CT-Thoracentesis O
( O
drainage O
) O
[ O
* O
* O
7 O
- O
13 O
* O
* O
] O

 O
IMPRESSION O
: O
Successful O
diagnostic O
and O
therapeutic O
thoracentesis O

 O
yielding O
270 O
cc O
of O
serosanguineous O
fluid O
from O
the O
right O
pleural O

 O
cavity O
. O
An O
8 O
French O

 O
pigtail O
catheter O
was O
placed O
within O
the O
pleural O
cavity O
and O
is O

 O
currently O

 O
attached O
to O
waterseal O
. O
Samples O
were O
sent O
for O
microbiology O
and O

 O
chemistry O
per O
the O
ordering O
team O
's O
request O
. O



 O
MR O
C/T/L-Spine O
[ O
* O
* O
7 O
- O
21 O
* O
* O
] O

 O
IMPRESSION O
: O

 O
1 O
. O
New O
soft O
tissue O
paraspinal O
pockets O
of O
fluid O
collection O
are O

 O
seen O
in O
the O

 O
lumbar O
region O
since O
the O
examination O
of O
[ O
* O
* O
2135 O
- O
7 O
- O
2 O
* O
* O
] O
and O
[ O
* O
* O
2135 O
- O
7 O
- O
4 O
* O
* O
] O
, O

 O
visualized O
in O
the O
lower O
lumbar O
region O
involving O
the O
psoas O

 O
muscles O
and O
the O
erector O
spinae O
muscles O
. O
The O
largest O
collection O

 O
in O
the O
right O
erector O
spinae O
muscle O
is O
approximately O
3 O
cm O
and O
the O

 O
largest O
collection O
in O
the O
right O
psoas O
muscle O
is O
approximately O
2 O

 O
cm O
. O
Additional O
left O
psoas O
muscle O
fluid O
pocket O
measures O
2.8 O
cm O
. O

 O
Smaller O
foci O
are O
also O
visualized O
. O

 O
2 O
. O
Lumbar O
epidural O
fluid O
collection O
ventral O
and O
dorsal O
to O
the O

 O
thecal O
sac O
in O
the O
lower O
lumbar O
region O
may O
be O
slightly O
smaller O

 O
compared O
to O
[ O
* O
* O
2135 O
- O
7 O
- O
2 O
* O
* O
] O
. O

 O
3 O
. O
Epidural O
collection O
in O
the O
cervical O
region O
extending O
from O
C2 O

 O
inferiorly O
is O
not O
significantly O
changed O
since O
the O
MRI O
of O

 O
[ O
* O
* O
2135 O
- O
7 O
- O
14 O
* O
* O
] O
. O
Minimal O
indentation O
on O
the O
spinal O
cord O
in O
cervical O

 O
region O
is O
unchanged O
. O
Postoperative O
changes O
and O
laminectomies O
are O

 O
seen O
in O
this O
region O
. O

 O
4 O
. O
Thoracic O
epidural O
collection O
has O
not O
changed O
and O
there O
is O
no O

 O
cord O

 O
compression O
in O
thoracic O
region O
. O

 O
4 O
. O
Laminectomies O
are O
seen O
in O
the O
lower O
thoracic/upper O
lumbar O

 O
region O
. O
Thin O

 O
rim O
of O
epidural O
collection O
again O
seen O
in O
the O
thoracic O
region O

 O
which O
is O

 O
unchanged O
. O
No O
cord O
compression O
is O
identified O
in O
the O
thoracic O

 O
region O
. O


 O
CT-Chest/Abdomen/Pelvis O
[ O
* O
* O
7 O
- O
26 O
* O
* O
] O

 O
IMPRESSION O
: O


 O
1 O
. O
Overall O
, O
stable O
appearance O
of O
multiple O
small O
fluid O
collection O

 O
seen O
in O
the O
paraspinal O
muscles O
along O
with O
the O
erector O
spinae O
and O

 O
psoas O
muscles O
, O
as O

 O
described O
above O
. O
No O
new O
intraabdominal O
or O
intrapelvic O

 O
collections O
identified O
. O

 O
2 O
. O
Stable O
bilateral O
pleural O
effusion O
with O
bibasilar O
airspace O

 O
disease O
. O

 O
3 O
. O
Stable O
appearance O
of O
mediastinal O
and O
bilateral O
hilar O

 O
lymphadenopathy O
. O


 O
U/S O
Abdomen O
[ O
* O
* O
7 O
- O
29 O
* O
* O
] O

 O
IMPRESSION O
: O

 O
1 O
. O
Cholelithiasis O
with O
edematous O
and O
thick O
walled O
but O
contracted O

 O
gallbladder O
. O
No O
son[**Name O
( O
NI O
) O
493 O
* O
* O
] O
evidence O
of O
acute O
cholecystitis O
. O

 O
Gallbladder O
wall O
thickening O
and O
edema O
may O
be O
caused O
by O
multiple O

 O
factors O
such O
as O
liver O
disease O
and O
hypoalbuminemia O
, O
and O
clinical O

 O
correlation O
is O
recommended O
. O

 O
2 O
. O
Splenomegaly O
. O



 O
CT-Chest/Abdomen/Pelvis O
[ O
* O
* O
8 O
- O
1 O
* O
* O
] O

 O
IMPRESSION O
: O

 O
1 O
. O
Multiple O
soft O
tissue O
abscesses O
appear O
similar O
to O
prior O

 O
examination O
with O

 O
erector O
spinae O
abscess O
on O
the O
right O
, O
left O
iliopsoas O
abscess O
, O
and O

 O
fluid O
pockets O
overlying O
the O
lower O
lumbar O
spine O
spinous O

 O
processes O
. O

 O
2 O
. O
Left O
posterior O
rotator O
cuff O
region O
possible O
new O
abscess O
, O
not O

 O
well O
seen O
on O
prior O
studies O
. O

 O
3 O
. O
Bilateral O
basal O
pulmonary O
volume O
loss O
and O
consolidation O
, O

 O
similar O
to O
prior O
examination O
in O
lesion O
addition O
to O
bilateral O

 O
pleural O
effusions O
, O
more O
pronounced O
and O
somewhat O
loculated O
on O
the O

 O
right O
but O
similar O
to O
prior O
study O
. O

 O
4 O
. O
Nonspecific O
gallbladder O
wall O
thickening O
. O
Cholecystitis O
is O
not O

 O
excluded O
, O

 O
although O
the O
appearance O
is O
stable O
compared O
to O
prior O
examination O

 O
and O
has O
been O
previously O
evaluated O
with O
ultrasound O
. O

 O
5 O
. O
Nonspecific O
lesion O
in O
the O
right O
renal O
upper O
pole O
. O
This O
was O

 O
not O
well O
seen O
on O
prior O
examination O
. O
If O
there O
is O
clinical O

 O
suspicion O
for O
renal O
abscess O
, O
targeted O
ultrasound O
could O
be O

 O
performed O
to O
further O
assess O
. O

 O
6 O
. O
Left O
proximal O
thigh O
abscess O
, O
incompletely O
assessed O
but O

 O
similar O
to O
prior O

 O
study O
allowing O
for O
difference O
in O
technique O
. O

 O
7 O
. O
Splenomegaly O
. O


 O
MRI O
C-Spine O
[ O
* O
* O
8 O
- O
6 O
* O
* O
] O

 O
IMPRESSION O
: O
Again O
, O
epidural O
enhancement O
and O
abscesses O
identified O

 O
in O
the O

 O
anterior O
cervical O
region O
. O
As O
described O
above O
, O
the O
fluid O

 O
collection O
around O

 O
C2-C3 O
level O
appears O
slightly O
increased O
in O
thickness O
, O
but O
the O

 O
differences O
in O
measurements O
are O
small O
and O
this O
could O
also O
be O
due O

 O
to O
partial O
volume O
averaging O
, O

 O
but O
continued O
followup O
is O
recommended O
. O
Otherwise O
, O
the O

 O
examination O
is O
stable O


 O
MRI O
T-Spine O
[ O
* O
* O
8 O
- O
6 O
* O
* O
] O

 O
IMPRESSION O
: O
Overall O
stable O
appearance O
of O
the O
thoracic O
spine O

 O
compared O
to O
the O
previous O
MRI O
of O
[ O
* O
* O
2135 O
- O
7 O
- O
21 O
* O
* O
] O
. O
Again O
, O
lower O
thoracic O

 O
and O
upper O
lumbar O

 O
laminectomies O
and O
epidural O
enhancement O
is O
seen O
in O
the O
thoracic O

 O
region O
without O
epidural O
abscess O
. O


 O
CT O
Scan O
Abd/Pelvis O
( O
[ O
* O
* O
8 O
- O
9 O
* O
* O
] O
) O
: O

 O
with O
abdominal O
pain O
of O
unclear O
etiology O
, O
look O
for O
possible O

 O
underlying O

 O
abdominal O
abscess O
. O


 O
COMPARISON O
: O
CT O
torso O
from O
[ O
* O
* O
2135 O
- O
8 O
- O
1 O
* O
* O
] O
. O


 O
TECHNIQUE O
: O
Non-contrast O
MDCT O
of O
the O
abdomen O
. O
The O
patient O
not O

 O
received O
any O

 O
oral B-ROU
or O
IV B-ROU
contrast B-DRUG
. I-DRUG



 O
FINDINGS O
: O
Of O
note O
, O
evaluation O
of O
abdominal O
organs O
is O
limited O

 O
without O
any O

 O
intravenous B-ROU
or O
oral B-ROU
contrast B-DRUG
administered O
. O
Once O
again O
, O
there O
are O

 O
bilateral O

 O
pleural O
effusions O
with O
overlying O
collapse/consolidation O
that O
has O

 O
slightly O

 O
improved O
from O
previous O
study O
. O
Once O
again O
, O
the O
right O
is O

 O
significantly O
greater O
than O
the O
left O
and O
appears O
loculated O
. O
A O

 O
nodular O
density O
previously O
seen O
in O
the O
right O
middle O
lobe O
is O
not O

 O
visualized O
in O
the O
current O
study O
. O


 O
CT O
ABDOMEN O
W/O O
Contrast B-DRUG
: I-DRUG

 O
There O
is O
no O
focal O
liver O
lesion O
seen O
. O
There O
is O
evidence O
of O
a O

 O
large O
stone O

 O
within O
the O
gallbladder O
; O
however O
, O
there O
are O
no O
signs O
of O

 O
gallbladder O
wall O

 O
thickening O
or O
other O
associated O
signs O
to O
suggest O
inflammation O
or O

 O
infection O
. O
The O
spleen O
is O
enlarged O
. O
There O
is O
no O
focal O
splenic O

 O
lesion O
or O
abscess O
seen O
. O

 O
Pancreas O
appears O
normal O
. O
Adrenals O
appear O
normal O
. O
The O
kidney O
is O

 O
normal O
in O

 O
appearance O
. O
Right O
kidney O
appears O
normal O
in O
appearance O
. O
The O
small O

 O
area O
of O

 O
hypoattenuation O
seen O
in O
the O
left O
kidney O
on O
the O
previous O
study O

 O
was O
not O

 O
appreciated O
on O
the O
current O
exam O
. O
Small O
periaortic O
and O
portacaval O

 O
lymph O
nodes O
are O
again O
seen O
, O
however O
, O
they O
do O
not O
meet O
CT O

 O
criteria O
for O
lymphadenopathy O
. O
There O
is O
no O
bowel O
obstruction O
. O
The O

 O
appendix O
is O
normal O
. O
There O
is O
no O
significant O
mesenteric O

 O
lymphadenopathy O
or O
fluid O
collection O
seen O
. O


 O
CT O
PELVIS O
W/O O
contrast B-DRUG
: I-DRUG
Once O
again O
seen O
is O
a O
low-attenuation O

 O
fluid O
collection O
in O
the O
left O
iliopsoas O
muscle O
, O
extending O
from O

 O
the O
lower O
lumbar-upper O
pelvic O
regions O
along O
the O
psoas O
. O
This O

 O
collection O
appears O
unchanged O
, O
both O
in O
size O
and O
in O
character O
and O

 O
further O
characterization O
is O
limited O
without O
contrast O
. O
Once O
again O

 O
seen O
are O
the O
small O
areas O
of O
low O
attenuation O
, O
representing O
fluid O

 O
in O
the O
proximal O
thigh O
as O
well O
as O
stranding O
in O
the O
left O
greater O

 O
trochanter O
. O
This O
appears O
unchanged O
from O
the O
previous O
study O
of O

 O
[ O
* O
* O
2135 O
- O
8 O
- O
1 O
* O
* O
] O
. O
There O
is O
no O
epidural O
abscess O
seen O
in O
the O

 O
thoracic O
region O
. O


 O
The O
rectum O
, O
sigmoid O
colon O
, O
bladder O
, O
and O
uterus O
are O
normal O
. O


 O
3D O
reconstructions O
, O
coronal O
and O
sagittal O
reconstructions O
were O

 O
essential O
in O

 O
delineating O
the O
anatomy O
and O
pathology O
. O


 O
BONES O
: O
There O
is O
no O
osseous O
destruction O
seen O
. O
As O
mentioned O
, O

 O
evidence O
of O
priorlaminectomies O
at O
the O
lower O
thoracic O
spine O
and O

 O
upper O
lumbar O
spine O
are O
seen O
. O
There O
are O
no O
epidural O
collections O

 O
suggestive O
of O
epidural O
abscess O
in O
the O
lumbaror O
visualized O

 O
thoracic O
spine O
. O



 O
IMPRESSION O
: O

 O
1 O
. O
Unchanged O
left O
iliopsoas O
abscess O

 O
2 O
. O
Slight O
interval O
decrease O
in O
bilateral O
basal O
pulmonary O
volume O

 O
loss O
and O

 O
consolidation O
and O
pleural O
effusions O
. O

 O
3 O
. O
Large O
gallstone O
within O
the O
gallbladder O
without O
sign O
of O

 O
gallbladder O

 O
inflammation O
. O

 O
4 O
. O
Unchanged O
fluid O
collection O
in O
the O
left O
proximal O
thigh O

 O
compared O
to O
prior O
. O

 O
5 O
. O
This O
study O
was O
discussed O
with O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
1169 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
at O
4:30 O
p.m. O

 O
on O
[ O
* O
* O
2135 O
- O
8 O
- O
9 O
* O
* O
] O
. O

 O
. O

 O
Unilateral O
upper O
extremity O
venous O
ultrasound O
. O
( O
[ O
* O
* O
8 O
- O
17 O
* O
* O
] O
) O

 O
COMPARISON O
: O
Upper O
extremity O
venous O
ultrasound O
[ O
* O
* O
2135 O
- O
7 O
- O
11 O
* O
* O
] O
. O

 O
FINDINGS O
: O
Color O
and O
grayscale O
son[**Name O
( O
NI O
) O
1417 O
* O
* O
] O
of O
bilateral O
subclavian O

 O
and O

 O
left-sided O
internal O
jugular O
, O
basilic O
, O
brachial O
and O
cephalic O

 O
vessels O
were O

 O
evaluated O
. O
Evaluated O
vessels O
demonstrated O
normal O
flow O
, O

 O
compressibility O
and O

 O
augmentation O
. O
There O
is O
a O
PICC O
line O
in O
the O
basilic O
. O
There O
is O

 O
duplication O
of O

 O
the O
brachial O
vessels O
. O

 O
IMPRESSION O
: O
PICC O
in O
the O
basilic O
vein O
but O
no O
DVT O
. O

 O
. O



 O
Brief O
Hospital O
Course O
: O

 O
Ms O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
is O
a O
54 O
yo O
female O
with O
no O
significant O
past O
medical O

 O
history O
who O
initially O
presented O
with O
back O
pain O
, O
urinary O

 O
retention O
on O
[ O
* O
* O
7 O
- O
3 O
* O
* O
] O
, O
found O
to O
have O
multiple O
epidural O
abscesses O
s/p O

 O
multiple O
surgical O
debridements O
with O
hospital O
course O
complicated O

 O
by O
episodes O
of O
flash O
pulmonary/respiratory O
compromise O
requiring O

 O
intubation O
and O
febrile B-ADE
neutropenia I-ADE
secondary O
to O
lasix B-DRUG
and O

 O
vancomycin B-DRUG
administration O
. O

 O
. O

 O
# O
Bacteremia/Abscesses/Antibiotic B-REA
therapy O

 O
. O

 O
Patient O
initially O
presented O
with O
back O
pain O
, O
associated O
urinary O

 O
retention O
and O
LE O
weakness O
. O
Admission O
imaging O
positive O
for O

 O
cervical B-REA
and I-REA
lumbar I-REA
epidural I-REA
abscesses I-REA
( O
though O
patient O
with O
no O

 O
known O
risk O
factors O
) O
. O
She O
was O
empirically O
started O
on O

 O
vancomycin/cefepime/levofloxacin B-DRUG
. I-DRUG
She O
underwent O
C2-C6/T12-L2 O

 O
bilateral O
laminectomies O
with O
insertion O
of O
4 O
drains O
on O
[ O
* O
* O
2135 O
- O
7 O
- O
3 O
* O
* O
] O
. O

 O
She O
subsequently O
developed O
a O
septic O
right O
knee O
and O
returned O
to O

 O
the O
OR O
on O
[ O
* O
* O
2135 O
- O
7 O
- O
4 O
* O
* O
] O
for O
right O
knee O
washout O
. O
Regarding O
further O

 O
initial O
infectious O
work-up O
at O
that O
time O
: O
a O
TEE O
was O
obtained O

 O
which O
showed O
no O
vegetations O
; O
CT O
head O
without O
evidence O
of O

 O
intracranial O
abscess O
. O

 O
. O


 O
On O
[ O
* O
* O
2135 O
- O
7 O
- O
6 O
* O
* O
] O
, O
antibiotic B-DRUG
coverage O
was O
narrowed O
to O
nafcillin B-DRUG
when O

 O
cultures O
from O
abscesses B-REA
, I-REA
right I-REA
knee I-REA
, I-REA
and O
blood B-REA
grew I-REA
MSSA I-REA
. I-REA

 O
However O
, O
due O
to O
signs O
and O
symptoms O
of O
leukocytosis O
, O
hypoxia O

 O
there O
was O
concern O
for O
hospital B-REA
acquired I-REA
pneumonia I-REA
and O
antibiotic B-DRUG

 I-DRUG
coverage O
was O
broadened O
to O
vancomycin B-DRUG
, I-DRUG
cefepime B-DRUG
, I-DRUG
and O

 O
ciprofloxacin B-DRUG
on O
[ O
* O
* O
7 O
- O
10 O
* O
* O
] O
. O
Patient O
remained O
febrile O
. O
Surveillance O

 O
imaging O
obtained O
on O
[ O
* O
* O
7 O
- O
12 O
* O
* O
] O
which O
demonstrated O
increased O
epidural O

 O
collection O
within O
anterior O
cervical O
epidural O
space O
and O

 O
displacement O
of O
the O
cervical O
cord O
. O
The O
patient O
returned O
to O
the O

 O
OR O
on O
[ O
* O
* O
7 O
- O
13 O
* O
* O
] O
for O
abscess O
decompression O
and O
evacuation O
and O
fusion O

 O
of O
C3 O
- O
4 O
, O
C4 O
- O
5 O
, O
and O
C5 O
- O
6 O
. O
After O
reviewing O
microbial O
date O
with O
all O

 O
cultures O
+ O
MSSA B-REA
, I-REA
her O
antibiotic B-DRUG
coverage O
was O
again O
narrowed O
to O

 O
nafcillin B-DRUG
. I-DRUG

 O
. O

 O
Patient O
had O
been O
doing O
well O
with O
normalized O
temperature O
and O
WBC O

 O
however O
four O
days O
after O
starting O
nafcillin B-DRUG
, I-DRUG
developed O
a O

 O
abdominal B-ADE
rash I-ADE
. I-ADE
Derm O
was O
consulted O
, O
biopsies O
were O
taken O
which O

 O
were O
c/w O
drug B-ADE
rash I-ADE
secondary O
to O
nafcillin B-DRUG
. I-DRUG
Nafcillin B-DRUG
was O

 O
subsequently O
discontinued O
and O
replaced O
by O
IV B-ROU
vancomycin B-DRUG
. I-DRUG

 O
. O

 O
Repeat O
MR O
spine O
with O
new O
paraspinal O
fluid O
collections O
, O
and O
mild O

 O
epidural O
fluid O
collection O
throughout O
the O
spine O
. O
Due O
to O
concern O

 O
for O
continued B-REA
infection I-REA
cefepime B-DRUG
was O
added O
to O
antibiotic B-DRUG

 I-DRUG
regimen O
. O
On O
[ O
* O
* O
7 O
- O
25 O
* O
* O
] O
, O
the O
patient O
underwent O
paraspinal O
abscess O

 O
drainage O
by O
interventional O
radiology O
. O
Follow-up O
CT O
torso O
was O

 O
obtained O
on O
[ O
* O
* O
8 O
- O
1 O
* O
* O
] O
due O
to O
persistent B-ADE
fevers I-ADE
on O
cefepime B-DRUG
and O
vanc B-DRUG
; I-DRUG

 O
finding O
were O
stable O
to O
previous O
imaging O
and O
cefepime B-DRUG
was O

 O
discontinued O
. O
On O
[ O
* O
* O
8 O
- O
5 O
* O
* O
] O
, O
her O
C-collar O
was O
removed O
. O
Surveilance O
MR O

 O
C/T-Spine O
on O
[ O
* O
* O
8 O
- O
6 O
* O
* O
] O
showed O
stable O
epidural O
enhancement O
and O

 O
abscesses O
identified O
in O
the O
anterior O
cervical O
region O
, O
thoracic O

 O
region O
without O
epidural O
abscess O
. O
CT O
scan O
on O
[ O
* O
* O
8 O
- O
9 O
* O
* O
] O
demonstrated O

 O
left O
iliopsoas O
abscess/phlegmen O
and O
left O
thigh O
fluid O
collection O
; O

 O
both O
of O
which O
were O
too O
small O
to O
be O
drained O
by O
IR O
. O

 O
. O


 O
Unfortunately O
side O
effects O
necessitated O
further O
antibiotic B-DRUG

 I-DRUG
adjustment O
. O
CBC O
with O
noted O
leukopenia B-ADE
on O
[ O
* O
* O
8 O
- O
5 O
* O
* O
] O
with O
progression O

 O
to O
neutropenia B-ADE
[ O
* O
* O
8 O
- O
8 O
* O
* O
] O
. O
  O
Out O
of O
concern O
that O
vancomycin B-DRUG
could O
be O

 O
contributing O
to O
decreasing O
counts O
, O
vanc B-DRUG
d/c'ed O
  O
and O
IV B-ROU

 I-ROU
daptomycin B-DRUG
started O
. O
Per O
ID O
will O
plan O
to O
treat O
MSSA B-REA

 I-REA
bacteremia/abscesses I-REA
with O
IV B-ROU
daptomycin B-DRUG
to O
total O
of O
6 B-DUR
- I-DUR
8wk I-DUR

 I-DUR
course O
. O
At O
time O
of O
discharge O
utility O
of O
repeat O
imaging O

 O
discussed O
. O
Plan O
to O
repeat O
CT O
abd/pelvis O
; O
MRI O
spine O
further O
into O

 O
antibiotic O
treatment O
. O

 O
. O

 O
# O
Febrile O
Neutropenia O

 O
. O

 O
Patient O
's O
WBC O
count O
began O
to O
slowly O
decline O
on O
[ O
* O
* O
8 O
- O
5 O
* O
* O
] O
with O

 O
progression O
to O
neutropenia O
on O
[ O
* O
* O
8 O
- O
8 O
* O
* O
] O
. O
Neutropenia B-ADE
was O
felt O

 O
secondary O
to O
medication O
effect O
; O
subsequently O
omeprazole B-DRUG
, I-DRUG

 O
furosemide B-DRUG
, I-DRUG
vancomycin B-DRUG
and O
seroquel B-DRUG
were O
discontinued O
. O

 O
Hematology O
was O
consulted O
, O
and O
felt O
that O
furosemide B-DRUG
or O
vancomycin B-DRUG

 I-DRUG
were O
likely O
offending O
agents O
. O
Antibiotic B-DRUG
coverage O
altered O
on O

 O
[ O
* O
* O
8 O
- O
8 O
* O
* O
] O
: O
vancomycin B-DRUG
discontinued O
and O
daptomycin B-DRUG
started O
for O

 O
treatment O
of O
MSSA B-REA
. I-REA
On O
[ O
* O
* O
8 O
- O
9 O
* O
* O
] O
she O
was O
febrile O
102.6 O
and O
meropenem B-DRUG

 I-DRUG
started O
for O
treatment O
of O
neutropenic B-REA
fever I-REA
. I-REA
GCSF B-DRUG
initiated O
. O

 O
After O
administration O
of O
GCSF B-DRUG
counts O
slowly O
became O
to O
rise O
and O

 O
fevers O
abated O
. O
GCSF B-DRUG
was O
stopped O
on O
[ O
* O
* O
8 O
- O
14 O
* O
* O
] O
when O
ANC>1000 O
for O
more O

 O
than O
48hrs O
. O

 O
. O

 O
Respiratory O
Distress O

 O
. O


 O
On O
admission O
patient O
found O
to O
be O
tachypnic O
. O
LENIs O
negative O
. O
On O

 O
[ O
* O
* O
7 O
- O
8 O
* O
* O
] O
, O
developed O
worsening O
tachypnea O
and O
hypoxemia O
( O
95 O
% O
on O
4L O
by O

 O
nasal O
canula O
) O
. O
The O
patient O
diureased B-REA
500ml B-DOS
on O
IV B-ROU
Lasix B-DRUG
and O

 O
improved O
slightly O
. O
CTA O
ruled O
out O
PE O
, O
however O
showed O
evidence O
of O

 O
bilateral O
loculated O
pleural O
effusions O
and O
multiple O
lung O
nodules O
. O

 O
Cardiac O
enzymes O
negative O
. O
Pro-BNP O
2777 O
on O
[ O
* O
* O
7 O
- O
8 O
* O
* O
] O
. O
Estimated O
EF O
by O

 O
TEE O
was O
> O
55 O
% O
; O
2 O
repeat O
echos O
without O
evidence O
of O
valvular O

 O
pathology O
. O
In O
MICU O
, O
IV B-ROU
Lasix B-DRUG
and O
morphine B-DRUG
lessened O
respiratory B-REA

 I-REA
distress I-REA
. I-REA
On O
[ O
* O
* O
7 O
- O
10 O
* O
* O
] O
, O
transferred O
to O
the O
floor O
; O
latered O
became O

 O
hypoxic O
and O
was O
transfered O
back O
to O
the O
MICU O
and O
started O
on O

 O
BiPAP O
. O
Pleural O
effusion O
studies O
suggested O
parapneumonic O

 O
effusion O
. O
Patient O
intubated O
and O
extubated O
several O
time O
while O
in O

 O
MICU O
. O
On O
[ O
* O
* O
7 O
- O
16 O
* O
* O
] O
, O
the O
patient O
was O
again O
extubated O
. O
She O
developed O

 O
hypertension O
to O
180 O
SBP O
and O
respiratory B-REA
distress I-REA
secondary I-REA
to I-REA

 I-REA
pulm I-REA
edema I-REA
, I-REA
which O
responded O
to O
lasix B-DRUG
and O
labetolol B-DRUG
. I-DRUG
On O
[ O
* O
* O
7 O
- O
19 O
* O
* O
] O
, O
she O

 O
was O
comfortable O
oxygenating O
with O
only O
nasal O
cannula O
. O
She O
was O

 O
electively O
intubated O
on O
[ O
* O
* O
7 O
- O
25 O
* O
* O
] O
for O
paraspinal O
abscess O
drainage O
and O

 O
extubated O
post-procedure O
. O
Unfortunately O
, O
again O
developed O

 O
worsening O
hypercarbic O
respiratory O
distress O
, O
requiring O

 O
reintubation O
on O
[ O
* O
* O
7 O
- O
27 O
* O
* O
] O
. O
  O
She O
was O
gently O
diuresed O
, O
in O
an O
effort O
to O

 O
decrease O
the O
work O
of O
breathing O
. O
On O
[ O
* O
* O
8 O
- O
3 O
* O
* O
] O
she O
was O
succesfully O

 O
extubated O
, O
satting O
well O
on O
face O
mask O
. O
On O
[ O
* O
* O
8 O
- O
5 O
* O
* O
] O
she O
was O
weaned O
to O

 O
NC O
. O
CT O
on O
[ O
* O
* O
8 O
- O
9 O
* O
* O
] O
showed O
improvement O
in O
pleural O
effusions O
and O

 O
basilar O
consolidations O
. O
She O
continued O
to O
do O
well O
on O
supplemental B-FOR

 I-FOR
oxygen B-DRUG
by O
nasal B-ROU
cannula I-ROU
. I-ROU
On O
the O
floor O
her O
oxygen O
requirement O
was O

 O
weaned O
. O
She O
had O
one O
episode O
of O
flash B-REA
pulmonary I-REA
edema I-REA
, I-REA
during O

 O
which O
she O
desaturated O
to O
high O
80s O
. O
She O
was O
diuresed B-REA
with O
bumex B-DRUG

 I-DRUG
with O
good O
effect O
. O
For O
the O
remainder O
of O
her O
stay O
, O
team O
allowed O

 O
for O
auto-diuresis O
. O
At O
time O
of O
discharge O
patient O
saturating O
94 O
% O

 O
RA O
, O
> O
95 O
% O
1L O
. O

 O
. O

 O
# O
Blood O
Pressure O

 O
. O


 O
During O
MICU O
stay O
pt O
had O
repeated O
episodes O
of O
transient O

 O
bradycardia O
and O
hypotension O
as O
well O
as O
episodes O
of O
paroxysmal O

 O
hypertension O
into O
the O
SBP O
180 O
- O
200s O
. O
Her O
hypertension B-REA
responded O

 O
to O
5mg-10 B-STR
mg I-STR
doses O
of O
IV B-ROU
labetalol B-DRUG
. I-DRUG
After O
significiant O
diuresis O
, O

 O
her O
SBP O
remained O
stable O
in O
the O
150 O
- O
160s O
. O
On O
the O
floor O
, O
BP B-REA
ran I-REA

 I-REA
consistently I-REA
high I-REA
. I-REA
Patient O
was O
started O
on O
metoprolol B-DRUG
and O

 O
amlodipine B-DRUG
. I-DRUG
These O
medications O
were O
gradually O
uptitrated O
and O
at O

 O
time O
of O
discharge O
pressures O
were O
better O
controlled O
on O
metoprolol B-DRUG

 I-DRUG
50 B-STR
mg I-STR
TID B-FRE
, I-FRE
amlopidine B-DRUG
10 B-STR
mg I-STR
QD B-FRE
. I-FRE
She O
was O
transitioned O
to O
toprol B-DRUG
xl I-DRUG

 I-DRUG
150 B-STR
mg I-STR
daily B-FRE
at O
the O
time O
of O
discharge O
. O

 O
. O

 O
# O
Nutrition O

 O
. O

 O
Patient O
underwent O
severeal O
video O
swallowing O
evaluation O
due O
to O

 O
concern O
for O
silent O
aspiration O
. O
In O
the O
MICU O
, O
several O
methods O
of O

 O
nutrition O
employed O
: O
NG O
tube O
feeds O
as O
well O
as O
PPN O
. O
On O
transfer O
to O

 O
floor O
patient O
on O
NG O
tube O
feeds O
. O
Repeat O
speech O
and O
swallow O
on O

 O
[ O
* O
* O
8 O
- O
15 O
* O
* O
] O
demonstrated O
improved O
oral O
and O
pharyngeal O
swallow O
with O

 O
continued O
swallow O
delay O
, O
premature O
spillover O
and O
reduced O
base O
of O

 O
tongue O
retraction O
. O
Patient O
continued O
to O
aspirate O
thin O
liquids O

 O
silently O
, O
but O
speech O
deemed O
it O
safe O
to O
initiate O
a O
PO O
diet O
of O

 O
nectar O
thick O
liquids O
and O
moist O
, O
ground O
solids O
with O
the O

 O
aspiration O
precautions O
documented O
below O
. O
It O
is O
important O
to O
note O

 O
aspiration O
is O
silent O
, O

 O
and O
she O
will O
need O
continued O
speech O
therapy O
follow O
up O
with O
likely O

 O
repeat O
video O
swallow O
before O
advancing O
her O
diet O
. O


 O
# O
Delirium B-REA

 I-REA
. O

 O
In O
the O
MICU O
observed O
waxing O
and O
[ O
* O
* O
Doctor O
Last O
Name O
688 O
* O
* O
] O
mental O
status O
worse O
at O

 O
night O
and O
with O
spikes O
in O
fever O
. O
Symptoms O
improved O
with O
zyprexa B-DRUG

 I-DRUG
at B-FRE
night I-FRE
. I-FRE
The O
pt O
became O
more O
alert O
following O
extubation O
on O
[ O
* O
* O
8 O
- O
3 O
* O
* O
] O
, O

 O
however O
, O
she O
had O
some O
disorientation B-REA
. I-REA
She O
received O
several O
doses O

 O
of O
seroquel B-DRUG
, I-DRUG
which O
was O
discontinued O
when O
the O
patient O
became O

 O
neutropenic B-ADE
, I-ADE
as O
it O
can O
be O
a O
potential O
cause O
of O
leukopenia B-ADE
. I-ADE
  O
Over O

 O
the O
course O
of O
the O
next O
few O
days O
, O
her O
became O
more O
alert O
and O

 O
interactive O
. O
  O
By O
time O
of O
transfer O
from O
MICU O
to O
floor O
on O
[ O
* O
* O
8 O
- O
10 O
* O
* O
] O
, O

 O
she O
was O
fully O
oriented O
and O
had O
a O
good O
understanding O
of O
the O

 O
medical O
plan O
. O
On O
the O
floor O
, O
patients O
mentation O
continued O
to O

 O
improve O
. O
At O
time O
of O
discharge O
patient O
mental O
status O
was O
clear O

 O
and O
coherent O
. O

 O
. O

 O
# O
Elbow O
mass O

 O
. O

 O
Mass O
noted O
on O
right O
elbow O
. O
  O
Derm O
consulted O
; O
felt O
to O
be O

 O
consistent O
with O
lipoma O
. O

 O
. O


 O
# O
UTI B-REA
: I-REA
  O
She O
developed O
low O
grade O
fevers O
on O
[ O
* O
* O
8 O
- O
21 O
* O
* O
] O
to O
100.4 O
, O

 O
prompting O
urinalysis O
, O
which O
demonstrated O
UTI O
. O
  O
She O
will O
complete O

 O
a O
10 B-DUR
day I-DUR
course O
of O
ciprofloxacin B-DRUG
500 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
to O
end O
[ O
* O
* O
2135 O
- O
9 O
- O
1 O
* O
* O
] O
. O


 O
Medications O
on O
Admission O
: O

 O
None O


 O
Discharge O
Medications O
: O

 O
. O

 O
1 O
. O
Fentanyl B-DRUG
25 B-STR
mcg/hr I-STR
Patch B-FOR
72 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Patch B-FOR
72 I-FOR
hr I-FOR

 I-FOR
Transdermal B-ROU
Q72H B-FRE
( I-FRE
every I-FRE
72 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Amlodipine B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
3 O
. O
Daptomycin B-DRUG
500 B-STR
mg I-STR
Recon B-FOR
Soln I-FOR
Sig O
: O
Six B-DOS
Hundred I-DOS
( I-DOS
600 I-DOS
) I-DOS
Recon B-FOR

 I-FOR
Soln I-FOR
Intravenous B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Heparin B-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
5,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Injection B-FOR
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
fever/pain B-REA
. I-REA

 O
6 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE

 I-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Heparin B-DRUG
Flush B-FOR
( O
10 B-STR
units/ml I-STR
) I-STR
2 B-DOS
mL I-DOS
IV B-ROU
PRN B-FRE
line B-REA
flush I-REA

 I-REA
PICC B-ROU
, I-ROU
heparin B-DRUG
dependent O
: O
Flush O
with O
10mL B-DOS
Normal B-DRUG
Saline I-DRUG
followed O

 O
by O
Heparin B-DRUG
as O
above O
daily B-FRE
and O
PRN B-FRE
per O
lumen B-ROU
. I-ROU

 O
8 O
. O
Outpatient O
Lab O
Work O

 O
Please O
check O
weekly O
CBC O
with O
differential O
, O
BUN/Cr O
, O
LFTs O
, O
CK O
, O

 O
ESR/CRP O

 O
. O

 O
All O
laboratory O
results O
should O
be O
faxed O
to O
Infectious O
disease O

 O
R.Ns O
. O
at O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1353 O
* O
* O
] O


 O
9 O
. O
Lidocaine B-DRUG
5 B-STR
% I-STR
( I-STR
700 I-STR
mg/patch I-STR
) I-STR
Adhesive B-FOR
Patch I-FOR
, I-FOR
Medicated I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Adhesive B-FOR
Patch I-FOR
, I-FOR
Medicated I-FOR
Topical B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Lidocaine B-DRUG
5 B-STR
% I-STR
( I-STR
700 I-STR
mg/patch I-STR
) I-STR
Adhesive B-FOR
Patch I-FOR
, I-FOR
Medicated I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Adhesive B-FOR
Patch I-FOR
, I-FOR
Medicated I-FOR
Topical B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Lorazepam B-DRUG
0.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE

 I-FRE
bedtime I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
anxiety B-REA
. I-REA

 O
12 O
. O
OXYGEN B-DRUG

 I-DRUG
At O
time O
of O
discharge O
patient O
requires O
1L B-DOS
nasal B-ROU
cannula I-ROU
for O

 O
comfort B-REA
. I-REA



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
105 O
* O
* O
] O
Northeast O
- O
[ O
* O
* O
Location O
( O
un O
) O
1110 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
PRIMARY O

 O
Methicillin O
Sensitive O
Staph O
Aureus O
Bacteremia O


 O
SECONDARY O

 O
Hypertension O

 O
Anemia O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O



 O
Discharge O
Instructions O
: O

 O
Dear O
Ms O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
it O
was O
a O
pleasure O
taking O
care O
of O
you O
. O

 O
. O


 O
You O
were O
initially O
admitted O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
due O
to O
symptoms O
of O
back O

 O
pain O
. O
Upon O
imaging O
it O
was O
found O
that O
you O
had O
several O
abscesses O

 O
throughout O
your O
spine O
as O
well O
as O
in O
your O
right O
knee O
. O
You O

 O
underwent O
several O
surgeries O
to O
evacuate O
these O
infection B-REA
and O
you O

 O
were O
also O
started O
on O
antibiotics B-DRUG
. I-DRUG
Your O
antibiotic B-DRUG
regimen O
was O

 O
altered O
several O
times O
due O
to O
significant O
side O
effects O
. O
You O

 O
experienced O
a O
rash B-ADE
after O
Nafcillin B-DRUG
, I-DRUG
and O
Vancomyocin B-DRUG
was O
thought O

 O
to O
contribute O
to O
low B-ADE
cell I-ADE
counts I-ADE
. I-ADE
You O
were O
placed O
on O
Daptomycin B-DRUG

 I-DRUG
without O
side O
effect O
for O
a O
planned O
8week B-DUR
course O
. O
A O
PICC B-ROU
line O
was O

 O
placed O
prior O
to O
discharge O
to O
faciliate O
antibiotic B-DRUG
administration O

 O
as O
an O
outpatient O
. O
You O
will O
receive O
repeat O
imaging O
after O

 O
completion O
of O
your O
antibiotic B-DRUG
therapy O
for O
interval O
evaluation O
of O

 O
infection B-REA
. I-REA

 O
. O

 O
Unfortunately O
, O
side O
effects O
from O
various O
medications O
prolonged O

 O
your O
hospital O
course O
. O
It O
was O
thought O
that O
a O
combination O
of O

 O
vancomycin B-DRUG
and O
lasix B-DRUG
contributed O
to O
decreased B-ADE
white I-ADE
blood I-ADE
cells I-ADE

 I-ADE
( I-ADE
WBC I-ADE
) I-ADE
. I-ADE
While O
your O
WBC B-REA
counts I-REA
were I-REA
low I-REA
you O
were O
placed O
on O
broad O

 O
spectrum O
antibiotics B-DRUG
to B-REA
protect I-REA
you I-REA
from I-REA
infection I-REA
. I-REA
We O

 O
discontinued O
the O
medications O
we O
felt O
responsible O
for O
declining B-ADE

 I-ADE
counts I-ADE
( O
lasix B-DRUG
and O
vancomycin B-DRUG
) I-DRUG
and O
also O
administered O
a O
medication O

 O
called O
Neupogen B-DRUG
to B-REA
increase I-REA
WBC I-REA
production I-REA
. I-REA
After O
several O
days O

 O
of O
Neupogen B-DRUG
treatment O
your O
white O
cell O
counts O
increased O
and O

 O
stabilized O
. O
Neupogen B-DRUG
as O
well O
as O
broad O
spectrum O
antibiotics B-DRUG
were O

 O
discontinued O
prior O
to O
discharge O
. O

 O
. O

 O
We O
also O
found O
your O
blood O
pressures O
to O
be O
elevated O
at O
times O

 O
during O
your O
hospitalization O
. O
You O
were O
started O
on O
medications O
, O

 O
metoprolol B-DRUG
and O
amlodipine B-DRUG
, I-DRUG
to B-REA
better I-REA
control I-REA
your I-REA
blood I-REA

 I-REA
pressure I-REA
. I-REA

 O
. O

 O
Regarding O
nutrition O
, O
after O
extubation O
you O
were O
noted O
to O
have O

 O
difficultly O
swallowing O
. O
Speech O
and O
swallow O
was O
consulted O
and O

 O
after O
several O
attempts O
you O
completed O
and O
passed O
your O
evaluation O
. O

 O
After O
completion O
, O
you O
were O
started O
on O
a O
thickened O
nectar O
liquid O

 O
regimen O
and O
a O
soft O
, O
ground O
solid O
diet O
. O
You O
will O
need O
repeat O

 O
speech O
and O
swallow O
evaluation O
at O
rehab O
. O

 O
. O

 O
CHANGES O
TO O
YOUR O
MEDICATIONS O
. O

 O
On O
arrival O
to O
the O
hospital O
you O
were O
no O
prescription O
medications O
. O

 O
. O

 O
MEDICATIONS O
WE O
STARTED O

 O
. O

 O
--To O
treat O
your O
infection O
we O
STARTED O
Daptomycin B-DRUG
600 B-STR
mg I-STR
IV B-ROU
Q24 B-FRE

 I-FRE
( O
start O
date O
: O
[ O
* O
* O
2135 O
- O
7 O
- O
26 O
* O
* O
] O
, O
stop O
date O
: O
[ O
* O
* O
2135 O
- O
9 O
- O
19 O
* O
* O
] O
( O
total O
8 B-DUR
weeks I-DUR
) I-DUR
) O

 O
. O


 O
--To O
treat O
PAIN B-REA
we O
STARTED O
: O

  O
1 O
. O
FENTANYL B-DRUG
25 B-STR
mcg/hr I-STR
Patch B-FOR
, I-FOR
which O
can O
be O
reapplied O
every B-FRE
72 I-FRE

 I-FRE
hr I-FRE
; I-FRE

  O
2 O
. O
Two B-DOS
LIDOCAINE B-DRUG
5 B-STR
% I-STR
( I-STR
700 I-STR
mg/patch I-STR
) I-STR
Adhesive B-FOR
Patchs I-FOR
, I-FOR
Apply O
each O

 O
Adhesive B-FOR
Patch I-FOR
daily B-FRE
to O
back B-ROU

  I-ROU
3 O
. O
ACETAMINOPHEN B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
; I-FOR
you O
can O
take O
1 B-DOS
- I-DOS
2 I-DOS
tablets B-FOR
by B-ROU

 I-ROU
mouth I-ROU
every B-FRE
6 I-FRE
hours I-FRE
. I-FRE

 O
. O

 O
--To O
treat O
your O
high B-REA
blood I-REA
pressure I-REA
we O
started O
: O

  O
1 O
. O
AMLODIPINE B-DRUG
10 B-STR
mg I-STR
daily B-FRE
; I-FRE
you O
will O
take O
two B-DOS
5 B-STR
mg I-STR
tablets B-FOR
daily B-FRE

  I-FRE
2 O
. O
Metoprolol B-DRUG
succinate I-DRUG
( I-DRUG
toprol I-DRUG
XL I-DRUG
) I-DRUG
150 B-STR
mg I-STR
tablet B-FOR
daily B-FRE

 I-FRE
. O

 O
-- O
To O
prevent B-REA
blood I-REA
clot I-REA
formation I-REA
while O
you O
heal O
and O
are O

 O
relatively O
limited O
in O
your O
movement O
you O
will O
continue O
to O

 O
receive O
: O
Heparin B-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
  O
5,000 B-STR
unit/mL I-STR
Solution B-FOR
  O
Injections B-ROU

 I-ROU
three B-FRE
times I-FRE
a I-FRE
day I-FRE

 I-FRE
. O

 O
--To O
help O
treat O
your O
anxiety B-REA
we O
started O
: O

 O
1 O
. O
Lorazepam B-DRUG
  O
0.5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
you O
can O
take O
one B-DOS
0.5 B-DOS
tablet B-FOR
by B-ROU

 I-ROU
mouth I-ROU
at O
at B-FRE
bedtime I-FRE
as I-FRE
needed I-FRE
for O
anxiety B-REA
. I-REA

 O
. O

 O
You O
will O
need O
Outpatient O
Lab O
Work O
which O
your O
facility O
can O
obtain O

 O
and O
fax O
to O
[ O
* O
* O
Hospital O
* O
* O
] O
clinic O

 O
. O

 O
New O
allergies O
: O
LASIX B-DRUG
- O
contraindication O
- O
neutropenia B-ADE

                I-ADE
NAFCILLIN B-DRUG
- O
contraindication O
- O
rash B-ADE

                I-ADE
VANCOMYCIN B-DRUG
( O
relative O
contraindication O
) O
- O

 O
neutropenia B-ADE





 I-ADE
Followup O
Instructions O
: O

 O
Department O
: O
INFECTIOUS O
DISEASE O

 O
When O
: O
FRIDAY O
[ O
* O
* O
2135 O
- O
9 O
- O
16 O
* O
* O
] O
at O
11:00 O
AM O

 O
With O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
27625 O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
457 O
* O
* O
] O

 O
Building O
: O
LM O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
Bldg O
( O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
) O
[ O
* O
* O
Hospital O
1422 O
* O
* O
] O

 O
Campus O
: O
WEST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
Garage O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2148 O
- O
10 O
- O
13 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2148 O
- O
10 O
- O
15 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2097 O
- O
9 O
- O
27 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
[ O
* O
* O
Doctor O
First O
Name O
147 O
* O
* O
] O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
668 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Dislodged O
Dophoff O
feeding O
tube O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Placement O
of O
dophoff O
catheter O
under O
fluro O



 O
History O
of O
Present O
Illness O
: O

 O
Pt O
with O
episode O
of O
hiccups O
, O
which O
pt O
had O
c/o O
for O
many O
months O
, O

 O
resulting O
in O
the O
dislodging O
of O
his O
dophoff O
feeding O
tube O


 O
Past O
Medical O
History O
: O

 O
anemia O

 O
Hepatitis O
C O

 O
CHF O

 O
CRI O

 O
DVT O

 O
portal O
hypertension O

 O
Depression O



 O
Social O
History O
: O

 O
Lives O
at O
[ O
* O
* O
Hospital O
106240 O
* O
* O
] O
Rehab O
Centersmoking O
15pack O
year O
hitoryno O

 O
etohremote O
IVDformer O
[ O
* O
* O
Company O
2318 O
* O
* O
] O
worker O


 O
Family O
History O
: O

 O
noncontributary O



 O
Physical O
Exam O
: O

 O
NAD O

 O
AAO O
times O
3 O

 O
RRR O
S1+S2 O

 O
CTA O
Bilat O

 O
Soft O
NT/ND O
, O
incision O
healing O
well O


 O
Pertinent O
Results O
: O

 O
US O
ABD O
LIMIT O
, O
SINGLE O
ORGAN O
  O
[ O
* O
* O
2148 O
- O
10 O
- O
14 O
* O
* O
] O
2:33 O
PM O

 O
REPORT O
: O
There O
is O
a O
dumb-bell O
shaped O
collection O
in O
the O

 O
gallbladder O
fossa O
which O
contains O
complex O
internal O
echoes O
. O
Each O

 O
of O
the O
limbs O
of O
the O
collection O
measure O
approximately O
4 O
cm O
in O

 O
diameter O
each O
. O
The O
lesion O
passes O
close O
to O
the O
stomach O

 O
posteriorly O
but O
is O
extragastric O
. O

 O
The O
liver O
parenchyma O
appears O
normal O
throughout O
. O
No O
focal O
hepatic O

 O
mass O
is O
identified O
otherwise O
. O
No O
subcapsular O
lesion O
is O
seen O
. O

 O
Status O
post O
cholecystectomy O
. O
The O
common O
bile O
duct O
measures O
7 O
mm O

 O
in O
maximum O
dimensions O
. O
The O
right O
kidney O
appears O
normal O
in O
size O

 O
shape O
and O
echotexture O
. O

 O
Doppler O
ultrasound O
. O
Doppler O
ultrasound O
was O
performed O
of O
the O

 O
anastomosed O
vessels O
. O
The O
hepatic O
veins O
appear O
normal O
. O
There O

 O
appears O
to O
be O
a O
clip O
intimately O
related O
to O
the O
middle O
hepatic O

 O
vein O
which O
appears O
narrowed O
at O
this O
point O
. O
Portal O
vein O
is O
patent O

 O
with O
centrifugal O
flow O
. O
The O
hepatic O
arteries O
have O
not O
been O

 O
examined O
. O



 O

Brief O
Hospital O
Course O
: O

 O
Pt O
admitted O
on O
[ O
* O
* O
10 O
- O
13 O
* O
* O
] O
after O
dophoff O
tube O
was O
accidentally O
d/c'd O

 O
after O
a O
episode O
of O
hiccups O
. O
A O
NG O
tube O
was O
placed O
on O
admission O
. O

 O
Pt O
had O
an O
episode O
of O
nausea O
and O
emesis O
around O
the O
tube O
. O
A O

 O
dophoff O
was O
placed O
on O
[ O
* O
* O
10 O
- O
14 O
* O
* O
] O
and O
the O
nausea O
and O
emesis O
resolved O
. O

 O
A O
RUQ O
US O
was O
performed O
which O
showed O
an O
evolving O
collection O
in O

 O
the O
gallbladder O
fossa O
but O
was O
otherwise O
unremarkable O
. O
Pt O

 O
improved O
and O
was O
D/C'd O
to O
return O
to O
rehab O
on O
[ O
* O
* O
10 O
- O
15 O
* O
* O
] O


 O
Discharge O
Medications O
: O

 O
1 O
. O
CellCept B-DRUG
[ O
* O
* O
Pager O
number O
* O
* O
] O
mg O
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE


 O
2 O
. O
Megestrol B-DRUG
Acetate I-DRUG
40 B-STR
mg/mL I-STR
Suspension B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
PO B-ROU
QID B-FRE
( I-FRE
4 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Lansoprazole B-DRUG
30 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
QD B-FRE
( I-FRE
once I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Methylphenidate B-DRUG
HCl I-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1.5 B-DOS
Tablets B-FOR
PO B-ROU
QD B-FRE
( I-FRE
once I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Hydralazine B-DRUG
HCl I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE

 I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
Levothyroxine B-DRUG
Sodium I-DRUG
150 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QD B-FRE

 I-FRE
( I-FRE
once I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Mirtazapine B-DRUG
15 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE

 I-FRE
bedtime I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Ribavirin B-DRUG
200 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
QD B-FRE
( I-FRE
once I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1.5 B-DOS
Tablets B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Valganciclovir B-DRUG
HCl I-DRUG
450 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Trimethoprim-Sulfamethoxazole B-DRUG
80 B-STR
- I-STR
400 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
QD B-FRE
( I-FRE
once I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Interferon B-DRUG
alfacon-1 I-DRUG
30 B-STR
mcg/mL I-STR
Injectable B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Subcutaneous B-ROU
TIW B-FRE
( O
) O
. O

 O
13 O
. O
Tacrolimus B-DRUG
1 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE


 O
14 O
. O
Prednisone B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QD B-FRE
( I-FRE
once I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
15 O
. O
Insulin B-DRUG
Lispro I-DRUG
( I-DRUG
Human I-DRUG
) I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Subcutaneous B-ROU
ASDIR B-FRE
( I-FRE
AS I-FRE
DIRECTED I-FRE
) I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
7 O
* O
* O
] O
& O
Rehab O
Center O
- O
[ O
* O
* O
Hospital1 O
8 O
* O
* O
] O



 O
Discharge O
Diagnosis O
: O

 O
Dislodged O
Dophoff O
feeding O
tube O



 O
Discharge O
Condition O
: O

 O
stable O


 O
Discharge O
Instructions O
: O

 O
Please O
return O
for O
all O
follow-up O
appointments O

 O
Take O
all O
medications O
as O
directed O
, O
and O
resume O
all O
previous O

 O
medications O

 O
Return O
to O
the O
ER O
if O
any O
increased O
pain O
, O
nausea O
and O
vomitting O
, O

 O
fevers O
, O
diarrhea O
, O
chest O
pain O
, O
or O
shortness O
of O
breath O


 O
Followup O
Instructions O
: O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
MD O
Where O
: O
LM O
[ O
* O
* O
Hospital O
Unit O
Name O
5628 O
* O
* O
] O

 O
Phone:[**Telephone/Fax O
( O
1 O
) O
673 O
* O
* O
] O
Date/Time:[**2148 O
- O
10 O
- O
16 O
* O
* O
] O
2:20 O




 O
Completed O
by:[**2148 O
- O
10 O
- O
15 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2107 O
- O
9 O
- O
30 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2027 O
- O
2 O
- O
6 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
99 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Hypotension O



 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
On O
pressor B-DRUG
support O

 O
Central O
line O
placement O

 O
PICC O
line O
placement O

 O
Post-pyloric O
feeding O
tube O
placement O

 O
Transfusion O
of O
packed B-DRUG
RBC I-DRUG



 I-DRUG
History O
of O
Present O
Illness O
: O

 O
80 O
yo O
male O
with O
hx O
of O
schizophrenia O
, O
dementia O
was O
admitted O
to O

 O
MICU O
from O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
after O
being O
found O
to O
be O
septic O
. O
Patient O
was O

 O
being O
transported O
to O
[ O
* O
* O
Hospital1 O
336**]/[**Hospital1 O
* O
* O
] O
for O
evaluation O
of O
vomiting O
x O

 O
few O
days O
( O
2 O
or O
4 O
days O
, O
depending O
on O
whose O
report O
you O
read O
) O
. O
He O

 O
was O
only O
responsive O
to O
verbal O
stimuli O
per O
EMS O
notes O
. O
and O
per O

 O
evaluation O
from O
the O
ambulance O
, O
his O
BP O
was O
70/30 O
, O
RR O
30s O
and O
HR O

 O
60s O
. O
Of O
note O
, O
patient O
has O
been O
having O
poor O
appetite O
x O
4 O
days O
. O

 O
KUB O
was O
apparently O
negative O
for O
obstruction O
. O

 O
. O

 O
From O
his O
RN O
home O
, O
he O
was O
noted O
to O
have O
: O

 O
- O
Cr O
of O
2.9 O
BUN O
of O
65 O
on O
[ O
* O
* O
2107 O
- O
9 O
- O
24 O
* O
* O
] O
and O
digoxin B-DRUG
level O
of O
1.5 O

 O
- O
INR O
of O
1.07 O
on O
[ O
* O
* O
2107 O
- O
9 O
- O
24 O
* O
* O
] O
and O
Pt O
of O
11.6 O

 O
. O

 O
In O
the O
ED O
: O

 O
He O
was O
alert O
and O
following O
commands O
. O
Initially O
BP O
responded O
to O

 O
fluids O
and O
was O
in O
the O
110s O
, O
then O
dropped O
to O
67/59 O
- O
started O
on O

 O
dopamine B-DRUG
. I-DRUG

 O
He O
was O
also O
initially O
bradycardic O
to O
the O
40s-50s O
( O
but O
then O
110s O

 O
for O
unclear O
reasons O
) O
. O
Dopamine B-DRUG
was O
titrated O
to O
10mcg/kg/min B-STR
and O

 O
then O
was O
placed O
on O
levophed B-DRUG
at O
0.5mcg/kg/min B-STR
and O
then O
titrated O

 O
up O
to O
3mcg/kg/min B-STR
. I-STR
On O
arrival O
to O
the O
floor O
, O
he O
was O
on O
only O

 O
Levophed B-DRUG
at O
3mcg/kg/min B-STR
. I-STR

 O
- O
increased O
pulmonary O
congestion O
and O
BiPAP O
was O
applied O
. O

 O
- O
received O
7L B-DOS
NS B-DRUG
in O
ED O

 O
- O
got O
Levo/Flagyl/Vanco B-DRUG

 I-DRUG
. O

 O
Access O
: O
A O
L O
groin O
was O
attempted O
. O
Then O
a O
R O
IJ O
was O
attempted O
- O

 O
which O
led O
to O
guidewire O
getting O
stuck O
in O
the O
IVC O
filter O
. O
This O
was O

 O
removed O
by O
Vascular O
Surgery O
. O
Finally O
, O
a O
R O
femoral O
line O
was O

 O
placed O
. O



 O
Past O
Medical O
History O
: O

 O
CAD O

 O
CHF O

 O
PVD O

 O
Dementia O

 O
Schizophrenia O

 O
CRI O

 O
Cardiac O
Dysrhythmias O



 O

Social O
History O
: O

 O
Lives O
at O
long-term O
care O
facility O
. O
  O
Sister O
, O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
976 O
* O
* O
] O
, O
is O

 O
his O
[ O
* O
* O
Name O
( O
NI O
) O
5993 O
* O
* O
] O
. O


 O
Family O
History O
: O

 O
Non-contributory O


 O
Physical O
Exam O
: O

 O
T:99.4 O
  O
BP:109/62 O
  O
P:112 O
   O
RR:28 O
   O
O2 O
sats:95 O
% O
BiPAP O

 O
Gen O
: O
Elderly O
man O
with O
nonsensical O
speech O

 O
HEENT O
: O

 O
CV O
: O
+ O
s1+s2 O
Quiet O
heart O
sounds O
. O
No O
murmurs O
appreciated O
. O

 O
Resp O
: O
Mild O
crackles O
and O
decreased O
sounds O
at O
lung O
bases O
. O

 O
Abd O
: O
Soft O
NT O
ND O

 O
Skin O
: O
Warm O
. O
Perfused O
. O

 O
Ext O
: O
RLE O
with O
cellulitis O
from O
area O
below O
knee O
to O
above O
the O
ankle O

 O
with O
area O
of O
increased O
erythema O
around O
R O
medial O
malleolus O
. O

 O
- O
+ O
DP O
and O
PT O
pulses O
B/L O
- O
need O
doppler O
to O
identify O
. O

 O
Neuro O
: O
Patient O
moving O
extremities O
x O
4 O

 O
. O

 O
EKG O
: O
Tachycardia O
w/ O
RBBB O


 O
Pertinent O
Results O
: O

 O
Labs O
on O
admission O
: O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
08:59PM O
BLOOD O
WBC-17.0 O
* O
RBC-3.77 O
* O
Hgb-11.8 O
* O
Hct-35.4 O
* O

 O
MCV-94 O
MCH-31.3 O
MCHC-33.3 O
RDW-15.9 O
* O
Plt O
Ct-180 O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
08:59PM O
BLOOD O
Neuts-76 O
* O
Bands-4 O
Lymphs-6 O
* O
Monos-5 O

 O
Eos-6 O
* O
Baso-3 O
* O
Atyps-0 O
Metas-0 O
Myelos-0 O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
08:59PM O
BLOOD O
PT-16.8 O
* O
PTT-27.4 O
INR(PT)-1.6 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
02:05AM O
BLOOD O
Fibrino-477 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
02:05AM O
BLOOD O
D-Dimer-2929 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
08:59PM O
BLOOD O
Glucose-117 O
* O
UreaN-81 O
* O
Creat-5.6 O
* O
Na-151 O
* O

 O
K-4.3 O
Cl-108 O
HCO3 O
- O
25 O
AnGap-22 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
08:59PM O
BLOOD O
CK(CPK)-124 O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
08:59PM O
BLOOD O
CK-MB-3 O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
08:59PM O
BLOOD O
cTropnT-0.67 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
08:59PM O
BLOOD O
Calcium-9.1 O
Phos-4.0 O
Mg-3.6 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
03:47AM O
BLOOD O
Cortsol-27.4 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
11:25PM O
BLOOD O
Digoxin-1.3 O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
11:40PM O
BLOOD O
Type-[**Last O
Name O
( O
un O
) O
* O
* O
] O
pO2 O
- O
140 O
* O
pCO2 O
- O
45 O
pH-7.28 O
* O

 O
calTCO2 O
- O
22 O
Base O
XS--5 O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
09:00PM O
BLOOD O
Lactate-4.3 O
* O

 O
. O


 O
Pertinent O
labs O
during O
hospital O
course O
: O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
08:14AM O
BLOOD O
CK(CPK)-372 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
04:00PM O
BLOOD O
CK(CPK)-357 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
27 O
* O
* O
] O
06:00AM O
BLOOD O
CK(CPK)-242 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
08:14AM O
BLOOD O
CK-MB-14 O
* O
MB O
Indx-3.8 O
cTropnT-1.22 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
04:00PM O
BLOOD O
CK-MB-11 O
* O
MB O
Indx-3.1 O
cTropnT-0.90 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
27 O
* O
* O
] O
06:00AM O
BLOOD O
CK-MB-6 O
cTropnT-0.57 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
28 O
* O
* O
] O
08:40AM O
BLOOD O
calTIBC-156 O
* O
VitB12 O
- O
1080 O
* O
Folate-13.8 O

 O
Ferritn-543 O
* O
TRF-120 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
01:15PM O
BLOOD O
Triglyc-125 O
HDL-28 O
CHOL/HD-3.9 O
LDLcalc-55 O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
11:40PM O
BLOOD O
Glucose-113 O
* O
Lactate-2.9 O
* O
Na-149 O
* O
K-4.0 O

 O
Cl-118 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
08:24AM O
BLOOD O
Lactate-1.3 O

 O
. O

 O
Labs O
on O
discharge O
: O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
30 O
* O
* O
] O
02:57AM O
BLOOD O
WBC-8.5 O
RBC-3.54 O
* O
Hgb-10.6 O
* O
Hct-32.3 O
* O

 O
MCV-91 O
MCH-30.0 O
MCHC-32.9 O
RDW-15.8 O
* O
Plt O
Ct-203 O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
30 O
* O
* O
] O
02:57AM O
BLOOD O
Neuts-71.6 O
* O
Lymphs-16.1 O
* O
Monos-3.7 O

 O
Eos-8.0 O
* O
Baso-0.6 O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
30 O
* O
* O
] O
02:57AM O
BLOOD O
PT-13.9 O
* O
PTT-29.8 O
INR(PT)-1.2 O
* O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
30 O
* O
* O
] O
02:57AM O
BLOOD O
Glucose-125 O
* O
UreaN-14 O
Creat-1.1 O
Na-138 O

 O
K-3.7 O
Cl-109 O
* O
HCO3 O
- O
19 O
* O
AnGap-14 O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
28 O
* O
* O
] O
04:12AM O
BLOOD O
ALT-13 O
AST-27 O
AlkPhos-82 O
TotBili-0.4 O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
30 O
* O
* O
] O
02:57AM O
BLOOD O
Calcium-8.3 O
* O
Phos-2.1 O
* O
Mg-1.7 O

 O
. O


 O
Microbiology O
: O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
Blood O
cx O
: O
2/2 O
bottles O
coag O
neg O
staph O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
Urine O
cx O
: O
  O
mixed O
flora O
, O
contaminant O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
Blood O
cx O
: O
  O
NGTD O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
Urine O
legionella O
: O
  O
negative O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
27 O
* O
* O
] O
Blood O
cx O
: O
  O
NGTD O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
27 O
* O
* O
] O
Sputum O
cx O
: O
  O
oropharyngeal O
flora O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
27 O
* O
* O
] O
Catheter O
tip O
cx O
: O
  O
Multimicrobial O
bacteria O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
28 O
* O
* O
] O
Blood O
cx O
: O
  O
NGTD O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
28 O
* O
* O
] O
Urine O
cx O
: O
  O
Negative O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
29 O
* O
* O
] O
Urine O
cx O
: O
  O
Negative O

 O
. O

 O
Imaging O
: O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
25 O
* O
* O
] O
CXR O
: O

 O
CHEST O
, O
SINGLE O
VIEW O
: O
No O
prior O
for O
comparison O
. O
  O
Lung O
volumes O
are O

 O
low O
. O
  O
The O

 O
cardiac O
shadow O
is O
slightly O
enlarged O
. O
  O
Aorta O
is O
ectatic O
. O

 O
Considerable O
right O
lung O
volume O
loss O
with O
collapse O
of O
right O
lower O

 O
lobe O
and O
partial O
atelectasis O
right O
middle O
lobe O
with O
questionable O

 O
cut-off O
of O
bronchus O
intermedius O
. O
Although O
possibly O
due O
to O

 O
secretions O
, O
an O
obstructing O
neoplastic O
mass O
should O
be O
considered O
. O

 O
Initial O
further O
evaluation O
with O
PA O
and O
lateral O
CXR O
is O

 O
recommended O
. O
If O
persistent O
, O
contrast-enhanced O
CT O
would O
be O

 O
recommended O
. O

 O
. O


 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
ECHOCARDIOGRAM O
: O

 O
Conclusions O
: O

 O
The O
left O
atrium O
is O
moderately O
dilated O
. O
Normal O
left O
ventricular O

 O
wall O

 O
thicknesses O
and O
cavity O
size O
. O
There O
is O
moderate O
regional O
left O

 O
ventricular O

 O
systolic O
dysfunction O
with O
akinesis O
of O
the O
distal O
half O
of O
the O

 O
inferior O
, O
septal O
, O
and O
anterior O
walls O
. O
The O
remaining O
segments O
are O

 O
mildly O
hypokinetic O
. O
Right O
ventricular O
chamber O
size O
and O
free O
wall O

 O
motion O
are O
normal O
. O
The O
aortic O
valve O
leaflets O
are O
moderately O

 O
thickened O
. O
There O
is O
moderate O
to O
severe O
aortic O
valve O
stenosis O
. O

 O
Mild O
( O
1 O
+ O
) O
aortic O
regurgitation O
is O
seen O
. O
The O
mitral O
valve O

 O
leaflets O
are O
mildly O
thickened O
. O
Mild O
to O
moderate O
( O
[**12 O
- O
13**]+ O
) O
mitral O

 O
regurgitation O
is O
seen O
. O
There O
is O
mild O
pulmonary O
artery O
systolic O

 O
hypertension O
. O
There O
is O
no O
pericardial O
  O
effusion O
. O

 O
IMPRESSION O
: O
Normal O
left O
ventricular O
cavity O
size O
with O
extensive O

 O
regional O

 O
dysfunction O
c/w O
multivessel O
coronary O
disease O
. O
Moderate O
to O
severe O

 O
aortic O
valve O
stenosis O
. O
Mild O
aortic O
regurgitation O
. O
Pulmonary O

 O
artery O
systolic O
hypertension O
. O

 O
Based O
on O
[ O
* O
* O
2097 O
* O
* O
] O
AHA O
endocarditis O
prophylaxis O
recommendations O
, O
the O

 O
echo O
findings O
indicate O
a O
moderate O
risk O
( O
prophylaxis O

 O
recommended O
) O
. O
Clinical O
decisions O
regarding O
the O
need O
for O

 O
prophylaxis O
should O
be O
based O
on O
clinical O
and O
echocardiographic O

 O
data O
. O

 O
. O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
26 O
* O
* O
] O
Bilateral O
lower O
extremity O
ultrasound O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
  O
Right O
deep O
venous O
thrombosis O
of O
indeterminate O
age O
( O
old O
clot O

 O
per O
radiology O
) O

 O
2 O
. O
  O
No O
evidence O
of O
deep O
venous O
thrombosis O
involving O
the O
left O

 O
lowerextremity O
. O

 O
. O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
27 O
* O
* O
] O
CXR O
: O

 O
CONCLUSION O
: O
  O
Short-interval O
improvement O
in O
the O
aeration O
of O
the O

 O
right O
lower O

 O
lung O
field O
, O
with O
some O
residual O
opacities O
present O
in O
the O
right O

 O
infrahilar O

 O
region O
. O

 O
. O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
30 O
* O
* O
] O
PICC O
line O
placement O
. O

 O
. O

 O
[ O
* O
* O
2107 O
- O
9 O
- O
30 O
* O
* O
] O
nasogastric O
tube O
placement O
. O



 O
Brief O
Hospital O
Course O
: O

 O
Patient O
is O
an O
80 O
year O
old O
male O
with O
history O
of O
CAD O
, O
CHF O
, O

 O
dementia O
, O
schizophrenia O
, O
chronic O
renal O
insufficiency O
, O
cardiac O

 O
dysrythmia O
who O
was O
admitted O
for O
sepsis O
. O

 O
. O


 O
1 O
. O
Septic O
shock/infectious O
disease O
issues O
: O
Patient O
presented O

 O
from O
his O
nursing O
home O
with O
hypotension O
, O
leukocytosis O
, O
acute O
on O

 O
chronic O
renal O
failure O
, O
indicating O
sepsis O
. O
  O
Initial O
studies O

 O
demonstrated O
CXR O
with O
right O
lower O
lobe O
pneumonia O
, O
and O
u/a O
that O

 O
was O
positive O
. O
  O
Patient O
also O
with O
some O
cellulitis O
in O
left O
lower O

 O
extremity O
. O
  O
Therefore O
, O
intially O
thought O
source O
of O
sepsis O
was O

 O
pneumonia O
vs O
UTI O
vs O
cellulitis O
. O
  O
Cortisol O
stimulation O
test O
was O

 O
negative O
, O
ruling O
out O
adrenal O
insufficiency O
on O
admission O
. O
  O
The O

 O
patient O
was O
fluid O
rescusitated O
and O
initially O
started O
on O
levaphed B-DRUG

 I-DRUG
for O
pressor B-REA
support I-REA
. I-REA
  O
He O
was O
maintained O
on O
vancomycin B-DRUG
and O
zosyn B-DRUG

 I-DRUG
for O
broad B-REA
spectrum I-REA
antibiotics I-REA
coverage I-REA
. I-REA

 O
Shortly O
after O
admission O
, O
patient O
had O
improved O
blood O
pressure O
and O

 O
levaphed B-DRUG
pressor O
was O
weaned O
off O
. O
  O
Blood O
cultures O
from O
admission O

 O
grew O
coag O
negative O
staph O
, O
2/2 O
bottles O
, O
likely O
source O
of O
this O

 O
infection O
being O
his O
left O
lower O
extremity O
cellulitis B-REA
. I-REA
  O
Therefore O

 O
he O
was O
maintained O
on O
vancomycin B-DRUG
to O
complete O
a O
14 B-DUR
day I-DUR
course I-DUR
. I-DUR

 O
Wound O
care O
nursing O
was O
also O
consulted O
and O
dressing O
changes O
were O

 O
applied O
per O
their O
recommendations O
. O

 O
For O
his O
pneumonia B-REA
, I-REA
sputum O
culture O
did O
not O
grow O
any O
bacteria O
. O

 O
Urine O
legionella O
antigen O
was O
negative O
. O
  O
Therefore O
patient O
was O

 O
empirically O
treated O
with O
vancomycin B-DRUG
to O
complete O
a O
14 B-DUR
day I-DUR
course I-DUR
, I-DUR

 O
as O
above O
, O
and O
zosyn B-DRUG
, I-DRUG
which O
was O
converted O
to O
levofloxacin B-DRUG
on O

 O
discharge O
, O
for O
gram B-REA
negative I-REA
coverage I-REA
to O
complete O
a O
7 B-DUR
day I-DUR

 I-DUR
course I-DUR
. I-DUR

 O
For O
his O
presumed O
UTI B-REA
, I-REA
the O
patient O
had O
2 O
positive O
U/A O
's O
during O

 O
the O
hospital O
course O
, O
with O
negative O
urine O
cultures O
. O
  O
The O
3rd O
u/a O

 O
prior O
to O
discharge O
was O
negative O
, O
with O
a O
corresponding O
negative O

 O
culture O
. O

 O
Therefore O
, O
upon O
discharge O
, O
patient O
had O
a O
very O
stable O
blood O

 O
pressure O
, O
stable O
oxygenation O
off O
of O
oxygen O
, O
and O
was O
discharged O

 O
on O
vancomycin B-DRUG
to O
complete O
a O
14 B-DUR
day I-DUR
course I-DUR
and O
levofloxacin B-DRUG
to O

 O
complete O
a O
7 B-DUR
day I-DUR
course I-DUR
( O
started O
with O
zosyn B-DRUG
) I-DRUG
. O
  O
He O
had O
a O
PICC O

 O
line O
placed O
prior O
to O
discharge O
. O

 O
. O


 O
2 O
. O
Cardiac O
: O

 O
A. O
Ischemia O
: O
  O
Patient O
has O
a O
history O
of O
coronary O
artery O
disease O
. O

 O
On O
presentation O
, O
EKG O
demonstrated O
right O
bundle O
branch O
block O

 O
( O
last O
EKG O
in O
our O
system O
is O
from O
[ O
* O
* O
2092 O
* O
* O
] O
that O
demonstrates O
no O
RBBB O
- O

 O
however O
, O
obtained O
outside O
hospital O
records O
that O
does O
show O
RBBB O
, O

 O
so O
not O
new O
) O
. O
  O
On O
admission O
, O
cardiac O
enzymes O
were O
elevated O
. O

 O
Cardiology O
was O
therefore O
consulted O
. O
  O
Patient O
was O
thought O
to O
be O

 O
having O
a O
demand O
ischemic B-REA
event I-REA
, I-REA
and O
therefore O
was O
started O
on O

 O
heparin B-DRUG
drip B-ROU
to O
complete O
48 B-DUR
hours I-DUR
per O
cardiology O

 O
recommendations O
. O
  O
His O
outpatient O
aspirin B-DRUG
dose O
was O
increased O
from O

 O
81 B-STR
mg I-STR
to O
325 B-STR
mg I-STR
daily B-FRE
. I-FRE
  O
He O
initially O
could O
not O
be O
on O
beta B-DRUG
blocker I-DRUG

 I-DRUG
therapy O
given O
his O
hypotensive O
sepsis O
. O
  O
Upon O
resolution O
of O
his O

 O
hypotension O
, O
his O
outpatient O
lopressor B-DRUG
was O
re-started O
and O

 O
titrated O
up O
to O
his O
outpatient O
dose O
of O
50 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O
  O
His O
CK O
peaked O

 O
at O
372 O
, O
and O
cardiac O
enzymes O
trended O
down O
throughout O
remainder O
of O

 O
hospital O
course O
. O
  O
No O
plans O
for O
cardiac O
catheterization O
given O
the O

 O
nature O
of O
his O
MI O
in O
setting O
of O
sepsis O
, O
and O
his O
co-morbid O

 O
conditions O
. O

 O
B. O
Rhythm O
: O
  O
Patient O
had O
a O
known O
history O
of O
some O
cardiac O

 O
dysrhythmia O
, O
but O
unknown O
type O
. O
  O
During O
hospital O
course O
, O
patient O

 O
was O
noted O
to O
have O
strange O
rhythm O
on O
telemetry O
and O
EKG O
. O
  O
The O

 O
electrophysiologist O
cardiologists O
were O
curbsided O
, O
and O
believed O

 O
the O
patient O
's O
rhythm O
to O
be O
due O
to O
wenkebach B-REA
rhythm I-REA
. I-REA
  O
They O

 O
recommended O
no O
further O
intervention O
and O
believed O
that O
the O

 O
patient O
's O
outpatient O
digoxin B-DRUG
could O
be O
discontinued O
. O
  O
Otherwise O

 O
patient O
was O
maintained O
on O
lipitor B-DRUG
, I-DRUG
as O
above O
. O

 O
C. O
Pump O
: O
  O
Patient O
has O
a O
history O
of O
CHF B-REA
, I-REA
and O
was O
on O
lisinopril B-DRUG

 I-DRUG
and O
lasix B-DRUG
and O
digoxin B-DRUG
as O
and O
outpatient O
. O
  O
All O
of O
these O

 O
medications O
were O
held O
on O
admission O
due O
to O
the O
patient O
's O
renal O

 O
failure O
and O
sepsis O
. O
  O
ECHO O
on O
admission O
demonstrated O
diffuse O

 O
disease O
, O
EF O
20 O
- O
25 O
% O
, O
mod-severe O
aortic O
stenosis O
, O
mild O
aortic O

 O
regurgitation O
, O
mild-mod O
mitral O
regurgiation O
. O
  O
Upon O
resolution O
of O

 O
the O
patient O
's O
sepsis/hypotension O
, O
his O
lisinopril B-DRUG
was O
restarted O
. O

 O
Digoxin B-DRUG
and O
lasix B-DRUG
were O
not O
restarted O
. O
  O
Spironolactone B-DRUG
was O

 O
initiated O
given O
the O
patient O
's O
heart B-REA
failure I-REA
and O
low B-REA
EF I-REA
. I-REA
  O
He O

 O
remained O
euvolemic O
during O
remainder O
of O
hospital O
course O
. O

 O
. O


 O
3 O
. O
Acute O
on O
chronic O
renal O
failure O
: O
  O
Patient O
with O
a O
history O
of O

 O
chronic O
renal O
insufficiency O
with O
baseline O
creatnine O
thought O
to O

 O
be O
2.0 O
. O
  O
On O
day O
of O
admission O
, O
Cr O
was O
elevated O
at O
2.9 O
and O
quickly O

 O
rose O
to O
peak O
of O
5.6 O
. O
  O
Patient O
was O
fluid O
rescusitated O
and O
Cr O

 O
dropped O
throughout O
admission O
and O
was O
down O
to O
1.1 O
at O
time O
of O

 O
discharge O
. O

 O
During O
hospital O
course O
, O
the O
patient O
's O
lisinopril B-DRUG
, I-DRUG
lasix B-DRUG
, I-DRUG
and O

 O
digoxin B-DRUG
were O
held O
due O
to O
the O
patient O
's O
renal O
failure O
. O
  O
Only O
his O

 O
lisinopril B-DRUG
was O
restarted O
, O
as O
above O
. O
  O
His O
antibiotics B-DRUG
were O

 O
renally O
dosed O
and O
adjusted O
throughout O
hospital O
course O
. O

 O
. O

 O
4 O
. O
Anemia B-REA
: I-REA
  O
Patient O
had O
a O
hematocrit O
of O
low O
30 O
's O
on O
admission O
, O

 O
trended O
down O
to O
low O
of O
26 O
during O
hospital O
course O
. O
  O
Iron O
studies O

 O
were O
consistent O
with O
anemia O
of O
chronic O
disease O
. O
  O
Patient O
was O

 O
transfused O
1 B-DOS
unit B-FOR
of O
pRBC B-DRUG
for O
Hct B-REA
of I-REA
26 I-REA
, I-REA
given O
his O
history O
of O

 O
CAD O
, O
and O
Hct O
bumped O
appropriately O
to O
29 O
, O
and O
remained O
stable O

 O
during O
remainder O
of O
. O
  O
? O
baseline O
. O
  O
Hct O
increased O
to O
29 O
w/ O
1 B-DOS

 I-DOS
unit B-FOR
pRBC B-DRUG
. I-DRUG
  O
Plan O
to O
: O

 O
- O
will O
f/u O
iron O
studies O

 O
- O
guaiac O
all O
stools O

 O
- O
tfs O
to O
keep O
hct O
> O
28 O

 O
- O
moniter O

 O
. O

 O
5 O
. O
Facial B-ADE
eccymoses I-ADE
and O
erythema B-ADE
: I-ADE
Patient O
had O
noted O
left O
sided O

 O
peri-orbital O
facial O
erythema O
and O
eccymoses O
on O
exam O
on O
[ O
* O
* O
9 O
- O
27 O
* O
* O
] O
. O

 O
Radiology O
and O
opthalmology O
were O
contact[**Name O
( O
NI O
) O
* O
* O
] O
as O
this O
was O
thought O

 O
possibley O
secondary O
to O
peri-orbital O
cellulitis O
. O
  O
MRI O
scan O
was O

 O
initially O
considered O
for O
futher O
evaluation O
. O
  O
However O
, O

 O
opthalmology O
evaluated O
the O
patient O
and O
thought O
it O
was O
unlikely O

 O
to O
be O
peri-orbital B-ADE
cellulitis I-ADE
, I-ADE
and O
therefore O
no O
imaging O
was O

 O
necessary O
. O
  O
This O
exam O
finding O
was O
thought O
likely O
secondary O
to O

 O
the O
heparin B-DRUG
drip B-ROU
that O
the O
patient O
was O
on O
for O
his O
cardiac O
issues O
, O

 O
and O
continued O
to O
improve O
throughout O
remainder O
of O
hospital O
course O

 O
once O
heparin B-DRUG
was O
discontinued O
. O

 O
. O

 O
6 O
. O
Guidewire O
caught O
on O
IVC O
filter O
: O
  O
Patient O
had O
a O
right O
IJ O

 O
guidewire O
get O
caught O
in O
his O
IVC O
filter O
during O
his O
ED O
course O
. O

 O
This O
was O
removed O
by O
vascular O
surgery O
. O
  O
Patient O
was O
given O
1U B-FOR
PRBC B-DRUG

 I-DRUG
in O
ED O
for O
fear B-REA
of I-REA
bleed I-REA
. I-REA
  O
Hematocrit O
remained O
stable O
. O
  O
Nothing O

 O
further O
was O
done O
. O

 O
. O


 O
7 O
. O
Mental O
status O
: O
  O
Patient O
was O
somnolent O
on O
admission O
, O
likely O

 O
secondary O
to O
his O
infectious O
status O
. O
  O
He O
returned O
quickly O
to O
his O

 O
baseline O
mental O
status O
that O
included O
being O
awake O
, O
alert O
, O

 O
pleasant O
, O
responsive O
, O
oriented O
only O
x O
1 O
to O
person O
. O
  O
He O
was O

 O
written O
for O
zyprexa B-DRUG
5 B-STR
mg I-STR
PRN B-FRE
for O
agitation B-REA
, I-REA
but O
did O
not O
receive O

 O
any O
during O
hospital O
course O
. O

 O
. O

 O
8 O
. O
Peripheral O
vascular O
disease O
: O
  O
Patient O
had O
dopplerable O
pulses O

 O
on O
this O
admission O
. O

 O
. O

 O
9 O
. O
Coagulopathy B-REA
: I-REA
Patient O
on O
coumadin B-DRUG
as O
outpatient O
for O

 O
dysrhythmias B-REA
and O
lower B-REA
extremity I-REA
DVT I-REA
. I-REA
  O
Coumadin B-DRUG
was O
initially O

 O
held O
given O
the O
patient O
's O
poor O
clinical O
condition O
. O
  O
It O
was O

 O
restarted O
during O
hospital O
course O
, O
and O
he O
was O
discharged O
on O
his O

 O
outpatient O
dose O
of O
1 B-STR
mg I-STR
qhs B-FRE
, I-FRE
with O
a O
subtherapeutic O
INR O
. O
  O
It O

 O
should O
be O
addressed O
with O
his O
outpatient O
primary O
care O
physician O

 O
whether O
or O
not O
to O
continue O
his O
coumadin B-DRUG
, I-DRUG
given O
his O
fall O
risk O
and O

 O
his O
risk O
vs O
benefit O
ratio O
. O

 O
. O

 O
10 O
. O
  O
Hypernatremia B-REA
: I-REA
  O
Patient O
was O
quite O
hypernatremic O
during O

 O
hospital O
course O
, O
with O
sodium O
of O
151 O
on O
admission O
. O
  O
This O
was O

 O
thought O
likely O
a O
hypovolemic O
hypernatremia O
. O
  O
His O
hypernatremia O

 O
improved O
slightly O
with O
initial O
fluid B-DRUG
rescusitation O
. O
  O
The O
patient O

 O
then O
proceded O
to O
get O
free O
water O
boluses O
per O
his O
NG O
tube O
, O
which O

 O
continued O
to O
control O
his O
hypernatremia O
. O

 O
. O

 O
11 O
. O
  O
Nutrition O
: O
  O
Patient O
underwent O
speech O
and O
swallow O
evaluation O

 O
early O
in O
hospital O
course O
which O
he O
failed O
. O
  O
Therefore O
he O
had O
an O

 O
NG O
tube O
placed O
and O
received O
tube O
feeds O
and O
medications O
per O
his O

 O
NG O
tube O
. O
  O
Upon O
improved O
alertness O
, O
patient O
underwent O
a O
repeat O

 O
bedside O
speech O
and O
swallow O
evaluation O
, O
which O
he O
also O
failed O
. O

 O
Following O
this O
, O
patient O
lost O
his O
NG O
tube O
. O
  O
He O
therefore O
had O
an O

 O
IR O
placed O
post-pyloric O
feeding O
tube O
to O
continue O
his O
tube O
feeds O

 O
and O
medications O
. O
  O
He O
was O
discharged O
with O
this O
tube O
in O
place O
with O

 O
plans O
for O
a O
repeat O
speech O
and O
swallow O
upon O
improvement O
at O
rehab O
. O

  O
If O
he O
fails O
this O
, O
the O
issue O
of O
PEG O
tube O
placement O
should O
be O

 O
brought O
up O
with O
his O
[ O
* O
* O
Name O
( O
NI O
) O
5993 O
* O
* O
] O
, O
his O
sister O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
976 O
* O
* O
] O
. O

 O
. O

 O
12 O
. O
  O
Prophylaxis O
: O
  O
Patient O
was O
initially O
maintained O
on O
heparin B-DRUG

 I-DRUG
drip B-ROU
for O
his O
non B-REA
ST I-REA
elevation I-REA
MI I-REA
for O
DVT B-REA
prophylaxis I-REA
, I-REA
which O
was O

 O
changed O
to O
subcutaneous B-ROU
heparin B-DRUG
after O
48 O
hours O
. O
  O
He O
was O
also O

 O
re-started O
on O
his O
coumadin B-DRUG
as O
above O
. O
  O
He O
was O
also O
maintained O
on O

 O
a O
PPI B-DRUG
. I-DRUG

 O
. O

 O
13 O
. O
Access O
: O
  O
PICC O
line O
was O
placed O
prior O
to O
discharge O
. O

 O
. O


 O
14 O
. O
Code O
: O
DNR/DNI O
- O
per O
nursing O
home O
records O
and O
confirmed O
by O

 O
[ O
* O
* O
Name O
( O
NI O
) O
5993 O
* O
* O
] O
, O
his O
sister O
. O

 O
. O

 O
15 O
. O
Contacts O
: O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
976 O
* O
* O
] O
( O
sister O
and O
[ O
* O
* O
Name2 O
( O
NI O
) O
5993 O
* O
* O
] O
) O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
94072 O
* O
* O
] O
, O
Nursing O
home O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
3504 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
69555 O
* O
* O
] O
, O
PCP O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O

 O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
68737 O
* O
* O
] O
. O


 O
Medications O
on O
Admission O
: O

 O
Meds O
: O

 O
- O
coumadin B-DRUG
: O
1 B-STR
mg I-STR
PO B-ROU
QD B-FRE

 I-FRE
- O
lopressor B-DRUG
: I-DRUG
50 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
- O
zyprexa B-DRUG
: I-DRUG
5 B-STR
mg I-STR
QHS B-FRE

 I-FRE
- O
vicodin B-DRUG
: I-DRUG
5/500 B-STR
: I-STR
1 B-DOS
tab B-FOR
PO B-ROU
QD B-FRE
1 O
hour O
prior O
to O
dressing O
change O

 O
- O
lanoxin-digoxin B-DRUG
: O
1 B-DOS
tab B-FOR
PO B-ROU
QD B-FRE

 I-FRE
- O
omeprazole B-DRUG
: I-DRUG
1 B-DOS
tab B-FOR
PO B-ROU
BID B-FRE

 I-FRE
- O
MVI B-DRUG

 I-DRUG
- O
Lasix B-DRUG
: O
40 B-STR
mg I-STR
QD B-FRE

 I-FRE
- O
Lisinopril B-DRUG
: I-DRUG
5 B-STR
mg I-STR
PO B-ROU
QD B-FRE

 I-FRE
- O
ASA B-DRUG
: O
81 B-STR
mg I-STR
QD B-FRE

 I-FRE
- O
Vitamin B-DRUG
C I-DRUG

 I-DRUG
- O
MOM B-DRUG
: I-DRUG
PRN B-FRE

 I-FRE
- O
Dulcolax B-DRUG
: I-DRUG
PRN B-FRE

 I-FRE
- O
Fleet B-DRUG
Enema I-DRUG
: O
PRN B-FRE

 I-FRE
- O
Maalox B-DRUG
: I-DRUG
PRN B-FRE

 I-FRE
- O
Tylenol B-DRUG
: I-DRUG
PRN B-FRE

 I-FRE
-Robitussin B-DRUG
: O
PRN B-FRE

 I-FRE
- O
duonebs B-DRUG
PRN B-FRE

 I-FRE
- O
cepacol B-DRUG
lozenges B-FOR



 I-FOR

Discharge O
Medications O
: O

 O
1 O
. O
Olanzapine B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Rapid I-FOR
Dissolve I-FOR
PO B-ROU
QHS B-FRE
( O
once O
a O
day O
( O
at O
bedtime O
) O
) O
as O
needed O
. O

 O
2 O
. O
Ascorbic B-DRUG
Acid I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
3 O
. O
Magnesium B-DRUG
Hydroxide I-DRUG
400 B-STR
mg/5 I-STR
mL I-STR
Suspension B-FOR
Sig O
: O
Thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS

 I-DOS
ML I-DOS
PO B-ROU
Q6H B-FRE
( O
every O
6 O
hours O
) O
as O
needed O
. O

 O
4 O
. O
Bisacodyl B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-DOS
, I-DOS
Delayed I-DOS
Release I-DOS
( I-DOS
E.C. I-DOS
) I-DOS
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
as O
needed O
. O

 O
5 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
6 O
. O
Erythromycin B-DRUG
5 B-STR
mg/g I-STR
Ointment B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
aplication B-FOR

 I-FOR
Ophthalmic B-ROU
  O
QID B-FRE
( O
4 O
times O
a O
day O
) O
for B-DUR
4 I-DUR
days I-DUR
. I-DUR

 O
7 O
. O
Artificial B-DRUG
Tear I-DRUG
with I-DRUG
Lanolin I-DRUG
0.1 B-STR
- I-STR
0.1 I-STR
% O
Ointment B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Appl B-FOR
Ophthalmic B-ROU
  O
PRN B-FRE
( O
as O
needed O
) O
. O

 O
8 O
. O
Warfarin B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
: O

 O
Please O
adjust O
dose O
to O
achieve O
INR O
of O
2 O
. O

 O
9 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( O
2 O
times O
a O
day O
) O
: O
Please O
hold O
for O
SBP O
< O
100 O
, O
HR O
< O
60 O
. O

 O
10 O
. O
Lisinopril B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
: O

 O
Please O
hold O
for O
SBP O
< O
100 O
. O

 O
11 O
. O
Atorvastatin B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
12 O
. O
Thiamine B-DRUG
HCl I-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
13 O
. O
Folic B-DRUG
Acid I-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O


 O
14 O
. O
Lansoprazole B-DRUG
30 B-STR
mg I-STR
Susp B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
for O
Recon O
Sig O
: O

 O
Thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS
mg I-DOS
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
: O
Per O
nasogastric B-ROU
tube I-ROU
. I-ROU

 O
15 O
. O
Spironolactone B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
16 O
. O
Levofloxacin B-DRUG
250 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q24H B-FRE

 I-FRE
( O
every O
24 O
hours O
) O
for B-DUR
2 I-DUR
days I-DUR
. I-DUR

 O
17 O
. O
Vancomycin B-DRUG
in I-DRUG
Dextrose I-DRUG
1 B-STR
g/200 I-STR
mL I-STR
Piggyback B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
gram B-FOR
Intravenous B-ROU
  O
Q B-FRE
24H I-FRE
( O
Every O
24 O
Hours O
) O
for B-DUR
9 I-DUR
days I-DUR
. I-DUR

 O
18 O
. O
PICC O
line O
care O

 O
PICC O
line O
care O
per O
protocol O

 O
19 O
. O
PICC O
line O
care O

 O
Please O
flush O
PICC O
line O
per O
protocol O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O



 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
105 O
* O
* O
] O
- O
[ O
* O
* O
Location O
( O
un O
) O
86 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Sepsis O

 O
Urinary O
tract O
infection O

 O
Pneumonia O

 O
Coag O
negative O
staph O
bacteremia O

 O
Wenkebach O
cardiac O
dysrrhythmia O

 O
Non O
ST O
elevation O
myocardial O
infarction O

 O
acute O
renal O
failure O



 O
Discharge O
Condition O
: O

 O
Stable O
. O



 O
Discharge O
Instructions O
: O

 O
Please O
contact O
physician O
if O
develop O
worsening O
cough O
, O
chest O

 O
pain/pressure O
, O
shortness O
of O
breath O
, O
fever O
, O
low O
blood O
pressure O
, O

 O
any O
other O
questions/concerns O
. O

 O
. O

 O
Please O
take O
medications O
as O
directed O
. O

 O
. O

 O
Please O
follow O
up O
with O
physician O
as O
directed O
. O


 O
Followup O
Instructions O
: O

 O
Please O
follow O
up O
with O
primary O
care O
physician O
, O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
in O
the O

 O
next O
1 O
- O
2 O
weeks O
. O
  O
Can O
contact O
him O
at O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
68737 O
* O
* O
] O
. O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2197 O
- O
8 O
- O
23 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2197 O
- O
8 O
- O
27 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2143 O
- O
5 O
- O
24 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Compazine B-DRUG
/ O
Methotrexate B-DRUG
/ O
Ceftazidime B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
5755 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
fever O
and O
hypotension O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
none O



 O
History O
of O
Present O
Illness O
: O

 O
This O
is O
a O
54yo O
M O
with O
Crohn O
's O
disease O
s/p O
multiple O
surgeries O

 O
with O
resultant O
short O
gut O
syndrome O
[ O
* O
* O
12 O
- O
22 O
* O
* O
] O
to O
colectomy O
and O
ileostomy O

 O
and O
TPN O
dependency O
who O
was O
recently O
admitted O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O

 O
evaluation O
of O
low O
grade O
fevers O
, O
history O
of O
multiple O
line O

 O
infections O
, O
MV O
endocarditis O
and O
osteomyelitis O
for O
which O
the O
pt O

 O
is O
on O
chronic O
vancomycin B-DRUG
for O
last O
4 B-DUR
years I-DUR
, I-DUR
hickman O
for O
TPN O
, O
now O

 O
present O
w/ O
fever O
and O
hypotension O
. O

 O
. O

 O
At O
home O
he O
became O
febrile O
( O
24 O
hr O
nursing O
care O
) O
w/ O
to O
103.4 O
. O
His O

 O
nurse O
called O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
(ID)on O
[ O
* O
* O
8 O
- O
23 O
* O
* O
] O
who O
was O
notified O

 O
that O
he O
developed O
fever O
to O
101 O
but O
subsequently O
deferveced O
. O
He O

 O
was O
instructed O
to O
call O
back O
if O
recurrent O
fever O
. O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
was O

 O
called O
back O
later O
that O
his O
temp O
was O
103 O
and O
she O
instructed O
him O

 O
to O
go O
to O
the O
ED O
. O
He O
also O
had O
+ O
fatigue O
. O
He O
had O
decreased O
activity O

 O
and O
appetite O
. O
+ O
Dyspnea O
w/any O
exertion O
. O

 O
. O

 O
He O
was O
recently O
admit O
to O
[ O
* O
* O
Hospital1 O
* O
* O
] O
2 O
weeks O
( O
[ O
* O
* O
Date O
range O
( O
1 O
) O
8403 O
* O
* O
] O
) O
ago O
for O
fever O
- O

 O
work O
up O
for O
etiology O
neg O
. O
Durint O
that O
admission O
, O
he O
had O
no O

 O
leukocytosis O
. O
CXR O
was O
negative O
for O
pneumonia O
. O
All O
blood O
cultures O

 O
were O
negative O
to O
date O
, O
including O
cultures O
for O
yeast O
, O
mycolytic O

 O
infections O
and O
for O
M. O
furfur O
. O
Urine O
culture O
was O
negative O
. O
TEE O

 O
was O
negative O
for O
endocarditis O
. O
CT O
of O
the O
cspine O
and O
bone O
scan O

 O
were O
negative O
for O
osteomyelitis O
. O
MRI O
showed O
subtle O
signal O

 O
changes O
which O
may O
suggest O
chronic O
osteomyelitis O
but O
no O
prior O
MRI O

 O
was O
available O
for O
comparision O
( O
last O
one O
was O
in O
[ O
* O
* O
2193 O
* O
* O
] O
, O
when O
he O
did O

 O
not O
have O
osteo).His O
Hickman O
was O
felt O
to O
be O
free O
of O
infection O
, O
so O

 O
it O
was O
not O
pulled O
. O

 O
. O


 O
He O
denies O
any O
headache O
, O
neck O
pain O
, O
CP O
, O
chills O
, O
lightheadedness O
, O

 O
headache O
, O
cough/sputum O
production O
, O
or O
change O
in O
bowel O
or O
urinary O

 O
habits O
( O
burning O
, O
frequency O
, O
etc O
. O
) O
. O
He O
also O
has O
noticed O
no O

 O
erythema O
, O
tenderness O
, O
or O
swelling O
around O
his O
Hickman O
line O
( O
last O

 O
changed O
[ O
* O
* O
2196 O
- O
7 O
- O
21 O
* O
* O
] O
) O
, O
though O
he O
notes O
that O
his O
previous O
line O

 O
infections O
have O
also O
been O
without O
external/visible O
changes O
. O
He O

 O
has O
no O
sick O
contacts O
or O
recent O
travel O
. O

 O
. O

 O
In O
the O
ED O
, O
he O
had O
bld O
cultures O
sent O
. O
Vanco B-DRUG
and O
zosyn B-DRUG
was O
given O

 O
( O
pt O
was O
already O
on O
vanco B-DRUG
qod B-FRE
) I-FRE
. O
ID O
was O
notified O
. O
CXR O
no O
evidence O

 O
no O
focal O
infiltrate O
or O
change O
from O
prior O
CXR O
. O
BP O
70s/40s O
. O
2L O
NS O
. O

 O
BP O
improved O
to O
80 O
- O
90s/40s O
. O
He O
did O
not O
have O
any O
signs O
of O
distress O

 O
and O
was O
mentating O
within O
his O
normal O
range O
Small O
rim O
of O
erythema O

 O
around O
Hickman O
, O
but O
obvious O
pus O
. O
Stoma O
was O
WNL O
. O

 O
. O

 O
He O
was O
transferred O
to O
the O
ICU O
for O
closer O
monitoring O
for O

 O
hypotension O
. O



 O
Past O
Medical O
History O
: O

 O
1 O
. O
Crohn O
's O
disease O
s/p O
multiple O
surgeries O
with O
resultant O

 O
ileostomy O
and O
shortgut O
syndrome O
dependent O
on O
TPN O
with O
chronic O

 O
hypocalcemia O
, O
vitamin O
D O
deficiency O
. O

 O
2 O
. O
Infectious O
: O
Staph O
epidermidis O
C4-C5 O
Osteomyelitis B-REA
( O
on O

 O
Chronic O
Vancomycin B-DRUG
) I-DRUG
, O
Endocarditis O
with O
Mitral O
Valve O
Vegetation O
, O

 O
Recurrent O
Polymicrobial O
Line O
Sepsis O
, O
Previous O
RLL O
PNA O
, O
LE O

 O
Cellulits O

 O
3 O
. O
Respiratory O
- O
COPD O
( O
Baseline O
PaCO2 O
of O
48 O
) O
, O
H/O O
ARDS O
x O
2 O
with O

 O
Intubations/Tracheostomy O
( O
[ O
* O
* O
2192 O
* O
* O
] O
and O
[ O
* O
* O
2193 O
* O
* O
] O
) O
, O
Klebsiella O
bacteremia O
. O


 O
4 O
. O
Severe O
MR O

 O
5 O
. O
CKD O
( O
Baseline O
Cr O
1.3 O
to O
1.4 O
) O

 O
6 O
. O
Anemia O
of O
Chronic O
Inflammation O
( O
on O
EPO O
) O

 O
7 O
. O
Mild O
Dementia O

 O
8 O
. O
Chronic B-REA
Pain I-REA
( O
Fentanyl B-DRUG
50 B-STR
mcg I-STR
Patch B-FOR
) I-FOR

 O
9 O
. O
Restless O
Leg O
Syndrome O

 O
10 O
. O
Steroid-Induced B-DRUG
Osteoporosis B-ADE

 I-ADE
11 O
. O
Multiple O
Spinal O
Compression O
Fx O

 O
12 O
. O
Peripheral O
Neuropathy O

 O
13 O
. O
UGIB/Duodenal O
Ulcer O
( O
[ O
* O
* O
2193 O
* O
* O
] O
) O

 O
14 O
. O
Depression O

 O
15 O
. O
Bilateral O
SVC O
Thrombi O
. O


 O
Social O
History O
: O

 O
Lives O
alone O
; O
24[**Hospital O
8018 O
* O
* O
] O
nursing O
care O
with O
multiple O
nurses O
; O
fully O

 O
intact O
ADLs O
; O
ambulates O
without O
assistance O
; O
never O
married O
; O
has O
no O


 O
children O
; O
has O
worked O
many O
odd O
jobs O
; O
he O
has O
five O
brothers O
and O
one O



 O
sister O
that O
are O
very O
supportive O
. O

 O
His O
brother O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
is O
his O
health O
care O
proxy O
. O

 O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
has O
a O
60-pack-year O
history O
of O
smoking O
. O
  O
He O
reports O
minimal O

 O
alcohol O
use O
and O
previous O
use O
of O
marijuana O
but O
denies O
any O
IVDU O
. O



 O
Family O
History O
: O

 O
F O
: O
Crohn O
's O
disease O

 O
M O
: O
TIA O
in O
her O
70s O

 O
GF O
: O
DM O


 O
Physical O
Exam O
: O

 O
On O
Admission O
: O

 O
VS O
BP O
98/65 O
P O
60 O
RR O
14 O
O2 O
98 O
% O
RA O

 O
Gen O
: O
NAD O
, O
tired O
appearing O
male O
in O
NAD O

 O
HEENT O
: O
PERRL O
, O
dry O
MM O
, O
oral O
pharynx O
clear O

 O
Neck O
: O
Supple O
, O
flat O
JVP O

 O
CV O
: O
RRR O
, O
III/VI O
SEM O
over O
LLSB O

 O
Resp O
: O
good O
inspiratory O
effort O
w/ O
occasional O
wheezing O

 O
Abd O
: O
Soft O
, O
non-tender O
, O
non-distended O
, O
stoma O
intact O

 O
Ext O
: O
warm O
, O
+ O
2 O
distal O
pulses O

 O
Neuro O
: O
A O
+ O
Ox3 O
, O
CN O
II-XII O
intact O
, O
motor O
and O
sensory O
grossly O
intact O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2197 O
- O
8 O
- O
23 O
* O
* O
] O
07:00PM O
BLOOD O
WBC-10.0 O
# O
RBC-3.92 O
* O
Hgb-12.4 O
* O
Hct-35.4 O
* O

 O
MCV-90 O
MCH-31.5 O
MCHC-34.9 O
RDW-15.3 O
Plt O
Ct-180 O

 O
[ O
* O
* O
2197 O
- O
8 O
- O
25 O
* O
* O
] O
05:37AM O
BLOOD O
WBC-3.4 O
* O
RBC-3.40 O
* O
Hgb-10.4 O
* O
Hct-30.9 O
* O

 O
MCV-91 O
MCH-30.5 O
MCHC-33.6 O
RDW-15.2 O
Plt O
Ct-162 O

 O
[ O
* O
* O
2197 O
- O
8 O
- O
23 O
* O
* O
] O
07:00PM O
BLOOD O
Neuts-83 O
* O
Bands-10 O
* O
Lymphs-2 O
* O
Monos-2 O

 O
Eos-3 O
Baso-0 O
Atyps-0 O
Metas-0 O
Myelos-0 O

 O
[ O
* O
* O
2197 O
- O
8 O
- O
25 O
* O
* O
] O
05:37AM O
BLOOD O
Plt O
Ct-162 O

 O
[ O
* O
* O
2197 O
- O
8 O
- O
25 O
* O
* O
] O
05:37AM O
BLOOD O
PT-12.9 O
PTT-33.2 O
INR(PT)-1.1 O

 O
[ O
* O
* O
2197 O
- O
8 O
- O
25 O
* O
* O
] O
05:37AM O
BLOOD O
Glucose-116 O
* O
UreaN-33 O
* O
Creat-2.0 O
* O
Na-137 O

 O
K-3.9 O
Cl-107 O
HCO3 O
- O
23 O
AnGap-11 O

 O
[ O
* O
* O
2197 O
- O
8 O
- O
24 O
* O
* O
] O
07:45AM O
BLOOD O
Glucose-98 O
UreaN-33 O
* O
Creat-2.0 O
* O
Na-140 O

 O
K-4.2 O
Cl-109 O
* O
HCO3 O
- O
22 O
AnGap-13 O

 O
[ O
* O
* O
2197 O
- O
8 O
- O
23 O
* O
* O
] O
07:00PM O
BLOOD O
ALT-21 O
AST-17 O
AlkPhos-848 O
* O
TotBili-3.1 O
* O

 O
[ O
* O
* O
2197 O
- O
8 O
- O
25 O
* O
* O
] O
05:37AM O
BLOOD O
Calcium-8.6 O
Phos-3.2 O
Mg-2.4 O

 O
[ O
* O
* O
2197 O
- O
8 O
- O
24 O
* O
* O
] O
07:45AM O
BLOOD O
calTIBC-178 O
* O
Ferritn-463 O
* O
TRF-137 O
* O

 O
[ O
* O
* O
2197 O
- O
8 O
- O
23 O
* O
* O
] O
07:18PM O
BLOOD O
Lactate-1.3 O

 O
Retic O
2.4 O
, O
hapto O
207 O
, O
LDH O
165 O
, O
FENa O
5.6 O
% O
, O
bili O
3.1->1.8 O
, O
alk O

 O
phos O
848->763 O
, O
ALT O
21 O
, O
AST O
17 O
, O
vanco O
12.5 O

 O
. O

 O
Microbiology O
: O

 O
TPN O
fungal O
culture O
: O
pending O

 O
Blood O
cultures O
: O
pending O

 O
Urine O
culture O
: O
negative O

 O
Fungal O
blood O
cultures O
: O
pending O

 O
Stool O
c O
diff O
negative O
x O
1 O

 O
. O


 O
RUQ O
U/S O
: O

 O
FINDINGS O
: O
The O
patient O
is O
status O
post O
cholecystectomy O
. O
There O
is O

 O
no O
intra- O
or O
extra-hepatic O
biliary O
ductal O
dilatation O
. O
The O
common O

 O
duct O
measures O
6 O
mm O
in O
diameter O
, O
which O
is O
not O
significantly O

 O
changed O
, O
allowing O
for O
differences O
in O
technique O
. O
The O
main O
portal O

 O
vein O
shows O
appropriate O
hepatopetal O
flow O
. O
No O
focal O
liver O
lesions O

 O
are O
identified O
, O
and O
the O
echotexture O
of O
the O
liver O
appears O
normal O
. O

 O
IMPRESSION O
: O
No O
evidence O
of O
biliary O
obstruction O
. O

 O
. O

 O
FRONTAL O
CHEST O
: O
Cardiac O
and O
mediastinal O
contours O
appear O
stable O
, O

 O
with O
mild O
cardiomegaly O
. O
No O
focal O
consolidations O
are O
identified O

 O
within O
the O
lungs O
. O
No O
evidence O
of O
pleural O
effusion O
. O
Multiple O

 O
right-sided O
rib O
fractures O
again O
seen O
. O
Right-sided O
central O
venous O

 O
line O
with O
tip O
overlying O
the O
distal O
SVC O
. O
Cervical O
fusion O
hardware O

 O
again O
noted O
. O

 O
IMPRESSION O
: O
No O
evidence O
of O
acute O
cardiopulmonary O
process O
or O

 O
significant O
change O
from O
prior O
study O
. O



 O
Brief O
Hospital O
Course O
: O

 O
Fever O
: O
Blood O
culture O
and O
urine O
cultures O
were O
sent O
. O
CXR O
on O

 O
admission O
did O
not O
show O
focal O
infiltrate O
. O
He O
was O
started O
on O
vanco B-DRUG

 I-DRUG
( O
increased O
from O
chronic O
qod B-FRE
to O
qd B-FRE
) I-FRE
and O
zosyn B-DRUG
( O
per O
discussion O
w/ O

 O
ID O
) O
. O
His O
recent O
hosp O
admission O
record O
[ O
* O
* O
7 O
- O
26 O
* O
* O
] O
was O
reviewed O
and O

 O
showed O
extensive O
infectious O
workup O
which O
was O
unrevealing O

 O
( O
including O
MRI O
c-spine O
, O
which O
revealed O
no O
significant O
new O

 O
changes O
; O
neg O
bone O
scan O
; O
negative O
blood O
cultures O
; O
negative O
TEE O
) O
. O

 O
GI O
and O
ID O
were O
concerned O
that O
his O
line O
( O
hickman O
placed O
in O
[ O
* O
* O
7 O
- O
25 O
* O
* O
] O
) O

 O
was O
the O
source O
of O
his O
fever O
. O
He O
has O
never O
had O
anything O
cultured O

 O
from O
the O
line O
and O
his O
cultures O
are O
again O
negative O
, O
though O
his O

 O
chronic O
vancomycin B-DRUG
may O
be O
suppressing O
the O
organism O
. O
ID O

 O
recommended O
his O
home O
TPN O
be O
cultured O
( O
including O
M O
furfur O
) O
. O

 O
Given O
negative O
cultures O
, O
the O
zosyn B-DRUG
was O
discontinued O
and O
his O

 O
vancomycin B-DRUG
was O
returned O
to O
[ O
* O
* O
Location O
* O
* O
] O
dosing O
. O
  O
The O
patient O
remained O

 O
afebrile O
x O
24 O
hours O
and O
was O
thus O
discharged O
home O
with O

 O
instructions O
to O
continue O
checking O
his O
temperature O
at O
least O
2 O

 O
times O
per O
day O
. O


 O
Hypotension-Pt O
was O
initially O
hypotensive O
to O
SBP O
70s O
in O
the O
ED O
. O

 O
He O
responded O
quickly O
to O
a O
number O
of O
500cc B-STR
IVF B-DRUG
boluses B-FOR
over O
the O

 O
initial O
48 B-DUR
hrs I-DUR
. I-DUR
His O
BP B-DRUG
meds I-DRUG
were O
initially O
held O
. O
  O
He O
will O

 O
follow-up O
with O
his O
primary O
care O
doctor O
for O
a O
repeat O
blood B-REA

 I-REA
pressure I-REA
check O
to O
consider O
restarting O
his O
lisinopril B-DRUG
given O
his O

 O
history O
of O
MR O
. O
  O
His O
norvasc B-DRUG
and O
lasix B-DRUG
are O
also O
being O
held O
. O



 O
Hyperbilirubinemia/Elevated O
ALk O
Phos- O
His O
alk O
phos O
and O
bili O
were O

 O
elevated O
on O
admission O
( O
rest O
of O
his O
LFTs O
was O
relatively O
stable O
) O
. O

 O
He O
did O
not O
complain O
of O
pain O
. O
RUQ O
u/s O
recommended O
by O
GI O
was O

 O
unremarkable O
. O
  O
Labs O
were O
improving O
at O
the O
time O
of O
discharge O


 O
Anemia-He O
has O
baseline O
anemia O
in O
the O
range O
of O
35 O
- O
37 O
. O
His O
hct O

 O
slowly O
drifted O
down O
to O
low O
30s O
on O
admission O
. O
Hemolysis O
labs O
were O

 O
sent O
but O
were O
normal O
. O
  O
Iron O
studies O
suggest O
anemia O
of O
chronic O

 O
disease O
. O
  O
Folate O
and O
B12 O
were O
normal O
. O


 O
Nutrition-Pt O
was O
initially O
given O
standard O
TPN O
as O
his O
home O

 O
formula O
was O
not O
available O
. O
Dr. O
[ O
* O
* O
Name O
( O
NI O
) O
79 O
* O
* O
] O
( O
pt O
's O
own O
GI O
specialist O
) O

 O
came O
by O
on O
[ O
* O
* O
8 O
- O
25 O
* O
* O
] O
and O
gave O
specific O
instruction O
on O
the O

 O
non-standard O
TPN O
formulation O
. O



 O
Medications O
on O
Admission O
: O

 O
1 O
. O
Polysaccharide B-DRUG
Iron I-DRUG
Complex I-DRUG
150 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
2 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
q B-FRE
24 I-FRE

 I-FRE
3 O
. O
Ascorbic B-DRUG
Acid I-DRUG
500 B-STR
mg I-STR
daily B-FRE

 I-FRE
4 O
. O
Calcium B-DRUG
Carbonate I-DRUG
1500 B-STR
mg I-STR
daily B-FRE

 I-FRE
5 O
. O
Calcitriol B-DRUG
0.25 B-STR
mcg I-STR
daily B-FRE

 I-FRE
6 O
. O
Ergocalciferol B-DRUG
( O
Vitamin B-DRUG
D2 I-DRUG
) I-DRUG
50,000 B-STR
unit I-STR
q B-FRE
wk I-FRE

 I-FRE
7 O
. O
Lisinopril B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
8 O
. O
Furosemide B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
9 O
. O
Zolpidem B-DRUG
5 B-STR
mg I-STR
qhs B-FRE

 I-FRE
10 O
. O
Risperidone B-DRUG
0.25 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
11 O
. O
Dronabinol B-DRUG
5 B-STR
mg I-STR
tid B-FRE

 I-FRE
12 O
. O
Glutamine B-DRUG
10 B-STR
g I-STR
tid B-FRE

 I-FRE
13 O
. O
Amlodipine B-DRUG
2.5 B-STR
mg I-STR
q B-FRE
2 I-FRE
pm I-FRE

 I-FRE
14 O
. O
Ursodiol B-DRUG
600 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
15 O
. O
Acetaminophen B-DRUG
325 B-STR
mg I-STR
prn B-FRE

 I-FRE
16 O
. O
Clonazepam B-DRUG
0.5 B-STR
mg I-STR
tid B-FRE
prn I-FRE

 I-FRE
17 O
. O
Albuterol B-DRUG
inhal B-ROU
q6 B-FRE
prn I-FRE

 I-FRE
18 O
. O
Lorazepam B-DRUG
1 B-STR
mg I-STR
qhs B-FRE
prn I-FRE

 I-FRE
19 O
. O
Opium B-DRUG
Tincture B-FOR
10 B-STR
mg/mL I-STR
Tincture B-FOR
Sig O
: O
Ten B-DOS
( I-DOS
10 I-DOS
) I-DOS
Drop B-FOR
PO B-ROU
Q4 B-FRE
- I-FRE
6H I-FRE

 I-FRE
prn I-FRE

 I-FRE
20 O
. O
Vancomycin B-DRUG
HCl I-DRUG
1000 B-STR
mg I-STR
IV B-ROU
Q48H B-FRE

 I-FRE
21 O
. O
Zofran B-DRUG
* O
NF O
* O
8 B-STR
mg I-STR
IV B-ROU
Q8H B-FRE
: I-FRE
PRN I-FRE
PRN I-FRE

 I-FRE
22 O
. O
Epoetin B-DRUG
Alfa I-DRUG
10,000 B-STR
unit/mL I-STR
qwk B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Polysaccharide B-DRUG
Iron I-DRUG
Complex I-DRUG
150 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Calcium B-DRUG
Carbonate I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Zolpidem B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
. I-FRE



 O
4 O
. O
Risperidone B-DRUG
0.25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
5 O
. O
Ascorbic B-DRUG
Acid I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
6 O
. O
Dronabinol B-DRUG
2.5 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
TID B-FRE
( O
3 O

 O
times O
a O
day O
) O
. O

 O
7 O
. O
Glutamine B-DRUG
10 B-STR
g I-STR
Packet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Packet B-FOR
PO B-ROU
TID B-FRE
( O
3 O
times O
a O

 O
day O
) O
. O

 O
8 O
. O
Calcitriol B-DRUG
0.25 B-STR
mcg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
9 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( O
E.C. O
) O
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( O
E.C. O
) O
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Ursodiol B-DRUG
300 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O

 O
a O
day O
) O
. O

 O
11 O
. O
Albuterol B-DRUG
90 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Inhalation B-ROU

 I-ROU
every B-FRE
4 I-FRE
- I-FRE
6 I-FRE
hours I-FRE
. I-FRE

 O
12 O
. O
Vitamin B-DRUG
D I-DRUG
50,000 B-STR
unit I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
once B-FRE
a I-FRE

 I-FRE
week I-FRE
. I-FRE

 O
13 O
. O
Clonazepam B-DRUG
0.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
three B-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
anxiety B-REA
: I-REA
hold O
for O
rr O
< O
8 O
or O
oversedation B-ADE
. I-ADE

 O
14 O
. O
Vancomycin B-DRUG
in I-DRUG
Dextrose I-DRUG
1 B-STR
g/200 I-STR
mL I-STR
Piggyback B-DOS
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
gram I-DOS
Intravenous B-ROU
  O
Q48H B-FRE
( I-FRE
every I-FRE
48 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
15 O
. O
Epogen B-DRUG
10,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
injection B-ROU

 I-ROU
Injection B-ROU
once B-FRE
a I-FRE
week I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
home O
therapy O


 O
Discharge O
Diagnosis O
: O

 O
hypotension O

 O
fever O

 O
acute O
renal O
failure O

 O
hyperbilirubinemia O

 O
anemia O
of O
chronic O
disease O

 O
history O
of O
short O
gut O
syndrome O
on O
TPN O

 O
history O
of O
cervical B-REA
osteomyelitis I-REA
on O
chronic B-DUR
vancomycin B-DRUG



 I-DRUG
Discharge O
Condition O
: O

 O
good O
: O
afebrile O
, O
wbc O
down O
, O
creatinine O
back O
to O
baseline O



 O
Discharge O
Instructions O
: O

 O
Please O
call O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
or O
go O
to O
the O
emergency O
room O
for O

 O
temperature O
> O
101 O
, O
low O
blood O
pressure O
, O
decreased O
urine O
output O
, O

 O
weight O
gain O
> O
3 O
pounds O
, O
chest O
pain O
, O
back/neck O
pain O
, O
or O
other O

 O
concerning O
symptoms O
. O


 O
Please O
store O
your O
TPN O
in O
a O
separate O
mini-refrigerator O
that O
you O

 O
should O
bleach O
one O
time O
per O
week O
to O
prevent O
TPN O
contamination O
. O


 O
Please O
continue O
your O
home O
TPN O
, O
as O
previously O
prescribed O
. O
  O
No O

 O
changes O
have O
been O
made O
. O


 O
Please O
stop O
taking O
supplemental O
IVF B-DRUG
each B-FRE
day I-FRE
. I-FRE



 O
Please O
follow-up O
with O
your O
primary O
care O
doctor O
or O
his O
nurse O

 O
practitioner O
within O
1 O
week O
for O
a O
blood O
pressure O
check O
and O
labs O

 O
including O
kidney B-REA
function I-REA
( O
creatinine O
) O
to O
consider O
restarting O

 O
your O
lisinopril B-DRUG
. I-DRUG
  O
For O
now O
, O
please O
do O
not O
take O
that O
medication O
. O

 O
Please O
also O
defer O
starting O
your O
amlodipine B-DRUG
and O
lasix B-DRUG
for O
now O
. O

 O
If O
your O
weight B-REA
increases I-REA
> I-REA
3 I-REA
pounds I-REA
, I-REA
please O
call O
your O
doctor O
to O

 O
discuss O
restarting O
the O
lasix B-DRUG
. I-DRUG


 O
Please O
continue O
getting O
weekly O
labs O
each O
Monday O
, O
which O
are O
faxed O

 O
to O
Dr. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
450 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
79 O
* O
* O
] O
. O


 O
You O
were O
hospitalized O
for O
fever O
of O
concern O
for O
infection B-REA
. I-REA
You O

 O
were O
given O
zosyn B-DRUG
( O
antibiotics B-DRUG
) I-DRUG
in O
addition O
to O
vancomycin B-DRUG
. I-DRUG
Blood O

 O
and O
urine O
cultures O
were O
drawn O
and O
your O
TPN O
was O
being O
cultured O

 O
for O
possible O
source O
of O
infection O
. O
Infectious O
disease O
was O

 O
consulted O
. O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
79 O
* O
* O
] O
also O
came O
by O
to O
evaluate O
you O
. O
A O
right O
upper O

 O
quadrant O
ultrasound O
showed O
no O
dilation O
of O
your O
bile O
ducts O
, O

 O
despite O
elevated O
bilirubin O
which O
has O
since O
improved O
. O
  O
Your O
blood O

 O
count O
is O
stable O
. O


 O
Followup O
Instructions O
: O

 O
Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
1037 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
2335 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
457 O
* O
* O
] O

 O
Date/Time:[**2197 O
- O
8 O
- O
29 O
* O
* O
] O
11:30 O

 O
Provider O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
1954 O
* O
* O
] O

 O
Date/Time:[**2197 O
- O
9 O
- O
27 O
* O
* O
] O
11:15 O
. O
PLEASE O
CALL O
HER O
OFFICE O
ON O
TUESDAY O

 O
MORNING O
TO O
SCHEDULE O
AN O
EARLIER O
APPOINTMENT O
( O
1 O
- O
2 O
WEEKS O
) O

 O
Provider O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
Phone:[**Telephone/Fax O
( O
1 O
) O
2422 O
* O
* O
] O
Date/Time:[**2197 O
- O
10 O
- O
16 O
* O
* O
] O

 O
11:30 O


 O
Please O
call O
Tuesday O
to O
schedule O
follow-up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
5717 O
* O
* O
] O
in O
[ O
* O
* O
11 O
- O
21 O
* O
* O
] O

 O
weeks O
. O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
250 O
* O
* O
] O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2142 O
- O
7 O
- O
27 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2142 O
- O
8 O
- O
28 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2084 O
- O
1 O
- O
25 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
SURGERY O


 O
Allergies O
: O

 O
Heparin B-DRUG
Agents I-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
2777 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Left O
lower O
extemity O
ischemia O
, O
transfered O
from O
OSH O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
20 O
* O
* O
] O
: O
Left O
AKA O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
2 O
* O
* O
] O
: O
Left O
guillotine O
amp O

 O
[ O
* O
* O
2142 O
- O
7 O
- O
30 O
* O
* O
] O
: O
LLE O
angio O
, O
thrombectomy O
of O
vein O
graft O
and O
tibial O

 O
vessles O
, O
patch O
angioplasty O
of O
proximal O
vein O
graft O

 O
[ O
* O
* O
2142 O
- O
7 O
- O
28 O
* O
* O
] O
: O
LLE O
angio O
, O
thrombectomy O
via O
graft O
and O
BKpop O
, O
Left O

 O
fem-BKpop O
with O
RT O
GSV O
, O
fasciotomy O
x4 O



 O
History O
of O
Present O
Illness O
: O

 O
This O
is O
a O
58 O
year O
old O
gentleman O
who O
is O
5 O
years O
status O
post O
left O

 O
femoral O
above O
knee O
popliteal O
with O
PTFE O
. O
The O
day O
prior O
to O

 O
admission O
he O
experienced O
acute O
onset O

 O
of O
left O
calf O
and O
foot O
pain O
and O
coolness O
consistent O
with O

 O
thrombosed O
fem-[**Doctor O
Last O
Name O
* O
* O
] O
graft O
on O
that O
side O
. O
Evaluated O
at O
OSH O
and O

 O
transfered O
to O
[ O
* O
* O
Hospital1 O
18**]/[**Doctor O
Last O
Name O
* O
* O
] O
for O
continued O
care O
. O


 O
Past O
Medical O
History O
: O

 O
DM O
2 O
, O
HTN O
, O
COPD O
, O
ETOH O
abuse O
, O
heavy O
smoker O

 O
L O
[ O
* O
* O
Doctor O
Last O
Name O
69803 O
* O
* O
] O
PTFE O
graft O



 O
Social O
History O
: O

 O
Lives O
at O
home O
with O
family O
. O

 O
Daily O
ETOH O

 O
1 O
- O
2ppd O
Smoking O
history O


 O
Family O
History O
: O

 O
n/c O


 O
Physical O
Exam O
: O

 O
Admission O
H&P O

 O
PE O
: O
96.9 O
, O
103 O
, O
142/82 O
, O
20 O
94%RA O

 O
General O
: O
NAD O
, O
pleasant O
, O
A&O O
X3 O

 O
cards O
: O
RRR O

 O
Lungs O
: O
CTA O

 O
Abd O
: O
soft O
, O
ND O
, O
+ O
BS O

 O
B/L O
palp O
fem O

 O
LLE O
cool O
below O
knee O
. O
dop O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
, O
-DP/PT O

 O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
palp O
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
, O
DP O
-PT O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
26 O
* O
* O
] O
WBC-7.7 O
RBC-3.36 O
* O
Hgb-9.8 O
* O
Hct-28.6 O
* O
MCV-85 O
MCH-29.1 O

 O
MCHC-34.2 O
RDW-14.5 O
Plt O
Ct-483 O
* O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
28 O
* O
* O
] O
PT-38.3 O
* O
PTT-32.8 O
INR(PT)-4.3 O
* O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
26 O
* O
* O
] O
Glucose-102 O
UreaN-11 O
Creat-0.5 O
Na-135 O
K-3.6 O
Cl-95 O
* O

 O
HCO3 O
- O
30 O
AnGap-14 O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
26 O
* O
* O
] O
Calcium-8.7 O
Phos-4.3 O
Mg-1.9 O



 O
[ O
* O
* O
2142 O
- O
8 O
- O
14 O
* O
* O
] O
5:36 O
pm O
SWAB O
      O
LEFT O
BKA O
STUMP O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2142 O
- O
8 O
- O
18 O
* O
* O
] O
* O
* O


    O
GRAM O
STAIN O
( O
Final O
[ O
* O
* O
2142 O
- O
8 O
- O
14 O
* O
* O
] O
) O
: O

       O
2 O
+ O
   O
( O
1 O
- O
5 O
per O
1000X O
FIELD O
) O
: O
   O
POLYMORPHONUCLEAR O

 O
LEUKOCYTES O
. O

       O
2 O
+ O
   O
( O
1 O
- O
5 O
per O
1000X O
FIELD O
) O
: O
   O
GRAM O
POSITIVE O
COCCI O
. O

                                     O
IN O
PAIRS O
. O


    O
WOUND O
CULTURE O
( O
Final O
[ O
* O
* O
2142 O
- O
8 O
- O
17 O
* O
* O
] O
) O
: O

       O
ENTEROCOCCUS O
SP O
.. O
    O
MODERATE O
GROWTH O
. O

       O
ACINETOBACTER O
BAUMANNII O
. O
    O
SPARSE O
GROWTH O
. O

          O
" O
Note O
, O
for O
Amp/sulbactam B-DRUG
, I-DRUG
higher-than-standard B-DOS
dosing I-DOS

 I-DOS
needs O
to O
be O

          O
used O
, O
since O
therapeutic O
efficacy O
relies O
on O
intrinsic O

 O
activity O
of O

          O
the O
sulbactam B-DRUG
component O
" O
. O


                               O
SENSITIVITIES O
: O
MIC O
expressed O
in O

 O
MCG/ML O


 O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O
_ O

                              O
ENTEROCOCCUS O
SP O
. O

                              O
| O
          O
ACINETOBACTER O
BAUMANNII O

                              O
| O
          O
| O

 O
AMPICILLIN------------ O
   O
< O
= O
2 O
S O

 O
AMPICILLIN/SULBACTAM-- O
             O
= O
> O
32 O
R O

 O
CEFEPIME-------------- O
               O
32 O
R O

 O
CEFTAZIDIME----------- O
             O
= O
> O
64 O
R O

 O
CIPROFLOXACIN--------- O
              O
= O
> O
4 O
R O

 O
GENTAMICIN------------ O
                O
2 O
S O

 O
IMIPENEM-------------- O
                O
8 O
I O

 O
LEVOFLOXACIN---------- O
                O
4 O
I O

 O
LINEZOLID------------- O
     O
2 O
S O

 O
PENICILLIN------------ O
     O
8 O
S O

 O
TOBRAMYCIN------------ O
              O
< O
= O
1 O
S O

 O
TRIMETHOPRIM/SULFA---- O
              O
< O
= O
1 O
S O

 O
VANCOMYCIN------------ O
  O
= O
> O
32 O
R O


    O
ANAEROBIC O
CULTURE O
( O
Final O
[ O
* O
* O
2142 O
- O
8 O
- O
18 O
* O
* O
] O
) O
: O
    O
NO O
ANAEROBES O
ISOLATED O



 O
Brief O
Hospital O
Course O
: O

 O
[ O
* O
* O
2142 O
- O
7 O
- O
28 O
* O
* O
] O
Transferred O
from O
OSH O
with O
cold O
, O
ischemic O
left O
leg O
and O

 O
taken O
urgently O
to O
OR O
. O
UnderwentLeft O
lower O
extremity O
angiography O
, O

 O
mechanical O
thrombectomy O
of O
left O
femoral O
popliteal O
PTFE O
graft O
. O

 O
Thrombectomy O
of O
below O
knee O
popliteal O
anterior O
tibialis O
and O

 O
peroneal O
arteries O
and O
posterior O
tibialis O
arteries O
, O
right O
greater O

 O
saphenous O
vein O
harvest O
, O
left O
femoral O
to O
below O
knee O
popliteal O

 O
bypass O
graft O
with O
right O
greater O
saphenous O
vein O
, O
angioscopy O
and O

 O
valve O
lysis O
and O
fasciotomy O
x4 O
. O
Surgery O
without O
complications O
and O

 O
was O
extubated O
in O
OR O
. O

 O
In O
[ O
* O
* O
Name O
( O
NI O
) O
13042 O
* O
* O
] O
, O
pt O
with O
symptoms O
of O
DTs B-REA
. I-REA
CIWA O
initiated O
and O
he O
received O

 O
Haldol B-DRUG
and O
Ativan B-DRUG
with O
effect O
. O
Transferred O
to O
VICU O
. O
Heparin B-DRUG
gtt B-FOR

 I-FOR
and O
ABX B-DRUG
continued O
. O
Patient O
continued O
to O
have O
tremors/DTs O
. O

 O
[ O
* O
* O
2142 O
- O
7 O
- O
30 O
* O
* O
] O
: O
Postop O
he O
was O
found O
to O
have O
a O
cooler O
foot O
and O
loss O
of O

 O
Doppler O
signal O
. O
The O
patient O
had O
already O
been O
systemically O

 O
heparinized B-DRUG
so O
was O
taken O
urgently O
back O
to O
the O
operating O
room O
and O

 O
underwent O
thrombectomy O
and O
revision O
of O
left O
common O
femoral O
to O

 O
below- O
knee O
popliteal O
artery O
bypass O
graft O
with O
vein O
patch O

 O
angioplasty O
. O
At O
the O
time O
of O
re-exploration O
, O
he O
was O
suspected O
of O

 O
having O
HIT B-REA
and O
was O
started O
on O
argatroban B-DRUG
. I-DRUG
HIT O
specimen O
positive O
. O

 O
Due O
to O
witnessed O
DT O
's O
preop O
, O
postop O
he O
remained O
intubated O
for O

 O
airway O
protection O
. O
While O
intubated O
, O
received O
tube O
feeds O
. O

 O
Transfused O
1uPRBCs O

 O
[ O
* O
* O
8 O
- O
2 O
* O
* O
] O
to O
OR O
for O
L O
guillotine O
BKA O
. O
Continue O
Vanco/Levo/Flagyl B-DRUG
ABX B-DRUG
. I-DRUG

  O
NS O
w-D O
dressings O
to O
BKA O
open O
stump O
. O
Transfused O
2uPRBCs B-DRUG
. I-DRUG

 O
Remained O
intubated O
for O
airway O
protection O
due O
to O
ETOH O
withdrawal O

 O
until O
[ O
* O
* O
2142 O
- O
8 O
- O
7 O
* O
* O
] O
. O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
7 O
* O
* O
] O
Extubated O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
8 O
* O
* O
] O
Speech O
and O
swallow O
evaluation O
for O
oral O
and O
pharyngeal O

 O
dysphagia O
following O
extubation O
. O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
10 O
* O
* O
] O
Transferred O
from O
SICU O
to O
VICU O
. O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
14 O
* O
* O
] O
Due O
to O
extensive O
necrosis O
of O
the O
patient O
's O
left O
BKA O

 O
stump O
, O
taken O
to O
OR O
for O
debridement O
.Surgery O
without O

 O
complication O
. O
Extubated O
and O
transferred O
to O
[ O
* O
* O
Month/Day/Year O
13042 O
* O
* O
] O
. O

 O
Pain B-REA
controlled O
with O
Morphine B-DRUG
, I-DRUG
fentanyl B-DRUG
patch B-FOR
. I-FOR
Transfused O
, O

 O
Electrolytes O
repleted O
. O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
20 O
* O
* O
] O
Underwent O
Left O
above-the-knee O
amputation O
for O
infected O

 O
open O
BKA O
. O
Surgery O
without O
complication O
. O
Extubated O
and O

 O
transferred O
to O
[ O
* O
* O
Month/Day/Year O
13042 O
* O
* O
] O
. O

 O

[ O
* O
* O
Date O
range O
( O
3 O
) O
69804 O
* O
* O
] O
Surgical O
dressing O
changed O
. O
VSS O
. O
Tolerating O
po O
and O

 O
urinating O
qs O
. O
Antibiotics B-DRUG
changed O
to O
Linezolid B-DRUG
, I-DRUG
Vanco B-DRUG
d'ced O

 O
( O
VRE O
) O
. O
B/L O
palpable O
femoral O
pulses O
. O
Amputation O
site O
healing O
. O

 O
Coumadin B-DRUG
started O
. O
Continued O
Argatroban B-DRUG
gtt B-FOR
. I-FOR
Daily B-FRE
coags B-DRUG
. I-DRUG

 O
Physical O
therapy O
initiated O
. O
Rehab O
screened O
. O

 O
Stable O
for O
transfer O
to O
acute O
rehab O
when O
bed O
available O
and O
INR O

 O
therapeutic O
. O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
27 O
* O
* O
] O
Argatroban B-DRUG
discontinued O

 O
[ O
* O
* O
2142 O
- O
8 O
- O
28 O
* O
* O
] O
INR O
4.3 O
. O
LT O
AKA O
stump O
c/d/i O
. O
VSS O
. O
Afebrile O
. O
Antibiotics B-DRUG

 I-DRUG
discontinued O
. O
B/L O
fem O
palpable O
. O
RT O
PT O
dopplerable O
. O
Continue O

 O
other O
current O
medications O
including O
Coumadin B-DRUG
5 B-STR
mg I-STR
daily B-FRE
( O
adjust O

 O
to O
keep B-REA
INR I-REA
2.0 I-REA
- I-REA
3.0 I-REA
) I-REA



 O

Discharge O
Medications O
: O

 O
1 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
2 O
. O
Simvastatin B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
3 O
. O
Albuterol B-DRUG
90 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Puffs B-FOR
Inhalation B-ROU

 I-ROU
Q4H B-FRE
( O
every O
4 O
hours O
) O
. O

 O
4 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
17 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Puff B-FOR
Inhalation B-ROU
Q6H B-FRE
( O
every O
6 O
hours O
) O
. O

 O
5 O
. O
Acetaminophen B-DRUG
160 B-STR
mg/5 I-STR
mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
PO B-ROU
Q4 B-FRE
- I-FRE
6H I-FRE

 I-FRE
( I-FRE
every I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
6 O
. O
Famotidine B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q12H B-FRE
( O
every O
12 O

 O
hours O
) O
. O

 O
7 O
. O
Quetiapine B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O
a O

 O
day O
) O
. O

 O
8 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
9 O
. O
Fentanyl B-DRUG
50 B-STR
mcg/hr I-STR
Patch B-FOR
72HR I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Patch B-FOR
72HR I-FOR

 I-FOR
Transdermal B-ROU
Q72H B-FRE
( O
every O
72 O
hours O
) O
. O

 O
10 O
. O
Gabapentin B-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
q8hr B-FRE
( O
) O
. O

 O
11 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( O
2 O
times O
a O
day O
) O
. O

 O
12 O
. O
Furosemide B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O
times O

 O
a O
day O
) O
. O

 O
13 O
. O
Warfarin B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( O
at O
bedtime O
) O
: O

 O
Adjust O
to O
maintain B-REA
INR I-REA
of I-REA
2.0 I-REA
- I-REA
3.0 I-REA
. I-REA

 O
14 O
. O
Oxycodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
325 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU

 I-ROU
Q4 B-FRE
- I-FRE
6H I-FRE
( I-FRE
every I-FRE
4 I-FRE
to I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
15 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE

 I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
16 O
. O
Bisacodyl B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
17 O
. O
Insulin B-DRUG

 I-DRUG
Breakfast B-FRE
and O
Bedtime- B-FRE
NPH B-DRUG
10 B-DOS
  I-DOS
Units I-DOS

 I-DOS
Fingerstick B-ROU
before O
meals O
and O
bed-cover O
with O
regulsr B-STR
sliding B-DOS

 I-DOS
scale I-DOS


 I-DOS
Insulin B-DRUG
SC B-ROU
Sliding B-DOS
Scale I-DOS

 I-DOS
Breakfast B-FRE
Lunch B-FRE
Dinner B-FRE
Bedtime B-FRE
Q0H B-FRE



 I-FRE
Glucose B-DRUG
Insulin B-DRUG
Dose O
Insulin B-DRUG
Dose O
Insulin B-DRUG
Dose O
Insulin B-DRUG
Dose O

 O
Insulin B-DRUG
Dose O

 O
0 O
- O
60 O
  O
mg/dL O
[ O
* O
* O
1 O
- O
15 O
* O
* O
] O
amp O
D50 O

 O
61 O
- O
120 O
  O
mg/dL O
0 B-DOS
Units I-DOS

 I-DOS
121 O
- O
140 O
mg/dL O
3 B-DOS
Units I-DOS

 I-DOS
141 O
- O
160 O
mg/dL O
6 B-DOS
Units I-DOS

 I-DOS
161 O
- O
180 O
mg/dL O
9 B-DOS
Units I-DOS

 I-DOS
181 O
- O
200 O
mg/dL O
12 B-DOS
Units I-DOS

 I-DOS
201 O
- O
220 O
mg/dL O
15 B-DOS
Units I-DOS

 I-DOS
221 O
- O
240 O
mg/dL O
18 B-DOS
Units I-DOS

 I-DOS
241 O
- O
260 O
mg/dL O
21 B-DOS
Units I-DOS

 I-DOS
261 O
- O
280 O
mg/dL O
24 B-DOS
Units I-DOS

 I-DOS
281 O
- O
300 O
mg/dL O
27 B-DOS
Units I-DOS

 I-DOS
301 O
- O
320 O
mg/dL O
30 B-DOS
Units I-DOS

 I-DOS
Notify O
M.D. O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital3 O
7665 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Peripheral O
arterial O
disease O

 O
DM O
2 O
, O
HTN O
, O
COPD O
, O
ETOH O
, O
heavy O
smoker O

 O
history O
of O
L O
[ O
* O
* O
Doctor O
Last O
Name O
69803 O
* O
* O
] O
PTFE O
graft O



 O
Discharge O
Condition O
: O

 O
Good O

 O
VSS O
. O
INR O
4.3 O
. O



 O
Discharge O
Instructions O
: O

 O
DISCHARGE O
INSTRUCTIONS O
FOLLOWING O
BELOW O
OR O
ABOVE O
KNEE O
AMPUTATION O


 O
This O
information O
is O
designed O
as O
a O
guideline O
to O
assist O
you O
in O
a O

 O
speedy O
recovery O
from O
your O
surgery O
. O
Please O
follow O
these O

 O
guidelines O
unless O
your O
physician O
has O
specifically O
instructed O
you O

 O
otherwise O
. O
Please O
call O
our O
office O
nurse O
if O
you O
have O
any O

 O
questions O
. O
Dial O
911 O
if O
you O
have O
any O
medical O
emergency O
. O


 O
ACTIVITY O
: O


 O
There O
are O
restrictions O
on O
activity O
. O
On O
the O
side O
of O
your O

 O
amputation O
you O
are O
non O
weight O
bearing O
until O
cleared O
by O
your O

 O
Surgeon O
. O
You O
should O
keep O
this O
amputation O
site O
elevated O
when O
ever O

 O
possible O
. O


 O
You O
may O
use O
the O
other O
leg O
to O
assist O
in O
transferring O
and O
pivots O
. O

 O
But O
try O
not O
to O
exert O
to O
much O
pressure O
on O
the O
amputation O
site O

 O
when O
transferring O
and O
or O
pivoting O
. O
Please O
keep O
knee O
immobilizer O

 O
on O
at O
all O
times O
to O
help O
keep O
the O
amputation O
site O
straight O
. O


 O
No O
driving O
until O
cleared O
by O
your O
Surgeon O
. O


 O
PLEASE O
CALL O
US O
IMMEDIATELY O
FOR O
ANY O
OF O
THE O
FOLLOWING O
PROBLEMS O
: O


 O
Redness O
in O
or O
drainage O
from O
your O
leg O
wound(s O
) O
. O


 O
Watch O
for O
signs O
and O
symptoms O
of O
infection O
. O
These O
are O
: O
a O
fever O

 O
greater O
than O
101 O
degrees O
, O
chills O
, O
increased O
redness O
, O
or O
pus O

 O
draining O
from O
the O
incision O
site O
. O
If O
you O
experience O
any O
of O
these O

 O
or O
bleeding O
at O
the O
incision O
site O
, O
CALL O
THE O
DOCTOR O
. O


 O
Exercise O
: O


 O
Limit O
strenuous O
activity O
for O
6 O
weeks O
. O


 O
Do O
not O
drive O
a O
car O
unless O
cleared O
by O
your O
Surgeon O
. O


 O
Try O
to O
keep O
leg O
elevated O
when O
able O
. O


 O
BATHING/SHOWERING O
: O



 O
You O
may O
shower O
immediately O
upon O
coming O
home O
. O
No O
bathing O
. O
A O

 O
dressing O
may O
cover O
you??????re O
amputation O
site O
and O
this O
should O
be O

 O
left O
in O
place O
for O
three O
( O
3 O
) O
days O
. O
Remove O
it O
after O
this O
time O
and O

 O
wash O
your O
incision(s O
) O
gently O
with O
soap O
and O
water O
. O
You O
will O
have O

 O
sutures O
, O
which O
are O
usually O
removed O
in O
4 O
weeks O
. O
This O
will O
be O
done O

 O
by O
the O
Surgeon O
on O
your O
follow-up O
appointment O
. O


 O
WOUND O
CARE O
: O

 O
Sutures O
/ O
Staples O
may O
be O
removed O
before O
discharge O
. O
If O
they O
are O

 O
not O
, O
an O
appointment O
will O
be O
made O
for O
you O
to O
return O
for O
staple O

 O
removal O
. O


 O
When O
the O
sutures O
are O
removed O
the O
doctor O
may O
or O
may O
not O
place O

 O
pieces O
of O
tape O
called O
steri-strips O
over O
the O
incision O
. O
These O
will O

 O
stay O
on O
about O
a O
week O
and O
you O
may O
shower O
with O
them O
on O
. O
If O
these O

 O
do O
not O
fall O
off O
after O
10 O
days O
, O
you O
may O
peel O
them O
off O
with O
warm O

 O
water O
and O
soap O
in O
the O
shower O
. O


 O
Avoid O
taking O
a O
tub O
bath O
, O
swimming O
, O
or O
soaking O
in O
a O
hot O
tub O
for O

 O
four O
weeks O
after O
surgery O
. O


 O
MEDICATIONS O
: O


 O
Unless O
told O
otherwise O
you O
should O
resume O
taking O
all O
of O
the O

 O
medications O
you O
were O
taking O
before O
surgery O
. O
You O
will O
be O
given O
a O

 O
new O
prescription O
for O
pain B-DRUG
medication I-DRUG
, I-DRUG
which O
can O
be O
taken O
every B-FRE

 I-FRE
three I-FRE
( I-FRE
3 I-FRE
) I-FRE
to I-FRE
four I-FRE
( I-FRE
4 I-FRE
) I-FRE
hours I-FRE
only I-FRE
if I-FRE
necessary I-FRE
. I-FRE


 O
Remember O
that O
narcotic B-DRUG
pain I-DRUG
meds I-DRUG
can O
be O
constipating B-ADE
and O
you O

 O
should O
increase O
the O
fluid O
and O
bulk O
foods O
in O
your O
diet O
. O
( O
Check O

 O
with O
your O
physician O
if O
you O
have O
fluid O
restrictions O
. O
) O
If O
you O
feel O

 O
that O
you O
are O
constipated B-REA
, I-REA
do O
not O
strain O
at O
the O
toilet O
. O
You O
may O

 O
use O
over O
the O
counter O
Metamucil B-DRUG
or O
Milk B-DRUG
of I-DRUG
Magnesia I-DRUG
. I-DRUG
Appetite O

 O
suppression O
may O
occur O
; O
this O
will O
improve O
with O
time O
. O
Eat O
small O

 O
balanced O
meals O
throughout O
the O
day O
. O


 O
CAUTIONS O
: O


 O
NO O
SMOKING O
! O
We O
know O
you O
've O
heard O
this O
before O
, O
but O
it O
really O
is O

 O
an O
important O
step O
to O
your O
recovery O
. O
Smoking O
causes O
narrowing O
of O

 O
your O
blood O
vessels O
which O
in O
turn O
decreases O
circulation O
. O
If O
you O

 O
smoke O
you O
will O
need O
to O
stop O
as O
soon O
as O
possible O
. O
Ask O
your O
nurse O

 O
or O
doctor O
for O
information O
on O
smoking O
cessation O
. O


 O
Avoid O
pressure O
to O
your O
amputation O
site O
. O


 O
No O
strenuous O
activity O
for O
6 O
weeks O
after O
surgery O
. O


 O
DIET O
: O


 O
There O
are O
no O
special O
restrictions O
on O
your O
diet O
postoperatively O
. O

 O
Poor O
appetite O
is O
expected O
for O
several O
weeks O
and O
small O
, O
frequent O

 O
meals O
may O
be O
preferred O
. O



 O
For O
people O
with O
vascular O
problems O
we O
would O
recommend O
a O

 O
cholesterol O
lowering O
diet O
: O
Follow O
a O
diet O
low O
in O
total O
fat O
and O

 O
low O
in O
saturated O
fat O
and O
in O
cholesterol O
to O
improve O
lipid O
profile O

 O
in O
your O
blood O
. O
Additionally O
, O
some O
people O
see O
a O
reduction O
in O

 O
serum O
cholesterol O
by O
reducing O
dietary O
cholesterol O
. O
Since O
a O

 O
reduction O
in O
dietary O
cholesterol O
is O
not O
harmful O
, O
we O
suggest O
that O

 O
most O
people O
reduce O
dietary O
fat O
, O
saturated O
fat O
and O
cholesterol O
to O

 O
decrease O
total O
cholesterol O
and O
LDL O
( O
Low O
Density O
Lipoprotein-the O

 O
bad O
cholesterol O
) O
. O
Exercise O
will O
increase O
your O
HDL O
( O
High O
Density O

 O
Lipoprotein-the O
good O
cholesterol O
) O
and O
with O
your O
doctor O
's O

 O
permission O
, O
is O
typically O
recommended O
. O
You O
may O
be O
self-referred O

 O
or O
get O
a O
referral O
from O
your O
doctor O
. O


 O
If O
you O
are O
overweight O
, O
you O
need O
to O
think O
about O
starting O
a O
weight O

 O
management O
program O
. O
Your O
health O
and O
its O
improvement O
depend O
on O

 O
it O
. O
We O
know O
that O
making O
changes O
in O
your O
lifestyle O
will O
not O
be O

 O
easy O
, O
and O
it O
will O
require O
a O
whole O
new O
set O
of O
habits O
and O
a O
new O

 O
attitude O
. O
If O
interested O
you O
can O
may O
be O
self-referred O
or O
can O
get O

 O
a O
referral O
from O
your O
doctor O
. O


 O
If O
you O
have O
diabetes O
and O
would O
like O
additional O
guidance O
, O
you O
may O

 O
request O
a O
referral O
from O
your O
doctor O
. O


 O
FOLLOW-UP O
APPOINTMENT O
: O


 O
Be O
sure O
to O
keep O
your O
medical O
appointments O
. O
The O
key O
to O
your O

 O
improving O
health O
will O
be O
to O
keep O
a O
tight O
reign O
on O
any O
of O
the O

 O
chronic O
medical O
conditions O
that O
you O
have O
. O
Things O
like O
high O
blood O

 O
pressure O
, O
diabetes O
, O
and O
high O
cholesterol O
are O
major O
villains O
to O

 O
the O
blood O
vessels O
. O
Do O
n't O

 O
Please O
call O
the O
office O
on O
the O
first O
working O
day O
after O
your O

 O
discharge O
from O
the O
hospital O
to O
schedule O
a O
follow-up O
visit O
. O
This O

 O
should O
be O
scheduled O
on O
the O
calendar O
for O
seven O
to O
fourteen O
days O

 O
after O
discharge O
. O
Normal O
office O
hours O
are O
8:30 O
- O
5 O
Monday O
through O

 O
Friday O
. O


 O
. O


 O
PLEASE O
FEEL O
FREE O
TO O
CALL O
THE O
OFFICE O
WITH O
ANY O
OTHER O
CONCERNS O
OR O

 O
QUESTIONS O
THAT O
MIGHT O
ARISE O





 O
Followup O
Instructions O
: O

 O
Call O
Dr.[**Last O
Name O
( O
STitle O
) O
* O
* O
] O
office O
for O
follow O
up O
in O
3 O
weeks O
. O
His O

 O
office O
is O
located O
at O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
439 O
* O
* O
] O
5B O
[ O
* O
* O
Location O
( O
un O
) O
86 O
* O
* O
] O
, O
[ O
* O
* O
Numeric O
Identifier O
718 O
* O
* O
] O




 O
Completed O
by:[**2142 O
- O
8 O
- O
28 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2202 O
- O
1 O
- O
8 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2202 O
- O
2 O
- O
1 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2163 O
- O
9 O
- O
18 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Keflex B-DRUG
/ O
Orencia B-DRUG
/ O
Remicade B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
2751 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
L O
leg O
pain O
and O
erythema O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
IR O
guided O
fluid O
drainage O

 O
Incision O
and O
drainage O

 O
Muscle O
biopsy O



 O
History O
of O
Present O
Illness O
: O

  O
Mr. O
[ O
* O
* O
Known O
lastname O
17385 O
* O
* O
] O
is O
a O
38 O
y.o O
. O
male O
with O
a O
history O
of O
psoriatic O

 O
arthritis O
on O
immunosuppresive O
therapy O
, O
HTN O
, O
HL O
, O
DM O
, O
cervicogenic O

 O
headaches O
who O
was O
recently O
discharged O
on O
[ O
* O
* O
1 O
- O
8 O
* O
* O
] O
for O
left O
leg O
pain O
. O

 O
Pt O
reprots O
that O
he O
presented O
to O
the O
ED O
on O
[ O
* O
* O
2202 O
- O
1 O
- O
3 O
* O
* O
] O
for O
L O
heel O
pain O

 O
radiating O
to O
knees O
. O
He O
was O
initially O
treated O
with O
vanc B-DRUG
and O
cipro B-DRUG

 I-DRUG
for O
question O
of O
septic B-REA
left I-REA
knee I-REA
; I-REA
the O
aspirate O
showed O
[ O
* O
* O
Numeric O
Identifier O
* O
* O
] O
WBC O

 O
and O
94 O
% O
PMN O
but O
neg O
gram O
stain O
and O
culture O
and O
no O
crystals O
so O

 O
abx B-DRUG
discontinued O
. O
LENI O
was O
negative O
for O
DVT O
or O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
cyst O
. O
No O

 O
fx O
on O
x-ray O
. O
This O
was O
thought O
to O
be O
a O
psoriatic O
arthritis O
flare O
, O

 O
so O
his O
prednisone B-DRUG
was O
increased O
from O
his O
home O
dose O
of O
30 B-STR
mg I-STR
to O

 O
60 B-STR
mg I-STR
daily B-FRE
with O
improvement O
in O
his O
inflammation B-REA
. I-REA
His O
pain O

 O
subsequently O
reutrned O
and O
repeat O
LENI O
was O
negative O
. O
Pt O
was O

 O
started O
on O
gabapentin B-DRUG
for O
presumed O
fibromyalgia B-REA
and O
discharged O

 O
yesterday O
on O
a O
stable O
pain B-DRUG
regimen I-DRUG
of O
MS B-DRUG
contin I-DRUG
with O
prn B-FRE

 I-FRE
dilaudid B-DRUG
. I-DRUG
He O
saw O
Rheum O
today O
who O
referred O
him O
to O
Derm O
for O

 O
evaluation O
of O
a O
superficial O
erythematous O
plaque O
, O
questioned O

 O
erythema O
nodosum O
. O
Derm O
did O
not O
think O
this O
was O
consistent O
but O
was O

 O
concerned O
about O
compartment O
syndrome O
so O
referred O
pt O
to O
ED O
. O

 O
. O


 O
In O
the O
ER O
, O
vitals O
were O
: O
T O
98.2 O
, O
P O
79 O
, O
BP O
145/77 O
, O
RR O
17 O
, O
O2sat O

 O
98 O
. O
LENI O
neg O
for O
DVT O
but O
pt O
was O
noted O
to O
have O
an O
extensive O
left O

 O
posterior O
calf O
subcutaneous O
complex O
fluid O
collection O
. O
Ortho O
did O

 O
not O
see O
evidence O
of O
compartment O
syndrome O
and O
recommended O

 O
vascular O
c/s O
to O
rule O
out O
necrotizing O
fasciitis O
given O
the O
fluid O

 O
collection O
. O
Vascular O
did O
not O
think O
this O
was O
consistent O
with O

 O
necrotizing O
fasciitis O
. O
An O
MRI O
of O
the O
LE O
was O
done O
per O
Rads O
recs O
, O

 O
and O
this O
showed O
small O
fluid O
collections O
concerning O
for O
abscess O

 O
in O
his O
gastrocnemius O
that O
were O
too O
small O
to O
be O
drained O
with O
no O

 O
evidence O
of O
osteomyelitis O
. O
He O
was O
given O
vancomycin B-DRUG
, I-DRUG
zosyn B-DRUG
, I-DRUG
and O

 O
clindaycin B-DRUG
. I-DRUG
He O
also O
received O
his O
home O
meds O
of O
gabapentin B-DRUG
, I-DRUG
MS B-DRUG

 I-DRUG
contin I-DRUG
, I-DRUG
and O
po B-ROU
dilaudid B-DRUG
. I-DRUG
He O
was O
admitted O
to O
medicine O
with O
VS O
on O

 O
transfer O
: O
T O
98.5 O
, O
P O
76 O
, O
BP O
136/68 O
, O
RR O
15 O
, O
O2sat O
98RA O
. O

 O
. O

 O
On O
evaluation O
on O
the O
floor O
, O
patient O
complains O
of O
persistent O
LE O

 O
pain O
and O
tenderness O
which O
is O
controlled O
on O
his O
pain O
regimen O
. O
His O

 O
LLE O
knee O
effusion O
has O
improved O
markedly O
since O
his O
recent O

 O
admission O
. O
He O
denies O
any O
fevers O
, O
chills O
, O
or O
night O
sweats O
. O

 O
. O

 O
ROS O
: O
Mild O
constipation O
d/t O
pain O
meds O
. O
Review O
of O
systems O

 O
otherwise O
negative O
. O

 O
. O


 O
Past O
Medical O
History O
: O

 O
-Psoriatic O
arthritis O
: O
Dx O
in O
early O
[ O
* O
* O
2198 O
* O
* O
] O
when O
pt O
presented O
with O
a O

 O
few O
lesions O
of O
psoriasis O
and O
symmetric O
polyarticular O
swelling O
of O

 O
MCPs O
, O
PIPs O
, O
MTPs O
, O
and O
dactylitis O
. O
Has O
failed O
trials O
of O
enbrel B-DRUG

 I-DRUG
and O
methotrexate B-DRUG
due O
to O
lack O
of O
response O
. O
Failed O
Arava B-DRUG
due O
to O

 O
Arava-induced B-DRUG
polyneuropathy B-ADE
. I-ADE
Failed O
remicade B-DRUG
and O
orencia B-DRUG
due O
to O

 O
infusion B-ADE
reactions I-ADE
. I-ADE
Imuran B-DRUG
was O
re-initiated O
in O
[ O
* O
* O
2201 O
- O
2 O
- O
25 O
* O
* O
] O
. O

 O
Started O
Simponi B-DRUG
in O
[ O
* O
* O
2201 O
- O
8 O
- O
27 O
* O
* O
] O
. O

 O
-Morbid O
obesity O

 O
-OSA O
on O
CPAP O

 O
-IBD O
vs O
IBS O
: O
never O
diagnosed O
as O
UC O
or O
Crohns O

 O
-HTN B-ADE
: I-ADE
prednisone-induced B-DRUG

 O
-DM2 B-ADE
: I-ADE
prednisone-induced B-DRUG
, O
followed O
by O
the O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O

 O
-Hyperlipidemia O

 O
-Peripheral O
neuropathy O

 O
-NAFLD B-ADE
, I-ADE
felt O
to O
be O
secondary O
to O
methotrexate B-DRUG

 I-DRUG
-Cervicogenic O
migraine/dystonic O
muscle O
spasm/occipital O

 O
neuralgia O
: O

 O
Followed O
by O
pain O
clinic O
. O
s/p O
intermittent O
trigger O
point O

 O
injections O
, O
greater O
occipital O
and O
auriculotemporal O
nerve O
blocks O


 O
combined O
with O
Botox B-DRUG
chemodenervation O
therapy O

 O
-Keratoconus O
s/p O
bilateral O
corneal O
transplant O
: O
1st O
in O
95 O
, O
2nd O
in O


 O
99 O

 O
-s/p O
4 O
anal O
fistulotomies O

 O
-s/p O
tonsillectomy O
x2 O
and O
adenoidectomy O

 O
-DJD O
s/p O
L4/L5 O
diskectomy O

 O
-Patello-femoral O
syndrome O
s/p O
arthroscopic O
surgery O
for O
both O

 O
knees O

 O
x O
3 O
each O

 O
. O



 O
Social O
History O
: O

 O
Patient O
has O
never O
smoked O
. O
Admits O
to O
1 O
beer O
per O
month O
. O
Admits O
to O

 O
1 O
x O
use O
of O
LSD O
in O
college O
. O
  O
Patient O
is O
married O
with O
4 O
children O
. O

 O
Only O
recent O
travel O
to O
[ O
* O
* O
Location O
( O
un O
) O
6408**]and O
[ O
* O
* O
Last O
Name O
( O
un O
) O
3625 O
* O
* O
] O
World O
. O
  O
Has O
only O

 O
ever O
been O
sexually O
active O
with O
wife O
. O



 O
Family O
History O
: O

 O
Mother O
has O
[ O
* O
* O
Name2 O
( O
NI O
) O
* O
* O
] O
, O
HTN O
, O
hypercholesterolemia O
and O
bipolar O
disorder O
. O

 O
Father O
has O
non-smoking O
induced O
COPD O
and O
hypertension O
. O
  O
Brother O

 O
has O
dermatologic O
psoriasis O
and O
UC O
. O
  O
Sister O
with O
HTN O
and O

 O
hypercholesterolemia O
. O
  O
Paternal O
Aunt O
with O
Crohn O
's O
and O

 O
sarcoidosis O
. O


 O
Physical O
Exam O
: O

 O
Vitals O
: O
T O
98.5 O
, O
BP O
135/87 O
, O
P O
78 O
, O
RR O
17 O
, O
O2sat O
99RA O
, O
Height O
6'1 O
" O
, O

 O
Weight O
153 O
kg O

 O
General O
: O
Well-appearing O
, O
pleasant O
, O
obese O
man O
in O
NAD O

 O
HEENT O
: O
NCAT O
, O
oropharynx O
clear O

 O
Neck O
: O
Supple O
, O
no O
LAD O

 O
Pulm O
: O
CTA O
b/l O

 O
CV O
: O
RRR O
, O
S1-S O
nl O

 O
Abd O
: O
BS+ O
, O
soft O
, O
obese O
, O
NT O
, O
ND O

 O
Extrem O
: O
Left O
knee O
perhaps O
mildly O
larger O
than O
right O
; O
erythema O
, O

 O
warmth O
, O
and O
tenderness O
over O
medial O
left O
calf O
, O
excoriations O
over O

 O
anteriolateral O
left O
calf O
. O
Pitting O
edema O
b/l O
. O
DP/PT O
pulses O
2 O
+ O

 O
b/l O
. O

 O
Neuro O
: O
AAOx3 O
, O
strength O
5/5 O
in O
LE O
. O


 O
Pertinent O
Results O
: O

 O
rtPCR O
RNA O
study O
NEG O

 O
URINE O
culture O
NGTD O

 O
Wound O
culture O
NGTD O

 O
Blood O
culture O
NGTD O
after O
[ O
* O
* O
1 O
- O
8 O
* O
* O
] O

 O
[ O
* O
* O
1 O
- O
8 O
* O
* O
] O
BLOOD O
CULTURE O
GRAM O
POSITIVE O
COCCUS(COCCI O
) O
IN O
CLUSTERS O
- O

 O
pan-sensitive O

 O
[ O
* O
* O
2202 O
- O
1 O
- O
9 O
* O
* O
] O
JOINT O
FLUID O
: O
Stain O
NEG O
; O
BACT/FUNGAL/ACID O
FAST O
CULTURE O

 O
NEG O

 O
[ O
* O
* O
2202 O
- O
1 O
- O
8 O
* O
* O
] O
LYME O
SEROLOGY O
NEG O

 O
[ O
* O
* O
2202 O
- O
1 O
- O
11 O
* O
* O
] O
HBsAg O
: O
NEG O
HBs-Ab O
: O
NEG O
  O
HAV-Ab O
: O
NEG O
HCV-Ab O
: O
NEG O

 O
[ O
* O
* O
2202 O
- O
1 O
- O
11 O
* O
* O
] O
ABSCESS O
Fluid O
- O
Fungal/GS O
NEG O

 O
. O

 O
Imaging O
: O

 O
[ O
* O
* O
2202 O
- O
1 O
- O
20 O
* O
* O
] O
US O
: O
No O
significant O
change O
in O
size O
of O
fluid O
collection O

 O
in O
the O
left O
popliteal O
fossa O
extending O
into O
the O
left O
posterior O

 O
calf O
, O
which O
contains O
small O
foci O
of O
gas O
. O

 O
. O

 O
[ O
* O
* O
2202 O
- O
1 O
- O
16 O
* O
* O
] O
US O
: O
1 O
. O
No O
evidence O
of O
left O
lower O
extremity O
DVT O
between O

 O
the O
left O
popliteal O
and O
common O
femoral O
veins O
. O
2 O
. O
Left O
popliteal O

 O
fossa O
collection O
extending O
into O
the O
calf O
, O
again O
seen O
. O

 O
. O


 O
[ O
* O
* O
2202 O
- O
1 O
- O
12 O
* O
* O
] O
CT O
of O
LLE O
- O
1 O
. O
Redemonstration O
of O
two O
loculated O
fluid O

 O
collections O
in O
the O
left O
calf O
. O
Slightly O
increased O
inferior O
extent O

 O
of O
the O
collection O
along O
the O
anteromedial O
edge O
of O
the O
medial O
head O

 O
of O
the O
gastrocnemius O
muscle O
. O
Otherwise O
no O
significant O
change O
. O
2 O
. O

 O
Subcutaneous O
edema O
along O
the O
anterior O
left O
leg O
, O
in O
keeping O
with O

 O
cellulitis O
, O
unchanged O
. O
3 O
. O
Small O
loculates O
of O
air O
within O
the O

 O
lower O
collection O
is O
attributed O
to O
recent O
aspiration O
procedure O
. O

 O
No O
other O
evidence O
of O
soft O
tissue O
emphysema O
identified O
. O

 O
. O

 O
[ O
* O
* O
2202 O
- O
1 O
- O
12 O
* O
* O
] O
TTE O
- O
The O
right O
atrium O
is O
moderately O
dilated O
. O
There O
is O

 O
mild O
symmetric O
left O
ventricular O
hypertrophy O
with O
normal O
cavity O

 O
size O
. O
Due O
to O
suboptimal O
technical O
quality O
, O
a O
focal O
wall O
motion O

 O
abnormality O
can O
not O
be O
fully O
excluded O
. O
Overall O
left O
ventricular O

 O
systolic O
function O
is O
normal O
( O
LVEF>55 O
% O
) O
. O
The O
aortic O
valve O

 O
leaflets O
( O
3 O
) O
appear O
structurally O
normal O
with O
good O
leaflet O

 O
excursion O
and O
no O
aortic O
stenosis O
. O
No O
masses O
or O
vegetations O
are O

 O
seen O
on O
the O
aortic O
valve O
, O
but O
can O
not O
be O
fully O
excluded O
due O
to O

 O
suboptimal O
image O
quality O
. O
No O
aortic O
regurgitation O
is O
seen O
. O
The O

 O
mitral O
valve O
leaflets O
are O
mildly O
thickened O
. O
There O
is O
no O
mitral O

 O
valve O
prolapse O
. O
No O
masses O
or O
vegetations O
are O
seen O
on O
the O
mitral O

 O
valve O
, O
but O
can O
not O
be O
fully O
excluded O
due O
to O
suboptimal O
image O

 O
quality O
. O
No O
mitral O
regurgitation O
is O
seen O
. O
There O
is O
mild O

 O
pulmonary O
artery O
systolic O
hypertension O
. O
There O
is O
no O
pericardial O

 O
effusion O
. O


 O
IMPRESSION O
: O
Suboptimal O
image O
quality O
. O
No O
obvious O

 O
echocardiographic O
evidence O
of O
endocarditis O
. O
Mild O
symmetric O
left O

 O
ventricular O
hypertrophy O
with O
preserved O
global O
LV O
systolic O

 O
function O
. O
Mild O
pulmonary O
hypertension O
. O

 O
If O
clinically O
suggested O
, O
the O
absence O
of O
a O
vegetation O
by O
2D O

 O
echocardiography O
does O
not O
exclude O
endocarditis O
. O


 O
[ O
* O
* O
2202 O
- O
1 O
- O
22 O
* O
* O
] O

 O
MRI O
calf O

 O
1 O
. O
Persisted O
popliteus O
muscle O
collection O
and O
collection O
at O
the O

 O
anteromedial O
aspect O
of O
the O
medial O
head O
of O
the O
gastrocnemius O

 O
muscle O
. O

 O
2 O
. O
Post-surgical O
findings O
following O
incision O
and O
drainage O
is O
a O

 O
new O
collection O
posterior O
to O
the O
medial O
head O
of O
the O
gastrocnemius O

 O
muscle O
, O
contiguous O
with O
the O
medial O
open O
skin O
defect O
and O
contains O

 O
low O
signal O
intensity O
foci O
, O
which O
may O
be O
due O
to O
air O
or O
possibly O

 O
packing O
. O

 O
3 O
. O
Muscle O
edema O
in O
the O
medial O
head O
of O
the O
gastrocnemius O
muscle O

 O
and O
vastus O

 O
medialis O
obliquus O
muscle O
, O
likely O
postoperative O
. O

 O
4 O
. O
A O
small O
knee O
joint O
effusion O
and O
mild O
synovitis O
without O

 O
definite O
findings O
of O
septic O
arthritis O
. O
As O
previously O
noted O
, O
the O

 O
popliteus O
tendon O
sheath O
can O
communicate O
with O
the O
knee O
joint O
. O

 O
Cartilage O
thinning O
and O
subchondral O
cysts O
along O
patella O
may O
be O

 O
degenerative O
. O
Clinical O
correlation O
is O
requested O
. O


 O
. O


 O
[ O
* O
* O
2202 O
- O
1 O
- O
12 O
* O
* O
] O
Radiology O
UNILAT O
LOWER O
EXT O
VEINS O
-1 O
. O
Large O
complex O

 O
fluid O
collection O
tracking O
from O
the O
left O
popliteal O
fossa O
along O

 O
the O
medial O
left O
calf O
to O
the O
proximal O
mid O
calf O
region O
. O
Since O
it O

 O
is O
difficult O
to O
fully O
assess O
the O
extent O
and O
geography O
of O
this O

 O
collection O
on O
ultrasound O
, O
an O
MRI O
is O
suggested O
for O
further O

 O
characterization O
. O
2 O
. O
Smaller O
fluid O
collection O
at O
the O
left O

 O
anterior O
knee O
measuring O
3.5 O
cm O
. O
3 O
. O
No O
evidence O
of O
deep O
vein O

 O
thrombosis O
in O
the O
left O
leg O
. O

 O
. O

 O
[ O
* O
* O
1 O
- O
8 O
* O
* O
] O
LENIS O
: O
No O
left O
lower O
extremity O
DVT O
. O
Extensive O
left O

 O
posterior O
calf O
subcutaneous O
complex O
fluid O
collection O
. O

 O
. O

 O
[ O
* O
* O
1 O
- O
8 O
* O
* O
] O
MRI O
calf O
: O
  O
1 O
. O
Two O
loculated O
fluid O
collections O
concerning O

 O
for O
abcess O
collections O
, O
one O
in O
the O
substance O
of O
the O
popliteus O

 O
muscle O
, O
and O
the O
other O
along O
the O
anteromedial O
edge O
of O
the O
medial O

 O
gastrocnemius O
muscle O
. O

 O
2 O
. O
Subcutaneous O
edema O
likely O
represents O
cellulitis O
in O
this O

 O
setting O
. O

 O
3 O
. O
No O
evidence O
of O
osteomyelitis O
. O

 O
4 O
. O
Limited O
assessment O
of O
knee O
joint O
-- O
please O
see O
comment O
( O
No O

 O
obvious O
direct O
communication O
between O
these O
collections O
and O
the O

 O
knee O
joint O
effusion O
is O
identified O
, O
but O
the O
popliteus O
abscess O

 O
does O
extend O
along O
the O
popliteus O
tendon O
, O
which O
can O
communicate O

 O
with O
the O
knee O
in O
some O
patients O
. O
Full O
assessment O
of O
the O

 O
relationship O
between O
the O
knee O
joint O
and O
popliteus O
is O
limited O
on O

 O
these O
views O
. O
) O


 O
Labs O
on O
admission O
: O


 O
[ O
* O
* O
2202 O
- O
1 O
- O
8 O
* O
* O
] O
01:35PM O
   O
GLUCOSE-152 O
* O
UREA O
N-28 O
* O
CREAT-1.2 O
SODIUM-136 O

 O
POTASSIUM-4.7 O
CHLORIDE-97 O
TOTAL O
CO2 O
- O
27 O
ANION O
GAP-17 O

 O
[ O
* O
* O
2202 O
- O
1 O
- O
8 O
* O
* O
] O
01:35PM O
   O
WBC-13.7 O
* O
RBC-4.37 O
* O
HGB-12.2 O
* O
HCT-37.4 O
* O

 O
MCV-86 O
MCH-27.9 O
MCHC-32.5 O
RDW-13.4 O

 O
[ O
* O
* O
2202 O
- O
1 O
- O
8 O
* O
* O
] O
01:35PM O
   O
NEUTS-87.6 O
* O
LYMPHS-8.4 O
* O
MONOS-3.8 O
EOS-0.1 O

 O
BASOS-0.1 O

 O
[ O
* O
* O
2202 O
- O
1 O
- O
8 O
* O
* O
] O
01:35PM O
   O
PLT O
COUNT-354 O

 O
[ O
* O
* O
2202 O
- O
1 O
- O
8 O
* O
* O
] O
01:35PM O
   O
PT-14.3 O
* O
PTT-21.7 O
* O
INR(PT)-1.2 O
* O


 O
Brief O
Hospital O
Course O
: O

 O
38 O
years O
old O
male O
with O
psoriatic B-REA
arthritis I-REA
on O
immunosuppression B-DRUG
, I-DRUG

 O
DM O
, O
HTN O
, O
HL O
p/w O
LLE O
erythema O
, O
swelling O
and O
pain O
, O
found O
to O
have O

 O
gastrocnemius O
abscesses O
and O
overlying O
cellulitis O
. O

 O
. O


 O
# O
Acute O
renal O
failure O
: O
Patient O
noted O
to O
have O
acutely O
elevated O

 O
creatinine O
after O
I&D O
by O
surgery O
. O
  O
All O
urine O
lytes O
testing O

 O
indicated O
pre-renal O
etiology O
. O
Resolved O
after O
fluid O
challenge O
. O
He O

 O
again O
had O
acute B-ADE
renal I-ADE
failure I-ADE
on O
[ O
* O
* O
2202 O
- O
1 O
- O
27 O
* O
* O
] O
in O
the O
setting O
of O
having O

 O
received O
increased O
doses O
of O
pain B-DRUG
medications I-DRUG
and O
resultant O

 O
hypoperfusion O
. O
His O
peak O
creatinine O
was O
3.0 O
, O
and O
resolved O
to O
his O

 O
baseline O
of O
0.8 O
- O
0.9 O
by O
the O
time O
of O
discharge O
. O

 O
. O

 O
# O
Left O
calf O
fluid O
collection O
with O
overlying O
cellulitis O
: O
No O
DVT O

 O
or O
[ O
* O
* O
Hospital O
Ward O
Name O
4675 O
* O
* O
] O
cyst O
on O
multiple O
imaging O
studies O
. O
  O
No O
compartment O

 O
syndrome O
per O
Orthopedic O
evaluation O
. O
  O
No O
osteomyelitis O
on O
MRI O
and O

 O
not O
consistent O
with O
necrotizing O
fascitis O
per O
Vascular O
surgery O
. O

 O
It O
was O
noted O
on O
imaging O
that O
he O
had O
gastroceminis O
fluid O

 O
collection O
and O
overlying O
cellulitis O
. O
  O
No O
signs O
of O
septic O
joint O

 O
from O
evaluation O
of O
knee O
aspiration O
. O
  O
He O
had O
one O
positive O
blood B-REA

 I-REA
culture I-REA
with I-REA
pan-sensitive I-REA
staph I-REA
. I-REA
  O
He O
was O
placed O
on O
zosyn B-DRUG
, I-DRUG
later O

 O
narrowed O
to O
nafcillin B-DRUG
. I-DRUG
  O
All O
other O
microbiology O
data O
were O

 O
negative O
. O
  O
IR O
and O
vascular O
surgery O
helped O
drained O
the O
fluid O

 O
collection O
. O
  O
Leg O
incision O
is O
to O
heal O
via O
secondary O
intention O
. O

 O
He O
developed O
a O
body O
rash O
that O
was O
determined O
to O
be O
folliculitis B-REA
. I-REA

  O
He O
completed O
the O
2 B-DUR
week I-DUR
course O
IV B-ROU
antibiotics B-DRUG
in O
house O
. O
  O
His O

 O
major O
issue O
remained O
to O
be O
pain B-REA
management I-REA
. I-REA
  O
He O
required O
a O
large O

 O
amount O
of O
narcotics B-DRUG
to O
control O
his O
pain B-REA
, I-REA
but O
after O
overdose O
( O
see O

 O
below O
) O
he O
was O
switched O
to O
a O
very O
conservative O
regimen O
. O
  O
It O
was O

 O
determined O
that O
the O
swelling/fluid O
collection O
is O
from O
psoriatic O

 O
arthritis O
versus O
idiopathic O
spondylarthropathy O
. O
He O
was O

 O
discharged O
in O
stable O
condition O
. O
Muscle O
biospy O
showed O
necrotic O

 O
muscle O
with O
granulation O
tissue O
. O

 O
. O


 O
# O
Medication O
overdose O
: O
On O
[ O
* O
* O
2202 O
- O
1 O
- O
26 O
* O
* O
] O
, O
on O
recommendation O
from O
the O

 O
pain O
service O
, O
patient O
's O
MS B-DRUG
Contin I-DRUG
dose O
was O
increased O
to O
160 B-STR
mg I-STR

 I-STR
TID B-FRE
from O
130 B-STR
mg I-STR
TID B-FRE
, I-FRE
in O
addition O
to O
being O
ordered O
for O
PRN B-FRE

 I-FRE
Dilaudid B-DRUG
. I-DRUG
Later O
that O
night O
, O
Pt O
fell O
while O
ambulating O
. O
He O
had O
a O

 O
CT O
scan O
which O
was O
negative O
for O
acute O
intracranial O
pathologu O
. O

 O
Morning O
after O
the O
fall O
, O
Pt O
was O
noted O
to O
be O
somnolent B-ADE
and O

 O
hypotensive B-ADE
. I-ADE
He O
was O
given O
Naloxone B-DRUG
0.4 B-STR
mg I-STR
X3 B-DOS
and O
would O
arouse O

 O
briefly O
after O
each O
dose O
. O
He O
continued O
to O
be O
hypotensive B-REA
after O
a O

 O
bolus B-DOS
of O
1L B-DOS
of O
NS B-DRUG
. I-DRUG
He O
was O
transferred O
to O
the O
MICU O
for O
further O

 O
monitoring O
. O
In O
the O
MICU O
he O
was O
monitored O
closely O
and O
his O

 O
hypotension O
and O
mental O
status O
gradually O
improved O
. O
He O
was O
called O

 O
out O
back O
to O
the O
floor O
on O
[ O
* O
* O
2202 O
- O
1 O
- O
28 O
* O
* O
] O
. O
He O
never O
required O
intubation O
. O

 O
After O
being O
called O
out O
, O
he O
was O
normotensive O
and O
alert O
and O

 O
oriented O
X O
3 O
. O
It O
was O
believed O
his O
hypotension O
and O
altered O
mental O

 O
status O
were O
caused O
by O
medication O
overdose O
in O
the O
setting O
of O

 O
acute O
kidney O
injury O
. O
  O
He O
was O
discharged O
on O
oxycodone B-DRUG
5 B-STR
mg I-STR
Q4 B-FRE

 I-FRE
hours I-FRE
, I-FRE
which O
he O
did O
well O
on O
for B-DUR
the I-DUR
3 I-DUR
days I-DUR
prior O
to O
his O

 O
discharge O
. O
He O
will O
follow O
up O
with O
the O
pain O
clinic O
as O
an O

 O
outpatient O
. O

 O
. O

 O
# O
Psoriatic B-REA
arthritis I-REA
: I-REA
On O
Golimumab B-DRUG
every B-FRE
month I-FRE
, I-FRE
azathioprine B-DRUG
, I-DRUG

 O
prednisone B-DRUG
. I-DRUG
Rheumatology O
was O
consulted O
and O
suggested O
to O
decrease O

 O
prednison B-DRUG
level O
to O
20 B-STR
mg I-STR
from O
30 B-STR
mg I-STR
. I-STR
  O
He O
continued O
on O
PCP O
[ O
* O
* O
Name9 O
( O
PRE O
) O
* O
* O
] O

 O
with O
Bactrim B-DRUG
. I-DRUG
  O
Indomethacin B-DRUG
was O
held O
due O
to O
renal B-ADE
failure I-ADE
but O

 O
restarted O
on O
discharge O
. O
  O
He O
will O
continue O
to O
follow O
with O

 O
rhematology O
as O
an O
outpatient O
. O

 O
. O

 O
# O
DM B-REA
: I-REA
Continued O
on O
Lantus B-DRUG
8u B-DOS
qAM B-FRE
, I-FRE
10u B-DOS
qPM B-FRE
with O
sliding O
scale O

 O
dictated O
by O
patient O
based O
on O
carbohydrate O
counting O
. O
  O
[ O
* O
* O
Last O
Name O
( O
un O
) O
* O
* O
] O
was O

 O
consulted O
and O
followed O
. O

 O
. O

 O
# O
HTN B-REA
: I-REA
Continued O
on O
HCTZ B-DRUG
25 B-STR
mg I-STR
, I-STR
lisinopril B-DRUG
40 B-STR
mg I-STR
, I-STR
metoprolol B-DRUG

 I-DRUG
succinate I-DRUG
100 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O
  O
Held O
HCTZ B-DRUG
and O
lisinopril B-DRUG
due O
to O

 O
ARF/hypotension B-ADE
and O
was O
restarted O
afterwards O
. O

 O
. O

 O
# O
Anemia O
: O
Patient O
found O
to O
be O
iron O
deficient O
and O
started O
on O

 O
supplementation O
. O
Patient O
informed O
he O
will O
need O
oupatient O

 O
evaluation O
to O
determine O
cause O
of O
this O
by O
his O
PCP O
. O
  O
( O
PCP O
informed O

 O
by O
letter O
) O
. O


 O
# O
HL B-REA
: I-REA
Continued O
pravastatin B-DRUG

 I-DRUG
. O

 O
# O
OSA O
: O
Continued O
CPAP O
qhs O

 O
. O

 O
# O
GERD B-REA
: I-REA
Continued O
Donnatal B-DRUG
prn B-FRE

 I-FRE
. O

 O
Code O
: O
FULL O



 O
Comm O
: O
With O
pt O
. O
HCP O
is O
wife O
[ O
* O
* O
Name O
( O
NI O
) O
5321 O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
17385 O
* O
* O
] O
( O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
35617 O
* O
* O
] O
H O
, O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
35618 O
* O
* O
] O
C O
) O



 O
Medications O
on O
Admission O
: O

 O
Prednisone B-DRUG
60 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Golimumab B-DRUG
( I-DRUG
Simponi I-DRUG
) I-DRUG
50 B-STR
mg I-STR
SQ B-ROU
monthly B-FRE

 I-FRE
Azathioprine B-DRUG
150 B-STR
mg I-STR
PO B-ROU
qAM B-FRE
, I-FRE
100 B-STR
mg I-STR
PO B-ROU
qPM B-FRE

 I-FRE
Indomethacin B-DRUG
50 B-STR
mg I-STR
PO B-ROU
TID B-FRE

 I-FRE
MS B-DRUG
contin I-DRUG
60 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Gabapentin B-DRUG
300 B-STR
mg I-STR
tid B-FRE

 I-FRE
Dilaudid B-DRUG
4 B-STR
- I-STR
8 I-STR
mg I-STR
q8h B-FRE
prn I-FRE
pain B-REA

 I-REA
Donnatal B-DRUG
16.2 B-STR
mg I-STR
1 B-DOS
- I-DOS
2 I-DOS
tabs B-FOR
PO B-ROU
QID B-FRE
prn I-FRE
for O
dyspepsia B-REA

 I-REA
Alendronate B-DRUG
35 B-STR
mg I-STR
PO B-ROU
qSunday B-FRE

 I-FRE
Calcium B-DRUG
500 B-STR
mg I-STR
daily B-FRE

 I-FRE
Vitamin B-DRUG
D2 I-DRUG
50,000 B-STR
unit I-STR
capsule B-FOR
PO B-ROU
3x B-FRE
per I-FRE
week I-FRE
( I-FRE
T/Th/F I-FRE
) I-FRE

 I-FRE
Bactrim B-DRUG
DS I-DRUG
1 B-DOS
tab B-FOR
3x B-FRE
per I-FRE
week I-FRE
( I-FRE
M/W/F I-FRE
) I-FRE

 I-FRE
Clobetasol B-DRUG
0.05 B-STR
% I-STR
to O
scalp B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
on B-FRE
weekends I-FRE

 I-FRE
Levemir B-DRUG
8u B-DOS
qAM B-FRE
, I-FRE
10u B-DOS
qPM B-FRE

 I-FRE
Aspart B-DRUG
based O
on O
carb O
counting O

 O
ASA B-DRUG
81 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
HCTZ B-DRUG
25 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Lisinopril B-DRUG
40 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Metoprolol B-DRUG
succinate I-DRUG
100 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
Pravastatin B-DRUG
80 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Montelukast B-DRUG
4 B-STR
mg I-STR
PO B-ROU
daily B-FRE


 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Sulfamethoxazole-Trimethoprim B-DRUG
800 B-STR
- I-STR
160 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
3X/WEEK B-FRE
( I-FRE
MO I-FRE
, I-FRE
WE I-FRE
, I-FRE
FR I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Azathioprine B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QAM B-FRE
( I-FRE
once I-FRE

 I-FRE
a I-FRE
day I-FRE
( I-FRE
in I-FRE
the I-FRE
morning I-FRE
) I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Azathioprine B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QPM B-FRE
( I-FRE
once I-FRE
a I-FRE

 I-FRE
day I-FRE
( I-FRE
in I-FRE
the I-FRE
evening I-FRE
) I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Prednisone B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
5 O
. O
Golimumab B-DRUG
50 B-STR
mg/0.5 I-STR
mL I-STR
Pen B-FOR
Injector I-FOR
Sig O
: O
Fifty B-DOS
( I-DOS
50 I-DOS
) I-DOS
mg I-DOS

 I-DOS
Subcutaneous B-ROU
once B-FRE
a I-FRE
month I-FRE
. I-FRE

 O
6 O
. O
Phenobarb-Hyoscy-Atropine-Scop B-DRUG
16.2 B-STR
- I-STR
0.1037 I-STR
-0.0194 I-STR
mg I-STR
Tablet B-FOR

 I-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
heartburn B-REA
. I-REA



 O
7 O
. O
Alendronate B-DRUG
70 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
QSUN B-FRE
( I-FRE
every I-FRE

 I-FRE
Sunday I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Metoprolol B-DRUG
Succinate I-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sustained I-FOR
Release I-FOR
24 I-FOR
hr I-FOR

 I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
Sustained I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Hydrochlorothiazide B-DRUG
12.5 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU

 I-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Lisinopril B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
11 O
. O
INSULIN B-DRUG

 I-DRUG
Please O
resume O
as O
you O
were O
taking O
before O
hospitalization O
: O

 O
Levemir B-DRUG
8u B-DOS
qAM B-FRE
, I-FRE
10u B-DOS
qPM B-FRE

 I-FRE
Aspart B-DRUG
based O
on O
carb O
counting O

 O
12 O
. O
Calcium B-DRUG
Carbonate I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Ergocalciferol B-DRUG
( I-DRUG
Vitamin I-DRUG
D2 I-DRUG
) I-DRUG
50,000 B-STR
unit I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
PO B-ROU
QTUTHFRI B-FRE
( O
) O
. O

 O
14 O
. O
Clobetasol B-DRUG
0.05 B-STR
% I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 O

 O
times O
a O
day O
) O
: O
on O
weekends O
. O

 O
15 O
. O
Oxycodone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
every B-FRE
four I-FRE
( I-FRE
4 I-FRE
) I-FRE

 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
: I-REA
Never O
drink O
alcohol O
, O
drive O
, O
or O
operate O

 O
heavy O
machinery O
with O
this O
medicine O
. O

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
16 O
. O
Pravastatin B-DRUG
80 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE
bedtime I-FRE
. I-FRE



 O
17 O
. O
Montelukast B-DRUG
4 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Chewable I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
18 O
. O
Ferrous B-DRUG
Sulfate I-DRUG
300 B-STR
  I-STR
mg I-STR
( O
60 B-STR
mg I-STR
Iron B-DRUG
) I-DRUG
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
19 O
. O
Acetaminophen B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
every B-FRE
six I-FRE

 I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
: I-FRE
Do O
not O
exceed O
4 O
grams O
in O
24 O
hours O
. O

 O
20 O
. O
Aspirin B-DRUG
81 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Chewable I-FOR

 I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
21 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE

 I-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
: I-FRE
hold O
for O
loose B-ADE
stools I-ADE
. I-ADE

 O
Disp:*60 O
Capsule(s B-FOR
) O
* O
Refills:*0 O
* O

 O
22 O
. O
Camphor-Menthol B-DRUG
0.5 B-STR
- I-STR
0.5 I-STR
% I-STR
Lotion B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU

 I-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( B-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
itchiness B-REA
: I-REA
Can O
apply O
to O
back O

 O
of O
calf O
or O
other O
regions O
of O
itchy O
skin O
. O
Avoid O
open O
wound O
- O

 O
please O
cover O
wound O
before O
application O
. O
. O

 O
Disp:*1 O
tube O
* O
Refills:*0 O
* O

 O
23 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
: I-FRE
hold O
for O
loose B-ADE
stools I-ADE
. I-ADE

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
24 O
. O
Omeprazole B-DRUG
40 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*30 O
Capsule O
, O
Delayed O
Release(E.C.)(s O
) O
* O
Refills:*0 O
* O

 O
25 O
. O
Mupirocin B-DRUG
Calcium I-DRUG
2 B-STR
% I-STR
Cream B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( B-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*1 O
tube O
* O
Refills:*0 O
* O

 O
26 O
. O
Indomethacin B-DRUG
50 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
three B-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
. I-FRE



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
[ O
* O
* O
First O
Name5 O
( O
NamePattern1 O
) O
189 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
269 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Idiopathic O
spondylarthropathy O

 O
Cellulitis O

 O
Hypotension B-ADE
in O
the O
setting O
of O
narcotic B-DRUG
overdose B-ADE

 I-ADE
Psoriatic O
arthritis O

 O
Acute O
renal O
failure O

 O
GERD O

 O
OSA O

 O
DM O

 O
HTN O

 O
HL O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O

 O
Activity O
Status O
: O
Ambulatory O
- O
requires O
assistance O
or O
aid O



 O
Discharge O
Instructions O
: O

 O
It O
was O
a O
pleasure O
taking O
care O
of O
you O
at O
[ O
* O
* O
Hospital1 O
827 O
* O
* O
] O
. O



 O
You O
were O
admitted O
because O
your O
left O
knee O
was O
swollen O
, O
red O
and O

 O
painful O
and O
you O
also O
had O
a O
pain O
on O
your O
left O
leg O
and O
foot O
. O
The O

 O
rheumatology O
team O
evaluated O
and O
took O
fluid O
from O
your O
knee O
. O
You O

 O
were O
initially O
treated O
with O
antibiotic B-DRUG
for O
possible O
infection B-REA

 I-REA
and O
pain B-DRUG
medications I-DRUG
. I-DRUG
The O
fluid O
was O
cultured O
for O
infection O
but O

 O
this O
was O
negative O
. O
  O
You O
did O
have O
a O
blood B-REA
culture I-REA
that I-REA
was I-REA

 I-REA
positive I-REA
and O
we O
provided O
you O
with O
a O
two B-DUR
week I-DUR
course O
of O

 O
antibiotics B-DRUG
. I-DRUG
  O
We O
also O
had O
interventional O
radiology O
and O
vascular O

 O
surgery O
to O
help O
drain O
the O
fluids O
from O
your O
leg O
. O
  O
This O
helped O

 O
your O
swelling O
. O
  O
You O
required O
a O
lot O
of O
pain B-DRUG
medications I-DRUG
to O

 O
control O
the O
pain B-REA
, I-REA
and O
at O
one O
point O
went O
to O
the O
ICU O
because O
your O

 O
system O
did O
not O
clear O
the O
medicines O
adequately O
. O
You O
are O
now O
on O
a O

 O
much O
more O
conservative O
pain O
regimen O
. O
You O
will O
follow O
up O
with O

 O
pain O
doctors O
as O
[ O
* O
* O
Name5 O
( O
PTitle O
) O
* O
* O
] O
outpatient O
. O
  O
We O
determined O
that O
the O
fluid O

 O
collection O
is O
not O
due O
to O
infection O
, O
and O
more O
likely O
a O

 O
rheumatological O
problem O
. O
  O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
will O
follow O
up O
with O
the O

 O
rheumatologists O
as O
an O
outpatient O
. O


 O
Please O
note O
we O
made O
the O
following O
changes O
to O
your O
medications O
. O

 O
1 O
. O
Decrease O
prednisone B-DRUG
from O
60 B-STR
mg I-STR
to O
20 B-STR
mg I-STR

 I-STR
2 O
. O
Stop O
MSContin B-DRUG

 I-DRUG
3 O
. O
Stop O
gabapentin B-DRUG

 I-DRUG
4 O
. O
Stop O
dilaudid B-DRUG

 I-DRUG
5 O
. O
Start O
oxycodone B-DRUG
every B-FRE
four I-FRE
hours I-FRE
for O
pain B-REA
control I-REA
. I-REA
Never O

 O
drink O
alcohol O
, O
drive O
, O
or O
operate O
heavy O
machinery O
with O
this O

 O
medication O
. O

 O
6 O
. O
Start O
iron B-DRUG
supplementation I-DRUG

 I-DRUG
7 O
. O
Start O
Sarna B-DRUG
lotion B-FOR
and O
mupirocin B-DRUG
cream B-FOR
for O
your B-REA
rash I-REA
and O

 O
follow O
up O
with O
your O
PCP O
for O
resolution O

 O
8 O
. O
Start O
tylenol B-DRUG
1 B-STR
gram I-STR
every B-FRE
six I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA
Do O

 O
not O
exceed O
4 O
grams O
in O
one O
day O
. O

 O
9 O
. O
  O
Start O
omeprazole B-DRUG
daily B-FRE
to O
protect O
your O
stomach O
lining O
while O

 O
you O
are O
taking O
prednisone B-DRUG
and O
indomethacin B-DRUG
( O
which O
can O
cause O

 O
irritation O
) O

 O
10 O
. O
Start O
colace B-DRUG
and O
senna B-DRUG
to O
ensure O
you O
have O
having O
bowel O

 O
movements O
while O
on O
oxycodone B-DRUG
and O
iron B-DRUG
supplementation I-DRUG
. I-DRUG
Do O
n't O

 O
take O
these O
medicines O
when O
you O
are O
having O
loose O
stools O
. O


 O
Follow O
up O
with O
your O
PCP O
and O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
for O
the O
results O
from O
your O

 O
muscle O
biopsy O
, O
which O
are O
still O
pending O
. O


 O
A O
visiting O
nurse O
will O
be O
coming O
to O
your O
home O
to O
help O
with O
your O

 O
wound O
vac O
. O
Follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
( O
vascular O
) O
as O
listed O

 O
below O
. O



 O
Followup O
Instructions O
: O

 O
You O
have O
the O
following O
appointments O
in O
place O
. O



 O
Provider O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
11595 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
11596 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
2226 O
* O
* O
] O
Date/Time:[**2202 O
- O
2 O
- O
1 O
* O
* O
] O

 O
8:00 O


 O
Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
1112 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
2604 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
1237 O
* O
* O
] O

 O
Date/Time:[**2202 O
- O
2 O
- O
11 O
* O
* O
] O
1:00 O


 O
Provider O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
2385 O
* O
* O
] O
, O
MD O
Phone:[**Telephone/Fax O
( O
1 O
) O
62 O
* O
* O
] O

 O
Date/Time:[**2202 O
- O
3 O
- O
29 O
* O
* O
] O
9:40 O


 O
Department O
: O
INFECTIOUS O
DISEASE O

 O
When O
: O
TUESDAY O
[ O
* O
* O
2202 O
- O
2 O
- O
2 O
* O
* O
] O
at O
9:00 O
AM O

 O
With O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
13896 O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
457 O
* O
* O
] O

 O
Building O
: O
LM O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
Bldg O
( O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
) O
[ O
* O
* O
Hospital O
1422 O
* O
* O
] O

 O
Campus O
: O
WEST O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
Garage O


 O
Name O
: O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
* O
* O
] O
, O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
-Primary O
Care O

 O
Address O
: O
[ O
* O
* O
Location O
( O
un O
) O
35619 O
* O
* O
] O
, O
[ O
* O
* O
Apartment O
Address(1 O
) O
* O
* O
] O
, O
[ O
* O
* O
Hospital1 O
* O
* O
] O
, O
[ O
* O
* O
Numeric O
Identifier O
23661 O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
35614 O
* O
* O
] O

 O
Appt O
: O
[ O
* O
* O
2 O
- O
8 O
* O
* O
] O
at O
2 O
pm O


 O
Department O
: O
PAIN O
MANAGEMENT O
CENTER O

 O
When O
: O
WEDNESDAY O
[ O
* O
* O
2202 O
- O
2 O
- O
17 O
* O
* O
] O
at O
10:20 O
AM O

 O
With O
: O
[ O
* O
* O
Name6 O
( O
MD O
) O
8673 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
8674 O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1652 O
* O
* O
] O

 O
Building O
: O
One O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
Place O
( O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
MA O
) O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Campus O
: O
OFF O
CAMPUS O
Best O
Parking O
: O
Parking O
on O
Site O

 O
You O
have O
been O
placed O
on O
an O
urgent O
patient O
cancellation O
list O
and O

 O
they O
will O
call O
you O
if O
there O
is O
an O
earlier O
appointment O
as O
well O
. O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2132 O
- O
3 O
- O
26 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2132 O
- O
5 O
- O
7 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2086 O
- O
9 O
- O
26 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
CARDIOTHORACIC O


 O
Allergies O
: O

 O
Ibuprofen B-DRUG
/ O
Aspirin B-DRUG


 I-DRUG
Attending:[**Last O
Name O
( O
NamePattern1 O
) O
1561 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Dyspnea/ O
Stridor O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
Y O
stent O
placement O
[ O
* O
* O
4 O
- O
25 O
* O
* O
] O
, O
# O
6 O
fenestrated O
cuffless O
trach O
placement O



 O
History O
of O
Present O
Illness O
: O

 O
45 O
M O
tracheoesophageal O
fistula O
repaired O
[ O
* O
* O
2087 O
* O
* O
] O
with O
multiple O

 O
tracheostomies O
, O
tracheomalacia O
, O
tracheal O
resection O

 O
[**2102**],tracheoplasty O
augmentation O

 O
with O
t-tube O
placement O
[ O
* O
* O
8 O
- O
18 O
* O
* O
] O
now O
with O
stridor O



 O
Past O
Medical O
History O
: O

 O
Rheumatoid O
arthritis O
, O
Diabetes O
Mellitus O
2 O
, O
tracheoesophageal O

 O
fistula O
repaired O
[ O
* O
* O
2087 O
* O
* O
] O
with O
multiple O
tracheostomies O
, O

 O
tracheomalacia O
, O
tracheal O
resection O
[**2102**],tracheoplasty O

 O
augmentation O

 O
with O
t-tube O
plcement O
[ O
* O
* O
8 O
- O
18 O
* O
* O
] O



 O
Social O
History O
: O

 O
Lives O
in O
  O
[ O
* O
* O
Location O
( O
un O
) O
69402**],[**State O
38104 O
* O
* O
] O
w/ O
wife O
. O
Referred O
to O
Airway O

 O
Center O
, O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
MD O
, O
[ O
* O
* O
Name8 O
( O
MD O
) O
952 O
* O
* O
] O
, O
MD O
. O

 O
[ O
* O
* O
First O
Name O
( O
Titles O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
Titles O
) O
* O
* O
] O
, O
ciggs O
or O
rec O
rx O
use O



 O
Family O
History O
: O

 O
F- O

 O
M- O
Alzheimers O
, O
bopolar O

 O
Sibling- O
thyroid O
disease O
. O


 O
Physical O
Exam O
: O

 O
Gen O
: O
NAD O

 O
CV O
: O
RRR O

 O
Chest O
: O
CTA O
Bilaterally O

 O
Ext:+ O
pulses O
, O
no O
edema O

 O
Wound O
: O
CDI O


 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2132 O
- O
3 O
- O
25 O
* O
* O
] O
08:15AM O
   O
GLUCOSE-214 O
* O
UREA O
N-17 O
CREAT-1.0 O
SODIUM-138 O

 O
POTASSIUM-4.1 O
CHLORIDE-104 O
TOTAL O
CO2 O
- O
24 O
ANION O
GAP-14 O

 O
[ O
* O
* O
2132 O
- O
3 O
- O
25 O
* O
* O
] O
08:15AM O
   O
WBC-5.8 O
RBC-4.81 O
# O
HGB-13.7 O
* O
# O
HCT-38.7 O
* O
# O

 O
MCV-80 O
* O
# O
MCH-28.5 O
MCHC-35.5 O
* O
RDW-14.0 O



 O
Brief O
Hospital O
Course O
: O

 O
45 O
M O
admitted O
with O
stridor O
found O
to O
tracheomalacia O
on O
bronch O
s/p O

 O
t-tube O
removal O
[**2132 O
- O
3 O
- O
26**].Tracheoplasty O
delayed O
secondary O
to O
desat O

 O
episode O
. O
on O
[ O
* O
* O
2132 O
- O
4 O
- O
2 O
* O
* O
] O
he O
underwent O
a O
flex O
bronch O
with O

 O
tracheobronchoplasty O
. O
Patient O
tolerated O
the O
procedure O
weel O
. O
On O

 O
POD O
2 O
bronch O
showed O
some O
collapse O
of O
distal O
trachea O
. O

 O
Rheumatology O
was O
consulted O
secondary O
to O
shoulder O
pain O
and O

 O
suggested O
injection O
and O
paon O
control O
. O
He O
passed O
a O
video O
swallow O

 O
test O
on O
[ O
* O
* O
4 O
- O
9 O
* O
* O
] O
and O
his O
diet O
was O
advanced O
. O
Respiratory O
therapy O

 O
followed O
him O
with O
trach O
care O
throughout O
his O
stay O
. O
A O
bronch O
on O

 O
[ O
* O
* O
4 O
- O
15 O
* O
* O
] O
showed O
some O
granulation O
tissue O
on O
posterior O
wall O
and O
mid O

 O
trachea O
. O
Mr O
[ O
* O
* O
Known O
lastname O
715 O
* O
* O
] O
was O
followed O
with O
serial O
bronch O
's O
which O
showed O

 O
a O
decrease O
in O
the O
granulation O
tissue O
. O
On O
[ O
* O
* O
4 O
- O
25 O
* O
* O
] O
a O
y-stent O
was O

 O
placed O
with O
improvement O
in O
breathing O
. O
He O
did O
very O
well O
and O
was O

 O
discharged O
on O
[ O
* O
* O
5 O
- O
7 O
* O
* O
] O
. O


 O
Medications O
on O
Admission O
: O

 O
glipizide B-DRUG
40 B-STR
' I-STR

 O
aciphex B-DRUG
20 B-STR
' I-STR

 O
clarinex B-DRUG

 I-DRUG
Percocet B-DRUG

 I-DRUG
Phenergan B-DRUG

 I-DRUG
Xopenex B-DRUG

 I-DRUG
albuterol B-DRUG

 I-DRUG
Pulmicort B-DRUG



 I-DRUG
Discharge O
Medications O
: O

 O
1 O
. O
Albuterol B-DRUG
90 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Puffs B-FOR
Inhalation B-ROU

 I-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
Disp:*1 O
* O
Refills:*0 O
* O

 O
2 O
. O
Fluticasone B-DRUG
110 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Puff B-FOR

 I-FOR
Inhalation B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
Disp:*1 O
* O
Refills:*0 O
* O

 O
3 O
. O
Camphor-Menthol B-DRUG
0.5 B-STR
- I-STR
0.5 I-STR
% I-STR
Lotion B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU

 I-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pruritus B-REA
. I-REA

 O
Disp:*1 O
* O
Refills:*0 O
* O

 O
4 O
. O
Magnesium B-DRUG
Hydroxide I-DRUG
400 B-STR
mg/5 I-STR
mL I-STR
Suspension B-FOR
Sig O
: O
Thirty B-DOS
( I-DOS
30 I-DOS
) I-DOS

 I-DOS
ML I-DOS
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
5 O
. O
Diltiazem B-DRUG
HCl I-DRUG
30 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1.5 B-DOS
Tablets B-FOR
PO B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*180 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
6 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
0.083 B-STR
% I-STR
Solution B-FOR
Sig O
: O
[ O
* O
* O
1 O
- O
15 O
* O
* O
] O
  O
Inhalation B-ROU
Q6H B-FRE

 I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
Disp:*90 O
* O
Refills:*0 O
* O

 O
7 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
0.02 B-STR
% I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Inhalation B-ROU

 I-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
Disp:*90 O
* O
Refills:*0 O
* O

 O
8 O
. O
Nystatin B-DRUG
100,000 B-STR
unit/g I-STR
Cream B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Topical B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
Disp:*1 O
* O
Refills:*0 O
* O

 O
9 O
. O
Fexofenadine B-DRUG
60 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
. I-FRE

 O
Disp:*120 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
10 O
. O
Guaifenesin B-DRUG
100 B-STR
mg/5 I-STR
mL I-STR
Syrup B-FOR
Sig O
: O
5 B-DOS
- I-DOS
10 I-DOS
MLs I-DOS
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
stent B-REA
management I-REA
. I-REA

 O
Disp:*400 O
ML(s O
) O
* O
Refills:*0 O
* O

 O
11 O
. O
Famotidine B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
12 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet O
, O
Delayed O
Release O
(E.C.)(s O
) O
* O
Refills:*0 O
* O

 O
13 O
. O
Linezolid B-DRUG
600 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE

 I-FRE
for B-DUR
1 I-DUR
months I-DUR
. I-DUR

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
14 O
. O
Hydrocodone-Acetaminophen B-DRUG
5 B-STR
- I-STR
500 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR

 I-FOR
PO B-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
Disp:*75 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
15 O
. O
Zofran B-DRUG
4 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
every B-FRE
eight I-FRE
( I-FRE
8) I-FRE

 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
. I-REA

 O
Disp:*15 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O

16 O
. O
Simethicone B-DRUG
80 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Chewable I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Chewable I-FOR
PO B-ROU
four B-FRE
times I-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Disp:*120 O
Tablet O
, O
Chewable(s O
) O
* O
Refills:*0 O
* O

 O
17 O
. O
NPH B-DRUG
insulin I-DRUG

 I-DRUG
5 B-DOS
units I-DOS
NPH B-DRUG
SQ B-ROU
with B-FRE
b-fast I-FRE
and I-FRE
dinner I-FRE

 I-FRE
18 O
. O
humalog B-DRUG
insulin I-DRUG

 I-DRUG
humalog B-DRUG
insulin I-DRUG
per O
sliding B-DOS
scale I-DOS

 I-DOS
19 O
. O
Syringe O
with O
Needle O
, O
Insulin B-DRUG
3 O
mL O
20 O
x O
1 O
  O
Syringe O
Sig O
: O
One O

 O
( O
1 O
) O
Syringe O
Miscellaneous O
AS O
DIRECTED O
. O

 O
Disp:*120 O
Syringe O
* O
Refills:*0 O
* O

 O
20 O
. O
Roxicet B-DRUG
5 B-STR
- I-STR
325 I-STR
mg/5 I-STR
mL I-STR
Solution B-FOR
Sig O
: O
[ O
* O
* O
5 O
- O
22 O
* O
* O
] O
mL O
PO B-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE

 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
Disp:*1200 O
mL O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Tracheomalacia O
, O
s/p O
tracheoplasty O
, O
complicated O
with O
necrosis O
of O

 O
the O
posterior O
membranous O
wall O
, O
s/p O
rigid O
bronch O
, O
T-tube O
removal O

 O
with O
trach O
cannulation O
, O
s/p O
Y O
stent O
placement O
[ O
* O
* O
4 O
- O
25 O
* O
* O
] O
and O
# O
6 O

 O
fenestrated O
cuffless O
trach O



 O
Discharge O
Condition O
: O

 O
Good O



 O
Discharge O
Instructions O
: O

 O
Call O
Dr.[**Name O
( O
NI O
) O
1816 O
* O
* O
] O
office O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O
if O
you O
develop O
chest O
pain O
, O

 O
shortness O
of O
breath O
, O
fever O
, O
chills O
, O
redness O
or O
drainage O
from O

 O
your O
incision/trach O
sites O
. O

 O
You O
may O
shower O
. O

 O
No O
tub O
bathing O
or O
swimming O
for O
3 O
- O
4 O
weeks O
. O


 O
Followup O
Instructions O
: O

 O
Call O
Dr.[**Name O
( O
NI O
) O
1816 O
* O
* O
] O
office O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
170 O
* O
* O
] O
for O
a O
follow O
up O

 O
appointment O
. O




 O
Completed O
by:[**2132 O
- O
5 O
- O
8 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2200 O
- O
10 O
- O
16 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2200 O
- O
11 O
- O
8 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2142 O
- O
1 O
- O
23 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Chlohexadine B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
4616 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
metastatic O
melanoma O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
1 O
. O
Right O
frontal O
craniotomy O
. O

 O
2 O
. O
Excision O
of O
tumor O
with O
stereotactic O
navigation O
. O



 O
History O
of O
Present O
Illness O
: O

 O
HPI O
: O
  O
Patient O
is O
a O
58 O
year O
old O
gentleman O
with O
a O
history O
of O

 O
malignant O
melanoma O
who O
presented O
to O
an O
outside O
hospital O

 O
complaining O
of O
nausea O
and O
headaches O
. O
He O
was O
previously O
on O

 O
hospice O
care O
but O
had O
a O
change O
of O
heart O
. O
  O
His O
melanoma O
had O

 O
previously O
metastasized O
to O
his O
lungs O
, O
brain O
, O
and O
bowels O
, O
which O

 O
required O
surgical O
intervention O
. O
CT O
scan O
recently O
at O
OSH O
showed O

 O
new O
lesions O
in O
the O
head O
necrosis O
vs. O
new O
mets O
. O
The O
patient O

 O
changed O
his O
mind O
RE O
hospice O
care O
and O
would O
like O
this O
treated O
. O
An O

 O
MRI O
today O
at O
the O
OSH O
showed O
edema O
concerning O
for O
metastatic O

 O
disease O
at O
R O
frontal O
parietal O
. O
There O
was O
also O
increase O
vasogenic O

 O
edema O
, O
and O
5 O
mm O
osseous O
neoplastic O
disease O
. O
  O
Was O
transfered O
here O

 O
to O
get O
Thallium O
PET O
. O
[ O
* O
* O
Month O
( O
only O
) O
116 O
* O
* O
] O
get O
cyberknife O
vs O
resection O
. O



 O
Past O
Medical O
History O
: O

 O
PAST O
MEDICAL O
HISTORY O
: O

 O
HTN O
( O
? O
) O

 O
Atrial O
fibrillation O
, O
[ O
* O
* O
2195 O
* O
* O
] O
, O
resolved O

 O
Depression O

 O
Bradycardia O



 O
Social O
History O
: O

 O
Lived O
with O
his O
brother O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
. O
Was O
a O
Polaroid O
technician O
. O
Never O

 O
smoked O
tobacco O
, O
rare O
EtOH O
use O
. O



 O
Family O
History O
: O

 O
Mom O
and O
dad O
with O
diabetes O
. O
Aunt O
with O
unknown O
malignancy O
, O
cousin O

 O
with O
breast O
ca O
. O



 O
Physical O
Exam O
: O

 O
On O
Admission O

 O
Vitals O
- O
T:97.6 O
BP:116/64 O
HR:74 O
RR:18 O
02 O
sat:94 O

 O
GENERAL O
: O
slow O
to O
respond O
, O
but O
AAOx3 O

 O
SKIN O
: O
warm O
and O
well O
perfused O
, O
no O
excoriations O
or O
lesions O
, O
no O

 O
rashes O
, O
some O
hemangiomas O
throughout O
body O
. O

 O
HEENT O
: O
AT/NC O
, O
EOMI O
, O
PERRLA O
, O
anicteric O
sclera O
, O
pink O
conjunctiva O
, O

 O
patent O
nares O
, O
MMM O
, O
good O
dentition O
, O
nontender O
supple O
neck O
, O
no O

 O
LAD O
, O
no O
JVD O
. O
Eyes O
dysconjugate O
. O

 O
CARDIAC O
: O
RRR O
, O
S1/S2 O
, O
no O
mrg O

 O
LUNG O
: O
CTAB O

 O
ABDOMEN O
: O
nondistended O
, O
+ O
BS O
, O
nontender O
in O
all O
quadrants O
, O
no O

 O
rebound/guarding O
, O
no O
hepatosplenomegaly O

 O
M/S O
: O
moving O
all O
extremities O
well O
, O
no O
cyanosis O
, O
clubbing O
or O

 O
edema O
, O
no O
obvious O
deformities O

 O
PULSES O
: O
2 O
+ O
DP O
pulses O
bilaterally O

 O
NEURO O
: O
CN O
II-XII O
intact O

 O
. O


 O
On O
Discharge O
: O

 O
Vitals O
- O
96.6 O
, O
122/70 O
, O
87 O
, O
16 O
, O
95RA O

 O
GENERAL O
: O
lying O
in O
bed O

 O
SKIN O
: O
warm O
and O
well O
perfused O
, O
no O
excoriations O
or O
lesions O
, O
no O

 O
rashes O
, O
some O
hemangiomas O
throughout O
body O
. O

 O
HEENT O
: O
AT/NC O
, O
EOMI O
, O
anicteric O
sclera O
, O
MMM O
, O
nontender O
supple O

 O
neck O
, O
no O
LAD O
, O
no O
JVD O
. O

 O
CARDIAC O
: O
RRR O
, O
S1/S2 O
, O
no O
mrg O

 O
LUNG O
: O
CTAB O

 O
ABDOMEN O
: O
nondistended O
, O
+ O
BS O
, O
nontender O
in O
all O
quadrants O
, O
no O

 O
rebound/guarding O
, O
no O
hepatosplenomegaly O

 O
M/S O
: O
moving O
all O
extremities O
well O
, O
no O
cyanosis O
, O
clubbing O
or O

 O
edema O
, O
no O
obvious O
deformities O

 O
PULSES O
: O
2 O
+ O
DP O
pulses O
bilaterally O

 O
NEURO O
: O
CN O
II-XII O
intact O



 O
Pertinent O
Results O
: O

 O
On O
Admission O
: O

 O
[ O
* O
* O
2200 O
- O
10 O
- O
17 O
* O
* O
] O
05:35AM O
BLOOD O
WBC-8.0 O
RBC-4.87 O
Hgb-14.1 O
Hct-43.5 O
MCV-89 O

 O
MCH-29.0 O
MCHC-32.5 O
RDW-12.4 O
Plt O
Ct-260 O

 O
[ O
* O
* O
2200 O
- O
10 O
- O
17 O
* O
* O
] O
05:35AM O
BLOOD O
Plt O
Ct-260 O

 O
[ O
* O
* O
2200 O
- O
10 O
- O
17 O
* O
* O
] O
05:35AM O
BLOOD O
Glucose-83 O
UreaN-16 O
Creat-0.8 O
Na-138 O

 O
K-4.0 O
Cl-101 O
HCO3 O
- O
29 O
AnGap-12 O

 O
[ O
* O
* O
2200 O
- O
10 O
- O
21 O
* O
* O
] O
06:00AM O
BLOOD O
ALT-21 O
AST-13 O
LD(LDH)-170 O
AlkPhos-87 O

 O
TotBili-0.2 O

 O
[ O
* O
* O
2200 O
- O
10 O
- O
17 O
* O
* O
] O
05:35AM O
BLOOD O
Calcium-8.8 O
Phos-2.9 O
Mg-2.0 O

 O
[ O
* O
* O
2200 O
- O
10 O
- O
31 O
* O
* O
] O
02:09PM O
BLOOD O
Type-ART O
pO2 O
- O
174 O
* O
pCO2 O
- O
24 O
* O
pH-7.61 O
* O

 O
calTCO2 O
- O
25 O
Base O
XS-4 O

 O
[ O
* O
* O
2200 O
- O
10 O
- O
31 O
* O
* O
] O
02:09PM O
BLOOD O
Glucose-98 O
Lactate-1.1 O
Na-135 O
K-2.8 O
* O

 O
Cl-107 O

 O
[ O
* O
* O
2200 O
- O
10 O
- O
31 O
* O
* O
] O
02:09PM O
BLOOD O
freeCa-0.99 O
* O

 O
. O

 O
Pertinent O
Results O
: O

 O
. O

 O
CT O
head O
[ O
* O
* O
2200 O
- O
11 O
- O
7 O
* O
* O
] O

 O
IMPRESSION O
: O
No O
acute O
hemorrhage O
or O
mass O
effect O
. O
Expected O

 O
post-surgical O

 O
changes O
. O

 O
. O

 O
CXR O
[ O
* O
* O
2200 O
- O
11 O
- O
2 O
* O
* O
] O

 O
FINDINGS O
: O
Right O
internal O
jugular O
vascular O
catheter O
has O
been O

 O
repositioned O
, O
now O
terminating O
in O
the O
mid O
superior O
vena O
cava O
, O

 O
with O
no O
visible O
pneumothorax O
. O
  O
Endotracheal O
tube O
and O
nasogastric O

 O
tube O
have O
been O
removed O
. O
Cardiomediastinal O
contours O
are O
stable O
in O

 O
appearance O
. O
Persistent O
right O
lower O
lobe O
scarring O
versus O

 O
atelectasis O
adjacent O
to O
surgical O
chain O
sutures O
as O
well O
as O
a O

 O
small O
right O
pleural O
effusion O
versus O
pleural O
thickening O
. O
No O
new O

 O
or O
worsening O
lung O
or O
pleural O
abnormalities O
. O

 O
. O


 O
ECG O
[ O
* O
* O
2200 O
- O
11 O
- O
2 O
* O
* O
] O

 O
Sinus O
tachycardia O
, O
rate O
107 O
with O
frequent O
ventricular O
premature O

 O
beats O
. O
There O
is O
moderate O
baseline O
artifact O
. O
Left O
atrial O

 O
abnormality O
. O
Compared O
to O
the O
previous O
tracing O
of O
[ O
* O
* O
2200 O
- O
10 O
- O
28 O
* O
* O
] O
, O

 O
except O
for O
the O
change O
in O
rate O
and O
the O
presence O
of O
frequent O

 O
ventricular O
premature O
beats O
, O
no O
diagnostic O
interval O
change O
. O

 O
. O

 O
Brain O
Tissue O
Biopsy O

 O
DIAGNOSIS O
: O

 O
I. O
Brain O
, O
right O
craniotomy O
: O

 O
Necrosis O
and O
changes O
consistent O
with O
radiation O
changes O
. O
See O

 O
note O
. O

 O
II O
. O
Brain O
, O
right O
craniotomy O
: O

 O
Necrosis O
and O
changes O
consistent O
with O
radiation O
changes O
. O
See O

 O
note O
. O

 O
. O

 O
MRI O
BRAIN O
[ O
* O
* O
2200 O
- O
10 O
- O
28 O
* O
* O
] O

 O
IMPRESSION O
: O

 O
1 O
. O
Right O
frontal O
enhancing O
mass O
from O
tumor/radiation O
necrosis O
at O

 O
the O

 O
resection O
site O
with O
associated O
significant O
perilesional O
edema/ O

 O
radiation O

 O
induced O
changes O
. O
There O
is O
extensive O
perilesional O
FLAIR O
and O
T2 O

 O
hyperintensity O

 O
surrounding O
this O
mass O
. O
There O
is O
mild O
decrease O
in O
enhancement O
as O

 O
compared O
to O
the O
previous O
MRIS O
with O
no O
change O
in O
the O
perilesional O

 O
hyperintensity O
. O
This O
mass O
is O
likely O
to O
represent O
radiation O

 O
induced O
necrosis O
rather O
than O
residual/ O
recurrent O
neoplasm O
. O
For O

 O
surgical O
planning O
. O

 O
2 O
. O
No O
evidence O
of O
new O
enhancing O
lesion O
. O

 O
. O

 O
Discharge O
Labs O
: O

 O
. O

 O
[ O
* O
* O
2200 O
- O
11 O
- O
7 O
* O
* O
] O
01:45PM O
BLOOD O
WBC-8.5 O
RBC-4.32 O
* O
Hgb-13.1 O
* O
Hct-37.1 O
* O

 O
MCV-86 O
MCH-30.2 O
MCHC-35.2 O
* O
RDW-12.9 O
Plt O
Ct-227 O

 O
[ O
* O
* O
2200 O
- O
10 O
- O
30 O
* O
* O
] O
07:45AM O
BLOOD O
WBC-12.0 O
* O
RBC-4.84 O
Hgb-14.7 O
Hct-41.6 O

 O
MCV-86 O
MCH-30.3 O
MCHC-35.3 O
* O
RDW-12.7 O
Plt O
Ct-270 O

 O
[ O
* O
* O
2200 O
- O
11 O
- O
7 O
* O
* O
] O
01:45PM O
BLOOD O
Glucose-91 O
UreaN-15 O
Creat-0.5 O
Na-134 O

 O
K-3.7 O
Cl-97 O
HCO3 O
- O
27 O
AnGap-14 O

 O
[ O
* O
* O
2200 O
- O
11 O
- O
7 O
* O
* O
] O
01:45PM O
BLOOD O
ALT-24 O
AST-20 O
AlkPhos-95 O
TotBili-1.2 O

 O
[ O
* O
* O
2200 O
- O
11 O
- O
7 O
* O
* O
] O
01:45PM O
BLOOD O
Albumin-3.5 O
Calcium-8.6 O
Phos-2.6 O
* O
Mg-1.6 O

 O
[ O
* O
* O
2200 O
- O
11 O
- O
1 O
* O
* O
] O
08:01PM O
BLOOD O
Type-ART O
pO2 O
- O
147 O
* O
pCO2 O
- O
40 O
pH-7.45 O

 O
calTCO2 O
- O
29 O
Base O
XS-4 O



 O
Brief O
Hospital O
Course O
: O

 O
Mr. O
[ O
* O
* O
Name14 O
( O
STitle O
) O
102120 O
* O
* O
] O
presented O
from O
an O
outside O
hospital O
with O
severe O

 O
headaches O
and O
nausea O
. O
Thallium O
scan O
that O
was O
inconclusive O
. O
The O

 O
neurosurgical O
team O
saw O
the O
patient O
and O
agreed O
to O
do O
a O
craniotomy O

 O
and O
biopsy O
. O
Following O
the O
surgery O
, O
was O
cared O
for O
by O
the O

 O
neurosurgical O
team O
for O
several O
days O
. O
The O
patient O
had O
some O
relief O

 O
to O
nausea O
and O
headache O
, O
but O
symptoms O
were O
not O
completely O

 O
resolved O
. O
The O
pathology O
shows O
necrosis O
and O
arrangements O
were O

 O
made O
for O
an O
outpatient O
family O
meeting O
with O
neuroncology O
next O

 O
week O
. O
  O
In O
the O
meantime O
, O
he O
will O
go O
to O
a O
living O
facility O
. O
During O

 O
his O
stay O
, O
Mr. O
[ O
* O
* O
Known O
lastname O
76901 O
* O
* O
] O
received O
PT O
for O
general O
weakness O
. O

 O
Palliative O
care O
provided O
significant O
input O
regarding O
medication O

 O
for O
pain O
and O
anxiety O
. O


 O
Medications O
on O
Admission O
: O

 O
Scopolamine B-DRUG
patch B-FOR
1.5 B-STR
mg I-STR
TD B-ROU
q3days B-FRE
( O
next O
change O
[ O
* O
* O
2200 O
- O
10 O
- O
17 O
* O
* O
] O
) O

 O
Dilaudid B-DRUG
4 B-STR
mg I-STR
PO B-ROU
q4h B-FRE
prn I-FRE
pain B-REA
[ O
* O
* O
1 O
- O
22 O
* O
* O
] O

 O
Dilaudid B-DRUG
6 B-STR
mg I-STR
PO B-ROU
q4h B-FRE
prn I-FRE
pain B-REA
[ O
* O
* O
6 O
- O
27 O
* O
* O
] O

 O
Senna B-DRUG
2tabs B-FOR
PO B-ROU
qhs B-FRE

 I-FRE
Bisacodyl B-DRUG
10 B-STR
mg I-STR
PR B-ROU
qod B-FRE

 I-FRE
Fentanyl B-DRUG
25mcg B-STR
TD B-ROU
q3days B-FRE
( O
next O
change O
[ O
* O
* O
2200 O
- O
10 O
- O
16 O
* O
* O
] O
) O

 O
Dilaudid B-DRUG
6 B-STR
mg I-STR
PO B-ROU
q4h B-FRE

 I-FRE
Decadron B-DRUG
4 B-STR
mg I-STR
PO B-ROU
q6h B-FRE

 I-FRE
Ativan B-DRUG
1 B-STR
mg I-STR
PO B-ROU
q6h B-FRE
prn I-FRE

 I-FRE
Compazine B-DRUG
10 B-STR
mg I-STR
PO B-ROU
q6h B-FRE
prn I-FRE

 I-FRE
Keppra B-DRUG
750 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
MVI B-DRUG
1tab B-FOR
PO B-ROU
daily B-FRE

 I-FRE
Miralax B-DRUG
17 B-STR
g I-STR
PO B-ROU
daily B-FRE

 I-FRE
Fioricet B-DRUG
2tab B-DOS
PO B-ROU
daily B-FRE

 I-FRE
Haldol B-DRUG
2 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Valium B-DRUG
10 B-STR
mg I-STR
PR B-ROU
prn B-FRE
q15min I-FRE
x O
4 B-DOS
doses I-DOS
until O
seizure B-REA
activity I-REA

 I-REA
subsides O

 O
Maalox B-DRUG
15mL B-DOS
q4h B-FRE
prn I-FRE

 I-FRE
Baclofen B-DRUG
5 B-STR
mg I-STR
PO B-ROU
TID B-FRE
prn I-FRE

 I-FRE
Effexor B-DRUG
37.5 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
Zofran B-DRUG
4 B-STR
mg I-STR
PO B-ROU
q6h B-FRE
prn I-FRE

 I-FRE
Levsin B-DRUG
0.125 B-STR
mg I-STR
PO B-ROU
daily B-FRE
QIDACHS I-FRE

 I-FRE
Levsin B-DRUG
0.125 B-STR
mg I-STR
PO B-ROU
q6h B-FRE
prn I-FRE
secretions B-REA

 I-REA
Reglan B-DRUG
10 B-STR
mg I-STR
PO B-ROU
QIDACHS B-FRE

 I-FRE
Colace B-DRUG
100 B-STR
mg I-STR
PO B-ROU
BID B-FRE



 I-FRE

Discharge O
Medications O
: O

 O
1 O
. O
venlafaxine B-DRUG
37.5 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Ext I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Ext I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
labetalol B-DRUG
100 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
dexamethasone B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q B-FRE
12h I-FRE
( O
) O
for B-DUR

 I-DUR
4 I-DUR
days I-DUR
. I-DUR

 O
6 O
. O
levetiracetam B-DRUG
250 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Three B-DOS
( I-DOS
3 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE

 I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain/fever B-REA
. I-REA

 O
8 O
. O
fentanyl B-DRUG
12 B-STR
mcg/hr I-STR
Patch B-FOR
72 I-FOR
hr I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Patch B-FOR
72 I-FOR
hr I-FOR

 I-FOR
Transdermal B-ROU
Q72H B-FRE
( I-FRE
every I-FRE
72 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
lorazepam B-DRUG
0.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
three B-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
as I-FRE
needed I-FRE
for O
  O
nausea B-REA
or O
anxiety B-REA
. I-REA

 O
10 O
. O
pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
nystatin B-DRUG
100,000 B-STR
unit/mL I-STR
Suspension B-FOR
Sig O
: O
Five B-DOS
( I-DOS
5 I-DOS
) I-DOS
ML I-DOS
PO B-ROU
QID B-FRE

 I-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
thrush B-REA
. I-REA

 O
12 O
. O
olanzapine B-DRUG
2.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE

 I-FRE
bedtime I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
ZOFRAN B-DRUG
ODT I-DRUG
4 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR

 I-FOR
Rapid I-FOR
Dissolve I-FOR
PO B-ROU
every B-FRE
eight I-FRE
( I-FRE
8) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
nausea B-REA
. I-REA



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital O
* O
* O
] O
Rehabilitation O
and O
Nursing O
Center O
- O
[ O
* O
* O
Location O
( O
un O
) O
701 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Metastatic O
Malignant O
Melanoma O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Confused O
- O
sometimes O
. O

 O
Level O
of O
Consciousness O
: O
Lethargic O
but O
arousable O
. O

 O
Activity O
Status O
: O
Out O
of O
Bed O
with O
assistance O
to O
chair O
or O

 O
wheelchair O
. O



 O
Discharge O
Instructions O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
76901 O
* O
* O
] O
, O
you O
presented O
to O
us O
with O
severe O
headaches O
and O

 O
nausea O
and O
were O
to O
be O
worked O
up O
for O
possible O
new O
brain O

 O
metastasis O
of O
your O
pre-existing O
cancer O
. O
While O
with O
us O
, O
you O

 O
underwent O
several O
imaging O
studies O
of O
your O
brain O
, O
and O
had O

 O
neurosurgical O
intervention O
to O
remove O
the O
mass O
from O
your O
head O
. O



 O
We O
have O
changed O
several O
of O
your O
medications O
. O
Please O
only O
take O

 O
the O
medications O
listed O
below O
. O
Do O
not O
take O
any O
medications O
not O

 O
listed O
below O
. O



 O
Followup O
Instructions O
: O

 O
Department O
: O
NEUROLOGY O

 O
When O
: O
TUESDAY O
[ O
* O
* O
2200 O
- O
11 O
- O
11 O
* O
* O
] O
at O
9:30 O
AM O

 O
With O
: O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
12567 O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1844 O
* O
* O
] O

 O
Building O
: O
SC O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Clinical O
Ctr O
[ O
* O
* O
Location O
( O
un O
) O
858 O
* O
* O
] O

 O
Campus O
: O
EAST O
     O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Garage O




 O
Completed O
by:[**2200 O
- O
11 O
- O
9 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2123 O
- O
11 O
- O
4 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2123 O
- O
11 O
- O
16 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2044 O
- O
3 O
- O
15 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Penicillins B-DRUG
/ O
Inderal B-DRUG
/ O
Morphine B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
898 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
post-op O
bleeding O
after O
tooth O
extraction O



 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
None O



 O
History O
of O
Present O
Illness O
: O

 O
79 O
yo O
woman O
with O
history O
of O
a-fib B-REA
, I-REA
CHF O
s/p O
bioprosthetic O
mitral O

 O
and O
s/p O
tricuspid O
valve O
annuloplasty O
, O
who O
initially O
was O
admitted O

 O
to O
[ O
* O
* O
11 O
- O
4 O
* O
* O
] O
after O
she O
presented O
to O
ED O
with O
persistent O
bleeding O

 O
following O
L O
tooth O
extractions O
and O
posterior O
superior O
palate O
I O

 O
and O
D. O
Patient O
initially O
had O
INR B-ADE
elevated I-ADE
to I-ADE
2.1 I-ADE
secondary O
to O

 O
warfarin B-DRUG
use O
for O
atrial B-REA
fibrillation I-REA
. I-REA
In O
ED O
ENT O
was O
consulted O

 O
and O
pt O
was O
packed O
to O
help O
control O
bleeding O
. O
Her O
INR B-REA
was I-REA
reversed I-REA

 I-REA
with O
vitamin B-DRUG
K I-DRUG
, I-DRUG
2 B-DOS
units I-DOS
FFP B-DRUG
and O
her O
INR O
now O
is O
1.1 O
. O
She O
was O

 O
hypotensive O
with O
SBP O
in O
80 O
's O
on O
admission O
and O
was O
admitted O
to O

 O
the O
ICU O
. O
Hct B-REA
was I-REA
21 I-REA
on O
admission O
( O
baseline O
30 O
) O
and O
the O
patient O

 O
required O
3 B-DOS
units I-DOS
of O
PRBCs B-DRUG
on O
[ O
* O
* O
11 O
- O
4 O
* O
* O
] O
. O
Her O
Hct O
has O
been O
stable O
at O

 O
28 O
- O
29 O
x O
more O
than O
24 O
hours O
and O
she O
was O
called O
out O
from O
the O
ICU O

 O
today O
. O

 O
. O

 O
Pt O
currently O
denies O
any O
feelings O
of O
light-headedness O
, O
no O
chest O

 O
pain O
or O
difficulty O
breathing O
. O
Denies O
pain O
in O
her O
mouth O
, O
no O

 O
recent O
fevers O
or O
chills O
. O
Further O
ROS O
negative O
. O



 O
Past O
Medical O
History O
: O

 O
- O
MVR O
in O
[ O
* O
* O
2089 O
* O
* O
] O
, O
[ O
* O
* O
2101 O
* O
* O
] O
, O
[ O
* O
* O
2114 O
* O
* O
] O
last O
with O
bioprosthetic O
valve O

 O
- O
Severe O
pulmonary O
HTN O

 O
- O
TR O

 O
- O
Right-sided O
heart O
failure O

 O
- O
Chronic O
AF O

 O
- O
CVA O
x O
2 O

 O
- O
HTN O

 O
- O
Mild O
renal O
insuff O
, O
hyperkalemia O

 O
- O
Anemia O
- O
Last O
c-scope O
> O
10 O
years O
ago O
- O
had O
a O
few O
polyps O
removed O


 O
- O
Aorto-Femoral O
bypass O

 O
- O
Last O
Echo O
[ O
* O
* O
1 O
- O
15 O
* O
* O
] O
: O
EF O
> O
65 O
% O
, O
mild O
LVH O
, O
severe O
Pulmonary O
HTN O
and O

 O
( O
4 O
+ O
) O
TR O
, O
1 O
+ O
MR/AR O
. O



 O
Social O
History O
: O

 O
Lives O
alone O
, O
children O
nearby O
. O
6 O
children O
and O
12 O
grandchildren O
. O

 O
Born O
in O
[ O
* O
* O
Country O
4754 O
* O
* O
] O
but O
moved O
to O
the O
US O
at O
a O
young O
age O
. O
Denies O
tob O
, O


 O
ETOH O
, O
IVDU O
. O
Walks O
with O
a O
cane O
. O



 O
Family O
History O
: O

 O
n/c O



 O
Physical O
Exam O
: O

 O
GEN O
: O
awake O
, O
alert O
, O
thin O
, O
NAD O

 O
HEENT O
: O
atraumatic O
, O
anicteric O
, O
gauze O
in O
mouth O
, O
no O
active O
bleeding O


 O
NECK O
: O
no O
LAD O
, O
no O
JVP O

 O
CV O
: O
[ O
* O
* O
3 O
- O
15 O
* O
* O
] O
holosystolic O
murmur O
heard O
throughout O
, O
irregularly O

 O
irregular O

 O
LUNGS O
: O
mild O
crackles O
at O
bases O
, O
good O
air O
movement O
, O
no O
accessory O

 O
muscle O
use O

 O
ABD O
: O
soft O
, O
nt O
, O
non-distended O
, O
nabs O

 O
EXT O
: O
warm O
, O
dry O
. O
Trace O
edema O
B/L O
, O
chronic O
venous O
stasis O

 O
pigmentation O
changes O
. O
Some O
eccymoses O
on O
UE O

 O
NEURO O
: O
A/O O
x3 O
, O
answers O
questions O
appropriately O
, O
follows O
commands O




 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
3 O
* O
* O
] O
10:50AM O
   O
PT-24.6 O
* O
PTT-35.8 O
* O
INR(PT)-2.5 O
* O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
3 O
* O
* O
] O
10:50AM O
   O
WBC-4.8 O
RBC-3.54 O
* O
HGB-10.0 O
* O
HCT-29.8 O
* O
MCV-84 O

 O
MCH-28.4 O
MCHC-33.7 O
RDW-16.6 O
* O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
3 O
* O
* O
] O
10:40PM O
   O
PT-26.6 O
* O
PTT-35.7 O
* O
INR(PT)-2.7 O
* O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
3 O
* O
* O
] O
10:40PM O
   O
WBC-4.9 O
RBC-3.24 O
* O
HGB-9.0 O
* O
HCT-27.1 O
* O
MCV-83 O

 O
MCH-27.7 O
MCHC-33.2 O
RDW-16.6 O
* O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
3 O
* O
* O
] O
10:40PM O
   O
GLUCOSE-120 O
* O
UREA O
N-90 O
* O
CREAT-2.5 O
* O
SODIUM-134 O

 O
POTASSIUM-4.5 O
CHLORIDE-96 O
TOTAL O
CO2 O
- O
27 O
ANION O
GAP-16 O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
4 O
* O
* O
] O
06:07AM O
   O
FIBRINOGE-304 O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
4 O
* O
* O
] O
06:07AM O
   O
NEUTS-75.7 O
* O
LYMPHS-14.3 O
* O
MONOS-7.3 O
EOS-1.9 O

 O
BASOS-0.8 O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
4 O
* O
* O
] O
06:07AM O
   O
WBC-3.1 O
* O
RBC-2.54 O
* O
HGB-7.1 O
* O
HCT-21.3 O
* O
MCV-84 O

 O
MCH-28.2 O
MCHC-33.5 O
RDW-16.6 O
* O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
4 O
* O
* O
] O
06:07AM O
   O
CALCIUM-9.1 O
PHOSPHATE-4.1 O
MAGNESIUM-2.7 O
* O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
4 O
* O
* O
] O
06:07AM O
   O
GLUCOSE-93 O
UREA O
N-91 O
* O
CREAT-2.3 O
* O
SODIUM-137 O

 O
POTASSIUM-4.5 O
CHLORIDE-100 O
TOTAL O
CO2 O
- O
31 O
ANION O
GAP-11 O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
4 O
* O
* O
] O
09:40AM O
   O
HCT-22.8 O
* O

 O
[ O
* O
* O
2123 O
- O
11 O
- O
4 O
* O
* O
] O
07:34PM O
   O
HCT-28.4 O
* O

 O
. O

 O
CHEST O
( O
PORTABLE O
AP O
) O
  O
[ O
* O
* O
2123 O
- O
11 O
- O
4 O
* O
* O
] O
2:39 O
AM O

 O
FINDINGS O
: O
There O
is O
stable O
cardiomegaly O
. O
Elevation O
of O
right O

 O
hemidiaphragm O
persists O
. O
There O
is O
chronic O
pleural O
thickening O
on O

 O
the O
right O
, O
with O
right O
basilar O
atelectasis O
and O
small O
pleural O

 O
effusion O
present O
. O
There O
are O
no O
consolidations O
. O
Pulmonary O

 O
vascularity O
is O
normal O
. O

 O
IMPRESSION O
: O
No O
radiographic O
evidence O
of O
congestive O
heart O

 O
failure O
. O
Right O
chronic O
pleural O
thickening O
. O
Small O
right-sided O

 O
pleural O
effusion O
, O
probably O
unchanged O
. O
Right O
basilar O
atelectasis O
. O

 O
. O


 O
EKG- O
HR O
86 O
Probable O
atrial O
fibrillation O
with O
multifocal O
PVCs O
or O

 O
aberrant O
ventricular O

 O
conduction O

 O
Right O
axis O
deviation O

 O
Right O
bundle O
branch O
block O

 O
Low O
QRS O
voltages O
in O
limb O
leads O

 O
. O

 O
CHEST O
( O
PA O
& O
LAT O
) O
  O
[ O
* O
* O
2123 O
- O
11 O
- O
14 O
* O
* O
] O
1:56 O
PM O

 O
Bilateral O
pleural O
effusions O
and O
bibasilar O
atelectasis O
. O
Pneumonia O

 O
is O
not O
excluded O
. O

 O
Cardiomegaly O
, O
unchanged O
. O

 O
Mild O
kyphotic O
angulation O
at O
a O
mid O
thoracic O
level O
. O
Finding O
may O
be O

 O
better O
assessed O
with O
dedicated O
thoracic O
spine O
radiographs O
, O
if O

 O
clinically O
indicated O
. O
No O
fracture O
is O
seen O
. O



 O
Brief O
Hospital O
Course O
: O

 O
79 O
yo O
female O
with O
h/o O
a O
Atrial O
Fibrillation O
, O
s/p O
bioprosthetic O

 O
mitral O
valve O
replacement O
, O
admitted O
with O
post-op O
bleeding O

 O
following O
dental O
extraction O
and O
palate O
I O
and O
D O
two O
days O
prior O
to O

 O
the O
admission O
in O
the O
setting O
of O
being O
anticoagulated O
( O
INR O
in O

 O
therapeutic O
range O
) O
. O

 O
. O

 O
# O
Bleeding B-ADE
: I-ADE
Post-op O
due O
to O
anticoagulation B-REA
with O
warfarin B-DRUG
use O
for O

 O
atrial B-REA
fibrillation I-REA
. I-REA
Bleeding O
started O
on O
[ O
* O
* O
11 O
- O
2 O
* O
* O
] O
, O
increased O
[ O
* O
* O
11 O
- O
3 O
* O
* O
] O

 O
in O
ED O
packed O
and O
pressure O
applied O
. O
INR O
2.7 O
, O
and O
hematocrit O
27 O
, O

 O
SBP O
in O
the O
80 O
's O
to O
90 O
's O
. O
  O
Hematocrit O
lowest O
at O
21 O
on O
admission O
. O

 O
Bleeding O
from O
posterior O
palate O
Incision O
and O
drainage O
site O
. O

 O
Bleeding O
resolved O
with O
no O
events O
in O
the O
ICU O
. O
HD O
stable O
. O
Last O

 O
transfusion O
on O
[ O
* O
* O
2123 O
- O
11 O
- O
4 O
* O
* O
] O
. O
Received O
2 B-DOS
units I-DOS
of O
FFP B-DRUG
, I-DRUG
one B-DOS
unit I-DOS
of O

 O
PRBC B-DRUG
, I-DRUG
fluid B-DRUG
boluses B-DOS
and O
vitamin B-DRUG
K. I-DRUG
To O
medicine O
floor O
at O

 O
Hematocrit O
stable O
[ O
* O
* O
11 O
- O
6 O
* O
* O
] O
, O
but O
that O
night O
encountered O
bleeding B-REA

 I-REA
from I-REA
I&D I-REA
site I-REA
, I-REA
Afrin B-DRUG
spray B-FOR
applied O
and O
pressure O
with O
resolution O
, O

 O
no O
PRBC B-DRUG
's I-DRUG
given O
, O
hematocrit O
27.7 O
. O
No O
further O
bleeding O
during O

 O
course O
of O
admission O
. O
Coumadin B-DRUG
restarted O
[ O
* O
* O
11 O
- O
10 O
* O
* O
] O
as O
per O
instruction O

 O
with O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
* O
* O
] O
, O
and O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
. O
3 B-STR
mg I-STR
initial O
dose O
, O
given O
risk O
for O

 O
stroke B-REA
in I-REA
patient I-REA
with O
A-fibb B-REA
. I-REA
As O
per O
wishes O
of O
patient O
and O

 O
family O
, O
patient O
remained O
in O
house O
until O
incision O
site O
appeared O

 O
healed O
, O
INR O
increased O
and O
no O
evidence O
of O
bleed O
. O
Discharged O
with O

 O
follow-up O
by O
cardiology O
and O
her O
oral O
surgeon O
. O
Clindamycin B-DRUG
450 B-STR
PO B-ROU

 I-ROU
Q6 B-FRE
for O
abscess B-REA
stopped O
after O
IV B-ROU
then O
PO B-ROU
course O
for O
10 B-DUR
days I-DUR
. I-DUR

 O
Coumadin B-DRUG
increased O
to O
5 B-STR
mg I-STR
on O
discharge O
. O

 O
. O


 O
# O
Atrial B-REA
fibrillation I-REA
: I-REA
Rate B-REA
control I-REA
with O
beta-blocker B-DRUG
. I-DRUG
Continue O

 O
Statin/ B-DRUG
beta-blocker B-DRUG
. I-DRUG
Held O
Coumadin B-DRUG
until O
[ O
* O
* O
11 O
- O
10 O
* O
* O
] O
when O
restarted O

 O
given O
decreasing O
concern O
of O
rebleed O
. O
In O
discussion O
with O
Dr. O

 O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
, O
pt O
's O
Cardiologist O
in O
regards O
to O
anticoagulation B-DRUG
. I-DRUG

 O
. O

 O
# O
CHF O
: O
EF O
> O
65 O
% O
in O
1/[**2123 O
* O
* O
] O
. O
Continued O
beta-blocker B-DRUG
. I-DRUG
Restarted O

 O
[ O
* O
* O
Year O
( O
4 O
digits O
) O
11573 O
* O
* O
] O
per O
outpatient O
dose O
4 O
days O
into O
admission O
. O
Had O
been O
held O

 O
in O
MICU O
given O
hypotension O
. O
Fluids B-DRUG
also O
given O
. O
Held O
Aldactone B-DRUG

 I-DRUG
during O
admission O
given O
elevated O
potassium O
and O
hypotension O
. O
With O

 O
increasing O
work O
of O
breathing O
3 O
days O
prior O
to O
discharge O
, O
evidence O

 O
of O
increasing O
overload O
on O
CXR O
, O
[ O
* O
* O
Year O
( O
4 O
digits O
) O
11573 O
* O
* O
] O
given O
. O
Pt O
stable O
on O
40 B-STR
PO B-ROU

 I-ROU
[ O
* O
* O
Year O
( O
4 O
digits O
) O
11573 O
* O
* O
] O
and O
resuming O
25 B-STR
Aldacton B-DRUG
[ O
* O
* O
Hospital1 O
* O
* O
] O
at O
discharge O
with O
follow-up O

 O
in O
the O
heart O
failure O
clinic O
. O

 O
. O

 O
# O
Hypotension O
: O
likely O
secondary O
to O
hypovolemia B-REA
. I-REA
Fluids B-DRUG
given O
on O

 O
admission O
. O
Stopped O
as O
evidence O
of O
overload O
. O
Baseline O
low O
normal O
. O

 O
. O

 O
# O
CRI O
: O
Creatinine O
slowly O
trending O
up O
. O
Baseline O
ranging O
from O

 O
1.9 O
- O
3.0 O
. O
Stable O
as O
baseline O
at O
discharge O
. O
Continued O
renal O
diet O


 O
. O

 O
# O
FEN O
: O
Soft O
diet O
given O
abscess O
site O
tenuous O
for O
rebleed O
. O

 O
. O

 O
# O
Contact O
: O
Daughter O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
26941 O
* O
* O
] O
[ O
* O
* O
Name O
( O
NI O
) O
1356 O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
26942 O
* O
* O
] O



 O
Medications O
on O
Admission O
: O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
11573 O
* O
* O
] O
40 O
mg O
twice O
a O
day O

 O
Toprol-XL B-DRUG
25 B-STR
mg I-STR
daily B-FRE

 I-FRE
spironolactone B-DRUG
50 B-STR
mg I-STR
daily B-FRE

 I-FRE
Lipitor B-DRUG
10 B-STR
mg I-STR
daily B-FRE

 I-FRE
Omeprazole B-DRUG
20 B-STR
mg I-STR
twice B-FRE
a I-FRE
day I-FRE

 I-FRE
Ferrous B-DRUG
Sulfate I-DRUG

 I-DRUG
Coumadin B-DRUG
2.5 B-STR
mg I-STR

 I-STR
Carafate B-DRUG
1 B-STR
gram I-STR
qid B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Ferrous B-DRUG
Sulfate I-DRUG
325 B-STR
( I-STR
65 I-STR
) I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Atorvastatin B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Calcium B-DRUG
Acetate I-DRUG
667 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
TID B-FRE

 I-FRE
W/MEALS I-FRE
( I-FRE
3 I-FRE
TIMES I-FRE
A I-FRE
DAY I-FRE
WITH I-FRE
MEALS I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Sucralfate B-DRUG
1 B-STR
g I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
Furosemide B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Pantoprazole B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
Q24H B-FRE
( I-FRE
every I-FRE
24 I-FRE
hours I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Spironolactone B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Coumadin B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
at B-FRE
bedtime I-FRE
: I-FRE
until O

 O
discussion O
with O
outpatient O
provider O
. O

 O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
357 O
* O
* O
] O
check O
INR O
in O
two O
days O
. O

 O
Disp:*10 O
Tablet(s B-FOR
) I-FOR
* I-FOR
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O
bleeding O
from O
palate O
abcess O
I&D O
and O
tooth O
extraction O

 O
site O


 O
Secondary O
: O
CHF O

            O
CRI O

            O
thrombocytopenia O



 O
Discharge O
Condition O
: O

 O
stable O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
with O
a O
bleed O
from O
an O
incision O
and O
drainage O

 O
site O
. O
Youe O
were O
transfused O
and O
have O
not O
had O
bleeding O
from O
your O

 O
mouth O
since O
[ O
* O
* O
11 O
- O
6 O
* O
* O
] O
. O

 O
-Please O
take O
all O
medications O
as O
you O
previously O
had O
in O
addition O

 O
to O
the O
increased O
dose O
of O
coumadin B-DRUG
to O
5 B-STR
mg I-STR
pending O
repeat O
INR O

 O
check O
and O
follow O
up O
with O
your O
doctor O
. O

 O
-Please O
check O
coumadin B-DRUG
level O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Hospital1 O
882 O
* O
* O
] O
labs O
, O
as O
previously O

 O
had O
with O
next O
check O
in O
two O
days O
. O

 O
-Please O
maintain O
follow O
up O
appointments O
. O

 O
-Please O
return O
to O
the O
hospital O
if O
you O
are O
experiencing O
shortness O

 O
of O
breath O
, O
weight O
gain O
, O
bleeding O
, O
chest O
pain O
, O
fainting O
, O
swelling O

 O
or O
any O
other O
symptoms O
concerning O
to O
you O
. O


 O
Followup O
Instructions O
: O

 O
Please O
follow O
up O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
3070 O
* O
* O
] O
, O
unable O
to O
be O

 O
reached O
, O
please O
call O
for O
an O
appointment O
. O



 O
Please O
have O
INR O
checked O
in O
two O
days O
, O
with O
information O
faxed O
to O

 O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
10865 O
* O
* O
] O
office O
. O
via O
[ O
* O
* O
Hospital1 O
882 O
* O
* O
] O
lab O
. O
Contact[**Name O
( O
NI O
) O
* O
* O
] O
Dr.[**Name O
( O
NI O
) O
19264 O
* O
* O
] O

 O
office O
with O
recs O
. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
870 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O
, O
M.D. O
Phone:[**Telephone/Fax O
( O
1 O
) O
9486 O
* O
* O
] O


 O
Please O
follow O
up O
with O
Dr. O
[ O
* O
* O
First O
Name O
( O
STitle O
) O
437 O
* O
* O
] O
in O
the O
heart O
failure O
clinic O

 O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
3512 O
* O
* O
] O
. O
They O
have O
been O
contact[**Name O
( O
NI O
) O
* O
* O
] O
and O
are O
awaiting O

 O
confirmation O
. O
Please O
call O
if O
you O
have O
not O
received O
confirmation O

 O
within O
one O
day O
. O

 O
. O

 O
Please O
contact O
your O
oral O
surgeon O
. O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
10166 O
* O
* O
] O
for O
follow-up O
on O

 O
abcess O
site O
, O
and O
bleed O
. O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2107 O
- O
11 O
- O
12 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2107 O
- O
12 O
- O
21 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2045 O
- O
12 O
- O
2 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Vancomycin B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
2763 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
renal O
failure O
s/p O
CRT O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
HD O
line O
placement O


 O
History O
of O
Present O
Illness O
: O

 O
61 O
M O
with O
history O
of O
ESRD O
s/p O
CRT O
[ O
* O
* O
2101 O
* O
* O
] O
, O
hypertension O
, O
diabetes O
, O

 O
diastolic O
CHF O
, O
admitted O
on O
[ O
* O
* O
2107 O
- O
11 O
- O
12 O
* O
* O
] O
with O
acute O
on O
chronic O

 O
dyspnea O
, O
now O
s/p O
PEA O
arrest O
. O
He O
presented O
on O
[ O
* O
* O
11 O
- O
12 O
* O
* O
] O
with O
2 O
days O
of O

 O
worsening O
dyspnea O
, O
cough O
, O
and O
fever/chills O
. O
  O
Also O
with O

 O
orthopnea O
, O
PND O
, O
and O
worsening O
edema O
in O
all O
4 O
extremities O
. O

 O
. O

 O
Labs O
showed O
ARF O
with O
creatinine O
of O
5.8 O
( O
up O
from O
2.9 O
) O
. O
  O
During O

 O
hospital O
course O
on O
the O
floor O
, O
renal O
function O
continued O
to O
worsen O

 O
and O
urine O
output O
was O
low O
even O
with O
furosemide B-DRUG
( O
unclear O
etiology O

 O
of O
ARF O
) O
. O
  O
Also O
noted O
to O
have O
intermittent O
somnolence O
but O

 O
arousable O
and O
fully O
oriented O
. O
  O
ABGs O
repeatedly O
with O
partially O

 O
compensated O
respiratory O
acidosis O
( O
has O
also O
had O
this O
in O
the O

 O
recent O
past O
) O
, O
team O
unsure O
how O
reliable O
ABGs O
were O
given O
bilateral O

 O
UE O
fistulas O
. O

 O
. O

 O
Patient O
was O
in O
angio O
having O
hemodialysis O
line O
placed O
when O
his O

 O
arrest O
event O
occurred O
. O
  O
He O
was O
placed O
in O
a O
lateral O
decubitus O

 O
position O
due O
to O
difficulty O
lying O
flat O
due O
to O
shortness O
of O

 O
breath O
. O
  O
Towards O
the O
end O
of O
his O
line O
placement O
, O
he O
became O
more O

 O
agitated O
and O
was O
pushing O
his O
facemask O
away O
. O
  O
O2 O
sats O
were O
unable O

 O
to O
be O
obtained O
. O
  O
He O
was O
then O
placed O
in O
supine O
position O
for O
line O

 O
suturing O
. O
  O
He O
was O
then O
noted O
to O
be O
nonresponsive O
, O
code O
blue O

 O
call O
. O
  O
Then O
noted O
to O
be O
pulseless O
. O
  O
CPR O
initiated O
and O
initial O

 O
rhythm O
asystole/very O
slow O
PEA O
, O
subsequently O
faster O
PEA B-REA
. I-REA
  O
Total O

 O
pulseless O
time O
13 O
minutes O
. O
  O
Received O
total O
2 B-STR
mg I-STR
epinephrine B-DRUG
, I-DRUG
2 B-DOS

 I-DOS
amps B-FOR
bicarb B-DRUG
, I-DRUG
1 B-STR
mg I-STR
atropine B-DRUG
, I-DRUG
insulin/D50 B-DRUG
, I-DRUG
IVFs B-DRUG
via O
new O
HD O
line O
. O

 O
Regained O
pulses O
with O
first O
SBP O
> O
180 O
. O
  O
Intubated O
. O

 O
. O

 O
In O
the O
MICU O
, O
patient O
seemed O
to O
be O
waking O
up O
some O
but O
with O
also O

 O
evidence O
of O
extensor O
posturing O
in O
upper O
and O
lower O
extremities O
. O

 O
Neuro O
consulted O
. O
  O
Aline O
and O
CVL O
placed O
. O

 O
. O

 O
Review O
of O
systems O
: O
unable O
to O
obtain O



 O

Past O
Medical O
History O
: O

 O
- O
Renal O
cell O
carcinoma O
s/p O
resection O
[ O
* O
* O
2093 O
* O
* O
] O

 O
- O
Severe O
obstructive O
sleep O
apnea,(not O
wearing O
CPAP O
at O
home O
) O

 O
- O
ESRD O
s/p O
CRT O
[ O
* O
* O
2101 O
* O
* O
] O
, O
complicated O
by O
transplant O
renal O
artery O

 O
stenosis O
necessitating O
stent O
placement O
in O
[ O
* O
* O
2103 O
* O
* O
] O

 O
- O
Resistant O
HTN O

 O
- O
Diastolic O
congestive O
heart O
failure O
, O
TTE O
[ O
* O
* O
2107 O
- O
8 O
- O
18 O
* O
* O
] O
: O
Moderate O

 O
diastolic O
LV O
dysfunction O
with O
elevated O
LVEDP O
. O
Mild O
pulmonary O

 O
hypertension O

 O
- O
Diabetes B-REA
, I-REA
type I-REA
2 I-REA
, I-REA
on O
insulin B-DRUG

 I-DRUG
- O
GERD O

 O
- O
Barrett O
's O
Esophagus O

 O
- O
s/p O
patella O
avulsion O
repair O

 O
- O
history O
of O
hypercalcemia O

 O
- O
hyperparathyroidism O


 O
Social O
History O
: O

 O
Married O
with O
seven O
children O

 O
Employment O
: O
Employed O
as O
a O
chef O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O

 O
Tobacco O
: O
No O
h/o O

 O
Alcohol O
: O
No O
h/o O


 O
Family O
History O
: O

 O
Mother O
with O
kidney O
disease O
. O


 O
Physical O
Exam O
: O

 O
Vitals O
: O
T O
: O
BP O
: O
P O
: O
R O
: O
18 O
O2 O
: O

 O
General O
: O
Intubated O
; O
initially O
not O
sedated O
. O
  O
Not O
opening O
eyes O
but O

 O
moving O
all O
extremities O
to O
pain O
and O
initally O
spontaneously O
. O

 O
? O
myoclonic O
and O
posturing O
as O
below O
. O

 O
HEENT O
: O
Sclera O
anicteric O
, O
pupils O
equal O
at O
2 O
mm O
though O
minimal O

 O
reactive O
. O
  O
ETT O
in O
place O
. O

 O
Neck O
: O
HD O
line O
in O
place O
. O
  O
Obese O
neck O
, O
difficult O
to O
appreciate O
JVD O

 O
Lungs O
: O
Clear O
to O
auscultation O
bilaterally O
, O
no O
wheezes O
, O
rales O
, O

 O
ronchi O

 O
CV O
: O
Regular O
rate O
and O
rhythm O
, O
normal O
S1 O
+ O
S2 O
, O
loud O
systolic O

 O
murmur O
best O
at O
RUSB O
and O
LUSB O
. O

 O
Abdomen O
: O
  O
soft O
, O
distended O
, O
appears O
non-tender O
, O
bowel O
sounds O

 O
present O
, O
no O
rebound O
tenderness O
or O
guarding O
, O
no O
organomegaly O
. O

 O
Ext O
: O
warm O
, O
well O
perfused O
, O
2 O
+ O
pulses O
, O
no O
clubbing O
, O
cyanosis O
. O

 O
[**2 O
- O
8**]+ O
bilateral O
LE O
edema O
, O
also O
+ O
bilateral O
UE O
edema O
, O
? O
right O

 O
slightly O
greater O
than O
left O

 O
Neuro O
: O
Moving O
some O
spontaneously O
and O
responsive O
to O
pain O
in O
the O

 O
UEs O
, O
not O
much O
pain O
response O
in O
the O
LEs O
. O
  O
Seems O
to O
be O

 O
intermittently O
with O
extensor O
posturing O
( O
lasts O
2 O
- O
3 O
seconds O
at O
a O

 O
time O
) O
, O
sometimes O
associated O
with O
? O
myoclonic O
movements O
of O
ankles O
. O

  O
+ O
significant O
bilateral O
ankle O
clonus O
. O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2107 O
- O
11 O
- O
12 O
* O
* O
] O
8:10p O

 O
. O

 O
Other O
Urine O
Chemistry O
: O

 O
UreaN:549 O

 O
Creat:199 O

 O
Na:<10 O

 O
TotProt:53 O

 O
Prot/Cr:0.3 O

 O
Osmolal:347 O

 O
. O

 O
Color O

 O
Yellow O
  O
Appear O
Clear O
  O
SpecGr O
1.013 O
  O
pH O
5.0 O
  O
Urobil O
Neg O
  O
Bili O
Neg O



 O
Leuk O
Tr O
  O
Bld O
Neg O
  O
Nitr O
Neg O
  O
Prot O
75 O
  O
Glu O
Neg O
  O
Ket O
Neg O
  O
RBC O
0 O
- O
2 O

 O
WBC O
[ O
* O
* O
6 O
- O
15 O
* O
* O
] O
  O
Bact O
None O
  O
Yeast O
None O
  O
Epi O
0 O
- O
2 O

 O
Other O
Urine O
Counts O

 O
RenalEp O
: O
0 O
- O
2 O

 O
CastHy O
: O
0 O
- O
2 O

 O
. O

 O
[ O
* O
* O
2107 O
- O
11 O
- O
12 O
* O
* O
] O
  O
4:10p O

 O
138 O
  O
103 O
  O
72 O

 O
------------- O
178 O

 O
5.0 O
  O
27 O
  O
5.8 O
& O
# O
8710 O
; O

 O
. O

 O
Ca O
: O
9.6 O
Mg O
: O
2.6 O
P O
: O
4.3 O
& O
# O
8710 O
; O

 O
CK O
: O
315 O
  O
MB O
: O
5 O
  O
Trop-T O
: O
0.08 O

 O
. O

 O
Alb O
: O
2.9 O

 O
proBNP O
: O
1817 O

 O
. O

 O
..... O
8.4 O

 O
5.5 O
----- O
212 O

 O
..... O
26.8 O

 O
N:68.5 O
L:21.8 O
M:6.9 O
E:2.4 O
Bas:0.5 O

 O
. O

 O
CXR O
[ O
* O
* O
2107 O
- O
11 O
- O
14 O
* O
* O
] O
: O
In O
comparison O
with O
the O
study O
of O
[ O
* O
* O
11 O
- O
12 O
* O
* O
] O
, O
there O
are O

 O
lower O
lung O
volumes O
. O
Enlargement O
of O
the O
cardiac O
silhouette O

 O
persists O
with O
mild O
vascular O
congestion O
suggested O
. O

 O
. O

 O
EKG O
: O
NSR O
at O
94 O
, O
NANI O
, O
low O
limb O
lead O
voltage O
, O
poor O
RWP O
( O
old O
) O
; O
no O

 O
significant O
change O
from O
prior O
. O

 O
. O

 O
TTE O
[ O
* O
* O
2107 O
- O
11 O
- O
14 O
* O
* O
] O
: O
The O
left O
atrium O
is O
moderately O
dilated O
. O
mild O

 O
symmetric O
left O
ventricular O
hypertrophy O
with O
normal O
cavity O
size O

 O
and O
regional/global O
systolic O
function O
( O
LVEF>55 O
% O
) O
. O
Tissue O
Doppler O

 O
imaging O
suggests O
an O
increased O
left O
ventricular O
filling O
pressure O

 O
( O
PCWP>18mmHg O
) O
. O
Right O
ventricular O
chamber O
size O
and O
free O
wall O

 O
motion O
are O
normal O
. O
The O
aortic O
arch O
is O
mildly O
dilated O
. O
There O
is O

 O
mild O
pulmonary O
artery O
systolic O
hypertension O
. O
There O
is O
a O
very O

 O
small O
circumferenital O
pericardial O
effusion O
. O

 O
. O

 O
Renal O
ultrasound O
[ O
* O
* O
11 O
- O
13 O
* O
* O
] O
: O
  O
No O
new O
findings O
. O

 O
. O

 O
CT O
Chest O
[ O
* O
* O
11 O
- O
15 O
* O
* O
] O
: O
  O
On O
CT O
, O
there O
is O
no O
evidence O
of O
air O
embolism O
. O

 O
Cardiomegaly O
, O
mild O
axillary O
and O
mediastinal O
lymphadenopathy O
. O

 O
Bilateral O
pleural O
effusions O
with O
areas O
of O
subsequent O

 O
atelectasis O
, O
patchy O
lower O
lobe O
predominant O
parenchymal O
opacity O

 O
is O
potentially O
suggestive O
of O
a O
combination O
of O
pneumonia O
and O

 O
atelectasis O
. O
No O
pathologic O
air O
collection O
in O
the O
mediastinum O
and O

 O
the O
lung O
interstitium O
. O

 O
. O

 O
CT O
Head O
[ O
* O
* O
11 O
- O
15 O
* O
* O
] O
: O
  O
1 O
. O
No O
acute O
intracranial O
hemorrhage O
or O
acute O

 O
vascular O
territorial O
infarction O
. O
There O
is O
no O
hydrocephalus O
. O

 O
2 O
. O
Opacification O
of O
sphenoid O
sinus O
, O
maxillary O
, O
ethmoid O
air O
cells O

 O
and O

 O
nasopharynx O
, O
most O
likely O
related O
to O
recent O
intubation O
. O

 O
. O


 O
CT O
Head O
[ O
* O
* O
11 O
- O
17 O
* O
* O
] O
: O
  O
1 O
. O
No O
acute O
intracranial O
hemorrhage O
or O
obvious O

 O
major O
territorial O
acute O
infarct O
, O
mass O
effect O
, O
or O
hydrocephalus O
. O

 O
If O
there O
is O
continued O
concern O
, O
MR O
of O
the O
head O
with O

 O
diffusion-weighted O
imaging O
sequence O
is O
more O
sensitive O
in O
the O

 O
detection O
of O
acute O
stroke O
. O

 O
2 O
. O
Diffuse O
opacification O
of O
the O
sphenoid O
sinus O
, O
nasopharynx O
, O
the O

 O
maxillary O

 O
and O
the O
ethmoid O
air O
cells O
partly O
related O
to O
mucosal O
thickening O
, O

 O
secretions O

 O
from O
intubation O
. O
However O
, O
patient O
also O
had O
a O
left O
antrochoanal O

 O
polyp O
in O
the O
past O
, O
which O
is O
incompletely O
assessed O
on O
the O
present O

 O
study O
. O

 O
3 O
. O
Discontinuous O
foci O
in O
the O
left O
parietal O
bone O
may O
relate O
to O

 O
thinning O
of O
the O
bone O
, O
from O
arachnoid O
granulations O
or O
other O

 O
etiology O
, O
to O
correlate O
with O
any O
history O
of O
surgery O
. O
However O
, O

 O
this O
appearance O
is O
unchanged O
compared O
to O
the O
prior O
CT O
sinus O

 O
study O
done O
on O
[ O
* O
* O
2102 O
- O
10 O
- O
19 O
* O
* O
] O
. O

 O
. O

 O
RUE O
US O
[ O
* O
* O
11 O
- O
20 O
* O
* O
] O
: O
  O
Although O
subclavian O
vein O
not O
evaluated O
, O
remainder O

 O
of O
right O
upper O
extremity O
venous O
system O
appears O
normal O
with O
no O

 O
evidence O
of O
DVT O
, O
and O
DVT O
would O
be O
likely O
in O
the O
subclavian O
vein O

 O
given O
respiratory O
variation O
and O
normal O
appearance O
of O
remainder O

 O
of O
the O
study O
. O

 O
. O

 O
MR O
[ O
* O
* O
Name13 O
( O
STitle O
) O
430 O
* O
* O
] O
[ O
* O
* O
11 O
- O
21 O
* O
* O
] O
: O
  O
1 O
. O
Severely O
limited O
examination O
demonstrates O

 O
changes O
of O
chronic O
microvascular O
white O
matter O
ischemic O
disease O

 O
with O
old O
left O
frontal O
encephalomalacia O
without O
evidence O
for O

 O
acute O
infarct O
. O

 O
2 O
. O
Extensive O
paranasal O
sinus O
and O
mastoid O
air O
cell O
disease O
. O

 O
. O

 O
KUB O
[ O
* O
* O
11 O
- O
25 O
* O
* O
] O
: O
  O
1 O
. O
Severely O
limited O
examination O
demonstrates O
changes O

 O
of O
chronic O
microvascular O
white O
matter O
ischemic O
disease O
with O
old O

 O
left O
frontal O
encephalomalacia O
without O
evidence O
for O
acute O

 O
infarct O
. O

 O
2 O
. O
Extensive O
paranasal O
sinus O
and O
mastoid O
air O
cell O
disease O
. O

 O
. O

 O
KUB O
[ O
* O
* O
11 O
- O
26 O
* O
* O
] O
: O
   O
There O
is O
no O
evidence O
of O
free O
air O
. O
NG O
tube O
tip O
is O
in O

 O
the O
stomach O
. O
Right O
femoral O
catheter O
remains O
in O
place O
. O
There O
is O

 O
no O
evidence O
of O
bowel O
obstruction O
. O
There O
is O
nonspecific O
bowel O
gas O

 O
pattern O
. O

 O
. O

 O
Portable O
Abdomen O
XR O
[ O
* O
* O
11 O
- O
29 O
* O
* O
] O
: O
  O
There O
is O
no O
evidence O
of O
ileus O
, O
small O

 O
or O
large O
bowel O
obstruction O
. O

 O
. O

 O
Abdominal O
US O
[ O
* O
* O
12 O
- O
6 O
* O
* O
] O
: O
  O
Normal O
right O
upper O
quadrant O
ultrasound O
with O

 O
no O
findings O
to O
suggest O
the O
cause O
of O
the O
patient O
's O
pain O
. O

 O
. O


 O
CT O
Abd/Pelvis O
[ O
* O
* O
12 O
- O
6 O
* O
* O
] O
: O
  O
1 O
. O
Small O
thrombus O
within O
the O
IVC O
and O
at O
the O

 O
junction O
of O
the O
right O
common O
iliac O
vein O
and O
transplanted O
renal O

 O
vein O
. O

 O
2 O
. O
Diffuse O
mesenteric O
stranding O
with O
no O
small O
or O
large O
bowel O

 O
pathology O

 O
identified O
. O

 O
. O

 O
CT O
Head O
[ O
* O
* O
12 O
- O
11 O
* O
* O
] O
: O
  O
1 O
. O
. O
No O
acute O
intracranial O
abnormality O
. O

 O
2 O
. O
Partial O
opacification O
of O
mastoid O
air O
cells O
bilaterally O
, O

 O
maxillary O
, O
ethmoid O
and O
sphenoid O
sinuses O
, O
partly O
polypoidal O
. O

 O
. O

 O
CT O
Abd/Pelvis O
[ O
* O
* O
12 O
- O
11 O
* O
* O
] O
: O
  O
1 O
. O
Very O
large O
spontaneous O
hematoma O

 O
involving O
a O
majority O
of O
the O
left O
hepatic O
lobe O
. O
A O
small O
amount O
of O

 O
perihepatic O
hematoma O
and O
scattered O
areas O
of O
blood O
within O
the O

 O
mesentery O
and O
along O
the O
left O
pericolic O
gutters O
tracking O
into O
the O

 O
pelvis O
. O
No O
definite O
site O
of O
active O
extravasation O
identified O
. O

 O
2 O
. O
Branches O
of O
left O
portal O
vein O
are O
attenuated O
and O
not O
well O

 O
visualized O
in O

 O
the O
midst O
of O
the O
hematoma O
but O
are O
patent O
. O

 O
3 O
. O
No O
change O
in O
small O
1.5 O
cm O
thrombus O
within O
the O
infrarenal O
IVC O
. O

 O
Second O

 O
separate O
smaller O
thrombus O
in O
the O
right O
common O
iliac O
vein O
near O

 O
the O
transplant O
renal O
vein O
anastomosis O
on O
the O
prior O
study O
not O

 O
definitely O
visualized O
and O
may O
have O
cleared O
with O
anticoagulation O
. O


 O
4 O
. O
Atelectasis O
of O
both O
dependent O
lower O
lobes O
. O

 O
5 O
. O
More O
confluent O
consolidative O
opacity O
of O
the O
superior O
right O

 O
lower O
lobe O

 O
could O
be O
explained O
with O
atelectasis O
but O
is O
concerning O
for O

 O
possible O
area O
of O

 O
aspiration O
or O
pneumonia O
. O

 O
. O

 O
CT O
Abdomen O
[ O
* O
* O
12 O
- O
16 O
* O
* O
] O
: O
  O
Limited O
study O
but O
no O
gross O
evidence O
of O

 O
obstruction O
. O

 O
. O

 O
CXR O
[ O
* O
* O
12 O
- O
19 O
* O
* O
] O
: O
  O
There O
is O
interval O
development O
of O
vascular O

 O
engorgement O
, O
perihilar O
opacities O
, O
and O
bibasilar O
opacities O
, O
left O

 O
more O
than O
right O
, O
findings O
which O
might O
be O
consistent O
with O

 O
interval O
progression O
of O
pulmonary O
edema O
. O
Evaluation O
after O

 O
diuresis O
is O
recommended O
to O
exclude O
the O
possibility O
of O
underlying O

 O
infectious O
process O
. O



 O

Brief O
Hospital O
Course O
: O

 O
61 O
M O
with O
ESRD O
s/p O
CRT O
, O
HTN O
, O
DM O
, O
admitted O
with O
dyspnea O
and O
ARF O
. O

 O
During O
IR O
placement O
of O
an O
HD O
catheter O
he O
suffered O
a O
PEA O
arrest O
x O

 O
2 O
. O
He O
was O
cooled O
using O
artic O
sun O
protocol O
. O
He O
slowly O
recovered O
, O

 O
but O
his O
hospitalization O
was O
complicated O
by O
prolonged O
intubation O

 O
leading O
to O
tacheostomy O
placement O
, O
Psuedomonas O
UTI O
, O
HAP O
, O

 O
Stenotrophomonas O
PNA O
, O
aspiration O
PNA O
, O
acute O
on O
chronic O
kidney O

 O
injury O
leading O
to O
loss O
of O
fuction O
of O
his O
transplanted O
kidney O
, O

 O
IVC O
thombosis O
, O
spontaneous O
intrahepatic O
hemorrage O
during O

 O
heparinization O
for O
his O
thrombus O
, O
gout O
flair O
, O
and O
altered O
mental O

 O
status O
which O
has O
slowly O
improved O
. O
After O
more O
than O
a O
month O
in O
the O

 O
hospital O
he O
has O
stabilized O
, O
is O
ambulating O
with O
assistance O
, O

 O
speaking O
through O
a O
Passe O
Muir O
valve O
, O
and O
tolerating O
tube O
feeds O
. O

 O
. O

 O
# O
Aspiration O
: O
  O
Patient O
had O
emesis O
[ O
* O
* O
2107 O
- O
12 O
- O
13 O
* O
* O
] O
and O
aspirated O
tube O

 O
feeds O
. O
Developed O
aspiration O
pneumonitis O
vs. O
aspiration O
PNA O
. O
CXR O

 O
showed O
no O
clear O
evidence O
of O
PNA O
but O
CT O
showed O
confluent O

 O
consolidative O
opacity O
of O
superior O
RLL O
. O
Pt O
was O
febrile O
following O

 O
aspiration O
event O
and O
ended O
up O
re-intubated O
. O
Now O
s/p O
7-day B-DUR
course O

 O
of O
vanc/zosyn B-DRUG
for O
aspiration B-REA
that O
ended O
on O
[ O
* O
* O
2107 O
- O
12 O
- O
18 O
* O
* O
] O
. O
Respiratory O

 O
status O
has O
dramatically O
improved O
and O
he O
is O
now O
on O
trach O
mask O

 O
only O
. O
He O
had O
a O
video O
swallow O
evaluation O
on O
[ O
* O
* O
2107 O
- O
12 O
- O
20 O
* O
* O
] O
which O
showed O

 O
silent O
aspiration O
. O
  O
It O
was O
suggested O
that O
he O
have O
a O
diet O
of O

 O
nectar O
thick O
liquids O
and O
soft O
consistency O
solids O
. O
  O
meds O
must O
be O

 O
crushed O
in O
purees O
with O
Q6 O
hour O
oral O
care O
. O
  O
He O
should O
have O
follow O

 O
up O
with O
speech O
therapy O
at O
rehab O
with O
repeat O
video O
swallow O
if O

 O
diet O
is O
to O
be O
advanced O
. O

 O
. O

 O
# O
Stenotrophomonas B-REA
PNA I-REA
: I-REA
Diagnosed O
from O
repeated O
sputum O
cultures O
. O

 O
On O
Bactrim B-DRUG
x14 B-DUR
day I-DUR
course O
, O
day O
1=[**12 O
- O
16 O
* O
* O
] O
to O
d/c O
[ O
* O
* O
12 O
- O
30 O
* O
* O
] O
. O
Note O
that O

 O
Bactrim B-DRUG
must O
be O
give O
FOLLOWING O
HD O
as O
it O
is O
dialyzed O
off O
. O

 O
Intially O
diagnosed O
[ O
* O
* O
12 O
- O
2 O
* O
* O
] O
, O
but O
was O
inadquately O
treated O
as O
Bactrim B-DRUG

 I-DRUG
was O
given O
prior O
to O
HD O
rather O
than O
after O
. O

 O
. O

 O
# O
Pseudomonas B-REA
UTI I-REA
: I-REA
Had O
a O
long O
course O
of O
Cefepime B-DRUG
for O
UCx O

 O
positive O
for O
Pseudomonas O
x O
2 O
. O

 O
. O


 O
# O
Line B-REA
infection I-REA
: I-REA
S/p O
Cefepime B-DRUG
initially O
for O
UTI B-REA
. I-REA
Then O
Linezolid B-DRUG

 I-DRUG
was O
added O
for O
purulent O
appearing O
CVL O
. O
His O
lines O
were O
exchanged O

 O
and O
complicated O
by O
PEA O
arrest O
during O
procedure O
. O
His O
CVL O
grew O
out O

 O
Micrococcus O
. O
According O
to O
ID O
, O
the O
Cefepime B-DRUG
should O
have O
covered O

 O
it O
. O
He O
received O
a O
14d B-DUR
course O
of O
Cefepime B-DRUG
and O
9d B-DUR
course O
of O

 O
Linezolid B-DRUG
. I-DRUG
A O
PICC O
line O
and O
new O
HD O
line O
were O
placed O
and O
have O
had O

 O
no O
further O
complications O
. O

 O
. O

 O
# O
Labile B-REA
blood I-REA
pressures I-REA
: I-REA
Pt O
had O
been O
intermittently O
hypotensive O

 O
( O
infectious O
source O
vs O
hypovolemia O
vs O
adrenal O
insufficiency O
) O
. O
His O

 O
infections O
were O
treated O
. O
He O
was O
given O
stress B-DOS
dose I-DOS
steroids B-DRUG
. I-DRUG
He O

 O
was O
on O
pressors B-DRUG
for O
hypotension B-REA
. I-REA
Ultimately O
this O
resolved O
and O
he O

 O
became O
persistently O
hypertensive B-REA
to O
the O
190s O
to O
220s O
. O
He O
was O

 O
started O
on O
a O
labetalol B-DRUG
drip B-ROU
as O
well O
as O
PRN B-FRE
hydralazine B-DRUG
. I-DRUG
He O
has O

 O
been O
transitioned O
from O
Labetalol B-DRUG
drip B-ROU
to O
PO B-ROU
Labetalol B-DRUG
on O
[ O
* O
* O
12 O
- O
9 O
* O
* O
] O
, O

 O
then O
switched O
to O
Labetalol B-DRUG
PRN B-FRE
. I-FRE
On O
[ O
* O
* O
12 O
- O
14 O
* O
* O
] O
, O
Labetalol B-DRUG
was O
d/c??????ed O
. O

 O
Continue O
atenolol B-DRUG
at O
50 B-STR
mg I-STR
daily B-FRE
. I-FRE
Continue O
lisinopril B-DRUG
10 B-STR
mg I-STR
daily B-FRE
. I-FRE


 O
. O

 O
# O
Foot O
Pain O
: O
  O
Likely O
gout O
, O
particularly O
given O
resolving O
hematoma O

 O
and O
renal O
failure O
. O
Receiveing O
pulse O
steroids B-DRUG
with O
Prednisone B-DRUG

 I-DRUG
40 B-STR
mg I-STR
daily B-FRE
x5 B-DUR
days I-DUR
starting O
on O
[ O
* O
* O
2107 O
- O
12 O
- O
20 O
* O
* O
] O
. O
Will O
resume O
chronic O

 O
Prednisone B-DRUG
5 B-STR
mg I-STR
PO B-ROU
daily B-FRE
for O
maintenance B-REA
of I-REA
transplanted I-REA
kidney I-REA

 I-REA
thereafter O
. O
[ O
* O
* O
Month O
( O
only O
) O
116 O
* O
* O
] O
need O
suppressive O
allopurinol B-DRUG
in O
the O
future O
for O

 O
his O
gout B-REA
. I-REA

 O
. O

 O
# O
DVT B-REA
: I-REA
Patient O
found O
to O
have O
venous O
thrombi O
in O
several O
vessels O

 O
including O
his O
IVC O
. O
  O
He O
was O
on O
a O
heparin B-DRUG
drip B-ROU
, I-ROU
being O
bridged O
with O

 O
coumadin B-DRUG
. I-DRUG
  O
However O
, O
all O
anticoagulation O
stopped O
when O
liver B-ADE

 I-ADE
hematoma I-ADE
developed O
( O
see O
helow O
) O
. O
Hematology O
was O
consulted O

 O
regarding O
whether O
it O
is O
appropriate O
to O
resume O
anticoagulation O

 O
given O
the O
risk O
of O
bleed O
, O
and O
recommended O
SC B-ROU
Heparin B-DRUG
tid B-FRE
until O
he O

 O
follows O
up O
with O
Hematology O
and O
possibly O
vascular O
surgery O

 O
regarding O
possible O
benefits O
vs. O
risks O
of O
an O
IVC O
filter O

 O
placement O
. O
The O
patient O
should O
not O
be O
anti-coagulated O
with O
agents O

 O
other O
than O
SC B-ROU
Heparin B-DRUG
given O
his O
high O
risk O
of O
bleed O
. O

 O
. O


 O
# O
Abdominal O
Distension O
: O
  O
Patient??????s O
abdomen O
became O
distended O
and O

 O
tympanitic O
during O
this O
hospitalization O
. O
CT O
abdomen O
[ O
* O
* O
12 O
- O
11 O
* O
* O
] O
showed O

 O
large O
liver O
hematoma O
with O
scattered O
areas O
of O
perihepatic O

 O
hematoma O
and O
scattered O
blood O
within O
the O
mesentery O
but O
without O

 O
definite O
sites O
of O
active O
extravasation O
. O
  O
Distension O
likely O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O

 O
chemical O
peritonitis O
which O
is O
resolving O
following O
reversal O
of O

 O
anticoagulation O
vs. O
functional O
ileus/[**Last O
Name O
( O
un O
) O
* O
* O
] O
? O
? O
? O
? O
? O
? O
s O
syndrome O
from O

 O
infection/sepsis O
, O
intra-abdominal O
bleed O
, O
narcotic B-DRUG
use O
, O
or O

 O
respiratory O
failure O
. O
  O
This O
is O
consistent O
with O
the O
patient??????s O

 O
continued O
+ O
bowel O
sounds O
and O
leukocytosis O
, O
but O
CT O
abdomen O
did O
not O

 O
show O
dilated O
R O
side O
of O
colon O
and O
loops O
of O
bowel O
were O
read O
as O

 O
WNL O
. O
  O
Currently O
improved O
abdominal O
pain O
and O
minimally O
improved O

 O
distension O
. O
Abd O
is O
much O
less O
tense O
than O
prior O
. O
  O
Continue O
Reglan B-DRUG

 I-DRUG
2.5 B-STR
mg I-STR
TID B-FRE
standing O
for O
treatment O
of O
presumed B-REA
diabetic I-REA

 I-REA
gastroparesis I-REA
. I-REA
Advancing O
diet O
as O
tolerated O
with O
tube O
feeds O
. O

 O
. O

 O
# O
Liver B-ADE
Hematoma I-ADE
: I-ADE
  O
As O
above O
, O
CT O
showed O
hematoma O
of O
liver O
while O

 O
on O
heparin B-DRUG
drip B-ROU
for O
IVC B-REA
thombus I-REA
. I-REA
  O
IR O
consulted O
re O
: O
possible O

 O
embolization O
, O
did O
not O
feel O
the O
bleed O
was O
acute O
( O
felt O
> O
48 O
hours O

 O
old O
) O
and O
wished O
to O
preserve O
hepatic O
artery O
and O
liver O
function O
if O

 O
possible O
, O
so O
recommended O
monitoring O
Hct O
. O
  O
General O
surgery O

 O
consulted O
re O
: O
possible O
relation O
to O
PEG O
placement O
, O
but O
did O
not O

 O
believe O
this O
was O
[ O
* O
* O
2 O
- O
7 O
* O
* O
] O
procedure O
based O
on O
the O
location O
of O
the O

 O
hematoma O
. O
  O
Recommended O
montoring O
q6h O
Hct O
and O
coags O
, O
transfusing O

 O
as O
needed O
and O
keeping O
Hct O
> O
20 O
. O
  O
Received O
total O
of O
3 B-DOS
unit I-DOS
pRBC B-DRUG

 I-DRUG
after O
reversal O
of O
PTT O
with O
FFP B-DRUG
. I-DRUG
Awaiting O
hematology O

 O
recommendation O
for O
long O
term O
anticoagulation O
given O
presence O
of O

 O
IVC O
thombus O
but O
complication O
of O
hemorrhage O
. O
( O
Ultimately O
decided O

 O
to O
hold O
all O
anticoagulation O
given O
severity O
of O
liver O
bleed O
. O
) O

 O
. O

 O
# O
Respiratory O
failure O
. O
Originally O
intubated O
in O
setting O
of O
arrest O

 O
with O
hypoxia O
beforehand O
. O
Was O
very O
difficult O
to O
wean O
from O
vent O

 O
due O
to O
persistent O
hypoxia O
, O
recurrent O
PNA O
, O
and O
altered O
mental O

 O
status O
. O
Trach O
and O
PEG O
placed O
on O
[ O
* O
* O
12 O
- O
2 O
* O
* O
] O
. O
Now O
stable O
on O
trach O
. O
Had O

 O
aspiration O
even O
as O
above O
leading O
to O
short O
tern O
re-intubation O
. O

 O
Now O
tolerating O
trach O
mask O
. O
Speaking O
with O
Passe O
Muir O
valve O
. O

 O
. O


 O
# O
Altered O
mental O
status O
s/p O
PEA O
arrest O
: O
S/p O
PEA O
arrest O
x O
2 O
. O

 O
Underwent O
Artic O
Sun O
cooling O
protocol O
. O
Suring O
weaning O
of O
sedation O

 O
was O
severely O
agitated O
. O
Ultimately O
was O
transitioned O
from O
fentanyl B-DRUG

 I-DRUG
to O
methadone B-DRUG
and O
then O
weaned O
on O
seroquel B-DRUG
. I-DRUG
He O
had O
a O
significant O

 O
set O
back O
from O
his O
liver O
hematoma O
and O
aspiration O
PNA O
. O
Neuro O
was O

 O
consulted O
and O
noted O
a O
staring O
spell O
that O
was O
concerning O
for O

 O
seizures O
. O
He O
was O
monitored O
with O
continuous O
EEG O
, O
which O
showed O

 O
epileptiform O
spikes O
but O
not O
outright O
seizure O
activity O
. O
Neuro O

 O
recommended O
startingKeppra B-DRUG
, I-DRUG
with O
Keppra B-DRUG
500 B-STR
mg I-STR
qday B-FRE
and O
an O
extra O

 O
250 B-STR
mg I-STR
after B-FRE
HD I-FRE
. I-FRE
The O
patient O
has O
slowly O
improved O
and O
is O
not O

 O
conversant O
, O
[ O
* O
* O
Location O
( O
un O
) O
1131 O
* O
* O
] O
, O
walking O
with O
assistance O
, O
and O
no O
longer O

 O
agitated O
. O
He O
is O
alert O
and O
oriented O
. O

 O
. O

 O
# O
Acute O
on O
chronic O
renal O
failure O
. O
He O
is O
s/p O
CRT O
in O
[ O
* O
* O
2101 O
* O
* O
] O
. O

 O
Etiology O
of O
ARF O
likely O
multifactorial O
due O
to O
hypotension O
from O

 O
PEA O
, O
sepsis O
, O
contrast O
loads O
, O
and O
nephrotoxic O
drugs O
. O
Her O
the O

 O
Renal O
Service O
, O
he O
will O
not O
recover O
renal O
function O
of O
his O
kidney O
. O

 O
He O
will O
require O
HD O
henceforth O
. O
Continue O
prednisone B-DRUG
5 B-STR
mg I-STR
PO B-ROU
daily B-FRE

 I-FRE
for O
rejection B-REA
as O
well O
as O
Renagel B-DRUG
800 B-STR
tid B-FRE
, I-FRE
Sevelemer B-DRUG
800 B-STR
tid B-FRE
. I-FRE

 O
. O

 O
# O
FEN O
: O
  O
Speech O
and O
Swallow O
Recs O
- O
video O
swallow O
: O
silent O

 O
aspiration O
seen O
on O
s/s O
for O
thin O
liquids O
. O
Recs O
: O
1 O
. O
Suggest O
a O
PO O

 O
diet O
of O
nectar O
thick O
liquids O
and O
soft O
consistency O
solids O
. O
2 O
. O
PMV O

 O
on O
for O
all O
POs O
. O
3 O
. O
Meds O
crushed O
with O
purees O
. O
4 O
. O
Monitor O
for O

 O
nutritional O
intake O
. O
5 O
. O
Q6 O
oral O
care O
. O
6 O
. O
Follow O
up O
speech O
therapy O

 O
in O
rehab O
s/p O
d/c O


 O
Medications O
on O
Admission O
: O

 O
-Amlodipine B-DRUG
10 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
-Calcitriol B-DRUG
0.25mcg B-STR
QD B-FRE

 I-FRE
-Cinacalcet B-DRUG
90 B-STR
mg I-STR
QD B-FRE

 I-FRE
-Clonidine B-DRUG
0.1 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
-Lasix B-DRUG
120 B-STR
mg I-STR
PO B-ROU
BID B-FRE

 I-FRE
-Labetalol B-DRUG
600 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Lisinopril B-DRUG
10 B-STR
mg I-STR
QHS B-FRE

 I-FRE
-Minoxidil B-DRUG
10 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
-Mycophenolate B-DRUG
Mofetil I-DRUG
500 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
-Prednisone B-DRUG
5 B-STR
mg I-STR
QD B-FRE

 I-FRE
Vardenafil B-DRUG
10 B-STR
mg I-STR
PRN B-FRE

 I-FRE
-Aspirin B-DRUG
81 B-STR
mg I-STR
QD B-FRE

 I-FRE
Insulin B-DRUG
NPH I-DRUG
& I-DRUG
Regular I-DRUG
Human I-DRUG
Ten B-DOS
( I-DOS
10 I-DOS
) I-DOS
units I-DOS
Subcutaneous B-ROU
qPM B-FRE
. I-FRE

 O
Insulin B-DRUG
NPH I-DRUG
& I-DRUG
Regular I-DRUG
Human I-DRUG
Twenty B-DOS
( I-DOS
20 I-DOS
) I-DOS
Units I-DOS
Subcutaneous B-ROU
qAM B-FRE
. I-FRE




 O

Discharge O
Medications O
: O

 O
1 O
. O
Heparin B-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
5,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
4000-[**Numeric B-DOS
Identifier I-DOS
2249 I-DOS
* I-DOS
* I-DOS
] I-DOS

 I-DOS
units I-DOS
Injection B-FOR
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
line B-REA
flush I-REA
. I-REA

 O
2 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
3 O
. O
Sucralfate B-DRUG
1 B-STR
gram I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE

 I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
Acetaminophen B-DRUG
160 B-STR
mg/5 I-STR
mL I-STR
Solution B-FOR
Sig O
: O
325 B-DOS
- I-DOS
650 I-DOS
mg I-DOS
PO B-ROU
Q6H B-FRE

 I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
fever B-REA
, I-REA
pain B-REA
. I-REA

 O
5 O
. O
Bisacodyl B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
, I-FOR
Delayed I-FOR
Release I-FOR
( I-FOR
E.C. I-FOR
) I-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE

 I-FRE
for O
constipation B-REA
. I-REA

 O
6 O
. O
Cinacalcet B-DRUG
30 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE


 O
7 O
. O
Polyvinyl B-DRUG
Alcohol-Povidone I-DRUG
1.4 B-STR
- I-STR
0.6 I-STR
% O
Dropperette B-FOR
Sig O
: O
[ O
* O
* O
1 O
- O
7 O
* O
* O
] O

 O
Drops B-FOR
Ophthalmic B-ROU
PRN B-FRE
( I-FRE
as I-FRE
needed I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
irritation B-REA
. I-REA

 O
8 O
. O
Bacitracin-Polymyxin B-DRUG
B I-DRUG
500 B-STR
- I-STR
10,000 I-STR
unit/g I-STR
Ointment B-FOR
Sig O
: O
One B-DOS

 I-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR
Ophthalmic B-ROU
QID B-FRE
( I-FRE
4 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Quetiapine B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Prednisone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
: I-FRE

 O
for O
renal B-REA
transplant I-REA
. I-REA

 O
11 O
. O
Trimethoprim-Sulfamethoxazole B-DRUG
160 B-STR
- I-STR
800 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Four B-DOS

 I-DOS
( I-DOS
4 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
QHD B-FRE
( I-FRE
each I-FRE
hemodialysis I-FRE
) I-FRE
: I-FRE
DC O
on O
[**12 O
- O
29**].09 O
. O
Give O

 O
AFTER B-FRE
HD I-FRE
. I-FRE

 O
12 O
. O
Metoclopramide B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
2.5 B-STR
mg I-STR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
13 O
. O
Lisinopril B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
: I-FRE
Increase O
as O
needed O
for O
persistent B-REA
HTN I-REA
. I-REA

 O
14 O
. O
Atenolol B-DRUG
50 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
15 O
. O
Sevelamer B-DRUG
HCl I-DRUG
400 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
TID B-FRE

 I-FRE
W/MEALS I-FRE
( I-FRE
3 I-FRE
TIMES I-FRE
A I-FRE
DAY I-FRE
WITH I-FRE
MEALS I-FRE
) I-FRE
. I-FRE

 O
16 O
. O
Albuterol B-DRUG
Sulfate I-DRUG
90 B-STR
mcg/Actuation I-STR
HFA B-FOR
Aerosol I-FOR
Inhaler I-FOR
Sig O
: O

 O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Puff B-FOR
Inhalation B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O

 O
dyspnea B-REA
, I-REA
wheeze B-REA
. I-REA

 O
17 O
. O
Ipratropium B-DRUG
Bromide I-DRUG
17 B-STR
mcg/Actuation I-STR
Aerosol B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Puff B-FOR
Inhalation B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
shortness B-REA
of I-REA

 I-REA
breath I-REA
, I-REA
dyspnea B-REA
. I-REA

 O
18 O
. O
Prednisone B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE

 I-FRE
for B-DUR
5 I-DUR
days I-DUR
: I-DUR
DC O
on O
[ O
* O
* O
2107 O
- O
12 O
- O
24 O
* O
* O
] O
. O
Please O
give O
IN O
ADDITION O
to O
standing O

 O
prednisone B-DRUG
5 B-STR
mg I-STR
PO B-ROU
daily B-FRE
for O
rejection B-REA
. I-REA

 O
19 O
. O
Heparin B-DRUG
Flush I-DRUG
( O
10 B-STR
units/ml I-STR
) I-STR
2 B-DOS
mL I-DOS
IV B-ROU
PRN B-FRE
line B-REA
flush I-REA

 I-REA
PICC O
, O
heparin B-DRUG
dependent O
: O
Flush O
with O
10mL B-DOS
Normal B-DRUG
Saline I-DRUG
followed O

 O
by O
Heparin B-DRUG
as O
above O
daily B-FRE
and I-FRE
PRN I-FRE
per B-ROU
lumen I-ROU
. I-ROU

 O
20 O
. O
Keppra B-DRUG
250 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
after B-FRE
HD I-FRE
: I-FRE
in O

 O
addition O
to O
daily O
dose O
of O
Keppra B-DRUG
500 B-STR
mg I-STR
PO B-ROU
BID B-FRE
. I-FRE

 O
21 O
. O
Keppra B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
22 O
. O
Heparin B-DRUG
( I-DRUG
Porcine I-DRUG
) I-DRUG
5,000 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Injection B-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
: I-FRE
For O
IVC B-REA
thrombi I-REA
until O
further O

 O
evaluated O
by O
vascular O
surgery O
as O
outpatient O
. O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital O
671 O
* O
* O
] O
[ O
* O
* O
Hospital O
4094 O
* O
* O
] O
Hospital O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O

 O
- O
Renal O
failure O

 O
- O
Volume O
overload O
/ O
acute O
on O
chronic O
CHF O

 O
- O
PEA O
arrest O

 O
- O
Altered O
mental O
status O

 O
- O
Bacterial O
pneumonia O

 O
- O
Ventilator O
associated O
pneumonia O

 O
- O
Aspiration O
pneumonia O

 O
- O
Urinary O
tract O
infection O

 O
- O
Hypertensive O
urgency O

 O
- O
Repiratory O
failure O

 O
. O

 O
Seconary O
: O

 O
- O
Renal O
cell O
carcinoma O
s/p O
resection O
[ O
* O
* O
2093 O
* O
* O
] O

 O
- O
Severe O
obstructive O
sleep O
apnea,(not O
wearing O
CPAP O
at O
home O
) O

 O
- O
ESRD O
s/p O
CRT O
[ O
* O
* O
2101 O
* O
* O
] O
, O
complicated O
by O
transplant O
renal O
artery O

 O
stenosis O
necessitating O
stent O
placement O
in O
[ O
* O
* O
2103 O
* O
* O
] O

 O
- O
Resistant O
HTN O

 O
- O
Diastolic O
congestive O
heart O
failure O
, O
TTE O
[ O
* O
* O
2107 O
- O
8 O
- O
18 O
* O
* O
] O
: O
Moderate O

 O
diastolic O
LV O
dysfunction O
with O
elevated O
LVEDP O
. O
Mild O
pulmonary O

 O
hypertension O

 O
- O
Diabetes B-REA
, I-REA
type I-REA
2 I-REA
, I-REA
on O
insulin B-DRUG

 I-DRUG
- O
GERD O

 O
- O
Barrett O
's O
Esophagus O

 O
- O
s/p O
patella O
avulsion O
repair O

 O
- O
history O
of O
hypercalcemia O

 O
- O
hyperparathyroidism O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Confused O
- O
sometimes O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O

 O
Activity O
Status O
: O
Out O
of O
Bed O
with O
assistance O
to O
chair O
or O

 O
wheelchair O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
initially O
for O
volume O
overload O
and O
shortness O
of O

 O
breath O
. O
You O
had O
a O
long O
and O
complicated O
hospitalization O
for O

 O
treatment O
of O
this O
and O
various O
complications O
. O
You O
suffered O
a O

 O
severe O
type O
of O
heart O
attack O
called O
a O
PEA O
arrest O
. O
You O
required O

 O
life O
support O
from O
this O
event O
and O
were O
dependent O
on O
a O
breathing O

 O
machine O
for O
several O
weeks O
. O
Due O
to O
this O
a O
tracheostomy O
( O
breathing O

 O
tube O
in O
your O
neck O
) O
and O
feeding O
tube O
were O
placed O
. O
You O
had O
several O

 O
infections O
including O
a O
urinary O
tract O
infection O
, O
blood O
infection O
, O

 O
and O
pneumonias O
. O
You O
developed O
a O
clot B-REA
in I-REA
your I-REA
veins I-REA
and O
was O

 O
placed O
on O
blood B-DRUG
thinners I-DRUG
. I-DRUG
Unfortunately O
, O
you O
bled B-ADE
while O
on O
the O

 O
blood B-DRUG
thinners I-DRUG
and O
these O
were O
stopped O
. O
Your O
kidney O
function O

 O
worsened O
and O
your O
transplanted O
kidney O
stopped O
functioning O
. O
You O

 O
were O
restarted O
on O
dialysis O
. O

 O
. O

 O
Please O
continue O
to O
take O
your O
medications O
as O
ordered O
. O

 O
. O

 O
Please O
attend O
your O
follow O
up O
appointments O
. O

 O
. O


 O
Followup O
Instructions O
: O

 O
Appointment O
# O
1 O

 O
MD O
: O
Dr O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O

 O
Specialty O
: O
Neurology O

 O
Date/ O
Time O
: O
Wednesday O
, O
[ O
* O
* O
1 O
- O
4 O
* O
* O
] O
at O
1 O
pm O

 O
Location O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
516 O
* O
* O
] O
, O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
bldg O
, O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O

 O
Phone O
number O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
44 O
* O
* O
] O


 O
Appointment O
# O
2 O

 O
MD O
: O
Dr O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O

 O
Specialty O
: O
Transplant O

 O
Date/ O
Time O
: O
[ O
* O
* O
Last O
Name O
( O
LF O
) O
766 O
* O
* O
] O
, O
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O
at O
3:20pm O

 O
Location O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
517 O
* O
* O
] O
, O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
Bldg O
, O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
439 O
* O
* O
] O
, O
[ O
* O
* O
Location O
( O
un O
) O
436 O
* O
* O
] O

 O
Phone O
number O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
673 O
* O
* O
] O



 O
Appointment O
# O
3 O

 O
MD O
: O
Dr O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
6944 O
* O
* O
] O

 O
Specialty O
: O
Hematology O

 O
Date/ O
Time O
: O
Wednesday O
, O
[ O
* O
* O
1 O
- O
25 O
* O
* O
] O
at O
1:40pm O

 O
Location O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
516 O
* O
* O
] O
, O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
bldg O
, O
[ O
* O
* O
Location O
( O
un O
) O
436 O
* O
* O
] O

 O
Phone O
number O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
6946 O
* O
* O
] O


 O
During O
your O
appointment O
with O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
6944 O
* O
* O
] O
( O
Hematology O
) O
, O
please O

 O
discuss O
whether O
you O
will O
need O
to O
be O
evaluated O
by O
vascular O

 O
surgery O
regarding O
possible O
placement O
of O
an O
Inferior O
Vena O
Cava O

 O
filter O
, O
and O
whether O
the O
benefits O
outweigh O
the O
risks O
, O
given O
your O

 O
blood O
clots O
. O



                              O
[ O
* O
* O
Name6 O
( O
MD O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(2 O
) O
2764 O
* O
* O
] O


 O
Completed O
by:[**2107 O
- O
12 O
- O
21 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2153 O
- O
1 O
- O
20 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2153 O
- O
2 O
- O
19 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2084 O
- O
11 O
- O
24 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
NEUROSURGERY O


 O
Allergies O
: O

 O
Heparin B-DRUG
Agents O
/ O
Motrin B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
1835 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
shoulder O
pain O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
S/P O
ACD O

 O
S/P O
POSTERIOR O
CERVICAL O
RECONSTRUCTION O



 O
History O
of O
Present O
Illness O
: O

 O
68 O
M O
PMH O
thyroid O
ca O
with O
mets O
to O
bone O
and O
liver O
, O
history O
of O

 O
intrathecal B-ROU
narcotics B-DRUG
requirement O
, O
who O
p/w O
increased O
pain O
. O
  O
The O

 O
pain O
is O
located O
in O
the O
L O
shoulder O
scapular O
to O
humoral O
region O
, O

 O
with O
no O
obvious O
radation O
, O
and O
was O
[ O
* O
* O
2156 O
- O
9 O
- O
14 O
* O
* O
] O
in O
severity O
. O
  O
He O
also O

 O
describes O
other O
chronic O
pains O
, O
including O
leg O
and O
some O
chest O
pain O

 O
with O
heavy O
coughing O
, O
but O
these O
have O
been O
stable O
. O
  O
He O
was O
seen O
by O

 O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
19 O
* O
* O
] O
on O
[ O
* O
* O
1 O
- O
16 O
* O
* O
] O
, O
where O
he O
was O
also O
noted O
to O
have O
some O
L O
sided O

 O
weakness O
, O
and O
was O
sent O
for O
an O
MRI O
to O
evaluate O
for O
metastatic O

 O
disease O
, O
which O
as O
noted O
below O
showed O
no O
new O
changes O
. O
  O
He O
was O

 O
attempting O
to O
increase O
his O
decadron B-DRUG
as O
indicated O
by O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
19 O
* O
* O
] O
, O

 O
when O
he O
could O
n't O
handle O
the O
pain O
this O
AM O
, O
and O
came O
to O
the O
ED O
. O

 O
He O
has O
also O
described O
some O
diffuse O
paresthesias O
of O
both O

 O
fingertips O
, O
although O
primarily O
on O
the O
L O
-- O
no O
apparent O
pattern O
. O

 O
Otherwise O
, O
he O
denies O
focal O
weakness O
, O
numbness O
, O
incontinence O
of O

 O
stool O
or O
urine O
, O
urinary O
retention O
, O
HA O
, O
as O
well O
as O
any O
F/C/NS O
, O

 O
LH O
, O
appetite O
changes O
, O
SOB O
, O
N/V O
, O
or O
abdominal O
pain O
. O
He O
has O
a O

 O
chronic O
cough O
[ O
* O
* O
3 O
- O
9 O
* O
* O
] O
radiation O
, O
and O
also O
noted O
poor O
fluid O
intake O

 O
over O
the O
past O
few O
days O
, O
although O
no O
apparent O
reason O
. O
  O
He O

 O
requires O
a O
walker O
to O
ambulate O
, O
but O
notes O
no O
change O
over O
the O
past O

 O
few O
days O
. O

 O
. O

 O
In O
the O
ED O
, O
given O
dilaudid B-DRUG
4 B-STR
mg I-STR
IV B-ROU
x O
2 B-DOS
, I-DOS
with O
pain B-REA
that O
was O
not O

 O
completely O
revolved O
, O
but O
" O
tolerable O
. O
" O



 O

Past O
Medical O
History O
: O

 O
Thyroid O
ca O
s/p O
thyroidectomy O
[ O
* O
* O
2147 O
* O
* O
] O
, O
with O
mets O
to O
bone O
and O
liver O

 O
-s/p O
implanted O
epidural B-ROU
narcotics B-DRUG
on O
prior O
admission O
; O
hx O
of O

 O
infected O
Port-A-Cath O
system O

 O
S/p O
carboplatin B-DRUG
[ O
* O
* O
1 O
- O
9 O
* O
* O
] O

 O
S/p O
cyperknife O
to O
T1 O
[ O
* O
* O
7 O
- O
10 O
* O
* O
] O

 O
Clear O
cell O
ca O
of O
L O
kidney O
s/p O
L O
nephrectomy O
[ O
* O
* O
6 O
- O
6 O
* O
* O
] O

 O
S/p O
appy O



 O
Social O
History O
: O

 O
History O
of O
smoking O
cigarettes O
, O
1 O
pack-per-day O
, O
for O
10 O

 O
years O
-- O
stopped O
in O
[ O
* O
* O
2126 O
* O
* O
] O
. O
  O
Occasional O
alcohol O
, O
1 O
- O
2 O
drinks O
per O

 O
week O
. O
He O
does O
not O
use O
any O
illicit O
drugs O
. O


 O
Family O
History O
: O

 O
His O
mother O
died O
of O
tuberculosis O
at O
age O
36 O
in O
[ O
* O
* O
2085 O
* O
* O
] O
. O
  O
His O
father O

 O
died O
at O
age O
73 O
from O
coronary O
artery O
disease O
. O

 O
His O
brother O
died O
of O
smoking-related O
lung O
cancer O
. O
  O
His O
sister O
and O

 O
his O
children O
are O
healthy O
. O



 O
Physical O
Exam O
: O

 O
Vitals O
: O
T O
98.8 O

         O
BP O
150/91 O

         O
HR O
93 O

         O
R O
20 O

         O
Sat O
97 O
% O
RA O

 O
* O

 O
PE O
: O
G O
: O
NAD O
, O
WN O
, O
WD O

     O
HEENT O
: O
Clear O
OP O
, O
MMM O

     O
Neck O
: O
Supple O
, O
No O
LAD O
, O
No O
JVD O

     O
Lungs O
: O
BS O
BL O
, O
No O
W/R/C O

     O
Cardiac O
: O
RR O
, O
NL O
rate O
. O
NL O
S1S2 O
. O
No O
murmurs O

     O
Abd O
: O
Soft O
, O
NT O
, O
ND O
. O
NL O
BS O
. O
  O
No O
HSM O
. O

     O
Ext O
: O
No O
edema O
. O
2 O
+ O
DP O
pulses O
BL O
. O

     O
Neuro O
: O
A&Ox3 O
. O
Appropriate O
. O
CN O
2 O
- O
12 O
grossly O
intact O
. O
Preserved O

 O
sensation O
throughout O
. O
Strength O
UE O
[ O
* O
* O
6 O
- O
9 O
* O
* O
] O
R O
, O
4/5 O
L O
throughout O
-- O
no O

 O
pattern O
and O
pt O
denies O
pain O
limiting O
, O
[ O
* O
* O
6 O
- O
9 O
* O
* O
] O
BL O
LE O
. O
2 O
+ O
reflexes O
, O

 O
equal O
BL O
. O
Ungoing O
toes O
BL O
. O
Past-pointing O
on O
L O
UE O
, O
NL O
on O
R. O



 O
Pertinent O
Results O
: O

 O
MR O
[ O
* O
* O
Name13 O
( O
STitle O
) O
2853 O
* O
* O
] O
[ O
* O
* O
2153 O
- O
1 O
- O
17 O
* O
* O
] O
: O
   O
There O
is O
no O
change O
from O
[ O
* O
* O
2152 O
- O
2 O
- O
12 O
* O
* O
] O
. O
  O
There O
is O

 O
metastatic O
disease O
at O
C7-T1 O
and O
T2 O
with O
collapse O
of O
T1 O
and O

 O
resultant O
kyphosis O
. O
  O
There O
is O
stable O
epidural O
disease O
. O
  O
There O

 O
have O
been O
posterior O
laminectomies O
and O
there O
is O
no O
spinal O
cord O

 O
compression O
, O
although O
there O
is O
probably O
some O
myelomalacia O
and O

 O
atrophy O
at O
the O
level O
of O
the O
surgery O
, O
unchanged O
. O

 O
* O

 O
L O
Shoulder/humerus O
Plain O
film O
: O
Read O
pending O
; O
no O
obvious O

 O
fracture O
, O
? O
metastatic O
involvement O
. O

 O
. O


 O
CXR O
[ O
* O
* O
1 O
- O
22 O
* O
* O
] O
: O
Patchy O
opacities O
most O
prominent O
in O
the O
right O
lower O

 O
lobe O
, O
worrisome O
for O
pneumonia O
. O

 O
. O

 O
CT O
spine O
[ O
* O
* O
1 O
- O
23 O
* O
* O
] O
: O
Progression O
of O
the O
lytic O
osseous O
and O
epidural O

 O
metastases O
, O
with O
progressed O
malalignment O
. O
Fracture O
through O
the O

 O
T2 O
pedicle O
screws O
bilaterally O

 O
. O

 O
CTA O
[ O
* O
* O
1 O
- O
23 O
* O
* O
] O
: O
1 O
) O
Right O
lower O
and O
right O
middle O
lobe O
air O
space O

 O
consolidation O
consistent O
with O
pneumonia O
. O
There O
appears O
to O
be O

 O
narrowing O
of O
the O
bronchus O
intermedius O
. O

 O
2 O
) O
Left O
lower O
lobe O
atelectasis O
and O
patchy O
multifocal O
bilateral O

 O
generalized O
foci O
of O
air O
space O
disease O
most O
likely O
reflecting O

 O
consolidations O
though O
metastases O
are O
not O
excluded O
. O

 O
3 O
) O
Progression O
of O
osseous O
vertebral O
and O
hepatic O
metastasis O
. O

 O
4 O
) O
No O
evidence O
of O
PE O
. O

 O
5 O
) O
Possible O
cervical O
instability O
. O

 O
. O

 O
Bone O
scan O
[ O
* O
* O
1 O
- O
23 O
* O
* O
] O
: O
  O
1 O
) O
No O
abnormal O
uptake O
in O
the O
left O
upper O

 O
extremity O
. O
2 O
) O
Uptakecorresponding O
to O
known O
metastases O
in O
the O

 O
sternum O
, O
cervical O
spine O
as O
above O
. O
The O
new O
uptake O
in O
the O
left O

 O
11th O
and O
12th O
rib O
ends O
likely O
post-traumatic O
. O


 O
Brief O
Hospital O
Course O
: O

 O
68 O
M O
thyroid O
ca O
to O
bone O
+ O
liver O
p/w O
increased O
pain O
L O
shoulder/ O

 O
humerus O
. O
  O
Pt O
was O
admitted O
to O
the O
Medicine O
service O
and O
treated O

 O
for O
the O
following O
problems O
: O

 O
. O

 O
# O
pneumonia B-REA
: I-REA
Patient O
had O
altered O
MS O
and O
low O
grade O
fevers O
[ O
* O
* O
1 O
- O
22 O
* O
* O
] O

 O
and O
CXR O
performed O
which O
suggested O
pna O
. O
Started O
on O
levo/flagyl B-DRUG

 I-DRUG
with O
concern O
for O
aspiration O
. O
[ O
* O
* O
1 O
- O
23 O
* O
* O
] O
, O
patient O
had O
new O
hypoxia O
and O

 O
hemoptysis O
. O
Hematocrit O
has O
remained O
stable O
. O
CTA O
negative O
for O
PE O

 O
but O
did O
confirm O
significant O
pneumonia O
. O
  O
No O
fevers O
since O
starting O

 O
levo/flagyl B-DRUG
. I-DRUG

 O
. O

 O
# O
L B-REA
shoulder/humerus I-REA
pain I-REA
: I-REA
Evaluated O
by O
radiation O
oncology O
who O

 O
felt O
that O
risks O
of O
radiation O
in O
setting O
of O
multiple O
prior O

 O
episodes O
was O
quite O
high O
especially O
given O
instability O
. O

 O
Neurosurgery O
consulted O
for O
cervical O
spine O
. O
  O
His O
pain O
was O

 O
initially O
difficult O
to O
control O
, O
but O
was O
ultimately O
dramatically O

 O
improved O
when O
he O
was O
changed O
to O
a O
dilaudid B-DRUG
PCA B-FOR
-- I-FOR
he O
did O
not O
have O

 O
relief O
from O
fentanyl B-DRUG
patch B-FOR
, I-FOR
likely O
b/c O
of O
soft O
tissue O
wasting O

 O
and O
future O
efforts O
at O
long O
acting O
medications O
should O
be O
PO O
. O

 O
. O

 O
# O
thyroid B-REA
ca I-REA
, I-REA
metastatic B-REA
disease I-REA
: I-REA
  O
progressive O
in O
spine O
and O

 O
likely O
contributing O
to O
current O
complaints O
. O
  O
Levothyroxine B-DRUG
was O

 O
continued O
. O
consider O
neupogen B-DRUG
. I-DRUG
Will O
d/w O
attending O
Oncologist O

 O
. O

 O
# O
thrush B-REA
: I-REA
The O
patient O
was O
admitted O
with O
thrush O
which O
was O

 O
succesfully O
treated O
with O
nystatin B-DRUG
S&S. B-FOR



 O
Neurosurgery O
team O
asked O
to O
eval O
this O
pt O
on O
[ O
* O
* O
2153 O
- O
1 O
- O
23 O
* O
* O
] O
  O
and O
was O

 O
transferred O
to O
our O
service O
for O
spinal O
deformity O
which O
was O
noted O

 O
on O
upper O
level O
of O
images O
( O
CT O
chest O
) O
to O
r/o O
PE O
. O
  O
CT O
of O
cervical O

 O
thoracic O
spine O
was O
obtained O
and O
results O
of O
T1 O
collapse O
noted O
. O

 O
Pts O
family O
, O
at O
that O
time O
wanted O
to O
continue O
care O
with O
prior O

 O
Neurosurgeon/Dr O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
1327 O
* O
* O
] O
. O
  O
This O
was O
communicated O
to O
this O

 O
neurosurgery O
team O
. O
  O
Some O
short O
time O
later O
the O
family O
wished O

 O
against O
transfer O
out O
to O
Dr.[**Name O
( O
NI O
) O
1334 O
* O
* O
] O
care O
and O
decided O
that O
they O

 O
would O
want O
surgery O
to O
correct O
spinal O
deformity/kyphosis O
here O
. O

 O
The O
pt O
was O
placed O
in O
[ O
* O
* O
Last O
Name O
( O
un O
) O
20482 O
* O
* O
] O
Halo O
traction O
at O
30lbs O
of O
traction O
. O

 O
This O
was O
in O
attempt O
to O
reduce O
kyphotic O
deformity O
for O

 O
pre-operative O
optimization O
. O
  O
A O
CT O
scan O
of O
the O
spine O
was O
obtained O

 O
in O
traction O
and O
good O
reduction O
of O
the O
deformity O
was O
noted O
. O
  O
The O

 O
pt O
was O
then O
medically O
optimized O
and O
pre-op'd O
and O
taken O
to O
the O
OR O

 O
on O
[ O
* O
* O
2153 O
- O
2 O
- O
8 O
* O
* O
] O
for O
C7 O
T1 O
T2 O
corpectomies/ O
anterior O
approach O
. O
There O

 O
was O
a O
lot O
of O
bleeding O
during O
the O
initial O
anterior O
approach O
/ O
the O

 O
case O
lasting O
approximately O
7 O
hours O
. O
  O
It O
was O
decided O
that O
the O
pt O

 O
would O
remain O
intubated O
and O
return O
to O
the O
OR O
on O
the O
5th O
( O
the O
next O

 O
day O
for O
continuation O
of O
the O
case O
. O
  O
The O
second O
portion O
of O
the O

 O
case O
was O
completed O
that O
day O
( O
the O
5th O
) O
. O
  O
Thoracic O
surgery O

 O
assisted O
because O
of O
mediastinal O
mass O
/ O
we O
needed O
sternotomy O
to O

 O
control O
bleeding O
and O
complete O
ant O
. O
approach O
. O
The O
total O
EBL O
was O

 O

7.5 O
liters O
with O
the O
pt O
being O
given O
22 B-DOS
units I-DOS
of O
PRBC B-DRUG
's I-DRUG
. I-DRUG
  O
He O
had O
a O

 O
chest O
tube O
placed O
on O
the O
left O
side O
intraoperatively O
. O
  O
This O
was O

 O
removed O
on O
approx O
1/7/7 O
. O
  O
Postoperatively O
he O
was O
started O
on O

 O
Fondiparinox B-DRUG
on O
[ O
* O
* O
2 O
- O
13 O
* O
* O
] O
as O
he O
is O
HIT B-REA
positive I-REA
. I-REA
On O
[ O
* O
* O
2153 O
- O
2 O
- O
14 O
* O
* O
] O
he O
had O
a O

 O
peg O
tube O
place O
. O
His O
postoperative O
  O
head O
CT O
and O
spine O
CT O
's O
were O

 O
stable O
. O
  O
His O
neurological O
status O
postoperatively O
was O
stable O
. O
All O

 O
extremeties O
are O
antigravity O
and O
his O
mentation O
is O
intact O
. O
  O
His O

 O
course O
complicated O
by O
intermittent O
low O
HCT O
's O
for O
which O
he O
was O

 O
transfused O
. O
  O
Temps B-REA
as I-REA
high I-REA
as I-REA
102.+ I-REA
for O
which O
he O
was O
started O
on O

 O
Zosyn B-DRUG
. I-DRUG
On O
[ O
* O
* O
2153 O
- O
2 O
- O
16 O
* O
* O
] O
his O
left O
upper O
extremity O
was O
noted O
to O
be O

 O
swollen O
and O
son[**Name O
( O
NI O
) O
* O
* O
] O
noted O
LUE O
DVT O
. O
  O
On O
the O
14th O
, O
the O
halo O
ring O

 O
that O
was O
initially O
placed O
for O
use O
of O
cervical O
traction O
and O
for O

 O
potential O
halo O
vest O
placement O
was O
removed O
. O
  O
He O
remains O
in O
a O

 O
cervical O
collar O
and O
had O
been O
OOB O
to O
chair O
. O
  O
The O
patient O
required O

 O
prolonged O
ventilation O
he O
had O
difficulty O
clearing O
his O
secretions O
. O

  O
His O
family O
was O
offered O
a O
trach O
but O
they O
felt O
the O
patient O
had O
a O

 O
difficult O
post O
operative O
course O
and O
was O
suffering O
they O
did O
not O

 O
want O
to O
the O
patient O
to O
under O
go O
further O
procedures O
. O
  O
The O
patient O

 O
had O
made O
his O
wishes O
clear O
to O
his O
family O
not O
to O
be O
dependent O
or O

 O
on O
a O
ventilator O
for O
a O
prolonged O
period O
. O
  O
After O
a O
long O
discussion O

 O
with O
the O
family O
and O
Dr O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
they O
decided O
to O
extubate O
the O

 O
patient O
and O
see O
if O
he O
could O
tolerate O
being O
extubated O
, O
he O
quickly O

 O
passed O
away O
in O
a O
few O
minutes O
with O
his O
family O
at O
his O
side O
. O


 O
Medications O
on O
Admission O
: O

 O
gabapentin B-DRUG
300/300/900 B-STR
, I-STR

 O
hydromorphone B-DRUG
4 B-STR
- I-STR
8 I-STR
mg I-STR
Q8H B-FRE
PRN B-FRE
, I-FRE

 O
tizanidine B-DRUG
2 B-STR
mg I-STR
t.i.d B-FRE
. I-FRE
, O

 O
fentanyl B-DRUG
patch B-FOR
75 B-STR
mcg I-STR
per I-STR
hour I-STR
every B-FRE
three I-FRE
days I-FRE
, I-FRE

 O
lidoderm B-DRUG
patch B-FOR
50 B-STR
, I-STR
3 B-DOS
patches B-FOR
a B-FRE
day I-FRE

 I-FRE
lorazepam B-DRUG
0.5 B-STR
mg I-STR
Q4 B-FRE
- I-FRE
6H I-FRE
PRN I-FRE

 I-FRE
levothyroxine B-DRUG
0.125 B-STR
qd B-FRE

 I-FRE
protonix B-DRUG
40 B-STR
qd B-FRE

 I-FRE
folic B-DRUG
acid I-DRUG

 I-DRUG
decadron B-DRUG
2 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
( O
incr O
to O
4 B-STR
mg I-STR
in O
AM O
today O
) O


 O
Discharge O
Medications O
: O

 O
N/A O


 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Discharge O
Diagnosis O
: O

 O
cervical O
spine O
harware O
failure O

 O
s/p O
cervical O
spine O
stabilization O

 O
metestatic O
disease O



 O
Discharge O
Condition O
: O

 O
Expired O


 O
Discharge O
Instructions O
: O

 O
N/A O


 O
Followup O
Instructions O
: O

 O
N/A O



 O
Completed O
by:[**2153 O
- O
2 O
- O
19 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2164 O
- O
10 O
- O
9 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2164 O
- O
10 O
- O
15 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2138 O
- O
5 O
- O
12 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
NEUROSURGERY O


 O
Allergies O
: O

 O
Morphine B-DRUG
Sulfate I-DRUG
/ O
Dilaudid B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
1835 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
headaches O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
[**2164 O
- O
10 O
- O
11**]- O
Right O
Frontal O
Craniotomy O
and O
Mass O
resection O



 O
History O
of O
Present O
Illness O
: O

 O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Known O
lastname O
13060 O
* O
* O
] O
is O
a O
26 O
y/o O
right O
handed O
woman O
with O
no O
significant O

 O
PMH O
who O
presented O
to O
the O
ED O
today O
after O
being O
asked O
to O
come O
in O

 O
by O

 O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
724 O
* O
* O
] O
for O
an O
abnormal O
MRI O
. O
She O
has O
never O
had O
a O
history O
of O

 O
headaches O
until O
she O
developed O
headaches O
in O
[ O
* O
* O
Month O
( O
only O
) O
* O
* O
] O
; O
these O
headaches O

 O
would O
occur O
in O
various O
locations O
of O
her O
head O
, O
though O
more O

 O
recently O
she O
describes O
them O
as O
occuring O
just O
left O
of O
the O
vertex O
. O

 O
She O
would O
get O
these O
headaches O
about O
20 O
days O
per O
months O
since O
its O

 O
onset O
in O
[ O
* O
* O
Month O
( O
only O
) O
* O
* O
] O
. O
At O
its O
worst O
, O
the O
headache O
would O
go O
up O
to O
a O
[ O
* O
* O
6 O
- O
16 O
* O
* O
] O

 O
in O
intensity O
and O
twice O
it O
resulted O
in O
her O
vomiting O
. O

 O
Occasionally O
, O

 O
it O
would O
be O
assoicated O
with O
photophobia O
but O
no O
son[**Name O
( O
NI O
) O
* O
* O
] O
. O
Of O

 O
note O
, O
there O
is O
a O
positional O
nature O
to O
these O
headaches O
as O
she O

 O
says O

 O
that O
the O
headache O
is O
usually O
worse O
when O
she O
wakes O
up O
in O
the O

 O
morning O
. O
Recently O
, O
she O
has O
also O
noted O
the O
onset O
of O

 O
lightheadedness O
with O
positional O
changes O
, O
but O
no O
vertigo O
. O
No O

 O
strength O
or O
sensory O
changes O
, O
no O
visual O
changes O
and O
no O
weight O

 O
loss O

 O
noted O
since O
[ O
* O
* O
Month O
( O
only O
) O
* O
* O
] O
. O
Her O
parents O
have O
not O
noted O
any O
behavioral O

 O
changes O
. O
No O
history O
of O
head O
trauma O
aside O
from O
recently O
banging O

 O
her O
forehead O
accidentally O
on O
the O
counter O
while O
bartending O
. O
No O

 O
history O
of O
seizures O
. O



 O
Past O
Medical O
History O
: O

 O
astigmatism O
, O
LEEP O
procedure O
for O
cervical O
dysplasia O



 O
Social O
History O
: O

 O
She O
currently O
works O
as O
a O
bartender O
but O
has O
recently O

 O
( O
prior O
[ O
* O
* O
Holiday O
* O
* O
] O
[ O
* O
* O
2162 O
* O
* O
] O
) O
traveled O
to O
[ O
* O
* O
Country O
27440 O
* O
* O
] O
to O
teach O
English O
. O

 O
She O
has O
also O
traveled O
to O
[ O
* O
* O
Country O
651 O
* O
* O
] O
, O
[ O
* O
* O
Country O
5142 O
* O
* O
] O
and O
[ O
* O
* O
Country O
3992 O
* O
* O
] O
. O
Reports O
no O

 O
illnesses O
from O
these O
travels O
. O
  O
She O
does O
not O
currently O
smoke O
or O

 O
do O

 O
illicit O
drugs O
, O
though O
has O
tried O
marijuana O
in O
high O
school O
. O
SHe O

 O
currently O
drinkns O
alcohol O
1 O
- O
2x O
per O
week O
, O
though O
notes O
binge O

 O
drinking O
in O
college O
. O



 O
Family O
History O
: O

 O
Parents O
are O
healthy O
. O
Maternal O
grandmother O
with O

 O
multiple O
cancers O
including O
stomach O
and O
kidney O
. O
No O
other O
family O

 O
history O
of O
cancer O
. O
Paternal O
grandfather O
in O
his O
80s O
with O

 O
Alzheimer O
's O
disease O
. O



 O
Physical O
Exam O
: O

 O
vitals O
: O
  O
T O
: O
98 O
BP O
: O
132/70 O
  O
HR O
: O
70 O
   O
R O
: O
18 O
    O
O2Sats O
: O
95 O
% O
RA O

 O
Gen O
: O
WD/WN O
, O
comfortable O
, O
NAD O
. O

 O
HEENT O
: O
PERRL O
, O
MMM O

 O
Neck O
: O
Supple O
. O
No O
lymphadenopathy O

 O
Chest O
: O
No O
breast O
masses O

 O
Lungs O
: O
CTA O
bilaterally O
. O

 O
Cardiac O
: O
RRR O
. O
S1/S2 O
. O

 O
Abd O
: O
Soft O
, O
NT O
, O
BS+ O

 O
Extrem O
: O
Warm O
and O
well-perfused O
. O

 O
Skin O
: O
moles O
on O
back O

 O
Neuro O
: O

 O
Mental O
status O
: O
Awake O
and O
alert O
, O
cooperative O
with O
exam O
, O
normal O

 O
affect O
. O
Attentive- O
able O
to O
name O
[ O
* O
* O
Doctor O
Last O
Name O
1841 O
* O
* O
] O
backwards O
. O
No O
evidence O
of O

 O
apraxia O
. O
Able O
to O
perform O
Luria O
sequencing O
without O
difficulty O
. O

 O
Orientation O
: O
Oriented O
to O
person O
, O
place O
, O
and O
date O
. O

 O
Recall O
: O
[ O
* O
* O
3 O
- O
11 O
* O
* O
] O
objects O
at O
5 O
minutes O
. O

 O
Language O
: O
Speech O
fluent O
with O
good O
comprehension O
and O
repetition O
. O

 O
Naming O
intact O
. O
No O
dysarthria O
or O
paraphasic O
errors O
. O


 O
Cranial O
Nerves O
: O

 O
I O
: O
Not O
tested O

 O
II O
: O
Pupils O
equally O
round O
and O
reactive O
to O
light O
, O
4 O
to O
2 O

 O
mm O
bilaterally O
. O
Visual O
fields O
are O
full O
to O
confrontation O
. O
Mild O

 O
papilledema O
on O
funsoscopic O
exam O
. O

 O
III O
, O
IV O
, O
VI O
: O
Extraocular O
movements O
intact O
bilaterally O
without O

 O
nystagmus O
. O

 O
V O
, O
VII O
: O
Facial O
strength O
and O
sensation O
intact O
and O
symmetric O
. O

 O
VIII O
: O
Hearing O
intact O
to O
voice O
. O

 O
IX O
, O
X O
: O
Palatal O
elevation O
symmetrical O
. O

 O
[ O
* O
* O
Doctor O
First O
Name O
81 O
* O
* O
] O
: O
Sternocleidomastoid O
and O
trapezius O
normal O
bilaterally O
. O

 O
XII O
: O
Tongue O
midline O
without O
fasciculations O
. O


 O
Motor O
: O
Normal O
bulk O
and O
tone O
bilaterally O
. O
No O
abnormal O
movements O
, O

 O
tremors O
. O
Strength O
full O
power O
[ O
* O
* O
4 O
- O
11 O
* O
* O
] O
throughout O
. O
No O
pronator O
drift O



 O
Sensation O
: O
Intact O
to O
light O
touch O
, O
propioception O
, O
pinprick O
and O

 O
vibration O
bilaterally O
. O


 O
Reflexes O
: O
B O
T O
Br O
Pa O
Ac O

 O
Right O
     O
2 O
2 O
2 O
  O
2 O
  O
2 O

 O
Left O
      O
2 O
2 O
2 O
  O
2 O
  O
2 O


 O
Toes O
downgoing O
bilaterally O


 O
Coordination O
: O
normal O
on O
finger-nose O
. O
Romberg O
absent O


 O
Gait O
: O
normal O
, O
able O
to O
tandem O
walk O


 O
EXAM O
ON O
DISCHARGE O
: O


 O
As O
above O
. O
Incision O
clean O
, O
dry O
and O
intact O



 O
Pertinent O
Results O
: O

 O
ADMISSION O
LABS O
: O


 O
[ O
* O
* O
2164 O
- O
10 O
- O
9 O
* O
* O
] O
01:50PM O
   O
PT-12.3 O
PTT-21.5 O
* O
INR(PT)-1.0 O

 O
[ O
* O
* O
2164 O
- O
10 O
- O
9 O
* O
* O
] O
01:50PM O
   O
WBC-5.2 O
RBC-4.77 O
HGB-14.1 O
HCT-41.9 O
MCV-88 O

 O
MCH-29.5 O
MCHC-33.5 O
RDW-13.6 O

 O
[ O
* O
* O
2164 O
- O
10 O
- O
9 O
* O
* O
] O
01:50PM O
   O
GLUCOSE-84 O
UREA O
N-9 O
CREAT-0.9 O
SODIUM-137 O

 O
POTASSIUM-4.1 O
CHLORIDE-102 O
TOTAL O
CO2 O
- O
26 O
ANION O
GAP-13 O


 O
DISCHARGE O
LABS O
: O


 O
[ O
* O
* O
2164 O
- O
10 O
- O
15 O
* O
* O
] O
08:40AM O
BLOOD O
WBC-11.5 O
* O
RBC-4.45 O
Hgb-13.2 O
Hct-38.2 O

 O
MCV-86 O
MCH-29.6 O
MCHC-34.4 O
RDW-13.5 O
Plt O
Ct-340 O

 O
[ O
* O
* O
2164 O
- O
10 O
- O
10 O
* O
* O
] O
11:30PM O
BLOOD O
Neuts-89.1 O
* O
Lymphs-7.3 O
* O
Monos-3.3 O
Eos-0.2 O

 O
Baso-0.2 O

 O
[ O
* O
* O
2164 O
- O
10 O
- O
15 O
* O
* O
] O
08:40AM O
BLOOD O
Glucose-109 O
* O
UreaN-11 O
Creat-0.7 O
Na-132 O
* O

 O
K-4.1 O
Cl-98 O
HCO3 O
- O
27 O
AnGap-11 O


 O
IMAGING O
: O

 O
CT O
Head O
[ O
* O
* O
10 O
- O
9 O
* O
* O
] O
: O

 O
1 O
. O
A O
large O
lesion O
in O
the O
right O
frontal O
lobe O
, O
measuring O
6.8 O
x O
5.2 O

 O
x O
9 O
cm O
, O
seen O
to O
extend O
into O
the O
region O
of O
the O
frontal O
[ O
* O
* O
Doctor O
Last O
Name O
534 O
* O
* O
] O
of O

 O
the O
right O
lateral O
ventricle O
, O
and O
in O
proximity O
to O
the O
septum O

 O
pellucidum O
. O
Given O
the O
large O
size O
and O
lack O
of O
priors O
, O
the O
exact O

 O
site O
of O
origin O
of O
the O
lesion O
is O
not O
clear O
. O
This O
can O
either O

 O
represent O
a O
low-grade O
neoplasm O
vs O
a O
complex O
cyst O
, O
with O
the O

 O
differential O
diagnosis O
including O
subependymoma O
, O
pleomorphic O

 O
xanthoastrocytoma O
, O
oligodendroglioma O
, O
the O
latter O
two O
being O
less O

 O
likely O
given O
the O
pattern O
of O
enhancement O
and O
lack O
of O

 O
calcifications O
. O
An O
unusual O
complex O
cyst O
can O
not O
be O
completely O

 O
excluded O
. O
The O
lesion O
does O
appear O
to O
have O
some O
vascularity O
, O
with O

 O
tiny O
vessels O
noted O
within O
the O
lesion O
. O
Wet O
read O
was O
entered O
on O

 O
[ O
* O
* O
2164 O
- O
10 O
- O
9 O
* O
* O
] O
, O
soon O
after O
the O
study O
. O


 O
CT O
Head O
[ O
* O
* O
10 O
- O
11 O
* O
* O
] O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
Expected O
post-surgical O
changes O
, O
status O
post O
right O
frontal O

 O
mass O
removal O
. O

 O
2 O
. O
Interval O
decrease O
of O
mass O
effect O
when O
compared O
to O
prior O
study O

 O
( O
[ O
* O
* O
2164 O
- O
10 O
- O
11 O
* O
* O
] O
) O
. O
No O
hemorrhage O
or O
major O
vascular O
territorial O

 O
infarction O
is O
noted O
. O



 O
MRI O
Head O
[ O
* O
* O
10 O
- O
12 O
* O
* O
] O
: O

 O
IMPRESSION O
: O

 O
1 O
. O
No O
evidence O
of O
infarction O
. O

 O
2 O
. O
FLAIR O
abnormality O
around O
the O
surgical O
resection O
margin O
may O
be O

 O
related O
to O
recent O
surgery O
, O
though O
residual O
tumor O
can O
not O
be O

 O
excluded O
. O
While O
there O
is O
no O
abnormal O
enhancement O
, O
there O
is O
no O

 O
enhancement O
of O
the O
tumor O
prior O
to O
surgery O
, O
so O
this O
can O
not O
be O

 O
used O
as O
metric O
. O



 O
Brief O
Hospital O
Course O
: O

 O
Patient O
presented O
to O
the O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
ED O
after O
having O
an O
MRI O
of O
her O

 O
brain O
for O
consistent O
headaches O
as O
an O
outpatient O
which O
showed O
her O

 O
to O
have O
a O
right O
frontal O
mass O
which O
communicated O
with O
the O
right O

 O
lateral O
ventricle O
. O
She O
was O
evaluated O
by O
neuromedicine O
and O

 O
neurosurgery O
in O
the O
ED O
and O
was O
admitted O
to O
the O
neurosurgery O

 O
service O
. O
A O
CTA/V O
was O
obtained O
to O
gain O
information O
on O
the O

 O
vascularity O
of O
the O
mass O
. O
On O
the O
evening O
of O
[ O
* O
* O
10 O
- O
10 O
* O
* O
] O
it O
was O
decided O

 O
that O
she O
would O
undergo O
surgical O
resection O
of O
the O
mass O
via O

 O
craniotomy O
on O
the O
morning O
of O
[ O
* O
* O
10 O
- O
11 O
* O
* O
] O
. O
  O
She O
remained O
stable O
on O
the O

 O
floor O
overnight O
and O
on O
[ O
* O
* O
10 O
- O
11 O
* O
* O
] O
was O
taken O
to O
the O
OR O
for O
surgery O
. O

 O
Surgery O
was O
without O
complication O
. O
She O
was O
admitted O
to O
the O
ICU O

 O
but O
remained O
in O
the O
PACU O
overnight O
. O
Post O
op O
CT O
revealed O
good O

 O
resection O
and O
no O
hemorrhage O
. O

 O
ON O
POD#1 O
she O
was O
neurologically O
intact O
. O
She O
was O
cleared O
for O

 O
transfer O
to O
the O
floor O
. O
post O
op O
MRI O
was O
completed O
and O
also O

 O
revealed O
excellent O
resection O
. O
PCA O
was O
discontinued O
and O
she O
was O

 O
started O
on O
PO B-ROU
pain B-DRUG
meds I-DRUG
with O
IV B-ROU
for O
breakthourgh B-REA
. I-REA
She O
did O

 O
require O
some O
IV B-ROU
pain B-DRUG
medication I-DRUG
on O
[ O
* O
* O
10 O
- O
13 O
* O
* O
] O
and O
remained O
on O
her O
PO O

 O
regimen O
. O
She O
was O
able O
to O
mobilize O
OOB O
on O
this O
day O
and O
walk O

 O
through O
the O
halls O
without O
difficulty O
. O
She O
was O
somewhat O

 O
orthostatic O
and O
complained O
of O
dizziness O
on O
[ O
* O
* O
10 O
- O
14 O
* O
* O
] O
when O
ambulating O

 O
and O
she O
was O
started O
on O
50cc/hr B-DOS
of O
IVF B-DRUG
and O
had O
no O
further O
issues O
. O



 O
She O
was O
discharged O
to O
home O
on O
[ O
* O
* O
2164 O
- O
10 O
- O
15 O
* O
* O
] O
. O


 O
Medications O
on O
Admission O
: O

 O
amitriptyline B-DRUG
, I-DRUG
OCP B-DRUG



 I-DRUG
Discharge O
Medications O
: O

 O
1 O
. O
levetiracetam B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*120 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
2 O
. O
amitriptyline B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
HS B-FRE
( I-FRE
at I-FRE

 I-FRE
bedtime I-FRE
) I-FRE
. I-FRE

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
3 O
. O
acetaminophen B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE

 I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
headache B-REA
. I-REA

 O
4 O
. O
famotidine B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
5 O
. O
docusate B-DRUG
sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
Disp:*60 O
Capsule(s O
) O
* O
Refills:*0 O
* O

 O
6 O
. O
diazepam B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q6H B-FRE
( I-FRE
every I-FRE
6 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
anxiety/spasm B-REA
. I-REA

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
7 O
. O
oxycodone B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q3H B-FRE
( I-FRE
every I-FRE
3 I-FRE
hours I-FRE
) I-FRE

 I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
8 O
. O
diphenhydramine B-DRUG
HCl I-DRUG
25 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
Q6H B-FRE

 I-FRE
( I-FRE
every I-FRE
6 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
itching B-REA
. I-REA

 O
9 O
. O
hydromorphone B-DRUG
4 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
1 B-DOS
- I-DOS
2 I-DOS
Tablets B-FOR
PO B-ROU
Q4H B-FRE
( I-FRE
every I-FRE
4 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
10 O
. O
dexamethasone B-DRUG
4 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q8 B-FRE
( O
) O
for B-DUR
2 I-DUR

 I-DUR
days I-DUR
. I-DUR

 O
Disp:*16 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
11 O
. O
dexamethasone B-DRUG
1.5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q8 B-FRE
( O
) O
for B-DUR

 I-DUR
2 I-DUR
days I-DUR
. I-DUR

 O
Disp:*32 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
12 O
. O
dexamethasone B-DRUG
2 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q8 B-FRE
( O
) O
for B-DUR
2 I-DUR

 I-DUR
days I-DUR
. I-DUR

 O
Disp:*16 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
13 O
. O
dexamethasone B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q8 B-FRE
( O
) O
for B-FRE
2 I-FRE

 I-FRE
days I-FRE
. I-FRE

 O
Disp:*16 O
Tablet(s O
) O
* O
Refills:*0 O
* O

 O
14 O
. O
Dulcolax B-DRUG
10 B-STR
mg I-STR
Suppository B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Rectal B-ROU
once B-FRE
a I-FRE
day I-FRE

 I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
Disp:*10 O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
R O
Frontal O
Mass O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O

Discharge O
Instructions O
: O

 O
? O
? O
? O
? O
? O
? O
	 O
Have O
a O
friend/family O
member O
check O
your O
incision O
daily O
for O

 O
signs O
of O
infection O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Take O
your O
pain B-DRUG
medicine I-DRUG
as O
prescribed O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Exercise O
should O
be O
limited O
to O
walking O
; O
no O
lifting O
, O
straining O
, O

 O
or O
excessive O
bending O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
may O
wash O
your O
hair O
only O
after O
sutures O
and/or O
staples O
have O

 O
been O
removed O
. O
If O
your O
wound O
closure O
uses O
dissolvable O
sutures O
, O

 O
you O
must O
keep O
that O
area O
dry O
for O
10 O
days O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
You O
may O
shower O
before O
this O
time O
using O
a O
shower O
cap O
to O
cover O

 O
your O
head O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Increase O
your O
intake O
of O
fluids O
and O
fiber O
, O
as O
narcotic B-DRUG
pain I-DRUG

 I-DRUG
medicine I-DRUG
can O
cause O
constipation B-ADE
. I-ADE
We O
generally O
recommend O
taking O

 O
an O
over O
the O
counter O
stool B-DRUG
softener I-DRUG
, I-DRUG
such O
as O
Docusate B-DRUG
( I-DRUG
Colace I-DRUG
) I-DRUG

 I-DRUG
while O
taking O
narcotic B-DRUG
pain I-DRUG
medication I-DRUG
. I-DRUG

 O
? O
? O
? O
? O
? O
? O
	 O
Unless O
directed O
by O
your O
doctor O
, O
do O
not O
take O
any O

 O
anti-inflammatory B-DRUG
medicines I-DRUG
such O
as O
Motrin B-DRUG
, I-DRUG
Aspirin B-DRUG
, I-DRUG
Advil B-DRUG
, I-DRUG
and O

 O
Ibuprofen B-DRUG
etc O
. O

 O
? O
? O
? O
? O
? O
? O
	  O
If O
you O
have O
been O
discharged O
on O
Keppra B-DRUG
( I-DRUG
Levetiracetam I-DRUG
) I-DRUG
, I-DRUG
you O

 O
will O
not O
require O
blood O
work O
monitoring O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
If O
you O
are O
being O
sent O
home O
on O
steroid B-DRUG
medication O
, O
make O
sure O

 O
you O
are O
taking O
a O
medication O
to O
protect O
your O
stomach O
( O
Prilosec B-DRUG
, I-DRUG

 O
Protonix B-DRUG
, I-DRUG
or O
Pepcid B-DRUG
) I-DRUG
, O
as O
these O
medications O
can O
cause O
stomach B-REA

 I-REA
irritation I-REA
. I-REA
  O
Make O
sure O
to O
take O
your O
steroid B-DRUG
medication O
with O

 O
meals O
, O
or O
a O
glass O
of O
milk O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Clearance O
to O
drive O
and O
return O
to O
work O
will O
be O
addressed O
at O

 O
your O
post-operative O
office O
visit O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Make O
sure O
to O
continue O
to O
use O
your O
incentive O
spirometer O
while O

 O
at O
home O
. O

 O
CALL O
YOUR O
SURGEON O
IMMEDIATELY O
IF O
YOU O
EXPERIENCE O
ANY O
OF O
THE O

 O
FOLLOWING O


 O
? O
? O
? O
? O
? O
? O
	 O
New O
onset O
of O
tremors O
or O
seizures O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Any O
confusion O
or O
change O
in O
mental O
status O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Any O
numbness O
, O
tingling O
, O
weakness O
in O
your O
extremities O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Pain O
or O
headache O
that O
is O
continually O
increasing O
, O
or O
not O

 O
relieved O
by O
pain O
medication O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Any O
signs O
of O
infection O
at O
the O
wound O
site O
: O
increasing O
redness O
, O

 O
increased O
swelling O
, O
increased O
tenderness O
, O
or O
drainage O
. O

 O
? O
? O
? O
? O
? O
? O
	 O
Fever O
greater O
than O
or O
equal O
to O
101 O
? O
? O
? O
? O
? O
? O
F. O



 O

Followup O
Instructions O
: O

 O
? O
? O
? O
? O
? O
? O
You O
have O
an O
appointment O
in O
the O
Brain O
[ O
* O
* O
Hospital O
341 O
* O
* O
] O
Clinic O
on O
[ O
* O
* O
2164 O
- O
10 O
- O
22 O
* O
* O
] O
@ O

 O
10:30AM O
. O
  O
The O
Brain O
[ O
* O
* O
Hospital O
341 O
* O
* O
] O
Clinic O
is O
located O
on O
the O
[ O
* O
* O
Hospital O
Ward O
Name O
516 O
* O
* O
] O

 O
of O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
, O
in O
the O
[ O
* O
* O
Hospital O
Ward O
Name O
23 O
* O
* O
] O
Building O
, O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
. O
Their O
phone O
number O

 O
is O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
1844 O
* O
* O
] O
. O
Please O
call O
if O
you O
need O
to O
change O
your O

 O
appointment O
, O
or O
require O
additional O
directions O
. O

 O
? O
? O
? O
? O
? O
? O
You O
will O
not O
need O
an O
MRI O
of O
the O
brain O
. O




 O
Completed O
by:[**2164 O
- O
10 O
- O
15 O
* O
* O
] O

Admission O
Date O
: O
  O
[ O
* O
* O
2194 O
- O
7 O
- O
4 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2194 O
- O
7 O
- O
11 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2122 O
- O
2 O
- O
12 O
* O
* O
] O
             O
Sex O
: O
   O
F O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Patient O
recorded O
as O
having O
No O
Known O
Allergies O
to O
Drugs O


 O
Attending:[**First O
Name3 O
( O
LF O
) O
1257 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
altered O
mental O
status O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
none O


 O
History O
of O
Present O
Illness O
: O

 O
72 O
year O
old O
spanish O
speaking O
woman O
with O
a O
history O
of O
a O

 O
hemorrhagic O
CVA O
in O
[ O
* O
* O
2164 O
* O
* O
] O
s/p O
craniotomy O
, O
hypertension O
, O

 O
hyperlipidemia O
, O
admitted O
to O
[ O
* O
* O
Hospital3 O
* O
* O
] O
on O
[ O
* O
* O
7 O
- O
1 O
* O
* O
] O
with O
two O

 O
weeks O
of O
increased O
confusion O
at O
home O
, O
slurred O
speech O
and O

 O
conversation O
not O
making O
any O
sense O
, O
unsteady O
gait O
, O
weakness O
, O
and O

 O
substernal O
chest O
pain O
. O

 O
. O

 O
First O
presented O
to O
LGH O
[ O
* O
* O
2194 O
- O
6 O
- O
30 O
* O
* O
] O
where O
she O
was O
141/80 O
  O
p82 O
  O
rr18 O

 O
98%RA O
. O
She O
had O
a O
positive O
UA O
for O
infxn B-REA
( O
Proteus O
Vulgaris O
, O
per O

 O
report O
) O
and O
she O
was O
given O
either O
Levaquin B-DRUG
, I-DRUG
Rocephin B-DRUG
, I-DRUG
or O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O

 O
( O
unclear O
) O
. O
CK O
was O
123 O
, O
MB O
2.3 O
, O
and O
TropI O
0.03 O
, O
subsequently O

 O
" O
negative O
x3 O
. O
" O
Other O
labs O
significant O
for O
hypercalcemia O
at O
10.4 O
, O

 O
WBC O
7.9 O
, O
Hct O
30.8 O
( O
normocytic O
) O
, O
Plts O
425k O
. O
Chemistry O

 O
unremarkable O
, O
Cr O
1.1 O
. O
EKG O
was O
non O
specific O
with O
some O
ST O
changes O

 O
in O
II O
. O
CT O
of O
head O
negative O
x2 O
for O
acute O
process O
with O

 O
post-operative O
changes O
, O
chronic O
ischemic O
changes O
. O
Carotid O
duplex O

 O
study O
pending O
. O

 O
. O

 O
Stress O
test O
positive O
for O
inferior O
ischemia O
( O
? O
unclear O
if O
pt O
got O

 O
the O
stress O
test O
, O
reports O
indicate O
that O
she O
was O
too O
agitated O
to O

 O
sit O
still O
for O
it O
) O
. O
Cathed O
today O
and O
found O
to O
have O
a O
tight O

 O
proximal O
90 O
% O
PDA O
lesion O
. O
5 O
French O
sheath O
in O
RFA O
. O
On O
aspirin B-DRUG

 I-DRUG
only O
, O
has O
not O
been O
prescribed O
plavix B-DRUG
. I-DRUG
Daughter O
speaks O
english O

 O
and O
has O
signed O
consent O
, O
will O
come O
with O
patient O
. O


 O
Past O
Medical O
History O
: O

 O
Cerebral O
aneurysm O
s/p O
cerebral O
( O
MCA O
) O
hemorrhage O
in O
[ O
* O
* O
2164 O
* O
* O
] O
, O
s/p O

 O
craniotomy O
and O
repair O
( O
clip O
placement O
) O
-- O
> O
anterior O
temporal O

 O
frontal O
encephalomalacia O

 O
Patchy O
white O
matter O
disease O
changes O
in O
the O
periventricular O
and O

 O
subcortical O
white O
matter O

 O
HTN O

 O
HL O


 O
Social O
History O
: O

 O
lives O
with O
her O
daughter O
. O

 O
non-[**Name2 O
( O
NI O
) O
1818 O
* O
* O
] O

 O
non-drinker O


 O
Family O
History O
: O

 O
N/C O



 O
Physical O
Exam O
: O

 O
On O
admission O
to O
ICU O
: O

 O
97.5 O
   O
183/83 O
   O
p98 O
   O
19 O
   O
98%RA O

 O
Large O
hispanic O
woman O
in O
no O
distress O
but O
with O
eyes O
closed O
and O

 O
moaning O
. O
Opens O
her O
eyes O
to O
voice O
and O
follows O
simple O
commands O
but O

 O
moans O
or O
says O
nonsensical O
things O
and O
dozes O
back O
off O
if O
not O

 O
stimulated O
. O
Not O
in O
respiratory O
distress O
. O

 O
Corneas O
with O
bilateral O
cataracts O
, O
pupils O
are O
constricted O
, O
but O

 O
EOMI O
are O
grossly O
intact O
and O
sclera O
normal O
appearing O

 O
No O
jugular O
distention O
noted O
. O

 O
CTAB O
no O
w/c/r/r O
noted O
anteriorly O
, O
good O
air O
movement O

 O
Regular O
rhythm O
but O
tachycardic O
, O
no O
murmurs O
or O
gallops O
are O
heard O
. O

 O
Bilateral O
radial O
and O
DP O
's O
pulses O
palpable O

 O
Abd O
soft O
, O
NT O
ND O
, O
BS O
hyperactive O

 O
No O
BLE O
edema O

 O
No O
rashes O
noted O

 O
Pt O
responsive O
but O
not O
coherently O
. O
Opens O
eyes O
to O
commands O
but O

 O
does O
n't O
answer O
questions O
appropriately O
. O
Pupils O
constricted O
to O

 O
1 O
- O
2 O
mm O
, O
EOMI O
grossly O
intact O
. O
No O
facial O
droop O
noted O
. O
Dysarthria O

 O
unable O
to O
be O
appropriately O
tested O
. O
Spontaneously O
moving O
all O
four O

 O
extremities O
, O
with O
normal O
tone O
, O
not O
rigid O
. O


 O
Pertinent O
Results O
: O

 O
OSH O
: O

 O
- O
UA/UCx O
: O
> O
100k O
Proteus O
Vulgaris O
: O
resistant O
-- O
amp B-DRUG
, I-DRUG

 O
nitrofurantoin B-DRUG
, I-DRUG
tetracycline B-DRUG
, I-DRUG
cefuroxime B-DRUG
, I-DRUG
cefazolin B-DRUG

 I-DRUG
sensitive O
-- O
ceftazadime B-DRUG
, I-DRUG
ceftriaxone B-DRUG
, I-DRUG
gent B-DRUG
, I-DRUG
levaquin B-DRUG
, I-DRUG
pip-tazo B-DRUG
, I-DRUG

 O
tobra B-DRUG
, I-DRUG
bactrim B-DRUG
, I-DRUG
cefoxitin B-DRUG
, I-DRUG
[ O
* O
* O
Name2 O
( O
NI O
) O
9847 O
* O
* O
] O

 O
-CARDIAC O
CATH O
performed O
at O
OSH O
demonstrated O
: O
90 O
% O
PDA O
stenosis O

 O
AO O
148/76 O
( O
106 O
) O

 O
LV O
156/4,11 O

 O
AO O
157/71 O
( O
107 O
) O

 O
LV O
161/3,10 O

 O
. O

 O
[ O
* O
* O
2194 O
- O
7 O
- O
8 O
* O
* O
] O
3:06 O
pm O
URINE O
      O
Source O
: O
Catheter O
. O


                             O
* O
* O
FINAL O
REPORT O
[ O
* O
* O
2194 O
- O
7 O
- O
9 O
* O
* O
] O
* O
* O


    O
URINE O
CULTURE O
( O
Final O
[ O
* O
* O
2194 O
- O
7 O
- O
9 O
* O
* O
] O
) O
: O
    O
NO O
GROWTH O
. O



 O
Brief O
Hospital O
Course O
: O

 O
# O
Coronary O
Artery O
Disease O
: O
The O
patient O
was O
transfered O
for O

 O
cardiac O
catheterization O
. O
Although O
the O
patient O
was O
found O
to O
have O

 O
90 O
% O
PDA O
lesion O
, O
her O
symptoms O
and O
stress O
test O
were O
unclear O
. O
It O

 O
was O
thought O
that O
the O
patient O
could O
benefit O
from O
medication O

 O
managment O
of O
CAD B-REA
with O
ASA B-DRUG
, I-DRUG
increased O
statin B-DRUG
and O
addition O
of O

 O
betablocker B-DRUG
. I-DRUG
  O
Therefore O
, O
she O
did O
not O
undergo O
repeat O
cardiac O

 O
catheterization O
. O
Plavix B-DRUG
was O
stopped O
. O
If O
she O
does O
develop O
more O

 O
chest O
pain O
in O
the O
future O
, O
she O
could O
have O
further O
optimization O
of O

 O
anti-anginal O
medications O
and O
then O
undergo O
repeat O
stress O
testing O
. O


 O
. O


 O
# O
Agitation/Altered B-REA
Mental I-REA
Status I-REA
: I-REA
Patient O
became O
agitated B-REA
in O

 O
the O
pre O
cath O
area O
and O
was O
given O
multiple O
doses O
of O
haldol B-DRUG
. I-DRUG
This O

 O
agitation O
was O
attributed O
to O
delirium O
[ O
* O
* O
3 O
- O
11 O
* O
* O
] O
UTI O
. O
She O
was O

 O
transferred O
from O
the O
CCU O
to O
the O
medicine O
service O
on O
[ O
* O
* O
2194 O
- O
7 O
- O
5 O
* O
* O
] O
. O

 O
She O
did O
well O
with O
the O
resolution O
of O
her O
UTI O
. O

 O
. O

 O
She O
was O
started O
on O
nighttime B-FRE
Zyprexa B-DRUG
which O
we O
should O
be O
stopped O

 O
in O
two B-DUR
weeks I-DUR
. I-DUR

 O
. O

 O
# O
HCT O
Drop O
: O
Thought O
to O
be O
[ O
* O
* O
3 O
- O
11 O
* O
* O
] O
Groin O
oozing O
into O
her O
leg O
. O
  O
Bedside O

 O
doppler O
was O
negative O
for O
pseudoanneurysm O
and O
there O
were O
no O

 O
bruits O
on O
exam O
. O
  O
Her O
HCT O
stabilized O
. O
  O
This O
was O
complicated O
by O

 O
iron B-REA
deficiency I-REA
anemia I-REA
, I-REA
for O
which O
she O
was O
started O
on O
iron B-DRUG
with I-DRUG

 I-DRUG
vitamin I-DRUG
C. I-DRUG

 O
. O

 O
# O
Urinary O
Tract O
Infection O
: O
  O
At O
the O
outside O
hospital O
prior O
to O

 O
transfer O
, O
she O
was O
noted O
to O
have O
a O
Proteus B-REA
UTI I-REA
, I-REA
and O
was O
started O

 O
on O
levofloxacin B-DRUG
on O
[ O
* O
* O
2194 O
- O
6 O
- O
30 O
* O
* O
] O
, O
switched O
to O
ceftriaxone B-DRUG
on O
[ O
* O
* O
7 O
- O
1 O
* O
* O
] O
, O

 O
then O
to O
ciprofloxacin B-DRUG
on O
[ O
* O
* O
7 O
- O
3 O
* O
* O
] O
, O
based O
on O
culture O
data O
. O
  O
While O

 O
here O
she O
was O
treated O
with O
ciprofloxacin B-DRUG
, I-DRUG
initially O
IV B-ROU
due O
to O

 O
agitation O
, O
and O
later O
with O
PO B-ROU
. I-ROU
  O
She O
completed O
her O
course O
in O
house O

 O
. O

 O
# O
s/p O
Arthroscopy O
: O
  O
Patient O
had O
R O
knee O
arthroscopy O
at O
[ O
* O
* O
Hospital3 O
12748 O
* O
* O
] O
in O
[ O
* O
* O
4 O
- O
16 O
* O
* O
] O
per O
her O
daughters O
. O
  O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O
right O
knee O
was O

 O
initially O
noted O
to O
be O
more O
swollen O
than O
the O
left O
, O
but O
with O
no O

 O
obvious O
effusion O
. O
  O
She O
was O
given O
one B-DOS
dose O
of O
vancomycin B-DRUG
, I-DRUG

 O
ultimately O
, O
her O
right O
knee O
did O
not O
appear O
infected O
w/o O
small O

 O
amount O
of O
suprapatellar O
swelling O
but O
no O
effusion O
, O
warmth O
or O
pain O

 O
on O
movement O
. O
Vancomycin B-DRUG
was O
discontinued O
. O


 O
Medications O
on O
Admission O
: O

 O
Home O
medications O
: O

 O
Multivitamin B-DRUG

 I-DRUG
ASA B-DRUG

 I-DRUG
Lovaza B-DRUG
( O
omega B-DRUG
3 I-DRUG
fish I-DRUG
oils I-DRUG
) I-DRUG

 O
. O

 O
MEDICATIONS O
ON O
TRANSFER O
: O

 O
Simvastatin B-DRUG

 I-DRUG
asa B-DRUG
81 B-STR
mg I-STR

 I-STR
Plavix B-DRUG
600 B-STR
mg I-STR
prior O
to O
cardiac B-REA
catheterization I-REA

 I-REA
seroquel B-DRUG

 I-DRUG
Ancef B-DRUG
1 B-STR
g I-STR
given O
at O
8 B-FRE
am I-FRE
( O
[ O
* O
* O
7 O
- O
4 O
* O
* O
] O
? O
) O
vs O
Ciprofloxacin B-DRUG



 I-DRUG

Discharge O
Medications O
: O

 O
1 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
constipation B-REA
. I-REA

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
2 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
Disp:*60 O
Capsule(s O
) O
* O
Refills:*2 O
* O

 O
3 O
. O
Simvastatin B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( O
Daily O
) O
. O

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
4 O
. O
Metoprolol B-DRUG
Tartrate I-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
Disp:*15 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
5 O
. O
Omeprazole B-DRUG
20 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
Disp:*60 O
Capsule O
, O
Delayed O
Release(E.C.)(s O
) O
* O
Refills:*2 O
* O

 O
6 O
. O
Lidocaine B-DRUG
5 O
% O
( O
700 B-STR
mg/patch I-STR
) I-STR
Adhesive B-FOR
Patch I-FOR
, I-FOR
Medicated I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Adhesive B-FOR
Patch I-FOR
, I-FOR
Medicated I-FOR
Topical B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
Disp:*30 O
Adhesive O
Patch O
, O
Medicated(s O
) O
* O
Refills:*2 O
* O

 O
7 O
. O
Ferrous B-DRUG
Sulfate I-DRUG
300 B-STR
  I-STR
mg I-STR
( O
60 B-STR
mg I-STR
Iron B-DRUG
) I-DRUG
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( O
Daily O
) O
. O

 O
Disp:*30 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
8 O
. O
Ascorbic B-DRUG
Acid I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( O
2 O

 O
times O
a O
day O
) O
. O

 O
Disp:*60 O
Tablet(s O
) O
* O
Refills:*2 O
* O

 O
9 O
. O
Olanzapine B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
, I-FOR
Rapid I-FOR
Dissolve I-FOR
Sig O
: O
0.5 B-DOS
Tablet B-FOR
, I-FOR
Rapid I-FOR

 I-FOR
Dissolve I-FOR
PO B-ROU
QHS B-FRE
( O
once O
a O
day O
( O
at O
bedtime O
) O
) O
for B-DUR
2 I-DUR
weeks I-DUR
. I-DUR

 O
Disp:*7 O
Tablet O
, O
Rapid O
Dissolve(s O
) O
* O
Refills:*0 O
* O

 O
10 O
. O
Tylenol B-DRUG
Extra I-DRUG
Strength I-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
every B-FRE
eight I-FRE
( I-FRE
8) I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
Disp:*90 O
Tablet(s O
) O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Home O
With O
Service O


 O
Facility O
: O

 O
All O
Care O
VNA O
of O
greater O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Urinary O
Tract O
Infection O

 O
Coronary O
Artery O
Disease O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Confused O
- O
sometimes O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O
Discharge O
Instructions O
: O

 O
You O
were O
admitted O
for O
chest O
pain O
, O
and O
for O
possible O
coronary O

 O
catheterization O
. O
  O
While O
here O
you O
were O
noted O
to O
be O
confused O
. O
  O
You O

 O
were O
found O
to O
have O
a O
urinary B-REA
tract I-REA
infection I-REA
, I-REA
and O
were O
treated O

 O
with O
the O
antibiotic B-DRUG
ciprofloxacin B-DRUG
. I-DRUG


 O
Followup O
Instructions O
: O

 O
Please O
arrange O
to O
see O
your O
primary O
care O
doctor O
within O
one O
week O

 O
of O
discharge O
. O

 O
. O


 O
PCP O
[ O
* O
* O
Name O
Initial O
( O
PRE O
) O
648 O
* O
* O
] O
: O
Tuesday O
, O
[ O
* O
* O
2194 O
- O
7 O
- O
15 O
* O
* O
] O
@4:15pm O

 O
With O
: O
Dr. O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
1399 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
* O
* O
] O

 O
Location O
: O
[ O
* O
* O
Location O
( O
un O
) O
85714 O
* O
* O
] O
, O
# O
204-[**Hospital1 O
487 O
* O
* O
] O
[ O
* O
* O
Numeric O
Identifier O
85352 O
* O
* O
] O

 O
Phone O
: O
( O
[ O
* O
* O
2194 O
* O
* O
] O


 O
Department O
: O
GASTROENTEROLOGY O

 O
When O
: O
FRIDAY O
[ O
* O
* O
2194 O
- O
7 O
- O
25 O
* O
* O
] O
at O
1:45 O
PM O

 O
With O
: O
[ O
* O
* O
First O
Name11 O
( O
Name O
Pattern1 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
2837 O
* O
* O
] O
, O
MD O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
463 O
* O
* O
] O

 O
Building O
: O
LM O
[ O
* O
* O
Hospital O
Unit O
Name O
* O
* O
] O
[ O
* O
* O
Location O
( O
un O
) O
858 O
* O
* O
] O

 O
Campus O
: O
WEST O
Best O
Parking O
: O
[ O
* O
* O
Hospital O
Ward O
Name O
* O
* O
] O
Garage O




 O
Completed O
by:[**2194 O
- O
7 O
- O
11 O
* O
* O
] O

Name O
: O
  O
[ O
* O
* O
Known O
lastname O
* O
* O
] O
, O
[ O
* O
* O
Known O
firstname O
* O
* O
] O
              O
Unit O
No O
: O
  O
[ O
* O
* O
Numeric O
Identifier O
5255 O
* O
* O
] O


 O
Admission O
Date O
: O
  O
[ O
* O
* O
2189 O
- O
9 O
- O
8 O
* O
* O
] O
     O
Discharge O
Date O
: O
  O
[ O
* O
* O
2189 O
- O
9 O
- O
25 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
   O
[ O
* O
* O
2154 O
- O
12 O
- O
25 O
* O
* O
] O
     O
Sex O
: O
  O
F O


 O
Service O
: O
  O
Gynecologic O
Oncology O


 O
ADDENDUM O
: O
  O
1 O
. O
  O
Left B-REA
leg I-REA
pain I-REA
: I-REA
  O
Additionally O
, O
the O
patient O
was O

 O
also O
on O
Doxepin B-DRUG
10 B-STR
mg I-STR
daily B-FRE
per O
recommendation O
of O
the O
pain O

 O
service O
. O
  O
This O
was O
discontinued O
after O
the O
patient O
had O
had O
her O

 O
narcotic B-DRUG
overdose B-ADE
episode O
. O





                           O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
First O
Name8 O
( O
NamePattern2 O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
, O
M.D. O
  O
[ O
* O
* O
MD O
Number(1 O
) O
4784 O
* O
* O
] O


 O
Dictated O
By:[**Name8 O
( O
MD O
) O
5256 O
* O
* O
] O


 O
MEDQUIST36 O


 O
D O
: O
  O
[ O
* O
* O
2189 O
- O
9 O
- O
29 O
* O
* O
] O
  O
11:33 O

 O
T O
: O
  O
[ O
* O
* O
2189 O
- O
9 O
- O
29 O
* O
* O
] O
  O
12:08 O

 O
JOB O
# O
: O
  O
[ O
* O
* O
Job O
Number O
5257 O
* O
* O
] O

 O

Admission O
Date O
: O
  O
[ O
* O
* O
2119 O
- O
4 O
- O
6 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2119 O
- O
4 O
- O
15 O
* O
* O
] O



 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Bactrim B-DRUG
Ds B-STR
/ O
Zyprexa B-DRUG
/ O
Lisinopril B-DRUG


 I-DRUG
Attending:[**First O
Name3 O
( O
LF O
) O
552 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
Altered O
Mental O
Status O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
CT O
head O

 O
MRI/MRA O

 O
LP O

 O
Larynoscopy O



 O

History O
of O
Present O
Illness O
: O

 O
HPI O
: O
The O
patient O
is O
an O
88 O
year O
old O
female O
, O
resident O
at O
[ O
* O
* O
First O
Name5 O
( O
NamePattern1 O
) O
553 O
* O
* O
] O

 O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
554 O
* O
* O
] O
[ O
* O
* O
Hospital3 O
* O
* O
] O
, O
with O
medical O
history O
pertinent O
for O

 O
Parkinson O
's O
disease O
, O
Diabetes O
, O
and O
recent O
cornea O
transplant O
who O

 O
now O
presents O
with O
altered O
mental O
status O
. O

 O
Per O
last O
progress O
note O
from O
patient O
's O
PCP O
, O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
patient O
has O
been O

 O
in O
her O
usual O
state O
of O
health O
with O
exception O
of O
management O
of O
a O

 O
cervical O
vertebral O
fracture O
secondary O
to O
fall O
as O
well O
as O
plans O

 O
for O
a O
repat O
penetrating O
keratoplasty O
( O
corneal O
transplant O
) O
s/p O

 O
failed O
prior O
. O
The O
patient O
was O
at O
that O
time O
apparently O
at O
her O

 O
baseline O
and O
cleared O
for O
surgery O
. O
The O
patient O
underwent O

 O
penetrating O
keratoplasty O
on O
[ O
* O
* O
2119 O
- O
3 O
- O
30 O
* O
* O
] O
for O
indication O
of O
failed O

 O
graft O
without O
complication O
. O
The O
patient O
was O
seen O
by O
her O

 O
ophthalmologist O
on O
[ O
* O
* O
2119 O
- O
4 O
- O
4 O
* O
* O
] O
with O
impression O
that O
there O
was O

 O
moderate O
lid O
edema O
present O
suggestive O
of O
hypersensitivity O
but O
no O

 O
discharge O
to O
suggest O
infection O
. O
Polysporin B-DRUG
was O
discontinued O

 O
( O
with O
concern O
for O
hypersensitivty B-ADE
per O
discussion O
with O
daughter O
) O

 O
and O
other O
meds O
( O
Pred B-DRUG
1 B-STR
% I-STR
TID B-FRE
OS B-ROU
, I-ROU
Timolol B-DRUG
0.5 B-STR
% I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
OU B-ROU
, I-ROU
Xalatan B-DRUG
QHS B-FRE

 I-FRE
OS B-ROU
, I-ROU
Tobradex B-DRUG

 I-DRUG
[ O
* O
* O
Doctor O
Last O
Name O
* O
* O
] O
OS O
QHS O
) O
continued O
. O

 O
The O
patient O
now O
presents O
form O
her O
[ O
* O
* O
Hospital3 O
* O
* O
] O
with O
concern O

 O
for O
altered O
mental O
status O
. O
Only O
limited O
information O
is O
available O

 O
from O
available O
staff O
at O
[ O
* O
* O
Hospital3 O
400 O
* O
* O
] O
, O
with O
report O
only O
that O

 O
patient O
was O
noted O
tonight O
to O
be O
acutely O
confused O
and O
" O
not O
making O

 O
sense O
" O
. O
Per O
discussion O
with O
the O
patient O
's O
daughter O
, O
the O
patient O

 O
was O
in O
her O
usual O
state O
of O
health O
as O
early O
as O
yesterday O
morning O
, O

 O
looking O
well O
. O
Later O
in O
the O
day O
, O
the O
patient O
was O
reported O
to O
be O

 O
walking O
up O
and O
down O
the O
hallway O
, O
refusing O
to O
go O
to O
her O
room O
. O
The O

 O
patient O
was O
noted O
to O
be O
shivering O
and O
unsteady O
on O
her O
feet O
. O

 O
Recommendation O
was O
made O
that O
patient O
be O
sent O
to O
hospital O
for O

 O
further O
evaluation O
. O
Per O
discussion O
with O
daughter O
, O
the O
patient O

 O
has O
had O
prior O
episodes O
of O
confusion O
in O
setting O
of O
underlying O

 O
infetion O
, O
usually O
UTI O
. O

 O
. O


 O
ED O
Course O
: O
98.4 O
- O
> O
102.8 O
rectal O
, O
186/84 O
, O
85 O
, O
20 O
, O
93 O
% O
RA O
. O
Labs O

 O
notable O
for O
WBC O
8.0 O
, O
lactate O
1.8 O
. O
Not O
signed O
out O
, O
but O
per O

 O
nursing O
report O
and O
discussion O
a O
central O
line O
was O
attempted O
given O

 O
poor O
PIV O
access O
for O
which O
the O
patient O
received O
Haldol B-DRUG
. I-DRUG
No O

 O
documentation O
of O
dose O
is O
available O
, O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
RN O
to O
RN O
signout O
this O

 O
was O
5 B-STR
mg I-STR
IV B-ROU
. I-ROU
Central O
line O
was O
not O
successfully O
placed O
and O

 O
ultimately O
a O
22 O
PIV O
in O
the O
hand O
was O
obtained O
. O

 O
The O
patient O
had O
a O
negative O
UA O
, O
CXR O
without O
obvious O
infiltrate O

 O
although O
limited O
. O
Ophthalmology O
was O
not O
contact[**Name O
( O
NI O
) O
* O
* O
] O
as O
[ O
* O
* O
Name O
( O
NI O
) O
* O
* O
] O

 O
impression O
was O
that O
eye O
was O
not O
infected O
. O
LP O
was O
recommended O
by O

 O
ED O
but O
patients O
' O
daughter O
declined O
this O
. O
The O
patient O
was O
given O

 O
Azithromycin B-DRUG
, I-DRUG
Vancomycin B-DRUG
, I-DRUG
and O
Ceftriaxone B-DRUG
empirically O
and O
is O
now O

 O
admitted O
to O
the O
medical O
service O
for O
ongoing O
care O
. O

 O
On O
arrival O
to O
floor O
patient O
is O
lethargic O
but O
wakes O
to O
voice O
. O
She O

 O
answers O
questions O
although O
requires O
repeat O
questioning O
at O
times O

 O
to O
wake O
her O
. O
Patient O
reports O
mild O
neck O
pain O
since O
having O
collar O

 O
removed O
, O
denies O
headache O
, O
chest O
pain O
, O
dyspnea O
, O
abdominal O
pain O
or O

 O
other O
localizing O
symptoms O
. O



 O
Past O
Medical O
History O
: O

 O
Parkinson O
's O
Disease O

 O
Dementia O
, O
mild O

 O
Hypertension O

 O
Hyperlipidemia O

 O
Hypothyroidism O

 O
Type O
II O
DM O
, O
diet O
controlled O

 O
Pernicious O
anemia O

 O
History O
of O
breast O
cancer O

 O
Urge O
incontinence O

 O
s/p O
penetrating O
keratoplasty O
[ O
* O
* O
2119 O
- O
3 O
- O
30 O
* O
* O
] O

 O
Cervical O
vertebral O
fracture O



 O
Social O
History O
: O

 O
She O
is O
widowed O
. O
  O
She O
had O
a O
6-year O
history O
of O
tobacco O
use O
but O

 O
quit O
decades O
ago O
. O
  O
Her O
daughter O
is O
in O
her O
50s O
and O
is O
healthy O
. O

 O
She O
denies O
alcohol O
use O
or O
abuse O
. O
  O
She O
formerly O
taught O
English O
in O

 O
[ O
* O
* O
Country O
532 O
* O
* O
] O
; O
she O
also O
worked O
as O
an O
interpreter O
of O
[ O
* O
* O
Doctor O
First O
Name O
533 O
* O
* O
] O
, O
Japanese O
, O

 O
and O
English O
. O



 O
Family O
History O
: O

 O
Non-contributory O



 O
Physical O
Exam O
: O

 O
On O
admission O
: O

 O
Vitals O
: O
98.3 O
, O
136/74 O
, O
76 O
, O
20 O
, O
94 O
% O
RA O

 O
General O
: O
elderly O
female O
. O
Lethargic O
but O
arousable O
to O
vocal O

 O
stimuli O
. O
Only O
opens O
eyes O
after O
extensive O
coaching O
. O
Can O
answer O

 O
questions O
but O
often O
does O
not O
respond O
the O
first O
time O
. O

 O
HEENT O
: O
+ O
mild O
erythema O
, O
yellow O
bruising O
, O
and O
mod O
edema O

 O
periorbital O
edema O
surrounding O
left O
eye O
. O
PERRL O

 O
Mouth O
: O
Significant O
tongue O
swelling O
and O
swollen O
lower O
lip O
. O
Barely O

 O
able O
to O
visualize O
uvula O
when O
using O
a O
tongue O
depressor O
. O
No O

 O
erythema O
of O
the O
mouth O
. O

 O
Neck O
: O
No O
LAD O

 O
Chest O
: O
Difficult O
to O
access O
given O
pt O
intermittently O
snoring O

 O
during O
exam O
despite O
repeatedly O
waking O
her O
up O
. O
No O
obvious O

 O
crackles O
. O

 O
Cardiac O
: O
RRR O
, O
III/VI O
systolic O
murmur O
loudest O
at O
LLSB O

 O
Abdomen O
: O
+ O
bs O
, O
soft O
, O
NTND O
, O
no O
HSM O

 O
Ext O
: O
erythema O
bilaterally O
at O
ankles O
with O
no O
skin O
breakdown O
, O
DP O

 O
pulses O
and O
PT O
pulses O
+ O
1 O
, O
radial O
pulses O
+ O
[ O
* O
* O
12 O
- O
30 O
* O
* O
] O
. O
No O
c/c/e O
. O

 O
Neuro O
: O
oriented O
to O
name O
only O
. O
States O
she O
is O
in O
her O
apartment O
. O
UE O

 O
reflexes O
+ O
2 O
, O
LE O
reflexes O
difficult O
to O
access O
as O
pt O
not O
relaxing O

 O
and O
is O
pulling O
away O
from O
babinski O
. O

 O
Motor O
: O
Due O
to O
lethargy O
pt O
has O
poor O
participation O
in O
exam O
. O
UE O

 O
strength O
4-/5 O
except O
for O
grip O
[ O
* O
* O
5 O
- O
2 O
* O
* O
] O
bilaterally O
. O
LE O
poor O
effort O
. O

 O
Sensation O
: O
Intact O
in O
face O
, O
UE O
and O
LE O
to O
touch O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
2119 O
- O
4 O
- O
5 O
* O
* O
] O
08:25PM O
   O
GLUCOSE-145 O
* O
UREA O
N-24 O
* O
CREAT-0.8 O
SODIUM-139 O

 O
POTASSIUM-4.4 O
CHLORIDE-104 O
TOTAL O
CO2 O
- O
24 O
ANION O
GAP-15 O

 O
[ O
* O
* O
2119 O
- O
4 O
- O
5 O
* O
* O
] O
08:25PM O
   O
ALT(SGPT)-16 O
AST(SGOT)-27 O
LD(LDH)-261 O
* O

 O
CK(CPK)-49 O
ALK O
PHOS-129 O
* O
AMYLASE-35 O
TOT O
BILI-0.3 O

 O
[ O
* O
* O
2119 O
- O
4 O
- O
5 O
* O
* O
] O
08:25PM O
   O
LIPASE-23 O

 O
[ O
* O
* O
2119 O
- O
4 O
- O
5 O
* O
* O
] O
08:25PM O
   O
CK-MB-NotDone O
cTropnT-<0.01 O

 O
[ O
* O
* O
2119 O
- O
4 O
- O
5 O
* O
* O
] O
08:25PM O
   O
ALBUMIN-4.0 O

 O
[ O
* O
* O
2119 O
- O
4 O
- O
5 O
* O
* O
] O
08:25PM O
   O
WBC-8.0 O
RBC-4.42 O
HGB-13.1 O
HCT-37.5 O
MCV-85 O

 O
MCH-29.7 O
MCHC-35.0 O
RDW-15.1 O

 O
[ O
* O
* O
2119 O
- O
4 O
- O
5 O
* O
* O
] O
08:25PM O
   O
NEUTS-75.4 O
* O
LYMPHS-17.2 O
* O
MONOS-6.0 O
EOS-1.3 O

 O
BASOS-0.2 O

 O
[ O
* O
* O
2119 O
- O
4 O
- O
5 O
* O
* O
] O
08:25PM O
   O
PLT O
COUNT-152 O

 O
[ O
* O
* O
2119 O
- O
4 O
- O
5 O
* O
* O
] O
08:25PM O
   O
PT-13.6 O
* O
PTT-24.4 O
INR(PT)-1.2 O
* O



 O
CT O
head O
[ O
* O
* O
4 O
- O
5 O
* O
* O
] O
: O

 O
1 O
. O
No O
acute O
intracranial O
hemorrhage O
or O
acute O
fracture O
. O

 O
2 O
. O
Diffuse O
cerebral O
atrophy O
with O
moderate O
sulcal O
and O
ventricular O

 O
prominence O
. O

 O
3 O
. O
Chronic O
microvascular O
infarcts O
, O
unchanged O
. O

 O
4 O
. O
Paranasal O
sinus O
disease O
as O
described O
, O
likely O
acute O
in O
the O

 O
sphenoid O
sinus O
. O


 O
CT O
neck O
[ O
* O
* O
4 O
- O
6 O
* O
* O
] O
: O

 O
1 O
. O
Significant O
swelling/inflammation O
of O
the O
soft O
tissues O
at O
the O

 O
base O
of O
tongue O
, O
oropharynx O
, O
with O
fullness O
in O
the O
vallecula O
and O

 O
the O
piriform O
sinuses O
, O
overall O
resulting O
in O
moderate O
to O
marked O

 O
narrowing O
of O
the O
oropharynx O
. O
The O
etiology O
of O
this O
finding O
is O

 O
uncertain O
from O
the O
present O
study O
. O
To O
correlate O
with O
direct O
ENT O

 O
examination O
. O

 O
2 O
. O
Fullness O
of O
the O
hypopharynx O
and O
adjacent O
portions O
of O

 O
esophagus O
- O
no O
adequately O
assessed O
on O
the O
present O
study- O
further O

 O
evaluation O
recommended O
. O

 O
3 O
. O
Increased O
attenuation O
of O
the O
fat O
in O
the O
carotid O
space O
, O
with O

 O
soft O
tissue O
attenuation O
opacity O
, O
with O
heterogeneous O
appearance O
, O

 O
causing O
indentation O
on O
the O
right O
internal O
jugular O
vein O
extending O

 O
down O
along O
the O
carotid O
space O
, O
into O
the O
region O
of O
the O
thoracic O

 O
inlet O
. O
This O
may O
relate O
to O
inflammation O
, O
phlegmon O
, O
and O

 O
radiation-related O
changes O
if O
there O
is O
history O
of O
radiation O
in O

 O
the O
past O
and O
less O
likely O
neoplastic O
. O
Close O
followup O
evaluation O
, O

 O
with O
ultrasound O
can O
be O
considered O
to O
evaluate O
for O
any O
abscess O
, O

 O
given O
the O
patient O
's O
symptoms O
of O
fever O
. O


 O
CT O
orbits O
: O

 O
1 O
. O
Increased O
attenuation O
of O
the O
preseptal O
soft O
tissues O
with O
some O

 O
enhancement O
, O
on O
the O
left O
side O
, O
likely O
due O
to O
inflamamtion/ O

 O
post-surgical O
changes- O
correlate O
with O
clinical O
examination O
. O
No O

 O
definite O
abscess O
on O
the O
present O
set O
of O
images O
. O
No O
intraconal O

 O
abnormality O
. O
F/u O
as O
clinically O
indicated O
. O

 O
2 O
. O
Moderate O
paranasal O
sinus O
disease O


 O
CT O
head O
[ O
* O
* O
4 O
- O
9 O
* O
* O
] O
: O

 O
1 O
. O
No O
acute O
intracranial O
process O
. O

 O
2 O
. O
Persistent O
cerebral O
atrophy O
. O

 O
3 O
. O
Chronic O
microvascular O
ischemic O
changes O
. O

 O
4 O
. O
Paranasal O
sinus O
disease O
. O


 O
MRI/MRA O
brain O
: O

 O
Final O
Report O

 O
HISTORY O
: O
Parkinson O
's O
, O
delirium O
, O
lethargy O
, O
right O
facial O
droop O
and O

 O
dysarthria O
. O

 O
Evaluate O
for O
signs O
of O
intracranial O
hemorrhage O
or O
acute O
stroke O
. O


 O
Comparison O
is O
made O
to O
most O
recent O
head O
CT O
of O
[ O
* O
* O
2119 O
- O
4 O
- O
9 O
* O
* O
] O


 O
TECHNIQUE O
: O
Multiplanar O
T1- O
and O
T2-weighted O
sequences O
were O

 O
obtained O
through O

 O
the O
brain O
without O
intravenous O
gadolinium O
. O
3D O
time-of-flight O
MR O

 O
arteriography O

 O
was O
also O
performed O
. O
Volume-rendering O
reconstructed O
images O
were O

 O
evaluated O
. O



 O
MRI O
OF O
THE O
BRAIN O
AND O
MRA O
OF O
THE O
BRAIN O
: O
There O
is O
no O
evidence O
of O

 O
intracranial O

 O
hemorrhage O
, O
masses O
, O
mass O
effect O
, O
or O
regions O
of O
restricted O

 O
diffusion O
to O
suggest O

 O
acute O
infarction O
. O
A O
few O
scattered O
periventricular O
T2/FLAIR O

 O
hyperintensities O

 O
are O
noted O
, O
which O
are O
nonspecific O
but O
likely O
suggest O
chronic O

 O
small O
vessel O

 O
ischemia O
. O
There O
are O
also O
adjacent O
prominent O
Virchow-[**Doctor O
First O
Name O
* O
* O
] O

 O
spaces O
. O
While O

 O
there O
is O
underlying O
global O
cerebral O
atrophy O
, O
the O
degree O
of O

 O
dilatation O
of O
the O

 O
ventricular O
system O
may O
be O
somewhat O
disproportionate O
to O
the O

 O
amount O
of O
central O

 O
atrophy O
. O
Small O
amount O
of O
fluid O
is O
noted O
in O
the O
mastoids O

 O
bilateral O
. O


 O
MR O
arteriography O
of O
the O
circle O
of O
[ O
* O
* O
Location O
( O
un O
) O
431 O
* O
* O
] O
displays O
no O
aneurysmal O

 O
dilatation O
. O

 O
Mild O
atherosclerosis O
is O
noted O
in O
the O
right O
M1 O
segment O
. O
Posterior O

 O
circulation O

 O
is O
left O
dominant O
. O


 O
IMPRESSION O
: O

 O
1 O
. O
No O
evidence O
of O
acute O
infarction O
. O
Scattered O
changes O
likely O

 O
related O
to O

 O
chronic O
small O
vessel O
ischemic O
disease O
. O


 O
2 O
. O
Question O
slightly O
disproportionate O
degree O
of O
ventricular O

 O
dilatation O
in O

 O
relation O
to O
the O
amount O
underlying O
cerebral O
atrophy O
. O
While O
this O

 O
finding O
is O

 O
nonspecific O
, O
in O
the O
appropriate O
clinical O
scenario O
it O
may O
reflect O

 O
underlying O

 O
NPH O
. O




 O
Brief O
Hospital O
Course O
: O

 O
This O
pt O
is O
a O
88yo O
female O
w O
h/o O
Parkinson O
's O
disease O
, O
mild O

 O
dementia O
and O
recent O
corneal O
transplant O
admitted O
to O
the O
hospital O

 O
for O
AMS O
and O
to O
the O
ICU O
for O
airway O
narrowing O
. O

 O
. O


 O
# O
Airway O
narrowing O
: O
She O
was O
noted O
to O
have O
swelling O
of O
the O
tongue O

 O
and O
lower O
lips O
on O
admission O
. O
A O
CT B-REA
of O
the O
Head O
and O
Neck O
with O
IV B-ROU

 I-ROU
contrast B-DRUG
showed O
no O
clear O
evidence O
of O
preseptal O
cellulitis O
and O
? O

 O
of O
soft O
tissue O
infection/edema O
of O
neck O
and O
throat O
. O
Over O
course O

 O
of O
day O
, O
noted O
to O
have O
increased O
audible O
upper O
airway O
sounds O
with O

 O
good O
O2 O
sat O
of O
97 O
% O
on O
2L O
which O
has O
been O
stable O
. O
ENT O
was O

 O
consulted O
and O
saw O
extensive O
edema O
and O
soft O
tissue O
swelling O
in O

 O
oropharynx O
with O
patent O
airway O
. O
Swelling O
around O
false O
cords O
, O

 O
tonsillar B-REA
edema I-REA
, I-REA
but O
true O
cords O
without O
edema O
. O
The O
team O
thought O

 O
the O
swelling B-REA
to O
be O
secondary O
to O
possible O
allergic O
reaction O
to O

 O
medications O
. O
She O
was O
started O
on O
solumedrol B-DRUG
60IV B-STR
and O
famotidine B-DRUG

 I-DRUG
20 B-STR
mg I-STR
. I-STR
She O
was O
given O
one B-DOS
dose O
of O
zosyn B-DRUG
and O
then O
switched O
to O

 O
unasyn B-DRUG
to O
cover O
for O
possible O
soft B-REA
tissue I-REA
infection I-REA
. I-REA
Pt O
without O

 O
leukocytosis O
, O
fever O
( O
was O
102.8 O
in O
the O
ED O
but O
afebrile O
since O
) O
, O
or O

 O
abcess O
. O
ENT O
and O
anesthesia O
recommended O
transfer O
to O
ICU O
for O

 O
further O
monitoring O
. O
She O
was O
monitored O
and O
continued O
on O
Decadron B-DRUG

 I-DRUG
for O
three B-DOS
doses O
. O
During O
successive O
scopes O
by O
ENT O
, O
oropharyngeal O

 O
edema O
and O
some O
secretions O
were O
seen O
, O
but O
airway O
remained O
patent O
. O

 O
Unclear O
etiology O
: O
possible O
allergic O
reaction O
vs O
infectious O

 O
process O
vs O
both O
given O
tonsils O
appear O
possibly O
infectious O
and O

 O
lower O
airway O
appears O
more O
edematous O
and O
less O
infectious O
. O

 O
Lisinopril B-DRUG
was O
stopped O
, O
and O
her O
laryngoscopic O
exam O
visibly O

 O
improved O
by O
the O
time O
she O
was O
called O
out O
to O
the O
floor O
. O

 O
-Pt O
was O
treated O
for O
10 O
days O
for O
? O
soft B-REA
tissue I-REA
infection I-REA
and O

 O
switched O
to O
Augmentin B-DRUG
for O
additional O
5 B-DUR
days I-DUR
at O
dc O

 O
-ENT O
follow O
up O
appt O
was O
set O
up O


 O
# O
s/p O
corneal O
TP O
: O
lid O
edema O
on O
exam O
. O
Ophtho O
believes O
likely O

 O
secondary O
to O
blockage O
of O
drainage O
and O
not O
as O
likely O
due O
to O

 O
allergy O
. O
  O
Ophtho O
felt O
the O
eye O
was O
improving O
and O
recommended O

 O
decreasing O
doses O
of O
eye B-DRUG
drops I-DRUG
. I-DRUG

 O
-FU O
appt O
with O
Optho O
set O
up O

 O
. O


 O
# O
. O
Altered B-ADE
Mental I-ADE
Status I-ADE
: I-ADE
On O
admission O
, O
she O
was O
lethargic B-ADE
, I-ADE

 O
possibly O
from O
the O
Haldol B-DRUG
she O
received O
in O
the O
ED O
. O
By O
the O
time O
she O

 O
was O
called O
out O
of O
the O
ICU O
, O
she O
was O
likely O
at O
her O
baseline O
mental O

 O
status O
, O
pleasant O
and O
easily O
conversant O
. O
Shortely O
thereafter O
, O

 O
however O
, O
she O
became O
agitated B-REA
and O
combative B-REA
and O
received O
1.5 B-STR
mg I-STR

 I-STR
Haldol B-DRUG
and O
later O
the O
same O
day O
5 B-STR
mg I-STR
of O
Zyprexa B-DRUG
. I-DRUG
She O
remained O

 O
agitated O
for O
about O
36 O
hours O
before O
she O
became O
lethargic O
and O

 O
barely O
arousable O
. O
Head O
CT O
was O
unchanged O
from O
before O
. O
She O
had O
not O

 O
had O
any O
new O
fevers O
or O
new O
signs O
of O
infection O
. O
She O
had O
a O
lumbar O

 O
puncture O
that O
was O
unremarkable O
. O
MRI/MRA O
was O
neg O
except O
for O
some O

 O
ventriculomegaly O
in O
setting O
of O
global O
atrophy O
which O
was O

 O
difficult O
to O
differentiate O
from O
NPH O
. O
Neurology O
thought O
it O
was O

 O
unlikely O
to O
be O
NPH O
. O
EEG O
showed O
some O
focal O
acitivity O
concerning O

 O
for O
sublinical B-REA
seizures I-REA
. I-REA
Pt O
was O
started O
on O
keppra B-DRUG
, I-DRUG
initially O

 O
continued O
to O
have O
periods O
of O
somnolence O
along O
with O
R O
sided O

 O
facial O
droop O
( O
which O
was O
thought O
be O
Neurology O
to O
represent O
a O

 O
post-ictal O
state O
with O
[ O
* O
* O
Doctor O
Last O
Name O
555 O
* O
* O
] O
paralysis O
) O
but O
day O
before O
discharge O

 O
had O
significant O
improvement O
in O
mental O
status O
and O
was O
alert O
and O

 O
conversive O
. O
Due O
to O
hx O
of O
dementia O
and O
also O
ongoing O
hypoactive O

 O
delirium O
, O
pt O
was O
not O
fully O
oriented O
but O
did O
have O
significant O

 O
improvement O
in O
level O
of O
alertness O
. O

 O
-Pt O
curently O
is O
on O
Keppra B-DRUG
1000 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
for B-DUR
one I-DUR
week I-DUR
and O
to O
be O

 O
increased O
to O
1500 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
later O
and O
kept O
at O
that O
dose O
. O

 O
-Pt O
should O
be O
followed O
by O
a O
neurologist O
at O
[ O
* O
* O
Hospital O
100 O
* O
* O
] O
Rehab O

 O
-Outpt O
FU O
w O
neurology O
is O
already O
set O
up O

 O
. O


 O
# O
. O
UTI B-REA
: I-REA
grew O
Enterococcus B-REA
in O
UCx O
. O
She O
was O
continued O
on O
Unasyn B-DRUG

 I-DRUG
for B-DUR
10 I-DUR
days I-DUR
. I-DUR

 O
. O

 O
# O
. O
Positive O
blood O
cultures O
: O
1/4 O
bottles O
growing O
coag O
negative O

 O
Staph O
. O
This O
was O
likely O
a O
contaminant O
so O
vancomycin B-DRUG
was O
stopped O
. O

 O
Repeat O
blood O
cultures O
were O
negative O
. O


 O
# O
. O
Parkinson B-REA
's I-REA
Disease I-REA
: I-REA
continued O
Sinemet B-DRUG
except O
when O
patient O

 O
was O
too O
lethargic O
to O
safely O
take O
meds O

 O
. O

 O
# O
. O
Hypertension B-REA
, I-REA
benign I-REA
: I-REA
Lisinopril B-DRUG
was O
stopped O
due O
to O
concern O

 O
of O
angioedema B-ADE
. I-ADE
Atenolol B-DRUG
was O
continued O
. O

 O
. O

 O
# O
. O
Hyperlipidemia B-REA
: I-REA
continued O
statin B-DRUG

 I-DRUG
. O

 O
# O
. O
Hypothyroidism B-REA
: I-REA
  O
TSH O
normal O
on O
[ O
* O
* O
2119 O
- O
4 O
- O
6 O
* O
* O
] O
so O
not O
a O
picture O
of O

 O
myxedema O
and O
can O
not O
account O
for O
MS O
change O
. O
Continued O

 O
levothyroxine B-DRUG
. I-DRUG



 O
# O
. O
Diabetes B-REA
II I-REA
, I-REA
diet O
controlled O
without O
complication O
: O

 O
- O
insulin B-DRUG
sliding B-DOS
scale I-DOS
while O
inpatient O
  O
and O
bs O
were O
wnl O
. O
Pt O
can O

 O
have O
[ O
* O
* O
Hospital1 O
* O
* O
] O
finger O
checks O
to O
Rehab O
but O
since O
not O
needing O
insulin B-DRUG
, I-DRUG

 O
does O
not O
have O
to O
be O
on O
sliding B-DOS
scale I-DOS


 I-DOS
# O
Deconditioning O
: O
per O
PT O
eval O
, O
pt O
was O
2 O
person O
assist O
and O
will O

 O
need O
significant O
PT O
therapy O
to O
get O
back O
to O
baseline O
where O
she O

 O
was O
walking O
with O
a O
walker O



 O
Medications O
on O
Admission O
: O

 O
Tylenol B-DRUG
1000 B-STR
mg I-STR
PO B-ROU
twice B-FRE
daliy I-FRE

 I-FRE
Aspirin B-DRUG
81 B-STR
mg I-STR
daily B-FRE

 I-FRE
Atenolol B-DRUG
25 B-STR
mg I-STR
daily B-FRE

 I-FRE
Carbidopa/Levodopa B-DRUG
25/100 B-STR
mg I-STR
three B-FRE
times I-FRE
daily I-FRE

 I-FRE
Enablex B-DRUG
7.5 B-STR
mg I-STR
SR O
daily B-FRE

 I-FRE
Fish B-DRUG
Oil I-DRUG
1000 B-STR
mg I-STR
daily B-FRE

 I-FRE
Levothyroxin B-DRUG
125mcg B-STR
daily B-FRE

 I-FRE
Lisinopril B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
Simvastatin B-DRUG
10 B-STR
mg I-STR
daily B-FRE

 I-FRE
Cyanocobalamin B-DRUG
1000mcg B-STR
daily B-FRE

 I-FRE
Docusate B-DRUG
100 B-STR
mg I-STR
daily B-FRE

 I-FRE
Pred B-DRUG
1 B-STR
% I-STR
TID B-FRE
OS B-ROU

 I-ROU
Timolol B-DRUG
0.5 B-STR
% I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
OU B-ROU

 I-ROU
Xalatan B-DRUG
QHS B-FRE
OS B-ROU

 I-ROU
Tobradex B-DRUG
OS B-ROU
QHS B-FRE



 I-FRE
Discharge O
Medications O
: O

 O
1 O
. O
Latanoprost B-DRUG
0.005 B-STR
% O
Drops B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Drop B-FOR
Ophthalmic B-ROU
HS B-FRE
( I-FRE
at I-FRE

 I-FRE
bedtime I-FRE
) I-FRE
. I-FRE

 O
2 O
. O
Tobramycin-Dexamethasone B-DRUG
0.3 B-STR
- I-STR
0.1 I-STR
% O
Ointment B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Appl B-FOR

 I-FOR
Ophthalmic B-ROU
QHS B-FRE
( I-FRE
once I-FRE
a I-FRE
day I-FRE
( I-FRE
at I-FRE
bedtime I-FRE
) I-FRE
) I-FRE
. I-FRE

 O
3 O
. O
Timolol B-DRUG
Maleate I-DRUG
0.5 B-STR
% O
Drops B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Drop B-FOR
Ophthalmic B-ROU
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
( O
2 B-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. O

 O
4 O
. O
Prednisolone B-DRUG
Acetate I-DRUG
1 O
% O
Drops B-FOR
, I-FOR
Suspension I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Drop B-FOR

 I-FOR
Ophthalmic B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
5 O
. O
Atenolol B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
6 O
. O
Carbidopa-Levodopa B-DRUG
25 B-STR
- I-STR
100 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU

 I-ROU
TID B-FRE
( I-FRE
3 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
7 O
. O
Levothyroxine B-DRUG
125 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
8 O
. O
Simvastatin B-DRUG
10 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE

 I-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
9 O
. O
Docusate B-DRUG
Sodium I-DRUG
100 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
10 O
. O
Senna B-DRUG
8.6 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE
times I-FRE
a I-FRE

 I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
11 O
. O
Bisacodyl B-DRUG
10 B-STR
mg I-STR
Suppository B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Suppository B-FOR
Rectal B-ROU

 I-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE

 O
12 O
. O
Aspirin B-DRUG
325 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
DAILY B-FRE
( I-FRE
Daily I-FRE
) I-FRE
. I-FRE



 O
13 O
. O
Levetiracetam B-DRUG
500 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
BID B-FRE
( I-FRE
2 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
: I-FRE
for B-DUR
one I-DUR
week I-DUR
, I-DUR
then O
increase O
to O
1500 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O
. O

 O
14 O
. O
Augmentin B-DRUG
875 B-STR
- I-STR
125 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE

 I-FRE
day I-FRE
for B-DUR
5 I-DUR
days I-DUR
. I-DUR

 O
Disp:*10 O
Tablet(s O
) O
* O
Refills:*0 O
* O



 O
Discharge O
Disposition O
: O

 O
Extended O
Care O


 O
Facility O
: O

 O
[ O
* O
* O
Hospital6 O
459 O
* O
* O
] O
for O
the O
Aged O
- O
[ O
* O
* O
Location O
( O
un O
) O
550 O
* O
* O
] O


 O
Discharge O
Diagnosis O
: O

 O
Primary O
: O
oropharyngeal O
swelling O
, O
delirium O
, O
urinary O
tract O

 O
infection O

 O
Secondary O
: O
Parkinson O
's O
disease O
, O
diabetes O
type O
2 O
, O
hypertension O
, O

 O
hyperlipidemia O



 O
Discharge O
Condition O
: O

 O
Good O



 O
Discharge O
Instructions O
: O

 O
You O
were O
evaluated O
for O
confusion O
and O
found O
to O
have O
swelling O
of O

 O
your O
tongue O
and O
throat O
as O
well O
as O
a O
urinary B-REA
tract I-REA
infection I-REA
. I-REA
You O

 O
improved O
with O
antibiotics B-DRUG
. I-DRUG
You O
became O
delirious O
in O
the O
hospital O

 O
but O
improved O
with O
conservative O
treatment O
. O


 O
If O
you O
have O
fevers O
, O
chills O
, O
confusion O
, O
or O
any O
other O
concerning O

 O
symptoms O
, O
call O
your O
doctor O
. O


 O
Followup O
Instructions O
: O

 O
1 O
. O
PCP O
, O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
, O
ph O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
250 O
* O
* O
] O
, O
please O
call O
and O
make O
appt O

 O
for O
fu O
in O
[ O
* O
* O
2 O
- O
1 O
* O
* O
] O
weeks O

 O
2 O
. O
Ophtho O
, O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
, O
ph O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
556 O
* O
* O
] O
, O
Appt O
is O
on O
[ O
* O
* O
2119 O
- O
4 O
- O
28 O
* O
* O
] O

 O
at O
11:00 O
AM O

 O
3 O
. O
ENT O
, O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
* O
* O
] O
, O
ph O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
41 O
* O
* O
] O
, O
Appt O
is O
on O
[ O
* O
* O
4 O
- O
20 O
* O
* O
] O
, O

 O
Thurs O
, O
12:00/noon O

 O
4 O
. O
Neurology O
, O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
557 O
* O
* O
] O
, O
ph O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
558 O
* O
* O
] O
, O
Appt O
is O
on O
[ O
* O
* O
5 O
- O
9 O
* O
* O
] O
, O

 O
Tuesday O
at O
9:30 O
AM O




 O

Admission O
Date O
: O
  O
[ O
* O
* O
2156 O
- O
4 O
- O
26 O
* O
* O
] O
              O
Discharge O
Date O
: O
   O
[ O
* O
* O
2156 O
- O
5 O
- O
1 O
* O
* O
] O


 O
Date O
of O
Birth O
: O
  O
[ O
* O
* O
2086 O
- O
12 O
- O
6 O
* O
* O
] O
             O
Sex O
: O
   O
M O


 O
Service O
: O
MEDICINE O


 O
Allergies O
: O

 O
Niacin B-DRUG
/ O
aspirin B-DRUG
/ O
Codeine B-DRUG


 I-DRUG
Attending:[**Last O
Name O
( O
NamePattern4 O
) O
290 O
* O
* O
] O

 O
Chief O
Complaint O
: O

 O
GI O
Bleed O


 O
Major O
Surgical O
or O
Invasive O
Procedure O
: O

 O
enteroscopy O
[ O
* O
* O
2156 O
- O
4 O
- O
29 O
* O
* O
] O
and O
[ O
* O
* O
2156 O
- O
4 O
- O
30 O
* O
* O
] O



 O
History O
of O
Present O
Illness O
: O

 O
HMED O
ATTENDING O
ADMISSION O
NOTE O

 O
. O

 O
ADMIT O
DATE O
: O
[ O
* O
* O
2156 O
- O
4 O
- O
26 O
* O
* O
] O

 O
ADMIT O
TIME O
: O
2345 O

 O
. O

 O
PCP O
: O
[ O
* O
* O
Name10 O
( O
NameIs O
) O
* O
* O
] O
, O
[ O
* O
* O
Name11 O
( O
NameIs O
) O
1575 O
* O
* O
] O
[ O
* O
* O
Name O
Initial O
( O
NameIs O
) O
* O
* O
] O
. O

 O
Address O
: O
[ O
* O
* O
Doctor O
Last O
Name O
32771 O
* O
* O
] O
, O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
, O
[ O
* O
* O
Numeric O
Identifier O
17464 O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
8340 O
* O
* O
] O

 O
Fax O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
8341 O
* O
* O
] O

 O
. O

 O
Cardiology O
: O
Dr. O
[ O
* O
* O
First O
Name4 O
( O
NamePattern1 O
) O
2855 O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern1 O
) O
32772 O
* O
* O
] O

 O
Address O
: O
[ O
* O
* O
Location O
( O
un O
) O
* O
* O
] O
[ O
* O
* O
Apartment O
Address(1 O
) O
32773 O
* O
* O
] O
. O
[ O
* O
* O
Location O
( O
un O
) O
936 O
* O
* O
] O

 O
Phone O
: O
[ O
* O
* O
Telephone/Fax O
( O
1 O
) O
14967 O
* O
* O
] O

 O
. O

 O
69 O
yo O
M O
with O
CAD O
s/p O
CABG O
complicated O
be O
restenosis O
requiring O

 O
multiple O
stents O
, O
mechanical B-REA
aortic I-REA
valve I-REA
on O
coumadin B-DRUG
, I-DRUG
recurrent B-ADE

 I-ADE
GI I-ADE
bleeding I-ADE
and O
IDDM O
who O
is O
transferred O
from O
[ O
* O
* O
Hospital3 O
* O
* O
] O
for O
advanced O
endoscopy O
for O
management O
of O
active O
upper O

 O
GI O
bleed O
. O

 O
. O


 O
Patient O
was O
admitted O
to O
[ O
* O
* O
Hospital6 O
33 O
* O
* O
] O
approximately O
one O

 O
week O
ago O
with O
melena O
and O
hematocrit O
of O
22 O
, O
found O
to O
have O
a O

 O
NSTEMI O
( O
medical O
management O
per O
cardiology O
, O
restarted O
on O
plavix B-DRUG
- O

 O
d/c'ed O
in O
[ O
* O
* O
2154 O
* O
* O
] O
given O
recurrent B-ADE
gi I-ADE
bleeds I-ADE
, I-ADE
1 O
month O
after O
BMS O

 O
placed O
) O
. O
  O
Upper O
endoscopy O
was O
unrevealing O
except O
for O
mild O

 O
gastritis O
. O
  O
Colonoscopy O
last O
done O
one O
year O
ago O
which O
was O

 O
unremarkable O
except O
for O
benign O
polyps O
. O
  O
Patient O
was O
transfused B-ROU
4 O

 O
units O
of O
pRBCs B-DRUG
, I-DRUG
hematorcrit O
increased O
to O
27 O
and O
discharged O
three O

 O
days O
ago O
. O
  O
Of O
note O
, O
he O
required O
diuresis O
for O
decompensated O
CHF O
. O

 O
Was O
seen O
in O
the O
ED O
on O
[ O
* O
* O
4 O
- O
21 O
* O
* O
] O
for O
chest O
pain O
, O
no O
EKG O
changes O
, O

 O
resolved O
with O
nitro O
, O
discharged O
home O
. O

 O
. O

 O
Patient O
was O
re-admitted O
to O
[ O
* O
* O
Hospital3 O
* O
* O
] O
today O
( O
[ O
* O
* O
2156 O
- O
4 O
- O
26 O
* O
* O
] O
) O
with O

 O
recurrent O
melena O
. O
  O
Last O
night O
he O
had O
two O
black/tarry O
stools O
. O
  O
He O

 O
also O
endorsed O
some O
mild O
chest O
pain O
. O
  O
His O
hematocrit O
on O
admission O

 O
was O
26.2 O
. O
  O
Patient O
transfused B-ROU
1 B-DOS
unit I-DOS
of O
packed B-DRUG
cells I-DRUG
. I-DRUG
  O
He O
ruled O

 O
out O
for O
ACS O
by O
three O
sets O
of O
negative O
cardiac O
enzymes O
and O

 O
non-ischemic O
EKG O
. O
  O
Patient O
underwent O
a O
CT O
angiogram O
which O

 O
revealed O
3 O
small O
bowel O
foci O
of O
hemorrhage O
likely O
in O
the O
proximal O

 O
ileum O
. O
  O
Given O
the O
location O
of O
the O
bleeding O
decision O
made O
by O

 O
gastroenterologist O
to O
transfer O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
for O
single O
balloon O

 O
enteroscopy O
. O
  O
Patient O
has O
been O
continued O
on O
plavix B-DRUG
given O
his O

 O
significant O
cardiac O
comorbidities O
. O
  O
He O
has O
been O
bridged O
with O
a O

 O
heparin B-DRUG
gtt B-ROU
for O
a B-REA
subtherapeutic I-REA
INR I-REA
of I-REA
1.9 I-REA
. I-REA

 O
. O

 O
Of O
note O
, O
patient O
had O
recurrent O
GI O
bleeding O
at O
site O
of O

 O
anastamosis O
from O
sigmoid O
colectomy O
in O
[ O
* O
* O
2154 O
* O
* O
] O
, O
requiring O
multiple O

 O
transfusions O
. O
  O
Was O
on O
asa/plavix/coumadin B-DRUG
with O
recent O
BMS O
placed O

 O
in O
diagonal O
. O
  O
ASA B-DRUG
stopped O
and O
plavix B-DRUG
discontinued O
1 O
month O
after O

 O
BMS O
placement O
given O
recurrent O
bleeding O
. O
  O
He O
had O
no O
further O

 O
bleeding O
issues O
until O
this O
past O
week O
. O

 O
. O

 O
Currently O
patient O
has O
no O
complaints O
. O
  O
Denies O
any O
current O
chest O

 O
pain O
, O
sob O
, O
lightheadedness O
or O
dizziness O
. O
  O
No O
nausea O
, O
vomiting O
or O

 O
abdominal O
pain O
. O
  O
Reports O
one O
episode O
of O
black O
stool O
prior O
to O

 O
transfer O
. O

 O
. O

 O
ROS O
as O
per O
HPI O
, O
10 O
pt O
ROS O
otherwise O
negative O
. O



 O
Past O
Medical O
History O
: O

 O
-CAD O
s/p O
CABG O
2v O
[ O
* O
* O
2135 O
* O
* O
] O
, O
restenosis O
requiring O
multiple O
stents O
, O

 O
[ O
* O
* O
2151 O
* O
* O
] O
DES O
for O
RCA O
stenosis O
, O
[ O
* O
* O
2152 O
* O
* O
] O
NSTEMI O
medically O
managed O
, O
[ O
* O
* O
2154 O
* O
* O
] O

 O
BMS O
diagonal O

 O
-St O
. O
[ O
* O
* O
Male O
First O
Name O
( O
un O
) O
923 O
* O
* O
] O
aortic O
valve O
replacement O
[ O
* O
* O
2135 O
* O
* O
] O

 O
-IDDM O

 O
-COPD O

 O
-Diverticulitis O
s/p O
sigmoid O
colectomy O
complicated O
by O
unstable O

 O
angina O
, O
s/p O
cardiac O
cath O
and O
BMS O
to O
diagonal O
, O
then O
developed O

 O
recurrent B-ADE
bleeding I-ADE
on O
asa/plavix/coumadin B-DRUG
therefore O
plavix B-DRUG

 I-DRUG
d/c'ed O
after O
1 B-DUR
month I-DUR

 I-DUR
-HTN O

 O
-Hypothyroidism O

 O
-CHF O

 O
-Anxiety O

 O
-S/p O
knee O
replacement O
[ O
* O
* O
2152 O
* O
* O
] O
complicated O
NSTEMI O
and O
CHF O

 O
exacerbation O

 O
-Hernia O
repair O


 O
Social O
History O
: O

 O
Lives O
with O
wife O
, O
[ O
* O
* O
Name O
( O
NI O
) O
32774 O
* O
* O
] O
and O
grandson O
in O
[ O
* O
* O
Name O
( O
NI O
) O
32775 O
* O
* O
] O
, O
MA O
. O
  O
Retired O

 O
heavy O
lift O
mechanic O
. O
  O
+ O
tobacco O
, O
1 O
ppd O
x O
55 O
yrs O
. O
  O
No O
etoh O
or O

 O
illicits O
. O


 O
Family O
History O
: O

 O
+ O
CAD O
and O
DM O
, O
no O
hx O
of O
gi O
bleeds O


 O
Physical O
Exam O
: O

 O
ON O
ADMISSION O
: O

 O
VS O
: O
97.9 O
  O
138/79 O
  O
56 O
  O
20 O
  O
96%RA O

 O
Appearance O
: O
alert O
, O
NAD O
, O
obese O

 O
Eyes O
: O
eomi O
, O
perrl O
, O
anicteric O

 O
ENT O
: O
OP O
clear O
s O
lesions O
, O
mmd O
, O
no O
JVD O
, O
neck O
supple O

 O
Cv O
: O
+ O
s1 O
, O
s2 O
  O
mechanical O
aortic O
click O
, O
no O
peripheral O
edema O
, O
2 O
+ O

 O
dp/pt O
bilaterally O

 O
Pulm O
: O
clear O
bilaterally O
, O
diminished O
at O
bases O

 O
Abd O
: O
soft O
, O
obese O
, O
midline O
scar O
, O
nt O
, O
nd O
, O
+ O
bs O

 O
Msk O
: O
5/5 O
strength O
throughout O
, O
no O
joint O
swelling O
, O
no O
cyanosis O
or O

 O
clubbing O

 O
Neuro O
: O
cn O
2 O
- O
12 O
grossly O
intact O
, O
no O
focal O
deficits O

 O
Skin O
: O
no O
rashes O

 O
Psych O
: O
appropriate O
, O
pleasant O

 O
Heme O
: O
no O
cervical O
[ O
* O
* O
Doctor O
First O
Name O
* O
* O
] O



 O
Pertinent O
Results O
: O

 O
[ O
* O
* O
Hospital6 O
33 O
* O
* O
] O
labs O
: O

 O
. O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
26 O
* O
* O
] O

 O
. O

 O
6.3 O
> O
[ O
* O
* O
10 O
- O
20 O
* O
* O
] O
< O
148 O

 O
. O

 O
138 O
  O
100 O
  O
18 O

 O
------------ O
< O
161 O

 O
3.2 O
  O
28 O
  O
1.0 O

 O
. O

 O
LFTs O
wnl O

 O
. O

 O
[ O
* O
* O
Hospital6 O
33 O
* O
* O
] O
Images O
: O

 O
. O


 O
[ O
* O
* O
2156 O
- O
4 O
- O
26 O
* O
* O
] O
CT O
angio O
a/p O
: O

 O
three O
small O
foci O
of O
hemorrhage O
, O
located O
in O
proximal O
ileum O
with O

 O
extravasation O
of O
intraluminal B-DRUG
intravenous I-DRUG
contrast I-DRUG
may O
be O
due O
to O

 O
angiodysplasia O
, O
no O
evidence O
for O
underlying O
mucosal O
masses O
; O

 O
colonic O
diverticulosis O
without O
diverticulitis O
, O
mild O
splenomegaly O

 O
. O


 O
[ O
* O
* O
2156 O
- O
5 O
- O
1 O
* O
* O
] O
: O
WBC O
3.1 O
HCT O
24.6 O
PLT O
95 O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
30 O
* O
* O
] O
HCT O
25.7 O
PLT O
105 O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
28 O
* O
* O
] O
05:05AM O
BLOOD O
WBC-3.6 O
* O
RBC-3.02 O
* O
Hgb-10.1 O
* O
Hct-29.2 O
* O

 O
MCV-97 O
MCH-33.6 O
* O
MCHC-34.7 O
RDW-17.8 O
* O
Plt O
Ct-129 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
09:04PM O
BLOOD O
Hct-29.9 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
03:16PM O
BLOOD O
Hct-30.9 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
09:00AM O
BLOOD O
Hct-28.5 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
05:15AM O
BLOOD O
WBC-3.7 O
* O
RBC-2.72 O
* O
Hgb-9.5 O
* O
Hct-26.8 O
* O

 O
MCV-99 O
* O
MCH-34.8 O
* O
MCHC-35.3 O
* O
RDW-17.2 O
* O
Plt O
Ct-134 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
12:40AM O
BLOOD O
WBC-4.0 O
# O
RBC-2.84 O
* O
# O
Hgb-9.5 O
* O
# O
Hct-27.7 O
* O

 O
MCV-98 O
# O
MCH-33.4 O
* O
# O
MCHC-34.3 O
RDW-17.1 O
* O
Plt O
Ct-134 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
12:40AM O
BLOOD O
Neuts-55 O
Bands-0 O
Lymphs-35 O
Monos-8 O
Eos-2 O

 O
Baso-0 O
Atyps-0 O
Metas-0 O
Myelos-0 O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
12:40AM O
BLOOD O
Hypochr-NORMAL O
Anisocy-2 O
+ O
Poiklo-2 O
+ O

 O
Macrocy-2 O
+ O
Microcy-NORMAL O
Polychr-NORMAL O
Ovalocy-1 O
+ O

 O
Pencil-OCCASIONAL O
Ellipto-OCCASIONAL O

 O
[ O
* O
* O
2156 O
- O
5 O
- O
1 O
* O
* O
] O
: O
INR O
1.7 O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
28 O
* O
* O
] O
06:40PM O
BLOOD O
PT-19.7 O
* O
PTT-75.3 O
* O
INR(PT)-1.9 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
28 O
* O
* O
] O
05:05AM O
BLOOD O
Plt O
Ct-129 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
28 O
* O
* O
] O
05:05AM O
BLOOD O
PT-19.2 O
* O
PTT-109.9 O
* O
INR(PT)-1.8 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
28 O
* O
* O
] O
02:48AM O
BLOOD O
PT-19.0 O
* O
PTT-112.8 O
* O
INR(PT)-1.8 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
08:55PM O
BLOOD O
PT-18.9 O
* O
PTT-56.0 O
* O
INR(PT)-1.8 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
01:00PM O
BLOOD O
PT-20.7 O
* O
PTT-42.6 O
* O
INR(PT)-2.0 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
05:15AM O
BLOOD O
Plt O
Ct-134 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
05:15AM O
BLOOD O
PT-22.3 O
* O
PTT-150 O
* O
INR(PT)-2.1 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
12:40AM O
BLOOD O
Plt O
Smr-LOW O
Plt O
Ct-134 O
* O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
12:40AM O
BLOOD O
PT-23.0 O
* O
PTT-45.1 O
* O
INR(PT)-2.2 O
* O

 O
RENAL O
& O
GLUCOSE O
Glucose O
UreaN O
Creat O
Na O
K O
Cl O
HCO3 O
AnGap O

 O
[ O
* O
* O
2156 O
- O
5 O
- O
1 O
* O
* O
] O
02:22 O
    O
glu131 O
* O
urea O
N9 O
cr0.9 O
na140 O
k3.5 O
cl108 O
hco3 O

 O
24 O
AG12 O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
28 O
* O
* O
] O
05:05AM O
BLOOD O
Glucose-85 O
UreaN-13 O
Creat-1.1 O
Na-141 O

 O
K-3.9 O
Cl-105 O
HCO3 O
- O
25 O
AnGap-15 O

 O

[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
05:15AM O
BLOOD O
Glucose-95 O
UreaN-11 O
Creat-0.9 O
Na-142 O

 O
K-3.4 O
Cl-104 O
HCO3 O
- O
26 O
AnGap-15 O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
12:40AM O
BLOOD O
Glucose-80 O
UreaN-12 O
Creat-1.0 O
Na-143 O

 O
K-3.7 O
Cl-105 O
HCO3 O
- O
28 O
AnGap-14 O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
12:40AM O
BLOOD O
Lipase-29 O

 O
[ O
* O
* O
2156 O
- O
5 O
- O
1 O
* O
* O
] O
ca8.0 O
* O
mg2.4 O
* O
phos1.8 O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
28 O
* O
* O
] O
05:05AM O
BLOOD O
Calcium-8.4 O
Phos-3.2 O
Mg-2.3 O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
05:15AM O
BLOOD O
Calcium-8.4 O
Phos-3.0 O
Mg-2.4 O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
27 O
* O
* O
] O
12:40AM O
BLOOD O
Calcium-8.5 O
Phos-3.1 O
Mg-1.0 O
* O

 O
. O

 O
[ O
* O
* O
4 O
- O
28 O
* O
* O
] O
ECHO O
: O

 O
The O
left O
atrium O
is O
mildly O
dilated O
. O
There O
is O
mild O
symmetric O
left O

 O
ventricular O
hypertrophy O
with O
normal O
cavity O
size O
and O
global O

 O
systolic O
function O
( O
LVEF>55 O
% O
) O
. O
Due O
to O
suboptimal O
technical O

 O
quality O
, O
a O
focal O
wall O
motion O
abnormality O
can O
not O
be O
fully O

 O
excluded O
. O
The O
ascending O
aorta O
is O
mildly O
dilated O
. O
The O
aortic O
arch O

 O
is O
mildly O
dilated O
. O
A O
mechanical O
aortic O
valve O
prosthesis O
is O

 O
present O
. O
The O
transaortic O
gradient O
is O
higher O
than O
expected O
for O

 O
this O
type O
of O
prosthesis O
. O
Trace O
aortic O
regurgitation O
is O
seen O
. O

 O
[ O
Normal O
for O
this O
prosthesis O
. O
] O
The O
mitral O
valve O
leaflets O
are O

 O
mildly O
thickened O
. O
A O
mitral O
valve O
annuloplasty O
ring O
is O
present O
. O

 O
The O
gradient O
across O
the O
mitral O
valve O
is O
slightly O
increased O
( O
mean O

 O
= O
3 O
- O
4 O
mmHg O
) O
resulting O
in O
trivial/minimal O
mitral O
stenosis O
. O
No O

 O
mitral O
regurgitation O
is O
seen O
. O
[ O
Due O
to O
acoustic O
shadowing O
, O
the O

 O
severity O
of O
mitral O
regurgitation O
may O
be O
significantly O

 O
UNDERestimated O
. O
] O
There O
is O
mild O
pulmonary O
artery O
systolic O

 O
hypertension O
. O
There O
is O
no O
pericardial O
effusion O
. O


 O
IMPRESSION O
: O
Suboptimal O
image O
quality O
. O
Well O
seated O
mechanical O

 O
aortic O
valve O
but O
with O
increased O
gradient O
. O
Well O
seated O
mitral O

 O
annuloplasty O
ring O
with O
trivial O
mitral O
stenosis O
. O
Mild O
symmetric O

 O
left O
ventricular O
hypertrophy O
with O
preserved O
global O
biventricular O

 O
systolic O
function O
. O
Pulmonary O
artery O
hypertension O
. O
Dilated O

 O
thoracic O
aorta O
. O

 O
Compared O
with O
the O
report O
of O
the O
prior O
study O
( O
images O
unavailable O

 O
for O
review O
) O
of O
[ O
* O
* O
2144 O
- O
12 O
- O
25 O
* O
* O
] O
, O
the O
aortic O
valve O
gradient O
is O
increased O

 O
and O
minimal O
mitral O
stenosis O
is O
now O
identified O
. O

 O
If O
clinically O
indicated O
, O
a O
TEE O
may O
be O
better O
able O
to O
define O
the O

 O
cause O
of O
the O
increased O
gradient O
across O
the O
aortic O
valve O
. O

 O
. O


 O
[ O
* O
* O
2156 O
- O
4 O
- O
30 O
* O
* O
] O
small O
bowel O
enteroscopy O
report O
: O
( O
from O
above O
) O

 O
Healthy O
surgical O
anastomosis O
at O
left O
colon O
corresponding O
to O
the O

 O
previous O
colectomy O
. O
  O
Moderate O
to O
severe O
diverticulosis O
in O
the O

 O
entire O
colon O
. O

 O
The O
terminal O
ileum O
was O
entered O
and O
the O
scope O
was O
advanced O
to O
the O

 O
proximal/mid O
ileum O
. O
A O
few O
tiny O
red O
spots O
were O
seen O
. O
But O
there O

 O
was O
no O
active O
bleeding O
. O
No O
AVM O
or O
mass O
lesions O
were O
seen O
. O

 O
Otherwise O
normal O
small O
bowel O
enteroscopy O
to O
third O
part O
of O
the O

 O
duodenum O
. O

 O
. O

 O
[ O
* O
* O
2156 O
- O
4 O
- O
29 O
* O
* O
] O
small O
bowel O
enteroscopy O
report O
: O
( O
from O
below O
) O

 O
The O
examined O
proximal O
ileum O
was O
normal O
. O
No O
active O
bleeding O
or O

 O
AVM O
or O
mass O
was O
seen O
. O
  O
Impression O
: O
Normal O
esophagus O
; O
A O
tiny O

 O
nonbleeding O
erosion O
seen O
at O
the O
antrum O
; O
Mild O
and O
pathy O
erythema O

 O
seen O
at O
duodenal O
bulb O
; O
Normal O
jejunum O
. O
No O
active O
bleeding O
or O
AVM O

 O
or O
mass O
seen O
. O
Itattooed O
for O
marking O
; O

 O
Normal O
proximal O
ileum O
. O
No O
active O
bleeding O
or O
AVM O
or O
mass O
seen O
. O

 O
Otherwise O
normal O
small O
bowel O
enteroscopy O
to O
distal O

 O
jejunum/proximal O
ileum O
. O




 O
Brief O
Hospital O
Course O
: O

 O
REASON O
FOR O
ICU O
ADMISSION O
: O

 O
Pt O
is O
a O
69 O
y.o O
male O
with O
h.o O
CAD O
s/p O
CABG O
complicated O
by O

 O
restenosis O
requiring O
multiple O
stents O
and O
recent O
NSTEMI O
, O

 O
mechanical B-REA
aortic I-REA
valve I-REA
on O
coumadin B-DRUG
, I-DRUG
recurrent B-ADE
GI I-ADE
bleeds I-ADE
and O

 O
IDDM O
who O
was O
transferred O
from O
OSH O
with O
melena O
and O
CTA O
showing O

 O
active O
bleeding O
in O
proximal O
ileum O
. O

 O
. O


 O
# O
upper O
GI O
bleed/acute O
blood O
loss/anemia-CTA O
per O
OSH O
report O

 O
showed O
active O
bleeding O
in O
the O
proximal O
ileum O
. O
Pt O
with O
recent O
EGD O

 O
with O
non-bleeding O
gastritis O
. O
Last O
colonoscopy O
1 O
yr O
ago O
with O

 O
polyps O
. O
UGIB B-ADE
in O
the O
setting O
of O
restarting O
plavix B-DRUG
1 O
week O
ago O
for O

 O
NSTEMI B-REA
. I-REA
PT O
also O
on O
couamdin B-DRUG
for O
mechanical B-REA
valve I-REA
, I-REA
and O
started O
on O

 O
heparin B-DRUG
ggt B-ROU
as O
coumadin B-DRUG
was O
held O
in O
setting O
of O
procedure O
. O
Hct O

 O
remained O
stable O
. O
Pt O
was O
placed O
on O
a O
protonix B-DRUG
gtt B-ROU
. I-ROU
Plavix B-DRUG
was O

 O
continued O
up O
until O
transfer O
to O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
, O
then O
restarted O
. O
Discussed O

 O
anticoagulation B-DRUG
with O
patient O
's O
cardiologist O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
32772 O
* O
* O
] O
who O
felt O

 O
as O
though O
pt O
should O
be O
on O
heparin B-DRUG
gtt B-ROU
as O
long O
as O
deemed O
safe O

 O
from O
GI O
procedure O
prospective O
. O
Would O
prefer O
to O
restart O
ASAP O

 O
after O
any O
procedure O
. O
In O
addition O
, O
outpt O
cardiologist O
felt O
as O

 O
though O
pt O
should O
be O
on O
plavix B-DRUG
unless O
there O
is O
presence O
of O

 O
hemodynamically O
significant O
GI O
bleeding O
. O
He O
agreed O
that O
pt O
does O

 O
not O
tolerate O
dual O
anti-platelet B-DRUG
therapy I-DRUG
( O
per O
pt O
, O
ASA B-DRUG
caused O

 O
bleeding B-ADE
) I-ADE
. O
Enteroscopy O
was O
performed O
at O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
[ O
* O
* O
2156 O
- O
4 O
- O
29 O
* O
* O
] O
which O

 O
showed O
no O
evidence O
of O
bleeding O
via O
approach O
from O
above O
. O
Small O

 O
bowel O
enteroscopy/colonoscopy O
was O
performed O
[ O
* O
* O
2156 O
- O
4 O
- O
30 O
* O
* O
] O
which O
was O

 O
similarly O
unremarkable O
. O
Pt O
was O
restarted O
on O
warfarin B-DRUG
and O
heparin B-DRUG

 I-DRUG
gtt B-ROU
. I-ROU
Pt O
went O
home O
[ O
* O
* O
2156 O
- O
5 O
- O
1 O
* O
* O
] O
on O
lovenox B-DRUG
as O
bridge O
, O
with O
INR O
checks O

 O
planned O
for O
[ O
* O
* O
2156 O
- O
5 O
- O
3 O
* O
* O
] O
and O
[ O
* O
* O
2156 O
- O
5 O
- O
5 O
* O
* O
] O
. O

 O
. O

 O
# O
CORONARY O
ARTERY O
DISEASE O
: O
s/p O
CABG O
and O
PCI O
x2 O
, O
severe O
CAD O
with O

 O
chronic O
angina O
medically O
managed O
. O
Recent O
NSTEMI B-REA
with O
decision O
to O

 O
restart O
plavix B-DRUG
after O
being O
held O
x2 O
years O
due O
to O
recurrent B-ADE
GI I-ADE

 I-ADE
bleeds I-ADE
. I-ADE
At O
[ O
* O
* O
Hospital1 O
18 O
* O
* O
] O
plavix B-DRUG
was O
held O
initially O
as O
GI O
team O
was O

 O
uncomfortable O
doing O
procedure O
on O
plavix B-DRUG
as O
interventions O
for O

 O
bleeding B-ADE
( O
ex O
. O
clipping O
, O
cauterization O
could O
lead O
to O
more O

 O
bleeding B-ADE
while O
on O
plavix B-DRUG
) I-DRUG
. O
In O
addition O
, O
it O
was O
felt O
that O
at O
the O

 O
time O
plavix B-DRUG
effects O
would O
still O
be O
in O
his O
system O
as O
there O
was O
no O

 O
complete O
washout O
period O
. O
As O
above O
, O
discussed O
case O
with O
pt O
's O

 O
outpatient O
cardiologist O
who O
felt O
that O
pt O
would O
need O
to O
remain O
on O

 O
plavix B-DRUG
unless O
life O
hemodynamically O
significant O
GI O
bleeding O
. O
Pt O

 O
was O
continued O
on O
imdur B-DRUG
, I-DRUG
statin B-DRUG
, I-DRUG
beta B-DRUG
blocker I-DRUG
held O
, O
see O

 O
bradycardia B-ADE
below O
. O
He O
was O
ruled O
out O
for O
MI O
at O
OSH O
prior O
to O

 O
transfer O
. O
He O
was O
monitored O
on O
tele O
. O
Without O
events O
. O

 O
. O


 O
# O
MECHANICAL O
AORTIC O
VALVE O
: O
placed O
at O
St. O
[ O
* O
* O
Male O
First O
Name O
( O
un O
) O
1525 O
* O
* O
] O
. O
Patient O
's O
goal O

 O
INR O
3.5 O
for O
  O
mechanical B-REA
valve I-REA
. I-REA
Was O
switched O
to O
heparin B-DRUG
which O
was O

 O
stopped O
6 O
hours O
prior O
to O
procedures O
. O
Given O
significant O
risk B-REA
of I-REA

 I-REA
thrombosis I-REA
, I-REA
heparin B-DRUG
was O
restarted O
after O
procedures O
, O
despite O

 O
patient O
's O
known O
GI O
bleed O
. O
HCT O
was O
monitored O
closely O
and O
remained O

 O
stable O
. O
Heparin B-DRUG
gtt B-ROU
was O
changed O
to O
lovenox B-DRUG
on O
discharge O
, O
see O

 O
above O
. O

 O
. O

 O
# O
Bradycardia B-ADE
: I-ADE
Patient O
noted O
to O
be O
bradycardic O
after O
procedure O
. O

 O
Thought O
to O
be O
related O
to O
sedation B-DRUG
for O
procedure O
. O
Improved O
as O
the O

 O
patient O
woke O
up O
from O
sedation O
. O
Still O
, O
HR O
remained O
in O
the O
50 O
- O
60 O

 O
range O
throughout O
hospitalization O
. O
Initially O
home O
beta B-DRUG
blocker I-DRUG

 I-DRUG
was O
held O
. O
Pt O
was O
monitored O
on O
telemetry O
without O
events O
. O
He O
was O

 O
asymptomatic O
. O
Home O
atenolol B-DRUG
restarted O
on O
discharge O
. O

 O
. O

 O
# O
DIABETES B-REA
MELLITUS I-REA
- I-REA
type I-REA
2 I-REA
, I-REA
with O
complications O
, O
peripheral O

 O
neuropathy O
. O
  O
Placed O
on O
conservative O
insulin B-DRUG
regimen O
while O
NPO O
. O

 O
Pt O
resumed O
meformin B-DRUG
and O
glyburide B-DRUG
upon O
discharge O
. O
Continued O

 O
gabapentin B-DRUG
for O
neuropathy B-REA
. I-REA

 O
. O

 O
# O
HYPERTENSION B-REA
- O
benign O
; O
initially O
held O
beta B-DRUG
blocker I-DRUG
in O
setting O

 O
of O
bradycardia B-ADE
. I-ADE
Continued O
imdur B-DRUG
. I-DRUG
Held O
lisinopril B-DRUG
while O
NPO O
. O
On O

 O
the O
morning O
of O
discharge O
his O
blood O
pressure O
was O
elevated O
in O
the O

 O
170s O
systolic O
. O
We O
then O
restarted O
his O
home O
medications O
( O
atenolol B-DRUG
, I-DRUG

 O
lisinopril B-DRUG
) I-DRUG
which O
we O
had O
been O
holding O
and O
felt O
these O
would O
be O

 O
adequate O
for O
blood B-REA
pressure I-REA
control I-REA
. I-REA

 O
. O

 O
# O
DIASTOLIC B-REA
HEART I-REA
FAILURE I-REA
- O
chronic O
, O
but O
with O
recent O
acute O

 O
exacerbation O
. O
Lasix B-DRUG
was O
held O
while O
pt O
was O
NPO O
, O
and O
also O
was O

 O
given O
with O
1u B-DOS
pRBCs B-DRUG
. I-DRUG

 O
. O

 O
# O
hypothyroidism-continued B-REA
synthroid B-DRUG

 I-DRUG
. O

 O
# O
HL-continued B-REA
simvastatin B-DRUG

 I-DRUG
. O

 O
# O
GERD-on B-REA
PPI B-DRUG
ggt B-ROU
for O
c/f O
GI B-REA
bleed I-REA
as O
above O
, O
transitioned O
to O
PO B-ROU

 I-ROU
PPI B-DRUG
on O
discharge O

 O
. O

 O
# O
leukopenia/thrombocytopenia-unclear O
etiology O
. O
Could O
be O
due O
to O

 O
acute O
process O
. O
Thrombocytopenia O
could O
be O
consumptive O
. O
PLT O
count O

 O
was O
monitored O
closely O
and O
remained O
stable O
. O

 O
. O

 O
Pt O
was O
maintained O
as O
FULL O
CODE O
throughout O
the O
course O
of O
this O

 O
hospitalization O
. O

 O
. O

 O
TRANSITIONAL O
ISSUES O
: O

 O
anticoagulation B-REA
: I-REA
pt O
sent O
home O
on O
warfarin B-DRUG
( O
subtherapeutic O
after O

 O
holding O
for O
procedures O
) O
and O
lovenox B-DRUG
. I-DRUG
He O
will O
need O
INR O
checked O

 O
Monday O
[ O
* O
* O
2156 O
- O
5 O
- O
3 O
* O
* O
] O
and O
Wednesday O
[ O
* O
* O
2156 O
- O
5 O
- O
5 O
* O
* O
] O
likely O
to O
DC O
lovenox B-DRUG
[ O
* O
* O
2156 O
- O
5 O
- O
5 O
* O
* O
] O

 O
as O
ideally O
he O
would O
have O
a O
48 O
hour O
therapeutic O
overlap O
. O
Pt O
was O

 O
instructed O
to O
follow O
up O
with O
PCP O
regarding O
this O
issue O
. O



 O
Medications O
on O
Admission O
: O

 O
Medications O
on O
Transfer O
: O

 O
Vicodin B-DRUG
5/500 B-STR
q6h B-FRE
prn I-FRE

 I-FRE
Ativan B-DRUG
2 B-STR
mg I-STR
po B-ROU
TID B-FRE
prn I-FRE

 I-FRE
Morphine B-DRUG
2 B-STR
mg I-STR
iv B-ROU
prn B-FRE

 I-FRE
NTG B-DRUG
0.4 B-STR
q5 B-FRE
mins I-FRE
prn I-FRE

 I-FRE
Protonix B-DRUG
gtt B-ROU

 I-ROU
Atenolol B-DRUG
25 B-STR
mg I-STR
po B-ROU
bid B-FRE

 I-FRE
Plavix B-DRUG
75 B-STR
mg I-STR
daily B-FRE

 I-FRE
Ferrous B-DRUG
sulfate I-DRUG
325 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Gabapentin B-DRUG
600 B-STR
mg I-STR
QID B-FRE

 I-FRE
Humalog B-DRUG
sliding B-DOS
scale I-DOS

 I-DOS
Synthroid B-DRUG
50mcg B-STR
daily B-FRE

 I-FRE
Kdur B-DRUG
? O
dose O
daily B-FRE

 I-FRE
Simvastatin B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
Heparin B-DRUG
gtt B-ROU

 I-ROU
Imdur B-DRUG
ER I-DRUG
60 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Lasix B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
Lantus B-DRUG
10 B-DOS
units I-DOS
qam B-FRE

 I-FRE
Lisinopril B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
. O

 O
Outpatient O
Medications O

 O
Lantus B-DRUG
20 B-DOS
units I-DOS
qam B-FRE

 I-FRE
Metformin B-DRUG
850 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Glyburide B-DRUG
10 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Atenolol B-DRUG
25 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O

 O
Plavix B-DRUG
75 B-STR
mg I-STR
daily B-FRE

 I-FRE
Tylenol B-DRUG
prn B-FRE

 I-FRE
vicodin B-DRUG
1 B-DOS
tablet B-FOR
q6h B-FRE
prn I-FRE

 I-FRE
Ativan B-DRUG
2 B-STR
mg I-STR
tid B-FRE
prn I-FRE

 I-FRE
NTG B-DRUG
prn B-FRE

 I-FRE
Lasix B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
Gabapentin B-DRUG
600 B-STR
mg I-STR
qid B-FRE

 I-FRE
Isosorbide B-DRUG
mononitrate I-DRUG
60 B-STR
mg I-STR
daily B-FRE

 I-FRE
Levoxyl B-DRUG
50mcg B-STR
daily B-FRE

 I-FRE
Lisinopril B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
Simvastatin B-DRUG
20 B-STR
mg I-STR
daily B-FRE

 I-FRE
Coumadin B-DRUG
5 B-STR
mg I-STR
all B-FRE
days I-FRE
except I-FRE
2.5 B-STR
mg I-STR
on O
M B-FRE
or I-FRE
F I-FRE

 I-FRE
Omeprazole B-DRUG
40 B-STR
mg I-STR
daily B-FRE

 I-FRE
KCl B-DRUG
20 B-STR
meq I-STR
daily B-FRE

 I-FRE
Ferrous B-DRUG
sulfate I-DRUG
325 B-STR
mg I-STR
[ O
* O
* O
Hospital1 O
* O
* O
] O



 O
Discharge O
Medications O
: O

 O
1 O
. O
enoxaparin B-DRUG
40 B-STR
mg/0.4 I-STR
mL I-STR
Syringe B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
  O
Subcutaneous B-ROU

 I-ROU
once B-FRE
a I-FRE
day I-FRE
for B-DUR
5 I-DUR
days I-DUR
: I-DUR
Continue O
until O
INR O
is O
therepeutic O
. O
. O

 O
Disp:*5 O
syringes O
* O
Refills:*2 O
* O

 O
2 O
. O
lorazepam B-DRUG
1 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
Q8H B-FRE
( I-FRE
every I-FRE
8 I-FRE

 I-FRE
hours I-FRE
) I-FRE
as I-FRE
needed I-FRE
for O
anxiety B-REA
. I-REA

 O
3 O
. O
gabapentin B-DRUG
300 B-STR
mg I-STR
Capsule B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Capsule B-FOR
PO B-ROU
QID B-FRE
( I-FRE
4 I-FRE

 I-FRE
times I-FRE
a I-FRE
day I-FRE
) I-FRE
. I-FRE

 O
4 O
. O
insulin B-DRUG
glargine I-DRUG
100 B-STR
unit/mL I-STR
Solution B-FOR
Sig O
: O
Twenty B-DOS
( I-DOS
20 I-DOS
) I-DOS
Units I-DOS

 I-DOS
Subcutaneous B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
5 O
. O
metformin B-DRUG
850 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
6 O
. O
atenolol B-DRUG
25 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
7 O
. O
clopidogrel B-DRUG
75 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
8 O
. O
glyburide B-DRUG
5 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
Two B-DOS
( I-DOS
2 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
9 O
. O
Vicodin B-DRUG
5 B-STR
- I-STR
500 I-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
every B-FRE
six I-FRE
( I-FRE
6 I-FRE
) I-FRE

 I-FRE
hours I-FRE
as I-FRE
needed I-FRE
for O
pain B-REA
. I-REA

 O
10 O
. O
Lasix B-DRUG
40 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
11 O
. O
isosorbide B-DRUG
mononitrate I-DRUG
60 B-STR
mg I-STR
Tablet B-FOR
Extended I-FOR
Release I-FOR
24 I-FOR
hr I-FOR

 I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
Extended I-FOR
Release I-FOR
24 I-FOR
hr I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
12 O
. O
Levoxyl B-DRUG
50 B-STR
mcg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
13 O
. O
lisinopril B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
14 O
. O
simvastatin B-DRUG
20 B-STR
mg I-STR
Tablet B-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE


 O
15 O
. O
omeprazole B-DRUG
40 B-STR
mg I-STR
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS

 I-DOS
Capsule B-FOR
, I-FOR
Delayed I-FOR
Release(E.C. I-FOR
) O
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
16 O
. O
potassium B-DRUG
chloride I-DRUG
20 B-STR
mEq I-STR
Tablet B-FOR
, I-FOR
ER I-FOR
Particles/Crystals I-FOR
Sig O
: O

 O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Tablet B-FOR
, I-FOR
ER I-FOR
Particles/Crystals I-FOR
PO B-ROU
once B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
17 O
. O
ferrous B-DRUG
sulfate I-DRUG
325 B-STR
mg I-STR
( O
65 B-STR
mg I-STR
iron B-DRUG
) I-DRUG
Capsule B-FOR
, I-FOR
Extended I-FOR

 I-FOR
Release I-FOR
Sig O
: O
One B-DOS
( I-DOS
1 I-DOS
) I-DOS
Capsule B-FOR
, I-FOR
Extended I-FOR
Release I-FOR
PO B-ROU
twice B-FRE
a I-FRE
day I-FRE
. I-FRE

 O
Capsule B-FOR
, I-FOR
Extended I-FOR
Release(s I-FOR
) O

 O
18 O
. O
Outpatient O
Lab O
Work O

 O
please O
have O
INR O
drawn O
[ O
* O
* O
2156 O
- O
5 O
- O
3 O
* O
* O
] O
and O
[ O
* O
* O
2156 O
- O
5 O
- O
5 O
* O
* O
] O



 O
Discharge O
Disposition O
: O

 O
Home O


 O
Discharge O
Diagnosis O
: O

 O
Acute O
blood O
loss O
anemia O
from O
gastrointestinal O
bleeding O

 O
CAD O
s/p O
stenting O
and O
mechanical O
aortic O
valve O

 O
Recent O
NSTEMI O

 O
HTN O



 O
Discharge O
Condition O
: O

 O
Mental O
Status O
: O
Clear O
and O
coherent O
. O

 O
Level O
of O
Consciousness O
: O
Alert O
and O
interactive O
. O

 O
Activity O
Status O
: O
Ambulatory O
- O
Independent O
. O



 O

Discharge O
Instructions O
: O

 O
Mr. O
[ O
* O
* O
Known O
lastname O
32776 O
* O
* O
] O
, O


 O
You O
were O
admitted O
for O
further O
evaluation O
of O
gastrointestinal O

 O
bleeding O
. O
For O
this O
, O
you O
had O
endoscopic O
procedures O
both O
from O

 O
above O
and O
below O
the O
level O
of O
the O
stomach O
, O
both O
which O
were O

 O
unrevealing O
for O
a O
source O
of O
bleeding O
. O
  O
This O
likely O
occurred O
in O

 O
the O
presence O
of O
multiple O
blood B-DRUG
thinners I-DRUG
, I-DRUG
causing O
leaking B-ADE
of I-ADE
a I-ADE

 I-ADE
vessel I-ADE
which O
stopped O
once O
we O
held O
your O
blood B-DRUG
thinners I-DRUG
. I-DRUG

  O
We O
discussed O
the O
risks O
and O
benefits O
of O
being O
on O
blood B-DRUG
thinners I-DRUG
. I-DRUG

  O
Given O
your O
cardiac B-REA
history I-REA
, I-REA
including B-REA
stents I-REA
and O
mechanical B-REA

 I-REA
heart I-REA
valves I-REA
, I-REA
it O
is O
necessary O
that O
your O
remain O
on O
warfarin B-DRUG
and O

 O
an O
antiplatelet B-DRUG
[ O
* O
* O
Doctor O
Last O
Name O
360 O
* O
* O
] O
( O
such O
as O
aspirin B-DRUG
or O
clopidogrel B-DRUG
AKA I-DRUG

 I-DRUG
Plavix I-DRUG
) I-DRUG
, O
to O
prevent O
a O
stroke O
and O
a O
heart O
attack O
respectively O
. O

 O
You O
will O
be O
discharged O
on O
warfarin B-DRUG
at O
your O
usual O
home O
dose O
as O

 O
well O
as O
clopidogrel B-DRUG
( I-DRUG
Plavix I-DRUG
) I-DRUG
. I-DRUG
  O
Please O
note O
to O
follow O
up O
with O

 O
your O
cardiologest O
within O
the O
week O
to O
assure O
you O
are O
on O
the O
most O

 O
appropriate O
therapy O
for O
your O
cardiac O
health O
. O

   O
As O
you O
know O
, O
your O
INR O
was O
below O
goal O
prior O
to O
discharge O
( O
goal O

 O
2.5 O
- O
3.5 O
) O
, O
since O
we O
held O
your O
warfarin B-DRUG
in O
the O
hospital O
so O
you O

 O
could O
have O
procedures O
. O
  O
You O
will O
be O
going O
home O
on O
enoxaparin B-DRUG

 I-DRUG
( I-DRUG
AKA I-DRUG
Lovenox)injections B-ROU
to O
keep O
your O
blood O
thin O
while O
your O
INR O

 O
becomes O
therepeutic O
. O


 O
Medication O
changes O
: O

 O
Please O
START O
taking O
Clopidogrel B-DRUG
( I-DRUG
AKA I-DRUG
Plavix I-DRUG
) I-DRUG
75 B-STR
mg I-STR
po B-ROU
qday B-FRE

 I-FRE
Please O
START O
taking O
Enoxaparin B-DRUG
subcutaneous B-ROU
injections I-ROU
until O

 O
your O
INR O
is O
therepeutic O

 O
Please O
continue O
taking O
the O
rest O
of O
your O
medications O
as O

 O
prescribed O
. O

 O
. O

 O
It O
has O
been O
a O
pleasure O
taking O
care O
of O
you O
Mr. O
[ O
* O
* O
Known O
lastname O
32776 O
* O
* O
] O
! O


 O
Followup O
Instructions O
: O

 O
Please O
arrange O
follow O
up O
with O
your O
primary O
care O
doctor O
and O
your O

 O
cardiologist O
within O
1 O
week O
of O
discharge O
. O
  O
You O
will O
need O
to O
have O

 O
your O
INR O
on O
Monday O
[ O
* O
* O
2156 O
- O
5 O
- O
3 O
* O
* O
] O
and O
Wednesday O
[ O
* O
* O
2156 O
- O
5 O
- O
5 O
* O
* O
] O
. O
Speak O
to O
your O

 O
primary O
care O
physician O
but O
you O
should O
stop O
lovenox B-DRUG
on O
Wednesday O

 O
[ O
* O
* O
2156 O
- O
5 O
- O
5 O
* O
* O
] O
if O
Dr. O
[ O
* O
* O
Last O
Name O
( O
STitle O
) O
26652 O
* O
* O
] O
approves O
. O



                              O
[ O
* O
* O
Initials O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Last O
Name O
( O
NamePattern4 O
) O
* O
* O
] O
[ O
* O
* O
Name8 O
( O
MD O
) O
* O
* O
] O
MD O
[ O
* O
* O
MD O
Number(1 O
) O
292 O
* O
* O
] O


 O

